PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Smith, AN; Finberg, KE; Wagner, CA; Lifton, RP; Devonald, MAJ; Su, Y; Karet, FE				Smith, AN; Finberg, KE; Wagner, CA; Lifton, RP; Devonald, MAJ; Su, Y; Karet, FE			Molecular cloning and characterization of Atp6n1b - A novel fourth murine vacuolar H+-ATPase a-subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; RENAL TUBULAR-ACIDOSIS; 116-KDA POLYPEPTIDE; RAT EPIDIDYMIS; PUMP SUBUNIT; 3 ISOFORMS; EXPRESSION; CELLS; 100-KDA; KIDNEY	The 116-kDa a-subunit of the vacuolar proton pump (H+-ATPase) exists as several isoforms encoded by different genes and with different patterns of tissue expression. Its function within the multisubunit pump complex has yet to be elucidated. To date, three isoforms have been identified in mouse (designated a1-a3). We now report the cloning and characterization of Atp6n1b, encoding a novel fourth murine isoform (a4). Murine a4 has 833 residues and shows 85% amino acid identity to the human kidney-specific ATP6N1B protein in which loss-of-function alterations cause autosomal recessive distal renal tubular acidosis. The human and murine genes have similar genomic organization; furthermore, Atp6n1b maps to a region of mouse chromosome 6 that is syntenic with the segment of human 7q33-34 containing ATP6N1B. Together these findings establish the two genes as orthologs. The mouse a4 protein is 61, 52, and 47% identical to a1, a2, and a3, respectively. Phylogenetic analysis confirms that among vertebrates there are four a-subunit families, with a4 most resembling al. Northern blot analysis of Atp6n1b reveals a 3.7-kilobase a4 transcript in kidney but not other major organs, and a reverse transcription polymerase chain reaction in 12 mouse tissues detects expression in kidney alone. Immunofluorescence studies in murine kidney demonstrate high intensity a4 staining at the surface of intercalated cells, with additional expression in the proximal tubule (not previously reported in human kidney). Similar apical a4 immunostaining is also present in male genital tissue. Identification of this novel murine kidney-enriched 116-kDa a-subunit provides a molecular tool for investigation of the currently unknown role of this protein, which is essential for proper function of the apical renal vacuolar H+-ATPase in man.	Univ Cambridge, Addenbrookes Hosp, Med Res Inst, Dept Med Genet, Cambridge CB2 2XY, England; Univ Cambridge, Addenbrookes Hosp, Med Res Inst, Dept Nephrol, Cambridge CB2 2XY, England; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, New Haven, CT 06510 USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Howard Hughes Medical Institute; Yale University	Finberg, KE (corresponding author), Univ Cambridge, Addenbrookes Hosp, Med Res Inst, Dept Med Genet, Box 139, Cambridge CB2 2XY, England.			Karet, Fiona/0000-0002-2457-2869				Brown D, 2000, J EXP BIOL, V203, P137; BROWN D, 1992, AM J PHYSIOL, V263, pC913, DOI 10.1152/ajpcell.1992.263.4.C913; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Crider BP, 1997, J BIOL CHEM, V272, P10721; Deng WJ, 2001, J BONE MINER RES, V16, P1136, DOI 10.1359/jbmr.2001.16.6.1136; Hermo L, 2000, J ANDROL, V21, P376; Karet FE, 1999, AM J HUM GENET, V65, P1656, DOI 10.1086/302679; KARET FE, 1994, NEPHROL DIAL TRANSPL, V9, P465, DOI 10.1093/ndt/9.5.465; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; LEE CK, 1990, MOL IMMUNOL, V27, P1137; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; Mattsson JP, 2000, EUR J BIOCHEM, V267, P4115, DOI 10.1046/j.1432-1327.2000.01445.x; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MUNROE DJ, 1994, GENOMICS, V19, P506, DOI 10.1006/geno.1994.1100; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Oka T, 1998, J BIOL CHEM, V273, P22570, DOI 10.1074/jbc.273.35.22570; Oka T, 2001, J BIOL CHEM, V276, P33079, DOI 10.1074/jbc.M101652200; PENG SB, 1994, J BIOL CHEM, V269, P17262; Peng SB, 1999, J BIOL CHEM, V274, P2549, DOI 10.1074/jbc.274.4.2549; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Pujol N, 2001, J BIOL CHEM, V276, P11913, DOI 10.1074/jbc.M009451200; Scott BB, 1998, EUR J PHARMACOL, V346, pR3, DOI 10.1016/S0014-2999(98)00163-0; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Steinmetz PR, 1996, KIDNEY INT, V49, P1655, DOI 10.1038/ki.1996.241; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; VANHILLE B, 1994, BIOCHEM J, V303, P191, DOI 10.1042/bj3030191	32	86	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42382	42388		10.1074/jbc.M107267200	http://dx.doi.org/10.1074/jbc.M107267200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11495928	hybrid			2022-12-25	WOS:000172450400110
J	Arcovito, A; Gianni, S; Brunori, M; Travaglini-Allocatelli, C; Bellelli, A				Arcovito, A; Gianni, S; Brunori, M; Travaglini-Allocatelli, C; Bellelli, A			Fast coordination changes in cytochrome c do not necessarily imply folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; ELECTRON-TRANSFER; FERROCYTOCHROME-C; CARBON-MONOXIDE; LIGAND; IRON; HEMOPROTEINS; RESOLUTION; PHOTOLYSIS; HEMOGLOBIN	Folding of globular proteins occurs with rates that range from microseconds to minutes; consequently, it has been necessary to develop new strategies to follow the faster processes that exceed stopped-flow capabilities. Rapid photochemical methods have been employed to study the rate of folding of reduced cytochrome c. In this protein, the iron of the covalently bound heme binds a His and a Met, proximal and distal. Unfolding by guanidine or urea weakens the Fe-Met bond, and the reduced unfolded cytochrome c easily binds CO and other heme ligands, which would react slowly or not at all with the native protein. Therefore in the presence of CO, reduced cytochrome c unfolds at lower denaturant concentrations than in the absence of this ligand, and rapid photochemical removal of CO from unfolded cytochrome c, is expected to trigger at least an incomplete refolding. This approach is complicated by the breakage of the proximal His-Fe bond that may occur as a consequence of CO photodissociation in the unfolded cytochrome c because of the so-called base elimination mechanism. Rebinding of CO to the four-coordinate heme yields kinetic intermediates unrelated to folding. Our hypothesis is supported by parallel observations carried out with protoheme and microperoxidase.	Univ Roma La Sapienza, Dipartimento Sci Biochim Alessandro Rossi Fanelli, CNR, Ctr Mol Biol, I-00185 Rome, Italy; Univ Roma La Sapienza, Inst Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome	Bellelli, A (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim Alessandro Rossi Fanelli, CNR, Ctr Mol Biol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.		Bellelli, Andrea/D-2785-2009; Arcovito, Alessandro/I-5552-2012; gianni, stefano/C-8536-2009	Arcovito, Alessandro/0000-0002-8384-4844; Travaglini-Allocatelli, Carlo/0000-0001-8735-1126; Brunori, Maurizio/0000-0002-7795-1635; Gianni, Stefano/0000-0003-1653-1925				BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; Chan CK, 1996, SCIENCE, V274, P628, DOI 10.1126/science.274.5287.628; Chan CK, 1997, P NATL ACAD SCI USA, V94, P1779, DOI 10.1073/pnas.94.5.1779; Chen EF, 1998, BIOCHEMISTRY-US, V37, P5589, DOI 10.1021/bi972369f; Colon W, 1997, BIOCHEMISTRY-US, V36, P12535, DOI 10.1021/bi971697c; Cutruzzola F, 1997, BIOCHEM J, V322, P35, DOI 10.1042/bj3220035; DETLEFSEN DJ, 1991, BIOCHEMISTRY-US, V30, P9040, DOI 10.1021/bi00101a019; GIACOMETTI GM, 1977, J BIOL CHEM, V252, P7447; Hagen SJ, 1997, J PHYS CHEM B, V101, P2352, DOI 10.1021/jp9622997; HARBURY HA, 1960, J BIOL CHEM, V235, P3640; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; JEHANLI AMT, 1976, EUR J BIOCHEM, V71, P613, DOI 10.1111/j.1432-1033.1976.tb11152.x; JONES CM, 1993, P NATL ACAD SCI USA, V90, P11860, DOI 10.1073/pnas.90.24.11860; Laberge M, 1998, J BIOMOL STRUCT DYN, V15, P1039, DOI 10.1080/07391102.1998.10508999; MOMENTEAU M, 1976, EUR J BIOCHEM, V71, P63, DOI 10.1111/j.1432-1033.1976.tb11090.x; Pascher T, 1996, SCIENCE, V271, P1558, DOI 10.1126/science.271.5255.1558; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; ROUGEE M, 1975, BIOCHEMISTRY-US, V14, P4100, DOI 10.1021/bi00689a028; Rumbley J, 2001, P NATL ACAD SCI USA, V98, P105, DOI 10.1073/pnas.98.1.105; SALEEM MMM, 1988, INORG CHIM A-BIOINOR, V153, P99, DOI 10.1016/S0020-1693(00)83866-9; TAKANO T, 1973, J BIOL CHEM, V248, P5234; TALER G, 1995, BIOCHEMISTRY-US, V34, P14209, DOI 10.1021/bi00043a027; Telford JR, 1998, ACCOUNTS CHEM RES, V31, P755, DOI 10.1021/ar970078t; Telford JR, 1999, BIOCHEMISTRY-US, V38, P1944, DOI 10.1021/bi981933z; Travaglini-Allocatelli C, 1999, J MOL BIOL, V289, P1459, DOI 10.1006/jmbi.1999.2852; WHITE DK, 1979, J AM CHEM SOC, V101, P2443, DOI 10.1021/ja00503a034; Wilson EK, 1999, BIOCHEMISTRY-US, V38, P7556, DOI 10.1021/bi990179u; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51	28	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41073	41078		10.1074/jbc.M105183200	http://dx.doi.org/10.1074/jbc.M105183200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11487579	hybrid, Green Published			2022-12-25	WOS:000171925600094
J	Berditchevski, F; Gilbert, E; Griffiths, MR; Fitter, S; Ashman, L; Jenner, SJ				Berditchevski, F; Gilbert, E; Griffiths, MR; Fitter, S; Ashman, L; Jenner, SJ			Analysis of the CD151 center dot alpha(3)beta(1) integrin and CD151 center dot tetraspanin interactions by mutagenesis.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; TRANSMEMBRANE-4 SUPERFAMILY; PLASMA-MEMBRANE; TM4SF PROTEINS; GROWTH-FACTOR; CD9 ANTIGEN; HB-EGF; COMPLEXES; ASSOCIATION; ALPHA-3-BETA-1	Transmembrane proteins of the tetraspanin superfamily are associated with various integrins and modulate their function. We performed mutagenesis analysis to establish structural requirements for the interaction of CD151 with the alpha (3)beta (1) integrin and with other tetraspanins. Using a panel of CD151/CD9 chimeras and CD151 deletion mutants we show that the minimal region, which confers stable (e.g. Triton X-100-resistant) association of the tetraspanin with alpha (3)beta (1), maps within the large extracellular loop (LECL) of CD151 (the amino acid sequence between residues Leu(149) and Glu(213)). Furthermore, the substitution of 11 amino acids (residues 195-205) from this region for a corresponding sequence from CD9 LECL or point mutations of cysteines in the conserved CCG and PXXCC motifs abolish the interaction. The removal of the LECL CD151 does not affect the association of the protein with other tetraspanins (e.g. CD9, CD81, CD63, and wild-type CD151). On the other hand, the mutation of the CCG motif selectively prevents the homotypic CD151-CD151 interaction but does not influence the association of the mutagenized CD151 with other tetraspanins. These results demonstrate the differences in structural requirements for the heterotypic and homotypic tetraspanin(.)tetraspanin interactions. Various deletions involving the small extracellular loop and the first three transmembrane domains prevent surface expression of the CD151 mutants but do not affect the CD151(.)alpha (3)beta (1), interaction. The CD151 deletion mutants are accumulated in the endoplasmic reticulum and redirected to the lysosomes. The assembly of the CD151(.)alpha (3)beta (1) complex occurs early during the integrin biosynthesis and precedes the interaction of CD151 with other tetraspanins. Collectively, these data show that the incorporation of CD151 into the "tetraspanin web" can be controlled at various levels by different regions of the protein.	Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Inst Med & Vet Sci, Hanson Ctr Canc Res, Div Haematol, Adelaide, SA, Australia	University of Birmingham; Institute Medical & Veterinary Science Australia	Berditchevski, F (corresponding author), Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.		ASHMAN, LEONIE/G-7631-2013	ASHMAN, LEONIE/0000-0003-3559-3611; Fitter, Stephen/0000-0003-1663-6807				ASHMAN LK, 1997, LEUKOCYTE TYPING, V6, P681; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; Boismenu R, 1996, SCIENCE, V271, P198, DOI 10.1126/science.271.5246.198; BRADBURY LE, 1993, J IMMUNOL, V151, P2915; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; FITTER S, 1995, BLOOD, V86, P1348, DOI 10.1182/blood.V86.4.1348.bloodjournal8641348; Fitter S, 1999, BIOCHEM J, V338, P61, DOI 10.1042/0264-6021:3380061; GOLBERG AFX, 1996, P NATL ACAD SCI USA, V93, P13726; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IMAI T, 1995, J IMMUNOL, V155, P1229; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; Lagaudriere-Gesbert C, 1997, CELL IMMUNOL, V182, P105, DOI 10.1006/cimm.1997.1223; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Lehmann M, 1996, BIOCHEM J, V317, P803, DOI 10.1042/bj3170803; LENTER M, 1994, J BIOL CHEM, V269, P12263; LEUBE RE, 1995, J CELL SCI, V108, P883; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Rigot V, 1999, EUR J BIOCHEM, V261, P659, DOI 10.1046/j.1432-1327.1999.00300.x; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Sakuma T, 1997, J BIOCHEM-TOKYO, V122, P474; Sincock PM, 1999, J CELL SCI, V112, P833; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Toyo-oka K, 1999, INT IMMUNOL, V11, P2043, DOI 10.1093/intimm/11.12.2043; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751	39	91	99	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41165	41174		10.1074/jbc.M104041200	http://dx.doi.org/10.1074/jbc.M104041200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11479292	hybrid			2022-12-25	WOS:000171925600106
J	Jensen, SA; Reinhardt, DP; Gibson, MA; Weiss, AS				Jensen, SA; Reinhardt, DP; Gibson, MA; Weiss, AS			Protein interaction studies of MAGP-1 with tropoelastin and fibrillin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN-ASSOCIATED MICROFIBRILS; GLYCOPROTEIN-1 MAGP-1; TERMINAL DOMAIN; CALCIUM; BINDS; TRANSGLUTAMINASE; COACERVATION; ORGANIZATION; EXPRESSION; COLLAGEN	Elastic fibers consist primarily of an amorphous elastin core associated with microfibrils, 10-12 nm in diameter, containing fibrillins and microfibril-associated glycoproteins (MAGPs). To investigate the interaction of MAGP-1 with tropoelastin and fibrillin-1, we expressed human MAGP-1 as a T7-tag fusion protein in Escherichia coli. Refolding of the purified protein produced a soluble form of MAGP-1 that displayed saturable binding to tropoelastin. Fragments of tropoelastin corresponding to the N-terminal, C-terminal, and central regions of the molecule were used to characterize the MAGP-1 binding site. Cleavage of tropoelastin with kallikrein, which cleaves after Arg(515) in the central region of the molecule, disrupted the interaction, suggesting that the separated N- and C-terminal fragments were insufficient to determine MAGP-1 binding to intact tropoelastin. In addition, no evidence of an interaction was observed between MAGP-1 and a tropoelastin construct consisting of domains 17-27 that brackets the kallikrein cleavage site, suggesting a complex mechanism of interaction be. tween the two molecules. Binding of MAGP-1 was also tested with overlapping recombinant fibrillin-1 fragments. MAGP-1 bound to a region at the N terminus of fibrillin-1 in a calcium-dependent manner. In summary, these results suggest a model for the interaction of elastin with the microfibrillar scaffold.	Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia; Med Univ Lubeck, Dept Med Mol Biol, D-23538 Lubeck, Germany; Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia	University of Sydney; University of Lubeck; University of Adelaide	Weiss, AS (corresponding author), Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia.		Weiss, Anthony S/GYV-0157-2022; Reinhardt, Dieter P/A-3102-2008; Jensen, Sacha A./AAB-4034-2019; Weiss, Anthony S/F-8103-2010	Reinhardt, Dieter P/0000-0001-6535-9872; Jensen, Sacha A./0000-0002-0560-9531; Weiss, Anthony S/0000-0002-8106-4836				BROWN PL, 1992, BIOCHEM BIOPH RES CO, V186, P549, DOI 10.1016/S0006-291X(05)80843-5; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; FARACO J, 1995, GENOMICS, V25, P630, DOI 10.1016/0888-7543(95)80004-6; Finnis ML, 1997, J BIOL CHEM, V272, P22817, DOI 10.1074/jbc.272.36.22817; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; HINEK A, 1993, J BIOL CHEM, V268, P1405; Jensen SA, 2000, J BIOL CHEM, V275, P28449, DOI 10.1074/jbc.M004265200; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; Keene DR, 1997, J HISTOCHEM CYTOCHEM, V45, P1069, DOI 10.1177/002215549704500805; KIELTY CM, 1993, FEBS LETT, V336, P323, DOI 10.1016/0014-5793(93)80829-J; MARTIN SL, 1995, GENE, V154, P159, DOI 10.1016/0378-1119(94)00848-M; Qian RQ, 1997, BIOCHEMISTRY-US, V36, P15841, DOI 10.1021/bi971036f; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Reinhardt DP, 1997, J BIOL CHEM, V272, P7368, DOI 10.1074/jbc.272.11.7368; TOMASINIJOHANSSON BR, 1993, MATRIX, V13, P203, DOI 10.1016/S0934-8832(11)80004-1; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Trask TM, 2000, J BIOL CHEM, V275, P24400, DOI 10.1074/jbc.M003665200; URRY DW, 1983, ULTRASTRUCT PATHOL, V4, P227, DOI 10.3109/01913128309140793; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; Wu WJ, 1999, J BIOL CHEM, V274, P21719, DOI 10.1074/jbc.274.31.21719	28	109	111	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39661	39666		10.1074/jbc.M104533200	http://dx.doi.org/10.1074/jbc.M104533200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11481325	hybrid, Green Published			2022-12-25	WOS:000171789200022
J	Dankort, D; Jeyabalan, N; Jones, N; Dumont, DJ; Muller, WJ				Dankort, D; Jeyabalan, N; Jones, N; Dumont, DJ; Muller, WJ			Multiple ErbB-2/Neu phosphorylation sites mediate transformation through distinct effector proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; PHOSPHOLIPASE C-GAMMA; SIGNAL-TRANSDUCTION; DOCKING PROTEIN; BREAST-CANCER; SH2 DOMAINS; RECEPTOR; KINASE; IDENTIFICATION; AMPLIFICATION	Amplification of the type I receptor tyrosine kinase ErbB-2 (HER2/Neu) is observed in 20-30% of human mammary carcinomas, correlating with a poor clinical prognosis. We have previously demonstrated that four (Tyr(1144), Tyr(1201), (1226/1227), or Tyr(1253)) of the five known Neu/ErbB-2 autophosphorylation sites can independently mediate transforming signals. The transforming potential of at least two of these autophosphorylation sites (Tyr(1144) and Tyr(1226/1227)) has been further correlated with their ability to associate with Grb2 and Shc adapter proteins, respectively. To confirm the specificity of these interactions, we have created a series of second site mutants in these phosphorylation sites. The results showed that Grb2 recruitment to site 1144 is absolutely required for transforming signal from this autophosphorylation site, whereas association of Shc-mediated transformation is dependent on conservation of the NPXY motif spanning Tyr(1227). A stretch of amino acid identity around tyrosines 1201 (ENPEYLTP)and 1253 (ENPEYLDL) exists, and mutation of key residues within this motif reveals distinct requirements for an intact protein tyrosine-binding protein (NPXY). We show that DOK-R, a protein tyrosine-binding site-containing protein implicated in Ras signaling, interacts with Neu/ErbB-2 at Tyr1253 as do two unidentified proteins, p150 and p34, the latter correlating with transformation. Together these data argue that ErbB-2/Neu is capable of mediating transformation through distinct effector pathways.	McMaster Univ, Inst Mol Biol & Biotechnol, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Inst Mol Biol & Biotechnol, Dept Pathol, Hamilton, ON L8S 4K1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	McMaster University; McMaster University; University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Muller, WJ (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, Dept Biol, Hamilton, ON L8S 4K1, Canada.			Dankort, David/0000-0002-5862-6829				Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; MAA MC, 1994, MOL CELL BIOL, V14, P5466, DOI 10.1128/MCB.14.8.5466; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RON D, 1992, BIOTECHNIQUES, V13, P866; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SEGATTO O, 1993, ONCOGENE, V8, P2105; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Suzu S, 2000, EMBO J, V19, P5114, DOI 10.1093/emboj/19.19.5114; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; Yamanashi Y, 2000, GENE DEV, V14, P11	26	68	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38921	38928		10.1074/jbc.M106239200	http://dx.doi.org/10.1074/jbc.M106239200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11500516	hybrid			2022-12-25	WOS:000171673200078
J	Unkila, M; McColl, KS; Thomenius, MJ; Heiskanen, K; Distelhorst, CW				Unkila, M; McColl, KS; Thomenius, MJ; Heiskanen, K; Distelhorst, CW			Unreliability of the cytochrome c-enhanced green fluorescent fusion protein as a marker of cytochrome c release in cells that overexpress Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; CASPASE ACTIVATION; INTRACELLULAR CALCIUM; ISOLATED-MITOCHONDRIA; CANCER CELLS; APOPTOSIS; BAX; THAPSIGARGIN; BCL-X(L)	A cytochrome c-enhanced green fluorescent protein chimera (cyt-c.EGFP) was used to monitor the release of cytochrome c from mitochondria in Bcl-2-negative and Bcl-2-positive MDA-MB-468 breast cancer cells. A comparison was made with the intracellular distribution of endogenous cytochrome c based on Western blotting of cell fractions and immunocytochemistry. The release of endogenous cytochrome c from mitochondria into the cytoplasm was detected in Bcl-2-negative cells treated with the kinase inhibitor staurosporine or the calcium-ATPase inhibitor thapsigargin. No release of endogenous cytochrome c was evident in Bcl-2-positive cells, consistent with earlier evidence that Bcl-2 overexpression inhibits cytochrome c release from mitochondria. Cyt-c.EGFP appeared to be localized to the mitochondria in Bcl-2-negative cells and to be released into the cytoplasm following treatment with either staurosporine or thapsigargin. However, in Bcl-2-positive cells the pattern of distribution of cytochrome c-EGFP was inconsistent with that of endogenous cytochrome c, due to accumulation of both cyt-c.EGFP and free EGFP in the cytoplasm of both treated and untreated cells. In summary, cyt-c.EGFP may be useful for monitoring cytochrome c release in living cells that do not express high levels of Bcl-2 but is an unreliable marker of cytochrome c release in cells that overexpress Bcl-2.	Case Western Reserve Univ, Dept Med, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Kuopio, Dept Pharmacol & Toxicol, Kuopio 70150, Finland	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; University of Eastern Finland	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Dept Med, Div Hematol Oncol, BRB 329,10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA085804, T32CA073515, R01CA079806] Funding Source: NIH RePORTER; NCI NIH HHS [CA85804, T32-CA73515, CA79806] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bossy-Wetzel E, 2000, METHOD ENZYMOL, V322, P235; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; Brustugun OT, 1998, CELL DEATH DIFFER, V5, P660, DOI 10.1038/sj.cdd.4400399; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Carthy CM, 1999, LAB INVEST, V79, P953; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FURUYA Y, 1994, CANCER RES, V54, P6167; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Jayaraman T, 2000, J BIOL CHEM, V275, P6417, DOI 10.1074/jbc.275.9.6417; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nguyen M, 1998, J BIOL CHEM, V273, P33099, DOI 10.1074/jbc.273.50.33099; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	40	9	9	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39132	39137		10.1074/jbc.M104986200	http://dx.doi.org/10.1074/jbc.M104986200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489892	hybrid			2022-12-25	WOS:000171673200105
J	Wang, Q; Jolly, JP; Surmeier, JD; Mullah, BM; Lidow, MS; Bergson, CM; Robishaw, JD				Wang, Q; Jolly, JP; Surmeier, JD; Mullah, BM; Lidow, MS; Bergson, CM; Robishaw, JD			Differential dependence of the D-1 and D-5 dopamine receptors on the G protein gamma(7) subunit for activation of adenylylcyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DIVERSITY; GENE-EXPRESSION; BETA; NEURONS; D1; RECONSTITUTION; STIMULATION; CYCLASE; BINDING; GOLF	The D-1 dopamine receptor, G protein gamma (7) subunit, and adenylylcyclase are selectively expressed in the striatum, suggesting their potential interaction in a common signaling pathway. To evaluate this possibility, a ribozyme strategy was used to suppress the expression of the G protein gamma (7) subunit in HEK 293 cells stably expressing the human Dl dopamine receptor. Prior in vitro analysis revealed that the gamma (7) ribozyme possessed cleavage activity directed exclusively toward the gamma (7) RNA transcript (Wang, Q., Mullah, B., Hansen, C., Asundi J., and Robishaw, J. D. (1997) J. Biol. Chem. 272, 26040 -26048). In vivo analysis of cells transfected with the gamma (7) ribozyme showed a specific reduction in the expression of the gamma (7) protein. Coincident with the loss of the gamma (7) protein, there was a noticeable reduction in the expression of the beta (1) protein, confirming their interaction in these cells. Finally, functional analysis of ribozyme-mediated suppression of the beta (1) and gamma (7) proteins revealed a significant attenuation of SKF81297-stimulated adenylylcyclase activity in D-1 dopamine receptor-expressing cells. By contrast, ribozyme-mediated suppression of the beta (1) and gamma (7) proteins showed no reduction of SKF81297-stimulated adenylylcyclase activity in D-5 dopamine receptor-expressing cells. Taken together, these data indicate that the structurally related Dl and D5 dopamine receptor subtypes utilize G proteins composed of distinct beta gamma subunits to stimulate adenylylcyclase in HEK 293 cells. Underscoring the physiological relevance of these findings, single cell reverse transcriptase-polymerase chain reaction analysis revealed that the D-1 dopamine receptor and the G protein gamma (7) subunit are coordinately expressed in substance P containing neurons in rat striatum, suggesting that the G protein gamma (7) subunit may be a new target for drugs to selectively alter dopaminergic signaling within the brain.	Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, Danville, PA 17822 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Northwestern Univ, Sch Med, Dept Physiol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Inst Neurosci, Chicago, IL 60611 USA; Appl Biosyst Inc, Foster City, CA 94404 USA; Univ Maryland, Dept Oral & Craniofacial Biol Sci, Baltimore, MD 21201 USA	University of Michigan System; University of Michigan; University System of Georgia; Augusta University; Northwestern University; Northwestern University; Thermo Fisher Scientific; Applied Biosystems; University System of Maryland; University of Maryland Baltimore	Robishaw, JD (corresponding author), Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, Danville, PA 17822 USA.				NIGMS NIH HHS [GM58191] Funding Source: Medline; NIMH NIH HHS [MH56608, P50 MH068789] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH056608, P50MH068789] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARNT J, 1992, EUR J PHARMACOL, V213, P259, DOI 10.1016/0014-2999(92)90690-6; Balcueva EA, 2000, EXP CELL RES, V257, P310, DOI 10.1006/excr.2000.4893; Bergson C, 1995, J NEUROSCI, V15, P7821; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Figler RA, 1996, MOL PHARMACOL, V50, P1587; FREMEAU RT, 1991, P NATL ACAD SCI USA, V88, P3772, DOI 10.1073/pnas.88.9.3772; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GRANDY DK, 1991, P NATL ACAD SCI USA, V88, P9175, DOI 10.1073/pnas.88.20.9175; HERVE D, 1993, J NEUROSCI, V13, P2237, DOI 10.1523/jneurosci.13-05-02237.1993; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KIMURA K, 1995, J BIOL CHEM, V270, P14672, DOI 10.1074/jbc.270.24.14672; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; LEMOINE C, 1995, J COMP NEUROL, V355, P418, DOI 10.1002/cne.903550308; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; McWhinney C, 2000, J BIOL CHEM, V275, P2087, DOI 10.1074/jbc.275.3.2087; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; ODOWD BF, 1993, J NEUROCHEM, V60, P804, DOI 10.1111/j.1471-4159.1993.tb03224.x; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; Ray K, 1996, TRENDS CARDIOVAS MED, V6, P115, DOI 10.1016/1050-1738(96)00021-7; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; ROBISHAW JD, 1994, METHOD ENZYMOL, V237, P498; Robishaw JD, 2002, METHOD ENZYMOL, V344, P435; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEEMAN P, 1987, SYNAPSE, V1, P133, DOI 10.1002/syn.890010203; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; Taylor JM, 1996, J BIOL CHEM, V271, P3336; TIBERI M, 1994, J BIOL CHEM, V269, P27925; Tkatch T, 1998, NEUROREPORT, V9, P1935, DOI 10.1097/00001756-199806220-00004; Wang Q, 1999, J BIOL CHEM, V274, P17365, DOI 10.1074/jbc.274.24.17365; Wang Q, 1997, J BIOL CHEM, V272, P26040, DOI 10.1074/jbc.272.41.26040; WATSON JB, 1994, J NEUROSCI RES, V39, P108, DOI 10.1002/jnr.490390113; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0; Zhuang XX, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-16-j0001.2000	44	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39386	39393		10.1074/jbc.M104981200	http://dx.doi.org/10.1074/jbc.M104981200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11500503	hybrid			2022-12-25	WOS:000171673200138
J	Ramakrishnan, B; Shah, PS; Qasba, PK				Ramakrishnan, B; Shah, PS; Qasba, PK			alpha-Lactalbumin (LA) stimulates milk beta-1,4-galactosyltransferase I (beta 4Gal-T1) to transfer glucose from UDP-glucose to N-acetylglucosamine - Crystal structure of beta 4Gal-T1-LA complex with UDP-Glc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-4-GALACTOSYLTRANSFERASE GENE FAMILY; GALACTOSYL TRANSFERASE; ESCHERICHIA-COLI; CLONING; EXPRESSION; CDNA; GALACTOSYLTRANSFERASE; PROTEIN; MEMBER; SITE	beta -1,4-Galactosyltransferase 1 (Gal-T1) transfers galactose (Gal) from UDP-Gal to N-acetylglucosamine (Glc-NAc), which constitutes its normal galactosyltransferase (Gal-T) activity. In the presence of alpha -lactalbumin (IA), it transfers Gal to Glc, which is its lactose synthase (LS) activity. It also transfers glucose (Glc) from UDP-Glc to GlcNAc, constituting the glucosyltransferase (Glc-T) activity, albeit at an efficiency of only 0.3-0.4% of Gal-T activity. In the present study, we show that LA increases this activity almost 30-fold. It also enhances the Glc-T activity toward various N-acyl substituted glucosamine acceptors. Steady state kinetic studies of Glc-T reaction show that the K-m for the donor and acceptor substrates are high in the absence of LA. In the presence of LA, the K-m for the acceptor substrate is reduced 30-fold, whereas for UDP-Glc it is reduced only 5-fold. In order to understand this property, we have determined the crystal structures of the Gal-TI-IA complex with UDP-Glc.Mn2+ and with N-butanoyl-glucosamine (N-butanoyl-GlcN), a preferred sugar acceptor in the Glc-T activity. The crystal structures reveal that although the binding of UDP-Glc is quite similar to UDP-Gal, there are few significant differences observed in the hydrogen bonding interactions between UDP-Glc and Gal-T1. Based on the present kinetic and crystal structural studies, a possible explanation for the role of LA in the Glc-T activity has been proposed.	NCI, Struct Glycobiol Sect, LECB, CCR,NIH, Ft Detrick, MD 21702 USA; NCI, Intramural Res Support Program, SAIC, Lab Expt & Computat Biol,Ctr Canc Res,NIH, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Qasba, PK (corresponding author), NCI, Struct Glycobiol Sect, LECB, CCR,NIH, Bldg 469,Rm 221, Ft Detrick, MD 21702 USA.				OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; ANDREE PJ, 1978, BIOCHIM BIOPHYS ACTA, V544, P489; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERLINER LJ, 1984, MOL CELL BIOCHEM, V62, P37, DOI 10.1007/BF00230075; BOEGGEMAN EE, 1993, PROTEIN ENG, V6, P779, DOI 10.1093/protein/6.7.779; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLYMER DJ, 1976, BIOCHEMISTRY-US, V15, P1093, DOI 10.1021/bi00650a022; DO KY, 1995, J BIOL CHEM, V270, P18447, DOI 10.1074/jbc.270.31.18447; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; GEREN CR, 1975, BIOCHEMISTRY-US, V14, P1461, DOI 10.1021/bi00678a017; HILL R, 1979, UCLA FORUM MED SCI, V21, P63; KARULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; KHATRA BS, 1974, EUR J BIOCHEM, V44, P537, DOI 10.1111/j.1432-1033.1974.tb03513.x; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; Navaza J, 1994, ACTA CRYSTALLOGR D, V50, P760; NOEL JP, 1991, BIOCHEMISTRY-US, V30, P11801, DOI 10.1021/bi00115a010; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205; Qasba PK, 1997, CRIT REV BIOCHEM MOL, V32, P255, DOI 10.3109/10409239709082574; QASBA PK, 1978, J BIOL CHEM, V253, P1167; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; Sato T, 1998, BIOCHEM BIOPH RES CO, V244, P637, DOI 10.1006/bbrc.1998.8327; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; Sprong H, 1998, J BIOL CHEM, V273, P25880, DOI 10.1074/jbc.273.40.25880; Takayama S, 1999, BIOORGAN MED CHEM, V7, P401, DOI 10.1016/S0968-0896(98)00249-1; WANG M, 1989, J BIOL CHEM, V264, P21116; YADAV SP, 1991, J BIOL CHEM, V266, P698; Yen TY, 2000, J MASS SPECTROM, V35, P990, DOI 10.1002/1096-9888(200008)35:8<990::AID-JMS27>3.0.CO;2-K; Zhang YN, 1999, GLYCOBIOLOGY, V9, P815, DOI 10.1093/glycob/9.8.815	34	97	109	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37665	37671		10.1074/jbc.M102458200	http://dx.doi.org/10.1074/jbc.M102458200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11485999	Green Accepted, hybrid			2022-12-25	WOS:000171375700104
J	Wang, L; Liu, F; Adamo, ML				Wang, L; Liu, F; Adamo, ML			Cyclic AMP inhibits extracellular signal-regulated kinase and phosphatidylinositol 3-kinase/Akt pathways by inhibiting Rap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; CELL-CYCLE; B-RAF; MAP KINASE; CAMP; PROLIFERATION; EXPRESSION; DIFFERENTIATION; ADENOSINE-3',5'-MONOPHOSPHATE	Cyclic AMP inhibited both ERK and Akt activities in rat C6 glioma cells. A constitutively active form of phosphatidylinositol 3-kinase (PI3K) prevented cAMP from inhibiting Akt, suggesting that the inactivation of Akt by cAMP is a consequence of PI3K inhibition. Neither protein kinase A nor Epac (Exchange protein directly activated by cAMP), two known direct effectors of cAMP, mediated the cAMP-induced inhibition of ERK and Akt phosphorylation. Cyclic AMP inhibited Rap1 activation in C6 cells. Moreover, inhibition of Rap1 by a Rap1 GTPase-activating protein-1 also resulted in a decrease in ERK and Akt phosphorylation, which was not further decreased by cAMP, suggesting that cAMP inhibits ERK and Akt by inhibiting Rap1. The role of Rap1 in ERK and Akt activity was further demonstrated by our observation that an active form of Epac, which activated Rap1 in the absence of cAMP, increased ERK and Akt phosphorylation. Inhibition of ERK and/or PI3K pathways mediated the inhibitory effects of cAMP on insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 gene expression. Moreover, cAMP, as well as ERK and PI3K inhibitors produced equivalent stimulation and inhibition, respectively, of p27(Kip1) and cyclin D2 protein levels, potentially explaining the observation that cAMP prevented C6 cells from entering S phase.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Adamo, ML (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, Mail Code 7760,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047357, R55DK047357, R01DK056166] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47357, DK-56166] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO ML, 1993, HDB ENDOCRINE RES TE, P421; Barth RF, 1998, J NEURO-ONCOL, V36, P91, DOI 10.1023/A:1005805203044; BEEBE SJ, 1994, SEMIN CANCER BIOL, V5, P285; BLOMHOFF HK, 1988, J CELL PHYSIOL, V137, P583, DOI 10.1002/jcp.1041370327; Carey KD, 2000, MOL CELL BIOL, V20, P8409, DOI 10.1128/MCB.20.22.8409-8419.2000; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HOLLENBERG MD, 1973, P NATL ACAD SCI USA, V70, P2964, DOI 10.1073/pnas.70.10.2964; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kawada N, 1999, J HEPATOL, V30, P1057, DOI 10.1016/S0168-8278(99)80260-8; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kurino M, 1996, J NEUROCHEM, V67, P2246; LUKAS J, 1995, ONCOGENE, V10, P2125; Mark MD, 1997, J BIOL CHEM, V272, P17238, DOI 10.1074/jbc.272.27.17238; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Mizumatsu S, 1999, CLIN CANCER RES, V5, P551; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Mumberg D, 1997, NUCLEIC ACIDS RES, V25, P2098, DOI 10.1093/nar/25.11.2098; NILSSON J, 1984, ATHEROSCLEROSIS, V53, P77, DOI 10.1016/0021-9150(84)90107-2; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Piva R, 1997, NEUROSCI LETT, V234, P127, DOI 10.1016/S0304-3940(97)00688-5; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang L, 2001, ENDOCRINOLOGY, V142, P3041, DOI 10.1210/en.142.7.3041; Wang L, 2001, ENDOCRINOLOGY, V142, P3917, DOI 10.1210/en.142.9.3917; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	48	96	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37242	37249		10.1074/jbc.M105089200	http://dx.doi.org/10.1074/jbc.M105089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479306	hybrid			2022-12-25	WOS:000171375700052
J	Ishiguro, H; Yoshida, H; Major, AS; Zhu, TL; Babaev, VR; Linton, MF; Fazio, S				Ishiguro, H; Yoshida, H; Major, AS; Zhu, TL; Babaev, VR; Linton, MF; Fazio, S			Retrovirus-mediated expression of apolipoprotein A-I in the macrophage protects against atherosclerosis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; BINDING CASSETTE TRANSPORTER-1; APOE-DEFICIENT MICE; TANGIER-DISEASE; GENE-EXPRESSION; TRANSGENIC MICE; BONE-MARROW; CHOLESTEROL; PLASMA; MOUSE	We have previously reported that the lack of apolipoprotein (apo) E expression by macrophages promotes foam cell formation in vivo. Because transgenic mice overexpressing human apoA-I from the liver (h-apoA-I TgN) are protected from the atherogenesis induced by apoE deficiency, we hypothesized that the presence of apoA-I in the vessel wall could reduce the negative effect of apoE deficiency on lesion growth. To address this issue, we used both retroviral transduction and transgenic approaches to produce in vivo systems where apoA-I is expressed from macrophages. In the retroviral transduction study, apoA-I-deficient (apoA-I-/-) mice reconstituted with apoE-deficient (apoE(-/-)) bone marrow cells that were infected with a retroviral vector expressing human apoA-I (MFG-HAI) had 95% lower atherosclerotic lesion area than that of recipients of apoE(-/-) bone marrow cells infected with the parental virus (MFG). To determine whether the protective effect of locally produced apoA-I was due to the lack of systemic apoA-I, we conducted a different experiment using h-apoA-I TgN mice as recipients of apoE(-/-) bone marrow with or without human apoA-I (driven by a macrophage-specific transgene defined as m phi -AI). Aortic lesion area in apoE(-/-)/m phi -Al --> h-apoA-I TgN mice was decreased by 85% compared with apoE(-/-) --> h-apoA-I TgN mice. These data demonstrate that expression of apoA-I from macrophages protects against atherogenesis without affecting plasma apoA-I and high density lipoprotein cholesterol levels.	Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Fazio, S (corresponding author), Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, Dept Med, 315 Med Res Bldg 2, Nashville, TN 37232 USA.			Ishiguro, Hiroyuki/0000-0003-4766-7139	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053989, R01HL065709, R01HL057986] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53989, HL57986, HL65709] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU SK, 1982, J BIOL CHEM, V257, P9788; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; Benoit P, 1999, CIRCULATION, V99, P105, DOI 10.1161/01.CIR.99.1.105; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Boisvert WA, 1999, ARTERIOSCL THROM VAS, V19, P525, DOI 10.1161/01.ATV.19.3.525; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; COHN ZA, 1965, J EXP MED, V121, P153, DOI 10.1084/jem.121.1.153; CORTI MC, 1995, JAMA-J AM MED ASSOC, V274, P539, DOI 10.1001/jama.274.7.539; DUVERGER N, 1993, BIOCHEMISTRY-US, V32, P12372, DOI 10.1021/bi00097a014; Duverger N, 1996, CIRCULATION, V94, P713, DOI 10.1161/01.CIR.94.4.713; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; FIELDING CJ, 1995, J LIPID RES, V36, P211; GELMAN BB, 1991, J NEUROPATH EXP NEUR, V50, P383, DOI 10.1097/00005072-199107000-00001; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Hasty AH, 1999, CIRCULATION, V99, P2571, DOI 10.1161/01.CIR.99.19.2571; HORVAI A, 1995, P NATL ACAD SCI USA, V92, P5391, DOI 10.1073/pnas.92.12.5391; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; NEARY RH, 1987, CLIN CHEM, V33, P1163; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHAEFER EJ, 1982, ARTERIOSCLEROSIS, V2, P16, DOI 10.1161/01.ATV.2.1.16; Tangirala RK, 1999, CIRCULATION, V100, P1816, DOI 10.1161/01.CIR.100.17.1816; Van Eck M, 2000, ATHEROSCLEROSIS, V150, P71, DOI 10.1016/S0021-9150(99)00372-X; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; YlaHerttuala S, 1996, ANN MED, V28, P89, DOI 10.3109/07853899609092931; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; Zhu YH, 1998, P NATL ACAD SCI USA, V95, P7585, DOI 10.1073/pnas.95.13.7585	32	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36742	36748		10.1074/jbc.M106027200	http://dx.doi.org/10.1074/jbc.M106027200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477092	hybrid			2022-12-25	WOS:000171194500091
J	Kaczynski, J; Zhang, JS; Ellenrieder, V; Conley, A; Duenes, T; Kester, H; van der Burg, B; Urrutia, R				Kaczynski, J; Zhang, JS; Ellenrieder, V; Conley, A; Duenes, T; Kester, H; van der Burg, B; Urrutia, R			The Sp1-like protein BTEB3 inhibits transcription via the basic transcription element box by interacting with mSin3A and HDAC-1 co-repressors and competing with Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; COFACTOR COMPLEX CRSP; CELL-CYCLE REGULATION; BINDING-PROTEIN; HISTONE DEACETYLASES; PROMOTER REGION; FACTOR EKLF; GENE; FINGER; CLONING	Sp1-like proteins are characterized by three conserved C-terminal zinc finger motifs that bind GC-rich sequences found in promoters of numerous genes essential for mammalian cell homeostasis. These proteins behave as transcriptional activators or repressors. Although significant information has been reported on the molecular mechanisms by which Sp1-like activators function, relatively little is known about mechanisms for repressor proteins. Here we report the functional characterization of BTEB3, a ubiquitously expressed Spl-like transcriptional repressor. GAL4 assays show that the N terminus of BTEB3 contains regions that can act as direct repressor domains. Immunoprecipitation assays reveal that BTEB3 interacts with the co-repressor mSin3A and the histone deacetylase protein HDAC-1. Gel shift assays demonstrate that BTEB3 specifically binds the BTE site, a well characterized GC-rich DNA element, with an affinity similar to that of Sp1. Reporter and gel shift assays in Chinese hamster ovary cells show that BTEB3 can also mediate repression by competing with Sp1 for BTE binding. Thus, the characterization of this protein expands the repertoire of BTEB-like members of the Sp1 family involved in transcriptional repression. Furthermore, our results suggest a mechanism of repression for BTEB3 involving direct repression by the N terminus via interaction with mSin3A and HDAC-1 and competition with Sp1 via the DNA-binding domain.	Mayo Clin, Gastroenterol Res Unit, Rochester, MN 55901 USA; Mayo Clin, Tumor Biol Program, Rochester, MN 55901 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55901 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Royal Netherlands Acad Arts & Sci, Netherlands Inst Dev Biol, NL-3584 Utrecht, Netherlands; Univ Calif San Diego, Dept Biol, La Jolla, CA 92039 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Diego	Urrutia, R (corresponding author), St Marys Hosp, Mayo Clin, GI Res Unit, Rochester, MN 55905 USA.			Gibson, Joanna/0000-0003-0406-4872	NIDDK NIH HHS [DK52913, R01 DK052913, R01 DK052913-06] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052913, R01DK052913] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asano H, 1999, MOL CELL BIOL, V19, P3571; Asano H, 2000, BLOOD, V95, P3578, DOI 10.1182/blood.V95.11.3578.011k48_3578_3584; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; BIRNBAUM MJ, 1995, BIOCHEMISTRY-US, V34, P7648, DOI 10.1021/bi00023a011; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500; Cook T, 1998, J BIOL CHEM, V273, P25929, DOI 10.1074/jbc.273.40.25929; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Denver RJ, 1999, J BIOL CHEM, V274, P23128, DOI 10.1074/jbc.274.33.23128; ElRouby S, 1996, ONCOGENE, V13, P2623; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; Gebelein B, 1998, J CLIN INVEST, V102, P1911, DOI 10.1172/JCI1919; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Imhof A, 1999, MOL CELL BIOL, V19, P194; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KOBAYASHI A, 1995, J BIOCHEM-TOKYO, V117, P91, DOI 10.1093/oxfordjournals.jbchem.a124727; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Martin KM, 2000, BIOCHEM J, V345, P529, DOI 10.1042/0264-6021:3450529; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Muller C, 1999, J BIOL CHEM, V274, P11220, DOI 10.1074/jbc.274.16.11220; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Perkins A, 1999, INT J BIOCHEM CELL B, V31, P1175, DOI 10.1016/S1357-2725(99)00083-7; PERKINS AC, 1995, NATURE, V375, P318; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Ryu SJ, 1999, P NATL ACAD SCI USA, V96, P7137, DOI 10.1073/pnas.96.13.7137; Scohy S, 2000, GENOMICS, V70, P93, DOI 10.1006/geno.2000.6362; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SOGAWA K, 1993, J BIOCHEM, V114, P605, DOI 10.1093/oxfordjournals.jbchem.a124224; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Song A, 1999, IMMUNITY, V10, P93, DOI 10.1016/S1074-7613(00)80010-2; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	50	72	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36749	36756		10.1074/jbc.M105831200	http://dx.doi.org/10.1074/jbc.M105831200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477107	hybrid			2022-12-25	WOS:000171194500092
J	Matthews, CP; Shera, K; Kiviat, N; McDougall, JK				Matthews, CP; Shera, K; Kiviat, N; McDougall, JK			Expression of truncated FHIT transcripts in cervical cancers and in normal human cells	ONCOGENE			English	Article						cervical carcinoma; FHIT; alternative transcripts	TUMOR-SUPPRESSOR GENE; SPLICE-SITE SELECTION; FREQUENT ALLELIC LOSS; MESSENGER-RNA; CHROMOSOME 3P; HUMAN HOMOLOG; UPF1 PROTEIN; CARCINOMA; TUMORIGENICITY; ABNORMALITIES	To analyse FHIT transcription patterns in cervical cancer, a series of primary cervical tumors and normal control samples were studied using RT - PCR. Full length and truncated FHIT transcripts were detectable in all samples tested. Interestingly, the expression of truncated FHIT transcripts by primary epithelial cells in vitro was associated with confluency. The breakpoints of most transcript deletions coincided with genuine splice site sequences, suggesting that they resulted from alternative splicing. These findings demonstrate that truncated FHIT transcripts are commonly detected in both normal and tumor tissues, and suggest that these altered transcripts are not causally related to tumorigenesis in cervical cancer.	Fred Hutchinson Canc Res Ctr, Canc Biol Program, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Matthews, CP (corresponding author), Fred Hutchinson Canc Res Ctr, Canc Biol Program, 1100 Fairview Ave N,POB 19024, Seattle, WA 98109 USA.				NCI NIH HHS [CA42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Applequist SE, 1997, NUCLEIC ACIDS RES, V25, P814, DOI 10.1093/nar/25.4.814; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; Chaudhuri AR, 1999, J BIOL CHEM, V274, P24378, DOI 10.1074/jbc.274.34.24378; Chu TY, 1998, INT J CANCER, V75, P199, DOI 10.1002/(SICI)1097-0215(19980119)75:2<199::AID-IJC6>3.0.CO;2-P; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; Druck T, 1997, CANCER RES, V57, P504; Druck T, 1998, ONCOL RES, V10, P341; Ferrer M, 1999, MOL CARCINOGEN, V25, P55, DOI 10.1002/(SICI)1098-2744(199905)25:1<55::AID-MC7>3.0.CO;2-3; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ji L, 1999, CANCER RES, V59, P3333; Julicher K, 1999, J NATL CANCER I, V91, P1563, DOI 10.1093/jnci/91.18.1563; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KOHNO T, 1993, ONCOGENE, V8, P1825; Larson AA, 1997, CANCER RES, V57, P4082; Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Mao L, 1998, J NATL CANCER I, V90, P412, DOI 10.1093/jnci/90.6.412; Mao L, 1996, CANCER RES, V56, P5128; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; MATTHEWS CP, 2000, THESIS U WASHINGTON; MITRA AB, 1994, CANCER RES, V54, P4481; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; Panagopoulos I, 1997, GENE CHROMOSOME CANC, V19, P215, DOI 10.1002/(SICI)1098-2264(199708)19:4<215::AID-GCC2>3.0.CO;2-#; Rader JS, 1998, GENE CHROMOSOME CANC, V22, P57, DOI 10.1002/(SICI)1098-2264(199805)22:1<57::AID-GCC8>3.0.CO;2-6; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; Sambrook J., 2002, MOL CLONING LAB MANU; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Segawa T, 1999, CANCER, V85, P2001, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2001::AID-CNCR18>3.0.CO;2-R; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sun XL, 1998, P NATL ACAD SCI USA, V95, P10009, DOI 10.1073/pnas.95.17.10009; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P220, DOI 10.1002/(SICI)1098-2264(199708)19:4<220::AID-GCC3>3.0.CO;2-Z; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Wang NM, 1999, INT J MOL MED, V3, P491; WHITE RA, 1990, CYTOMETRY, V11, P314, DOI 10.1002/cyto.990110214; Wistuba II, 1997, CANCER RES, V57, P3154; Wu R, 2000, J NATL CANCER I, V92, P338, DOI 10.1093/jnci/92.4.338; YOKOTA J, 1989, CANCER RES, V49, P3598; Zimonjic DB, 1997, CANCER RES, V57, P1166	47	10	15	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4665	4675		10.1038/sj.onc.1204622	http://dx.doi.org/10.1038/sj.onc.1204622			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498789				2022-12-25	WOS:000170208600007
J	Yin, XY; Landay, MF; Han, WP; Levitan, ES; Watkins, SC; Levenson, RM; Farkas, DL; Prochownik, EV				Yin, XY; Landay, MF; Han, WP; Levitan, ES; Watkins, SC; Levenson, RM; Farkas, DL; Prochownik, EV			Dynamic in vivo interactions among Myc network members	ONCOGENE			English	Article						Max; Mad Mxi1; green fluorescent protein (GFP); SC-35; transcription	RNA-POLYMERASE-II; C-MYC; DNA-BINDING; TRANSCRIPTIONAL REPRESSORS; HISTONE DEACETYLASE; LEUCINE-ZIPPER; LARGE SUBUNIT; CELL-GROWTH; MAD FAMILY; N-COR	Members of the Myc oncoprotein network (c-Myc, Max, and Mad) play important roles in proliferation, differentiation, and apoptosis. We expressed chimeric green fluorescent protein (GF-P) fusions of c-Myc,. Max, and three Mad proteins in fibroblasts.. Individually, c-Myc and Mad proteins localized in subnuclear speckles, whereas Max assumed a homogeneous nuclear pattern. These distributions were co-dominant and dynamic, however, as each protein assumed the pattern of its heterodimeric partner when the latter was co-expressed at a higher level. Deletion mapping of two Mad members, Mad1 and Mxi1, demonstrated that the domains responsible for nuclear localization and speckling are separable. A non-speckling Mxi1 mutant was also less effective as a transcriptional repressor than wild-type Mxi1. c-Myc nuclear speckles were distinct from SC-35 domains involved in mRNA processing. However, in the presence of co-expressed Max, c-Myc, but not Mad, co-localized to a subset of SC-35 loci. These results show that Myc network proteins comprise dynamic subnuclear structures and behave co-dominantly when co-expressed with their normal heterodimerization partners. In addition, c-Myc-Max heterodimers, but not Max-Mad heterodimers, localize to foci actively engaged in pre-mRNA transcription/processing. These findings suggest novel means by which Myc network members promote transcriptional activation or repression.	Childrens Hosp Pittsburgh, Dept Pediat, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Ctr Light Microscope Imaging & Biotechnol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, Hematol Oncol Sect, 3705 5th Ave, Pittsburgh, PA 15213 USA.	edward_prochownik@poplar.chp.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NATIONAL CANCER INSTITUTE [R01CA078259] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78259] Funding Source: Medline; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; Cardoso MC, 1997, J CELL BIOL, V139, P579, DOI 10.1083/jcb.139.3.579; Cardoso MC, 1998, J CELL BIOCHEM, V70, P222, DOI 10.1002/(SICI)1097-4644(19980801)70:2<222::AID-JCB8>3.0.CO;2-Q; Chen YM, 1996, CANCER RES, V56, P3168; Clemson CM, 1996, J CELL BIOCHEM, V62, P181, DOI 10.1002/(SICI)1097-4644(199608)62:2<181::AID-JCB6>3.0.CO;2-O; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; LARSSON LG, 1994, ONCOGENE, V9, P1247; Leonhardt H, 1995, INT REV CYTOL, V162B, P303; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MOEN PT, 1995, HUM MOL GENET, V4, P1779, DOI 10.1093/hmg/4.suppl_1.1779; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; RABBITS PH, 1985, NATURE, V314, P363; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHULMAN IG, 1977, LEUKEMIA S, V3, P376; Smith KP, 1999, J CELL BIOL, V144, P617, DOI 10.1083/jcb.144.4.617; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1987, ONCOGENE, V1, P5; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635; Yin XY, 1999, ONCOGENE, V18, P6621, DOI 10.1038/sj.onc.1203097; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	67	29	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4650	4664		10.1038/sj.onc.1204606	http://dx.doi.org/10.1038/sj.onc.1204606			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498788				2022-12-25	WOS:000170208600006
J	Del Bello, B; Valentini, MA; Zunino, F; Comporti, M; Maellaro, E				Del Bello, B; Valentini, MA; Zunino, F; Comporti, M; Maellaro, E			Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells	ONCOGENE			English	Article						Bcl-2 cleavage; hydrogen peroxide; cisplatin; apoptosis; melanoma cells	MALIGNANT-MELANOMA; PROTEIN EXPRESSION; DEATH; INHIBITION; RELEASE; FAMILY; BAX	Although the anti-apoptotic effect of Bcl-2 is well established, the role of Bcl-2 in tumour response to therapy and drug resistance is still unclear. The posttranslational modifications of Bcl-2 are likely involved in the control of the apoptotic pathway. In the present study we have investigated the role of Bcl-2 in cellular response to oxidative stress (hydrogen peroxide) and cisplatin using a clone of human metastatic melanoma, which, in spite of Bcl-2 (over)expression, exhibited a moderate chemosensitivity. With both treatments melanoma cells died through an apoptotic process, associated with detachment of cells from the monolayer. In the floating apoptotic cells generated by either hydrogen peroxide or cisplatin, along with morphological and biochemical features of apoptosis, we detected a significant Bcl-2 cleavage, yielding the Bax-like fragment of 23 kDa. Preincubation of cells with the caspase-3/-7 inhibitor DEVD-CHO completely suppressed Bcl-2 cleavage, thus confirming that such a specific proteolysis requires activation of caspase-3/-7. The oxidant- and cisplatin-induced processing of Bcl-2 documented in the present study may represent a regulatory mechanism to circumvent the survival function of Bcl-2 upon apoptosis triggering and to enhance apoptotic response. Since the Bcl-2 cleavage should be regarded as a pro-apoptotic event, Bcl-2 expression is expected to increase susceptibility to apoptosis. Thus, such a pathway could be exploited to improve the efficacy of cytotoxic therapy of melanomas expressing Bcl-2.	Univ Siena, Dept Pathophysiol & Expt Med, I-53100 Siena, Italy; Ist Nazl Tumori, I-20133 Milan, Italy	University of Siena; Fondazione IRCCS Istituto Nazionale Tumori Milan	Maellaro, E (corresponding author), Univ Siena, Dept Pathophysiol & Expt Med, Via A Moro, I-53100 Siena, Italy.	maellaro@unisi.it						Beale PJ, 2000, BRIT J CANCER, V82, P436; Brockhaus F, 1998, EXP CELL RES, V238, P33, DOI 10.1006/excr.1997.3778; CERRONI L, 1995, AM J DERMATOPATH, V17, P7, DOI 10.1097/00000372-199502000-00002; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHU G, 1994, J BIOL CHEM, V269, P787; Del Bello B, 1999, FASEB J, V13, P69; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Maellaro E, 2000, J CELL SCI, V113, P2671; Marin MC, 1996, ONCOGENE, V12, P2259; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Reed JC, 1997, APOPTOSIS AND CANCER, P64; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rigel DS, 1996, J AM ACAD DERMATOL, V35, P1012, DOI 10.1016/S0190-9622(96)90139-5; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; Serrone L, 1999, MELANOMA RES, V9, P51, DOI 10.1097/00008390-199902000-00007; Tang LR, 1998, CLIN CANCER RES, V4, P1865; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRON VA, 1995, AM J PATHOL, V146, P643; VANDENOORD JJ, 1994, AM J PATHOL, V145, P294; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Yamamoto AM, 1998, LEUKEMIA, V12, P1467, DOI 10.1038/sj.leu.2401132; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	32	47	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4591	4595		10.1038/sj.onc.1204618	http://dx.doi.org/10.1038/sj.onc.1204618			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494156				2022-12-25	WOS:000170074900018
J	Hislop, JN; Everest, HM; Flynn, A; Harding, T; Uney, JB; Troskie, BE; Millar, RP; McArdle, CA				Hislop, JN; Everest, HM; Flynn, A; Harding, T; Uney, JB; Troskie, BE; Millar, RP; McArdle, CA			Differential internalization of mammalian and non-mammalian gonadotropin-releasing hormone receptors - Uncoupling of dynamin-dependent internalization from mitogen-activated protein kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; COUPLED RECEPTORS; TYROSINE KINASE; BETA-ARRESTIN; ACUTE DESENSITIZATION; MEDIATED ENDOCYTOSIS; C-SRC; CLATHRIN; CELLS; PITUITARY	Desensitization and internalization of G-protein-coupled receptors can reflect receptor phosphorylation-dependent binding of beta -arrestin, which prevents G-protein activation and targets receptors for internalization via clathrin-coated vesicles. These can be pinched off by a dynamin collar, and proteins controlling receptor internalization can also mediate mitogen-activated protein kinase signaling. Gonadotropin-releasing hormone (GnRH) stimulates internalization of its receptors via clathrin-coated vesicles. Mammalian GnRH receptors (GnRH-Rs) are unique in that they lack C-terminal tails and do not rapidly desensitize, whereas non-mammalian GnRH-R have C-terminal tails and, where investigated, do rapidly desensitize and internalize. Using recombinant adenovirus expressing human and Xenopus GnRH-Rs we have explored the relationship between receptor internalization and mitogen-activated protein kinase signaling in HeLa cells with regulated tetracycline-controlled expression of wild-type or a dominant negative mutant (K44A) of dynamin. These receptors were phospholipase C-coupled and had appropriate ligand affinity and specificity. K44A dynamin expression did not alter human GnRH-R internalization but dramatically reduced internalization of Xenopus GnRH-R (and epidermal growth factor (EGF) receptor). Blockade of clathrin-mediated internalization (sucrose) abolished internalization of all three receptors. Both GnRH-Rs also mediated phosphorylation of ERK 2 and for both receptors, this was inhibited by K44A dynamin. The same was true for EGF- and protein kinase C-mediated ERK 2 phosphorylation. ERK 2 phosphorylation was also inhibited by a protein kinase C inhibitor but not affected by an EGF receptor tyrosine kinase inhibitor. We conclude that a) desensitizing and non-desensitizing GnRH-Rs are targeted for clathrin-coated vesicle-mediated internalization by functionally distinct mechanisms, b) GnRII-R signaling to ERK 2 is dynamin-dependent and c) this does not reflect a dependence on dynamin-dependent GnRH-R internalization.	Univ Bristol, Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England; MRC, Human Reprod Sci Unit, Edinburgh EH3 9ET, Midlothian, Scotland; Univ Cape Town, Dept Biochem Med, ZA-7925 Observatory, South Africa	University of Bristol; University of Cape Town	McArdle, CA (corresponding author), Univ Bristol, Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England.	craig.mcardle@bris.ac.uk	McArdle, Craig/AAQ-5660-2021; Millar, Robert P/A-4853-2012	McArdle, Craig/0000-0003-4836-5351; Millar, Robert P/0000-0003-3606-2708				Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; Blomenrohr M, 1999, MOL PHARMACOL, V56, P1229, DOI 10.1124/mol.56.6.1229; Bremnes T, 2000, J BIOL CHEM, V275, P17596, DOI 10.1074/jbc.M000142200; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; CLAYTON RN, 1980, ENDOCRINOLOGY, V107, P699, DOI 10.1210/endo-107-3-699; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAVIDSON JS, 1994, BIOCHEM J, V300, P299, DOI 10.1042/bj3000299; FASANO S, 1990, BIOCHEM BIOPH RES CO, V168, P923, DOI 10.1016/0006-291X(90)91117-B; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; GUTKIND JS, 2000, SCI SIGNAL TRANSDUCT; Heding A, 1998, J BIOL CHEM, V273, P11472, DOI 10.1074/jbc.273.19.11472; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hislop JN, 2000, ENDOCRINOLOGY, V141, P4564, DOI 10.1210/en.141.12.4564; JENNES L, 1983, ENDOCRINOLOGY, V113, P1683, DOI 10.1210/endo-113-5-1683; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Lee KB, 2000, J BIOL CHEM, V275, P9284, DOI 10.1074/jbc.275.13.9284; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; LI GP, 1993, J BIOL CHEM, V268, P24475; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; McArdle CA, 1996, J BIOL CHEM, V271, P23711, DOI 10.1074/jbc.271.39.23711; McArdle CA, 1999, MOL CELL ENDOCRINOL, V151, P129, DOI 10.1016/S0303-7207(99)00024-6; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Pawson AJ, 1998, J ENDOCRINOL, V156, pR9, DOI 10.1677/joe.0.156R009; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Roseberry AG, 2001, J CELL SCI, V114, P739; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Willars GB, 1999, J BIOL CHEM, V274, P30146, DOI 10.1074/jbc.274.42.30146; Willars GB, 1998, BIOCHEM J, V333, P301, DOI 10.1042/bj3330301	43	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39685	39694		10.1074/jbc.M104542200	http://dx.doi.org/10.1074/jbc.M104542200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11495905	hybrid			2022-12-25	WOS:000171789200025
J	Ko, YG; Kang, YS; Park, H; Seol, W; Kim, J; Kim, T; Park, HS; Choi, EJ; Kim, S				Ko, YG; Kang, YS; Park, H; Seol, W; Kim, J; Kim, T; Park, HS; Choi, EJ; Kim, S			Apoptosis signal-regulating kinase 1 controls the proapoptotic function of death-associated protein (Daxx) in the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASE; CYTOCHROME-C; INTERACTING PROTEIN; BINDING PROTEIN; 1 ASK1; ACTIVATION; REQUIREMENT; INHIBITION; PML; JNK	Although Daxx (death-associated protein) was first reported to mediate the apoptotic signal from Fas to JNK in the cytoplasm, other data suggested that Daxx is mainly located in the nucleus as a transcriptional regulator. Here, we demonstrated that cellular localization of Daxx could be determined by the relative concentration of a proapoptotic kinase, apoptosis signal-regulating kinase 1 (ASK1) by using immunofluorescence and transcriptional reporter assay. ASK1 sequestered Daxx in the cytoplasm and inhibited the repressive activity of Daxx in transcription. In addition, Daxx was bound to the activated Fas only in the presence of ASK1, accelerating the Fas-mediated apoptosis. These results suggest that Daxx requires ASK1 for its cytoplasmic localization and Fas-mediated signaling. Taken together, we could conclude that ASK1 controls the dual function of Daxx as a transcriptional repressor in the nucleus and as a proapoptotic signal mediator in the cytoplasm.	Seoul Natl Univ, Coll Pharm, Natl Creat Res Initiat Ctr ARS Network, Seoul 151742, South Korea; Korea Univ, Grad Sch Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Seoul 110799, South Korea	Seoul National University (SNU); Korea University	Kim, S (corresponding author), Seoul Natl Univ, Coll Pharm, Natl Creat Res Initiat Ctr ARS Network, San 56-1, Seoul 151742, South Korea.	sungkim@snu.ac.kr	Kim, Sunghoon/AAE-8314-2020	KIM, Jin Young/0000-0003-4438-1872				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chang HY, 1999, P NATL ACAD SCI USA, V96, P1252, DOI 10.1073/pnas.96.4.1252; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; GELEZIUNAS R, 2001, SCIENCE, V410, P834; Gongora R, 2001, IMMUNITY, V14, P727, DOI 10.1016/S1074-7613(01)00152-2; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Ko YG, 2001, J BIOL CHEM, V276, P6030, DOI 10.1074/jbc.M006189200; Ko YG, 2000, J CELL BIOL, V149, P567, DOI 10.1083/jcb.149.3.567; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Pluta AF, 1998, J CELL SCI, V111, P2029; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Tobiume K, 1997, BIOCHEM BIOPH RES CO, V239, P905, DOI 10.1006/bbrc.1997.7580; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	28	98	110	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39103	39106		10.1074/jbc.M105928200	http://dx.doi.org/10.1074/jbc.M105928200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495919	hybrid			2022-12-25	WOS:000171673200101
J	Leung, JK; Berube, N; Venable, S; Ahmed, S; Timchenko, N; Pereira-Smith, OM				Leung, JK; Berube, N; Venable, S; Ahmed, S; Timchenko, N; Pereira-Smith, OM			MRG15 activates the B-myb promoter through formation of a nuclear complex with the retinoblastoma protein and the novel protein PAM14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOSAGE COMPENSATION; DROSOPHILA; EXPRESSION; PROLIFERATION; TRANSCRIPTION; CHROMATIN; CELLS; REGULATORS; REPRESSION; CANCER	The MORF4-Related Gene on chromosome 15 (MRG15) is a member of a novel family of genes originally identified in studies to reveal cell senescence-inducing factors. MRG15 contains several predicted protein motifs, including a nuclear localization signal, a helix-loop-helix region, a leucine zipper, and a chromodomain. These motifs are commonly associated with transcription factors, suggesting that MRG15 may likewise function as a transcriptional regulator. To examine the potential function(s) of MRG15, we sought to identify cellular factors associated with this MRG family member. In this regard, we have found that both the retinoblastoma tumor suppressor (Rb) and a novel nuclear protein PAM14 (Protein Associated with MRG, 14 kDa) specifically associate with MRG15. We have further demonstrated that these interactions require the helix-loop-helix and leucine zipper domains of MRG15. Interestingly we have found all three proteins present in a multiprotein complex, suggesting that at least some of their functions may be interdependent. Although the functions of PAM14 have yet to be elucidated, Rb has several well characterized activities, including repression of E2F-activated promoters such as that of B-myb. Significantly we have demonstrated that MRG15 blocks the Rb-induced repression of this promoter, leading to B-myb promoter activation. Collectively these results suggest that MRG15 regulates transcription through interactions with a cellular protein complex containing Rb and PAM14.	Baylor Coll Med, Roy M & Phyllis Gough Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Leung, JK (corresponding author), Baylor Coll Med, Roy M & Phyllis Gough Huffington Ctr Aging, M320,1 Baylor Plaza, Houston, TX 77030 USA.		Berube, Nathalie G/E-3885-2015		NATIONAL INSTITUTE ON AGING [T32AG000183, R37AG005333] Funding Source: NIH RePORTER; NIA NIH HHS [T32AG00183, R37AG05333] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARSURA M, 1992, BLOOD, V79, P2708; Bashaw GJ, 1996, CURR OPIN GENET DEV, V6, P496, DOI 10.1016/S0959-437X(96)80073-6; Bertram MJ, 2001, GENE, V266, P111, DOI 10.1016/S0378-1119(01)00372-9; Bone JR, 1996, GENETICS, V144, P705; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; He S, 2000, MOL CELL BIOL, V20, P363, DOI 10.1128/MCB.20.1.363-371.2000; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jones DO, 2000, BIOESSAYS, V22, P124, DOI 10.1002/(SICI)1521-1878(200002)22:2&lt;124::AID-BIES4&gt;3.0.CO;2-E; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; Micklatcher C, 1999, CURR OPIN CHEM BIOL, V3, P724, DOI 10.1016/S1367-5931(99)00031-9; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1999, J CELL PHYSIOL, V179, P245; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	23	43	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39171	39178		10.1074/jbc.M103435200	http://dx.doi.org/10.1074/jbc.M103435200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11500496	hybrid			2022-12-25	WOS:000171673200110
J	Smelkova, N; Marians, KJ				Smelkova, N; Marians, KJ			Timely release of both replication forks from oriC requires modulation of origin topology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-REPLICATION; IN-VITRO; CHROMOSOMAL ORIGIN; TOPOISOMERASE-IV; PROTEIN; INITIATION; HELICASE; PRIMASE; INVITRO	Initiation of DNA replication at oriC occurs bidirectionally both in vivo and in vitro. Although the proteins involved in establishing the replication forks are known, little is known about the events that ensure that initiation is bidirectional. We show here that in the absence of DNA gyrase, replication fork progression from oriC on a plasmid template in vitro is unidirectional, although both replication forks have formed at the origin. There was no bias in the release of one fork or the other, ruling out protein blockage of one fork as a possible reason for the asymmetric release. Timely release of both forks required the presence of either DNA gyrase or topoisomerase IV, suggesting that modulation of the topology of the origin region is the governing factor.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Smelkova, N (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.				NIGMS NIH HHS [GM34557] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; BIRD RE, 1972, J MOL BIOL, V70, P549, DOI 10.1016/0022-2836(72)90559-1; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P16371; Hiasa H, 1999, J BIOL CHEM, V274, P27244, DOI 10.1074/jbc.274.38.27244; HIASA H, 1994, J BIOL CHEM, V269, P2093; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HWANG DS, 1992, J BIOL CHEM, V267, P23083; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Lemon KP, 2000, MOL CELL, V6, P1321, DOI 10.1016/S1097-2765(00)00130-1; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MCGLYNN P, 2001, P NATL ACAD SCI USA, V98, P8325; MINDEN JS, 1986, J BIOL CHEM, V261, P1906; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PRESCOTT DM, 1972, P NATL ACAD SCI USA, V69, P2842, DOI 10.1073/pnas.69.10.2842; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	24	13	13	3	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39186	39191		10.1074/jbc.M104411200	http://dx.doi.org/10.1074/jbc.M104411200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504719	hybrid			2022-12-25	WOS:000171673200112
J	Velentza, AV; Schumacher, AM; Weiss, C; Egli, M; Watterson, DM				Velentza, AV; Schumacher, AM; Weiss, C; Egli, M; Watterson, DM			A protein kinase associated with apoptosis and tumor suppression - Structure, activity, and discovery of peptide substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; DAP-KINASE; SERINE/THREONINE KINASE; DEATH-DOMAIN; CELL-DEATH; PROMOTER HYPERMETHYLATION; PHOSPHORYLASE-KINASE; CALMODULIN-BINDING; CATALYTIC-ACTIVITY; CPG ISLAND	Death-associated protein kinase (DAPK) has been implicated in apoptosis and tumor suppression, depending on cellular conditions, and associated with mechanisms of disease. However, DAPK has not been characterized as an enzyme due to the lack of protein or peptide substrates. Therefore, we determined the structure of DAPK catalytic domain, used a homology model of docked peptide substrate, and synthesized positional scanning substrate libraries in order to discover peptide substrates with K(m) values in the desired 10 muM range and to obtain knowledge about the preferences of DAPK for phosphorylation site sequences. Mutagenesis of DAPK catalytic domain at amino acids conserved among protein kinases or unique to DAPK provided a link between structure and activity. An enzyme assay for DAPK was developed and used to measure activity in adult brain and monitor protein purification based on the physical and chemical properties of the open reading frame of the DAPK cDNA. The results allow insight into substrate preferences and regulation of DAPK, provide a foundation for proteomic investigations and inhibitor discovery, and demonstrate the utility of the experimental approach, which can be extended potentially to kinase open reading frames identified by genome sequencing projects or functional genetics screens and lacking a known substrate.	Northwestern Univ, Drug Discovery Program, Chicago, IL 60611 USA; Northwestern Univ, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA; Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA	Northwestern University; Northwestern University; Vanderbilt University	Watterson, DM (corresponding author), Northwestern Univ, Drug Discovery Program, 303 E Chicago Ave,Ward 8-196, Chicago, IL 60611 USA.	m-watterson@northwestern.edu	Weiss, Craig/K-8910-2018	Watterson, Daniel/0000-0001-7605-5866	NCRR NIH HHS [S10-RR13810] Funding Source: Medline; NIA NIH HHS [T32-AG00260] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000260] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Habelhah H, 2001, J BIOL CHEM, V276, P18090, DOI 10.1074/jbc.M011396200; Inbal B, 2000, MOL CELL BIOL, V20, P1044, DOI 10.1128/MCB.20.3.1044-1054.2000; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kawai T, 1999, ONCOGENE, V18, P3471, DOI 10.1038/sj.onc.1202701; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kim JW, 2001, J BIOL CHEM, V276, P27064, DOI 10.1074/jbc.M009364200; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Lukas TJ, 1999, J MED CHEM, V42, P910, DOI 10.1021/jm980573a; Lukas TJ, 1998, CALMODULIN AND SIGNAL TRANSDUCTION, P65; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; Nakatsuka S, 2000, LAB INVEST, V80, P1651, DOI 10.1038/labinvest.3780175; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Raveh T, 2000, P NATL ACAD SCI USA, V97, P1572, DOI 10.1073/pnas.020519497; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Shani G, 2001, EMBO J, V20, P1099, DOI 10.1093/emboj/20.5.1099; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; VANELDIK LJ, 1983, P NATL ACAD SCI USA, V22, P6775; Watterson DM, 1999, J CELL BIOCHEM, V75, P481, DOI 10.1002/(SICI)1097-4644(19991201)75:3<481::AID-JCB12>3.0.CO;2-5; WATTERSON DM, 1995, FEBS LETT, V373, P217; Yamamoto M, 1999, J NEUROSCI RES, V58, P674, DOI 10.1002/(SICI)1097-4547(19991201)58:5<674::AID-JNR8>3.0.CO;2-3; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; ZHOU ZHL, 1995, BIOCHEM J, V310, P517, DOI 10.1042/bj3100517	34	55	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38956	38965		10.1074/jbc.M104273200	http://dx.doi.org/10.1074/jbc.M104273200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11483604	hybrid, Green Submitted			2022-12-25	WOS:000171673200083
J	Zhang, HM; Whitelegge, JP; Cramer, WA				Zhang, HM; Whitelegge, JP; Cramer, WA			Ferredoxin : NADP(+) oxidoreductase is a subunit of the chloroplast cytochrome b(6)f complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION-MASS-SPECTROMETRY; BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; LUMEN-SIDE DOMAIN; B-F COMPLEX; NADP+ OXIDOREDUCTASE; OXYGENIC PHOTOSYNTHESIS; SPINACH-CHLOROPLASTS; ANGSTROM RESOLUTION; CHLAMYDOMONAS-REINHARDTII	Purified detergent-soluble cytochrome b(6)f complex from chloroplast thylakoid membranes (spinach) and cyanobacteria (Mastigocladus laminosus) was highly active, transferring 300-350 electrons per cyt f/s. Visible absorbance spectra showed a red shift of the cytochrome f alpha -band and the Qy chlorophyll a band in the cyanobacterial complex and an absorbance band in the flavin 450-480-nm region of the chloroplast complex. An additional high molecular weight (M-r similar to 35,000) polypeptide in the chloroplast complex was seen in SDS-polyacrylamide gel electrophoresis at a stoichiometry of similar to0.9 (cytochrome f)(-1). The extra polypeptide did not stain for heme and was much more accessible to protease than cytochrome f. Electrospray ionization mass spectrometry of CNBr fragments of the 35-kDa polypeptide was diagnostic for ferredoxin:NADP(+) oxidoreductase (FNR), as were antibody reactivity to FNR and diaphorase activity. The absence of FNR in the cyanobacterial complex did not impair decyl-plastoquinolferricyanide activity. The activity of the FNR in the chloroplast b(6)f complex was also shown by NADPH reduction, in the presence of added ferredoxin, of 0.8 heme equivalents of the cytochrome b(6) subunit. It was inferred that the b(6)f complex with bound FNR, one equivalent per monomer, provides the membrane protein connection to the main electron transfer chain for ferredoxin-dependent cyclic electron transport.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Biochem, Program Mol Biol, W Lafayette, IN 47907 USA; Univ Calif Los Angeles, Pasarow Mass Spectrometry Lab, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Pasarow Mass Spectrometry Lab, Dept Psychiat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Pasarow Mass Spectrometry Lab, Dept Biobehav Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90095 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Cramer, WA (corresponding author), Purdue Univ, Dept Biol Sci, Lilly Hall,B-410, W Lafayette, IN 47907 USA.	wac@bilbo.bio.purdue.edu			NIAID NIH HHS [AI-12601, AI-29733] Funding Source: Medline; NIGMS NIH HHS [GM-18457] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012601, R56AI012601, R01AI029733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018457] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSKY MA, 1956, ARCH BIOCHEM BIOPHYS, V65, P475, DOI 10.1016/0003-9861(56)90207-7; ALT J, 1984, CURR GENET, V8, P551, DOI 10.1007/BF00410443; [Anonymous], 2000, CURRENT PROTOCOLS MO; Bald D., 1992, P629; BATIE CJ, 1981, J BIOL CHEM, V256, P7756; BOUGESBOCQUET B, 1978, FEBS LETT, V85, P340, DOI 10.1016/0014-5793(78)80487-6; Breyton C, 2000, J BIOL CHEM, V275, P13195, DOI 10.1074/jbc.275.18.13195; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Carrell CJ, 1999, BIOCHEMISTRY-US, V38, P9590, DOI 10.1021/bi9903190; Chi YI, 2000, BIOCHEMISTRY-US, V39, P7689, DOI 10.1021/bi000090k; CLARK RD, 1983, J BIOL CHEM, V258, P348; CLARK RD, 1984, FEBS LETT, V174, P137, DOI 10.1016/0014-5793(84)81092-3; COUGHLAN S, 1985, J BIOL CHEM, V260, P4891; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; Crofts AR, 2000, TRENDS MICROBIOL, V8, P107, DOI 10.1016/S0966-842X(99)01695-9; FURBACHER PN, 1989, BIOCHEMISTRY-US, V28, P8990, DOI 10.1021/bi00449a006; Golbeck JH, 1994, MOL BIOL CYANOBACTER, P319; HALEY J, 1989, P NATL ACAD SCI USA, V86, P1534, DOI 10.1073/pnas.86.5.1534; Hamel P, 2000, J BIOL CHEM, V275, P17072, DOI 10.1074/jbc.M001468200; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HUANG D, 1999, PHOTOSYNTHESIS MECH, V3, P1577; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; HURT E, 1981, EUR J BIOCHEM, V117, P591; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KATOH S, 1962, J BIOCHEM-TOKYO, V51, P32, DOI 10.1093/oxfordjournals.jbchem.a127497; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; le Coutre J, 2000, BIOCHEMISTRY-US, V39, P4237, DOI 10.1021/bi000150m; Martinez SE, 1996, PROTEIN SCI, V5, P1081; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; MATTHIJS HCP, 1986, J BIOL CHEM, V261, P2154; MORAND LZ, 1993, BIOCHIM BIOPHYS ACTA, V1141, P105, DOI 10.1016/0005-2728(93)90195-L; MOSS DA, 1984, BIOCHIM BIOPHYS ACTA, V767, P389, DOI 10.1016/0005-2728(84)90036-7; Mosser G, 1997, J BIOL CHEM, V272, P20263, DOI 10.1074/jbc.272.32.20263; Muhlenhoff U, 1996, EUR J BIOCHEM, V235, P324, DOI 10.1111/j.1432-1033.1996.00324.x; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; Ponamarev MV, 2000, BIOCHEMISTRY-US, V39, P5971, DOI 10.1021/bi9928997; ROMANOWSKA E, 1994, PLANT CELL PHYSIOL, V35, P557, DOI 10.1093/oxfordjournals.pcp.a078630; Sainz G, 2000, BIOCHEMISTRY-US, V39, P9164, DOI 10.1021/bi0004596; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHLUCHTER WM, 1992, BIOCHEMISTRY-US, V31, P3092, DOI 10.1021/bi00127a009; SONCINI FC, 1989, J BIOL CHEM, V264, P21112; SZCZEPANIAK A, 1989, Z NATURFORSCH C, V44, P453; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vermeglio A, 2000, TRENDS MICROBIOL, V8, P106, DOI 10.1016/S0966-842X(99)01694-7; Whitelegge JP, 1999, P NATL ACAD SCI USA, V96, P10695, DOI 10.1073/pnas.96.19.10695; Whitelegge JP, 1998, PROTEIN SCI, V7, P1423, DOI 10.1002/pro.5560070619; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; Zhang HM, 1999, J BIOL CHEM, V274, P1581, DOI 10.1074/jbc.274.3.1581; Zhang JM, 1996, J BIOL CHEM, V271, P31360, DOI 10.1074/jbc.271.49.31360	54	206	210	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38159	38165						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11483610				2022-12-25	WOS:000171526500059
J	Zhou, JZ; Low, PS				Zhou, JZ; Low, PS			Characterization of the reversible conformational equilibrium in the cytoplasmic domain of human erythrocyte membrane band 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; BINDING-SITE; HEREDITARY SPHEROCYTOSIS; 3-ANKYRIN INTERACTION; HEMOLYTIC-ANEMIA; LIPID VESICLES; PROTEIN; ANKYRIN; DEFICIENCY; SKELETON	The cytoplasmic domain of erythrocyte membrane band 3 (cdb3) serves as a center of membrane organization, interacting with such proteins as ankyrin, protein 4.1, protein 4.2, hemoglobin, several glycolytic enzymes, and a tyrosine kinase, p72(syk). cdb3 exists in a reversible, pH-dependent conformational equilibrium characterized by large changes in Stokes radius (I I A) and intrinsic fluorescence (2-fold). Based on the crystallographic structure of the cdb3 dimer, we hypothesized that the above conformational equilibrium might involve the movement of flanking peripheral protein binding domains away from a shared dimerization domain. To test this hypothesis, we have mutated both donor (W105L) and acceptor (D316A) residues of a prominent H bond that bridges the above two domains and have examined the effect on the resulting conformational equilibrium. Analysis of the intrinsic fluorescence, Stokes radius, thermal stability, urea stability, and segmental mobility of these mutants reveals that the above H bond is indeed present in the low pH conformation of cdb3 and broken in a higher pH conformation. The data further reveal that cdb3 exists in three native pH-dependent conformations and that rupture of the aforementioned H bond occurs only during conversion of the low pH conformation to the mid-pH conformation. Conversion of the mid-pH conformation to the high pH conformation would now appear to involve structural changes primarily in the peripheral protein binding domain. Because ankyrin associates avidly with the low pH conformation of cdb3, ankyrin occupancy should strongly influence this structural equilibrium and thereby affect band 3 and perhaps global membrane properties.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Low, PS (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.			Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM 24417] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024417, R01GM024417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An XL, 1996, J BIOL CHEM, V271, P33187, DOI 10.1074/jbc.271.52.33187; APPELL KC, 1981, J BIOL CHEM, V256, P1104; APPELL KC, 1982, BIOCHEMISTRY-US, V21, P2151, DOI 10.1021/bi00538a026; BENNETT V, 1980, J BIOL CHEM, V255, P6424; Che A, 1997, BIOCHEMISTRY-US, V36, P9588, DOI 10.1021/bi971074z; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; HARRISON ML, 1994, J BIOL CHEM, V269, P955; Jarolim P, 1996, BLOOD, V88, P4366; JAROLIM P, 1992, BLOOD, V80, P523; JAROLIM P, 1994, J CLIN INVEST, V93, P121, DOI 10.1172/JCI116935; JENKINS JD, 1984, J BIOL CHEM, V259, P9374; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; KANNAN R, 1991, BIOCHEM J, V278, P57, DOI 10.1042/bj2780057; KORSGREN C, 1988, J BIOL CHEM, V263, P10212; LEPKE S, 1976, BIOCHIM BIOPHYS ACTA, V455, P353, DOI 10.1016/0005-2736(76)90311-4; Low P S, 1989, Prog Clin Biol Res, V319, P525; LOW PS, 1987, J BIOL CHEM, V262, P4592; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1984, J BIOL CHEM, V259, P3070; LOW PS, 1991, BLOOD, V77, P1581; LOW PS, 1993, J BIOL CHEM, V268, P14627; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; Salhany JM, 1998, BBA-BIOMEMBRANES, V1371, P107, DOI 10.1016/S0005-2736(98)00009-1; Southgate CD, 1996, NAT GENET, V14, P227, DOI 10.1038/ng1096-227; STECK TL, 1978, J SUPRAMOL STR CELL, V8, P311, DOI 10.1002/jss.400080309; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; THEVENIN BJM, 1994, P NATL ACAD SCI USA, V91, P1741, DOI 10.1073/pnas.91.5.1741; TSAI IH, 1982, J BIOL CHEM, V257, P1438; WALDER JA, 1984, J BIOL CHEM, V259, P238; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; WANG CC, 1995, J BIOL CHEM, V270, P17892, DOI 10.1074/jbc.270.30.17892; WAUGH SM, 1985, BIOCHEMISTRY-US, V24, P34, DOI 10.1021/bi00322a006; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; Zhang DC, 2000, BLOOD, V96, P2925; Zhou JZ, 2000, BIOCHEMISTRY-US, V39, P12019, DOI 10.1021/bi001221k	39	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38147	38151						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11477080				2022-12-25	WOS:000171526500057
J	Bobik, TA; Rasche, ME				Bobik, TA; Rasche, ME			Identification of the human methylmalonyl-CoA racemase gene based on the analysis of prokaryotic gene arrangements - Implications for decoding the human genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A RACEMASE; REACTIVATING FACTOR; DIOL DEHYDRATASE; PROTEIN FUNCTION	In this report, we identify the human DL-methylmalonyl-CoA racemase gene by analyzing prokaryotic gene arrangements and extrapolating the information obtained to human genes by homology searches. Sequence similarity searches were used to identify two groups of homologues that were frequently arranged with prokaryotic methylmalonyl-CoA mutase genes, and that were of unknown function. Both gene groups had homologues in the human genome. Because methylmalonyl-CoA mutases are involved in the metabolism of propionyl-CoA, we inferred that conserved neighbors of methylmalonyl-CoA mutase genes and their human homologues were also involved in this process. Subsequent biochemical studies confirmed this inference by showing that the prokaryotic gene PH0272 and its human homologue both encode DL-methylmalonyl-CoA racemases. To our knowledge this is the first report in which the function of a eukaryotic gene was determined based on the analysis of prokaryotic gene arrangements. Importantly, such analyses are rapid and may be generally applicable for the identification of human genes that lack homologues of known function or that have been misidentified on the basis of sequence similarity searches.	Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Bobik, TA (corresponding author), Univ Florida, Dept Microbiol & Cell Sci, Bldg 981,Rm 1220, Gainesville, FL 32611 USA.				NIGMS NIH HHS [GM59486] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM059486] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN SHG, 1963, J BIOL CHEM, V238, P1637; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Banerjee R., 1999, Chemistry and biochemistry of B12., P707; Bork P, 1998, J MOL BIOL, V283, P707, DOI 10.1006/jmbi.1998.2144; CLAROS MG, 1996, EUR J BIOCHEM, V241, P770, DOI DOI 10.1111/J.1432-1033.1996.00779.X; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; DEMOZ A, 1995, J CHROMATOGR B, V667, P148, DOI 10.1016/0378-4347(94)00595-V; Eisenberg D, 2000, NATURE, V405, P823, DOI 10.1038/35015694; Johnson CLV, 2001, J BACTERIOL, V183, P1577, DOI 10.1128/JB.183.5.1577-1584.2001; LEADLAY PF, 1981, BIOCHEM J, V197, P413, DOI 10.1042/bj1970413; Maniatis T., 1982, MOL CLONING LAB MANU; Marcotte EM, 2000, CURR OPIN STRUC BIOL, V10, P359, DOI 10.1016/S0959-440X(00)00097-X; MONTGOMERY JA, 1983, J CLIN INVEST, V72, P1937, DOI 10.1172/JCI111158; Mori K, 1997, J BIOL CHEM, V272, P32034, DOI 10.1074/jbc.272.51.32034; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; ROSENBLATT DS, 1999, CHEM BIOCH B12, P3067; Seifert C, 2001, EUR J BIOCHEM, V268, P2369, DOI 10.1046/j.1432-1327.2001.02123.x; STABLER SP, 1985, ARCH BIOCHEM BIOPHYS, V241, P252, DOI 10.1016/0003-9861(85)90381-9; Toraya T, 1999, J BIOL CHEM, V274, P3372, DOI 10.1074/jbc.274.6.3372	19	38	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37194	37198		10.1074/jbc.M107232200	http://dx.doi.org/10.1074/jbc.M107232200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11481338	hybrid			2022-12-25	WOS:000171375700045
J	Jacob, AL; Lund, J; Martinez, P; Hedin, L				Jacob, AL; Lund, J; Martinez, P; Hedin, L			Acetylation of steroidogenic factor 1 protein regulates its transcriptional activity and recruits the coactivator GCN5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; ORPHAN NUCLEAR RECEPTOR; ELEMENT-BINDING PROTEIN; BOVINE CYP17 GENE; R2C LEYDIG-CELLS; FACTOR-I; DEPENDENT TRANSACTIVATION; CHROMATIN STRUCTURE; GONADAL DEVELOPMENT; PROMOTER ACTIVITY	Steroidogenic factor-1 (SF-1) is an orphan nuclear receptor that plays an essential role in the development of the hypothalamic-pituitary-gonadal axis in both sexes. SF-1 belongs to the hormone nuclear receptor superfamily and possesses an N-terminal DNA binding domain and a C-terminal ligand binding domain. Activation function domain 2 is located C-terminal of the ligand binding domain of SF-1 and is important for the transactivation of target genes. Coactivators with histone acetyltransferase activity such as cAMP response element-binding protein-binding protein and steroid receptor coactivator 1 interact and increase SF-1-mediated transcriptional activity. In this study we demonstrate that SF-1 is acetylated in vivo. Histone acetyltransferase GCN5 acetylates SF-1 in vitro. Moreover, we found that SF-1 recruited a novel coactivator GCN5, which can be a newly identified coactivator for SF-1. Acetylation of SF-1 stimulates its transcriptional activity. Inhibition of deacetylation by trichostatin A, a histone deacetylase inhibitor, increased SF-1-mediated transactivation and stabilized and induced the nuclear export of the SF-1 protein.	Univ Bergen, Dept Anat & Cell Biol, N-5009 Bergen, Norway	University of Bergen	Jacob, AL (corresponding author), Univ Bergen, Dept Anat & Cell Biol, Arstadveien 19, N-5009 Bergen, Norway.		Martinez, Pedro/O-5025-2014	Martinez, Pedro/0000-0003-3956-7541				Achermann JC, 1999, NAT GENET, V22, P125, DOI 10.1038/9629; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; BAKKE M, 1995, MOL ENDOCRINOL, V9, P327, DOI 10.1210/me.9.3.327; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Cammas FM, 1997, MOL ENDOCRINOL, V11, P867, DOI 10.1210/me.11.7.867; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; FITZPATRICK SL, 1994, MOL ENDOCRINOL, V8, P1309, DOI 10.1210/me.8.10.1309; FITZPATRICK SL, 1993, J STEROID BIOCHEM, V44, P429, DOI 10.1016/0960-0760(93)90246-S; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Halvorson LM, 1996, J BIOL CHEM, V271, P6645, DOI 10.1074/jbc.271.12.6645; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hu ZZ, 1997, J BIOL CHEM, V272, P14263, DOI 10.1074/jbc.272.22.14263; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; Ito M, 2000, MOL ENDOCRINOL, V14, P66, DOI 10.1210/me.14.1.66; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Jacob AL, 1998, J BIOL CHEM, V273, P13391, DOI 10.1074/jbc.273.22.13391; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lalli E, 2000, MOL CELL BIOL, V20, P4910, DOI 10.1128/MCB.20.13.4910-4921.2000; Lenk U, 2000, J BIOL CHEM, V275, P39403, DOI 10.1074/jbc.M006949200; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LUO XR, 1995, ENDOCR RES, V21, P517, DOI 10.3109/07435809509030469; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Sambrook J., 2002, MOL CLONING LAB MANU; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Sugawara T, 1997, STEROIDS, V62, P5, DOI 10.1016/S0039-128X(96)00152-3; Sugawara T, 1997, BIOCHEMISTRY-US, V36, P7249, DOI 10.1021/bi9628984; Syntichaki P, 1998, J BIOL CHEM, V273, P24414, DOI 10.1074/jbc.273.38.24414; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	57	67	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37659	37664		10.1074/jbc.M104427200	http://dx.doi.org/10.1074/jbc.M104427200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479297	hybrid			2022-12-25	WOS:000171375700103
J	Kosman, J; Jonas, A				Kosman, J; Jonas, A			Deletion of specific glycan chains affects differentially the stability, local structures, and activity of lecithin-cholesterol acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HUMAN PLASMA; INTERFACIAL RECOGNITION; TERMINAL TRUNCATION; ACYL TRANSFERASE; LCAT; IDENTIFICATION; GLYCOSYLATION; MUTAGENESIS; MUTANTS	The enzymatic and interfacial binding activity of lecithin-cholesterol acyltransferase (LCAT) is affected differentially by the location and extent of its glycosylation. Two LCAT glycosylation-deficient mutants, N84Q and N384Q, were constructed, permanently expressed in Chinese hamster ovary cells, and purified to determine the effects of deleting individual glycan chains on its stability, structure, and function. These purified mutants were studied by spectroscopic structural methods and enzymatic and binding assays to develop a molecular rationale for the relationship between LCAT glycosylation and activity. The N84Q LCAT mutant did not possess measurable enzymatic activity or interfacial binding affinity for reconstituted high-density lipoproteins. In addition, in thermal and chemical denaturation studies, N84Q LCAT was found to be significantly less stable than wild-type LCAT. The N384Q variant was initially more enzymatically active than wild-type LCAT, but gradually lost activity within months; however, it retained full interfacial binding activity. Significant changes were detected over time by circular dichroism in the alpha -helical content of N384Q LCAT and in the beta -sheet content of N84Q LCAT, compared with wild-type LCAT. Fluorescence measurements with the probe 1-anilinonapthalene-8-sulfonate suggested an alteration of the active site cavity in both mutants. In conclusion, both mutants lost catalytic activity, N84Q shortly after purification and N384Q more gradually, and were destabilized, probably because the deletion of the glycan chains altered local structural elements near the active site cavity and/or the interfacial binding regions.	Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Jonas, A (corresponding author), Univ Illinois, Coll Med, Dept Biochem, 506 S Mathews Ave, Urbana, IL 61801 USA.				NHLBI NIH HHS [HL-29939] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029939] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adimoolam S, 1998, J BIOL CHEM, V273, P32561, DOI 10.1074/jbc.273.49.32561; Adimoolam S, 1997, BIOCHEM BIOPH RES CO, V232, P783, DOI 10.1006/bbrc.1997.6375; Adimoolam S, 1998, BIOCHEM BIOPH RES CO, V243, P337, DOI 10.1006/bbrc.1997.7995; Ayyobi AF, 2000, BBA-MOL CELL BIOL L, V1484, P1, DOI 10.1016/S1388-1981(99)00199-7; BONELLI FS, 1989, J BIOL CHEM, V264, P14723; BYRNE MP, 1995, PROTEIN SCI, V4, P2545, DOI 10.1002/pro.5560041211; DANIEL E, 1966, BIOCHEMISTRY-US, V5, P1893, DOI 10.1021/bi00870a016; Davidson WS, 1999, BIOCHEMISTRY-US, V38, P14387, DOI 10.1021/bi991428h; FIELDING CJ, 1995, J LIPID RES, V36, P211; Francone OL, 1996, J LIPID RES, V37, P1609; FRANCONE OL, 1993, BIOCHIM BIOPHYS ACTA, V1166, P301, DOI 10.1016/0005-2760(93)90110-U; GHOSH D, 1995, STRUCTURE, V3, P279, DOI 10.1016/S0969-2126(01)00158-7; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; HILL OK, 1993, BIOCHEM J, V294, P879; Jin LH, 1999, BIOCHEMISTRY-US, V38, P15659, DOI 10.1021/bi9916729; Jin LH, 1997, J LIPID RES, V38, P1085; Jonas A, 1998, PROG LIPID RES, V37, P209, DOI 10.1016/S0163-7827(98)00007-1; Lacko AG, 1998, J LIPID RES, V39, P807; Lee YP, 1997, BBA-LIPID LIPID MET, V1344, P250, DOI 10.1016/S0005-2760(96)00149-X; Miller KR, 1996, J LIPID RES, V37, P551; Peelman F, 2000, CURR OPIN LIPIDOL, V11, P155, DOI 10.1097/00041433-200004000-00008; Peelman F, 1998, PROTEIN SCI, V7, P587, DOI 10.1002/pro.5560070307; Peelman F, 1999, PROTEIN ENG, V12, P71, DOI 10.1093/protein/12.1.71; Peelman F, 1999, J LIPID RES, V40, P59; QU SJ, 1993, BIOCHEMISTRY-US, V32, P8732, DOI 10.1021/bi00085a002; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; SCHINDLER PA, 1995, PROTEIN SCI, V4, P791; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TOYADA T, 2000, J BIOCHEM-TOKYO, V128, P731; Vanloo B, 2000, J LIPID RES, V41, P752; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P7299, DOI 10.1021/bi9517704; YANG C, 1987, J BIOL CHEM, V262, P644; 1995, BIOCH BIOPHYS ACTA, V1254, P193	34	11	11	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37230	37236		10.1074/jbc.M104326200	http://dx.doi.org/10.1074/jbc.M104326200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11486003	hybrid			2022-12-25	WOS:000171375700050
J	Colcombet, J; Thomine, S; Guern, J; Frachisse, JM; Barbier-Brygoo, H				Colcombet, J; Thomine, S; Guern, J; Frachisse, JM; Barbier-Brygoo, H			Nucleotides provide a voltage-sensitive gate for the rapid anion channel of Arabidopsis hypocotyl cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; GUARD-CELLS; ELICITOR; MG-2+; ACID; SUSPENSIONS; PROTOPLASTS; DEPENDENCE; RESPONSES; NEURONS	The rapid anion channel of Arabidopsis hypocotyl cells is highly voltage-dependent. At hyperpolarized potentials, the channel is closed, and membrane depolarization is required for channel activation. We have previously shown that channel gating is regulated by intracellular nucleotides. In the present study, we further analyze the channel gating, and we propose a mechanism to explain its regulation by voltage. In the absence of intracellular nucleotides, closure at hyperpolarized voltages is abolished. Structure-function studies of adenyl nucleotides show that the apparent gating charge of the current increases with the negative charge carried by nucleotides. We propose that the fast anion channel is gated by the voltage-dependent entry of free nucleotides into the pore, leading to a voltage-dependent block at hyperpolarized potentials. In agreement with this mechanism in which intracellular nucleotides need to be recruited to the channel pore, kinetic analyses of whole-cell and single-channel currents show that the rate of closure is faster when intracellular nucleotide concentration is increased, whereas the rate of channel activation is unchanged. Furthermore, decreasing the concentration of extracellular chloride enhances the intracellular nucleotide block. This result supports the hypothesis of a mechanism in which blocking nucleotides and permeant anions interact within the channel pore.	CNRS, Inst Sci Vegetales, UPR 2355, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Colcombet, J (corresponding author), CNRS, Inst Sci Vegetales, UPR 2355, F-91198 Gif Sur Yvette, France.		Jean-Marie, Frachisse/AAE-4350-2022; Frachisse, Jean Marie/AAY-7177-2020; Thomine, Sébastien/V-9029-2019; BARBIER-BRYGOO, HELENE/A-8435-2013	Frachisse, Jean Marie/0000-0002-9755-6536; Thomine, Sebastien/0000-0003-0045-1701				ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Barbier-Brygoo H, 2000, BBA-BIOMEMBRANES, V1465, P199, DOI 10.1016/S0005-2736(00)00139-5; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cazale AC, 1998, PLANT PHYSIOL, V116, P659, DOI 10.1104/pp.116.2.659; Chen TY, 1996, J GEN PHYSIOL, V108, P237, DOI 10.1085/jgp.108.4.237; Dietrich P, 1998, PLANT J, V15, P479, DOI 10.1046/j.1365-313X.1998.00225.x; Frachisse JM, 1999, PLANT PHYSIOL, V121, P253, DOI 10.1104/pp.121.1.253; Frachisse JM, 2000, PLANT J, V21, P361, DOI 10.1046/j.1365-313x.2000.00689.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEDRICH R, 1994, PLANT J, V6, P741, DOI 10.1046/j.1365-313X.1994.6050741.x; HEDRICH R, 1993, EMBO J, V12, P897, DOI 10.1002/j.1460-2075.1993.tb05730.x; LOHSE G, 1995, PLANTA, V197, P546, DOI 10.1007/BF00196677; MARTEN I, 1991, NATURE, V353, P758, DOI 10.1038/353758a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; NURNBERGER T, 1994, CELL, V78, P449, DOI 10.1016/0092-8674(94)90423-5; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; Pei ZM, 1997, PLANT CELL, V9, P409, DOI 10.1105/tpc.9.3.409; Pei ZM, 1998, SCIENCE, V282, P287, DOI 10.1126/science.282.5387.287; Pugin A, 1997, PLANT CELL, V9, P2077, DOI 10.1105/tpc.9.11.2077; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; SAINTGES V, 1991, EUR J BIOCHEM, V200, P477, DOI 10.1111/j.1432-1033.1991.tb16207.x; SCHROEDER JI, 1993, PLANT CELL, V5, P1831, DOI 10.1105/tpc.5.12.1831; SchulzLessdorf B, 1996, PLANT J, V10, P993, DOI 10.1046/j.1365-313X.1996.10060993.x; Schwarz M, 1998, FEBS LETT, V428, P177, DOI 10.1016/S0014-5793(98)00526-2; Thomine S, 1997, J MEMBRANE BIOL, V159, P71, DOI 10.1007/s002329900270; Thomine S, 1995, PLANT CELL, V7, P2091, DOI 10.1105/tpc.7.12.2091; ZIMMERMANN S, 1994, PLANT J, V6, P707, DOI 10.1046/j.1365-313X.1994.6050707.x; Zimmermann S, 1998, PLANT PHYSIOL BIOCH, V36, P665, DOI 10.1016/S0981-9428(98)80015-6	31	21	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36139	36145		10.1074/jbc.M103126200	http://dx.doi.org/10.1074/jbc.M103126200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11473110	hybrid			2022-12-25	WOS:000171194500014
J	Niino, YS; Irie, T; Takaishi, M; Hosono, T; Huh, N; Tachikawa, T; Kuroki, T				Niino, YS; Irie, T; Takaishi, M; Hosono, T; Huh, N; Tachikawa, T; Kuroki, T			PKC theta II, a new isoform of protein kinase C specifically expressed in the seminiferous tubules of mouse testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JURKAT T-CELLS; IL-2 PROMOTER; NPKC-ETA; ACTIVATION; DIFFERENTIATION; LYMPHOCYTES; MEMBER; LOCALIZATION; CALCINEURIN; INDUCTION	Protein kinase C (PKC) theta, a Ca2+-independent isoform of PKC, has been known to be expressed in skeletal muscle and T cells. In the present study, we isolated and characterized a smaller transcript expressed in the mouse testis, the cDNA of which is referred hereafter as PKC theta II and the original PKC theta as PKC thetaI. The cDNA clone of PKC theta II has 2184 base pairs and 464 amino acids in the possible open reading frame, consisting of the 5' unique sequence of 20 amino acids and the PKC thetaI sequence of 444 amino acids. Genomic DNA analysis revealed that transcription of PKC theta II is initiated from the PKC theta II-specific exon, which is located between exons 7 and 8 of the PKC theta gene, indicating that alternative splicing is the mechanism by which PKC theta II is generated. PKC theta II is expressed exclusively in the testis in an age-dependent manner with sexual maturation. In situ hybridization and reverse transcription-polymerase chain reaction of microdissected tissues clearly demonstrated that PKC theta II is expressed in the seminiferous tubules of the mouse testis. Consistent with its molecular structure lacking the C1 regulatory domain, PKC theta II is constitutively active as determined by an in vitro kinase assay, being independent of PKC activators, e.g. phosphatidylserine and phorbol ester. PKC theta II may play a crucial role in spermatogenesis or some related function of the testis.	Showa Univ, Inst Mol Oncol, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Dept Pathol, Fac Dent, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Ctr Biotechnol, Shinagawa Ku, Tokyo 1428555, Japan; Okayama Univ, Dept Cell Biol, Grad Sch Med & Dent, Okayama 7008558, Japan	Showa University; Showa University; Showa University; Okayama University	Niino, YS (corresponding author), Showa Univ, Sch Med, Dept Anat, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.		Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351				Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Blanco G, 1997, MAMM GENOME, V8, P70, DOI 10.1007/s003359900355; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Croft L, 2000, NAT GENET, V24, P340, DOI 10.1038/74153; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; HECHT NB, 1986, EXP CELL RES, V164, P183, DOI 10.1016/0014-4827(86)90465-9; Kashiwagi M, 2000, ONCOGENE, V19, P6334, DOI 10.1038/sj.onc.1204028; KILEY SC, 1995, J CELL SCI, V108, P1003; Kim HM, 1999, LIFE SCI, V65, P805, DOI 10.1016/S0024-3205(99)00307-0; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Kofler K, 1998, MOL GEN GENET, V259, P398, DOI 10.1007/s004380050829; Koga M, 1998, BIOL REPROD, V58, P261, DOI 10.1095/biolreprod58.1.261; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Meller N, 1998, STEM CELLS, V16, P178, DOI 10.1002/stem.160178; MISCHAK H, 1993, FEBS LETT, V326, P51, DOI 10.1016/0014-5793(93)81759-S; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; Sambrook J., 2002, MOL CLONING LAB MANU; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Ueyama T, 2000, BIOCHEM BIOPH RES CO, V269, P557, DOI 10.1006/bbrc.2000.2331; Villunger A, 1999, EUR J IMMUNOL, V29, P3549, DOI 10.1002/(SICI)1521-4141(199911)29:11<3549::AID-IMMU3549>3.0.CO;2-Q; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75	39	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36711	36717		10.1074/jbc.M104348200	http://dx.doi.org/10.1074/jbc.M104348200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11470790	hybrid			2022-12-25	WOS:000171194500087
J	Tan, SM; Robinson, MK; Drbal, K; van Kooyk, Y; Shaw, JM; Law, SKA				Tan, SM; Robinson, MK; Drbal, K; van Kooyk, Y; Shaw, JM; Law, SKA			The N-terminal region and the mid-region complex of the integrin beta(2) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING REGION; I-DOMAIN; PROPELLER DOMAIN; CRYSTAL-STRUCTURE; DISULFIDE BONDS; ADHESION; LFA-1; CD11A/CD18; ANTIBODIES; CD18	In the primary sequence of the integrin beta subunit, the N-terminal region (NTR) and mid-region are separated by the I-like domain. To determine the spatial relationship and functional properties of the integrin beta (2) NTR and mid-region, we constructed beta (2)/beta (7) chimeras in which the NTR, I-like domain, and the mid-region of the beta (2) subunit were replaced by those of beta (7). Changing either the beta (2) NTR or mid-region, but not the I-like domain to that of beta (7) did not affect LFA-1 (alpha (L)beta (2)) formation and surface expression. Thus, the specificity of alpha (L)beta (2) pairing is conferred by the I-like domain but not the NTR or mid-region. Using these chimeras, the epitopes of six anti-beta (2) mAbs (H52, 7E4, AZN-L18, AZN-L27, KIM202, and MEM-148) were mapped. All except H52 require both the NTR and mid-region for epitope expression. Since these mAbs have distinct properties in terms of epitope expression and effect on LFA-1 binding to ICAM-1, we conclude that the beta (2) NTR and mid-region interact extensively. Although the I-like domain is located between the NTR and mid-region, its removal does not affect the folding of the beta (2) NTR/mid-region complex because this complex alone can be expressed as a soluble protein and precipitated by the appropriate mAbs. Finally, the mAbs H52 and 7E4, abrogated KIM185- but not Mg/EGTA-induced LFA-1/ICAM-1 binding and the epitope of MEM-148 is expressed on Mg/EGTA-activated but not resting LFA-1. These results suggest that the NTR/mid-region complex is involved in the regulation of LFA-1 function.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Celltech Plc, Slough SL1 4EN, Berks, England; Acad Sci Czech Republ, Inst Mol Genet, Prague, Czech Republic; Univ Nijmegen, Dept Tumor Immunol, NL-6525 EX Nijmegen, Netherlands	University of Oxford; Celltech Group Ltd; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Radboud University Nijmegen	Law, SKA (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.	alaw@molbiol.ox.ac.uk	Drbal, Karel/G-9329-2011; Tan, Suet/A-2224-2011; Law, Alex/A-2212-2011	Drbal, Karel/0000-0003-4450-4625; Tan, Suet-Mien/0000-0003-2371-8739				BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1994, J BIOL CHEM, V269, P20913; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; COE AP, 2001, J BIOL CHEM; Douglass WA, 1998, FEBS LETT, V440, P414, DOI 10.1016/S0014-5793(98)01498-7; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Drbal K, 2000, BIOCHEM BIOPH RES CO, V275, P295, DOI 10.1006/bbrc.2000.3299; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HILDRETH JEK, 1985, J IMMUNOL, V134, P3272; Hogg N, 1999, J CLIN INVEST, V103, P97, DOI 10.1172/JCI3312; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lu CF, 1998, J BIOL CHEM, V273, P15138, DOI 10.1074/jbc.273.24.15138; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; Si XN, 2001, J BIOL CHEM, V276, P32875, DOI 10.1074/jbc.M010400200; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Stephens P, 1995, CELL ADHES COMMUN, V3, P375, DOI 10.3109/15419069509081292; Stephens PE, 2000, CELL ADHES COMMUN, V7, P377, DOI 10.3109/15419060009109020; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Wilkins JA, 1996, J BIOL CHEM, V271, P3046, DOI 10.1074/jbc.271.6.3046; WRIGHT AH, 1995, EUR J IMMUNOL, V25, P717, DOI 10.1002/eji.1830250313; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200; Zang Q, 2000, J BIOL CHEM, V275, P22202, DOI 10.1074/jbc.M002883200; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211	41	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36370	36376		10.1074/jbc.M102392200	http://dx.doi.org/10.1074/jbc.M102392200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477072	hybrid			2022-12-25	WOS:000171194500043
J	Picard, F; Kapur, S; Perreault, M; Marette, A; Deshaies, Y				Picard, F; Kapur, S; Perreault, M; Marette, A; Deshaies, Y			Nitric oxide mediates endotoxin-induced hypertriglyceridemia through its action on skeletal muscle lipoprotein lipase	FASEB JOURNAL			English	Article						endotoxemia; inducible nitric oxide synthase; triglycerides	TUMOR-NECROSIS-FACTOR; TISSUE-SPECIFIC EXPRESSION; ADIPOSE-TISSUE; LIPID-METABOLISM; FACTOR-ALPHA; BROWN ADIPOCYTES; PPAR-GAMMA; SYNTHASE; INSULIN; RAT	Hypertriglyceridemia (hyperTG) is a common characteristic of endotoxemia. At high doses of endotoxin, hyperTG is caused by a reduction in the activity of lipoprotein lipase (LPL), the enzyme responsible for TG intravascular clearance. The present studies were aimed at evaluating the role of nitric oxide (NO), overproduced in endotoxemia through the activation of inducible NO synthase (iNOS), in the decrease in tissue LPL activity brought about by lipopolysaccharide (LPS, 15 mg/kg). In rats, the specific iNOS inhibitor aminoguanidine (AGN, 100 mg/kg) prevented the LPS-induced threefold elevation in plasma TG concentration, through actions that were not related to changes in hepatic TG secretion. AGN administration abrogated the LPS-induced reduction in LPL activity in skeletal muscle but not that in white adipose tissue (WAT). Quantification of LPL mRNA revealed that AGN prevented LPS-mediated alterations in muscle LPL activity through posttranscriptional mechanisms. The above findings were confirmed in iNOS (-/-) knockout mice injected with endotoxin. LPS increased plasma TG concentration in wild-type mice by 75%, whereas hyperTG did not occur in knockout mice. Skeletal muscle LPL activity decreased by 40% in wild-type mice but remained unchanged in knockout mice 6 h after LPS injection, whereas WAT LPL activity decreased to one-third of control levels in both genotypes. These findings demonstrate that, after LPS administration, reduced muscle LPL activity and the resulting hyperTG are caused by the overproduction of NO via the induction of iNOS. The findings further provide evidence for a central role of muscle LPL in the response of TG metabolism to acute endotoxemia.	Univ Laval, Sch Med, Dept Anat & Physiol, Ctr Res Energy Metab, Quebec City, PQ G1K 7P4, Canada; Univ Laval, CHUQ, Lipid Res Unit, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Deshaies, Y (corresponding author), Univ Laval, Sch Med, Dept Anat & Physiol, Ctr Res Energy Metab, Quebec City, PQ G1K 7P4, Canada.	yves.deshaies@phs.ulaval.ca	Marette, Andre/E-9342-2013; Deshaies, Yves/E-9858-2013	Deshaies, Yves/0000-0002-6242-4592				AMIN AR, 1995, P NATL ACAD SCI USA, V92, P7926, DOI 10.1073/pnas.92.17.7926; BAGBY GJ, 1987, AM J PHYSIOL, V253, pE59, DOI 10.1152/ajpendo.1987.253.1.E59; BAGBY GJ, 1987, LIPOPROTEIN LIPASE, P247; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; Bedard S, 1997, BIOCHEM J, V325, P487, DOI 10.1042/bj3250487; Bennett MJ, 2000, AM J PHYSIOL-ENDOC M, V278, pE802, DOI 10.1152/ajpendo.2000.278.5.E802; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; FEINGOLD KR, 1992, J LIPID RES, V33, P1765; FEINGOLD KR, 1994, ARTERIOSCLER THROMB, V14, P1866, DOI 10.1161/01.ATV.14.11.1866; GOUNI I, 1993, J LIPID RES, V34, P139; GRUNFELD C, 1992, P SOC EXP BIOL MED, V200, P224; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; HARRIS HW, 1993, J CLIN INVEST, V91, P1028, DOI 10.1172/JCI116259; Hill MR, 1997, ENDOCRINOLOGY, V138, P3073, DOI 10.1210/en.138.7.3073; Kapur S, 1997, DIABETES, V46, P1691, DOI 10.2337/diabetes.46.11.1691; Kapur S, 1999, AM J PHYSIOL-ENDOC M, V276, pE635, DOI 10.1152/ajpendo.1999.276.4.E635; KRAEGEN EW, 1983, AM J PHYSIOL, V245, pE1, DOI 10.1152/ajpendo.1983.245.1.E1; Lanza-Jacoby S, 1998, SHOCK, V9, P46, DOI 10.1097/00024382-199801000-00007; LanzaJacoby S, 1997, J LIPID RES, V38, P701; LANZAJACOBY S, 1992, BIOCHIM BIOPHYS ACTA, V1124, P233, DOI 10.1016/0005-2760(92)90134-H; Liaudet L, 2000, CRIT CARE MED, V28, pN37, DOI 10.1097/00003246-200004001-00005; LopezSoriano J, 1997, MOL CELL ENDOCRINOL, V132, P93, DOI 10.1016/S0303-7207(97)00125-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEMON RA, 1993, ENDOCRINOLOGY, V132, P2246, DOI 10.1210/en.132.5.2246; Moldawer LL, 1997, CANCER-AM CANCER SOC, V79, P1828; Murad F, 1999, BIOSCIENCE REP, V19, P133, DOI 10.1023/A:1020265417394; NILSSONEHLE P, 1987, LIPOPROTEIN LIPASE, P59; Nishida K, 1997, BIOCHEM BIOPH RES CO, V236, P275, DOI 10.1006/bbrc.1997.6972; Picard F, 1999, DIABETES, V48, P452, DOI 10.2337/diabetes.48.3.452; Picard F, 2000, DIABETOLOGIA, V43, P866, DOI 10.1007/s001250051463; Pilon G, 2000, HORM METAB RES, V32, P480, DOI 10.1055/s-2007-978674; Reid MB, 2001, J APPL PHYSIOL, V90, P724, DOI 10.1152/jappl.2001.90.2.724; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; Rosato EF, 1997, J SURG RES, V73, P73, DOI 10.1006/jsre.1997.5199; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; STEFANOVICRACIC M, 1994, ARTHRITIS RHEUM, V37, P1062, DOI 10.1002/art.1780370712; Stoclet JC, 1999, EUR J PHARMACOL, V375, P139, DOI 10.1016/S0014-2999(99)00221-6; Uchida Y, 1997, ANN NY ACAD SCI, V813, P369, DOI 10.1111/j.1749-6632.1997.tb51720.x; Uchida Y, 1997, EUR J PHARMACOL, V335, P235, DOI 10.1016/S0014-2999(97)01181-3; VERDON CP, 1995, ANAL BIOCHEM, V224, P502, DOI 10.1006/abio.1995.1079; WARREN HS, 1988, INFECT IMMUN, V56, P204, DOI 10.1128/IAI.56.1.204-212.1988; WILLIAMS G, 1994, AM J PHYSIOL-REG I, V267, pR1020, DOI 10.1152/ajpregu.1994.267.4.R1020; ZECHNER R, 1988, MOL CELL BIOL, V8, P2394, DOI 10.1128/MCB.8.6.2394; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005	47	23	23	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1828	+		10.1096/fj.00-0830fje	http://dx.doi.org/10.1096/fj.00-0830fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481244				2022-12-25	WOS:000169261200008
J	Glomb, MA; Pfahler, C				Glomb, MA; Pfahler, C			Amides are novel protein modifications formed by physiological sugars	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADVANCED MAILLARD REACTION; IMIDAZOLIUM CROSS-LINKS; OXIDATIVE STRESS; GLYOXAL; MECHANISM; GLYCATION; METHYLGLYOXAL; PRODUCTS; LYSINE; GLYCOSYLATION	The Maillard reaction, or nonenzymatic browning, proceeds in vivo, and the resulting protein modifications (advanced glycation end products) have been associated with various pathologies. Despite intensive research only very few structures have been established in vivo. We report here for the first time N-6-{2-[(5-amino-5-carboxypentyl)amino]-2-oxoethyl}lysine (GOLA) and N-6-glycoloyllysine (GAIA) as prototypes for novel amide protein modifications produced by reducing sugars. Their identity was confirmed by independent synthesis and coupled liquid chromatography/mass spectrometry. Model reactions with N-alpha-t-butoxycarbonyl-lysine showed that glyoxal and glycolaldehyde are immediate precursors, and reaction pathways are directly linked to N-epsilon-carboxymethyllysine via glyoxal-imine structures. GOLA, the amide cross-link, and 1,3-bis(5-amino-5-carboxypentyl)imidazolium salt (GOLD), the imidazolium cross-link, share a common intermediate. The ratio of GOLA to GOLD is greater when glyoxal levels are low at constant lysine concentrations. GOLA and GALA formation from the Amadori product of glucose and lysine depends directly upon oxidation. With the advanced glycation end product inhibitors aminoguanidine and pyridoxamine we were able to dissect oxidative fragmentation of the Amadori product as a second mechanism of GOLA formation exactly coinciding with N-epsilon-carboxymethyllysine synthesis. In contrast, the formation of GALA appears to depend solely upon glyoxal-imines. After enzymatic hydrolysis GOLA was found at 66 pmol/mg of brunescent lens protein. This suggests amide protein modifications as important markers of pathophysiological processes.	Tech Univ Berlin, Inst Food Chem, D-13355 Berlin, Germany	Technical University of Berlin	Glomb, MA (corresponding author), Tech Univ Berlin, Inst Food Chem, Gustav Meyer Allee 25,TIB 4-3-1, D-13355 Berlin, Germany.	marcus.glomb@tu-berlin.de						Buttner U, 1997, CARBOHYD RES, V300, P265, DOI 10.1016/S0008-6215(97)00059-1; Chellan P, 1999, ARCH BIOCHEM BIOPHYS, V368, P98, DOI 10.1006/abbi.1999.1291; EBLE AS, 1983, J BIOL CHEM, V258, P9406; FU MX, 1992, DIABETES, V41, P42, DOI 10.2337/diab.41.2.S42; Glomb MA, 2001, J AGR FOOD CHEM, V49, P1493, DOI 10.1021/jf001082d; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; GUPTA S, 1993, EUR J BIOCHEM, V214, P515, DOI 10.1111/j.1432-1033.1993.tb17949.x; HENLE T, 1991, Z LEBENSM UNTERS FOR, V193, P119, DOI 10.1007/BF01193359; Khalifah RG, 1999, BIOCHEM BIOPH RES CO, V257, P251, DOI 10.1006/bbrc.1999.0371; Lederer MO, 1999, BIOORGAN MED CHEM, V7, P2499, DOI 10.1016/S0968-0896(99)00212-6; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; LO TWC, 1994, J BIOL CHEM, V269, P32299; LUSTENBERGER N, 1972, ANGEW CHEM, V84, P255; Monnier VM, 1996, NEPHROL DIAL TRANSPL, V11, P20; Monnier VM, 1996, DIABETES, V45, pS67, DOI 10.2337/diab.45.3.S67; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; Nagaraj RH, 1999, FEBS LETT, V453, P327, DOI 10.1016/S0014-5793(99)00571-2; NAKAMURA Y, 1993, AM J PATHOL, V143, P1649; NARAYANAN K, 1994, J MED CHEM, V37, P885, DOI 10.1021/jm00033a004; Odani H, 1998, FEBS LETT, V427, P381, DOI 10.1016/S0014-5793(98)00416-5; Odani H, 1999, BIOCHEM BIOPH RES CO, V256, P89, DOI 10.1006/bbrc.1999.0221; Padayatti PS, 2001, INVEST OPHTH VIS SCI, V42, P1299; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; SELL DR, 1989, CONNECT TISSUE RES, V19, P77, DOI 10.3109/03008208909016816; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; Tyler AN, 1996, ANAL CHEM, V68, P3561, DOI 10.1021/ac9603791; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT KJ, 1995, J ORG CHEM, V60, P6246, DOI 10.1021/jo00125a001; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A	32	114	116	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41638	41647		10.1074/jbc.M103557200	http://dx.doi.org/10.1074/jbc.M103557200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11493602	hybrid			2022-12-25	WOS:000172450400015
J	Bevilaqua, LRM; Graham, ME; Dunkley, PR; von Nagy-Felsobuki, EI; Dickson, PW				Bevilaqua, LRM; Graham, ME; Dunkley, PR; von Nagy-Felsobuki, EI; Dickson, PW			Phosphorylation of Ser(19) alters the conformation of tyrosine hydroxylase to increase the rate of phosphorylation of Ser(40)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; GLYCOGEN-SYNTHASE KINASE-3; SITE-DIRECTED MUTAGENESIS; MASS-SPECTROMETRY; PROTEIN-KINASE; IDENTIFICATION; ACTIVATION; EXPRESSION; MECHANISM; DOPAMINE	The effect of phosphorylation on the shape of tyrosine hydroxylase (TH) was studied directly using gel filtration and indirectly using electrospray ionization mass spectrometry. Phosphorylation of Ser(19) and Ser(40) produced a TH molecule with a more open conformation than the non-phosphorylated form. The conformational effect of Ser(19) phosphorylation is less pronounced than that of the Ser(40) phosphorylation. The effect of Ser(19) and Ser(40) phosphorylation appears to be additive. Binding of dopamine produced a more compact form when compared with the non-dopamine-bound TH. The interdependence of Ser(19) and Ser(40) phosphorylation was probed using electrospray ionization mass spectrometry. The rate constants for the phosphorylation of Ser(19) and Ser(40) were determined by electrospray ionization mass spectrometry using a consecutive reaction model. The rate constant for the phosphorylation of Ser(40) is similar to2 to 3-fold higher if Ser(19) is already phosphorylated. These results suggest that phosphorylation of Ser(19) alters the conformation of tyrosine hydroxylase to allow increased accessibility of Ser(40) to kinases.	Univ Newcastle, Fac Med & Hlth Sci, Sch Biomed Sci, Callaghan, NSW 2308, Australia; Univ Newcastle, Sch Biol & Chem Sci, Callaghan, NSW 2308, Australia	University of Newcastle; University of Newcastle	Dickson, PW (corresponding author), Univ Newcastle, Fac Med & Hlth Sci, Sch Biomed Sci, Callaghan, NSW 2308, Australia.		Graham, Mark E/A-6480-2014	Graham, Mark E/0000-0002-7290-1217; Bevilaqua, Lia/0000-0001-8537-1289				Bobrovskaya L, 2001, J NEUROCHEM, V78, P490, DOI 10.1046/j.1471-4159.2001.00445.x; Bobrovskaya L, 1998, J NEUROCHEM, V70, P2565; BUNN SJ, 1995, J NEUROCHEM, V64, P1370; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cheah TB, 1999, J NEUROSCI METH, V87, P167, DOI 10.1016/S0165-0270(99)00002-3; CRAIG AG, 1991, BIOL MASS SPECTROM, V20, P565, DOI 10.1002/bms.1200200910; DAUBNER SC, 1993, PROTEIN SCI, V2, P1452, DOI 10.1002/pro.5560020909; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; DICKSON PW, 1994, J BIOL CHEM, V269, P20369; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; Fitzpatrick PF, 1999, ANNU REV BIOCHEM, V68, P355, DOI 10.1146/annurev.biochem.68.1.355; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; Graham ME, 2000, ANAL BIOCHEM, V281, P98, DOI 10.1006/abio.2000.4548; HAAVIK J, 1988, BIOCHIM BIOPHYS ACTA, V953, P142, DOI 10.1016/0167-4838(88)90019-2; Harcourt A. V, 1866, PHILOS T R SOC LONDO, V156, P193, DOI [DOI 10.1098/RSTL.1866.0010, 10.1098/rstl.1866.0010]; Haycock JW, 1998, J NEUROCHEM, V71, P1670; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HAYCOCK JW, 1991, J BIOL CHEM, V266, P5650; Itagaki C, 1999, BIOCHEMISTRY-US, V38, P15673, DOI 10.1021/bi9914255; Kleppe R, 2001, J NEUROCHEM, V77, P1097, DOI 10.1046/j.1471-4159.2001.00318.x; Kumer SC, 1996, J NEUROCHEM, V67, P443; LAZAR MA, 1981, J NEUROCHEM, V36, P677, DOI 10.1111/j.1471-4159.1981.tb01641.x; Lengyel I, 2001, J NEUROCHEM, V76, P149, DOI 10.1046/j.1471-4159.2001.00058.x; McCulloch RI, 1999, ARCH BIOCHEM BIOPHYS, V367, P143, DOI 10.1006/abbi.1999.1259; Michaelis L, 1913, BIOCHEM Z, V49, P333; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; POULTER L, 1987, BIOCHIM BIOPHYS ACTA, V929, P296, DOI 10.1016/0167-4889(87)90256-4; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Quinsey NS, 1996, J NEUROCHEM, V66, P908; Ramsey AJ, 1998, BIOCHEMISTRY-US, V37, P8980, DOI 10.1021/bi980582l; RIBEIRO P, 1992, P NATL ACAD SCI USA, V89, P9593, DOI 10.1073/pnas.89.20.9593; ROSTAS JAP, 1988, J NEUROCHEM, V50, P945, DOI 10.1111/j.1471-4159.1988.tb03003.x; Weckwerth W, 2000, RAPID COMMUN MASS SP, V14, P1677, DOI 10.1002/1097-0231(20000930)14:18<1677::AID-RCM84>3.3.CO;2-E; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404	37	74	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40411	40416		10.1074/jbc.M105280200	http://dx.doi.org/10.1074/jbc.M105280200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11502746	hybrid			2022-12-25	WOS:000171925600009
J	Burns, TF; El-Deiry, WS				Burns, TF; El-Deiry, WS			Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; LIGAND-INDUCED APOPTOSIS; MEDIATED APOPTOSIS; DECOY RECEPTOR; CANCER-CELLS; APO-2 LIGAND; CASPASE-8; FADD; FAMILY; BCL-2	The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in tumor cell lines, whereas normal cells appear to be protected from its cytotoxic effects. Therefore TRAIL holds promise as a potential therapeutic agent against cancer. To elucidate some of the critical factors that contribute to TRAIL resistance, we performed a genetic screen in the human colon carcinoma cell line SW480 by infecting this TRAIL-sensitive cell line with a human placental cDNA retroviral library and isolating TRAIL-resistant clones. Characterization of the resulting clones for inhibitors of TRAIL-induced death (ITIDs) led to the isolation of c-FLIPS, Bax inhibitor 1, and Bcl-X-L as candidate suppressors of TRAIL signaling. We have demonstrated that c-FLIPS and Bcl-X-L are sufficient when overexpressed to convey resistance to TRAIL treatment in previously sensitive cell lines. Furthermore both c-FLIPS and Bcl-X-L protected against overexpression of the TRAIL receptors DR4 and KILLER/DR5. When c-FLIPS and Bcl-X-L were overexpressed together in SW480 and HCT 116, an additive inhibitory effect was observed after TRAIL treatment suggesting that these two molecules function in the same pathway in the cell lines tested. Furthermore, we have demonstrated for the first time that a proapoptotic member of the Bcl-2 family, Bax, is required for TRAIL-mediated apoptosis in HCT 116 cells. Surprisingly, we have found that the serine/threonine protein kinase Akt, which is an upstream regulator of both c-FLIPS and Bcl-X-L, is not sufficient when overexpressed to protect against TRAIL in the cell lines tested. These results suggest a key role for c-FLIPS, Bcl-X-L, and Bax in determining tumor cell sensitivity to TRAIL.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Eggert A, 2001, CANCER RES, V61, P1314; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Gazitt Y, 1999, CYTOKINE, V11, P1010, DOI 10.1006/cyto.1999.0536; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Griffith TS, 1998, J IMMUNOL, V161, P2833; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lee SH, 1999, CANCER RES, V59, P5683; Leverkus M, 2000, CANCER RES, V60, P553; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; McDonald ER, 2001, J BIOL CHEM, V276, P14939, DOI 10.1074/jbc.M100399200; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; Meng RD, 1998, CLIN CANCER RES, V4, P251; Mori S, 1999, J IMMUNOL, V162, P5616; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ozoren N, 2000, CANCER RES, V60, P6259; Ozoren N, 2000, INT J ONCOL, V16, P917; Pai SI, 1998, CANCER RES, V58, P3513; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Qin JZ, 2001, NAT MED, V7, P385, DOI 10.1038/86401; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang XD, 1999, CANCER RES, V59, P2747	67	151	158	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37879	37886						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11486001				2022-12-25	WOS:000171526500023
J	Garton, KJ; Gough, PJ; Blobel, CP; Murphy, G; Greaves, DR; Dempsey, PJ; Raines, EW				Garton, KJ; Gough, PJ; Blobel, CP; Murphy, G; Greaves, DR; Dempsey, PJ; Raines, EW			Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-6 RECEPTOR; TRANSMEMBRANE PROTEINS; CELL ACTIVATION; FLOW CONDITIONS; FIRM ADHESION; CX(3)CR1; EXPRESSION; CHEMOKINE; BIOLOGY; METALLOPROTEINASE	Fractalkine (CX3CL1) is an unusual member of the chemokine family that is synthesized with its chemokine domain at the end of a mucin-rich, transmembrane stalk. This membrane-bound localization allows fractalkine to function as an adhesion molecule for cells bearing its receptor, CX3CR1. In addition, fractalkine can be proteolytically released from the cell surface, generating a soluble molecule that functions as a chemoattractant similar to the other members of the chemokine family. In this study, we have examined the mechanisms that regulate the conversion between these two functionally distinct forms of fractalkine. We demonstrate that under normal conditions fractalkine is synthesized as an intracellular precursor that is rapidly transported to the cell surface where it becomes a target for metalloproteinase-dependent cleavage that causes the release of a fragment containing the majority of the fractalkine extracellular domain. We show that the cleavage of fractalkine can be markedly enhanced by stimulating cells with phorbol 12-myristate 13-acetate (PMA), and we identify tumor necrosis factor-alpha converting enzyme (TACE; ADAM17) as the protease responsible for this PMA-induced fractalkine release. In addition, we provide data showing that TACE-mediated fractalkine cleavage occurs at a site distinct from the dibasic juxtamembrane motif that had been suggested previously based on protein sequence homologies. The identification of TACE as a major protease responsible for the conversion of fractalkine from a membrane-bound adhesion molecule to a soluble chemoattractant will provide new information for understanding the physiological function of this chemokine.	Univ Washington, Harborview Med Ctr, Dept Pathol, Seattle, WA 98104 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Pacifis NW Res Inst, Seattle, WA 98122 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Memorial Sloan Kettering Cancer Center; University of East Anglia; University of Oxford	Raines, EW (corresponding author), Univ Washington, Harborview Med Ctr, Dept Pathol, 325 9th Ave,Box 359791, Seattle, WA 98104 USA.			Greaves, David/0000-0003-2856-9410	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059778] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645] Funding Source: Medline; NIDDK NIH HHS [DK59778] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BERG M, 1990, BLOOD, V76, P2381; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Chapman GA, 2000, EUR J PHARMACOL, V392, P189, DOI 10.1016/S0014-2999(00)00117-5; Chapman GA, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-15-j0004.2000; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; DAbaco GM, 1996, MOL CELL BIOL, V16, P884; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Feng LL, 1999, KIDNEY INT, V56, P612, DOI 10.1046/j.1523-1755.1999.00604.x; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Fraticelli P, 2001, J CLIN INVEST, V107, P1173, DOI 10.1172/JCI11517; Furuichi K, 2001, NEPHRON, V87, P314, DOI 10.1159/000045936; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Greaves DR, 2001, ARTERIOSCL THROM VAS, V21, P923, DOI 10.1161/01.ATV.21.6.923; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; Hirata M, 2001, BIOCHEM BIOPH RES CO, V283, P915, DOI 10.1006/bbrc.2001.4879; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Lucas AD, 2001, AM J PATHOL, V158, P855, DOI 10.1016/S0002-9440(10)64034-5; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Patel IR, 1998, J IMMUNOL, V160, P4570; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Robinson LA, 2000, J IMMUNOL, V165, P6067, DOI 10.4049/jimmunol.165.11.6067; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Satoh M, 2000, J AM COLL CARDIOL, V36, P1288, DOI 10.1016/S0735-1097(00)00827-5; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279	43	502	520	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37993	38001						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11495925				2022-12-25	WOS:000171526500039
J	Malkowski, MG; Thuresson, ED; Lakkides, KM; Rieke, CJ; Micielli, R; Smith, WL; Garavito, RM				Malkowski, MG; Thuresson, ED; Lakkides, KM; Rieke, CJ; Micielli, R; Smith, WL; Garavito, RM			Structure of eicosapentaenoic and linoleic acids in the cyclooxygenase site of prostaglandin endoperoxide H synthase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; H SYNTHASE-1; ARACHIDONIC-ACID; ACTIVE-SITE; CRYSTAL-STRUCTURE; GENE-EXPRESSION; ARGININE 120; BINDING; OXYGENATION; BIOSYNTHESIS	Prostaglandin endoperoxide H synthases-1 and -2 (PGHSs) can oxygenate 18-22 carbon polyunsaturated fatty acids, albeit with varying efficiencies. Here we report the crystal structures of eicosapentaenoic acid (EPA, 20:5 n-3) and linoleic acid (LA, 18:2 n-6) bound in the cyclooxygenase active site of Co3+ protoporphyrin IX-reconstituted ovine PGHS-1 (Co3+-oPGHS-1) and compare the effects of active site substitutions on the rates of oxygenation of EPA, LA, and arachidonic acid (AA). Both EPA and IA bind in the active site with orientations similar to those seen previously with AA and dihomo-gamma -linolenic acid (DHLA). For EPA, the presence of an additional double bond (C-17/C-18) causes this substrate to bind in a "strained" conformation in which C-13 is misaligned with respect to Tyr-385, the residue that abstracts hydrogen from substrate fatty acids. Presumably, this misalignment is responsible for the low rate of EPA oxygenation. For LA, the carboxyl half binds in a more extended configuration than AA, which results in positioning C-11 next to Tyr-385. Val-349 and Ser-530, recently identified as important determinants for efficient oxygenation of DHLA by PGHS-1, play similar roles in the oxygenation of EPA and I-A. Approximately 750- and 175-fold reductions in the oxygenation efficiency of EPA and LA were observed with V349A oPGHS-1, compared with a 2-fold change for AA. Val-349 contacts C-2 and C-3 of EPA and C-4 of LA orienting the carboxyl halves of these substrates so that the omega -ends are aligned properly for hydrogen abstraction. An S530T substitution decreases the V-max/K-m of EPA and LA by 375- and 140-fold. Ser-530 makes six contacts with EPA and four with LA involving C-8 through C-16; these interactions influence the alignment of the substrate for hydrogen abstraction. Interestingly, replacement of Phe-205 increases the volume of the cyclooxygenase site allowing EPA to be oxygenated more efficiently than with native oPGHS-1.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Smith, WL (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, 513 Biochem Bldg, E Lansing, MI 48824 USA.	smithww@pilot.msu.edu; garavito@magaera.bch.msu.edu	Malkowski, Michael G/G-4939-2011	Malkowski, Michael G/0000-0003-1025-0014; Malkowski, Michael/0000-0002-1203-7463	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056773, F32HL010170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057323] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL56773, F32 HL10170] Funding Source: Medline; NIGMS NIH HHS [P01 GM57323] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYWARDENA MY, 1989, BIOCHIM BIOPHYS ACTA, V1003, P161, DOI 10.1016/0005-2760(89)90250-6; BAER AN, 1990, J LIPID RES, V31, P125; BAER AN, 1991, BIOCHIM BIOPHYS ACTA, V1085, P45, DOI 10.1016/0005-2760(91)90230-F; BALAZY M, 1991, J BIOL CHEM, V266, P23561; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; DeWitt DL, 1999, MOL PHARMACOL, V55, P625; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; ELLIOTT WJ, 1985, J BIOL CHEM, V260, P987; ENGELS F, 1986, FEBS LETT, V209, P249, DOI 10.1016/0014-5793(86)81121-8; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FOEGH ML, 1989, PROSTAGLANDINS CLIN, P17; GRAFF G, 1982, METHOD ENZYMOL, V86, P386; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; GUPTA BL, 1973, MICROCHEM J, V18, P363, DOI 10.1016/0026-265X(73)90059-3; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HSI LC, 1993, J LIPID MEDIATOR, V6, P131; HULKOWER KI, 1994, ARTHRITIS RHEUM-US, V37, P653, DOI 10.1002/art.1780370508; JONES DA, 1993, J BIOL CHEM, V268, P9049; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KNAPP HR, 1990, PROSTAGLANDINS, V39, P407, DOI 10.1016/0090-6980(90)90122-C; Koshkin V, 1999, BBA-PROTEIN STRUCT M, V1430, P341, DOI 10.1016/S0167-4838(99)00016-3; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1987, PROSTAGLANDINS, V34, P225, DOI 10.1016/0090-6980(87)90246-2; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAGARDE M, 1984, BIOMED BIOCHIM ACTA, V43, pS319; LANDS WEM, 1973, ADV BIOSCI, V9, P15; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; Larsen LN, 1996, BBA-LIPID LIPID MET, V1299, P47, DOI 10.1016/0005-2760(95)00188-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAVER HA, 1991, PROSTAG LEUKOTR ESS, V42, P217, DOI 10.1016/0952-3278(91)90086-K; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Malkowski MG, 2000, ARCH BIOCHEM BIOPHYS, V380, P39, DOI 10.1006/abbi.2000.1906; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; Marnett LJ, 1999, TRENDS PHARMACOL SCI, V20, P465, DOI 10.1016/S0165-6147(99)01385-1; NEEDLEMAN P, 1980, PROSTAG OTH LIPID M, V19, P165, DOI 10.1016/0090-6980(80)90163-X; NUGTEREN DH, 1987, PROSTAGLANDINS, V33, P403, DOI 10.1016/0090-6980(87)90022-0; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V305, P288, DOI 10.1006/abbi.1993.1425; OLIW EH, 1984, J BIOL CHEM, V259, P2716; OTTO JC, 1993, J BIOL CHEM, V268, P18234; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RAZ A, 1990, ADV PROSTAGLANDIN TH, P22; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Smith WL, 2000, E SCHERING RES FDN W, V31, P53; SPECTOR AA, 1983, J LIPID RES, V24, P1595; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501; Thuresson ED, 2001, J BIOL CHEM, V276, P10358, DOI 10.1074/jbc.M009378200; Thuresson ED, 2001, J BIOL CHEM, V276, P10347, DOI 10.1074/jbc.M009377200; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742	68	104	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37547	37555		10.1074/jbc.M105982200	http://dx.doi.org/10.1074/jbc.M105982200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11477109	hybrid			2022-12-25	WOS:000171375700090
J	Schmidt, MO; Brosh, RM; Oliver, DB				Schmidt, MO; Brosh, RM; Oliver, DB			Escherichia coli SecA helicase activity is not required in vivo for efficient protein translocation or autogenous regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; DISTINCT ATP-BINDING; BOX RNA HELICASE; DNA HELICASE; PREPROTEIN TRANSLOCATION; CRYSTAL-STRUCTURE; INNER MEMBRANE; PLASMA-MEMBRANE; MOTIF-III; IN-VIVO	SecA is an essential ATP-driven motor protein that binds to preproteins and the translocon to promote protein translocation across the eubacterial plasma membrane. Escherichia coli SecA contains seven conserved motifs characteristic of superfamily II of DNA and RNA helicases, and it has been shown previously to possess RNA helicase activity. SecA has also been shown to be an autogenous repressor that binds to its translation initiation region on secM-secA mRNA, thereby blocking, and dissociating 30 S ribosomal subunits. Here we show that SecA is an ATP-dependent helicase that unwinds a mimic of the repressor helix of secM-secA mRNA. Mutational analysis of the seven conserved helicase motifs in SecA allowed us to identify mutants that uncouple SecA-dependent protein translocation activity from its helicase activity. Helicase-defective secA mutants displayed normal protein translocation activity and autogenous repression of secA in vivo. Our studies indicate that SecA helicase activity is nonessential and does not appear to be necessary for efficient protein secretion and secA autoregulation.	Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA; NIA, Genet Mol Lab, NIH, Baltimore, MD 21224 USA	Wesleyan University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Oliver, DB (corresponding author), Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA.	doliver@wesleyan.edu	Schmidt, Marcel/AAV-8054-2021	Schmidt, Marcel/0000-0002-3991-2766	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; Brosh RM, 1997, J BIOL CHEM, V272, P572; Cabelli RJ, 1991, THESIS STATE U NEW Y; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; Dillingham MS, 1999, NUCLEIC ACIDS RES, V27, P3310, DOI 10.1093/nar/27.16.3310; DOLAN KM, 1991, J BIOL CHEM, V266, P23329; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1998, J BIOL CHEM, V273, P21675, DOI 10.1074/jbc.273.34.21675; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Hall MC, 1997, J BIOL CHEM, V272, P18614, DOI 10.1074/jbc.272.30.18614; Hall MC, 1998, J MOL BIOL, V277, P257, DOI 10.1006/jmbi.1997.1614; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HUIE JL, 1995, J BACTERIOL, V177, P3518, DOI 10.1128/jb.177.12.3518-3526.1995; JAROSIK GP, 1991, J BACTERIOL, V173, P860, DOI 10.1128/jb.173.2.860-868.1991; JONES CA, 1984, EMBO J, V3, P1181, DOI 10.1002/j.1460-2075.1984.tb01948.x; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; KOONIN EV, 1992, FEBS LETT, V298, P6, DOI 10.1016/0014-5793(92)80009-6; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Matsumoto G, 1998, P NATL ACAD SCI USA, V95, P13567, DOI 10.1073/pnas.95.23.13567; Matsumoto G, 2000, GENES CELLS, V5, P991, DOI 10.1046/j.1365-2443.2000.00388.x; McNicholas P, 1997, J MOL BIOL, V265, P128, DOI 10.1006/jmbi.1996.0723; MCNICHOLAS P, 1995, J BACTERIOL, V177, P7231, DOI 10.1128/jb.177.24.7231-7237.1995; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Miller JH., 1972, EXPT MOL GENETICS; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; Nakatogawa H, 2000, J BIOCHEM-TOKYO, V127, P1071, DOI 10.1093/oxfordjournals.jbchem.a022700; Nakatogawa H, 2000, J BIOL CHEM, V275, P33209, DOI 10.1074/jbc.C000550200; Nakatogawa H, 2001, MOL CELL, V7, P185, DOI 10.1016/S1097-2765(01)00166-6; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Oliver D, 1998, J BACTERIOL, V180, P5240, DOI 10.1128/JB.180.19.5240-5242.1998; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Park SK, 1997, BIOCHEM BIOPH RES CO, V235, P593, DOI 10.1006/bbrc.1997.6834; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; RAJAPANDI T, 1994, BIOCHEM BIOPH RES CO, V200, P1477, DOI 10.1006/bbrc.1994.1617; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; RAJAPANDI T, 1991, J BACTERIOL, V173, P7092, DOI 10.1128/jb.173.22.7092-7097.1991; RIGGS PD, 1988, GENETICS, V118, P571; ROLLO EE, 1988, J BACTERIOL, V170, P3281, DOI 10.1128/jb.170.7.3281-3282.1988; SALAVATI R, 1995, RNA, V1, P745; Salavati R, 1997, J MOL BIOL, V265, P142, DOI 10.1006/jmbi.1996.0724; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmidt M, 2000, J BIOL CHEM, V275, P15440, DOI 10.1074/jbc.M000605200; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Tian HP, 2000, P NATL ACAD SCI USA, V97, P4730, DOI 10.1073/pnas.090087297; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3	67	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37076	37085		10.1074/jbc.M104584200	http://dx.doi.org/10.1074/jbc.M104584200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11477104	hybrid			2022-12-25	WOS:000171375700030
J	Tada, K; Okazaki, T; Sakon, S; Kobarai, T; Kurosawa, K; Yamaoka, S; Hashimoto, H; Mak, TW; Yagita, H; Okumura, K; Yeh, WC; Nakano, H				Tada, K; Okazaki, T; Sakon, S; Kobarai, T; Kurosawa, K; Yamaoka, S; Hashimoto, H; Mak, TW; Yagita, H; Okumura, K; Yeh, WC; Nakano, H			Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE LIVER DEGENERATION; ALPHA-INDUCED APOPTOSIS; GAMMA-DEFICIENT MICE; KINASE COMPLEX; DEFECTIVE INTERLEUKIN-1; INCONTINENTIA PIGMENTI; TERMINAL KINASE; IKK ACTIVATION; TNF RECEPTOR; MEK KINASE-1	Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) were identified as signal transducers for the TNF receptor superfamily. However, the exact roles of TRAF2 and TRAF5 in TNF-induced NF-kappaB activation still remain controversial. To address this issue, we generated TRAF2 and TRAF5 double knockout (DKO) mice. TNF- but not interleukin-1-induced nuclear translocation of NF-kappaB was severely impaired in murine embryonic fibroblasts (MEFs) derived from DKO mice. Moreover, DKO MEFs were more susceptible to TNF-induced cytotoxicity than TRAF2 knockout MEFs. Collectively, these results indicate that both TRAF2 and TRAF5 are involved in TNF-induced NF-kappaB activation and protection from cell death.	Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Dept Rheumatol & Internal Med, Bunkyo Ku, Tokyo 1138421, Japan; Japan Sci & Technol Corp, PRESTO, Shibuya Ku, Tokyo 1510053, Japan; CREST, Japan Sci & Techol Corp, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 1138519, Japan; Univ Toronto, Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	Juntendo University; Juntendo University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Nakano, H (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.			OKAZAKI, TATSUMA/0000-0002-7110-3168; Komazawa-Sakon, Sachiko/0000-0002-6244-1974; Nakano, Hiroyasu/0000-0003-4843-1427				Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Rudolph D, 2000, GENE DEV, V14, P854; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	44	243	250	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36530	36534		10.1074/jbc.M104837200	http://dx.doi.org/10.1074/jbc.M104837200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11479302	hybrid			2022-12-25	WOS:000171194500065
J	Fujino, T; Takei, YA; Sone, H; Ioka, RX; Kamataki, A; Magoori, K; Takahashi, S; Sakai, J; Yamamoto, TT				Fujino, T; Takei, YA; Sone, H; Ioka, RX; Kamataki, A; Magoori, K; Takahashi, S; Sakai, J; Yamamoto, TT			Molecular identification and characterization of two medium-chain Acyl-CoA synthetases, MACS1 and the Sa gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RAT; BLOOD-PRESSURE; GLYCINE CONJUGATION; PROXIMAL TUBULE; SENSITIVE RATS; EXPRESSION; KIDNEY; COSEGREGATION; PROTEINS; CLONING	In this study, we identified and characterized two murine cDNAs encoding medium-chain acyl-CoA synthetase (MACS). One, designated MACS1, is a novel protein and the other the product of the Sa gene (Sa protein), which is preferentially expressed in spontaneously hypertensive rats. Based on the murine MACS1 sequence, we also identified the location and organization of the human MACS1 gene, showing that the human MACS1 and Sa genes are located in the opposite transcriptional direction within a 150-kilobase region on chromosome 16p13.1. Murine MACS1 and Sa protein were overexpressed in COS cells, purified to homogeneity, and characterized. Among C4-C16 fatty acids, MACS1 preferentially utilizes octanoate, whereas isobutyrate is the most preferred fatty acid among C2-C6 fatty acids for Sa protein. Like Sa gene transcript, MACS1 mRNA was detected mainly in the liver and kidney. Subcellular fractionation revealed that both MACS1 and Sa protein are localized in the mitochondrial matrix. C-14-Fatty acid incorporation studies indicated that acyl-CoAs produced by MACS1 and Sa protein are utilized mainly for oxidation.	Tohoku Univ, Ctr Gene Res, Sendai, Miyagi 9818555, Japan; Fukui Med Univ, Dept Internal Med 3, Fukui 9101193, Japan; Tohoku Univ, Grad Sch Med, Dept Med, Div Nephrol Endocrinol & Vasc Med, Sendai, Miyagi 9808574, Japan	Tohoku University; University of Fukui; Tohoku University	Yamamoto, TT (corresponding author), Tohoku Univ, Ctr Gene Res, Aoba Ku, 1-1 Tsutsumidori Amamiya, Sendai, Miyagi 981, Japan.			Sakai, Juro/0000-0003-4043-1035				Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; Fujino T, 2001, J BIOL CHEM, V276, P11420, DOI 10.1074/jbc.M008782200; Garrett MR, 1998, GENOME RES, V8, P711, DOI 10.1101/gr.8.7.711; GU L, 1995, MAMM GENOME, V6, P683, DOI 10.1007/BF00352385; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRIS EL, 1993, AM J HYPERTENS, V6, P330, DOI 10.1093/ajh/6.4.330; Hilgers KF, 1998, KIDNEY INT, V54, P1444, DOI 10.1046/j.1523-1755.1998.00143.x; Hubner N, 1999, HYPERTENSION, V34, P643, DOI 10.1161/01.HYP.34.4.643; Iijima H, 1996, EUR J BIOCHEM, V242, P186, DOI 10.1111/j.1432-1033.1996.0186r.x; IWAI N, 1991, HYPERTENSION, V17, P161, DOI 10.1161/01.HYP.17.2.161; IWAI N, 1992, BIOCHEM BIOPH RES CO, V188, P64, DOI 10.1016/0006-291X(92)92350-7; IWAI N, 1992, J HYPERTENS, V10, P1155, DOI 10.1097/00004872-199210000-00007; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; Karan D, 2001, GENE, V265, P95, DOI 10.1016/S0378-1119(01)00358-4; Kasuya F, 1996, BIOCHEM PHARMACOL, V51, P805, DOI 10.1016/0006-2952(95)02399-2; Kasuya F, 1999, CHEM-BIOL INTERACT, V118, P233, DOI 10.1016/S0009-2797(99)00084-8; LINDPAINTNER K, 1993, J HYPERTENS, V11, P19, DOI 10.1097/00004872-199301000-00004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; OSMUNDSEN H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P141, DOI 10.1016/0005-2760(91)90089-Z; PATEL HR, 1994, J HYPERTENS, V12, P1347; SAMANI NJ, 1993, J CLIN INVEST, V92, P1099, DOI 10.1172/JCI116616; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; Yang TX, 1996, HYPERTENSION, V27, P541, DOI 10.1161/01.HYP.27.3.541	29	51	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35961	35966		10.1074/jbc.M106651200	http://dx.doi.org/10.1074/jbc.M106651200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11470804	hybrid			2022-12-25	WOS:000171109300098
J	Tirona, RG; Leake, BF; Merino, G; Kim, RB				Tirona, RG; Leake, BF; Merino, G; Kim, RB			Polymorphisms in OATP-C - Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION TRANSPORTER; GILBERTS-SYNDROME; P-GLYCOPROTEIN; HUMAN LIVER; BILE-ACID; POLYPEPTIDE; EXPRESSION; FAMILY; GENE; RAT	The human organic anion transporting polypeptide-C (OATP-C) (gene SLC21A6) is a liver-specific transporter importantly involved in the hepatocellular uptake of a variety of endogenous and foreign chemicals. In this study, we demonstrate the presence of multiple functionally relevant single-nucleotide polymorphisms (SNPs) in OATP-C in a population of African- and European-Americans. Moreover, examination of 14 nonsynonymous polymorphisms indicated that genotypic frequencies were dependent on race. Functional assessment of 16 OATP-C alleles in vitro revealed that several variants exhibited markedly reduced uptake of the OATP-C substrates estrone sulfate and estradiol 17 beta -D-glucuronide. Specifically, alterations in transport were associated with SNPs that introduce amino acid changes within the transmembrane-spanning domains (T217C (Phe-73 --> Leu), T245C (Val-82 --> Ala), T521C (Val-174 --> Ala), and T1058C (Ile-353 --> Thr)) and also with those that modify extracellular loop 5 (A1294G (Asn-432 --> Asp), A1385G (Asp-462 --> Gly), and A1463C (Gly-488 --> Ala)). Cell surface biotinylation experiments indicated that the altered transport activity of some OATP-C variants was due, in part, to decreased plasma membrane expression. Given the relatively high genotypic frequency of the T521C (14%) transition in European-Americans and the G1463C (9%) transversion in African-Americans, SNPs in OATP-C may represent a heretofore unrecognized factor influencing drug disposition.	Vanderbilt Univ, Div Clin Pharmacol, Dept Med, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Div Clin Pharmacol, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Kim, RB (corresponding author), Vanderbilt Univ, Div Clin Pharmacol, Dept Med, Sch Med, 572 RRB-1,23rd Ave & Pierce Ave, Nashville, TN 37232 USA.		Kim, Richard/D-6971-2011; Merino, Gracia/H-8811-2015	Kim, Richard/0000-0001-8148-1632; Merino, Gracia/0000-0002-7620-3475	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031304, R55GM054724, R01GM054724] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54724, GM31304] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe T, 1999, J BIOL CHEM, V274, P17159, DOI 10.1074/jbc.274.24.17159; BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; Cui Y, 2001, J BIOL CHEM, V276, P9626, DOI 10.1074/jbc.M004968200; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; Hsiang BN, 1999, J BIOL CHEM, V274, P37161, DOI 10.1074/jbc.274.52.37161; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; Kim RB, 1999, PHARMACEUT RES, V16, P408; Kim RB, 2001, CLIN PHARMACOL THER, V70, P189, DOI 10.1067/mcp.2001.117412; Kim RB, 1999, J PHARMACOL EXP THER, V291, P1204; Konig J, 2000, J BIOL CHEM, V275, P23161, DOI 10.1074/jbc.M001448200; Konig J, 2000, AM J PHYSIOL-GASTR L, V278, pG156, DOI 10.1152/ajpgi.2000.278.1.G156; Kullak-Ublick GA, 2001, GASTROENTEROLOGY, V120, P525, DOI 10.1053/gast.2001.21176; MARTIN JF, 1976, GASTROENTEROLOGY, V70, P385; Meier PJ, 1997, HEPATOLOGY, V26, P1667, DOI 10.1002/hep.510260641; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; Nebert DW, 2000, PHARMACOGENETICS, V10, P279, DOI 10.1097/00008571-200006000-00001; Persico M, 2001, HEPATOLOGY, V33, P627, DOI 10.1053/jhep.2001.22499; SENIOR PA, 1994, BRIT MED J, V309, P327, DOI 10.1136/bmj.309.6950.327; Tamai I, 2000, BIOCHEM BIOPH RES CO, V273, P251, DOI 10.1006/bbrc.2000.2922; Yamazaki M, 1996, PHARMACEUT RES, V13, P1559, DOI 10.1023/A:1016044032571	22	490	521	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35669	35675		10.1074/jbc.M103792200	http://dx.doi.org/10.1074/jbc.M103792200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11477075	hybrid			2022-12-25	WOS:000171109300062
J	Zhao, X; Ito, A; Kane, CD; Liao, TS; Bolger, TA; Lemrow, SM; Means, AR; Yao, TP				Zhao, X; Ito, A; Kane, CD; Liao, TS; Bolger, TA; Lemrow, SM; Means, AR; Yao, TP			The modular nature of histone deacetylase HDAC4 confers phosphorylation-dependent intracellular trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEF2 TRANSCRIPTION FACTOR; RECEPTOR FUNCTION; GENE-EXPRESSION; CO-REPRESSOR; MUSCLE; DIFFERENTIATION; 14-3-3-PROTEINS	In C2C12 myoblasts, endogenous histone deacetylase HDAC4 shuttles between cytoplasmic and nuclear compartments, supporting the hypothesis that its subcellular localization is dynamically regulated. However, upon differentiation, this dynamic equilibrium is disturbed and we find that HDAC4 accumulates in the nuclei of myotubes, suggesting a positive role of nuclear HDAC4 in muscle differentiation. Consistent with the notion of regulation of HDAC4 intracellular trafficking, we reveal that HDAC4 contains a modular structure consisting of a C-terminal autonomous nuclear export domain, which, in conjunction with an internal regulatory domain responsive to calcium/calmodulin-dependent protein kinase IV (CaMKIV), determines its subcellular localization. CaMKIV phosphorylates HDAC4 in vitro and promotes its nuclear-cytoplasmic shuttling in vivo. However, although 14-3-3 binding of HDAC4 has been proposed to be important for its cytoplasmic retention, we find this interaction to be independent of CaMKIV. Rather, the HDAC4.14-3-3 complex exists in the nucleus and is required to confer CaMKIV responsiveness. Our results suggest that the subcellular localization of HDAC4 is regulated by sequential phosphorylation events. The first event is catalyzed by a yet to be identified protein kinase that promotes 14-3-3 binding, and the second event, involving protein kinases such as CaMKIV, leads to efficient nuclear export of the HDAC4.14-3-3 complex.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Yao, TP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, POB 3813, Durham, NC 27710 USA.		Kane, Christopher/C-8256-2019; Ito, Akihiro/A-6100-2015	Kane, Christopher/0000-0002-0469-1668; 	NICHD NIH HHS [HD07503] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200	21	113	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35042	35048		10.1074/jbc.M105086200	http://dx.doi.org/10.1074/jbc.M105086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11470791	hybrid			2022-12-25	WOS:000171024600093
J	Satyamoorthy, K; Muyrers, J; Meier, F; Patel, D; Herlyn, M				Satyamoorthy, K; Muyrers, J; Meier, F; Patel, D; Herlyn, M			Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication	ONCOGENE			English	Article						melanoma; cell-cell adhesion; antisense MEL-CAM; MUC1	CELL-ADHESION MOLECULE; INTERCELLULAR COMMUNICATION; IMMUNOGLOBULIN SUPERFAMILY; RETROVIRAL VECTORS; MAMMALIAN-CELLS; POTENTIAL ROLE; HIGH-TITER; PROGRESSION; ANTIGEN; EXPRESSION	Normal human melanocytes are interspersed singly among keratinocytes along the basement membrane of the epidermis, whereas melanoma cells readily adhere to each other during invasion of the dermis or distant organs. The tumorigenic and metastatic phenotype of melanoma cells often correlates with increased expression of cell-cell and cell-matrix adhesion receptors. Mel-CAM (MCAM, MUC 18, CD146) is a cell-cell adhesion receptor highly expressed by melanoma cells but not normal melanocytes. We show here that inhibition of Mel-CAM expression in metastatic melanoma cells using genetic suppressor elements of Mel-CAM cDNA leads to inhibition of adhesion between melanoma cells and to downregulation of the tumorigenic phenotype. Growth was not inhibited in genetic suppressor elements-transduced melanoma cells cultured in monolayers but was inhibited when cells were maintained anchorage-independently in soft agar and greatly reduced in immunodeficient mice. A three-dimensional epidermal skin equivalent model demonstrated that Mel-CANT allows melanoma cells to separate from the epidermis and invade the basement membrane zone and dermis. However, melanoma cells with little or no Mel-CAM were poorly invasive, possibly due to their loss of gap junctional communication. These results suggest the multifunctional role of a melanoma-associated cell-cell adhesion receptor in tumor progression.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	HerlynM@wistar.upenn.edu	Satyamoorthy, Kapaettu/H-3254-2015	Satyamoorthy, Kapaettu/0000-0002-2368-5490	NCI NIH HHS [CA25874, CA74294, CA76674, CA10815, CA47159] Funding Source: Medline; NIDDK NIH HHS [DK50306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076674, R01CA047159, P30CA010815, P01CA025874, P01CA074294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anfosso F, 1998, J BIOL CHEM, V273, P26852, DOI 10.1074/jbc.273.41.26852; Bardin N, 1996, TISSUE ANTIGENS, V48, P531, DOI 10.1111/j.1399-0039.1996.tb02666.x; Bryant PJ, 1997, DEV GENET, V20, P75, DOI 10.1002/(SICI)1520-6408(1997)20:2<75::AID-DVG1>3.3.CO;2-G; Cochlovius B, 1998, ADV EXP MED BIOL, V451, P345; Degen WGJ, 1998, AM J PATHOL, V152, P805; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERLYN D, 1990, CANCER RES, V50, P2296; HERLYN M, 1996, MOL CELLULAR BIOL ME, P1; HOLNESS CL, 1994, J CELL SCI, V107, P2065; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; JOHNS DR, 1994, J NEURO-OPHTHALMOL, V14, P130; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; Johnson JP, 1997, INT J CANCER, V73, P769; Johnson JP, 1996, CURR TOP MICROBIOL, V213, P95; KATH R, 1991, CANCER RES, V51, P2205; Kraus A, 1997, MELANOMA RES, V7, pS75; Krutovskikh V, 1997, HISTOL HISTOPATHOL, V12, P761; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Levenson VV, 1999, SOMAT CELL MOLEC GEN, V25, P9; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; LYNCH CM, 1991, J VIROL, V65, P3887, DOI 10.1128/JVI.65.7.3887-3890.1991; Marcusson EG, 1999, MOL BIOTECHNOL, V12, P1, DOI 10.1385/MB:12:1:1; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; MORGAN RA, 1992, NUCLEIC ACIDS RES, V20, P1293, DOI 10.1093/nar/20.6.1293; Morimoto C, 1996, Hum Cell, V9, P163; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NESBIT M, 1994, INVAS METAST, V14, P131; PESTOV DG, 1994, P NATL ACAD SCI USA, V91, P12549, DOI 10.1073/pnas.91.26.12549; Pickl WF, 1997, J IMMUNOL, V158, P2107; RONINSON IB, 1995, CANCER RES, V55, P4023; Rummel MM, 1996, CANCER RES, V56, P2218; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; SERS C, 1994, CANCER RES, V54, P5689; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shih IM, 1997, CANCER RES, V57, P3835; SHIH IM, 1994, CANCER RES, V54, P2514; St Croix B, 2000, SCIENCE, V289, P1197; Xie SH, 1997, CANCER RES, V57, P2295; Yagi T, 2000, GENE DEV, V14, P1169; Yamasaki H, 1996, MUTAT RES-REV GENET, V365, P91, DOI 10.1016/S0165-1110(96)90014-7	46	65	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4676	4684		10.1038/sj.onc.1204616	http://dx.doi.org/10.1038/sj.onc.1204616			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498790				2022-12-25	WOS:000170208600008
J	McKenna, S; Spyracopoulos, L; Moraes, T; Pastushok, L; Ptak, C; Xiao, W; Ellison, MJ				McKenna, S; Spyracopoulos, L; Moraes, T; Pastushok, L; Ptak, C; Xiao, W; Ellison, MJ			Noncovalent interaction between ubiquitin and the human DNA repair protein mms2 is required for ubc13-mediated polyubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; KAPPA-B-ALPHA; CONJUGATING-ENZYME; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; BINDING INTERFACE; COMPLEX; SYSTEM; PATHWAY	Ubiquitin-conjugating enzyme variants share significant sequence similarity with typical E2 (ubiquitin-conjugating) enzymes of the protein ubiquitination pathway but lack their characteristic active site cysteine residue. The MMS2 gene of Saccharomyces cerevisiae encodes one such ubiquitin-conjugating enzyme variant that is involved in the error-free DNA postreplicative repair pathway through its association with Ubc13, an E2. The Mms2-Ubc13 heterodimer is capable of linking ubiquitin molecules to one another through an isopeptide bond between the C terminus and Lys-63. Using highly purified components, we show here that the human forms of Mms2 and Ubc13 associate into a heterodimer that is stable over a range of conditions. The ubiquitin-thiol ester form of the heterodimer can be produced by the direct activation of its Ubc13 subunit with El (ubiquitin-activating enzyme) or by the association of Mms2 with the Ubc13-ubiquitin thiol ester. The activated heterodimer is capable of transferring its covalently bound ubiquitin to Lys-63 of an untethered ubiquitin molecule, resulting in diubiquitin as the predominant species. In H-1 N-15 HSQC (H-1 N-15 heteronuclear single quantum coherence) NMR experiments, we have mapped the surface determinants of tethered and untethered ubiquitin that interact with Mms2 and Ubc13 in both their monomeric and dimeric forms. These results have identified a surface of untethered ubiquitin that interacts with Mms2 in the monomeric and heterodimeric form. Furthermore, the C-terminal tail of ubiquitin does not participate in this interaction. These results suggest that the role of Mms2 is to correctly orient either a target-bound or untethered ubiquitin molecule such that its Lys-63 is placed proximally to the C terminus of the ubiquitin molecule that is linked to the active site of Ubc13.	Univ Saskatchewan, Dept Microbiol & Immunol, Saskatoon, SK SYN 5E5, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Inst Biomol Design, Edmonton, AB T6G 2H7, Canada	University of Saskatchewan; University of Alberta; University of Alberta	Xiao, W (corresponding author), Univ Saskatchewan, Dept Microbiol & Immunol, Saskatoon, SK SYN 5E5, Canada.	xioaow@sask.usask.ca; mike.ellison@ualberta.ca		McKenna, Sean/0000-0002-9407-7257; Xiao, Wei/0000-0001-7568-0782				Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Giraud MF, 1998, ACTA CRYSTALLOGR D, V54, P891, DOI 10.1107/S0907444998002480; Hamilton KS, 2000, J BIOMOL NMR, V18, P319, DOI 10.1023/A:1026773008237; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hodgins R, 1996, J BIOL CHEM, V271, P28766, DOI 10.1074/jbc.271.46.28766; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Jiang F, 1999, BIOCHEMISTRY-US, V38, P6471, DOI 10.1021/bi9901329; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; PETERS JM, 1998, UBIQUITIN BIOL CELL, P345; PTAK C, 1994, J BIOL CHEM, V269, P26539; Rothofsky ML, 1997, GENE, V195, P141, DOI 10.1016/S0378-1119(97)00097-8; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; Xiao W, 1998, NUCLEIC ACIDS RES, V26, P3908, DOI 10.1093/nar/26.17.3908; Xiao W, 2000, GENETICS, V155, P1633; Yamaguchi T, 1996, J BIOCHEM-TOKYO, V120, P494; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	43	111	112	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40120	40126		10.1074/jbc.M102858200	http://dx.doi.org/10.1074/jbc.M102858200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11504715	hybrid			2022-12-25	WOS:000171789200083
J	Yang, DM; Pan, Z; Takeshima, H; Wu, CH; Nagaraj, RY; Ma, JJ; Cheng, HP				Yang, DM; Pan, Z; Takeshima, H; Wu, CH; Nagaraj, RY; Ma, JJ; Cheng, HP			RyR3 amplifies RyR1-mediated Ca2+-induced Ca2+ release in neonatal mammalian skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL RYANODINE RECEPTOR; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; CONTRACTION; EXPRESSION; TYPE-3; CDNA; ISOFORMS; MYOTUBES; MYOCYTES	The neonatal mammalian skeletal muscle contains both type 1 and type 3 ryanodine receptors (RyR1 and RyR3) located in the sarcoplasmic reticulum membrane. An allosteric interaction between RyR1 and dihydropyridine receptors located in the plasma membrane mediates voltage-induced Ca2+ release (VICR) from the sarcoplasmic reticulum. RyR3, which disappears in adult muscle, is not involved in VICR, and the role of the transiently expressed RyR3 remains elusive. Here we demonstrate that RyR1 participates in both VICR an Ca2+-induced Ca2+ release (CICR) and that RyR3 amplifies RyR1-mediated CICR in neonatal skeletal muscle. Confocal measurements of intracellular Ca2+ in primary cultured mouse skeletal myotubes reveal active sites of Ca2+ release caused by peripheral coupling between dihydropyridine receptors and RyR1. In myotubes lacking RyR3, the peripheral VICR component is unaffected, and RyR1s alone are able to support inward CICR propagation in most cells at an average speed of similar to 190 mum/s. With the co-presence of RyR1 and RyR3 in wild-type cells, unmitigated radial CICR propagates at 2,440 mum/s. Because neonatal skeletal muscle lacks a well developed transverse tubule system, the RyM reinforcement of CICR seems to ensure a robust, uniform, and synchronous activation of Ca2+ release throughout the cell body. Such functional interplay between RyR1 and RyR3 can serve important roles in Ca2+ signaling of cell differentiation and muscle contraction.	NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, NIH, Baltimore, MD 21224 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Peking Univ, Coll Life Sci, Natl Lab Biomembrane & Membrane Biotechnol, Beijing 100871, Peoples R China; Kurume Univ, Inst Life Sci, Div Cell Biol, Fukuoka 8390861, Japan	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Case Western Reserve University; Peking University; Kurume University	Ma, JJ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	maj2@umdnj.edu	Heping, Cheng/AAE-2680-2019; cheng, heping/A-7299-2011	Heping, Cheng/0000-0002-9604-6702; Takeshima, Hiroshi/0000-0003-4525-3725; Pan, Zui/0000-0003-4105-901X	NCI NIH HHS [R01-CA95739] Funding Source: Medline; NIA NIH HHS [R01-AG15556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barone V, 1998, FEBS LETT, V422, P160, DOI 10.1016/S0014-5793(98)00003-9; Bertocchini F, 1997, EMBO J, V16, P6956, DOI 10.1093/emboj/16.23.6956; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Cheng H, 1996, AM J PHYSIOL-CELL PH, V270, pC148; Conklin MW, 2000, BIOPHYS J, V78, P1777, DOI 10.1016/S0006-3495(00)76728-2; Dietze B, 1998, J PHYSIOL-LONDON, V513, P3, DOI 10.1111/j.1469-7793.1998.003by.x; Flucher BE, 1999, J CELL BIOL, V146, P621, DOI 10.1083/jcb.146.3.621; GYORKE S, 1994, BIOPHYS J, V66, P1879; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; Huser J, 1996, J PHYSIOL-LONDON, V494, P641; Jeyakumar LH, 1998, J BIOL CHEM, V273, P16011, DOI 10.1074/jbc.273.26.16011; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Miura M, 1998, AM J PHYSIOL-HEART C, V274, pH266, DOI 10.1152/ajpheart.1998.274.1.H266; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1997, P NATL ACAD SCI USA, V94, P1019, DOI 10.1073/pnas.94.3.1019; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Ogawa Y, 1999, ADV BIOPHYS, V36, P27, DOI 10.1016/S0065-227X(99)80004-5; OTSU K, 1990, J BIOL CHEM, V265, P13472; Protasi F, 2000, BIOPHYS J, V79, P2494, DOI 10.1016/S0006-3495(00)76491-5; RIOS E, 1991, J MUSCLE RES CELL M, V12, P127, DOI 10.1007/BF01774031; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; Shirokova N, 1999, J PHYSIOL-LONDON, V521, P483, DOI 10.1111/j.1469-7793.1999.00483.x; Song LS, 1998, J PHYSIOL-LONDON, V512, P677, DOI 10.1111/j.1469-7793.1998.677bd.x; Sonnleitner A, 1998, EMBO J, V17, P2790, DOI 10.1093/emboj/17.10.2790; Sorrentino V, 1999, TRENDS CARDIOVAS MED, V9, P54, DOI 10.1016/S1050-1738(99)00003-1; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; Tarroni P, 1997, J BIOL CHEM, V272, P19808, DOI 10.1074/jbc.272.32.19808; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; Ward CW, 2000, J PHYSIOL-LONDON, V525, P91, DOI 10.1111/j.1469-7793.2000.t01-2-00091.x; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	37	42	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40210	40214		10.1074/jbc.M106944200	http://dx.doi.org/10.1074/jbc.M106944200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11500519	hybrid			2022-12-25	WOS:000171789200093
J	Nishida, T; Kaneko, F; Kitagawa, M; Yasuda, H				Nishida, T; Kaneko, F; Kitagawa, M; Yasuda, H			Characterization of a novel mammalian SUMO-1/Smt3-specific isopeptidase, a homologue of rat Axam, which is an Axin-binding protein promoting beta-catenin degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; ACUTE PROMYELOCYTIC LEUKEMIA; GTPASE-ACTIVATING PROTEIN; WNT SIGNALING PATHWAY; SUMO-1 MODIFICATION; PML; RANGAP1; ENZYME; CONJUGATION	A novel SUMO-1/Smt3-specific isopeptidase, SMT3IP2/ Axam2 (Smt3-specific isopeptidase 2), was cloned and characterized. The catalytic domains in the carboxyl-terminal region were very much similar to those of other SUMO-1/Smt3-specific proteases, but the amino-terminal part was quite different. The enzyme specifically bound to Smt3a and Smt3b but not to SUMO-1. The SMT3IP2 expressed by Escherichia coli could cleave SUMO-1, Smt3a, or Smt3b from a SUMO-1/RanGAP1, Smt3a/RanGAP1, or Smt3b/RanGAP1 conjugate, respectively, and had the activity of a carboxyl-terminal hydrolase to produce a glycine residue in the carboxyl terminus of these ubiquitin-like proteins. The sequence data indicated that the amino acid sequence of SMT3IP2 was mostly identical to that of rat Axam, which binds to Axin and promotes the degradation of beta -catenin, although its amino-terminal region was much shorter than that of Axam. Therefore, we designated this isopeptidase SMT3IP2/Axam2. When human SW480 cells were transfected with wild-type SMT3IP2/Axam2, the beta -catenin disappeared. When the cells were transfected with the SMT3IP2/Axam2 C500A mutant, which had neither isopeptidase nor carboxyl-terminal hydrolase activity, or with the 1-352 mutant, which lacked the catalytic domain of the enzyme, again the beta -catenin disappeared, indicating that the enzyme activities were not necessary for the instability of beta -catenin in this transfection assay system and that its competition with Dvl for binding to Axin may be important for the instability of beta -catenin as suggested previously for Axam (Kadoya, T., Kishida, S., Fukui, A., Hinoi, T., Michiue, T., Asashima, M., and Kikuchi, A. (2000) J. BioL Chem. 275, 37030-37037). The involvement of its enzyme activities in the Writ signaling pathway remains to be elucidated.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Tokyo 1920392, Japan; Hamamatsu Univ Sch Med, Dept Biochem 1, Hamamatsu, Shizuoka 4313192, Japan	Tokyo University of Pharmacy & Life Sciences; Hamamatsu University School of Medicine	Yasuda, H (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, 1432-1 Horinouchi, Tokyo 1920392, Japan.	yasuda@ls.toyaku.ac.jp						Boddy MN, 1996, ONCOGENE, V13, P971; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mannen H, 1996, BIOCHEM BIOPH RES CO, V222, P178, DOI 10.1006/bbrc.1996.0717; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	32	94	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39060	39066		10.1074/jbc.M103955200	http://dx.doi.org/10.1074/jbc.M103955200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489887	hybrid			2022-12-25	WOS:000171673200096
J	Parrinello, S; Lin, CQ; Murata, K; Itahana, Y; Singh, J; Krtolica, A; Campisi, J; Desprez, PY				Parrinello, S; Lin, CQ; Murata, K; Itahana, Y; Singh, J; Krtolica, A; Campisi, J; Desprez, PY			Id-1, ITF-2, and Id-2 comprise a network of helix-loop-helix proteins that regulate mammary epithelial cell proliferation, differentiation, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTING TRANSCRIPTION FACTOR; DNA-BINDING; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; INHIBITOR ID2; SUPPRESSION; ACTIVATION; MECHANISM; LACTATION	Mammary epithelial cells proliferate, invade the stroma, differentiate, and die in adult mammals by mechanisms that are poorly understood. We found that Id-1, an inhibitor of basic helix-loop-helix transcription factors, regulates mammary epithelial cell growth, differentiation, and invasion in culture. Here, we show that Id-1 is expressed highly during mammary development in virgin mice and during early pregnancy, when proliferation and invasion are high. During mid-pregnancy, Id-1 expression declined to undetectable levels as the epithelium differentiated fully. Surprisingly, Id-1 increased during involution, when the epithelium undergoes extensive apoptosis. To determine whether Id-1 regulates both proliferation and apoptosis, we constitutively expressed Id-1 in mammary epithelial cell cultures. Id-1 stimulated proliferation in sparse cultures but induced apoptosis in dense cultures, which reflect epithelial cell density during early pregnancy and involution, respectively. To understand how Id-1 acts, we screened a yeast two-hybrid library from differentiating mammary epithelial cells and identified ITF-2, a basic helix-loop-helix transcription factor, as an Id-l-interacting protein. Overexpression of ITF-2 significantly reduced Id-1-stimulated proliferation and apoptosis. We show further that, in contrast to Id-1, Id-2 was expressed highly in differentiated mammary epithelial cells in vivo and in culture. In culture, Id-2 antisense transcripts blocked differentiation. Our results suggest that Id-1, ITF-2, and Id-2 comprise a network of interacting molecular switches that govern mammary epithelial cell phenotypes.	Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, San Francisco, CA 94115 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	California Pacific Medical Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Desprez, PY (corresponding author), Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, Stern Bldg,2330 Clay St, San Francisco, CA 94115 USA.				NATIONAL CANCER INSTITUTE [R01CA082548] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82548] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andres-Barquin PJ, 1999, EXP CELL RES, V247, P347, DOI 10.1006/excr.1998.4360; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BORST DW, 1982, J EXP ZOOL, V221, P245, DOI 10.1002/jez.1402210216; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS JC, 1995, DEVELOPMENT, V121, P2513; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; Desprez Pierre-Yves, 1993, Molecular and Cellular Differentiation, V1, P99; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; HARPER JW, 1993, CELL, V75, P805; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P677, DOI 10.1093/nar/18.3.677; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P678, DOI 10.1093/nar/18.3.678; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lin CQ, 2000, CANCER RES, V60, P1332; LISTER J, 1995, J BIOL CHEM, V270, P17939, DOI 10.1074/jbc.270.30.17939; Lund LR, 1996, DEVELOPMENT, V122, P181; Maniatis T., 1989, MOL CLONING LAB MANU; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Melnikova IN, 1999, EXP CELL RES, V247, P94, DOI 10.1006/excr.1998.4330; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Morrow MA, 1999, MOL IMMUNOL, V36, P491, DOI 10.1016/S0161-5890(99)00071-1; Nakajima T, 1998, P NATL ACAD SCI USA, V95, P10590, DOI 10.1073/pnas.95.18.10590; NEUMAN K, 1995, FEBS LETT, V374, P279, DOI 10.1016/0014-5793(95)01128-2; Nogueira MM, 2000, BIOCHEM BIOPH RES CO, V276, P803, DOI 10.1006/bbrc.2000.3543; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; Singh J, 2001, J BIOL CHEM, V276, P11852, DOI 10.1074/jbc.M006931200; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; TRAURIG HH, 1967, ANAT REC, V159, P239, DOI 10.1002/ar.1091590213; TRAURIG HH, 1967, ANAT REC, V157, P489, DOI 10.1002/ar.1091570309; Wice BM, 1998, J BIOL CHEM, V273, P25310, DOI 10.1074/jbc.273.39.25310; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZWIERZCHOWSKI L, 1984, DIFFERENTIATION, V28, P179, DOI 10.1111/j.1432-0436.1984.tb00281.x	45	86	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39213	39219		10.1074/jbc.M104473200	http://dx.doi.org/10.1074/jbc.M104473200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11498533	hybrid, Green Submitted, Green Published			2022-12-25	WOS:000171673200116
J	Prekeris, R; Davies, JM; Scheller, RH				Prekeris, R; Davies, JM; Scheller, RH			Identification of a novel Rab11/25 binding domain present in eferin and Rip proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; RADIXIN; MOESIN; FAMILY; EZRIN; ASSOCIATION; TRAFFICKING; SPECIFICITY; ENDOSOME	Rab11, a low molecular weight GTP-binding protein, has been shown to play a key role in a variety of cellular processes, including endosomal recycling, phagocytosis, and transport of secretory proteins from the trans-Golgi network. In this study we have described a novel Rab11 effector, EF-hands-containing Rab11-interacting protein (Eferin). In addition, we have identified a 20-amino acid domain that is present at the C terminus of Eferin and other Rab11/25-interacting proteins, such as Rip11 and nRip11. Using biochemical techniques we have demonstrated that this domain is necessary and sufficient for Rab11 binding in vitro and that it is required for localization of Rab11 effector proteins in vivo. The data suggest that various Rab effectors compete with each other for binding to Rab11/25 possibly accounting for the diversity of Rab11 functions.	Genentech Inc, S San Francisco, CA 94080 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Roche Holding; Genentech; Howard Hughes Medical Institute; Stanford University	Scheller, RH (corresponding author), Genentech Inc, 1 DNA Way, S San Francisco, CA 94080 USA.							BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Chen D, 2001, J BIOL CHEM, V276, P13127, DOI 10.1074/jbc.M009424200; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; Dumas JJ, 1999, STRUCTURE, V7, P413, DOI 10.1016/S0969-2126(99)80054-9; Esters H, 2000, J MOL BIOL, V298, P111, DOI 10.1006/jmbi.2000.3645; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; Kessler A, 2000, DIABETOLOGIA, V43, P1518, DOI 10.1007/s001250051563; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Mammoto A, 1999, J BIOL CHEM, V274, P25517, DOI 10.1074/jbc.274.36.25517; Merithew E, 2001, J BIOL CHEM, V276, P13982, DOI 10.1074/jbc.M009771200; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; SATO N, 1992, J CELL SCI, V103, P131; Steegmaier M, 2000, TRAFFIC, V1, P553, DOI 10.1034/j.1600-0854.2000.010705.x; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840	24	89	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38966	38970		10.1074/jbc.M106133200	http://dx.doi.org/10.1074/jbc.M106133200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11481332	hybrid			2022-12-25	WOS:000171673200084
J	Schiffer, SG; Foley, S; Kaffashan, A; Hronowski, X; Zichittella, AE; Yeo, CY; Miatkowski, K; Adkins, HB; Damon, B; Whitman, M; Salomon, D; Sanicola, M; Williams, KP				Schiffer, SG; Foley, S; Kaffashan, A; Hronowski, X; Zichittella, AE; Yeo, CY; Miatkowski, K; Adkins, HB; Damon, B; Whitman, M; Salomon, D; Sanicola, M; Williams, KP			Fucosylation of Cripto is required for its ability to facilitate nodal signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-EYED-PINHEAD; LEFT-RIGHT ASYMMETRY; O-LINKED FUCOSE; IMMUNOHISTOCHEMICAL DETECTION; GROWTH; EXPRESSION; PROTEIN; GENE; XENOPUS; FRINGE	O-Linked fucose modification is rare and has been shown to occur almost exclusively within epidermal growth factor (EGF)-like modules. We have found that the EGF-CFC family member human Cripto-1 (CR) is modified with fucose and through a combination of peptide mapping, mass spectrometry, and sequence analysis localized the site of attachment to Thr-88. The identification of a fucose modification on human CR within its EGF-like domain and the presence of a consensus fucosylation site within all EGF-CFC family members suggest that this is a biologically important modification in CR, which functionally distinguishes it from the EGF ligands that bind the type 1 erbB growth factor receptors. A single CR point mutation, Thr-88 --> Ala results in a form of the protein that is not fucosylated and has substantially weaker activity in cell-based CR/Nodal signaling assays, indicating that fucosylation is functionally important for CR to facilitate Nodal signaling.	Biogen Inc, Cambridge, MA 02142 USA; Harvard Univ, Sch Med, PhD Program Biol & Biomed Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; NCI, Tumor Immunol & Biol Lab, Tumor Growth Factor Sect, NIH, Bethesda, MD 20892 USA	Biogen; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Williams, KP (corresponding author), Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA.	kevin_williams@biogen.com		Yeo, Chang-Yeol/0000-0002-4440-1215; Cheung, Anne/0000-0001-6041-692X				ALLEN G, 1989, LAB TECHNIQUES BIOCH, V9, P232; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Blair SS, 2000, CURR BIOL, V10, pR608, DOI 10.1016/S0960-9822(00)00633-3; BRANDT R, 1994, J BIOL CHEM, V269, P17320; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Byrne RL, 1998, J PATHOL, V185, P108; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Colas JF, 2000, GENE, V255, P205, DOI 10.1016/S0378-1119(00)00337-1; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; De Angelis E, 1999, INT J ONCOL, V14, P437; De Santis ML, 1997, CELL GROWTH DIFFER, V8, P1257; DONO R, 1993, DEVELOPMENT, V118, P1157; Faure S, 2000, DEVELOPMENT, V127, P2917; Fortini ME, 2000, NATURE, V406, P357, DOI 10.1038/35019233; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; HESSION C, 1991, J BIOL CHEM, V266, P6682; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hiller KM, 2000, MOL CARCINOGEN, V27, P280, DOI 10.1002/(SICI)1098-2744(200004)27:4<280::AID-MC6>3.0.CO;2-L; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Ito H, 1997, INT J CANCER, V71, P556, DOI 10.1002/(SICI)1097-0215(19970516)71:4<556::AID-IJC9>3.3.CO;2-J; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; Kao YH, 1999, BIOCHEMISTRY-US, V38, P7097, DOI 10.1021/bi990234z; Kiecker C, 2000, MECH DEVELOP, V94, P37, DOI 10.1016/S0925-4773(00)00329-4; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Kumar A, 2001, J BIOL CHEM, V276, P656, DOI 10.1074/jbc.M004649200; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Lohmeyer M, 1997, BIOCHEMISTRY-US, V36, P3837, DOI 10.1021/bi961542p; Lopez-Ferrer A, 2000, GUT, V47, P349, DOI 10.1136/gut.47.3.349; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Minchiotti G, 2000, MECH DEVELOP, V90, P133, DOI 10.1016/S0925-4773(99)00235-X; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Niemeyer CC, 1999, INT J CANCER, V81, P588, DOI 10.1002/(SICI)1097-0215(19990517)81:4<588::AID-IJC14>3.0.CO;2-I; Niemeyer CC, 1998, CELL DEATH DIFFER, V5, P440, DOI 10.1038/sj.cdd.4400368; Normanno N, 1998, CANCER DETECT PREV, V22, P62; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; SAEKI T, 1992, CANCER RES, V52, P3467; Saijoh Y, 2000, MOL CELL, V5, P35, DOI 10.1016/S1097-2765(00)80401-3; Salomon DS, 1999, BIOESSAYS, V21, P61, DOI 10.1002/(SICI)1521-1878(199901)21:1&lt;61::AID-BIES8&gt;3.0.CO;2-H; Salomon DS, 2000, ENDOCR-RELAT CANCER, V7, P199, DOI 10.1677/erc.0.0070199; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Seno M, 1998, GROWTH FACTORS, V15, P215, DOI 10.3109/08977199809002118; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; Shen MM, 1997, DEVELOPMENT, V124, P429; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Yan YT, 1999, GENE DEV, V13, P2527, DOI 10.1101/gad.13.19.2527; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6; Zhou X L, 1999, Yi Chuan Xue Bao, V26, P142	59	73	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37769	37778						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11500501				2022-12-25	WOS:000171526500008
J	Korn, SH; Wouters, EFM; Vos, N; Janssen-Heininger, YMW				Korn, SH; Wouters, EFM; Vos, N; Janssen-Heininger, YMW			Cytokine-induced activation of nuclear factor-kappa B is inhibited by hydrogen peroxide through oxidative inactivation of I kappa B kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHOINOSITIDE 3-KINASE; TNF-ALPHA; PROTEIN; DEGRADATION; APOPTOSIS; SIGNAL; TRANSLOCATION; INVOLVEMENT	Rapid activation of the I kappaB kinase (IKK) complex is considered an obligatory step in the activation of nuclear factor-kappaB (NF-kappaB) in response to diverse stimuli. Since oxidants have been implicated in the regulation of NF-kappaB, the focus of the present study was the activation of IKK by tumor necrosis factor alpha (TNF alpha) in the presence or absence of hydrogen peroxide (H2O2). Exposure of mouse alveolar epithelial cells to H2O2 was not sufficient to activate IKK degrade I kappaB alpha, or activate NF-kappaB. In contrast, TNF alpha induced IKK activity rapidly and transiently resulting in I kappaB alpha degradation and NF-kappaB activation. Importantly, in the presence of H2O2 the ability of TNF alpha to induce IKK activity was markedly decreased and resulted in prevention of I kappaB alpha degradation and NF-kappaB activation. Neither tyrosine kinases nor phosphatidylinositol 3-kinases, known regulators of NF-kappaB by oxidants, were involved in IKK inhibition by H2O2 Direct addition of H2O2 to the immunoprecipitated IKK complex inhibited enzyme activity. Inhibition of IKK activity by H2O2 was associated with direct oxidation of cysteine residues present in the IKK complex and occurred only in enzymatically active IKK. In contrast to previously published observations, our findings demonstrate that the oxidant H2O2 reduces NF-kappaB activation by inhibiting activated IKK activity.	Univ Vermont, Dept Pathol, Burlington, VT 05405 USA; Maastricht Univ, Dept Pulmonol, NL-6200 MD Maastricht, Netherlands	University of Vermont; Maastricht University	Janssen-Heininger, YMW (corresponding author), Univ Vermont, Dept Pathol, Med Alumni Bldg A143, Burlington, VT 05405 USA.	yjanssen@zoo.uvm.edu	Wouters, Emiel/ABD-6200-2021		NHLBI NIH HHS [HL60014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Awane M, 1999, J IMMUNOL, V162, P5337; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Canty TG, 1999, CIRCULATION, V100, P361; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Ito K, 2001, FASEB J, V15, pA473; Janssen YMW, 1997, AM J PATHOL, V151, P389; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Jeon KI, 2000, J IMMUNOL, V164, P5981, DOI 10.4049/jimmunol.164.11.5981; Kaminsky DA, 1999, J ALLERGY CLIN IMMUN, V104, P747, DOI 10.1016/S0091-6749(99)70283-6; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Malkinson AM, 1997, TOXICOLOGY, V123, P53, DOI 10.1016/S0300-483X(97)00108-X; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; MENON SD, 1995, J BIOL CHEM, V270, P18881; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; Oka S, 2000, FEBS LETT, V472, P196, DOI 10.1016/S0014-5793(00)01464-2; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Repine JE, 1997, AM J RESP CRIT CARE, V156, P341, DOI 10.1164/ajrccm.156.2.9611013; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Weber CK, 2000, GASTROENTEROLOGY, V119, P1209, DOI 10.1053/gast.2000.19458; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1999, MOL CELL BIOL, V19, P4547	47	161	164	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35693	35700		10.1074/jbc.M104321200	http://dx.doi.org/10.1074/jbc.M104321200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11479295	hybrid			2022-12-25	WOS:000171109300065
J	Schleip, I; Heiss, E; Lehle, L				Schleip, I; Heiss, E; Lehle, L			The yeast SEC20 gene is required for N- and O-glycosylation in the Golgi - Evidence that impaired glycosylation does not correlate with the secretory defect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED GLYCOSYLATION; OUTER CHAIN ELONGATION; SACCHAROMYCES-CEREVISIAE; GLYCOPROTEIN-BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; APPARATUS; MUTANTS; PATHWAY; OLIGOSACCHARIDES	The Golgi plays a fundamental role in posttranslational glycosylation, transport, and sorting of proteins. The mechanism of protein transport through the Golgi has been seen as controversial in recent years. During the characterization of N-glycosylation-defective mutants (ngd) previously isolated by this laboratory, it was found that ngd20 is allelic to sec20. SEC20 was reported to be required for transport from endoplasmic reticulum to Golgi, but its precise function remains to be determined. We show now that SEC20 is also required for N- and O-glycosylation in the Golgi but not in the Ell, in a cargo-specific manner, and that the glycosylation defect does not correlate with the secretory defect. By pulse-chase labeling experiments in combination with mannose linkage-specific antibodies, invertase and carboxypeptidase were found to be efficiently secreted to their final compartment, even upon shift to the nonpermissive temperature, while glycosylation in the Golgi was severely impaired. Using microsomal membranes isolated from ngd20, we found that mannosyl transfer from GDP-Man to various mannose-oligosaccharides, indicative for Golgi mannosylation, was strongly diminished. Analysis of the carbohydrate component of chitinase, an exclusively O-mannosylated protein, or of the bulk mannoprotein indicates that O-mannosylation is also reduced. The results demonstrate that in addition to secretion SEC20 also affects glycosylation in the Golgi, presumably because it exerts a more general role in maintenance and function of the Golgi compartments.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93053 Regensburg, Germany	University of Regensburg	Lehle, L (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, Univ Str 31, D-93053 Regensburg, Germany.	ludwig.lehle@biologie.uni-regensburg.de	Heiss, Elke/B-6086-2015	Heiss, Elke/0000-0001-7618-5505				ALLEN BB, 1999, SCIENCE, V285, P63; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; Brigance WT, 2000, MOL BIOL CELL, V11, P171, DOI 10.1091/mbc.11.1.171; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; COSSON P, 1997, EUR J CELL BIOL, V73, P92; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; Glick BS, 1997, FEBS LETT, V414, P177, DOI 10.1016/S0014-5793(97)00984-8; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHLE L, 1979, J BIOL CHEM, V254, P2209; LEHLE L, 1995, FEBS LETT, V370, P41, DOI 10.1016/0014-5793(95)00789-C; Lehle L., 1995, GLYCOPROTEINS A, V29a, P475; LEHLE L, 1994, BIOCHIM BIOPHYS ACTA, V350, P225; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; Manas P, 1997, GLYCOBIOLOGY, V7, P487, DOI 10.1093/glycob/7.4.487; NAGASU T, 1992, YEAST, V8, P535, DOI 10.1002/yea.320080705; NAKAJIMA T, 1975, P NATL ACAD SCI USA, V72, P3912, DOI 10.1073/pnas.72.10.3912; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Pelham HRB, 1998, TRENDS CELL BIOL, V8, P45, DOI 10.1016/S0962-8924(97)01185-9; Rayner JC, 1998, J BIOL CHEM, V273, P26836, DOI 10.1074/jbc.273.41.26836; REDDY VA, 1988, J BIOL CHEM, V263, P6978; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; SWEET DJ, 1993, EMBO J, V12, P2831, DOI 10.1002/j.1460-2075.1993.tb05944.x; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; Warren G, 1998, CURR OPIN CELL BIOL, V10, P493, DOI 10.1016/S0955-0674(98)80064-1	46	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28751	28758		10.1074/jbc.M103753200	http://dx.doi.org/10.1074/jbc.M103753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11477110	hybrid			2022-12-25	WOS:000170346000016
J	Kozlova, NI; Morozevich, GE; Chubukina, AN; Berman, AE				Kozlova, NI; Morozevich, GE; Chubukina, AN; Berman, AE			Integrin alpha v beta 3 promotes anchorage-dependent apoptosis in human intestinal carcinoma cells	ONCOGENE			English	Article						integrins; apoptosis; anoikis; extracellular matrix	ENDOTHELIAL-CELLS; MELANOMA-CELLS; EXPRESSION; SURVIVAL; ACTIVATION; ADHESION; MATRIX; ANGIOGENESIS; INDUCTION; COLLAGEN	A population of cells surviving during prolonged incubation in suspension (anoikis-negative cells) were selected from the original anoikis-positive human intestinal carcinoma cell line Caco-2. Anoikis-negative cells are characterized by a strong transcriptional downregulation of the alphav-integrin chain as detected by FACS analysis, RT-PCR and Northern blotting. This finding suggested that ow-integrin generates a signal stimulating apoptosis of Caco-2 cells upon their detachment from the extracellular matrix. Two lines of evidence supporting this suggestion were provided. First, activation of the alphav beta3 integrin on Caco-2 cells by their treatment with an alphav beta3-specific monoclonal antibody resulted in marked stimulation of anoikis. Second, treatment of Caco-2 cells with alphav-specific antisense oligonucleotide resulted in downregulation of the expression of alphav chain and in elevated resistance of these cells to anoikis. Thus, for the first time, our data prove that alphav beta3 integrin can be an active transducer of apoptosis-stimulating signals generated in response to disruption of the cell-matrix contacts.	Russian Acad Med Sci, Inst Biomed Chem, Moscow 119832, Russia	Russian Academy of Medical Sciences; Institute of Biomedical Chemistry	Berman, AE (corresponding author), Russian Acad Med Sci, Inst Biomed Chem, Pogodinskaya Str 10, Moscow 119832, Russia.		Kozlova, Nadezda/ABD-7878-2020; Morozevich, Galina/ABD-7858-2020; EBerman, Albert/F-5042-2017					Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bachelder RE, 1999, J BIOL CHEM, V274, P20733, DOI 10.1074/jbc.274.29.20733; BERMAN A, 1993, BIOCHEM BIOPH RES CO, V194, P351, DOI 10.1006/bbrc.1993.1827; Berman A E, 2000, Membr Cell Biol, V13, P207; Brassard DL, 1999, EXP CELL RES, V251, P33, DOI 10.1006/excr.1999.4559; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Danen EHJ, 1996, BIOCHEM BIOPH RES CO, V226, P75, DOI 10.1006/bbrc.1996.1313; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Eble J.A., 1997, MOL B INT U, P1; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEHLSEN KR, 1992, CLIN EXP METASTAS, V10, P111, DOI 10.1007/BF00114587; Heino J, 1996, INT J CANCER, V65, P717, DOI 10.1002/(SICI)1097-0215(19960315)65:6<717::AID-IJC1>3.3.CO;2-P; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Kuzuya M, 1999, EXP CELL RES, V248, P498, DOI 10.1006/excr.1999.4422; MARSHALL JF, 1991, INT J CANCER, V49, P924, DOI 10.1002/ijc.2910490621; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miao JY, 1997, BIOCHEM BIOPH RES CO, V233, P182, DOI 10.1006/bbrc.1997.6422; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Morozevich GE, 1998, VOP MED KHIM, V44, P77; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Vuori K, 1998, J MEMBRANE BIOL, V165, P191, DOI 10.1007/s002329900433; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	36	51	54	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4710	4717		10.1038/sj.onc.1204619	http://dx.doi.org/10.1038/sj.onc.1204619			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498793				2022-12-25	WOS:000170208600011
J	Yang, SN; Yu, J; Mayr, GW; Hofmann, F; Larsson, O; Berggren, PO				Yang, SN; Yu, J; Mayr, GW; Hofmann, F; Larsson, O; Berggren, PO			Inositol hexakisphosphate increases L-type Ca2+ channel activity by stimulation of adenylyl cyclase	FASEB JOURNAL			English	Article						adenylyl cyclase; calcium channel; hippocampus; inositol polyphosphate; protein kinase A	DEPENDENT PROTEIN-KINASE; RAT HIPPOCAMPAL-NEURONS; CALCIUM CHANNELS; SYNAPTIC TRANSMISSION; CREB PHOSPHORYLATION; TRANSMITTER RELEASE; BINDING-PROTEINS; C ACTIVATORS; N-TYPE; CELL	Inositol hexakisphosphate (InsP(6))is a most abundant inositol polyphosphate that changes simultaneously with inositol 1,4,5- trisphosphate in depolarized neurons. However, the role of InsP6 in neuronal signaling is unknown. Mass assay reveals that the basal levels of InsP6 in several brain regions tested are similar. InsP6 mass is significantly elevated in activated brain neurons and lowered by inhibition of neuronal activity. Furthermore, the hippocampus is most sensitive to electrical challenge with regard to percentage accumulation of InsP6. In hippocampal neurons, InsP6 stimulates adenylyl cyclase (AC) without influencing cAMP phosphodiesterases, resulting in activation of protein kinase A (PKA) and thereby selective enhancement of voltage-gated L- type Ca2+ channel activity. This enhancement was abolished by preincubation with PKA and AC inhibitors. These data suggest that InsP6 increases L- type Ca2+ channel activity by facilitating phosphorylation of PKA phosphorylation sites. Thus, in hippocampal neurons, InsP6 serves as an important signal in modulation of voltage-gated L-type Ca2+ channel activity.	Karolinska Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res L3, S-17176 Stockholm, Sweden; Univ Hamburg, Krankenhaus Eppendorf, Inst Med Biochem & Mol Biol, D-20246 Hamburg, Germany; Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	Karolinska Institutet; Karolinska University Hospital; University of Hamburg; University of Freiburg	Yang, SN (corresponding author), Karolinska Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res L3, S-17176 Stockholm, Sweden.	yang.shaonian@enk.ks.se	Tuluc, Petronel/C-2527-2011	Berggren, Per-Olof/0000-0001-8991-413X				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURON A, 1994, PFLUG ARCH EUR J PHY, V427, P510, DOI 10.1007/BF00374268; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DOERNER D, 1988, J NEUROSCI, V8, P4069; DOERNER D, 1988, NEURON, V1, P693, DOI 10.1016/0896-6273(88)90168-7; Efanov AM, 1997, P NATL ACAD SCI USA, V94, P4435, DOI 10.1073/pnas.94.9.4435; FISHMAN RA, 2000, CEREBROSPINAL FLUID; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Guillou JL, 1999, J NEUROSCI, V19, P6183, DOI 10.1523/JNEUROSCI.19-14-06183.1999; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; HELL JW, 1995, EMBO J, V14, P3036, DOI 10.1002/j.1460-2075.1995.tb07306.x; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; JACKSON TR, 1987, EMBO J, V6, P49, DOI 10.1002/j.1460-2075.1987.tb04717.x; Kavalali ET, 1997, J NEUROSCI, V17, P5334; Kavalali ET, 1997, NEURON, V18, P651, DOI 10.1016/S0896-6273(00)80305-0; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; Larsson O, 1997, SCIENCE, V278, P471, DOI 10.1126/science.278.5337.471; MAYR GW, 1991, BIOCHEM J, V280, P631, DOI 10.1042/bj2800631; MAYR GW, 1988, BIOCHEM J, V254, P585, DOI 10.1042/bj2540585; MEYERS DER, 1989, J NEUROPHYSIOL, V61, P467, DOI 10.1152/jn.1989.61.3.467; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MIRONOV SL, 1991, NEUROSCI LETT, V133, P175, DOI 10.1016/0304-3940(91)90563-9; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; PARENT A, 1994, EUR J NEUROSCI, V6, P67, DOI 10.1111/j.1460-9568.1994.tb00248.x; Reid CA, 1998, J NEUROSCI, V18, P2849; SASAKAWA N, 1994, MOL PHARMACOL, V46, P380; SASAKAWA N, 1993, BRAIN RES, V623, P155, DOI 10.1016/0006-8993(93)90023-G; SCULIER JP, 1993, SUPPORT CARE CANCER, V1, P135, DOI 10.1007/BF00366059; SCULPTOREANU A, 1995, AM J PHYSIOL-CELL PH, V269, pC725, DOI 10.1152/ajpcell.1995.269.3.C725; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; Shears S B, 1996, Subcell Biochem, V26, P187; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; Talley EM, 1999, J NEUROSCI, V19, P1895; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; THEIBERT AB, 1992, J BIOL CHEM, V267, P9071; Thibault O, 1996, SCIENCE, V272, P1017, DOI 10.1126/science.272.5264.1017; Tsien RW, 1998, NATURE, V391, P839, DOI 10.1038/35981; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; Wu LG, 1998, P NATL ACAD SCI USA, V95, P4720, DOI 10.1073/pnas.95.8.4720; Yang SN, 1999, J NEUROPHYSIOL, V81, P781, DOI 10.1152/jn.1999.81.2.781; Zhang KH, 1999, DEV BRAIN RES, V112, P11, DOI 10.1016/S0165-3806(98)00150-3	45	36	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2001	15	10					1753	1763		10.1096/fj.00-0799com	http://dx.doi.org/10.1096/fj.00-0799com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481223				2022-12-25	WOS:000170809900011
J	Benaud, CM; Dickson, RB				Benaud, CM; Dickson, RB			Adhesion-regulated G1 cell cycle arrest in epithelial cells requires the downregulation of c-Myc	ONCOGENE			English	Article						adhesion; c-Myc; cell cycle; p27	GROWTH-FACTOR-BETA; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; FUNCTIONAL INACTIVATION; DEPENDENT EXPRESSION; NEGATIVE REGULATORS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CDK COMPLEXES; MESSENGER-RNA	Adhesion to the extracellular matrix is required for the expression and activation of the cyclin-cyclin-dependent kinase (CDK) complexes, and for G1 phase progression of non-transformed cells. However, in non-adherent cells no molecular mechanism has yet been proposed for the cell adhesion-dependent up-regulation of the p27 cyclin-dependent kinase inhibitor (CKI), and the associated inhibition of cyclin E-CDK2. We now show that in epithelial cells the expression of c-Myc is tightly regulated by cell-substrate adhesion. When deprived of adhesion, two independently derived mammary epithelial cell lines, 184AlN4 and MCF-10A, rapidly decrease their level of c-Myc mRNA and protein. This decrease in levels of c-Myc correlates with G1 phase arrest, as indicated by hypophosphorylation of pRb and inhibition of the activity of the cyclin E-CDK2 complex. In 184AlN4 cells, cell-substrate adhesion is required for the suppression of p27, and induction of cyclin E, E2F-1, but not cyclins D1 and D3. Enforced expression of c-Myc in non-adherent 184AIN4 and MCF-10A cells reverses the adhesion-dependent inhibition of cell cycle progression. Restoration of c-Myc in non-adherent cells induces the expression of E2F-1, and hyperphosphorylation of pRb in response to EGF treatment. In addition, expression of c-Myc results in the anchorage-independent activation of the CDK2 complex, the associated upregulation of cyclin E, and the destabilization and degradation of p27 by the ubiquitin-proteasome pathway. Our study thus suggests that c-Myc is the link between cell adhesion and the regulation of p27 and cyclin ECDK2. Furthermore, we describe a role for c-Myc in adhesion-mediated regulation of E2F-1.	Georgetown Univ, Med Ctr, Dept Cell Biol, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Oncol, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University; Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Dept Cell Biol, Vincent T Lombardi Canc Ctr, 3970 Reservoir Rd NW, Washington, DC 20007 USA.	dicksonr@gunet.georgetown.edu	Benaud, Christelle/M-1178-2018		NIA NIH HHS [R01 AG1496] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Carstens CP, 1996, EXP CELL RES, V229, P86, DOI 10.1006/excr.1996.0346; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dike LE, 1996, J CELL SCI, V109, P2855; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KUMATORI A, 1991, BIOCHEM BIOPH RES CO, V178, P480, DOI 10.1016/0006-291X(91)90132-Q; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Liao DJ, 2000, ONCOGENE, V19, P1307, DOI 10.1038/sj.onc.1203430; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUHISA T, 1981, EXP CELL RES, V135, P393, DOI 10.1016/0014-4827(81)90176-2; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nass SJ, 1998, CLIN CANCER RES, V4, P1813; Nijjar T, 1999, CANCER RES, V59, P5112; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SEJERSEN T, 1985, J CELL PHYSIOL, V125, P465, DOI 10.1002/jcp.1041250315; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SOULE HD, 1990, CANCER RES, V50, P6075; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	64	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4554	4567		10.1038/sj.onc.1204609	http://dx.doi.org/10.1038/sj.onc.1204609			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494151				2022-12-25	WOS:000170074900013
J	Ricci, JE; Lang, V; Luciano, F; Belhacene, N; Giordanengo, V; Michel, F; Bismuth, G; Auberger, P				Ricci, JE; Lang, V; Luciano, F; Belhacene, N; Giordanengo, V; Michel, F; Bismuth, G; Auberger, P			An absolute requirement for Fyn in T cell receptor-induced caspase activation and apoptosis	FASEB JOURNAL			English	Article						TCR-mediated apoptosis; Fyn knockout mice	PROTEIN-TYROSINE KINASES; LYMPHOCYTE STIMULATION; ANTIGEN RECEPTOR; B-CELLS; CLEAVAGE; PHOSPHORYLATION; DEGRADATION; INHIBITION; MICE; DNA	The mechanisms by which caspases are stimulated following T cell receptor engagement are presently unknown. We show here that TCR cross-linking induces caspase activation, annexin V binding, loss of cell viability, Fyn cleavage, and apoptosis in a T cell hybridoma. All these events are increased in T cells overexpressing wild-type Fyn and are inhibited in cells expressing a kinase dead mutant or a soluble form of Fyn. Moreover, DNA fragmentation mediated by various proapoptotic stimuli and anti-CD3-induced caspase activation and DNA fragmentation are reduced significantly in mouse embryo fibroblasts and thymocytes from Fyn knockout mice respectively. These results indicate that an active and membrane-anchored Fyn is required for T cell receptor-induced caspase activation and apoptosis in T lymphocytes and point out a specific role of Fyn in caspase activation and apoptosis in T cells.	LNC Label, INSERM, U526, IFR 50, F-06107 Nice 2, France; Ctr Hosp Pitie Salpetriere, Cellular Immunol Lab, CNRS, UMR 7627, F-75013 Paris, France; Inst Pasteur, Dept Immunol, Lab Mol Immunol, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Auberger, P (corresponding author), LNC Label, INSERM, U526, IFR 50, Av Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	RICCI, Jean Ehrland/AAS-4379-2020; AUBERGER, Patrick/G-1491-2013; luciano, frederic/P-6264-2016; Ricci, Jean Ehrland/I-7117-2016	RICCI, Jean Ehrland/0000-0003-1585-8117; AUBERGER, Patrick/0000-0002-2481-8275; luciano, frederic/0000-0001-9253-4998; Ricci, Jean Ehrland/0000-0003-1585-8117; Michel, Frederique/0000-0002-3524-2232; giordanengo, valerie/0000-0002-5114-1124				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; BLANK U, 1993, EUR J IMMUNOL, V23, P3057, DOI 10.1002/eji.1830231203; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Denny MF, 2000, MOL CELL BIOL, V20, P1426, DOI 10.1128/MCB.20.4.1426-1435.2000; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fusaki N, 1996, J IMMUNOL, V156, P1369; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Guerin S, 1997, FASEB J, V11, P1003, DOI 10.1096/fasebj.11.12.9337153; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jiang D, 1999, CELL DEATH DIFFER, V6, P402, DOI 10.1038/sj.cdd.4400513; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KATAGIRI T, 1990, P NATL ACAD SCI USA, V87, P2865; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Lang V, 1999, J IMMUNOL, V162, P7224; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; Maruo A, 1999, INT IMMUNOL, V11, P1371, DOI 10.1093/intimm/11.9.1371; Michel F, 1998, J BIOL CHEM, V273, P31932, DOI 10.1074/jbc.273.48.31932; MIGITA K, 1995, IMMUNOLOGY, V85, P550; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Paget WJ, 1999, SOZ PRAVENTIV MED, V44, P1, DOI 10.1007/BF01624804; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; QUILL H, 1992, J IMMUNOL, V149, P2887; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; RON D, 1999, J BIOL CHEM, V274, P19203; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096	37	22	22	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1777	+		10.1096/fj.00-0665fje	http://dx.doi.org/10.1096/fj.00-0665fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481227				2022-12-25	WOS:000169261200016
J	Sauer, K; Liou, J; Singh, SB; Yablonski, D; Weiss, A; Perlmutter, RM				Sauer, K; Liou, J; Singh, SB; Yablonski, D; Weiss, A; Perlmutter, RM			Hematopoietic progenitor kinase 1 associates physically and functionally with the adaptor proteins B cell linker protein and SLP-76 in lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL; ANTIGEN-RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASES; INTERLEUKIN-2 PRODUCTION; CATALYTIC SPECIFICITY; INTERACTIONS DEFINE; CRYSTAL-STRUCTURES; PEPTIDE LIBRARIES; RAS ACTIVATION	B cell linker protein (BLNK) is a SLP-76-related adaptor protein essential for signal transduction from the BCR. To identify components of BLNK-associated signaling pathways, we performed a phosphorylation-dependent yeast two-hybrid analysis using BLNK probes. Here we report that the serine/threonine kinase hematopoietic progenitor kinase 1 (HPK1), which is activated upon antigen-receptor stimulation and which has been implicated in the regulation of MAP kinase pathways, interacts physically and functionally with BLNK in B cells and with SLP-76 in T cells. This interaction requires Tyr(379) of HPK1 and the Src homology 2 (SH2) domain of BLNK/SLP-76. Via homology modeling, we defined a consensus binding site within ligands for SLP family SH2 domains. We further demonstrate that the SH2 domain of SLP-76 participates in the regulation of AP-1 and NFAT activation in response to T cell receptor (TCR) stimulation and that HPK1 inhibits AP-1 activation in a manner partially dependent on its interaction with SLP-76. Our data are consistent with a model in which full activation of HPK1 requires its own phosphorylation on tyrosine and subsequent interaction with adaptors of the SLP family, providing a mechanistic basis for the integration of this kinase into antigen receptor signaling cascades.	Merck Res Labs, Dept Immunol & Rheumatol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Mol Syst, Rahway, NJ 07065 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel	Merck & Company; Merck & Company; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Sauer, K (corresponding author), Merck Res Labs, Dept Immunol & Rheumatol, Rahway, NJ 07065 USA.	Karsten_Sauer@Merck.com		Yablonski, Deborah/0000-0003-2979-0440	NCI NIH HHS [R01 CA72531] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072531] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Arnold R, 2001, J BIOL CHEM, V276, P14675, DOI 10.1074/jbc.M008343200; Boerth NJ, 2000, J BIOL CHEM, V275, P5143, DOI 10.1074/jbc.275.7.5143; Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; BUDAY L, 1995, ONCOGENE, V11, P1327; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; Cao MY, 1999, J EXP MED, V190, P1527, DOI 10.1084/jem.190.10.1527; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; daSilva AJ, 1997, BIOCHEM SOC T, V25, P361, DOI 10.1042/bst0250361; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Dente L, 1997, J MOL BIOL, V269, P694, DOI 10.1006/jmbi.1997.1073; Fang N, 1996, J IMMUNOL, V157, P3769; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Geng LP, 1999, J IMMUNOL, V163, P5753; Goitsuka R, 2000, INT IMMUNOL, V12, P573, DOI 10.1093/intimm/12.4.573; Goitsuka R, 1998, J IMMUNOL, V161, P5804; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; Hu MCT, 1999, ONCOGENE, V18, P5514, DOI 10.1038/sj.onc.1202740; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Huber Michael, 2000, EMBO Reports, V1, P308, DOI 10.1093/embo-reports/kvd078; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Klarlund JK, 1996, J BIOL CHEM, V271, P16674, DOI 10.1074/jbc.271.28.16674; KUOSAKI T, 2000, IMMUNITY, V12, P1; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; Ling P, 2001, J BIOL CHEM, V276, P18908, DOI 10.1074/jbc.M101485200; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu J, 1998, P NATL ACAD SCI USA, V95, P8779, DOI 10.1073/pnas.95.15.8779; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Ma WB, 2001, ONCOGENE, V20, P1703, DOI 10.1038/sj.onc.1204224; Marie-Cardine A, 1998, J BIOL CHEM, V273, P25789, DOI 10.1074/jbc.273.40.25789; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Muller K, 1996, J BIOL CHEM, V271, P16500; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Myung PS, 2000, CURR OPIN IMMUNOL, V12, P256, DOI 10.1016/S0952-7915(00)00085-6; Norian LA, 2000, SEMIN IMMUNOL, V12, P43; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Pawson T, 2000, GENE DEV, V14, P1027; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Raab M, 1999, J BIOL CHEM, V274, P21170, DOI 10.1074/jbc.274.30.21170; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TINKER DA, 1992, ANTICANCER RES, V12, P123; Tsuji S, 2001, J EXP MED, V194, P529, DOI 10.1084/jem.194.4.529; Veale M, 1999, J BIOL CHEM, V274, P28427, DOI 10.1074/jbc.274.40.28427; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yankee TM, 2000, FASEB J, V14, pA966; Yasuda T, 2000, J EXP MED, V191, P641, DOI 10.1084/jem.191.4.641; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhao H, 1997, J BIOL CHEM, V272, P21625, DOI 10.1074/jbc.272.34.21625; Zhao H, 1998, J BIOL CHEM, V273, P12061, DOI 10.1074/jbc.273.20.12061; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133; Zhou SY, 1999, PROG BIOPHYS MOL BIO, V71, P359, DOI 10.1016/S0079-6107(98)00045-5	81	86	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45207	45216		10.1074/jbc.M106811200	http://dx.doi.org/10.1074/jbc.M106811200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11487585	hybrid			2022-12-25	WOS:000172406700114
J	Elble, RC; Pauli, BU				Elble, RC; Pauli, BU			Tumor suppression by a proapoptotic calcium-activated chloride channel in mammary epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; WILD-TYPE P53; CYSTIC-FIBROSIS; INTRACELLULAR ACIDIFICATION; BICARBONATE PERMEABILITY; CELL-LINE; APOPTOSIS; CLONING; GENE; PROLIFERATION	Little is known of the roles played by ion channels in cancer. Here we describe a pair of closely related calcium-activated chloride channels whose differential regulation in normal, apoptotic, and transformed mouse cells suggests that channel function is proapoptotic and antineoplastic. While mCLCA1 predominates over mCLCA2 under normal physiological conditions, this relationship is reversed by apoptotic stress both in developing mammary gland and in cultured HC11 mammary epithelial cells. Consistent with an apoptosis-promoting role, splicing of mCLCA2 is disrupted in apoptosis-resistant tumor cell lines and in HC11 cells selected for resistance to detachment-induced apoptosis (anoikis). Unexpectedly, mCLCA1 message is also down-regulated in these cells by at least 30-fold. These results suggest that both genes antagonize survival of mammary tumor cells by sensitizing them to anoikis. When MCF7 or HEK293 tumor cells were transfected with plasmids encoding either mCLCA1 or mCLCA2, colony formation was greatly reduced relative to a vector-transfected control, demonstrating that calcium-sensitive chloride channel (CLCA) expression is deleterious to tumor cell survival. Furthermore, mammary epithelial cells overexpressing mCLCA2 had twice the rate of apoptosis of normal cells when subjected to serum starvation and formed multinuclear giants at a high frequency in normal culture, suggesting that mCLCA2 can promote either apoptosis or senescence.	Cornell Univ, Coll Vet Med, Canc Biol Labs, Ithaca, NY 14853 USA; Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University; Cornell University	Elble, RC (corresponding author), Cornell Univ, Coll Vet Med, Canc Biol Labs, Ithaca, NY 14853 USA.	rce3@cornell.edu			NATIONAL CANCER INSTITUTE [R01CA047668] Funding Source: NIH RePORTER; NCI NIH HHS [CA47668] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agnel M, 1999, FEBS LETT, V455, P295, DOI 10.1016/S0014-5793(99)00891-1; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Anderson JM, 2000, GASTROENTEROLOGY, V119, P1783, DOI 10.1053/gast.2000.20821; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BARRY MA, 1993, CANCER RES, V53, P2349; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; CHAO TY, 1989, CANCER IMMUNOL IMMUN, V25, P93; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; DEANE KHO, 1992, EUR J IMMUNOL, V22, P1165, DOI 10.1002/eji.1830220509; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; EBRALIDZE AK, 1989, GENETIKA+, V25, P932; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P3587, DOI 10.1073/pnas.93.8.3587; GOTTLIEB RA, 1995, BLOOD, V86, P2414, DOI 10.1182/blood.V86.6.2414.bloodjournal8662414; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Grignani F, 1998, CANCER RES, V58, P14; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1998, HISTOCHEM CELL BIOL, V110, P43, DOI 10.1007/s004180050263; Gruber AD, 1999, CANCER RES, V59, P5488; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Komiya T, 1999, BIOCHEM BIOPH RES CO, V255, P347, DOI 10.1006/bbrc.1999.0168; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; KUNZELMANN K, 1991, PFLUG ARCH EUR J PHY, V417, P616, DOI 10.1007/BF00372960; Lee D, 1999, BIOCHEM BIOPH RES CO, V264, P933, DOI 10.1006/bbrc.1999.1583; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Malhi H, 2000, J BIOL CHEM, V275, P26050, DOI 10.1074/jbc.M001576200; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; MERIO GR, 1997, CELL GROWTH DIFFER, V8, P251; MERLO GR, 1994, ONCOGENE, V9, P443; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Murray A W, 1994, Chem Biol, V1, P191, DOI 10.1016/1074-5521(94)90009-4; NILIUS B, 1992, J PHYSIOL-LONDON, V445, P537, DOI 10.1113/jphysiol.1992.sp018938; Osborne BA, 1996, J CELL BIOCHEM, V60, P18, DOI 10.1002/(SICI)1097-4644(19960101)60:1<18::AID-JCB4>3.0.CO;2-6; PAPPAS CA, 1994, NEUROREPORT, V6, P193, DOI 10.1097/00001756-199412300-00049; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; Souktani R, 2000, AM J PHYSIOL-CELL PH, V279, pC158, DOI 10.1152/ajpcell.2000.279.1.C158; SPECTOR DL, 1998, APOPTOSIS ASSAYS CEL, V1; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; TABCHARANI JA, 1989, J MEMBRANE BIOL, V112, P109, DOI 10.1007/BF01871272; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; Teraki Y, 1999, EUR J DERMATOL, V9, P413; Ullrich N, 1997, AM J PHYSIOL-CELL PH, V273, pC1290, DOI 10.1152/ajpcell.1997.273.4.C1290; VILLAZ M, 1995, J PHYSIOL-LONDON, V488, P689, DOI 10.1113/jphysiol.1995.sp021000; Wang SY, 1998, J CELL PHYSIOL, V176, P456, DOI 10.1002/(SICI)1097-4652(199809)176:3<456::AID-JCP2>3.0.CO;2-N; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; WILSON GF, 1993, J PHYSIOL-LONDON, V470, P501, DOI 10.1113/jphysiol.1993.sp019872; Wohlrab D, 1999, SKIN PHARMACOL APPL, V12, P257, DOI 10.1159/000066250; WOODFORK KA, 1995, J CELL PHYSIOL, V162, P163, DOI 10.1002/jcp.1041620202; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189	58	84	95	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40510	40517		10.1074/jbc.M104821200	http://dx.doi.org/10.1074/jbc.M104821200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11483609	hybrid			2022-12-25	WOS:000171925600021
J	Liang, XH; Liu, L; Michaeli, S				Liang, XH; Liu, L; Michaeli, S			Identification of the first trypanosome H/ACA RNA that guides pseudouridine formation on rRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNAS; RIBOSOMAL-RNA; LEPTOMONAS-COLLOSOMA; PRERIBOSOMAL RNA; PRECURSOR SNORNA; BINDING PROTEIN; BOX-C/D; METHYLATION; BRUCEI; YEAST	In trypanosomes small nucleolar RNA (snoRNA) genes are clustered, and the clusters encode for either single or multiple RNAs. We previously reported on a genomic locus in Leptomonas collosoma that encodes for multiple C/D snoRNAs whose expression is regulated at the processing level (Xu, Y., Liu, L., Lopez-Estrano, C., and Michaeli, S. (2001) J. Biol. Chem. 276, 14289-14298). In this study we have characterized, in the same genomic locus, the first trypanosome H/ACA RNA, which we termed hl. Having a length of 69 nucleotides, hl has the potential to guide pseudouridylation on 28 S rRNA. The hl is processed from a long polycistronic transcript that carries both the C/D and hl snoRNAs. The h1/rRNA duplex obeys the rules for guiding pseudouridylation. Mapping of the pseudouridine site indicated that the predicted U is indeed modified. However, in contrast to all H/ACA RNAs, hl consists of a single hairpin structure and is the shortest H/ACA RNA described so far.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.		Michaeli, Shulamit/AAC-8255-2022	Liu, Li/0000-0002-3733-6961				Bachellerie JP, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P191; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; Bortolin ML, 1999, EMBO J, V18, P457, DOI 10.1093/emboj/18.2.457; CAFFARELLI E, 1994, MOL CELL BIOL, V14, P2966, DOI 10.1128/MCB.14.5.2966; CAMPBELL DA, 1987, J MOL BIOL, V196, P113, DOI 10.1016/0022-2836(87)90514-6; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; Das A, 1996, J BIOL CHEM, V271, P15675, DOI 10.1074/jbc.271.26.15675; Djikeng A, 2001, MOL BIOCHEM PARASIT, V113, P109, DOI 10.1016/S0166-6851(00)00384-4; Dunbar DA, 2000, NUCLEIC ACIDS RES, V28, P2855, DOI 10.1093/nar/28.15.2855; Dunbar DA, 2000, J BIOL CHEM, V275, P14767, DOI 10.1074/jbc.M001180200; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Ganot P, 1997, GENE DEV, V11, P941, DOI 10.1101/gad.11.7.941; Henras A, 1998, EMBO J, V17, P7078, DOI 10.1093/emboj/17.23.7078; KISS T, 1995, GENE DEV, V9, P1411, DOI 10.1101/gad.9.11.1411; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Leader DJ, 1997, EMBO J, V16, P5742, DOI 10.1093/emboj/16.18.5742; Leader DJ, 1999, PLANT MOL BIOL, V39, P1091, DOI 10.1023/A:1006157022319; Levitan A, 1998, NUCLEIC ACIDS RES, V26, P1775, DOI 10.1093/nar/26.7.1775; Li L, 2000, J BIOL CHEM, V275, P2259, DOI 10.1074/jbc.275.4.2259; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Ofengand J, 1997, J MOL BIOL, V266, P246, DOI 10.1006/jmbi.1996.0737; Ooi SL, 1998, RNA, V4, P1096, DOI 10.1017/S1355838298980785; Petfalski E, 1998, MOL CELL BIOL, V18, P1181, DOI 10.1128/MCB.18.3.1181; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Roberts TG, 1998, MOL CELL BIOL, V18, P4409, DOI 10.1128/MCB.18.8.4409; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; Villa T, 1998, MOL CELL BIOL, V18, P3376, DOI 10.1128/MCB.18.6.3376; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Xu Y, 2000, ISRAEL MED ASSOC J, V2, P58; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473; Xu YX, 2001, J BIOL CHEM, V276, P14289, DOI 10.1074/jbc.M007007200	39	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40313	40318		10.1074/jbc.M104488200	http://dx.doi.org/10.1074/jbc.M104488200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11483606	hybrid			2022-12-25	WOS:000171789200108
J	Tao, JC; Malbon, CC; Wang, HY				Tao, JC; Malbon, CC; Wang, HY			G alpha(i2) enhances insulin signaling via suppression of protein-tyrosine phosphatase 1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F9 TERATOCARCINOMA CELLS; FACTOR-I RECEPTOR; PHOSPHOLIPASE-C; GROWTH-FACTOR; PRIMITIVE ENDODERM; PERTUSSIS-TOXIN; RAT ADIPOCYTES; ALPHA-SUBUNIT; DIABETIC RATS; ANTISENSE RNA	Suppression of the expression of the heterotrimeric G-protein G alpha (i2) in vivo has been shown to provoke insulin resistance, whereas enhanced insulin signaling is observed when G alpha (i2) is overexpressed in vivo. The basis for G alpha (i2) regulation of insulin signaling was explored in transgenic mice with targeted expression of the GTPase-deficient, constitutively active Q205L G alpha (i2) in fat and skeletal muscle. Phosphorylation of insulin receptor and IRS-1 in response to insulin challenge in vivo was markedly amplified in fat and skeletal muscle expressing Q205L G alpha (i2) The expression and activity of the protein-tyrosine phosphatase 1B (PTP1B), but not protein-tyrosine phosphatases SHP-1, SHP-2, and LAR, were constitutively decreased in tissues expressing the Q205L G alpha (i2), providing a direct linkage between insulin signaling and Gai2. The loss of PTP1B expression may explain, in part, the loss of PTP1B activity in the iQ205L transgenic mice. Activation of G alpha (i2) in mouse adipocytes with lysophosphatidic acid was shown to decrease PTP1B activity, whereas pertussis toxin inactivates G alpha (i2), blocks lysophosphatidic acid-stimulated inhibition of PTP1B activity, and blocks tonic suppression of PTP1B activity by G alpha (i2). Elevation of intracellular cAMP in fat cells is shown to increase PTP1B activity, whereas either depression of cAMP levels or direct activation of G alpha (i2) suppresses PTP1B. These data provide the first molecular basis for the interplay between G alpha (i2) and insulin signaling, i.e. activation of G alpha (i2) can suppress both the expression and activity of PTP1B in insulin-sensitive tissues.	SUNY Stony Brook, Pharmacol HSC, Ctr Med, Dept Mol Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Med Ctr, Dept Physiol & Biophys, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Malbon, CC (corresponding author), SUNY Stony Brook, Pharmacol HSC, Ctr Med, Dept Mol Pharmacol, Stony Brook, NY 11794 USA.	craig@pharm.som.sunysb.edu	malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; BRAUTIGAN DL, 1993, MOL CELL BIOCHEM, V128, P121; CARO JF, 1994, J CELL BIOCHEM, V54, P309, DOI 10.1002/jcb.240540307; Chen JF, 1997, J MOL MED, V75, P283, DOI 10.1007/s001090050113; Crespo P, 1998, BIOCHEM BIOPH RES CO, V245, P554, DOI 10.1006/bbrc.1998.8480; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Ferrara CM, 1999, BIOCHEM J, V343, P571, DOI 10.1042/0264-6021:3430571; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; GAO P, 1995, AM J PHYSIOL-CELL PH, V268, pC1460, DOI 10.1152/ajpcell.1995.268.6.C1460; Gao P, 1996, J BIOL CHEM, V271, P30692, DOI 10.1074/jbc.271.48.30692; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; Gordeladze JO, 1997, J CELL BIOCHEM, V64, P242, DOI 10.1002/(SICI)1097-4644(199702)64:2<242::AID-JCB8>3.0.CO;2-X; Haire RN, 1997, IMMUNOGENETICS, V46, P349, DOI 10.1007/s002510050282; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hazeki O, 1998, LIFE SCI, V62, P1555, DOI 10.1016/S0024-3205(98)00106-4; Hovik KE, 1999, LIPIDS, V34, P355, DOI 10.1007/s11745-999-0373-9; Hunter T, 1998, Harvey Lect, V94, P81; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Kanoh Y, 2000, CELL SIGNAL, V12, P223, DOI 10.1016/S0898-6568(99)00081-9; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin S, 2000, DIGEST DIS SCI, V45, P1517, DOI 10.1023/A:1005596407496; Liu JL, 1997, J BIOL CHEM, V272, P29438, DOI 10.1074/jbc.272.47.29438; Liu T, 1999, J BIOL CHEM, V274, P33539, DOI 10.1074/jbc.274.47.33539; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; Liu XX, 1998, J BIOL CHEM, V273, P11685, DOI 10.1074/jbc.273.19.11685; Luft FC, 1997, J MOL MED-JMM, V75, P233; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MOXHAM CM, 1993, DEV GENET, V14, P266, DOI 10.1002/dvg.1020140404; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Poirier LA, 2001, BIOCHEM J, V354, P323, DOI 10.1042/0264-6021:3540323; Pryor Paul R., 1997, Biochemical Society Transactions, V25, p475S; RECORD RD, 1993, EXP CELL RES, V206, P36, DOI 10.1006/excr.1993.1117; Rizzo Mark A., 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P167; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Sanchez-Margalet V, 1999, CELL MOL LIFE SCI, V55, P142, DOI 10.1007/s000180050279; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmidt M, 2000, J BIOL CHEM, V275, P32603, DOI 10.1074/jbc.M004784200; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Uehara T, 1999, EUR J BIOCHEM, V259, P801, DOI 10.1046/j.1432-1327.1999.00100.x; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; Wang HY, 1999, J BIOL CHEM, V274, P32159, DOI 10.1074/jbc.274.45.32159; Wang HY, 2000, METH MOL B, V136, P241; Wang LH, 2000, BIOCHEM J, V345, P543, DOI 10.1042/0264-6021:3450543; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; Yang JM, 1999, EXP MOL MED, V31, P179, DOI 10.1038/emm.1999.29; Zheng XL, 1998, J BIOL CHEM, V273, P23649, DOI 10.1074/jbc.273.37.23649	58	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39705	39712		10.1074/jbc.M105216200	http://dx.doi.org/10.1074/jbc.M105216200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11500506	hybrid			2022-12-25	WOS:000171789200027
J	Andreeva, AY; Krause, E; Muller, EC; Blasig, IE; Utepbergenov, DI				Andreeva, AY; Krause, E; Muller, EC; Blasig, IE; Utepbergenov, DI			Protein kinase C regulates the phosphorylation and cellular localization of occludin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION PERMEABILITY; EPITHELIAL-CELLS; POSSIBLE INVOLVEMENT; MEMBRANE-PROTEIN; DOMAIN; IDENTIFICATION; REDISTRIBUTION; DISSOCIATION; ASSOCIATION; INCREASE	Occludin is an integral membrane phosphoprotein specifically associated with tight junctions, contributing to the structure and function of this intercellular seal. Occludin function is thought to be regulated by phosphorylation, but no information is available on the molecular pathways involved. In the present study, the involvement of the protein kinase C pathway in the regulation of the phosphorylation and cellular distribution of occludin has been investigated. Phorbol 12-myristate 13-acetate and 1,2-dioctanoylglycerol induced the rapid phosphorylation of occludin in Madin-Darby canine kidney cells cultured in low extracellular calcium medium with a concomitant translocation of occludin to the regions of cell-cell contact. The extent of occludin phosphorylation as well as its incorporation into tight junctions induced by protein kinase C activators or calcium switch were markedly decreased by the protein kinase C inhibitor GF-109203X. In addition, in vitro experiments showed that the recombinant COOH-terminal domain of murine occludin could be phosphorylated by purified protein kinase C. Ser(338) of occludin was identified as an in vitro protein kinase C phosphorylation site using peptide mass fingerprint analysis and electrospray ionization tandem mass spectroscopy. These findings indicate that protein kinase C is involved in the regulation of occludin function at tight junctions.	Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Humboldt Univ, Charite, D-13092 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Blasig, IE (corresponding author), Forschungsinst Mol Pharmakol, Bldg 81,Rm A2-06,Robert Rossle Str 10, D-13125 Berlin, Germany.		Utepbergenov, Darkhan/N-9881-2014; Utepbergenov, Darkhan/AAA-1249-2021	Utepbergenov, Darkhan/0000-0002-9005-4103; Utepbergenov, Darkhan/0000-0002-9005-4103				Balda MS, 2000, SEMIN CELL DEV BIOL, V11, P281, DOI 10.1006/scdb.2000.0177; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Bamforth SD, 1999, J CELL SCI, V112, P1879; BIEMANN K, 1987, SCIENCE, V237, P992, DOI 10.1126/science.3303336; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; Clarke H, 2000, J CELL SCI, V113, P3187; Cordenonsi M, 1999, EUR J BIOCHEM, V264, P374, DOI 10.1046/j.1432-1327.1999.00616.x; Dodane V, 1996, J MEMBRANE BIOL, V149, P199, DOI 10.1007/s002329900020; Farshori P, 1999, J MEMBRANE BIOL, V170, P147, DOI 10.1007/s002329900544; Fleming TP, 2000, SEMIN CELL DEV BIOL, V11, P291, DOI 10.1006/scdb.2000.0179; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Godson C, 1996, BBA-MOL CELL RES, V1313, P63, DOI 10.1016/0167-4889(96)00050-X; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Hirase T, 1997, J CELL SCI, V110, P1603; Hirase T, 2001, J BIOL CHEM, V276, P10423, DOI 10.1074/jbc.M007136200; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Lacaz-Vieira F, 1999, J MEMBRANE BIOL, V168, P289, DOI 10.1007/s002329900518; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Mitic LL, 1999, J CELL BIOL, V146, P683, DOI 10.1083/jcb.146.3.683; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Nusrat A, 2000, J CELL SCI, V113, P1771; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Sheth B, 2000, DEVELOPMENT, V127, P831; STADDON JM, 1995, J CELL SCI, V108, P609; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; VanItallie CM, 1997, J CELL SCI, V110, P1113; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Wong V, 1997, AM J PHYSIOL-CELL PH, V273, pC1859, DOI 10.1152/ajpcell.1997.273.6.C1859	34	163	171	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38480	38486		10.1074/jbc.M104923200	http://dx.doi.org/10.1074/jbc.M104923200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11502742	hybrid			2022-12-25	WOS:000171673200022
J	Dewilde, S; Kiger, L; Burmester, T; Hankeln, T; Baudin-Creuza, V; Aerts, T; Marden, MC; Caubergs, R; Moens, L				Dewilde, S; Kiger, L; Burmester, T; Hankeln, T; Baudin-Creuza, V; Aerts, T; Marden, MC; Caubergs, R; Moens, L			Biochemical characterization and ligand binding properties of neuroglobin, a novel member of the globin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HEMOGLOBIN; OXYGEN; HEME; BRAIN; FOLD	Neuroglobin is a recently discovered member of the globin superfamily that is suggested to enhance the O-2 supply of the vertebrate brain. Spectral measurements with human and mouse recombinant neuroglobin provide evidence for a hexacoordinated deoxy ferrous (Fe2+) form, indicating a His-Fe2+-His binding scheme. O-2 or CO can displace the endogenous protein ligand, which is identified as the distal histidine by mutagenesis. The ferric (Fe3+) form of neuroglobin is also hexacoordinated with the protein ligand E7-His and does not exhibit pH dependence. Flash photolysis studies show a high recombination rate (k(on)) and a slow dissociation rate (k(off)) for both O-2 and CO, indicating a high intrinsic affinity for these ligands. However, because the rate-limiting step in ligand combination with the deoxy hexacoordinated form involves the dissociation of the protein ligand, O-2 and CO binding is suggested to be slow in vivo. Because of this competition, the observed O-2 affinity of recombinant human neuroglobin is average (1 torr at 37 degrees C). Neuroglobin has a high autoxidation rate, resulting in an oxidation at 37 degrees C by air within a few minutes. The oxidation/reduction potential of mouse neuroglobin (E'(o) = -129 mV) lies within the physiological range. Under natural conditions, recombinant mouse neuroglobin occurs as a monomer with disulfide-dependent formation of dimers. The biochemical and kinetic characteristics are discussed in view of the possible functions of neuroglobin in the vertebrate brain.	Univ Instelling Antwerp, Dept Biochem, B-2610 Antwerp, Belgium; Hop Bicetre, INSERM, F-94275 Le Kremlin Bicetre, France; Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Mol Genet Biosafety Res & Consulting, D-55099 Mainz, Germany; Univ Instelling Antwerp, Dept Biol, B-2610 Antwerp, Belgium	University of Antwerp; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Antwerp	Moens, L (corresponding author), Univ Instelling Antwerp, Dept Biochem, Univ Pl 1, B-2610 Antwerp, Belgium.	lmoens@uia.ua.ac.be	Kiger, Laurent/Q-1686-2018; Marden, Michael C/G-3139-2012; Burmester, Thorsten/I-7225-2013; Marden, Michael/AAA-5923-2020; BAUDIN-CREUZA, Véronique/K-7309-2017	Marden, Michael C/0000-0002-5254-6385; Burmester, Thorsten/0000-0002-5772-7863; BAUDIN-CREUZA, Véronique/0000-0003-1032-3236				ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Baudin-Creuza V, 1999, J BIOL CHEM, V274, P25550, DOI 10.1074/jbc.274.36.25550; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; COUTURE M, 2001, IN PRESS J BIOL CHEM, V276; Das TK, 1999, BIOCHEMISTRY-US, V38, P15360, DOI 10.1021/bi991237e; Das TK, 1999, J BIOL CHEM, V274, P4207, DOI 10.1074/jbc.274.7.4207; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; DOELLER JE, 1988, BIOL BULL, V174, P67, DOI 10.2307/1541760; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; Dutton P L, 1978, Methods Enzymol, V54, P411; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HUNT PW, 2001, IN PRESS J PLANT MOL; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KELLY L, 1990, BIOCHEMISTRY-US, V29, P5062, DOI 10.1021/bi00473a010; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; MITCHELL DT, 1995, J MOL BIOL, V251, P421, DOI 10.1006/jmbi.1995.0445; Moens L, 2000, NATURE, V407, P461, DOI 10.1038/35035181; Pesce A, 2000, EMBO J, V19, P2424, DOI 10.1093/emboj/19.11.2424; SHIRE SJ, 1991, BIOCHEMISTRY-US, V30, P7703, DOI 10.1021/bi00245a006; Sowa AW, 1999, ACTA BIOCHIM POL, V46, P431, DOI 10.18388/abp.1999_4175; STRITTMATTER P, 1963, BIOCHIM BIOPHYS ACTA, V78, P562, DOI 10.1016/0006-3002(63)90928-4; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; Vandergon TL, 1998, J BIOL CHEM, V273, P16998, DOI 10.1074/jbc.273.27.16998; VANWIELINK JE, 1982, BIOCHIM BIOPHYS ACTA, V681, P177, DOI 10.1016/0005-2728(82)90021-4; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; Wilson G S, 1978, Methods Enzymol, V54, P396; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; Wittenberg J.B., 1992, Advances in Comparative and Environmental Physiology, V13, P59; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	36	392	427	1	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38949	38955		10.1074/jbc.M106438200	http://dx.doi.org/10.1074/jbc.M106438200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11473128	hybrid			2022-12-25	WOS:000171673200082
J	Goel, M; Jain, D; Kaur, KJ; Kenoth, R; Maiya, BG; Swamy, MJ; Salunke, DM				Goel, M; Jain, D; Kaur, KJ; Kenoth, R; Maiya, BG; Swamy, MJ; Salunke, DM			Functional equality in the absence of structural similarity - An added dimension to molecular mimicry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CONCANAVALIN-A; PROTEIN INTERACTIONS; SOYBEAN AGGLUTININ; PEPTIDE LIGANDS; BINDING PROTEIN; DRUG DESIGN; CARBOHYDRATE; COMPLEX; LECTIN	The crystal structure of meso-tetrasulfonatophenyl-porphyrin complexed with concanavalin A (ConA) was determined at 1.9 Angstrom resolution. Comparison of this structure with that of ConA bound to methyl alpha -D-mannopyranoside provided direct structural evidence of molecular mimicry in the context of ligand receptor binding. The sulfonatophenyl group of meso-tetrasulfonatophenylporphyrin occupies the same binding site on ConA as that of methyl alpha -D-mannopyranoside, a natural ligand. A pair of stacked porphyrin molecules stabilizes the crystal structure by end-to-end cross-linking with ConA resulting in a network similar to that observed upon agglutination of cells by lectins. The porphyrin binds to ConA predominantly through hydrogen bonds and water-mediated interactions. The sandwiched water molecules in the complex play a cementing role, facilitating favorable binding of porphyrin. Seven of the eight hydrogen bonds observed between methyl alpha -D-mannopyranoside and ConA are mimicked by the sulfonatophenyl group of porphyrin after incorporating two water molecules. Thus, the similarity in chemical interactions was manifested in terms of functional mimicry despite the obvious structural dissimilarity between the sugar and the porphyrin.	Natl Inst Immunol, Struct Biol Unit, New Delhi 110067, India; Univ Hyderabad, Sch Chem, Hyderabad 500046, Andhra Pradesh, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); University of Hyderabad	Salunke, DM (corresponding author), Natl Inst Immunol, Struct Biol Unit, New Delhi 110067, India.		Gagneja, Kanwalinderjit K/K-3204-2017; Swamy, Musti/B-9418-2009; Kenoth, Roopa/ABH-5650-2020; Jain, Deepti/G-6921-2011; Kenoth, Roopa/F-3942-2010	Gagneja, Kanwalinderjit K/0000-0001-7844-8583; Swamy, Musti/0000-0002-3108-3633; Kenoth, Roopa/0000-0003-1992-3465; Jain, Deepti/0000-0002-8631-7230				Appelmelk BJ, 1997, TRENDS MICROBIOL, V5, P70, DOI 10.1016/S0966-842X(96)10084-6; BEELEY N, 1994, TRENDS BIOTECHNOL, V12, P213, DOI 10.1016/0167-7799(94)90117-1; Bhanu K, 1997, CURR SCI INDIA, V73, P598; BOURNE Y, 1990, J BIOL CHEM, V265, P18161; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; Braden BC, 1996, J MOL BIOL, V264, P137, DOI 10.1006/jmbi.1996.0629; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chavali GB, 1997, J MOL BIOL, V272, P731, DOI 10.1006/jmbi.1997.1274; Cheng W, 1998, J BIOL CHEM, V273, P35016, DOI 10.1074/jbc.273.52.35016; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; Grewal N, 1997, BIOPHYS J, V73, P1190, DOI 10.1016/S0006-3495(97)78151-7; Hamelryck TW, 2000, J MOL BIOL, V299, P875, DOI 10.1006/jmbi.2000.3785; Huang XF, 2000, CHIRALITY, V12, P237, DOI 10.1002/(SICI)1520-636X(2000)12:4<237::AID-CHIR10>3.0.CO;2-6; Jain D, 2000, BIOCHEM BIOPH RES CO, V272, P843, DOI 10.1006/bbrc.2000.2871; Jain D, 2000, J BIOL CHEM, V275, P16098, DOI 10.1074/jbc.275.21.16098; Kaur KJ, 1997, J BIOL CHEM, V272, P5539, DOI 10.1074/jbc.272.9.5539; Kaur KJ, 2001, VACCINE, V19, P3124, DOI 10.1016/S0264-410X(01)00027-5; Kim K. H., 1995, MOL SIMILARITY DRUG; Komath SS, 2000, BIOSCIENCE REP, V20, P265, DOI 10.1023/A:1026440907227; Komath SS, 2000, J PHOTOCH PHOTOBIO B, V55, P49, DOI 10.1016/S1011-1344(00)00026-9; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; Lee X, 1998, J BIOL CHEM, V273, P6312, DOI 10.1074/jbc.273.11.6312; Lipscomb LA, 1996, BIOCHEMISTRY-US, V35, P2818, DOI 10.1021/bi952443z; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; MARIUZZA RA, 1993, CURR OPIN IMMUNOL, V5, P50, DOI 10.1016/0952-7915(93)90080-C; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OH BH, 1994, J BIOL CHEM, V269, P26323; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; Oldstone MBA, 1998, FASEB J, V12, P1255, DOI 10.1096/fasebj.12.13.1255; Olsen LR, 1997, BIOCHEMISTRY-US, V36, P15073, DOI 10.1021/bi971828+; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; Ravishankar R, 1997, CURR SCI INDIA, V72, P855; ROSENBERG FE, 1998, BIOCHEMISTRY-US, V37, P14404; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; Sleigh SH, 1999, J MOL BIOL, V291, P393, DOI 10.1006/jmbi.1999.2929; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; VLATAKIS G, 1993, NATURE, V361, P645, DOI 10.1038/361645a0; Wright CS, 1996, STRUCTURE, V4, P1339, DOI 10.1016/S0969-2126(96)00141-4	42	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39277	39281		10.1074/jbc.M105387200	http://dx.doi.org/10.1074/jbc.M105387200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504727	hybrid			2022-12-25	WOS:000171673200125
J	Miyazaki, M; Kim, HJ; Man, WC; Ntambi, JM				Miyazaki, M; Kim, HJ; Man, WC; Ntambi, JM			Oleoyl-CoA is the major de novo product of stearoyl-CoA desaturase 1 gene isoform and substrate for the biosynthesis of the Harderian gland 1-alkyl-2,3-diacylglycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 PREADIPOCYTES; MOUSE-LIVER; FATTY; CHOLESTEROL; EXPRESSION; ENZYMES; MICE	1-Alkyl-2,3-diacylglycerol (ADG) is a unique neutral lipid found in the eyeball-associated Harderian gland (HG) of the mouse and acts as a lubricant to facilitate eyelid movement. We found that the HG of the mice with a disruption in the gene for stearoyl-CoA desaturase 1 (SCD1) (SCD1-/-) is deficient in ADG. The amount of C20:1n-9, which is a major fatty acid of ADG, was reduced by greater than 90% despite normal elongase enzyme activity proposed to elongate it from C18:1n-9. HG from SCD1-/- mice exhibited high desaturase activity toward C16:0-CoA as substrate but had very low desaturase activity toward C18:0-CoA. Feeding diets containing high levels of oleate to the SCD1-/- mice did not increase the levels of C18:1n-9 or C20:1n-9 in the HG and failed to restore the ADG to the levels found in the HG of the wild-type mouse. De novo ADG synthesis as measured by the incorporation of [H-3]glycerol and [C-14]glucose was high in the SCD1+/+ mouse but was reduced by greater than 90% in the HG of SCD1-/- mouse. The deficiencies in the levels of ADG and C20:1n-9 were not compensated for by the expression of SCD2 and SCD3 isoforms in the HG of the SCD1-/- mouse. These observations demonstrate that SCD1-synthesized oleoyl-CoA is a major substrate required for the biosynthesis of normal levels of ADG and that the SCD isoforms present in the HG have different substrate specificity.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ntambi, JM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.							ANDERSON GJ, 1985, ARCH BIOCHEM BIOPHYS, V237, P177, DOI 10.1016/0003-9861(85)90267-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Buzzell GR, 1997, J EXP ZOOL, V277, P99, DOI 10.1002/(SICI)1097-010X(19970201)277:2&lt;99::AID-JEZ2&gt;3.0.CO;2-4; ENOCH HG, 1978, BIOCHEMISTRY-US, V17, P4927, DOI 10.1021/bi00616a011; Harder J., 1694, ACTA ERUDITORUM LIPS, V43, P49; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KASAMA K, 1989, J BIOL CHEM, V264, P9453; KASAMA K, 1970, Biochimica et Biophysica Acta, V202, P56; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; Kim YC, 2000, J LIPID RES, V41, P1310; Kudo N, 1997, TOXICOL APPL PHARM, V145, P285, DOI 10.1006/taap.1997.8186; Miyazaki M, 2001, J NUTR, V131, P2260, DOI 10.1093/jn/131.9.2260; Miyazaki M, 2001, J LIPID RES, V42, P1018; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Ntambi JM, 1999, J LIPID RES, V40, P1549; PAYNE AP, 1994, J ANAT, V185, P1; Samuel W, 2001, J BIOL CHEM, V276, P28744, DOI 10.1074/jbc.M103587200; SEYAMA Y, 1992, PORPHYRIN METABOLISM, P195; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; WATANABE M, 1980, J MORPHOL, V163, P349, DOI 10.1002/jmor.1051630308; Watts JL, 2000, BIOCHEM BIOPH RES CO, V272, P263, DOI 10.1006/bbrc.2000.2772; Zheng Y, 1999, NAT GENET, V23, P268, DOI 10.1038/15446; Zheng Y, 2001, GENOMICS, V71, P182, DOI 10.1006/geno.2000.6429	25	87	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39455	39461		10.1074/jbc.M106442200	http://dx.doi.org/10.1074/jbc.M106442200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11500518	hybrid			2022-12-25	WOS:000171673200146
J	Rajini, B; Shridas, P; Sundari, CS; Muralidhar, D; Chandani, S; Thomas, F; Sharma, Y				Rajini, B; Shridas, P; Sundari, CS; Muralidhar, D; Chandani, S; Thomas, F; Sharma, Y			Calcium binding properties of gamma-crystallin - Calcium ion binds at the Greek key beta gamma-crystallin fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORE COAT PROTEIN; DYE STAINS-ALL; X-RAY-ANALYSIS; EYE LENS; PRECURSOR STRUCTURE; NONLENS MEMBER; SUPERFAMILY; VERTEBRATE; CALMODULIN; EVOLUTION	The beta- and gamma -crystalline are closely related lens proteins that are members of the beta gamma -crystallin superfamily, which also include many non-lens members. Although beta -crystallin is known to be a calcium-binding protein, this property has not been reported in gamma -crystallin. We have studied the calcium binding properties of gamma -crystallin, and we show that it binds 4 mol eq of calcium with a dissociation constant of 90 muM. It also binds the calcium-mimic spectral probes, terbium and Stains-all. Calcium binding does not significantly influence protein secondary and tertiary structures. We present evidence that the Greek key crystallin fold is the site for calcium ion binding in gamma -crystallin. Peptides corresponding to Greek key motif of gamma -crystallin (42 residues) and their mutants were synthesized and studied for calcium binding. These peptides adopt beta -sheet conformation and form aggregates producing beta -sandwich. Our results with peptides show that, in Greek key motif, the amino acid adjacent to the conserved aromatic corner in the "a" strand and three amino acids of the "d" strand participate in calcium binding. We suggest that the beta gamma superfamily represents a novel class of calcium-binding proteins with the Greek key beta gamma -crystallin fold as potential calcium-binding sites. These results are of significance in understanding the mechanism of calcium homeostasis in the lens.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; NHLBI, NIH, Bethesda, MD 20892 USA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sharma, Y (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	yogendra@ccmb.ap.nic.in						Antuch W, 1996, NAT STRUCT BIOL, V3, P662, DOI 10.1038/nsb0896-662; BAGBY S, 1994, P NATL ACAD SCI USA, V91, P4308, DOI 10.1073/pnas.91.10.4308; BALASUBRAMANIAN D, 1991, NOVEL CALCIUM BINDIN, P361; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; CADAY CG, 1986, BIOPOLYMERS, V25, P1579, DOI 10.1002/bip.360250814; CADAY CG, 1985, J BIOL CHEM, V260, P5985; Chan CWM, 1999, GENE, V231, P21, DOI 10.1016/S0378-1119(99)00101-8; Chirgadze YN, 1996, PROTEIN ENG, V9, P745, DOI 10.1093/protein/9.9.745; Clout NJ, 2001, STRUCTURE, V9, P115, DOI 10.1016/S0969-2126(01)00573-1; Das C, 2000, J PEPT RES, V56, P307, DOI 10.1034/j.1399-3011.2000.00775.x; DUNCAN G, 1994, PROG RETIN EYE RES, V13, P623, DOI 10.1016/1350-9462(94)90025-6; DUNCAN G, 1984, CIBA FOUND S, V206, P132; FAIRWELL T, 1987, P NATL ACAD SCI USA, V84, P4796, DOI 10.1073/pnas.84.14.4796; HEMMINGSEN JM, 1994, PROTEIN SCI, V3, P1927, DOI 10.1002/pro.5560031104; HORROCKS WDW, 1993, METHOD ENZYMOL, V226, P495, DOI 10.1016/0076-6879(93)26023-3; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; KLOTZ IM, 1948, J AM CHEM SOC, V70, P939, DOI 10.1021/ja01183a015; KLOTZ IM, 1984, J BIOL CHEM, V259, P60; Kretschmar W, 1999, J MOL BIOL, V289, P701, DOI 10.1006/jmbi.1999.2833; LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MERRIFIELD RB, 1969, ADV ENZYMOL RAMB, V32, P221; Ogawa M, 1998, DEV GROWTH DIFFER, V40, P465; Ogawa M, 1997, DEV GENES EVOL, V206, P417, DOI 10.1007/s004270050071; Ohno A, 1998, J MOL BIOL, V282, P421, DOI 10.1006/jmbi.1998.2022; Ray ME, 1997, P NATL ACAD SCI USA, V94, P3229, DOI 10.1073/pnas.94.7.3229; Rosinke B, 1997, J MOL BIOL, V271, P645, DOI 10.1006/jmbi.1997.1184; SHARMA Y, 1989, J BIOL CHEM, V264, P20923; Sharma Y, 1996, OPHTHALMIC RES, V28, P44, DOI 10.1159/000267942; SHARMA Y, 1989, J BIOL CHEM, V264, P12794; Sharma Y, 1997, EUR J BIOCHEM, V243, P42, DOI 10.1111/j.1432-1033.1997.0042a.x; Sharma Y, 1991, NOVEL CALCIUM BINDIN, P51; TEINTZE M, 1988, J BIOL CHEM, V263, P1199; VanMarle J, 1997, EXP EYE RES, V65, P83, DOI 10.1006/exer.1997.0313; Vrensen GFJM, 1996, OPHTHALMIC RES, V28, P78, DOI 10.1159/000267960; VRENSEN GFJM, 1995, INVEST OPHTH VIS SCI, V36, pS198; Wenk M, 1999, J MOL BIOL, V286, P1533, DOI 10.1006/jmbi.1999.2582; Wenk M, 1998, EUR J BIOCHEM, V255, P604, DOI 10.1046/j.1432-1327.1998.2550604.x; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0; WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940; WISTOW G, 1985, NATURE, V315, P771, DOI 10.1038/315771a0; WISTOW G, 1995, EXP EYE RES, V61, P637, DOI 10.1016/S0014-4835(05)80058-2; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403	44	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38464	38471		10.1074/jbc.M102164200	http://dx.doi.org/10.1074/jbc.M102164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11502736	hybrid			2022-12-25	WOS:000171673200020
J	Caughey, GE; Cleland, LG; Gamble, JR; James, MJ				Caughey, GE; Cleland, LG; Gamble, JR; James, MJ			Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets - Role of thromboxane A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PROSTAGLANDIN-H SYNTHASE-2; ACTIVATED PROTEIN-KINASE; HUMAN MONOCYTES; GROWTH-FACTOR; SHEAR-STRESS; EXPRESSION; PROSTACYCLIN; INDUCTION; RECEPTORS	Platelet-vascular endothelial cell interactions are central to the maintenance of vascular homeostasis. Thromboxane A(2) (TXA(2)) and prostacyclin (prostaglandin (PG) I-2) are the major products of cyclooxygenase (COX) metabolism by platelets and the vascular endothelium, respectively. Here we report the effects of platelet-endothelial interactions on human umbilical vein endothelial cells (HUVECs) COX-2 expression and prostanoid synthesis. Co-incubation of platelets with HUVECs resulted in a dose-dependent induction in COX-2 expression. This was accompanied by a relatively small increase in thromboxane B-2 synthesis (2 ng) by comparison to the production of 6-keto-PGF(1 alpha) and PGE(2), which increased by similar to 14 and 12 ng, respectively. Abrogation of platelet-HUVEC interactions excluded direct cell-cell contact as a required event. Preincubation of HUVECs with SQ29548, a TXA(2) receptor antagonist, dose-dependently inhibited platelet-induced COX-2 expression and prostanoid synthesis. Similarly, if platelet TXA(2) synthesis was inhibited no induction of COX-2 was observed. Furthermore, a TXA(2) analog, carbocyclic TXA(2), induced HUVEC COX-2 expression and the synthesis of 6-keto-PGF(1 alpha). and PGE2. This was also associated with an increase in the expression and activity of PGI synthase and PGE synthase but not TX synthase. Platelet co-incubation (or TXA(2)) also selectively activated the p44/42 mitogen-activated protein kinase pathway to regulate HUVEC COX-2 expression. Thus it seems that platelet-derived TXA(2) can act in a paracrine manner to up-regulate endothelial COX-2 expression and PGI(2) synthesis. These observations are of particular importance given the recent observations regarding selective COX-2 inhibitors and the suppression of PGI(2) synthesis.	Royal Adelaide Hosp, Rheumatol Unit, Adelaide, SA 5000, Australia; Hanson Ctr Canc Res, Div Human Immunol, Adelaide, SA 5000, Australia	Royal Adelaide Hospital	Caughey, GE (corresponding author), Royal Adelaide Hosp, Rheumatol Unit, Adelaide, SA 5000, Australia.	gillian.caughey@adelaide.edu.au	Caughey, Gillian E/A-3041-2011	Gamble, Jennifer/0000-0002-0179-9964; Caughey, Gillian/0000-0003-1192-4121				Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; BUNTING S, 1983, BRIT MED BULL, V39, P271, DOI 10.1093/oxfordjournals.bmb.a071832; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; Crofford LJ, 2000, ARTHRITIS RHEUM, V43, P1891, DOI 10.1002/1529-0131(200008)43:8<1891::AID-ANR28>3.0.CO;2-R; CROFFORD LJ, 1997, J RHEUMATOL, V1, P132; Demasi M, 2000, INFLAMM RES, V49, P737, DOI 10.1007/s000110050655; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FU JY, 1990, J BIOL CHEM, V265, P16737; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; Gimbrone MA, 1999, AM J PATHOL, V155, P1, DOI 10.1016/S0002-9440(10)65090-0; Goppelt-Struebe M, 1998, J CELL PHYSIOL, V175, P341, DOI 10.1002/(SICI)1097-4652(199806)175:3<341::AID-JCP12>3.0.CO;2-8; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; JAMES MJ, 1988, PROSTAG LEUKOTR ESS, V31, P91, DOI 10.1016/0952-3278(88)90081-6; Karim S, 1997, BIOCHEM J, V326, P593, DOI 10.1042/bj3260593; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Laporte JD, 1999, AM J PHYSIOL-LUNG C, V277, pL943, DOI 10.1152/ajplung.1999.277.5.L943; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MONCADA S, 1982, ARTERIOSCLEROSIS, V2, P193, DOI 10.1161/01.ATV.2.3.193; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; Okahara K, 1998, ARTERIOSCL THROM VAS, V18, P1922, DOI 10.1161/01.ATV.18.12.1922; OKUBO S, 1996, PROSTAGLANDINS, V52, P403; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; Patrono C, 2001, J CLIN INVEST, V108, P7, DOI 10.1172/JCI13418; Pawate S, 1998, J BIOL CHEM, V273, P22753, DOI 10.1074/jbc.273.35.22753; Pouliot M, 1997, J IMMUNOL, V158, P4930; Ridley SH, 1997, J IMMUNOL, V158, P3165; Rodriguez LAG, 2000, EPIDEMIOLOGY, V11, P376, DOI 10.1097/00001648-200007000-00003; Rodriguez LAG, 2001, EPIDEMIOLOGY, V12, P88, DOI 10.1097/00001648-200101000-00015; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; Smith TJ, 1999, J BIOL CHEM, V274, P15622, DOI 10.1074/jbc.274.22.15622; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; WALL RT, 1978, J CELL PHYSIOL, V96, P203, DOI 10.1002/jcp.1040960209; Yan ZP, 2000, J BIOL CHEM, V275, P4949, DOI 10.1074/jbc.275.7.4949; Zimmermann KC, 1998, MOL PHARMACOL, V54, P536, DOI 10.1124/mol.54.3.536	44	71	73	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37839	37845						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11483590				2022-12-25	WOS:000171526500018
J	Hudrisier, D; Riond, J; Mazarguil, H; Gairin, JE				Hudrisier, D; Riond, J; Mazarguil, H; Gairin, JE			Pleiotropic effects of post-translational modifications on the fate of viral glycopeptides as cytotoxic T cell epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CLASS-I MOLECULES; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN EPITOPE; GLYCOSYLATION SITE; ANTIGENIC PEPTIDES; CYSTEINE RESIDUES; ANCHOR RESIDUES; MHC MOLECULES	The fate of viral glycopeptides as cytotoxic T lymphocyte (CTL) epitopes is unclear. We have dissected the mechanisms of antigen presentation and CTL recognition of the peptide GP392-400 (WLVT (NGS) over bar YL) from the lymphocytic choriomeningitis virus (LCMV) and compared them with those of the previously reported GP92-101 antigen (CSA (NNS) over bar HHYI). Both GP392-400 and GP92-101 bear a glycosylation motif, are naturally N-glycosylated in the mature viral glycoproteins, bind to major histocompatibility complex H-2D(b) molecules, and are immunogenic. However, post-translational modifications differentially affected GP92-101 and GP392-400. Upon N-glycosylation or de-N-glycosylation, a marked decrease in major histocompatibility complex binding was observed for GP392-400 but not for GP92-101. Further, under its N-glycosylated or de-N-glycosylated form, GP392-400 then lost its initial ability to generate a CTL response in mice, whereas GP92-101 was still immunogenic under the same conditions. The genetically encoded form of GP392-400, which on the basis of its immunogenicity could still be presented with H-2D(b) during the course of LCMV infection, does not in fact appear at the surface of LCMV-infected cells. Our results show that post-translational modifications of viral glycopeptides can have pleiotropic effects on their presentation to and recognition by CTL that contribute to either creation of neo-epitopes or destruction of potential epitopes.	Univ Toulouse 3, Lab Immunopharmacol Struct, Inst Pharmacol & Biol Struct, UMR5089,CNRS, F-31400 Toulouse, France; CHU Purpan, INSERM, U395, F-31024 Toulouse 03, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Gairin, JE (corresponding author), Univ Toulouse 3, Lab Immunopharmacol Struct, Inst Pharmacol & Biol Struct, UMR5089,CNRS, 205 Route Narbonne, F-31400 Toulouse, France.		Riond, Joelle/R-6414-2016	Riond, Joelle/0000-0002-6281-2376; Hudrisier, Denis/0000-0002-3631-9561				AbdelMotal UM, 1996, EUR J IMMUNOL, V26, P544, DOI 10.1002/eji.1830260307; Andersen MH, 1999, J IMMUNOL, V163, P3812; Bacik I, 1997, J EXP MED, V186, P479, DOI 10.1084/jem.186.4.479; BARBER LD, 1994, J EXP MED, V180, P1191, DOI 10.1084/jem.180.4.1191; Chen WS, 1996, J IMMUNOL, V157, P1000; Chen WS, 1999, J EXP MED, V189, P1757, DOI 10.1084/jem.189.11.1757; Corthay A, 1998, EUR J IMMUNOL, V28, P2580, DOI 10.1002/(SICI)1521-4141(199808)28:08<2580::AID-IMMU2580>3.0.CO;2-X; DECK B, 1995, J IMMUNOL, V155, P1074; DUDLER T, 1995, EUR J IMMUNOL, V25, P538, DOI 10.1002/eji.1830250235; ELLIOTT T, 1995, J EXP MED, V181, P1481, DOI 10.1084/jem.181.4.1481; Ferris RL, 1996, J IMMUNOL, V156, P834; GAIRIN JE, 1995, J VIROL, V69, P2297, DOI 10.1128/JVI.69.4.2297-2305.1995; GalliStampino L, 1997, CANCER RES, V57, P3214; Glithero A, 1999, IMMUNITY, V10, P63, DOI 10.1016/S1074-7613(00)80007-2; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; HARDING CV, 1993, J IMMUNOL, V151, P2419; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P2740, DOI 10.1073/pnas.88.7.2740; Haurum JS, 1999, J EXP MED, V190, P145, DOI 10.1084/jem.190.1.145; HAURUM JS, 1994, J EXP MED, V180, P739, DOI 10.1084/jem.180.2.739; Haurum JS, 1995, EUR J IMMUNOL, V25, P3270, DOI 10.1002/eji.1830251211; HUDRISIER D, 1995, MOL IMMUNOL, V32, P895, DOI 10.1016/0161-5890(95)00043-E; Hudrisier D, 1999, J BIOL CHEM, V274, P36274, DOI 10.1074/jbc.274.51.36274; Hudrisier D, 1996, J BIOL CHEM, V271, P17829, DOI 10.1074/jbc.271.30.17829; Hudrisier D, 2001, J VIROL, V75, P2468, DOI 10.1128/JVI.75.5.2468-2471.2001; Jensen T, 1997, J IMMUNOL, V158, P3769; Jensen T, 1996, EUR J IMMUNOL, V26, P1342, DOI 10.1002/eji.1830260625; Jensen T, 1999, EUR J IMMUNOL, V29, P2759, DOI 10.1002/(SICI)1521-4141(199909)29:09<2759::AID-IMMU2759>3.0.CO;2-4; Kittlesen DJ, 1998, J IMMUNOL, V160, P2099; KLAVINSKIS LS, 1990, VIROLOGY, V178, P393, DOI 10.1016/0042-6822(90)90336-P; Luckey CJ, 1998, J IMMUNOL, V161, P112; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; Michaelsson E, 1996, EUR J IMMUNOL, V26, P1906, DOI 10.1002/eji.1830260835; MICHAELSSON E, 1994, J EXP MED, V180, P745, DOI 10.1084/jem.180.2.745; Morel S, 2000, IMMUNITY, V12, P107, DOI 10.1016/S1074-7613(00)80163-6; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Nandi D, 1998, CURR TOP MICROBIOL, V232, P15; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; OLDSTONE MBA, 1995, J VIROL, V69, P7423, DOI 10.1128/JVI.69.12.7423-7429.1995; Ossendorp F, 1996, IMMUNITY, V5, P115, DOI 10.1016/S1074-7613(00)80488-4; OZATO K, 1980, J IMMUNOL, V125, P2473; Pierce RA, 1999, J IMMUNOL, V163, P6360; SAITO Y, 1993, J BIOL CHEM, V268, P21309; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; Skipper JCA, 1996, J EXP MED, V183, P527, DOI 10.1084/jem.183.2.527; SNYDER HL, 1994, J EXP MED, V180, P2389, DOI 10.1084/jem.180.6.2389; Speir JA, 1999, IMMUNITY, V10, P51, DOI 10.1016/S1074-7613(00)80006-0; Theobald M, 1998, J EXP MED, V188, P1017, DOI 10.1084/jem.188.6.1017; Valmori D, 1999, J EXP MED, V189, P895, DOI 10.1084/jem.189.6.895; van der Most RG, 1998, VIROLOGY, V240, P158, DOI 10.1006/viro.1997.8934; vanderBurg SH, 1996, J IMMUNOL, V156, P3308; Wood P, 1998, J EXP MED, V188, P773, DOI 10.1084/jem.188.4.773; WRIGHT KE, 1990, VIROLOGY, V177, P175, DOI 10.1016/0042-6822(90)90471-3; Yewdell JW, 1996, J IMMUNOL, V157, P1823; Zarling AL, 2000, J EXP MED, V192, P1755, DOI 10.1084/jem.192.12.1755	55	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38255	38260						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11479317				2022-12-25	WOS:000171526500073
J	Kins, S; Crameri, A; Evans, DRH; Hemmings, BA; Nitsch, RM; Gotz, J				Kins, S; Crameri, A; Evans, DRH; Hemmings, BA; Nitsch, RM; Gotz, J			Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; SUBUNIT C-ALPHA; ALZHEIMER-DISEASE BRAIN; NEUROFIBRILLARY DEGENERATION; PHOSPHORYLATION STATE; REGULATORY SUBUNIT; ABNORMAL PHOSPHORYLATION; CULTURED NEURONS; RECOMBINANT-TAU; OKADAIC ACID	Hyperphosphorylated isoforms of the microtubule-associated. protein tau are the major components of neurofibrillary lesions in Alzheimer's disease (AD). Protein phosphatase (PP) 2A is a major phosphatase implicated in tau dephosphorylation in vitro. Dephosphorylation of tau can be blocked in vivo by okadaic acid, a potent inhibitor of PP2A. Moreover, activity of PP2A is reduced in AD brains. To elucidate the role of PP2A in tau phosphorylation and pathogenesis, we expressed a dominant negative mutant form of the catalytic subunit Ca of PP2A, L199P, in mice by using a neuron-specific promoter. We obtained mice with high expression levels of Ca L199P in cortical, hippocampal, and cerebellar neurons. PP2A activity in brain homogenates of transgenic mice was reduced to 66%. Endogenous tau protein was hyperphosphorylated at distinct sites including the AT8 epitope Ser-202/Thr-205, a major AD-associated tau phosphoepitope. AT8-positive tau aggregates accumulated in the soma and dendrites of cortical pyramidal cells and cerebellar Purkinje cells and co-localized with ubiquitin. Our data establish that PP2A plays a crucial role in tau phosphorylation. Our results also show that reduced PP2A activity is associated with altered compartmentalization and ubiquitination of tau, resembling a key pathological finding in AD.	Univ Zurich, Div Psychiat Res, CH-8008 Zurich, Switzerland; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	University of Zurich; Friedrich Miescher Institute for Biomedical Research	Gotz, J (corresponding author), Univ Zurich, Div Psychiat Res, August Forel Str 1, CH-8008 Zurich, Switzerland.	goetz@bli.unizh.ch	Götz, Jürgen/C-2448-2014	Götz, Jürgen/0000-0001-8501-7896				Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; ARENDT T, 1995, NEUROSCIENCE, V69, P691, DOI 10.1016/0306-4522(95)00347-L; BAUM L, 1995, MOL BRAIN RES, V34, P1, DOI 10.1016/0169-328X(95)00111-5; Bennecib M, 2001, FEBS LETT, V490, P15, DOI 10.1016/S0014-5793(01)02127-5; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; Brewis N, 2000, AM J PHYSIOL-HEART C, V279, pH1307, DOI 10.1152/ajpheart.2000.279.3.H1307; BueeScherrer V, 1996, MOL BRAIN RES, V39, P79, DOI 10.1016/0169-328X(96)00003-4; Bussiere T, 1999, ACTA NEUROPATHOL, V97, P221, DOI 10.1007/s004010050978; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; Delacourte A, 1998, ANN NEUROL, V43, P193, DOI 10.1002/ana.410430209; DICKSON DW, 1995, NEUROBIOL AGING, V16, P285, DOI 10.1016/0197-4580(95)00013-5; DONELLADEANA A, 1994, EUR J BIOCHEM, V219, P109, DOI 10.1111/j.1432-1033.1994.tb19920.x; DREWES G, 1993, FEBS LETT, V336, P425, DOI 10.1016/0014-5793(93)80850-T; Evans DRH, 2000, GENETICS, V156, P21; Evans DRH, 1999, J BIOL CHEM, V274, P24038, DOI 10.1074/jbc.274.34.24038; Gartner U, 1998, NEUROBIOL AGING, V19, P535, DOI 10.1016/S0197-4580(98)00094-3; GARVER TD, 1995, MOL PHARMACOL, V47, P745; Goedert M, 2000, J NEUROCHEM, V75, P2155, DOI 10.1046/j.1471-4159.2000.0752155.x; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1995, NEUROBIOL AGING, V16, P325, DOI 10.1016/0197-4580(95)00017-9; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; GONG CX, 1994, FEBS LETT, V341, P94, DOI 10.1016/0014-5793(94)80247-5; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; Gotz J, 1999, BIOL CHEM, V380, P1117, DOI 10.1515/BC.1999.139; Gotz J, 2000, MECH DEVELOP, V93, P83, DOI 10.1016/S0925-4773(00)00267-7; GOTZ J, 1995, EMBO J, V14, P1304, DOI 10.1002/j.1460-2075.1995.tb07116.x; Gotz J, 2001, BRAIN RES REV, V35, P266, DOI 10.1016/S0165-0173(01)00055-8; Gotz J, 2001, J BIOL CHEM, V276, P529, DOI 10.1074/jbc.M006531200; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; Iqbal K, 1998, J NEURAL TRANSM-SUPP, P169; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; Kayyali US, 1997, J NEUROCHEM, V68, P1668; Kim D, 1999, BRAIN RES, V839, P253, DOI 10.1016/S0006-8993(99)01724-2; Kins S, 2000, NAT NEUROSCI, V3, P22, DOI 10.1038/71096; KOLLIAS G, 1987, P NATL ACAD SCI USA, V84, P1492, DOI 10.1073/pnas.84.6.1492; Lee JH, 2000, NEUROSCI LETT, V282, P49, DOI 10.1016/S0304-3940(00)00863-6; LOWE J, 1993, BRAIN PATHOL, V3, P55, DOI 10.1111/j.1750-3639.1993.tb00726.x; Luthi A, 1997, J NEUROSCI, V17, P4688; MATSUSHITA M, 1995, NEUROREPORT, V6, P1267, DOI 10.1097/00001756-199506090-00009; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Merrick SE, 1996, J BIOL CHEM, V271, P5589, DOI 10.1074/jbc.271.10.5589; Mudher AK, 2001, NEUROSCI LETT, V301, P5, DOI 10.1016/S0304-3940(01)01593-2; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; SAITO T, 1995, FEBS LETT, V376, P238, DOI 10.1016/0014-5793(95)01292-0; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Sergeant N, 1999, J NEUROCHEM, V72, P1243, DOI 10.1046/j.1471-4159.1999.0721243.x; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Sironi JJ, 1998, FEBS LETT, V436, P471, DOI 10.1016/S0014-5793(98)01185-5; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Tolnay M, 1997, ACTA NEUROPATHOL, V93, P477, DOI 10.1007/s004010050642; Trojanowski JQ, 1995, FASEB J, V9, P1570, DOI 10.1096/fasebj.9.15.8529836; VINCENT IJ, 1990, BRAIN RES, V531, P127, DOI 10.1016/0006-8993(90)90765-4; Vogelsberg-Ragaglia V, 2001, EXP NEUROL, V168, P402, DOI 10.1006/exnr.2001.7630; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; WERA S, 1995, J BIOL CHEM, V270, P21374, DOI 10.1074/jbc.270.36.21374; WISNIEWSKI HM, 1988, CIBA F SYMP, V135, P224; Xie HQ, 1998, BRAIN RES, V798, P173, DOI 10.1016/S0006-8993(98)00407-7; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	79	170	187	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38193	38200						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11473109				2022-12-25	WOS:000171526500064
J	Law, GL; Raney, A; Heusner, C; Morris, DR				Law, GL; Raney, A; Heusner, C; Morris, DR			Polyamine regulation of ribosome pausing at the upstream open reading frame of S-adenosylmethionine decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO TRANSLATION; MESSENGER-RNA; INHIBITION; BINDING; LEADER	Synthesis of S-adenosylmethionine decarboxylase (AdoMetDC), a key regulated enzyme in the pathway of polyamine biosynthesis, is feedback-controlled at the level of translation by spermidine and spermine. The peptide product of an upstream open reading frame uORF in the mRNA is solely responsible for polyamine regulation of AdoMetDC translation. Using a primer extension inhibition assay and in vitro protein synthesis reactions, we found ribosomes paused at or close to the termination codon of the uORF. This pause was greatly diminished with the altered uORFs' sequences that abolish uORF regulation in vivo. The half-life of the ribosome pause was related to the concentration of polyamines present but was unaffected by magnesium concentration. Furthermore, inhibition of translation initiation at a reporter gene placed downstream of the AdoMetDC uORF directly correlated with the stability of the ribosome pause at the uORF. These observations are consistent with a model in which regulation of ribosome pausing at the uORF by polyamines controls ribosome access to the downstream AdoMetDC reading frame.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Morris, DR (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	dmorris@u.Washington.edu	Morris, David/G-4503-2011		NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER; NCI NIH HHS [CA39053] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTHONY DD, 1992, J BIOL CHEM, V267, P1554; Cao JH, 1996, MOL CELL BIOL, V16, P603; CARRASCO L, 1976, MOL CELL BIOCHEM, V10, P97, DOI 10.1007/BF01742203; CELMA ML, 1970, FEBS LETT, V6, P273, DOI 10.1016/0014-5793(70)80076-X; Geballe AP, 2000, COLD SPRING HARBOR M, V39, P595; GONZALEZ A, 1978, BIOCHIM BIOPHYS ACTA, V521, P459, DOI 10.1016/0005-2787(78)90287-3; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HILL JR, 1993, J BIOL CHEM, V268, P726; HILL JR, 1992, J BIOL CHEM, V267, P21886; Ioannou M, 1998, MOL PHARMACOL, V53, P1089; MACH M, 1986, J BIOL CHEM, V261, P1697; Marton LJ, 1987, INHIB POLYAM METABOL, P79; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; Mize GJ, 2001, RNA, V7, P374, DOI 10.1017/S1355838201001972; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Morris DR, 1997, MOD CELL B, V17, P165; MUNRO HN, 1968, NATURE, V219, P944, DOI 10.1038/219944a0; Raney A, 2000, J BIOL CHEM, V275, P24444, DOI 10.1074/jbc.M003364200; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; RUAN HJ, 1994, J BIOL CHEM, V269, P17905; Ryabova LA, 2000, GENE DEV, V14, P817; Sonenberg N, 2000, TRANSLATIONAL CONTRO; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Wang Z, 1997, J BIOL CHEM, V272, P255; Wang Z, 1998, MOL CELL BIOL, V18, P7528, DOI 10.1128/MCB.18.12.7528; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; [No title captured]	29	101	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38036	38043						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11489903				2022-12-25	WOS:000171526500044
J	Nakajima, H; Nakagawa, E; Kobayashi, K; Tagawa, S; Aono, S				Nakajima, H; Nakagawa, E; Kobayashi, K; Tagawa, S; Aono, S			Ligand-switching intermediates for the CO-sensing transcriptional activator CooA measured by pulse radiolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ELECTRON-TRANSFER; SITE-DIRECTED MUTAGENESIS; RHODOSPIRILLUM-RUBRUM; HEME PROTEIN; PROXIMAL HISTIDINE; NITRITE REDUCTASE; GENE-EXPRESSION; HUMAN MYOGLOBIN; CYTOCHROME-C; TARGET DNA	CooA is a heme-containing and CO-sensing transcriptional activator whose activity is regulated by CO. The protoheme that acts as a CO sensor in CooA shows unique properties for its coordination structure. The Cys(75) axial ligand of the ferric heme is replaced by His(77) upon the reduction of the heme iron and vice versa. In this work, the ligand-switching process induced by the reduction of the heme was investigated by the technique of pulse radiolysis. Hydrated electron reduced the heme iron in ferric CooA within 1 mus to form the first intermediate with the Soret peak at 440 nm, suggesting that a six-coordinate ferrous heme with a thiolate axial ligand was formed initially. The first intermediate was converted into the second intermediate with the time constant of 40 mus (k = 2.5 x 10(4) s(-1)). In the second intermediate, the thiolate from Cys(75) was thought to be protonated and/or the Fe-S bond was thought to be elongated. The second intermediate was converted into the final reduced form with the time constant of 2.9 ms (k = 3.5 x 10(2) s(-1)) for wild-type CooA. The ligand exchange between Cys(75) and His(77) took place during the conversion of the second intermediate into the final reduced form.	Japan Adv Inst Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan; Osaka Univ, Inst Sci & Ind Res, Ibaraki, Osaka 5670047, Japan	Japan Advanced Institute of Science & Technology (JAIST); Osaka University	Aono, S (corresponding author), Japan Adv Inst Sci & Technol, Sch Mat Sci, 1-1 Asahidai, Tatsunokuchi, Ishikawa 9231292, Japan.		Kobayashi, Kazuo/H-9279-2012; Aono, Shigetoshi/ABD-7618-2020	Kobayashi, Kazuo/0000-0002-5586-9112; Aono, Shigetoshi/0000-0002-2870-3694				ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; ADACHI S, 1991, BIOCHEM BIOPH RES CO, V180, P138, DOI 10.1016/S0006-291X(05)81266-5; Aono S, 1997, BIOCHEM BIOPH RES CO, V240, P783, DOI 10.1006/bbrc.1997.7746; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 2000, PROG REACT KINET MEC, V25, P65, DOI 10.3184/007967400103165128; Aono S, 2000, J INORG BIOCHEM, V82, P51, DOI 10.1016/S0162-0134(00)00139-2; Aono S, 1999, COORDIN CHEM REV, V190, P267, DOI 10.1016/S0010-8545(99)00070-3; Aono S, 1999, BIOCHEM BIOPH RES CO, V261, P270, DOI 10.1006/bbrc.1999.1046; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; Dhawan IK, 1999, BIOCHEMISTRY-US, V38, P12805, DOI 10.1021/bi991303c; Fox JD, 1996, J BACTERIOL, V178, P6200, DOI 10.1128/jb.178.21.6200-6208.1996; HANSON LK, 1976, J AM CHEM SOC, V98, P2672, DOI 10.1021/ja00425a050; HASEGAWA T, 1984, J BIOCHEM-TOKYO, V96, P265, DOI 10.1093/oxfordjournals.jbchem.a134822; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; JUNG C, 1985, CHEM PHYS LETT, V113, P589, DOI 10.1016/0009-2614(85)85038-7; KERY V, 1994, J BIOL CHEM, V269, P25283; KOBAYASHI K, 1981, J BIOL CHEM, V256, P2350; Kobayashi K, 1999, BIOCHEMISTRY-US, V38, P5913, DOI 10.1021/bi982088n; KOBAYASHI K, 1989, J BIOL CHEM, V264, P7976; KOBAYASHI K, 1987, J BIOL CHEM, V262, P5445; KOBAYASHI K, 1993, J BIOL CHEM, V268, P24642; Kobayashi K, 1999, J BIOCHEM, V126, P408, DOI 10.1093/oxfordjournals.jbchem.a022465; LAND EJ, 1971, ARCH BIOCHEM BIOPHYS, V145, P365, DOI 10.1016/0003-9861(71)90049-X; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Nakajima H, 2001, J BIOL CHEM, V276, P7055, DOI 10.1074/jbc.M003972200; Nakajima H, 1999, CHEM LETT, P1233, DOI 10.1246/cl.1999.1233; OMURA T, 1984, J BIOCHEM-TOKYO, V96, P1491, DOI 10.1093/oxfordjournals.jbchem.a134978; RAPHAEL AL, 1991, J AM CHEM SOC, V113, P1038, DOI 10.1021/ja00003a045; Reynolds MF, 1998, J AM CHEM SOC, V120, P9080, DOI 10.1021/ja981146p; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SUZUKI S, 1994, J AM CHEM SOC, V116, P11145, DOI 10.1021/ja00103a035; Suzuki S, 1997, J BIOL INORG CHEM, V2, P265, DOI 10.1007/s007750050132; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; Thorsteinsson MV, 2001, J BIOL CHEM, V276, P26807, DOI 10.1074/jbc.M102758200; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200	41	36	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37895	37899						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11487580				2022-12-25	WOS:000171526500025
J	Polster, BM; Kinnally, KW; Fiskum, G				Polster, BM; Kinnally, KW; Fiskum, G			BH3 death domain peptide induces cell type-selective mitochondrial outer membrane permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; ADENINE-NUCLEOTIDE TRANSLOCATOR; RAT-LIVER MITOCHONDRIA; BAX PROTEIN; TRANSITION PORE; NERVOUS-SYSTEM; CEREBRAL-ISCHEMIA; CHANNEL ACTIVITY; UP-REGULATION	The BH3 domain is essential for the release of cytochrome e from mitochondria by pro-apoptotic Bcl-2 family proteins during apoptosis. This study tested the hypothesis that a Bax peptide that includes the BH3 domain can permeabilize the mitochondrial outer membrane and release cytochrome c in the absence of a permeability transition at the mitochondrial inner membrane. BH3 peptide (0.1-60 muM) released cytochrome c from mitochondria in the presence of physiological concentrations of ions in a cell type-selective manner, whereas a BH3 peptide with a single amino acid substitution was ineffective. The release of cytochrome c by BH3 peptide correlated with the presence of endogenous Bax at the mitochondria and its integral membrane insertion. Cytochrome c release was accompanied by adenylate kinase release, was not associated with mitochondrial swelling or substantial loss of electrical potential across the inner membrane, and was unaffected by inhibitors of the permeability transition pore. Cytochrome c release was, however, inhibited by Bcl-2. Although energy-coupled respiration was inhibited after the release of cytochrome e, mitochondria maintained membrane potential in the presence of ATP due to the reversal of the ATP synthase. Overall, results support the hypothesis that BH3 peptide releases cytochrome c by a Bax-dependent process that is independent of the mitochondrial permeability transition pore but regulated by Bcl-2.	Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Neurosci Program, Baltimore, MD 21201 USA; NYU, Coll Dent, Dept Basic Sci, New York, NY 10010 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; New York University	Fiskum, G (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, MSTF 5-34,685 W Baltimore St, Baltimore, MD 21201 USA.	gfiskum@anesthlab.umm.edu		Polster, Brian/0000-0003-2571-7510	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034152] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57249] Funding Source: Medline; NINDS NIH HHS [NS34152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Atlante A, 2000, J BIOL CHEM, V275, P37159, DOI 10.1074/jbc.M002361200; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Doran E, 2000, BIOCHEM J, V348, P343, DOI 10.1042/0264-6021:3480343; Ekegren T, 1999, ACTA NEUROL SCAND, V100, P317; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fiskum G, 2000, METHOD ENZYMOL, V322, P222; Fiskum G, 2000, PHARMACOLOGY OF CEREBRAL ISCHEMIA 2000, P177; FUKUYAMA R, 1993, MOL BRAIN RES, V17, P17, DOI 10.1016/0169-328X(93)90067-Y; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hajek P, 2001, J BIOL CHEM, V276, P606, DOI 10.1074/jbc.M007871200; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Kowaltowski AJ, 2000, AM J PHYSIOL-CELL PH, V279, pC852, DOI 10.1152/ajpcell.2000.279.3.C852; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kushnareva YE, 2001, ARCH BIOCHEM BIOPHYS, V386, P251, DOI 10.1006/abbi.2000.2201; LAPIDUS RG, 1993, ARCH BIOCHEM BIOPHYS, V306, P246, DOI 10.1006/abbi.1993.1507; LOHRET TA, 1995, J BIOL CHEM, V270, P15950, DOI 10.1074/jbc.270.27.15950; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; MacGibbon GA, 1997, BRAIN RES, V750, P223, DOI 10.1016/S0006-8993(96)01351-0; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mather M, 2001, BBA-BIOENERGETICS, V1503, P357, DOI 10.1016/S0005-2728(00)00231-0; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; McKenna MC, 1995, NEUROCHEM RES, V20, P1491, DOI 10.1007/BF00970599; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; MOREADITH RW, 1984, ANAL BIOCHEM, V137, P360, DOI 10.1016/0003-2697(84)90098-8; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; ROSENTHAL RE, 1987, J CEREBR BLOOD F MET, V7, P752, DOI 10.1038/jcbfm.1987.130; Sadoul R, 1998, CELL DEATH DIFFER, V5, P805, DOI 10.1038/sj.cdd.4400438; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SCHOUSHOE A, 1989, DISSECTION TISSUE CU; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Stefanelli C, 2000, BIOCHEM J, V347, P875, DOI 10.1042/0264-6021:3470875; Su JH, 1997, J NEUROPATH EXP NEUR, V56, P86, DOI 10.1097/00005072-199701000-00009; Sugimoto T, 1996, NEUROSCI LETT, V215, P37, DOI 10.1016/S0304-3940(96)12946-3; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; VILA, 2001, P NATL ACAD SCI US, V98, P2837; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Vukosavic S, 1999, J NEUROCHEM, V73, P2460, DOI 10.1046/j.1471-4159.1999.0732460.x; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	65	112	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37887	37894						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11483608				2022-12-25	WOS:000171526500024
J	Khatri, JJ; Joyce, KM; Brozovich, FV; Fisher, SA				Khatri, JJ; Joyce, KM; Brozovich, FV; Fisher, SA			Role of myosin phosphatase isoforms in cGMP-mediated smooth muscle relaxation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE; INTRACELLULAR CALCIUM; SIGNAL-TRANSDUCTION; POTASSIUM CHANNELS; REGULATORY SUBUNIT; BINDING SUBUNIT; CHICKEN GIZZARD; RHO-KINASE	In vitro experiments showing the activation of the myosin phosphatase via heterophilic leucine zipper interactions between its targeting subunit (MYPT1) and cGMP-dependent protein kinase I suggested a pathway for smooth muscle relaxation (Surks, H. K., Mochizuki, N., Kasai, Y., Georgescu, S. P., Tang, K. M., Ito, M., Lincoln, T. M., and Mendelsohn, M. E. (1999) Science 286, 1583-1587). The relationship between MYPT1 isoform expression and smooth muscle responses to cGMP signaling in vivo has not been explored. MYPT1 isoforms that contain or lack a C-terminal leucine zipper are generated in birds and mammals by cassette-type alternative splicing of a 31-nucleotide exon. The avian and mammalian C-terminal isoforms are highly conserved and expressed in a tissue-specific fashion. In the mature chicken the tonic contracting aorta and phasic contracting gizzard exclusively express the leucine zipper positive and negative MYPT1 isoforms, respectively. Expression of the MYPT1 isoforms is also developmentally regulated in the gizzard, which switches from leucine zipper positive to negative isoforms around the time of hatching. This switch coincides with the development in the gizzard of a cGMP-resistant phenotype, ie. inability to dephosphorylate myosin and relax in response to 8-bromo-cGMP after calcium activation. Furthermore, association of cGMP-dependent protein kinase I with MYPT1 is detected by immunoprecipitation only in the tissue that expresses the leucine zipper positive isoform of MYPT1 These results suggest that the regulated splicing of MYPT1 is an important determinant of smooth muscle phenotypic diversity and the variability in the response of smooth muscles to the calcium desensitizing effect of cGMP signaling.	Case Western Reserve Univ, Sch Med, Dept Med Cardiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Fisher, SA (corresponding author), 422 BRB,2109 Adelbert Rd, Cleveland, OH 44106 USA.	saf9@po.cwru.edu			NHLBI NIH HHS [R01 HL64137, KO8 HL03275-05, R01 HL66171-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003275, R01HL064137, R01HL066171] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; Arimura T, 2001, J BIOL CHEM, V276, P6073, DOI 10.1074/jbc.M008566200; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; Beall AC, 1997, J BIOL CHEM, V272, P11283; BERGH CM, 1995, AM J PHYSIOL-HEART C, V268, pH202, DOI 10.1152/ajpheart.1995.268.1.H202; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; DIAMOND J, 1983, J PHARMACOL EXP THER, V225, P422; Dirksen WP, 2000, AM J PHYSIOL-CELL PH, V278, pC589, DOI 10.1152/ajpcell.2000.278.3.C589; DiSanto ME, 1997, AM J PHYSIOL-CELL PH, V272, pC1532, DOI 10.1152/ajpcell.1997.272.5.C1532; Eddinger TJ, 2001, AM J PHYSIOL-CELL PH, V280, pC309, DOI 10.1152/ajpcell.2001.280.2.C309; Eddinger TJ, 1997, COMP BIOCHEM PHYS B, V117, P29, DOI 10.1016/S0305-0491(96)00312-4; Eigenthaler M, 1999, Rev Physiol Biochem Pharmacol, V135, P173, DOI 10.1007/BFb0033673; Fisher SA, 1997, CIRC RES, V80, P885; Fujioka M, 1998, GENOMICS, V49, P59, DOI 10.1006/geno.1998.5222; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GASTON B, 1994, J PHARMACOL EXP THER, V268, P978; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HATHAWAY DR, 1985, AM J PHYSIOL, V249, pC345; Hennan JK, 2001, AM J PHYSIOL-HEART C, V280, pH1565, DOI 10.1152/ajpheart.2001.280.4.H1565; Herring BP, 2001, AM J PHYSIOL-CELL PH, V280, pC12, DOI 10.1152/ajpcell.2001.280.1.C12; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; Hofmann F, 2000, J CELL SCI, V113, P1671; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Huber A, 1998, AM J PHYSIOL-GASTR L, V275, pG629, DOI 10.1152/ajpgi.1998.275.4.G629; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Johnson D, 1997, EUR J BIOCHEM, V244, P931, DOI 10.1111/j.1432-1033.1997.00931.x; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; KEILBACH A, 1992, EUR J BIOCHEM, V208, P467, DOI 10.1111/j.1432-1033.1992.tb17209.x; Khatri JJ, 2000, BIOPHYS J, V78, p363A; Khatri JJ, 2001, BIOPHYS J, V80, p388A; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; Koh SD, 1995, J PHYSIOL-LONDON, V489, P735, DOI 10.1113/jphysiol.1995.sp021087; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Lincoln T.M., 2000, NITRIC OXIDE BIOL PA, P401; Mabuchi K, 1999, BBA-PROTEIN STRUCT M, V1434, P296, DOI 10.1016/S0167-4838(99)00182-X; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; MILLER VM, 1989, AM J PHYSIOL, V257, pH1127, DOI 10.1152/ajpheart.1989.257.4.H1127; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; MORGAN JP, 1984, J PHYSIOL-LONDON, V351, P155, DOI 10.1113/jphysiol.1984.sp015239; Ogut O, 2000, AM J PHYSIOL-CELL PH, V279, pC1722, DOI 10.1152/ajpcell.2000.279.6.C1722; OKUBO S, 1994, BIOCHEM BIOPH RES CO, V200, P429, DOI 10.1006/bbrc.1994.1467; OWENS GK, 1995, PHYSIOL REV, V75, P487; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; PFITZER G, 1986, PFLUG ARCH EUR J PHY, V407, P87, DOI 10.1007/BF00580726; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SCHIAFFINO S, 1994, J APPL PHYSIOL, V77, P493, DOI 10.1152/jappl.1994.77.2.493; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Stull JT, 1998, ACTA PHYSIOL SCAND, V164, P471, DOI 10.1111/j.1365-201X.1998.tb10699.x; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Szymanski PT, 1998, AM J PHYSIOL-CELL PH, V275, pC684, DOI 10.1152/ajpcell.1998.275.3.C684; Takahashi N, 1997, GENOMICS, V44, P150, DOI 10.1006/geno.1997.4859; Takeuchi T, 1996, BRIT J PHARMACOL, V117, P1204, DOI 10.1111/j.1476-5381.1996.tb16717.x; TRINKLEMULCAHY L, 1995, J BIOL CHEM, V270, P18191, DOI 10.1074/jbc.270.31.18191; Wissmann A, 1997, GENE DEV, V11, P409, DOI 10.1101/gad.11.4.409; Word RA, 1998, AM J PHYSIOL-CELL PH, V274, pC748, DOI 10.1152/ajpcell.1998.274.3.C748; WORD RA, 1991, AM J PHYSIOL, V91, pC861; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362	73	103	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37250	37257		10.1074/jbc.M105275200	http://dx.doi.org/10.1074/jbc.M105275200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11486008	hybrid			2022-12-25	WOS:000171375700053
J	Korotchkina, LG; Patel, MS				Korotchkina, LG; Patel, MS			Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE KIDNEY; COMPLEX; PHOSPHATASE; MECHANISM; MUSCLE; EXPRESSION; STARVATION; BINDING; CLONING	Activity of the mammalian pyruvate dehydrogenase complex is regulated by phosphorylation-dephosphorylation of three specific serine residues (site 1, Ser-264; site 2, Ser-271; site 3, Ser-203) of the alpha subunit of the pyruvate dehydrogenase (EI) component. Phosphorylation is carried out by four pyruvate dehydrogenase kinase (PDK) isoenzymes. Specificity of the four mammalian PDKs toward the three phosphorylation sites of E1 was investigated using the recombinant E1 mutant proteins with only one functional phosphorylation site present. All four PDKs phosphorylated site 1 and site 2, however, with different rates in phosphate buffer (for site 1, PDK2 > PDK4 approximate to PDK1 > PDK3; for site 2, PDK3 > PDK4 > PDK2 > PDK1). Site 3 was phosphorylated by PDK1 only. The maximum activation by dihydrolipoamide acetyltransferase was demonstrated by PDK3. In the free form, all PDKs phosphorylated site 1, and PDK4 had the highest activity toward site 2. The activity of the four PDKs was stimulated to a different extent by the reduction and acetylation state of the lipoyl moieties of dihydrolipoamide acetyltransferase with the maximum stimulation of PDK2. Substitution of the site I serine with glutamate, which mimics phosphorylation-dependent inactivation of El, did not affect phosphorylation of site 2 by four PDKs and of site 3 by PDK1. Site specificity for phosphorylation of four PDKs with unique tissue distribution could contribute to the tissue-specific regulation of the pyruvate dehydrogenase complex in normal and pathophysiological states.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Patel, MS (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	mspatel@buffalo.edu			NIDDK NIH HHS [DK20478] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020478] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker JC, 2000, J BIOL CHEM, V275, P15773, DOI 10.1074/jbc.M909488199; Bowker-Kinley M, 1999, BIOCHEM J, V344, P47, DOI 10.1042/0264-6021:3440047; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER JR, 1977, BIOCHEM BIOPH RES CO, V74, P1667, DOI 10.1016/0006-291X(77)90636-2; Chen W, 1998, ARCH BIOCHEM BIOPHYS, V353, P181, DOI 10.1006/abbi.1998.0627; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; JONES BS, 1991, BIOCHEM J, V275, P781, DOI 10.1042/bj2750781; Katsube T, 1997, DNA CELL BIOL, V16, P335, DOI 10.1089/dna.1997.16.335; KHAILOVA LS, 1989, ANN NY ACAD SCI, V573, P36, DOI 10.1111/j.1749-6632.1989.tb14985.x; KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297; KOROTCHKINA LG, 1995, PROTEIN EXPRES PURIF, V6, P79, DOI 10.1006/prep.1995.1011; Korotchkina LG, 2001, J BIOL CHEM, V276, P5731, DOI 10.1074/jbc.M007558200; LIU TC, 1995, J BIOL CHEM, V270, P15545, DOI 10.1074/jbc.270.26.15545; Obayashi M, 2001, FEBS LETT, V491, P50, DOI 10.1016/S0014-5793(01)02149-4; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PETTIT FH, 1975, BIOCHEM BIOPH RES CO, V65, P575, DOI 10.1016/S0006-291X(75)80185-9; PRATT ML, 1979, J BIOL CHEM, V254, P7191; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; ROCHE TE, 1974, BIOCHEM BIOPH RES CO, V59, P1341, DOI 10.1016/0006-291X(74)90461-6; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; STEPP LR, 1983, J BIOL CHEM, V258, P9454; Sugden MC, 2000, BIOCHEM J, V352, P731, DOI 10.1042/0264-6021:3520731; SUGDEN PH, 1978, BIOCHEM J, V173, P659, DOI 10.1042/bj1730659; Thelen JJ, 2000, BIOCHEM J, V349, P195, DOI 10.1042/0264-6021:3490195; Thelen JJ, 1998, J BIOL CHEM, V273, P26618, DOI 10.1074/jbc.273.41.26618; WU P, 1965, BIOCHEM J, V329, P197; Wu PF, 2000, ARCH BIOCHEM BIOPHYS, V381, P1, DOI 10.1006/abbi.2000.1946; Wu PF, 1999, DIABETES, V48, P1593, DOI 10.2337/diabetes.48.8.1593; Yang DQ, 1998, J BIOL CHEM, V273, P14130, DOI 10.1074/jbc.273.23.14130; YEAMAN SJ, 1978, BIOCHEMISTRY-US, V17, P2364, DOI 10.1021/bi00605a017	33	159	171	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37223	37229		10.1074/jbc.M103069200	http://dx.doi.org/10.1074/jbc.M103069200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11486000	hybrid			2022-12-25	WOS:000171375700049
J	Re, F; Strominger, JL				Re, F; Strominger, JL			Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE-SYSTEM; HUMAN MONOCYTES; CUTTING EDGE; SIGNALING PATHWAYS; WALL COMPONENTS; HOST-DEFENSE; KAPPA-B; RECOGNITION; EXPRESSION; CHEMOKINE	Toll-like receptors (TLRs) mediate cell activation by various microbial products. Here, we demonstrate that activation of dendritic cells by TLR2 or TLR4 agonists, although it led to comparable activation of NF-kappaB and mitogen-activated protein kinase (MAPK) family members, resulted in striking differences in cytokine and chemokine gene transcription, suggesting that TLR2 and TLR4 signaling is not equivalent. A TLR4 agonist specifically promoted the production of the Th1-inducing cytokine interleukin (IL) 12 p70 and the chemokine interferon-gamma inducible protein (IP)-10, which is also associated to Th1 responses. In contrast, TLR2 stimulation failed to induce IL-12 p70 and interferon-gamma inducible protein (IP)-10 but resulted in the release of the IL-12 inhibitory p40 homodimer, producing conditions that are predicted to favor Th2 development. TLR2 stimulation also resulted in preferential induction of IL-8 and p19/IL-23. Involvement of phosphatidylinositol 3-kinase and p38 MAPK in the TLR-mediated induction of several cytokine and chemokine messages was demonstrated using specific inhibitors. Thus, TLRs can translate the information regarding the nature of pathogens into differences in the cytokines and chemokines produced by dendritic cells and therefore may contribute to the polarization of the acquired immune response.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University	Re, F (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [5R35-CA47554] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; HAYES MP, 1995, BLOOD, V86, P646, DOI 10.1182/blood.V86.2.646.bloodjournal862646; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LING P, 1995, J IMMUNOL, V154, P116; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Snijders A, 1996, J IMMUNOL, V156, P1207; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; TAUB DD, 1995, J IMMUNOL, V155, P3877; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Yoshimura A, 1999, J IMMUNOL, V163, P1	34	539	586	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37692	37699		10.1074/jbc.M105927200	http://dx.doi.org/10.1074/jbc.M105927200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11477091	hybrid			2022-12-25	WOS:000171375700108
J	Stulnig, TM; Huber, J; Leitinger, N; Imre, EM; Angelisova, P; Nowotny, P; Waldhaus, W				Stulnig, TM; Huber, J; Leitinger, N; Imre, EM; Angelisova, P; Nowotny, P; Waldhaus, W			Polyunsaturated eicosapentaenoic acid displaces proteins from membrane rafts by altering raft lipid composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOCYTE PROLIFERATION; GPI-ANCHORED PROTEINS; FATTY-ACIDS; TYROSINE KINASE; SIGNAL-TRANSDUCTION; MASS-SPECTROMETRY; CELL-RECEPTOR; CHOLESTEROL; ACYLATION; PALMITOYLATION	Polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (20:5 (n-3)) inhibit T lymphocyte activation probably by displacing acylated signaling proteins from membrane lipid rafts. Under physiological conditions, saturated fatty acyl residues of such proteins partition into the cytoplasmic membrane lipid leaflet with high affinity for rafts that are enriched in saturated fatty acyl-containing lipids. However, the biochemical alteration causing displacement of acylated proteins from rafts in PUFA-treated T cells is still under debate but could principally be attributed to altered protein acylation or changes in raft lipid composition. We show that treatment of Jurkat T cells with polyunsaturated eicosapentaenoic acid (20:5 (n-3)) results in marked enrichment of PUFAs (20:5; 22:5) in lipids from isolated rafts. Moreover, PUFAs were significantly incorporated into phosphatidylethanolamine that predominantly resides in the cytoplasmic membrane lipid leaflet. Notably, palmitate-labeled Src family kinase Lck and the linker for activation of T cells (LAT) were both displaced from lipid rafts indicating that acylation by PUFAs is not required for protein displacement from rafts in PUFA-treated T cells. In conclusion, these data provide strong evidence that displacement of acylated proteins from rafts in PUFA-treated T cells is predominantly due to altered raft lipid composition.	Univ Vienna, Dept Internal Med 3, A-1090 Vienna, Austria; Univ Vienna, Dept Vasc Biol, A-1090 Vienna, Austria; Acad Sci Czech Republ, Inst Mol Genet, CR-14220 Prague 4, Czech Republic	University of Vienna; University of Vienna; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Stulnig, TM (corresponding author), Karolinska Inst, Novum, Dept Med Nutr, S-14157 Huddinge, Sweden.	Thomas.Stulnig@biosci.ki.se	Angelisova, Pavla/G-3131-2014; Horejsi, Vaclav/G-3113-2014	Horejsi, Vaclav/0000-0003-4925-0142; Stulnig, Thomas/0000-0003-3300-6161				Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Belluzzi A, 1996, NEW ENGL J MED, V334, P1557, DOI 10.1056/NEJM199606133342401; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P2138; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown Deborah A., 1992, Trends in Cell Biology, V2, P338; Calder PC, 1998, NUTR REV, V56, pS70; CALDER PC, 1992, IMMUNOLOGY, V75, P108; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Cerny J, 1996, EUR J IMMUNOL, V26, P2335, DOI 10.1002/eji.1830261010; CHOW SC, 1991, BIOCHIM BIOPHYS ACTA, V1092, P358, DOI 10.1016/S0167-4889(97)90013-6; DeMar JC, 1997, J BIOL CHEM, V272, P31362, DOI 10.1074/jbc.272.50.31362; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Fridriksson EK, 1999, BIOCHEMISTRY-US, V38, P8056, DOI 10.1021/bi9828324; HALLAK H, 1994, J BIOL CHEM, V269, P4713; Han XL, 1996, BIOCHEMISTRY-US, V35, P5822, DOI 10.1021/bi952927v; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Huster D, 1998, BIOCHEMISTRY-US, V37, P17299, DOI 10.1021/bi980078g; James MJ, 1997, SEMIN ARTHRITIS RHEU, V27, P85, DOI 10.1016/S0049-0172(97)80009-1; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KWONG J, 1995, BIOCHEM BIOPH RES CO, V207, P868, DOI 10.1006/bbrc.1995.1266; Laposata M, 1996, LIPIDS, V31, pS217, DOI 10.1007/BF02637079; Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291; LEPAGE G, 1986, J LIPID RES, V27, P114; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MEYDANI SN, 1993, J CLIN INVEST, V92, P105, DOI 10.1172/JCI116537; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; SANTOLI D, 1990, J CLIN INVEST, V85, P424, DOI 10.1172/JCI114455; SCARIA AMS, 1994, J CELL BIOL, V126, P353; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHOU X, 1992, J LIPID RES, V33, P1233; Zurier RB, 1999, PROSTAG LEUKOTR ESS, V60, P371, DOI 10.1016/S0952-3278(99)80015-5	52	267	279	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37335	37340		10.1074/jbc.M106193200	http://dx.doi.org/10.1074/jbc.M106193200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11489905	hybrid			2022-12-25	WOS:000171375700064
J	Couture, M; Burmester, T; Hankeln, T; Rousseau, DL				Couture, M; Burmester, T; Hankeln, T; Rousseau, DL			The heme environment of mouse neuroglobin - Evidence for the presence of two conformations of the heme pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN EVIDENCE; ELEPHANT MYOGLOBIN; LIGAND-BINDING; CATALYTIC SITE; DISTAL POCKET; HEMOGLOBIN; CO; OXYGEN; COMPLEX; MUTANT	Neuroglobin (Ngb) is a newly discovered oxygen-binding heme protein that is primarily expressed in the brain of humans and other vertebrates. To characterize the structure/function relationships of this new heme protein, we have used resonance Raman spectroscopy to determine the structure of the heme environment in Ngb from mice. In the Fe2+CO complex, two conformations of the Fe-CO unit are present, one of which arises from an open conformation of the heme pocket in which the CO is not interacting with any nearby residue, and the other arises from a closed conformation where a positively charged residue near the CO group stabilizes the complex. For the Fe2+O2 complex, we detect a single upsilon (Fe-OO) stretching mode at a frequency similar to that of oxymyoglobins and oxyhemoglobins of vertebrates (571 cm(-1)). Based on the Fe-C-O frequencies of the closed conformation of Ngb, a highly polar distal environment is indicated from which the O-2 off-rate is predicted to be lower than that of Mb. In the absence of exogenous ligands, a heme pocket residue coordinates to the heme iron, forming a six-coordinate complex, thereby predicting a low on-rate for exogenous ligands. These structural properties of the heme pocket of Ngb are discussed with respect to its proposed in vivo oxygen delivery function.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Univ Mainz, Inst Mol Genet Biosafety Res & Consulting, D-55099 Mainz, Germany	Yeshiva University; Albert Einstein College of Medicine; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave,Ullmann 313, Bronx, NY 10461 USA.		Burmester, Thorsten/I-7225-2013; Couture, Manon/F-8326-2015	Burmester, Thorsten/0000-0002-5772-7863; Couture, Manon/0000-0001-8296-8055	NIGMS NIH HHS [GM54806, GM54812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054812, R01GM054806] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderton CL, 1997, BBA-PROTEIN STRUCT M, V1338, P107, DOI 10.1016/S0167-4838(96)00194-X; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P21, DOI 10.1016/S0968-0004(00)01698-4; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; Chu GC, 1999, J BIOL CHEM, V274, P24490, DOI 10.1074/jbc.274.35.24490; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Das TK, 2000, BIOCHEMISTRY-US, V39, P837, DOI 10.1021/bi9922087; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Das TK, 1999, J BIOL CHEM, V274, P4207, DOI 10.1074/jbc.274.7.4207; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Hargrove MS, 2000, BIOPHYS J, V79, P2733, DOI 10.1016/S0006-3495(00)76512-X; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; HIROTA S, 1994, J AM CHEM SOC, V116, P10564, DOI 10.1021/ja00102a025; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; KERR EA, 1985, J BIOL CHEM, V260, P8360; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Mukai M, 2001, J BIOL CHEM, V276, P7272, DOI 10.1074/jbc.M009280200; PARK KD, 1991, BIOCHEMISTRY-US, V30, P2333, DOI 10.1021/bi00223a007; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; POTTER WT, 1987, BIOCHEMISTRY-US, V26, P4699, DOI 10.1021/bi00389a016; RAMSDEN J, 1989, BIOCHEMISTRY-US, V28, P3125, DOI 10.1021/bi00434a001; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SONG SH, 1993, BIOCHEMISTRY-US, V32, P6330, DOI 10.1021/bi00076a005; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; VANWART HE, 1985, J BIOL CHEM, V260, P8372; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Wang J., 1996, METHODS NITRIC OXIDE, P427; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; Wittenberg J.B., 1992, Advances in Comparative and Environmental Physiology, V13, P59; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; ZHAO XF, 1995, J BIOL CHEM, V270, P20763, DOI 10.1074/jbc.270.35.20763	39	112	127	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36377	36382		10.1074/jbc.M103907200	http://dx.doi.org/10.1074/jbc.M103907200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11473111	hybrid			2022-12-25	WOS:000171194500044
J	Erbay, E; Chen, J				Erbay, E; Chen, J			The mammalian target of rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; GROWTH-FACTORS; DIFFERENTIATION; PHOSPHORYLATION; EXPRESSION; INITIATION; MYOBLASTS; RECEPTOR; FAMILY	Rapamycin inhibits differentiation of mouse C2C12 myoblasts, a tissue culture model for skeletal muscle differentiation. The mechanism by which a rapamycin-sensitive signaling pathway regulates myogenesis is largely unknown. The mammalian target of rapamycin (mTOR) is a central regulator of cell growth and proliferation, but its role in myogenesis has not been examined directly. Here we report the investigation of the function of mTOR and its downstream effectors in muscle differentiation. Rapamycin exerts an inhibitory effect on C2C12 myogenesis at different stages, implying that a rapamycin-sensitive pathway may be required for multiple processes during muscle differentiation. The mTOR protein level increases 10-fold during differentiation, via a post-transcriptional mechanism. As the first direct demonstration of the essential role of mTOR in muscle differentiation, we show that a rapamycin-resistant mTOR, but not S6 kinase 1, can rescue rapamycin-inhibited myogenesis. Remarkably, the myogenic function of mTOR does not require its kinase activity. Two downstream effectors of the rapamycin-sensitive pathway, S6 kinase 1 and eIF4E-binding protein 1, undergo differential regulation during myogenesis, but neither protein is the relevant effector for the myogenic signaling of mTOR. Taken together, our observations suggest a novel mTOR signaling mechanism essential for skeletal muscle differentiation.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Chen, J (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA.	jiechen@uiuc.edu		Chen, Jie/0000-0002-7887-3747; Erbay, Ebru/0000-0001-9584-1803	NIGMS NIH HHS [GM58064] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058064, R55GM058064] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Canicio J, 1998, ENDOCRINOLOGY, V139, P5042, DOI 10.1210/en.139.12.5042; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Conejo R, 2001, J CELL PHYSIOL, V186, P82, DOI 10.1002/1097-4652(200101)186:1<82::AID-JCP1001>3.0.CO;2-R; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; FUMAGALLI S, TRANSLATIONAL CONTRO, P695; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	27	118	120	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36079	36082		10.1074/jbc.C100406200	http://dx.doi.org/10.1074/jbc.C100406200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11500483	hybrid			2022-12-25	WOS:000171194500006
J	Igarashi, J; Michel, T				Igarashi, J; Michel, T			Sphingosine 1-phosphate and isoform-specific activation of phosphoinositide 3-kinase beta - Evidence for divergence and convergence of receptor-regulated endothelial nitric-oxide synthase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMALEMMAL CAVEOLAE; GAMMA-SUBUNITS; GROWTH-FACTOR; CELLS; SPHINGOSINE-1-PHOSPHATE; EXPRESSION; EDG-1; CALCIUM	Sphingosine 1-phosphate (SIP) is a platelet-derived sphingolipid that elicits diverse biological responses, including angiogenesis, via the activation of G protein-coupled EDG receptors. SIP activates the endothelial isoform of nitric-oxide synthase (eNOS), associated with eNOS phosphorylation at Ser-1179, a site phosphorylated by protein kinase Akt. We explored the proximal signaling pathways that mediate Akt activation and eNOS regulation by S1P/EDG receptors. Akt is regulated by the lipid kinase phosphoinositide 3-kinase (PI3-K). We found that bovine aortic endothelial cells (BAEC) express both alpha and beta isoforms of PI3-K, while lacking the gamma isoform. SIP treatment led to the rapid and isoform-specific activation of PI3-K beta in BAEC. PI3-K beta can be regulated by G protein beta gamma subunits (G beta gamma). The overexpression of a peptide inhibitor of G beta gamma attenuated S1P-induced eNOS enzyme activation, as well as S1P-induced phosphorylation of eNOS and Akt. In contrast, bradykinin, a classical eNOS agonist, neither activated any PI3-K isoform nor induced eNOS phosphorylation at Ser-1179, despite activating eNOS in BAEC. Vascular endothelial growth factor activated both PI3-K alpha and PI3-K beta via tyrosine kinase pathways and promoted eNOS phosphorylation that was unaffected by G beta gamma inhibition. These findings indicate that PI3-K beta (regulated by G beta gamma) may represent a novel molecular locus for eNOS activation by EDG receptors in vascular endothelial cells. These studies also indicate that different eNOS agonists activate distinct signaling pathways that diverge proximally following receptor activation but converge distally to activate eNOS.	Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc, Sch Med, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, Boston, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc, Sch Med, Thorn Bldg,Rm 1210A,75 Francis St, Boston, MA 02115 USA.							Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; Bony C, 2001, J CELL BIOL, V152, P717, DOI 10.1083/jcb.152.4.717; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Chavakis E, 2001, CIRCULATION, V103, P2102; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Hayashi K, 1998, J BIOL CHEM, V273, P28860, DOI 10.1074/jbc.273.44.28860; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KU DD, 1993, AM J PHYSIOL, V265, P586; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MOMBOULI JV, 1995, ANNU REV PHARMACOL, V35, P679, DOI 10.1146/annurev.pa.35.040195.003335; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nakajima N, 2000, EUR J BIOCHEM, V267, P5679, DOI 10.1046/j.1432-1327.2000.01656.x; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; Sase K, 1997, TRENDS CARDIOVAS MED, V7, P28, DOI 10.1016/S1050-1738(96)00121-1; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Takasuga S, 1999, J BIOL CHEM, V274, P19545, DOI 10.1074/jbc.274.28.19545; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yatomi Y, 1997, J BIOCHEM, V121, P969; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	56	115	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36281	36288		10.1074/jbc.M105628200	http://dx.doi.org/10.1074/jbc.M105628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11470796	hybrid			2022-12-25	WOS:000171194500032
J	Mendoza-Alvarez, H; Alvarez-Gonzalez, R				Mendoza-Alvarez, H; Alvarez-Gonzalez, R			Regulation of p53 sequence-specific DNA-binding by covalent poly(ADP-ribosyl)ation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADENOSINE DIPHOSPHATE RIBOSE); GENE-EXPRESSION; POLYMERASE PARP; TERMINAL DOMAIN; ACTIVATION; INHIBITION; APOPTOSIS; PROTEIN; DAMAGE; ALPHA	We have characterized the covalent poly(ADP-ribosyl)ation of p53 using an in vitro reconstituted system. We used recombinant wild type p53, recombinant poly(ADP-ribose) polymerase-1 (PARP-1) (EC 2.4.2.30), and beta NAD(+). Our results show that the covalent poly(ADP-ribosyl)ation of p53 is a time-dependent protein-poly(ADP-ribosyl)ation reaction and that the addition of this tumor suppressor protein to a PARP-1 automodification mixture stimulates total protein-poly(ADP-ribosyl)ation 3- to 4-fold. Electrophoretic analysis of the products synthesized indicated that short oligomers predominate early during hetero-poly(ADP-ribosyl)ation, whereas longer ADP-ribose chains are synthesized at later times of incubation. A more drastic effect in the complexity of the ADP-ribose chains generated was observed when the beta NAD(+) concentration was varied. As expected, increasing the beta NAD(+) concentration from low nanomolar to high micromolar levels resulted in the slower electrophoretic migration of the p53-(ADP-ribose). adducts. Increasing the concentration of p53 protein from low nanomolar (40 nm) to low micromolar (1.0 mum) yielded higher amounts of poly(ADP-ribosyl)ated p53 as well. Thus, the reaction was acceptor protein concentration-dependent. The hetero-poly(ADP-ribosyl)ation of p53 also showed that high concentrations of p53 specifically stimulated the automodification reaction of PARP-1. The covalent modification of p53 resulted in the inhibition of the binding ability of this transcription factor to its DNA consensus sequence as judged by electrophoretic mobility shift assays. In fact, controls carried out with calf thymus DNA, beta NAD(+), PARP-1, and automodified PARP-1 confirmed our conclusion that the covalent poly(ADP-ribosyl)ation of p53 results in the transcriptional inactivation of this tumor suppressor protein.	Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center	Alvarez-Gonzalez, R (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA.	ralvarez@hsc.unt.edu	Gonzalez, Rafael Alvarez/I-4560-2019	Alvarez-Gonzalez, Rafael/0000-0003-1038-7512	NIGMS NIH HHS [GM45451] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045451] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMIETZ P, 1987, EUR J BIOCHEM, V169, P365, DOI 10.1111/j.1432-1033.1987.tb13621.x; Alvarez-Gonzalez R, 1999, J BIOL CHEM, V274, P32122, DOI 10.1074/jbc.274.45.32122; ALVAREZGONZALEZ R, 1999, ADP RIBOSYLATION REA; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Appella E, 2000, PATHOL BIOL, V48, P227; Atorino L, 2000, ARCH BIOCHEM BIOPHYS, V381, P111, DOI 10.1006/abbi.2000.1926; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BOULIKAS T, 1989, P NATL ACAD SCI USA, V86, P3499, DOI 10.1073/pnas.86.10.3499; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHANG WJ, 2001, IN PRESS J BIOL CHEM; Chatterjee S, 1999, MOL CELL BIOCHEM, V193, P23, DOI 10.1023/A:1006983304079; Chiarugi V, 1998, ONCOL RES, V10, P55; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DESMARAIS Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P179, DOI 10.1016/0167-4838(91)99007-F; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; JUMP DB, 1980, BIOCHEMISTRY-US, V19, P1024, DOI 10.1021/bi00546a030; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kumari SR, 1998, CANCER RES, V58, P5075; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; MAYR GA, 1995, CANCER RES, V55, P2140; Mendoza-Alvarez H, 2000, IUBMB LIFE, V50, P145, DOI 10.1080/15216540050212187; Mendoza-Alvarez H, 2001, FASEB J, V15, pA888; MENDOZAALVAREZ H, 1993, J BIOL CHEM, V268, P22575; Menegazzi M, 1999, MOL CARCINOGEN, V25, P256, DOI 10.1002/(SICI)1098-2744(199908)25:4<256::AID-MC4>3.0.CO;2-W; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; OEI SL, 1997, REV PHYSIOL BIOCHEM, V131, P4135; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; Wiederschain D, 2001, J BIOL CHEM, V276, P27999, DOI 10.1074/jbc.M102400200; Yakovlev AG, 2000, J BIOL CHEM, V275, P21302, DOI 10.1074/jbc.M001087200; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; ZHANG W, 1994, CANCER RES, V54, P4448	51	84	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36425	36430		10.1074/jbc.M105215200	http://dx.doi.org/10.1074/jbc.M105215200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477085	hybrid			2022-12-25	WOS:000171194500051
J	Teyssier, C; Belguise, K; Galtier, F; Chalbos, D				Teyssier, C; Belguise, K; Galtier, F; Chalbos, D			Characterization of the physical interaction between estrogen receptor alpha and JUN proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTOR; CBP-INDUCED STIMULATION; DNA-BINDING ACTIVITY; C-JUN; GLUCOCORTICOID RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; LEUCINE ZIPPER; IN-VITRO; FOS; GENE	Activated estrogen receptor alpha (ER alpha) modulates transcription triggered by the transcription factor activator protein-1 (AP-1), which consists of Jun-Jun homodimers and Jun-Fos heterodimers. Previous studies have demonstrated that the interference occurs without binding of ER alpha to DNA but probably results from protein-protein interactions. However, involvement of a direct interaction between ER alpha and AP-I is still debated. Using glutathione S-transferase pull-down assays, we demonstrated that ER alpha bound directly to c-Jun and JunB but not to FOS family members, in a ligand-independent manner. The interaction could occur when c-Jun was bound onto DNA, as shown in a protein-protein-DNA assay. It implicated the C-terminal part of c-Jun and amino acids 259-302 present in the ER alpha hinge domain. ER alpha but not an ER alpha mutant deleted of amino acids 250-303 (ER241G), also associated with c-Jun in intact cells, in the presence of estradiol, as shown by two-hybrid and coimmunoprecipitation assays. We also show that ER alpha, c-Jun, and the p160 coactivator GRIP1 can form a multiprotein complex in vitro and in intact cells and that the ER alpha -c-Jun interaction could be crucial for the stability of this complex. VP16-ER alpha and c-Jun, which both interact with GRIP1, had synergistic effect on GAL4-GRIP1-induced transcription in the presence of estradiol, and this synergistic effect was not observed with the ER alpha mutant VP16-ER241G or when c-Fos, which bound GRIP1 but not ER alpha, was used instead of c-Jun. Finally, ER241G was inefficient for regulation of AP-1 activity, and an ER alpha truncation mutant encompassing the hinge domain had a dominant negative effect on ER alpha action. These results altogether demonstrate that ER alpha can bind to c-Jun in vitro and in intact cells and that this interaction, by stabilizing a multiprotein complex containing p160 coactivator, is likely to be involved in estradiol regulation of AP-1 responses.	INSERM, U540, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Chalbos, D (corresponding author), INSERM, U540, 60 Rue Navacelles, F-34090 Montpellier, France.		Teyssier, Catherine/AAC-2395-2020	Teyssier, Catherine/0000-0003-4937-6503; Belguise, Karine/0000-0003-3426-8040				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; BUTLER AJ, 1995, NUCLEIC ACIDS RES, V23, P4143, DOI 10.1093/nar/23.20.4143; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ELLISTON JF, 1990, J BIOL CHEM, V265, P11517; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KERR L D, 1992, Current Opinion in Cell Biology, V4, P496, DOI 10.1016/0955-0674(92)90017-7; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; MATSUI M, 1990, ONCOGENE, V5, P249; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; ONATE SA, 1995, SCIENCE, V270, P1354; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; ROUX P, 1991, ONCOGENE, V6, P2155; Roux S, 1996, MOL ENDOCRINOL, V10, P1214, DOI 10.1210/me.10.10.1214; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Thenot S, 1999, MOL ENDOCRINOL, V13, P2137, DOI 10.1210/me.13.12.2137; TOURAY M, 1991, ONCOGENE, V6, P1227; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1216; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513	58	104	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36361	36369		10.1074/jbc.M101806200	http://dx.doi.org/10.1074/jbc.M101806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477071	hybrid			2022-12-25	WOS:000171194500042
J	Li, YQ; Ren, J; Yu, WH; Li, Q; Kuwahara, H; Yin, L; Carraway, KL; Kufe, D				Li, YQ; Ren, J; Yu, WH; Li, Q; Kuwahara, H; Yin, L; Carraway, KL; Kufe, D			The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; ASSOCIATION; PROTEIN; TRANSFORMATION; CELLS; GRB2; DF3	The DF3/MUC1 mucin-like, transmembrane glycoprotein is aberrantly overexpressed in most human carcinomas. The MUC1 cytoplasmic domain interacts with the c-Src tyrosine kinase and thereby increases binding of MUC1 and beta -catenin. In the present work, coimmunoprecipitation studies demonstrate that MUC1 associates constitutively with the epidermal growth factor receptor (EGF-R) in human ZR-75-1 breast carcinoma cells. Immunofluorescence studies show that EGF-R and MUC1 associate at the cell membrane. We also show that the activated EGF-R phosphorylates the MUC1 cytoplasmic tail on tyrosine at a YEKV motif that functions as a binding site for the c-Src SH2 domain. The results demonstrate that EGF-R-mediated phosphorylation of MUC1 induces binding of MUC1 to c-Src in cells. Moreover, in vitro and in vivo studies demonstrate that EGF-R increases binding of MUC1 and beta -catenin. These findings support a novel role for EGF-R in regulating interactions of MUC1 with c-Src and beta -catenin.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Div New Born Med, Boston, MA 02115 USA; Univ Calif Davis, Dept Biol Chem, Sacramento, CA 95817 USA; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; University of California System; University of California Davis; University of California System; University of California Davis	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.		Yu, Wei Hsuan/AAF-7129-2021	YU, WEI-HSUAN/0000-0002-1782-3738	NCI NIH HHS [CA87421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA087421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GENDLER S, 1988, J BIOL CHEM, V263, P12820; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	20	223	246	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35239	35242		10.1074/jbc.C100359200	http://dx.doi.org/10.1074/jbc.C100359200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11483589	hybrid			2022-12-25	WOS:000171109300005
J	Burns, TF; Bernhard, EJ; El-Deiry, WS				Burns, TF; Bernhard, EJ; El-Deiry, WS			Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo	ONCOGENE			English	Article						p53; apoptosis; gamma irradiation; KILLER/DR5; c-FLIP-s; real-time RT-PCR	RADIATION-INDUCED APOPTOSIS; DAMAGE-INDUCED APOPTOSIS; DEFICIENT MICE; CYTOCHROME-C; DEATH; ACTIVATION; INHIBITION; PROTEIN; TRAIL; CELLS	The p53 tumor suppressor plays a key role in the cell's response to genotoxic stress and loss of this 'guardian of the genome' is an important step in carcinogenesis. The ability of p53 to induce apoptosis through transactivation of its target genes is critical for its function as tumor suppressor. We have found that overexpression of p53 in human cancer cell lines resulted in apoptosis as measured by PARP cleavage. Furthermore we observed cleavage of both caspase 9 and caspase 8 after overexpression of p53 and found that p53-dependent apoptosis was inhibited by either cellular (c-Flip-s, BCI-X-L) or pharmacological inhibitors of caspase 8 or caspase 9 respectively. These results indicate that p53 is mediating apoptosis through both the mitochondrial and death receptor pathways. To elucidate the relevant p53 target genes and examine the caspase pathways utilized in vivo, we treated p53+/+ and age matched p53-/- mice with 5 Gy ionizing radiation or 0.5 mg/animal dexamethasone and harvested tissues at 0, 6 and 24 h. We examined the mRNA expression of p21, bax, KILLER/DR5, FAS/APO1 and EI24/PIG8 using TaqMan real time quantitative RT-PCR in the spleen, thymus and small intestine. Although the basal mRNA levels of these genes did not depend on the presence of p53, we observed a p53-dependent induction of all these targets in response to gamma -radiation and a p53-independent regulation for p21 and KILLER/DR5 in response to dexamethasone. Furthermore, we have demonstrated that the relative induction of these p53 target genes is tissue specific. Despite observing otherwise similar levels of death in these tissues, our findings suggest that in some cases apoptosis mediated through p53 occurs by redundant pathways or by a 'group effect' while in other tissues one or few targets may play a key role in p53-dependent apoptosis. Surprisingly, KILLER/DR5 is the dominantly induced transcript in both the spleen and small intestine suggesting a potentially important role for this p53 target gene in vivo.	Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NATIONAL CANCER INSTITUTE [R01CA075454, P01CA075138] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75454, CA 75138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Fuchs EJ, 1997, CANCER RES, V57, P2550; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; KASTAN MB, 1991, CANCER RES, V51, P6304; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lee SH, 1999, CANCER RES, V59, P5683; Lehar SM, 1996, ONCOGENE, V12, P1181; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; Meng RD, 1998, CLIN CANCER RES, V4, P251; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Ozoren N, 2000, CANCER RES, V60, P6259; Pai SI, 1998, CANCER RES, V58, P3513; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhao RB, 2000, GENE DEV, V14, P981; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	54	113	118	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4601	4612		10.1038/sj.onc.1204484	http://dx.doi.org/10.1038/sj.onc.1204484			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498783				2022-12-25	WOS:000170208600001
J	Little, NA; Jochemsen, AG				Little, NA; Jochemsen, AG			Hdmx and Mdm2 can repress transcription activation by p53 but not by p63	ONCOGENE			English	Article						p53; p63; Mdmx; Mdm2; transcriptional activation	PROTEIN; HOMOLOG; P73; DEGRADATION; ONCOPROTEIN; PRODUCTS; MUTANTS; LIGASE; LIMB	The p53 protein is involved in cell cycle arrest and apoptosis. To ensure that cells under non-stressed conditions are able to grow, p53 sets up a negative feedback loop by inducing Mdm2. Mdm2 is able to both inhibit the transcriptional regulation by p53 and to degrade it, thus maintaining p53 inactive until it is required. The Mdm2 related protein, Hdmx, has also been shown to inhibit the transcriptional activation of p53 but is unable to degrade it. A few years ago, the p53 family member, p63 was identified. Like p53, p63 is able to induce p53 target genes and it was shown to be able to cause cell cycle arrest and apoptosis. In this study we report that, despite the similarities between p53 and p63, neither Hdmx nor Mdm2 are able to interact with p63, to repress p63-induced transcription or to affect its half-life.	Leiden Univ, Med Ctr, Dept Mol & Cell Biol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jochemsen, AG (corresponding author), Leiden Univ, Med Ctr, Dept Mol & Cell Biol, POB 9503, NL-2300 RA Leiden, Netherlands.	a.g.jochemsen@lumc.nl						Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Lee LA, 1999, J INVEST DERMATOL, V113, P146, DOI 10.1046/j.1523-1747.1999.00651.x; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shimada A, 1999, CANCER RES, V59, P2781; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2000, J BIOL CHEM, V275, P28039; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; van der Eb A J, 1980, Methods Enzymol, V65, P826; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	36	53	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4576	4580		10.1038/sj.onc.1204615	http://dx.doi.org/10.1038/sj.onc.1204615			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494153				2022-12-25	WOS:000170074900015
J	Guidotti, JE; Mallet, VO; Mitchell, C; Fabre, M; Schoevaert, D; Opolon, P; Parlier, D; Lambert, M; Kahn, A; Gilgenkrantz, H				Guidotti, JE; Mallet, VO; Mitchell, C; Fabre, M; Schoevaert, D; Opolon, P; Parlier, D; Lambert, M; Kahn, A; Gilgenkrantz, H			Selection of in vivo retrovirally transduced hepatocytes leads to efficient and predictable mouse liver repopulation	FASEB JOURNAL			English	Article						liver repopulation; molecular therapy; retrovirus; apoptosis	MEDIATED GENE-TRANSFER; IN-VIVO; LONG-TERM; THERAPY; MICE; TRANSPLANTATION; INTEGRATION; EXPRESSION; HEMOPHILIA; HEPATITIS	Stable liver gene transfer is generally limited by the low efficiency of commonly used vectors. One way to circumvent this difficulty is to confer a selective advantage on transduced hepatocytes, allowing them to progressively repopulate the liver. We have used a strategy for in vivo selection and controlled amplification of a small percentage of retrovirally engineered hepatocytes. Using a bicistronic retroviral vector encoding a reporter gene and Bcl2, which confers on liver cells a survival advantage against the Fas apoptotic pathway, we demonstrate that 1.5% of initially transduced hepatocytes repopulate up to 85% of the liver after 10 injections of a Fas agonist antibody. Moreover, we show that the kinetics of liver repopulation is highly predictable. This system provides a general means of expanding at will engineered hepatocytes in vivo and offering the possibility to obtain a genetically modified liver expressing a gene of interest in a desired proportion of hepatocytes.	Inst Cochin Genet Mol, INSERM, U129, F-75014 Paris, France; Hop Cochin, Serv Reanimat Polyvalente, F-75014 Paris, France; Hop Bicetre, Anat Pathol Lab, F-94275 Le Kremlin Bicetre, France; Inst Gustave Roussy, CNRS IGR Aventis, UMR 1582, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Gilgenkrantz, H (corresponding author), Inst Cochin Genet Mol, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	gilgenkrantz@cochin.inserm.fr	Gilgenkrantz, Helene/G-5534-2017; Guidotti, Jacques-Emmanuel/M-9014-2018; Mallet, Vincent/G-4623-2011	guidotti, jacques-emmanuel/0000-0001-9285-8167; gilgenkrantz, helene/0000-0001-6770-4561; Mallet, Vincent/0000-0003-2219-9201				Aurisicchio L, 2000, J VIROL, V74, P4816, DOI 10.1128/JVI.74.10.4816-4823.2000; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FERRY N, 1991, P NATL ACAD SCI USA, V88, P8377, DOI 10.1073/pnas.88.19.8377; Guha C, 1999, CANCER RES, V59, P5871; Guidotti JE, 2001, HEPATOLOGY, V33, P10, DOI 10.1053/jhep.2001.20678; Ji W, 1997, J VIRAL HEPATITIS, V4, P167, DOI 10.1046/j.1365-2893.1997.00144.x; Jin LQ, 2000, NAT GENET, V26, P64, DOI 10.1038/79194; Kaufman RJ, 1999, HUM GENE THER, V10, P2091, DOI 10.1089/10430349950017095; Kay MA, 1998, HAEMOPHILIA, V4, P389, DOI 10.1046/j.1365-2516.1998.440389.x; Kitten O, 1997, HUM GENE THER, V8, P1491, DOI 10.1089/hum.1997.8.12-1491; Laconi E, 1998, AM J PATHOL, V153, P319, DOI 10.1016/S0002-9440(10)65574-5; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Miao CH, 1998, NAT GENET, V19, P13, DOI 10.1038/ng0598-13; Mignon A, 1998, NAT MED, V4, P1185, DOI 10.1038/2681; Mitchell C, 2000, HUM MOL GENET, V9, P1597, DOI 10.1093/hmg/9.11.1597; Nakai H, 1998, BLOOD, V91, P4600, DOI 10.1182/blood.V91.12.4600.412k22_4600_4607; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; Park F, 2000, NAT GENET, V24, P49, DOI 10.1038/71673; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; Tangirala RK, 1999, CIRCULATION, V100, P1816, DOI 10.1161/01.CIR.100.17.1816; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568	22	20	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1849	+		10.1096/fj.00-0892fje	http://dx.doi.org/10.1096/fj.00-0892fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481251				2022-12-25	WOS:000169261200036
J	Koudinov, AR; Koudinova, NV				Koudinov, AR; Koudinova, NV			Essential role for cholesterol in synaptic plasticity and neuronal degeneration	FASEB JOURNAL			English	Article						amyloid beta protein; Alzheimer's disease; Down's syndrome; cholesterol and phospholipid efflux and synthesis; hippocampal slices; Niemann-Pick type C disease; tau phosphorylation; lipoprotein LDL LRP VLDL receptor	DENSITY-LIPOPROTEIN RECEPTOR; AMYLOID-BETA-PROTEIN; CEREBROSPINAL-FLUID LIPOPROTEINS; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; NORMAL HUMAN PLASMA; APOLIPOPROTEIN-E; MEMBRANE CHOLESTEROL; TRANSMITTER RELEASE; GENE-EXPRESSION	There is no understanding of the role of cholesterol and phospholipids in the mechanisms of synaptic function and neurodegeneration. Here we report that cholesterol disbalance is critical for synaptic transmission and plasticity as investigated by a study of paired pulse facilitation and long-term potentiation (LTP). Extracellular recording of field-evoked postsynaptic potentials showed enhanced PPF ratio and an impairment of LTP in CA1 subfield of adult rat ex-vivo hippocampal slices subjected to cyclodextrin- or normal human CSF-HDL3-mediated cholesterol efflux. Immunofluorescence with antibodies against neurofilament and tau revealed that cholesterol and phospholipids depletion causes alteration of normal hippocampal neurites and the appearance of PHF-tau in the mossy fibers. We further find that LTP and amyloid beta protein increase [C-14] acetate label incorporation into newly synthesized hippocampal membrane lipids. Our results indicate the importance of neuronal cholesterol redistribution and synthesis for synaptic plasticity and neurodegeneration.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Russian Acad Med Sci, Inst Biomed Chem, Moscow 121359, Russia; Russian Acad Med Sci, Natl Mental Hlth Res Ctr, Moscow 121359, Russia	Weizmann Institute of Science; Russian Academy of Medical Sciences; Institute of Biomedical Chemistry; Russian Academy of Medical Sciences	Koudinov, AR (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Candiotti Bldg, IL-76100 Rehovot, Israel.	koudin@imb.ac.ru						Albert AD, 1996, BBA-BIOMEMBRANES, V1285, P47, DOI 10.1016/S0005-2736(96)00145-9; ARENDT T, 1995, NEUROSCIENCE, V69, P691, DOI 10.1016/0306-4522(95)00347-L; AUER IA, 1995, ACTA NEUROPATHOL, V90, P547; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Berretta N, 2000, NEUROPHARMACOLOGY, V39, P2288, DOI 10.1016/S0028-3908(00)00076-9; BINDER LI, 1986, DYNAMIC ASPECTS MICR, P145; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; CHAMPAGNE D, 2000, SOC NEUR ABSTR, V26, P1546; CORNELIUS F, 1995, BBA-BIOMEMBRANES, V1235, P205, DOI 10.1016/0005-2736(95)80006-2; CREWS FT, 1983, BRAIN RES, V261, P155, DOI 10.1016/0006-8993(83)91296-9; Demeester N, 2000, J LIPID RES, V41, P963; DISTL R, 2000, NEUROBIOL AGING, V21, pS21; EISENSAMER B, 2000, SOC NEUR ABSTR, V26, P2159; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Fagan AM, 2000, ANN NEUROL, V48, P201, DOI 10.1002/1531-8249(200008)48:2<201::AID-ANA10>3.0.CO;2-X; Fan QW, 2001, J NEUROCHEM, V76, P391, DOI 10.1046/j.1471-4159.2001.00063.x; Friedman LK, 1999, J NEUROSCI, V19, P9412; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Gong C.-X., 1996, Neurobiology of Aging, V17, pS133, DOI 10.1016/S0197-4580(96)80536-7; Goussakov IV, 2000, J NEUROSCI, V20, P3434, DOI 10.1523/JNEUROSCI.20-09-03434.2000; Hall GF, 2000, CELL MOTIL CYTOSKEL, V46, P166, DOI 10.1002/1097-0169(200007)46:3<166::AID-CM2>3.0.CO;2-8; Hanaka S, 2000, BRAIN DEV-JPN, V22, P321, DOI 10.1016/S0387-7604(00)00129-7; Heicklen-Klein A, 2000, BRAIN RES, V874, P1, DOI 10.1016/S0006-8993(00)02539-7; Henze DA, 2000, NEUROSCIENCE, V98, P407, DOI 10.1016/S0306-4522(00)00146-9; Igbavboa U, 1997, J NEUROCHEM, V69, P1661; IGBAVBOA U, 2000, NEUROSCI LETT S, V55, pS25; ISHIGURO M, 1995, MOL BRAIN RES, V33, P37, DOI 10.1016/0169-328X(95)00104-Z; Kaplan B, 1999, CLIN CHIM ACTA, V280, P147, DOI 10.1016/S0009-8981(98)00190-9; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Korkotian E, 1997, J NEUROSCI, V17, P1670; Koudinov A.R., 2000, SOC NEUR ABSTR, V26, P497; Koudinov AR, 1996, BIOCHEM MOL BIOL INT, V38, P747; Koudinov AR, 1996, BIOCHEM BIOPH RES CO, V223, P592, DOI 10.1006/bbrc.1996.0940; Koudinov AR, 1998, CLIN CHIM ACTA, V270, P75, DOI 10.1016/S0009-8981(97)00207-6; Koudinov AR, 1997, CELL BIOL INT, V21, P265, DOI 10.1006/cbir.1996.0126; KOUDINOV AR, 2000, NEUROSCI LETT S, V55, pS30; Koudinova NV, 1996, VOP MED KHIM, V42, P253; Koudinova NV, 2000, NEUROCHEM RES, V25, P653, DOI 10.1023/A:1007511120099; Krucker T, 2000, P NATL ACAD SCI USA, V97, P6856, DOI 10.1073/pnas.100139797; Kuchel GA, 1997, NEUROREPORT, V8, P799, DOI 10.1097/00001756-199702100-00044; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; LASALDE JA, 1995, BBA-BIOMEMBRANES, V1235, P361, DOI 10.1016/0005-2736(95)80025-B; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Liu YB, 1998, P NATL ACAD SCI USA, V95, P13266, DOI 10.1073/pnas.95.22.13266; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; Matthies H, 1997, NEUROSCIENCE, V79, P341, DOI 10.1016/S0306-4522(96)00703-8; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; Morell P, 1997, NUTR METAB CARDIOVAS, V7, P187; Muller WE, 1997, NUTR METAB CARDIOVAS, V7, P210; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Nilova N S, 1996, Neurosci Behav Physiol, V26, P23, DOI 10.1007/BF02391152; NORTH P, 1983, J BIOL CHEM, V258, P1242; OKUIZUMI K, 1995, NAT GENET, V11, P207, DOI 10.1038/ng1095-207; Oleskevich S, 2000, J PHYSIOL-LONDON, V526, P349, DOI 10.1111/j.1469-7793.2000.t01-1-00349.x; Page KJ, 1998, NEUROSCIENCE, V85, P1161, DOI 10.1016/S0306-4522(97)00661-1; Paris D, 2000, NEUROBIOL AGING, V21, P183, DOI 10.1016/S0197-4580(99)00111-6; PERRY G, 1991, J NEUROSCI, V11, P1748; PITAS RE, 1987, J BIOL CHEM, V262, P14352; PITHA J, 1994, J PHARM SCI, V83, P833, DOI 10.1002/jps.2600830615; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; QIU Z, 2000, SOC NEUR ABSTR, V26, P2289; QUINTERO EM, 2000, SOC NEUR ABSTR, V26, P2059; Rebeck GW, 1998, EXP NEUROL, V149, P175, DOI 10.1006/exnr.1997.6710; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; Roses AD, 1997, ANN NY ACAD SCI, V826, P200, DOI 10.1111/j.1749-6632.1997.tb48471.x; RUNZ H, 2000, NEUROBIOL AGING, V21, pS189; Scharnagl H, 1999, LAB INVEST, V79, P1271; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Sooksawate T, 2001, NEUROPHARMACOLOGY, V40, P178, DOI 10.1016/S0028-3908(00)00159-3; Sparks DL, 1996, NEUROBIOL AGING, V17, P291, DOI 10.1016/0197-4580(95)02067-5; SU JH, 1993, BRAIN RES, V625, P228, DOI 10.1016/0006-8993(93)91063-X; Swanson L. W, 1998, BRAIN MAPS STRUCTURE; Takei Y, 2000, J CELL BIOL, V150, P989, DOI 10.1083/jcb.150.5.989; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; TOVEY S, 1995, BIOCHEM SOC T, V23, pS429, DOI 10.1042/bst023429s; Turley SD, 1996, J LIPID RES, V37, P1953; Volgushev M, 2000, NEUROSCIENCE, V98, P9, DOI 10.1016/S0306-4522(00)00109-3; Wegiel J, 1998, BRAIN RES, V802, P259, DOI 10.1016/S0006-8993(98)00542-3; WHETTON AD, 1983, BIOCHEM J, V212, P331, DOI 10.1042/bj2120331; Wood WG, 1999, LIPIDS, V34, P225, DOI 10.1007/s11745-999-0357-9; Yamazaki T, 2001, J BIOL CHEM, V276, P4454, DOI 10.1074/jbc.M009598200; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	88	218	227	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1858	+		10.1096/fj.00-0815fje	http://dx.doi.org/10.1096/fj.00-0815fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481254				2022-12-25	WOS:000169261200017
J	Kretzler, M; Teixeira, VPC; Unschuld, PG; Cohen, CD; Wanke, R; Edenhofer, I; Mundel, P; Schlondorff, D; Holthofer, H				Kretzler, M; Teixeira, VPC; Unschuld, PG; Cohen, CD; Wanke, R; Edenhofer, I; Mundel, P; Schlondorff, D; Holthofer, H			Integrin linked kinase as a candidate downstream effector in proteinuria	FASEB JOURNAL			English	Article						glomerulus; nephrotic syndrome; actin; actinin; extracellular matrix	CONGENITAL NEPHROTIC SYNDROME; GLOMERULAR EPITHELIAL-CELL; RAT NEPHRIN; RAPID COMMUNICATION; MESSENGER-RNA; EXPRESSION; MOUSE; RECEPTORS; KIDNEY; GLOMERULOSCLEROSIS	The kidney glomerulus is responsible for the generation of a protein-free ultrafiltrate. After injury, it shows a characteristic, uniform response leading to progressive renal failure. Recent studies of hereditary proteinuric diseases have revealed mutations in molecules involved in podocyte cell-cell and cell-matrix interaction. Associated cellular signaling events activated in proteinuria have not been analyzed so far. To identify proteinuria-induced molecules, we used mRNA differential display in glomeruli from children with congenital nephrotic syndrome of the Finnish type. An increase in integrin linked kinase (ILK) mRNA, beta (1)-integrin coupled serine threonine kinase, was identified. Observations suggest a role for ILK in glomerular failure. An up-regulation of glomerular and Single-podocyte ILK mRNA was found in two murine models of proteinuria. In cultured podocytes, integrin attachment to matrix inhibited ILK activity and podocyte damage with puromycin activated ILK. Stable overexpression of ILK in murine podocytes caused reduced matrix adhesion and led to considerable phenotype alteration compared with expression of a kinase-defective ILK, paralleling aspects of in vivo podocyte damage. These results are consistent with ILK as a relevant player in the orchestration of podocyte matrix interaction and a candidate downstream regulator of podocyte permselectivity in glomerular diseases.	Univ Munich, Med Poliklin, D-80336 Munich, Germany; Univ Munich, Inst Vet Pathol, D-80336 Munich, Germany; Albert Einstein Coll Med, Dept Anat & Cell Biol, New York, NY USA; Univ Helsinki, Dept Immunol, FIN-00014 Helsinki, Finland	University of Munich; University of Munich; Yeshiva University; University of Helsinki	Kretzler, M (corresponding author), Univ Munich, Med Poliklin, Schillerstr 42, D-80336 Munich, Germany.	kretzler@medpoli.med.uni-muenchen.de	Unschuld, Paul G/N-7294-2013	Unschuld, Paul G/0000-0002-6116-3386; Wanke, Rudiger/0000-0002-0153-224X				Adler S, 1996, AM J PATHOL, V149, P987; ADLER S, 1992, AM J PATHOL, V141, P571; ADLER S, 1994, KIDNEY INT S, V45, P86; Ahola H, 1999, AM J PATHOL, V155, P907, DOI 10.1016/S0002-9440(10)65190-5; Barisoni L, 2000, KIDNEY INT, V58, P137, DOI 10.1046/j.1523-1755.2000.00149.x; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Haltia A, 1999, EXP NEPHROL, V7, P52; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Holthofer H, 1999, AM J PATHOL, V155, P1681, DOI 10.1016/S0002-9440(10)65483-1; Holzman LB, 1999, KIDNEY INT, V56, P1481, DOI 10.1046/j.1523-1755.1999.00719.x; HUTTUNEN NP, 1976, NEPHRON, V16, P401, DOI 10.1159/000180664; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kawachi H, 2000, KIDNEY INT, V57, P1949, DOI 10.1046/j.1523-1755.2000.00044.x; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Kretzler M, 1996, AM J PHYSIOL-RENAL, V271, pF770; Kriz W, 1996, KIDNEY INT, V49, P1570, DOI 10.1038/ki.1996.227; Kriz W, 1996, KIDNEY BLOOD PRESS R, V19, P245, DOI 10.1159/000174083; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; NEUGARTEN J, 1995, J AM SOC NEPHROL, V5, P1903; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OMEARA YM, 1992, AM J PHYSIOL, V262, pF1083, DOI 10.1152/ajprenal.1992.262.6.F1083; Putaala H, 2000, J AM SOC NEPHROL, V11, P991, DOI 10.1681/ASN.V116991; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; Reiser J, 2000, KIDNEY INT, V57, P2035, DOI 10.1046/j.1523-1755.2000.00070.x; Schadde E, 2000, NEPHROL DIAL TRANSPL, V15, P1046, DOI 10.1093/ndt/15.7.1046; Schroppel B, 1998, KIDNEY INT, V53, P119, DOI 10.1046/j.1523-1755.1998.00742.x; Shankland SJ, 2000, KIDNEY INT, V58, P674, DOI 10.1046/j.1523-1755.2000.00213.x; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Smoyer WE, 1997, AM J PHYSIOL-RENAL, V273, pF150, DOI 10.1152/ajprenal.1997.273.1.F150; WANKE R, 1991, PEDIATR NEPHROL, V5, P513, DOI 10.1007/BF01453693; WHITESIDE CI, 1993, AM J PATHOL, V142, P1641; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528	36	92	106	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1843	+		10.1096/fj.00-0832fje	http://dx.doi.org/10.1096/fj.00-0832fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481249				2022-12-25	WOS:000169261200025
J	Nemoto, Y; Wenk, MR; Watanabe, M; Daniell, L; Murakami, T; Ringstad, N; Yamada, H; Takei, K; De Camilli, P				Nemoto, Y; Wenk, MR; Watanabe, M; Daniell, L; Murakami, T; Ringstad, N; Yamada, H; Takei, K; De Camilli, P			Identification and characterization of a synaptojanin 2 splice isoform predominantly expressed in nerve terminals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; CLATHRIN-MEDIATED ENDOCYTOSIS; PROTEIN-PROTEIN INTERACTIONS; 170 KDA ISOFORM; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; BREAST-CANCER; YEAST GOLGI; SH3 DOMAIN; AMPHIPHYSIN	We have previously identified synaptojanin 1, a phosphoinositide phosphatase predominantly expressed in the nervous system, and synaptojanin 2, a broadly expressed isoform. Synaptojanin 1 is concentrated in nerve terminals, where it has been implicated in synaptic vesicle recycling and actin function. Synaptojanin 2A is targeted to mitochondria via a PDZ domain-mediated interaction. We have now characterized an alternatively spliced form of synaptojanin 2 that shares several properties with synaptojanin 1. This isoform, synaptojanin 2B, undergoes further alternative splicing to generate synaptojanin 2B1 and 2B2. Both amphiphysin and endophilin, two partners synaptojanin 1, bind synaptojanin 2B2, whereas only amphiphysin binds synaptojanin 2B1. Sequence similar to the endophilin-binding site in synaptojanin 1 is present only in synaptojanin 2B2, and this sequence was capable of affinity purifying endophilin from rat brain. The Sac1 domain of synaptojanin 2 exhibited phosphoinositide phosphatase activity very similar to that of the Sac1 domain of synaptojanin 1. Site-directed mutagenesis further illustrated its functional similarity to the catalytic domain of Sac1 proteins. Antibodies raised against the synaptojanin 2B-specific carboxyl-terminal region identified a 160-kDa protein in brain and testis. Immunofluorescence showed that synaptojanin 2B is localized at nerve terminals in brain and at the spermatid manchette in testis. Active Rac1 GTPase affects the intracellular localization of synaptojanin 2, but not of synaptojanin 1. These results suggest that synaptojanin 2B has a partially overlapping function with synaptojanin 1 in nerve terminals, with additional roles in neurons and other cells including dspermatids.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Okayama Univ, Grad Sch Med & Dent, Dept Urol, Okayama 700, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Neurosci, Okayama 7008558, Japan; Inst Phys & Chem Res, Brain Sci Inst, Neuronal Mechanisms Res Grp, Wako, Saitama 3510198, Japan	Howard Hughes Medical Institute; Yale University; Yale University; Okayama University; Okayama University; RIKEN	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06510 USA.		YAMADA, Hiroshi/B-2251-2011; Wenk, Markus Rene/D-1441-2014; Yamada, Hiroshi/AGZ-4497-2022	YAMADA, Hiroshi/0000-0002-9328-3446; Yamada, Hiroshi/0000-0002-9328-3446; Takei, Kohji/0000-0002-6555-9425	NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Bensen ES, 2000, GENETICS, V154, P83; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Cremona O, 2001, J CELL SCI, V114, P1041; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Cremona O, 2000, CYTOGENET CELL GENET, V88, P89, DOI 10.1159/000015493; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DECAMILLI P, 1993, J EXP MED, V178, P2219, DOI 10.1084/jem.178.6.2219; DECAMILLI P, 1999, GUIDEBOOK CYTOSKELET, P541; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; FAWCETT DW, 1971, DEV BIOL, V26, P220, DOI 10.1016/0012-1606(71)90124-2; Floyd S, 1998, MOL MED, V4, P29, DOI 10.1007/BF03401727; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Haffner C, 2000, CURR BIOL, V10, P471, DOI 10.1016/S0960-9822(00)00446-2; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Harlow E., 1988, ANTIBODIES LAB MANUA; Harris TW, 2000, J CELL BIOL, V150, P589, DOI 10.1083/jcb.150.3.589; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hughes WE, 2000, BIOCHEM J, V350, P337, DOI 10.1042/0264-6021:3500337; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Khvotchev M, 1998, J BIOL CHEM, V273, P2306, DOI 10.1074/jbc.273.4.2306; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; Ma L, 1998, J CELL BIOL, V140, P1125; Malecz N, 2000, CURR BIOL, V10, P1383, DOI 10.1016/S0960-9822(00)00778-8; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1998, BIOCHEM BIOPH RES CO, V244, P701, DOI 10.1006/bbrc.1998.8331; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Meistrich ML, 1993, MOL BIOL MALE REPROD, P67; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Modregger J, 2000, J CELL SCI, V113, P4511; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; NAGAO Y, 1989, IN VITRO CELL DEV B, V25, P1088, DOI 10.1007/BF02621259; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nemoto Y, 1999, EMBO J, V18, P2991, DOI 10.1093/emboj/18.11.2991; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; Nemoto Y, 2000, J BIOL CHEM, V275, P34293, DOI 10.1074/jbc.M003923200; NOVICK P, 1989, GENETICS, V121, P659; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Ooms LM, 2000, MOL CELL BIOL, V20, P9376, DOI 10.1128/MCB.20.24.9376-9390.2000; Phillips SE, 1999, MOL CELL, V4, P187, DOI 10.1016/S1097-2765(00)80366-4; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; RATTNER JB, 1972, J ULTRA MOL STRUCT R, V41, P209, DOI 10.1016/S0022-5320(72)90065-2; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Ritter B, 1999, FEBS LETT, V454, P356, DOI 10.1016/S0014-5793(99)00830-3; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; Sambrook J., 2002, MOL CLONING LAB MANU; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Seet LF, 1998, BIOCHEM BIOPH RES CO, V247, P116, DOI 10.1006/bbrc.1998.8564; Singer-Kruger B, 1998, J CELL SCI, V111, P3347; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; So CW, 2000, BIOCHEM J, V348, P447, DOI 10.1042/0264-6021:3480447; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; Stolz LE, 1998, GENETICS, V148, P1715; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; TAKEI K, 1992, J NEUROSCI, V12, P489; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Woscholski R, 1997, J BIOL CHEM, V272, P9625; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401	79	52	57	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41133	41142		10.1074/jbc.M106404200	http://dx.doi.org/10.1074/jbc.M106404200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11498538	hybrid			2022-12-25	WOS:000171925600102
J	Abreu, IA; Saraiva, LM; Soares, CM; Teixeira, M; Cabelli, DE				Abreu, IA; Saraiva, LM; Soares, CM; Teixeira, M; Cabelli, DE			The mechanism of superoxide scavenging by Archaeoglobus fulgidus neelaredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS ATCC-27774; OXYGEN DETOXIFICATION; PROTEIN; DESULFOFERRODOXIN; DISMUTASE; REDUCTASE; REACTIVITY; RADIOLYSIS; VULGARIS; GIGAS	Neelaredoxin is a mononuclear iron protein widespread among prokaryotic anaerobes and facultative aerobes, including human pathogens. It has superoxide scavenging activity, but the exact mechanism by which this process occurs has been controversial. In this report, we present the study of the reaction of superoxide with the reduced form of neelaredoxin from the hyperthermophilic archaeon Archaeoglobus fulgidus by pulse radiolysis. This protein reduces superoxide very efficiently (k = 1.5 x 10(9) M-1 s(-1)), and the dismutation activity is rate-limited, in steady-state conditions, by the much slower superoxide oxidation step. These data show unambiguously that the superfamily of neelaredoxin-like proteins (including desulfoferrodoxin) presents a novel type of reactivity toward superoxide, a result of particular relevance for the understanding of both oxygen stress response mechanisms and, in particular, how pathogens may respond to the oxidative burst produced by the defense cells in eukaryotes. The actual in vivo functioning of these enzymes will depend strongly on the cell redox status. Further insight on the catalytic mechanism was obtained by the detection of a transient intermediate ferric species upon oxidation of neelaredoxin by superoxide, detectable by visible spectroscopy with an absorption maximum at 610 nm, blueshifted similar to 50 nm from the absorption of the resting ferric state. The role of the iron sixth ligand, glutamate-12, in the reactivity of neelaredoxin toward superoxide was assessed by studying two site-directed mutants: E12Q and E12V.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal; Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA	Universidade Nova de Lisboa; United States Department of Energy (DOE); Brookhaven National Laboratory	Teixeira, M (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Rua Quinta Grande 6,Apt 127, P-2780156 Oeiras, Portugal.	miguel@itqb.unl.pt	Teixeira, Miguel/M-1509-2019; Teixeira, Miguel/A-9098-2011; Abreu, Isabel A/I-5081-2013; Saraiva, Ligia M/H-8537-2012; Soares, Claudio M/E-2675-2012	Teixeira, Miguel/0000-0003-4124-6237; Teixeira, Miguel/0000-0003-4124-6237; Abreu, Isabel A/0000-0002-5566-2146; Saraiva, Ligia M/0000-0002-0675-129X; Soares, Claudio M/0000-0003-1154-556X				Abreu IA, 2000, MOL MICROBIOL, V38, P322, DOI 10.1046/j.1365-2958.2000.02121.x; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; CHEN LA, 1994, EUR J BIOCHEM, V226, P613, DOI 10.1111/j.1432-1033.1994.tb20087.x; Coelho AV, 1997, J BIOL INORG CHEM, V2, P680, DOI 10.1007/s007750050184; Coulter ED, 2000, J AM CHEM SOC, V122, P11555, DOI 10.1021/ja005583r; FISCHER DS, 1964, CLIN CHEM, V10, P21, DOI 10.1016/0009-8981(64)90210-4; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; Jovanovic T, 2000, J BIOL CHEM, V275, P28439, DOI 10.1074/jbc.M003314200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liochev SI, 2000, J BIOL CHEM, V275, P38482, DOI 10.1074/jbc.M007891200; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; Lombard M, 2001, BIOCHEMISTRY-US, V40, P5032, DOI 10.1021/bi0023908; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOURA I, 1990, J BIOL CHEM, V265, P21596; Nicholls A., 1992, GRASP GRAPHICAL REPR; Pianzzola MJ, 1996, J BACTERIOL, V178, P6736, DOI 10.1128/jb.178.23.6736-6742.1996; Romao CV, 1999, EUR J BIOCHEM, V261, P438, DOI 10.1046/j.1432-1327.1999.00278.x; RUSH JD, 1985, J PHYS CHEM-US, V89, P5062, DOI 10.1021/j100269a035; Sali A, 1999, TRENDS CELL BIOL, V9, pM20, DOI 10.1016/S0962-8924(99)01685-2; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 2000, NAT STRUCT BIOL, V7, P986, DOI 10.1038/80776; SCHWARZ HA, 1981, J CHEM EDUC, V58, P101, DOI 10.1021/ed058p101; Silva G, 1999, EUR J BIOCHEM, V259, P235, DOI 10.1046/j.1432-1327.1999.00025.x; Silva G, 2001, J BACTERIOL, V183, P4413, DOI 10.1128/JB.183.4.4413-4420.2001; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WIMPENNY JW, 1972, J BACTERIOL, V11, P24, DOI 10.1128/JB.111.1.24-32.1972; Yeh AP, 2000, BIOCHEMISTRY-US, V39, P2499, DOI 10.1021/bi992428k	30	46	48	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38995	39001		10.1074/jbc.M103232200	http://dx.doi.org/10.1074/jbc.M103232200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489883	hybrid			2022-12-25	WOS:000171673200088
J	Huang, H; Cheville, JC; Pan, YQ; Roche, PC; Schmidt, LJ; Tindall, DJ				Huang, H; Cheville, JC; Pan, YQ; Roche, PC; Schmidt, LJ; Tindall, DJ			PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; TRANSCRIPTION FACTOR; RESPONSE ELEMENT; PHOSPHATASE-ACTIVITY; INDUCED APOPTOSIS; PTEN/MMAC1 GENE; CARCINOMA-CELLS; CYCLE ARREST; PROTEIN; GROWTH	The tumor suppressor gene PTEN (MMAC1/TEP1) is lost frequently in advanced prostate cancer (PCa). However, the function of PTEN in tumorigenesis is not understood fully. In this study, we demonstrate that expression of Bcl-2 in prostate tumors correlates with loss of the PTEN protein. This finding was verified by studies in the PCa cell lines DU145, PC-3, LNCaP, and an androgen-refractory subline of LNCaP. Transient transfection of PTEN into the PTEN-null cells resulted in decreased levels of Bcl-2 mRNA and protein. These effects appear to be mediated at the level of gene transcription, since a Bcl-2 promoter-reporter construct was down-regulated by ectopic expression of PTEN in LNCaP cells. The inhibition of Bcl-2 required the lipid-phosphatase activity of PTEN and was blocked by overexpression of a constitutively active form of Akt. Moreover, the transcription-regulatory protein cAMP-response element-binding protein (CREB) may be involved, since decreased phosphorylation of CREB at Ser(133) was detected following PTEN expression, and ectopic expression of CREB repressed completely the PTEN-induced inhibition of Bcl-2 promoter activity. Furthermore, cotransfection of Bcl-2 and PTEN expression vectors rescued PTEN-induced cell death but not Gl cell cycle arrest. Finally, forced expression of PTEN sensitized LNCaP cells to cell death induced by staurosporine, doxorubicin, and vincristine, and this chemosensitivity was attenuated by exogenous expression of Bcl-2. Taken together, these data demonstrate that loss of PTEN leads to up-regulation of the bcl-2 gene, thus contributing to survival and chemoresistance of PCa cells. These findings suggest that the PTEN gene and its regulated pathway are potential therapeutic targets in prostate cancer.	Mayo Clin & Mayo Fdn, Dept Urol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Tindall, DJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Urol & Biochem Mol Biol, Rochester, MN 55905 USA.	tindall.donald@mayo.edu			NATIONAL CANCER INSTITUTE [P30CA015083, P50CA091956] Funding Source: NIH RePORTER; NCI NIH HHS [CA15083, CA91956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1990, ONCOGENE, V5, P1653; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Beham AW, 1998, INT J MOL MED, V1, P953; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Cairns P, 1997, CANCER RES, V57, P4997; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Cheville JC, 1998, MODERN PATHOL, V11, P324; COLOMBEL M, 1992, CANCER RES, V52, P4313; COLOMBEL M, 1993, AM J PATHOL, V143, P390; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1999, CANCER RES, V59, P2551; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Dorai T, 1999, INT J CANCER, V82, P846, DOI 10.1002/(SICI)1097-0215(19990909)82:6<846::AID-IJC13>3.0.CO;2-C; Dorai T, 1997, ANTICANCER RES, V17, P3307; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Furnari FB, 1998, CANCER RES, V58, P5002; Gleave M, 1999, CLIN CANCER RES, V5, P2891; Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Haldar S, 1996, CANCER RES, V56, P1253; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;60::AID-IJC11&gt;3.0.CO;2-B; Huang HJ, 1999, CANCER RES, V59, P2981; Huggins C, 1941, CANCER RES, V1, P293; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KOKONTIS J, 1994, CANCER RES, V54, P1566; Krajewska M, 1996, AM J PATHOL, V148, P1567; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; McConkey DJ, 1996, CANCER RES, V56, P5594; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; McMenamin ME, 1999, CANCER RES, V59, P4291; Miayake H, 2000, J NATL CANCER I, V92, P34, DOI 10.1093/jnci/92.1.34; MIYASHITA T, 1994, CANCER RES, V54, P3131; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Panvichian R, 1999, UROLOGY, V54, P746, DOI 10.1016/S0090-4295(99)00224-1; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; RAFFO AJ, 1995, CANCER RES, V55, P4438; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki H, 1998, CANCER RES, V58, P204; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tanaka M, 2000, ONCOGENE, V19, P5406, DOI 10.1038/sj.onc.1203918; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; TU SM, 1995, CANCER LETT, V93, P147, DOI 10.1016/0304-3835(95)03795-X; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zhong H, 2000, CANCER RES, V60, P1541	70	160	171	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38830	38836		10.1074/jbc.M103632200	http://dx.doi.org/10.1074/jbc.M103632200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495901	hybrid			2022-12-25	WOS:000171673200067
J	Knipper, M; Richardson, G; Mack, A; Muller, M; Goodyear, R; Limberger, A; Rohbock, K; Kopschall, I; Zenner, HP; Zimmermann, U				Knipper, M; Richardson, G; Mack, A; Muller, M; Goodyear, R; Limberger, A; Rohbock, K; Kopschall, I; Zenner, HP; Zimmermann, U			Thyroid hormone-deficient period prior to the onset of hearing is associated with reduced levels of beta-tectorin protein in the tectorial membrane - Implication for hearing loss	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TECTORIN; CONGENITAL HYPOTHYROIDISM; MOLECULAR-CLONING; EXPRESSION; GENE; RECEPTOR; COCHLEA; DOMAIN; BRAIN; PREGNANCY	The genes for alpha- and beta -tectorin encode the major noncollagenous proteins of the tectorial membrane. Recently, a targeted deletion of the mouse alpha -tectorin gene was found to cause loss of cochlear sensitivity (1). Here we describe that mRNA levels for beta -tectorin, but not alpha -tectorin, are significantly reduced in the cochlear epithelium under constant hypothyroid conditions and that levels of beta -tectorin protein in the tectorial membrane are lower. A delay in the onset of thyroid hormone supply prior to onset of hearing, recently described to result in permanent hearing defects and loss of active cochlear mechanics (2), can also lead to permanently reduced beta -tectorin protein levels in the tectorial membrane. beta -Tectorin protein levels remain low in the tectorial membrane up to one year after the onset of thyroid hormone supply has been delayed until postnatal day 8 or later and are associated with an abnormally structured tectorial membrane and the loss of active cochlear function. These data indicate that a simple delay in thyroid hormone supply during a critical period of development can lead to low beta -tectorin levels in the tectorial membrane and suggest for the first time that beta -tectorin may be required for development of normal hearing.	Univ Tubingen, Dept Otorhinolaryngol, Tubingen Ctr Hearing Res, D-72076 Tubingen, Germany; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England; Univ Tubingen, Dept Anat, D-72074 Tubingen, Germany	Eberhard Karls University of Tubingen; University of Sussex; Eberhard Karls University of Tubingen	Knipper, M (corresponding author), Univ Tubingen, Dept Otorhinolaryngol, Tubingen Ctr Hearing Res, Rontgenweg 11, D-72076 Tubingen, Germany.		Müller, Marcus/B-3877-2016	Müller, Marcus/0000-0001-5881-7708; Mack, Andreas/0000-0001-7591-4374				Alloisio N, 1999, EUR J HUM GENET, V7, P255, DOI 10.1038/sj.ejhg.5200273; Balciuniene J, 1998, AM J HUM GENET, V63, P786, DOI 10.1086/302012; BAYER ME, 1964, J CELL BIOL, V21, P265, DOI 10.1083/jcb.21.2.265; BECKS GP, 1991, MED CLIN N AM, V75, P121, DOI 10.1016/S0025-7125(16)30475-8; BERNAL J, 1995, EUR J ENDOCRINOL, V133, P390, DOI 10.1530/eje.0.1330390; Biebermann H, 1997, NEW ENGL J MED, V336, P1390, DOI 10.1056/NEJM199705083361914; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; CALVO R, 1990, J CLIN INVEST, V86, P889, DOI 10.1172/JCI114790; Coutinho P, 1999, HEARING RES, V130, P62, DOI 10.1016/S0378-5955(98)00213-5; DEOL MS, 1973, J MED GENET, V10, P235, DOI 10.1136/jmg.10.3.235; FLETCHER AP, 1970, BIOCHIM BIOPHYS ACTA, V214, P299, DOI 10.1016/0005-2795(70)90007-3; Forrest D, 1996, NAT GENET, V13, P354, DOI 10.1038/ng0796-354; Gestwa G, 1999, J COMP NEUROL, V414, P33, DOI 10.1002/(SICI)1096-9861(19991108)414:1<33::AID-CNE3>3.0.CO;2-M; GREVE JM, 1985, J MOL BIOL, V181, P253, DOI 10.1016/0022-2836(85)90089-0; GRONDIN G, 1992, EUR J CELL BIOL, V57, P155; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hughes DC, 1998, GENOMICS, V48, P46, DOI 10.1006/geno.1997.5159; KILLICK R, 1995, J CELL BIOL, V129, P535, DOI 10.1083/jcb.129.2.535; Kim HJ, 1998, GENOMICS, V53, P419, DOI 10.1006/geno.1998.5543; Knipper M, 1999, J NEUROBIOL, V38, P338, DOI 10.1002/(SICI)1097-4695(19990215)38:3<338::AID-NEU4>3.3.CO;2-T; Knipper M, 1998, DEVELOPMENT, V125, P3709; Knipper M, 2000, J NEUROPHYSIOL, V83, P3101, DOI 10.1152/jn.2000.83.5.3101; Knipper M, 1997, CELL TISSUE RES, V287, P23; Legan PK, 2000, NEURON, V28, P273, DOI 10.1016/S0896-6273(00)00102-1; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; Lind P, 1997, ACTA MED AUST, V24, P157; MCQUEEN EG, 1966, LANCET, V1, P397; MEYERHOFF WL, 1980, LARYNGOSCOPE, V89, P19; Mustapha M, 1999, HUM MOL GENET, V8, P409, DOI 10.1093/hmg/8.3.409; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; OPPENHEIMER JH, 1994, EUR J ENDOCRINOL, V130, P15, DOI 10.1530/eje.0.1300015; Patuzzi R., 1996, COCHLEA, P186; PORTER KR, 1955, J BIOL CHEM, V212, P135; PROBST R, 1991, J ACOUST SOC AM, V89, P2027, DOI 10.1121/1.400897; REFETOFF S, 1967, J CLIN ENDOCR METAB, V27, P279, DOI 10.1210/jcem-27-2-279; RITTER FN, 1967, LARYNGOSCOPE, V77, P1427, DOI 10.1288/00005537-196708000-00016; Rusch A, 1998, P NATL ACAD SCI USA, V95, P15758, DOI 10.1073/pnas.95.26.15758; STEVENSON FK, 1971, BIOCHIM BIOPHYS ACTA, V236, P59, DOI 10.1016/0005-2795(71)90149-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P43; TROTTER WR, 1960, BRIT MED BULL, V16, P92, DOI 10.1093/oxfordjournals.bmb.a069828; UZIEL A, 1981, ACTA OTO-LARYNGOL, V92, P469, DOI 10.3109/00016488109133286; Uziel A, 1985, Brain Res, V351, P111; Uziel A, 1985, Brain Res, V351, P123; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; Wiechers B, 1999, J NEUROSCI, V19, P3033; ZUREK PM, 1985, J ACOUST SOC AM, V78, P340, DOI 10.1121/1.392496	46	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39046	39052		10.1074/jbc.M103385200	http://dx.doi.org/10.1074/jbc.M103385200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489885	hybrid			2022-12-25	WOS:000171673200094
J	Manabe, I; Owens, GK				Manabe, I; Owens, GK			The smooth muscle myosin heavy chain gene exhibits smooth muscle subtype-selective modular regulation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING; CARG ELEMENTS; TRANSCRIPTIONAL REGULATION; EXPRESSION; PROMOTER; CELLS; SKELETAL; DNA; DIFFERENTIATION; IDENTIFICATION	Previous studies in our laboratory demonstrated that the transgene consisting of the -4.2 to +11.6 kilobase (kb) region of the smooth muscle (SM) myosin heavy chain (MHC) gene was expressed in virtually all SM tissue types in vivo in transgenic mice and that the multiple CArG elements within this region were differentially required in SMC subtypes, implying that the SM-MHC gene was controlled by multiple transcriptional regulatory modules. To investigate this hypothesis, we analyzed specific regulatory regions within the SM-MHC -4.2 to +11.6 kb region by a combination of deletion analyses of various SM-MHC transgenes as well as by DNaseI hypersensitivity assays and in vivo footprinting in intact SMC tissues. The results showed that SM-MHC transgene expression depended on a large number of required regulatory modules that were widely spread over the -4.2 to +11.6 region. Moreover, the results revealed several unexpected novel features of regulation of the SM-MHC gene including: 1) unique combinations of regulatory modules were required for SM-MHC expression in different SMC-subtypes; 2) repressor modules as well as activator modules were both critical for SMC specificity of the gene; 3) certain modules were required in certain contexts but were dispensable in others within a given SMC-subtype (i.e. the net activity of the module was determined by interaction between modules not simply by the sum of module activities); and 4) we identified a highly conserved 200-base pair transcriptional regulatory module at +8 kb that was required in the large arteries but dispensable in the coronary arteries and airways in transgenic mice and contained multiple potential cis-elements that were occupied by nuclear proteins in the intact aorta based on in vivo footprinting. Taken together, the results suggest a model of complex modular control of expression of the SM-MHC gene that varies between SMC subtypes. Moreover, the studies establish the possibility of designing derivatives of the SM-MHC promoter that might be used for targeting gene expression to specific SMC subtypes in vivo.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia	Owens, GK (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, POB 800736, Charlottesville, VA 22908 USA.	gko@virginia.edu	Manabe, Ichiro/E-1529-2014; Manabe, Ichiro/AAE-5105-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057353] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL57353, R01HL28854] Funding Source: Medline; NICHD NIH HHS [U54HD28934] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AIKAWA M, 1995, ANN NY ACAD SCI, V748, P578; Aikawa M, 1997, CIRCULATION, V96, P82; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Firulli AB, 1997, TRENDS GENET, V13, P364, DOI 10.1016/S0168-9525(97)01171-2; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; Grange T, 1997, METHODS, V11, P151, DOI 10.1006/meth.1996.0401; Harris VK, 2000, J BIOL CHEM, V275, P28539, DOI 10.1074/jbc.M001677200; Hsieh CM, 1999, J BIOL CHEM, V274, P14344, DOI 10.1074/jbc.274.20.14344; Johnson AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1420, DOI 10.1152/ajpcell.1999.276.6.C1420; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Kumar MS, 1999, FASEB J, V13, pA531; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li QL, 1999, TRENDS GENET, V15, P403, DOI 10.1016/S0168-9525(99)01780-1; Li XY, 1999, NAT BIOTECHNOL, V17, P241, DOI 10.1038/6981; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1997, J BIOL CHEM, V272, P29842, DOI 10.1074/jbc.272.47.29842; Madsen CS, 1998, CIRC RES, V82, P908; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; Malyankar UM, 1999, EXP CELL RES, V250, P535, DOI 10.1006/excr.1999.4537; Manabe I, 2001, J CLIN INVEST, V107, P823, DOI 10.1172/JCI11385; Moessler H, 1996, DEVELOPMENT, V122, P2415; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; OWENS GK, 1995, PHYSIOL REV, V75, P487; Regan CP, 2000, CIRC RES, V87, P363; Schwartz RJ, 1999, DEVELOPMENT, V126, P4187; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Summerbell D, 2000, DEVELOPMENT, V127, P3745; Watanabe M, 1996, CIRC RES, V78, P978, DOI 10.1161/01.RES.78.6.978; Ymer S, 1996, BIOTECHNIQUES, V20, P834; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896; Yuh CH, 2001, DEVELOPMENT, V128, P617	35	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39076	39087		10.1074/jbc.M105402200	http://dx.doi.org/10.1074/jbc.M105402200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489897	hybrid			2022-12-25	WOS:000171673200098
J	Quimby, BB; Leung, SW; Bayliss, R; Harreman, MT; Thirumala, G; Stewart, M; Corbett, AH				Quimby, BB; Leung, SW; Bayliss, R; Harreman, MT; Thirumala, G; Stewart, M; Corbett, AH			Functional analysis of the hydrophobic patch on nuclear transport factor 2 involved in interactions with the nuclear pore in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA1 GENE-PRODUCT; PROTEIN IMPORT; COMPLEX PROTEINS; MOLECULAR MECHANISM; ENGINEERED MUTANTS; STRUCTURAL BASIS; LIVING CELLS; RAN-GTPASE; GDP-RAN; IN-VIVO	Nuclear transport factor 2 (NTF2) is a small homodimeric protein that interacts simultaneously with both RanGDP and FxFG nucleoporins. The interaction between NTF2 and Ran is essential for the import of Ran into the nucleus. Here we use mutational analysis to dissect the in vivo role of the interaction between NTF2 and nucleoporins. We identify a series of surface residues that form a hydrophobic patch on NTF2, which when mutated disrupt the NTF2-nucleoporin interaction. Analysis of these mutants in vivo demonstrates that the strength of this interaction can be significantly reduced without affecting cell viability. However, cells cease to be viable if the interaction between NTF2 and nucleoporins is abolished completely, indicating that this interaction is essential for the function of NTF2 in vivo. In addition, we have isolated a dominant negative mutant of NTF2, N77Y, which has increased affinity for nucleoporins. Overexpression of the N77Y protein blocks nuclear protein import and concentrates Ran at the nuclear rim. These data support a mechanism in which NTF2 interacts transiently with FxFG nucleoporins to translocate through the pore and import RanGDP into the nucleus.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Emory University; MRC Laboratory Molecular Biology	Corbett, AH (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd NE, Atlanta, GA 30322 USA.		Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895; Bayliss, Richard/0000-0003-0604-2773	NIGMS NIH HHS [R01 GM058728] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058728] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam SA, 1999, CURR OPIN CELL BIOL, V11, P402, DOI 10.1016/S0955-0674(99)80056-8; ARIS JP, 1989, J CELL BIOL, V108, P2059, DOI 10.1083/jcb.108.6.2059; Bayliss R, 2000, TRAFFIC, V1, P448, DOI 10.1034/j.1600-0854.2000.010602.x; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bayliss R, 1999, J MOL BIOL, V293, P579, DOI 10.1006/jmbi.1999.3166; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Bullock TL, 1996, J MOL BIOL, V260, P422, DOI 10.1006/jmbi.1996.0411; Chaillan-Huntington C, 2000, J BIOL CHEM, V275, P5874, DOI 10.1074/jbc.275.8.5874; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Clarkson WD, 1997, J MOL BIOL, V272, P716, DOI 10.1006/jmbi.1997.1255; Clarkson WD, 1996, J MOL BIOL, V263, P517, DOI 10.1006/jmbi.1996.0594; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GROTE M, 1995, J CELL SCI, V108, P2963; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kent HM, 1999, J MOL BIOL, V289, P565, DOI 10.1006/jmbi.1999.2775; Kose S, 1999, FEBS LETT, V463, P327, DOI 10.1016/S0014-5793(99)01641-5; Lane CM, 2000, J CELL BIOL, V151, P321, DOI 10.1083/jcb.151.2.321; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; ORRWEAVER TL, 1983, P NATL ACAD SCI-BIOL, V80, P4417, DOI 10.1073/pnas.80.14.4417; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Quimby BB, 2000, MOL BIOL CELL, V11, P2617, DOI 10.1091/mbc.11.8.2617; Quimby BB, 2000, J BIOL CHEM, V275, P28575, DOI 10.1074/jbc.M005055200; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rose MD., 1990, METHODS YEAST GENETI; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Sambrook J., 2002, MOL CLONING LAB MANU; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; Stewart M, 2000, CELL STRUCT FUNCT, V25, P217, DOI 10.1247/csf.25.217; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wong DH, 1997, MOL CELL BIOL, V17, P3755, DOI 10.1128/MCB.17.7.3755	56	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38820	38829		10.1074/jbc.M105054200	http://dx.doi.org/10.1074/jbc.M105054200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489893	hybrid			2022-12-25	WOS:000171673200066
J	Sanchez-Elsner, T; Botella, LM; Velasco, B; Corbi, A; Attisano, L; Bernabeu, C				Sanchez-Elsner, T; Botella, LM; Velasco, B; Corbi, A; Attisano, L; Bernabeu, C			Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; HEREDITARY HEMORRHAGIC TELANGIECTASIA; ACTIVATOR INHIBITOR-1 GENE; RECEPTOR-LIKE KINASE-1; TGF-BETA; SMAD PROTEINS; DNA-BINDING; INDUCED TRANSCRIPTION; FUNCTIONAL COOPERATION; TUMOR-SUPPRESSOR	Signaling by transforming growth factor (TGF)-beta family members is mediated by Smad proteins that regulate gene transcription through functional cooperativity and association with other DNA-binding proteins. The hypoxia-inducible factor (HIF)-1 is a transcriptional complex that plays a key role in oxygen-regulated gene expression. We demonstrate that hypoxia and TGF-beta cooperate in the induction of the promoter activity of vascular endothelial growth factor (VEGF), which is a major stimulus in the promotion of angiogenesis. This cooperation has been mapped on the human VEGF promoter within a region at -1006 to -954 that contains functional DNA-binding sequences for HIF-1 and Smads. Optimal HIF-1 alpha -dependent induction of the VEGF promoter was obtained in the presence of Smad3, suggesting an interaction between these proteins. Consistent with this, co-immunoprecipitation experiments revealed that HIF-1 alpha physically associates with Smad3. These results demonstrate that both TGF-beta and hypoxia signaling pathways can synergize in the regulation of VEGF gene expression at the transcriptional level.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; Univ Toronto, Fac Med, Dept Anat & Cell Biol, Toronto, ON M5S 1A8, Canada	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Toronto	Bernabeu, C (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.		Corbi, Angel/B-7194-2011; Botella, Luisa M/L-1392-2014; Bernabeu, Carmelo/P-4662-2019; Corbí, Angel L./ABC-8146-2020; Bernabeu, Carmelo/L-3226-2014	Corbi, Angel/0000-0003-1980-5733; Bernabeu, Carmelo/0000-0002-1563-6162; Corbí, Angel L./0000-0003-1980-5733; Bernabeu, Carmelo/0000-0002-1563-6162; Sanchez-Elsner, Tilman/0000-0003-1915-2410				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Caniggia I, 2000, J CLIN INVEST, V105, P577, DOI 10.1172/JCI8316; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chua CC, 2000, BBA-MOL CELL RES, V1497, P69, DOI 10.1016/S0167-4889(00)00040-9; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; FALANGA V, 1991, J INVEST DERMATOL, V97, P634, DOI 10.1111/1523-1747.ep12483126; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gleadle JM, 1998, MOL MED TODAY, V4, P122, DOI 10.1016/S1357-4310(97)01198-2; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Helmlinger G, 2000, NATURE, V405, P139, DOI 10.1038/35012132; Hogg N, 1999, ENDOTHELIUM-J ENDOTH, V7, P35, DOI 10.3109/10623329909165310; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Rius C, 1998, BLOOD, V92, P4677; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Urness LD, 2000, NAT GENET, V26, P328, DOI 10.1038/81634; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Yang X, 1999, DEVELOPMENT, V126, P1571; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	73	303	320	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38527	38535		10.1074/jbc.M104536200	http://dx.doi.org/10.1074/jbc.M104536200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11486006	hybrid, Green Published			2022-12-25	WOS:000171673200028
J	Leali, D; Belleri, M; Urbinati, C; Coltrini, D; Oreste, P; Zoppetti, G; Ribatti, D; Rusnati, M; Presta, M				Leali, D; Belleri, M; Urbinati, C; Coltrini, D; Oreste, P; Zoppetti, G; Ribatti, D; Rusnati, M; Presta, M			Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYO CHORIOALLANTOIC MEMBRANE; ENDOTHELIAL-CELLS; CAPSULAR POLYSACCHARIDE; BIOLOGICAL-ACTIVITY; MOLECULAR-WEIGHT; DNA-SYNTHESIS; TUMOR-GROWTH; TAT PROTEIN; HEPARIN; ANGIOGENESIS	The angiogenic basic fibroblast growth factor (FGF2) interacts with tyrosine kinase receptors (FGFRs) and heparan sulfate proteoglycans (HSPGs) in endothelial cells. Here, we report the FGF2 antagonist and antiangiogenic activity of novel sulfated derivatives of the Escherichia coli K5 polysaccharide. K5 polysaccharide was chemically sulfated in N- and/or O-position after N-deacetylation. O-Sulfated and N,O-sulfated K5 derivatives with a low degree and a high degree of sulfation compete with heparin for binding to I-125-FGF2 with different potency. Accordingly, they abrogate the formation of the HSPG.FGF2.FGFR ternary complex, as evidenced by their capacity to prevent FGF2-mediated cell-cell attachment of FGFR1-overexpressing HSPG-deficient Chinese hamster ovary (CHO) cells to wildtype CHO cells. They also inhibited I-125-FGF2 binding to FGFR1-overexpressing HSPG-bearing CHO cells and adult bovine aortic endothelial cells. K5 derivatives also inhibited FGF2-mediated cell proliferation in endothelial GM 7373 cells and in human umbilical vein endothelial (HUVE) cells. In all these assays, the N-sulfated K5 derivative and unmodified K5 were poorly effective. Also, highly O-sulfated and N,O-sulfated K5 derivatives prevented the sprouting of FGF2-transfected endothelial FGF2-T-MAE cells in fibrin gel and spontaneous angiogenesis in vitro on Matrigel of FGF2-T-MAE and HUVE cells. Finally, the highly N,O-sulfated K5 derivative exerted a potent antiangiogenic activity on the chick embryo chorioallantoic membrane. These data demonstrate the possibility of generating FGF2 antagonists endowed with antiangiogenic activity by specific chemical sulfation of bacterial K5 polysaccharide. In particular, the highly N,O-sulfated K5 derivative may provide the basis for the design of novel angiostatic compounds.	Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; Glycores 2000 Srl, I-20155 Milan, Italy; Univ Bari, Inst Human Anat Histol & Embryol, I-70124 Bari, Italy	University of Brescia; Universita degli Studi di Bari Aldo Moro	Presta, M (corresponding author), Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, Via Valsabbina 19, I-25123 Brescia, Italy.	presta@med.unibs.it	Presta, Marco/B-4345-2010; Rusnati, Marco/F-1168-2010	Rusnati, Marco/0000-0001-9968-5908; PRESTA, Marco/0000-0002-4398-8376; Urbinati, Chiara Eva/0000-0002-0138-7871				Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H; ANDRIUOLI G, 1989, ANN NY ACAD SCI, V556, P416; ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CASU B, 1994, CARBOHYD RES, V263, P271, DOI 10.1016/0008-6215(94)00172-3; CASU B, 1975, CARBOHYD RES, V39, P168, DOI 10.1016/S0008-6215(00)82654-3; CASU B, 1986, ARZNEIMITTEL-FORSCH, V36-1, P637; Chang E, 1997, J PEDIAT HEMATOL ONC, V19, P237, DOI 10.1097/00043426-199705000-00011; COLTRINI D, 1994, BIOCHEM J, V303, P583, DOI 10.1042/bj3030583; Compagni A, 2000, CANCER RES, V60, P7163; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; EDELMAN ER, 1993, P NATL ACAD SCI USA, V90, P1513, DOI 10.1073/pnas.90.4.1513; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FIRSCHING A, 1995, CANCER RES, V55, P4957; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOTO F, 1993, LAB INVEST, V69, P508; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HAHNENBERGER R, 1993, GLYCOBIOLOGY, V3, P567, DOI 10.1093/glycob/3.6.567; HARENBERG J, 1983, J CHROMATOGR, V261, P287, DOI 10.1016/S0021-9673(01)87952-8; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Keshet E, 1999, J CLIN INVEST, V104, P1497, DOI 10.1172/JCI8849; Konerding MA, 1998, AM J PATHOL, V152, P1607; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Liekens S, 1999, MOL PHARMACOL, V56, P204, DOI 10.1124/mol.56.1.204; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Norrby K, 1996, INT J MICROCIRC, V16, P8, DOI 10.1159/000179145; OHTANI H, 1993, LAB INVEST, V68, P520; PESENTI E, 1992, BRIT J CANCER, V66, P367, DOI 10.1038/bjc.1992.272; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; Rak J, 1997, NAT MED, V3, P1083, DOI 10.1038/nm1097-1083; Ribatti D, 1998, J SUBMICR CYTOL PATH, V30, P127; RIBATTI D, 1995, DEV BIOL, V170, P39, DOI 10.1006/dbio.1995.1193; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; Rusnati M, 2000, FASEB J, V14, P1917, DOI 10.1096/fj.99-0902com; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; RUSNATI M, 1994, BIOCHEM BIOPH RES CO, V203, P450, DOI 10.1006/bbrc.1994.2203; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHULZEOSTHOFF K, 1990, AM J PATHOL, V137, P85; Slaton JW, 2001, AM J PATHOL, V158, P735, DOI 10.1016/S0002-9440(10)64016-3; Sola Francesco, 1997, Angiogenesis, V1, P102, DOI 10.1023/A:1018309200629; STATUTO M, 1993, INT J CANCER, V53, P5, DOI 10.1002/ijc.2910530103; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; Takahashi Y, 1996, ONCOL RES, V8, P163; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; YAMANAKA Y, 1993, CANCER RES, V53, P5289; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZAGZAG D, 1990, CANCER RES, V50, P7393; ZUGMAIER G, 1992, J NATL CANCER I, V84, P1716, DOI 10.1093/jnci/84.22.1716	61	75	92	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37900	37908						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11473122				2022-12-25	WOS:000171526500026
J	Lam, MHC; Michell, BJ; Fodero-Tavoletti, MT; Kemp, BE; Tonks, NK; Tiganis, T				Lam, MHC; Michell, BJ; Fodero-Tavoletti, MT; Kemp, BE; Tonks, NK; Tiganis, T			Cellular stress regulates the nucleocytoplasmic distribution of the protein-tyrosine phosphatase TCPTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNALS; GROWTH-FACTOR RECEPTOR; IMPORTIN-BETA; KINASE; ACTIVATION; TRANSPORT; CRM1; PHOSPHORYLATION; SEQUENCE; CELLS	Specific cellular stresses, including hyperosmotic stress, caused a dramatic but reversible cytoplasmic accumulation of the otherwise nuclear 45-kDa variant of the protein-tyrosine phosphatase TCPTP (TC45). In the cytoplasm, TC45 dephosphorylated the epidermal growth factor receptor and down-regulated the hyperosmotic stress-induced activation of the c-Jun N-terminal kinase. The hyperosmotic stress-induced nuclear exit of TC45 was not inhibited by leptomycin B, indicating that TC45 nuclear exit was independent of the exportin CRM-1. Moreover, hyperosmotic stress did not induce the cytoplasmic accumulation of a green fluorescent protein-TC45 fusion protein that was too large to diffuse across the nuclear pore. Our results indicate that TC45 nuclear exit may occur by passive diffusion and that cellular stress may induce the cytoplasmic accumulation of TC45 by inhibiting nuclear import. Neither p42(Erk2) nor the stress-activated c-Jun N-terminal kinase or p38 mediated the stress-induced redistribution of TC45. We found that only those stresses that stimulated the metabolic stress-sensing enzyme AMP-activated protein kinase (AMPK) induced the redistribution of TC45. In addition, specific pharmacological activation of the AMPK was sufficient to cause the accumulation of TC45 in the cytoplasm. Our studies indicate that specific stress-activated signaling pathways that involve the AMPK can alter the nucleocytoplasmic distribution of TC45 and thus regulate TC45 function in vivo.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Monash University; St. Vincent's Institute of Medical Research; Cold Spring Harbor Laboratory	Tiganis, T (corresponding author), Monash Univ, Dept Biochem & Mol Biol, POB 13D, Clayton, Vic 3800, Australia.	Tony.Tiganis@med.monash.edu.au	Tiganis, Tony/AAV-3495-2020; Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Tiganis, Tony/0000-0002-8065-9942; Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082	NCI NIH HHS [CA53840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P1203; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Czubryt MP, 2000, J CELL BIOL, V148, P7, DOI 10.1083/jcb.148.1.7; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Hardie DG, 1999, BIOCHEM SOC SYMP, P13; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Ibarra-Sanchez MD, 2000, SEMIN IMMUNOL, V12, P379, DOI 10.1006/smim.2000.0220; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kehlenbach RH, 2000, J BIOL CHEM, V275, P17848, DOI 10.1074/jbc.M001455200; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Li LW, 2000, SEMIN IMMUNOL, V12, P75, DOI 10.1006/smim.2000.0209; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; Michell BJ, 1996, J BIOL CHEM, V271, P28445, DOI 10.1074/jbc.271.45.28445; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Soros V, 2001, VIROLOGY, V280, P199, DOI 10.1006/viro.2000.0752; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	43	54	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37700	37707		10.1074/jbc.M105128200	http://dx.doi.org/10.1074/jbc.M105128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479308	hybrid			2022-12-25	WOS:000171375700109
J	Waditee, R; Hibino, T; Tanaka, Y; Nakamura, T; Incharoensakdi, A; Takabe, T				Waditee, R; Hibino, T; Tanaka, Y; Nakamura, T; Incharoensakdi, A; Takabe, T			Halotolerant cyanobacterium Aphanothece halophytica contains an Na+/H+ antiporter, homologous to eukaryotic ones, with novel ion specificity affected by C-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLERANCE; MEMBRANE; EXCHANGER; SODIUM; YEAST; GENE; DNAK; OVEREXPRESSION; LOCALIZATION; RESIDUES	Recently, a cyanobacterium Synechocystis sp. PCC 6803 has been shown to contain an Na+/H+ antiporter gene homologous to plants (SOS1 and AtNHX1 from Arabidopsis) and mammalians (NHEs from human) but not to Escherichia coli (nhaA and nhaB). Here, we examined whether a halotolerant cyanobacterium Aphanothece halophytica has homologous genes. It turned out that A. halophytica contains an Na+/H+ antiporter homologous to plants, mammalians, and some bacteria (nhaP from Pseudomonas and synnhaP from Synechocystis) but with novel ion specificity. Its gene product, ApNhaP (Na+/H+ antiporter from Aphanothece halophytica), exhibited the Na+/H+ antiporter activity over a wide pH range between 5 and 9 and complemented the Na+-sensitive phenotype of the antiporter-deficient E. coli mutant. The ApNhaP had virtually no activity for the Li+/H+ antiporter but showed high Ca2+/H+ antiporter activity at alkaline pH. The ApNhaP complemented the Ca2+-sensitive phenotype of the E. coli mutant but not the Li+-sensitive phenotype. The replacement of a long C-terminal tail of ApNhaP with that of Synechocystis altered the ion specificity of the antiporter. These results suggest that the ion specificity of an Na+/H+ antiporter is partly determined by the structural properties of the C-terminal tail, which was well exemplified in the case of A. halophytica.	Meijo Univ, Res Inst, Tenpaku Ku, Nagoya, Aichi 4688502, Japan; Meijo Univ, Fac Sci & Technol, Dept Chem, Tenpaku Ku, Nagoya, Aichi 4688502, Japan; Chulalongkorn Univ, Fac Sci, Dept Biochem, Bangkok 10330, Thailand; Chiba Univ, Fac Pharmaceut Sci, Mol Cell Biol Lab, Chiba 2638522, Japan	Meijo University; Meijo University; Chulalongkorn University; Chiba University	Takabe, T (corresponding author), Meijo Univ, Res Inst, Tenpaku Ku, Nagoya, Aichi 4688502, Japan.	takabe@meijo-u.ac.jp						Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; Biemesderfer D, 1998, J BIOL CHEM, V273, P12391, DOI 10.1074/jbc.273.20.12391; Blumwald E, 2000, BBA-BIOMEMBRANES, V1465, P140, DOI 10.1016/S0005-2736(00)00135-8; BROCKMAN RW, 1968, BIOCHEMISTRY-US, V7, P2554, DOI 10.1021/bi00847a016; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; Hamada A, 2001, PLANT PHYSIOL, V125, P437, DOI 10.1104/pp.125.1.437; Hibino T, 1999, PLANT MOL BIOL, V40, P409, DOI 10.1023/A:1006273124726; HOFMANN K, 1992, COMPUT APPL BIOSCI, V8, P331; INOUE H, 1995, FEBS LETT, V363, P264, DOI 10.1016/0014-5793(95)00331-3; ISHITANI M, 1993, AUST J PLANT PHYSIOL, V20, P693, DOI 10.1071/PP9930693; IVEY DM, 1993, J BIOL CHEM, V268, P11296; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee BH, 1997, PLANT MOL BIOL, V35, P763, DOI 10.1023/A:1005867420619; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKAMURA T, 1995, BBA-BIOENERGETICS, V1230, P170, DOI 10.1016/0005-2728(95)00053-L; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; OHYAMA T, 1994, J BACTERIOL, V176, P4311, DOI 10.1128/jb.176.14.4311-4315.1994; Ono K, 2001, PLANT SCI, V160, P455, DOI 10.1016/S0168-9452(00)00412-X; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Padan E., 1996, HDB BIOL PHYS, V2, P501; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; Shi HZ, 2000, P NATL ACAD SCI USA, V97, P6896, DOI 10.1073/pnas.120170197; Sugino M, 1999, PLANT SCI, V146, P81, DOI 10.1016/S0168-9452(99)00086-2; TAKABE T, 1988, PLANT PHYSIOL, V88, P1120, DOI 10.1104/pp.88.4.1120; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; Ueoka-Nakanishi H, 1999, EUR J BIOCHEM, V262, P417, DOI 10.1046/j.1432-1327.1999.00377.x; Utsugi J, 1998, BBA-GENE STRUCT EXPR, V1398, P330, DOI 10.1016/S0167-4781(98)00058-X; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wells KM, 2001, J BIOL CHEM, V276, P3401, DOI 10.1074/jbc.M001688200	32	58	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36931	36938		10.1074/jbc.M103650200	http://dx.doi.org/10.1074/jbc.M103650200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479290	hybrid			2022-12-25	WOS:000171375700012
J	Phiel, CJ; Zhang, F; Huang, EY; Guenther, MG; Lazar, MA; Klein, PS				Phiel, CJ; Zhang, F; Huang, EY; Guenther, MG; Lazar, MA; Klein, PS			Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; CENTRAL-NERVOUS-SYSTEM; NEURAL-TUBE DEFECTS; BETA-CATENIN; TRANSCRIPTIONAL ACTIVATION; CAENORHABDITIS-ELEGANS; MOLECULAR MECHANISM; SODIUM VALPROATE; GENE-EXPRESSION; XENOPUS EMBRYOS	Valproic acid is widely used to treat epilepsy and bipolar disorder and is also a potent teratogen, but its mechanisms of action in any of these settings are unknown. We report that valproic acid activates Wnt-dependent gene expression, similar to lithium, the mainstay of therapy for bipolar disorder. Valproic acid, however, acts through a distinct pathway that involves direct inhibition of histone deacetylase (IC50 for HDAC1 = 0.4 mM). At therapeutic levels, valproic acid mimics the histone deacetylase inhibitor trichostatin A, causing hyperacetylation of histones in cultured cells. Valproic acid, like trichostatin A, also activates transcription from diverse exogenous and endogenous promoters. Furthermore, valproic acid and trichostatin A have remarkably similar teratogenic effects in vertebrate embryos, while non-teratogenic analogues of valproic acid do not inhibit histone deacetylase and do not activate transcription. Based on these observations, we propose that inhibition of histone deacetylase provides a mechanism for valproic acid-induced birth defects and could also explain the efficacy of valproic acid in the treatment of bipolar disorder.	Univ Penn, Sch Med, Howard Hughes Med Inst, Grad Program Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Grad Program Cell & Mol Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Klein, PS (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Grad Program Pharmacol, CRB 370,415 Curie Blvd, Philadelphia, PA 19104 USA.		Lazar, Mitchell A/AAF-3738-2019	Phiel, Christopher/0000-0002-9265-2676	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK043806, R01DK045586, R01DK043806] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43806, DK45586] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMOUZNI G, 1994, DEV BIOL, V165, P654, DOI 10.1006/dbio.1994.1283; Asghari V, 1998, MOL BRAIN RES, V58, P95, DOI 10.1016/S0169-328X(98)00107-7; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Bordonaro M, 1999, CELL GROWTH DIFFER, V10, P713; Buggy JJ, 2000, BIOCHEM J, V350, P199, DOI 10.1042/0264-6021:3500199; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Chen G, 1999, MOL BRAIN RES, V64, P52, DOI 10.1016/S0169-328X(98)00303-9; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DAVIES JA, 1995, SEIZURE, V4, P267, DOI 10.1016/S1059-1311(95)80003-4; DAWSON DA, 1991, TERATOLOGY, V44, P531, DOI 10.1002/tera.1420440507; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; Dixon JF, 1997, P NATL ACAD SCI USA, V94, P4757, DOI 10.1073/pnas.94.9.4757; Driever PH, 1999, KLIN PADIATR, V211, P323, DOI 10.1055/s-2008-1043809; Fredieu JR, 1997, DEV BIOL, V186, P100, DOI 10.1006/dbio.1997.8566; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; HAMMOND EJ, 1982, BRAIN RES, V240, P195, DOI 10.1016/0006-8993(82)90664-3; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Huang EY, 2000, GENE DEV, V14, P45; Huang HJ, 1999, CANCER RES, V59, P2981; Inokoshi J, 1999, BIOCHEM BIOPH RES CO, V256, P372, DOI 10.1006/bbrc.1999.0316; Jennings HR, 1999, ANN PHARMACOTHER, V33, P1113, DOI 10.1345/aph.19014; Johannessen CU, 2000, NEUROCHEM INT, V37, P103, DOI 10.1016/S0197-0186(00)00013-9; KINOSHITA K, 1995, DEVELOPMENT, V121, P1581; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lampen A, 1999, TOXICOL APPL PHARM, V160, P238, DOI 10.1006/taap.1999.8770; Lenox RH, 1998, J CLIN PSYCHIAT, V59, P37; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; MANDELKOW EM, 1993, ANN NY ACAD SCI, V695, P209, DOI 10.1111/j.1749-6632.1993.tb23054.x; Manji HK, 1999, BIOL PSYCHIAT, V46, P1328, DOI 10.1016/S0006-3223(99)00235-8; Manji HK, 1999, AUST NZ J PSYCHIAT, V33, pS65, DOI 10.1111/j.1440-1614.1999.00670.x; Mannervik M, 1999, P NATL ACAD SCI USA, V96, P6797, DOI 10.1073/pnas.96.12.6797; MEUNIER H, 1963, Therapie, V18, P435; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Mora A, 1999, EUR J BIOCHEM, V266, P886, DOI 10.1046/j.1432-1327.1999.00919.x; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Murray M, 2000, MOL MICROBIOL, V36, P651, DOI 10.1046/j.1365-2958.2000.01886.x; NARUSE I, 1988, TERATOLOGY, V38, P87, DOI 10.1002/tera.1420380113; NAU H, 1991, PHARMACOL TOXICOL, V69, P310, DOI 10.1111/j.1600-0773.1991.tb01303.x; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; Nonaka S, 1998, J PHARMACOL EXP THER, V286, P539; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PENG HB, 1991, METHODS CELL BIOL, V36; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; ROBERT E, 1982, LANCET, V2, P937, DOI 10.1016/s0140-6736(82)90908-4; Salinas PC, 1999, BIOCHEM SOC SYMP, V65, P101; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Saunders N, 1999, CANCER RES, V59, P399; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Solari F, 2000, CURR BIOL, V10, P223, DOI 10.1016/S0960-9822(00)00343-2; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Svensson K, 1998, DEVELOPMENT, V125, P61; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Tunnicliff G, 1999, J PHYSIOL PHARMACOL, V50, P347; Vaden DL, 2001, J BIOL CHEM, V276, P15466, DOI 10.1074/jbc.M004179200; VADNAL R, 1995, NEUROPSYCHOPHARMACOL, V12, P277, DOI 10.1016/0893-133X(94)00088-H; VanLint C, 1996, GENE EXPRESSION, V5, P245; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Wang JF, 1999, MOL PHARMACOL, V55, P521; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149	67	1366	1432	5	127	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36734	36741		10.1074/jbc.M101287200	http://dx.doi.org/10.1074/jbc.M101287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11473107	hybrid			2022-12-25	WOS:000171194500090
J	Xu, WP; Takahashi, Y; Sakashita, T; Iwasaki, T; Hattori, H; Yoshimoto, T				Xu, WP; Takahashi, Y; Sakashita, T; Iwasaki, T; Hattori, H; Yoshimoto, T			Low density lipoprotein receptor-related protein is required for macrophage-mediated oxidation of low density lipoprotein by 12/15-lipoxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; DEFICIENT MICE; ATHEROSCLEROTIC LESIONS; PERITONEAL-MACROPHAGES; LIPOXYGENASE; GENE; EXPRESSION; BINDING; 15-LIPOXYGENASE; ATHEROGENESIS	The oxidative modification of low density lipoprotein (LDL) has been implicated in the early stage of atherosclerosis through multiple potential pathways, and 12/15-lipoxygenase is suggested to be involved in this oxidation process. We demonstrated previously that the 12/15-lipoxygenase overexpressed in mouse macrophage-like J774A.1 cells was required for the cell-mediated LDL oxidation. However, the mechanism of the oxidation of extracellular LDL by the intracellular 12/15-lipoxygenase has not yet been elucidated. In the present study, we found that not only the LDL receptor but also LDL receptor-related protein (LRP), both of which are cell surface native LDL-binding receptors, were down-regulated by the preincubation of the cells with cholesterol or LDL and up-regulated by lipoprotein-deficient serum. Moreover, 12/15-lipoxygenase-expressing cell-mediated LDL oxidation was decreased by the preincubation of the cells with LDL or cholesterol and increased by the preincubation with lipoprotein-deficient serum. Heparin-binding protein 44, an antagonist of the LDL receptor family, also suppressed the cell-mediated LDL oxidation in a dose-dependent manner. The cell-mediated LDL oxidation was dose-dependently blocked by an anti-LRP antibody but not by an anti-LDL receptor antibody. Furthermore, antisense oligodeoxyribonucleotides against LRP reduced the cell-mediated LDL oxidation under the conditions in which the expression of LRP was decreased. The results taken together indicate that LRP was involved essentially for the cell-mediated LDL oxidation by 12/15-lipoxygenase expressed in J774A.1 cells, suggesting an important pathophysiological role of this receptor-enzyme system as the initial trigger of the progression of atherosclerosis.	Kanazawa Univ, Grad Sch Med, Dept Mol Pharmacol, Kanazawa, Ishikawa 9208640, Japan; Kanazawa Univ, Grad Sch Med, Dept Mol Genet Cardiovasc Disorders, Kanazawa, Ishikawa 9208640, Japan; BML Inc, R&D Ctr, Dept Res, Kawagoe, Saitama 3501101, Japan	Kanazawa University; Kanazawa University; BML, Inc.	Yoshimoto, T (corresponding author), Kanazawa Univ, Grad Sch Med, Dept Mol Pharmacol, Kanazawa, Ishikawa 9208640, Japan.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8; BROWN MS, 1990, NATURE, V343, P508, DOI 10.1038/343508a0; Cathcart MK, 2000, FREE RADICAL BIO MED, V28, P1726, DOI 10.1016/S0891-5849(00)00230-6; CATHCART MK, 1991, J LIPID RES, V32, P63; CATHCART MK, 1995, J LIPID RES, V36, P1857; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; de Villiers WJS, 1999, J LEUKOCYTE BIOL, V66, P740, DOI 10.1002/jlb.66.5.740; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; Harats D, 2000, ARTERIOSCL THROM VAS, V20, P2100, DOI 10.1161/01.ATV.20.9.2100; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1991, J BIOL CHEM, V266, P21232; Hiltunen TP, 1998, ATHEROSCLEROSIS, V137, pS81, DOI 10.1016/S0021-9150(97)00307-9; KIM JA, 1995, ARTERIOSCL THROM VAS, V15, P942, DOI 10.1161/01.ATV.15.7.942; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KUHN H, 1994, J LIPID RES, V35, P1749; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; Kuhn H, 1997, J CLIN INVEST, V99, P888, DOI 10.1172/JCI119253; Kuhn H, 1997, CURR OPIN LIPIDOL, V8, P111; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Qiao N, 1999, BBA-MOL CELL BIOL L, V1438, P131, DOI 10.1016/S1388-1981(99)00035-9; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Sakashita T, 1999, EUR J BIOCHEM, V265, P825, DOI 10.1046/j.1432-1327.1999.00803.x; SIGAL E, 1994, ANN NY ACAD SCI, V714, P211, DOI 10.1111/j.1749-6632.1994.tb12046.x; SPARROW CP, 1988, J LIPID RES, V29, P745; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEPHAN ZF, 1993, J LIPID RES, V34, P325; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Swarnakar S, 2001, J BIOL CHEM, V276, P21121, DOI 10.1074/jbc.M101691200; TAKAHASHI Y, 1993, EUR J BIOCHEM, V218, P165, DOI 10.1111/j.1432-1033.1993.tb18362.x; Tangirala RK, 1996, J LIPID RES, V37, P835; Willnow TE, 1999, J MOL MED-JMM, V77, P306, DOI 10.1007/s001090050356; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Wu SM, 1996, ARCH BIOCHEM BIOPHYS, V326, P39, DOI 10.1006/abbi.1996.0044; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; Yonekura H, 1999, NUCLEIC ACIDS RES, V27, P2591, DOI 10.1093/nar/27.13.2591; YOSHIMOTO T, 1995, J LIPID MEDIAT CELL, V12, P195, DOI 10.1016/0929-7855(95)00019-M; Zhuang DM, 2000, J BIOCHEM, V127, P451, DOI 10.1093/oxfordjournals.jbchem.a022627	51	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36454	36459		10.1074/jbc.M105093200	http://dx.doi.org/10.1074/jbc.M105093200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11479307	Green Submitted, hybrid			2022-12-25	WOS:000171194500055
J	Birch, JM; Alston, RD; McNally, RJQ; Evans, DGR; Kelsey, AM; Harris, M; Eden, OB; Varley, JM				Birch, JM; Alston, RD; McNally, RJQ; Evans, DGR; Kelsey, AM; Harris, M; Eden, OB; Varley, JM			Relative frequency and morphology of cancers in carriers of germline TP53 mutations	ONCOGENE			English	Article						germline TP53 mutations; cancer frequency; cancer predisposition	LI-FRAUMENI-SYNDROME; TUMOR-SUPPRESSOR GENE; P53 MUTATIONS; BREAST-CANCER; FAMILY SYNDROME; ADRENOCORTICAL CARCINOMA; YOUNG-CHILDREN; PRONE FAMILIES; OSTEOSARCOMA; SARCOMA	The spectrum and frequency of cancers associated with germline TP53 mutations are uncertain. To address this issue a cohort of individuals from 28 families with Li-Fraumeni syndrome, segregating germline TP53 mutations was established. Predicted cancers were estimated by applying age, morphology, site and sex-specific UK cancer statistics to person-years at risk. Observed and predicted cancers were compared and two-sided P-values calculated. Cancer types occurring to excess and showing P-values <0.02, were designated strongly associated with germline TP53 mutations. These were removed from the data and a second round of analyses performed. Cancer types with P-values <0.02 and 0.02-0.05 in the second round analyses were considered moderately and weakly associated respectively. Strongly associated cancers were: breast carcinoma, soft tissue sarcomas, osteosarcoma, brain tumours, adrenocortical carcinoma, Wilms' tumour and phyllodes tumour. Carcinoma of pancreas was moderately associated. Leukaemia and neuroblastoma were weakly associated. Other common carcinomas including lung, colon, bladder, prostate, cervix and ovary did not occur to excess. Although breast carcinoma and sarcomas were numerically most frequent, the greatest increases relative to general population rates were in adrenocortical carcinoma and phyllodes tumour. We conclude that germline TP53 mutations do not simply increase general cancer risk. There are tissue-specific effects.	Royal Manchester Childrens Hosp, CRC, Paediat & Familial Canc Res Grp, Manchester M27 4HA, Lancs, England; Royal Manchester Childrens Hosp, Dept Pathol, Manchester M27 4HA, Lancs, England; St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Pathol, Acad Unit Paediat Oncol, Manchester M20 4BX, Lancs, England; Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Canc Genet Grp, Manchester M20 4BX, Lancs, England	Royal Manchester Children's Hospital; Royal Manchester Children's Hospital; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Birch, JM (corresponding author), Royal Manchester Childrens Hosp, CRC, Paediat & Familial Canc Res Grp, Hosp Rd, Manchester M27 4HA, Lancs, England.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784; McNally, Richard/0000-0001-6685-6467				Ayan I, 1997, ONCOL REP, V4, P679; BERNSTEIN L, 1993, CANCER-AM CANCER SOC, V71, P3020, DOI 10.1002/1097-0142(19930515)71:10<3020::AID-CNCR2820711022>3.0.CO;2-G; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BIRCH JM, 1994, CANCER RES, V54, P1298; BOL FJ, 1998, DIAGN MOL PATHOL, V7, P295; BORRESEN AL, 1992, CANCER RES, V52, P3234; BRUGIERES L, 1993, CANCER RES, V53, P452; CHEN PC, 1995, CANCER GENET CYTOGEN, V82, P106, DOI 10.1016/0165-4608(94)00213-U; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; Evans SC, 1998, HUM GENET, V102, P681, DOI 10.1007/s004390050761; FREBOURG T, 1995, AM J HUM GENET, V56, P608; Goi K, 1997, CANCER RES, V57, P1895; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; HARTLEY AL, 1993, CANCER GENET CYTOGEN, V67, P133, DOI 10.1016/0165-4608(93)90166-J; HARTLEY AL, 1987, J MED GENET, V24, P664, DOI 10.1136/jmg.24.11.664; Huusko P, 1999, CANCER GENET CYTOGEN, V112, P9, DOI 10.1016/S0165-4608(98)00258-1; JOLLY KW, 1994, ONCOGENE, V9, P97; Kleihues P, 1997, AM J PATHOL, V150, P1; KYRITSIS AP, 1994, JNCI-J NATL CANCER I, V86, P344, DOI 10.1093/jnci/86.5.344; LI FP, 1988, CANCER RES, V48, P5358; Li YJ, 1995, INT J CANCER, V64, P383, DOI 10.1002/ijc.2910640606; LUBBE J, 1995, BRAIN PATHOL, V5, P15, DOI 10.1111/j.1750-3639.1995.tb00572.x; LYNCH HT, 1990, ONCOLOGY-BASEL, V47, P75; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Malkin D, 1997, NEW ENGL J MED, V336, P734, DOI 10.1056/NEJM199703063361018; MAZOYER S, 1994, ONCOGENE, V9, P1237; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; Nichols KE, 2001, CANCER EPIDEM BIOMAR, V10, P83; Pivnick EK, 1998, J MED GENET, V35, P328, DOI 10.1136/jmg.35.4.328; PORTER DE, 1992, J BONE JOINT SURG BR, V74, P883; PROSSER J, 1992, BRIT J CANCER, V65, P527, DOI 10.1038/bjc.1992.109; Rines RD, 1998, CARCINOGENESIS, V19, P979, DOI 10.1093/carcin/19.6.979; RUSSO CL, 1994, MED PEDIATR ONCOL, V23, P354, DOI 10.1002/mpo.2950230407; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; Varley JM, 1999, AM J HUM GENET, V65, P995, DOI 10.1086/302575; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Varley JM, 2001, ONCOGENE, V20, P2647, DOI 10.1038/sj.onc.1204369; Verselis SJ, 2000, ONCOGENE, V19, P4230, DOI 10.1038/sj.onc.1203758; Vital A, 1998, J NEUROPATH EXP NEUR, V57, P1061, DOI 10.1097/00005072-199811000-00009; WAGNER J, 1994, JNCI-J NATL CANCER I, V86, P1707, DOI 10.1093/jnci/86.22.1707; Wang Q, 1996, INT J CANCER, V65, P554; Zhou XP, 1999, ANN NEUROL, V46, P913, DOI 10.1002/1531-8249(199912)46:6<913::AID-ANA15>3.0.CO;2-X	48	320	330	0	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4621	4628		10.1038/sj.onc.1204621	http://dx.doi.org/10.1038/sj.onc.1204621			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498785				2022-12-25	WOS:000170208600003
J	Galy, B; Creancier, L; Prado-Lourenco, L; Prats, AC; Prats, H				Galy, B; Creancier, L; Prado-Lourenco, L; Prats, AC; Prats, H			p53 directs conformational change and translation initiation blockade of human fibroblast growth factor 2 mRNA	ONCOGENE			English	Article						FGF; p53; translational control; RNA-protein interactions; RNA structure	WILD-TYPE P53; ALTERNATIVE TRANSLATION; NUCLEIC-ACIDS; MESSENGER-RNA; PROTEIN; GROWTH-FACTOR-2; RIBOSOMES; DOMAIN; ENTRY; CELLS	Tumour suppressor p53 has been shown to inhibit fibroblast growth factor 2 expression post-transcriptionally in cultured cells. Here we have investigated the mechanism responsible for this post-transcriptional blockade. Deletion mutagenesis of the FGF-2 mRNA leader revealed the requirement of at least four RNA cis-acting elements to mediate the inhibitory effect of p53 in SK-Hep-1 transfected cells, suggesting the involvement of RNA secondary or tertiary structures. Recombinant wild-type, but not Ala(143) mutant p53, was able to specifically repress FGF-2 mRNA translation in rabbit reticulocyte lysate, in a dose dependent manner. Sucrose gradient experiments showed that p53 blocks translation initiation by preventing 80S ribosome formation on an mRNA bearing the FGF-2 mRNA leader sequence. Interaction of wild-type and mutant p53 with different RNAs showed no significant correlation between p53 RNA binding activity and its translational inhibiting effect. However, by checking the accessibility of the FGF-2 mRNA leader to complementary oligonucleotide probes, we showed that the binding to RNA of wild-type, but not mutant p53, induced RNA conformational changes that might be responsible for the translational blockade. This strongly suggests that p53 represses FGF-2 mRNA translation by a direct mechanism involving its nucleic acid unwinding-annealing activity.	CHU Rangueil, INSERM, U397, Inst Fed Rech Louis Bugnard, F-31403 Toulouse 04, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prats, AC (corresponding author), CHU Rangueil, INSERM, U397, Inst Fed Rech Louis Bugnard, F-31403 Toulouse 04, France.		Prats, Anne-Catherine/E-5051-2016	Prats, Anne-Catherine/0000-0002-5282-3776; Galy, Bruno/0000-0002-0501-6357; Prats, Herve/0000-0002-4861-2167				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Galy B, 1999, CANCER RES, V59, P165; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497	18	45	45	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4613	4620		10.1038/sj.onc.1204630	http://dx.doi.org/10.1038/sj.onc.1204630			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498784				2022-12-25	WOS:000170208600002
J	Trzewik, J; Mallipattu, SK; Artmann, GM; Delano, FA; Schmid-Schonbein, GW				Trzewik, J; Mallipattu, SK; Artmann, GM; Delano, FA; Schmid-Schonbein, GW			Evidence for a second valve system in lymphatics: endothelial microvalves	FASEB JOURNAL			English	Article						initial lymphatics; lymphatic endothelium; lymphatic valves; rat; cremaster muscle; interstitium; permeability	INITIAL LYMPHATICS; SKELETAL-MUSCLE; BLOOD-VESSELS; FLUID; CELLS; MECHANISMS; MICROSCOPY; SKIN; RAT	The mechanism for interstitial fluid uptake into the lymphatics remains speculative and unresolved. A system of intralymphatic valves exists that prevents reflow along the length of the lymphatic channels. However, these valves are not sufficient to provide unidirectional flow at the level of the initial lymphatics. We investigate here the hypothesis that initial lymphatics have a second, separate valve system that permits fluid to enter from the interstitium into the initial lymph channels but prevents escape back out into the tissue. The transport of fluorescent microspheres (0.31 mum) across endothelium of initial lymphatics in rat cremaster muscle was investigated with micropipette manipulation techniques. The results indicate that microspheres can readily pass from the interstitium across the endothelium into the lumen of the initial lymphatics. Once inside the lymphatic lumen, the microspheres cannot be forced out of the lumen even after elevation of the lymphatic pressure by outflow obstruction. Reaspiration of the microspheres inside the lymphatic lumen with a micropipette is blocked by the lymphatic endothelium. This blockade exists whether the aspiration is carried out at the microsphere entry site or anywhere along the initial lymphatics. Nevertheless, puncture of the initial lymphatic endothelium with the micropipette leads to rapid aspiration of intralymphatic microspheres. Investigation of lymphatic endothelial sections fixed during lymph pumping shows open interendothelial junctions not found in resting initial lymphatics. These results suggest that initial lymphatics have a (primary) valve system at the level of the endothelium. In conjunction with the classical (secondary) intralymphatic valves, the primary valves provide the mechanism that facilitates the unidirectional flow during periodic compression and expansion of initial lymphatics.	Univ Calif San Diego, Whitaker Inst Biomed Engn, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Schmid-Schonbein, GW (corresponding author), Univ Calif San Diego, Whitaker Inst Biomed Engn, Dept Bioengn, 9500 Gilman Dr,Engn Bldg 1,Room 5606, La Jolla, CA 92093 USA.	gwsc@bioeng.ucsd.edu	Mallipattu, Sandeep/M-7009-2014	Trzewik, Juergen/0000-0002-0678-2299				AUKLAND K, 1993, PHYSIOL REV, V73, P1, DOI 10.1152/physrev.1993.73.1.1; Azzali G, 1999, MICROVASC RES, V57, P30, DOI 10.1006/mvre.1998.2101; BAEZ S, 1973, MICROVASC RES, V5, P384, DOI 10.1016/0026-2862(73)90054-X; BRACE RA, 1977, MICROVASC RES, V14, P243, DOI 10.1016/0026-2862(77)90023-1; Casley-Smith JR, 1977, MICROCIRCULATION, P423; CASLEYSMITH JR, 1972, ANGIOLOGICA, V9, P106; CASTENHOLZ A, 1984, SCAN ELECTRON MICROS, P1343; COLLAN Y, 1974, LYMPHOLOGY, V7, P175; Ikomi F, 1996, J APPL PHYSIOL, V81, P2060, DOI 10.1152/jappl.1996.81.5.2060; Ikomi F, 1996, AM J PHYSIOL-HEART C, V271, pH173, DOI 10.1152/ajpheart.1996.271.1.H173; Ikomi F, 1997, LYMPHOLOGY, V30, P13; INTAGLIETTA M, 1982, INT J MICROCIRC, V1, P55; MAZZONI MC, 1990, AM J PHYSIOL, V259, pH1860, DOI 10.1152/ajpheart.1990.259.6.H1860; MAZZONI MC, 1987, BLOOD VESSELS, V24, P304; OHHASHI T, 1991, RECENT ADV CARDIOVAS, P125; OHTANI O, 1987, CELL TISSUE RES, V248, P365; Parsons RJ, 1938, J EXP MED, V68, P353, DOI 10.1084/jem.68.3.353; Sauter B, 1998, J HISTOCHEM CYTOCHEM, V46, P165, DOI 10.1177/002215549804600205; SCHMELZ M, 1994, DIFFERENTIATION, V57, P97, DOI 10.1046/j.1432-0436.1994.5720097.x; SCHMIDSCHONBEIN GW, 1990, ARCH HISTOL CYTOL, V53, P107, DOI 10.1679/aohc.53.Suppl_107; SIMMONDS WJQ, 1957, J EXP PHYSL, V42, P205; SKALAK TC, 1984, MICROVASC RES, V28, P95, DOI 10.1016/0026-2862(84)90032-3; Swartz MA, 1999, J BIOMECH, V32, P1297, DOI 10.1016/S0021-9290(99)00125-6; WENZELHORA BI, 1987, LYMPHOLOGY, V20, P126; White JC, 1933, AM J PHYSIOL, V103, P34	25	109	118	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2001	15	10					1711	1717		10.1096/fj.01-0067com	http://dx.doi.org/10.1096/fj.01-0067com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481218				2022-12-25	WOS:000170809900006
J	Weiske, J; Schoneberg, T; Schroder, W; Hatzfeld, M; Tauber, R; Huber, O				Weiske, J; Schoneberg, T; Schroder, W; Hatzfeld, M; Tauber, R; Huber, O			The fate of desmosomal proteins in apoptotic cells.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; BETA-CATENIN; E-CADHERIN; INTERMEDIATE-FILAMENTS; CLEAVAGE; PLAKOGLOBIN; MOLECULES; DESMOCOLLINS; DESMOPLAKIN; PP125(FAK)	Activation of caspases results in the disruption of structural and signaling networks in apoptotic cells. Recent biochemical and cell biological studies have shown that components of the cadherin-catenin adhesion complex in epithelial adherens junctions are targeted by caspases during apoptosis. In epithelial cells, desmosomes represent a second type of anchoring junctions mediating strong cell-cell contacts. Using antibodies directed against a set of desmosomal proteins, we show that desmosomes are proteolytically targeted during apoptosis. Desmogleins and desmocollins, representing desmosome-specific members of the cadherin superfamily of cell adhesion molecules, are specifically cleaved after onset of apoptosis. Similar to E-cadherin, the desmoglein-3 cytoplasmic tail is cleaved by caspases. In addition the extracellular domains of desmoglein-3 and desmocollin-3 are released from the cell surface by a metalloproteinase activity. In the presence of caspase and/or metalloproteinase inhibitors, both cleavage reactions are almost completely inhibited. As reported previously, the desmosomal plaque protein plakoglobin is cleaved by caspase-3 during apoptosis. Our studies now show that plakophilin-1 and two other major plaque proteins, desmoplakin-1 and -2, are also cleaved by caspases. Immunofluorescence analysis confirmed that this cleavage results in the disruption of the desmosome structure and thus contributes to cell rounding and disintegration of the intermediate filament system.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Chem & Pathobiochem, D-12200 Berlin, Germany; Inst Pharmacol, D-14195 Berlin, Germany; Inst Biochem, D-14195 Berlin, Germany; Univ Halle Wittenberg, Mol Biol Grp, Fac Med, D-06097 Halle An Der Saale, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Martin Luther University Halle Wittenberg	Huber, O (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Chem & Pathobiochem, Hindenburgdamm 30, D-12200 Berlin, Germany.	otmar.huber@medizin.fu-berlin.de	Huber, Otmar/AAA-4548-2021	Huber, Otmar/0000-0003-4359-1747				Abreu MT, 2000, GASTROENTEROLOGY, V119, P1524, DOI 10.1053/gast.2000.20232; Amagai M, 2000, NAT MED, V6, P1275, DOI 10.1038/81385; Brancolini C, 1998, CELL DEATH DIFFER, V5, P1042, DOI 10.1038/sj.cdd.4400443; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Charpentier E, 2000, J CELL BIOL, V149, P503, DOI 10.1083/jcb.149.2.503; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; Crouch DH, 1996, ONCOGENE, V12, P2689; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; GREEN KJ, 1999, GUIDEBOOK EXTRACELLU, P102; Hakimelahi S, 2000, J BIOL CHEM, V275, P10905, DOI 10.1074/jbc.275.15.10905; Hanakawa Y, 2000, J CELL SCI, V113, P1803; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Hatzfeld M, 2000, J CELL BIOL, V149, P209, DOI 10.1083/jcb.149.1.209; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hofmann I, 2000, J CELL SCI, V113, P2471; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Marcozzi C, 1998, J CELL SCI, V111, P495; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MOLL R, 1986, LAB INVEST, V54, P4; North AJ, 1999, J CELL SCI, V112, P4325; Nuber UA, 1996, EUR J CELL BIOL, V71, P1; ODAKE S, 1994, BIOCHEM BIOPH RES CO, V199, P1442, DOI 10.1006/bbrc.1994.1392; OWARIBE K, 1999, GUIDEBOOK EXTRACELLU, P105; PARKER AE, 1991, J BIOL CHEM, V266, P10438; Proby CM, 2000, BRIT J DERMATOL, V142, P321, DOI 10.1046/j.1365-2133.2000.03328.x; Ruhrberg C, 1997, CURR OPIN GENET DEV, V7, P392, DOI 10.1016/S0959-437X(97)80154-2; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schmeiser K, 1999, CELL DEATH DIFFER, V6, P377, DOI 10.1038/sj.cdd.4400504; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; Vallorosi CJ, 2000, J BIOL CHEM, V275, P3328, DOI 10.1074/jbc.275.5.3328; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; WICHE G, 1999, GUIDEBOOK EXTRACELLU, P107; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	50	108	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41175	41181		10.1074/jbc.M105769200	http://dx.doi.org/10.1074/jbc.M105769200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11500511	hybrid			2022-12-25	WOS:000171925600107
J	Babcock, GJ; Mirzabekov, T; Wojtowicz, W; Sodroski, J				Babcock, GJ; Mirzabekov, T; Wojtowicz, W; Sodroski, J			Ligand binding characteristics of CXCR4 incorporated into paramagnetic proteoliposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN-COUPLED RECEPTORS; GP120 ENVELOPE GLYCOPROTEIN; HUMAN MONOCLONAL-ANTIBODY; HIV-1 ENTRY; CHEMOKINE RECEPTORS; V3 LOOP; EXPRESSION; CCR5; CD4	The G protein-coupled receptor CXCR4 is a coreceptor, along with CD4, for the human immunodeficiency virus type 1 (HIV-1) and has been implicated in breast cancer metastasis. We studied the binding of the HIV-1 gp120 envelope glycoprotein (gp) to CXCR4 but found that the gp120s from CXCR4-using HIV-1 strains bound nonspecifically to several cell lines lacking human CXCR4 expression. Therefore, we constructed paramagnetic proteoliposomes (CXCR4-PMPLs) containing pure, native CXCR4. CXCR4-PMPLs specifically bound the natural ligand, SDF-1 alpha, and the gp120s from CXCR4-using HIV-1 strains. Conformation-dependent anti-CXCR4 antibodies and the CXCR4 antagonist AMD3100 blocked HIV-1 gp120 binding to CXCR4-PMPLs. The gp120-CXCR4 interaction was blocked by anti-gp120 antibodies directed against the third variable (V3) loop and CD4-induced epitopes, structures that have also been implicated in the binding of gp120 to the other HIV-1 coreceptor, CCR5. Compared with the binding of R5 HIV-1 gp120s to CCR5, the gp120-CXCR4 interaction exhibited a lower affinity (K-d = 200 nM) and was dependent upon prior CD4 binding, even at low temperature. Thus, although similar regions of X4 and R5 HIV-1 gp120s appear to be involved in binding CXCR4 and CCR5, respectively, differences exist in nonspecific binding to cell surfaces, affinity for the chemokine receptor, and CD4 dependence at low temperature.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Div AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Sodroski, J (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, JFB824,44 Binney St, Boston, MA 02115 USA.				NIAID NIH HHS [AI41851, AI42848, AI46725, AI31783] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042848, R01AI031783, U01AI046725, R01AI041851] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Drews J, 1996, NAT BIOTECHNOL, V14, P1516, DOI 10.1038/nbt1196-1516; Edwards TG, 2001, J VIROL, V75, P5230, DOI 10.1128/JVI.75.11.5230-5239.2001; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Hoffman TL, 2000, P NATL ACAD SCI USA, V97, P11215, DOI 10.1073/pnas.190274097; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; Kolchinsky P, 2001, J VIROL, V75, P3435, DOI 10.1128/JVI.75.7.3435-3443.2001; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Meister S, 2001, VIROLOGY, V284, P287, DOI 10.1006/viro.2001.0852; Mirzabekov T, 2000, NAT BIOTECHNOL, V18, P649, DOI 10.1038/76501; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Mondor I, 1998, VIROLOGY, V248, P394, DOI 10.1006/viro.1998.9282; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; Seddiki N, 1999, AIDS RES HUM RETROV, V15, P381, DOI 10.1089/088922299311358; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; Tate CG, 1996, TRENDS BIOTECHNOL, V14, P426, DOI 10.1016/0167-7799(96)10059-7; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514	41	87	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38433	38440		10.1074/jbc.M106229200	http://dx.doi.org/10.1074/jbc.M106229200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489906	hybrid			2022-12-25	WOS:000171673200016
J	Kin, Y; Li, G; Shibuya, M; Maru, Y				Kin, Y; Li, G; Shibuya, M; Maru, Y			The Dbl homology domain of BCR is not a simple spacer in P210BCR-ABL of the Philadelphia chromosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-B PROTEIN; TYROSINE PHOSPHORYLATION; ABL ONCOGENE; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; ADAPTER PROTEIN; KINASE-ACTIVITY; JUN KINASE; TRANSFORMATION; LEUKEMIA	The Dbl homology (DH) domain of BCR in P210BCR-ABL (P210/WT) has been thought to have a negative effect on the activation of BCR-ABL because P185BCR-ABL, in which this region is physically deleted, has stronger biochemical and biological activities. To study the role of the DH domain of BCR in the background of P210/WT, the region was replaced with homologous sequences derived from Dbl (P210/Dbl) or CDC24 (P210/ CDC24) or with irrelevant sequences from LacZ (P210/ LacZ) or luciferase (P210/Luci). Surprisingly, the abilities to transform Rat1 cells or mouse bone marrow cells and induce growth factor independence in interleukin 3-dependent mouse Ba/F3 cells were retained only in P210/Dbl. However, even P210/Dbl could not achieve the wild type level of surviving potential against genotoxins in Rat1 cells and in Ba/F3 cells. Activation of Akt correlated with the biological changes in Rat1 cells but did not correlate with the biological changes in Ba/F3 cells. The DH domain was not tyrosine-phosphorylated in vitro, nor could we find any differences in peptide mapping between in vitro phosphorylated P210/WT and P210/Dbl. Although functions of the DH domain remain to be discovered, we propose that the DH domain makes positive contributions to P210BCR-ABL.	Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1080071, Japan	University of Tokyo	Maru, Y (corresponding author), Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1080071, Japan.	ymaru@ims.u-tokyo.ac.jp						ADAMS JM, 1992, ONCOGENE, V7, P611; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; JONG RD, 1995, J BIOL CHEM, V270, P21468; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; LIU JX, 1993, ONCOGENE, V8, P101; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Maru Y, 1999, BIOCHEM BIOPH RES CO, V260, P309, DOI 10.1006/bbrc.1999.0822; Maru Y, 1998, J CELL PHYSIOL, V176, P223, DOI 10.1002/(SICI)1097-4652(199808)176:2<223::AID-JCP1>3.0.CO;2-Q; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Olson MF, 1996, J MOL MED-JMM, V74, P563, DOI 10.1007/s001090050060; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219	40	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39462	39468		10.1074/jbc.M105484200	http://dx.doi.org/10.1074/jbc.M105484200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11502748	hybrid			2022-12-25	WOS:000171673200147
J	Longley, MJ; Nguyen, D; Kunkel, TA; Copeland, WC				Longley, MJ; Nguyen, D; Kunkel, TA; Copeland, WC			The fidelity of human DNA polymerase gamma with and without exonucleolytic proofreading and the p55 accessory subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASES; BASE EXCISION-REPAIR; MITOCHONDRIAL-DNA; OXIDATIVE DAMAGE; MISMATCH REPAIR; SUBSTRATE-SPECIFICITY; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; XENOPUS-LAEVIS; HUMAN-CELLS	Mutations in human mitochondrial DNA influence aging, induce severe neuromuscular pathologies, cause maternally inherited metabolic diseases, and suppress apoptosis. Since the genetic stability of mitochondrial DNA depends on the accuracy of DNA polymerase gamma (pol gamma), we investigated the fidelity of DNA synthesis by human pol gamma. Comparison of the wild-type 140-kDa catalytic subunit to its exonuclease-deficient derivative indicates poly has high base substitution fidelity that results from high nucleotide selectivity and exonucleolytic proofreading. pol gamma is also relatively accurate for single-base additions and deletions in non-iterated and short repetitive sequences. However, when copying homopolymeric sequences longer than four nucleotides, poly has low frameshift fidelity and also generates base substitutions inferred to result from a primer dislocation mechanism. The ability of pol gamma both to make and to proofread dislocation intermediates is the first such evidence for a family A polymerase. Including the p55 accessory subunit, which confers processivity to the pol gamma catalytic subunit, decreases frameshift and base substitution fidelity. Kinetic analyses indicate that p55 promotes extension of mismatched termini to lower the fidelity. These data suggest that homopolymeric runs in mitochondrial DNA may be particularly prone to frameshift mutation in vivo due to replication errors by pol gamma.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Copeland, WC (corresponding author), NIEHS, Mol Genet Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	copelan1@niehs.nih.gov	Kunkel, Thomas A./D-5088-2019; Copeland, William/C-4242-2019	Kunkel, Thomas A./0000-0002-9900-1788; Copeland, William/0000-0002-0359-0953	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065078, Z01ES065078] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 2000, COLD SPRING HARB SYM, V65, P81, DOI 10.1101/sqb.2000.65.81; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; Carrodeguas JA, 2000, NUCLEIC ACIDS RES, V28, P1237, DOI 10.1093/nar/28.5.1237; Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8; CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370; Croteau DL, 1999, MUTAT RES-DNA REPAIR, V434, P137, DOI 10.1016/S0921-8777(99)00025-7; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; DOMENA JD, 1985, BIOCHEMISTRY-US, V24, P7320, DOI 10.1021/bi00346a045; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; ERIKSSON S, 1995, J BIOL CHEM, V270, P18929, DOI 10.1074/jbc.270.32.18929; Fan L, 1999, P NATL ACAD SCI USA, V96, P9527, DOI 10.1073/pnas.96.17.9527; Fan L, 2001, BIOCHEMISTRY-US, V40, P4780, DOI 10.1021/bi010102h; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; GRAY H, 1992, J BIOL CHEM, V267, P5835; Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HUBER HE, 1987, J BIOL CHEM, V262, P16224; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P38090; KAGUNI LS, 1989, P NATL ACAD SCI USA, V86, P6469, DOI 10.1073/pnas.86.17.6469; KAGUNI LS, 1988, CANCER CELL, V6, P425; Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798; Kogelnik AM, 1996, NUCLEIC ACIDS RES, V24, P177, DOI 10.1093/nar/24.1.177; Kroutil LC, 1999, NUCLEIC ACIDS RES, V27, P3481, DOI 10.1093/nar/27.17.3481; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LeDoux SP, 1999, MUTAT RES-DNA REPAIR, V434, P149, DOI 10.1016/S0921-8777(99)00026-9; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; Lefai E, 2000, J BIOL CHEM, V275, P33123, DOI 10.1074/jbc.M003024200; Lewis DL, 1996, J BIOL CHEM, V271, P23389, DOI 10.1074/jbc.271.38.23389; Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197; Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; Mandavilli BS, 2000, BRAIN RES, V885, P45, DOI 10.1016/S0006-8993(00)02926-7; Marcelino LA, 1999, MUTAT RES-DNA REPAIR, V434, P177, DOI 10.1016/S0921-8777(99)00028-2; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; Mott JL, 2001, MUTAT RES-FUND MOL M, V474, P35, DOI 10.1016/S0027-5107(00)00159-7; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; OLSON MW, 1992, J BIOL CHEM, V267, P23136; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9; Pinz KG, 1998, MOL CELL BIOL, V18, P1257, DOI 10.1128/MCB.18.3.1257; REENAN RAG, 1992, GENETICS, V132, P975; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; ROPP PA, 1995, GENE, V165, P103, DOI 10.1016/0378-1119(95)00412-Y; Sawyer DE, 1999, MUTAT RES-DNA REPAIR, V434, P161, DOI 10.1016/S0921-8777(99)00027-0; Sia EA, 2000, P NATL ACAD SCI USA, V97, P250, DOI 10.1073/pnas.97.1.250; Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200; Stierum RH, 1999, NUCLEIC ACIDS RES, V27, P3712, DOI 10.1093/nar/27.18.3712; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Vaisman A, 1999, BIOCHEMISTRY-US, V38, P11026, DOI 10.1021/bi9909187; Vanderstraeten S, 1998, J BIOL CHEM, V273, P23690, DOI 10.1074/jbc.273.37.23690; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481; Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333	77	192	193	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38555	38562		10.1074/jbc.M105230200	http://dx.doi.org/10.1074/jbc.M105230200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504725	hybrid			2022-12-25	WOS:000171673200032
J	Parry, DAD; Marekov, LN; Steinert, PM				Parry, DAD; Marekov, LN; Steinert, PM			Subfilamentous protofibril structures in fibrous proteins - Cross-linking evidence for protofibrils in intermediate filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL KERATIN FILAMENTS; HARD ALPHA-KERATIN; COLLAGEN FIBRILS; MOLECULAR PACKING; ASSEMBLED INVITRO; VIMENTIN; MODEL; MASS; POLYMORPHISM; MECHANISM	The packing of the constituent molecules in some fibrous proteins such as collagen and intermediate filaments (IF) is thought to consist of several hierarchical levels, the penultimate of which is the organization of subfilamentous units termed protofibrils. However, to date only indirect evidence, such as electron microscopic images of unraveling fibers or the existence of mass quanta, has been adduced in support of the existence of protofibrils. We have reexamined this issue in IF. Cross-links have been induced in trichocyte keratin, cytokeratin, and vimentin IF proteins. Using improved experimental conditions, several additional and reproducible cross-links have been characterized. Notably, many of these link between columns of molecular strands four apart on two-dimensional surface lattices. These data provide robust support for the concept of an 8-chain (4-molecule) protofibril entity in IF. Further, their positions correspond to the axial displacements predicted for protofibrils in the different types of IF. Also, the data are consistent with intact IF containing four protofibrils. In addition, the positions of these novel cross-links suggest that there are multiple possible groupings of four molecular strands to form a protofibril, suggesting a promiscuous association of molecules to form a protofibril. This may underlie the reason that organized elongated protofibrils cannot be visualized by conventional microscopic methods.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; Massey Univ, Inst Fundamental Sci, Palmerston North, New Zealand	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Massey University	Steinert, PM (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldg 6,Rm 152, Bethesda, MD 20892 USA.	steinerp@mail.nih.gov						AEBI U, 1983, J CELL BIOL, V97, P1131, DOI 10.1083/jcb.97.4.1131; CREWTHER WG, 1983, INT J BIOL MACROMOL, V5, P267, DOI 10.1016/0141-8130(83)90040-5; ENGEL A, 1985, J ULTRA MOL STRUCT R, V90, P323, DOI 10.1016/S0022-5320(85)80010-1; Fraser R.D.B., 1972, KERATINS THEIR COMPO; FRASER RDB, 1973, POLYMER, V14, P61, DOI 10.1016/0032-3861(73)90097-9; FRASER RDB, 1983, J MOL BIOL, V167, P497, DOI 10.1016/S0022-2836(83)80347-7; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; HEINS S, 1994, CURR OPIN CELL BIOL, V6, P25, DOI 10.1016/0955-0674(94)90112-0; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; Herrmann H, 1998, CURR OPIN STRUC BIOL, V8, P177, DOI 10.1016/S0959-440X(98)80035-3; Herrmann H, 1999, CELL MOL LIFE SCI, V55, P1416, DOI 10.1007/s000180050382; Herrmann H, 2000, J MOL BIOL, V298, P817, DOI 10.1006/jmbi.2000.3719; HULMES DJS, 1979, NATURE, V282, P878, DOI 10.1038/282878a0; Jones LN, 1997, BIOPHYS CHEM, V68, P83, DOI 10.1016/S0301-4622(97)00013-6; LUTHER PK, 1981, J MOL BIOL, V151, P703, DOI 10.1016/0022-2836(81)90430-7; PARRY DAD, 1979, NATURE, V282, P213, DOI 10.1038/282213a0; Parry DAD, 1999, Q REV BIOPHYS, V32, P99, DOI 10.1017/S0033583500003516; PARRY DAD, 1988, BIOPHYS CHEM, V29, P195, DOI 10.1016/0301-4622(88)87039-X; PARRY DAD, 1995, PROTEINS, V22, P267, DOI 10.1002/prot.340220307; PARRY DAD, 1995, INTERMEDIATE FILAMEN; PARRY DAD, 1999, GUIDEBOOK CYTOSKELET, P285; RUGGERI A, 1979, J ULTRA MOL STRUCT R, V68, P101, DOI 10.1016/S0022-5320(79)90146-1; SMITH JW, 1968, NATURE, V219, P157, DOI 10.1038/219157a0; Squire J, 1998, J STRUCT BIOL, V122, P128, DOI 10.1006/jsbi.1998.3995; Squire J. M., 1986, Comments on Molecular and Cellular Biophysics. Comments on Modern Biology: Part A, V3, P155; SQUIRE JM, 1973, J MOL BIOL, V77, P291, DOI 10.1016/0022-2836(73)90337-9; STEINERT PM, 1994, J INVEST DERMATOL, V103, pS19, DOI 10.1111/1523-1747.ep12398900; STEINERT PM, 1993, BIOCHEMISTRY-US, V32, P10046, DOI 10.1021/bi00089a021; STEINERT PM, 1993, J BIOL CHEM, V268, P24916; Steinert PM, 1999, J BIOL CHEM, V274, P1657, DOI 10.1074/jbc.274.3.1657; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; Steinert PM, 2001, CURR PROBL DERM-US, V13, P193, DOI 10.1016/S1040-0486(01)70013-0; STEINERT PM, 1991, BIOCH PHYSL SKIN, P113; STEVEN AC, 1983, J CELL BIOL, V97, P1939, DOI 10.1083/jcb.97.6.1939; STEVEN AC, 1983, J BIOL CHEM, V258, P8323; Wang H, 2000, J CELL BIOL, V151, P1459, DOI 10.1083/jcb.151.7.1459; Wess TJ, 1998, J STRUCT BIOL, V122, P92, DOI 10.1006/jsbi.1998.3991; Wu KC, 2000, MOL BIOL CELL, V11, P3539, DOI 10.1091/mbc.11.10.3539	39	43	45	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39253	39258		10.1074/jbc.M104604200	http://dx.doi.org/10.1074/jbc.M104604200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495907	hybrid			2022-12-25	WOS:000171673200121
J	Zha, XH; Genest, J; McPherson, R				Zha, XH; Genest, J; McPherson, R			Endocytosis is enhanced in Tangier fibroblasts - Possible role of ATP-binding cassette protein A1 in endosomal vesicular transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN DEFICIENCY; CHOLESTEROL EFFLUX; PLASMA-MEMBRANE; APOPTOTIC CELLS; LIVING CELLS; DISEASE; ABC1; PHOSPHATIDYLSERINE; MACROPHAGES; ENGULFMENT	A human genetic disorder, Tangier disease, has been linked recently to mutations in ATP-binding cassette protein A1 (ABCA1). In addition to its function in apoprotein A-I-mediated lipid removal, ABCA1 was also shown to be a phosphatidylserine (PS) translocase that facilitates PS exofacial flipping. This PS translocation is crucial for the plasma membrane to produce protrusions enabling the engulfment of apoptotic cells. In this report, we show that ABCA1 also plays a role in endocytosis. Receptor-mediated endocytosis, probed by both transferrin and low density lipoprotein, is up-regulated by more than 50% in homozygous Tangier fibroblasts in comparison with controls. Fluid-phase uptake is increased similarly. We also demonstrate that bulk membrane flow, including lipid endocytosis and exocytosis, is accelerated greatly in Tangier cells. Moreover, endocytosis is similarly enhanced in normal fibroblasts when ABCA1 function is inhibited by glyburide, whereas glyburide has no effect on endocytosis in Tangier cells. In addition, we demonstrate a decreased annexin V binding in Tangier fibroblasts as compared with controls, supporting the notion that PS transmembrane distribution is indeed defective in the presence of ABCA1 mutations. Furthermore, adding a PS analog to the exofacial leaflet of the plasma membrane normalizes endocytosis in Tangier cells. Taken together, these data demonstrate that ABCA1 plays an important role in endocytosis. We speculate that this is related to the PS translocase function of ABCA1. A loss of functional ABCA1, as in the case of Tangier cells, enhances membrane inward bending and facilitates endocytosis.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada; McGill Univ, Ctr Hlth, Div Cardiol, Montreal, PQ H3A 1A1, Canada	University of Ottawa; University of Ottawa Heart Institute; McGill University	Zha, XH (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.							ASSMANN G, 1989, METABOLIC BASIS INHE, P1267; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Betz WJ, 1996, CURR OPIN NEUROBIOL, V6, P365, DOI 10.1016/S0959-4388(96)80121-8; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chen CY, 1999, J CELL BIOL, V147, P1223, DOI 10.1083/jcb.147.6.1223; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; Devaux PF, 2000, BIOCHIMIE, V82, P497, DOI 10.1016/S0300-9084(00)00209-1; DUNN KW, 1990, NONINVASIVE TECHNIQU, P153; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Farge E, 1999, AM J PHYSIOL-CELL PH, V276, pC725, DOI 10.1152/ajpcell.1999.276.3.C725; Farge E, 1995, BIOPHYS J, V69, P2501, DOI 10.1016/S0006-3495(95)80120-7; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Haidar B, 2001, J LIPID RES, V42, P249; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; NECKERS LM, 1986, EXP CELL RES, V166, P151, DOI 10.1016/0014-4827(86)90515-X; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1999, J LIPID RES, V40, P1769; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; Pomorski T, 2001, SEMIN CELL DEV BIOL, V12, P139, DOI 10.1006/scdb.2000.0231; Rauch C, 2000, BIOPHYS J, V78, P3036, DOI 10.1016/S0006-3495(00)76842-1; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SACKMANN E, 1994, FEBS LETT, V346, P3, DOI 10.1016/0014-5793(94)00484-6; Schmitz G, 2000, CURR OPIN LIPIDOL, V11, P493, DOI 10.1097/00041433-200010000-00007; SCHMITZ G, 1985, P NATL ACAD SCI USA, V82, P6305, DOI 10.1073/pnas.82.18.6305; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Walter M, 1996, J CLIN INVEST, V98, P2315, DOI 10.1172/JCI119043; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zha XH, 1997, ARTERIOSCL THROM VAS, V17, P1421, DOI 10.1161/01.ATV.17.7.1421; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39	50	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39476	39483		10.1074/jbc.M105067200	http://dx.doi.org/10.1074/jbc.M105067200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504722	hybrid			2022-12-25	WOS:000171673200149
J	Muro-Pastor, MI; Reyes, JC; Florencio, FJ				Muro-Pastor, MI; Reyes, JC; Florencio, FJ			Cyanobacteria perceive nitrogen status by sensing intracellular 2-oxoglutarate levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN PCC-6803; GLUTAMINE-SYNTHETASE ACTIVITY; SYNECHOCYSTIS SP PCC-6803; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; GLNN GENE; P-II; ASSIMILATION; PROTEIN	The regulatory circuits that control nitrogen metabolism are relatively well known in several bacterial model groups. However, much less is understood about how the nitrogen status of the cell is perceived in vivo. In cyanobacteria, the transcription factor NtcA is required for regulation (activation or repression) of an extensive number of genes involved in nitrogen metabolism. In contrast, how NtcA activity is regulated is largely unknown. Assimilation of ammonium by most microorganisms occurs through the sequential action of two enzymes: glutamine synthetase (GS) and glutamate synthase. Interestingly, regulation of the expression of NtcA-dependent genes in the cyanobacterium. Synechocystis sp. PCC 6803 is altered in mutants with modified levels of GS activity. Two types of mutants were analyzed: glnA null mutants that lack GS type I and gif mutants unable to inactivate GS in the presence of ammonium. Changes in the intracellular pools of 19 different amino acids and the keto acid 2-oxoglutarate were recorded in wild-type and mutant strains under different nitrogen conditions. Our data strongly indicate that the nitrogen status in cyanobacteria is perceived as changes in the intracellular 2-oxoglutarate pool.	Univ Seville, Consejo Super Invest Cient, Inst Bioquim Vegetal & Fotosintesis, Ctr Invest Cient Isla de la Cartuja, E-41092 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-JA-USE - Centro de Investigaciones Cientificas Isla de La Cartuja (CICIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF)	Florencio, FJ (corresponding author), Univ Seville, Consejo Super Invest Cient, Inst Bioquim Vegetal & Fotosintesis, Ctr Invest Cient Isla de la Cartuja, Ave Amer Vespucio S-N, E-41092 Seville, Spain.	floren@cica.es	Florencio, Francisco J/K-7716-2014; Muro-Pastor, M. Isabel/C-6045-2015; Muro-Pastor, M. Isabel/AAC-3154-2022; Reyes, Jose C/K-3699-2014	Florencio, Francisco J/0000-0002-2068-7861; Muro-Pastor, M. Isabel/0000-0001-7366-7904; Muro-Pastor, M. Isabel/0000-0001-7366-7904; Reyes, Jose C/0000-0002-8042-5142				Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; COLLIER JL, 1994, EMBO J, V13, P1039, DOI 10.1002/j.1460-2075.1994.tb06352.x; Coruzzi GM, 2001, CURR OPIN PLANT BIOL, V4, P247, DOI 10.1016/S1369-5266(00)00168-0; Crespo JL, 1998, MOL MICROBIOL, V30, P1101, DOI 10.1046/j.1365-2958.1998.01143.x; DEUEL TF, 1974, J BIOL CHEM, V249, P257; Fisher SH, 1999, MOL MICROBIOL, V32, P223, DOI 10.1046/j.1365-2958.1999.01333.x; FORCHHAMMER K, 1995, J BACTERIOL, V177, P2033, DOI 10.1128/jb.177.8.2033-2040.1995; Garcia-Dominguez M, 2000, MOL MICROBIOL, V35, P1192, DOI 10.1046/j.1365-2958.2000.01789.x; Garcia-Dominguez M, 1999, P NATL ACAD SCI USA, V96, P7161, DOI 10.1073/pnas.96.13.7161; Garcia-Dominguez M, 1997, PLANT MOL BIOL, V35, P723, DOI 10.1023/A:1005846626187; Harlow E., 1999, USING ANTIBODIES LAB; Herrero A, 2001, J BACTERIOL, V183, P411, DOI 10.1128/JB.183.2.411-425.2001; HERRERO A, 1981, J BACTERIOL, V145, P175, DOI 10.1128/JB.145.1.175-180.1981; Hu P, 1999, J BACTERIOL, V181, P5042, DOI 10.1128/JB.181.16.5042-5050.1999; Ikeda TP, 1996, J MOL BIOL, V259, P589, DOI 10.1006/jmbi.1996.0342; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HM, 1998, FEBS LETT, V427, P291, DOI 10.1016/S0014-5793(98)00451-7; MARQUES S, 1992, PLANTA, V187, P247, DOI 10.1007/BF00201947; Marzluf GA, 1997, MICROBIOL MOL BIOL R, V61, P17, DOI 10.1128/.61.1.17-32.1997; MERIDA A, 1990, J BACTERIOL, V172, P4732, DOI 10.1128/jb.172.8.4732-4735.1990; MERIDA A, 1991, J BACTERIOL, V173, P4095, DOI 10.1128/jb.173.13.4095-4100.1991; MERRICK MJ, 1995, MICROBIOL REV, V59, P604, DOI 10.1128/MMBR.59.4.604-622.1995; MuroPastor MI, 1996, J BACTERIOL, V178, P4070, DOI 10.1128/jb.178.14.4070-4076.1996; Ninfa AJ, 2000, CURR TOP CELL REGUL, V36, P31; Reitzer L.J., 1996, ESCHERICHIA COLI SAL, P391; Reyes JC, 1997, J BACTERIOL, V179, P2678, DOI 10.1128/jb.179.8.2678-2689.1997; REYES JC, 1994, J BACTERIOL, V176, P1260, DOI 10.1128/jb.176.5.1260-1267.1994; REYES JC, 1995, PLANT MOL BIOL, V27, P789, DOI 10.1007/BF00020231; REYES JC, 1994, J BACTERIOL, V176, P7516, DOI 10.1128/JB.176.24.7516-7523.1994; RHEE SG, 1989, ADV ENZYMOL RAMB, V62, P37; Richaud C, 2001, J BACTERIOL, V183, P2989, DOI 10.1128/JB.183.10.2989-2994.2001; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SENIOR PJ, 1975, J BACTERIOL, V123, P407, DOI 10.1128/JB.123.2.407-418.1975; STADTMAN ER, 1990, METHOD ENZYMOL, V182, P793; STANIER RY, 1977, ANNU REV MICROBIOL, V31, P225, DOI 10.1146/annurev.mi.31.100177.001301; STEWART WDP, 1975, BIOCHEM BIOPH RES CO, V65, P846, DOI 10.1016/S0006-291X(75)80463-3; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; SUZUKI I, 1993, PLANT CELL PHYSIOL, V34, P1311; VIOQUE A, 1992, NUCLEIC ACIDS RES, V20, P6331, DOI 10.1093/nar/20.23.6331	39	248	256	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38320	38328						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11479309				2022-12-25	WOS:000171526500080
J	Viriyakosol, S; Tobias, PS; Kitchens, RL; Kirkland, TN				Viriyakosol, S; Tobias, PS; Kitchens, RL; Kirkland, TN			MD-2 binds to bacterial lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; CUTTING EDGE; SIGNAL-TRANSDUCTION; CROSS-LINKING; CELL-SURFACE; SOLUBLE CD14; PROTEIN; LPS; ENDOTOXIN; IDENTIFICATION	The exact roles and abilities of the individual components of the lipopolysaccharide (LPS) receptor complex of proteins remain unclear. MD-2 is a molecule found in association with toll-like receptor 4. We produced recombinant human MD-2 to explore its LPS binding ability and role in the LPS receptor complex. MD-2 binds to highly purified rough LPS derived from Salmonella minnesota and Escherichia coli in five different assays; one assay yielded an apparent KD of 65 nm. MD-2 binding to LPS did not require LPS-binding proteins LBP and CD14; in fact LBP competed with MD-2 for LPS : MD-2 enhanced the biological activity of LPS in toll-like receptor 4-transfected Chinese hamster ovary cells but inhibited LPS activation of U373 astrocytoma cells and of monocytes in human whole blood. These data indicate that MD-2 is a genuine LPS-binding protein and strongly suggest that MD-2 could play a role in regulation of cellular activation by LPS depending on its local availability.	Vet Adm San Diego Healthcare Syst, San Diego, CA 92161 USA; Univ Calif San Diego, Dept Pathol & Med, San Diego, CA 92161 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of California System; University of California San Diego; Scripps Research Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Viriyakosol, S (corresponding author), Vet Adm San Diego Healthcare Syst, 9111F,3350 La Jolla Village Dr, San Diego, CA 92161 USA.		Kirkland, Theo/ADK-9674-2022		NIAID NIH HHS [AI32021] Funding Source: Medline; NIGMS NIH HHS [P01GM37696] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Delude RL, 1998, J IMMUNOL, V161, P3001; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAZIOT A, 1994, J IMMUNOL, V152, P5868; Heine H, 1999, J IMMUNOL, V162, P6971; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; KIRKLAND TN, 1990, J BIOL CHEM, V265, P9520; Kitchens RL, 1999, J BIOL CHEM, V274, P34116, DOI 10.1074/jbc.274.48.34116; Kitchens RL, 1998, J IMMUNOL, V160, P1920; Leturcq DJ, 1996, J CLIN INVEST, V98, P1533, DOI 10.1172/JCI118945; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; STANLEY HA, 1985, P NATL ACAD SCI USA, V82, P6272, DOI 10.1073/pnas.82.18.6272; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Viriyakosol S, 2000, J BIOL CHEM, V275, P3144, DOI 10.1074/jbc.275.5.3144; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	26	251	264	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38044	38051						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11500507				2022-12-25	WOS:000171526500045
J	Gallie, DR; Browning, KS				Gallie, DR; Browning, KS			eIF4G functionally differs from eIFiso4G in promoting internal initiation, cap-independent translation, and translation of structured mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; FACTOR 4G EIF4G; POLY(A) BINDING-PROTEIN; RNA HELICASE ACTIVITY; GLOBIN MESSENGER-RNA; WHEAT-GERM; POLY(A)-BINDING PROTEIN; SECONDARY STRUCTURE; ISOZYME FORM; HEAT-SHOCK	Eukaryotic initiation factor (eIF) 4G plays an important role in assembling the initiation complex required for ribosome binding to an mRNA. Plants, animals, and yeast each express two eIF4G homologs, which share only 30, 46, and 53% identity, respectively. We have examined the functional differences between plant eIF4G proteins, referred to as eIF4G and eIFiso4G, when present as subunits of eIF4F and eIFiso4F, respectively. The degree to which a 5'-cap stimulated translation was inversely correlated with the concentration of eIF4F or eIFiso4F and required the poly(A)-binding protein for optimal function. Although eIF4F and eIFiso4F directed translation of unstructured mRNAs, eIF4F supported translation of an mRNA containing 5'-proximal secondary structure substantially better than did eIFiso4F. Moreover, eIF4F stimulated translation from uncapped monocistronic or dicistronic mRNAs to a greater extent than did eIFiso4F. These data suggest that at least some functions of plant eIFiso4F and eIF4F have diverged in that eIFiso4F promotes translation preferentially from unstructured mRNAs, whereas eIF4F can promote translation also from mRNAs that contain a structured 5'-leader and that are uncapped or contain multiple cistrons. This ability may also enable eIF4F to promote translation from standard mRNAs under cellular conditions in which cap-dependent translation is inhibited.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of California System; University of California Riverside; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Gallie, DR (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	drgallie@citrus.ucr.edu						ABRAMSON RD, 1988, J BIOL CHEM, V263, P5462; ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; BROWNING KS, 1987, J BIOL CHEM, V262, P538; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P1624, DOI 10.1021/bi00220a026; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P4542, DOI 10.1021/bi00232a025; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; FLETCHER L, 1990, J BIOL CHEM, V265, P19582; Fraser CS, 1999, J BIOL CHEM, V274, P196, DOI 10.1074/jbc.274.1.196; GALLIE DR, 1995, PLANT PHYSIOL, V108, P1703, DOI 10.1104/pp.108.4.1703; Gallie DR, 2000, NUCLEIC ACIDS RES, V28, P2943, DOI 10.1093/nar/28.15.2943; Gallie DR, 1998, PLANT J, V14, P715, DOI 10.1046/j.1365-313x.1998.00175.x; Gallie DR, 1997, J BIOL CHEM, V272, P1046, DOI 10.1074/jbc.272.2.1046; Goldstaub D, 2000, MOL CELL BIOL, V20, P1271, DOI 10.1128/MCB.20.4.1271-1277.2000; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; Korneeva NL, 2000, J BIOL CHEM, V275, P41369, DOI 10.1074/jbc.M007525200; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LAX SR, 1986, METHOD ENZYMOL, V118, P109; LAX SR, 1986, J BIOL CHEM, V261, P5632; Le H, 2000, J BIOL CHEM, V275, P17452, DOI 10.1074/jbc.M001186200; Le H, 1997, EUR J BIOCHEM, V243, P350, DOI 10.1111/j.1432-1033.1997.0350a.x; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; MADER S, 1995, MOL CELL BIOL, V15, P4990; Metz AM, 1996, J BIOL CHEM, V271, P31033, DOI 10.1074/jbc.271.49.31033; Neff CL, 1999, MOL CELL BIOL, V19, P5557; Niepel M, 1999, FEBS LETT, V462, P79, DOI 10.1016/S0014-5793(99)01514-8; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; RAY BK, 1985, J BIOL CHEM, V260, P7651; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Svitkin YV, 2001, RNA, V7, P1743; Svitkin YV, 1999, J VIROL, V73, P3467, DOI 10.1128/JVI.73.4.3467-3472.1999; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	61	111	116	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36951	36960		10.1074/jbc.M103869200	http://dx.doi.org/10.1074/jbc.M103869200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11483601	hybrid			2022-12-25	WOS:000171375700015
J	Pirkl, F; Fischer, E; Modrow, S; Buchner, J				Pirkl, F; Fischer, E; Modrow, S; Buchner, J			Localization of the chaperone domain of FKBP52	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; PROGESTERONE-RECEPTOR COMPLEXES; PROLYL CIS/TRANS ISOMERASES; BINDING-PROTEIN; 59-KILODALTON PROTEIN; TRIGGER FACTOR; HSP90 BINDING; IMMUNOPHILIN; CATALYSIS; SITE	FKBP52, a multidomain peptidyl prolyl cis/trans-isomerase (PPIase), is found in complex with the chaperone Hsp90 and the co-chaperone p23. It displays both PPIase and chaperone activity in vitro. To localize these two activities to specific regions of the protein, we created and analyzed a set of fragments of FKBP52. The PPIase activity toward both peptides and proteins is confined entirely to domain 1 (amino acids 1-148). The chaperone activity, however, resides in the C-terminal part of FKBP52, mainly in the region between amino acids 264 and 400 (domain 3). Interestingly, this domain also contains the tetratricopeptide repeats, which are responsible for the binding to C-terminal amino acids of Hsp90. Competition assays with a C-terminal Hsp90 peptide suggest that the non-native protein and Hsp90 are bound by different regions within this domain.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Univ Klinikum Regensburg, Inst Med Mikrobiol & Hyg, D-93042 Regensburg, Germany	Technical University of Munich; University of Regensburg	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany.		Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; ATHERTON E, 1978, J CHEM SOC CHEM COMM, P537, DOI 10.1039/c39780000537; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; Brix J, 2000, J MOL BIOL, V303, P479, DOI 10.1006/jmbi.2000.4120; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; CHAMBRAUD B, 1993, BIOCHEM BIOPH RES CO, V196, P160, DOI 10.1006/bbrc.1993.2229; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Furutani M, 2000, BIOCHEMISTRY-US, V39, P453, DOI 10.1021/bi9911076; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P761; HOFFMANN K, 1995, BIOCHEM J, V307, P5, DOI 10.1042/bj3070005; Horowitz P M, 1995, Methods Mol Biol, V40, P361; Janowski B, 1997, ANAL BIOCHEM, V252, P299, DOI 10.1006/abio.1997.2330; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; MASSOL N, 1992, BIOCHEM BIOPH RES CO, V187, P1330, DOI 10.1016/0006-291X(92)90448-T; MUCKE M, 1994, J MOL BIOL, V239, P713, DOI 10.1006/jmbi.1994.1408; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; Pierce MM, 1999, METHODS, V19, P213, DOI 10.1006/meth.1999.0852; Pirkl F, 2001, J MOL BIOL, V308, P795, DOI 10.1006/jmbi.2001.4595; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; Scholz C, 1997, J MOL BIOL, V273, P752, DOI 10.1006/jmbi.1997.1301; Scholz C, 1997, FEBS LETT, V414, P69, DOI 10.1016/S0014-5793(97)00979-4; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Smith DF, 1998, BIOL CHEM, V379, P283; SMITH DF, 1990, J BIOL CHEM, V265, P3996; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YEM AW, 1993, BIOCHEMISTRY-US, V32, P12571, DOI 10.1021/bi00210a004; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Zarnt T, 1997, J MOL BIOL, V271, P827, DOI 10.1006/jmbi.1997.1206	58	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37034	37041		10.1074/jbc.M102595200	http://dx.doi.org/10.1074/jbc.M102595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11473108	hybrid			2022-12-25	WOS:000171375700025
J	Bastin-Shanower, SA; Brill, SJ				Bastin-Shanower, SA; Brill, SJ			Functional analysis of the four DNA binding domains of replication protein A - The role of RPA2 in ssDNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; NUCLEOTIDE EXCISION-REPAIR; POLYMERASE-ALPHA PRIMASE; SIMIAN VIRUS-40 DNA; SACCHAROMYCES-CEREVISIAE; 70-KDA SUBUNIT; COMPLEX-FORMATION; FACTOR-A; YEAST; INVITRO	Replication Protein A (RPA), the heterotrimeric single-stranded DNA (ssDNA)-binding protein of eukaryotes, contains four ssDNA binding domains (DBDs) within its two largest subunits, RPA1 and RPA2. We analyzed the contribution of the four DBDs to ssDNA binding affinity by assaying recombinant yeast RPA in which a single DBD (A, B, C, or D) was inactive. Inactivation was accomplished by mutating the two conserved aromatic stacking residues present in each DBD. Mutation of domain A had the most severe effect and eliminated binding to a short substrate such as (dT)12. RPA containing mutations in DBDs B and C bound to substrates (dT)12,17, and 23 but with reduced affinity compared with wild type RPA. Mutation of DBD-D had little or no effect on the binding of RPA to these substrates. However, mutations in domain D did affect the binding to oligonucleotides larger than 23 nucleotides (nt). Protein-DNA cross-linking indicated that DBD-A (in RPA1) is essential for RPA1 to interact efficiently with substrates of 12 nt or less and that DBD-D (RPA2) interacts efficiently with oligonucleotides of 27 nt or larger. The data support a sequential model of binding in which DBD-A is responsible for the initial interaction with ssDNA, that domains A, B, and C (RPA1) contact 12-23 nt of ssDNA, and that DBD-D (RPA2) is needed for RPA to interact with substrates that are 23-27 nt in length.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Brill, SJ (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA.	brill@mbcl.rutgers.edu			NIGMS NIH HHS [R01 GM055583, R01 GM055583-03, GM55583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055583] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; ATRAZHEV A, 1992, EUR J BIOCHEM, V210, P855, DOI 10.1111/j.1432-1033.1992.tb17489.x; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 2001, EMBO J, V20, P612, DOI 10.1093/emboj/20.3.612; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; Bochkareva E, 2000, J BIOL CHEM, V275, P27332; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; Brill SJ, 1998, MOL CELL BIOL, V18, P7225, DOI 10.1128/MCB.18.12.7225; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P10558, DOI 10.1021/bi9607517; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; Ikegami T, 1998, NAT STRUCT BIOL, V5, P701, DOI 10.1038/1400; Jacobs DM, 1999, J BIOMOL NMR, V14, P321, DOI 10.1023/A:1008373009786; KENNY MK, 1990, J BIOL CHEM, V265, P769; KIM C, 1995, BIOCHEMISTRY-US, V34, P2058, DOI 10.1021/bi00006a028; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; Kim HS, 2001, MOL CELL BIOL, V21, P3725, DOI 10.1128/MCB.21.11.3725-3737.2001; Lavrik OI, 1999, NUCLEIC ACIDS RES, V27, P4235, DOI 10.1093/nar/27.21.4235; Mass G, 1998, MOL CELL BIOL, V18, P6399, DOI 10.1128/MCB.18.11.6399; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Walther AP, 1999, BIOCHEMISTRY-US, V38, P3963, DOI 10.1021/bi982370u; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	45	98	99	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36446	36453		10.1074/jbc.M104386200	http://dx.doi.org/10.1074/jbc.M104386200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11479296	Green Accepted, hybrid			2022-12-25	WOS:000171194500054
J	Buratti, E; Baralle, FE				Buratti, E; Baralle, FE			Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROSIS TRANSMEMBRANE CONDUCTANCE; PARTIAL PENETRANCE; CRYSTAL-STRUCTURE; TELOMERIC DNA; HNRNP A1; PROTEIN; RECOGNITION; DOMAINS; REPEATS; RIBONUCLEOPROTEIN	Variations in a polymorphic (TG)m sequence near exon 9 of the human CFTR gene have been associated with variable proportions of exon skipping and occurrence of disease. We have recently identified nuclear factor TDP-43 as a novel splicing regulator capable of binding to this element in the CFTR pre-mRNA and inhibiting recognition of the neighboring exon. In this study we report the dissection of the RNA binding properties of TDP-43 and their functional implications in relationship with the splicing process. Our results show that this protein contains two fully functional RNA recognition motif (RRM) domains with distinct RNA/DNA binding characteristics. Interestingly, TDP-43 can bind a minimum number of six UG (or TG) single-stranded dinucleotide stretches, and binding affinity increases with the number of repeats. In particular, the highly conserved Phe residues in the first RRM region play a key role in nucleic acid recognition.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Baralle, FE (corresponding author), Padriciano 99, I-34012 Trieste, Italy.	baralle@icgeb.trieste.it	Buratti, Emanuele/K-4691-2016	Buratti, Emanuele/0000-0002-1356-9074; Baralle, Francisco/0000-0002-4645-2809	Telethon [E.1038] Funding Source: Medline	Telethon(Fondazione Telethon)		AbdulManan N, 1996, NUCLEIC ACIDS RES, V24, P4063, DOI 10.1093/nar/24.20.4063; ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; BIAMONTI G, 1994, FEBS LETT, V340, P1, DOI 10.1016/0014-5793(94)80162-2; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Buratti E, 2001, EMBO J, V20, P1774, DOI 10.1093/emboj/20.7.1774; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BUVOLI M, 1990, NUCLEIC ACIDS RES, V18, P6595, DOI 10.1093/nar/18.22.6595; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; Csink AK, 1998, TRENDS GENET, V14, P200, DOI 10.1016/S0168-9525(98)01444-9; Cuppens H, 1998, J CLIN INVEST, V101, P487, DOI 10.1172/JCI639; Dallaire F, 2000, J BIOL CHEM, V275, P14509, DOI 10.1074/jbc.275.19.14509; DELANEY SJ, 1993, NAT GENET, V4, P426, DOI 10.1038/ng0893-426; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Gabellini N, 2001, EUR J BIOCHEM, V268, P1076, DOI 10.1046/j.1432-1327.2001.01974.x; Gendrel CG, 2000, GENE DEV, V14, P1261; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; IGNATIUS SH, 1995, J VIROL, V69, P3584, DOI 10.1128/JVI.69.6.3584-3596.1995; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; Johnston SD, 1999, MOL CELL BIOL, V19, P923; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; Lukacsovich T, 1999, GENOMICS, V57, P43, DOI 10.1006/geno.1999.5746; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Majewski J, 2000, GENOME RES, V10, P1108, DOI 10.1101/gr.10.8.1108; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Niksic M, 1999, HUM MOL GENET, V8, P2339, DOI 10.1093/hmg/8.13.2339; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pagani F, 2000, J BIOL CHEM, V275, P21041, DOI 10.1074/jbc.M910165199; RaveHarel N, 1997, AM J HUM GENET, V60, P87; REDMAN JB, 1993, JAMA-J AM MED ASSOC, V269, P1960, DOI 10.1001/jama.269.15.1960; Rozmahel R, 1997, GENOMICS, V45, P554, DOI 10.1006/geno.1997.4968; Serin G, 1997, J BIOL CHEM, V272, P13109, DOI 10.1074/jbc.272.20.13109; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SHELLEY CS, 1987, NUCLEIC ACIDS RES, V15, P3787, DOI 10.1093/nar/15.9.3787; STRONG TV, 1993, HUM MOL GENET, V2, P225, DOI 10.1093/hmg/2.3.225; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; Takahashi N, 2000, BIOCHEM BIOPH RES CO, V277, P518, DOI 10.1006/bbrc.2000.3694; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	49	471	480	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36337	36343		10.1074/jbc.M104236200	http://dx.doi.org/10.1074/jbc.M104236200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11470789	hybrid			2022-12-25	WOS:000171194500039
J	Charette, SJ; Lambert, H; Landry, J				Charette, SJ; Lambert, H; Landry, J			A kinase-independent function of Ask1 in caspase-independent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CYTOCHROME-C; APOPTOSIS; ACTIVATION; DAXX; MITOCHONDRIA; BCL-2; PHOSPHORYLATES; INHIBITION; RELEASE	Ask1 ((a) under bar poptosis (s) under bar ignal-regulating (k) under bar inase (1) under bar) is activated as a consequence of cell exposure to a variety of stresses and can then initiate apoptosis. A known pathway of apoptosis downstream of Ask1 involves the activation of the stress-activated protein kinases, the release of cytochrome c from mitochondria, the activation of caspases, and the fragmentation of nuclei. Here, we characterized a novel mechanism of Ask1-mediated cell killing that is triggered by the interaction with Daxx. Co-transfection of Ask1 and Daxx induced a caspase-independent cell-death process characterized at the morphological level by distinctive crumpled nuclei easily distinguishable from the condensed and fragmented nuclei seen during classical caspase-dependent apoptosis. The kinase activity of Ask1 was not involved in this process, because mutants lacking kinase activity were as efficient as wild type Ask1 in mediating Daxx-induced cell death. Ask1N, a deletant that lacks the C-terminal half including the kinase domain of Ask1, was constitutively active in producing crumpled nuclei. In contrast, Ask1 DeltaN, the reciprocal deletant that possesses constitutive kinase activity, produced fragmented nuclei typical of caspase-dependent death processes. We conclude that in addition to a caspase-dependent proapoptotic function that depends on its kinase activity, Ask1 possesses a caspase-independent killing function that is independent on its kinase activity and is activable by interaction with Daxx. In the physiological situation, such an activity is induced as a consequence of the translocation of Daxx from the nucleus to the cytoplasm, a condition that occurs following activation of the death receptor Fas.	Univ Laval, Hotel Dieu, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada	Laval University	Landry, J (corresponding author), Univ Laval, Hotel Dieu, Ctr Rech Cancerol, 9 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	jacques.landry@med.ulaval.ca	Charette, Steve/GYJ-3058-2022					Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Charette SJ, 2000, ANN NY ACAD SCI, V926, P126; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; Everett RD, 1999, J CELL SCI, V112, P3443; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Hayashi S, 1999, GENES CELLS, V4, P111, DOI 10.1046/j.1365-2443.1999.00243.x; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Ko YG, 2001, J BIOL CHEM, V276, P6030, DOI 10.1074/jbc.M006189200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Mochida Y, 2000, J BIOL CHEM, V275, P32747, DOI 10.1074/jbc.M003042200; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Noguchi K, 2001, BIOCHEM BIOPH RES CO, V281, P1313, DOI 10.1006/bbrc.2001.4498; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wang XHS, 1996, J BIOL CHEM, V271, P31607; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	36	50	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36071	36074		10.1074/jbc.C100340200	http://dx.doi.org/10.1074/jbc.C100340200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11493600	hybrid			2022-12-25	WOS:000171194500004
J	Dabbeni-Sala, F; Floreani, M; Franceschini, D; Skaper, SD; Giusti, P				Dabbeni-Sala, F; Floreani, M; Franceschini, D; Skaper, SD; Giusti, P			Kainic acid induces selective mitochondrial oxidative phosphorylation enzyme dysfunction in cerebellar granule neurons: protective effects of melatonin and GSH ethyl ester	FASEB JOURNAL			English	Article						neurotoxicity; mitochondrial respiratory chain; complex II; BN-PAGE analysis	KAINATE-INDUCED EXCITOTOXICITY; BLUE-NATIVE-ELECTROPHORESIS; ELECTRON-TRANSPORT CHAIN; METHYL-D-ASPARTATE; PARKINSONS-DISEASE; RESPIRATORY-CHAIN; PRIMARY CULTURES; NITRIC-OXIDE; IN-VITRO; GLUTATHIONE DEPLETION	Kainic acid (KA), a potent central excitotoxin, may elicit neuronal death via generation of reactive oxygen species (ROS). The present study was undertaken to further characterize KA neurotoxicity and its relationship to ROS production and mitochondrial dysfunction. Exposure of rat cerebellar granule neurons at 14 days in vitro to 0.5 mM KA for 30 min resulted in the death of 53% of cells 24 h later. ROS production, evaluated by 2',7'-dichlorofluorescein diacetate, increased in KA-treated granule neurons. Resolution of mitochondrial oxidative phosphorylation enzymes by blue native polyacrylamide gel electrophoresis, followed by histochemical staining, showed that KA induced a strong decrease (-40%, P< 0.01) in succinate dehydrogenase (SDH) activity of complex II. Western analysis revealed a marked reduction in quantity of the catalytic portion of complex II enzyme in KA-treated cells. No significant changes were observed in the activities of other mitochondrial complex enzymes. The actions of KA at the mitochondrial level, as well as on ROS generation and cell viability, were prevented by the KA receptor-selective antagonist 6,7-dinitroquinoxaline-2,3(1H, 4H)-dione. Pretreatment of granule neurons with melatonin, a direct scavenger of ROS, or with the reduced glutathione (GSH) delivery agent GSH ethyl ester, before KA challenge prevented both the decrease in cell viability and complex II damage. The last result supports a link between KA-induced mitochondrial oxidative enzyme dysfunction and ROS generation. Together the results suggest mitochondria to be a critical target in KA injury to neurons.	Univ Padua, Dept Pharmacol, I-35131 Padua, Italy; SmithKline Beecham Pharmaceut, Dept Neurosci Res, Harlow CM19 5AW, Essex, England	University of Padua; GlaxoSmithKline	Giusti, P (corresponding author), Univ Padua, Dept Pharmacol, Largo E Meneghetti 2, I-35131 Padua, Italy.	giusti@ux1.unipd.it		GIUSTi, Pietro/0000-0001-9352-4046				Absi E, 2000, J PINEAL RES, V29, P40, DOI 10.1034/j.1600-079X.2000.290106.x; Ackrell BAC, 2000, FEBS LETT, V466, P1, DOI 10.1016/S0014-5793(99)01749-4; Atlante A, 1999, J NEUROCHEM, V73, P237, DOI 10.1046/j.1471-4159.1999.0730237.x; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIDGES RJ, 1991, EUR J PHARMACOL, V192, P199, DOI 10.1016/0014-2999(91)90093-6; Carriedo SG, 2000, J NEUROSCI, V20, P240, DOI 10.1523/JNEUROSCI.20-01-00240.2000; Carriedo SG, 1998, J NEUROSCI, V18, P7727; Ceccon M, 2000, BRAIN RES, V862, P83, DOI 10.1016/S0006-8993(00)02074-6; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; COYLE JT, 1978, J COMP NEUROL, V180, P301, DOI 10.1002/cne.901800208; DYKENS JA, 1987, J NEUROCHEM, V49, P1222, DOI 10.1111/j.1471-4159.1987.tb10014.x; DYKENS JA, 1994, J NEUROCHEM, V63, P584; Floreani M, 1997, FASEB J, V11, P1309, DOI 10.1096/fasebj.11.14.9409550; Floreani M, 1997, FREE RADICAL RES, V26, P449, DOI 10.3109/10715769709084481; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; Giusti P, 1996, J PINEAL RES, V20, P226, DOI 10.1111/j.1600-079X.1996.tb00263.x; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Heales SJR, 1996, NEUROCHEM RES, V21, P35, DOI 10.1007/BF02527669; Hoyt KR, 1998, J PHYSIOL-LONDON, V509, P103, DOI 10.1111/j.1469-7793.1998.103bo.x; Kaal ECA, 2000, J NEUROCHEM, V74, P1158; KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martin M, 2000, J PINEAL RES, V28, P242, DOI 10.1034/j.1600-079X.2000.280407.x; MEISTER A, 1994, J BIOL CHEM, V269, P9397; Merad-Boudia M, 1998, BIOCHEM PHARMACOL, V56, P645, DOI 10.1016/S0006-2952(97)00647-3; MIZUI T, 1992, AM J PHYSIOL, V262, pH313, DOI 10.1152/ajpheart.1992.262.2.H313; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NADLER JV, 1980, J COMP NEUROL, V192, P333, DOI 10.1002/cne.901920209; NICOLETTI F, 1986, J NEUROSCI, V6, P1905; OLNEY JW, 1974, BRAIN RES, V77, P507, DOI 10.1016/0006-8993(74)90640-4; Pang Z, 1997, J NEUROSCI, V17, P3064; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; PATEL J, 1990, J NEUROCHEM, V55, P114, DOI 10.1111/j.1471-4159.1990.tb08828.x; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; PUTTFARCKEN PS, 1993, BRAIN RES, V624, P223, DOI 10.1016/0006-8993(93)90081-W; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; Schulz JB, 1996, J NEUROSCI, V16, P4696; Schulz JB, 1997, MOL CELL BIOCHEM, V174, P193, DOI 10.1023/A:1006852306789; Schulz JB, 1996, J NEUROCHEM, V67, P430; SHAPIRA AHV, 1999, BIOCHIM BIOPHYS ACTA, V1410, P159; SKAPER SD, 1990, METHODS NEUROSCIENCE, V2, P17; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; SUN AY, 1992, MOL CHEM NEUROPATHOL, V17, P51, DOI 10.1007/BF03159981; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131	54	29	29	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1786	+		10.1096/fj.00-0427fje	http://dx.doi.org/10.1096/fj.00-0427fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481230				2022-12-25	WOS:000169261200027
J	Soetens, O; De Craene, JO; Andre, B				Soetens, O; De Craene, JO; Andre, B			Ubiquitin is required for sorting to the vacuole of the yeast general amino acid permease, Gap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE PROTEINS; DOA4 DEUBIQUITINATING ENZYME; SACCHAROMYCES-CEREVISIAE; TRYPTOPHAN PERMEASE; URACIL PERMEASE; DOWN-REGULATION; FACTOR RECEPTOR; ENDOCYTOSIS; DEGRADATION; TRANSPORTER	In yeast, ubiquitin plays a central role in proteolysis of a multitude of proteins and serves also as a signal for endocytosis of many plasma membrane proteins. We showed previously that ubiquitination of the general amino acid permease (Gap1) is essential to its endocytosis followed by vacuolar degradation. These processes occur when NH4+, a preferential source of nitrogen, is added to cells growing on proline or urea, i.e. less favored nitrogen sources. In this study, we show that Gap1 is ubiquitinated on two lysine residues in the cytosolic N terminus (positions 9 and 16). A mutant Gap1 in which both lysines are mutated (Gap1(K9K16)) remains fully stable at the plasma membrane after NH4+ addition. Furthermore, each of the two lysines harbors a polyubiquitin chain in which ubiquitin is linked to the lysine 63 of the preceding ubiquitin. The Gap1(K9) and Gap1(K16) mutants, in which a single lysine is mutated, are downregulated in response to NH4+ although more slowly. In proline-grown cells lacking Npr1, a protein kinase involved in the control of Gap1 trafficking, newly synthesized Gap1 is sorted from the Golgi to the vacuole without passing through the plasma membrane (accompanying article, De Craene, J.-O., Soetens, O., and Andre, B. (2001) J. Biol. Chem. 276,43939-43948). We show here that ubiquitination of Gap1 is also required for this direct sorting to the vacuole. In an npr1 Delta mutant, neo-synthesized Gap1(K9K16) is rerouted to and accumulates at the plasma membrane. Finally, Bu11 and Bu12, two proteins interacting with Npil/Rsp5, are essential to ubiquitination and down-regulation of cell-surface Gap1, as well as to sorting of neosynthesized Gap1 to the vacuole, as occurs in an npr1 Delta mutant. Our results reveal a novel role of ubiquitin in the control of Gap1 trafficking, i.e. direct sorting from the late secretory pathway to the vacuole. This result reinforces the growing evidence that ubiquitin plays an important role not only in internalization of plasma membrane proteins but also in their sorting in the endosomes and/or trans-Golgi.	Free Univ Brussels, Inst Biol & Med Mol, Lab Physiol Cellulaire, B-6041 Gosselies, Belgium		Andre, B (corresponding author), Free Univ Brussels, Inst Biol & Med Mol, Lab Physiol Cellulaire, CP300,12 Rue Professeurs Jeneer & Brachet, B-6041 Gosselies, Belgium.		De Craene, Johan-Owen/J-6461-2019; André, Bruno/D-1725-2010	De Craene, Johan-Owen/0000-0001-9654-2143; 				Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BECHET J, 1970, EUR J BIOCHEM, V12, P31, DOI 10.1111/j.1432-1033.1970.tb00817.x; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; De Craene JO, 2001, J BIOL CHEM, V276, P43939, DOI 10.1074/jbc.M102944200; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gilstring CF, 2000, J BIOL CHEM, V275, P31488, DOI 10.1074/jbc.M005047200; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; GRENSON M, 1983, EUR J BIOCHEM, V133, P141, DOI 10.1111/j.1432-1033.1983.tb07439.x; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P339, DOI 10.1016/0304-4165(66)90388-6; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Hein C, 1997, MOL MICROBIOL, V24, P607, DOI 10.1046/j.1365-2958.1997.3771735.x; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Horak J, 1997, J BACTERIOL, V179, P1541, DOI 10.1128/jb.179.5.1541-1549.1997; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOBS P, 1980, J MOL BIOL, V139, P691, DOI 10.1016/0022-2836(80)90055-8; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li Y, 1999, MOL CELL BIOL, V19, P3588; Losko S, 2001, MOL BIOL CELL, V12, P1047, DOI 10.1091/mbc.12.4.1047; Marchal C, 2000, J BIOL CHEM, V275, P23608, DOI 10.1074/jbc.M001735200; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Ponting CP, 1997, J MOL MED-JMM, V75, P467; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Springael JY, 1999, BIOCHEM BIOPH RES CO, V257, P561, DOI 10.1006/bbrc.1999.0505; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Springael JY, 1999, J CELL SCI, V112, P1375; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Yashiroda H, 1998, GENE, V225, P39, DOI 10.1016/S0378-1119(98)00535-6; Yashiroda H, 1996, MOL CELL BIOL, V16, P3255	54	197	203	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43949	43957		10.1074/jbc.M102945200	http://dx.doi.org/10.1074/jbc.M102945200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11500494	Green Published, hybrid			2022-12-25	WOS:000172297700062
J	Kearns, AE; Donohue, MM; Sanyal, B; Demay, MB				Kearns, AE; Donohue, MM; Sanyal, B; Demay, MB			Cloning and characterization of a novel protein kinase that impairs osteoblast differentiation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; GROWTH-FACTOR RECEPTOR-2; IN-VITRO; CLEIDOCRANIAL DYSPLASIA; TRANSCRIPTION FACTOR; EXPRESSION; GENE; CELLS; FIBROBLAST; CBFA1	The bone morphogenic proteins (BMPs) play a key role in skeletal development and patterning. Using the technique of differential display polymerase chain reaction (ddPCR), we have identified a novel gene whose expression is increased during BMP-2-induced differentiation of the prechondroblastic cell line, MLB13MYC clone 17, to an osteoblastic phenotype. The 6.5-kilobase mRNA recognized by this ddPCR product is increased 10-fold by BMP-2 treatment of the MLB13MYC clone 17 cells. The mRNA recognized by this ddPCR product is also increased as MC3T3-E1 cells recapitulate the program of osteoblast differentiation during prolonged culture. The full-length transcript corresponding to this ddPCR product was cloned from a MLB13MYC clone 17 cell cDNA library. Analysis of the deduced amino acid sequence demonstrated that this gene encodes a novel 126-kDa putative serine/threonine protein kinase containing a nuclear localization signal. The kinase domain, expressed in Escherichia coli, is capable of autophosphorylation as well as phosphorylation of myelin basic protein. The gene was, therefore, named BIKe (BMP-2-Inducible Kinase). The BIKe nuclear localization signal is able to direct green fluorescent protein to the nucleus in transfected COS-7 cells. When stably expressed in MC3T3-E1 cells, BIKe significantly decreases alkaline phosphatase activity and osteocalcin mRNA levels and retards mineral deposition relative to vector control. This novel kinase, therefore, is likely to play an important regulatory role in attenuating the program of osteoblast differentiation.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02114 USA; Mayo Clin & Mayo Fdn, Div Endocrinol Diabet Metab & Nutr, Rochester, MN 55905 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Mayo Clinic	Demay, MB (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Wellman 503,50 Blossom St, Boston, MA 02114 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR045011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036597] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-45011] Funding Source: Medline; NIDDK NIH HHS [DK-36597] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson J, 1998, HUM MOL GENET, V7, P1475, DOI 10.1093/hmg/7.9.1475; Choundhury GG, 1999, J BIOL CHEM, V274, P10897; Das D, 2001, J BIOL CHEM, V276, P32597, DOI 10.1074/jbc.M011792200; Divieti P, 1998, J BONE MINER RES, V13, P1835, DOI 10.1359/jbmr.1998.13.12.1835; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; GINDLER EM, 1972, AM J CLIN PATHOL, V58, P376; Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; Kearns AE, 2000, J CELL BIOCHEM, V79, P80, DOI 10.1002/1097-4644(2000)79:1<80::AID-JCB80>3.0.CO;2-K; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Liu BY, 1998, ENDOCRINOLOGY, V139, P1952, DOI 10.1210/en.139.4.1952; MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322; Malaval L, 1999, J CELL BIOCHEM, V74, P616; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; Martin KM, 2000, BIOCHEM J, V345, P529, DOI 10.1042/0264-6021:3450529; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Michelitsch MD, 2000, P NATL ACAD SCI USA, V97, P11910, DOI 10.1073/pnas.97.22.11910; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; MonsoroBurq AH, 1996, DEVELOPMENT, V122, P3607; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; POCKWINSE SM, 1995, EXP CELL RES, V216, P244, DOI 10.1006/excr.1995.1031; QUARLES LD, 1991, ENDOCRINOLOGY, V128, P3144, DOI 10.1210/endo-128-6-3144; Reddi A. Hari, 1992, Current Opinion in Cell Biology, V4, P850; ReemKalma Y, 1995, P NATL ACAD SCI USA, V92, P12141, DOI 10.1073/pnas.92.26.12141; ROSEN V, 1994, J BONE MINER RES, V9, P1759; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Takazawa Y, 2000, J ENDOCRINOL, V165, P579, DOI 10.1677/joe.0.1650579; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7	38	42	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42213	42218		10.1074/jbc.M106163200	http://dx.doi.org/10.1074/jbc.M106163200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11500515	hybrid			2022-12-25	WOS:000172450400090
J	Andag, U; Neumann, T; Schmitt, HD				Andag, U; Neumann, T; Schmitt, HD			The coatomer-interacting protein Dsl1p is required for Golgi-to-endoplasmic reticulum retrieval in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DILYSINE-TAGGED PROTEINS; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; MEMBRANE-FUSION; SNARE PROTEINS; CIS-GOLGI; TRANSMEMBRANE PROTEINS; RETROGRADE TRANSPORT; VESICLE FORMATION; SYNTHETIC LETHAL	Sec22p is an endoplasmic reticulum (ER)-Golgi v-SNARE protein whose retrieval from the Golgi compartment to the endoplasmic reticulum (ER) is mediated by COPI vesicles. Whether Sec22p exhibits its primary role at the ER or the Golgi apparatus is still a matter of debate. To determine the role of Sec22p in intracellular transport more precisely, we performed a synthetic lethality screen. We isolated mutant yeast strains in which SEC22 gene function, which in a wild type strain background is non-essential for cell viability, has become essential. In this way a novel temperature-sensitive mutant allele, dsl1-22, of the essential gene DSL1 was obtained. The dsl1-22 mutation causes severe defects in Golgi-to-ER retrieval of ER-resident SNARE proteins and integral membrane proteins harboring a C-terminal KXXX retrieval motif, as well as of the soluble ER protein BiP/Kar2p, which utilizes the HDEL receptor, Erd2p, for its recycling to the ER. DSL1 interacts genetically with mutations that affect components of the Golgi-to-ER recycling machinery, namely sec20-1, tip20-5, and COPI-encoding genes. Furthermore, we demonstrate that Dsl1p is a peripheral membrane protein, which in vitro specifically binds to coatomer, the major component of the protein coat of COPI vesicles.	Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany	Max Planck Society	Schmitt, HD (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany.							Ballensiefen W, 1998, J CELL SCI, V111, P1507; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; BOECKE JD, 1984, MOL GEN GENET, V197, P345; BOEHM J, 1994, EMBO J, V13, P3696, DOI 10.1002/j.1460-2075.1994.tb06679.x; Boehm J, 1997, J CELL SCI, V110, P991; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Cosson P, 1997, EUR J CELL BIOL, V73, P93; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; De Antoni A, 2000, GENE, V246, P179, DOI 10.1016/S0378-1119(00)00083-4; Dogic D, 2001, EUR J CELL BIOL, V80, P151, DOI 10.1078/0171-9335-00145; DUDEN R, 1994, J BIOL CHEM, V269, P24486; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Entian KD, 1999, MOL GEN GENET, V262, P683, DOI 10.1007/PL00013817; EVAN GI, 1985, MOL CELL BIOL, P3610; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Frigerio G, 1998, YEAST, V14, P633, DOI 10.1002/(SICI)1097-0061(199805)14:7<633::AID-YEA267>3.0.CO;2-3; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; Gotte M, 1998, TRENDS CELL BIOL, V8, P215, DOI 10.1016/S0962-8924(98)01272-0; Gotte M, 1997, FEBS LETT, V411, P48, DOI 10.1016/S0014-5793(97)00575-9; Grote E, 2000, MOL BIOL CELL, V11, P4051, DOI 10.1091/mbc.11.12.4051; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HARDWICK KG, 1992, EMBO J, V11, P4187, DOI 10.1002/j.1460-2075.1992.tb05512.x; Hatsuzawa K, 2000, J BIOL CHEM, V275, P13713, DOI 10.1074/jbc.275.18.13713; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; MCNEW JA, 1997, J BIOL CHEM, V272, P1776; NEWMAN AP, 1992, MOL CELL BIOL, V12, P3663, DOI 10.1128/MCB.12.8.3663; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; NISHIKAWA S, 1994, MOL BIOL CELL, V5, P1129, DOI 10.1091/mbc.5.10.1129; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; Ossipov D, 1999, J CELL SCI, V112, P4135; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; Schroder-Kohne S, 1998, J CELL SCI, V111, P3459; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; Sherman F., 1981, METHODS YEAST GENETI; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; SWEET D, 1999, EMBO J, V11, P423; Todorow Z, 2000, P NATL ACAD SCI USA, V97, P13643, DOI 10.1073/pnas.250472397; Tsui MMK, 2001, MOL BIOL CELL, V12, P521, DOI 10.1091/mbc.12.3.521; VanRheenen SM, 1999, J CELL BIOL, V147, P729, DOI 10.1083/jcb.147.4.729; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; VanRheenen SM, 2001, TRAFFIC, V2, P212, DOI 10.1034/j.1600-0854.2001.020307.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Xu DL, 2000, J BIOL CHEM, V275, P39631, DOI 10.1074/jbc.M007684200; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	73	78	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39150	39160		10.1074/jbc.M105833200	http://dx.doi.org/10.1074/jbc.M105833200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11493604	Green Published, hybrid			2022-12-25	WOS:000171673200108
J	Gama, L; Wilt, SG; Breitwieser, GE				Gama, L; Wilt, SG; Breitwieser, GE			Heterodimerization of calcium sensing receptors with metabotropic glutamate receptors in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CA2+ RECEPTOR; EXTRACELLULAR CA2+-SENSING RECEPTOR; CELL-SURFACE EXPRESSION; N-LINKED GLYCOSYLATION; OUTWARD K+ CHANNEL; SYNAPTIC CLEFT; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; HETEROMERIC COMPLEXES; MUSCARINIC RECEPTORS	Calcium sensing (CaR) and Group I metabotropic glutamate receptors exhibit overlapping expression patterns in brain, and share common signal transduction pathways. To determine whether CaR and Group I metabotropic glutamate receptors (mGluRs) (mGluR1 alpha and mGluR5) can form heterodimers, we immunoprecipitated CaR from bovine brain and observed co-precipitation of mGluR1a. CaR and mGluR1 alpha co-localize in hippocampal and cerebellar neurons, but are expressed separately in other brain regions. In vitro transfection studies in HEK-293 cells established the specificity and disulfide-linked nature of the CaR:mGluR1 alpha (CaR: mGluR5) interactions. CaR:mGluR1 alpha (CaR:mGluR5) heterodimers exhibit altered trafficking via Homer 1c when compared with CaR:CaR homodimers. CaR becomes sensitive to glutamate-mediated internalization when present in CaR:mGluR1 alpha heterodimers. These results demonstrate cross-family covalent heterodimerization of CaR with Group I mGluRs, and increase the potential role(s) for CaR in modulating neuronal function.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Bronx Vet Affairs Med Ctr, Res Serv, Bronx, NY 10468 USA	Johns Hopkins University; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center	Breitwieser, GE (corresponding author), Syracuse Univ, Dept Biol, 122 Lyman Hall,108 Coll Pl, Syracuse, NY 13244 USA.		Centeno, Patricia Pacios/O-8368-2016	Breitwieser, Gerda/0000-0001-9081-0362; Gama, Lucio/0000-0001-9511-012X	NIGMS NIH HHS [GM58578] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058578] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; AVISSAR S, 1983, P NATL ACAD SCI-BIOL, V80, P156, DOI 10.1073/pnas.80.1.156; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; Borst JGG, 1999, J PHYSIOL-LONDON, V521, P123, DOI 10.1111/j.1469-7793.1999.00123.x; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brown EM, 2000, ANNU REV NUTR, V20, P507, DOI 10.1146/annurev.nutr.20.1.507; CATANIA MV, 1994, NEUROSCIENCE, V61, P481, DOI 10.1016/0306-4522(94)90428-6; Chattopadhyay N, 1999, GLIA, V26, P64, DOI 10.1002/(SICI)1098-1136(199903)26:1<64::AID-GLIA7>3.0.CO;2-X; Chattopadhyay N, 1997, DEV BRAIN RES, V100, P13, DOI 10.1016/S0165-3806(97)00009-6; Chattopadhyay N, 1998, GLIA, V24, P449, DOI 10.1002/(SICI)1098-1136(199812)24:4<449::AID-GLIA10>3.3.CO;2-0; Chattopadhyay N, 2000, INT J BIOCHEM CELL B, V32, P789, DOI 10.1016/S1357-2725(00)00031-5; Ciruela F, 2000, MOL CELL NEUROSCI, V15, P36, DOI 10.1006/mcne.1999.0808; Ciruela F, 2001, J BIOL CHEM, V276, P18345, DOI 10.1074/jbc.M006960200; Ciruela F, 1999, BIOCHEM J, V341, P795, DOI 10.1042/0264-6021:3410795; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; CONKLIN BR, 1994, NATURE, V367, P22, DOI 10.1038/367022a0; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; ENGELMAN DM, 1999, BIOPHYS J, V76, P1856; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; Ferraguti F, 1998, J COMP NEUROL, V400, P391; Ferry S, 2000, EUR J NEUROSCI, V12, P872, DOI 10.1046/j.1460-9568.2000.00980.x; FOTUHI M, 1994, MOL BRAIN RES, V21, P283, DOI 10.1016/0169-328X(94)90259-3; Gama L, 1999, BIOTECHNIQUES, V26, P814, DOI 10.2144/99265bm03; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Goldsmith PK, 1997, J BONE MINER RES, V12, P1780, DOI 10.1359/jbmr.1997.12.11.1780; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Hauache OM, 2000, ENDOCRINOLOGY, V141, P4156, DOI 10.1210/en.141.11.4156; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM J, V330, P287; Hu JX, 2000, J BIOL CHEM, V275, P16382, DOI 10.1074/jbc.M000277200; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kammermeier PJ, 2000, J NEUROSCI, V20, P7238; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; Kubokawa K, 1996, FEBS LETT, V392, P71, DOI 10.1016/0014-5793(96)00786-7; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Mitsuma T, 1999, Endocr Regul, V33, P55; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Nash MS, 2001, J BIOL CHEM, V276, P19286, DOI 10.1074/jbc.M007600200; Neto FL, 2000, MOL BRAIN RES, V81, P140; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; POTTER LT, 1991, MOL PHARMACOL, V39, P211; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Riccardi D, 1999, ARCH MED RES, V30, P436, DOI 10.1016/S0188-4409(99)00071-5; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rogers KV, 1997, BRAIN RES, V744, P47, DOI 10.1016/S0006-8993(96)01070-0; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Stanley EF, 2000, J NEUROPHYSIOL, V83, P477, DOI 10.1152/jn.2000.83.1.477; Stinehelfer S, 2000, BRAIN RES, V861, P37, DOI 10.1016/S0006-8993(00)01952-1; Tadokoro S, 1999, P NATL ACAD SCI USA, V96, P13801, DOI 10.1073/pnas.96.24.13801; Tallaksen-Greene SJ, 1998, BRAIN RES, V780, P210, DOI 10.1016/S0006-8993(97)01141-4; Tanaka J, 2000, EUR J NEUROSCI, V12, P781, DOI 10.1046/j.1460-9568.2000.00959.x; TESTA CM, 1995, J COMP NEUROL, V354, P241, DOI 10.1002/cne.903540207; Tsuji Y, 2000, J BIOL CHEM, V275, P28144; Vassilev PM, 1997, BIOPHYS J, V72, P2103, DOI 10.1016/S0006-3495(97)78853-2; VENTER JC, 1983, TRENDS PHARMACOL SCI, V4, P256; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Yamaguchi T, 2000, ADV PHARMACOL, V47, P209; Ye CP, 1996, BIOCHEM BIOPH RES CO, V224, P271, DOI 10.1006/bbrc.1996.1019; Ye CP, 1997, BRAIN RES BULL, V44, P75, DOI 10.1016/S0361-9230(97)00088-9	69	126	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39053	39059		10.1074/jbc.M105662200	http://dx.doi.org/10.1074/jbc.M105662200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489900	hybrid			2022-12-25	WOS:000171673200095
J	Marcello, A; Cinelli, RAG; Ferrari, A; Signorelli, A; Tyagi, M; Pellegrini, V; Beltram, F; Giacca, M				Marcello, A; Cinelli, RAG; Ferrari, A; Signorelli, A; Tyagi, M; Pellegrini, V; Beltram, F; Giacca, M			Visualization of in vivo direct interaction between HIV-1 TAT and human cyclin T1 in specific subcellular compartments by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FACTOR P-TEFB; PERIPHERAL-BLOOD LYMPHOCYTES; CARBOXY-TERMINAL DOMAIN; RNA-POLYMERASE-II; TYPE-1 TAT; FUNCTIONAL INTERACTION; SPLICING FACTOR; TRANSCRIPTION; PROTEIN	Human cyclin T1, a component of the P-TEFb kinase complex, was originally identified through its biochemical interaction with the Tat transactivator protein of human immunodeficiency virus type 1 (HIV-1). Current understanding suggests that binding of Tat to P-TEFb is required to promote efficient transcriptional elongation of viral RNAs. However, the dynamics and the subnuclear localization of this process are still largely unexplored in vivo. Here we exploit high resolution fluorescence resonance energy transfer (FRET) to visualize and quantitatively analyze the direct interaction between Tat and cyclin Tl inside the cells. We observed that cyclin TI resides in specific subnuclear foci which are in close contact with nuclear speckles and that Tat determines its redistribution outside of these compartments. Consistent with this observation, strong FRET was observed between the two proteins both in the cytoplasm and in regions of the nucleus outside of cyclin Tl foci and overlapping with Tat localization. These results are consistent with a model by which Tat recruits cyclin T1 outside of the nuclear compartments where the protein resides to promote transcriptional activation.	Int Ctr Genet Engn & Biotechnol, Mol Med Lab, I-34012 Trieste, Italy; INFM, NEST, I-56126 Pisa, Italy; Scuola Normale Super Pisa, I-56126 Pisa, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Scuola Normale Superiore di Pisa	Giacca, M (corresponding author), Int Ctr Genet Engn & Biotechnol, Mol Med Lab, Padriciano 99, I-34012 Trieste, Italy.	giacca@icgeb.trieste.it	Ferrari, Aldo/H-5209-2012; Giacca, Mauro/J-9287-2016; Beltram, Fabio/F-2920-2013; Beltram, Fabio/L-9486-2019	Giacca, Mauro/0000-0003-2927-7225; Beltram, Fabio/0000-0002-6081-436X; Beltram, Fabio/0000-0002-6081-436X				Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; CARROLL R, 1992, J VIROL, V66, P2000, DOI 10.1128/JVI.66.4.2000-2007.1992; Cinelli RAG, 2000, PHOTOCHEM PHOTOBIOL, V71, P771, DOI 10.1562/0031-8655(2000)071<0771:TEGFPA>2.0.CO;2; Cubitt AB, 1999, METHOD CELL BIOL, V58, P19; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; CULLEN BR, 1988, J VIROL, V62, P2498, DOI 10.1128/JVI.62.7.2498-2501.1988; Day RN, 1998, MOL ENDOCRINOL, V12, P1410, DOI 10.1210/me.12.9.1410; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; ECHETEBU CO, 1994, J ACQ IMMUN DEF SYND, V7, P655; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garber ME, 1999, CURR OPIN IMMUNOL, V11, P460, DOI 10.1016/S0952-7915(99)80077-6; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Garriga J, 1998, ONCOGENE, V17, P3093, DOI 10.1038/sj.onc.1202548; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Herrmann CH, 1998, J VIROL, V72, P9881, DOI 10.1128/JVI.72.12.9881-9888.1998; Herrmann CH, 2001, J CELL SCI, V114, P1491; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Ivanov D, 1999, J MOL BIOL, V288, P41, DOI 10.1006/jmbi.1999.2663; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Marcello A, 2001, IUBMB LIFE, V51, P175, DOI 10.1080/152165401753544241; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955-0674(98)80007-0; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Periasamy A, 1999, METHOD CELL BIOL, V58, P293; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Ramanathan Y, 1999, J VIROL, V73, P5448, DOI 10.1128/JVI.73.7.5448-5458.1999; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; Veschambre P, 1997, J GEN VIROL, V78, P2235, DOI 10.1099/0022-1317-78-9-2235; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693; WUBAER F, 1995, P NATL ACAD SCI USA, V92, P7153, DOI 10.1073/pnas.92.16.7153; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Zhang J, 2000, J BIOL CHEM, V275, P34314, DOI 10.1074/jbc.M006804200; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	51	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39220	39225		10.1074/jbc.M104830200	http://dx.doi.org/10.1074/jbc.M104830200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504720	hybrid			2022-12-25	WOS:000171673200117
J	Saiardi, A; Nagata, E; Luo, HR; Snowman, AM; Snyder, SH				Saiardi, A; Nagata, E; Luo, HR; Snowman, AM; Snyder, SH			Identification and characterization of a novel inositol hexakisphosphate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHOINOSITOL PENTAKISPHOSPHATE; IN-VITRO; CELLS; TETRAKISPHOSPHATE; POLYPHOSPHATES; PURIFICATION; INHIBITION; METABOLISM; PHOSPHATE; MESSENGER	The inositol pyrophosphate disphosphoinositol pentakisphosphate (PP-InsP(3)/InsP(7)) is formed in mammals by two recently cloned inositol hexakiphosphate kinases, InsP(6)K1 and InsP(6)K2 (Saiardi, A., Erdjument-Bromage, H., Snowman, A. M., Tempst, P., and Snyder, S. H. (1999) Curr. Biol. 9,1323-1326). We now report the identification, cloning, and characterization of a third InsP(7) forming enzyme designated InsP(6)K3. InsP(6)K3 displays 50 and 45% sequence identity to InsP(6)K1 and InsP(6)K2, respectively, with a smaller mass (46 kDa) and a more basic character than the other two enzymes. InsP(6)K3 is most enriched in the brain where its localization resembles InsP(6)K1 and InsP(6)K2. Intracellular disposition discriminates the three enzymes with InsP(6)K2 being exclusively nuclear, InsP(6)K3 predominating in the cytoplasm, and InsP(6)K1 displaying comparable nuclear and cytosolic densities.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.			Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00074] Funding Source: Medline; NIMH NIH HHS [MH18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; Bird GSJ, 1996, J BIOL CHEM, V271, P6766, DOI 10.1074/jbc.271.12.6766; Dewaste V, 2000, BIOCHEM J, V352, P343, DOI 10.1042/0264-6021:3520343; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; GAWLER DJ, 1990, BIOCHEM J, V272, P519, DOI 10.1042/bj2720519; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hermosura MC, 2000, NATURE, V408, P735, DOI 10.1038/35047115; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Ismailov II, 1996, P NATL ACAD SCI USA, V93, P10505, DOI 10.1073/pnas.93.19.10505; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Luo HR, 2001, NEURON, V31, P439, DOI 10.1016/S0896-6273(01)00384-1; Maniatis T., 1989, MOL CLONING LAB MANU; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; SHEARS SB, 1995, J BIOL CHEM, V270, P10489, DOI 10.1074/jbc.270.18.10489; SHEARS SB, 1997, SIGNALLING INOSITIDE, P33; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; Togashi S, 1997, BIOCHEM J, V326, P221, DOI 10.1042/bj3260221; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; Voglmaier SM, 1996, P NATL ACAD SCI USA, V93, P4305, DOI 10.1073/pnas.93.9.4305; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	29	107	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39179	39185		10.1074/jbc.M106842200	http://dx.doi.org/10.1074/jbc.M106842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11502751	hybrid			2022-12-25	WOS:000171673200111
J	Shenk, JL; Fisher, CJ; Chen, SY; Zhou, XF; Tillman, K; Shemshedini, L				Shenk, JL; Fisher, CJ; Chen, SY; Zhou, XF; Tillman, K; Shemshedini, L			p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TATA-BINDING PROTEIN; TUMOR-SUPPRESSOR P53; C-JUN; TRANSCRIPTIONAL ACTIVATION; RECEPTOR GENE; CANCER-CELLS; GLUCOCORTICOID RECEPTOR; FUNCTIONAL INTERACTIONS; DNA-BINDING	Prostate-specific antigen (PSA) is highly overexpressed in prostate cancer. One important regulator of PSA expression is the androgen receptor (AR), the nuclear receptor that mediates the biological actions of androgens. AR is able to up-regulate PSA expression by directly binding and activating the promoter of this gene. We provide evidence here that that this AR activity is repressed by the tumor suppressor protein p53. p53 appears to exert its inhibition of human AR (hAR) by disrupting its amino- to carboxyl-terminal (N-to-C) interaction, which is thought to be responsible for the homodimerization of this receptor. Consistent with this, p53 is also able to block hAR DNA binding in vitro. Our previous data have shown that c-Jun can mediate hAR transactivation, and this appears to result from a positive effect on hAR N-to-C interaction and DNA binding. Interestingly, c-Jun is able to relieve the negative effects of p53 on hAR transactivation, N-to-C interaction, and DNA binding, demonstrating antagonistic activities of these two proteins. Importantly, a p53 mutation found in metastatic prostate cancer severely disrupts the p53 negative activity on hAR, suggesting that the inability of p53 mutants to down-regulate hAR is, in part, responsible for the metastatic phenotype.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA	University System of Ohio; University of Toledo	Shemshedini, L (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.		CHEN, Shaoyong/ABF-3357-2021					Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Alen P, 1999, MOL CELL BIOL, V19, P6085; Bangma CH, 1999, SEMIN ONCOL, V26, P422; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Barthold JS, 2000, J UROLOGY, V164, P497, DOI 10.1016/S0022-5347(05)67411-3; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Bubulya A, 2000, ENDOCRINE, V13, P55, DOI 10.1385/ENDO:13:1:55; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Butz K, 1999, ONCOGENE, V18, P2381, DOI 10.1038/sj.onc.1202557; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Culig Z, 2000, MICROSC RES TECHNIQ, V51, P447; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; DINJENS WNM, 1994, INT J CANCER, V56, P630, DOI 10.1002/ijc.2910560504; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Eastham JA, 2000, J UROLOGY, V164, P814, DOI 10.1016/S0022-5347(05)67320-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.0.CO;2-A; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hardy DO, 1996, J CLIN ENDOCR METAB, V81, P4400, DOI 10.1210/jc.81.12.4400; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hong TM, 2001, J BIOL CHEM, V276, P1510, DOI 10.1074/jbc.M008231200; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; HUPP TR, 1994, CURR BIOL, V4, P864; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; ISAACS WB, 1991, CANCER RES, V51, P4716; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; Jenster G, 1999, SEMIN ONCOL, V26, P407; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; JUVEN T, 1993, ONCOGENE, V8, P3411; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kantoff P, 1998, BBA-REV CANCER, V1378, pC1; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kelly C, 1996, CHILD PSYCHOL PSYCHI, V1, P59; Ko SC, 1996, HUM GENE THER, V7, P1683, DOI 10.1089/hum.1996.7.14-1683; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang JY, 1999, PROSTATE, V38, P228; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIYASHITA T, 1995, CELL, V80, P293; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Park JJ, 2000, CANCER RES, V60, P5946; Perez-Stable CM, 2000, MOL CELL ENDOCRINOL, V167, P43, DOI 10.1016/S0303-7207(00)00300-2; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; SEMINTAL JA, 1991, J BIOL CHEM, V266, P510; Sengupta S, 2000, EMBO J, V19, P6051, DOI 10.1093/emboj/19.22.6051; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; THOLE HH, 1994, J STEROID BIOCHEM, V48, P463, DOI 10.1016/0960-0760(94)90194-5; THUMMEL C, 1995, CELL, V83, P571; TILLEY WD, 1990, CANCER RES, V50, P5382; Tillman K, 1998, ENDOCRINE, V9, P193, DOI 10.1385/ENDO:9:2:193; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wilson J D, 1981, Recent Prog Horm Res, V37, P1; Wise SC, 1998, ONCOGENE, V16, P2001, DOI 10.1038/sj.onc.1201697; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9	88	85	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38472	38479		10.1074/jbc.M103652200	http://dx.doi.org/10.1074/jbc.M103652200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504717	hybrid			2022-12-25	WOS:000171673200021
J	Sencer, S; Papineni, RVL; Halling, DB; Pate, P; Krol, J; Zhang, JZ; Hamilton, SL				Sencer, S; Papineni, RVL; Halling, DB; Pate, P; Krol, J; Zhang, JZ; Hamilton, SL			Coupling of RYR1 and L-type calcium channels via calmodulin binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; MUSCLE DIHYDROPYRIDINE RECEPTOR; SKELETAL-MUSCLE; RYANODINE RECEPTOR; INACTIVATION; PROTEINS; LOOP	In skeletal muscle the L-type Ca2+ channel directly controls the opening of the sarcoplasmic reticulum Ca2+ release channel (RYR1), and RYR1, in turn, prevents L-type Ca2+ channel inactivation. We demonstrate that the two proteins interact using calmodulin binding regions of both proteins. A recombinant protein representing amino acids 1393-1527 (D1393-1527) of the carboxyl-terminal tail of the skeletal muscle L-type voltage-dependent calcium channel binds Ca2+, Ca2+ calmodulin, and apocalmodulin. In the absence of calmodulin, D1393-1527 binds to both RYR1 and a peptide representing the calmodulin binding site of RYR1 (amino acids 3609-3643). In addition, biotinylated R3609-3643 peptide can be used with streptavidin beads to pull down [H-3]PN200-110-labeled L-type channels from detergent-solubilized transverse tubule membranes. The binding of the L-type channel carboxyl-terminal tail to the calmodulin binding site on RYR1 may stabilize the contact between the two proteins, provide a mechanism for Ca2+ and/or calmodulin regulation of their interaction, or participate directly in functional signaling between these two proteins. A unique aspect of this study is the finding that calmodulin binding sequences can serve as specific binding motifs for proteins other than calmodulin.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Baylor College of Medicine	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.			Hamilton, Susan/0000-0003-0241-9369				BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; FESSENDEN JD, 1999, BIOPHYS J, V76, P394; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Klinger M, 2001, BIOCHEM J, V355, P827, DOI 10.1042/bj3550827; KRETSINGER RH, 1976, ANNU REV BIOCHEM, V45, P239, DOI 10.1146/annurev.bi.45.070176.001323; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Moore CP, 1999, J BIOL CHEM, V274, P36831, DOI 10.1074/jbc.274.52.36831; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Romanin C, 2000, FEBS LETT, V487, P301, DOI 10.1016/S0014-5793(00)02361-9; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Slavik KJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1475, DOI 10.1152/ajpcell.1997.272.5.C1475; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017; Zhang JZ, 1999, AM J PHYSIOL-CELL PH, V276, pC46; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	27	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38237	38241						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11500484				2022-12-25	WOS:000171526500070
J	Bagowski, CP; Myers, JW; Ferrell, JE				Bagowski, CP; Myers, JW; Ferrell, JE			The classical progesterone receptor associates with p42 MAPK and is involved in phosphatidylinositol 3-kinase signaling in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MEIOTIC CELL-CYCLE; LAEVIS OOCYTES; ADENYLATE-CYCLASE; STEROID-HORMONE; PLASMA-MEMBRANE; MOUSE OOCYTES; IN-VITRO; GOOD EGG; MATURATION	The induction of Xenopus laevis oocyte maturation by progesterone is a striking example of a steroid hormone-mediated event that does not require transcription. Here we have investigated the role of the classical progesterone receptor in this nongenomic signaling. The Xenopus progesterone receptor (XPR) was predominantly cytoplasmic; however, a significant fraction (similar to5%) of one form of the receptor (p82 XPR) was associated with the plasma membrane-containing P-10,000 fraction, compatible with the observation that membrane-impermeant derivatives of progesterone can induce maturation. XPR co-precipitated with active phosphatidylinositol 3-kinase. The phosphatidylinositol 3-kinase (PI3-K) inhibitor wortmannin delayed progesterone-induced maturation and completely blocked the insulin-dependent maturation, indicating that the association of XPR with PI3-K could be functionally important. We also examined whether the nongenomic signaling properties of XPR can account for the ability of glucocorticoids and the progesterone antagonist RU486 to induce maturation. We found that none of these steroids cause XPR to become associated with active PI3-K; thus, association of XPR with active PI3-K is progesterone-specific. Finally, we showed that p42 mitogen-activated protein kinase (MAPK) associates with XPR after progesterone-induced germinal vesicle breakdown and that active recombinant MAPK is able to phosphorylate p110 XPR in vitro. These findings demonstrate that the classical progesterone receptor is involved in progesterone-induced nongenomic signaling in Xenopus oocytes and provide evidence that p42 MAPK and PI3-K activity are directly associated with the classical progesterone receptor.	Stanford Univ, Div Chem Biol, Stanford, CA 94305 USA	Stanford University	Ferrell, JE (corresponding author), Stanford Univ, Div Chem Biol, 269 W Campus Dr, Stanford, CA 94305 USA.	james.ferrell@stanford.edu			NIGMS NIH HHS [GM46383] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046383] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 2001, J CELL SCI, V114, P257; BAULIEU EE, 1978, NATURE, V275, P593, DOI 10.1038/275593a0; Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BLONDEAU JP, 1984, BIOCHEM J, V219, P785, DOI 10.1042/bj2190785; Byskov AG, 1999, J EXP ZOOL, V285, P237, DOI 10.1002/(SICI)1097-010X(19991015)285:3&lt;237::AID-JEZ6&gt;3.0.CO;2-S; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; DREYER C, 1987, DEVELOPMENT, V101, P829; Ferrell JE, 1999, BIOESSAYS, V21, P866, DOI 10.1002/(SICI)1521-1878(199910)21:10<866::AID-BIES9>3.0.CO;2-1; Ferrell JE, 1999, BIOESSAYS, V21, P833, DOI 10.1002/(SICI)1521-1878(199910)21:10<833::AID-BIES5>3.0.CO;2-P; FINIDORILEPICARD J, 1981, NATURE, V292, P255, DOI 10.1038/292255a0; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; GODEAU JF, 1978, P NATL ACAD SCI USA, V75, P2353, DOI 10.1073/pnas.75.5.2353; Grondahl C, 1998, BIOL REPROD, V58, P1297, DOI 10.1095/biolreprod58.5.1297; Hegele-Hartung C, 1999, BIOL REPROD, V61, P1362, DOI 10.1095/biolreprod61.5.1362; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; ISHIKAWA K, 1977, MOL CELL ENDOCRINOL, V9, P91, DOI 10.1016/0303-7207(77)90049-1; Iwashita J, 1998, P NATL ACAD SCI USA, V95, P4392, DOI 10.1073/pnas.95.8.4392; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Levin E R, 2000, Novartis Found Symp, V230, P41, DOI 10.1002/0470870818.ch5; LIU XJ, 1995, MOL CELL BIOL, V15, P3563; Maller JL, 1998, BIOL CELL, V90, P453, DOI 10.1016/S0248-4900(99)80003-3; Maller JL, 2001, P NATL ACAD SCI USA, V98, P8, DOI 10.1073/pnas.98.1.8; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Moore FL, 1999, BRAIN BEHAV EVOLUT, V54, P41, DOI 10.1159/000006610; Morrison T, 2000, ENDOCRINOLOGY, V141, P2145, DOI 10.1210/en.141.6.2145; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P6661, DOI 10.1128/MCB.13.11.6661; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Ruehlmann DO, 2000, CURR MED CHEM, V7, P533, DOI 10.2174/0929867003375038; SADLER SE, 1985, ADV CYCLIC NUCL PROT, V19, P179; SADLER SE, 1981, J BIOL CHEM, V256, P6368; Schmidt BMW, 2000, FRONT NEUROENDOCRIN, V21, P57, DOI 10.1006/frne.1999.0189; SCHUETZ AW, 1967, J EXP ZOOL, V166, P347, DOI 10.1002/jez.1401660307; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SMITH LD, 1969, DEV BIOL, V19, P281, DOI 10.1016/0012-1606(69)90065-7; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197	40	102	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37708	37714		10.1074/jbc.M104582200	http://dx.doi.org/10.1074/jbc.M104582200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479298	hybrid			2022-12-25	WOS:000171375700110
J	Dai, YS; Markham, BE				Dai, YS; Markham, BE			p300 functions as a coactivator of transcription factor GATA-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; HEAVY-CHAIN GENE; RNA-POLYMERASE-II; NATRIURETIC-FACTOR GENE; ACETYLTRANSFERASE ACTIVITY; HISTONE ACETYLATION; DNA-BINDING; ACTIVATES TRANSCRIPTION; CARDIAC-HYPERTROPHY; TERMINAL DOMAIN	Transcription factor GATA-4 plays critical roles in controlling heart development and cardiac hypertrophy. To understand how GATA-4 functions under diverse conditions, we sought to identify its coactivators. We tested p300 as a coactivator in GATA-4-dependent transient transcription assays in NIH3T3 cells and found that p300 synergistically activated GATA-4-dependent transcription on both synthetic and natural promoters. Direct physical interactions between the Nand C-zinc finger domains of GATA-4 and the cysteine/ histidine-rich region 3 (C/H3) of p300 were identified in immunoprecipitation and glutathione S-transferase pull-down experiments. Deletion of the C/H3 region of p300 abolished its coactivator activity indicating that the physical interaction was required for functional synergy. Through the use of a series of GATA-4 zinc ringer mutants, the amino acids WRR in the C finger were identified as critical to the interaction. The adenoviral E1A protein or a peptide encoding the C/H3 region of p300 could inhibit GATA-4-dependent transcription, presumably by competing for p300 binding. Furthermore, deletion of the region of p300 encoding the histone acetyltransferase activity abolished its effect on GATA-4-dependent transcriptional activity. These results establish that p300 acts as a GATA-4 coactivator and that the p300 histone acetyltransferase activity is necessary for the functional interaction.	Pfizer Global Res & Dev, Dept Mol Sci, Ann Arbor, MI 48105 USA	Pfizer	Markham, BE (corresponding author), Pfizer Global Res & Dev, Dept Mol Sci, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.			Dai, Yanshan/0000-0001-5048-7417				ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Bishopric NH, 1997, J BIOL CHEM, V272, P20584, DOI 10.1074/jbc.272.33.20584; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Charron F, 1999, MOL CELL BIOL, V19, P4355; Clerk A, 1999, AM J CARDIOL, V83, p64H; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; ECKNER R, 1994, COLD SPRING HARB SYM, V59, P85, DOI 10.1101/SQB.1994.059.01.012; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Grepin C, 1997, DEVELOPMENT, V124, P2387; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Hasegawa K, 1997, CIRCULATION, V96, P3943; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Molkentin JD, 1997, CIRCULATION, V96, P3833; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; Morimoto T, 1999, J BIOL CHEM, V274, P12811, DOI 10.1074/jbc.274.18.12811; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Partington GA, 1999, NUCLEIC ACIDS RES, V27, P1168, DOI 10.1093/nar/27.4.1168; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Slepak TI, 2001, J BIOL CHEM, V276, P7575, DOI 10.1074/jbc.M004625200; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Svensson EC, 2000, J BIOL CHEM, V275, P20762, DOI 10.1074/jbc.M001522200; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Wada H, 2000, J BIOL CHEM, V275, P25330, DOI 10.1074/jbc.M000828200; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zeng XY, 2001, J BIOL CHEM, V276, P48, DOI 10.1074/jbc.C000722200	61	130	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37178	37185		10.1074/jbc.M103731200	http://dx.doi.org/10.1074/jbc.M103731200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11481322	hybrid			2022-12-25	WOS:000171375700043
J	Klein, C; Georges, G; Kunkele, AP; Huber, R; Engh, RA; Hansen, S				Klein, C; Georges, G; Kunkele, AP; Huber, R; Engh, RA; Hansen, S			High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; MUTANT P53; WILD-TYPE; TETRAMERIZATION DOMAIN; QUANTITATIVE-ANALYSIS; P53-RELATED PROTEIN; GLOBULAR-PROTEINS; CRYSTAL-STRUCTURE; CANCER MUTATIONS; NEW-GENERATION	The p53 protein is the major tumor suppressor in mammals. The discovery of the p53 homologs p63 and p73 defined a family of p53 members with distinct roles in tumor suppression, differentiation, and development. Here, we describe the biochemical characterization of the core DNA-binding domain of a human isoform of p63, p63-delta, and particularly novel features in comparison with p53. In contrast to p53, the free p63 core domain did not show specific binding to p53 DNA consensus sites. However, glutathione S-transferase-fused and thus dimerized p63 and p53 core domains had similar affinity and specificity for the p53 consensus sites p21, gadd45, cyclin G, and bax. Furthermore, the fold of p63 core was remarkably stable compared with p53 as judged by differential scanning calorimetry (T-m = 61 degreesC versus 44 degreesC for p53) and equilibrium unfolding ([urea](50%) = 5.2 M versus 3.1 M for p53). A homology model of p63 core highlights differences at a segment near the H1 helix hypothetically involved in the formation of the dimerization interface in p53, which might reduce cooperativity of p63 core DNA binding compared with p53. The model also shows differences in the electrostatic and hydrophobic potentials of the domains relevant to folding stability.	Roche Diagnost GmbH, Pharma Res, D-82372 Penzberg, Germany; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany	Roche Holding; Max Planck Society	Klein, C (corresponding author), Roche Diagnost GmbH, Pharma Res, D-82372 Penzberg, Germany.		Klein, Christian/G-1336-2010	Klein, Christian/0000-0001-7594-7280; Engh, Richard/0000-0002-6207-0560				ALMOG N, 1998, BIOCHIM BIOPHYS ACTA, V1378, pF43; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Arrowsmith CH, 1996, ONCOGENE, V12, P1379; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GURUPRASAD K, 1990, PROTEIN ENG, V4, P155, DOI 10.1093/protein/4.2.155; Hansen S, 1996, J BIOL CHEM, V271, P3917; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IKAI A, 1980, J BIOCHEM-TOKYO, V88, P1895; Jaenicke R, 2000, J BIOTECHNOL, V79, P193, DOI 10.1016/S0168-1656(00)00236-4; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Levrero M, 2000, J CELL SCI, V113, P1661; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; Matsumura I, 1999, PROTEIN SCI, V8, P731; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Meplan C, 2000, BIOCHEM PHARMACOL, V59, P25, DOI 10.1016/S0006-2952(99)00297-X; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pace C N, 1986, Methods Enzymol, V131, P266; PAVIETICH NP, 1993, GENE DEV, V7, P2556; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; SALAMOV AA, 1995, J MOL BIOL, V247, P11, DOI 10.1006/jmbi.1994.0116; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Shimada A, 1999, CANCER RES, V59, P2781; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang WK, 2001, ACTA CRYSTALLOGR D, V57, P545, DOI 10.1107/S0907444901002529; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Xirodimas DP, 1999, J BIOL CHEM, V274, P28042, DOI 10.1074/jbc.274.39.28042; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao KH, 2001, J BIOL CHEM, V276, P12120, DOI 10.1074/jbc.M011644200; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 1998, CANCER RES, V58, P5061	93	66	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37390	37401		10.1074/jbc.M103801200	http://dx.doi.org/10.1074/jbc.M103801200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11477076	hybrid			2022-12-25	WOS:000171375700071
J	Kohn, AB; Anderson, PAV; Roberts-Misterly, JM; Greenberg, RM				Kohn, AB; Anderson, PAV; Roberts-Misterly, JM; Greenberg, RM			Schistosome calcium channel beta subunits - Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CLONING; JELLYFISH	Schistosomes are parasitic flatworms that cause schistosomiasis, a major tropical disease. The current drug of choice against schistosomiasis is praziquantel (PZQ), which has minimal side effects and is potent against all schistosome species. The mode of action of PZQ is unknown, though the drug clearly affects Ca2+ homeostasis in worms, and there is indirect evidence for interaction of PZQ with schistosome voltage-gated Ca2+ channels. We have cloned and expressed two Ca2+ channel beta subunits, one from Schistosoma mansoni and one from Schistosoma japonicum. These two subunits (SmCa(v)betaA and SjCa(v)beta) have structural motifs that differ from those found in other known beta subunits. Surprisingly, coexpression of either SmCa(v)betaA or SjCa(v)beta with a cnidarian (CyCa(v)1) or mammalian (Ca(v)2.3) Ca2+ channel a, subunit results in a striking reduction in current amplitude. In the case of Ca(v)2.3, this current reduction can be partially reversed by addition of 100 nm PZQ, which results in a significant increase in current amplitude. Thus, these unusual schistosome beta subunits can confer PZQ sensitivity to an otherwise PZQ-insensitive mammalian Ca2+ channel, indicating that a possible target for PZQ action is the interaction between beta subunits and pore-forming alpha (1) subunits in schistosomes.	Univ Florida, Whitney Lab, St Augustine, FL 32080 USA; Univ Florida, Dept Neurosci, St Augustine, FL 32080 USA; Univ Florida, Dept Physiol, St Augustine, FL 32080 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Greenberg, RM (corresponding author), Univ Florida, Whitney Lab, 9505 Ocean Shore Blvd, St Augustine, FL 32080 USA.				NIAID NIH HHS [AI 40522, R01 AI040522] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040522] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS P, 1985, PHARMACOL THERAPEUT, V29, P129, DOI 10.1016/0163-7258(85)90020-8; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Bourinet E, 1996, J NEUROSCI, V16, P4983; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; DAY TA, 1992, PARASITOL TODAY, V8, P342, DOI 10.1016/0169-4758(92)90070-I; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; GRABNER M, 1994, J BIOL CHEM, V269, P23668; Jeziorski MC, 2000, FEBS LETT, V483, P125, DOI 10.1016/S0014-5793(00)02098-6; Jeziorski MC, 1998, J BIOL CHEM, V273, P22792, DOI 10.1074/jbc.273.35.22792; Jeziorski MC, 1999, RECEPTOR CHANNEL, V6, P375; KOHN AB, 2001, IN PRESS PARASITOLOG; Redman CA, 1996, PARASITOL TODAY, V12, P14, DOI 10.1016/0169-4758(96)80640-5; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361	15	98	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36873	36876		10.1074/jbc.C100273200	http://dx.doi.org/10.1074/jbc.C100273200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11500482	hybrid			2022-12-25	WOS:000171375700004
J	Patel, U; Yan, YP; Hobbs, FW; Kaczmarczyk, J; Slee, AM; Pompliano, DL; Kurilla, MG; Bobkova, EV				Patel, U; Yan, YP; Hobbs, FW; Kaczmarczyk, J; Slee, AM; Pompliano, DL; Kurilla, MG; Bobkova, EV			Oxazolidinones mechanism of action: Inhibition of the first peptide bond formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; RIBOSOMAL-RNA; ANTIBACTERIAL AGENTS; A-SITE; INITIATION; BACTERIA; BINDING; SUBUNIT; INVITRO; TARGET	Oxazolidinones are potent inhibitors of bacterial protein biosynthesis. Previous studies have demonstrated that this new class of antimicrobial agent blocks translation by inhibiting initiation complex formation, while post-initiation translation by polysomes and poly(U)-dependent translation is not a target for these compounds. We found that oxazolidinones inhibit translation of natural mRNA templates but have no significant effect on poly(A)-dependent translation. Here we show that various oxazolidinones inhibit ribosomal peptidyltransferase activity in the simple reaction of 70 S ribosomes using initiator-tRNA or N-protected CCA-Phe as a P-site substrate and puromycin as an A-site substrate. Steady-state kinetic analysis shows that oxazolidinones display a competitive inhibition pattern with respect to both the P-site and A-site substrates. This is consistent with a rapid equilibrium, ordered mechanism of the peptidyltransferase reaction, wherein binding of the A-site substrate can occur only after complex formation between peptidyltransferase and the P-site substrate. We propose that oxazolidinones inhibit bacterial protein biosynthesis by interfering with the binding of initiator fMet-tRNA(i)(Met) to the ribosomal peptidyltransferase P-site, which is vacant only prior to the formation of the first peptide bond.	Dupont Merck Pharmaceut Co, Wilmington, DE 19880 USA	DuPont	Bobkova, EV (corresponding author), Dupont Merck Pharmaceut Co, POB 80400, Wilmington, DE 19880 USA.							Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BHUTA P, 1982, BIOCHIM BIOPHYS ACTA, V696, P208, DOI 10.1016/0167-4781(82)90030-6; BOBKOVA EV, 1999, RIBOSOME STRUCTURE F; BOMMER UA, 1997, SUBCELLULAR FRACTION, P287; BREMER H, 1996, ESCHERICHIA COLI SAL, P13; Brickner SJ, 1996, J MED CHEM, V39, P673, DOI 10.1021/jm9509556; BRUMFITT W, 1992, DIAGN MICR INFEC DIS, V15, P621, DOI 10.1016/0732-8893(90)90040-3; Burghardt H, 1998, FEBS LETT, V425, P40, DOI 10.1016/S0014-5793(98)00194-X; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; DUBNOFF JS, 1971, METHOD ENZYMOL, V20, P248; ELLMAN J, 1991, METHOD ENZYMOL, V2520, P302; EUSTICE DC, 1988, BIOCHEM BIOPH RES CO, V150, P965, DOI 10.1016/0006-291X(88)90723-1; EUSTICE DC, 1988, ANTIMICROB AGENTS CH, V32, P1218, DOI 10.1128/AAC.32.8.1218; FERNANDEZMUNOZ R, 1973, MOL BIOL REP, V1, P27, DOI 10.1007/BF00357402; FROMM HJ, 1995, METHOD ENZYMOL, V249, P123; Green R, 1998, SCIENCE, V280, P286, DOI 10.1126/science.280.5361.286; GREGORY WA, 1990, J MED CHEM, V33, P2569, DOI 10.1021/jm00171a035; HALL CC, 1992, J ANTIBIOT, V45, P1697, DOI 10.7164/antibiotics.45.1697; HOWE JG, 1983, J BIOL CHEM, V258, P1954; Kloss P, 1999, J MOL BIOL, V294, P93, DOI 10.1006/jmbi.1999.3247; KUKHANOVA M, 1979, FEBS LETT, V102, P198, DOI 10.1016/0014-5793(79)80959-X; Lin AH, 1997, ANTIMICROB AGENTS CH, V41, P2127, DOI 10.1128/AAC.41.10.2127; Matassova NB, 1999, RNA, V5, P939, DOI 10.1017/S1355838299990210; MILLS JA, 1999, RIBOSOME STRUCTURE F; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; PICKING WD, 1991, J BIOL CHEM, V266, P1534; Segel I. H., 1993, ENZYME KINETICS BEHA, P274; Shinabarger DL, 1997, ANTIMICROB AGENTS CH, V41, P2132, DOI 10.1128/AAC.41.10.2132; SLEE AM, 1987, ANTIMICROB AGENTS CH, V31, P1791, DOI 10.1128/AAC.31.11.1791; SPEDDING G, 1990, RIBOSOMES PROTEIN SY, P1; Swaney SM, 1998, ANTIMICROB AGENTS CH, V42, P3251, DOI 10.1128/AAC.42.12.3251; Tomsic J, 2000, EMBO J, V19, P2127, DOI 10.1093/emboj/19.9.2127	32	34	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37199	37205		10.1074/jbc.M102966200	http://dx.doi.org/10.1074/jbc.M102966200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11483595	hybrid			2022-12-25	WOS:000171375700046
J	Hara, I; Ueno, T; Ozaki, S; Itoh, S; Lee, K; Ueyama, N; Watanabe, Y				Hara, I; Ueno, T; Ozaki, S; Itoh, S; Lee, K; Ueyama, N; Watanabe, Y			Oxidative modification of tryptophan 43 in the heme vicinity of the F43W/H64L myoglobin mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLAMINE DEHYDROGENASE; CRYSTAL-STRUCTURE; PROSTHETIC GROUP; SPERM WHALE; COORDINATION; COFACTOR; TRYPTOPHYLQUINONE; SPECTROSCOPY; EPOXIDATION; RESOLUTION	The F43W/H64L myoglobin mutant was previously constructed to investigate the effects of electron-rich tryptophan residue in the heme vicinity on the catalysis, where we found that Trp-43 in the mutant was oxidatively modified in the reaction with m-chloroperbenzoic acid (mCPBA). To identify the exact structure of the modified tryptophan in this study, the mCPBA-treated F43W/H64L mutant has been digested stepwise with Lys-C achromobacter and trypsin to isolate two oxidation products by preparative fast protein liquid chromatography. The close examinations of the H-1 NMR spectra of peptide fragments reveal that two forms of the modified tryptophan must have 2,6-disubstituted indole substructures. The C-13 NMR analysis suggests that one of the modified tryptophan bears a unique hydroxyl group in stead of the NH2 group at the amino-terminal. The results together with mass spectrometry (MS)/MS analysis (30 Da increase in mass of Trp-43) indicate that oxidation products of Trp-43 are 2,6-dihydro-2,6-dioxoindole and 2,6-dihydro-2-imino-6-oxoindole derivatives. Our finding is the first example of the oxidation of aromatic carbons by the myoglobin mutant system.	Inst Mol Sci, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Dept Struct Mol Sci, Okazaki, Aichi 4448585, Japan; Ctr Integrat Biosci, Okazaki, Aichi 4448585, Japan; Yamagata Univ, Fac Educ, Yamagata 9908560, Japan; Osaka City Univ, Grad Sch Sci, Dept Chem, Sumiyoshi Ku, Osaka 5588585, Japan; Osaka Univ, Grad Sch Sci, Dept Macromol Sci, Toyonaka, Osaka 5600043, Japan	National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Yamagata University; Osaka Metropolitan University; Osaka University	Watanabe, Y (corresponding author), Inst Mol Sci, Myodaiji, Okazaki, Aichi 4448585, Japan.		Itoh, Shinobu/AAF-4038-2020					ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHEN LY, 1991, FEBS LETT, V287, P163, DOI 10.1016/0014-5793(91)80041-Z; de Montellano P. R. O., 1995, CYTCOCHROME P450 STR, P245; GIACOMETTI GM, 1981, J MOL BIOL, V146, P363, DOI 10.1016/0022-2836(81)90393-4; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; ITOH S, 1995, J AM CHEM SOC, V117, P1485, DOI 10.1021/ja00110a004; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MORIKIS D, 1990, J BIOL CHEM, V265, P12143; Ozaki S, 1997, J AM CHEM SOC, V119, P6666, DOI 10.1021/ja970453c; Ozaki S, 2001, BIOCHEMISTRY-US, V40, P1044, DOI 10.1021/bi001579g; Ozaki S, 2000, COORDIN CHEM REV, V198, P39, DOI 10.1016/S0010-8545(00)00234-4; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAO SI, 1993, J BIOL CHEM, V268, P803; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TANIZAWA K, 1995, J BIOCHEM, V118, P671, DOI 10.1093/oxfordjournals.jbchem.a124962; Wan LL, 1998, P NATL ACAD SCI USA, V95, P12825, DOI 10.1073/pnas.95.22.12825; WATANABE Y, 1997, OXYGENASES MODEL SYS, P223; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; YONETANI T, 1987, J BIOL CHEM, V262, P9547	24	37	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36067	36070		10.1074/jbc.C100371200	http://dx.doi.org/10.1074/jbc.C100371200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11481319	hybrid			2022-12-25	WOS:000171194500003
J	Tani, TT; Mercurio, AM				Tani, TT; Mercurio, AM			PDZ interaction sites in integrin alpha subunits - TIP-2/GIPC binds to a type I recognition sequence in alpha(6a)/alpha(5) and a novel sequence in alpha(6B)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; LIGAND-BINDING; C-TERMINUS; PROTEIN; MECHANISM; MIGRATION; LAMININ; ALPHA-6-BETA-4; ACTIVATION; VARIANTS	We used published peptide library data to identify PDZ recognition sequences in integrin a subunit cytoplasmic domains and found that the alpha (6)A and a. subunits contain a type I PDZ binding site (TSDA*) (asterisk indicates the stop codon). The alpha (6)A cytoplasmic domain was used for screening a two-hybrid library to find interacting proteins. The bulk of the captured cDNAs (60%) coded for TIP-2/GIPC, a cytoplasmic protein with one PDZ domain. The interaction of TIP-2/GIPC with different integrin subunits was tested in two-hybrid and in vitro binding assays. Surprisingly, TIP-2/GIPC bound strongly to the C terminus of both alpha (6)A and alpha B-6, although the alpha B-6 sequence (ESYS*) is not suggestive of a PDZ binding site because of its polar C-terminal residue. For high affinity interaction with TIP-2/GIPC, at least one of the residues at positions -1 and -3 must be negatively charged. An aliphatic residue at position 0 increases the affinity of but is not required for this interaction. The alpha (5) integrin subunit also bound to TIP-2/GIPC. The alpha (6) integrin and TIP-2/GIPC co-localize in retraction fibers in carcinoma cells plated on laminin, a finding suggesting a functional interaction in vivo. Our results demonstrate that both splice variants of alpha (6) integrin contain a conserved PDZ binding site that enables interaction with TIP-2/GIPC. The binding site in alpha B-6 defines a new subclass of type I PDZ interaction site, characterized by a non-aliphatic residue at position 0.	Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mercurio, AM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, 330 Brookline Ave, Boston, MA 02215 USA.	amercuri@caregroup.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA080789] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039264] Funding Source: NIH RePORTER; NCI NIH HHS [CA80789] Funding Source: Medline; NIAID NIH HHS [AI39264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alahari SK, 2000, J CELL BIOL, V151, P1141, DOI 10.1083/jcb.151.6.1141; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; Chao C, 1996, CANCER RES, V56, P4811; de Melker AA, 1999, BIOESSAYS, V21, P499, DOI 10.1002/(SICI)1521-1878(199906)21:6<499::AID-BIES6>3.0.CO;2-D; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; Gee SH, 2000, BIOCHEMISTRY-US, V39, P14638, DOI 10.1021/bi001633t; Gimond C, 1998, J CELL BIOL, V143, P253, DOI 10.1083/jcb.143.1.253; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; KAWAGUCHI S, 1994, MOL BIOL CELL, V5, P977, DOI 10.1091/mbc.5.9.977; Klekotka PA, 2001, J BIOL CHEM, V276, P9503, DOI 10.1074/jbc.M006286200; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; Liu SC, 2000, J CELL SCI, V113, P3563; Liu SC, 2000, J BIOL CHEM, V275, P22736, DOI 10.1074/jbc.M000388200; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; SHAW LM, 1993, J BIOL CHEM, V268, P11401; SHAW LM, 1994, MOL BIOL CELL, V5, P679, DOI 10.1091/mbc.5.6.679; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tochio H, 2000, J MOL BIOL, V295, P225, DOI 10.1006/jmbi.1999.3350; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	34	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36535	36542		10.1074/jbc.M105785200	http://dx.doi.org/10.1074/jbc.M105785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11479315	hybrid			2022-12-25	WOS:000171194500066
J	Crepieux, P; Marion, S; Martinat, N; Fafeur, V; Le Vern, Y; Kerboeuf, D; Guillou, F; Reiter, E				Crepieux, P; Marion, S; Martinat, N; Fafeur, V; Le Vern, Y; Kerboeuf, D; Guillou, F; Reiter, E			The ERK-dependent signalling is stage-specifically modulated by FSH, during primary Sertoli cell maturation	ONCOGENE			English	Article						ERK MAP kinases; cAMP/PKA; FSH; cell proliferation; cell differentiation	ACTIVATED PROTEIN-KINASE; FOLLICLE-STIMULATING-HORMONE; CYCLIN D1 EXPRESSION; OVARIAN GRANULOSA-CELLS; MAP KINASE; SIGNALING PATHWAY; COUPLED RECEPTORS; TRANSFERRIN GENE; CAMP; PHOSPHORYLATION	Primary cultures of Sertoli cells provide an interesting model to study how signalling pathways induced by a single hormone in a single cell type evolve, depending. on the developmental stage. In vivo, follicle-stimulating hormone (FSH) induces proliferation of Sertoli cells in neonate and controls the subsequent differentiation of the entire population. Molecular mechanisms underlying Sertoli cell pleiotropic responses to FSH have long been investigated. But to date, only cAMP-dependent kinase (PKA) activation has been reported to account for most FSH biological activities in male. Here, we demonstrate that FSH activates the ERK MAP kinase pathway following dual coupling of the FSH-R both to Gs and to Gi heterotrimeric proteins, in a PKA- and also Src-dependent manner. This activation is required for FSH-induced proliferation of Sertoli cells isolated 5 days after birth. Consistently, we show that the ERK-mediated FSH mitogenic effect triggers upregulation of cyclin D1. In sharp contrast, at 19 days after birth, as cells proceed through their differentiation program, the ERK pathway is dramatically inhibited by FSH treatment. Taken together, these results show that FSH can exert opposite effects on the ERK signalling cascade during the maturation process of Sertoli cells. Thus, signalling modules triggered by the FSH-R evolve dynamically throughout development of FSH natural target cells.	Univ Tours, Lab Physiol Reprod & Comportements, Inst Natl Rech Agron, CNRS,UMR 6073, Nouzilly, France; Ctr Rech Tours, Lab Pathol Aviaire & Parasitol, F-37380 Tours, France; CNRS, FRE 2353, Inst Biol Lille, Inst Pasteur Lille, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Universite de Tours; INRAE; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Crepieux, P (corresponding author), Univ Tours, Lab Physiol Reprod & Comportements, Inst Natl Rech Agron, CNRS,UMR 6073, Nouzilly, France.	crepieux@tours.inra.fr	Fafeur, Veronique/L-9072-2018; Crepieux, Pascale/X-3217-2019	Marion, Sebastien/0000-0002-3302-3845				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Cameron MR, 1996, BIOL REPROD, V55, P111, DOI 10.1095/biolreprod55.1.111; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; COFFER P, 1994, ONCOGENE, V9, P911; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Fuller PJ, 1998, J CLIN ENDOCR METAB, V83, P274, DOI 10.1210/jc.83.1.274; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUILLOU F, 1991, J BIOL CHEM, V266, P9876; GUILLOU F, 1986, BIOCHIM BIOPHYS ACTA, V887, P196, DOI 10.1016/0167-4889(86)90055-8; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANSSON V, 2000, J STEROID BIOCHEM, V72, P81; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Maizels ET, 1998, ENDOCRINOLOGY, V139, P3353, DOI 10.1210/en.139.7.3353; MONN E, 1972, ENDOCRINOLOGY, V91, P716, DOI 10.1210/endo-91-3-716; NIKULA H, 1990, MOL CELL ENDOCRINOL, V70, P247, DOI 10.1016/0303-7207(90)90215-T; ORTH JM, 1984, ENDOCRINOLOGY, V115, P1248, DOI 10.1210/endo-115-4-1248; PAULSSEN RH, 1991, BIOL REPROD, V45, P566, DOI 10.1095/biolreprod45.4.566; Penn RB, 1999, J PHARMACOL EXP THER, V288, P428; PURUSHOTHAM KR, 1994, BIOCHEM BIOPH RES CO, V202, P743, DOI 10.1006/bbrc.1994.1993; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; SAEZ JM, 1991, HORM RES, V36, P104, DOI 10.1159/000182142; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SPITERIGRECH J, 1993, J REPROD FERTIL, V98, P1; Stanislaus D, 1998, MOL CELL ENDOCRINOL, V144, P1, DOI 10.1016/S0303-7207(98)00126-9; Suire S, 1997, MOL REPROD DEV, V48, P168, DOI 10.1002/(SICI)1098-2795(199710)48:2&lt;168::AID-MRD4&gt;3.0.CO;2-Q; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Troispoux C, 1998, MOL CELL ENDOCRINOL, V142, P75, DOI 10.1016/S0303-7207(98)00115-4; Troispoux C, 1999, MOL ENDOCRINOL, V13, P1599, DOI 10.1210/me.13.9.1599; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	51	151	161	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4696	4709		10.1038/sj.onc.1204632	http://dx.doi.org/10.1038/sj.onc.1204632			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498792				2022-12-25	WOS:000170208600010
J	Brakenhielm, E; Cao, RH; Cao, YH				Brakenhielm, E; Cao, RH; Cao, YH			Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes	FASEB JOURNAL			English	Article						resveratrol; red wine; cancer; angiogenesis; MAP kinase	GREEN TEA; IN-VIVO; CANCER; ANGIOSTATIN; INHIBITOR; RATS; PROLIFERATION; TUMORIGENESIS; PROTECTION; DISEASE	Resveratrol (3,5,4'-trihydroxystilbene) is a natural compound found in several plants, including grapes, peanuts, and pines, and in their related products. Red wine is probably the most frequently consumed drink that is enriched in resveratrol. We investigated whether drinking resveratrol could suppress angiogenesis, a process of blood vessel growth involved in initiation, development, and progression of many diseases, including cancer, metastasis, and diabetic retinopathy. We found that resveratrol suppresses the growth of new blood vessels in animals. It directly inhibits capillary endothelial cell growth. It blocks both VEGF- and FGF-receptor-mediated angiogenic responses. In addition, resveratrol inhibits the phosphorylation of mitogen-activated kinase isoforms (MAPK(p44)/MAPK(p42)) induced by fibroblast growth factor-2 in proliferating endothelial cells in a dose-dependent manner. Oral administration of resveratrol significantly inhibits the growth of a murine fibrosarcoma in mice, and it significantly delays angiogenesis-dependent wound healing in mice. Our findings suggest that ingestion of resveratrol-enriched food could be beneficial for the prevention of cancer. However, its antiangiogenic effect could delay wound healing and possibly other angiogenesis-dependent processes under physiological conditions.	Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Angiogenesis Res, S-17177 Stockholm, Sweden	Karolinska Institutet	Cao, YH (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Angiogenesis Res, S-17177 Stockholm, Sweden.	yihai.cao@mtc.ki.se	Brakenhielm, Ebba/E-9758-2011	Brakenhielm, Ebba/0000-0003-3378-8300				AUERBACH W, 1994, PHARMACOL THERAPEUT, V63, P265, DOI 10.1016/0163-7258(94)90027-2; Bertelli AAE, 1998, DRUG EXP CLIN RES, V24, P51; Bertelli AAE, 1998, DRUG EXP CLIN RES, V24, P207; Caderni G, 2000, CARCINOGENESIS, V21, P1965, DOI 10.1093/carcin/21.11.1965; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Cao YH, 1999, HAEMATOLOGICA, V84, P643; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; DVORAK HF, SEMIN PERINATOL, V24, P75; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garbisa S, 1999, NAT MED, V5, P1216, DOI 10.1038/15145; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Hsieh TC, 1999, CANCER RES, V59, P2596; Hung LM, 2000, CARDIOVASC RES, V47, P549, DOI 10.1016/S0008-6363(00)00102-4; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; LaMontagne KR, 2000, AM J PATHOL, V157, P1937, DOI 10.1016/S0002-9440(10)64832-8; Mathe G, 1999, BIOMED PHARMACOTHER, V53, P165, DOI 10.1016/S0753-3322(99)80084-5; Mauceri HJ, 1998, NATURE, V394, P287, DOI 10.1038/28412; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PACEASCIAK CR, 1995, CLIN CHIM ACTA, V235, P207, DOI 10.1016/0009-8981(95)06045-1; Turner RT, 1999, ENDOCRINOLOGY, V140, P50, DOI 10.1210/en.140.1.50; Webb T, 2000, J NATL CANCER I, V92, P1038, DOI 10.1093/jnci/92.13.1038	26	283	292	1	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1798	+		10.1096/fj.01-0028fje	http://dx.doi.org/10.1096/fj.01-0028fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481234				2022-12-25	WOS:000169261200038
J	Iwakura, Y; Nagano, T; Kawamura, M; Horikawa, H; Ibaraki, K; Takei, N; Nawa, H				Iwakura, Y; Nagano, T; Kawamura, M; Horikawa, H; Ibaraki, K; Takei, N; Nawa, H			N-methyl-D-aspartate-induced alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptor down-regulation involves interaction of the carboxyl terminus of GluR2/3 with Pick1 - Ligand-binding studies using sindbis vectors carrying AMPA receptor decoys	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-II; IONOTROPIC GLUTAMATE RECEPTORS; CULTURED HIPPOCAMPAL-NEURONS; DOMAIN-CONTAINING PROTEINS; POSTSYNAPTIC DENSITY; SYNAPTIC PLASTICITY; FUNCTIONAL EXPRESSION; C-ALPHA; PHOSPHORYLATION; REDISTRIBUTION	The dynamics of alpha -amino-3-hydroxy-5-methyl-4-isox-azoleproprionic acid (AMPA)-type glutamate receptors, as represented by their exocytosis, endocytosis and cytoskeletal linkage, has often been implicated in N-methyl-D-aspartate (NMDA)-dependent synaptic plasticity. To explore the molecular mechanisms underlying the AMPA receptor dynamics, cultured hippocampal neurons were stimulated with 100 mum NMDA, and the biochemical and pharmacological changes in the ligand binding activity of AMPA receptor complexes and its subunits, GluR1 and GluR2/3, were investigated. The NMDA treatment reduced the total amount of bound [H-3]AMPA on the surface of the neurons but not in their total membrane fraction. This process was mimicked by a protein kinase C activator, phorbol ester, but blocked by an inhibitor of the same kinase, calphostin C. The NMDA-induced down-regulation of the ligand binding activity was also reflected by the decreased AMPA-triggered channel activity as well as by the cells' reduced immunoreactivity for GluR1. In parallel, the NMDA treatment markedly altered the interaction between the AMPA receptor subunits and their associating molecule(s); the association of PDZ molecules, including Pick1, with GluR2/3 was enhanced in a protein-kinase-C-dependent manner. Viral expression vectors carrying GluR1 and GluR2 C-terminal decoys, both fused to enhanced green fluorescent protein, were transfected into hippocampal neurons to disrupt their interactions. The overexpression of the C-terminal decoy for GluR2 specifically and significantly blocked the NMDA-triggered reduction in [H-3]AMPA binding, whereas that for GluR1 had no effects. Co-immunoprecipitation using anti-Pick1 antibodies revealed that the overexpressed GluR2 C-terminal decoy indeed prevented Pick1 from interacting with the endogenous GluR2/3. Therefore, these observations suggest that the NMDA-induced down-regulation of the functional AMPA receptors involves the interaction between GluR2/3 subunits and Pick1.	Niigata Univ, Brain Res Inst, Div Mol Neurobiol, Niigata 9518585, Japan	Niigata University	Nawa, H (corresponding author), Niigata Univ, Brain Res Inst, Div Mol Neurobiol, Asahimachi Dori 1-757, Niigata 9518585, Japan.							Andreoni G, 1997, EXP NEUROL, V148, P281, DOI 10.1006/exnr.1997.6647; Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; Brenman JE, 1998, J NEUROSCI, V18, P8805; Carroll RC, 1998, J NEUROPHYSIOL, V80, P2797, DOI 10.1152/jn.1998.80.5.2797; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Chung HJ, 2000, J NEUROSCI, V20, P7258; Corsi L, 1998, J NEUROCHEM, V70, P1898; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; Dev KK, 2000, J NEUROSCI, V20, P7252; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Dong HL, 1999, J NEUROSCI, V19, P6930, DOI 10.1523/JNEUROSCI.19-16-06930.1999; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Haberecht MF, 1997, J NEUROSCI RES, V47, P416; HALL RA, 1994, J NEUROCHEM, V63, P1658; Hall RA, 1997, NEUROSCIENCE, V78, P361, DOI 10.1016/S0306-4522(96)00525-8; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; Hussain RJ, 2000, DEV BRAIN RES, V121, P243, DOI 10.1016/S0165-3806(00)00051-1; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kennedy MB, 1998, BRAIN RES REV, V26, P243, DOI 10.1016/S0165-0173(97)00043-X; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim JH, 1999, CURR OPIN CELL BIOL, V11, P248, DOI 10.1016/S0955-0674(99)80033-7; KNUSEL B, 1991, J NEUROCHEM, V57, P955, DOI 10.1111/j.1471-4159.1991.tb08243.x; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Lissin DV, 1999, J NEUROSCI, V19, P1263; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; MADISON DV, 1995, CURR TOP MICROBIOL I, V195, P5; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Marley PD, 1996, BIOCHEM BIOPH RES CO, V221, P15, DOI 10.1006/bbrc.1996.0536; Matsuda S, 1999, J NEUROCHEM, V73, P1765, DOI 10.1046/j.1471-4159.1999.731765.x; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; Miyamoto E, 1996, NEUROSCI RES, V24, P117, DOI 10.1016/0168-0102(95)00991-4; Nagano T, 1999, KEIO UNIV SYMP LIFE, V2, P386; NAWA H, 1993, J NEUROCHEM, V60, P772, DOI 10.1111/j.1471-4159.1993.tb03216.x; O'Brien RJ, 1999, NEURON, V23, P309, DOI 10.1016/S0896-6273(00)80782-5; SCHMIDT JT, 1994, J NEUROBIOL, V25, P555, DOI 10.1002/neu.480250508; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	61	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40025	40032		10.1074/jbc.M103125200	http://dx.doi.org/10.1074/jbc.M103125200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11498531	hybrid			2022-12-25	WOS:000171789200071
J	Bai, YD; Hajek, P; Chomyn, A; Chan, E; Seo, BB; Matsuno-Yagi, A; Yagi, T; Attardi, G				Bai, YD; Hajek, P; Chomyn, A; Chan, E; Seo, BB; Matsuno-Yagi, A; Yagi, T; Attardi, G			Lack of complex I activity in human cells carrying a mutation in MtDNA-encoded ND4 subunit is corrected by the Saccharomyces cerevisiae NADH-quinone oxidoreductase (NDI1) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROTENONE-INSENSITIVE NADH; RESPIRATORY-CHAIN; CYTOCHROME-C; DNA; MITOCHONDRIA; DEHYDROGENASE; DISEASE; ENZYME; ORGANIZATION; TRANSFECTION	The gene for the single subunit, rotenone-insensitive, and flavone-sensitive internal NADH-quinone oxidoreductase of Saccharomyces cerevisiae (NDI1) can completely restore the NADH dehydrogenase activity in mutant human cells that lack the essential mitochondria) DNA (mtDNA)-encoded subunit ND4. In particular, the NDI1 gene was introduced into the nuclear genome of the human 143B.TK- cell line derivative C4T, which carries a homoplasmic frameshift mutation in the ND4 gene. Two transformants with a low or high level of expression of the exogenous gene were chosen for a detailed analysis. In these cells the corresponding protein is localized in mitochondria, its NADH-binding site faces the matrix compartment as in yeast mitochondria, and in perfect correlation with its abundance restores partially or fully NADH-dependent respiration that is rotenone-insensitive, flavone-sensitive, and antimycin A-sensitive. Thus the yeast enzyme has become coupled to the downstream portion of the human respiratory chain. Furthermore, the P:O ratio with malate/glutamate-dependent respiration in the transformants is approximately two-thirds of that of the wild-type 143B.TK- cells, as expected from the lack of proton pumping activity in the yeast enzyme. Finally, whereas the original mutant cell line C4T fails to grow in medium containing galactose instead of glucose, the high NDI1-expressing transformant has a fully restored capacity to grow in galactose medium. The present observations substantially expand the potential of the yeast NDI1 gene for the therapy of mitochondrial diseases involving complex I deficiency.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA; Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA	California Institute of Technology; Scripps Research Institute	Attardi, G (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.		Bai, Yidong/A-4959-2012		NIDDK NIH HHS [R01 DK 53244] Funding Source: Medline; NIGMS NIH HHS [GM 11726] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053244] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000; BERNARDI P, 1981, J BIOL CHEM, V256, P7187; BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; DEVRIES S, 1988, EUR J BIOCHEM, V176, P377; DEVRIES S, 1992, EUR J BIOCHEM, V203, P587; Enriquez JA, 2000, J BIOL CHEM, V275, P11207, DOI 10.1074/jbc.275.15.11207; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; Hofhaus G, 1996, Methods Enzymol, V264, P476, DOI 10.1016/S0076-6879(96)64043-9; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; Kitajima-Ihara T, 1998, FEBS LETT, V421, P37, DOI 10.1016/S0014-5793(97)01533-0; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; Seo BB, 2000, J BIOL CHEM, V275, P37774, DOI 10.1074/jbc.M007033200; Seo BB, 1999, BBA-BIOENERGETICS, V1412, P56, DOI 10.1016/S0005-2728(99)00051-1; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Villani G, 2001, METHOD CELL BIOL, V65, P119, DOI 10.1016/S0091-679X(01)65007-6; Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4; YAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P1, DOI 10.1016/0005-2728(93)90182-F; YAGI T, 1991, J BIOENERG BIOMEMBR, V23, P211, DOI 10.1007/BF00762218	24	92	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38808	38813		10.1074/jbc.M106363200	http://dx.doi.org/10.1074/jbc.M106363200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11479321	hybrid			2022-12-25	WOS:000171673200064
J	Dubrez, L; Coll, JL; Hurbin, A; Solary, E; Favrot, MC				Dubrez, L; Coll, JL; Hurbin, A; Solary, E; Favrot, MC			Caffeine sensitizes human H358 cell line to p53-mediated apoptosis by inducing mitochondrial translocation and conformational change of BAX protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; CYTOCHROME-C RELEASE; TUMOR-SUPPRESSOR P53; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; IN-VIVO; CASPASE ACTIVATION; ULTRAVIOLET-LIGHT; GROWTH ARREST; BCL-2 FAMILY	The mechanisms involved in p53-mediated cell death remain controversial. In the present study, we investigated this cell death pathway by stably transfecting the p53-null H358 cell line with a tetracycline-dependent wild type p53-expressing vector. Restoration of p53 triggered a G(2)/M cell cycle arrest and enhanced BAX protein expression, without inducing apoptosis or potentiating the cytotoxic effect of etoposide, vincristine, and cisplatinum. Accordingly, overexpression of BAX in H358 cells, through stable transfection of a tetracycline-regulated expression vector, did not induce cell death. Interestingly, the methylxanthine caffeine (4 mm) promoted the translocation of BAX from the cytosol to the mitochondria. In the setting of an overexpression of BAY, caffeine induced a conformational change of the protein and apoptosis. The consequences of caffeine were independent of its cell cycle-related activities. All together, caffeine synergizes with p53 for inducing cell death through a cell cycle-independent mechanism, involving mitochondrial translocation and conformational change of BAX protein.	Inst Albert Bonniot, INSERM, Grp Rech Canc Poumon, F-38706 La Tronche, France; Fac Med Pharm, INSERM, U517, F-21033 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Favrot, MC (corresponding author), Inst Albert Bonniot, INSERM, Grp Rech Canc Poumon, E9924, F-38706 La Tronche, France.		Dubrez, Laurence/I-4971-2016; Laurence, Dubrez/P-9472-2019; Coll, Jean-Luc/G-2520-2013; Hurbin, Amandine/M-2693-2013	Dubrez, Laurence/0000-0002-7030-2181; Laurence, Dubrez/0000-0002-7030-2181; Coll, Jean-Luc/0000-0002-2453-3552; Solary, Eric/0000-0002-8629-1341; Hurbin, Amandine/0000-0003-0535-1945				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Chan TA, 2000, GENE DEV, V14, P1584; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Coll JL, 1998, HUM GENE THER, V9, P2063, DOI 10.1089/hum.1998.9.14-2063; DeFrank JS, 1996, CANCER RES, V56, P5365; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Favrot M, 1998, GENE THER, V5, P728, DOI 10.1038/sj.gt.3300661; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; LOCK RB, 1994, CANCER RES, V54, P4933; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; Merchant AK, 1996, ONCOGENE, V13, P2631; MIYASHITA T, 1995, CELL, V80, P293; Moser BA, 2000, MOL CELL BIOL, V20, P4288, DOI 10.1128/MCB.20.12.4288-4294.2000; Mukhopadhyay T, 1998, ONCOGENE, V17, P241, DOI 10.1038/sj.onc.1201909; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nomura M, 1999, CANCER RES, V59, P5542; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pryde JG, 2000, J BIOL CHEM, V275, P33574, DOI 10.1074/jbc.M001008200; Ribeiro JCC, 1999, INT J RADIAT BIOL, V75, P481, DOI 10.1080/095530099140410; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Strobel T, 1997, ONCOGENE, V14, P2753, DOI 10.1038/sj.onc.1201132; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YOA SL, 1996, NAT MED, V2, P1140; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	55	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38980	38987		10.1074/jbc.M102683200	http://dx.doi.org/10.1074/jbc.M102683200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489880	hybrid, Green Submitted			2022-12-25	WOS:000171673200086
J	Dufour, EK; Denault, JB; Bissonnette, L; Hopkins, PCR; Lavigne, P; Leduc, R				Dufour, EK; Denault, JB; Bissonnette, L; Hopkins, PCR; Lavigne, P; Leduc, R			The contribution of arginine residues within the P6-P1 region of alpha(1)-antitrypsin to its reaction with furin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPROTEIN-PROCESSING ENZYME; TIGHT-BINDING INHIBITORS; ANTICHYMOTRYPSIN INTERACTION; PROPARATHYROID HORMONE; PROTEINASE INHIBITION; SEQUENCE REQUIREMENTS; SECRETORY PATHWAY; ESCHERICHIA-COLI; CLEAVAGE; COMPLEX	A series of mutants incorporating furin recognition sequences within the P6-P1 region of the reactive site loop of al-antitrypsin were constructed. Variants containing different combinations of basic residues in the P1, P2, P4, and P6 positions replacing the wild type (P6)LEAIPM(P1) sequence were evaluated for their capacity to establish SDS-resistant complexes with furin, to affect association rate constants (k(ass) and k'(ass)), or to inhibit furin-dependent proteolysis of a model precursor in vivo. Each variant abolished processing of pro-von Willebrand factor in transfected hEK293 cells. The k(ass) of all variants were found to be similar (1.1-1.7 x 10(6) M-1 s(-1)) except for one mutant, RERIRR, which had a k(ass) of 3.3 x 10(5) M-1 s(-1). However, the stoichiometry of inhibition varied with values ranging from 2.9 to >24, indicating rapid formation of the acyl-enzyme intermediate (high k'(ass)). Moreover, those variants having high stoichiometry of inhibition values were accompanied by the rapid formation of cleaved forms of the inhibitors. The data suggest that the rate of conversion of the acyl-enzyme (EI') into the highly stable complex (EI*) was affected by replacement of specific residues within the reactive site loop. Taken together, the results reveal how furin recognition sequences within the context of the biochemical properties of serpins will play a role in the capacity of the protein to follow either the inhibitory or the substrate pathway.	Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA	University of Sherbrooke; University of California System; University of California San Francisco; The J David Gladstone Institutes	Leduc, R (corresponding author), Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada.	rleduc0l@courrier.usherb.ca	Denault, Jean-Bernard/AAC-5945-2019; Hopkins, Paul/E-5215-2010					ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; ANGLIKER H, 1995, J MED CHEM, V38, P4014, DOI 10.1021/jm00020a016; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; Cameron A, 2000, J BIOL CHEM, V275, P36741, DOI 10.1074/jbc.M003848200; ChaillanHuntington CE, 1997, BIOCHEMISTRY-US, V36, P9562, DOI 10.1021/bi970651g; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; COURTNEY M, 1984, P NATL ACAD SCI-BIOL, V81, P669, DOI 10.1073/pnas.81.3.669; Dahlen JR, 1998, J BIOL CHEM, V273, P1851, DOI 10.1074/jbc.273.4.1851; DENAULT JB, 1995, PROTEIN EXPRES PURIF, V19, P113; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; DREWS R, 1995, P NATL ACAD SCI USA, V92, P10462, DOI 10.1073/pnas.92.23.10462; Dufour EK, 1998, FEBS LETT, V426, P41, DOI 10.1016/S0014-5793(98)00307-X; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; HENDY GN, 1995, J BIOL CHEM, V270, P9517, DOI 10.1074/jbc.270.16.9517; Horovitz A, 1996, FOLD DES, V1, pR121, DOI 10.1016/S1359-0278(96)00056-9; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; Komiyama T, 2000, BIOCHEMISTRY-US, V39, P15156, DOI 10.1021/bi001907c; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; KWON KS, 1995, BBA-PROTEIN STRUCT M, V1247, P179, DOI 10.1016/0167-4838(94)00224-5; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; Luo Y, 1999, J BIOL CHEM, V274, P17733, DOI 10.1074/jbc.274.25.17733; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Nash P, 2000, FEBS LETT, V475, P1, DOI 10.1016/S0014-5793(00)01620-3; O'Malley KM, 2001, J BIOL CHEM, V276, P6631, DOI 10.1074/jbc.M008478200; OWEN MC, 1991, FEBS LETT, V280, P216, DOI 10.1016/0014-5793(91)80296-F; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; TAKAHASHI S, 1994, J BIOCHEM-TOKYO, V116, P47, DOI 10.1093/oxfordjournals.jbchem.a124501; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; VANDEVEN WJM, 1991, ENZYME, V45, P257, DOI 10.1159/000468900; WALEY SG, 1985, BIOCHEM J, V227, P843, DOI 10.1042/bj2270843; WARSHEL A, 1991, ANNU REV BIOPHYS BIO, V20, P267, DOI 10.1146/annurev.biophys.20.1.267; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	48	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38971	38979		10.1074/jbc.M102959200	http://dx.doi.org/10.1074/jbc.M102959200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11479287	hybrid			2022-12-25	WOS:000171673200085
J	Ikegami, M; Elhalwagi, BM; Palaniyar, N; Dienger, K; Korfhagen, T; Whitsett, JA; McCormack, FX				Ikegami, M; Elhalwagi, BM; Palaniyar, N; Dienger, K; Korfhagen, T; Whitsett, JA; McCormack, FX			The collagen-like region of surfactant protein A (SP-A) is required for correction of surfactant structural and functional defects in the SP-A null mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; PULMONARY SURFACTANT; II CELLS; PHOSPHOLIPID AGGREGATION; TUBULAR MYELIN; LUNG; SECRETION; MICE; INHIBITION; LIPIDS	Pulmonary surfactant isolated from gene-targeted surfactant protein A null mice (SP-A(-/-)) is deficient in the surfactant aggregate tubular myelin and has surface tension-lowering activity that is easily inhibited by serum proteins in vitro. To further elucidate the role of SP-A and its collagen-like region in surfactant function, we used the human SP-C promoter to drive expression of rat SP-A (rSPA) or SP-A containing a deletion of the collagen-like domain (Delta G8-P80) in the Clara cells and alveolar type II cells of SP-A(-/-) mice. The level of the SP-A in the alveolar wash of the SP-A(-/-,rSP-A) and SP-A(-/-,Delta G8-P80) mice was 6.1-and 1.3-fold higher, respectively, than in the wild type controls. Tissue levels of saturated phosphatidylcholine were slightly reduced in the SP-A(-/-,rSP-A) mice compared with SP-A(-/-) littermates. Tubular myelin was present in the large surfactant aggregates isolated from the SP-A(-/-,rSP-A) lines but not in the SP-A(-/-,Delta G8-P80) mice or SP-A(-/-) controls. The equilibrium and minimum surface tensions of surfactant from the SP-A(-/-,rSP-A) mice were similar to SP-A(-/-) controls, but both were markedly elevated in the SP-A(-/-,Delta G8-P80) mice. There was no defect in the surface tension-lowering activity of surfactant from SP-A(+/+,Delta G8-P80) mice, indicating that the inhibitory effect of Delta G8-P80 on surface activity can be overcome by wild type levels of mouse SP-A. The surface activity of surfactant isolated from the SP-A(-/-rSP-A) but not the SP-A(-/-,Delta G8-P80) mice was more resistant than SP-A(-/-) littermate control animals to inhibition by serum proteins in vitro. Pressure volume relationships of lungs from the SP-A(-/-), SP-A(-/-rSP-A), and SP-A(-/-,Delta G8-P80) lines were very similar. These data indicate that expression of SP-A in the pulmonary epithelium of SP-A(-/-) animals restores tubular myelin formation and resistance of isolated surfactant to protein inhibition by a mechanism that is dependent on the collagen-like region.	Univ Cincinnati, Sch Med, Dept Med, Div Pulm & Crit Care Med, Cincinnati, OH 45229 USA; Childrens Hosp Res Fdn, Dept Pediat, Div Pulm Biol, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	McCormack, FX (corresponding author), POB 670564, Cincinnati, OH 45267 USA.		McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464; Palaniyar, Nades/0000-0002-2170-8548	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL061646, R01HL061612] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61612, HL-61646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; Elhalwagi BM, 1997, BIOCHEMISTRY-US, V36, P7018, DOI 10.1021/bi970100q; Elhalwagi BM, 1999, AM J RESP CELL MOL, V21, P380, DOI 10.1165/ajrcmb.21.3.3676; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; Goerke J., 1986, HDB PHYSL RESP SYSTE, P247; HALLER EM, 1992, J HISTOCHEM CYTOCHEM, V40, P1491, DOI 10.1177/40.10.1527372; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; Ikegami M, 2000, J APPL PHYSIOL, V89, P644, DOI 10.1152/jappl.2000.89.2.644; Ikegami M, 1998, AM J PHYSIOL-LUNG C, V275, pL247, DOI 10.1152/ajplung.1998.275.2.L247; KING RJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P294, DOI 10.1016/0005-2760(89)90114-8; KING RJ, 1973, AM J PHYSIOL, V224, P788, DOI 10.1152/ajplegacy.1973.224.4.788; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON RJ, 1976, J LIPID RES, V17, P281; McCormack FX, 1997, J BIOL CHEM, V272, P27971, DOI 10.1074/jbc.272.44.27971; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P13963, DOI 10.1021/bi970745q; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; McCormack FX, 1999, J BIOL CHEM, V274, P3173, DOI 10.1074/jbc.274.5.3173; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; Palaniyar N, 2000, BIOCHEMISTRY-US, V39, P6310, DOI 10.1021/bi992793b; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SCHURCH S, 1989, J APPL PHYSIOL, V67, P2389, DOI 10.1152/jappl.1989.67.6.2389; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; VENKITARAMAN AR, 1990, CHEM PHYS LIPIDS, V56, P185, DOI 10.1016/0009-3084(90)90101-V; VOORHOUT WF, 1991, J HISTOCHEM CYTOCHEM, V39, P1331, DOI 10.1177/39.10.1940306; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WHITSETT JA, 1985, J BIOL CHEM, V260, P5273; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; YUKITAKE K, 1995, PEDIATR RES, V37, P21, DOI 10.1203/00006450-199501000-00005	34	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38542	38548		10.1074/jbc.M102054200	http://dx.doi.org/10.1074/jbc.M102054200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504713	hybrid			2022-12-25	WOS:000171673200030
J	Kennedy, MA; Venkateswaran, A; Tarr, PT; Xenarios, I; Kudoh, J; Shimizu, N; Edwards, PA				Kennedy, MA; Venkateswaran, A; Tarr, PT; Xenarios, I; Kudoh, J; Shimizu, N; Edwards, PA			Characterization of the human ABCG1 gene - Liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING CASSETTE; DROSOPHILA WHITE GENE; DIPHOSPHATE SYNTHASE GENE; TANGIER-DISEASE; LXR-ALPHA; GENOMIC ORGANIZATION; CHOLESTEROL EFFLUX; MOLECULAR-CLONING; PLASMA-MEMBRANE; HUMAN HOMOLOG	The human ABCG1 gene encodes a member of the ATP-binding cassette (ABC) superfamily of transporter proteins and is highly induced when macrophages are incubated with oxysterols. Using mRNA from oxysterol-treated human THP-1 cells together with 5'-rapid amplification of eDNA ends and polymerase chain reaction, we identified a novel ABCG1 transcript that encodes a putative protein of 786 residues containing a new amino terminus of 203 amino acids. Characterization of the genomic organization and structure of the human ABCG1 gene demonstrates that: (i) the gene consists of 23 exons spanning 98 kilobase pairs (kb) on chromosome 21q22.3, (ii) the 203 amino acids are encoded on three previously unidentified exons, 8-10, and (iii) a promoter, containing a TATA box and two liver X receptor (LXR) alpha response elements (LXREs), is located upstream of exon 8. Northern analysis using exon-specific probes confirms that oxysterol treatment results in >10-fold induction of ABCG1 transcripts that are derived from either exons 8-23 or exons 5, 7, and 11-23. Electromobility shift assays demonstrate that LXR alpha and retinoid X receptor a bind to the two LXREs in intron 7. Cells were transiently transfected with reporter luciferase constructs under the control of either (i) 9 kb of genomic DNA corresponding to intron 7 and part of exon 8 and containing either wild-type or mutant LXREs or (ii) two copies of the wild-type or mutant LXRE. In all cases, the wild-type construct was regulated in an LXR- and oxysterol-dependent manner, and this regulation was attenuated when the LXREs were mutated. In conclusion, the human ABCG1 gene contains multiple promoters, spans more than 98 kb and comprises 23 exons that give rise to alternative transcripts encoding proteins with different amino-terminal sequences. Elucidation of the various roles of different ABCG1 isoforms will be important for our understanding of mammalian cholesterol homeostasis.	Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Keio Univ, Sch Med, Dept Mol Biol, Tokyo 1608582, Japan	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Keio University	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257, Los Angeles, CA 90095 USA.		Xenarios, Ioannis/ABD-5045-2021	Xenarios, Ioannis/0000-0002-3413-6841	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ambudkar SV, 1998, METHOD ENZYMOL, V292, P504; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P433; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chen HM, 1996, AM J HUM GENET, V59, P66; Costet P, 2000, J BIOL CHEM, V275, P28240; Croop JM, 1997, GENE, V185, P77, DOI 10.1016/S0378-1119(96)00633-6; DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; EWART GD, 1994, J BIOL CHEM, V269, P10370; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GERRITY RG, 1981, AM J PATHOL, V103, P181; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Langmann T, 2000, BBA-GENE STRUCT EXPR, V1494, P175, DOI 10.1016/S0167-4781(00)00215-3; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lorkowski S, 2001, BIOCHEM BIOPH RES CO, V280, P121, DOI 10.1006/bbrc.2000.4089; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Pullinger CR, 2000, BIOCHEM BIOPH RES CO, V271, P451, DOI 10.1006/bbrc.2000.2652; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rocchi E, 2000, BIOCHEM BIOPH RES CO, V271, P42, DOI 10.1006/bbrc.2000.2590; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; Savary S, 1996, MAMM GENOME, V7, P673, DOI 10.1007/s003359900203; SCHUG J, 1997, CBILTR19971001V0 0 U; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Shani N, 1996, P NATL ACAD SCI USA, V93, P11901, DOI 10.1073/pnas.93.21.11901; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; WINGENDER E, 1994, J BIOTECHNOL, V35, P273, DOI 10.1016/0168-1656(94)90041-8	57	207	215	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39438	39447		10.1074/jbc.M105863200	http://dx.doi.org/10.1074/jbc.M105863200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11500512	hybrid			2022-12-25	WOS:000171673200144
J	Rubinfeld, B; Tice, DA; Polakis, P				Rubinfeld, B; Tice, DA; Polakis, P			Axin-dependent phosphorylation of the adenomatous polyposis coli protein mediated by casein kinase 1 epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APC TUMOR-SUPPRESSOR; WNT SIGNALING PATHWAY; BETA-CATENIN STABILITY; NEGATIVE REGULATOR; GENE-PRODUCT; GSK-3-BETA-DEPENDENT PHOSPHORYLATION; XENOPUS EMBRYOS; DOWN-REGULATION; PHOSPHATASE 2A; CANCER	Axin and the adenomatous polyposis coli protein (APC) interact to down-regulate the proto-oncogene beta -catenin. We show that transposition of an axin-binding site can confer beta -catenin regulatory activity to a fragment of APC normally lacking this activity. The fragment containing the axin-binding site also underwent hyperphosphorylation when coexpressed with axin. The phosphorylation did not require glycogen synthase kinase 3 beta but instead required casein kinase 1 epsilon, which bound directly to axin. Mutation of conserved serine residues in the beta -catenin regulatory motifs of APC interfered with both axin-dependent phosphorylation and phosphorylation by CKI epsilon and impaired the ability of APC to regulate beta -catenin. These results suggest that the axin-dependent phosphorylation of APC is mediated in part by CKI epsilon and is involved in the regulation of APC function.	Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Polakis, P (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, S San Francisco, CA 94080 USA.			Rubinfeld, Bonnee/0000-0001-9861-6775				Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Kawahara K, 2000, J BIOL CHEM, V275, P8369, DOI 10.1074/jbc.275.12.8369; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Lagna G, 1999, MECH DEVELOP, V80, P101, DOI 10.1016/S0925-4773(98)00208-1; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; MIYAKI M, 1994, CANCER RES, V54, P3011; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Webster MT, 2000, GENE CHROMOSOME CANC, V28, P443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	46	100	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39037	39045		10.1074/jbc.M105148200	http://dx.doi.org/10.1074/jbc.M105148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11487578	hybrid			2022-12-25	WOS:000171673200093
J	Wadskov-Hansen, SLL; Willemoes, M; Martinussen, J; Hammer, K; Neuhard, J; Larsen, S				Wadskov-Hansen, SLL; Willemoes, M; Martinussen, J; Hammer, K; Neuhard, J; Larsen, S			Cloning and verification of the Lactococcus lactis pyrG gene and characterization of the gene product, CTP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE TRIPHOSPHATE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PYRIMIDINE BIOSYNTHESIS; NUCLEOTIDE-SEQUENCE; URACIL PHOSPHORIBOSYLTRANSFERASE; OPERON; PURIFICATION; ORGANIZATION; STREPTOCOCCI	The pyrG gene of Lactococcus lactis subsp. cremoris, encoding CTP synthase, has been cloned and sequenced. It is flanked upstream by an open reading frame showing homology to several aminotransferases and downstream by an open reading frame of unknown function. L. lactis strains harboring disrupted pyrG alleles were constructed. These mutants required cytidine for growth, proving that in L. lactis, the pyrG product is the only enzyme responsible for the amination of UTP to CTP. In contrast to the situation in Escherichia coli, an L. lactis pyrG mutant could be constructed in the presence of a functional cdd gene encoding cytidine deaminase. A characterization of the enzyme revealed similar properties as found for CTP synthases from other organisms. However, unlike the majority of CTP synthases the lactococcal enzyme can convert dUTP to dCTP, although a half saturation concentration of 0.6 mM for dUTP makes it unlikely that this reaction plays a significant physiological role. As for other CTP synthases, the oligomeric structure of the lactococcal enzyme was found to be a tetramer, but unlike most of the other previously characterized enzymes, the tetramer was very stable even at dilute enzyme concentrations.	Tech Univ Denmark, Dept Microbiol, DK-2800 Lyngby, Denmark; Univ Copenhagen, Dept Chem, Ctr Crystallog Studies, DK-2100 Copenhagen O, Denmark; Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, DK-1307 Copenhagen, Denmark	Technical University of Denmark; University of Copenhagen; University of Copenhagen	Willemoes, M (corresponding author), Tech Univ Denmark, Dept Microbiol, Bldg 301, DK-2800 Lyngby, Denmark.		Larsen, Sine/A-4487-2017; Willemoës, Martin/K-4359-2014; Martinussen, Jan/I-4738-2013	Larsen, Sine/0000-0003-3848-1789; Willemoës, Martin/0000-0003-1689-2712; Martinussen, Jan/0000-0001-6223-9322				Andersen PS, 1996, J BACTERIOL, V178, P5005, DOI 10.1128/jb.178.16.5005-5012.1996; ANDERSEN PS, 1994, J BACTERIOL, V176, P3975, DOI 10.1128/JB.176.13.3975-3982.1994; ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; Bearne SL, 2001, BIOCHEM J, V356, P223, DOI 10.1042/0264-6021:3560223; BECK CF, 1972, J BACTERIOL, V110, P219, DOI 10.1128/JB.110.1.219-228.1972; BECK CF, 1972, MOL GEN GENET, V115, P208, DOI 10.1007/BF00268884; BECK CF, 1971, MOL GEN GENET, V111, P303, DOI 10.1007/BF00569782; Clark RA, 2000, J ACQ IMMUN DEF SYND, V23, P99; Elagoz A, 1996, GENE, V182, P37, DOI 10.1016/S0378-1119(96)00461-1; FRIESEN JD, 1976, J BACTERIOL, V127, P917, DOI 10.1128/JB.127.2.917-922.1976; Fromm H J, 1979, Methods Enzymol, V63, P42; GASSON MJ, 1983, J BACTERIOL, V154, P1; GHIM SY, 1994, J BACTERIOL, V176, P3698, DOI 10.1128/JB.176.12.3698-3707.1994; Hammer-Jespersen K., 1983, METABOLISM NUCLEOTID, P203; HAMMERJESPERSEN K, 1973, MOL GEN GENET, V126, P177, DOI 10.1007/BF00330992; Harrison RW, 1997, BIOTECHNIQUES, V22, P650, DOI 10.2144/97224bm17; Holo H, 1995, Methods Mol Biol, V47, P195; JENSEN PR, 1993, APPL ENVIRON MICROB, V59, P4363, DOI 10.1128/AEM.59.12.4363-4366.1993; JOHANSEN E, 1992, J DAIRY SCI, V75, P1186, DOI 10.3168/jds.S0022-0302(92)77865-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOURGEOIS P, 1992, GENE, V111, P109, DOI 10.1016/0378-1119(92)90610-2; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3365, DOI 10.1021/bi00794a008; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LI XT, 1995, J BACTERIOL, V177, P6866, DOI 10.1128/jb.177.23.6866-6873.1995; Lim RLH, 1996, MOL BIOCHEM PARASIT, V78, P249, DOI 10.1016/S0166-6851(96)02635-7; LONG CW, 1970, J BIOL CHEM, V245, P80; LONG CW, 1967, J BIOL CHEM, V242, P4715; Lukashin AV, 1998, NUCLEIC ACIDS RES, V26, P1107, DOI 10.1093/nar/26.4.1107; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Martinussen J, 1998, J BACTERIOL, V180, P4380, DOI 10.1128/JB.180.17.4380-4386.1998; MARTINUSSEN J, 1994, J BACTERIOL, V176, P6457, DOI 10.1128/JB.176.21.6457-6463.1994; Martinussen J, 2001, J BACTERIOL, V183, P2785, DOI 10.1128/JB.183.9.2785-2794.2001; MARTINUSSEN J, 1995, MICROBIOL-UK, V141, P1883, DOI 10.1099/13500872-141-8-1883; MARTINUSSEN J, 1994, J BACTERIOL, V176, P1514, DOI 10.1128/jb.176.5.1514-1516.1994; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; O'Sullivan W J, 1979, Methods Enzymol, V63, P294; Pappas A, 1998, J BIOL CHEM, V273, P15954, DOI 10.1074/jbc.273.26.15954; Pappas A, 1999, BIOCHEMISTRY-US, V38, P16671, DOI 10.1021/bi9920127; QUINN CL, 1991, J BIOL CHEM, V266, P9113; ROBERTSON JG, 1995, BIOCHEMISTRY-US, V34, P7533, DOI 10.1021/bi00022a029; ROBERTSON JG, 1993, BIOCHEMISTRY-US, V32, P3769, DOI 10.1021/bi00065a032; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEIT KH, 1982, EUR J BIOCHEM, V126, P57, DOI 10.1111/j.1432-1033.1982.tb06745.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONG BH, 1989, MOL GEN GENET, V216, P462, DOI 10.1007/BF00334391; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; THOMAS PE, 1988, BIOCHIM BIOPHYS ACTA, V953, P334, DOI 10.1016/0167-4838(88)90042-8; VANKUILENBURG ABP, 1994, ANTICANCER RES, V14, P411; Wadskov-Hansen SLL, 2000, GENE, V241, P157, DOI 10.1016/S0378-1119(99)00452-7; WENG M, 1986, J BIOL CHEM, V261, P5568; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028	52	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38002	38009						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11500486				2022-12-25	WOS:000171526500040
J	Thompson, J; Pobrish, SA; Immel, S; Lichtenthaler, FW; Hall, BG; Pikis, A				Thompson, J; Pobrish, SA; Immel, S; Lichtenthaler, FW; Hall, BG; Pikis, A			Metabolism of sucrose and its five linkage-isomeric alpha-D-glucosyl-D-fructoses by Klebsiella pneumoniae - Participation and properties of sucrose-6-phosprate hydrolase and phospho-alpha-glucosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; PHOSPHOTRANSFERASE SYSTEM; CRYSTAL-STRUCTURE; MOLECULAR-STRUCTURE; BACILLUS-SUBTILIS; FAMILY 4; MALTITOL 4-O-ALPHA-D-GLUCOPYRANOSYL-D-GLUCITOL; FUSOBACTERIUM-MORTIFERUM; MALTOSE MONOHYDRATE; NUCLEIC-ACIDS	Klebsiella pneumoniae is presently unique among bacterial species in its ability to metabolize not only sucrose but also its five linkage-isomeric alpha -D-glucosyl-D-fructoses: trehalulose, turanose, maltulose, leucrose, and palatinose. Growth on the isomeric compounds induced a protein of molecular mass similar to 50 kDa that was not present in sucrose-grown cells and which we have identified as an NAD(+) and metal ion-dependent 6-phospho-alpha -glucosidase (AglB). The aglB gene has been cloned and sequenced, and AglB (M-r = 49,256) has been purified from a high expression system using the chromogenic p-nitrophenyl alpha -glucopyranoside 6-phosphate as substrate. Phospho-alpha -glucosidase catalyzed the hydrolysis of a wide variety of 6-phospho-alpha -glucosides including maltose-6'-phosphate, maltitol-6-phosphate, isomaltose-6'-phosphate, and all five 6'-phosphorylated isomers of sucrose (K-m similar to 1-5 mM) yet did not hydrolyze sucrose-6-phosphate. By contrast, purified sucrose-6-phosphate hydrolase (M-r similar to 53,000) hydrolyzed only sucrose-6-phosphate (K-m similar to 80 muM). Differences in molecular shape and lipophilicity potential between sucrose and its isomers may be important determinants for substrate discrimination by the two phosphoglucosyl hydrolases. Phospho-alpha -glucosidase and sucrose-6-phosphate hydrolase exhibit no significant homology, and by sequence-based alignment, the two enzymes are assigned to Families 4 and 32, respectively, of the glycosyl hydrolase superfamily. The phospho-alpha -glucosidase gene (aglB) lies adjacent to a second gene (aglA), which encodes an EII(CB) component of the phosphoenolpyruvate-dependent sugar: phosphotransferase system. We suggest that the products of the two genes facilitate the phosphorylative translocation and subsequent hydrolysis of the five alpha -D-glucosyl-D-fructoses by K. pneumoniae.	NIDCR, Microbial Biochem & Genet Unit, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; Tech Univ Darmstadt, Inst Organ Chem, D-64287 Darmstadt, Germany; Univ Rochester, Dept Biol, Rochester, NY 14627 USA; NIDCR, Vaccine & Therapeut Dev Sect, Oral & Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; Childrens Natl Med Ctr, Dept Infect Dis, Washington, DC 20010 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Technical University of Darmstadt; University of Rochester; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Children's National Health System	Thompson, J (corresponding author), NIDCR, Microbial Biochem & Genet Unit, Oral Infect & Immun Branch, NIH, Bldg 30,Rm 528,Convent Dr MSC-4350, Bethesda, MD 20892 USA.		PIKIS, ANDREAS/AFU-1192-2022					ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bouma CL, 1997, J BACTERIOL, V179, P4129, DOI 10.1128/jb.179.13.4129-4137.1997; BRICKAMNN J, 1996, MOLCAD MOL COMPUTER; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROWN GM, 1973, ACTA CRYSTALLOGR B, VB 29, P790, DOI 10.1107/S0567740873003353; *CAMBR CRYST DAT C, 2001, CAMBR STRUCT DAT VER; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DREISSIG W, 1973, Acta Crystallographica Section B Structural Crystallography and Crystal Chemistry, V29, P514, DOI 10.1107/S0567740873002839; GRESS ME, 1977, ACTA CRYSTALLOGR B, V33, P2490; HANSON JC, 1973, ACTA CRYSTALLOGR B, V29, P797, DOI 10.1107/S0567740873003365; HEIDEN W, 1993, J COMPUT AID MOL DES, V7, P503, DOI 10.1007/BF00124359; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; IMMEL S, 1995, LIEBIGS ANN, P1925, DOI 10.1002/jlac.1995199511272; *IUPAC, 1996, IUPAC REC NOM CARB; JEFFREY GA, 1985, CARBOHYD RES, V137, P21, DOI 10.1016/0008-6215(85)85146-6; KANTERS JA, 1978, ACTA CRYSTALLOGR B, V34, P1873, DOI 10.1107/S0567740878006871; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; KUNST F, 1974, EUR J BIOCHEM, V42, P611, DOI 10.1111/j.1432-1033.1974.tb03376.x; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; Lichtenthaler F. W., 1995, International Sugar Journal, V97, P12; LICHTENTHALER FW, 1990, J CHEM SOC PERK T 2, P1489, DOI 10.1039/p29900001489; LICHTENTHALER FW, 1991, STARCH-STARKE, V43, P121, DOI 10.1002/star.19910430402; LICHTENTHALER FW, 1993, CORRELATIONS HYDROPH, P21; LOESCHE WJ, 1986, MICROBIOL REV, V50, P353, DOI 10.1128/MMBR.50.4.353-380.1986; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Moynihan PJ, 1998, J DENT, V26, P209, DOI 10.1016/S0300-5712(97)00010-9; Newbrun E, 1989, CARIOLOGY, V3rd; NILSSON L, 1986, J COMPUT CHEM, V7, P591, DOI 10.1002/jcc.540070502; OHNO S, 1982, CARBOHYD RES, V108, P163, DOI 10.1016/S0008-6215(00)81786-3; OOSHIMA T, 1990, CARIES RES, V24, P48, DOI 10.1159/000261238; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Pons T, 1998, PROTEINS, V33, P383, DOI 10.1002/(SICI)1097-0134(19981115)33:3<383::AID-PROT7>3.0.CO;2-R; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; QUIGLEY GJ, 1970, J AM CHEM SOC, V92, P5834, DOI 10.1021/ja00723a003; Raasch C, 2000, EXTREMOPHILES, V4, P189, DOI 10.1007/PL00010711; REILING S, 1995, MACROMOL THEOR SIMUL, V4, P725, DOI 10.1002/mats.1995.040040409; Reiling S, 1996, J COMPUT CHEM, V17, P450, DOI 10.1002/(SICI)1096-987X(199603)17:4<450::AID-JCC6>3.0.CO;2-T; REIZER J, 1994, PROTEIN SCI, V3, P440; REIZER J, 1988, CRC CR REV MICROBIOL, V15, P297, DOI 10.3109/10408418809104461; SAPICO V, 1968, J BACTERIOL, V96, P51, DOI 10.1128/JB.96.1.51-54.1968; SCHIWECK H, 1990, ZUCKERINDUSTRIE, V115, P555; Schouten A, 1999, CARBOHYD RES, V322, P298, DOI 10.1016/S0008-6215(99)00235-9; SCHWENGERS D, 1991, CARBOHYDRATES AS ORGANIC RAW MATERIALS, P183; SPRENGER GA, 1988, J GEN MICROBIOL, V134, P1635; *SWISS I BIOINF, 2000, SWISS PROT PROT SEQ; TAKAZOE I, 1985, SWED DENT J, V9, P81; TESCHNER M, 1994, J MOL GRAPH MODEL, V12, P98, DOI 10.1016/0263-7855(94)80074-X; THIEM J, 1989, CARBOHYD RES, V189, P65, DOI 10.1016/0008-6215(89)84086-8; Thompson J, 1999, J BACTERIOL, V181, P7339, DOI 10.1128/JB.181.23.7339-7345.1999; Thompson J, 1998, J BIOL CHEM, V273, P27347, DOI 10.1074/jbc.273.42.27347; THOMPSON J, 1991, J BIOL CHEM, V266, P14573; THOMPSON J, 1995, J BACTERIOL, V177, P2505, DOI 10.1128/jb.177.9.2505-2512.1995; Thompson J, 2001, CARBOHYD RES, V331, P149, DOI 10.1016/S0008-6215(01)00028-3; Thompson J., 1987, SUGAR TRANSPORT META, P13; Titgemeyer F, 1996, MOL GEN GENET, V250, P197; Varrot A, 1999, ACTA CRYSTALLOGR D, V55, P1212, DOI 10.1107/S0907444999003790; Waldherr-Teschner M., 1992, Advances in Scientific Visualization, P58; Yamamoto H, 1996, MICROBIOL-SGM, V142, P1417, DOI 10.1099/13500872-142-6-1417; Yamamoto H, 2001, J BACTERIOL, V183, P5110, DOI 10.1128/JB.183.17.5110-5121.2001	61	41	45	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37415	37425		10.1074/jbc.M106504200	http://dx.doi.org/10.1074/jbc.M106504200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11473129	hybrid			2022-12-25	WOS:000171375700074
J	Burgess, HA; Reiner, O				Burgess, HA; Reiner, O			Cleavage of doublecortin-like kinase by calpain releases an active kinase fragment from a microtubule anchorage domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEINS; NEURITE OUTGROWTH; GROWTH CONE; NEURONAL MIGRATION; FUNCTIONAL DOMAINS; BRAIN-DEVELOPMENT; RAT-BRAIN; CALCIUM; EXPRESSION; CELLS	Doublecortin-like kinase (DCLK) is widely expressed in postmitotic neurons throughout the embryonic nervous system. DCLK consists of an N-terminal doublecortin domain, responsible for its localization to microtubules, and a C-terminal serine-threonine kinase domain. Here we report that DCLK is a physiological substrate for the cysteine protease calpain. Cleavage of DCLK by calpain severs the kinase domain from its microtubule anchorage domain and releases it into the cytoplasm. The isolated kinase domain retains catalytic activity and is structurally similar to CPG16, a second product of the DCLK gene expressed in the adult brain that lacks the doublecortin domain. We propose that in neurons cleavage of DCLK by calpain represents a calcium-responsive mechanism to regulate localization of the DCLK kinase domain.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Reiner, O (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		Burgess, Harold/B-8474-2015; Reiner, Orly/E-9455-2010	Burgess, Harold/0000-0003-1966-7801; Reiner, Orly/0000-0001-7560-9599				Arnold SE, 1996, J COMP NEUROL, V367, P293, DOI 10.1002/(SICI)1096-9861(19960401)367:2<293::AID-CNE10>3.0.CO;2-S; AVILA J, 1994, INT J DEV BIOL, V38, P13; BARNES JA, 1995, MOL CELL BIOCHEM, V149, P17, DOI 10.1007/BF01076559; Bi X, 1997, NEUROSCIENCE, V81, P1123, DOI 10.1016/S0306-4522(97)00218-2; Burgess HA, 1999, J NEUROSCI RES, V58, P567, DOI 10.1002/(SICI)1097-4547(19991115)58:4<567::AID-JNR9>3.3.CO;2-K; Burgess HA, 2000, MOL CELL NEUROSCI, V16, P529, DOI 10.1006/mcne.2000.0891; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Carillo S, 1996, BIOCHEM J, V313, P245, DOI 10.1042/bj3130245; CHAMAK B, 1989, DEVELOPMENT, V106, P483; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; des Portes V, 1998, CELL, V92, P51; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Gitler D, 1998, NEURON, V20, P1123, DOI 10.1016/S0896-6273(00)80494-8; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Goldberg DJ, 1999, NEURON, V22, P423, DOI 10.1016/S0896-6273(00)80697-2; Gomez TM, 2000, J NEUROBIOL, V44, P174, DOI 10.1002/1097-4695(200008)44:2<174::AID-NEU7>3.3.CO;2-I; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hasselgren PO, 1999, MOL BIOL REP, V26, P71, DOI 10.1023/A:1006916206260; IMAMURA K, 1992, NEUROSCI RES, V13, P33, DOI 10.1016/0168-0102(92)90032-8; Kato M, 2000, J BIOCHEM, V127, P297, DOI 10.1093/oxfordjournals.jbchem.a022607; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lin PT, 2000, J NEUROSCI, V20, P9152; Mizuguchi M, 1999, AM J PATHOL, V155, P1713, DOI 10.1016/S0002-9440(10)65486-7; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; MUGURUMA M, 1995, J BIOCHEM-TOKYO, V117, P1036, DOI 10.1093/oxfordjournals.jbchem.a124803; Nguyen TH, 1999, J NEUROCHEM, V73, P1995; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; ODA A, 1993, J BIOL CHEM, V268, P12603; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PERLMUTTER LS, 1988, SYNAPSE, V2, P79, DOI 10.1002/syn.890020111; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sapir T, 2000, HUM MOL GENET, V9, P703, DOI 10.1093/hmg/9.5.703; SHEA TB, 1995, J NEUROCHEM, V65, P517; SHEA TB, 1991, J NEUROCHEM, V56, P842, DOI 10.1111/j.1471-4159.1991.tb02000.x; Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631; SONG DK, 1994, J NEUROSCI RES, V39, P474, DOI 10.1002/jnr.490390414; Usui H, 1996, DEV BRAIN RES, V97, P185, DOI 10.1016/S0165-3806(96)00152-6; VIERECK C, 1989, J NEUROSCI, V9, P3547; VITTO A, 1986, J NEUROCHEM, V47, P1039; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Wilson MT, 2000, J NEUROBIOL, V43, P159, DOI 10.1002/(SICI)1097-4695(200005)43:2<159::AID-NEU6>3.0.CO;2-N; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	50	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36397	36403		10.1074/jbc.M105153200	http://dx.doi.org/10.1074/jbc.M105153200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11473121	hybrid			2022-12-25	WOS:000171194500047
J	Ning, ZQ; Li, J; McGuinness, M; Arceci, RJ				Ning, ZQ; Li, J; McGuinness, M; Arceci, RJ			STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity	ONCOGENE			English	Article						STAT3; c-Kit mutation; tumorigenicity	RECEPTOR TYROSINE KINASE; LIGAND-INDEPENDENT ACTIVATION; ACUTE MYELOID-LEUKEMIA; STEM-CELL FACTOR; CONSTITUTIVE ACTIVATION; SIGNALING PATHWAYS; NIH3T3 FIBROBLASTS; CATALYTIC DOMAIN; GENE-REGULATION; POINT MUTATION	Activating mutations of c-kit at codon 816 (Asp(816)) have been identified in variety of malignancies, including acute myeloid leukemia (AML), mastocytosis and germ cell tumors. The mutant c-Kit receptor confers cytokine independence and induces tumorigenicity. However, the molecular mechanisms, particularly the changes in the signal transduction pathways, responsible for these biological effects induced by mutant c-Kit are largely undefined. Using the human embryonic kidney cell line, 293, we show in the current report that constitutive activation of STAT3 and STAT1 is associated with D816H mutant c-Kit. Transfection of dominant negative STAT3, but not STAT1 inhibits mutant c-Kit mediated anchorage-independent growth in vitro and tumor formation in vivo. Expression of constitutively activated STAT3 restores the mutant c-Kit receptor's transforming ability in 293 cells. These results demonstrate that activation of STAT3 by Asp(816) mutant c-Kit is required for the anchorage-independent growth and tumorigenicity induced by Asp(816) mutant c-Kit.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD 21231 USA; Childrens Hosp, Med Ctr, Div Hematol Oncol, Cincinnati, OH 45229 USA	Johns Hopkins University; Johns Hopkins Medicine; Cincinnati Children's Hospital Medical Center	Arceci, RJ (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD 21231 USA.							ALEXANDER WS, 1991, EMBO J, V10, P3683, DOI 10.1002/j.1460-2075.1991.tb04936.x; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Ashman LK, 1999, LEUKEMIA LYMPHOMA, V34, P451, DOI 10.3109/10428199909058472; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caruana G, 1998, ONCOGENE, V16, P179, DOI 10.1038/sj.onc.1201494; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CROSIER PS, 1993, BLOOD, V82, P1151; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Ferrao P, 1997, BLOOD, V90, P4539; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hashimoto K, 1996, AM J PATHOL, V148, P189; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; Hunter MG, 2000, BLOOD, V95, P2132, DOI 10.1182/blood.V95.6.2132; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KANAKURA Y, 1994, LEUKEMIA, V8, pS18; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Leslie NR, 1998, BLOOD, V92, P4798, DOI 10.1182/blood.V92.12.4798.424k12_4798_4807; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; Moriyama Y, 1996, J BIOL CHEM, V271, P3347; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; NING ZQ, 2001, IN PRESS LEUK LYMPHO; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; PIETRA D, 1998, GENE, V213, P119; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; TSUJIMURA T, 1994, BLOOD, V83, P2619; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; Wooten DK, 2000, J BIOL CHEM, V275, P26566, DOI 10.1074/jbc.M003495200; Yajima T, 1998, HUM GENE THER, V9, P779, DOI 10.1089/hum.1998.9.6-779; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	56	70	73	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4528	4536		10.1038/sj.onc.1204590	http://dx.doi.org/10.1038/sj.onc.1204590			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494148				2022-12-25	WOS:000170074900010
J	Archer, SL; London, B; Hampl, V; Wu, XC; Nsair, A; Puttagunta, L; Hashimoto, K; Waite, RE; Michelakis, ED				Archer, SL; London, B; Hampl, V; Wu, XC; Nsair, A; Puttagunta, L; Hashimoto, K; Waite, RE; Michelakis, ED			Impairment of hypoxic pulmonary vasoconstriction in mice lacking the voltage-gated potassium channel Kv1.5	FASEB JOURNAL			English	Article						pulmonary circulation; Kv1.1; 4-aminopyridine; pulmonary artery; oxygen sensing; knockout mice; pulmonary hypertension; iberiotoxin	RECTIFIER K+ CURRENT; SMOOTH-MUSCLE CELLS; VASCULAR TONE; MOLECULAR-IDENTIFICATION; ARTERY MYOCYTES; RAT; INHIBITION; MECHANISM; HYPERTENSION; FENFLURAMINE	Hypoxic pulmonary vasoconstriction (HPV) is initiated by the inhibition of several 4-aminopyridine (4-AP)-sensitive, voltage-gated, K+ channels (Kv). Several O-2-sensitive candidate channels (Kv1.2, Kv1.5, Kv2.1, and Kv3.1b) have been proposed, based on similarities between their characteristics in expression systems and the properties of the O-2-sensitive K+ current (I-K) in pulmonary artery smooth muscle cells (PASMCs). We used gene targeting to delete Kv1.5 in mice by creating a SWAP mouse that is functionally a Kv1.5 knockout. We hypothesized that SWAP mice would display impaired HPV. The Kv1.5 alpha -subunits present in the endothelium and PASMCs of wild-type mice were absent in the lungs of SWAP mice, whereas expression of other channels Kv (1.1, 1.2, 2.1, 3.1, 4.3), Kir 3.1, Kir 6.1, and BKCa was unaltered. In isolated lungs and resistance PA rings, HPV was reduced significantly in SWAP versus wild-type mice. Consistent with this finding, PASMCs from SWAP PAs were slightly depolarized and lacked I-Kv1.5, a 4-AP and hypoxia-sensitive component of I-K that activated between -50 mV and -30 mV. We conclude that a K+ channel containing Kv1.5 alpha -subunits is an important effector of HPV in mice.	Univ Alberta, Dept Med, Div Cardiol,Vasc Biol Grp, Heart & Stroke Chair Cardiovasc Res, Edmonton, AB T6G 2B7, Canada; Univ Alberta, Dept Physiol, Edmonton, AB T6G 2B7, Canada; Univ Pittsburgh, Cardiovasc Inst, Pittsburgh, PA USA; Charles Univ, Dept Physiol, Sch Med 2, Prague, Czech Republic; Univ Alberta, Dept Pathol, Edmonton, AB T6G 2B7, Canada	University of Alberta; University of Alberta; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Charles University Prague; University of Alberta	Archer, SL (corresponding author), Univ Alberta, Dept Med, Div Cardiol,Vasc Biol Grp, Heart & Stroke Chair Cardiovasc Res, WMC 2C2-36,8440 112th St, Edmonton, AB T6G 2B7, Canada.	sarcher@cha.ab.ca	Hampl, Václav/A-2732-2009; Archer, Stephen L/C-3621-2013	Hampl, Václav/0000-0001-5776-4624; London, Barry/0000-0003-1506-3947				Archer SL, 2000, ADV EXP MED BIOL, V475, P219; ARCHER SL, 1986, HERZ, V11, P127; ARCHER SL, 1993, CIRC RES, V73, P1100, DOI 10.1161/01.RES.73.6.1100; Archer SL, 1999, P NATL ACAD SCI USA, V96, P7944, DOI 10.1073/pnas.96.14.7944; Archer SL, 1998, J CLIN INVEST, V101, P2319, DOI 10.1172/JCI333; Archer SL, 1996, CIRC RES, V78, P431, DOI 10.1161/01.RES.78.3.431; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; Clement-Chomienne O, 1999, J PHYSIOL-LONDON, V515, P653, DOI 10.1111/j.1469-7793.1999.653ab.x; ClementChomienne O, 1996, J PHYSIOL-LONDON, V495, P689, DOI 10.1113/jphysiol.1996.sp021626; COLLEY PS, 1977, ANESTHESIOLOGY, V47, P338, DOI 10.1097/00000542-197710000-00003; Conforti L, 1997, J PHYSIOL-LONDON, V502, P293, DOI 10.1111/j.1469-7793.1997.293bk.x; DANTZKER DR, 1981, J APPL PHYSIOL, V51, P607, DOI 10.1152/jappl.1981.51.3.607; DUPRAT F, 1995, P NATL ACAD SCI USA, V92, P11796, DOI 10.1073/pnas.92.25.11796; Euler Us V, 1946, ACTA PHYSL SCAND, V12, P301, DOI [10.1111/j.1748-1716.1946.tb00389.x, DOI 10.1111/J.1748-1716.1946.TB00389.X]; Gelband CH, 1997, CIRCULATION, V96, P3647; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HASUNUMA K, 1991, AM REV RESPIR DIS, V144, P884, DOI 10.1164/ajrccm/144.4.884; Hulme JT, 1999, CIRC RES, V85, P489, DOI 10.1161/01.RES.85.6.489; JIANG C, 1994, P NATL ACAD SCI USA, V91, P7198, DOI 10.1073/pnas.91.15.7198; London B, 2001, CIRC RES, V88, P940, DOI 10.1161/hh0901.090929; London B, 1998, J PHYSIOL-LONDON, V509, P171, DOI 10.1111/j.1469-7793.1998.171bo.x; LOPEZBARNEO J, 1988, SCIENCE, V241, P580, DOI 10.1126/science.2456613; MADDEN JA, 1992, AM J PHYSIOL, V263, pL384, DOI 10.1152/ajplung.1992.263.3.L384; MCMURTRY IF, 1976, CIRC RES, V38, P99, DOI 10.1161/01.RES.38.2.99; MCMURTRY IF, 1978, AM J PHYSIOL, V235, pH104, DOI 10.1152/ajpheart.1978.235.1.H104; Michelakis E, 2000, LANCET, V356, P134, DOI 10.1016/S0140-6736(00)02452-1; MOHAZZABH KM, 1995, AM J PHYSIOL-LUNG C, V269, pL637, DOI 10.1152/ajplung.1995.269.5.L637; OPARIL S, 1995, AM J PHYSIOL-LUNG C, V268, pL95, DOI 10.1152/ajplung.1995.268.1.L95; Osipenko ON, 2000, CIRC RES, V86, P534, DOI 10.1161/01.RES.86.5.534; Patel AJ, 1997, EMBO J, V16, P6615, DOI 10.1093/emboj/16.22.6615; POST JM, 1995, CIRC RES, V77, P131, DOI 10.1161/01.RES.77.1.131; POST JM, 1992, AM J PHYSIOL, V262, pC882, DOI 10.1152/ajpcell.1992.262.4.C882; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; Reeve HL, 2001, J APPL PHYSIOL, V90, P2249, DOI 10.1152/jappl.2001.90.6.2249; Sato K, 2000, AM J PHYSIOL-LUNG C, V278, pL434, DOI 10.1152/ajplung.2000.278.3.L434; Shimoda L, 1998, AM J PHYSIOL-LUNG C, V274, pL842, DOI 10.1152/ajplung.1998.274.5.L842; SHIRAI M, 1991, JPN J PHYSIOL, V41, P129, DOI 10.2170/jjphysiol.41.129; SMIRNOV SV, 1994, AM J PHYSIOL, V266, pH365, DOI 10.1152/ajpheart.1994.266.1.H365; Uebele VN, 1996, J BIOL CHEM, V271, P2406, DOI 10.1074/jbc.271.5.2406; Wang J, 1997, J CLIN INVEST, V100, P2347, DOI 10.1172/JCI119774; Wang JA, 1998, LANCET, V352, P290, DOI 10.1016/S0140-6736(05)60264-4; WARD JPT, 1995, EXP PHYSIOL, V80, P793, DOI 10.1113/expphysiol.1995.sp003887; Weir EK, 1996, CIRCULATION, V94, P2216, DOI 10.1161/01.CIR.94.9.2216; WEIR EK, 1995, FASEB J, V9, P183, DOI 10.1096/fasebj.9.2.7781921; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0; YUAN XJ, 1995, CIRC RES, V77, P370, DOI 10.1161/01.RES.77.2.370; YUAN XJ, 1996, CIRCULATION, V94, P1; ZHAO Y, 1993, AM J PHYSIOL, V265, pL87	49	116	121	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1801	+		10.1096/fj.00-0649fje	http://dx.doi.org/10.1096/fj.00-0649fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481235				2022-12-25	WOS:000169261200019
J	Muller, DN; Heissmeyer, V; Dechend, R; Hampich, F; Park, JK; Fiebeler, A; Shagdarsuren, E; Theuer, J; Elger, M; Pilz, B; Breu, V; Schroer, K; Ganten, D; Dietz, R; Haller, H; Scheidereit, C; Luft, FC				Muller, DN; Heissmeyer, V; Dechend, R; Hampich, F; Park, JK; Fiebeler, A; Shagdarsuren, E; Theuer, J; Elger, M; Pilz, B; Breu, V; Schroer, K; Ganten, D; Dietz, R; Haller, H; Scheidereit, C; Luft, FC			Aspirin inhibits NF-kappa B and protects from angiotensin II-induced organ damage	FASEB JOURNAL			English	Article						angiotensin II; aspirin, NF-kappa B; end-organ damage; inflammation	VASCULAR SMOOTH-MUSCLE; SODIUM-SALICYLATE; TRANSCRIPTION FACTOR; TISSUE FACTOR; IKK COMPLEX; ACTIVATION; RENIN; PHOSPHORYLATION; EXPRESSION; TARGET	Angiotensin (Ang)-II induces vascular wall inflammation by activating NF-kappaB. Aspirin inhibits IKK beta in vitro; however, the in vivo relevance of the phenomenon is unclear. We tested the hypothesis that aspirin protects from Ang II-induced endorgan damage by inhibiting NF-kappaB activation in vivo. Rats harboring human renin and angiotensinogen genes received high- (600 mg/kg/day) or low- (25 mg/kg/day) dose aspirin. High-dose aspirin reduced mortality, cardiac hypertrophy, fibrosis, and albuminuria independent of blood pressure, whereas both doses reduced cyclooxygenase activity. High-dose aspirin inhibited NF-kappaB and AP-1 activation and inflammation in heart and kidney. These in vivo results serve to explain the clinical utility of high- dose aspirin in inflammatory disorders and suggest additional therapeutic avenues that may be relevant to cardiovascular disease.	Humboldt Univ, Fac Med Charite, Franz Volhard Clin, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Hannover Med Sch, Hannover, Germany; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland; Free Univ Berlin, D-1000 Berlin, Germany; Univ Dusseldorf, D-4000 Dusseldorf, Germany	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Hannover Medical School; Roche Holding; Free University of Berlin; Heinrich Heine University Dusseldorf	Luft, FC (corresponding author), Humboldt Univ, Fac Med Charite, Franz Volhard Clin, Wiltberg Str 50, D-13125 Berlin, Germany.	luft@fvk-berlin.de	Shagdarsuren, Erdenechimeg/AGG-0467-2022	Muller, Dominik N/0000-0003-3650-5644; Heissmeyer, Vigo/0000-0002-2263-8545; Luft, Friedrich/0000-0002-8635-1199				AARONS L, 1989, PHARMACEUT RES, V6, P660, DOI 10.1023/A:1015978104017; ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; Alpert D, 2000, J BIOL CHEM, V275, P10925, DOI 10.1074/jbc.275.15.10925; AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Berk BC, 1999, J AM SOC NEPHROL, V10, pS62; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hernandez-Presa MA, 1998, AM J PATHOL, V153, P1825, DOI 10.1016/S0002-9440(10)65697-0; INGELFINGER JR, 1991, J AM SOC NEPHROL, V2, pS9; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Khoshnan A, 1999, J IMMUNOL, V163, P5444; Klahr S, 2000, KIDNEY INT, V57, pS7, DOI 10.1046/j.1523-1755.2000.07509.x; Klahr S, 1997, KIDNEY INT, pS111; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Krappmann D, 2000, J BIOL CHEM, V275, P29779, DOI 10.1074/jbc.M003902200; KRIZ W, 1995, KIDNEY INT, V48, P1435, DOI 10.1038/ki.1995.433; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Malik FS, 1997, AM HEART J, V134, P514, DOI 10.1016/S0002-8703(97)70089-9; Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124; Mervaala E, 2000, HYPERTENSION, V35, P587, DOI 10.1161/01.HYP.35.2.587; Moriguchi Y, 1999, CIRC RES, V84, P1073, DOI 10.1161/01.RES.84.9.1073; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Morrissey JJ, 1997, KIDNEY INT, V52, P926, DOI 10.1038/ki.1997.414; Muller DN, 2000, AM J PATHOL, V157, P111, DOI 10.1016/S0002-9440(10)64523-3; Muller DN, 2000, HYPERTENSION, V36, P282, DOI 10.1161/01.HYP.36.2.282; Muller DN, 2000, HYPERTENSION, V35, P193, DOI 10.1161/01.HYP.35.1.193; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; O'Neill EA, 1998, NATURE, V396, P15, DOI 10.1038/23810; Pierce JW, 1996, J IMMUNOL, V156, P3961; Ruiz-Ortega M, 1998, J IMMUNOL, V161, P430; Ruiz-Ortega M, 2000, CIRC RES, V86, P1266, DOI 10.1161/01.RES.86.12.1266; Sadoshima J, 2000, CIRC RES, V86, P1187, DOI 10.1161/01.RES.86.12.1187; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; Tomita N, 2000, J AM SOC NEPHROL, V11, P1244, DOI 10.1681/ASN.V1171244; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Viedt C, 2000, ARTERIOSCL THROM VAS, V20, P940, DOI 10.1161/01.ATV.20.4.940; Vos IHC, 2000, FASEB J, V14, P815, DOI 10.1096/fasebj.14.5.815; Weir MR, 1999, AM J HYPERTENS, V12, p205S; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; WIENTJES MG, 1988, J PHARMACOL EXP THER, V245, P809; Wu KK, 2000, CIRCULATION, V102, P2022, DOI 10.1161/01.CIR.102.17.2022; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	48	79	83	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1822	+		10.1096/fj.00-0843fje	http://dx.doi.org/10.1096/fj.00-0843fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481242				2022-12-25	WOS:000169261200014
J	Au, WC; Pitha, PM				Au, WC; Pitha, PM			Recruitment of multiple interferon regulatory factors and histone acetyltransferase to the transcriptionally active interferon A promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-INFECTION; GENE-EXPRESSION; POSITIVE FEEDBACK; ALPHA GENES; ACTIVATION; INDUCTION; COACTIVATOR; BINDING; PROTEIN; IRF-1	Type I interferon (IFN) plays a critical role in the innate immunity against viral infection. Expression of IFNA genes in infected cells is cell type-dependent and is regulated at the transcriptional level. The present study is focused on the molecular mechanism underlying the differential expression of human IFNA1 and A2 genes. Two nucleotides, at positions -98 and -81 of IFNA1 and A2 promoter, were pivotal to the differential expression. The DNA pull-down and chromatin precipitation assays have shown that nuclear interferon regulatory factor (IRF)-3 and IRF-7 as well as IRF-1 bind to IFNA1 virus-responsive element (VRE). Interestingly, overexpression of IRF-7 increased the otherwise weak binding of both IRF-3 and IRF-7 to IFNA2 VRE. These data together with the results of two-step chromatin immunoprecipitation strongly suggest that the IRF-3 and IRF-7 bind to IFNA1 promoter as a dimer. Furthermore, binding of IRF-3 and IRF-7 to IFNA VRE is associated with the presence of acetylated histone H3, suggesting that histone acetyltransferase(s) is tethered together with virus-activated IRF-3 and IRF-7 to the IFNA1 promoter. In addition, the constitutively active IRF-3 (5D) and IRF-7 (2D) mutants activate the endogenous IFNA genes in uninfected cells; however, the expression profile of IFNA is not identical to that induced by viral infection.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Genet, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University	Pitha, PM (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Canc Res Bldg,1650 Orleans St, Baltimore, MD 21231 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019373, R21AI048081] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 48081, AI-19373-18] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Au WC, 2001, VIROLOGY, V280, P273, DOI 10.1006/viro.2000.0782; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Burysek L, 1999, J VIROL, V73, P7334; Burysek L, 1999, J HUMAN VIROL, V2, P19; Dent CL, 1996, J INTERF CYTOK RES, V16, P99, DOI 10.1089/jir.1996.16.99; Escalante CR, 1997, FEBS LETT, V414, P219, DOI 10.1016/S0014-5793(97)00996-4; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; HISCOTT J, 1995, SEMIN VIROL, V6, P161, DOI 10.1006/smvy.1995.0021; HISCOTT J, 1984, NUCLEIC ACIDS RES, V12, P3727, DOI 10.1093/nar/12.9.3727; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Lubyova B, 2000, J VIROL, V74, P8194, DOI 10.1128/JVI.74.17.8194-8201.2000; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; Masumi A, 1999, MOL CELL BIOL, V19, P1810; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEGYERI K, 1995, MOL CELL BIOL, V15, P2207; Meraro D, 1999, J IMMUNOL, V163, P6468; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Xie RL, 2001, J BIOL CHEM, V276, P18624, DOI 10.1074/jbc.M010391200; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yeow WS, 2001, J VIROL, V75, P3021, DOI 10.1128/JVI.75.6.3021-3027.2001; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748	45	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41629	41637		10.1074/jbc.M105121200	http://dx.doi.org/10.1074/jbc.M105121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11473119	hybrid			2022-12-25	WOS:000172450400014
J	Dolci, S; Pellegrini, M; Di Agostino, S; Geremia, R; Rossi, P				Dolci, S; Pellegrini, M; Di Agostino, S; Geremia, R; Rossi, P			Signaling through extracellular signal-regulated kinase is required for spermatogonial proliferative response to stem cell factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE; C-KIT PROTOONCOGENE; MESSENGER-RNA; DNA-SYNTHESIS; GERM-CELLS; W-LOCUS; MOUSE; EXPRESSION; ACTIVATION; RECEPTOR	In vitro addition of stem cell factor (SCF) to c-kit-expressing A(1)-A(4) spermatogonia from prepuberal mice stimulates their progression into the mitotic cell cycle and significantly reduces apoptosis in these cells. SCF addition results in a transient activation of extracellular signal-regulated kinases (Erk)1/2 as well as of phosphatidylinositol 3-kinase (PI3K)-dependent Akt kinase. These events are followed by a rapid redistribution of cyclin D3, which becomes predominantly nuclear, whereas its total cellular amount does not change. Nuclear accumulation of cyclin D3 is coupled to transient activation of the associated kinase activity, assayed using the retinoblastoma protein (Rb) as a substrate. These events were followed by a transient accumulation of cyclin E, stimulation of the associated histone HI-kinase activity, a delayed accumulation of cyclin A2, and Rb hyper-phosphorylation. All the events associated with SCF-induced cell cycle progression are inhibited by the addition of either a PI3K inhibitor or a mitogen-activated protein-kinase kinase (MEK) inhibitor, indicating that both MEK and PI3K are essential for c-kit-mediated proliferative response. On the contrary, the anti-apoptotic effect of SCF is not influenced by the separate addition of either MEK or PI3K inhibitors. Thus, SCF effects on mitogenesis and survival in c-kit expressing spermatogonia rely on different signal transduction pathways.	Univ Roma Tor Vergata, Sezione Anat, Dipartimento Sanita Pubbl & Biol Cellulare, I-00173 Rome, Italy	University of Rome Tor Vergata	Rossi, P (corresponding author), Univ Roma Tor Vergata, Sezione Anat, Dipartimento Sanita Pubbl & Biol Cellulare, Via O Raimondo 8, I-00173 Rome, Italy.	pellegrino.rossi@med.uniroma2.it	Pellegrini, manuela/AAC-1423-2022; dolci, susanna/B-8363-2013; Di Agostino, Silvia/S-8566-2019; Rossi, Pellegrino/AAA-7072-2019; Di Agostino, Silvia/H-1121-2018	dolci, susanna/0000-0002-6864-3673; Di Agostino, Silvia/0000-0003-3730-1125; pellegrini, manuela/0000-0001-6387-5187; ROSSI, PELLEGRINO/0000-0003-4796-327X; GEREMIA, Raffaele/0000-0001-9056-6603				Albanesi C, 1996, DEVELOPMENT, V122, P1291; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Beumer TL, 2000, BIOL REPROD, V63, P1893, DOI 10.1095/biolreprod63.6.1893; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; BRANNAN CI, 1992, GENE DEV, V6, P1832, DOI 10.1101/gad.6.10.1832; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Depoortere F, 1998, J CELL BIOL, V140, P1427, DOI 10.1083/jcb.140.6.1427; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Hakovirta H, 1999, ENDOCRINOLOGY, V140, P1492, DOI 10.1210/en.140.3.1492; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Kissel H, 2000, EMBO J, V19, P1312, DOI 10.1093/emboj/19.6.1312; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MANOVA K, 1991, DEV BIOL, V146, P312, DOI 10.1016/0012-1606(91)90233-S; MONESI V, 1962, J CELL BIOL, V14, P1, DOI 10.1083/jcb.14.1.1; Ohta H, 2000, DEVELOPMENT, V127, P2125; PACKER AI, 1995, MOL REPROD DEV, V42, P303, DOI 10.1002/mrd.1080420307; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Ravnik SE, 1996, DEV BIOL, V173, P69, DOI 10.1006/dbio.1996.0007; ROSSI P, 1991, BIOCHEM BIOPH RES CO, V176, P910, DOI 10.1016/S0006-291X(05)80272-4; ROSSI P, 1992, DEV BIOL, V152, P203, DOI 10.1016/0012-1606(92)90172-D; ROSSI P, 1993, DEV BIOL, V155, P68, DOI 10.1006/dbio.1993.1007; Schrans-Stassen BHGJ, 1999, ENDOCRINOLOGY, V140, P5894, DOI 10.1210/en.140.12.5894; Sette C, 2000, INT J DEV BIOL, V44, P599; Sette C, 1998, J CELL BIOL, V142, P1063, DOI 10.1083/jcb.142.4.1063; Sette C, 1997, DEVELOPMENT, V124, P2267; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SORRENTINO V, 1991, ONCOGENE, V6, P149; SUNG WK, 1986, GAMETE RES, V14, P245, DOI 10.1002/mrd.1120140308; TAJIMA Y, 1994, J REPROD FERTIL, V102, P117, DOI 10.1530/jrf.0.1020117; Tong W, 1999, MOL CELL BIOL, V19, P2251; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Wu M, 2000, GENE DEV, V14, P301; Yan W, 2000, J CELL SCI, V113, P161; Yan W, 1999, ENDOCRINOLOGY, V140, P1499, DOI 10.1210/en.140.3.1499; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; Zhang Q, 1999, ENDOCRINOLOGY, V140, P2790, DOI 10.1210/en.140.6.2790	42	100	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40225	40233		10.1074/jbc.M105143200	http://dx.doi.org/10.1074/jbc.M105143200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11502745	hybrid			2022-12-25	WOS:000171789200095
J	Brinkworth, RI; Prociv, P; Loukas, A; Brindley, PJ				Brinkworth, RI; Prociv, P; Loukas, A; Brindley, PJ			Hemoglobin-degrading, aspartic proteases of blood-feeding parasites - Substrate specificity revealed by homology models	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOOKWORM ANCYLOSTOMA-CANINUM; HUMAN CATHEPSIN-D; PLASMODIUM-FALCIPARUM; SCHISTOSOMA-MANSONI; CYSTEINE PROTEINASE; PLASMEPSIN-II; ENZYME; DEGRADATION; GENERATION; INHIBITION	Blood-feeding parasites, including schistosomes, hookworms, and malaria parasites, employ aspartic proteases to make initial or early cleavages in ingested host hemoglobin. To better understand the substrate affinity of these aspartic proteases, sequences were aligned with and/or three-dimensional, molecular models were constructed of the cathepsin D-like aspartic proteases of schistosomes and hookworms and of plasmepsins of Plasmodium falciparum and Plasmodium vivax, using the structure of human cathepsin D bound to the inhibitor pepstatin as the template. The catalytic subsites S5 through S4' were determined for the modeled parasite proteases. Subsequently, the crystal structure of mouse renin complexed with the nonapeptidyl inhibitor t-butyl-CO-His-Pro-Phe-His-Leu [CHOHCH2]Leu-Tyr-Tyr-Ser-NH2 (CH-66) was used to build homology models of the hemoglobin-degrading peptidases docked with a series of octapeptide substrates. The modeled octapeptides included representative sites in hemoglobin known to be cleaved by both Schistosoma japonicum cathepsin D and human cathepsin D, as well as sites cleaved by one but not the other of these enzymes. The peptidase-octapeptide substrate models revealed that differences in cleavage sites were generally attributable to the influence of a single amino acid change among the P5 to P4' residues that would either enhance or diminish the enzymatic affinity. The difference in cleavage sites appeared to be more profound than might be expected from sequence differences in the enzymes and hemoglobins. The findings support the notion that selective inhibitors of the hemoglobin-degrading peptidases of blood-feeding parasites at large could be developed as novel anti-parasitic agents.	Tulane Univ, Hlth Sci Ctr, Dept Trop Med, Sch Publ Hlth & Trop Med, New Orleans, LA 70112 USA; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia; Queensland Inst Med Res, Div Infect Dis & Immunol, Brisbane, Qld 4029, Australia	Tulane University; University of Queensland; University of Queensland; QIMR Berghofer Medical Research Institute	Brindley, PJ (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Trop Med, Sch Publ Hlth & Trop Med, SL29A,1430 Tulane Ave, New Orleans, LA 70112 USA.		Loukas, Alex/B-7355-2014	Loukas, Alex/0000-0002-0896-8441; Brindley, Paul J./0000-0003-1765-0002				BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY, P919; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P801; BECKER MM, 1995, J BIOL CHEM, V270, P24496, DOI 10.1074/jbc.270.41.24496; Becker MM, 1997, J BIOL CHEM, V272, P17246; Bernstein NK, 1999, NAT STRUCT BIOL, V6, P32, DOI 10.1038/4905; Beyer BM, 1996, J BIOL CHEM, V271, P15590, DOI 10.1074/jbc.271.26.15590; Brady CP, 2000, ARCH BIOCHEM BIOPHYS, V380, P46, DOI 10.1006/abbi.2000.1905; Brindley PJ, 2001, MOL BIOCHEM PARASIT, V112, P103, DOI 10.1016/S0166-6851(00)00351-0; Brinkworth RI, 2000, INT J BIOCHEM CELL B, V32, P373, DOI 10.1016/S1357-2725(99)00129-6; Brinkworth RI, 1996, BBA-PROTEIN STRUCT M, V1298, P4, DOI 10.1016/S0167-4838(96)00150-1; Brinkworth RI, 2000, INT J PARASITOL, V30, P785, DOI 10.1016/S0020-7519(00)00045-X; CONNER GE, 1998, HDB PROTEOLYTIC ENZY, P828; COPELAND TD, 1990, BIOCHEM BIOPH RES CO, V169, P310, DOI 10.1016/0006-291X(90)91469-9; Despommier D, 2000, PARASITIC DIS; DHANARAJ V, 1992, NATURE, V357, P466, DOI 10.1038/357466a0; Fruitier I, 1998, BIOCHEM BIOPH RES CO, V246, P719, DOI 10.1006/bbrc.1998.8614; Ghoneim H, 1995, INT J PARASITOL, V25, P1515, DOI 10.1016/0020-7519(95)00079-8; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1998, HDB PROTEOLYTIC ENZY, P860; GOLDBERG DE, 1998, HDB PROTEOLYTIC ENZY, P858; Harrop SA, 1996, BIOCHEM BIOPH RES CO, V227, P294, DOI 10.1006/bbrc.1996.1503; Hewitt EW, 1997, J IMMUNOL, V159, P4693; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; McKerrow JH, 1999, INT J PARASITOL, V29, P833, DOI 10.1016/S0020-7519(99)00044-2; Moon RP, 1998, ADV EXP MED BIOL, V436, P397; RICH DH, 1985, BIOCHEMISTRY-US, V24, P3165, DOI 10.1021/bi00334a014; SCARBOROUGH PE, 1993, PROTEIN SCI, V2, P264; Shear HL, 1998, BLOOD, V92, P2520, DOI 10.1182/blood.V92.7.2520.2520_2520_2526; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; TANG J, 1998, HDB PROTEOLYTIC ENZY, P806; VANNOORT JM, 1989, J BIOL CHEM, V264, P14159; Wong JYM, 1997, BBA-PROTEIN STRUCT M, V1338, P156, DOI 10.1016/S0167-4838(97)00019-8	33	55	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38844	38851		10.1074/jbc.M101934200	http://dx.doi.org/10.1074/jbc.M101934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495896	hybrid			2022-12-25	WOS:000171673200069
J	Opavsky, R; Haviernik, P; Jurkovicova, D; Garin, MT; Copeland, NG; Gilbert, DJ; Jenkins, NA; Bies, J; Garfield, S; Pastorekova, S; Oue, A; Wolff, L				Opavsky, R; Haviernik, P; Jurkovicova, D; Garin, MT; Copeland, NG; Gilbert, DJ; Jenkins, NA; Bies, J; Garfield, S; Pastorekova, S; Oue, A; Wolff, L			Molecular characterization of the mouse Tem1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; ENDOTHELIAL-CELLS; CYTOPLASMIC DOMAIN; THROMBOMODULIN; ANGIOGENESIS; PROTEIN; THROMBIN; SURFACE; CANCER; IDENTIFICATION	Human tumor endothelial marker 1/endosialin (TEM1/ endosialin) was recently identified as a novel tumor endothelial cell surface marker potentially involved in angiogenesis, although no specific function for this novel gene has been assigned so far. It was reported to be expressed in tumor endothelium but not in normal endothelium with the exception of perhaps the corpus luteum. Here we describe the cDNA and genomic sequences for the mouse Tem1/endosialin homolog, the identification and characterization of its promoter region, and an extensive characterization of its expression pattern in murine and human tissues and murine cell lines in vitro. The single copy gene that was mapped to chromosome 19 is intronless and encodes a 92-kDa protein that has 77.5% overall homology to the human protein. The remarkable findings are 1) this gene is ubiquitously expressed in normal human and mouse somatic tissues and during development, and 2) its expression at the mRNA level is density-dependent and up-regulated in serum-starved cells. In vitro, its expression is limited to cells of embryonic, endothelial, and preadipocyte origin, suggesting that the wide distribution of its expression in vivo is due to the presence of vascular endothelial cells in all the tissues. The ubiquitous expression in vivo is in contrast to previously reported expression limited to corpus luteum and highly angiogenic tissues such as tumors and wound tissue.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; NCI, Mouse Canc Genet Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Slovak Acad Sci, Mol Virol Lab, Canc Res Inst, Bratislava 83392, Slovakia; NCI, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Slovak Acad Sci, Inst Virol, Bratislava 84245, Slovakia; NCI, Basic Res Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; NIMH, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Slovak Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Slovak Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Wolff, L (corresponding author), NCI, Cellular Oncol Lab, NIH, Bldg 37,Rm 2D11,37 Convent Dr, Bethesda, MD 20892 USA.		Pastorekova, Silvia/C-6685-2018	Jurkovicova, Dana/0000-0002-7997-6932				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Berra E, 2000, BIOCHEM PHARMACOL, V60, P1171, DOI 10.1016/S0006-2952(00)00423-8; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carmeliet P, 2000, J PATHOL, V190, P387; Chang JHT, 1997, J NEUROSCI, V17, P5881; Christian S, 2001, J BIOL CHEM, V276, P7408, DOI 10.1074/jbc.M009604200; Cines DB, 1998, BLOOD, V91, P3527; CONWAY EM, 1994, J CELL PHYSIOL, V158, P285, DOI 10.1002/jcp.1041580211; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DONOGHUE DJ, 1983, J VIROL, V45, P607, DOI 10.1128/JVI.45.2.607-617.1983; Duncker BP, 1997, MOL GEN GENET, V254, P291, DOI 10.1007/s004380050418; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Gentles AJ, 1999, TRENDS GENET, V15, P47, DOI 10.1016/S0168-9525(98)01648-5; Gonzalez-Amaro R, 1999, CRIT REV IMMUNOL, V19, P389; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KODAMA H, 1984, J CELL PHYSIOL, V118, P233, DOI 10.1002/jcp.1041180303; Lafay M, 1998, THROMB HAEMOSTASIS, V79, P848, DOI 10.1055/s-0037-1615076; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Li JM, 2000, J VASC SURG, V32, P804, DOI 10.1067/mva.2000.107992; Masuda M, 1996, VIROLOGY, V215, P142, DOI 10.1006/viro.1996.0017; Nepomuceno RR, 1999, J IMMUNOL, V162, P3583; Olivot JM, 2001, CIRC RES, V88, P681, DOI 10.1161/hh0701.088769; Osoegawa K, 2000, GENOME RES, V10, P116; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RETTIG WJ, 1992, P NATL ACAD SCI USA, V89, P10832, DOI 10.1073/pnas.89.22.10832; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Sadler JE, 1997, THROMB HAEMOSTASIS, V78, P392; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; St Croix B, 2000, SCIENCE, V289, P1197; TEASDALE MS, 1994, IMMUNOL CELL BIOL, V72, P480, DOI 10.1038/icb.1994.72; Thompson WD, 2000, J PATHOL, V190, P330, DOI 10.1002/(SICI)1096-9896(200002)190:3<330::AID-PATH588>3.0.CO;2-4; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; WeilerGuettler H, 1996, DEVELOPMENT, V122, P2271; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	39	51	66	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38795	38807		10.1074/jbc.M105241200	http://dx.doi.org/10.1074/jbc.M105241200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489895	hybrid			2022-12-25	WOS:000171673200063
J	Sampath, J; Sun, DX; Kidd, VJ; Grenet, J; Gandhi, A; Shapiro, LH; Wang, QJ; Zambetti, GP; Schuetz, JD				Sampath, J; Sun, DX; Kidd, VJ; Grenet, J; Gandhi, A; Shapiro, LH; Wang, QJ; Zambetti, GP; Schuetz, JD			Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; P-GLYCOPROTEIN; TUMOR-SUPPRESSOR; GENE-EXPRESSION; WILD-TYPE; TRANSCRIPTIONAL REPRESSION; COLORECTAL-CANCER; TERMINAL DOMAIN; POOR-PROGNOSIS; IN-VIVO	The most frequently expressed drug resistance genes, MDR1 and MRP1, occur in human tumors with mutant p53. However, it was unknown if mutant p53 transcriptionally regulated both MDR1 and MRP1. We demonstrated that mutant p53 did not activate either the MRP1 promoter or the endogenous gene. In contrast, mutant p53 strongly up-regulated the MDR1 promoter and expression of the endogenous MDR1 gene. Notably, cells that expressed either a transcriptionally inactive mutant p53 or the empty vector showed no endogenous MDR1 up-regulation. Transcriptional activation of the MDR1 promoter by mutant p53 required an Ets binding site, and mutant p53 and Ets-1 synergistically activated MDR1 transcription. Biochemical analysis revealed that Ets-1 interacted exclusively with mutant p53s in vivo but not with wild-type p53. These findings are the first to demonstrate the induction of endogenous MDR1 by mutant p53 and provide insight into the mechanism.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Schuetz, JD (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	john.schuetz@stjude.org	Zambetti, Gerard/N-8093-2018; Schuetz, John D/N-2692-2018	Zambetti, Gerard/0000-0002-0929-5007; 	NCI NIH HHS [P30 CA21765, CA23099, CA63203] Funding Source: Medline; NHLBI NIH HHS [P01 HL070694] Funding Source: Medline; NIEHS NIH HHS [ES05851] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, P01CA023099] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005851, R29ES005851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Buttitta F, 1997, BRIT J CANCER, V75, P230, DOI 10.1038/bjc.1997.38; DEANGELIS P, 1995, BRIT J CANCER, V72, P307, DOI 10.1038/bjc.1995.329; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Djelloul S, 1997, FEBS LETT, V406, P234, DOI 10.1016/S0014-5793(97)00208-1; FAN SJ, 1994, CANCER RES, V54, P5824; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Fukushima Y, 1999, EUR J CANCER, V35, P935, DOI 10.1016/S0959-8049(99)00035-0; Gallagher WM, 1999, ONCOGENE, V18, P3608, DOI 10.1038/sj.onc.1202937; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Lecureur V, 2000, MOL PHARMACOL, V57, P24; Lecureur V, 2001, ONCOGENE, V20, P303, DOI 10.1038/sj.onc.1204065; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; Linn SC, 1996, BRIT J CANCER, V74, P63, DOI 10.1038/bjc.1996.316; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; Oka M, 1997, JPN J CANCER RES, V88, P738, DOI 10.1111/j.1349-7006.1997.tb00445.x; Ralhan R, 1999, INT J CANCER, V84, P80, DOI 10.1002/(SICI)1097-0215(19990219)84:1<80::AID-IJC15>3.0.CO;2-G; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Sigal A, 2000, CANCER RES, V60, P6788; Sullivan GF, 2000, J CLIN INVEST, V105, P1261, DOI 10.1172/JCI9290; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; Thottassery JV, 1999, J BIOL CHEM, V274, P3199, DOI 10.1074/jbc.274.5.3199; Tillman DM, 1998, CELL DEATH DIFFER, V5, P450, DOI 10.1038/sj.cdd.4400369; VOGELSTEIN B, 1994, COLD SPRING HARB SYM, V59, P517, DOI 10.1101/SQB.1994.059.01.057; Wang LH, 1998, ANTICANCER RES, V18, P321; Wang QJ, 1998, CANCER RES, V58, P5762; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	43	174	185	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39359	39367		10.1074/jbc.M103429200	http://dx.doi.org/10.1074/jbc.M103429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11483599	hybrid			2022-12-25	WOS:000171673200135
J	Deane, CM; Lummis, SCR				Deane, CM; Lummis, SCR			The role and predicted propensity of conserved proline residues in the 5-HT3 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS PEPTIDE-BONDS; LIGAND-BINDING; PROTEIN; SUBUNIT; LOOP; CONFORMATIONS; MUTAGENESIS; EXPRESSION; M2-M3; STEP	5-HT3, receptors possess a number of highly conserved proline residues. We changed each of these to alanine, expressed the mutants as homomeric 5-HT3A receptors in HEK293 cells, and analyzed them with radioligand binding, electrophysiology, and immunocytochemistry. Mutation of Pro(58), Pro(104), Pro(123), and Pro(170) resulted in ablation of radioligand binding, whereas mutation of Pro(257) and Pro(301) did not. Only the latter were expressed at the plasma membrane but were non-functional. Thus the former, which are in the N-terminal domain, may be involved in forming correct receptor structure, while those in the transmembrane region (Pro(257) and Pro(301)) are necessary for the function of the protein. To explore the conformational preference (propensity) of these residues we examined the proportion of cis-prolines and the influence of adjacent residues in known protein structures. 4.7% of prolines in the protein data base were in the cis conformation, and the distribution of amino acids adjacent to cis-prolines was not randomly distributed. Comparison of the proportion of each amino acid residue adjacent to a cis-proline revealed that aromatic and bend-facilitating residues were favored while those with beta -branched chains were not. Thus five residues (Gly, Pro, Tyr, Trp, Phe) and three residues (Pro, Tyr, Phe) were found more frequently than expected before and after cis-prolines respectively, whereas five residues (Val, Ile, Leu, Asp, Thr) and two residues (Asp, Glu) were found less frequently. Of the 20 proline residues in the 5-HT3A receptor subunit only Pro(170) has adjacent residues that are favorable. Mutating these to non-favorable residues resulted in ablation of ligand binding, whereas replacement with alternative favorable residues did not. We therefore propose that Pro(170), which is part of the characteristic cys-loop found in this family of proteins, may be in the cis conformation.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge	Lummis, SCR (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1GA, England.	s.lummis@mole.bio.cam.ac.uk		Deane, Charlotte/0000-0003-1388-2252				Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Dang H, 2000, MOL PHARMACOL, V57, P1114; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; Deane CM, 1999, PROTEIN ENG, V12, P1025, DOI 10.1093/protein/12.12.1025; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; Fu DX, 1996, J BIOL CHEM, V271, P31479, DOI 10.1074/jbc.271.49.31479; Grosman C, 2000, J GEN PHYSIOL, V116, P327, DOI 10.1085/jgp.116.3.327; HARGREAVES AC, 1994, MOL PHARMACOL, V46, P1120; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; Jabs A, 1999, J MOL BIOL, V286, P291, DOI 10.1006/jmbi.1998.2459; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUSAMA T, 1994, NEUROREPORT, V5, P1209, DOI 10.1097/00001756-199406020-00012; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; North R.A., 1995, HDB RECEPTORS CHANNE; ODEFEY C, 1995, J MOL BIOL, V245, P69, DOI 10.1006/jmbi.1994.0007; Pal D, 1999, J MOL BIOL, V294, P271, DOI 10.1006/jmbi.1999.3217; Reimer U, 1998, J MOL BIOL, V279, P449, DOI 10.1006/jmbi.1998.1770; Rovira JC, 1998, FEBS LETT, V433, P89, DOI 10.1016/S0014-5793(98)00889-8; Rovira JC, 1999, PFLUG ARCH EUR J PHY, V439, P86, DOI 10.1007/s004240051131; SALI A, 1994, PROTEIN SCI, V3, P1582, DOI 10.1002/pro.5560030923; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; SEPULVEDA MI, 1991, BRIT J PHARMACOL, V104, P536, DOI 10.1111/j.1476-5381.1991.tb12464.x; Spier AD, 1999, MOL BRAIN RES, V67, P221; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J	30	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37962	37966						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11495906				2022-12-25	WOS:000171526500034
J	Arthur, JF; Matkovich, SJ; Mitchell, CJ; Biden, TJ; Woodcock, EA				Arthur, JF; Matkovich, SJ; Mitchell, CJ; Biden, TJ; Woodcock, EA			Evidence for selective coupling of alpha(1)-adrenergic receptors to phospholipase C-beta(1) in rat neonatal cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN-KINASE-C; ALPHA-SUBUNITS; INOSITOL 1,4,5-TRISPHOSPHATE; CARDIAC MYOCYTES; ACTIVATION; GQ; STIMULATION; ISOZYMES; CALCIUM	Activation of phospholipase C (PLC) in neonatal rat cardiomyocytes (NCM) generates primarily inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) in response to rises in intracellular Ca2+, or inositol 1,4-bisphosphate (Ins(1,4)P-2) in response to norepinephrine (NE) (Matkovich, S. J. and Woodcock, E. A. (2000) J. Biol. Chem. 275,10845-10850). To examine the PLC subtype mediating the alpha (1)-adrenergic receptor response, PLC-beta (1) and PLC-beta (3) were overexpressed in NCM using adenoviral infection (Ad-PLC-beta (1) NCM and Ad-PLC-beta (3) NCM, respectively) and PLC responses assessed from [H-3]inositol phosphate (InsP) generation in the presence of 10 mM LiCl. The [H-3]InsP response to NE (100 muM) was enhanced in Ad-PLC-beta (1) NCM relative to cells infected with blank virus (Ad-MX NCM), but was reduced in Ad-PLC-beta (3) NCM. In contrast, the [H-3]InsP response to ATP (100 muM) was not elevated in Ad-PLC-beta (1) NCM and was enhanced rather than diminished in Ad-PLC-beta (3) NCM, showing that effects of the two PLC-beta isoforms were specific for particular receptor types. PLC-delta (1) overexpression selectively reduced NE-induced [H-3]InsP responses, without affecting the ATP stimulation. The reduced NE response was associated with a selective loss of PLC-beta (1), expression in Ad-PLC-delta (1) NCM. alpha (1)-Adrenergic receptor activation caused phosphorylation of PLC-beta (1), but not PLC-beta (3), whereas stimulation by ATP induced phosphorylation of PLC-beta (3), but not PLC-beta (1). Taken together, these studies provide evidence that NE-stimulated InsP generation in NCM is primarily mediated by PLC-beta (1), despite the presence of both PLC-beta (1) and PLC-beta (3) isoforms.	Baker Med Res Inst, Cellular Biochem Lab, Melbourne, Vic 8008, Australia; Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	Baker Heart and Diabetes Institute; Garvan Institute of Medical Research	Woodcock, EA (corresponding author), Baker Med Res Inst, Cellular Biochem Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.		Biden, Trevor/AAW-2829-2021; Matkovich, Scot J/AFP-0908-2022; Matkovich, Scot J/B-9077-2009; ARTHUR, JANE/AAW-9983-2020	Matkovich, Scot J/0000-0002-7398-6857; Matkovich, Scot J/0000-0002-7398-6857; Biden, Trevor/0000-0001-5211-0234				Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BAHK YY, 1994, J BIOL CHEM, V269, P8240; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CannonCarlson S, 1997, ANAL BIOCHEM, V246, P146, DOI 10.1006/abio.1997.2002; Cocco L, 2001, BBA-MOL CELL BIOL L, V1530, P1, DOI 10.1016/S1388-1981(00)00169-4; Cocco L, 2000, EUR J HISTOCHEM, V44, P45; Cook B, 2000, NAT CELL BIOL, V2, P296, DOI 10.1038/35010571; DU XJ, 1995, CIRCULATION, V91, P2712, DOI 10.1161/01.CIR.91.11.2712; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Felzen B, 1998, CIRC RES, V82, P438, DOI 10.1161/01.RES.82.4.438; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Gasa R, 1999, DIABETES, V48, P1035, DOI 10.2337/diabetes.48.5.1035; GILBERT JC, 1991, CIRC RES, V69, P1632, DOI 10.1161/01.RES.69.6.1632; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; Jacobsen AN, 1996, CIRCULATION, V93, P23, DOI 10.1161/01.CIR.93.1.23; JHON DY, 1993, J BIOL CHEM, V268, P6654; Lipp P, 2000, CURR BIOL, V10, P939, DOI 10.1016/S0960-9822(00)00624-2; Martelli AM, 2000, FEBS LETT, V486, P230, DOI 10.1016/S0014-5793(00)02313-9; Matkovich SJ, 2000, J BIOL CHEM, V275, P10845, DOI 10.1074/jbc.275.15.10845; Mitchell CJ, 2001, J BIOL CHEM, V276, P19072, DOI 10.1074/jbc.M101406200; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NEWTON AC, 1995, TRENDS BIOCHEM SCI, V20, P2; PARK DG, 1993, J BIOL CHEM, V268, P4573; Puceat M, 1996, BIOCHEM J, V318, P723, DOI 10.1042/bj3180723; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RYBIN V, 1996, METH NEUROSCI, V29, P344; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; SPESSOT R, 1989, VIROLOGY, V168, P378, DOI 10.1016/0042-6822(89)90279-1; Strassheim D, 2000, J BIOL CHEM, V275, P39767, DOI 10.1074/jbc.M007775200; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; Tall EG, 2000, CURR BIOL, V10, P743, DOI 10.1016/S0960-9822(00)00541-8; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Woodcock EA, 1997, MOL CELL BIOCHEM, V172, P121, DOI 10.1023/A:1006871722652; WOODCOCK EA, 1995, CIRC RES, V76, P252, DOI 10.1161/01.RES.76.2.252; WU DQ, 1992, J BIOL CHEM, V267, P25798; Xia CZ, 2001, J BIOL CHEM, V276, P19770, DOI 10.1074/jbc.M006266200; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023	47	44	44	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37341	37346		10.1074/jbc.M106572200	http://dx.doi.org/10.1074/jbc.M106572200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11489909	hybrid			2022-12-25	WOS:000171375700065
J	Crawford, DF; Piwnica-Worms, H				Crawford, DF; Piwnica-Worms, H			The G(2) DNA damage checkpoint delays expression of genes encoding mitotic regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; PROTEIN-KINASE; TRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; AUXILIARY PROTEIN; POLYMERASE-DELTA; 14-3-3 BINDING; INDUCER CDC25; CANCER-CELLS	Transcriptional control of gene expression contributes to the regulation of diverse cellular processes including cell cycle progression and the cellular response to DNA damage. Global gene expression profiling was performed using p53-deficient human cells to identify genes with G(2)/M-specific and DNA damage-responsive expression. Numerous cell cycle-regulated genes were identified, but surprisingly the analysis failed to identify genes activated by ionizing radiation. Instead, significant delays in expression of G(2)/M-specific genes, including known mitotic regulators, were observed following DNA damage. Thus, in the absence of p53, gene induction does not contribute to the G(2) arrest following DNA damage. Rather, the DNA damage checkpoint elicits a G(2) cell cycle arrest, in part, by delaying accumulation of proteins required in mitosis.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Piwnica-Worms, H (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.		Piwnica-Worms, Helen/C-5214-2012		PHS HHS [K08] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1995, CANCER RES, V55, P1649; Favaloro J, 1980, Methods Enzymol, V65, P718; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JENH CH, 1985, MOL CELL BIOL, V5, P2527, DOI 10.1128/MCB.5.10.2527; JOHNSON LF, 1984, RECOMBINANT DNA CELL, P25; Kao GD, 1997, CANCER RES, V57, P753; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KASTAN MB, 1991, CANCER RES, V51, P6304; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KREK W, 1995, METHOD ENZYMOL, V254, P114; Kudoh K, 2000, CANCER RES, V60, P4161; Kuhl NM, 2000, CELL MOL LIFE SCI, V57, P450, DOI 10.1007/PL00000707; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lo PK, 1999, ONCOGENE, V18, P7765, DOI 10.1038/sj.onc.1203167; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; MACKEY MA, 1992, CANCER RES, V52, P1101; Maniatis T., 1982, MOL CLONING LAB MANU; MCKINNEY JD, 1991, TRENDS BIOCHEM SCI, V16, P430, DOI 10.1016/0968-0004(91)90170-Z; MOIR D, 1982, GENETICS, V100, P547; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Radji M, 2001, YEAST, V18, P195, DOI 10.1002/1097-0061(200102)18:3<195::AID-YEA660>3.0.CO;2-L; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zolzer F, 2001, RADIAT RES, V155, P50, DOI 10.1667/0033-7587(2001)155[0050:GPDAIA]2.0.CO;2; Zucman-Rossi J, 1996, GENOMICS, V38, P247, DOI 10.1006/geno.1996.0625; Zwicker J, 1995, Prog Cell Cycle Res, V1, P91; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	67	57	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37166	37177		10.1074/jbc.M103414200	http://dx.doi.org/10.1074/jbc.M103414200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11483598	hybrid			2022-12-25	WOS:000171375700042
J	Everett, AD; Stoops, T; McNamara, CA				Everett, AD; Stoops, T; McNamara, CA			Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE FAMILY; TRANSLOCATION; TRANSCRIPTION; SEQUENCE; HOMOLOGY; PROTEIN; P52; DNA	We recently identified hepatoma-derived growth factor (HDGF) as a nuclear targeted vascular smooth muscle cell (VSM) mitogen that is expressed in developing vascular lesions. In the present study, VSM in culture express endogenous HDGF only in the nucleus and target a green fluorescent protein (GFP)-HDGF fusion to the nucleus. To define the features of the HDGF molecule that are essential for nuclear localization and mitogenic function, deletion and site-directed mutagenesis were performed. Deletion analysis identified the carboxyl-terminal half of HDGF to be responsible for nuclear targeting in VSM. Overexpression of tagged HDGF proteins with point mutations in the putative bipartite nuclear localization sequence in the carboxyl terminus demonstrated that single Lys --> Asn mutations randomized HDGF expression to both the nucleus and cytoplasm similar to the empty vector. Importantly, the Lys --> Asn mutation of all three lysines blocked nuclear entry. Point mutation of a p34(cdc2) kinase consensus motif within the nuclear localization sequence had no effect on nuclear targeting. Moreover, nuclear entry was essential for the HDGF mitogenic effect, as transfection with the triple Lys --> Asn mutant HA-HDGF significantly attenuated bromodeoxyuridine uptake when compared with transfection with wild type HA-HDGF. We conclude that HDGF contains a true bipartite nuclear localization sequence with all three lysines necessary for nuclear targeting. Nuclear targeting of HDGF is required for HDGF stimulation of DNA replication in VSM.	Univ Virginia, Hlth Sci Ctr, Dept Pediat, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Div Cardiovasc, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Everett, AD (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pediat, MR4 Bldg,POB 801356, Charlottesville, VA 22908 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062522] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62522] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; CLOWES AW, 1983, LAB INVEST, V49, P327; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Everett AD, 2000, J CLIN INVEST, V105, P567, DOI 10.1172/JCI7497; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Ikegame K, 1999, BIOCHEM BIOPH RES CO, V266, P81, DOI 10.1006/bbrc.1999.1733; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Izumoto Y, 1997, BIOCHEM BIOPH RES CO, V238, P26, DOI 10.1006/bbrc.1997.7233; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NAKAMURA H, 1994, J BIOL CHEM, V269, P25143; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; Oliver JA, 1998, J CLIN INVEST, V102, P1208, DOI 10.1172/JCI785; RABOWCZSZULCZYN.EM, 1986, P NATL ACAD SCI USA, V83, P3728; RAINES EW, 1993, BRIT HEART J, V69, pS30; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; TOSHIFUMI K, 1999, BIOCHEM BIOPH RES CO, V262, P433; Waltenberger J, 1997, CIRCULATION, V96, P4083; YOSHIDA Y, 1988, ARCH PATHOL LAB MED, V112, P987	23	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37564	37568		10.1074/jbc.M105109200	http://dx.doi.org/10.1074/jbc.M105109200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11481329	hybrid			2022-12-25	WOS:000171375700092
J	Schubert, LA; Jeffrey, E; Zhang, Y; Ramsdell, F; Ziegler, SF				Schubert, LA; Jeffrey, E; Zhang, Y; Ramsdell, F; Ziegler, SF			Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHORETICULAR DISEASE; SF MUTATION; MOUSE; BINDING; GENE; PROMOTER; PROTEIN; EXPRESSION; CONTAINS; CLONING	We have recently identified and cloned Foxp3, the gene defective in mice with the scurfy mutation. The immune dysregulation documented in these mice and in humans with mutations in the orthologous gene indicates that the foxp3 gene product, scurfin, is involved in the regulation of T cell activation and differentiation. The autoimmune state observed in these patients with the immune dysregulation polyendocrinopathy, enteropathy, X-linked syndrome, or X-linked autoimmunity-allergic dysregulation syndrome also points to a critical role for scurfin in the regulation of T cell homeostasis. FOXP3 encodes a novel member of the forkhead family of transcription factors. Here we demonstrate that this structural domain is required for nuclear localization and DNA binding. Scurfin, transiently expressed in heterologous cells, represses transcription of a reporter containing a multimeric forkhead binding site. Upon overexpression in CD4 T cells, scurfin attenuates activation-induced cytokine production and proliferation. We have identified FKH binding sequences adjacent to critical NFAT regulatory sites in the promoters of several cytokine genes whose expression is sensitive to changes in SFN abundance. Our findings indicate that the ability of scurfin to bind DNA, and presumably repress transcription, plays a paramount role in determining the amplitude of the response of CD4 T cells to activation.	Virginia Mason Res Ctr, Dept Immunol, Program Immunol, Seattle, WA 98101 USA; Celltech Chirosci R&D, Bothell, WA 98021 USA	Virginia Mason Medical Center	Ziegler, SF (corresponding author), Virginia Mason Res Ctr, Dept Immunol, Program Immunol, 1201 9th Ave, Seattle, WA 98101 USA.	sziegler@vmresearch.org						Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; BLAIR PJ, 1994, J IMMUNOL, V153, P3764; BLAIR PJ, 1994, MAMM GENOME, V5, P652, DOI 10.1007/BF00411464; Bodor J, 1998, J BIOL CHEM, V273, P9544, DOI 10.1074/jbc.273.16.9544; Bodor J, 2000, J LEUKOCYTE BIOL, V67, P774, DOI 10.1002/jlb.67.6.774; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Chambers CA, 1997, IMMUNITY, V7, P885, DOI 10.1016/S1074-7613(00)80406-9; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Clark LB, 1999, J IMMUNOL, V162, P2546; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; DaSilva L, 1998, GENE, V221, P135, DOI 10.1016/S0378-1119(98)00441-7; DERRY JMJ, 1995, GENOMICS, V29, P471, DOI 10.1006/geno.1995.9979; GODFREY VL, 1994, AM J PATHOL, V145, P281; GODFREY VL, 1991, P NATL ACAD SCI USA, V88, P5528, DOI 10.1073/pnas.88.13.5528; GODFREY VL, 1991, AM J PATHOL, V138, P1379; Hellqvist M, 1998, J BIOL CHEM, V273, P23335, DOI 10.1074/jbc.273.36.23335; HODGE MR, 1995, J IMMUNOL, V154, P6397; Jin CW, 1999, J MOL BIOL, V289, P683, DOI 10.1006/jmbi.1999.2819; Kaestner KH, 2000, GENE DEV, V14, P142; Kanangat S, 1996, EUR J IMMUNOL, V26, P161, DOI 10.1002/eji.1830260125; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Leenders H, 2000, EUR J IMMUNOL, V30, P2980, DOI 10.1002/1521-4141(200010)30:10<2980::AID-IMMU2980>3.0.CO;2-9; LI C, 1993, P NATL ACAD SCI USA, V90, P11583, DOI 10.1073/pnas.90.24.11583; LYON MF, 1990, P NATL ACAD SCI USA, V87, P2433, DOI 10.1073/pnas.87.7.2433; Mahlapuu M, 1998, DEV BIOL, V202, P183, DOI 10.1006/dbio.1998.9010; Marsden I, 1998, J MOL BIOL, V278, P293, DOI 10.1006/jmbi.1998.1703; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; Perrone L, 2000, BIOCHEM BIOPH RES CO, V275, P203, DOI 10.1006/bbrc.2000.3232; PETRAK D, 1994, J IMMUNOL, V153, P2046; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; SCHUBERT LA, 1995, J BIOL CHEM, V270, P29624; Schuddekopf K, 1996, P NATL ACAD SCI USA, V93, P9661, DOI 10.1073/pnas.93.18.9661; Shu WG, 2001, J BIOL CHEM, V276, P27488, DOI 10.1074/jbc.M100636200; Sutton J, 1996, J BIOL CHEM, V271, P23126, DOI 10.1074/jbc.271.38.23126; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Tsai EY, 1996, MOL CELL BIOL, V16, P459; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Zahorsky-Reeves JL, 2001, EUR J IMMUNOL, V31, P196, DOI 10.1002/1521-4141(200101)31:1<196::AID-IMMU196>3.0.CO;2-9	46	420	469	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37672	37679		10.1074/jbc.M104521200	http://dx.doi.org/10.1074/jbc.M104521200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11483607	hybrid			2022-12-25	WOS:000171375700105
J	Steussy, CN; Popov, KM; Bowker-Kinley, MM; Sloan, RB; Harris, RA; Hamilton, JA				Steussy, CN; Popov, KM; Bowker-Kinley, MM; Sloan, RB; Harris, RA; Hamilton, JA			Structure of pyruvate dehydrogenase kinase - Novel folding pattern for a serine protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOYL ACETYLTRANSFERASE; LIPOYL DOMAIN; ANOMALOUS DIFFRACTION; CRYSTAL-STRUCTURE; BINDING; COMPLEX; FAMILY; MUTL; SITE; CHEA	The structure of mitochondrial pyruvate dehydrogenase kinase isozyme 2 is of interest because it represents a family of serine-specific protein kinases that lack sequence similarity with all other eukaryotic protein kinases. Similarity exists instead with key motifs of prokaryotic histidine protein kinases and a family of eukaryotic ATPases. The 2.5-Angstrom crystal structure reported here reveals that pyruvate dehydrogenase kinase isozyme 2 has two domains of about the same size. The N-terminal half is dominated by a bundle of four amphipathic alpha -helices, whereas the C-terminal half is folded into an alpha/beta sandwich that contains the nucleotide-binding site. Analysis of the structure reveals this C-terminal domain to be very similar to the nucleotide-binding domain of bacterial histidine kinases, but the catalytic mechanism appears similar to that of the eukaryotic serine kinases and ATPases.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Missouri System; University of Missouri Kansas City	Hamilton, JA (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	jsteinra@iupui.edu			NIDDK NIH HHS [R01 DK056898, DK56898, R01 DK047844, DK47844] Funding Source: Medline; NIGMS NIH HHS [R01 GM051262, GM51262, R29 GM051262, R01 GM051262-09] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047844, R01DK056898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051262, R29GM051262] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker JC, 2000, J BIOL CHEM, V275, P15773, DOI 10.1074/jbc.M909488199; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; Bilwes AM, 2001, NAT STRUCT BIOL, V8, P353, DOI 10.1038/86243; Bowker-Kinley M, 1999, BIOCHEM J, V344, P47, DOI 10.1042/0264-6021:3440047; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; BREMAN H, 2000, NUCLEIC ACIDS RES, V28, P235; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *COLL COMP PROJ 4, 1999, ACTA CRYSTALLOGR D, V50, P760; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; GREEN JDF, 1995, J MOL BIOL, V248, P328, DOI 10.1006/jmbi.1995.0225; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARRIS RA, 1995, ADV ENZYME REGUL, V35, P147, DOI 10.1016/0065-2571(94)00020-4; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; STEPP LR, 1983, J BIOL CHEM, V258, P9454; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Terwilliger TC, 1997, METHOD ENZYMOL, V276, P530; Tuganova A, 2001, J BIOL CHEM, V276, P17994, DOI 10.1074/jbc.M009327200; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Yang F, 2000, ACTA CRYSTALLOGR D, V56, P959, DOI 10.1107/S0907444900007162; Zhou HJ, 1997, BIOCHEMISTRY-US, V36, P699, DOI 10.1021/bi961663p	38	71	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37443	37450		10.1074/jbc.M104285200	http://dx.doi.org/10.1074/jbc.M104285200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11483605	Green Accepted, hybrid			2022-12-25	WOS:000171375700078
J	Mignen, O; Thompson, JL; Shuttleworth, TJ				Mignen, O; Thompson, JL; Shuttleworth, TJ			Reciprocal regulation of capacitative and arachidonate-regulated noncapacitative Ca2+ entry pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM CURRENT; CURRENT I-CRAC; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; <CA2+>(I) OSCILLATIONS; ADENOPHOSTIN-A; HEK293 CELLS; FATTY-ACIDS; CL CURRENTS; MAST-CELLS	Receptor-activated Ca2+ entry is usually thought to occur via capacitative or store-operated Ca2+ channels. However, at physiological levels of stimulation, where Ca2+ store depletion is only transient and/or partial, evidence has suggested that an arachidonic acid-dependent noncapacitative Ca2+ entry is responsible. Recently, we have described a novel arachidonate-regulated Ca2+-selective (ARC) conductance that is entirely distinct from store-operated conductances in the same cell. We now show that these ARC channels are indeed specifically activated by low agonist concentrations and provide the predominant route of Ca2+ entry under these conditions. We further demonstrate that sustained elevations in cytosolic Ca2+, such as those resulting from activation of store-operated Ca2+ entry by high This agonist concentrations, inhibit the ARC channels. explains earlier failures to detect the presence of this noncapacitative pathway in experiments where store-operated entry had already been fully activated. The result is that the respective activities of ARC and store-operated Ca2+ channels display a unique reciprocal regulation that is related to the specific nature of the [Ca2+](i) signals generated at different agonist concentrations. Importantly, these data show that at physiologically relevant levels of stimulation, it is the noncapacitative ARC channels that provide the predominant route for the agonist-activated entry of Ca2+.	Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Shuttleworth, TJ (corresponding author), Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Box 711,601 Elmwood Ave, Rochester, NY 14642 USA.		MIGNEN, Olivier/M-3258-2019	MIGNEN, Olivier/0000-0001-7913-6119	NIGMS NIH HHS [GM 40457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P565, DOI 10.1113/jphysiol.1984.sp015351; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Broad LM, 1999, J BIOL CHEM, V274, P32881, DOI 10.1074/jbc.274.46.32881; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Denson DD, 2000, AM J PHYSIOL-CELL PH, V279, pC1211, DOI 10.1152/ajpcell.2000.279.4.C1211; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Fierro L, 2000, J PHYSIOL-LONDON, V522, P247, DOI 10.1111/j.1469-7793.2000.t01-1-00247.x; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; Hartzell HC, 1997, MOL PHARMACOL, V51, P683, DOI 10.1124/mol.51.4.683; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang Y, 1998, J BIOL CHEM, V273, P31815, DOI 10.1074/jbc.273.48.31815; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; Kerschbaum HH, 1998, J GEN PHYSIOL, V111, P521, DOI 10.1085/jgp.111.4.521; LeppleWienhues A, 1996, BIOPHYS J, V71, P787, DOI 10.1016/S0006-3495(96)79278-0; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Luo DL, 2001, J BIOL CHEM, V276, P20186, DOI 10.1074/jbc.M100327200; MARTIN SC, 1994, PFLUG ARCH EUR J PHY, V426, P231, DOI 10.1007/BF00374776; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; Mignen O, 2001, J BIOL CHEM, V276, P21365, DOI 10.1074/jbc.M102311200; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Munaron L, 1997, CELL CALCIUM, V22, P179, DOI 10.1016/S0143-4160(97)90011-7; Osterhout JL, 2000, J BIOL CHEM, V275, P8248, DOI 10.1074/jbc.275.11.8248; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Shuttleworth TJ, 1999, CELL CALCIUM, V25, P237, DOI 10.1054/ceca.1999.0022; Shuttleworth TJ, 1996, BIOCHEM J, V316, P819, DOI 10.1042/bj3160819; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; Shuttleworth TJ, 1996, BIOCHEM J, V313, P815, DOI 10.1042/bj3130815; SHUTTLEWORTH TJ, 1994, CELL CALCIUM, V15, P457, DOI 10.1016/0143-4160(94)90110-4; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; THORN P, 1995, J PHYSIOL-LONDON, V482, P275, DOI 10.1113/jphysiol.1995.sp020516; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6259	48	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35676	35683		10.1074/jbc.M105626200	http://dx.doi.org/10.1074/jbc.M105626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11470795	hybrid			2022-12-25	WOS:000171109300063
J	Ten Broeke, R; Folkerts, G; Leusink-Muis, T; van der Linde, HJ; Villain, M; Manion, MK; De Clerck, F; Blalock, JE; Nijkamp, FP				Ten Broeke, R; Folkerts, G; Leusink-Muis, T; van der Linde, HJ; Villain, M; Manion, MK; De Clerck, F; Blalock, JE; Nijkamp, FP			Calcium sensors as new therapeutic targets for airway hyperresponsiveness and asthma	FASEB JOURNAL			English	Article						calcium-like peptide; nitric oxide; epithelium; tracheal reactivity	NITRIC-OXIDE SYNTHASE; CA2+-SENSITIVE INACTIVATION; CA2+ CHANNELS; EPITHELIUM; CALMODULIN; LUNG; INHIBITION; EXACERBATIONS; EXPRESSION; MEDIATOR	Airway hyperresponsiveness and epithelial damage are key features in asthma, a disease reaching epidemic proportions in the developed world. To investigate and modulate airway hyperresponsiveness, we used two novel peptides, CALP1 and CALP2, which interact with calcium-binding EF hand motifs and regulate calcium channels. We found that CALP1 induced, whereas CALP2 blocked, airway hyperresponsiveness. Both effects were epithelium-dependent. In epithelial cells, CALP1 blocked agonist-induced increase in [Ca (2+)](i), whereas CALP2 increased agonist-induced elevation in [Ca (2+)](i). CALP2 causes the release of nitric oxide (NO), a mediator that relaxes airway smooth muscle. We conclude that epithelial calcium channels play a key role in regulating airway hyperresponsiveness by controlling [Ca (2+)](i) and consequently the production of NO. These results bring new insights into the mechanism of airway hyperresponsiveness and suggest new therapeutic targets for asthma.	Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, NL-3508 TB Utrecht, Netherlands; Univ Alabama Birmingham, Ctr Neuroimmunol, Dept Physiol & Biophys, Birmingham, AL USA; Univ Geneva, Dept Med Biochem, Geneva, Switzerland; Janssen Res Fdn, B-2340 Beerse, Belgium	Utrecht University; University of Alabama System; University of Alabama Birmingham; University of Geneva; Johnson & Johnson	Folkerts, G (corresponding author), Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, POB 80-082, NL-3508 TB Utrecht, Netherlands.	G.Folkerts@pharm.uu.nl		Blalock, J. Edwin/0000-0001-5303-8123				ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BIALECKI RA, 1995, AM J PHYSIOL-LUNG C, V268, pL152, DOI 10.1152/ajplung.1995.268.1.L152; Boitano S, 1995, AM J PHYSIOL-CELL PH, V269, pC1547, DOI 10.1152/ajpcell.1995.269.6.C1547; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; Dietl P, 1995, AM J PHYSIOL-LUNG C, V269, pL873, DOI 10.1152/ajplung.1995.269.6.L873; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; FOLKERTS G, 1995, AM J RESP CRIT CARE, V151, P1666; FOLKERTS G, 1995, J CLIN INVEST, V95, P26, DOI 10.1172/JCI117649; Folkerts G, 2000, IMMUNOL TODAY, V21, P249, DOI 10.1016/S0167-5699(00)01631-5; Folkerts G, 1998, TRENDS PHARMACOL SCI, V19, P334, DOI 10.1016/S0165-6147(98)01232-2; FOLKERTS G, 2000, EUR RESPIR REV, V10, P249; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hart CM, 1999, CHEST, V115, P1407, DOI 10.1378/chest.115.5.1407; HOGMAN M, 1993, AM REV RESPIR DIS, V148, P1474; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; LEIPZIGER J, 1994, PFLUG ARCH EUR J PHY, V426, P427, DOI 10.1007/BF00388306; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; Li HG, 2000, J PATHOL, V190, P244, DOI 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8; Liu Q, 1996, METHOD ENZYMOL, V268, P311; Manion MK, 2000, FASEB J, V14, P1297, DOI 10.1096/fj.14.10.1297; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; MEANS AR, 1991, INTRACELLULAR MESSEN, P265; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; NIJKAMP FP, 1993, AM REV RESPIR DIS, V148, P727, DOI 10.1164/ajrccm/148.3.727; PAVLOVIC D, 1989, J APPL PHYSIOL, V67, P2522, DOI 10.1152/jappl.1989.67.6.2522; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; PERSSON MG, 1993, ACTA PHYSIOL SCAND, V149, P461, DOI 10.1111/j.1748-1716.1993.tb09643.x; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; Sanders SP, 1999, AM J RESP CELL MOL, V21, P147, DOI 10.1165/ajrcmb.21.2.f158; SHAUL PW, 1994, J CLIN INVEST, V94, P2231, DOI 10.1172/JCI117585; Sherman TS, 1999, AM J PHYSIOL-LUNG C, V276, pL383, DOI 10.1152/ajplung.1999.276.2.L383; Taylor DA, 1998, THORAX, V53, P483, DOI 10.1136/thx.53.6.483; Villain M, 2000, J BIOL CHEM, V275, P2676, DOI 10.1074/jbc.275.4.2676; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287	39	19	19	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1831	+		10.1096/fj.01-0018fje	http://dx.doi.org/10.1096/fj.01-0018fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481245				2022-12-25	WOS:000169261200037
J	De Craene, JO; Soetens, O; Andre, B				De Craene, JO; Soetens, O; Andre, B			The Npr1 kinase controls biosynthetic and endocytic sorting of the yeast Gap1 permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASES; NITROGEN CATABOLITE REPRESSION; UBIQUITIN-PROTEIN LIGASE; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; PLASMA-MEMBRANE; TRANSPORT VESICLES; ENDOPLASMIC-RETICULUM; TRYPTOPHAN PERMEASE; REGULATORY MUTATION	Membrane trafficking of the general amino acid permease (Gap1) of Saccharomyces cerevisiae is under nitrogen regulation. In cells growing on proline or urea as the sole nitrogen source, newly synthesized Gap1 is delivered to the plasma membrane, where it accumulates. Upon addition of NH4+, a preferential nitrogen source, Gapl is endocy-tosed and targeted to the vacuole, where it is degraded. This down-regulation requires ubiquitination of the permease, and this ubiquitination is dependent on the essential Npil/Rsp5 ubiquitin ligase. In this study, we investigated the role of the Npr1 kinase in the regulation of Gap1 trafficking. We show that Npr1 is required for stabilization of Gap1 at the plasma membrane: when an npr1(t8) mutant growing on proline is shifted to the restrictive temperature, Gap1 down-regulation is triggered, as it is when NH4+ is added to wild-type cells. The fate of newly synthesized Gap1 en route to the plasma membrane is also under Npr1 control: in an npr1 Delta mutant, neosynthesized Gap1 is sorted from the Golgi to the vacuole without passing via the plasma membrane. Similar direct sorting of neosynthesized Gap1 to the vacuole was observed in wild-type cells grown on NH4+. Finally, Gap I is phosphorylated in NPR1 cells, but this phosphorylation is not strictly dependent on Npr1. Our results show that Npr1 kinase plays a central role in the physiological control of Gap1 trafficking and that this control is exerted not only on Gap1 present at the plasma membrane but also on Gap1 late in the secretory pathway. Npr1 belongs to a subgroup of protein kinases, some of which are reported to exert a positive control on the activity of other permeases. We propose that these kinases also function as regulators of permease trafficking.	Free Univ Brussels, Lab Physiol Cellulaire, Inst Biol & Med Mol, B-6041 Gosselies, Belgium		Andre, B (corresponding author), Free Univ Brussels, Lab Physiol Cellulaire, Inst Biol & Med Mol, 12 Rue Professeurs Jeneer & Brachet, B-6041 Gosselies, Belgium.		De Craene, Johan-Owen/J-6461-2019; André, Bruno/D-1725-2010	De Craene, Johan-Owen/0000-0001-9654-2143; 				ANDRE B, 1993, MOL GEN GENET, V237, P17; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BECHET J, 1970, EUR J BIOCHEM, V12, P31, DOI 10.1111/j.1432-1033.1970.tb00817.x; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Coffman JA, 1996, MOL CELL BIOL, V16, P847; DEKERCHOVE DA, 1995, J BIOL CHEM, V270, P23828; delaFuente N, 1997, FEBS LETT, V411, P308, DOI 10.1016/S0014-5793(97)00721-7; DUBOIS E, 1979, MOL GEN GENET, V175, P67, DOI 10.1007/BF00267857; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gilstring CF, 1999, MOL BIOL CELL, V10, P3549, DOI 10.1091/mbc.10.11.3549; Goossens A, 2000, MOL CELL BIOL, V20, P7654, DOI 10.1128/MCB.20.20.7654-7661.2000; GRENSON M, 1982, MOL GEN GENET, V188, P261, DOI 10.1007/BF00332685; GRENSON M, 1983, EUR J BIOCHEM, V133, P141, DOI 10.1111/j.1432-1033.1983.tb07439.x; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P339, DOI 10.1016/0304-4165(66)90388-6; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Hein C, 1997, MOL MICROBIOL, V24, P607, DOI 10.1046/j.1365-2958.1997.3771735.x; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOBS P, 1980, J MOL BIOL, V139, P691, DOI 10.1016/0022-2836(80)90055-8; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kaouass M, 1997, MOL CELL BIOL, V17, P2994, DOI 10.1128/MCB.17.6.2994; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis MJ, 2000, MOL BIOL CELL, V11, P23, DOI 10.1091/mbc.11.1.23; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mulet JM, 1999, MOL CELL BIOL, V19, P3328; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Pinson B, 1996, EUR J BIOCHEM, V239, P439, DOI 10.1111/j.1432-1033.1996.0439u.x; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; RAI R, 1988, J BACTERIOL, V170, P266, DOI 10.1128/jb.170.1.266-271.1988; Roberg KJ, 1997, GENETICS, V147, P1569; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SHORTLE D, 1984, P NATL ACAD SCI-BIOL, V81, P4889, DOI 10.1073/pnas.81.15.4889; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Springael JY, 1999, J CELL SCI, V112, P1375; STANBROUGH M, 1995, P NATL ACAD SCI USA, V92, P9450, DOI 10.1073/pnas.92.21.9450; VANDENBOL M, 1990, MOL GEN GENET, V222, P393, DOI 10.1007/BF00633845; VANDENBOL M, 1987, EUR J BIOCHEM, V164, P607, DOI 10.1111/j.1432-1033.1987.tb11170.x; VOLLAND C, 1992, J BIOL CHEM, V267, P23767; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wiederkehr A, 2000, J CELL BIOL, V149, P397, DOI 10.1083/jcb.149.2.397; ZUBENKO GS, 1983, P NATL ACAD SCI-BIOL, V80, P510, DOI 10.1073/pnas.80.2.510	62	134	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43939	43948		10.1074/jbc.M102944200	http://dx.doi.org/10.1074/jbc.M102944200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11500493	Green Published, hybrid			2022-12-25	WOS:000172297700061
J	Garcia-Pineres, AJ; Castro, V; Mora, G; Schmidt, TJ; Strunck, E; Pahl, HL; Merfort, I				Garcia-Pineres, AJ; Castro, V; Mora, G; Schmidt, TJ; Strunck, E; Pahl, HL; Merfort, I			Cysteine 38 in p65/NF-kappa B plays a crucial role in DNA binding inhibition by sesquiterpene lactones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; TRANSCRIPTION FACTOR; ARNICA-MONTANA; TNF-ALPHA; ACTIVATION; HELENALIN; SUBUNIT; HELENANOLIDES; RECOGNITION	Sesquiterpene lactones (SLs) have potent antiinflammatory properties. We have shown previously that they exert this effect in part by inhibiting activation of the transcription factor NF-kappaB, a central regulator of the immune response. We have proposed a molecular mechanism for this inhibition based on computer molecular modeling data. In this model, SLs directly alkylate the p65 subunit of NF-kappaB, thereby inhibiting DNA binding. Nevertheless, an experimental evidence for the proposed mechanism was lacking. Moreover, based on experiments using the SL parthenolide, an alternative mode of action has been proposed by other authors in which SLs inhibit I kappaB-alpha degradation. Here we report the construction of p65/NF-kappaB point mutants that lack the cysteine residues alkylated by SLs in our model. In contrast to wild type p65, DNA-binding of the Cys(38) --> Ser and Cys(38,1120) --> Ser mutants is no longer inhibited by SLs. In addition, we provide evidence that parthenolide uses a similar mechanism to other SLs in inhibiting NF-kappaB. Contrary to previous reports, we show that parthenolide, like other SLs, inhibits NF-kappaB most probably by alkylating p65 at Cys(38). Although a slight inhibition of I kappaB degradation was detected for all SLs, the amount of remaining I kappaB was too low to explain the observed NF-kappaB inhibition.	Univ Freiburg, Inst Pharmaceut Biol, D-79104 Freiburg, Germany; Univ Costa Rica, Escuela Quim, San Jose, Costa Rica; CIPRONA, San Jose, Costa Rica; Univ Dusseldorf, Inst Pharmaceut Biol, D-4000 Dusseldorf, Germany; Univ Hosp, Dept Expt Anaesthesiol, Freiburg, Germany	University of Freiburg; Universidad Costa Rica; Heinrich Heine University Dusseldorf; University of Freiburg	Merfort, I (corresponding author), Univ Freiburg, Inst Pharmaceut Biol, Stefan Meier Str 19, D-79104 Freiburg, Germany.	merfort@uni-freiburg.de	Pahl, Heike/AGM-5260-2022; Schmidt, Thomas J/M-1678-2016	Schmidt, Thomas J/0000-0003-2634-9705				Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Castro V, 2000, PHYTOCHEMISTRY, V53, P257, DOI 10.1016/S0031-9422(99)00510-5; Castro V, 2000, PLANTA MED, V66, P591, DOI 10.1055/s-2000-8649; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Cho JY, 1998, PLANTA MED, V64, P594, DOI 10.1055/s-2006-957528; DUPUIS G, 1974, CAN J BIOCHEM CELL B, V52, P575, DOI 10.1139/o74-083; HALL IH, 1980, J PHARM SCI, V69, P537, DOI 10.1002/jps.2600690516; HALL IH, 1979, J PHARM SCI, V68, P537, DOI 10.1002/jps.2600680505; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KNIGHT DW, 1995, NAT PROD REP, V12, P271, DOI 10.1039/np9951200271; Koch E, 2001, BIOCHEM PHARMACOL, V62, P795, DOI 10.1016/S0006-2952(01)00714-6; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; Lee HJ, 1999, PLANTA MED, V65, P104, DOI 10.1055/s-1999-13968; Li XQ, 1999, J BIOL CHEM, V274, P21244, DOI 10.1074/jbc.274.30.21244; LOFQUIST AK, 1995, MOL CELL BIOL, V15, P1737; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; Mazor RL, 2000, CYTOKINE, V12, P239, DOI 10.1006/cyto.1999.0526; MERFORT I, 1985, PLANTA MED, V51, P136, DOI 10.1055/s-2007-969428; MERFORT I, 1990, HAGERS HDB PHARM PRA, P342; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Peet GW, 1999, J BIOL CHEM, V274, P32655, DOI 10.1074/jbc.274.46.32655; PICMAN AK, 1979, CHEM-BIOL INTERACT, V28, P83, DOI 10.1016/0009-2797(79)90116-9; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Rungeler P, 1999, BIOORGAN MED CHEM, V7, P2343, DOI 10.1016/S0968-0896(99)00195-9; Rungeler P, 1998, PLANTA MED, V64, P588, DOI 10.1055/s-2006-957527; Schinella GR, 1998, J PHARM PHARMACOL, V50, P1069, DOI 10.1111/j.2042-7158.1998.tb06924.x; Schmidt TJ, 1997, BIOORGAN MED CHEM, V5, P645, DOI 10.1016/S0968-0896(97)00003-5; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRODER H, 1990, THROMB RES, V57, P839, DOI 10.1016/0049-3848(90)90151-2; Tsai SH, 1999, J CELL BIOCHEM, V74, P606, DOI 10.1002/(SICI)1097-4644(19990915)74:4<606::AID-JCB10>3.3.CO;2-N; TZEN CY, 1994, EXP CELL RES, V211, P12, DOI 10.1006/excr.1994.1052; URBAN MB, 1991, NEW BIOL, V3, P279; WILLUHN G, 1990, PLANTA MED, V56, P111, DOI 10.1055/s-2006-960899; WILLUHN G, 2000, HERBAL MED PRODUCTS, P105; Wong HR, 1999, BIOCHEM BIOPH RES CO, V262, P375, DOI 10.1006/bbrc.1999.1207; Zidorn C, 1999, PLANTA MED, V65, P704, DOI 10.1055/s-1999-14046	46	357	366	0	23	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39713	39720		10.1074/jbc.M101985200	http://dx.doi.org/10.1074/jbc.M101985200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11500489	hybrid			2022-12-25	WOS:000171789200028
J	Pfeifer, V; Nicholson, GJ; Ries, J; Recktenwald, J; Schefer, AB; Shawky, RM; Schroder, J; Wohlleben, W; Pelzer, S				Pfeifer, V; Nicholson, GJ; Ries, J; Recktenwald, J; Schefer, AB; Shawky, RM; Schroder, J; Wohlleben, W; Pelzer, S			A polyketide synthase in glycopeptide biosynthesis - The biosynthesis of the non-proteinogenic amino acid (S)-3,5-dihydroxyphenylglycine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; VANCOMYCIN GROUP; GENES; ANTIBIOTICS; EXPRESSION; PATHWAY; BALHIMYCIN; SEQUENCE; CLONING; BINDING	Balhimycin, a vancomycin-type antibiotic from Amycolatopsis mediterranei, contains the unusual amino acid (S)-3,5-dihydroxyphenylglycine (Dpg), with an acetate-derived carbon backbone. After sequence analysis of the biosynthetic gene cluster, one gene, dpgA, for a predicted polyketide synthase (PKS) was identified, sharing 20-30% identity with plant chalcone synthases. Inactivation of dpgA resulted in loss of balhimycin production, and restoration was achieved by supplementation with 3,5-dihydroxyphenylacetic acid, which is both a possible product of a PKS reaction and a likely precursor of Dpg. Enzyme assays with the protein expressed in Streptomyces lividans showed that this PKS uses only malonyl-CoA as substrate to synthesize 3,5-dihydroxyphenylacetic acid. The PKS gene is organized in an operon-like structure with three downstream genes that are similar to enoyl-CoA-hydratase genes and a dehydrogenase gene. The heterologous co-expression of all four genes led to accumulation of 3,5-dihydroxy-phenylglyoxylic acid. Therefore, we now propose a reaction sequence. The final step in the pathway to Dpg is a transamination. A predicted transaminase gene was inactivated, resulting in abolished antibiotic production and accumulation of 3,5-dihydroxyphenylglyoxylic acid. Interestingly, restoration was only possible by simultaneous supplementation with (S)-3,5-dihydroxyphenylglycine and (S)-4-hydroxyphenylglycine, indicating that the transaminase is essential for the formation of both amino acids.	Univ Tubingen, Inst Mikrobiol & Biotechnol, D-72076 Tubingen, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; University of Freiburg	Wohlleben, W (corresponding author), Univ Tubingen, Inst Mikrobiol & Biotechnol, Morgenstelle 28, D-72076 Tubingen, Germany.	wowo@biotech.uni-tuebingen.de						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bischoff D, 2001, ANGEW CHEM INT EDIT, V40, P1693, DOI 10.1002/1521-3773(20010504)40:9<1693::AID-ANIE16930>3.0.CO;2-8; Boynton ZL, 1996, J BACTERIOL, V178, P3015, DOI 10.1128/jb.178.11.3015-3024.1996; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Chen HW, 2000, P NATL ACAD SCI USA, V97, P11942, DOI 10.1073/pnas.210395097; Choroba OW, 2000, J AM CHEM SOC, V122, P5389, DOI 10.1021/ja000076v; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cooper RDG, 1996, J ANTIBIOT, V49, P575, DOI 10.7164/antibiotics.49.575; Eckermann S, 1998, NATURE, V396, P387, DOI 10.1038/24652; EICHLER K, 1994, MOL MICROBIOL, V13, P775, DOI 10.1111/j.1365-2958.1994.tb00470.x; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; FOLDES M, 1983, J ANTIMICROB CHEMOTH, V11, P21, DOI 10.1093/jac/11.1.21; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; HAMMOND SJ, 1982, J CHEM SOC CHEM COMM, P344, DOI 10.1039/c39820000344; Henne A, 1999, APPL ENVIRON MICROB, V65, P3901; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HUBBARD BK, 1980, CHEM BIOL LOND, V42, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Moore BS, 2001, CHEMBIOCHEM, V2, P35, DOI 10.1002/1439-7633(20010105)2:1<35::AID-CBIC35>3.3.CO;2-T; MUTH G, 1988, MOL GEN GENET, V211, P424, DOI 10.1007/BF00425695; MUTH G, 1989, MOL GEN GENET, V219, P341, DOI 10.1007/BF00259605; NADKARNI SR, 1994, J ANTIBIOT, V47, P334, DOI 10.7164/antibiotics.47.334; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; Pelter S, 1997, J BIOTECHNOL, V56, P115, DOI 10.1016/S0168-1656(97)00082-5; Pelzer S, 1999, ANTIMICROB AGENTS CH, V43, P1565, DOI 10.1128/AAC.43.7.1565; PELZER S, 2000, Patent No. 0077182; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schroder J, 1997, TRENDS PLANT SCI, V2, P373, DOI 10.1016/S1360-1385(97)01104-7; Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361; SUSSMUTH RD, 1999, ANGEW CHEM, V111, P2096; Tenover FC, 1999, J HOSP INFECT, V43, pS3, DOI 10.1016/S0195-6701(99)90060-9; van Wageningen AMA, 1998, CHEM BIOL, V5, P155, DOI 10.1016/S1074-5521(98)90060-6	37	125	129	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38370	38377		10.1074/jbc.M106580200	http://dx.doi.org/10.1074/jbc.M106580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495926	hybrid			2022-12-25	WOS:000171673200008
J	Vasquez, KM; Dagle, JM; Weeks, DL; Glazer, PM				Vasquez, KM; Dagle, JM; Weeks, DL; Glazer, PM			Chromosome targeting at short polypurine sites by cationic triplex-forming oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTABLE MAMMALIAN GENE; DOUBLE-HELICAL DNA; CROSS-LINKING; MEDIATED INHIBITION; SHUTTLE VECTOR; RAS PROMOTER; MOUSE CELLS; MUTAGENESIS; CLEAVAGE; TRANSCRIPTION	Triplex-forming oligonucleotides (TFOs) bind specifically to duplex DNA and provide a strategy for site-directed modification of genomic DNA. Recently we demonstrated TFO-mediated targeted gene knockout following systemic administration in animals. However, a limitation to this approach is the requirement for a polypurine tract (typically 15-30 base pairs (bp)) in the target DNA to afford high affinity third strand binding, thus restricting the number of sites available for effective targeting. To overcome this limitation, we have investigated the ability of chemically modified TFOs to target a short (10 bp) site in a chromosomal locus in mouse cells and induce site-specific mutations. We report that replacement of the phosphodiester backbone with cationic phosphoramidate linkages, either N,N-diethylethylenediamine or N,N-dimethylaminopropylamine, in a 10-nucleotide, psoralen-conjugated TFO confers substantial increases in binding affinity in vitro and is required to achieve targeted modification of a chromosomal reporter gene in mammalian cells. The triplex-directed, site-specific induction of mutagenesis in the chromosomal target was charge- and modification-dependent, with the activity of N,N-diethylethylenediamine > N,N-dimethylaminopropylamine phosphodiester, resulting in 10-, 6-, and <2-fold induction of target gene mutagenesis, respectively. Similarly, N,N-diethylethylenediamine and N,N-dimethylaminopropylamine TFOs were found to enhance targeting at a 16-by G:C bp-rich target site in a chromatinized episomal target in monkey COS cells, although this longer site was also targetable by a phosphodiester TFO. These results indicate that replacement of phosphodiester bonds with positively charged N,N-diethylethylenediamine linkages enhances intracellular activity and allows targeting of relatively short polypurine sites, thereby substantially expanding the number of potential triplex target sites in the genome.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	Yale University; Yale University; University of Iowa; University of Iowa	Glazer, PM (corresponding author), POB 208040, New Haven, CT 06520 USA.	peter.glazer@yale.edu	Weeks, Daniel/F-6216-2010; Glazer, Peter/S-7651-2019	Glazer, Peter/0000-0003-4525-5560; Weeks, Daniel/0000-0002-4977-2410; Dagle, John/0000-0002-8238-6159	NCI NIH HHS [CA75723, CA64186] Funding Source: Medline; NHLBI NIH HHS [HL62178] Funding Source: Medline; NICHD NIH HHS [HD27748] Funding Source: Medline; NIGMS NIH HHS [GM54791, GM/OD56277] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA075723, R01CA064186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL062178] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056277] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antony T, 1999, ANTISENSE NUCLEIC A, V9, P13, DOI 10.1089/oli.1.1999.9.13; Bailey C, 2000, NUCLEIC ACIDS RES, V28, P1154, DOI 10.1093/nar/28.5.1154; Bailey CP, 1998, NUCLEIC ACIDS RES, V26, P4860, DOI 10.1093/nar/26.21.4860; Barre FX, 2000, P NATL ACAD SCI USA, V97, P3084, DOI 10.1073/pnas.050368997; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; Chan PP, 1999, J BIOL CHEM, V274, P11541, DOI 10.1074/jbc.274.17.11541; CHENG AJ, 1993, NUCLEIC ACIDS RES, V21, P5630, DOI 10.1093/nar/21.24.5630; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; Dagle JM, 1996, NUCLEIC ACIDS RES, V24, P2143, DOI 10.1093/nar/24.11.2143; Faruqi AF, 2000, MOL CELL BIOL, V20, P990, DOI 10.1128/MCB.20.3.990-1000.2000; Faruqi AF, 1996, MOL CELL BIOL, V16, P6820; Faruqi AF, 1997, NUCLEIC ACIDS RES, V25, P633, DOI 10.1093/nar/25.3.633; Faruqi AF, 1998, P NATL ACAD SCI USA, V95, P1398, DOI 10.1073/pnas.95.4.1398; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; GLAZER PM, 1986, P NATL ACAD SCI USA, V83, P1041, DOI 10.1073/pnas.83.4.1041; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; GUIEYSSE AL, 1995, BIOCHEM BIOPH RES CO, V217, P186, DOI 10.1006/bbrc.1995.2762; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HAVRE PA, 1993, P NATL ACAD SCI USA, V90, P7879, DOI 10.1073/pnas.90.16.7879; HAVRE PA, 1993, J VIROL, V67, P7324, DOI 10.1128/JVI.67.12.7324-7331.1993; ING NH, 1993, NUCLEIC ACIDS RES, V21, P2789, DOI 10.1093/nar/21.12.2789; LEDOAN T, 1991, ANTISENSE RES DEV, V1, P43, DOI 10.1089/ard.1991.1.43; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; Luo ZJ, 2000, P NATL ACAD SCI USA, V97, P9003, DOI 10.1073/pnas.160004997; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; MAYFIELD C, 1994, J BIOL CHEM, V269, P18232; MAYFIELD C, 1994, BIOCHEMISTRY-US, V33, P3358, DOI 10.1021/bi00177a029; MILLIGAN JF, 1993, NUCLEIC ACIDS RES, V21, P327, DOI 10.1093/nar/21.2.327; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PILCH DS, 1991, BIOCHEMISTRY-US, V30, P6083, DOI 10.1021/bi00239a001; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; RAO TS, 1995, BIOCHEMISTRY-US, V34, P765, DOI 10.1021/bi00003a009; SANDOR Z, 1995, BBA-GENE STRUCT EXPR, V1263, P235, DOI 10.1016/0167-4781(95)00109-T; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; TAKASUGI M, 1991, P NATL ACAD SCI USA, V88, P5602, DOI 10.1073/pnas.88.13.5602; THOMAS TJ, 1995, NUCLEIC ACIDS RES, V23, P3594, DOI 10.1093/nar/23.17.3594; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859; VASQUEZ KM, 1995, BIOCHEMISTRY-US, V34, P7243, DOI 10.1021/bi00021a040; Vasquez KM, 1999, NUCLEIC ACIDS RES, V27, P1176, DOI 10.1093/nar/27.4.1176; Vasquez KM, 2000, SCIENCE, V290, P530, DOI 10.1126/science.290.5491.530; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; Vasquez KM, 1996, BIOCHEMISTRY-US, V35, P10712, DOI 10.1021/bi960881f; VOLKMANN S, 1995, NUCLEIC ACIDS RES, V23, P1204, DOI 10.1093/nar/23.7.1204; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; ZENDEGUI JG, 1992, NUCLEIC ACIDS RES, V20, P307, DOI 10.1093/nar/20.2.307	52	69	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38536	38541		10.1074/jbc.M101797200	http://dx.doi.org/10.1074/jbc.M101797200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504712	hybrid			2022-12-25	WOS:000171673200029
J	Chappell, J; Leitner, JW; Solomon, S; Golovchenko, I; Goalstone, ML; Draznin, B				Chappell, J; Leitner, JW; Solomon, S; Golovchenko, I; Goalstone, ML; Draznin, B			Effect of insulin on cell cycle progression in MCF-7 breast cancer cells - Direct and potentiating influence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; SMOOTH-MUSCLE CELLS; RHO SMALL GTPASE(S); DIABETES-MELLITUS; PHOSPHATIDYLINOSITOL 3-KINASE; RESTRICTION POINT; MAMMARY-CARCINOMA; DEPENDENT KINASES; GENE-EXPRESSION; CDK INHIBITORS	We recently demonstrated that in MCF-7 breast cancer cells, insulin promoted the phosphorylation and activation of geranylgeranyltransferase I (GGTI-I), increased the amounts of geranylgeranylated Rho-A and potentiated the transactivating activity of lysophosphatidic acid (LPA) (Chappell, J., Golovchenko, I., Wall, K., Stjernholm, R., Leitner, J., Goalstone, M., and Draznin, B. (2000) J. BioL Chem. 275, 31792-31797). In the present study, we explored the mechanism of this potentiating effect of insulin on LPA. Insulin (10 nM) potentiated the ability of LPA to stimulate cell cycle progression and DNA synthesis in MCF-7 cells. The potentiating effect of insulin appears to involve increases in the expression of cyclin E and decreases in the expression of the cyclin-dependent kinase inhibitor p27(Kip1). All potentiating effects of insulin were inhibited in the presence of an inhibitor of GGTase I, GGTI-286 (3 pm) or by an expression of a dominant negative mutant of Rho-A. In contrast to its potentiating action, a direct mitogenic effect of insulin in MCF-7 cells involves activation of phosphatidylinositol 3-kinase and increased expression of cyclin D-1. We conclude that the ability of insulin to increase the cellular amounts of geranylgeranylated Rho-A results in potentiation of the LPA effect on cyclin E expression and degradation of p27(Kip1) and cell cycle progression in MCF-7 breast cancer cells.	Dept Vet Affairs, Res Serv, Denver, CO 80220 USA		Draznin, B (corresponding author), Vet Affairs Hosp, 151,1055 Clermont St, Denver, CO 80220 USA.				NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NCI NIH HHS [2P30CA46934-09] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Belfiore A, 1996, ANN NY ACAD SCI, V784, P173, DOI 10.1111/j.1749-6632.1996.tb16235.x; BENSON EA, 1982, CANCER RES, V42, P1137; BENTEL JM, 1995, J CELL PHYSIOL, V165, P212, DOI 10.1002/jcp.1041650124; Chappell J, 2000, J BIOL CHEM, V275, P31792, DOI 10.1074/jbc.M004798200; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Cocca C, 1998, EUR J CANCER, V34, P889, DOI 10.1016/S0959-8049(97)10077-6; COHEN ND, 1975, P SOC EXP BIOL MED, V148, P339; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; FRITTITTA L, 1995, J CELL BIOCHEM, V57, P666, DOI 10.1002/jcb.240570411; Ghosh PM, 1999, J CELL BIOCHEM, V74, P532; GIOVANNUCCI E, 1995, CANCER CAUSE CONTROL, V6, P164, DOI 10.1007/BF00052777; Gitig DM, 2000, METH MOL B, V142, P109; Gliozzo B, 1998, J CELL BIOCHEM, V70, P268, DOI 10.1002/(SICI)1097-4644(19980801)70:2<268::AID-JCB12>3.0.CO;2-J; Goalstone ML, 1998, ENDOCRINOLOGY, V139, P4067, DOI 10.1210/en.139.10.4067; Goalstone ML, 1998, J BIOL CHEM, V273, P23892, DOI 10.1074/jbc.273.37.23892; Goalstone ML, 1999, J BIOL CHEM, V274, P2880, DOI 10.1074/jbc.274.5.2880; Goalstone ML, 1996, J BIOL CHEM, V271, P27585, DOI 10.1074/jbc.271.44.27585; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; GOALSTONE ML, 1997, ENDOCRINOLOGY, V3, P155; Golovchenko I, 2000, CIRC RES, V87, P746, DOI 10.1161/01.RES.87.9.746; GOODWIN PJ, 2000, AM SOC CLIN ONCOLOGY; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HEUSON JC, 1972, CANCER RES, V32, P226; HEUSON JC, 1972, CANCER RES, V32, P233; Hirai A, 1997, J BIOL CHEM, V272, P13; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; JIANG W, 1993, ONCOGENE, V8, P3447; Kaaks R, 1996, CANCER CAUSE CONTROL, V7, P605, DOI 10.1007/BF00051703; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KESSLER II, 1971, J CHRON DIS, V23, P579, DOI 10.1016/0021-9681(71)90133-0; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LAVECCHIA C, 1994, BRIT J CANCER, V70, P950, DOI 10.1038/bjc.1994.427; Leitner JW, 1997, ENDOCRINOLOGY, V138, P2211, DOI 10.1210/en.138.5.2211; LEVINE W, 1990, AM J EPIDEMIOL, V131, P254, DOI 10.1093/oxfordjournals.aje.a115495; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; MILAZZO G, 1992, CANCER RES, V52, P3924; MOUNTJOY KG, 1987, CANCER RES, V47, P6500; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OMARA BA, 1985, J CHRON DIS, V38, P435, DOI 10.1016/0021-9681(85)90139-0; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; POLLAK M, 1990, J NATL CANCER I, V82, P1693, DOI 10.1093/jnci/82.21.1693; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RAGOZZINO M, 1982, J CHRON DIS, V35, P13, DOI 10.1016/0021-9681(82)90025-X; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SHAFIE SM, 1978, CANCER RES, V38, P759; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stoll BA, 1996, BREAST CANCER RES TR, V38, P239, DOI 10.1007/BF01806141; Tanaka T, 1998, J BIOL CHEM, V273, P26772, DOI 10.1074/jbc.273.41.26772; Weiderpass E, 1997, INT J CANCER, V71, P360, DOI 10.1002/(SICI)1097-0215(19970502)71:3<360::AID-IJC9>3.0.CO;2-W; Wideroff L, 1997, J NATL CANCER I, V89, P1360, DOI 10.1093/jnci/89.18.1360; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WIMMEL A, 1994, ONCOGENE, V9, P995; Yang XF, 1996, CANCER RES, V56, P1509	65	85	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38023	38028						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11500498				2022-12-25	WOS:000171526500042
J	Heller, H; Gredinger, E; Bengal, E				Heller, H; Gredinger, E; Bengal, E			Rac1 inhibits myogenic differentiation by preventing the complete withdrawal of myoblasts from the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE DIFFERENTIATION; DISTINCT SIGNALING PATHWAYS; GENE-EXPRESSION; GROWTH-FACTOR; MOUSE MUSCLE; RHO GTPASES; FAMILY; MYOD; RAS	The small GTPase protein Rac1 is involved in a wide range of biological processes, yet its role in cell differentiation is mostly unknown. Here we show that Rac1 activity is high in proliferating myoblasts and decreases during the differentiation process. To analyze the involvement of Rac1 in muscle differentiation, different forms of the protein were expressed in muscle cells. A constitutively activated form of Rac1 (Rac1Q61L) inhibited the activity of MyoD in promoting muscle differentiation, whereas a dominant negative form of Rac1 (Rac1T17N) induced the activity of MyoD in promoting muscle differentiation. Expression of Rac1T17N imposed myogenic differentiation on myoblasts growing under mitogenic conditions. In inquiring whether Rac1 affected the withdrawal of myoblasts from the cell cycle, we analyzed the expression of cyclin D1 and p21(WAF1) and the phosphorylation state of the retinoblastoma protein. According to these markers and bromodeoxyuridine incorporation, C2 myoblasts expressing Rac1T17N exited the cell cycle earlier than control C2 cells. Myoblasts expressing Rac1Q61L did not permanently withdraw from the cell cycle. An indication of the possible involvement of the mitogen-activated protein kinase (MAPK) pathway in Rac1-mediated myoblast proliferation was obtained by the use of MAPK kinase inhibitors U0126 and PD098059. These inhibitors arrested C2-Rac1Q61L cell cycling. Taken together, our results show that Rac1 activation interferes with myoblast exit from the cell cycle via or in concert with the MAPK pathway.	Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, Dept Biochem, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Bengal, E (corresponding author), Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, Dept Biochem, POB 9649, IL-31096 Haifa, Israel.							BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Fanto M, 2000, CURR BIOL, V10, P979, DOI 10.1016/S0960-9822(00)00645-X; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MARTELLI F, 1994, ONCOGENE, V9, P3579; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Samuel DS, 1999, HORM METAB RES, V31, P55, DOI 10.1055/s-2007-978699; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; VAN AL, 1997, GENE DEV, V11, P2295; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	53	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37307	37316		10.1074/jbc.M103195200	http://dx.doi.org/10.1074/jbc.M103195200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11489882	hybrid			2022-12-25	WOS:000171375700061
J	Jung, D; Hagenbuch, B; Gresh, L; Pontoglio, M; Meier, PJ; Kullak-Ublick, GA				Jung, D; Hagenbuch, B; Gresh, L; Pontoglio, M; Meier, PJ; Kullak-Ublick, GA			Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTION FACTORS; GENOMIC ORGANIZATION; FUNCTIONAL-CHARACTERIZATION; BILE-ACID; EXPRESSION; IDENTIFICATION; HNF-1-ALPHA	OATP-C (SLC21A6) is the predominant Na+-independent uptake system for bile salts and bilirubin of human liver and is expressed exclusively at the basolateral (sinusoidal) hepatocyte membrane. To investigate the basis of liver-specific expression of OATP-C, we studied promoter function in the two hepatocyte-derived cell lines HepG2 and Huh7 and in nonhepatic HeLa cells. OATP-C promoter constructs containing from 66 to 950 nucleotides of 5'-regulatory sequence were active in HepG2 and Huh7 but not HeLa cells, indicating that determinants of hepatocyte-specific expression reside within the minimal promoter. Deoxyribonuclease I footprint analysis revealed a single region that was protected by HepG2 and Huh7 but not HeLa cell nuclear extracts. The liver-enriched transcription factor hepatocyte nuclear factor 1 alpha (HNF1 alpha) was shown by mobility shift assays to bind within this footprint. Coexpression of HNF1 alpha stimulated OATP-C promoter activity 30-fold in HepG2 and 49-fold in HeLa cells. Mutation of the HNF1 site abolished promoter function, indicating that HNF1 alpha is critical for hepatocyte-specific OATP-C gene expression. The human OATP8 (SLC21A8) and mouse Oatp4 (Slc21a6) promoters were also responsive to HNF1 alpha coexpression in HepG2 cells. These data support a role for HNF1 alpha as a global regulator of liver-specific bile salt and organic anion transporter genes.	Univ Zurich Hosp, Dept Internal Med, Div Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Internal Med, Lab Mol Gastroenterol & Hepatol, CH-8091 Zurich, Switzerland; Inst Pasteur, Unite Virus Oncogenes, F-75724 Paris, France	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Kullak-Ublick, GA (corresponding author), Univ Zurich Hosp, Dept Internal Med, Div Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland.	kullak@kpt.unizh.ch	Hagenbuch, Bruno/M-5294-2016	Hagenbuch, Bruno/0000-0002-2938-8630; Gresh, Lionel/0000-0002-2333-1748				Abe T, 1999, J BIOL CHEM, V274, P17159, DOI 10.1074/jbc.274.24.17159; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Chen J, 1999, BIOCHEM BIOPH RES CO, V260, P829, DOI 10.1006/bbrc.1999.0980; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coffinier C, 1999, DEVELOPMENT, V126, P4785; Cui Y, 2001, J BIOL CHEM, V276, P9626, DOI 10.1074/jbc.M004968200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Hayashi Y, 1999, J CLIN PATHOL-MOL PA, V52, P19; Hsiang BN, 1999, J BIOL CHEM, V274, P37161, DOI 10.1074/jbc.274.52.37161; Kakyo M, 1999, GASTROENTEROLOGY, V117, P770, DOI 10.1016/S0016-5085(99)70333-1; Karpen SJ, 1996, J BIOL CHEM, V271, P15211, DOI 10.1074/jbc.271.25.15211; Konig J, 2000, J BIOL CHEM, V275, P23161, DOI 10.1074/jbc.M001448200; Konig J, 2000, AM J PHYSIOL-GASTR L, V278, pG156, DOI 10.1152/ajpgi.2000.278.1.G156; Kullak-Ublick G A, 2000, Clin Liver Dis, V4, P357, DOI 10.1016/S1089-3261(05)70114-8; Kullak-Ublick GA, 2001, GASTROENTEROLOGY, V120, P525, DOI 10.1053/gast.2001.21176; KullakUblick GA, 1997, HEPATOLOGY, V26, P991, DOI 10.1002/hep.510260429; KULLAKUBLICK GA, 1995, GASTROENTEROLOGY, V109, P1274, DOI 10.1016/0016-5085(95)90588-X; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; LIU SY, 1995, DNA CELL BIOL, V14, P285, DOI 10.1089/dna.1995.14.285; Ogura K, 2000, BIOCHEM BIOPH RES CO, V272, P563, DOI 10.1006/bbrc.2000.2830; Ogura K, 2001, BIOCHEM BIOPH RES CO, V281, P431, DOI 10.1006/bbrc.2001.4387; Oswald M, 2001, LIVER, V21, P247, DOI 10.1034/j.1600-0676.2001.021004247.x; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Trauner M, 1998, J CLIN INVEST, V101, P2092, DOI 10.1172/JCI1680; Tronche F, 1997, J MOL BIOL, V266, P231, DOI 10.1006/jmbi.1996.0760	29	117	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37206	37214		10.1074/jbc.M103988200	http://dx.doi.org/10.1074/jbc.M103988200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11483603	hybrid			2022-12-25	WOS:000171375700047
J	Morra, M; Simarro-Grande, M; Martin, M; Chen, ASI; Lanyi, A; Silander, O; Calpe, S; Davis, J; Pawson, T; Eck, MJ; Sumegi, J; Engel, P; Li, SC; Terhorst, C				Morra, M; Simarro-Grande, M; Martin, M; Chen, ASI; Lanyi, A; Silander, O; Calpe, S; Davis, J; Pawson, T; Eck, MJ; Sumegi, J; Engel, P; Li, SC; Terhorst, C			Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; T-CELL ACTIVATION; CUTTING EDGE; ENCODING GENE; PROTEIN SAP; RECEPTOR; SLAM; INFECTION; 2B4; EXPRESSION	X-linked lymphoproliferative disease (XLP) is a primary immunodeficiency characterized by extreme susceptibility to Epstein-Barr virus. The XLP disease gene product SH2D1A (SAP) interacts via its SH2 domain with a motif (TIYXXV) present in the cytoplasmic tail of the cell-surface receptors CD150/SLAM, CD84, CD229/Ly-9, and CD244/2B4. Characteristically, the SH2D1A three-pronged interaction with Tyr(281) of CD150 can occur in absence of phosphorylation. Here we analyze the effect of SH2D1A protein missense mutations identified in 10 XLP families. Two sets of mutants were found: (i) mutants with a marked decreased protein half-life (e.g. Y7C, S28R, Q99P, P101L, V102G, and X129R) and (ii) mutants with structural changes that differently affect the interaction with the four receptors. In the second group, mutations that disrupt the interaction between the SH2D1A hydrophobic cleft and Val +3 of its binding motif (e.g. T68I) and mutations that interfere with the SH2D1A phosphotyrosine-binding pocket (e.g. C42W) abrogated SH2D1A binding to all four receptors. Surprisingly, a mutation in SH2D1A able to interfere with Thr -2 of the CD150 binding motif (mutant T53I) severely impaired non-phosphotyrosine interactions while preserving unaffected the binding of SH2D1A to phosphorylated CD150. Mutant T53I, however, did not bind to CD229 and CD224, suggesting that SH2D1A controls several critical signaling pathways in T and natural killer cells. Because no correlation is present between identified types of mutations and XLP patient clinical presentation, additional unidentified genetic or environmental factors must play a strong role in XLP disease manifestations.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA; Univ Barcelona, Fac Med, Dept Cellular Biol & Pathol, Barcelona 08036, Spain; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X5, Canada; Univ Western Ontario, Fac Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Barcelona; University of Nebraska System; University of Nebraska Medical Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Western University (University of Western Ontario)	Terhorst, C (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Immunol, RE-204,330 Brookline Ave, Boston, MA 02215 USA.		Andorra, Margarita Martin/H-2025-2015; Pawson, Tony J/E-4578-2013; Engel, Pablo/R-5907-2019; Simarro, Maria/M-3947-2015	Andorra, Margarita Martin/0000-0002-9245-4899; Engel, Pablo/0000-0001-8410-252X; Silander, Olin/0000-0003-4105-8316; Simarro, Maria/0000-0001-8917-7328	NIAID NIH HHS [P01-AI-35714] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035714] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSUBEL FM, 1995, CURRENT PROTOCOLS S, V17; Aversa G, 1997, IMMUNOL CELL BIOL, V75, P202, DOI 10.1038/icb.1997.30; Benoit L, 2000, J IMMUNOL, V165, P3549, DOI 10.4049/jimmunol.165.7.3549; Brandau O, 1999, HUM MOL GENET, V8, P2407, DOI 10.1093/hmg/8.13.2407; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Castro AG, 1999, J IMMUNOL, V163, P5860; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; DANLIKER WB, 1981, METHOD ENZYMOL, V74, P3; de la Fuente MA, 2001, BLOOD, V97, P3513, DOI 10.1182/blood.V97.11.3513; GRIERSON HL, 1991, AM J MED GENET, V40, P294, DOI 10.1002/ajmg.1320400309; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; Howie D, 2000, CURR OPIN IMMUNOL, V12, P474, DOI 10.1016/S0952-7915(00)00123-0; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Latchman Y, 1998, J IMMUNOL, V161, P5809; Lewis J, 2001, CLIN IMMUNOL, V100, P15, DOI 10.1006/clim.2001.5035; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; Mavaddat N, 2000, J BIOL CHEM, V275, P28100; Morra M, 2001, ANNU REV IMMUNOL, V19, P657, DOI 10.1146/annurev.immunol.19.1.657; Nagy N, 2000, INT J CANCER, V88, P439, DOI 10.1002/1097-0215(20001101)88:3<439::AID-IJC17>3.0.CO;2-#; Nakajima H, 2000, HUM IMMUNOL, V61, P39, DOI 10.1016/S0198-8859(99)00170-6; Nichols K E, 2000, Rev Immunogenet, V2, P256; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; PURTILO D T, 1975, Lancet, V1, P935; Sayos J, 2001, BLOOD, V97, P3867, DOI 10.1182/blood.V97.12.3867; Sayos J, 2000, INT IMMUNOL, V12, P1749, DOI 10.1093/intimm/12.12.1749; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schuster V, 2000, IMMUNOL REV, V178, P21, DOI 10.1034/j.1600-065X.2000.17819.x; SEEMAYER TA, 1995, PEDIATR RES, V38, P471, DOI 10.1203/00006450-199510000-00001; Strahm B, 2000, BRIT J HAEMATOL, V108, P377; Sullivan JL, 1999, CURR OPIN IMMUNOL, V11, P431, DOI 10.1016/S0952-7915(99)80072-7; Sumegi J, 2000, BLOOD, V96, P3118; Sylla BS, 2000, P NATL ACAD SCI USA, V97, P7470, DOI 10.1073/pnas.130193097; Tangye SG, 2000, SEMIN IMMUNOL, V12, P149, DOI 10.1006/smim.2000.0217; Tangye SG, 2000, J IMMUNOL, V165, P2932, DOI 10.4049/jimmunol.165.6.2932; Tangye SG, 1999, J IMMUNOL, V162, P6981; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; Wang N, 2001, IMMUNOGENETICS, V53, P382, DOI 10.1007/s002510100337	40	70	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36809	36816		10.1074/jbc.M101305200	http://dx.doi.org/10.1074/jbc.M101305200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477068	hybrid			2022-12-25	WOS:000171194500100
J	Saric, T; Beninga, J; Graef, CI; Akopian, TN; Rock, KL; Goldberg, AL				Saric, T; Beninga, J; Graef, CI; Akopian, TN; Rock, KL; Goldberg, AL			Major histocompatibility complex class I-presented antigenic peptides are degraded in cytosolic extracts primarily by thimet oligopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; PUROMYCIN-SENSITIVE AMINOPEPTIDASE; DISTINCT PROTEOLYTIC PROCESSES; T-LYMPHOCYTE EPITOPES; INTERFERON-GAMMA; RAT-BRAIN; PZ-PEPTIDASE; SOLUBLE METALLOENDOPEPTIDASE; LEUCINE AMINOPEPTIDASE; ENDO-OLIGOPEPTIDASE	Nearly all peptides generated by proteasomes during protein degradation are digested rapidly to amino acids, but a few proteasomal products escape this fate and are presented to the immune system on cell surface major histocompatibility complex class I molecules. To test whether these antigenic peptides may be inherently resistant to cytosolic peptidases, six different antigenic peptides were incubated with HeLa cell extracts. All six were degraded rapidly by a process involving o-phenanthroline-sensitive metallopeptidases. One antigenic peptide, FAPGNYPAL, was rapidly destroyed in the extracts by a bestatin-sensitive exopeptidase, apparently by the puromycin-sensitive aminopeptidase. The disappearance of the other five was reduced 30-90% by a specific inhibitor of the cytosolic endopeptidase, thimet oligopeptidase (TOP) (EC 3.4.24.15), whose physiological function(s) have been unclear and controversial. All these peptides were sensitive to pure recombinant TOP. Furthermore, upon fractionation of the extracts, the major peptidase peak that degraded the ovalbumin-derived epitope, SIINFEKL, co-purified with TOP. In the extracts, TOP also catalyzed rapid degradation of N-extended variants of SIINFEKL and of other antigenic peptides, which in vivo can serve as precursors of these major histocompatibility complex-presented epitopes. This enzyme (unlike cell proteins that promote production of antigenic peptides) is not regulated by interferon-gamma. TOP seems to be primarily responsible for the rapid breakdown of antigenic peptides in cytosolic extracts, and our related studies (A. X. Y. Mo, K. Lemerise, W. Zeng, Y. Shen, C. R. Abraham, A. L. Goldberg, and K. L. Rock, submitted for publication) indicate that TOP by destroying such peptides limits antigen presentation in vivo.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Saric, Tomo/B-3415-2015	Saric, Tomo/0000-0001-8344-1095				AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; BALOW RM, 1986, J BIOL CHEM, V261, P2409; BARRETT AJ, 1995, METHOD ENZYMOL, V248, P529; Beninga J, 1998, J BIOL CHEM, V273, P18734, DOI 10.1074/jbc.273.30.18734; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; CARVALHO KM, 1981, BIOCHEMISTRY-US, V20, P7082, DOI 10.1021/bi00528a005; Cascio P, 2001, EMBO J, V20, P2357, DOI 10.1093/emboj/20.10.2357; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; CHU TG, 1984, BIOCHEMISTRY-US, V23, P3598, DOI 10.1021/bi00311a005; Conn KJ, 1996, J NEUROCHEM, V66, P2011; CONSTAM DB, 1995, J BIOL CHEM, V270, P26931, DOI 10.1074/jbc.270.45.26931; Crack PJ, 1999, BRAIN RES, V835, P113, DOI 10.1016/S0006-8993(99)01494-8; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Fruh K, 1999, CURR OPIN IMMUNOL, V11, P76, DOI 10.1016/S0952-7915(99)80014-4; GACZYNSKA M, 1993, ENZYME PROTEIN, V47, P354, DOI 10.1159/000468693; GRANT EP, 1995, J IMMUNOL, V155, P3750; HARRIS CA, 1992, J BIOL CHEM, V267, P6865; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; JIRACEK J, 1995, J BIOL CHEM, V270, P21701, DOI 10.1074/jbc.270.37.21701; JOHNSON GD, 1990, ARCH BIOCHEM BIOPHYS, V276, P305, DOI 10.1016/0003-9861(90)90724-D; Kato A, 1997, J BIOL CHEM, V272, P15313, DOI 10.1074/jbc.272.24.15313; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Lucchiari-Hartz M, 2000, J EXP MED, V191, P239, DOI 10.1084/jem.191.2.239; MACPHERSON E, 1987, BIOCHEM J, V248, P259, DOI 10.1042/bj2480259; Massarelli EE, 1999, BRAIN RES, V851, P261, DOI 10.1016/S0006-8993(99)02135-6; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; Mo XY, 1999, J IMMUNOL, V163, P5851; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1988, BIOCHEMISTRY-US, V27, P597, DOI 10.1021/bi00402a015; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; POLGAR L, 1994, METHOD ENZYMOL, V244, P188; Portaro FCV, 1999, BIOCHEM BIOPH RES CO, V255, P596, DOI 10.1006/bbrc.1999.0251; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Shrimpton CN, 2000, J PEPT SCI, V6, P251, DOI 10.1002/1099-1387(200006)6:6<251::AID-PSC266>3.0.CO;2-O; Silva CL, 1999, BIOCHEM BIOPH RES CO, V255, P591, DOI 10.1006/bbrc.1999.0250; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; STOITZE L, 2000, NAT IMMUNOL, V1, P413; TISLJAR U, 1993, BIOL CHEM H-S, V374, P91; TISLJAR U, 1990, FEBS LETT, V264, P84, DOI 10.1016/0014-5793(90)80771-A; TISLJAR U, 1989, BIOCHEM BIOPH RES CO, V162, P1460, DOI 10.1016/0006-291X(89)90838-3; TISLJAR U, 1990, ANAL BIOCHEM, V186, P112, DOI 10.1016/0003-2697(90)90582-T; Tomkinson B, 1999, TRENDS BIOCHEM SCI, V24, P355, DOI 10.1016/S0968-0004(99)01435-8; Van den Eynde BJ, 2001, CURR OPIN IMMUNOL, V13, P147, DOI 10.1016/S0952-7915(00)00197-7; Yewdell JW, 2001, CURR OPIN IMMUNOL, V13, P13, DOI 10.1016/S0952-7915(00)00175-8; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369; York IA, 1999, IMMUNOL REV, V172, P49, DOI 10.1111/j.1600-065X.1999.tb01355.x	54	119	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36474	36481		10.1074/jbc.M105517200	http://dx.doi.org/10.1074/jbc.M105517200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11479311	hybrid			2022-12-25	WOS:000171194500058
J	Liang, OD; Chavakis, T; Kanse, SM; Preissner, KT				Liang, OD; Chavakis, T; Kanse, SM; Preissner, KT			Ligand binding regions in the receptor for urokinase-type plasminogen activator - Structural requirements for a multidomain binding region and receptor-receptor interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE DISPLAY TECHNOLOGY; IN-VIVO; DIFFERENT MECHANISMS; CANCER METASTASIS; CELLULAR RECEPTOR; TUMOR-GROWTH; IDENTIFICATION; ADHESION; DOMAIN; SYSTEM	The interaction between urokinase plasminogen activator (uPA) and its cellular receptor (uPAR) is a key event in cell surface-associated plasminogen activation, relevant for cell migration and invasion. In order to define receptor recognition sites for uPA, we have expressed uPAR fragments as fusion products with the minor coat protein on the surface of M13 bacteriophages. Sequence analysis of cDNA fragments encoding uPA-binding peptides indicated the existence of a composite uPA-binding structure including all three uPAR domains. This finding was confirmed by experiments using an overlapping 15-mer peptide array covering the entire uPAR molecule. Four regions within the uPAR sequence were found to directly bind to uPA: two distinct regions containing amino acids 13-20 and amino acids 74-84 of the uPAR domain 1, and regions in the putative loop 3 of the domains II and III. All the uPA-binding fragments from the three domains were shown to have an agonistic effect on uPA binding to immobilized uPAR. Furthermore, uPAR-(154-176) increased uPAR-transfected BAF3-cell adhesion on vitronectin in the presence of uPA, whereas uPAR-(247-276) stimulated the cell adhesion both in the absence or presence of uPA. The latter fragment was also able to augment the binding of vitronectin to uPAR in a purified system, thereby mimicking the effect of uPA on this interaction. These results indicate that uPA binding can take place to particular part(s) on several uPAR molecules an that direct uPAR-uPAR contacts may contribute to receptor activation and ligand binding.	Univ Giessen, Inst Biochem, Fachbereich Humannmed, D-35392 Giessen, Germany; Univ Giessen, Med Klin & Poliklin 3, D-35385 Giessen, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen	Preissner, KT (corresponding author), Univ Giessen, Inst Biochem, Fachbereich Humannmed, Friedrichstr 24, D-35392 Giessen, Germany.		Chavakis, Triantafyllos/ABE-8845-2020	Kanse, Sandip/0000-0003-0782-9957				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; APPELLA E, 1987, J BIOL CHEM, V262, P4437; Bdeir K, 2000, J BIOL CHEM, V275, P28532, DOI 10.1074/jbc.M001595200; BEHRENDT N, 1993, METHOD ENZYMOL, V223, P207; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; Behrendt N, 1998, FIBRINOLYSIS PROTEOL, V12, P191, DOI 10.1016/S0268-9499(98)80013-1; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 1999, BLOOD, V93, P2976; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Dumler I, 1999, CURR BIOL, V9, P1468, DOI 10.1016/S0960-9822(00)80116-5; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1995, J BIOTECHNOL, V41, P259, DOI 10.1016/0168-1656(95)00062-U; Gardsvoll H, 1999, J BIOL CHEM, V274, P37995, DOI 10.1074/jbc.274.53.37995; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; Hill HR, 1996, MOL MICROBIOL, V20, P685, DOI 10.1111/j.1365-2958.1996.tb02508.x; Hoogenboom HR, 2000, IMMUNOL TODAY, V21, P371, DOI 10.1016/S0167-5699(00)01667-4; Koshelnick Y, 1999, THROMB HAEMOSTASIS, V82, P305, DOI 10.1055/s-0037-1615847; KOST C, 1992, J BIOL CHEM, V267, P12098; List K, 1999, J IMMUNOL METHODS, V222, P125, DOI 10.1016/S0022-1759(98)00189-6; NELLES L, 1987, J BIOL CHEM, V262, P5682; ONEIL KT, 1994, METHOD ENZYMOL, V245, P370; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Ploug M, 1998, BIOCHEMISTRY-US, V37, P16494, DOI 10.1021/bi981203r; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN JJ, 1993, BLOOD, V82, P2719; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Rabbani SA, 1995, INT J CANCER, V63, P840, DOI 10.1002/ijc.2910630615; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Shliom O, 2000, J BIOL CHEM, V275, P24304, DOI 10.1074/jbc.M002024200; Sidenius N, 2000, FEBS LETT, V475, P52, DOI 10.1016/S0014-5793(00)01624-0; Sitrin RG, 2000, J IMMUNOL, V165, P3341, DOI 10.4049/jimmunol.165.6.3341; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; Tegge WJ, 1998, METH MOL B, V87, P99; Tressler RJ, 1999, APMIS, V107, P168, DOI 10.1111/j.1699-0463.1999.tb01540.x; Trigwell S, 2000, BIOCHEM BIOPH RES CO, V278, P440, DOI 10.1006/bbrc.2000.3818; vanZonneveld AJ, 1995, GENE, V167, P49, DOI 10.1016/0378-1119(95)00614-1; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285	53	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28946	28953		10.1074/jbc.M011437200	http://dx.doi.org/10.1074/jbc.M011437200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11501527	hybrid			2022-12-25	WOS:000170346000043
J	Senzaki, H; Smith, CJ; Juang, GJ; Isoda, T; Mayer, SP; Ohler, A; Paolocci, N; Tomaselli, GF; Hare, JM; Kass, DA				Senzaki, H; Smith, CJ; Juang, GJ; Isoda, T; Mayer, SP; Ohler, A; Paolocci, N; Tomaselli, GF; Hare, JM; Kass, DA			Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure	FASEB JOURNAL			English	Article						tissue activity; protein expression; coronary blood flow; PDE5	DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE; CYCLIC-GMP; MOLECULAR-CLONING; GENE FAMILY; BINDING; EXPRESSION; SYNTHASE; LOCALIZATION; INHIBITION	Recent studies implicate increased cGMP synthesis as a postreceptor contributor to reduced cardiac sympathetic responsiveness. Here we provide the first evidence that modulation of this interaction by cGMP-specific phosphodiesterase PDE5A is also diminished in failing hearts, providing a novel mechanism for blunted beta -adrenergic signaling in this disorder. In normal conscious dogs chronically instrumented for left ventricular pressure-dimension analysis, PDE5A inhibition by EMD82639 had modest basal effects but markedly blunted dobutamine-enhanced systolic and diastolic function. In failing hearts (tachypacing model), however, EMD82639 had negligible effects on either basal or dobutamine-stimulated function. Whole myocardium from failing hearts had 50% lower PDE5A protein expression and 30% less total and EMD92639-inhibitable cGMP-PDE activity. Although corresponding myocyte protein and enzyme activity was similar among groups, the proportion of EMD82639-inhibitable activity was significantly lower in failure cells. Immunohistochemistry confirmed PDE5A expression in both the vasculature and myocytes of normal and failing hearts, but there was loss of z-band localization in failing myocytes that suggested altered intracellular localization. Thus, PDE5A regulation of cGMP in the heart can potently modulate beta -adrenergic stimulation, and alterations in enzyme localization and reduced synthesis may blunt this pathway in cardiac failure, contributing to dampening of the beta -adrenergic response.	Johns Hopkins Med Inst, Div Cardiol, Dept Med, Baltimore, MD 21287 USA; New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA	Johns Hopkins University; Johns Hopkins Medicine; New York Medical College	Kass, DA (corresponding author), Johns Hopkins Med Inst, Div Cardiol, Dept Med, Halsted 500,600 N Wolfe St, Baltimore, MD 21287 USA.	dkass@bme.jhu.edu	paolocci, nazareno/A-7124-2009	Paolocci, Nazareno/0000-0001-7011-997X; Senzaki, Hideaki/0000-0002-8289-0953	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003228, R01HL047511, R29HL054081] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO8 HL03228, HL47511, R29 HL54081] Funding Source: Medline; PHS HHS [P50-52307] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Balligand JL, 1999, CARDIOVASC RES, V43, P607, DOI 10.1016/S0008-6363(99)00163-7; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1993, J CLIN INVEST, V92, P2737, DOI 10.1172/JCI116891; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; Chen HH, 1999, P ASSOC AM PHYSICIAN, V111, P406, DOI 10.1111/paa.1999.111.5.406; Cohen AH, 1996, J CLIN INVEST, V97, P172, DOI 10.1172/JCI118386; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; DUNDORE RL, 1992, J CARDIOVASC PHARM, V19, P937, DOI 10.1097/00005344-199206000-00015; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; Gauthier C, 1998, J CLIN INVEST, V102, P1377, DOI 10.1172/JCI2191; Grantham JA, 1997, CIRCULATION, V96, P388; Hare JM, 2000, CIRC RES, V86, P1085, DOI 10.1161/01.RES.86.10.1085; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; HARE JM, 1995, CIRCULATION, V92, P2198, DOI 10.1161/01.CIR.92.8.2198; Haywood GA, 1996, CIRCULATION, V93, P1087, DOI 10.1161/01.CIR.93.6.1087; Jackson G, 1999, AM J CARDIOL, V83, p13C; Koch WJ, 1999, TRENDS CARDIOVAS MED, V9, P77, DOI 10.1016/S1050-1738(99)00009-2; Kotera J, 2000, J HISTOCHEM CYTOCHEM, V48, P685, DOI 10.1177/002215540004800512; Kotera J, 1998, J BIOL CHEM, V273, P26982, DOI 10.1074/jbc.273.41.26982; Kotera J, 1999, EUR J BIOCHEM, V262, P866, DOI 10.1046/j.1432-1327.1999.00450.x; LaFevre-Bernt M, 1998, BBA-PROTEIN STRUCT M, V1386, P97, DOI 10.1016/S0167-4838(98)00088-0; Loughney K, 1999, GENE, V234, P109, DOI 10.1016/S0378-1119(99)00171-7; Loughney K, 1998, GENE, V216, P139, DOI 10.1016/S0378-1119(98)00303-5; MARZO KP, 1991, CIRC RES, V69, P1546, DOI 10.1161/01.RES.69.6.1546; Mohan P, 1996, CIRCULATION, V93, P1223, DOI 10.1161/01.CIR.93.6.1223; MOVSESIAN MA, 1991, J CLIN INVEST, V88, P15, DOI 10.1172/JCI115272; O'Rourke B, 1999, CIRC RES, V84, P562, DOI 10.1161/01.RES.84.5.562; Senzaki H, 2000, CIRCULATION, V101, P1040, DOI 10.1161/01.CIR.101.9.1040; SHAH AM, 1994, CIRC RES, V74, P970, DOI 10.1161/01.RES.74.5.970; Smith Carolyn J., 1998, Cell Biochemistry and Biophysics, V29, P67, DOI 10.1007/BF02737829; Smith CJ, 1996, CIRC RES, V78, P58, DOI 10.1161/01.RES.78.1.58; Smith JA, 1997, EXERC IMMUNOL REV, V3, P96; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; Stacey P, 1998, BIOCHEM BIOPH RES CO, V247, P249, DOI 10.1006/bbrc.1998.8769; Straznicka M, 1999, J CARDIOVASC PHARM, V34, P229, DOI 10.1097/00005344-199908000-00008; Traverse JH, 2000, CIRCULATION, V102, P2997; Varghese P, 2000, J CLIN INVEST, V106, P697, DOI 10.1172/JCI9323; Vejlstrup NG, 1998, J MOL CELL CARDIOL, V30, P1215, DOI 10.1006/jmcc.1998.0686; Vila-Petroff MG, 1999, CIRC RES, V84, P1020, DOI 10.1161/01.RES.84.9.1020; Wallis RM, 1999, AM J CARDIOL, V83, p3C; Yanaka N, 1998, EUR J BIOCHEM, V255, P391, DOI 10.1046/j.1432-1327.1998.2550391.x	47	176	183	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2001	15	10					1718	1726		10.1096/fj.00-0538com	http://dx.doi.org/10.1096/fj.00-0538com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481219				2022-12-25	WOS:000170809900007
J	Fuhrmann, G; Leisser, C; Rosenberger, G; Grusch, M; Huettenbrenner, S; Halama, T; Mosberger, I; Sasgary, S; Cerni, C; Krupitza, G				Fuhrmann, G; Leisser, C; Rosenberger, G; Grusch, M; Huettenbrenner, S; Halama, T; Mosberger, I; Sasgary, S; Cerni, C; Krupitza, G			Cdc25A phosphatase suppresses apoptosis induced by serum deprivation	ONCOGENE			English	Article						Cdc25; apoptosis; survival; Akt; Raf1; c-myc; signal transduction	CELL-CYCLE REGULATION; S-PHASE ENTRY; C-MYC; PROTEIN-KINASES; TNF-ALPHA; ACTIVATION; INDUCTION; PHOSPHORYLATION; EXPRESSION; 14-3-3-PROTEINS	The phosphatase Cdc25A was shown to be a target of the transcription factor c-Myc. Myc-induced apoptosis appeared dependent on Cdc25A expression and Cdc25A over-expression could substitute for Myc-triggered apoptosis. These findings suggested that an important downstream component of Myc-mediated apoptosis was identified. However and in contrast, we recently reported that during TNF alpha -induced apoptosis, which required c-Myc function, Cdc25A was down-regulated in a human carcinoma cell line. We now provide evidence that Cdc25A rendered the non-transformed rat embryonic cell line 423 refractory to apoptosis, which was induced by serum deprivation and in absence of detectable c-myc levels. The survival promoting activity of cdc25A was abolished upon infection of cells with a full-length cdc25A antisense construct. To identify the signaling proteins mediating the survival function of the phosphatase, cdc25A- and akt- over-expressing pooled clones were exposed to selected chemicals, which inhibit or activate key proteins in signaling pathways. Inhibition of apoptosis by SU4984, NF023 and Rapamycin placed Cdc25A and Akt function downstream of FGF.R, PDGF.R, and compensated G-protein- and PP2A-activity. Interestingly, upon treatment with LY-294002, cdc25A- and akt- over-expressing clones exhibited similar apoptotic patterns as control cells, which indicates that neither Akt- nor Cdc25A-mediated survival functions are dependent on PI.3 kinase activity in rat 423 cells. In cdc25A-overexpressing cells increased levels of serine 473 phosphorylated Akt were found, which coprecipitated with Cdc25A and Raf1. Since activation of proteins requires dephosphorylation of particular residues in addition to site-specific phosphorylation, the antiapoptotic effect of Cdc25A might derive from its participation in a multimeric protein complex with phosphoAkt and Raf1, two prominent components of survival pathways.	Univ Vienna, Inst Clin Pathol, A-1090 Vienna, Austria; Univ Vienna, Dept Gen Dermatol, A-1090 Vienna, Austria; Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna	Krupitza, G (corresponding author), Univ Vienna, Inst Clin Pathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Grusch, Michael/C-1183-2008	Grusch, Michael/0000-0001-5486-9340; Krupitza, Georg/0000-0003-2949-7906				CERNI C, 1990, VIROLOGY, V177, P427, DOI 10.1016/0042-6822(90)90506-M; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Das G, 1999, SCAND J IMMUNOL, V49, P307, DOI 10.1046/j.1365-3083.1999.00486.x; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Grusch M, 1999, CELL DEATH DIFFER, V6, P736, DOI 10.1038/sj.cdd.4400546; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jaworowski A, 1999, IMMUNOL CELL BIOL, V77, P90, DOI 10.1046/j.1440-1711.1999.00798.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; JOLLES J, 1993, DEMENTIA, V4, P81, DOI 10.1159/000107301; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; Krupitza G, 1998, CELL DEATH DIFFER, V5, P758, DOI 10.1038/sj.cdd.4400417; KRUPITZA G, 1995, INT J CANCER, V61, P649, DOI 10.1002/ijc.2910610511; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Simonitsch I, 1998, BRIT J CANCER, V78, P862, DOI 10.1038/bjc.1998.594; Spitkovsky D, 1996, ONCOGENE, V12, P2549; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xia K, 1999, MOL CELL BIOL, V19, P4819	45	28	30	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4542	4553		10.1038/sj.onc.1204499	http://dx.doi.org/10.1038/sj.onc.1204499			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494150				2022-12-25	WOS:000170074900012
J	Giorgetti-Peraldi, S; Murdaca, J; Mas, JC; Van Obberghen, E				Giorgetti-Peraldi, S; Murdaca, J; Mas, JC; Van Obberghen, E			The adapter protein, Grb10, is a positive regulator of vascular endothelial growth factor signaling	ONCOGENE			English	Article						Grb10; VEGF receptor; KDR; angiogenesis	INSULIN-RECEPTOR SUBSTRATE-1; TYROSINE KINASE; FLK-1/KDR ACTIVATION; PLECKSTRIN HOMOLOGY; BINDING-PROTEIN; NITRIC-OXIDE; SH2 DOMAINS; I RECEPTOR; ANGIOGENESIS; CELLS	Vascular endothelial growth factor (VEGF) is an important regulator of vasculogenesis and angiogenesis. Activation of VEGF receptors leads to the recruitment of SH2 containing proteins which link the receptors to the activation of signaling pathways. Here we report that Grb10, an adapter protein of which the biological role remains unknown, is tyrosine phosphorylated in response to VEGF in endothelial cells (HUVEC) and in 293 cells expressing the VEGF receptor KDR, An intact SH2 domain is required for Grb10 tyrosine phosphorylation in response to VEGF, and this phosphorylation is mediated in part through the activation of Src, In HUVEC, VEGF increases Grb10 mRNA level. Expression of Grb10 in HUVEC or in KDR expressing 293 cells results in an increase in the amount and in the tyrosine phosphorylation of KDR, In 293 cells, this is correlated with the activation of signaling molecules, such as MAP kinase, By expressing mutants of Grb10, we found that the positive action of Grb10 is independent of its SH2 domain. Moreover, these Grb10 effects on KDR seem to be specific since Grb10 has no effect on the insulin receptor, and Grb2, another adapter protein, does not mimic the effect of Grb10 on KDR, In conclusion, we propose that VEGF up-regulates Grb10 level, which in turn increases KDR molecules, suggesting that Grb10 could be involved in a positive feedback loop in VEGF signaling.	Fac Med Nice, IFR 50, INSERM, U145, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Giorgetti-Peraldi, S (corresponding author), Fac Med Nice, IFR 50, INSERM, U145, Ave Valombrose, F-06107 Nice 2, France.			Giorgetti-Peraldi, Sophie/0000-0002-2751-2618				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; BARBIERI B, 1981, P SOC EXP BIOL MED, V168, P204; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Langlais P, 2000, ONCOGENE, V19, P2895, DOI 10.1038/sj.onc.1203616; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OOI J, 1995, ONCOGENE, V10, P1621; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096	31	31	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					3959	3968		10.1038/sj.onc.1204520	http://dx.doi.org/10.1038/sj.onc.1204520			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494124				2022-12-25	WOS:000169681500004
J	Matroule, JY; Carthy, CM; Granville, DJ; Jolois, O; Hunt, DWC; Piette, J				Matroule, JY; Carthy, CM; Granville, DJ; Jolois, O; Hunt, DWC; Piette, J			Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization	ONCOGENE			English	Article						photosensitization; photodynamic therapy; pyropheophorbide; apoptosis; caspase; NF-kappa B	NF-KAPPA-B; CYTOCHROME-C RELEASE; MITOCHONDRIAL PERMEABILITY TRANSITION; ACTIVATED PROTEIN-KINASE; PHOTODYNAMIC THERAPY; CASPASE ACTIVATION; SINGLET OXYGEN; HELA-CELLS; INDUCTION; NECROSIS	Pyropheophorbide-a methylester (PPME) is a second generation of photosensitizers used in photodynamic therapy (PDT), We demonstrated that PPME photosensitization triggered apoptosis of colon cancer cells as measured by using several classical parameters such as DNA laddering, PARP cleavage, caspase activation and mitochondrial release of cytochrome c, Preincubation of cells with N-acetyl cysteine (NAC) or pyrolidine dithiocarbamate (PDTC) protected against apoptosis mediated by PPME photosensitization showing that reactive oxygen species (ROS) are involved as second messengers. On the other hand, photosensitization carried out in the presence of deuterium oxide (D2O) which enhances singlet oxygen (O-1(2)) lifetime only increases necrosis without affecting apoptosis, Since PPME was localized in the endoplasmic reticulum (ER)/Golgi system and lysosomes, other messengers than ROS were tested such as calcium, Bid, Bap31, phosphorylated Bcl-2 and caspase-12 but none was clearly identified as being involved in triggering cytochrome c release from mitochondria, On the other hand, we demonstrated that the transduction pathways leading to NF-kappaB activation and apoptosis were clearly independent although NF-kappaB was shown to counteract apoptosis mediated by PPME photosensitization.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Univ Liege, Lab Human Histol, B-4000 Liege, Belgium; QLT Inc, Vancouver, BC V5T 4T5, Canada	University of Liege; University of Liege	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	jpiette@ulg.ac.be						Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Granville D J, 2000, Curr Opin Drug Discov Devel, V3, P232; Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Henderson BW, 1997, CANCER RES, V57, P4000; Hirpara JL, 2000, BLOOD, V95, P1773, DOI 10.1182/blood.V95.5.1773.005k17_1773_1780; Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Katschinski DM, 2000, J BIOL CHEM, V275, P21094, DOI 10.1074/jbc.M001629200; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; Kim DK, 2000, EXP CELL RES, V257, P82, DOI 10.1006/excr.2000.4868; Korbelik M, 1996, J Clin Laser Med Surg, V14, P329; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; LEE C, 1995, CANCER RES, V55, P2063; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lin CP, 2000, EXP CELL RES, V259, P351, DOI 10.1006/excr.2000.4979; MacDonald IJ, 1999, PHOTOCHEM PHOTOBIOL, V70, P789, DOI 10.1111/j.1751-1097.1999.tb08284.x; Matroule JY, 1999, PHOTOCHEM PHOTOBIOL, V70, P540, DOI 10.1111/j.1751-1097.1999.tb08249.x; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; MILLER GG, 1995, PHOTOCHEM PHOTOBIOL, V61, P632, DOI 10.1111/j.1751-1097.1995.tb09880.x; Monney L, 1998, EUR J BIOCHEM, V251, P295, DOI 10.1046/j.1432-1327.1998.2510295.x; Morgan J, 2000, PHOTOCHEM PHOTOBIOL, V71, P747, DOI 10.1562/0031-8655(2000)071<0747:COPTIA>2.0.CO;2; Murphree AL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1348, DOI 10.1001/archopht.1996.01100140548005; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Pandey RK, 1996, PHOTOCHEM PHOTOBIOL, V64, P194, DOI 10.1111/j.1751-1097.1996.tb02442.x; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; Plumpe J, 2000, AM J PHYSIOL-GASTR L, V278, pG173, DOI 10.1152/ajpgi.2000.278.1.G173; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Ruck A, 2000, PHOTOCHEM PHOTOBIOL, V72, P210, DOI 10.1562/0031-8655(2000)072<0210:LIAIAD>2.0.CO;2; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimura M, 2000, J LEUKOCYTE BIOL, V68, P87; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; Tajiri H, 1998, CANCER LETT, V128, P205, DOI 10.1016/S0304-3835(98)00066-4; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200; Zhuang SG, 1999, EXP CELL RES, V250, P203, DOI 10.1006/excr.1999.4501; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	65	113	124	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4070	4084		10.1038/sj.onc.1204546	http://dx.doi.org/10.1038/sj.onc.1204546			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494135				2022-12-25	WOS:000169681500015
J	Perrella, MA; Pellacani, A; Layne, MD; Patel, A; Zhao, DZ; Schreiber, BM; Storch, J; Feinberg, MW; Hsieh, CM; Haber, E; Lee, ME				Perrella, MA; Pellacani, A; Layne, MD; Patel, A; Zhao, DZ; Schreiber, BM; Storch, J; Feinberg, MW; Hsieh, CM; Haber, E; Lee, ME			Absence of adipocyte fatty acid binding protein prevents the development of accelerated atherosclerosis in hypercholesterolemic mice	FASEB JOURNAL			English	Article						macrophage; adipocyte; fatty acids; atheroma	E-DEFICIENT MICE; COLONY-STIMULATING FACTOR; APOLIPOPROTEIN-E; TRANSPLANT ARTERIOSCLEROSIS; ADIPOSE CONVERSION; RECEPTOR-DEFICIENT; AP2(-/-) MICE; EXPRESSION; AP2; METABOLISM	Lipid deposition in arterial walls due to elevated levels of plasma cholesterol is central to the development of atherosclerosis and involves the uptake of oxidized low-density lipoprotein (oxLDL) by macrophages. Fatty acid binding proteins (FABPs) belong to a family of low molecular weight cytoplasmic proteins that are involved with intracellular transport and metabolism of fatty acids, and adipocyte FABP (aP2) has recently been shown to be expressed in macrophages. Here, we investigate the role of aP2 in the development of atherosclerosis in mice. We show that atherosclerotic lesions from hypercholesterolemic, apolipoprotein E deficient (ApoE(-/-)) mice (but not arterial walls from normal mice) contain high levels of aP2 mRNA. We also identified aP2 in inflammatory cells that localized in these lesions, as confirmed by its presence in isolated mouse and human macrophages, and demonstrated that aP2 is induced by oxLDL. To determine the importance of aP2 in atherosclerosis, we generated mice lacking both ApoE and aP2 (ApoE(-/-) aP2(-/-)). In comparison with ApoE(-/-) mice, ApoE(-/-)aP2(-/-) mice developed trivial lesions that were markedly smaller, less complex, and less macrophage-rich even though the ApoE(-/-)aP2(-/-) mice remained hypercholesterolemic. Absence of aP2 did not prevent lesion formation and macrophage accumulation in transplant-associated arteriosclerosis that does not depend on elevated levels of cholesterol. These results indicate a critical role for aP2 in the development of hypercholesterolemia-induced atherosclerosis.	Brigham & Womens Hosp, Div Cardiovasc, Program Dev Cardiovasc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Div Biol Sci, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Cambridge, MA 02138 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Rutgers State University New Brunswick	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Program Dev Cardiovasc Biol, 75 Francis St, Boston, MA 02115 USA.	mperrella@rics.bwh.harvard.edu		Schreiber, Barbara/0000-0001-8560-4249; Feinberg, Mark/0000-0001-9523-3859; Storch, Judith/0000-0001-5482-1777; Layne, Matthew/0000-0003-0007-4870	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK038389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNLOHR DA, 1985, BIOCHEM BIOPH RES CO, V132, P850, DOI 10.1016/0006-291X(85)91209-4; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; CATALA A, 1986, ACTA PHYSIOL PHARM L, V36, P19; Coe NR, 1999, J LIPID RES, V40, P967; COLIGAN JE, 1994, CURR PROTOCOLS IMMUN, V2; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Jain MK, 1998, CIRC RES, V83, P980, DOI 10.1161/01.RES.83.10.980; LEENEN PJ, 1994, J IMMUNOL METHODS, V14, P5; LUNZER MA, 1977, J BIOL CHEM, V252, P5483; MALEWIAK MI, 1988, INT J OBESITY, V12, P543; OCKNER RK, 1976, J CLIN INVEST, V58, P632, DOI 10.1172/JCI108510; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; Perrow C., 1994, TECHNOLOGY STUDIES, V1, P1; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Powell-Braxton L, 1998, NAT MED, V4, P934, DOI 10.1038/nm0898-934; Qiao JH, 1997, AM J PATHOL, V150, P1687; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rossberg R., 1995, Microsystem Technologies, V2, P11, DOI 10.1007/BF02739522; Scheja L, 1999, DIABETES, V48, P1987, DOI 10.2337/diabetes.48.10.1987; SCHREIBER BM, 1988, ATHEROSCLEROSIS, V69, P69, DOI 10.1016/0021-9150(88)90290-0; Shaughnessy S, 2000, DIABETES, V49, P904, DOI 10.2337/diabetes.49.6.904; Shi CW, 1997, CIRCULATION, V96, P2722, DOI 10.1161/01.CIR.96.8.2722; SHI CW, 1994, CIRC RES, V75, P199, DOI 10.1161/01.RES.75.2.199; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SPIEGELMAN BM, 1980, J BIOL CHEM, V255, P8811; STJOHN LC, 1987, J NUTR, V117, P2021; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhang SH, 1997, J CLIN INVEST, V99, P2858, DOI 10.1172/JCI119479	34	32	34	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1774	+		10.1096/fj.01-0017fje	http://dx.doi.org/10.1096/fj.01-0017fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481226				2022-12-25	WOS:000169261200031
J	Arnesano, F; Banci, L; Bertini, I; Cantini, F; Ciofi-Baffoni, S; Huffman, DL; O'Halloran, TV				Arnesano, F; Banci, L; Bertini, I; Cantini, F; Ciofi-Baffoni, S; Huffman, DL; O'Halloran, TV			Characterization of the binding interface between the copper chaperone Atx1 and the first cytosolic domain of Ccc2 ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ANISOTROPIC ROTATIONAL DIFFUSION; HETERONUCLEAR NMR-SPECTROSCOPY; PULSED-FIELD GRADIENTS; WILSON-DISEASE GENE; SACCHAROMYCES-CEREVISIAE; MENKES-DISEASE; BACKBONE DYNAMICS; CANDIDATE GENE; IRON TRANSPORT	The interaction of the copper chaperone Atx1 and the first cytosolic domain of Ccc2 ATPase, Ccc2a, was investigated by NAM in solution. In particular, a solution of Cu(I)-(15)NAtx1 was titrated with apo-Ccc2a, and, vice versa, a solution of Cu(I)-(15)NCcc2a was titrated with apo-Atx1. By following the N-15 and H-1 chemical shifts, a new species is detected in both experiments. This species is the same in both titrations and is in fast exchange with the parent species on the NMR time scale. Nuclear relaxation data are consistent with the formation of an adduct. Judging from the nuclear Overhauser effect spectroscopy patterns, the structure of Cu(I)-(15)NCcc2a in the presence of apo-Atx1 is not significantly altered, whereas Cu(I)-(15)NAtx1 in the presence of apo-Ccc2a experiences some changes with respect to both the apoproteins and the Cu(I)-loaded proteins. The structure of the Cu(I)-(15)NAtx1 moiety in the adduct was obtained from 1137 nuclear Overhauser effects to a final root mean square deviation to the mean structure of 0.76 +/- 0.13 Angstrom for the backbone and 1.11 +/- 0.11 Angstrom for the heavy atoms. N-15 and 1H chemical shifts suggest the regions of interaction that, together with independent information, allow a structural model of the adduct to be proposed. The apo form of Atx1 displays significant mobility in loops 1 and 5, the N-terminal part of helix alpha (1), and the C-terminal part of helix alpha (2) on the ms-ps time scale. These regions correspond to the metal binding site. Such mobility is largely reduced in the free Cu(I)-Atx1 and in the adduct with apo-Ccc2a. The analogous mobility of Ccc2a in both Cu(I) and apo forms is reduced with respect to Atx1. Such an adduct is relevant as a structural and kinetic model for copper transfer from Atx1 to Ccc2a in physiological conditions.	Univ Florence, Magnet Resonance Ctr CERM, I-50019 Florence, Italy; Univ Florence, Dept Chem, I-50019 Florence, Italy; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	University of Florence; University of Florence; Northwestern University; Northwestern University	Bertini, I (corresponding author), Univ Florence, Magnet Resonance Ctr CERM, Via Luigi Sacconi 6, I-50019 Florence, Italy.		Arnesano, Fabio/C-3066-2016; O'Halloran, Thomas/ABE-6125-2021; Cantini, Francesca/O-1220-2015; Ciofi-Baffoni, Simone/AAH-9778-2021	Arnesano, Fabio/0000-0002-8399-0964; O'Halloran, Thomas/0000-0001-8732-5059; Cantini, Francesca/0000-0003-0526-6732; Ciofi Baffoni, Simone/0000-0002-2376-3321; BANCI, LUCIA/0000-0003-0562-5774	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054111] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BLOOM M, 1965, J CHEM PHYS, V42, P1615, DOI 10.1063/1.1696168; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHEESMAN BV, 1988, J AM CHEM SOC, V110, P6359, DOI 10.1021/ja00227a014; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Corazza A, 1996, EUR J BIOCHEM, V236, P697, DOI 10.1111/j.1432-1033.1996.0697d.x; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P2517, DOI 10.1021/bi962924y; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Hubbard TJP, 1997, NUCLEIC ACIDS RES, V25, P236, DOI 10.1093/nar/25.1.236; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee LK, 1997, J BIOMOL NMR, V9, P287, DOI 10.1023/A:1018631009583; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Luginbuhl P, 1997, BIOCHEMISTRY-US, V36, P7305, DOI 10.1021/bi963161h; MACURA S, 1982, J MAGN RESON, V47, P351, DOI 10.1016/0022-2364(82)90128-7; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; OREKHOV VY, 1994, EUR J BIOCHEM, V219, P887, DOI 10.1111/j.1432-1033.1994.tb18570.x; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; PENG JW, 1994, METHOD ENZYMOL, V239, P563; PENG JW, 1992, BIOCHEMISTRY-US, V31, P8571, DOI 10.1021/bi00151a027; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Powlowski J, 1999, J BIOL CHEM, V274, P33320, DOI 10.1074/jbc.274.47.33320; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; QIN J, 1993, BIOPHYS J, V65, P2178, DOI 10.1016/S0006-3495(93)81270-0; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; SCHURR JM, 1994, J MAGN RESON SER B, V105, P211, DOI 10.1006/jmrb.1994.1127; Steele RA, 1997, BIOCHEMISTRY-US, V36, P6885, DOI 10.1021/bi9631632; Tjandra N, 1996, J BIOMOL NMR, V8, P273, DOI 10.1007/BF00410326; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zinn-Justin S, 1997, J BIOMOL NMR, V10, P363, DOI 10.1023/A:1018365815186	72	123	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41365	41376		10.1074/jbc.M104807200	http://dx.doi.org/10.1074/jbc.M104807200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11500502	hybrid			2022-12-25	WOS:000171925600131
J	Fan, JL; Unoki, H; Kojima, N; Sun, HJ; Shimoyamada, H; Deng, HY; Okazaki, M; Shikama, H; Yamada, N; Watanabe, T				Fan, JL; Unoki, H; Kojima, N; Sun, HJ; Shimoyamada, H; Deng, HY; Okazaki, M; Shikama, H; Yamada, N; Watanabe, T			Overexpression of lipoprotein lipase in transgenic rabbits inhibits diet-induced hypercholesterolemia and atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; FOAM CELL-FORMATION; APOLIPOPROTEIN-E; CHOLESTEROL ACYLTRANSFERASE; HEPATIC LIPASE; KNOCKOUT MICE; LDL RECEPTOR; IN-VIVO; PLASMA; METABOLISM	Lipoprotein lipase (LPL) is a key enzyme in the hydrolysis of TG-rich lipoproteins. To elucidate the physiological roles of LPL in lipid and lipoprotein metabolism, we generated transgenic rabbits expressing human LPL. In postheparinized plasma of transgenic rabbits, the human LPL protein levels were about 650 ng/ml, and LPL enzymatic activity was found at levels up to 4-fold greater than that in nontransgenic littermates. Increased LPL activity in transgenic rabbits was associated with as much as an 80% decrease in plasma triglycerides and a 59% decrease in high density lipoprotein-cholesterol. Analysis of the lipoprotein density fractions revealed that increased expression of the LPL transgene resulted in a remarkable reduction in the level of very low density lipoproteins as well as in the level of intermediate density lipoproteins. In addition, LDL cholesterol levels in transgenic rabbits were significantly increased. When transgenic rabbits were fed a cholesterol-rich diet, the development of hypercholesterolemia and aortic atherosclerosis was dramatically suppressed in transgenic rabbits. These results demonstrate that systemically increased LPL activity functions in the metabolism of all classes of lipoproteins, thereby playing a crucial role in plasma triglyceride hydrolysis and lipoprotein conversion, and that overexpression of LPL protects against diet-induced hypercholesterolemia and atherosclerosis.	Univ Tsukuba, Inst Basic Med Sci, Dept Pathol, Tsukuba, Ibaraki 3058575, Japan; Tokyo Med & Dent Univ, Coll Liberal Arts & Sci, Chem Lab, Chiba 2820827, Japan; Tsukuba Res Inst, Yamanouchi Pharmaceut Co Ltd, Tsukuba, Ibaraki 3058585, Japan; Univ Tsukuba, Inst Clin Med, Div Metab & Endocrinol, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; Tokyo Medical & Dental University (TMDU); Astellas Pharmaceuticals; Novartis; University of Tsukuba	Fan, JL (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Pathol, Tsukuba, Ibaraki 3058575, Japan.		Unoki-Kubota, Hiroyuki/H-7268-2019	Unoki-Kubota, Hiroyuki/0000-0003-4827-8805; Fan, Jianglin/0000-0002-1737-6130				Amar M, 2000, CIRCULATION, V102, P45; Araki M, 1998, ACTA HISTOCHEM CYTOC, V31, P485, DOI 10.1267/ahc.31.485; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; Babaev VR, 2000, J BIOL CHEM, V275, P26293, DOI 10.1074/jbc.M002423200; Barter P, 2000, ARTERIOSCL THROM VAS, V20, P2029, DOI 10.1161/01.ATV.20.9.2029; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Benlian P, 1996, NEW ENGL J MED, V335, P848, DOI 10.1056/NEJM199609193351203; Brousseau ME, 1999, J LIPID RES, V40, P365; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; Fan JL, 1998, J CLIN INVEST, V101, P2151, DOI 10.1172/JCI1599; Fan JL, 2000, J LIPID RES, V41, P1004; Fan JL, 2001, ARTERIOSCL THROM VAS, V21, P88, DOI 10.1161/01.ATV.21.1.88; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; Fan JL, 1999, PATHOL INT, V49, P583, DOI 10.1046/j.1440-1827.1999.00923.x; Goldberg IJ, 1996, J LIPID RES, V37, P693; Havel RJ, 2000, CURR OPIN LIPIDOL, V11, P615, DOI 10.1097/00041433-200012000-00008; HERSCOWITZ HB, 1981, MANUAL MACROPHAGE ME, P1; Hoeg JM, 1996, P NATL ACAD SCI USA, V93, P11448, DOI 10.1073/pnas.93.21.11448; IKEDA Y, 1990, J LIPID RES, V31, P1911; Jensen DR, 1997, AM J PHYSIOL-REG I, V273, pR683, DOI 10.1152/ajpregu.1997.273.2.R683; KAWAMURA M, 1994, ARTERIOSCLER THROMB, V14, P235, DOI 10.1161/01.ATV.14.2.235; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; Lindsey J. R., 1994, The biology of the laboratory rabbit., P293; LIU MS, 1994, J BIOL CHEM, V269, P11417; MAHLEY RW, 1977, J LIPID RES, V18, P314; Mahley RW, 1999, J LIPID RES, V40, P1; Mehlum A, 1997, APMIS, V105, P861, DOI 10.1111/j.1699-0463.1997.tb05095.x; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; Merkel M, 1998, J CLIN INVEST, V102, P893, DOI 10.1172/JCI2912; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; Okazaki M, 1998, J CHROMATOGR B, V709, P179, DOI 10.1016/S0378-4347(98)00064-4; OKAZAKI M, 2000, HDB LIPOPROTEIN TEST, P647; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; Olivecrona T, 1997, P NUTR SOC, V56, P723, DOI 10.1079/PNS19970072; Rinninger F, 1998, J LIPID RES, V39, P1335; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SEHAYEK E, 1991, J CLIN INVEST, V88, P553, DOI 10.1172/JCI115339; Shimada M, 1996, P NATL ACAD SCI USA, V93, P7242, DOI 10.1073/pnas.93.14.7242; SHIMADA M, 1994, J BIOL CHEM, V269, P11673; SHIMANO H, 1992, J CLIN INVEST, V90, P2084, DOI 10.1172/JCI116091; STEIN O, 1983, BIOCHIM BIOPHYS ACTA, V750, P306, DOI 10.1016/0005-2760(83)90033-4; Taylor JM, 1997, ANN NY ACAD SCI, V811, P146, DOI 10.1111/j.1749-6632.1997.tb51997.x; Yagyu H, 1999, J LIPID RES, V40, P1677; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005; ZSIGMOND E, 1994, J BIOL CHEM, V269, P18757; Zsigmond E, 1997, HUM GENE THER, V8, P1921, DOI 10.1089/hum.1997.8.16-1921	47	80	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40071	40079		10.1074/jbc.M105456200	http://dx.doi.org/10.1074/jbc.M105456200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11477088	hybrid			2022-12-25	WOS:000171789200077
J	Lee, HG; Kang, H; Kim, DH; Park, WJ				Lee, HG; Kang, H; Kim, DH; Park, WJ			Interaction of HRC (Histidine-rich Ca2+-binding protein) and triadin in the lumen of sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; RYANODINE RECEPTOR; CALCIUM-RELEASE; MOLECULAR-CLONING; CALSEQUESTRIN; BINDING; CA-2+; IDENTIFICATION; LOCALIZATION; PURIFICATION	HRC (histidine-rich Ca2+ binding protein) has been identified from skeletal and cardiac muscle and shown to bind Ca2+ with high capacity and low affinity. While HRC resides in the lumen of the sarcoplasmic reticulum, the physiological function of HRC is largely unknown. In the present study, we have performed co-immunoprecipitation experiments and show that HRC binds directly to triadin, which is an integral membrane protein of the sarcoplasmic reticulum. Using a fusion protein binding assay, we further identified the histidine-rich acidic repeats of HRC as responsible for the binding of HRC to triadin. These motifs may represent a novel protein-protein interaction domain. The HRC binding domain of triadin was also localized by fusion protein binding assay to the lumenal region containing the KEKE motif that was previously shown to be involved in the binding of triadin to calsequestrin. Notably, the interaction of HRC and triadin is Ca2+-sensitive. Our data suggest that HRC may play a role in the regulation of Ca2+ release from the sarcoplasmic reticulum by interaction with triadin.	K JIST, Dept Life Sci, Puk Gu, Kwangju 500712, South Korea; K JIST, Natl Res Lab, Puk Gu, Kwangju 500712, South Korea		Park, WJ (corresponding author), K JIST, Dept Life Sci, Puk Gu, 1 Oryong Dong, Kwangju 500712, South Korea.	wjpark@kjist.ac.kr						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; DAMIANI E, 1995, BIOCHEM BIOPH RES CO, V209, P457, DOI 10.1006/bbrc.1995.1524; Donoso P, 1996, BIOCHEMISTRY-US, V35, P13419, DOI 10.1021/bi9616209; Groh S, 1999, J BIOL CHEM, V274, P12278, DOI 10.1074/jbc.274.18.12278; Gu W, 1996, SOC GEN PHY, V51, P19; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; HOFMANN SL, 1989, J BIOL CHEM, V264, P8260; HOFMANN SL, 1989, J BIOL CHEM, V264, P18083; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; KIM DH, 1984, BIOCHIM BIOPHYS ACTA, V775, P320, DOI 10.1016/0005-2736(84)90187-1; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; Kobayashi YM, 2000, J BIOL CHEM, V275, P17639, DOI 10.1074/jbc.M002091200; Kobayashi YM, 1999, J BIOL CHEM, V274, P28660, DOI 10.1074/jbc.274.40.28660; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; Ohkura M, 1998, BIOCHEMISTRY-US, V37, P12987, DOI 10.1021/bi972803d; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; PICELLO E, 1992, BIOCHEM BIOPH RES CO, V186, P659, DOI 10.1016/0006-291X(92)90797-O; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; REALINI C, 1995, J BIOL CHEM, V270, P29664; Sacchetto R, 1999, J MUSCLE RES CELL M, V20, P403, DOI 10.1023/A:1005580609414; Shin DW, 2000, FEBS LETT, V486, P178, DOI 10.1016/S0014-5793(00)02246-8; Suk JY, 1999, BIOCHEM BIOPH RES CO, V263, P667, DOI 10.1006/bbrc.1999.1432; West RW, 2000, GENE, V243, P195, DOI 10.1016/S0378-1119(99)00510-7; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	31	56	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39533	39538		10.1074/jbc.M010664200	http://dx.doi.org/10.1074/jbc.M010664200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11504710	hybrid			2022-12-25	WOS:000171789200006
J	Fu, X; Menke, JG; Chen, YL; Zhou, GC; MacNaul, KL; Wright, SD; Sparrow, CP; Lund, EG				Fu, X; Menke, JG; Chen, YL; Zhou, GC; MacNaul, KL; Wright, SD; Sparrow, CP; Lund, EG			27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; OXYSTEROL 7-ALPHA-HYDROXYLASE GENE; STEROL 27-HYDROXYLASE GENE; ACID BIOSYNTHETIC ENZYME; LOW-DENSITY LIPOPROTEIN; CEREBROTENDINOUS XANTHOMATOSIS; LXR-ALPHA; TANGIER-DISEASE; CELLULAR CHOLESTEROL; PROTEIN-1C GENE	The nuclear receptors liver X receptor alpha (LXR alpha) (NR1H3) and LXR beta (NR1H2) are important regulators of genes involved in lipid metabolism, including ABCA1, ABCG1, and sterol regulatory element-binding protein-1c (SREBP-1c). Although it has been demonstrated that oxysterols are LXR ligands, little is known about the identity of the physiological activators of these receptors. Here we confirm earlier studies demonstrating a dose-dependent induction of ABCA1 and ABCG1 in human monocyte-derived macrophages by cholesterol loading. In addition, we show that formation of 27-hydroxycholesterol and cholestenoic acid, products of CYP27 action on cholesterol, is dependent on the dose of cholesterol used to load the cells. Other proposed LXR ligands, including 20(S)-hydroxycholesterol, 22(R)hydroxycholesterol, and 24(S),25-epoxycholesterol, could not be detected under these conditions. A role for CYP27 in regulation of cholesterol-induced genes was demonstrated by the following findings. 1) Introduction of CYP27 into HEK-293 cells conferred an induction of ABCG1 and SREBP-1c; 2) upon cholesterol loading, CYP27-expressing cells induce these genes to a greater extent than in control cells; 3) in CYP27-deficient human skin fibroblasts, the induction of ABCA1 in response to cholesterol loading was ablated; and 4) in a coactivator association assay, 27-hydroxycholesterol functionally activated LXR. We conclude that 27-hydroxylation of cholesterol is an important pathway for LXR activation in response to cholesterol overload.	Merck Res Labs, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Metab Res, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Lund, EG (corresponding author), Merck Res Labs, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA.							Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Babiker A, 1999, J LIPID RES, V40, P1417; Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Behulova D, 2000, J INHERIT METAB DIS, V23, P413, DOI 10.1023/A:1005668305864; BJORKHEM I, 1992, J LIPID RES, V33, P455; Bjorkhem I, 2001, J LIPID RES, V42, P366; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BJORKHEM I, 1995, METABOLIC MOL BASES, V2, P2073; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CALI JJ, 1991, J BIOL CHEM, V266, P7779; Costet P, 2000, J BIOL CHEM, V275, P28240; Crisby M, 1997, BBA-LIPID LIPID MET, V1344, P278, DOI 10.1016/S0005-2760(96)00152-X; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; FUJIYAMA J, 1991, CLIN CHIM ACTA, V200, P1, DOI 10.1016/0009-8981(91)90328-A; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Hailman E, 1996, J IMMUNOL, V156, P4384; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hulten LM, 1996, J CLIN INVEST, V97, P461, DOI 10.1172/JCI118436; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Javitt NB, 2000, BBA-MOL CELL BIOL L, V1529, P136, DOI 10.1016/S1388-1981(00)00143-8; KALUZNY MA, 1985, J LIPID RES, V26, P135; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; KUDO K, 1989, J LIPID RES, V30, P1097; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16536, DOI 10.1074/jbc.M001811200; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; OFTEBRO H, 1980, J CLIN INVEST, V65, P1418, DOI 10.1172/JCI109806; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; REISS AB, 1994, J LIPID RES, V35, P1026; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SAMBROOK J, 2000, MOL CLONING LAB MANU; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Setchell KDR, 1998, J CLIN INVEST, V102, P1690, DOI 10.1172/JCI2962; SHORE V, 1981, J CLIN INVEST, V68, P1295, DOI 10.1172/JCI110376; SKREDE S, 1986, J CLIN INVEST, V78, P729, DOI 10.1172/JCI112633; Song C, 2000, ENDOCRINOLOGY, V141, P4180, DOI 10.1210/en.141.11.4180; SPENCER TA, 1985, J BIOL CHEM, V260, P3391; SPENCER TA, 1994, ACCOUNTS CHEM RES, V27, P83, DOI 10.1021/ar00039a004; Spencer TA, 2001, J MED CHEM, V44, P886, DOI 10.1021/jm0004749; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wakamatsu N, 1999, J NEUROL NEUROSUR PS, V67, P195, DOI 10.1136/jnnp.67.2.195; Westman J, 1998, ARTERIOSCL THROM VAS, V18, P554, DOI 10.1161/01.ATV.18.4.554; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zhang Z, 2001, J LIPID RES, V42, P649; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	64	427	445	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38378	38387		10.1074/jbc.M105805200	http://dx.doi.org/10.1074/jbc.M105805200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504730	hybrid			2022-12-25	WOS:000171673200009
J	Tureckova, J; Wilson, EM; Cappalonga, JL; Rotwein, P				Tureckova, J; Wilson, EM; Cappalonga, JL; Rotwein, P			Insulin-like growth factor-mediated muscle differentiation - Collaboration between phosphatidylinositol 3-kinase-Akt-signaling pathways and myogenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNALING PATHWAYS; CELL SURVIVAL; FACTOR-II; IGF-I; 3-KINASE; AKT; EXPRESSION; REQUIRES; MEF2	The differentiation and maturation of skeletal muscle require interactions between signaling pathways activated by hormones and growth factors and an intrinsic regulatory network controlled by myogenic transcription factors. Insulin-like growth factors (IGFs) play key roles in muscle development in the embryo and in regeneration in the adult. To study mechanisms of IGF action in muscle, we developed a myogenic cell line that overexpresses IGF-binding protein-5. C2BP5 cells remain quiescent in low serum differentiation medium until the addition of IGF-I. Here we use this cell line to identify signaling pathways controlling IGF-mediated differentiation. Induction of myogenin by IGF-I and myotube formation were prevented by the phosphatidylinositol (PI) 3-kinase inhibitor, LY294002, even when included 2 days after growth factor addition, whereas expression of active PI 3-kinase could promote differentiation in the absence of IGF-I. Differentiation also was induced by myogenin but was blocked by LY294002. The differentiation-promoting effects of IGF-I were mimicked by a modified membrane-targeted inducible Akt-1 (iAkt), and iAkt was able to stimulate differentiation of C2 myoblasts and primary mouse myoblasts incubated with otherwise inhibitory concentrations of LY294002. These results show that an IGF-regulated PI 3-kinase-Akt pathway controls muscle differentiation by mechanisms acting both upstream and downstream of myogenin.	Oregon Hlth & Sci Univ, Dept Med, Div Mol Med, Portland, OR 97201 USA	Oregon Health & Science University	Rotwein, P (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Div Mol Med, Portland, OR 97201 USA.	rotweinp@ohsu.edu	Rotwein, Peter/R-5783-2019; Tureckova, Jolana/G-6344-2014	Rotwein, Peter/0000-0002-9505-1817	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042748] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK042748, 5RO1-DK42748] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Calera MR, 1998, BIOCHEM BIOPH RES CO, V251, P835, DOI 10.1006/bbrc.1998.9566; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; ERDINGER E, 1998, J BIOL CHEM, V273, P10436; EWTON DZ, 1994, J CELL PHYSIOL, V161, P277, DOI 10.1002/jcp.1041610212; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; James PL, 1996, J CELL BIOL, V133, P683, DOI 10.1083/jcb.133.3.683; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Jones J, 1999, J PEPT SCI, V5, P3, DOI 10.1002/(SICI)1099-1387(199901)5:1<3::AID-PSC194>3.0.CO;2-6; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256-3265.2000; Li YQ, 2000, CELL SIGNAL, V12, P751, DOI 10.1016/S0898-6568(00)00120-0; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Montarras D, 1996, J CELL SCI, V109, P551; Musaro A, 1999, MOL CELL BIOL, V19, P3115; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ozes ON, 1999, NATURE, V401, P82; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sarbassov DD, 1997, MOL ENDOCRINOL, V11, P2038, DOI 10.1210/me.11.13.2038; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; Stewart CEH, 1996, J CELL PHYSIOL, V169, P23, DOI 10.1002/(SICI)1097-4652(199610)169:1<23::AID-JCP3>3.0.CO;2-G; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Xu Q, 2000, J BIOL CHEM, V275, P36750, DOI 10.1074/jbc.M005030200; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	54	150	158	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39264	39270		10.1074/jbc.M104991200	http://dx.doi.org/10.1074/jbc.M104991200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11500504	hybrid			2022-12-25	WOS:000171673200123
J	Narayanaswami, V; Szeto, SSW; Ryan, RO				Narayanaswami, V; Szeto, SSW; Ryan, RO			Lipid association-induced N- and C-terminal domain reorganization in human apolipoprotein E3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAIN; INDUCED CONFORMATIONAL-CHANGES; AQUEOUS-SOLUTIONS; ENERGY-TRANSFER; LIPOPROTEINS; PROTEIN; ARGININE-61; PATHWAY; E4	Apolipoprotein E (apoE) is a 299 amino acid, antiatherogenic protein that plays a key role in regulating plasma lipoprotein metabolism. It is composed of an N-terminal (NT) domain (residues 1-191) that is responsible for binding to members of the low density lipoprotein receptor family and a C-terminal (CT) domain (residues 216-299) that anchors the protein to lipoprotein particles by virtue of its high-affinity lipid binding characteristics. Isoform-specific differences in the NT domain that modulate the lipoprotein binding preference elicited by the CT domain suggest the existence and importance of domain interactions in this protein. Employing steady state fluorescence quenching and resonance energy transfer techniques, spatial proximity relationships between the N- and C-terminal domains were investigated in recombinant human apoE3. ApoE3 containing a single Trp at position 264 and an N-iodoacetyl-N'-(5-sulfo-1-napthyl) ethylenediamine (AEDANS) moiety covalently attached to the lone Cys residue at position 112 was used (AEDANS-apoE3/W@264). Fluorescence quenching studies revealed a solvent-exposed location for Trp-264. In the lipid-free state, fluorescence resonance energy transfer (FRET) was noted between Trp-264 and AEDANS, with a calculated distance of 27 Angstrom between the two fluorophores. Control experiments established that FRET observed in this system is intramolecular. FRET was abolished upon proteolysis in the linker region connecting the NT and CT domains. Lowering the solution pH to 4 induced an increase in the efficiency of intramolecular energy transfer, with the two domains reorienting about 5 Angstrom closer to one another. Interdomain FRET was retained in the presence of 0.6-1.0 M guanidine hydrochloride but was lost at higher concentrations, a manifestation of unfolding of the domains and increased distance between the donor-acceptor pair. Interaction of AEDANS-apoE3/W@264 with lipid induced a loss of FRET, attributed to spatial repositioning of the domains by > 80 Angstrom. The data provide biophysical evidence that, in addition to reported conformational changes in the four-helix bundle configuration induced by lipid association, lipid binding of apoE is accompanied by reorientation of the tertiary disposition of the NT and CT domains.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of Alberta	Narayanaswami, V (corresponding author), Childrens Hosp, Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.			Narayanaswami, Vasanthy/0000-0001-7088-4057	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL064159, R01HL064159] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64159] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Clement-Collin V, 1999, EUR J BIOCHEM, V264, P358, DOI 10.1046/j.1432-1327.1999.00608.x; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; DePauw M, 1997, BIOCHEMISTRY-MOSCOW+, V62, P251; DERGUNOV AD, 1992, BIOL CHEM H-S, V373, P323, DOI 10.1515/bchm3.1992.373.1.323; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Dong WJ, 1999, J BIOL CHEM, V274, P31382, DOI 10.1074/jbc.274.44.31382; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 2000, J BIOL CHEM, V275, P33601, DOI 10.1074/jbc.M002643200; Fisher CA, 1997, BIOCHEM CELL BIOL, V75, P45, DOI 10.1139/bcb-75-1-45; Forster T., 1966, MODERN QUANTUM CHEM, P93; Forstner M, 1999, PROTEIN EXPRES PURIF, V17, P267, DOI 10.1006/prep.1999.1144; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; Lakowitcz J.R, 1999, PRINCIPLES FLUORESCE, P237, DOI DOI 10.1007/978-1-4757-3061-6_8; Lindeberg M, 2000, J MOL BIOL, V295, P679, DOI 10.1006/jmbi.1999.3396; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; Narayanaswami V, 1996, J BIOL CHEM, V271, P26855, DOI 10.1074/jbc.271.43.26855; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; Perugini MA, 2000, J BIOL CHEM, V275, P36758, DOI 10.1074/jbc.M005565200; SEGREST JP, 1992, J LIPID RES, V33, P141; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; SHIMANO H, 1992, J CLIN INVEST, V90, P2084, DOI 10.1172/JCI116091; SPARROW JT, 1992, BIOCHEMISTRY-US, V31, P1065, DOI 10.1021/bi00119a015; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TEALE FWJ, 1957, BIOCHEM J, V65, P476, DOI 10.1042/bj0650476; Wang GS, 1996, BIOCHEMISTRY-US, V35, P10358, DOI 10.1021/bi960934t; Weers PMM, 2001, EUR J BIOCHEM, V268, P3728, DOI 10.1046/j.1432-1327.2001.02282.x; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WINDLER E, 1980, J BIOL CHEM, V255, P5475; YOKOYAMA S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P99, DOI 10.1016/0005-2760(90)90266-Z; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	42	51	53	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37853	37860						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11483594				2022-12-25	WOS:000171526500020
J	Ohnishi, A; Oda, Y; Hayakawa, Y				Ohnishi, A; Oda, Y; Hayakawa, Y			Characterization of receptors of insect cytokine, growth-blocking peptide, in human keratinocyte and insect Sf9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMATOCYTE-SPREADING PEPTIDE; MANDUCA-SEXTA; PSEUDOPLUSIA-INCLUDENS; PARALYTIC PEPTIDES; BIOGENIC PEPTIDE; HEMOLYMPH; IDENTIFICATION; PROTEINS; ARMYWORM; CLONING	Insect cytokine, growth-blocking peptide (GBP), enhances cell proliferation of human keratinocyte cells with a potency almost equivalent to that of human epidermal growth factor (EGF). GBP consists of 25 amino acid residues containing a core region that shows a striking similarity to the C-terminal beta -loop domain of EGF and disordered N and C termini. The present study demonstrates that, although GBP lacks the N-terminal half-portion of EGF molecule, at least five amino acids of the disordered N-terminal six-amino acid region are indispensable for affecting the cell growth activity of GBP. Upon stimulating mitogenesis in keratinocyte cells, GBP directly binds and activates their EGF receptors. GBP also effects proliferative activity on insect Sf9 cells through the binding and activation of the specific receptor, which consists of a heterodimeric complex: a binding subunit (60 kDa) and a tyrosine phosphorylation subunit (58 kDa). These results indicate that GBP enhances cell proliferation of human keratinocyte and insect Sf9 cells through the activation of EGF and GBP receptors, respectively.	Hokkaido Univ, Inst Low Temp Sci, Kita Ku, Sapporo, Hokkaido 0600819, Japan	Hokkaido University	Hayakawa, Y (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Kita Ku, Kita 19,Nishi 8, Sapporo, Hokkaido 0600819, Japan.	hayakawa@orange.lowtem.hokudai.ac.jp		Ohnishi, Atsushi/0000-0003-1213-4439				Aizawa T, 1999, J BIOL CHEM, V274, P1887, DOI 10.1074/jbc.274.4.1887; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Clark KD, 1997, J BIOL CHEM, V272, P23440, DOI 10.1074/jbc.272.37.23440; Feinmesser RL, 1999, J BIOL CHEM, V274, P16168, DOI 10.1074/jbc.274.23.16168; Furuya K, 1999, PEPTIDES, V20, P53, DOI 10.1016/S0196-9781(98)00148-X; Hayakawa Y, 1998, BIOCHEM BIOPH RES CO, V250, P194, DOI 10.1006/bbrc.1998.8959; HAYAKAWA Y, 1995, J INSECT PHYSIOL, V41, P1, DOI 10.1016/0022-1910(94)00077-T; HAYAKAWA Y, 1990, J BIOL CHEM, V265, P10813; HAYAKAWA Y, 1991, J BIOL CHEM, V266, P7982; HAYAKAWA Y, 1995, FEBS LETT, V376, P185, DOI 10.1016/0014-5793(95)01273-7; Hayakawa Y, 1998, EUR J BIOCHEM, V253, P810, DOI 10.1046/j.1432-1327.1998.2530810.x; HEATH WF, 1986, P NATL ACAD SCI USA, V83, P6367, DOI 10.1073/pnas.83.17.6367; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Ohnishi A, 1995, INSECT BIOCHEM MOLEC, V25, P1121, DOI 10.1016/0965-1748(95)00054-2; SARAH MP, 1996, J BIOL CHEM, V271, P30392; SATO JD, 1987, METHOD ENZYMOL, V146, P63; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SKINNER WS, 1991, J BIOL CHEM, V266, P12873; SKINNER WS, 1993, COMP BIOCHEM PHYS C, V104, P133, DOI 10.1016/0742-8413(93)90124-4; Strand MR, 1999, ARCH INSECT BIOCHEM, V42, P213, DOI 10.1002/(SICI)1520-6327(199911)42:3&lt;213::AID-ARCH5&gt;3.0.CO;2-4; Strand MR, 2000, J INSECT PHYSIOL, V46, P817, DOI 10.1016/S0022-1910(99)00171-7; VLIET AVD, 1998, J BIOL CHEM, V273, P31860; Volkman BF, 1999, J BIOL CHEM, V274, P4493, DOI 10.1074/jbc.274.8.4493; Wang Y, 1999, INSECT BIOCHEM MOLEC, V29, P1075, DOI 10.1016/S0965-1748(99)00086-7; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; Yu XQ, 1999, J PEPT RES, V54, P256, DOI 10.1034/j.1399-3011.1999.00136.x; YUEN S, 1987, METHOD ENZYMOL, V146, P42	31	31	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37974	37979						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11495909				2022-12-25	WOS:000171526500036
J	Yi-Brunozzi, HY; Stephens, OM; Beal, PA				Yi-Brunozzi, HY; Stephens, OM; Beal, PA			Conformational changes that occur during an RNA-editing adenosine deamination reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; ECORI DNA METHYLTRANSFERASE; GLUR-B; BASE; FLUORESCENCE; MECHANISM; PROTEINS; BINDING; SITE; PURIFICATION	ADARs are adenosine deaminases responsible for RNA-editing reactions that occur within duplex RNA. Currently little is known regarding the nature of the protein-RNA interactions that lead to site-selective adenosine deamination. We previously reported that ADAR2 induced changes in 2-aminopurine fluorescence of a modified substrate, consistent with a base-flipping mechanism. Additional data have been obtained using full-length ADAR2 and a protein comprising only the RNA binding domain (RBD) of ADAR2. The increase in 2-aminopurine fluorescence is specific to the editing site and dependent on the presence of the catalytic domain. Hydroxyl radical footprinting demonstrates that the RBD protects a region of the RNA duplex around the editing site, suggesting a significant role for the RBD in identifying potential ADAR2 editing sites. Nucleotides near the editing site on the non-edited strand become hypersensitive to hydrolytic cleavage upon binding of ADAR2 RBD. Therefore, the RBD may assist base flipping by increasing the conformational flexibility of nucleotides in the duplex adjacent to its binding site. In addition, an increase in tryptophan fluorescence is observed when ADAR2 binds duplex RNA, suggesting a conformational change in the catalytic domain of the enzyme. Furthermore, acrylamide quenching experiments indicate that RNA binding creates heterogeneity in the solvent accessibility of ADAR2 tryptophan residues, with one out of five tryptophans more solvent-accessible in the ADAR2.RNA complex.	Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Beal, PA (corresponding author), Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA.				NIGMS NIH HHS [GM-61115] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061115] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Cal S, 1997, J BIOL CHEM, V272, P490; CARTER CW, 1995, BIOCHIMIE, V77, P92, DOI 10.1016/0300-9084(96)88110-7; DOCKBREGEON AC, 1987, COLD SPRING HARB SYM, V52, P113, DOI 10.1101/SQB.1987.052.01.016; Easterwood LM, 2000, J AM CHEM SOC, V122, P11537, DOI 10.1021/ja003171c; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; GROSJEAN H, 1998, MODIFICATION EDITING, P551; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; Hough RF, 1997, RNA, V3, P356; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LEY HL, 2001, THESIS U UTAH; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MAEGLEY KA, 1992, J BIOL CHEM, V267, P18527; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; OConnell MA, 1997, J BIOL CHEM, V272, P473; Ohman M, 2000, RNA, V6, P687, DOI 10.1017/S1355838200000200; Polson AG, 1996, NATURE, V380, P454; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; Stephens OM, 2000, BIOCHEMISTRY-US, V39, P12243, DOI 10.1021/bi0011577; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; VLASSOV VV, 1995, NUCLEIC ACIDS RES, V23, P3161, DOI 10.1093/nar/23.16.3161; Vuyisich M, 2000, NUCLEIC ACIDS RES, V28, P2369, DOI 10.1093/nar/28.12.2369; WARD DC, 1969, J BIOL CHEM, V244, P1228; Wong SK, 2001, RNA, V7, P846, DOI 10.1017/S135583820101007X; Yang JH, 1997, P NATL ACAD SCI USA, V94, P4354, DOI 10.1073/pnas.94.9.4354	34	51	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37827	37833						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11479320				2022-12-25	WOS:000171526500016
J	Bijur, GN; Jope, RS				Bijur, GN; Jope, RS			Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; HEAT-SHOCK; DNA-BINDING; PHOSPHATIDYLINOSITOL 3-KINASE; NEUROBLASTOMA-CELLS; TAU-PHOSPHORYLATION; ACTIVATION; APOPTOSIS; INCREASES; TYROSINE	The goal of this study was to determine whether the intracellular distribution of the proapoptotic enzyme glycogen synthase kinase-3 beta (GSK-3 beta) is dynamically regulated by conditions that activate apoptotic signaling cascades. In untreated human neuroblastoma SHSY5Y cells, GSK-3 beta was predominantly cytosolic, although a low level was also detected in the nucleus. The nuclear level of GSK-3 beta was rapidly increased after exposure of cells to serum-free media, heat shock, or staurosporine. Although each of these conditions caused changes in the serine 9 and/or tyrosine phosphorylation of GSK-3 beta, neither of these modifications was correlated with nuclear accumulation of GSK-3 beta. Heat shock and staurosporine treatments increased nuclear GSK-3 beta prior to activation of caspase-9 and caspase-3, and this nuclear accumulation of GSK-3 beta was unaltered by pretreatment with a general caspase inhibitor. The GSK-3 beta inhibitor lithium did not alter heat shock-induced nuclear accumulation of GSK-3 beta but increased the nuclear level of cyclin D1, indicating that cyclin D1 is a substrate of nuclear GSK-3 beta. Thus, the intracellular distribution of GSK-3 beta is dynamically regulated by signaling cascades, and apoptotic stimuli cause increased nuclear levels of GSK-3 beta, which facilitates interactions with nuclear substrates.	Univ Alabama, Dept Psychiat & Behav Neurobiol, Sparks Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Jope, RS (corresponding author), Univ Alabama, Dept Psychiat & Behav Neurobiol, Sparks Ctr, Rm 1057, Birmingham, AL 35294 USA.				NIA NIH HHS [R01 AG021045-01A1, R01 AG021045] Funding Source: Medline; NIMH NIH HHS [R56 MH038752, R01 MH038752, MH38752, R01 MH038752-16] Funding Source: Medline; NINDS NIH HHS [R01 NS037768-01A1, R01 NS037768] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R56MH038752, R01MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021045] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Chakravarthy BR, 1999, J NEUROCHEM, V72, P933, DOI 10.1046/j.1471-4159.1999.0720933.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; GOODE N, 1992, J BIOL CHEM, V267, P16878; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; GRIMES CA, 2001, IN PRESS J NEUROCHEM; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hartigan JA, 1999, J BIOL CHEM, V274, P21395, DOI 10.1074/jbc.274.30.21395; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; Hetman M, 2000, J NEUROSCI, V20, P2567; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; JOPE RS, 2001, IN PRESS MOL PSYCHIA; Kehlenbach RH, 2000, J BIOL CHEM, V275, P17848, DOI 10.1074/jbc.M001455200; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kuhl NM, 2000, CELL MOL LIFE SCI, V57, P450, DOI 10.1007/PL00000707; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; LI X, 2001, IN PRESS BIPOLAR DIS; Maggirwar SB, 1999, J NEUROCHEM, V73, P578, DOI 10.1046/j.1471-4159.1999.0730578.x; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Posmantur R, 1997, J NEUROCHEM, V68, P2328; Ragano-Caracciolo M, 1998, BIOCHEM BIOPH RES CO, V249, P422, DOI 10.1006/bbrc.1998.9159; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; WANG QM, 1994, J BIOL CHEM, V269, P14566; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200	37	183	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37436	37442		10.1074/jbc.M105725200	http://dx.doi.org/10.1074/jbc.M105725200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11495916	Green Accepted, hybrid			2022-12-25	WOS:000171375700077
J	Boudreaux, B; MacMillan, F; Teutloff, C; Agalarov, R; Gu, FF; Grimaldi, S; Bittl, R; Brettel, K; Redding, K				Boudreaux, B; MacMillan, F; Teutloff, C; Agalarov, R; Gu, FF; Grimaldi, S; Bittl, R; Brettel, K; Redding, K			Mutations in both sides of the photosystem I reaction center identify the phylloquinone observed by electron paramagnetic resonance spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; SITE-DIRECTED MUTAGENESIS; A(1)(CENTER DOT-); ACCEPTOR A(1); F-B; CHLAMYDOMONAS-REINHARDTII; P-700(CENTER DOT+); TRANSFER KINETICS; TRANSIENT EPR; AXIAL LIGANDS	The core of photosystem I (PS1) is composed of the two related integral membrane polypeptides, PsaA and PsaB, which bind two symmetrical branches of cofactors, each consisting of two chlorophylls and a phylloquinone, that potentially link the primary electron donor and the tertiary acceptor. In an effort to identify amino acid residues near the phylloquinone binding sites, all tryptophans and histidines that are conserved between PsaA and PsaB in the region of the 10th and 11th transmembrane alpha -helices were mutated in Chlamydomonas reinhardtii. The mutant PS1 reaction centers appear to assemble normally and possess photochemical activity. An electron paramagnetic resonance (EPR) signal attributed to the phylloquinone anion radical(A(1)(-)) can be observed either transiently or after illumination of reaction centers with pre-reduced iron-sulfur clusters. Mutation of PsaA-Trp(693) to Phe resulted in an inability to photo-accumulate A(1)(-), whereas mutation of the analogous tryptophan in PsaB (PsaB-Trp(673)) did not produce this effect. The PsaA-W693F mutation also produced spectral changes in the time-resolved EPR spectrum of the P-700(+) A(1)(-) radical pair, whereas the analogous mutation in PsaB had no observable effect. These observations indicate that the A(1)(-) phylloquinone radical observed by EPR occupies the phylloquinone-binding site containing PsaA-Trp(693). However, mutation of either tryptophan accelerated charge recombination from the terminal Fe-S clusters.	Univ Alabama, Dept Chem, Tuscaloosa, AL 35487 USA; Univ Alabama, Dept Biol Sci, Tuscaloosa, AL 35487 USA; Goethe Univ Frankfurt, Inst Phys & Theoret Chem, D-60439 Frankfurt, Germany; Tech Univ Berlin, Max Volmer Inst, D-10623 Berlin, Germany; CEA Saclay, Dept Biol Cellulaire & Mol, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; CEA Saclay, Sect Bioenerget, F-91191 Gif Sur Yvette, France	University of Alabama System; University of Alabama Tuscaloosa; University of Alabama System; University of Alabama Tuscaloosa; Goethe University Frankfurt; Technical University of Berlin; CEA; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay	Redding, K (corresponding author), Univ Alabama, Dept Chem, 120 lloyd Hall,6th Ave, Tuscaloosa, AL 35487 USA.	kevin.redding@mail.ua.edu	Grimaldi, Stephane/AAF-7138-2020; MacMillan, Fraser/AAM-4483-2020; MacMillan, Fraser/B-7619-2011; Grimaldi, Stephane/G-9884-2013; Bittl, Robert/I-8149-2013	Grimaldi, Stephane/0000-0002-9559-6112; MacMillan, Fraser/0000-0002-2410-4790; MacMillan, Fraser/0000-0002-2410-4790; Bittl, Robert/0000-0003-4103-3768; Redding, Kevin/0000-0003-2819-4022				ALLEN KD, 1994, PLANTA, V194, P42; Bennoun P, 1982, METHODS CHLOROPLAST, P25; Bittl R, 1997, J PHYS CHEM B, V101, P1429, DOI 10.1021/jp962256q; Bittl R, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P509; Bittl R, 1997, BIOCHEMISTRY-US, V36, P12001, DOI 10.1021/bi971645n; BOCK CH, 1989, FEBS LETT, V247, P91, DOI 10.1016/0014-5793(89)81247-5; BRETTEL K, 1988, FEBS LETT, V239, P93, DOI 10.1016/0014-5793(88)80552-0; BRETTEL K, 1987, BIOCHIM BIOPHYS ACTA, V893, P109, DOI 10.1016/0005-2728(87)90030-2; Brettel K, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P611; Brettel K, 1995, PHOTOSYNTH RES, V45, P183, DOI 10.1007/BF00015559; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; Diaz-Quintana A, 1998, BIOCHEMISTRY-US, V37, P3429, DOI 10.1021/bi972469l; Dorlet P, 2000, BIOCHEMISTRY-US, V39, P7826, DOI 10.1021/bi000175l; Fischer N, 1997, BIOCHEMISTRY-US, V36, P93, DOI 10.1021/bi962244v; FISH LE, 1985, MOL BIOL PHOTOSYNTHE, P111; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; Guergova-Kuras M, 2001, P NATL ACAD SCI USA, V98, P4437, DOI 10.1073/pnas.081078898; Hanley J, 1997, BIOCHEMISTRY-US, V36, P11543, DOI 10.1021/bi971360a; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; Hastings G, 2001, BIOCHEMISTRY-US, V40, P3681, DOI 10.1021/bi0023100; HEATHCOTE P, 1980, FEBS LETT, V111, P381, DOI 10.1016/0014-5793(80)80832-5; HEATHCOTE P, 1993, BIOCHIM BIOPHYS ACTA, V1144, P54, DOI 10.1016/0005-2728(93)90030-J; Joliot P, 1999, BIOCHEMISTRY-US, V38, P11130, DOI 10.1021/bi990857c; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Jordan R, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P663; Kamlowski A, 1998, J PHYS CHEM B, V102, P8278, DOI 10.1021/jp9824611; Klukas O, 1999, J BIOL CHEM, V274, P7361, DOI 10.1074/jbc.274.11.7361; Krabben L, 2000, BIOCHEMISTRY-US, V39, P13012, DOI 10.1021/bi001200q; Kusumoto N, 1999, BIOCHEMISTRY-US, V38, P12124, DOI 10.1021/bi990452s; LEIBL W, 1995, BIOCHEMISTRY-US, V34, P10237, DOI 10.1021/bi00032a018; MacMillan F, 1997, BIOCHEMISTRY-US, V36, P9297, DOI 10.1021/bi971097d; MacMillan F, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P715; MATHIS P, 1988, FEBS LETT, V237, P65, DOI 10.1016/0014-5793(88)80173-X; MOENNELOCCOZ P, 1994, BIOCHEMISTRY-US, V33, P10037, DOI 10.1021/bi00199a030; OHAD I, 1990, J BIOL CHEM, V265, P1972; Patzlaff JS, 1996, BIOCHEMISTRY-US, V35, P7802, DOI 10.1021/bi960056z; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PRINCE RC, 1983, FEBS LETT, V160, P273, DOI 10.1016/0014-5793(83)80981-8; Purton S, 2001, BIOCHEMISTRY-US, V40, P2167, DOI 10.1021/bi0019489; Redding K, 1998, EMBO J, V17, P50, DOI 10.1093/emboj/17.1.50; Redding K, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P591; Rigby SEJ, 1996, BIOCHEMISTRY-US, V35, P6651, DOI 10.1021/bi952619x; Rochaix JD, 2000, BIOCHIMIE, V82, P635, DOI 10.1016/S0300-9084(00)00604-0; RUSTANDI RR, 1990, BIOCHEMISTRY-US, V29, P8030, DOI 10.1021/bi00487a006; SETIF P, 1993, BIOCHEMISTRY-US, V32, P7846, DOI 10.1021/bi00082a002; SETIF P, 1985, BIOCHIM BIOPHYS ACTA, V808, P112, DOI 10.1016/0005-2728(85)90033-7; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; Teutloff C, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P607; VALLON O, 1993, EUR J BIOCHEM, V214, P907, DOI 10.1111/j.1432-1033.1993.tb17994.x; VANDEREST A, 1994, BIOCHEMISTRY-US, V33, P11789, DOI 10.1021/bi00205a015; Webber AN, 1996, BIOCHEMISTRY-US, V35, P12857, DOI 10.1021/bi961198w; Yang F, 1998, J PHYS CHEM B, V102, P8288, DOI 10.1021/jp981952i; Zech SG, 1997, BIOCHEMISTRY-US, V36, P9774, DOI 10.1021/bi970754z	54	56	64	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37299	37306		10.1074/jbc.M102327200	http://dx.doi.org/10.1074/jbc.M102327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11489879	hybrid			2022-12-25	WOS:000171375700060
J	Yan, L; Borregaard, N; Kjeldsen, L; Moses, MA				Yan, L; Borregaard, N; Kjeldsen, L; Moses, MA			The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL) - Modulation of MMP-9 activity by NGAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER; IDENTIFICATION; METASTASIS; EXPRESSION; CELLS; SERUM; PROGELATINASE; ACTIVATION; INHIBITORS; GRANULES	Detection of matrix metalloproteinase (MMP) activities in the urine from patients with a variety of cancers has been closely correlated to disease status. Among these activities, the presence of a group of high molecular weight (HAM) MMPs independently serves as a multivariate predictor of the metastatic phenotype (1). The identity of these HMW MMP activities has remained unknown despite their novelty and their potentially important applications in non-invasive cancer diagnosis and/or prognosis. Here, we report the identification of one of these HMW urinary MMPs of similar to 125-kDa as being a complex of gelatinase B (MMP-9) and neutrophil gelatinase-associated lipocalin (NGAL). Multiple biochemical approaches verified this identity. Analysis using substrate gel electrophoresis demonstrated that the 125-kDa urinary MMP activity co-migrates with purified human neutrophil MMP-9.NGAL complex. The 125-kDa urinary MMP9.NGAL complex was recognized by a purified antibody against human NGAL as well as by a monospecific antihuman MMP-9 antibody. Furthermore, these same two antibodies were independently capable of specifically immunoprecipitating the 125-kDa urinary MMP activity in a dose-dependent manner. In addition, the complex of MMP-9.NGAL could be reconstituted in vitro by mixing MMP-9 and NGAL in gelatinase buffers with pH values in the range of urine and in normal urine as well. Finally, the biochemical consequences of the NGAL and MMP-9 interaction were investigated both in vitro using recombinant human NGAL and MMP-9 and in cell culture by overexpressing NGAL in human breast carcinoma cells. Our data demonstrate that NGAL is capable of protecting MMP-9 from degradation in a dose-dependent manner and thereby preserving MMP-9 enzymatic activity. In summary, this study identifies the 125-kDa urinary gelatinase as being a complex of MMP-9 and NGAL and provides evidence that NGAL modulates MMP-9 activity by protecting it from degradation.	Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA; Rigshosp, Univ Hosp, Dept Hematol, DK-2100 Copenhagen, Denmark	Harvard University; Boston Children's Hospital; Harvard Medical School; Rigshospitalet; University of Copenhagen	Moses, MA (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Enders 1009,320 Longwood Ave, Boston, MA 02115 USA.	marsha.moses@tch.harvard.edu	Kjeldsen, Lars/AAF-2096-2019					AXELSSON L, 1995, SCAND J CLIN LAB INV, V55, P577, DOI 10.3109/00365519509110257; BAKER T, 1994, BRIT J CANCER, V70, P506, DOI 10.1038/bjc.1994.336; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; BRAUNHUT SJ, 1994, J BIOL CHEM, V269, P13472; CAULFIEL.JP, 1974, J CELL BIOL, V63, P883, DOI 10.1083/jcb.63.3.883; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Cowland JB, 1997, GENOMICS, V45, P17, DOI 10.1006/geno.1997.4896; Friedl A, 1999, HISTOCHEM J, V31, P433, DOI 10.1023/A:1003708808934; Furutani M, 1998, CANCER LETT, V122, P209, DOI 10.1016/S0304-3835(97)00391-1; GARBISA S, 1992, CANCER RES, V52, P4548; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; HRABARENEVEY S, 1989, ONCOGENE, V4, P601; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KJELDSEN L, 1994, BLOOD, V83, P799; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Lochter A, 1998, ANN NY ACAD SCI, V857, P180, DOI 10.1111/j.1749-6632.1998.tb10116.x; MARGULIES IMK, 1992, CANCER EPIDEM BIOMAR, V1, P467; Moses MA, 1998, CANCER RES, V58, P1395; NAKAJIMA M, 1993, CANCER RES, V53, P5802; Nielsen BS, 1996, GUT, V38, P414, DOI 10.1136/gut.38.3.414; SOPATA I, 1991, ACTA BIOCHIM POL, V38, P67; Stoesz SP, 1998, INT J CANCER, V79, P565, DOI 10.1002/(SICI)1097-0215(19981218)79:6<565::AID-IJC3>3.3.CO;2-6; Stoesz SP, 1995, ONCOGENE, V11, P2233; Yan L, 2000, J CELL SCI, V113, P3979; ZUCKER S, 1994, ANN NY ACAD SCI, V732, P248, DOI 10.1111/j.1749-6632.1994.tb24740.x	27	531	573	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37258	37265		10.1074/jbc.M106089200	http://dx.doi.org/10.1074/jbc.M106089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11486009	hybrid			2022-12-25	WOS:000171375700054
J	DeCoursey, TE; Cherny, VV; Morgan, D; Katz, BZ; Dinauer, MC				DeCoursey, TE; Cherny, VV; Morgan, D; Katz, BZ; Dinauer, MC			The gp91(phox) component of NADPH oxidase is not the voltage-gated proton channel in phagocytes, but it helps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; ALVEOLAR EPITHELIAL-CELLS; HUMAN-NEUTROPHILS; H+ CHANNEL; FLAVOCYTOCHROME B(558); ELECTRON CURRENTS; CONDUCTANCE; PH; GP91-PHOX; MEMBRANE	During the "respiratory burst," the NADPH oxidase complex of phagocytes produces reactive oxygen species that kill bacteria and other invaders (Babior, B. M. (1999) Blood 93, 1464-1476). Electron efflux through NADPH oxidase is electrogenic (Henderson, L. M., Chappell, J. B., and Jones, O. T. G. (1987) Biochem. J. 246, 325-329) and is compensated by H+ efflux through proton channels that reportedly are contained within the gp91(phox) subunit of NADPH oxidase. To test whether gp91(phox) functions as a proton channel, we studied H+ currents in granulocytes from X-linked chronic granulomatous disease patients lacking gp91(phox) (X-CGD), the human myelocytic PLB-985 cell line, PLB-985 cells in which gp91(phox) was knocked out by gene targeting (PLBKO), and PLB-985 knockout cells re-transfected with gp91(phox) (PLB91). H+ currents in unstimulated PLBKO cells had amplitude and gating kinetics similar to PLB91 cells. Furthermore, stimulation with the phorbol ester phorbol 12-myristate 13-acetate increased H+ currents to a similar extent in X-CGD, PLBKO, and PLB91 cells. Thus, gp91(phox) is not the proton channel in unstimulated phagocytes and does not directly mediate the increase of proton conductance during the respiratory burst. Changes in H+ channel gating kinetics during NADPH oxidase activity are likely crucial to the activation of H+ flux during the respiratory burst.	Rush Presbyterian St Lukes Med Ctr, Dept Mol Biophys & Physiol, Chicago, IL 60612 USA; Northwestern Univ, Childrens Mem Hosp, Sch Med, Dept Pediat, Chicago, IL 60614 USA; Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Dept Pediat & Med & Mol Genet, Indianapolis, IN 46202 USA	Rush University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Indiana University System; Indiana University-Purdue University Indianapolis	DeCoursey, TE (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Mol Biophys & Physiol, 1750 W Harrison St, Chicago, IL 60612 USA.		DeCoursey, Thomas/A-6820-2009	DeCoursey, Thomas/0000-0002-4263-180X	NHLBI NIH HHS [R01 HL061437] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061437] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banfi B, 1999, J EXP MED, V190, P183, DOI 10.1084/jem.190.2.183; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Biberstine-Kinkade KJ, 1999, J BIOL CHEM, V274, P10451, DOI 10.1074/jbc.274.15.10451; BILBERSTINEKINK.KJ, 2001, J BIOL CHEM, V276, P31105; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Cherny V V, 1997, Membr Cell Biol, V11, P337; Cherny VV, 2001, J PHYSIOL-LONDON, V535, P783, DOI 10.1111/j.1469-7793.2001.00783.x; Cherny VV, 1999, J GEN PHYSIOL, V114, P819, DOI 10.1085/jgp.114.6.819; CHERNY VV, 1995, J GEN PHYSIOL, V105, P861, DOI 10.1085/jgp.105.6.861; DeCoursey TE, 2000, P NATL ACAD SCI USA, V97, P6885, DOI 10.1073/pnas.100047297; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; DeCoursey TE, 2001, J PHYSIOL-LONDON, V535, P767, DOI 10.1111/j.1469-7793.2001.00767.x; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; Eder C, 2001, PROG NEUROBIOL, V64, P277, DOI 10.1016/S0301-0082(00)00062-9; Henderson LM, 1999, J GEN PHYSIOL, V114, P771, DOI 10.1085/jgp.114.6.771; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1988, BIOCHEM J, V255, P285; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; Henderson LM, 1998, J BIOL CHEM, V273, P33216, DOI 10.1074/jbc.273.50.33216; Henderson LM, 1996, BBA-BIOENERGETICS, V1273, P87, DOI 10.1016/0005-2728(95)00140-9; Henderson LM, 1997, BIOCHEM J, V325, P701, DOI 10.1042/bj3250701; Heyworth PG, 2001, BLOOD CELL MOL DIS, V27, P16, DOI 10.1006/bcmd.2000.0347; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; Maturana A, 2001, J BIOL CHEM, V276, P30277, DOI 10.1074/jbc.M010438200; NANDA A, 1993, P NATL ACAD SCI USA, V90, P760, DOI 10.1073/pnas.90.2.760; NANDA A, 1994, J BIOL CHEM, V269, P27280; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; Schrenzel J, 1998, NATURE, V392, P734, DOI 10.1038/33725; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	31	62	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36063	36066		10.1074/jbc.C100352200	http://dx.doi.org/10.1074/jbc.C100352200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477065	hybrid			2022-12-25	WOS:000171194500002
J	Porceddu, A; Stals, H; Reichheldt, JP; Segers, G; De Veylder, L; Barroco, RD; Casteels, P; Van Montagu, M; Inze, D; Mironov, V				Porceddu, A; Stals, H; Reichheldt, JP; Segers, G; De Veylder, L; Barroco, RD; Casteels, P; Van Montagu, M; Inze, D; Mironov, V			A plant-specific cyclin-dependent kinase is involved in the control of G(2)/M progression in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; ARABIDOPSIS-THALIANA; PROTEIN-KINASE; FISSION YEAST; FUNCTIONAL HOMOLOG; TRANSGENIC TOBACCO; ALFALFA CELLS; ORYZA-SATIVA; CDC2 GENE; S-PHASE	Cyclin-dependent kinases (CDKs) control the key transitions in the eukaryotic cell cycle. All the CDKs known to control G(2)/M progression in yeast and animals are distinguished by the characteristic PSTAIRE motif in their cyclin-binding domain and are closely related. Higher plants contain in addition a number of more divergent non-PSTAIRE CDKs with still obscure functions. We show that a plant-specific type of non-PSTAIRE CDKs is involved in the control of the G(2)/M progression. In synchronized tobacco BY-2 cells, the corresponding protein, accumulated in a cell cycle-regulated fashion, peaking at the G(2)/M transition. The associated histone HI kinase activity reached a maximum in mitosis and required a yet unidentified subunit to be fully active. Down-regulation of the associated kinase activity in transgenic tobacco plants using a dominant-negative mutation delayed G(2)/M transition. These results provide the first evidence that non-PSTAIRE CDKs are involved in the control of the G(2)/M progression in plants.	Univ Ghent, Vakgrp Mol Genet, B-9000 Ghent, Belgium; State Univ Ghent VIB, Dept Plantengenet, B-9000 Ghent, Belgium	Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University	Inze, D (corresponding author), Univ Ghent, Vakgrp Mol Genet, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	diinz@gengenp.rug.ac.be	Inzé, Dirk/AAW-6381-2021; de veylder, lieven/AAM-9909-2020	Inzé, Dirk/0000-0002-3217-8407; de veylder, lieven/0000-0003-1150-4426				COLASANTI J, 1991, P NATL ACAD SCI USA, V88, P3377, DOI 10.1073/pnas.88.8.3377; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FERREIRA PCG, 1991, PLANT CELL, V3, P531, DOI 10.1105/tpc.3.5.531; Fobert PR, 1996, PLANT CELL, V8, P1465, DOI 10.1105/tpc.8.9.1465; GALBRAITH DW, 1983, SCIENCE, V220, P1049, DOI 10.1126/science.220.4601.1049; GATZ C, 1992, PLANT J, V2, P397, DOI 10.1046/j.1365-313X.1992.t01-37-00999.x; Gendreau E, 1997, PLANT PHYSIOL, V114, P295, DOI 10.1104/pp.114.1.295; HASHIMOTO J, 1992, MOL GEN GENET, V233, P10, DOI 10.1007/BF00587555; HATA S, 1991, FEBS LETT, V279, P149, DOI 10.1016/0014-5793(91)80271-4; HEMERLY A, 1995, EMBO J, V14, P3925, DOI 10.1002/j.1460-2075.1995.tb00064.x; HEROUART D, 1994, PLANT PHYSIOL, V104, P873, DOI 10.1104/pp.104.3.873; HIRAYAMA T, 1991, GENE, V105, P159, DOI 10.1016/0378-1119(91)90146-3; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; IMAJUKU Y, 1992, FEBS LETT, V304, P73, DOI 10.1016/0014-5793(92)80592-5; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Joubes J, 2000, PLANT MOL BIOL, V43, P607, DOI 10.1023/A:1006470301554; KIDOU SI, 1994, DNA SEQUENCE, V5, P125, DOI 10.3109/10425179409039714; LABIB K, 1995, J CELL SCI, V108, P3285; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; MAGYAR Z, 1993, PLANT J, V4, P151, DOI 10.1046/j.1365-313X.1993.04010151.x; Magyar Z, 1997, PLANT CELL, V9, P223, DOI 10.1105/tpc.9.2.223; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Mironov V, 1999, PLANT CELL, V11, P509; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Pines J, 1996, BIOCHEM SOC T, V24, P15, DOI 10.1042/bst0240015; Porceddua A, 1999, FEBS LETT, V446, P182, DOI 10.1016/S0014-5793(99)00211-2; REICHHELD JP, 1995, PLANT J, V7, P245, DOI 10.1046/j.1365-313X.1995.7020245.x; SEGERS G, 1997, PLANT CELL PROLIFERA, P1; Setiady YY, 1996, PLANT CELL PHYSIOL, V37, P369, DOI 10.1093/oxfordjournals.pcp.a028955; Stals H, 1997, FEBS LETT, V418, P229, DOI 10.1016/S0014-5793(97)01368-9; Stern B, 1996, TRENDS GENET, V12, P345; Umeda M, 1999, PLANT PHYSIOL, V119, P31, DOI 10.1104/pp.119.1.31; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Yoshizumi T, 1999, PLANT CELL, V11, P1883, DOI 10.1105/tpc.11.10.1883	36	132	146	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36354	36360		10.1074/jbc.M011060200	http://dx.doi.org/10.1074/jbc.M011060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477067	hybrid			2022-12-25	WOS:000171194500041
J	Inoue, Y; Kishimoto, A; Hirao, J; Yoshida, M; Taguchi, H				Inoue, Y; Kishimoto, A; Hirao, J; Yoshida, M; Taguchi, H			Strong growth polarity of yeast prion fiber revealed by single fiber imaging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; SACCHAROMYCES-CEREVISIAE; SUP35 PROTEIN; IN-VITRO; PROPAGATION; DETERMINANT; DOMAIN; HYPOTHESIS; PSI(+); URE2P	Using the yeast prion as a model, we have developed a novel system to observe the growth of individual prion fibers directly. NM fragments, the prion-determining region of the yeast protein Sup35p, were labeled by either red or green fluorescent dyes, and the fiber growth was observed under a fluorescence microscope. When green-Sup35NM was added to the preformed fibers made of red-Sup35NM, 70-97% of green fibers grew unidirectionally, from only one end of individual red fibers, whereas the remainder grew from both ends. Similarly, the majority of red fibers grew from only one end of green fibers when the order of addition was reversed. Sonication of preformed fibers to expose fresh ends did not change the results, excluding a possibility of occasional deformation of one end as the reason of the apparent unidirectional growth. These results indicate the polarity of Sup35 prion fibers and impose constraints on the models of fiber growth.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp	taguchi, hideki/AAM-2663-2021; Taguchi, Hideki/B-6946-2009; Inoue, Yuji/B-5267-2013	taguchi, hideki/0000-0002-6612-9339; Taguchi, Hideki/0000-0002-6612-9339; Inoue, Yuji/0000-0002-2932-4733				AIZAWA SI, 1990, J MOL BIOL, V211, P673, DOI 10.1016/0022-2836(90)90064-S; ASAKURA S, 1968, J MOL BIOL, V35, P227, DOI 10.1016/S0022-2836(68)80050-6; Blackley HKL, 2000, J MOL BIOL, V298, P833, DOI 10.1006/jmbi.2000.3711; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; KIKUCHI Y, 1988, EMBO J, V7, P1175, DOI 10.1002/j.1460-2075.1988.tb02928.x; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; King CY, 2001, J MOL BIOL, V307, P1247, DOI 10.1006/jmbi.2001.4542; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Li LM, 2000, SCIENCE, V287, P661, DOI 10.1126/science.287.5453.661; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Scheibel T, 2001, CURR BIOL, V11, P366, DOI 10.1016/S0960-9822(01)00099-9; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; TERAVANESYAN MD, 1994, GENETICS, V137, P671; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	27	58	59	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35227	35230		10.1074/jbc.C100304200	http://dx.doi.org/10.1074/jbc.C100304200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11473105	hybrid			2022-12-25	WOS:000171109300002
J	Medh, RD; Wang, AX; Zhou, F; Thompson, EB				Medh, RD; Wang, AX; Zhou, F; Thompson, EB			Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells	ONCOGENE			English	Article						cell cycle; caspase 3; TUNEL; Max; p53; p27	MESSENGER-RNA; MEDIATED APOPTOSIS; GENE-TRANSCRIPTION; INDUCED RELEASE; BINDING DOMAIN; GROWTH ARREST; OKADAIC ACID; E-BOX; PROTEIN; CYCLE	Sensitivity to glueocorticoid (GC)-evoked apoptosis in lymphoid cell lines correlates closely with GC-mediated suppression of c-Myc expression. To establish a functional role for c-Myc in GC-mediated apoptosis, we have stably expressed MycER (TM), the human c-Myc protein fused to the modified ligand-binding domain of the murine estrogen receptor a, in GC-sensitive CEM-C7-14 cells. In CEM-C7-14 cells, MycER (TM) constitutively imparts c-Myc functions. Cells expressing MycERT (TM) (C7-MycER (TM)) exhibited a marked reduction in cell death after 72 h in 100 nm dexamethasone (Dex), with 10-20-fold more viable cells when compared to the parental CEM-C7-14 clone. General GC responsiveness was not compromised, as evidenced by Dex-mediated suppression of endogenous c-Mye and cyclin D3, and induction of c-Jun and the glucocorticoid receptor. MycER (TM) also blunted Dex-mediated upregulation of p271(kipI) and suppression of the Myc target p53. In comparison to parental CEM-C7-14 cells, Dex-evoked DNA strand breaks were negligible and caspase activation was delayed, but the extent of GI cell cycle arrest was similar in C7-MycER (TM) cells. Myc-ER (TM) did not result in permanent, complete resistance to GC however, and the GC-treated cells eventually died, indicative of redundant or interactive mechanisms in the GC-evoked lytic response of lymphoid cells. Our results emphasize the importance of c-Myc suppression in GC-evoked apoptosis of CEM-C7-14 cells.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Medh, RD (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.	rmedh@utmb.edu; bthompso@utmb.edu			NCI NIH HHS [R01 CA041407, 2RO1 CA41047, R01 CA041407-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041407, R01CA041047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afrakhte M, 1998, CELL GROWTH DIFFER, V9, P983; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; BRUNO S, 1992, CANCER RES, V52, P470; Casteels KM, 1998, DIABETES, V47, P1033, DOI 10.2337/diabetes.47.7.1033; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIARUGI V, 1994, CELL MOL BIOL RES, V40, P603; DOWD DR, 1991, J BIOL CHEM, V266, P18423; EASTMANREKS SB, 1986, CANCER RES, V46, P2457; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gaynon PS, 1999, ADV EXP MED BIOL, V457, P593; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HOMODELARCHE F, 1984, CANCER RES, V44, P431; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KIGUCHI K, 1994, CELL GROWTH DIFFER, V5, P995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG K, 1975, ENDOCRINOLOGY, V97, P744, DOI 10.1210/endo-97-3-744; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Loffler M, 1999, ONCOGENE, V18, P4626, DOI 10.1038/sj.onc.1202820; Martins TC, 1998, IMMUNOLOGY, V95, P377; Medh RD, 1998, CANCER RES, V58, P3684; Medh RD, 2000, CELL TISSUE RES, V301, P101, DOI 10.1007/s004419900159; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Montague J W, 1995, Curr Top Microbiol Immunol, V200, P51; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; REISMAN D, 1995, MOL ENDOCRINOL, V9, P1500, DOI 10.1210/me.9.11.1500; RHEE K, 1995, CANCER RES, V55, P4188; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SRINIVASAN G, 1994, MOL ENDOCRINOL, V8, P189, DOI 10.1210/me.8.2.189; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; THOMPSON EB, 1995, ANN NY ACAD SCI, V761, P261, DOI 10.1111/j.1749-6632.1995.tb31383.x; Thompson EB, 1999, TRENDS ENDOCRIN MET, V10, P353, DOI 10.1016/S1043-2760(99)00187-3; THULASI R, 1993, J BIOL CHEM, V268, P18306; TOBIAS KE, 1995, ONCOGENE, V11, P1721; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WOOD KM, 1984, MOL CELL ENDOCRINOL, V37, P169, DOI 10.1016/0303-7207(84)90049-2; Yatouji S, 2000, CELL PROLIFERAT, V33, P51, DOI 10.1046/j.1365-2184.2000.00163.x; Yerly-Motta V, 1999, BIOTECH HISTOCHEM, V74, P119, DOI 10.3109/10520299909047963; YUH YS, 1989, J BIOL CHEM, V264, P10904; Zhou F, 1996, MOL ENDOCRINOL, V10, P306, DOI 10.1210/me.10.3.306	60	35	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4629	4639		10.1038/sj.onc.1204680	http://dx.doi.org/10.1038/sj.onc.1204680			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498786	Green Accepted			2022-12-25	WOS:000170208600004
J	Lang, CH; Silvis, C; Nystrom, G; Frost, RA				Lang, CH; Silvis, C; Nystrom, G; Frost, RA			Regulation of myostatin by glucocorticoids after thermal injury	FASEB JOURNAL			English	Article						burns; dexamethasone; TNF binding protein; IGF-I; IGF-II; muscle	IGF-BINDING-PROTEINS; SKELETAL-MUSCLE; MESSENGER-RNA; BURN INJURY; EXPRESSION; CYTOKINE; SYSTEM	Myostatin is a negative regulator of muscle mass that may contribute to the muscle wasting observed in response to traumatic injury. The purpose of this study was to determine whether muscle myostatin mRNA abundance was altered by different traumatic insults and whether the change in myostatin was associated with alterations in insulin-like growth factor (IGF)-I and IGF-II mRNA in gastrocnemius, or the concentration of glucocorticoids in plasma. The abundance of myostatin mRNA was increased three- to fourfold in gastrocnemius 24 h after a 30% total body surface area burn injury. In contrast, neither the injection of endotoxin nor the induction of peritonitis significantly altered myostatin mRNA at the same time point. IGF-I mRNA in muscle was decreased (40-60%) by all insults, whereas the abundance of IGF-II mRNA was unaltered. The plasma concentration of corticosterone was increased approximately threefold after burn injury, was only transiently elevated after endotoxin, and was only mildly increased (25%) in septic rats at the time of sacrifice. Pretreatment with the type II glucocorticoid receptor antagonist RU486 prevented the increased myostatin mRNA and decreased muscle protein content after burn. A single injection of dexamethasone in naive control animals increased muscle myostatin mRNA by 60% and 2.7-fold at 4 h and 24 h, respectively. In contrast, pretreatment of burn rats with tumor necrosis factor binding protein (TNFBP), which antagonizes the actions of this cytokine, failed to prevent the burn-induced increase in myostatin mRNA or the loss of muscle protein. The results of this study indicate that thermal injury, but not endotoxin or sepsis, increases myostatin mRNA content. Moreover, the burn-induced increase in myostatin appears to be largely mediated by the enhanced endogenous secretion of glucocorticoids and independent of changes in IGF-I, IGF-II, or TNF.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol H166, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Surg, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Lang, CH (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol H166, Hershey, PA 17033 USA.	clang@psu.edu						Bark TH, 1998, AM J PHYSIOL-ENDOC M, V275, pE118, DOI 10.1152/ajpendo.1998.275.1.E118; BOSCHE WJ, 1995, J CELL PHYSIOL, V164, P324, DOI 10.1002/jcp.1041640213; CANNON JG, 1992, CRIT CARE MED, V20, P1414, DOI 10.1097/00003246-199210000-00009; Carlson CJ, 1999, AM J PHYSIOL-REG I, V277, pR601, DOI 10.1152/ajpregu.1999.277.2.R601; Cooney R, 1999, AM J PHYSIOL-ENDOC M, V276, pE611, DOI 10.1152/ajpendo.1999.276.4.E611; Cooney RN, 1997, SHOCK, V7, P1, DOI 10.1097/00024382-199701000-00001; ELAHI D, 1993, AM J PHYSIOL, V265, pE831, DOI 10.1152/ajpendo.1993.265.6.E831; ESPAT NJ, 1995, J SURG RES, V59, P153, DOI 10.1006/jsre.1995.1147; Fan J, 1996, AM J PHYSIOL-REG I, V270, pR621, DOI 10.1152/ajpregu.1996.270.3.R621; FAN J, 1995, AM J PHYSIOL-REG I, V269, pR1204, DOI 10.1152/ajpregu.1995.269.5.R1204; FANG CH, 1995, J AM COLL SURGEONS, V180, P33; Fang CH, 1998, AM J PHYSIOL-REG I, V275, pR1091, DOI 10.1152/ajpregu.1998.275.4.R1091; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FONG Y, 1989, AM J PHYSIOL, V256, pR659, DOI 10.1152/ajpregu.1989.256.3.R659; Frost R A, 1998, Curr Opin Clin Nutr Metab Care, V1, P195, DOI 10.1097/00075197-199803000-00010; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Ji SQ, 1998, AM J PHYSIOL-REG I, V275, pR1265, DOI 10.1152/ajpregu.1998.275.4.R1265; Kataranovski M, 1999, PHYSIOL RES, V48, P473; KIRK S, 1966, J ENDOCRINOL, V149, P81; Lang CH, 1996, AM J PHYSIOL-ENDOC M, V270, pE430, DOI 10.1152/ajpendo.1996.270.3.E430; Lang CH, 2000, AM J PHYSIOL-ENDOC M, V278, pE1133, DOI 10.1152/ajpendo.2000.278.6.E1133; Lang CH, 2000, AM J PHYSIOL-ENDOC M, V278, pE1087, DOI 10.1152/ajpendo.2000.278.6.E1087; LANG CH, 1984, AM J PHYSIOL, V248, pR471; Lee SJ, 1999, CURR OPIN GENET DEV, V9, P604, DOI 10.1016/S0959-437X(99)00004-0; Li YH, 1997, AM J PHYSIOL-REG I, V272, pR1990, DOI 10.1152/ajpregu.1997.272.6.R1990; MAO J, 1992, MOL CELL BIOCHEM, V109, P1; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Savary I, 1998, BRIT J NUTR, V79, P297, DOI 10.1079/BJN19980047; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V278, pE76, DOI 10.1152/ajpendo.2000.278.1.E76; Sharma M, 1999, J CELL PHYSIOL, V180, P1; SHIVJI R, 1999, 81 ANN M END SOC JUN; Taylor WE, 2001, AM J PHYSIOL-ENDOC M, V280, pE221, DOI 10.1152/ajpendo.2001.280.2.E221; Wehling M, 2000, FASEB J, V14, P103, DOI 10.1096/fasebj.14.1.103; ZAMIR O, 1991, J SURG RES, V50, P579, DOI 10.1016/0022-4804(91)90045-N	35	72	90	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1807	+		10.1096/fj.00-0849fje	http://dx.doi.org/10.1096/fj.00-0849fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481237				2022-12-25	WOS:000169261200024
J	Uz, T; Dwivedi, Y; Qeli, A; Peters-Golden, M; Pandey, G; Manev, H				Uz, T; Dwivedi, Y; Qeli, A; Peters-Golden, M; Pandey, G; Manev, H			Glucocorticoid receptors are required for up-regulation of neuronal 5-lipoxygenase (5LOX) expression by dexamethasone	FASEB JOURNAL			English	Article						cerebellar granule neurons; leukotrienes; arachidonic acid; cerebellar granule neurons	CEREBELLAR GRANULE CELLS; MESSENGER-RNA STABILITY; CENTRAL-NERVOUS-SYSTEM; LEUKOTRIENE C-4; PUTATIVE ROLE; ACTIVATING PROTEIN; PRIMARY CULTURES; GENE-EXPRESSION; BRAIN; ACID	5- lipoxygenase (5LOX) is the key enzyme in the synthesis of leukotrienes from arachidonic acid. Hyperglucocorticoidemia, dexamethasone, and aging up-regulate 5LOX in the brain, including the cerebellum in vivo. We studied the mechanisms of dexamethasone-triggered 5LOX upregulation in primary cultures of rat cerebellar granule neurons (CGN). We measured 5LOX mRNA and protein contents, and the formation of cysteinyl leukotrienes (LTC4, LTD4, and LTE4). The dexamethasone (0.1 muM or 1 muM)-increased 5LOX mRNA and protein contents were already observed at 3 h of treatment, and they persisted for at least 24 h. Dexamethasone also increased the content of cysteinyl leukotrienes, assayed in the presence of 2 muM calcium ionophore A23187 and 10 muM arachidonic acid. The stimulatory effect of dexamethasone on 5LOX expression was inhibited by the glucocorticoid receptor (GR) antagonist RU486 and by reducing the CGN content of GR receptor protein with a GR-specific antisense oligonucleotide. The 5LOX mRNA half-life was longer in dexamethasone than in vehicle-treated CGNs. Our results indicate that dexamethasone increases 5LOX expression in CGNs in a GR-dependent manner and that it also increases the stability of 5LOX mRNA. Further studies are warranted to elucidate the physiologic/pathologic significance of glucocorticoid-regulated expression of 5LOX in the central nervous system.	Univ Illinois, Coll Med, Dept Psychiat, Inst Psychiat, Chicago, IL 60612 USA; Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Michigan System; University of Michigan	Manev, H (corresponding author), Univ Illinois, Coll Med, Dept Psychiat, Inst Psychiat, 1601 W Taylor St,MC 912, Chicago, IL 60612 USA.	HManev@psych.uic.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015347] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG15347] Funding Source: Medline; NIMH NIH HHS [R01-MH56528] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHIMA RS, 1991, ENDOCRINOLOGY, V129, P226, DOI 10.1210/endo-129-1-226; Ahlbom E, 2000, P NATL ACAD SCI USA, V97, P14726, DOI 10.1073/pnas.260501697; BIRMINGHAM MK, 1993, CELL MOL NEUROBIOL, V13, P373, DOI 10.1007/BF00711578; Cadepond F, 1997, ANNU REV MED, V48, P129; Chabot C, 1998, HIPPOCAMPUS, V8, P299, DOI 10.1002/(SICI)1098-1063(1998)8:3<299::AID-HIPO11>3.0.CO;2-W; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Colamorea T, 1999, BIOCHEM BIOPH RES CO, V265, P617, DOI 10.1006/bbrc.1999.1732; de Kloet ER, 1999, TRENDS NEUROSCI, V22, P422, DOI 10.1016/S0166-2236(99)01438-1; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; HINES D, 1994, J RECEPTOR RES, V14, P297, DOI 10.3109/10799899409066038; Korte SM, 1996, EUR J PHARMACOL, V301, P19, DOI 10.1016/0014-2999(96)00064-7; Lammers CH, 1996, J NEUROCHEM, V66, P147; Magri F, 2000, DEMENT GERIATR COGN, V11, P90, DOI 10.1159/000017220; Manev H, 1999, ANN NY ACAD SCI, V890, P183, DOI 10.1111/j.1749-6632.1999.tb07994.x; Manev H, 2000, MED HYPOTHESES, V54, P75, DOI 10.1054/mehy.1998.0824; Manev H, 2000, J NEUROCHEM, V74, pS64; Manev H, 2000, FASEB J, V14, P1464, DOI 10.1096/fj.14.10.1464; Marlier LNJL, 1997, J MOL NEUROSCI, V9, P1, DOI 10.1007/BF02789390; Mayatepek E, 2000, EUR J PEDIATR, V159, P811, DOI 10.1007/s004310000601; Moore FL, 1999, BRAIN BEHAV EVOLUT, V54, P41, DOI 10.1159/000006610; Morimoto M, 1996, NEUROSCI RES, V26, P235, DOI 10.1016/S0168-0102(96)01105-4; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249, DOI 10.1152/ajpheart.1995.268.3.H1249; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; Paris D, 2000, ANN NY ACAD SCI, V903, P97, DOI 10.1111/j.1749-6632.2000.tb06355.x; Peters-Golden M, 1998, CLIN EXP ALLERGY, V28, P1059; PETERSGOLDEN M, 1989, AM REV RESPIR DIS, V140, P1210, DOI 10.1164/ajrccm/140.5.1210; Poon M, 1999, MOL CELL BIOL, V19, P6471; PSHENICHKIN SP, 1995, J BIOL CHEM, V270, P5994, DOI 10.1074/jbc.270.11.5994; QU T, 2001, J NEUROPSYCH CLIN NE; Qu TY, 2000, NEUROBIOL AGING, V21, P647, DOI 10.1016/S0197-4580(00)00167-6; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Riddick CA, 1997, EUR J BIOCHEM, V246, P112, DOI 10.1111/j.1432-1033.1997.00112.x; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; Sanchez MM, 2000, J NEUROSCI, V20, P4657, DOI 10.1523/JNEUROSCI.20-12-04657.2000; SANTI MR, 1994, J NEUROCHEM, V63, P1207; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; SIMMET T, 1991, BRAIN RES, V540, P283, DOI 10.1016/0006-8993(91)90519-2; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Uz T, 1999, J NEUROCHEM, V73, P693, DOI 10.1046/j.1471-4159.1999.0730693.x; Uz T, 1998, FASEB J, V12, P439, DOI 10.1096/fasebj.12.6.439; Uz T, 1997, J NEUROCHEM, V69, P2220; Vaughan CW, 1997, NATURE, V390, P611, DOI 10.1038/37610; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Xu ZX, 1997, AM J PHYSIOL-LUNG C, V272, pL860, DOI 10.1152/ajplung.1997.272.5.L860	44	28	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1792	+		10.1096/fj.00-0836fje	http://dx.doi.org/10.1096/fj.00-0836fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481232	Green Submitted			2022-12-25	WOS:000169261200034
J	Duk, M; Reinhold, BB; Reinhold, VN; Kusnierz-Alejska, G; Lisowska, E				Duk, M; Reinhold, BB; Reinhold, VN; Kusnierz-Alejska, G; Lisowska, E			Structure of a neutral glycosphingolipid recognized by human antibodies in polyagglutinable erythrocytes from the rare NOR phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; EPITOPE; XENOTRANSPLANTATION; GLYCOPHORIN; ANTIGEN; GAL	NOR is a rare inheritable polyagglutination phenomenon that has been described in two families. Our recent studies on these erythrocytes showed they contained at least two unique neutral glycosphingolipids, and based on their reactivity with Griffonia simplicifolia IB4 (GSL-IB4) isolectin (Kusnierz-Alejska, G., Duk, M., Storry, J. R., Reid, M. E., Wiecek, B., Seyfried, H., and Lisowska, E. (1999) Transfusion 39,32-38), both oligosaccharide chains terminated with an a-galactose residue. The reactivity with GSL-IB4 suggested that these oligosaccharide chains terminated with a Gal alpha1 --> 3Gal- sequence and that anti-NOR agglutinins were common human anti-Gal alpha1 --> 3Gal xenoantibodies. In this report we describe the structure of one NOR component (NOR1) that migrated on thin-layer chromatographic plates in the region of pentaglycosylceramides. Treatment of this sample with a-galactosidase and beta -N-acetylhexosaminidase was followed by highperformance thin-layer chromatography with product detection by lectins and the anti-Gb(4) monoclonal antibody. The results suggested that NOR1 was an a-galactosylated Gb(4)Cer with a beta -N-acetylhexosaminidase-resistant GalNAC residue. Gas phase disassembly by ion trap mass spectrometry analysis showed the sequence to be Hex1 --> 4HexN1 --> 3Hex1 --> 4Hex1 --> 4Hex linked to a ceramide composed of C-18 sphingosine and a C-24 monounsaturated fatty acid. Together these data indicate NOR1 to be a novel Gal alpha1 --> 4GalNAc beta1 --> 3Gal alpha1 --> 4Gal beta1 -->4 Glc-Cer structure. Additionally it has been shown that NOR glycolipids are recognized by human antibodies that were distinct from the known anti-Gal alpha1 --> 3Gal xenoantibodies.	Univ New Hampshire, Dept Chem, Durham, NH 03824 USA; Polish Acad Sci, Ludwik Hirszfeld Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA; Natl Ctr Blood Transfus Transfus Med, PL-00957 Warsaw, Poland	University System Of New Hampshire; University of New Hampshire; Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences; University System Of New Hampshire; University of New Hampshire	Reinhold, VN (corresponding author), Univ New Hampshire, Dept Chem, Durham, NH 03824 USA.				NIGMS NIH HHS [GM54045] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck ML, 2000, SEMIN HEMATOL, V37, P186, DOI 10.1016/S0037-1963(00)90043-X; CARCHON H, 1975, CARBOHYD RES, V41, P175, DOI 10.1016/S0008-6215(00)87017-2; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DUK M, 1994, ANAL BIOCHEM, V221, P266, DOI 10.1006/abio.1994.1410; Galili U, 1999, TRENDS GLYCOSCI GLYC, V11, P317, DOI 10.4052/tigg.11.317; GALILI U, 1987, J BIOL CHEM, V262, P4683; HARRIS PA, 1982, VOX SANG, V42, P134, DOI 10.1111/j.1423-0410.1982.tb01083.x; IUPAC-IUB Commission on Biochemical Nomenclature, 1977, LIPIDS, V12, P455; Joziasse DH, 1999, BBA-MOL BASIS DIS, V1455, P403, DOI 10.1016/S0925-4439(99)00056-3; KANNAGI R, 1983, J BIOL CHEM, V258, P8934; KROTKIEWSKI H, 1988, GLYCOCONJUGATE J, V5, P35, DOI 10.1007/BF01048330; Kusnierz-Alejska G, 1999, TRANSFUSION, V39, P32, DOI 10.1046/j.1537-2995.1999.39199116892.x; LISOWSKA E, 1987, MOL IMMUNOL, V24, P605, DOI 10.1016/0161-5890(87)90041-1; MADASSERY J V, 1991, Journal of Immunology, V147, P823; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4831, DOI 10.1021/bi00693a009; OSTRANDER GK, 1988, J BIOL CHEM, V263, P18716; REINHOLD BB, 1994, ORG MASS SPECTROM, V29, P736, DOI 10.1002/oms.1210291206; Reinhold VN, 1996, METHOD ENZYMOL, V271, P377; REINHOLD VN, 1998, ANAL BIOCHEM, V259, P3053; SAITO S, 1994, J BIOL CHEM, V269, P5644; SAITO T, 1971, J LIPID RES, V12, P257; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; WIESLANDER J, 1990, GLYCOCONJUGATE J, V7, P85, DOI 10.1007/BF01050405; WOOD C, 1979, ARCH BIOCHEM BIOPHYS, V198, P1, DOI 10.1016/0003-9861(79)90389-8	26	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40574	40582		10.1074/jbc.M102711200	http://dx.doi.org/10.1074/jbc.M102711200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11504714	hybrid			2022-12-25	WOS:000171925600028
J	Levy, E; Menard, D; Delvin, E; Stan, S; Mitchell, G; Lambert, M; Ziv, E; Feoli-Fonseca, JC; Seidman, E				Levy, E; Menard, D; Delvin, E; Stan, S; Mitchell, G; Lambert, M; Ziv, E; Feoli-Fonseca, JC; Seidman, E			The polymorphism at codon 54 of the FABP2 gene increases fat absorption in human intestinal explants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-PROTEIN; TRIGLYCERIDE TRANSFER PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; HUMAN FETAL INTESTINE; HEP G2 CELLS; LIPOPROTEIN SYNTHESIS; APO-B; INTRACELLULAR DEGRADATION; APOLIPOPROTEIN SYNTHESIS; INSULIN-RESISTANCE	Based on titration microcalorimetry and Caco-2 cell line transfection studies, it has been suggested that the A54T of the FABP2 gene plays a significant role in the assimilation of dietary fatty acids. However, reports were divergent with regard to the in vivo interaction between this polymorphism and postprandial lipemia. We therefore determined the influence of this intestinal fatty acid-binding protein polymorphism on intestinal fat transport using the human jejunal organ culture model, thus avoiding the interference of various circulating factors capable of metabolizing in vivo postprandial lipids. Analysis of DNA samples from 32 fetal intestines revealed 22 homozygotes for the wild-type Ala-54/Ala-54 genotype (0.83) and 10 heterozygotes for the polymorphic Thr-54/Ala-54 genotype (0.17). The Thr-encoding allele was associated with increased secretion of newly esterified triglycerides, augmented de novo apolipoprotein B synthesis, and elevated chylomicron output. On the other hand, no alterations were found in very low density lipoprotein and high density lipoprotein production, apolipoprotein A-I biogenesis, or microsomal triglyceride transfer protein mass and activity. Similarly, the alanine to threonine substitution at residue 54 did not result in changes in brush border hydrolytic activities (sucrase, glucoamylase, lactase, and alkaline phosphatase) or in glucose uptake or oxidation. Our data clearly document that the A54T polymorphism of FABP2 specifically influences small intestinal lipid absorption without modifying glucose uptake or metabolism. It is proposed that, in the absence of confounding factors such as environmental and genetic variables, the FABP2 polymorphism has an important effect on postprandial lipids in vivo, potentially influencing plasma levels of lipids and atherogenesis.	Univ Montreal, Dept Nutr, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Pediat, Montreal, PQ H3T 1C5, Canada; Univ Sherbrooke, Dept Anat & Cellular Biol, Sherbrooke, PQ J1H 5N4, Canada; Hadassah Med Sch, Diabet Unit, IL-91120 Jerusalem, Israel	Universite de Montreal; Universite de Montreal; Universite de Montreal; University of Sherbrooke; Hebrew University of Jerusalem	Levy, E (corresponding author), Hop St Justine, 3175 Cote Ste Catherines Rd, Montreal, PQ H3T 1C5, Canada.	levye@justine.umontreal.ca						Agren JJ, 1998, ARTERIOSCL THROM VAS, V18, P1606, DOI 10.1161/01.ATV.18.10.1606; BAIER LJ, 1995, J CLIN INVEST, V95, P1281, DOI 10.1172/JCI117778; Baier LJ, 1996, J BIOL CHEM, V271, P10892, DOI 10.1074/jbc.271.18.10892; BERG K, 1990, ACTA GENET MED GEMEL, V39, P15, DOI 10.1017/S0001566000005559; BLACK DD, 1995, J PEDIATR GASTR NUTR, V20, P125, DOI 10.1097/00005176-199502000-00002; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; BOREN J, 1992, J BIOL CHEM, V267, P9858; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; DALLONGEVILLE J, 1991, ARTERIOSCLER THROMB, V11, P272, DOI 10.1161/01.ATV.11.2.272; Darimont C, 2000, J LIPID RES, V41, P84; DASHTI N, 1989, J LIPID RES, V30, P1365; Davidson N. O., 1993, TXB GASTROENTEROLOGY, P428; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Dutta-Roy AK, 2000, CELL MOL LIFE SCI, V57, P1360, DOI 10.1007/PL00000621; FIELD FJ, 1995, PROG LIPID RES, V34, P185, DOI 10.1016/0163-7827(95)00005-K; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hegele RA, 1997, ARTERIOSCL THROM VAS, V17, P1060, DOI 10.1161/01.ATV.17.6.1060; JEPPESEN J, 1995, ARTERIOSCL THROM VAS, V15, P320, DOI 10.1161/01.ATV.15.3.320; KALDERON B, 1986, DIABETES, V35, P717, DOI 10.2337/diabetes.35.6.717; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; LEVY E, 1992, J LIPID RES, V33, P1607; Levy E, 1996, AM J PHYSIOL-GASTR L, V270, pG813, DOI 10.1152/ajpgi.1996.270.5.G813; Levy E, 1996, FEBS LETT, V393, P253, DOI 10.1016/0014-5793(96)00896-4; LEVY E, 1994, BIOCHEM BIOPH RES CO, V204, P1340, DOI 10.1006/bbrc.1994.2610; LEVY E, 1987, J LIPID RES, V28, P1263; Levy E, 2000, J LIPID RES, V41, P12; LEVY E, 1995, FASEB J, V9, P626, DOI 10.1096/fasebj.9.8.7768354; Levy E, 1996, CLIN INVEST MED, V19, P317; Levy E, 2001, AM J PHYSIOL-GASTR L, V280, pG563, DOI 10.1152/ajpgi.2001.280.4.G563; Levy E, 2000, MICROSC RES TECHNIQ, V49, P363, DOI 10.1002/(SICI)1097-0029(20000515)49:4<363::AID-JEMT5>3.3.CO;2-U; LOIRDIGHI N, 1992, BIOCHIM BIOPHYS ACTA, V1175, P100, DOI 10.1016/0167-4889(92)90015-4; Loirdighi N, 1997, J CELL BIOCHEM, V66, P65, DOI 10.1002/(SICI)1097-4644(19970701)66:1<65::AID-JCB8>3.0.CO;2-W; LOWE JB, 1987, J BIOL CHEM, V262, P5931; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANSBACH CM, 1993, AM J PHYSIOL, V264, pG1082, DOI 10.1152/ajpgi.1993.264.6.G1082; MENARD D, 1985, GASTROENTEROLOGY, V88, P691, DOI 10.1016/0016-5085(85)90139-8; MENARD D, 1988, GASTROENTEROLOGY, V53, P319; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Ordovas JM, 2000, BRIT J NUTR, V83, pS127; Pihlajamaki J, 1997, ARTERIOSCL THROM VAS, V17, P1039, DOI 10.1161/01.ATV.17.6.1039; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SCHREZENMEIR J, 1993, ANN NY ACAD SCI, V683, P302; Sipilainen R, 1997, J CLIN ENDOCR METAB, V82, P2629, DOI 10.1210/jc.82.8.2629; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; SYVANEN AC, 1993, AM J HUM GENET, V52, P46; Taghibiglou C, 2000, J LIPID RES, V41, P499; TSO P, 1986, AM J PHYSIOL, V250, pG715, DOI 10.1152/ajpgi.1986.250.6.G715; Vassileva G, 2000, FASEB J, V14, P2040, DOI 10.1096/fj.99-0959com; Vidgren HM, 1997, EUR J CLIN INVEST, V27, P405, DOI 10.1046/j.1365-2362.1997.1320679.x; WETTERAU JR, 1992, SCIENCE, V258, P999; Wittekoek ME, 1998, CIRCULATION, V97, P729, DOI 10.1161/01.CIR.97.8.729; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	55	92	101	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39679	39684		10.1074/jbc.M105713200	http://dx.doi.org/10.1074/jbc.M105713200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11487582	hybrid			2022-12-25	WOS:000171789200024
J	Machner, MP; Urbanke, C; Barzik, M; Otten, S; Sechi, AS; Wehland, J; Heinz, DW				Machner, MP; Urbanke, C; Barzik, M; Otten, S; Sechi, AS; Wehland, J; Heinz, DW			ActA from Listeria monocytogenes can interact with up to four Ena/VASP homology 1 domains simultaneously	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH REGION; STIMULATED PHOSPHOPROTEIN; ARP2/3 COMPLEX; EVH1 DOMAIN; BACTERIAL PATHOGEN; FOCAL ADHESION; VIRULENCE GENE; PROTEIN; MOTILITY; BINDING	The facultative intracellular human pathogenic bacterium Listeria monocytogenes actively recruits host actin to its surface to achieve motility within infected cells. The bacterial surface protein ActA is solely responsible for this process by mimicking fundamental steps of host cell actin dynamics. ActA., a modular protein, contains an N-terminal actin nucleation site and a central proline-rich motif of the 4-fold repeated consensus sequence FPPPP (FP4). This motif is specifically recognized by members of the EnaNASP protein family. These proteins additionally recruit the profilin-G-actin complex increasing the local concentration of G-actin close to the bacterial surface. By using analytical ultracentrifugation, we show that a single ActA molecule can simultaneously interact with four Ena/VASP homology 1 (EVH1) domains. The four FP4 sites have roughly equivalent affinities with dissociation constants of about 4 muM. Mutational analysis of the FP4 Motifs indicate that the phenylalanine is mandatory for ActA-EVH1 interaction, whereas in each case exchange of the third proline was tolerated. Finally, by using sedimentation equilibrium centrifugation techniques, we demonstrate that ActA is a monomeric protein. By combining these results, we formulate a stoichiometric model to describe how ActA enables Listeria to utilize efficiently resources of the host cell microfilament for its own intracellular motility.	CBF, German Res Ctr Biotechnol, Dept Biol Struct, D-38124 Braunschweig, Germany; CBF, German Res Ctr Biotechnol, Dept Cell Biol, D-38124 Braunschweig, Germany; Hannover Med Sch, Inst Biophys Chem, D-3000 Hannover, Germany; Univ Giessen, Inst Med Microbiol, D-35385 Giessen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Helmholtz-Center for Infection Research; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Helmholtz-Center for Infection Research; Hannover Medical School; Justus Liebig University Giessen	Heinz, DW (corresponding author), CBF, German Res Ctr Biotechnol, Dept Biol Struct, Mascheroder Weg 1, D-38124 Braunschweig, Germany.	dih@gbf.de	Machner, Matthias/G-2758-2015; Sechi, Antonio S/A-5595-2009; Barzik, Melanie/AAJ-9269-2021	Sechi, Antonio S/0000-0002-1374-1794; Barzik, Melanie/0000-0003-3003-1281; Machner, Matthias/0000-0002-6971-7451				Ball LJ, 2000, EMBO J, V19, P4903, DOI 10.1093/emboj/19.18.4903; Cameron LA, 1999, P NATL ACAD SCI USA, V96, P4908, DOI 10.1073/pnas.96.9.4908; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Cicchetti G, 1999, J BIOL CHEM, V274, P33616, DOI 10.1074/jbc.274.47.33616; CLAVERIE JM, 1975, BIOPOLYMERS, V14, P1685, DOI 10.1002/bip.1975.360140811; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Geese M, 2000, J CELL SCI, V113, P1415; GELLIN BG, 1989, JAMA-J AM MED ASSOC, V261, P1313, DOI 10.1001/jama.261.9.1313; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAY ML, 1966, BACTERIOL REV, V30, P309, DOI 10.1128/MMBR.30.2.309-382.1966; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KOCKS C, 1995, MOL MICROBIOL, V18, P413, DOI 10.1111/j.1365-2958.1995.mmi_18030413.x; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; May RC, 1999, CURR BIOL, V9, P759, DOI 10.1016/S0960-9822(99)80337-6; MOUNIER J, 1990, INFECT IMMUN, V58, P1048, DOI 10.1128/IAI.58.4.1048-1058.1990; Mourrain P, 1997, P NATL ACAD SCI USA, V94, P10034, DOI 10.1073/pnas.94.19.10034; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PARK SF, 1990, GENE, V94, P129, DOI 10.1016/0378-1119(90)90479-B; PISTOR S, 1994, EMBO J, V13, P758, DOI 10.1002/j.1460-2075.1994.tb06318.x; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; Pistor S, 2000, J CELL SCI, V113, P3277; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Purich DL, 1997, BIOCHEM BIOPH RES CO, V231, P686, DOI 10.1006/bbrc.1997.6158; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; Schlech WF, 2000, CLIN INFECT DIS, V31, P770, DOI 10.1086/314008; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SMITH GA, 1995, MOL MICROBIOL, V17, P945, DOI 10.1111/j.1365-2958.1995.mmi_17050945.x; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; URBANKE C, 1980, FRESEN Z ANAL CHEM, V301, P139, DOI 10.1007/BF00467783; Welch MD, 1998, METHOD ENZYMOL, V298, P52, DOI 10.1016/S0076-6879(98)98008-9; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Wiedmann M, 1997, INFECT IMMUN, V65, P2707, DOI 10.1128/IAI.65.7.2707-2716.1997; [No title captured]	48	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40096	40103		10.1074/jbc.M104279200	http://dx.doi.org/10.1074/jbc.M104279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11489888	hybrid			2022-12-25	WOS:000171789200080
J	Tylzanowski, P; Verschueren, K; Huylebroeck, D; Luyten, FP				Tylzanowski, P; Verschueren, K; Huylebroeck, D; Luyten, FP			Smad-interacting protein 1 is a repressor of liver/bone/kidney alkaline phosphatase transcription in bone morphogenetic protein-induced osteogenic differentiation of C2C12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; 5'-FLANKING REGION; MESSENGER-RNA; GENE; DELTA-EF1; PROMOTER; FAMILY; CBFA1	Up-regulation of liver/bone/kidney alkaline phosphatase (LBK-ALP) has been associated with the onset of osteogenesis in vitro. Its transcription can be up-regulated by bone morphogenetic proteins (BMPs), constitutively active forms of their cognate receptors, or appropriate Smads. The promoter of LBK-ALP has been characterized partially, but not much is known about its transcriptional modulation by BMPs. A few Smad-interacting transcriptional factors have been isolated to date. One of them, Smad-interacting protein 1 (SIP1), belongs to the family of two-handed zinc finger proteins binding to E2-box sequences present, among others, in the promoter of mouse LBK-ALP. In the present study we investigated whether SIP1 could be a candidate regulator of LBK-ALP transcription in C2C12 cells. We demonstrate that SIP1 can repress LBK-ALP promoter activity induced by constitutively active Alk2-Smad1/Smad5 and that this repression depends on the binding of SIP1 to the CACCT/CACCTG cluster present in this promoter. Interestingly, SIP1 and alkaline phosphatase expression domains in developing mouse limb are mutually exclusive, suggesting the possibility that SIP1 could also be involved in the transcriptional regulation of LBK-ALP in vivo. Taken together, these results offer an intriguing possibility that ALP up-regulation at the onset of BMP-induced osteogenesis could involve Smad/SIP1 interactions, resulting in the derepression of that gene.	Univ Leuven, Lab Skeletal Dev & Joint Disorders, B-3000 Louvain, Belgium; Univ Leuven VIB, Dept Cell Growth Differentiat & Dev, B-3000 Louvain, Belgium; Univ Leuven, Mol Biol Lab, B-3000 Louvain, Belgium	KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven	Tylzanowski, P (corresponding author), Univ Leuven, Lab Skeletal Dev & Joint Disorders, Herestraat 49, B-3000 Louvain, Belgium.	przemko@med.kuleuven.ac.be	Tylzanowski, Przemko/G-8881-2013; Luyten, Frank/GPS-7793-2022	Huylebroeck, Danny/0000-0003-4862-1079; Tylzanowski, Przemko/0000-0003-0769-559X				Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FILVAROFF EH, 1994, DEVELOPMENT, V120, P1085; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; HAHNEL AC, 1990, DEVELOPMENT, V110, P555; HEATH JK, 1992, MOL ENDOCRINOL, V6, P636, DOI 10.1210/me.6.4.636; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; JohnsonPais TL, 1996, EXP CELL RES, V226, P67, DOI 10.1006/excr.1996.0203; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kobayashi T, 1998, BIOCHEM MOL BIOL INT, V44, P683; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lerchner W, 2000, DEVELOPMENT, V127, P2729; MACGREGOR GR, 1995, DEVELOPMENT, V121, P1487; MANES T, 1990, GENOMICS, V8, P541, DOI 10.1016/0888-7543(90)90042-S; Marty T, 2000, NAT CELL BIOL, V2, P745, DOI 10.1038/35036383; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; MATSUURA S, 1990, BIOCHEM BIOPH RES CO, V168, P993, DOI 10.1016/0006-291X(90)91127-E; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Muraoka O, 2000, DEV BIOL, V228, P29, DOI 10.1006/dbio.2000.9909; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; OLIVER G, 1995, DEVELOPMENT, V121, P693; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Patel K, 1996, DEVELOPMENT, V122, P1147; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Sekido R, 1996, GENE, V173, P227, DOI 10.1016/0378-1119(96)00185-0; Takagi T, 1998, DEVELOPMENT, V125, P21; TERAO M, 1990, BIOCHEM J, V268, P641, DOI 10.1042/bj2680641; Tsumaki N, 1999, J CELL BIOL, V144, P161, DOI 10.1083/jcb.144.1.161; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; WEISS MJ, 1988, J BIOL CHEM, V263, P12002; WILKINSON DG, 1999, IN SITU HYBRIDIZATIO; Wolfman NM, 1997, J CLIN INVEST, V100, P321, DOI 10.1172/JCI119537; Xu PX, 1997, P NATL ACAD SCI USA, V94, P11974, DOI 10.1073/pnas.94.22.11974	36	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40001	40007		10.1074/jbc.M104112200	http://dx.doi.org/10.1074/jbc.M104112200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11477103	hybrid			2022-12-25	WOS:000171789200068
J	Della-Bianca, V; Rossi, F; Armato, U; Dal-Pra, I; Costantini, C; Perini, G; Politi, V; Della Valle, G				Della-Bianca, V; Rossi, F; Armato, U; Dal-Pra, I; Costantini, C; Perini, G; Politi, V; Della Valle, G			Neurotrophin p75 receptor is involved in neuronal damage by prion peptide-(106-126)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CELL-DEATH; PROTEIN; APOPTOSIS; NEUROTOXICITY; TRANSDUCTION; INDUCTION; MECHANISM; P75(NTR); INSIGHTS	In this work we have investigated the molecular basis of the neuronal damage induced by the prion peptide by searching for a surface receptor whose activation could be the first step of a cascade of events responsible for cell death. By using a human neuroblastoma cell line lacking all the neurotrophin receptors and derived clones expressing the full-length or truncated forms of the low affinity neurotrophin receptor (p75(NTR)), we have been able to demonstrate that the neuronal death induced by the prion protein fragment PrP-(106-126) is an active process mediated by a) the binding of the peptide to the extracellular region of p75(NTR), b) the signaling function of the intracytoplasmic region of the receptor, and c) the activation of caspase-8 and the production of oxidant species.	Univ Verona, Dept Pathol, Sect Gen Pathol, I-37134 Verona, Italy; Univ Verona, Dept Biomed & Surg Sci, Sect Histol & Embryol, I-37134 Verona, Italy; Univ Bologna, Dept Biol, I-40126 Bologna, Italy	University of Verona; University of Verona; University of Bologna	Rossi, F (corresponding author), Univ Verona, Dept Pathol, Sect Gen Pathol, Strada Grazie 8, I-37134 Verona, Italy.	Filippo.Rossi@univr.it	Dal Prà, Ilaria Pierpaola/R-3534-2017; Armato, Ubaldo/N-2255-2019; DAL PRÀ, Ilaria Pierpaola/AAR-4216-2021	Dal Prà, Ilaria Pierpaola/0000-0001-5523-4910; Armato, Ubaldo/0000-0002-7804-6143; DAL PRÀ, Ilaria Pierpaola/0000-0001-5523-4910; Costantini, Claudio/0000-0002-1433-7830				Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown DR, 2000, BIOCHEM J, V352, P511, DOI 10.1042/0264-6021:3520511; Bunone G, 1997, ONCOGENE, V14, P1463, DOI 10.1038/sj.onc.1200972; Coulson EJ, 1999, MOL NEUROBIOL, V20, P29, DOI 10.1007/BF02741363; Ettaiche M, 2000, J BIOL CHEM, V275, P36487, DOI 10.1074/jbc.C000579200; Florio T, 1998, J NEUROSCI RES, V54, P341, DOI 10.1002/(SICI)1097-4547(19981101)54:3<341::AID-JNR5>3.0.CO;2-G; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Frade JM, 1996, NATURE, V383, P166; Guentchev M, 2000, NEUROBIOL DIS, V7, P270, DOI 10.1006/nbdi.2000.0290; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KRISTENSSON K, 1993, NEUROLOGY, V43, P2335, DOI 10.1212/WNL.43.11.2335; Kuner P, 1998, J NEUROSCI RES, V54, P798, DOI 10.1002/(SICI)1097-4547(19981215)54:6<798::AID-JNR7>3.3.CO;2-K; Le YY, 2001, J IMMUNOL, V166, P1448, DOI 10.4049/jimmunol.166.3.1448; Lin MX, 1997, J BIOL CHEM, V272, P44; Martins VR, 2001, BRAZ J MED BIOL RES, V34, P585, DOI 10.1590/S0100-879X2001000500005; Martins VR, 1997, NAT MED, V3, P1376, DOI 10.1038/nm1297-1376; Meldolesi J, 2000, TRENDS PHARMACOL SCI, V21, P242, DOI 10.1016/S0165-6147(00)01497-8; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Oh JD, 2000, BRAIN RES, V853, P174, DOI 10.1016/S0006-8993(99)02054-5; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RABIZADEH S, 1994, P NATL ACAD SCI USA, V91, P10703, DOI 10.1073/pnas.91.22.10703; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Rymer DL, 2000, J NEUROCHEM, V75, P2536, DOI 10.1046/j.1471-4159.2000.0752536.x; SELVAGGINI C, 1993, BIOCHEM BIOPH RES CO, V194, P1380, DOI 10.1006/bbrc.1993.1977; SPECTOR DL, 1998, CELLS LAB MANUAL, V1; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yan SD, 2000, NAT MED, V6, P643, DOI 10.1038/76216	30	65	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38929	38933		10.1074/jbc.M107454200	http://dx.doi.org/10.1074/jbc.M107454200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489911	hybrid			2022-12-25	WOS:000171673200079
J	Sturtz, LA; Diekert, K; Jensen, LT; Lill, R; Culotta, VC				Sturtz, LA; Diekert, K; Jensen, LT; Lill, R; Culotta, VC			A fraction of yeast Cu,Zn-superoxide dismutase and its metallochaperone, CCS, localize to the intermembrane space of mitochondria - A physiological role for SOD1 in guarding against mitochondrial oxidative damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; AMYOTROPHIC-LATERAL-SCLEROSIS; COPPER CHAPERONE CCS; C HEME LYASE; SACCHAROMYCES-CEREVISIAE; CYTOCHROME-C; STATIONARY-PHASE; HEART-MITOCHONDRIA; PROTEIN OXIDATION; HYDROGEN-PEROXIDE	Cu,Zn-superoxide dismutase (SOD1) is an abundant, largely cytosolic enzyme that scavenges superoxide anions. The biological role of SOD1 is somewhat controversial because superoxide is thought to arise largely from the mitochondria where a second SOD (manganese SOD) already resides. Using bakers'yeast as a model, we demonstrate that Cu,Zn-SOD1 helps protect mitochondria from oxidative damage, as sod1 Delta mutants show elevated protein carbonyls in this organelle. In accordance with this connection to mitochondria, a fraction of active SOD1 localizes within the intermembrane space (IMS) of mitochondria together with its copper chaperone, CCS. Neither CCS nor SOD1 contains typical Nterminal presequences for mitochondrial uptake; however, the mitochondrial accumulation of SOD1 is strongly influenced by CCS. When CCS synthesis is repressed, mitochondrial SOD1 is of low abundance, and conversely IMS SOD1 is very high when CCS is largely mitochondrial. The mitochondrial form of SOD1 is indeed protective against oxidative damage because yeast cells enriched for IMS SOD1 exhibit prolonged survival in the stationary phase, an established marker of mitochondrial oxidative stress. Cu,Zn-SOD1 in the mitochondria appears important for reactive oxygen physiology and may have critical implications for SOD1 mutations linked to the fatal neurodegenerative disorder, amyotrophic lateral sclerosis.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Univ Marburg, Inst Zytobiol, D-35033 Marburg, Germany	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Philipps University Marburg	Culotta, VC (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Room 7032, Baltimore, MD 21205 USA.			Jensen, Laran/0000-0003-3199-1743; Lill, Roland/0000-0002-8345-6518	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM050016, R01GM050016] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 07141] Funding Source: Medline; NIGMS NIH HHS [GM50016] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashrafi K, 1999, P NATL ACAD SCI USA, V96, P9100, DOI 10.1073/pnas.96.16.9100; Beal MF, 2000, BRAIN, V123, P1291, DOI 10.1093/brain/123.7.1291; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; Borthwick GM, 1999, ANN NEUROL, V46, P787, DOI 10.1002/1531-8249(199911)46:5<787::AID-ANA17>3.0.CO;2-8; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; CANTO MCD, 1994, AM J PATHOL, V145, P1271; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; Cleveland DW, 2000, NAT MED, V6, P1320, DOI 10.1038/82122; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DAUM G, 1982, J BIOL CHEM, V257, P3028; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Dhaliwal GK, 2000, NEUROREPORT, V11, P2507, DOI 10.1097/00001756-200008030-00032; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; GELLER BL, 1982, J BIOL CHEM, V257, P8945; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; HORECKA J, 1995, GENE, V162, P87, DOI 10.1016/0378-1119(95)00325-Z; Jakubowski W, 2000, FREE RADICAL BIO MED, V28, P659, DOI 10.1016/S0891-5849(99)00266-X; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LIU XF, 1992, J BIOL CHEM, V267, P18298; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; Lyons TJ, 1998, J BIOL INORG CHEM, V3, P650, DOI 10.1007/s007750050279; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NYE SH, 1990, MOL CELL BIOL, V10, P5763, DOI 10.1128/MCB.10.11.5763; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rae TD, 2001, J BIOL CHEM, V276, P5166, DOI 10.1074/jbc.M008005200; Rothstein JD, 1999, J NEUROCHEM, V72, P422, DOI 10.1046/j.1471-4159.1999.0720422.x; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Sherman F., 1978, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Wang XY, 1996, J BIOL CHEM, V271, P6594, DOI 10.1074/jbc.271.12.6594; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972	70	508	527	5	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38084	38089						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11500508				2022-12-25	WOS:000171526500050
J	Buhler, C; Lebbink, JHG; Bocs, C; Ladenstein, R; Forterre, P				Buhler, C; Lebbink, JHG; Bocs, C; Ladenstein, R; Forterre, P			DNA topoisomerase VI generates ATP-dependent double-strand breaks with two-nucleotide overhangs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEON SULFOLOBUS-SHIBATAE; GYRASE-B-PROTEIN; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; MEIOSIS; PURIFICATION; YEAST; CLEAVAGE; SPO11	A key step in the DNA transport by type II DNA topoisomerase is the formation of a double-strand break with the enzyme being covalently linked to the broken DNA ends (referred to as the cleavage complex). In the present study, we have analyzed the formation and structure of the cleavage complex catalyzed by Sufolobus shibatae DNA topoisomerase VI (topoVI), a member of the recently described type IIB DNA topoisomerase family. A purification procedure of a fully soluble recombinant topoVI was developed by expressing both subunits simultaneously in Escherichia coli. Using this recombinant enzyme, we observed that the formation of the double-strand breaks on supercoiled or linear DNA is strictly dependent on the presence of ATP or AMP-PNP. This result suggests that ATP binding is required to stabilize an enzyme conformation able to cleave the DNA backbone. The structure of cleavage complexes on a linear DNA fragment have been analyzed at the nucleotide level. Similarly to other type II DNA topoisomerases, topoVI is covalently attached to the 5'-ends of the broken DNA. However, sequence analysis of the double-strand breaks revealed that they are all characterized by staggered two-nucleotide long 5' overhangs, contrasting with the four-base staggered double-strand breaks catalyzed by type IIA DNA topoisomerases. While no clear consensus sequences surrounding the cleavage sites could be described, interestingly A and T nucleotides are highly represented on the 5' extensions, giving a first insight on the preferred sequences recognized by this type II DNA topoisomerase.	Univ Paris 11, Inst Genet & Microbiol, CNRS, UMR 8621, F-91405 Orsay, France; Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Karolinska Institutet	Buhler, C (corresponding author), Univ Paris 11, Inst Genet & Microbiol, CNRS, UMR 8621, Bat 409, F-91405 Orsay, France.	cyril.buhler@igmors.u-psud.fr		Buhler, Cyril/0000-0003-0397-7653				Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Berger JM, 1998, P NATL ACAD SCI USA, V95, P7876, DOI 10.1073/pnas.95.14.7876; BERGERAT A, 1994, J BIOL CHEM, V269, P27663; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; Buhler C, 1998, NUCLEIC ACIDS RES, V26, P5157, DOI 10.1093/nar/26.22.5157; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; DEMASSY B, 1995, EMBO J, V14, P4589, DOI 10.1002/j.1460-2075.1995.tb00138.x; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Fass D, 1999, NAT STRUCT BIOL, V6, P322; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; Grelon M, 2001, EMBO J, V20, P589, DOI 10.1093/emboj/20.3.589; Hartung F, 2000, NUCLEIC ACIDS RES, V28, P1548, DOI 10.1093/nar/28.7.1548; KATO J, 1992, J BIOL CHEM, V267, P25676; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KEENEY S, 1995, P NATL ACAD SCI USA, V92, P11274, DOI 10.1073/pnas.92.24.11274; LEE MP, 1989, J BIOL CHEM, V264, P13510; LIU JH, 1995, EMBO J, V14, P4599, DOI 10.1002/j.1460-2075.1995.tb00139.x; Liu QY, 1999, P NATL ACAD SCI USA, V96, P881, DOI 10.1073/pnas.96.3.881; MORRISON A, 1979, CELL, V17, P175, DOI 10.1016/0092-8674(79)90305-2; Ng WV, 2000, P NATL ACAD SCI USA, V97, P12176, DOI 10.1073/pnas.190337797; Nichols MD, 1999, EMBO J, V18, P6177, DOI 10.1093/emboj/18.21.6177; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; SANDER M, 1983, J BIOL CHEM, V258, P8421; Shannon M, 1999, FEBS LETT, V462, P329, DOI 10.1016/S0014-5793(99)01546-X; Smith KN, 1998, CURR OPIN GENET DEV, V8, P200, DOI 10.1016/S0959-437X(98)80142-1; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; Xu F, 1996, GENETICS, V143, P1115	36	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37215	37222		10.1074/jbc.M101823200	http://dx.doi.org/10.1074/jbc.M101823200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11485995	hybrid			2022-12-25	WOS:000171375700048
J	Mootz, HD; Finking, R; Marahiel, MA				Mootz, HD; Finking, R; Marahiel, MA			4 '-phosphopantetheine transfer in primary and secondary metabolism of Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; POLYKETIDE ANTIBIOTIC TA; FATTY-ACID BIOSYNTHESIS; ESCHERICHIA-COLI; PEPTIDE SYNTHETASES; MYXOCOCCUS-XANTHUS; CRYSTAL-STRUCTURE; PDXJ OPERON; SYNTHASE; GENES	4'-Phosphopantetheine transferases (PPTases) transfer the 4'-phosphopantetheine moiety of coenzyme A onto a conserved serine residue of acyl carrier proteins (ACPs) of fatty acid and polyketide synthases as well as peptidyl carrier proteins (PCPs) of nonribosomal peptide synthetases. This posttranslational modification converts ACPs and PCPs from their inactive apo into the active holo form. We have investigated the 4'-phosphopantetheinylation reaction in Bacillus subtilis, an organism containing in total 43 ACPs and PCPs but only two PPTases, the acyl carrier protein synthase AcpS of primary metabolism and Sfp, a PPTase of secondary metabolism associated with the nonribosomal peptide synthetase for the peptide antibiotic surfactin. We identified and cloned ydcB encoding AcpS from B. subtilis, which complemented an Escherichia coli acps disruption mutant. B. subtilis AcpS and its substrate ACP were bio chemically characterized. AcpS also modified the D-alanyl carrier protein but failed to recognize PCP and an acyl carrier protein of secondary metabolism discovered in this study, designated AcpK, that was not identified by the Bacillus genome project. On the other hand, Sfp was able to modify in vitro all acyl carrier proteins tested. We thereby extend the reported broad specificity of this enzyme to the homologous ACP. This in vitro cross-interaction between primary and secondary metabolism was confirmed under physiological in vivo conditions by the construction of a ydcB deletion in a B. subtilis sfp(+) strain. The genes coding for Sfp and its homolog Gsp from Bacillus brevis could also complement the E. coli acps disruption. These results call into question the essential role of AcpS in strains that contain a Sfp-like PPTase and consequently the suitability of AcpS as a microbial target in such strains.	Univ Marburg, Fachbereich Chem Biochem, D-35032 Marburg, Germany	Philipps University Marburg	Marahiel, MA (corresponding author), Univ Marburg, fachbereich Chem Biochem, Hans Meerwein Str, D-35032 Marburg, Germany.							ALBERTINI AM, 1995, MICROBIOL-SGM, V141, P299, DOI 10.1099/13500872-141-2-299; BORCHERT S, 1994, J BACTERIOL, V176, P2458, DOI 10.1128/JB.176.8.2458-2462.1994; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; Chirgadze NY, 2000, EMBO J, V19, P5281, DOI 10.1093/emboj/19.20.5281; COOPER DG, 1981, APPL ENVIRON MICROB, V42, P408, DOI 10.1128/AEM.42.3.408-412.1981; Debabov DV, 1996, J BACTERIOL, V178, P3869, DOI 10.1128/jb.178.13.3869-3876.1996; Fichtlscherer F, 2000, EUR J BIOCHEM, V267, P2666, DOI 10.1046/j.1432-1327.2000.01282.x; FISCHL AS, 1990, J BACTERIOL, V172, P5445, DOI 10.1128/jb.172.9.5445-5449.1990; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Gehring AM, 1997, CHEM BIOL, V4, P17, DOI 10.1016/S1074-5521(97)90233-7; GueroutFleury AM, 1995, GENE, V167, P335, DOI 10.1016/0378-1119(95)00652-4; HOCH JA, 1973, GENETICS, V73, P193; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; JACKOWSKI S, 1983, J BIOL CHEM, V258, P5186; Kealey JT, 1998, P NATL ACAD SCI USA, V95, P505, DOI 10.1073/pnas.95.2.505; KLEIN C, 1992, APPL ENVIRON MICROB, V58, P132, DOI 10.1128/AEM.58.1.132-142.1992; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAM HM, 1992, J BACTERIOL, V174, P1554, DOI 10.1128/jb.174.5.1554-1567.1992; Lambalot RH, 1997, METHOD ENZYMOL, V279, P254; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658, DOI 10.1074/jbc.270.42.24658; May JJ, 2001, J BIOL CHEM, V276, P7209, DOI 10.1074/jbc.M009140200; McAllister KA, 2000, J BIOL CHEM, V275, P30864, DOI 10.1074/jbc.M004475200; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Mootz HD, 2000, P NATL ACAD SCI USA, V97, P5848, DOI 10.1073/pnas.100075897; Morbidoni HR, 1996, J BACTERIOL, V178, P4794, DOI 10.1128/jb.178.16.4794-4800.1996; NAKANO MM, 1992, MOL GEN GENET, V232, P313, DOI 10.1007/BF00280011; NAKANO MM, 1988, J BACTERIOL, V170, P5662, DOI 10.1128/jb.170.12.5662-5668.1988; Paitan Y, 1999, MICROBIOL-SGM, V145, P3059, DOI 10.1099/00221287-145-11-3059; Paitan Y, 1999, J MOL BIOL, V286, P465, DOI 10.1006/jmbi.1998.2478; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; PEREGO M, 1995, J BIOL CHEM, V270, P15598, DOI 10.1074/jbc.270.26.15598; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Reuter K, 1999, EMBO J, V18, P6823, DOI 10.1093/emboj/18.23.6823; Sambrook J., 2002, MOL CLONING LAB MANU; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; TAKIFF HE, 1992, J BACTERIOL, V174, P1544, DOI 10.1128/jb.174.5.1544-1553.1992; Walsh CT, 1997, CURR OPIN CHEM BIOL, V1, P309, DOI 10.1016/S1367-5931(97)80067-1; Weber T, 2000, STRUCT FOLD DES, V8, P407, DOI 10.1016/S0969-2126(00)00120-9	41	141	153	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37289	37298		10.1074/jbc.M103556200	http://dx.doi.org/10.1074/jbc.M103556200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11489886	hybrid			2022-12-25	WOS:000171375700059
J	Petranka, J; Wright, G; Forbes, RA; Murphy, E				Petranka, J; Wright, G; Forbes, RA; Murphy, E			Elevated calcium in preneoplastic cells activates NF-kappa B and confers resistance to apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NEOPLASTIC PROGRESSION; ALPHA DEGRADATION; B/REL ACTIVATION; EXPRESSION; GENE; PATHWAY; CA2+; ACCUMULATION; MECHANISMS	Early preneoplastic cells (sup+) exhibit increased susceptibility to apoptosis, which is lost in late stage pre. neoplastic cells (sup-). Sup+ cells, which undergo apoptosis when cultured in low serum, show little or no DNA binding activity to nuclear factor (NF)-kappaB either in 10% or 0.2% serum. In contrast sup- cells, which are resistant to apoptosis in low serum, show a sustained constitutive activation of NF-kappaB. The constitutive activation of NF-kappaB observed in sup - cells is not due to loss of I kappaB alpha. We considered that the activation of NF-kappaB in sup- cells might be secondary to an increase in cytosolic Ca2+ since sup - cells have a cytosolic Ca2+ level that is double that in sup+ cells. In support of a role for Ca2+, lowering cytosolic Ca2+ in sup - cells by addition of the cell-permeable Ca2+ chelator 1,2 bis(O-aminophenoxy)ethane-N, N,N',N'-tetraacetic acid-acetoxymethyl ester (BAPTA-AM) reduced cytosolic Ca2+ by similar to 31% relative to untreated sup- cells, concomitant with a 65% reduction in NF-kappaB DNA binding activity and a reduction in I kappaB kinase (IKK) activity. In sup- cells in low serum, addition of BAPTA-AM also resulted in a significant (similar to 50%) increase in caspase-3 activity. Raising extracellular Ca2+ in sup+ cells resulted in a slight activation of I kappaB kinase and in enhanced NF-kappaB DNA binding activity. Using proteasome and calpain inhibitors, we determined that the basal activity of NF-kappaB in sup- cells is largely proteasome-independent, but sensitive to calpain inhibitors. Taken together these data suggest that the elevated Ca2+ in sup- cells causes a modest activation of IKK, which likely contributes to the enhanced basal activation of NF-kappaB in sup- cells; however, the predominant effect of Ca2+ appears to be mediated by Ca2+-enhanced degradation by calpain.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Murphy, E (corresponding author), NIEHS, Lab Signal Transduct, NIH, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	murphy1@niehs.nih.gov.DD			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050142] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Chen F, 2000, AM J PHYSIOL-CELL PH, V279, pC709, DOI 10.1152/ajpcell.2000.279.3.C709; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fields ER, 2000, J IMMUNOL, V164, P4762, DOI 10.4049/jimmunol.164.9.4762; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Han B, 2000, AM J PHYSIOL-CELL PH, V278, pC344, DOI 10.1152/ajpcell.2000.278.2.C344; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Jayadev S, 1999, J BIOL CHEM, V274, P8261, DOI 10.1074/jbc.274.12.8261; Kanno T, 1996, J IMMUNOL, V157, P5277; KOI M, 1986, P NATL ACAD SCI USA, V83, P5992, DOI 10.1073/pnas.83.16.5992; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Marinovich M, 1996, EXP CELL RES, V226, P98, DOI 10.1006/excr.1996.0207; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; Ouellet M, 1999, J BIOL CHEM, V274, P35029, DOI 10.1074/jbc.274.49.35029; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; PRESTON GA, 1994, CANCER RES, V54, P4214; Preston GA, 1997, CANCER RES, V57, P537; SchulteHermann R, 1995, MUTAT RES-FUND MOL M, V333, P81, DOI 10.1016/0027-5107(95)00134-4; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tando Y, 1999, AM J PHYSIOL-GASTR L, V277, pG678, DOI 10.1152/ajpgi.1999.277.3.G678; Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WOJNOWSKI L, 1994, PFLUG ARCH EUR J PHY, V426, P89, DOI 10.1007/BF00374675	34	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37102	37108		10.1074/jbc.M008448200	http://dx.doi.org/10.1074/jbc.M008448200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479282	hybrid			2022-12-25	WOS:000171375700033
J	Petrescu, AD; Gallegos, AM; Okamura, Y; Strauss, JF; Schroeder, F				Petrescu, AD; Gallegos, AM; Okamura, Y; Strauss, JF; Schroeder, F			Steroidogenic acute regulatory protein binds cholesterol and modulates mitochondrial membrane sterol domain dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY ACYL-COENZYME; CARRIER PROTEIN-2; LIPID-BINDING; TARGETED DISRUPTION; LIGAND-BINDING; STAR; ACID; FLUORESCENCE; EXPRESSION; SENSITIVITY	The steroidogenic acute regulatory protein (StAR) mediates the rate-limiting step of steroidogenesis, delivery of cholesterol to the inner mitochondrial membrane. However, the mechanism whereby cholesterol translocation is accomplished has not been resolved. Recombinant StAR proteins lacking the first N-terminal 62 amino acids comprising the mitochondrial-targeting sequence were used to determine if StAR binds cholesterol and alters mitochondrial membrane cholesterol domains to enhance sterol transfer. First, a fluorescent NBD-cholesterol binding assay revealed 2 sterol binding sites (K-d values near 32 nM), whereas the inactive A218V N-62 StAR mutant had only a single binding site with 8-fold lower affinity. Second, NBD-cholesterol spectral shifts and fluorescence resonance energy transfer from StAR Trp residues to NBD-cholesterol showed (i) close molecular interaction between these molecules (R-2/3 = 33 Angstrom) and (ii) sensitized NBD-cholesterol emission from only one of the two sterol binding sites. Third, circular dichroism showed that cholesterol binding induced a change in StAR secondary structure. Fourth, a fluorescent sterol transfer assay that did not require separation of donor and acceptor mitochondrial membranes demonstrated that StAR enhanced mitochondrial sterol transfer as much as 100-fold and induced/increased the formation of rapidly transferable cholesterol domains in isolated mitochondrial membranes. SLAR was 67-fold more effective in transferring cholesterol from mitochondria of steroidogenic MA-10 cells than from human fibroblast mitochondria. In contrast, sterol carrier protein-2 (SCP-2) was only 2.2-fold more effective in mediating sterol transfer from steroidogenic cell mitochondria. Taken together these data showed that StAR is a cholesterol-binding protein, preferentially enhances sterol transfer from steroidogenic cell mitochondria, and interacts with mitochondrial membranes to alter their sterol domain structure and dynamics.	Texas A&M Univ, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	Texas A&M University System; Texas A&M University College Station; University of Pennsylvania; Pennsylvania Medicine	Schroeder, F (corresponding author), Texas A&M Univ, TVMC, Dept Physiol & Pharmacol, College Stn, TX 77843 USA.	fschroeder@cvm.tamu.edu			NICHD NIH HHS [HD06274, HD34449] Funding Source: Medline; NIGMS NIH HHS [GM31651] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD034449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031651] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Avdulov NA, 1999, BBA-MOL CELL BIOL L, V1437, P37, DOI 10.1016/S0005-2760(98)00178-7; Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Bose HS, 1998, BIOCHEMISTRY-US, V37, P9768, DOI 10.1021/bi980588a; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Chanderbhan RF, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P197; Cherradi N, 1997, J BIOL CHEM, V272, P7899, DOI 10.1074/jbc.272.12.7899; Choi YS, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P109; Christenson LK, 2000, BBA-MOL CELL BIOL L, V1529, P175, DOI 10.1016/S1388-1981(00)00147-5; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; Fielding CJ, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P273; FISCHER R T, 1985, Journal of Biological Physics, V13, P13, DOI 10.1007/BF01872877; FISCHER RT, 1984, CHEM PHYS LIPIDS, V36, P1, DOI 10.1016/0009-3084(84)90086-0; FISCHER RT, 1985, BIOCHEMISTRY-US, V24, P3322, DOI 10.1021/bi00334a037; FORSTER TH., 1967, COMPREHENSIVE BIOCH, P61; Frolov A, 1996, J LIPID RES, V37, P1862; Frolov A, 1996, J BIOL CHEM, V271, P16075, DOI 10.1074/jbc.271.27.16075; Frolov A, 1998, J BIOL CHEM, V273, P11049, DOI 10.1074/jbc.273.18.11049; Frolov A, 1997, LIPIDS, V32, P1201, DOI 10.1007/s11745-997-0154-5; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Gallegos AM, 2000, CHEM PHYS LIPIDS, V105, P9, DOI 10.1016/S0009-3084(99)00128-0; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; Iyer LM, 2001, PROTEINS, V43, P134, DOI 10.1002/1097-0134(20010501)43:2<134::AID-PROT1025>3.3.CO;2-9; Jatzke C, 1999, BBA-PROTEIN STRUCT M, V1432, P265, DOI 10.1016/S0167-4838(99)00114-4; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Lakowicz J. R., 1991, TOPICS FLUORESCENCE; Lakowitcz J.R, 1999, PRINCIPLES FLUORESCE, P237, DOI DOI 10.1007/978-1-4757-3061-6_8; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Liu RH, 2000, BIOCHEMISTRY-US, V39, P14927, DOI 10.1021/bi0018786; Liu Z, 1996, BIOL REPROD, V54, P549; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUURA JE, 1993, BIOCHEMISTRY-US, V32, P567, DOI 10.1021/bi00053a023; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Neufeld EB, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P93; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; PARKER CA, 1968, PHOTOLUMINESCENCE SO, P84; PFEIFER SM, 1993, J STEROID BIOCHEM, V47, P167, DOI 10.1016/0960-0760(93)90071-4; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; ROSENBLUM MF, 1981, ENDOCRINOLOGY, V109, P1518, DOI 10.1210/endo-109-5-1518; SCHROEDER F, 1990, J BIOL CHEM, V265, P151; SCHROEDER F, 1993, MOL CELL BIOCHEM, V123, P73, DOI 10.1007/BF01076477; Schroeder F, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P213; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; SCHROEDER F, 1985, J BIOL CHEM, V260, P2904; Schroeder F, 2000, J BIOL CHEM, V275, P25547, DOI 10.1074/jbc.M000431200; SCHROEDER F, 2001, IN PRESS EXP BIOL ME; Seedorf U, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P235; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; SEGEL IH, 1983, ENZYME KINETICS, P347; Smart EJ, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P253; Stocco DM, 2000, BBA-MOL CELL BIOL L, V1486, P184, DOI 10.1016/S1388-1981(00)00056-1; Stocco DM, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P169; STOCCO DM, 1996, LEYDIG CELL, P241; Stolowich N, 1999, J BIOL CHEM, V274, P35425, DOI 10.1074/jbc.274.50.35425; Thomson M, 1998, HORM METAB RES, V30, P16, DOI 10.1055/s-2007-978825; TOREN D, 1964, STEROIDS, V3, P381, DOI 10.1016/0039-128X(64)90002-9; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; WOODFORD JK, 1995, MOL CELL BIOCHEM, V152, P51; WOODFORD JK, 1995, CHEM PHYS LIPIDS, V76, P73, DOI 10.1016/0009-3084(95)02436-M; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134	63	94	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36970	36982		10.1074/jbc.M101939200	http://dx.doi.org/10.1074/jbc.M101939200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11489878	hybrid			2022-12-25	WOS:000171375700017
J	Tsuchida, K; Shioi, J; Yamada, S; Boghosian, G; Wu, AF; Cai, HY; Sugahara, K; Robakis, NK				Tsuchida, K; Shioi, J; Yamada, S; Boghosian, G; Wu, AF; Cai, HY; Sugahara, K; Robakis, NK			Appican, the proteoglycan form of contains chondroitin sulfate E in region and 4-O-sulfated galactose the amyloid precursor protein, the repeating disaccharide in the linkage region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG MAST-CELLS; ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; HEXASACCHARIDE SEQUENCES; EXTRACELLULAR-MATRIX; HAGFISH NOTOCHORD; SQUID CARTILAGE; NERVOUS-SYSTEM; FACTOR MIDKINE; CNS INJURY	Chondroitin sulfate (CS)-D and CS-E, which are characterized by oversulfated disaccharide units, have been shown to regulate neuronal adhesion, cell migration, and neurite outgrowth. CS proteoglyeans (CSPGs) consist of a core protein to which one or more CS chains are attached via a serine residue. Although several brain CSPGs, including mouse DSD-1-PG/phosphacan, have been found to contain the oversulfated D disaccharide motif, no brain CSPG has been reported to contain the oversulfated E motif. Here we analyzed the CS chain of appican, the CSPG form of the Alzheimer's amyloid precursor protein. Appican is expressed almost exclusively by astrocytes and has been reported to have brain- and astrocyte-specific functions including stimulation of both neural cell adhesion and neurite outgrowth. The present findings show that the CS chain of appican has a molecular mass of 25-50 kDa. This chain contains a significant fraction (14.3%) of the oversulfated E motif GlcUA beta1-3GalNAc(4,6-O-disulfate). The rest of the chain consists of GlcUA beta1-3GalNAc(4-O-sulfate) (81.2%) and minor fractions of GlcUA beta1-3GalNAc and GlcUA beta1-3GalNAc(6-O-sulfate). We also show that the CS chain of appican contains in its linkage region the 4-O-sulfated Gal structure. Thus, appican is the first example of a specific brain CSPG that contains the E disaccharide unit in its sugar backbone and the 4-O-sulfated Gal residue in its linkage region. The presence of the E unit is consistent with and may explain the neurotrophic activities of appican.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA	Kobe Pharmaceutical University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Shioi, J (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan.		Robakis, Nikolaos/AAA-1838-2021		NATIONAL INSTITUTE ON AGING [R01AG008200] Funding Source: NIH RePORTER; NIA NIH HHS [AG05138, AG08200] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANNO K, 1971, BIOCHIM BIOPHYS ACTA, V237, P173, DOI 10.1016/0304-4165(71)90046-8; ASCHNER M, 1993, J TOXICOL ENV HEALTH, V38, P329, DOI 10.1080/15287399309531721; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; Castillo GM, 1999, J NEUROCHEM, V72, P1681, DOI 10.1046/j.1471-4159.1999.721681.x; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; DEWITT DA, 1993, EXP NEUROL, V121, P149, DOI 10.1006/exnr.1993.1081; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FERNAUDESPINOSA I, 1994, J CELL SCI, V107, P1437; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; Garwood J, 1999, J NEUROSCI, V19, P3888; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; HABUCHI O, 1977, J BIOL CHEM, V252, P4570; HEINEGAR.D, 1972, BIOCHIM BIOPHYS ACTA, V285, P193, DOI 10.1016/0005-2795(72)90191-2; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; KATOHSEMBA R, 1995, EUR J NEUROSCI, V7, P613, DOI 10.1111/j.1460-9568.1995.tb00665.x; KIDO H, 1990, BIOCHEM BIOPH RES CO, V167, P716, DOI 10.1016/0006-291X(90)92084-D; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; KINOSHITA A, 1998, 19 INT CARB S SAN DI; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; LAFONT F, 1992, DEVELOPMENT, V114, P17; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; Li H, 1996, MOL BRAIN RES, V36, P309, DOI 10.1016/0169-328X(95)00269-X; Lindahl B, 1996, J BIOL CHEM, V271, P16991, DOI 10.1074/jbc.271.29.16991; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; McLaurin J, 1999, EUR J BIOCHEM, V266, P1101, DOI 10.1046/j.1432-1327.1999.00957.x; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; PANGALOS MN, 1995, J NEUROCHEM, V65, P762; PANGALOS MN, 1995, J BIOL CHEM, V270, P10388, DOI 10.1074/jbc.270.18.10388; Pangalos MN, 1996, NEURODEGENERATION, V5, P445, DOI 10.1006/neur.1996.0061; PERRY G, 1991, J NEUROSCI, V11, P3679; RAZIN E, 1982, J BIOL CHEM, V257, P7229; SAIGO K, 1970, J NEUROCHEM, V17, P633, DOI 10.1111/j.1471-4159.1970.tb00543.x; Sakaguchi H, 2001, J BIOCHEM-TOKYO, V129, P107, DOI 10.1093/oxfordjournals.jbchem.a002820; Salinero O, 2000, J NEUROSCI RES, V60, P87, DOI 10.1002/(SICI)1097-4547(20000401)60:1<87::AID-JNR9>3.0.CO;2-C; SHIOI J, 1993, NEUROSCI LETT, V154, P121, DOI 10.1016/0304-3940(93)90186-O; SHIOI J, 1995, J BIOL CHEM, V270, P11839, DOI 10.1074/jbc.270.20.11839; SHIOI J, 1992, J BIOL CHEM, V267, P13819; SHIOI J, 2000, NEUROBIOL AGING, V21, pS183; SHIOI J, 1996, TRENDS GLYCOSCI GLYC, V8, P252; SNOW AD, 1994, AM J PATHOL, V144, P337; SNOW AD, 1988, AM J PATHOL, V133, P456; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; SNOW DM, 1991, DEVELOPMENT, V113, P1473; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; STREIT A, 1993, J CELL BIOL, V120, P799, DOI 10.1083/jcb.120.3.799; SU JH, 1992, NEUROSCIENCE, V51, P801, DOI 10.1016/0306-4522(92)90521-3; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; SUZUKI S, 1960, J BIOL CHEM, V235, P3580; THINAKARAN G, 1994, J BIOL CHEM, V269, P22099; THOMPSON HL, 1988, J IMMUNOL, V140, P2708; TSUCHIDA K, 2000, 21 JAP CARB S NAG JA, P102; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Ueoka C, 1999, GLYCOCONJUGATE J, V16, P291, DOI 10.1023/A:1007022229813; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; Wu AF, 1997, J NEUROSCI, V17, P4987; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523	69	46	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37155	37160		10.1074/jbc.M105818200	http://dx.doi.org/10.1074/jbc.M105818200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479316	hybrid			2022-12-25	WOS:000171375700040
J	Hirano, Y; Yoshida, M; Shimizu, M; Sato, R				Hirano, Y; Yoshida, M; Shimizu, M; Sato, R			Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; SITE-1 PROTEASE; GENE; PROTEOLYSIS; EXPRESSION; CLEAVAGE; SREBP-2; EXPORT	Sterol regulatory element-binding proteins (SREBPs) are synthesized as membrane-bound precursors and processed to generate transcriptionally active forms. The active SREBPs translocate to the nucleus, induce the expression of responsive genes, and are degraded very rapidly. Treatment with proteasome inhibitors elevates the amount of the endogenous nuclear SREBPs, but not the precursors, in HeLa cells. Nuclear forms of human SREBP-1a (amino acids 1-487) and SREBP-2 (amino acids 1-481), which are transiently expressed in stable Chinese hamster ovary cell lines (CHO-487 and -481), are also stabilized by proteasome inhibitors, suggesting that the nuclear SREBPs are likely to be substrates for the proteasome-dependent proteolysis. The stabilized nuclear SREBPs actively induce the expression of responsive genes including hydroxymethylglutaryl (EMG)-CoA synthase, fatty acid synthase, and the low density lipoprotein receptor. The rapid turnover of nuclear SREBP-1a is not affected by the intracellular sterol levels, and the half-life is estimated to be similar to3 h. The nuclear SREBPs are found conjugated with a polyubiquitin chain. When this conjugation is inhibited by overexpression of mutant ubiquitin that is defective in polyubiquitination, the nuclear SREBPs are partly stabilized and induce the expression of the responsive gene, suggesting that the ubiquitin-conjugated SREBPs are substrates for the proteasome. Taken together, these results demonstrate that the ubiquitin-proteasome system degrades SREBPs and that this system controls the expression of SREBP-responsive genes.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan	University of Tokyo; University of Tokyo	Sato, R (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Tokyo 1138657, Japan.		Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; Maki CG, 1996, CANCER RES, V56, P2649; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nagoshi E, 2001, MOL CELL BIOL, V21, P2779, DOI 10.1128/MCB.21.8.2779-2789.2001; NISHI K, 1994, J BIOL CHEM, V269, P6320; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; SATO R, 1994, J BIOL CHEM, V269, P17267; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	45	130	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36431	36437		10.1074/jbc.M105200200	http://dx.doi.org/10.1074/jbc.M105200200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477106	hybrid			2022-12-25	WOS:000171194500052
J	Rubi, B; Ishihara, H; Hegardt, FG; Wollheim, CB; Maechler, P				Rubi, B; Ishihara, H; Hegardt, FG; Wollheim, CB; Maechler, P			GAD65-mediated glutamate decarboxylation reduces glucose-stimulated insulin secretion in pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; MITOCHONDRIAL ACTIVATION; RELEASE; GABA; RAT; EXPRESSION; ISLETS; MOUSE; CA2+; MODULATION	Mitochondrial metabolism plays a pivotal role in the pancreatic beta cell by generating signals that couple glucose sensing to insulin secretion. We have demonstrated previously that mitochondrially derived glutamate participates directly in the stimulation of insulin exocytosis. The aim of the present study was to impose altered cellular glutamate levels by overexpression of glutamate decarboxylase (GAD) to repress elevation of cytosolic glutamate. INS-1E cells infected with a recombinant adenovirus vector encoding GAD65 showed efficient overexpression of the GAD protein with a parallel increase in enzyme activity. In control cells glutamate levels were slightly increased by 7.5 nim glucose (1.4-fold) compared with the effect at 15 mm (2.3-fold) versus basal 2.5 mm glucose. Upon GAD overexpression, glutamate concentrations were no longer elevated by 15 mm glucose as compared with controls (-40%). Insulin secretion was stimulated in control cells by glucose at 7.5 mm (2.5-fold) and more efficiently at 15 mm (5.2-fold). INS-1E cells overexpressing GAD exhibited impaired insulin secretion on stimulation with 15 mm glucose (-37%). The secretory response to 30 mm KCI, used to raise cytosolic Ca2+ levels, was unaffected. Similar results were obtained in perifused rat pancreatic islets following adenovirus transduction. This GAD65-mediated glutamate decarboxylation correlating with impaired glucose-induced insulin secretion is compatible with a role for glutamate as a glucose-derived factor participating in insulin exocytosis.	Ctr Med Univ Geneva, Div Biochim Clin, Dept Internal Med, CH-1211 Geneva 4, Switzerland; Univ Barcelona, Sch Pharm, Dept Biochem, E-08028 Barcelona, Spain	University of Geneva; University of Barcelona	Maechler, P (corresponding author), Ctr Med Univ Geneva, Div Biochim Clin, Dept Internal Med, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.			Maechler, Pierre/0000-0002-2005-1433				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; CHRISTGAU S, 1991, J BIOL CHEM, V266, P21257; Corkey BE, 2000, J NUTR, V130, p299S, DOI 10.1093/jn/130.2.299S; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GILON P, 1991, ENDOCRINOLOGY, V129, P2521, DOI 10.1210/endo-129-5-2521; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; HUDSON RC, 1993, COMP BIOCHEM PHYS B, V106, P767, DOI 10.1016/0305-0491(93)90031-Y; ISHIHARA I, 2000, EUR J CELL BIOL, V79, P187; Janjic D, 1999, BIOCHEM PHARMACOL, V57, P639, DOI 10.1016/S0006-2952(98)00346-3; KARLSEN AE, 1991, P NATL ACAD SCI USA, V88, P8337, DOI 10.1073/pnas.88.19.8337; KAWAI K, 1983, ENDOCRINOLOGY, V113, P111, DOI 10.1210/endo-113-1-111; KIM J, 1993, DIABETES, V42, P1799, DOI 10.2337/diabetes.42.12.1799; MacDonald MJ, 2000, J BIOL CHEM, V275, P34025, DOI 10.1074/jbc.C000411200; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905; Maechler P, 2000, IUBMB LIFE, V50, P27, DOI 10.1080/15216540050176557; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Maechler P, 2000, J PHYSIOL-LONDON, V529, P49, DOI 10.1111/j.1469-7793.2000.00049.x; MICHALIK M, 1993, DIABETES, V42, P1506, DOI 10.2337/diabetes.42.10.1506; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Namchuk M, 1997, J BIOL CHEM, V272, P1548, DOI 10.1074/jbc.272.3.1548; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; SATO Y, 1992, DIABETES, V41, P438, DOI 10.2337/diabetes.41.4.438; Schuit FC, 2001, DIABETES, V50, P1, DOI 10.2337/diabetes.50.1.1; Shi YG, 2000, AM J PHYSIOL-ENDOC M, V279, pE684, DOI 10.1152/ajpendo.2000.279.3.E684; Smismans A, 1997, DIABETOLOGIA, V40, P1411, DOI 10.1007/s001250050843; SORENSON RL, 1991, DIABETES, V40, P1365, DOI 10.2337/diabetes.40.11.1365; Vandewalle CL, 1997, DIABETES CARE, V20, P1547, DOI 10.2337/diacare.20.10.1547; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Yamada H, 2001, DIABETES, V50, P1012, DOI 10.2337/diabetes.50.5.1012	40	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36391	36396		10.1074/jbc.M104999200	http://dx.doi.org/10.1074/jbc.M104999200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11473118	hybrid, Green Published			2022-12-25	WOS:000171194500046
J	Gu, YJ; Misonou, H; Sato, T; Dohmae, N; Takio, K; Ihara, Y				Gu, YJ; Misonou, H; Sato, T; Dohmae, N; Takio, K; Ihara, Y			Distinct intramembrane cleavage of the beta-amyloid precursor protein family resembling gamma-secretase-like cleavage of Notch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; SUBSTRATE; PEPTIDES; DOMAIN	The intramembrane cleavage of beta -amyloid precursor protein by gamma -secretase is the final step in the generation of amyloid beta -protein. A 59- or 57-residue C-terminal fragment called CTF gamma is produced concomitantly. Putative CTF gamma generated in rat brain membrane preparations was purified and sequenced. Instead of CTF gamma, shorter 50- and 49-residue fragments were identified. In addition, we found similar C-terminal fragments of beta -amyloid precursor-like proteins 1 and 2; these were also cleaved at corresponding sites. This newly identified cleavage occurs at a site two to five residues inside the cytoplasmic membrane boundary, which is very similar to gamma -secretase-like cleavage of Notch 1.	Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, Core Res & Evolut Sci & Technol, Kawaguchi 3320012, Japan; RIKEN, Div Biomol Characterizat, Wako, Saitama 3510198, Japan	University of Tokyo; Japan Science & Technology Agency (JST); RIKEN	Ihara, Y (corresponding author), Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	yihara@m.u-tokyo.ac.jp	Dohmae, Naoshi/C-2040-2011	Dohmae, Naoshi/0000-0002-5242-9410; Misono, Hiroaki/0000-0001-5892-1804				Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kwok JBJ, 2000, ANN NEUROL, V47, P249, DOI 10.1002/1531-8249(200002)47:2<249::AID-ANA18>3.3.CO;2-#; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; TAKIO K, 1989, BIOCHEM BIOPH RES CO, V160, P1296, DOI 10.1016/S0006-291X(89)80144-5; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b	18	258	266	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35235	35238		10.1074/jbc.C100357200	http://dx.doi.org/10.1074/jbc.C100357200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11483588	hybrid			2022-12-25	WOS:000171109300004
J	Wijayaratne, AL; McDonnell, DP				Wijayaratne, AL; McDonnell, DP			The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; NUCLEAR RECEPTOR; MEDIATED PROTEOLYSIS; ANTIESTROGEN ICI-182780; MULTIUBIQUITIN CHAIN; PEPTIDE ANTAGONISTS; HORMONE RECEPTOR; IN-VIVO; N-COR; PROTEASOME	The human estrogen receptor a-isoform (ER alpha) is a nuclear transcription factor that displays a complex pharmacology. In addition to classical agonists and antagonists, the transcriptional activity of ER alpha can be regulated by selective estrogen receptor modulators, a new class of drugs whose relative agonist/antagonist activity is determined by cell context. It has been demonstrated that the binding of different ligands to ER alpha results in the formation of unique ER alpha -ligand conformations. These conformations have been shown to influence ER alpha -cofactor binding and, therefore, have a profound impact on ER alpha pharmacology. In this study, we demonstrate that the nature of the bound ligand also influences the stability of ER alpha, revealing an additional mechanism by which the pharmacological activity of a compound is determined. Of note we found that although all ER alpha -ligand complexes can be ubiquitinated and degraded by the 26 S proteasome in vivo, the mechanisms by which they are targeted for proteolysis appear to be different. Specifically, for agonist-activated ER alpha, an inverse relationship between transcriptional activity and receptor stability was observed. This relationship does not extend to selective estrogen receptor modulators and pure antagonists. Instead, it appears that with these compounds, the determinant of receptor stability is the ligand-induced conformation of ER alpha. We conclude that the different conformational states adopted by ER alpha in the presence of different ligands influence transcriptional activity directly by regulating cofactor binding and indirectly by modulating receptor stability.	Duke Univ, Med Ctr, Dept Pharmacol & Mol Canc Biol, Durham, NC 27710 USA	Duke University	McDonnell, DP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Mol Canc Biol, Box 3813, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048807, R01DK048807] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48807] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chang CY, 1999, MOL CELL BIOL, V19, P8226; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Connor CE, 2001, CANCER RES, V61, P2917; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; ECKERT RL, 1984, ENDOCRINOLOGY, V114, P629, DOI 10.1210/endo-114-2-629; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GOTTARDIS MM, 1988, CANCER RES, V48, P5183; GREGORI L, 1990, J BIOL CHEM, V265, P8354; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; KATZENELLENBOGEN BS, 1995, J STEROID BIOCHEM, V53, P387, DOI 10.1016/0960-0760(95)00084-D; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Lin X, 2000, Curr Opin Drug Discov Devel, V3, P383; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Mak HY, 1999, MOL CELL BIOL, V19, P3895; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; MONSMA FJ, 1984, ENDOCRINOLOGY, V115, P143, DOI 10.1210/endo-115-1-143; NARDULLI AM, 1986, ENDOCRINOLOGY, V119, P2038, DOI 10.1210/endo-119-5-2038; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; ONATE SA, 1995, SCIENCE, V270, P1354; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; SCHOLL S, 1984, ENDOCRINOLOGY, V115, P1295, DOI 10.1210/endo-115-4-1295; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VOM BAUR, 1995, EMBO J, V14, P110; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	56	354	368	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35684	35692		10.1074/jbc.M101097200	http://dx.doi.org/10.1074/jbc.M101097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11473106	hybrid			2022-12-25	WOS:000171109300064
J	Chan, HW				Chan, HW			Bone builders: preventing and treating osteoporosis	FASEB JOURNAL			English	Editorial Material																			0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					1677	1677		10.1096/fj.01-0536bkt	http://dx.doi.org/10.1096/fj.01-0536bkt			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481213				2022-12-25	WOS:000170809900002
J	Berquin, IM; Dziubinski, ML; Nolan, GP; Ethier, SP				Berquin, IM; Dziubinski, ML; Nolan, GP; Ethier, SP			A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin	ONCOGENE			English	Article						EGF; EGFR; amphiregulin; breast cancer; autocrine growth factor	HUMAN-BREAST-CANCER; DIFFERENTIATION FACTOR HEREGULIN; FACTOR RECEPTOR; ESTROGEN-RECEPTOR; CARCINOMA CELLS; POOR RESPONSE; FACTOR-I; EXPRESSION; HORMONE; NEU	To gain better understanding of the molecular alterations responsible for the aggressive growth potential of epidermal growth factor receptor (EGFR)-positive breast cancers, we utilized an expression cloning strategy to seek gene products that mediate the EGF-independent growth of human breast cancer cells, A retroviral cDNA expression library was constructed from the EGFR-positive SUM-149PT cell line, and transduced into growth factor-dependent human mammary epithelial (HME) cells. Recipient cells were functionally selected for their ability to proliferate in serum-free, EGF-free medium. Library cDNAs were recovered from EGF-independent colonies by PCR amplification or by biological rescue. Clone H55a#1 contained a library insert encoding amphiregulin, This EGFR ligand,vas able to confer EGF independence when transduced into HME cells. SUM-149PT and H55a#1 cells overexpressed amphiregulin transcripts, and secreted moderate EGF-like activity in conditioned media, indicating a possible autocrine loop. EGFR membrane levels and constitutive phosphorylation were consistent with this hypothesis, as well as the sensitivity of the cells to an ErbB-specific kinase inhibitor. Expression of the WT1 Wilms' tumor suppressor gene, a transcriptional activator of amphiregulin, did not parallel amphiregulin transcript levels, suggesting that another factor regulates amphiregulin in SUM-149PT, Our data confirm the importance of amphiregulin in the etiology of breast cancer.	Univ Michigan, Dept Radiat Oncol, Div Radiat & Canc Biol, Ann Arbor, MI 48109 USA; Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	University of Michigan System; University of Michigan; Stanford University	Ethier, SP (corresponding author), 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	spethier@umich.edu	Nolan, Garry/AAE-7903-2019	Nolan, Garry/0000-0002-8862-9043	NCI NIH HHS [R01 CA77416] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077416] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BATTAGLIA F, 1988, EUR J CANCER CLIN ON, V24, P1685, DOI 10.1016/0277-5379(88)90068-5; Brown P, 2000, CONT ENDOCRINOL, P49; Clarke RB, 1997, CANCER RES, V57, P4987; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; ETHIER SP, 1991, CELL GROWTH DIFFER, V2, P593; ETHIER SP, 1987, J CELL PHYSIOL, V132, P161, DOI 10.1002/jcp.1041320123; Ethier SP, 1996, MOL CARCINOGEN, V15, P134; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; ETHIER SP, 1990, CANCER RES, V50, P5351; ETHIER SP, 1991, BREAST CANCER RES TR, V17, P221, DOI 10.1007/BF01806371; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; HOLDAWAY IM, 1983, CANCER, V52, P479, DOI 10.1002/1097-0142(19830801)52:3<479::AID-CNCR2820520317>3.0.CO;2-O; Ignatoski KMW, 1999, BREAST CANCER RES TR, V54, P173, DOI 10.1023/A:1006135331912; Ignatoski KMW, 1999, ENDOCRINOLOGY, V140, P3615, DOI 10.1210/en.140.8.3615; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LEJEUNE S, 1993, CANCER RES, V53, P3597; Ma L, 1999, ONCOGENE, V18, P6513, DOI 10.1038/sj.onc.1203042; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; NICHOLSON S, 1989, LANCET, V1, P182; NICHOLSON S, 1990, J STEROID BIOCHEM, V37, P811, DOI 10.1016/0960-0760(90)90424-J; NICHOLSON S, 1988, INT J CANCER, V42, P36, DOI 10.1002/ijc.2910420108; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; OSBORNE CK, 1985, SEMIN ONCOL, V12, P317; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pfeiffer JK, 1999, J VIROL, V73, P8441, DOI 10.1128/JVI.73.10.8441-8447.1999; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; Salomon DS, 2000, CONT ENDOCRINOL, P137; SCHRANK R, 1994, HARVARD BUS REV, V72, P77; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Smaill JB, 2000, J MED CHEM, V43, P1380, DOI 10.1021/jm990482t; SOULE HD, 1990, CANCER RES, V50, P6075; Tannheimer SL, 2000, BREAST CANCER RES, V2, P311, DOI 10.1186/bcr73; TOI M, 1989, INT J CANCER, V43, P220, DOI 10.1002/ijc.2910430208; Visscher DW, 1997, BREAST CANCER RES TR, V45, P75, DOI 10.1023/A:1005845512804; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	53	33	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4019	4028		10.1038/sj.onc.1204537	http://dx.doi.org/10.1038/sj.onc.1204537			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494130				2022-12-25	WOS:000169681500010
J	Macaulay, VM; Salisbury, AJ; Bohula, EA; Playford, MP; Smorodinsky, NI; Shiloh, Y				Macaulay, VM; Salisbury, AJ; Bohula, EA; Playford, MP; Smorodinsky, NI; Shiloh, Y			Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase	ONCOGENE			English	Article						insulin-like growth factors; IGF receptor; Atm; melanoma; radiosensitivity	FACTOR-I RECEPTOR; BREAST-CANCER CELLS; HUMAN SQUAMOUS CARCINOMA; IONIZING-RADIATION; ATAXIA-TELANGIECTASIA; ANTISENSE RNA; MONOCLONAL-ANTIBODY; GAMMA-IRRADIATION; DNA-DAMAGE; P53	The type 1 insulin-like growth factor receptor (IGF1R) is required for growth, tumorigenicity and protection from apoptosis, IGF1R overexpression is associated with radioresistance in breast cancer. We used antisense (AS) RNA to downregulate IGF1R expression in mouse melanoma cells. Cells expressing AS-IGF1R transcripts were more radiosensitive in vitro and in vivo than controls. Also they showed reduced radiation-induced p53 accumulation and p53 serine 18 phosphorylation, and radioresistant DNA synthesis. These changes were reminiscent of the cellular phenotype of the human genetic disorder ataxia-telangiectasia (A-T), caused by mutations in the A TM gene. Cellular Atm protein levels mere lower in AS-IGF1R-transfected cells than in control cells, although there was no difference in Atm expression at,the transcriptional level. AS-IGF1R cells had detectable basal Atm kinase activity, but failed to induce kinase activity after irradiation. This suggests that IGF1R signalling can modulate the function of Atm, and supports the concept of targeted IGF1R downregulation as a potential treatment for malignant melanoma and other radioresistant tumours.	Weatherall Inst Mol Med, Mol Oncol Labs, IGF Grp, Oxford OX3 9DS, England; Tel Aviv Univ, George S Wise Fac Life Sci, Hybridoma Unit, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel	University of Oxford; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Macaulay, VM (corresponding author), Weatherall Inst Mol Med, Mol Oncol Labs, IGF Grp, Oxford OX3 9DS, England.	macaulay@icrf.icnet.uk	Bohula, Erin/AAW-7276-2020		NINDS NIH HHS [R01 NS31763] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chernicky CL, 2000, CANCER GENE THER, V7, P384, DOI 10.1038/sj.cgt.7700126; Dunn SE, 1997, CANCER RES, V57, P2687; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fan ZH, 2000, CANCER GENE THER, V7, P1307, DOI 10.1038/sj.cgt.0243; Fukao T, 1999, BLOOD, V94, P1998; Fukuchi K, 2000, BBA-MOL CELL RES, V1496, P207, DOI 10.1016/S0167-4889(00)00018-5; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Guha C, 2000, GENE THER, V7, P852, DOI 10.1038/sj.gt.3301174; Hartmann A, 1996, INT J CANCER, V67, P313, DOI 10.1002/(SICI)1097-0215(19960729)67:3<313::AID-IJC1>3.0.CO;2-U; HARTMANN KKP, 1992, J CELL BIOCHEM, V48, P81, DOI 10.1002/jcb.240480112; Huang SM, 1999, CANCER RES, V59, P1935; Jenrette JM, 1996, SEMIN ONCOL, V23, P759; JONES RF, 1994, MOL CARCINOGEN, V9, P95, DOI 10.1002/mc.2940090207; Kanter-Lewensohn L, 2000, GROWTH FACTORS, V17, P193, DOI 10.3109/08977190009001068; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KELLAND LR, 1989, INT J RADIAT BIOL, V55, P119, DOI 10.1080/09553008914550121; Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kizilian N, 1999, BIOTECHNIQUES, V27, P926, DOI 10.2144/99275bm10; KOZAK RW, 1987, CELL IMMUNOL, V109, P318, DOI 10.1016/0008-8749(87)90315-7; KWOK TT, 1989, J NATL CANCER I, V81, P1020, DOI 10.1093/jnci/81.13.1020; LAVIN MF, 2000, NATURE CELL BIOL, V2, pE1; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Lee CT, 1996, CANCER RES, V56, P3038; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu XD, 1998, CANCER RES, V58, P5432; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nakamura S, 1997, EXP CELL RES, V235, P287, DOI 10.1006/excr.1997.3683; OLIVE PL, 1991, CANCER RES, V51, P4671; Pandita TK, 2000, ONCOGENE, V19, P1386, DOI 10.1038/sj.onc.1203444; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pietras RJ, 1999, CANCER RES, V59, P1347; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Ramsay J, 1998, BRIT J CANCER, V77, P11, DOI 10.1038/bjc.1998.2; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; ROFSTAD EK, 1992, INT J RADIAT ONCOL, V23, P63, DOI 10.1016/0360-3016(92)90544-R; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Savitsky K, 1997, NUCLEIC ACIDS RES, V25, P1678, DOI 10.1093/nar/25.9.1678; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SHILOH Y, 2001, IN PRESS COLD SPRING, V65; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; Tsuboi K, 1997, Brain Tumor Pathol, V14, P19, DOI 10.1007/BF02478864; Turner BC, 1997, CANCER RES, V57, P3079; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; VOJTESEK B, 1995, ONCOGENE, V10, P389; Wang H, 2000, ADV EXP MED BIOL, V465, P265; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Westphal CH, 1997, CANCER RES, V57, P1664; Whitesell L, 1999, METHODS, V18, P296, DOI 10.1006/meth.1999.0787; WOLLMAN R, 1994, INT J RADIAT ONCOL, V30, P91, DOI 10.1016/0360-3016(94)90523-1; Wouters BG, 1999, ONCOGENE, V18, P6540, DOI 10.1038/sj.onc.1203053; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zhang LJ, 1999, J BIOL CHEM, V274, P13118, DOI 10.1074/jbc.274.19.13118; Zhang N, 1998, ONCOGENE, V17, P811, DOI 10.1038/sj.onc.1202007; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	76	110	114	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4029	4040		10.1038/sj.onc.1204565	http://dx.doi.org/10.1038/sj.onc.1204565			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494131				2022-12-25	WOS:000169681500011
J	Schafer, K; Fujisawa, K; Konstantinides, S; Loskutoff, DJ				Schafer, K; Fujisawa, K; Konstantinides, S; Loskutoff, DJ			Disruption of the plasminogen activator inhibitor-1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice	FASEB JOURNAL			English	Article						obesity; insulin resistance; animal models; gene disruption; tumor necrosis factor alpha	TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA; POLYMERASE-CHAIN-REACTION; FACTOR-ALPHA; INSULIN-RESISTANCE; IN-VIVO; CELLULAR-LOCALIZATION; FIBRINOLYTIC-ACTIVITY; DEFICIENT MICE; MESSENGER-RNA	Elevated levels of plasma and adipose tissue plasminogen activator inhibitor-1 (PAI-1) are observed frequently in obese humans and rodents. In this report, genetically obese (ob/ob) mice lacking the PAI-1 gene (PAI-1(-/-)) were generated and then used to test the hypothesis that the presence of PAI-1 promotes the hyperglycemia, hyperinsulinemia, and insulin resistance associated with obesity. Both wild-type (WT) ob/ob and PAI-1(-/-) ob/ob mice developed substantial adiposity compared with their lean counterparts. However, the PAI-1(-/-) ob/ob mice weighed significantly less than the WT ob/ob mice, and their hyperglycemia and hyperinsulinemia improved significantly. Although intraperitoneal glucose administration resulted in a dramatic increase in serum insulin levels in WT ob/ob mice, the increase in PAI-1(-/-) ob/ob mice was relatively small. Reverse transcription polymerase chain reaction assays and in situ hybridization studies demonstrated that tumor necrosis factor alpha (TNF-alpha) mRNA expression increased significantly in the adipose tissue of WT ob/ob mice at most ages tested. However, it was not increased, or only mildly increased, in the adipose tissue of the PAI-1(-/-) ob/ob mice. The concentration and rate of secretion of TNF-alpha protein in adipose tissue from PAI-1(-/-) ob/ob mice also were significantly lower compared with their WT ob/ob counterparts as shown by immunohistochemistry and ELISA. These results suggest that PAI-1 contributes to the development of the characteristic hyperglycemia and hyperinsulinemia associated with murine obesity, possibly by facilitating increased adipose tissue TNF-alpha gene expression.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Univ Gottingen, Dept Cardiol, D-37075 Gottingen, Germany; Tokyo Metropolitan Bokutou Gen Hosp, Dept Endocrinol, Toshima Ku, Tokyo 170002, Japan	Scripps Research Institute; University of Gottingen	Loskutoff, DJ (corresponding author), Scripps Res Inst, Dept Vasc Biol, VB-3,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	loskutof@scripps.edu	Konstantinides, Stavros/AAL-3174-2021; Schäfer, Katrin/P-4728-2015	Konstantinides, Stavros/0000-0001-6359-7279; Schafer, Katrin/0000-0003-0846-4718				Alessi MC, 1997, DIABETES, V46, P860, DOI 10.2337/diabetes.46.5.860; ASPLUNDCARLSON A, 1993, DIABETOLOGIA, V36, P817, DOI 10.1007/BF00400356; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; CallesEscandon J, 1996, AM J CLIN NUTR, V64, P7, DOI 10.1093/ajcn/64.1.7; Carmassi F, 1999, AM J MED, V107, P344, DOI 10.1016/S0002-9343(99)00240-5; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; CHOY LN, 1992, J BIOL CHEM, V267, P12736; Chung WK, 1997, OBES RES, V5, P183, DOI 10.1002/j.1550-8528.1997.tb00291.x; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P2108, DOI 10.1210/jc.82.7.2108; EVERETT RM, 1983, MOUSE BIOMEDICAL RES; Fearns C, 1997, AM J PATHOL, V150, P579; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Glantz SA., 1997, PRIMER BIOSTATISTICS; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; *JACKS LAB, 1998, BOD WEIGHTS SEL STRA; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JOHNSON PR, 1972, J LIPID RES, V13, P2; JuhanVague I, 1997, THROMB HAEMOSTASIS, V78, P656; KEETON M, 1993, AM J PATHOL, V142, P59; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; LANDIN K, 1990, METABOLISM, V39, P1044, DOI 10.1016/0026-0495(90)90164-8; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; Lemne C, 1996, EUR J CLIN INVEST, V26, P692, DOI 10.1111/j.1365-2362.1996.tb02155.x; Lundgren CH, 1996, CIRCULATION, V93, P106, DOI 10.1161/01.CIR.93.1.106; MCGILL JB, 1994, DIABETES, V43, P104, DOI 10.2337/diabetes.43.1.104; Morange PE, 2000, ARTERIOSCL THROM VAS, V20, P1150, DOI 10.1161/01.ATV.20.4.1150; Morange PE, 1999, DIABETES, V48, P890, DOI 10.2337/diabetes.48.4.890; MURRAY LJ, 1990, EUR J IMMUNOL, V20, P163, DOI 10.1002/eji.1830200124; PLATZER C, 1992, EUR J IMMUNOL, V22, P1179, DOI 10.1002/eji.1830220511; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Samad F, 1997, MOL MED, V3, P37, DOI 10.1007/BF03401666; Samad F, 1999, P NATL ACAD SCI USA, V96, P6902, DOI 10.1073/pnas.96.12.6902; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Samad F, 1996, MOL MED, V2, P568, DOI 10.1007/BF03401641; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; Schreyer SA, 1998, J CLIN INVEST, V102, P402, DOI 10.1172/JCI2849; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; VAGUE P, 1986, METABOLISM, V35, P250, DOI 10.1016/0026-0495(86)90209-X; VANLOON BJP, 1993, METABOLISM, V42, P945, DOI 10.1016/0026-0495(93)90005-9	53	154	161	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1840	+		10.1096/fj.00-0750fje	http://dx.doi.org/10.1096/fj.00-0750fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481248				2022-12-25	WOS:000169261200011
J	Muthalif, MM; Hefner, Y; Canaan, S; Harper, J; Zhou, HL; Parmentier, JH; Aebersold, R; Gelb, MH; Malik, KU				Muthalif, MM; Hefner, Y; Canaan, S; Harper, J; Zhou, HL; Parmentier, JH; Aebersold, R; Gelb, MH; Malik, KU			Functional interaction of calcium-/calmodulin-dependent protein kinase II and cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ARACHIDONIC-ACID RELEASE; PHOSPHORYLATION SITES; NUCLEAR-ENVELOPE; HUMAN PLATELETS; MAP KINASE; ACTIVATION; TRANSLOCATION; IDENTIFICATION; MECHANISMS	Calcium-/calmodulin-dependent protein kinase II (CaM kinase II), a decoder of Ca2+ signals, and cytosolic phospholipase A(2) (cPLA(2)), an enzyme involved in arachidonate release, are involved in many physiological and pathophysiological processes. Activation of CaM kinase Il in norepinephrine-stimulated vascular smooth muscle cells leads to activation of cPLA(2) and arachidonic acid release. Surface plasmon resonance, mass spectrometry, and kinetic studies show that CaM kinase II binds to cPLA(2) resulting in cPLA(2) phosphorylation on Ser-515 and an increase in its enzymatic activity. Phosphopeptide mapping studies with cPLA(2) from norepinephrine-stimulated smooth muscle cells indicates that phosphorylation of cPLA(2) on Ser-515, but not on Ser-505 or Ser-727, occurs in vivo. This novel signaling pathway for arachidonate release is shown to be cPLA(2)-dependent by use of a recently described and highly selective inhibitor of this enzyme.	Univ Tennessee, Coll Med, Hlth Sci Ctr, 3ept Pharmacol, Memphis, TN 38163 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Inst Syst Biol, Seattle, WA 98105 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Institute for Systems Biology (ISB)	Gelb, MH (corresponding author), Univ Tennessee, Coll Med, Hlth Sci Ctr, Dept Pharmacol, Memphis, TN 38163 USA.	gelb@chem.washington.edu; kmalik@utmem.edu		gelb, michael/0000-0001-7000-5219	NCI NIH HHS [R33 CA84698] Funding Source: Medline; NHLBI NIH HHS [HL50040] Funding Source: Medline; NIAID NIH HHS [AI41109-01] Funding Source: Medline; PHS HHS [19134-26] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA084698] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Elgersma Y, 1999, CURR OPIN NEUROBIOL, V9, P209, DOI 10.1016/S0959-4388(99)80029-4; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Feinmesser RL, 1999, J BIOL CHEM, V274, P16168, DOI 10.1074/jbc.274.23.16168; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Handlogten ME, 2001, J BIOL CHEM, V276, P13941, DOI 10.1074/jbc.M007306200; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; LESLIE CC, 1990, METHOD ENZYMOL, V187, P216; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Muthalif MM, 1998, J PHARMACOL EXP THER, V284, P388; Muthalif MM, 1998, P NATL ACAD SCI USA, V95, P12701, DOI 10.1073/pnas.95.21.12701; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; NAFELSKI EA, 1994, J BIOL CHEM, V269, P18239; NEBIGIL C, 1992, J PHARMACOL EXP THER, V260, P849; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Seno K, 2000, J MED CHEM, V43, P1041, DOI 10.1021/jm9905155; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622	37	81	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39653	39660		10.1074/jbc.M103136200	http://dx.doi.org/10.1074/jbc.M103136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11479288	hybrid			2022-12-25	WOS:000171789200021
J	Aitsebaomo, J; Kingsley-Kallesen, ML; Wu, YX; Quertermous, T; Patterson, C				Aitsebaomo, J; Kingsley-Kallesen, ML; Wu, YX; Quertermous, T; Patterson, C			Vezf1/DB1 is an endothelial cell-specific transcription factor that regulates expression of the endothelia-1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; VASCULAR DEVELOPMENT; FUNCTIONAL-ANALYSIS; SCL GENE; PROTEIN; MICE; BINDING; VASCULOGENESIS; KDR/FLK-1; SP1	Coordinated gene regulation within the vascular endothelium is required for normal cardiovascular patterning during development and for vascular homeostasis during adulthood, yet little is known about the mechanisms that regulate endothelial transcriptional events. Vascular endothelial zinc finger 1 (Vezf1)/DB1 is a recently identified zinc finger-containing protein that is expressed specifically within endothelial cells during development. In this report, we demonstrate that Vezf1/ DB1 is a nuclear localizing protein that potently and specifically activates transcription mediated by the human endothelin-1 promoter, in a Tax-independent manner, in transient transfection assays. Using a combination of deletion mutagenesis and electrophoretic mobility shift assays, a novel Vezf1/DB1-responsive element was localized to a 6-base pair (bp) motif, ACCCCC, located 47 by upstream of the endothelin-1 transcription start site. Recombinant Vezf1/DB1 also bound to this sequence, and a 2-by mutation in this element abolished Vezf1/DB1 responsiveness by the endothelin-1 promoter. Vezf1/DB1 could be identified with a specific antibody in nuclear complexes from endothelial cells that bound to this element. Regulation of endothelin-1 promoter activity by Vezf1/DB1 provides a mechanism for endothelin-1 expression in the vascular endothelium during development and to maintain vascular tone; Vezf1/DB1 itself is a candidate transcription factor for modifying endothelial cell phenotypes in order to appropriately assemble and maintain the cardiovascular system.	Univ N Carolina, Div Cardiol, Program Mol Cardiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ Texas, Med Branch, Sealy Ctr Mol Cardiol, Galveston, TX 77555 USA; Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Palo Alto, CA 94305 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Medical Branch Galveston; Stanford University	Patterson, C (corresponding author), Univ N Carolina, Div Cardiol, Program Mol Cardiol, 324 Burnett Womack Bldg, Chapel Hill, NC 27599 USA.			Quertermous, Thomas/0000-0002-7645-9067	NHLBI NIH HHS [HL03658, HL61656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003658, R01HL061656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Griendling KK, 1996, FASEB J, V10, P283, DOI 10.1096/fasebj.10.2.8641561; HARATS D, 1995, J CLIN INVEST, V95, P1335, DOI 10.1172/JCI117784; Her S, 1999, J BIOL CHEM, V274, P8698, DOI 10.1074/jbc.274.13.8698; Hernandez-Perera O, 2000, CIRC RES, V87, P616, DOI 10.1161/01.RES.87.7.616; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; Kappel A, 2000, BLOOD, V96, P3078; KAWANA M, 1995, MOL CELL BIOL, V15, P42256; KOYANONAKAGAWA N, 1994, MOL CELL BIOL, V14, P5099, DOI 10.1128/MCB.14.8.5099; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Lebowitz PF, 1998, CELL ADHES COMMUN, V6, P277, DOI 10.3109/15419069809010787; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE ME, 1991, J BIOL CHEM, V266, P19034; MILLER WL, 1989, J CLIN INVEST, V83, P317, DOI 10.1172/JCI113876; Minami T, 2001, J BIOL CHEM, V276, P5395, DOI 10.1074/jbc.M008798200; NISHIDA J, 1991, INT IMMUNOL, V3, P245, DOI 10.1093/intimm/3.3.245; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Owens GK, 1998, ACTA PHYSIOL SCAND, V164, P623, DOI 10.1111/j.1365-201X.1998.tb10706.x; Parks CL, 1996, J BIOL CHEM, V271, P4417; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; PLENDL J, 1993, IN VITRO CELL DEV-AN, V29A, P25; Porcher C, 1999, DEVELOPMENT, V126, P4603; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Serneri GGN, 2000, CIRC RES, V86, P377, DOI 10.1161/01.RES.86.4.377; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Thomas T, 1998, DEVELOPMENT, V125, P3005; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Wu YX, 1999, J BIOL CHEM, V274, P3207, DOI 10.1074/jbc.274.5.3207; Xiong JW, 1999, DEV BIOL, V206, P123, DOI 10.1006/dbio.1998.9144; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	40	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39197	39205		10.1074/jbc.M105166200	http://dx.doi.org/10.1074/jbc.M105166200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504723	hybrid			2022-12-25	WOS:000171673200114
J	Akiyama, TE; Nicol, CJ; Fievet, C; Staels, B; Ward, JM; Auwerx, J; Lee, SST; Gonzalez, FJ; Peters, JM				Akiyama, TE; Nicol, CJ; Fievet, C; Staels, B; Ward, JM; Auwerx, J; Lee, SST; Gonzalez, FJ; Peters, JM			Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity - Studies with congenic mouse lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; PPAR-ALPHA; GENE-EXPRESSION; DEFICIENT MICE; TARGETED DISRUPTION; ADAPTIVE RESPONSE; TRANSGENIC MICE; BILE-ACID; NULL MICE; KAPPA-B	Considerable controversy exists in determining the role of peroxisome proliferator-activated receptor-a (PPAR alpha) in obesity. Two purebred congenic strains of PPAR alpha -null mice were developed to study the role of this receptor in modulating lipid transport and storage. Weight gain and average body weight in wild-type and PPAR alpha -null mice on either an Sv/129 or a C57BL/6N background were not markedly different between genotypes from 3 to 9 months of age. However, gonadal adipose stores were significantly greater in both strains of male and female PPAR alpha -null mice. Hepatic accumulation of lipids was greater in both strains and sexes of PPAR alpha -null mice compared with wild-type controls. Administration of the peroxisome proliferator WY-14643 caused hepatomegaly, alterations in mRNAs encoding proteins that regulate lipid metabolism, and reduced serum triglycerides in a PPAR alpha -dependent mechanism. Constitutive differences in serum cholesterol and triglycerides in PPAR alpha -null mice were found between genetic backgrounds. Results from this work establish that PPAR alpha is a critical modulator of lipid homeostasis in two congenic mouse lines. This study demonstrates that disruption of the murine gene encoding PPAR alpha results in significant alterations in constitutive serum, hepatic, and adipose tissue lipid metabolism. However, an overt, obese phenotype in either of the two congenic strains was not observed. In contrast to earlier published work, this study establishes that PPAR alpha is not associated with obesity in mice.	Penn State Univ, Dept Vet Sci, Ctr Mol Toxicol, University Pk, PA 16802 USA; NCI, Met Lab, NIH, Bethesda, MD 20892 USA; Inst Pasteur, INSERM, Dept Atherosclerose, F-59019 Lille, France; NCI, Vet & Tumour Pathol Sect, Off Lab Anim Resources, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA; Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67400 Illkirch Graffenstaden, France; Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Chinese University of Hong Kong	Peters, JM (corresponding author), Penn State Univ, Dept Vet Sci, Ctr Mol Toxicol, 226 Fenske Lab, University Pk, PA 16802 USA.	jmp21@psu.edu	Staels, Bart/N-9497-2016; Peters, Jeffrey/D-8847-2011	Staels, Bart/0000-0002-3784-1503; Auwerx, Johan/0000-0002-5065-5393; Peters, Jeffrey/0000-0003-2782-2998				Anderson SP, 1999, MOL CARCINOGEN, V26, P226, DOI 10.1002/(SICI)1098-2744(199912)26:4<226::AID-MC2>3.0.CO;2-Q; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Assmann G, 1999, ARTERIOSCL THROM VAS, V19, P1819, DOI 10.1161/01.ATV.19.8.1819; Barclay TB, 1999, J PHARMACOL EXP THER, V290, P1250; Belury MA, 1998, TOXICOL APPL PHARM, V151, P254, DOI 10.1006/taap.1998.8443; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Casas F, 2000, FEBS LETT, V482, P71, DOI 10.1016/S0014-5793(00)02023-8; Corton JC, 1998, MOL PHARMACOL, V54, P463, DOI 10.1124/mol.54.3.463; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Djouadi F, 1999, PROSTAG LEUKOTR ESS, V60, P339, DOI 10.1016/S0952-3278(99)80009-X; Edgar AD, 1998, TOXICOL LETT, V98, P13, DOI 10.1016/S0378-4274(98)00042-3; Fan LQ, 1998, J ENDOCRINOL, V158, P237, DOI 10.1677/joe.0.1580237; Fourcade S, 2001, EUR J BIOCHEM, V268, P3490, DOI 10.1046/j.1432-1327.2001.02249.x; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; Gonzalez FJ, 1997, ADV EXP MED BIOL, V422, P109; Gueraud F, 1999, J LIPID RES, V40, P152; Guidotti LG, 1999, J VIROL, V73, P10377, DOI 10.1128/JVI.73.12.10377-10386.1999; Hanley K, 2000, J BIOL CHEM, V275, P11484, DOI 10.1074/jbc.275.15.11484; Hashimoto T, 2000, J BIOL CHEM, V275, P28918, DOI 10.1074/jbc.M910350199; Hunt MC, 2000, J LIPID RES, V41, P814; Hunt MC, 2000, J BIOL CHEM, V275, P28947, DOI 10.1074/jbc.M002782200; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kockx M, 1999, BLOOD, V93, P2991; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; Le May C, 2000, FEBS LETT, V475, P163, DOI 10.1016/S0014-5793(00)01648-3; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Louet JF, 2001, BIOCHEM J, V354, P189, DOI 10.1042/0264-6021:3540189; Motojima K, 1997, BIOCHEM BIOPH RES CO, V230, P155, DOI 10.1006/bbrc.1996.5906; Nakajima T, 2000, CARCINOGENESIS, V21, P677, DOI 10.1093/carcin/21.4.677; PAPAIOANNOU V, 1993, GENE TARGETING PRACT, P106; Patel DD, 2001, J LIPID RES, V42, P328; Peters JM, 1998, CARCINOGENESIS, V19, P1989, DOI 10.1093/carcin/19.11.1989; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; Peters JM, 1996, MOL PHARMACOL, V50, P67; Peters JM, 1997, TERATOLOGY, V56, P311, DOI 10.1002/(SICI)1096-9926(199711)56:5<311::AID-TERA4>3.0.CO;2-#; Poirier H, 2001, BIOCHEM J, V355, P481, DOI 10.1042/0264-6021:3550481; POLAND A, 1990, MOL PHARMACOL, V38, P306; POLAND A, 1994, MOL PHARMACOL, V46, P915; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Turunen M, 2000, J MOL BIOL, V297, P607, DOI 10.1006/jmbi.2000.3596; Vanden Heuvel JP, 1998, TOXICOL APPL PHARM, V152, P107, DOI 10.1006/taap.1998.8478; Ward JM, 1998, TOXICOL PATHOL, V26, P240, DOI 10.1177/019262339802600208; Watanabe K, 2000, J BIOL CHEM, V275, P22293, DOI 10.1074/jbc.M000248200	54	113	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39088	39093		10.1074/jbc.M107073200	http://dx.doi.org/10.1074/jbc.M107073200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495927	hybrid			2022-12-25	WOS:000171673200099
J	Alley, SC; Trakselis, MA; Mayer, MU; Ishmael, FT; Jones, AD; Benkovic, SJ				Alley, SC; Trakselis, MA; Mayer, MU; Ishmael, FT; Jones, AD; Benkovic, SJ			Building a replisome solution structure by elucidation of protein-protein interactions in the bacteriophage T4 DNA polymerise holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; C-TERMINAL REGION; SLIDING CLAMP; REPLICATION FORK; PROCESSIVITY FACTOR; CRYSTAL-STRUCTURE; CARBOXYL-TERMINUS; CATALYTIC SUBUNIT; III HOLOENZYME; COMPLEX	Assembly of DNA replication systems requires the coordinated actions of many proteins. The multiprotein complexes formed as intermediates on the pathway to the final DNA polymerase holoenzyme have been shown to have distinct structures relative to the ground-state structures of the individual proteins. By using a variety of solution-phase techniques, we have elucidated additional information about the solution structure of the bacteriophage T4 holoenzyme. Photocross-linking and mass spectrometry were used to demonstrate interactions between I107C of the sliding clamp and the DNA polymerase. Fluorescence resonance energy transfer, analytical ultracentrifugation, and isothermal titration calorimetry measurements were used to demonstrate that the C terminus of the DNA polymerase can interact at two distinct locations on the sliding clamp. Both of these binding modes may be used during holoenzyme assembly, but only one of these binding modes is found in the final holoenzyme. Present and previous solution interaction data were used to build a model of the holoenzyme that is consistent with these data.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, Hershey Med Ctr, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, 414 Wartik Lab, University Pk, PA 16802 USA.		Jones, Arthur D/C-2670-2013; Trakselis, Michael/V-3806-2019	Jones, A. Daniel/0000-0002-7408-6690; Trakselis, Michael/0000-0001-7054-8475	NIDDK NIH HHS [DK19691] Funding Source: Medline; NIGMS NIH HHS [GM13306, GM19492] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK019691, R01DK019691, R37DK019691] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alley SC, 1999, J BIOL CHEM, V274, P24485, DOI 10.1074/jbc.274.35.24485; Alley SC, 2000, BIOCHEMISTRY-US, V39, P3076, DOI 10.1021/bi992377r; Alley SC, 1999, BIOCHEMISTRY-US, V38, P7696, DOI 10.1021/bi9827971; Alley SC, 2000, J AM CHEM SOC, V122, P6126, DOI 10.1021/ja000591t; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; Berdis AJ, 1996, P NATL ACAD SCI USA, V93, P12822, DOI 10.1073/pnas.93.23.12822; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; Bridges KG, 2000, J BIOL CHEM, V275, P472, DOI 10.1074/jbc.275.1.472; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HASS E, 1978, BIOCHEMISTRY-US, V17, P5064; Herendeen DR, 1996, CELL, V84, P5, DOI 10.1016/S0092-8674(00)80069-0; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; JONSSON ZO, 1995, EMBO J, V14, P5745, DOI 10.1002/j.1460-2075.1995.tb00261.x; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P9515, DOI 10.1073/pnas.96.17.9515; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Latham GJ, 1996, J MOL BIOL, V264, P426, DOI 10.1006/jmbi.1996.0651; Leipe DD, 1999, NUCLEIC ACIDS RES, V27, P3389, DOI 10.1093/nar/27.17.3389; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NOSSAL NG, 1979, J BIOL CHEM, V254, P6026; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; Pietroni P, 1997, J BIOL CHEM, V272, P31666, DOI 10.1074/jbc.272.50.31666; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; RUSH J, 1989, J BIOL CHEM, V264, P10943; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; Sanders GM, 1997, EMBO J, V16, P3124, DOI 10.1093/emboj/16.11.3124; Schumacher SB, 2000, NUCLEIC ACIDS RES, V28, P620, DOI 10.1093/nar/28.2.620; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Sexton DJ, 1996, J BIOL CHEM, V271, P28045, DOI 10.1074/jbc.271.45.28045; Sexton DJ, 1997, CURR OPIN CHEM BIOL, V1, P316, DOI 10.1016/S1367-5931(97)80068-3; Sexton DJ, 1998, BIOCHEMISTRY-US, V37, P7749, DOI 10.1021/bi980088h; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Soumillion P, 1998, BIOCHEMISTRY-US, V37, P1819, DOI 10.1021/bi972526a; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Trakselis MA, 2001, P NATL ACAD SCI USA, V98, P8368, DOI 10.1073/pnas.111006698; Von Hippel PH, 2000, TRENDS BIOCHEM SCI, V25, P155, DOI 10.1016/S0968-0004(00)01571-1; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WANG CC, 1995, J BIOL CHEM, V270, P26558, DOI 10.1074/jbc.270.44.26558; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; ZHANG SJ, 1995, J BIOL CHEM, V270, P7988, DOI 10.1074/jbc.270.14.7988; Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0	51	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39340	39349		10.1074/jbc.M104956200	http://dx.doi.org/10.1074/jbc.M104956200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504721	hybrid			2022-12-25	WOS:000171673200133
J	Chiba, N; Parvin, JD				Chiba, N; Parvin, JD			Redistribution of BRCA1 among four different protein complexes following replication blockage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II HOLOENZYME; DNA-DAMAGE RESPONSE; INTERACT IN-VIVO; GENE-EXPRESSION; MEIOTIC CELLS; TRANSCRIPTION; CANCER; ASSOCIATION; ACTIVATION; REPAIR	The BRCA1 protein is known to participate in multiple cellular processes. In these experiments, we resolved four distinct BRCA1-containing complexes. We found BRCA1 associated with the RNA polymerase II holoenzyme (holo-pol), a large mass complex called the fraction 5 complex, the Rad50-Mre11-Nbs1 complex, and a complex that has not been described previously. We observed this new complex after treating cells with hydroxyurea, suggesting that the hydroxyurea-induced complex (HUIC) is involved with the response to DNA replication blockage. After hydroxyurea treatment of cells, BRCA1 content decreased in the holo-pol and the fraction 5 complex, and BRCA1 was redistributed to the HUIC. The HUIC was shown not to contain a number of holo-pol components or the Rad50-Mre11-Nbs1 complex but was associated with the BRCA1-associated RING domain protein BARD1. These data suggest that BRCA1 participates in multiple cellular processes by multiple protein complexes and that the BRCA1 content of these complexes is dynamically altered after DNA replication blockage.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Parvin, JD (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.		Parvin, Jeffrey D/C-8955-2009					Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Cho H, 1997, J BIOL CHEM, V272, P11495; Deng CX, 2000, BIOESSAYS, V22, P728; EASTON DF, 1993, AM J HUM GENET, V52, P678; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Parvin JD, 2001, P NATL ACAD SCI USA, V98, P5952, DOI 10.1073/pnas.121184998; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Venkitaraman Ashok R., 2000, Biochimica et Biophysica Acta, V1470, pR41, DOI 10.1016/S0304-419X(00)00007-X; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Y, 2000, GENE DEV, V14, P927; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	35	51	54	3	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38549	38554		10.1074/jbc.M105227200	http://dx.doi.org/10.1074/jbc.M105227200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504724	hybrid			2022-12-25	WOS:000171673200031
J	Fukumoto, T; Watanabe-Fukunaga, R; Fujisawa, K; Nagata, S; Fukunaga, R				Fukumoto, T; Watanabe-Fukunaga, R; Fujisawa, K; Nagata, S; Fukunaga, R			The fused protein kinase regulates Hedgehog-stimulated transcriptional activation in Drosophila Schneider 2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUBITUS-INTERRUPTUS PROTEIN; SERINE-THREONINE KINASE; KINESIN-RELATED PROTEIN; TARGET GENE-EXPRESSION; SIGNAL-TRANSDUCTION; SUBCELLULAR-LOCALIZATION; POSTERIOR COMPARTMENT; NEGATIVE REGULATOR; REPRESSOR FORMS; FACTOR-RECEPTOR	The Drosophila segment polarity gene fused encodes a putative protein-serine/threonine kinase, and plays a critical role in the signal transduction for Hedgehog (Hh)-dependent gene expression. We show that the Drosophila Schneider 2 (S2) cell line has the potential to transduce the Hh-triggered intracellular signals, leading to the activation of target gene expression, when a transcription factor, Cubitus interruptus (Ci), is provided exogenously. Using S2 cells transfected with the Ci-expressing plasmid and a patched promoter reporter construct, we demonstrate that the forced expression of Fused (Fu) stimulates Hh-triggered and Ci-dependent transcriptional activation. The N-terminal kinase domain of Fu is required for this activity, but the C-terminal domain is not. Two kinase-inactive Fu mutants fail to enhance the reporter activation, indicating that the kinase catalytic activity is essential for this function. Negative components of the Hh-signaling pathway, Costal-2 and Suppressor of Fused, strongly antagonize the Fu activity, irrespective of the presence or absence of the Fu C-terminal domain, suggesting an indirect mechanism for the inhibition of Fu by these proteins. Furthermore, mutational analyses of threonine 158 and serine 159, in the activation segment of the Fu protein kinase, indicate that threonine 158 is essential for Fu activity and that phosphorylation of this threonine residue may be involved in the activation of the kinase catalytic activity upon Hh stimulation.	Osaka Univ, Sch Med, Dept Genet, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Fukunaga, R (corresponding author), Osaka Univ, Sch Med, Dept Genet, B-3,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Nagata, Shigekazu/AAG-3203-2019; Fukunaga, Rikiro/CAG-2891-2022	Nagata, Shigekazu/0000-0001-9758-8426; 				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alves G, 1998, MECH DEVELOP, V78, P17, DOI 10.1016/S0925-4773(98)00130-0; ANGELICHIO ML, 1991, NUCLEIC ACIDS RES, V19, P5037, DOI 10.1093/nar/19.18.5037; Aza-Blanc P, 1999, TRENDS GENET, V15, P458, DOI 10.1016/S0168-9525(99)01869-7; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; Chen Y, 1999, DEVELOPMENT, V126, P3607; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Kondo T, 1997, P NATL ACAD SCI USA, V94, P11951, DOI 10.1073/pnas.94.22.11951; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Mann RK, 2000, BBA-MOL CELL BIOL L, V1529, P188, DOI 10.1016/S1388-1981(00)00148-7; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Methot N, 2000, DEVELOPMENT, V127, P4001; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Mukae N, 2000, J BIOL CHEM, V275, P21402, DOI 10.1074/jbc.M909611199; Murone M, 2000, NAT CELL BIOL, V2, P310, DOI 10.1038/35010610; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; PHAM A, 1995, GENETICS, V140, P587; PREAT T, 1993, GENETICS, V135, P1047; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; Price MA, 1999, DEVELOPMENT, V126, P4331; Ramirez-Weber FA, 2000, MOL CELL, V6, P479, DOI 10.1016/S1097-2765(00)00046-0; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; SLUSARSKI DC, 1995, GENETICS, V139, P229; Stegman MA, 2000, J BIOL CHEM, V275, P21809, DOI 10.1074/jbc.C000043200; Stone DM, 1999, J CELL SCI, V112, P4437; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; Therond P, 1996, GENETICS, V142, P1181; Therond PP, 1999, DEVELOPMENT, V126, P4039; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Wang GL, 2000, GENE DEV, V14, P2893, DOI 10.1101/gad.843900; Wang GL, 1999, GENE DEV, V13, P2828, DOI 10.1101/gad.13.21.2828; Wang QT, 2000, DEVELOPMENT, V127, P3131; Wang QT, 1999, DEVELOPMENT, V126, P5097	53	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38441	38448		10.1074/jbc.M105871200	http://dx.doi.org/10.1074/jbc.M105871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495917	hybrid			2022-12-25	WOS:000171673200017
J	Gorman, JJ; Mckimm-Breschkin, JL; Norton, RS; Barnham, KJ				Gorman, JJ; Mckimm-Breschkin, JL; Norton, RS; Barnham, KJ			Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE ANALYSIS; CENTRAL CONSERVED REGION; G-PROTEIN; SUBGROUP-B; ENVELOPE GLYCOPROTEINS; ANTIGENIC STRUCTURE; O-GLYCOSYLATION; ESCAPE MUTANTS; CELL-FUSION; INFECTION	Segments of the cystine noose-containing nonglycosylated central subdomain, residues 149-197, of the attachment (G) glycoprotein of human respiratory syncytial virus (HRSV) have been assessed for impact on the cytopathic effect (CPE) of respiratory syncytial virus (RSV). N alpha -acetyl residues 149-197-amide (G149-197), 6149-189, and 6149-177 of the A2 strain of HRSV protected 50% of human epithelial HEp-2 cells from the CPE of the A2 strain at concentrations (IC50) between 5 and 80 muM. Cystine noose-containing peptides G171-197 and G173-197 did not inhibit the CPE even at concentrations above 150 muM. Systematic C- and N-terminal truncations from 6149-189 and 6149-177 and alanine substitutions within G154-177 demonstrated that residues 166-170 (EVFNF), within a sequence that is conserved in HRSV strains, were critical for inhibition. Concordantly, G154-177 of bovine RSV and of an antibody escape mutant of HRSV with residues 166-170 of QTLPY and EVSNP, respectively, were not inhibitory. Surprisingly, a variant of G154-177 with an E166A substitution had an IC50 of 750 nm. NMR analysis demonstrated that G149-177 adopted a well-defined conformation in solution, clustered around F168 and F170. G154-170, particularly EVFNF, may be important in binding of RSV to host cells. These findings constitute a promising platform for the development of antiviral agents for RSV.	Biomol Res Inst, Parkville, Vic 3052, Australia		Gorman, JJ (corresponding author), CSIRO Hlth Sci & Nutr, 343 Royal Parade, Parkville, Vic 3052, Australia.		McKimm-Breschkin, Jennifer L/D-1880-2013	McKimm-Breschkin, Jennifer/0000-0002-2345-6786; Norton, Raymond/0000-0001-8893-0584				AKERLINDSTOPNER B, 1990, J VIROL, V64, P5143, DOI 10.1128/JVI.64.10.5143-5148.1990; ALANSARI H, 1993, VIROLOGY, V196, P873, DOI 10.1006/viro.1993.1549; Barnham KJ, 1998, PROTEIN SCI, V7, P1738, DOI 10.1002/pro.5560070808; Bastien N, 1997, VIROLOGY, V234, P118, DOI 10.1006/viro.1997.8632; CANE PA, 1991, J GEN VIROL, V72, P2091, DOI 10.1099/0022-1317-72-9-2091; CHOPPIN PW, 1980, REV INFECT DIS, V2, P40; COLLINS PL, 1992, J GEN VIROL, V73, P849, DOI 10.1099/0022-1317-73-4-849; Collins PL, 1996, FIELDS VIROLOGY, P1313; COLLINS PL, 1991, PARAMYXOVIRUSES, P103; Doreleijers JF, 1996, BIOCHEMISTRY-US, V35, P14684, DOI 10.1021/bi9621627; Feldman SA, 2000, J VIROL, V74, P6442, DOI 10.1128/JVI.74.14.6442-6447.2000; Feldman SA, 1999, J VIROL, V73, P6610, DOI 10.1128/JVI.73.8.6610-6617.1999; GARCIA O, 1994, J VIROL, V68, P5448; Gorman JJ, 1997, PROTEIN SCI, V6, P1308, DOI 10.1002/pro.5560060619; GRUBER C, 1985, J GEN VIROL, V66, P417, DOI 10.1099/0022-1317-66-3-417; Hallak LK, 2000, VIROLOGY, V271, P264, DOI 10.1006/viro.2000.0293; Hallak LK, 2000, J VIROL, V74, P10508, DOI 10.1128/JVI.74.22.10508-10513.2000; HEILMAN CA, 1990, J INFECT DIS, V161, P402, DOI 10.1093/infdis/161.3.402; HEMINWAY BR, 1994, VIROLOGY, V200, P801, DOI 10.1006/viro.1994.1245; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JOHNSON PR, 1987, P NATL ACAD SCI USA, V84, P5625, DOI 10.1073/pnas.84.16.5625; Karger A, 2001, J GEN VIROL, V82, P631, DOI 10.1099/0022-1317-82-3-631; Karron RA, 1997, P NATL ACAD SCI USA, V94, P13961, DOI 10.1073/pnas.94.25.13961; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krusat T, 1997, ARCH VIROL, V142, P1247, DOI 10.1007/s007050050156; LAMBERT DM, 1988, VIROLOGY, V164, P458, DOI 10.1016/0042-6822(88)90560-0; LAMBERT DM, 1983, VIROLOGY, V130, P204, DOI 10.1016/0042-6822(83)90128-9; Langedijk JPM, 1998, VIROLOGY, V243, P293, DOI 10.1006/viro.1998.9066; Langedijk JPM, 1996, J GEN VIROL, V77, P1249, DOI 10.1099/0022-1317-77-6-1249; Langedijk JPM, 1997, J VIROL, V71, P4055, DOI 10.1128/JVI.71.5.4055-4061.1997; LAPTHORN AJ, 1995, NAT STRUCT BIOL, V2, P266, DOI 10.1038/nsb0495-266; LERCH RA, 1990, J VIROL, V64, P5559, DOI 10.1128/JVI.64.11.5559-5569.1990; LEVIN MJ, 1994, J PEDIATR-US, V124, pS22, DOI 10.1016/S0022-3476(94)70187-3; LEVINE S, 1987, J GEN VIROL, V68, P2521, DOI 10.1099/0022-1317-68-9-2521; MARKWELL MAK, 1991, PARAMYXOVIRUSES, P407; Martinez I, 2000, J GEN VIROL, V81, P2715, DOI 10.1099/0022-1317-81-11-2715; MCINTOSH K, 1990, VIROLOGY, P1045; Melero JA, 1997, J GEN VIROL, V78, P2411, DOI 10.1099/0022-1317-78-10-2411; MORRISON T, 1991, PARAMYXOVIRUSES, P347; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NORRBY E, 1987, P NATL ACAD SCI USA, V84, P6572, DOI 10.1073/pnas.84.18.6572; PALLAGHY PK, 1993, J MOL BIOL, V234, P405, DOI 10.1006/jmbi.1993.1595; Pastey MK, 1997, J GEN VIROL, V78, P1885, DOI 10.1099/0022-1317-78-8-1885; Power UF, 1997, VIROLOGY, V230, P155, DOI 10.1006/viro.1997.8465; RICHMAN AV, 1971, APPL MICROBIOL, V21, P1099, DOI 10.1128/AEM.21.6.1099-1100.1971; RUEDA P, 1994, VIROLOGY, V198, P653, DOI 10.1006/viro.1994.1077; SATAKE M, 1985, NUCLEIC ACIDS RES, V13, P7795, DOI 10.1093/nar/13.21.7795; Simard C, 1995, ANTIVIR RES, V28, P303, DOI 10.1016/0166-3542(95)00053-4; Simard C, 1997, VACCINE, V15, P423, DOI 10.1016/S0264-410X(97)00189-8; Sullender WM, 1999, VIROLOGY, V264, P230, DOI 10.1006/viro.1999.9987; SULLENDER WM, 1990, VIROLOGY, V178, P195, DOI 10.1016/0042-6822(90)90394-7; SULLENDER WM, 1991, J VIROL, V65, P5425, DOI 10.1128/JVI.65.10.5425-5434.1991; SULLENDER WM, 1991, PARAMYXOVIRUSES, P383; Teng MN, 1998, J VIROL, V72, P5707, DOI 10.1128/JVI.72.7.5707-5716.1998; TRUDEL M, 1991, VIROLOGY, V185, P749, DOI 10.1016/0042-6822(91)90546-N; VANGEET AL, 1970, ANAL CHEM, V42, P679, DOI 10.1021/ac60288a022; Walsh EE, 1998, J GEN VIROL, V79, P479, DOI 10.1099/0022-1317-79-3-479; WALSH EE, 1984, J GEN VIROL, V65, P761, DOI 10.1099/0022-1317-65-4-761; WERTZ GW, 1989, J VIROL, V63, P4767, DOI 10.1128/JVI.63.11.4767-4776.1989; WERTZ GW, 1985, P NATL ACAD SCI USA, V82, P4075, DOI 10.1073/pnas.82.12.4075; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wuthrich K, 1986, NMR PROTEINS NUCL AC; [No title captured]	64	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38988	38994		10.1074/jbc.M106288200	http://dx.doi.org/10.1074/jbc.M106288200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11487583	hybrid			2022-12-25	WOS:000171673200087
J	Karsdal, MA; Fjording, MS; Foged, NT; Delaisse, JM; Lochter, A				Karsdal, MA; Fjording, MS; Foged, NT; Delaisse, JM; Lochter, A			Transforming growth factor-beta-induced osteoblast elongation regulates osteoclastic bone resorption through a p38 mitogen-activated protein kinase- and matrix metalloproteinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATENT TGF-BETA; SIGNAL-TRANSDUCTION; MAP KINASE; EPITHELIAL-CELLS; IN-VITRO; CHEMOTACTIC RESPONSE; GENE-EXPRESSION; DIFFERENTIATION; IDENTIFICATION; PHENOTYPE	Transforming growth factor-beta (TGF-beta) is a powerful modulator of bone metabolism, and both its anabolic and catabolic effects on bone have been described. Here we have tested the hypothesis that TGF-beta -induced changes in osteoblast shape promote bone resorption by increasing the surface area of bone that is accessible to osteoclasts. The addition of TGF-beta1 to MC3T3-E1 cells resulted in cytoskeletal reorganization, augmented expression of focal adhesion kinase, and cell elongation, accompanied by an increase in the area of cell-free substratum. TGF-beta1 also triggered activation of Erk1/2 and p38 mitogen-activated protein (MAP) kinase. The p38 MAP kinase inhibitor PD169316, but not an inhibitor of the Erk1/2 pathway, abrogated the effect of TGF-beta1 on cell shape. The matrix metalloproteinase inhibitor GM6001 also interfered with osteoblast elongation. Treatment of MC3T3-E1 cells seeded at confluence onto bone slices to mimic a bone lining cell layer with TGF-beta1 also induced cell elongation and increased pit formation by subsequently added osteoclasts. These effects were again blocked by PD169316 and GM6001. We propose that this novel pathway regulating osteoblast morphology plays an important role in the catabolic effects of TGF-beta on bone metabolism.	OSTEOPRO AS, DK-2730 Herlev, Denmark; Ctr Clin & Basic Res, DK-2750 Ballerup, Denmark; Leo Pharmaceut Prod, Dept Biochem, DK-2750 Ballerup, Denmark	Center Clinical & Basic Research	Karsdal, MA (corresponding author), OSTEOPRO AS, Herlev Hovedgade 207, DK-2730 Herlev, Denmark.	mk@osteopro.dk	Foged, Niels T/AHA-2122-2022	Delaisse, Jean-Marie/0000-0001-7370-1500; Karsdal, Morten/0000-0001-5026-8740				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666; Bidwell JP, 1998, J BONE MINER RES, V13, P155, DOI 10.1359/jbmr.1998.13.2.155; Bonewald L. F., 1996, P647; BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312; BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261; BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend-5-6-741; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; BREEN EC, 1994, J CELL PHYSIOL, V160, P323, DOI 10.1002/jcp.1041600214; Buchardt J, 1999, CHEM-EUR J, V5, P2877, DOI 10.1002/(SICI)1521-3765(19991001)5:10<2877::AID-CHEM2877>3.0.CO;2-Z; CARY LA, 1999, FRONT BIOSCI, V4, P102; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; DAVIES B, 1993, CANCER RES, V53, P2087; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Geiser AG, 1998, BONE, V23, P87, DOI 10.1016/S8756-3282(98)00078-7; GROBELNY D, 1992, BIOCHEMISTRY-US, V31, P7152, DOI 10.1021/bi00146a017; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Hay ED, 1995, ACTA ANAT, V154, P8; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Heuertz RM, 1999, J BIOL CHEM, V274, P17968, DOI 10.1074/jbc.274.25.17968; Horner A, 1998, BONE, V23, P95, DOI 10.1016/S8756-3282(98)00080-5; Hosoi T, 1996, CALCIFIED TISSUE INT, V59, P305, DOI 10.1007/s002239900128; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; Hurley MM, 1996, J BONE MINER RES, V11, P1256; HURLEY MM, 1994, J BIOL CHEM, V269, P9392; IBBOTSON KJ, 1989, J BONE MINER RES, V4, P37; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; Kozawa O, 1999, J CELL BIOCHEM, V74, P479, DOI 10.1002/(SICI)1097-4644(19990901)74:3<479::AID-JCB15>3.3.CO;2-0; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; LUCAS PA, 1989, BONE, V10, P459, DOI 10.1016/8756-3282(89)90079-3; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; MILLER SS, 1976, SCIENCE, V192, P1340, DOI 10.1126/science.1273593; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Mostov K, 1997, SCIENCE, V276, P219, DOI 10.1126/science.276.5310.219; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; OURSLER MJ, 1994, J BONE MINER RES, V9, P443; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303; PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P825; PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024; Reimann T, 1997, FEBS LETT, V403, P57, DOI 10.1016/S0014-5793(97)00024-0; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; ROSEN DM, 1988, J CELL PHYSIOL, V134, P337, DOI 10.1002/jcp.1041340304; Rosier RN, 1998, CLIN ORTHOP RELAT R, pS294; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Serra R, 1997, J CELL BIOL, V139, P541, DOI 10.1083/jcb.139.2.541; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Suda Tatsuo, 1996, P87; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177; Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091; Takeuchi Y, 1996, J BIOL CHEM, V271, P3938; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; TRAM KKT, 1993, BIOCHEM MOL BIOL INT, V29, P981; Visser JA, 1998, MOL CELL ENDOCRINOL, V146, P7, DOI 10.1016/S0303-7207(98)00198-1; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; ZALLONE AZ, 1984, CELL TISSUE RES, V235, P561; Zhang WY, 1999, J BONE MINER RES, V14, P528, DOI 10.1359/jbmr.1999.14.4.528; Zhen XC, 1997, J BONE MINER RES, V12, P36, DOI 10.1359/jbmr.1997.12.1.36	74	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39350	39358		10.1074/jbc.M008738200	http://dx.doi.org/10.1074/jbc.M008738200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11477097	hybrid			2022-12-25	WOS:000171673200134
J	Naemsch, LN; Dixon, SJ; Sims, SM				Naemsch, LN; Dixon, SJ; Sims, SM			Activity-dependent development of P2X(7) current and Ca2+ entry in rabbit osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; ISOLATED RAT OSTEOCLASTS; ATP RECEPTOR; NUCLEOTIDE RECEPTOR; NONSELECTIVE CATION; ENDOTHELIAL-CELLS; EXTRACELLULAR ATP; STRUCTURAL MOTIF; CALCIUM; RELEASE	Bone remodeling is regulated by local factors and modulated by mechanical stimuli. Mechanical stimulation can cause release of ATP, an agent that stimulates osteoclastic resorption at low concentrations and inhibits at high concentrations. We examined whether osteoclasts express P2X(7) receptors, which are activated by high concentrations of ATP and can behave as ion channels or cause the formation of membrane pores. Rabbit osteoclasts were studied using patch clamp techniques. Successive or prolonged applications of 2'- & 3'-O-(4-benzoylbenzoyl)-ATP (BzATP, a relatively potent P2X(7) agonist) or high concentrations of ATP caused the development of a slowly deactivating inward current. The underlying channel was permeable only to small cations, ruling out pore formation. Divalent cations reduced current magnitude, consistent with the presence of P2X(7) receptors, a finding confirmed in rat osteoclasts by immunocytochemistry. Successive applications of BzATP also elicited [Ca2+](i) elevations that required extracellular Ca2+. The BzATP-induced current and the rise of [Ca2+](i) were temporally associated, and both were inhibited by PPADS, a P2X(7) antagonist. This study demonstrates that high concentrations of ATP activate P2X(7) receptors and provides the first functional evidence for an extracellular ligand-gated Ca2+ influx pathway in osteoclasts. ATP released in response to mechanical stimuli may act through P2X(7) receptors to inhibit osteoclastic resorption.	Univ Western Ontario, Dept Physiol, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada; Univ Western Ontario, Fac Med & Dent, Div Oral Biol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Sims, SM (corresponding author), Univ Western Ontario, Dept Physiol, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada.		Dixon, S. Jeffrey/G-3657-2013; Sims, Stephen/G-4510-2013	Dixon, S. Jeffrey/0000-0001-9162-1686; 				Bianchi BR, 1999, EUR J PHARMACOL, V376, P127, DOI 10.1016/S0014-2999(99)00350-7; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Bodin P, 1998, INFLAMM RES, V47, P351, DOI 10.1007/s000110050341; BOWLER WB, 1995, J BONE MINER RES, V10, P1137; Bowler WB, 1998, BONE, V22, P195, DOI 10.1016/S8756-3282(97)00280-9; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x; CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104; Collo G, 1996, J NEUROSCI, V16, P2495; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Dixon SJ, 2000, DRUG DEVELOP RES, V49, P187, DOI 10.1002/(SICI)1098-2299(200003)49:3<187::AID-DDR9>3.0.CO;2-F; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Graff RD, 2000, ARTHRITIS RHEUM-US, V43, P1571, DOI 10.1002/1529-0131(200007)43:7<1571::AID-ANR22>3.3.CO;2-C; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hoebertz A, 2001, FASEB J, V15, P1139, DOI 10.1096/fj.00-0395com; Hoebertz A, 2000, BONE, V27, P503, DOI 10.1016/S8756-3282(00)00351-3; Humphreys BD, 1998, MOL PHARMACOL, V54, P22, DOI 10.1124/mol.54.1.22; KENNEDY C, 1995, NATURE, V377, P385, DOI 10.1038/377385a0; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; MODDERMAN WE, 1994, CALCIFIED TISSUE INT, V55, P141, DOI 10.1007/BF00297190; Morrison MS, 1998, J PHYSIOL-LONDON, V511, P495, DOI 10.1111/j.1469-7793.1998.495bh.x; MURGIA M, 1993, J BIOL CHEM, V268, P8199; Naemsch LN, 1999, J CELL SCI, V112, P4425; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC766, DOI 10.1152/ajpcell.1999.277.4.C766; Seguela P, 1996, J NEUROSCI, V16, P448; SIMS SM, 1991, PFLUG ARCH EUR J PHY, V419, P358, DOI 10.1007/BF00371118; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Virginio C, 1997, NEUROPHARMACOLOGY, V36, P1285, DOI 10.1016/S0028-3908(97)00141-X; Weidema AF, 1997, J PHYSIOL-LONDON, V503, P303, DOI 10.1111/j.1469-7793.1997.303bh.x; Weidema AF, 2001, AM J PHYSIOL-CELL PH, V280, pC1531, DOI 10.1152/ajpcell.2001.280.6.C1531; Wiebe SH, 1999, CELL PHYSIOL BIOCHEM, V9, P323, DOI 10.1159/000016326; WILTINK A, 1995, PFLUG ARCH EUR J PHY, V429, P663, DOI 10.1007/BF00373987; WOOD DA, 1991, J BIOL CHEM, V266, P15369; YU HS, 1993, BIOCHEM BIOPH RES CO, V191, P357, DOI 10.1006/bbrc.1993.1225; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	47	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39107	39114		10.1074/jbc.M105881200	http://dx.doi.org/10.1074/jbc.M105881200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495918	hybrid			2022-12-25	WOS:000171673200102
J	Yamashita, Y; Kajigaya, S; Yoshida, K; Ueno, S; Ota, J; Ohmine, K; Ueda, M; Miyazato, A; Ohya, K; Kitamura, T; Ozawa, K; Mano, H				Yamashita, Y; Kajigaya, S; Yoshida, K; Ueno, S; Ota, J; Ohmine, K; Ueda, M; Miyazato, A; Ohya, K; Kitamura, T; Ozawa, K; Mano, H			Sak serine-threonine kinase acts as an effector of Tec tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SERINE/THREONINE KINASE; MOLECULAR-CLONING; DROSOPHILA; GENE; IDENTIFICATION; EXPRESSION; DEGRADATION; ENCODES; GROWTH; INVIVO	The murine sak gene encodes a putative serine-threonine kinase which is homologous to the members of the Plk/Polo family. Although Sak protein is presumed to be involved in cell growth mechanism, efforts have failed to demonstrate its kinase activity. Little has been, therefore, elucidated how Sak is regulated and how Sak contributes to cell proliferation. Tee is a cytoplasmic protein-tyrosine kinase (PTK) which becomes activated by the stimulation of cytokine receptors, lymphocyte surface antigens, heterotrimeric G protein-linked receptors, and integrins. To clarify the in vivo function of Tee, we have tried to isolate the second messengers of Tee by using the yeast two-hybrid screening. One of such Tec-binding proteins turned out to be Sak. In human kidney 293 cells, Sak became tyrosine-phosphorylated by Tee, and the serine-threonine kinase activity of Sak was detected only under the presence of Tee, suggesting Sak to be an effector molecule of Tee. In addition, Tee activity efficiently protects Sak from the "PEST" sequence-dependent proteolysis. Internal deletion of the PEST sequences led to the stabilization of Sak proteins, and expression of these mutants acted suppressive to cell growth. Our data collectively supports a novel role of Sak acting in the PTK-mediated signaling pathway.	Jichi Med Sch, Div Funct Genom, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Div Cardiol, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Div Hematol, Minami Kawachi, Tochigi 3290498, Japan; NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA; Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Tokyo 1088639, Japan	Jichi Medical University; Jichi Medical University; Jichi Medical University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Tokyo	Mano, H (corresponding author), Jichi Med Sch, Div Funct Genom, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.		Kitamura, Toshio/AAA-2071-2021					CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; Fode C, 1996, MOL CELL BIOL, V16, P4665; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; MANO H, 1995, BLOOD, V85, P343; Mano H, 1999, INT J HEMATOL, V69, P6; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Mano H, 1996, FASEB J, V10, P637, DOI 10.1096/fasebj.10.5.8621063; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; Onishi M, 1996, EXP HEMATOL, V24, P324; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Weil R, 1997, J BIOL CHEM, V272, P9942; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yamashita Y, 1998, BLOOD, V91, P1496, DOI 10.1182/blood.V91.5.1496.1496_1496_1507	27	35	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39012	39020		10.1074/jbc.M106249200	http://dx.doi.org/10.1074/jbc.M106249200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489907	hybrid			2022-12-25	WOS:000171673200090
J	Bessman, MJ; Walsh, JD; Dunn, CA; Swaminathan, J; Weldon, JE; Shen, JY				Bessman, MJ; Walsh, JD; Dunn, CA; Swaminathan, J; Weldon, JE; Shen, JY			The gene ygdP, associated with the invasiveness of Escherichia coli K1, designates a nudix hydrolase, Orf176, active on adenosine (5 ')-pentaphospho-(5 ')-adenosine (Ap(5)A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARTONELLA-BACILLIFORMIS; DIADENOSINE POLYPHOSPHATES; MUTT; INVASION; FAMILY; TETRAPHOSPHATE; TRIPHOSPHATE; NUCLEOTIDES; APPPPA; ENZYME	ygdP, a gene associated with the invasion of brain microvascular endothelial cells by Escherichia coli K1 (Badger, J. L., Wass, C. A., and Him, K. S. (2000) Mol. Microbiol. 36,174-182), the primary Gram-negative bacterium causing meningitis in newborns, has been cloned and expressed in E. coli. The protein, YgdP, was purified to near homogeneity and identified as a member of the Nudix hydrolase subfamily of dinucleoside oligophosphate pyrophosphatases. It catalyzes the hydrolysis of diadenosine tetra-, penta-, and hexa-phosphates with a preference for diadenosine penta-phosphate, from which it forms ATP and ADP. The enzyme has a requirement for a divalent metal cation that can be met with Mg2+, Zn2+, or Mn2+ and, like most of the Nudix hydrolases, has an alkaline pH optimum between 8.5 and 9. This is the second identification of a gene associated with the invasiveness of a human pathogen as a member of the Nudix hydrolase subfamily of dinucleoside oligophosphate pyrophosphatases, and an examination of homologous proteins in other invasive bacteria suggests that this may be a common feature of cellular invasion.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	zoot@jhu.edu		Dunn, Christopher/0000-0001-7899-0110; Weldon, John/0000-0002-6516-9064	NIGMS NIH HHS [GM 18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; Aguilar JS, 2001, EUR J BIOCHEM, V268, P1289, DOI 10.1046/j.1432-1327.2001.01987.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMES BN, 1960, J BIOL CHEM, V235, P769; Badger JL, 2000, MOL MICROBIOL, V36, P174, DOI 10.1046/j.1365-2958.2000.01840.x; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BOCHNER BR, 1984, CELL, V37, P225, DOI 10.1016/0092-8674(84)90318-0; Burgstahler R, 2001, NEUROREPORT, V12, P679, DOI 10.1097/00001756-200103260-00012; Cartwright JL, 1999, BIOCHEM BIOPH RES CO, V256, P474, DOI 10.1006/bbrc.1999.0354; Coleman SA, 2001, INFECT IMMUN, V69, P4373, DOI 10.1128/IAI.69.7.4373-4381.2001; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; FRICK DN, 1995, BIOCHEMISTRY-US, V34, P5577, DOI 10.1021/bi00016a032; Fujii Y, 1999, J BIOL CHEM, V274, P38251, DOI 10.1074/jbc.274.53.38251; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Jovanovic A, 1997, BIOCHEM PHARMACOL, V54, P219, DOI 10.1016/S0006-2952(97)00262-1; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; Kisselev LL, 1998, FEBS LETT, V427, P157, DOI 10.1016/S0014-5793(98)00420-7; LEE PC, 1983, P NATL ACAD SCI-BIOL, V80, P7496, DOI 10.1073/pnas.80.24.7496; Mateo J, 1997, AM J PHYSIOL-CELL PH, V273, pC918, DOI 10.1152/ajpcell.1997.273.3.C918; McLennan AG, 2000, PHARMACOL THERAPEUT, V87, P73, DOI 10.1016/S0163-7258(00)00041-3; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MITCHELL SJ, 1995, INFECT IMMUN, V63, P1552, DOI 10.1128/IAI.63.4.1552-1562.1995; Pintor J, 2000, PHARMACOL THERAPEUT, V87, P103, DOI 10.1016/S0163-7258(00)00049-8; Swarbrick JD, 2000, J MOL BIOL, V302, P1165, DOI 10.1006/jmbi.2000.4085; Vartanian A, 1997, FEBS LETT, V415, P160, DOI 10.1016/S0014-5793(97)01086-7; von Drygalski A, 2000, BIOFACTORS, V11, P179; ZAMECNIK PC, 1966, BIOCHEM BIOPH RES CO, V24, P91, DOI 10.1016/0006-291X(66)90415-3	27	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37834	37838						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11479323				2022-12-25	WOS:000171526500017
J	Harris, CA; Johnson, EM				Harris, CA; Johnson, EM			BH3-only Bcl-2 family members are coordinately regulated by the JNK pathway and require Bax to induce apoptosis in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CEREBELLAR GRANULE CELLS; CYTOCHROME-C RELEASE; SYMPATHETIC NEURONS; CHANNEL ACTIVITY; PROTEIN; SURVIVAL; BH3; MITOCHONDRIA; INTERACTS	The Bcl-2 family of proteins are key regulators of programmed cell death. A distinct subfamily of BH3-only molecules has been identified, but their exact mechanism of action remains unclear. Here we show that the BH3-only Bcl-2 family members, Dp5/Hrk and Bim, are induced upstream of the Bax checkpoint in neuronal apoptosis in a manner that shows significant dependence on JNK signaling. We also show that Dp5 and other BH3-only proteins kill cerebellar granule neurons in a Bax-dependent manner. These studies demonstrate that BH3-only members do not act independently in their proapoptotic activities but rather require the action of multidomain proapoptotic Bcl-2 family members to produce cell death.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Johnson, EM (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 4566 Scott Ave,Box 8103, St Louis, MO 63110 USA.				NIA NIH HHS [AG12947] Funding Source: Medline; NINDS NIH HHS [NS38651] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012947] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; DEL PL, 1997, SCIENCE, V278, P687; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; JOHNSON MI, 1983, METHOD ENZYMOL, V103, P334; Kaipia A, 1997, ENDOCRINOLOGY, V138, P5497, DOI 10.1210/en.138.12.5497; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maroney AC, 1998, J NEUROSCI, V18, P104; Miller TM, 1996, J NEUROSCI, V16, P7487; Miller TM, 1997, J BIOL CHEM, V272, P9847; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Moulder KL, 1999, J NEUROSCI, V19, P705; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Putcha GV, 2000, J CELL BIOL, V149, P1011, DOI 10.1083/jcb.149.5.1011; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	40	262	265	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37754	37760						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11495903				2022-12-25	WOS:000171526500006
J	Davis, CA; Monnier, JM; Nick, HS				Davis, CA; Monnier, JM; Nick, HS			A coding region determinant of instability regulates levels of manganese superoxide dismutase mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; 3' UNTRANSLATED REGION; DESTABILIZING ELEMENTS; STABILITY REQUIRES; HALF-LIFE; IN-VIVO; CELLS; INDUCTION; DECAY; GENE	The mitochondria-localized manganese superoxide dismutase (MnSOD), serves a key cytoprotective role against reactive oxygen species arising from a variety of cellular processes and immunological stresses. Previous data from our laboratory suggest that the regulation of the rat MnSOD gene may occur not only at the transcriptional but quite possibly at the post-transcriptional level. To verify this hypothesis, we have attempted to identify regions within the rat MnSOD cDNA that may be functionally involved in regulating the stability of the mRNA. Using a c-fos-based promoter activation system, we have identified an similar to 280-nucleotide fragment within the MnSOD mRNA coding region that, when fused to a rabbit beta -globin gene, destabilizes the normally stable beta -globin mRNA. This cis-directed destabilization phenomenon confers its effects independent of position and stimulus. Most importantly, the MnSOD coding region determinant functions when placed in the 3'-untranslated region of the beta -globin transcript, demonstrating its activity in the absence of ribosome transit. We feel that these data provide a mechanistic basis for both the basal and stimulus-dependent post-transcriptional regulation of MnSOD.	Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Nick, HS (corresponding author), Univ Florida, Dept Neurosci, Box 100244, Gainesville, FL 32610 USA.	hnick@ufl.edu			NHLBI NIH HHS [R01 HL39593] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039593] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; Canete-Soler R, 1998, J BIOL CHEM, V273, P12650, DOI 10.1074/jbc.273.20.12650; CARON JM, 1985, NATURE, V317, P648, DOI 10.1038/317648a0; Caskey C T, 1973, Adv Protein Chem, V27, P243, DOI 10.1016/S0065-3233(08)60449-0; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; Chung DJ, 1998, BIOCHEMISTRY-US, V37, P16298, DOI 10.1021/bi980935g; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907; EASTGATE J, 1993, BLOOD, V81, P639; Epperly MW, 2000, RADIAT RES, V154, P365, DOI 10.1667/0033-7587(2000)154[0365:DPRROM]2.0.CO;2; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Hilleren P, 1999, ANNU REV GENET, V33, P229, DOI 10.1146/annurev.genet.33.1.229; Hohmeier HE, 1998, J CLIN INVEST, V101, P1811, DOI 10.1172/JCI1489; HURT J, 1992, NUCLEIC ACIDS RES, V20, P2985, DOI 10.1093/nar/20.12.2985; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kuo SY, 1999, J BIOL CHEM, V274, P3345, DOI 10.1074/jbc.274.6.3345; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Loflin PT, 1999, METHODS, V17, P11, DOI 10.1006/meth.1998.0702; Mantymaa P, 2000, BRIT J HAEMATOL, V108, P574, DOI 10.1046/j.1365-2141.2000.01852.x; MARZLUFF WF, 1988, TRENDS BIOCHEM SCI, V13, P49, DOI 10.1016/0968-0004(88)90027-8; Mates JM, 2000, TOXICOLOGY, V153, P83, DOI 10.1016/S0300-483X(00)00306-1; MELENDEZ JA, 1993, FREE RADICAL BIO MED, V14, P601, DOI 10.1016/0891-5849(93)90141-G; Pistoi S, 1996, MOL CELL BIOL, V16, P5107; Ragheb JA, 1999, J IMMUNOL, V163, P120; RAYMOND V, 1989, ONCOGENE RES, V5, P1; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; Rogers RJ, 2000, BIOCHEM J, V347, P233, DOI 10.1042/0264-6021:3470233; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; Shetty S, 1999, MOL CELL BIOCHEM, V199, P189, DOI 10.1023/A:1006914800447; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Sokolowski M, 1998, J VIROL, V72, P1504, DOI 10.1128/JVI.72.2.1504-1515.1998; STAUBER C, 1988, NUCLEIC ACIDS RES, V16, P9399, DOI 10.1093/nar/16.20.9399; van Dijk EL, 2000, J MOL BIOL, V300, P449, DOI 10.1006/jmbi.2000.3856; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WELLINGTON CL, 1993, MOL CELL BIOL, V13, P5034, DOI 10.1128/MCB.13.8.5034; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611	49	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37317	37326		10.1074/jbc.M104378200	http://dx.doi.org/10.1074/jbc.M104378200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11489890	hybrid			2022-12-25	WOS:000171375700062
J	Liu, QY; Guan, XM; Martin, WJ; McDonald, TP; Clements, MK; Jiang, QP; Zeng, ZZ; Jacobson, M; Williams, DL; Yu, H; Bomford, D; Figueroa, D; Mallee, J; Wang, RP; Evans, J; Gould, R; Austin, CP				Liu, QY; Guan, XM; Martin, WJ; McDonald, TP; Clements, MK; Jiang, QP; Zeng, ZZ; Jacobson, M; Williams, DL; Yu, H; Bomford, D; Figueroa, D; Mallee, J; Wang, RP; Evans, J; Gould, R; Austin, CP			Identification and characterization of novel mammalian neuropeptide FF-like peptides that attenuate morphine-induced antinociception	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; MODULATING PEPTIDES; RAT-BRAIN; PAIN; FMRFAMIDE; GENE; TRANSCRIPTION; DEPENDENCE; TOLERANCE; ANTISERUM	The two mammalian neuropeptides NPFF and NPAF have been shown to have important roles in nociception, anxiety, learning and memory, and cardiovascular reflex. Two receptors (FF1 and FF2) have been molecularly identified for NPFF and NPAF. We have now characterized a novel gene designated NPVF that encodes two neuropeptides highly similar to NPFF. NPVF mRNA was detected specifically in a region between the dorsomedial and ventromedial hypothalamic nuclei. NPVF-derived peptides displayed higher affinity for FF1 than NPFF-derived peptides, but showed poor agonist activity for FF2. Following intracerebral ventricular administration, a NPVF-derived peptide blocked morphine-induced analgesia more potently than NPFF in both acute and inflammatory models of pain. In situ hybridization analysis revealed distinct expression patterns of FF1 and FF2 in the rat central nervous system. FF1 was broadly distributed, with the highest levels found in specific regions of the limbic system and the brainstem where NPVF-producing neurons were shown to project. FF2, in contrast, was mostly expressed in the spinal cord and some regions of the thalamus. These results indicate that the endogenous ligands for FF1 and FF2 are NPVF- and NPFF-derived peptides, respectively, and suggest that the NPVF/FF1 system may be an important part of endogenous anti-opioid mechanism.	Merck Res Labs, Dept Pharmacol, W Point, PA 19486 USA; Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA; Merck Res Labs, Dept Pharmacol, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company	Liu, QY (corresponding author), Merck Res Labs, Dept Pharmacol, W Point, PA 19486 USA.		Martin, William J/L-9033-2017	Martin, William J/0000-0002-2749-3365				AARNISALO AA, 1995, NEUROSCIENCE, V65, P175, DOI 10.1016/0306-4522(94)00459-I; ALLARD M, 1992, NEUROSCIENCE, V49, P101, DOI 10.1016/0306-4522(92)90078-G; Altier N, 2000, EUR J PHARMACOL, V407, P245, DOI 10.1016/S0014-2999(00)00668-3; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDREWS PC, 1989, EXPERIENTIA S, V56, P192; Bonini JA, 2000, J BIOL CHEM, V275, P39324, DOI 10.1074/jbc.M004385200; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Davis M, 1998, BIOL PSYCHIAT, V44, P1239, DOI 10.1016/S0006-3223(98)00288-1; DOCKRAY GJ, 1983, NATURE, V305, P328, DOI 10.1038/305328a0; Dupouy V, 1996, SYNAPSE, V24, P282, DOI 10.1002/(SICI)1098-2396(199611)24:3<282::AID-SYN11>3.0.CO;2-Z; Elshourbagy NA, 2000, J BIOL CHEM, V275, P25965, DOI 10.1074/jbc.M004515200; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; GOUARDERES C, 1993, EUR J PHARMACOL, V237, P73, DOI 10.1016/0014-2999(93)90095-Y; GREENBERG MJ, 1992, PROG BRAIN RES, V92, P25, DOI 10.1016/S0079-6123(08)61162-0; Guan XM, 1998, MOL BRAIN RES, V59, P273, DOI 10.1016/S0169-328X(98)00150-8; Harrison LM, 1998, PEPTIDES, V19, P1603, DOI 10.1016/S0196-9781(98)00126-0; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; KAVALIERS M, 1989, PEPTIDES, V10, P741, DOI 10.1016/0196-9781(89)90106-X; Kotani M, 2001, BRIT J PHARMACOL, V133, P138, DOI 10.1038/sj.bjp.0704038; LAKE JR, 1991, NEUROSCI LETT, V132, P29, DOI 10.1016/0304-3940(91)90425-S; Li C, 1999, BRAIN RES, V848, P26, DOI 10.1016/S0006-8993(99)01972-1; Liu QY, 1999, BIOCHEM BIOPH RES CO, V266, P174, DOI 10.1006/bbrc.1999.1796; Lynch KR, 1999, NATURE, V399, P789; MALIN DH, 1990, PEPTIDES, V11, P969, DOI 10.1016/0196-9781(90)90018-Z; McDonald T, 1998, BIOCHEM BIOPH RES CO, V247, P266, DOI 10.1006/bbrc.1998.8774; Panula P, 1999, BRAIN RES, V848, P191, DOI 10.1016/S0006-8993(99)02044-2; PANULA P, 1987, MED BIOL, V65, P127; Panula P, 1996, PROG NEUROBIOL, V48, P461, DOI 10.1016/0301-0082(96)00001-9; Perry SJ, 1997, FEBS LETT, V409, P426, DOI 10.1016/S0014-5793(97)00557-7; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Roumy M, 1998, EUR J PHARMACOL, V345, P1, DOI 10.1016/S0014-2999(97)01604-X; Satake H, 2001, BIOCHEM J, V354, P379, DOI 10.1042/0264-6021:3540379; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; TANG J, 1984, P NATL ACAD SCI-BIOL, V81, P5002, DOI 10.1073/pnas.81.15.5002; Vilim FS, 1999, MOL PHARMACOL, V55, P804; WEBER E, 1981, SCIENCE, V214, P1248, DOI 10.1126/science.7029714; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757; ZASTAWNY RL, 1999, Patent No. 2269192; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	41	222	232	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36961	36969		10.1074/jbc.M105308200	http://dx.doi.org/10.1074/jbc.M105308200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11481330	hybrid			2022-12-25	WOS:000171375700016
J	Skiba, NP; Martemyanov, KA; Elfenbein, A; Hopp, JA; Bohm, A; Simonds, WF; Arshavsky, VY				Skiba, NP; Martemyanov, KA; Elfenbein, A; Hopp, JA; Bohm, A; Simonds, WF; Arshavsky, VY			RGS9-G beta 5 substrate selectivity in photoreceptors - Opposing effects of constituent domains yield high affinity of RGS interaction with the G protein-effector complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; TRANSDUCIN GTPASE ACTIVITY; CGMP PHOSPHODIESTERASE; SUBUNIT G-BETA(5); BETA-SUBUNIT; REGULATORS; PURIFICATION; MEMBRANES; DISTINCT; BINDING	RGS proteins regulate the duration of G protein signaling by increasing the rate of GTP hydrolysis on G protein a subunits. The complex of RGS9 with type 5 G protein beta subunit (G beta5) is abundant in photoreceptors, where it stimulates the GTPase activity of transducin. An important functional feature of RGS9-G beta5 is its ability to activate transducin GTPase much more efficiently after transducin binds to its effector, cGMP phosphodiesterase. Here we show that different domains of RGS9-G beta5 make opposite contributions toward this selectivity. G beta5 bound to the G protein gamma subunit-like domain of RGS9 acts to reduce RGS9 affinity for transducin, whereas other structures restore this affinity specifically for the transducin-phosphodiesterase complex. We suggest that this mechanism may serve as a general principle conferring specificity of RGS protein action.	Harvard Univ, Sch Med, Dept Ophthalmol, Howe Labs MEEI, Boston, MA 02114 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; Boston Biomedical Research Institute; Tufts University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Arshavsky, VY (corresponding author), Harvard Univ, Sch Med, Dept Ophthalmol, Howe Labs MEEI, 243 Charles St, Boston, MA 02114 USA.	vadim_arshavsky@meei.harvard.edu			NATIONAL EYE INSTITUTE [R01EY012859] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043304] Funding Source: NIH RePORTER; NEI NIH HHS [EY-12859] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; Burchett SA, 2000, J NEUROCHEM, V75, P1335, DOI 10.1046/j.1471-4159.2000.0751335.x; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Cowan CW, 2001, PROG NUCLEIC ACID RE, V65, P341; Cowan CW, 2000, METHOD ENZYMOL, V315, P524; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; KUTUZOV M, 1994, EUR J BIOCHEM, V220, P963, DOI 10.1111/j.1432-1033.1994.tb18700.x; Lan KL, 2000, J BIOL CHEM, V275, P33497, DOI 10.1074/jbc.M005785200; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Liang JJ, 2000, J NEUROSCI RES, V60, P58, DOI 10.1002/(SICI)1097-4547(20000401)60:1<58::AID-JNR6>3.0.CO;2-L; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; McEntaffer RL, 1999, BIOCHEMISTRY-US, V38, P4931, DOI 10.1021/bi982636x; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Rahman Z, 1999, J NEUROSCI, V19, P2016; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Skiba NP, 2000, J BIOL CHEM, V275, P32716, DOI 10.1074/jbc.C000413200; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Sowa ME, 2001, NAT STRUCT BIOL, V8, P234, DOI 10.1038/84974; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TING TD, 1993, METH NEUROSCI, V15, P180; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Wong HC, 2000, NAT STRUCT BIOL, V7, P1178; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000	41	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37365	37372		10.1074/jbc.M106431200	http://dx.doi.org/10.1074/jbc.M106431200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11495924	hybrid			2022-12-25	WOS:000171375700068
J	Kajiura, H; Mori, K; Tobimatsu, T; Toraya, T				Kajiura, H; Mori, K; Tobimatsu, T; Toraya, T			Characterization and mechanism of action of a reactivating factor for adenosylcobalamin-dependent glycerol dehydratase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-12-DEPENDENT DIOL DEHYDRATASE; KLEBSIELLA-PNEUMONIAE; COENZYME; EXPRESSION; ENTEROBACTERIACEAE; FERMENTATION; PROTEINS; ANALOGS; GENERA; HSP70	Adenosylcobalamin-dependent glycerol dehydratase undergoes mechanism-based inactivation by its physiological substrate glycerol. We identified two genes (gdrAB) of Klebsiella pneumoniae for a glycerol dehydratase-reactivating factor (Tobimatsu, T., Kajiura, H., Yunoki, M., Azuma, M., and Toraya, T. (1999) J. Bacteriol 181, 4110-4113). Recombinant GdrA and GdrB proteins formed a tight complex of (GdrA)(2)(GdrB)(2), which is a putative reactivating factor. The purified factor reactivated the glycerol-inactivated and O-2-inactivated glycerol dehydratases as well as activated the enzyme-cyanocobalamin complex in vitro in the presence of ATP, Mg2+, and adenosylcobalamin. The factor mediated the exchange of the enzyme-bound, adenine-lacking cobalamins for free, adenine-containing cobalamins in the presence of ATP and Mg2+ through intermediate formation of apoenzyme. The factor showed extremely low ATP-hydrolyzing activity and formed a tight complex with apoenzyme in the presence of ADP. Incubation of the enzyme-cyanocobalamin complex with the reactivating factor in the presence of ADP brought about release of the enzyme-bound cobalamin. The resulting tight inactive complex of apoenzyme with the factor dissociated upon incubation with ATP, forming functional apoenzyme and a low affinity form of factor. Thus, it was established that the reactivation of the inactivated holoenzymes takes place in two steps: ADP-dependent cobalamin release and ATP-dependent dissociation of the apoenzyme-factor complex. We propose that the glycerol dehydratase-reactivating factor is a molecular chaperone that participates in reactivation of the inactivated enzymes.	Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 7008530, Japan	Okayama University	Toraya, T (corresponding author), Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, 3-1-1 Tsushima Naka, Okayama 7008530, Japan.		MORI, Koichi/B-2567-2011; TOBIMATSU, Takamasa/B-2646-2011; Mori, Koichi/ABC-7268-2021	Mori, Koichi/0000-0001-8865-2107				BACHOVCHIN WW, 1977, BIOCHEMISTRY-US, V16, P1082, DOI 10.1021/bi00625a009; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FORAGE RG, 1982, J BACTERIOL, V151, P591, DOI 10.1128/JB.151.2.591-599.1982; FORAGE RG, 1982, J BACTERIOL, V149, P413, DOI 10.1128/JB.149.2.413-419.1982; FORAGE RG, 1979, BIOCHIM BIOPHYS ACTA, V569, P249, DOI 10.1016/0005-2744(79)90060-3; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HONDA S, 1980, J BACTERIOL, V143, P1458, DOI 10.1128/JB.143.3.1458-1465.1980; Johnson B C, 1975, Methods Enzymol, V42, P315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mangold H. K., 1969, THIN LAYER CHROMATOG, V2nd, P786; Mori K, 1999, BIOCHEMISTRY-US, V38, P13170, DOI 10.1021/bi9911738; Mori K, 1997, J BIOL CHEM, V272, P32034, DOI 10.1074/jbc.272.51.32034; PAWELKIEWICZ J, 1965, ACTA BIOCHIM POL, V12, P207; POZNANSKAJA AA, 1979, ARCH BIOCHEM BIOPHYS, V194, P379, DOI 10.1016/0003-9861(79)90630-1; POZNANSKAYA AA, 1977, BIOCHIM BIOPHYS ACTA, V484, P236, DOI 10.1016/0005-2744(77)90128-0; ROBINSON SP, 1989, ARCH BIOCHEM BIOPHYS, V268, P93, DOI 10.1016/0003-9861(89)90568-7; SANDO GN, 1976, BIOCHIM BIOPHYS ACTA, V428, P228; SCHNEBLI HP, 1970, J BIOL CHEM, V245, P1115; SCHNEIDER Z, 1966, ACTA BIOCHIM POL, V13, P311; Seifert C, 2001, EUR J BIOCHEM, V268, P2369, DOI 10.1046/j.1432-1327.2001.02123.x; SMILEY KL, 1962, ARCH BIOCHEM BIOPHYS, V97, P538, DOI 10.1016/0003-9861(62)90118-2; Tobimatsu T, 1999, J BACTERIOL, V181, P4110, DOI 10.1128/JB.181.13.4110-4113.1999; Tobimatsu T, 2000, ARCH MICROBIOL, V174, P81, DOI 10.1007/s002030000179; Tobimatsu T, 1996, J BIOL CHEM, V271, P22352, DOI 10.1074/jbc.271.37.22352; TORAYA T, 1994, MET IONS BIOL SYST, V30, P217; Toraya T, 1999, J BIOL CHEM, V274, P3372, DOI 10.1074/jbc.274.6.3372; TORAYA T, 1977, J BIOL CHEM, V252, P963; TORAYA T, 1986, J BIOL CHEM, V261, P9289; TORAYA T, 1983, J BIOL CHEM, V258, P9296; TORAYA T, 1976, BIOCHEM BIOPH RES CO, V69, P475, DOI 10.1016/0006-291X(76)90546-5; Toraya T, 2000, CELL MOL LIFE SCI, V57, P106, DOI 10.1007/s000180050502; TORAYA T, 1980, J BACTERIOL, V141, P1439, DOI 10.1128/JB.141.3.1439-1442.1980; TORAYA T, 1979, J BACTERIOL, V139, P39, DOI 10.1128/JB.139.1.39-47.1979; USHIO K, 1982, J NUTR SCI VITAMINOL, V28, P225; YAKUSHEVA MI, 1974, ANAL BIOCHEM, V60, P293, DOI 10.1016/0003-2697(74)90157-2	40	52	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36514	36519		10.1074/jbc.M105182200	http://dx.doi.org/10.1074/jbc.M105182200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11470792	hybrid			2022-12-25	WOS:000171194500063
J	Luchin, A; Suchting, S; Merson, T; Rosol, TJ; Hume, DA; Cassady, AI; Ostrowski, MC				Luchin, A; Suchting, S; Merson, T; Rosol, TJ; Hume, DA; Cassady, AI; Ostrowski, MC			Genetic and physical interactions between Microphthalmia transcription factor and PU.1 are necessary for osteoclast gene expression and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLEEN-CELLS; MITF GENE; OSTEOPETROSIS; MICE; MOUSE; MACROPHAGES; ACTIVATION; MUTATIONS; FAMILY; LOCUS	The microphthalmia transcription factor (MITF), a basic-helix-loop-helix zipper factor, regulates distinct target genes in several cell types. We hypothesized that interaction with the Ets family factor PU.1, whose expression is limited to hematopoietic cells, might be necessary for activation of target genes like tartrate-resistant acid phosphatase (TRAP) in osteoclasts. Several lines of evidence were consistent with this model. The combination of MITF and PU.1 synergistically activated the TRAP promoter in transient assays. This activation was dependent on intact binding sites for both factors in the TRAP promoter. MITF and PU.1 physically interacted when coexpressed in COS cells or in vitro when purified recombinant proteins were studied. The minimal regions of MITF and PU.1 required for the interaction were the basic-helix-loop-helix zipper domain and the Ets DNA binding domain, respectively. Significantly, mice heterozygous for both the mutant mi allele and a PU.1 null allele developed osteopetrosis early in life which resolved with age. The size and number of osteoclasts were not altered in the double heterozygous mutant mice, indicating that the defect lies in mature osteoclast function. Taken in total, the results afford an example of how lineage-specific gene regulation can be achieved by the combinatorial action of two broadly expressed transcription factors.	Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld, Australia	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Queensland; University of Queensland	Ostrowski, MC (corresponding author), Ohio State Univ, Dept Mol Genet, 484 W 12th Ave,Riffe Bldg,Rm 834, Columbus, OH 43210 USA.		Rosol, Thomas/G-9585-2011; Cassady, Alan/AAY-2962-2021; Hume, David A/C-7695-2013; Merson, Tobias D/D-5375-2015; Ostrowski, Michael/H-3108-2011	Rosol, Thomas/0000-0003-3737-1190; Cassady, Alan/0000-0001-8585-5427; Merson, Tobias D/0000-0002-7246-3608; Ostrowski, Michael/0000-0003-2948-6297; Hume, David/0000-0002-2615-1478	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044719] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-44719] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; Amiel J, 1998, CLIN DYSMORPHOL, V7, P17; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; CIELINSKI MJ, 1994, BONE, V15, P707, DOI 10.1016/8756-3282(94)90321-2; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Hallsson JH, 2000, GENETICS, V155, P291; Hayman AR, 1996, DEVELOPMENT, V122, P3151; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HOLTROP ME, 1981, METAB BONE DIS RELAT, V3, P123, DOI 10.1016/0221-8747(81)90030-8; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; Lichanska AM, 1999, BLOOD, V94, P127, DOI 10.1182/blood.V94.1.127.413k07_127_138; Lodie TA, 1997, J IMMUNOL, V158, P1848; Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451; Luna LG, 1968, MANUAL HIST STAINING, pxii; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Miyazaki Y, 1996, ONCOGENE, V13, P1721; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Perkel JM, 1998, J IMMUNOL, V160, P241; Rehli M, 1999, GENOMICS, V56, P111, DOI 10.1006/geno.1998.5588; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Ross IL, 1998, J BIOL CHEM, V273, P6662, DOI 10.1074/jbc.273.12.6662; ROSS IL, 1994, ONCOGENE, V9, P121; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Sato M, 1999, BIOCHEM BIOPH RES CO, V254, P384, DOI 10.1006/bbrc.1998.9918; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Simon MC, 1998, SEMIN IMMUNOL, V10, P111, DOI 10.1006/smim.1998.0112; Singh H, 1999, COLD SPRING HARB SYM, V64, P13, DOI 10.1101/sqb.1999.64.13; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; THESINGH CW, 1985, BONE, V6, P43, DOI 10.1016/8756-3282(85)90406-5; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WALKER DG, 1975, SCIENCE, V190, P785, DOI 10.1126/science.1198094; Weilbaecher KN, 1998, J EXP MED, V187, P775, DOI 10.1084/jem.187.5.775; Wu M, 2000, GENE DEV, V14, P301; Yang BS, 1996, MOL CELL BIOL, V16, P538	43	95	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36703	36710		10.1074/jbc.M106418200	http://dx.doi.org/10.1074/jbc.M106418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11481336	hybrid			2022-12-25	WOS:000171194500086
J	McCartney, RR; Schmidt, MC				McCartney, RR; Schmidt, MC			Regulation of Snf1 kinase - Activation requires phosphorylation of threonine 210 by an upstream kinase as well as a distinct step mediated by the Snf4 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; YEAST SNF1; SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; CATALYTIC DOMAIN; GENE-EXPRESSION; TYROSINE KINASE; BETA-SUBUNITS; IDENTIFICATION; PURIFICATION	The yeast Snf1 kinase and its metazoan orthologues, the AMP-activated protein kinases, are activated in response to nutrient limitation. Activation requires the phosphorylation of a conserved threonine residue in the activation loop of the catalytic subunit. A phosphopeptide antibody was generated that specifically recognizes Snf1 protein that is phosphorylated in its activation loop on threonine 210. Using this reagent, we show that phosphorylation of threonine 210 correlates with Snf1 activity, since it is detected in cells subjected to glucose limitation but not in cells grown in abundant glucose. A Snf1 mutant completely lacking kinase activity was phosphorylated normally on threonine 210 in glucose-starved cells, eliminating the possibility that the threonine 210 modification is due to an autophosphorylation event. Cells lacking the Reg1 protein, a regulatory subunit for the Glc7 phosphatase, showed constitutive phosphorylation of Snf1 threonine 210. Exposure of cells to high concentrations of sodium chloride also induced phosphorylation of Snf1. Interestingly, Mig1, a downstream target of Snf1 kinase, is phosphorylated in glucose-stressed but not sodium-stressed cells. Finally, cells lacking the gamma subunit of the Snf1 kinase complex encoded by the SNF4 gene exhibited normal regulation of threonine 210 phosphorylation in response to glucose limitation but are unable to phosphorylate Mig1 efficiently. Our data indicate that activation of the Snf1 kinase complex involves two steps, one that requires a distinct upstream kinase and one that is mediated by the gamma subunit of the kinase itself.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schmidt, MC (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA.	mcs2@pitt.edu			NIGMS NIH HHS [GM46443] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046443, R01GM046443] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alepuz PM, 1997, MOL MICROBIOL, V26, P91, DOI 10.1046/j.1365-2958.1997.5531917.x; Ashrafi K, 1998, J BIOL CHEM, V273, P25864, DOI 10.1074/jbc.273.40.25864; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Carlson M, 1998, CURR OPIN GENET DEV, V8, P560, DOI 10.1016/S0959-437X(98)80011-7; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Cullen PJ, 2000, P NATL ACAD SCI USA, V97, P13619, DOI 10.1073/pnas.240345197; DAVIES SP, 1994, EUR J BIOCHEM, V223, P351, DOI 10.1111/j.1432-1033.1994.tb19001.x; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; ESTRUCH F, 1992, GENETICS, V132, P639; Ganster RW, 1998, GENETICS, V150, P31; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; NEIGEBORN L, 1984, GENETICS, V108, P845; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Sato K, 1996, J BIOL CHEM, V271, P13250, DOI 10.1074/jbc.271.22.13250; Schmidt MC, 2000, EMBO J, V19, P4936, DOI 10.1093/emboj/19.18.4936; Schmidt MC, 1999, MOL CELL BIOL, V19, P4561; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Smith FC, 1999, FEBS LETT, V453, P219, DOI 10.1016/S0014-5793(99)00725-5; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Vincent O, 1998, EMBO J, V17, P7002, DOI 10.1093/emboj/17.23.7002; Vincent O, 2001, GENE DEV, V15, P1104, DOI 10.1101/gad.879301; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; WOODS A, 1994, J BIOL CHEM, V269, P19509; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; [No title captured]	47	203	211	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36460	36466		10.1074/jbc.M104418200	http://dx.doi.org/10.1074/jbc.M104418200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11486005	hybrid			2022-12-25	WOS:000171194500056
J	Hughes, K; Edin, S; Antonsson, A; Grundstrom, T				Hughes, K; Edin, S; Antonsson, A; Grundstrom, T			Calmodulin-dependent kinase II mediates T cell receptor/CD3-and phorbol ester-induced activation of I kappa B kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTORS; IKK-ALPHA; LIVER DEGENERATION; MICE LACKING; CAM KINASE; COMPLEX; PHOSPHORYLATION; EXPRESSION; INHIBITOR	Numerous fundamental biological processes involve the NF kappaB family of transcription factors. The mechanisms by which this family of proteins is regulated are therefore of widespread importance. In most cells, NF kappaB is bound to inhibitory I kappaB proteins and sequestered in the cytoplasm. NF kappaB-inducing signals result in activation of a large multisubunit kinase complex, IKK, which phosphorylates I kappaB. I kappaB is subsequently degraded, releasing NF kappaB, which translocates to the nucleus. We previously reported that inhibitors of the calcium-binding protein calmodulin (CaM) prevent phorbol ester-induced phosphorylation of I kappaB. Here we show that KN93, an inhibitor of CaM-dependent kinases (CaMKs), also inhibits the phosphorylation of I kappaB. The effect of both CaM and CaMK inhibitors on I kappaB phosphorylation is due to the inhibition of the activity of CaMK II because neither drug has any effect when a derivative of CaMK II that is insensitive to these inhibitors is expressed. When CaMK II is inhibited, phorbol ester is no longer able to activate IKK, placing CaMK II in the signaling pathway that leads to IKK activation. CaM and CaMK inhibitors also block T cell receptor/CD3-induced activation but have no effect on the ability of the cytokine tumor necrosis factor alpha or the phosphatase inhibitor calyculin A to induce degradation of I kappaB. Finally we show that expression of a constitutively active CaMK II results in the activation of NF kappaB. The results identify CaMK Il as a mediator of IKK activation specifically in response to T cell receptor/CD3 and phorbol ester stimulation.	Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden	Umea University	Grundstrom, T (corresponding author), Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden.							ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dupont G, 1998, BIOESSAYS, V20, P607, DOI 10.1002/(SICI)1521-1878(199808)20:8<607::AID-BIES2>3.3.CO;2-2; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; HIDAKA H, 1992, CELL CALCIUM, V13, P465, DOI 10.1016/0143-4160(92)90059-2; HIDAKA H, 1983, METHOD ENZYMOL, V102, P185; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Hughes K, 1998, FEBS LETT, V441, P132, DOI 10.1016/S0014-5793(98)01537-3; Ishida A, 1998, J BIOL CHEM, V273, P1904, DOI 10.1074/jbc.273.4.1904; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kitani T, 1999, J BIOCHEM-TOKYO, V125, P1022, DOI 10.1093/oxfordjournals.jbchem.a022381; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liljeholm S, 1998, J GEN VIROL, V79, P2117, DOI 10.1099/0022-1317-79-9-2117; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Lukas TJ, 1998, CALMODULIN AND SIGNAL TRANSDUCTION, P65; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; OLWIN BB, 1984, J BIOL CHEM, V259, P949; Onions J, 1997, J BIOL CHEM, V272, P23930, DOI 10.1074/jbc.272.38.23930; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; SCHULMAN H, 1995, PROG BRAIN RES, V105, P95; Schwaninger M, 1999, J NEUROCHEM, V73, P1461, DOI 10.1046/j.1471-4159.1999.0731461.x; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; WAXHAM MN, 1993, BIOCHEMISTRY-US, V32, P2923, DOI 10.1021/bi00062a024; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	55	91	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					36008	36013		10.1074/jbc.M106125200	http://dx.doi.org/10.1074/jbc.M106125200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11470799	hybrid			2022-12-25	WOS:000171109300104
J	Richmonds, CR; Kaminski, HJ				Richmonds, CR; Kaminski, HJ			Nitric oxide synthase expression and effects of nitric oxide modulation on contractility of rat extraocular muscle	FASEB JOURNAL			English	Article						extraocular muscle; nitric oxide; muscle contractility; neuronal nitric oxide synthase	NEURONAL NADPH DIAPHORASE; FUNCTION IN-VITRO; SKELETAL-MUSCLE; SUPERIOR RECTUS; FIBERS; NITROSYLATION; STIMULATION; PROTEINS; PRODUCTS; LEVATOR	Extraocular muscles (EOMs) are specialized skeletal muscles that are constantly active, generate low levels of force for cross sectional area, have rapid contractile speeds, and are highly fatigue resistant. The neuronal isoform of nitric oxide synthase (nNOS) is concentrated at the sarcolemma of fast-twitch muscles fibers, and nitric oxide (NO) modulates contractility. This study evaluated nNOS expression in EOM and the effect of NO modulation on lateral rectus muscle's contractility. nNOS activity was highest in EOM compared with diaphragm, extensor digitorum longus, and soleus. Neuronal NOS was concentrated to the sarcolemma of orbital and global singly innervated fibers, but not evident in the multi-innervated fibers. The N-G-nitro-L-arginine methyl ester (L-NAME, a NOS inhibitor), increased submaximal tetanic and peak twitch forces. The NO donors S-nitroso-N-acetylcysteine (SNAC) and spermineNONOate reduced submaximal tetanic and peak twitch forces. The effect of NO on the contractile force of lateral rectus muscle is greater than previously observed on other skeletal muscle. NO appears more important in modulating contraction of EOM compared with other skeletal muscles, which could be important for the EOM's specialized role in generation of eye movements.	Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med,Dept Neurol, Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med,Dept Neurosci, Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; US Department of Veterans Affairs; Veterans Health Administration (VHA); Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; US Department of Veterans Affairs; Veterans Health Administration (VHA); Louis Stokes Cleveland Veterans Affairs Medical Center	Kaminski, HJ (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med,Dept Neurol, Louis Stokes Cleveland Vet Affairs Med Ctr, 11100 Euclid Ave, Cleveland, OH 44106 USA.	hjk3@po.cwru.edu		Kaminski, Henry/0000-0002-8195-0141	NATIONAL EYE INSTITUTE [R01EY011998, R01EY013238] Funding Source: NIH RePORTER; NEI NIH HHS [EY-13238, EY-11998, EY-113373-01A1] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andrade FH, 2000, MICROSC RES TECHNIQ, V48, P192, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<192::AID-JEMT7>3.0.CO;2-J; Andrade FH, 1998, J PHYSIOL-LONDON, V509, P577, DOI 10.1111/j.1469-7793.1998.577bn.x; ASMUSSEN G, 1981, PFLUG ARCH EUR J PHY, V392, P183, DOI 10.1007/BF00581270; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Burke R.E., 1981, HDB PHYSL SECTION 1, VII, P345, DOI 10.1002/cphy.cp010210; Christen S, 1996, METHOD ENZYMOL, V269, P267; CLOSE RI, 1974, J PHYSIOL-LONDON, V236, P259, DOI 10.1113/jphysiol.1974.sp010434; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DEMEIS L, 1967, AM J PHYSIOL, V212, P92, DOI 10.1152/ajplegacy.1967.212.1.92; Demer JL, 2000, INVEST OPHTH VIS SCI, V41, P1280; Espey MG, 2000, ANN NY ACAD SCI, V899, P209; FRUEH BR, 1994, J PHYSIOL-LONDON, V475, P327, DOI 10.1113/jphysiol.1994.sp020073; Galler S, 1997, PFLUG ARCH EUR J PHY, V434, P242, DOI 10.1007/s004240050391; Gross WL, 1996, P NATL ACAD SCI USA, V93, P5604, DOI 10.1073/pnas.93.11.5604; HANSON J, 1977, ACTA OPHTHALMOL, V55, P88; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; JACOBY J, 1989, J NEUROPHYSIOL, V61, P116, DOI 10.1152/jn.1989.61.1.116; KAMINSKI HJ, 2001, IN PRESS NEUROMUSC D; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; Kroncke KD, 1996, METHOD ENZYMOL, V269, P279; Kusner LL, 1996, BRAIN RES, V730, P238; Loughlin M., 1993, MUSCLE BIOPSY LAB IN; LYNCH GS, 1994, J PHYSIOL-LONDON, V475, P337, DOI 10.1113/jphysiol.1994.sp020074; MENDEZ J, 1960, METABOLISM, V9, P184; MESZAROS L G, 1991, Biophysical Journal, V59, p252A; MURRANT CL, 1995, CAN J PHYSIOL PHARM, V73, P736, DOI 10.1139/y95-096; MURRANT CL, 1994, CAN J PHYSIOL PHARM, V72, P1089, DOI 10.1139/y94-152; Murrant CL, 1997, CAN J PHYSIOL PHARM, V75, P414, DOI 10.1139/y97-096; Park JH, 1998, J NEUROSCI, V18, P5463, DOI 10.1523/JNEUROSCI.18-14-05463.1998; PORTER JD, 1995, SURV OPHTHALMOL, V39, P451, DOI 10.1016/S0039-6257(05)80055-4; Porter JD, 1996, NEUROLOGY, V46, P30, DOI 10.1212/WNL.46.1.30; Redford EJ, 1997, BRAIN, V120, P2149, DOI 10.1093/brain/120.12.2149; Reid MB, 1998, ACTA PHYSIOL SCAND, V162, P401, DOI 10.1046/j.1365-201X.1998.0303f.x; Reid MB, 1998, COMP BIOCHEM PHYS A, V119, P211, DOI 10.1016/S1095-6433(97)00417-0; Richmonds CR, 1999, MECH AGEING DEV, V109, P177, DOI 10.1016/S0047-6374(99)00035-4; Richmonds CR, 2000, MECH AGEING DEV, V113, P183, DOI 10.1016/S0047-6374(99)00106-2; Ruff R, 1989, Bull Soc Belge Ophtalmol, V237, P321; SARTORE S, 1987, J MUSCLE RES CELL M, V8, P161, DOI 10.1007/BF01753992; SHALL MS, 1992, BRAIN RES, V587, P291, DOI 10.1016/0006-8993(92)91010-C; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; Spencer R F, 1988, Rev Oculomot Res, V2, P33; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; WIECZOREK DF, 1985, J CELL BIOL, V101, P618, DOI 10.1083/jcb.101.2.618; Wolosker H, 1996, FEBS LETT, V392, P274, DOI 10.1016/0014-5793(96)00829-0	48	20	20	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2001	15	10					1764	1770		10.1096/fj.00-0899com	http://dx.doi.org/10.1096/fj.00-0899com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481224				2022-12-25	WOS:000170809900012
J	Azuma, Y; Tan, SH; Cavenagh, MM; Ainsztein, AM; Saitoh, H; Dasso, M				Azuma, Y; Tan, SH; Cavenagh, MM; Ainsztein, AM; Saitoh, H; Dasso, M			Expression and regulation of the mammalian SUMO-1 E1 enzyme	FASEB JOURNAL			English	Article						SUMO-1; Uba2; Aos1; Ubc9	UBIQUITIN-CONJUGATING ENZYME; GTPASE-ACTIVATING PROTEIN; NUCLEAR-PORE COMPLEX; YEAST; HOMOLOG; RANGAP1; DEGRADATION; KINASE; RANBP2; UBC9P	SUMO-1 is a small ubiquitin-related protein. SUMO-1 conjugation requires enzymes with sequence and biochemical similarity to ubiquitin E1 and E2 enzymes. We have examined the expression, localization, and biochemical behavior of Aos1 and Uba2, subunits of the mammalian SUMO-1 E1 enzyme. Both of these proteins are expressed in multiple tissues and localized to the nucleus. Aos1 protein levels vary through the cell cycle. These changes in Aos1 concentration may play a role in the regulation of the SUMO-1 pathway, because they correlate with changes in the abundance of some SUMO-1-conjugated species. Biochemical analysis reveals that Aos1 and Uba2 associate with each other in a simple heterodimeric complex without other subunits, unlike the budding yeast Uba2 homologue, which apparently associates with several different proteins. Although it is possible to reconstitute SUMO-1 conjugation with purified Uba2, Aos1, and Ubc9, this reaction is significantly less efficient than conjugation observed in cellular extracts, suggesting the possibility that there may be activators of SUMO-1 conjugation in vivo that have not yet been characterized. Taken together, these observations reveal that the SUMO-1 pathway is controlled on multiple levels during the cell cycle.	NICHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dasso, M (corresponding author), NICHD, Mol Embryol Lab, NIH, Bldg 18,Room 106, Bethesda, MD 20892 USA.	mdasso@helix.nih.gov	Tan, Shyh-Han/I-7037-2013	Tan, Shyh-Han/0000-0001-8250-7005; Dasso, Mary/0000-0002-5410-1371	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001902] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001902] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALKHODAIRY F, 1995, J CELL SCI, V108, P486; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Harlow E., 1988, ANTIBODIES LAB MANUA; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shayeghi M, 1997, NUCLEIC ACIDS RES, V25, P1162, DOI 10.1093/nar/25.6.1162; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Tanaka K, 1998, MOL CELLS, V8, P503; Tanaka K, 1999, MOL CELL BIOL, V19, P8660; Tarsounas M, 1997, MOL BIOL CELL, V8, P1405, DOI 10.1091/mbc.8.8.1405; Tashiro K, 1997, P NATL ACAD SCI USA, V94, P7862, DOI 10.1073/pnas.94.15.7862; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	26	44	50	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1825	+		10.1096/fj.00-0818fje	http://dx.doi.org/10.1096/fj.00-0818fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481243				2022-12-25	WOS:000169261200028
J	Garcia, JRC; Krause, A; Schulz, S; Rodriguez-Jimenez, FJ; Kluver, E; Adermann, K; Forssmann, U; Frimpong-Boateng, A; Bals, R; Forssmann, WG				Garcia, JRC; Krause, A; Schulz, S; Rodriguez-Jimenez, FJ; Kluver, E; Adermann, K; Forssmann, U; Frimpong-Boateng, A; Bals, R; Forssmann, WG			Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity	FASEB JOURNAL			English	Article						peptide antibiotics; mucosal immunity; cystic fibrosis; host defense; synergism	INNATE HOST-DEFENSE; HUMAN BETA-DEFENSIN-1; GENE-EXPRESSION; ANTIBIOTICS; ACTIVATION; EPITHELIA; INFECTION; CHEMOKINE; LUNG	beta Defensins are antibiotic peptides involved in host defense at the epithelial surface. Three human beta -defensins (hBDs)-hBD-1, hBD-2, and hBD-3-have been identified so far. We have characterized a new member of the beta -defensin family, hBD-4, based on screening of genomic sequences and subsequent functional analysis. In contrast to hBD-1, hBD-2, and hBD-3, which are diffusely expressed throughout many organs, hBD-4 mRNA expression is confined to testis, stomach, uterus, neutrophils, thyroid, lung, and kidney. hBD-4 expression was up-regulated by infection with gram-positive and gram-negative bacteria in human respiratory epithelial cells, and in response to phorbol 12-myristate 13-acetate, but not in response to other inflammatory factors that up-regulate the expression of hBD-2 or hBD-3. Synthetic hBD-4 exhibits a selective, salt-sensitive spectrum of antimicrobial activity, and it represents one of the most active antimicrobial peptides against Pseudomonas aeruginosa (minimal inhibitory concentration: 4.1 mug/ml) known to date. This new defensin is chemotactic for human blood monocytes, but it is inactive on neutrophils and eosinophils. These findings demonstrate the existence of a family of beta -defensin genes with different functions against diverse classes of microorganisms, regulated by different stimuli, and specific signal pathways, and confirm the relevance of antimicrobial peptides in host defense.	IPF PharmaCeut GmbH, D-30625 Hannover, Germany; Univ Munich, Med Klin 1, D-81377 Munich, Germany	University of Munich	Forssmann, WG (corresponding author), IPF PharmaCeut GmbH, Feodor Lynen Str 31, D-30625 Hannover, Germany.	wgforssmann@gmx.de	Conejo-Garcia, Jose R/V-1897-2019	Conejo-Garcia, Jose R/0000-0001-6431-4074				Bals R, 1999, INFECT IMMUN, V67, P3542, DOI 10.1128/IAI.67.7.3542-3547.1999; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Bevins CL, 1999, GUT, V45, P911, DOI 10.1136/gut.45.6.911; Bieche I, 1999, CANCER RES, V59, P2759; BUCHLER P, 2001, IN PRESS PANCREAS; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Diamond G, 1998, CLIN IMMUNOL IMMUNOP, V88, P221, DOI 10.1006/clin.1998.4587; Diamond G, 2000, INFECT IMMUN, V68, P113, DOI 10.1128/IAI.68.1.113-119.2000; Eliopoulos G.M., 1991, ANTIBIOTICS LAB MED, V3rd Edn, P432; Fehlbaum P, 2000, P NATL ACAD SCI USA, V97, P12723, DOI 10.1073/pnas.220424597; Friedrich C, 1999, ANTIMICROB AGENTS CH, V43, P1542, DOI 10.1128/AAC.43.7.1542; Ganz T, 1999, SCIENCE, V286, P420, DOI 10.1126/science.286.5439.420; GARCIA JRC, 2001, IN PRESS CELL TISSUE; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; Jia HP, 2000, J BIOL CHEM, V275, P33314, DOI 10.1074/jbc.M006603200; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Linzmeier R, 1999, GENE, V233, P205, DOI 10.1016/S0378-1119(99)00136-5; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; Monick MM, 2001, J IMMUNOL, V166, P2681, DOI 10.4049/jimmunol.166.4.2681; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; Pardigol A, 1998, P NATL ACAD SCI USA, V95, P6308, DOI 10.1073/pnas.95.11.6308; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; TANG YQ, 1993, J BIOL CHEM, V268, P6649; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yu QT, 2000, J BIOL CHEM, V275, P3943, DOI 10.1074/jbc.275.6.3943	38	401	446	2	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1819	+		10.1096/fj.00-0865fje	http://dx.doi.org/10.1096/fj.00-0865fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481241				2022-12-25	WOS:000169261200026
J	van der Goes, A; Wouters, D; van der Pol, SMA; Huizinga, R; Ronken, E; Adamson, P; Greenwood, J; Dijkstra, CD; de Vries, HE				van der Goes, A; Wouters, D; van der Pol, SMA; Huizinga, R; Ronken, E; Adamson, P; Greenwood, J; Dijkstra, CD; de Vries, HE			Reactive oxygen species enhance the migration of monocytes across the blood-brain barrier in vitro	FASEB JOURNAL			English	Article						multiple sclerosis; cerebral endothelial cells; signal transduction; transendothelial migration	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; EXPERIMENTAL OPTIC NEURITIS; CENTRAL-NERVOUS-SYSTEM; FOCAL ADHESION KINASE; ENDOTHELIAL-CELLS; FREE-RADICALS; TYROSINE PHOSPHORYLATION; SUPEROXIDE ANION; XANTHINE-OXIDASE; PERMEABILITY	Reactive oxygen species (ROS) are involved in the pathogenesis of several inflammatory and degenerative diseases, including multiple sclerosis (MS), an inflammatory disease of the central nervous system. We investigated the potential involvement of ROS in the interaction of monocytes with cerebral endothelium, because this is likely to be an early event in the development of MS lesions. ROS are produced via two main pathways, one involving NADPH oxidase complex and the other involving xanthine oxidase (XO). We examined the effects of ROS, ROS scavengers, and ROS inhibitors of both pathways on the migration of monocytes across the blood-brain barrier in vitro. Scavengers and inhibitors of XO predominantly inhibited monocyte migration, whereas inhibitors and scavengers of the NADPH oxidase complex had no effect. Exposure of cerebral endothelial cells (CEC) to superoxide (O(2)(-)) resulted in enhanced migration and adhesion of monocytes as well as disruption of the tight junctions, whereas hydroxyl radicals and hydrogen peroxide induced no significant effect on these parameters. Underlying mechanisms of the observed changes were found to reside in the phospholipase C-mediated signal transduction cascade, subsequent accumulation of inositol 1,4,5- trisphosphate, and mobilization of intracellular calcium. We conclude that O(2)(-) is a signaling molecule that is produced during the firm adhesion of monocytes to CEC, which triggers cytoskeletal rearrangements allowing infiltration of monocytes into the brain.	Vrije Univ Amsterdam, Fac Med, Dept Mol Cell Biol, NL-1081 BT Amsterdam, Netherlands; Solvay Pharmaceut BV, Solvay Res Labs, Weesp, Netherlands; UCL, Inst Ophthalmol, London, England	Vrije Universiteit Amsterdam; Solvay SA; University of London; University College London	de Vries, HE (corresponding author), VUMC, Dept Mol Cell Biol, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	HE.de_Vries.Cell@med.vu.nl		Greenwood, John/0000-0003-4496-2984				Arduini A, 1985, Free Radic Res Commun, V1, P129, DOI 10.3109/10715768509056546; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BRETT R, 1993, NEUROCHEM INT, V23, P35, DOI 10.1016/0197-0186(93)90141-Q; CHIA LS, 1983, BIOCHEM BIOPH RES CO, V117, P141, DOI 10.1016/0006-291X(83)91552-8; DELMAESTRO RF, 1982, CAN J PHYSIOL PHARM, V60, P1406; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; ETINEEMANNEVILL.S, 2000, AM J PHYSIOL, V165, P3375; GLABINSKI A, 1993, ACTA NEUROL SCAND, V88, P174; Gozin A, 1998, FREE RADICAL BIO MED, V25, P1021, DOI 10.1016/S0891-5849(98)00134-8; GREENWOOD J, 1995, IMMUNOLOGY, V86, P408; Grisham MB, 1998, FREE RADICAL BIO MED, V25, P404, DOI 10.1016/S0891-5849(98)00094-X; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUY J, 1993, OPHTHALMIC RES, V25, P253, DOI 10.1159/000267321; GUY J, 1989, CURR EYE RES, V8, P467, DOI 10.3109/02713688909000027; HARTUNG HP, 1988, ANN NEUROL, V23, P453, DOI 10.1002/ana.410230505; Ichikawa H, 1997, AM J PHYSIOL-GASTR L, V273, pG342, DOI 10.1152/ajpgi.1997.273.2.G342; Imaizumi S, 1996, NEUROCHEM INT, V29, P205, DOI 10.1016/0197-0186(95)00120-4; KONAT GW, 1985, J NEUROCHEM, V45, P1113, DOI 10.1111/j.1471-4159.1985.tb05530.x; Lagrange P, 1999, FREE RADICAL BIO MED, V27, P667, DOI 10.1016/S0891-5849(99)00112-4; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LIN RF, 1993, J EXP MED, V178, P643, DOI 10.1084/jem.178.2.643; OLESEN SP, 1987, ACTA PHYSIOL SCAND, V129, P181, DOI 10.1111/j.1748-1716.1987.tb08057.x; PUIG JG, 1989, ANN RHEUM DIS, V48, P883, DOI 10.1136/ard.48.11.883; RUBANYI GM, 1988, FREE RADICAL BIO MED, V4, P107, DOI 10.1016/0891-5849(88)90071-8; RUULS SR, 1995, J NEUROIMMUNOL, V56, P207, DOI 10.1016/0165-5728(94)00154-G; Soldi R, 1996, ONCOGENE, V13, P515; TAKAO S, 1996, AM J PHYSIOL, V271, pC1274; TERADA LS, 1991, J CELL PHYSIOL, V148, P191, DOI 10.1002/jcp.1041480202; TOSHNIWAL PK, 1992, NEUROCHEM RES, V17, P205, DOI 10.1007/BF00966801; van der Goes A, 1998, J NEUROIMMUNOL, V92, P67, DOI 10.1016/S0165-5728(98)00175-1; Ye JM, 1999, AM J PHYSIOL-RENAL, V277, pF524, DOI 10.1152/ajprenal.1999.277.4.F524	31	127	129	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1852	+		10.1096/fj.00-0881fje	http://dx.doi.org/10.1096/fj.00-0881fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481252				2022-12-25	WOS:000169261200012
J	Kovalsky, O; Lung, FDT; Roller, PP; Fornace, AJ				Kovalsky, O; Lung, FDT; Roller, PP; Fornace, AJ			Oligomerization of human Gadd45a protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; DNA-DAMAGE; NUCLEAR ANTIGEN; GROWTH; MYD118; REPAIR; GENES; PCNA; P53; ACCESSIBILITY	Gadd45a is an 18-kDa acidic protein that is induced by genotoxic and certain other cellular stresses. The exact function of this protein is not known. However, there is evidence for its involvement in growth control, maintenance of genomic stability, DNA repair, cell cycle control, and apoptosis. Consistently, Gadd45a has previously been shown to interact in vitro and/or in vivo with a number of proteins playing central roles in these cellular processes: proliferating cell nuclear antigen, p21(Cip1/Waf1), Cdc2-CyclinB complex, MTK1, and histories. Adding to this complexity, we have found that Gadd45a self-associates in solution, both in vitro and when expressed in the cell. Moreover, Gadd45a can complex with the two other members of the Gadd45 family of stress-induced proteins, human Gadd45b (MyD118) and Gadd45g (CR6). Gel-exclusion chromatography, native gel electrophoretic analysis, enzyme-linked immunosorbent assay, and chemical cross-linking showed that recombinant Gadd45a forms dimeric, trimeric, and tetrameric species in vitro, the dimers being the predominant form. Deletion mutant and peptide scanning analyses suggest that Gadd45a has two self-association sites: within N-terminal amino acids 33-61 and within 40 C-terminal amino acids. Despite the low abundance of Gadd45a in the cell, oligomer-forming concentrations can probably be achieved in the foci-like nuclear structures formed by the protein upon overexpression. Evidence for a potential role of Gadd45a self-association in altering DNA accessibility on damaged nucleosomes is presented.	NCI, NIH, Gene Response Sect, Bethesda, MD 20892 USA; Frederick Canc Res Ctr, Med Chem Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fornace, AJ (corresponding author), NCI, NIH, Gene Response Sect, Bldg 37,9000 Rockville Pike, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHEN IT, 1995, ONCOGENE, V11, P1931; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Engel J, 2000, MATRIX BIOL, V19, P283, DOI 10.1016/S0945-053X(00)00075-5; Fan W, 1999, ONCOGENE, V18, P6573, DOI 10.1038/sj.onc.1203054; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; GALLAGHER SR, 1999, CURRENT PROTOCOLS MO, V2, DOI DOI 10.12B.11-10.12B.15; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Heuer KH, 1996, BIOCHEMISTRY-US, V35, P9069, DOI 10.1021/bi952817o; Hollander MC, 2001, CANCER RES, V61, P2487; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kovalsky OI, 1998, J BIOL CHEM, V273, P21009, DOI 10.1074/jbc.273.33.21009; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; RODBARD D, 1971, ANAL BIOCHEM, V40, P95, DOI 10.1016/0003-2697(71)90086-8; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906	35	69	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39330	39339		10.1074/jbc.M105115200	http://dx.doi.org/10.1074/jbc.M105115200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11498536	hybrid			2022-12-25	WOS:000171673200132
J	Alonso, AD; Zaidi, T; Novak, M; Barra, HS; Grundke-Iqbal, I; Iqbal, K				Alonso, AD; Zaidi, T; Novak, M; Barra, HS; Grundke-Iqbal, I; Iqbal, K			Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; NEUROFIBRILLARY TANGLES; MICROTUBULE-BINDING; FETAL TAU; DEMENTIA; BRAIN; ASSAY; LOCALIZATION; EXPRESSION; MECHANISM	The microtubule-associated protein tau is a family of six isoforms that becomes abnormally hyperphosphorylated and accumulates in neurons undergoing neurodegeneration in the brains of patients with Alzheimer disease (AD). We investigated the isoform-specific interaction of normal tau with AD hyperphosphorylated tau (AD P-tau). We found that the binding of AD P-tau to normal human recombinant tau was tau 4L > tau 4S > tau4 and tau 3L > tau 3S > tau3, and that its binding to tau 4L was greater than to tau 3L. AD P-tau also inhibited the assembly of microtubules promoted by each tau isoform and caused disassembly when added to preassembled microtubules. This inhibition and depolymerization of microtubules by the AD P-tau corresponded directly to the degree of its interaction with the different tau isoforms. In vitro hyperphosphorylation of recombinant tau (P-tau) conferred AD P-tau-like characteristics. Like AD P-tau, P-tau interacted with and sequestered normal tau and inhibited microtubule assembly. These studies suggest that the AD P-tau interacts preferentially with the tau isoforms that have the amino-terminal inserts and four microtubule binding domain repeats and that hyperphosphorylation of tau appears to be sufficient to acquire AD P-tau characteristics. Thus, lack of amino-terminal inserts and extra microtubule binding domain repeat in fetal human brain might be protective from Alzheimer's neurofibrillary degeneration.	New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA; Consejo Nacl Invest Cient & Tecn, Ctr Invest Quim Biol Cordoba, Fac Ciencias Quim, Dept Quim Biol, RA-5000 Cordoba, Argentina; Slovak Acad Sci, Inst Neuroimmunol, Bratislava 84246, Slovakia	Institute for Basic Research in Developmental Disabilities; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Slovak Academy of Sciences	Iqbal, K (corresponding author), New York State Inst Basic Res Dev Disabil, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	kiqbal@admin.con2.com			FIC NIH HHS [TW00507] Funding Source: Medline; NIA NIH HHS [AG08076, AG05892] Funding Source: Medline; NIMH NIH HHS [MH/NS 31862] Funding Source: Medline; NINDS NIH HHS [NS18105] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW000507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH031862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008076, R01AG005892] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALAFUZOFF I, 1987, ACTA NEUROPATHOL, V74, P209, DOI 10.1007/BF00688184; Alonso AD, 1997, P NATL ACAD SCI USA, V94, P298, DOI 10.1073/pnas.94.1.298; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Arrasate M, 1999, FEBS LETT, V446, P199, DOI 10.1016/S0014-5793(99)00210-0; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GRUNDKEIQBAL I, 1988, MOL BRAIN RES, V4, P43, DOI 10.1016/0169-328X(88)90017-4; HASEGAWA M, 1993, J NEUROCHEM, V60, P2068, DOI 10.1111/j.1471-4159.1993.tb03491.x; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; IQBAL K, 1986, LANCET, V2, P421; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; IQBAL K, 1995, NEUROBIOL AGING, V16, P375, DOI 10.1016/0197-4580(95)00033-B; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; KOPKE E, 1993, J BIOL CHEM, V268, P24374; KREMER L, 1988, ANAL BIOCHEM, V175, P91, DOI 10.1016/0003-2697(88)90365-X; KSIEZAKREDING H, 1995, J NEUROSCI RES, V41, P583, DOI 10.1002/jnr.490410504; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LIU WK, 1993, AM J PATHOL, V142, P387; MERCKEN M, 1992, ACTA NEUROPATHOL, V84, P265, DOI 10.1007/BF00227819; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; NOVAK M, 1991, P NATL ACAD SCI USA, V88, P5837, DOI 10.1073/pnas.88.13.5837; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Ruben GC, 1997, SYNAPSE, V27, P208, DOI 10.1002/(SICI)1098-2396(199711)27:3<208::AID-SYN7>3.0.CO;2-H; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SINGH TJ, 1995, FEBS LETT, V358, P267, DOI 10.1016/0014-5793(94)01445-7; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Spillantini MG, 2000, ANN NEUROL, V48, P939; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Terry R.D., 1972, AGING BRAIN, P89; TOMLINSON BE, 1970, J NEUROL SCI, V11, P205, DOI 10.1016/0022-510X(70)90063-8; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; Wang JZ, 1996, NAT MED, V2, P871, DOI 10.1038/nm0896-871; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WISNIEWSKI HM, 1984, J NEUROPATH EXP NEUR, V43, P643, DOI 10.1097/00005072-198411000-00008; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787	57	134	140	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37967	37973						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11495914				2022-12-25	WOS:000171526500035
J	Sanker, S; Campbell, HA; Kent, C				Sanker, S; Campbell, HA; Kent, C			Negative cooperativity of substrate binding but not enzyme activity in wild-type and mutant forms of CTP : glycerol-3-phosphate cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; TRANSFER RNA-SYNTHETASE; BACILLUS-SUBTILIS; GLYCEROL-3-PHOSPHATE CYTIDYLYLTRANSFERASE; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; TEICHOIC-ACID; FLUORESCENCE; PURIFICATION; EXPRESSION	CTP:glycerol-3-phosphate cytidylyltransferase (GCT) catalyzes the synthesis of CDP-glycerol for teichoic acid biosynthesis in certain Gram-positive bacteria. This enzyme is a model for a cytidylyltransferase family that includes the enzymes that synthesize CDP-choline and CDP-ethanolamine for phosphatidylcholine and phosphatidylethanolamine biosynthesis. We have used quenching of intrinsic tryptophan fluorescence to measure binding affinities of substrates to the GCT from Bacillus subtilis. Binding of either CTP or glycerol-3-phosphate to GCT was biphasic, with two binding constants of about 0.1-0.3 and 20-40 mum for each substrate. The stoichiometry of binding was 2 molecules of substrate/enzyme dimer, so the two binding constants represented distinctly different affinities of the enzyme for the first and second molecule of each substrate. The biphasic nature of binding was observed with the wildtype GCT as well as with several mutants with altered K-m or k(cat) values. This negative cooperativity of binding was also seen when a catalytically defective mutant was saturated with two molecules of CTP and then titrated with glycerol-3-phosphate. Despite the pronounced negative cooperativity of substrate binding, negative cooperativity of enzyme activity was not observed. These data support a mechanism in which catalysis occurs only when the enzyme is fully loaded with 2 molecules of each substrate/enzyme dimer.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kent, C (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 4417 Med Sci 1, Ann Arbor, MI 48109 USA.			Adams, Heidi/0000-0001-7563-3126	NATIONAL CANCER INSTITUTE [R01CA064159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060510] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA64159] Funding Source: Medline; NIDDK NIH HHS [P60DK-20572] Funding Source: Medline; NIGMS NIH HHS [GM60510] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; Bladergroen BA, 1997, BBA-LIPID LIPID MET, V1348, P91, DOI 10.1016/S0005-2760(97)00113-6; CHEAH SC, 1982, J GEN MICROBIOL, V128, P593; CHEAH SC, 1981, EUR J BIOCHEM, V118, P497, DOI 10.1111/j.1432-1033.1981.tb05546.x; CHEN RF, 1965, ANAL BIOCHEM, V13, P523, DOI 10.1016/0003-2697(65)90347-7; CHOY PC, 1980, J BIOL CHEM, V255, P1070; DELARUE M, 1993, BIOESSAYS, V15, P675, DOI 10.1002/bies.950151007; ELLIS J, 1991, BIOCHEMISTRY-US, V30, P10806, DOI 10.1021/bi00108a029; ENGEL PC, 1981, ENZYME KINETICS STEA; Friesen JA, 1999, J BIOL CHEM, V274, P13384, DOI 10.1074/jbc.274.19.13384; HUSSEY H, 1978, EUR J BIOCHEM, V82, P169, DOI 10.1111/j.1432-1033.1978.tb12008.x; JONES MD, 1986, BIOCHEMISTRY-US, V25, P1887, DOI 10.1021/bi00356a008; KELLN RA, 1975, J BACTERIOL, V124, P764, DOI 10.1128/JB.124.2.764-774.1975; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAUEL C, 1991, J GEN MICROBIOL, V137, P929, DOI 10.1099/00221287-137-4-929; Neet K E, 1980, Methods Enzymol, V64, P139; Park YS, 1997, J BIOL CHEM, V272, P15161, DOI 10.1074/jbc.272.24.15161; PARK YS, 1993, J BIOL CHEM, V268, P16648; POOLE HM, 1991, J GEN MICROBIOL, V137, P921, DOI 10.1099/00221287-137-4-921; ROSENBERGER RF, 1976, BIOCHIM BIOPHYS ACTA, V428, P516, DOI 10.1016/0304-4165(76)90060-X; SCHWARTZ M, 1975, J BACTERIOL, V121, P814, DOI 10.1128/JB.121.3.814-822.1975; Segel I. H., 1975, ENZYME KINETICS, pxxii; VILLADSEN IS, 1977, J BACTERIOL, V130, P136, DOI 10.1128/JB.130.1.136-143.1977; WARD LD, 1985, METHOD ENZYMOL, V117, P400; Weber CH, 1999, STRUCTURE, V7, P1113, DOI 10.1016/S0969-2126(99)80178-6; WEBER J, 1993, J BIOL CHEM, V268, P20126; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503	31	16	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37922	37928						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11487587				2022-12-25	WOS:000171526500029
J	Chappell, SA; Owens, GC; Mauro, VP				Chappell, SA; Owens, GC; Mauro, VP			A 5 ' leader of Rbm3, a cold stress-induced mRNA, mediates internal initiation of translation with increased efficiency under conditions of mild hypothermia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-ENTRY-SITE; C-MYC; PROTEIN-SYNTHESIS; UNTRANSLATED REGION; CELLS; IDENTIFICATION; DROSOPHILA; GENE; IRES; COMPLEMENTARITY	Although mild hypothermia generally reduces protein synthesis in mammalian cells, the expression of a small number of proteins, including Rbm3, is induced under these conditions. In this study, we identify an Rbm3 mRNA with a complex 5' leader sequence containing multiple upstream open reading frames. Although these are potentially inhibitory to translation, monocistronic reporter mRNAs containing this leader were translated relatively efficiently. In addition, when tested in the intercistronic region of dicistronic mRNAs, this leader dramatically enhanced second cistron translation, both in transfected cells and in cell-free lysates, suggesting that the Rbm3 leader mediates cap-independent translation via an internal ribosome entry site (IRES). Inasmuch as Rbm3 mRNA and protein levels are both increased in cells exposed to mild hypothermia, the activity of this IRES was evaluated at a cooler temperature. Compared to 37 degreesC, IRES activity at 33 degreesC was enhanced up to 5-fold depending on the cell line. Moderate enhancements also occurred with constructs containing other viral and cellular IRESes. These effects of mild hypothermia on translation were not caused by decreased cell growth, as similar effects were not observed when cells were serum starved. The results suggest that cap-independent mechanisms may facilitate the translation of particular mRNAs during mild hypothermia.	Scripps Res Inst, Dept Neurobiol, La Jolla, CA 92037 USA; Inst Neurosci, San Diego, CA 92121 USA; Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Mauro, VP (corresponding author), Scripps Res Inst, Dept Neurobiol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	vmauro@scripps.edu			NIGMS NIH HHS [GM61725] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061725] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Borman AM, 1997, NUCLEIC ACIDS RES, V25, P925, DOI 10.1093/nar/25.5.925; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Cai A, 1999, BIOCHEMISTRY-US, V38, P8538, DOI 10.1021/bi9830213; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Danno S, 1997, BIOCHEM BIOPH RES CO, V236, P804, DOI 10.1006/bbrc.1997.7059; Danno S, 2000, AM J PATHOL, V156, P1685, DOI 10.1016/S0002-9440(10)65039-0; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; Fujita Jun, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P243; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; Geballe AP, 2000, COLD SPRING HARBOR M, V39, P595; GRAY NK, 1994, MOL BIOL REP, V19, P195, DOI 10.1007/BF00986961; HICKEY ED, 1976, P NATL ACAD SCI USA, V73, P19, DOI 10.1073/pnas.73.1.19; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hu MCY, 1999, P NATL ACAD SCI USA, V96, P1339, DOI 10.1073/pnas.96.4.1339; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Keiper BD, 1997, NUCLEIC ACIDS RES, V25, P395, DOI 10.1093/nar/25.2.395; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lundquist EA, 1996, DEVELOPMENT, V122, P1601; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mauro VP, 1997, P NATL ACAD SCI USA, V94, P422, DOI 10.1073/pnas.94.2.422; Meijer HA, 2000, J BIOL CHEM, V275, P30787, DOI 10.1074/jbc.M005531200; NAKAMURA M, 1994, NEURON, V13, P67, DOI 10.1016/0896-6273(94)90460-X; Nishiyama H, 1997, GENE, V204, P115, DOI 10.1016/S0378-1119(97)00530-1; Nishiyama H, 1997, J CELL BIOL, V137, P899, DOI 10.1083/jcb.137.4.899; Owens GC, 2001, P NATL ACAD SCI USA, V98, P1471, DOI 10.1073/pnas.98.4.1471; PANET R, 1983, J MEMBRANE BIOL, V75, P219, DOI 10.1007/BF01871952; Phadtare S, 1999, CURR OPIN MICROBIOL, V2, P175, DOI 10.1016/S1369-5274(99)80031-9; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; Sheikh MS, 1997, J BIOL CHEM, V272, P26720, DOI 10.1074/jbc.272.42.26720; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Tranque P, 1998, P NATL ACAD SCI USA, V95, P12238, DOI 10.1073/pnas.95.21.12238; Wassmann H, 1998, NEUROL RES, V20, pS61; Zhou W, 2001, P NATL ACAD SCI USA, V98, P1531, DOI 10.1073/pnas.98.4.1531	43	71	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36917	36922		10.1074/jbc.M106008200	http://dx.doi.org/10.1074/jbc.M106008200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11470798	hybrid			2022-12-25	WOS:000171375700010
J	Park, J; Hill, MM; Hess, D; Brazil, DP; Hofsteenge, J; Hemmings, BA				Park, J; Hill, MM; Hess, D; Brazil, DP; Hofsteenge, J; Hemmings, BA			Identification of tyrosine phosphorylation sites on 3-phosphoinositide-dependent protein kinase-1 and their role in regulating kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE-DEPENDENT KINASE-1; INSULIN SIGNAL-TRANSDUCTION; PLECKSTRIN HOMOLOGY DOMAIN; C-ZETA; IN-VIVO; PHOSPHATASE INHIBITORS; INOSITOL PHOSPHATES; CARBOXYL-TERMINUS; GAMMA ISOFORMS; RAT ADIPOCYTES	3-Phosphoinositide-dependent protein kinase-1 (PDK1) plays a central role in signal transduction pathways that activate phosphoinositide 3-kinase. Despite its key role as an upstream activator of enzymes such as protein kinase B and p70 ribosomal protein S6 kinase, the regulatory mechanisms controlling PDK1 activity are poorly understood. PDK1 has been reported to be constitutively active in resting cells and not further activated by growth factor stimulation (Casamayor, A., Morrice, N. A., and Alessi, D. R. (1999) Biochem. J. 342, 287-292). Here, we report that PDK1 becomes tyrosine-phosphorylated and translocates to the plasma membrane in response to pervanadate and insulin. Following pervanadate treatment, PDK1 kinase activity increased 1.5- to 3-fold whereas the activity of PDK1 associated with the plasma membrane increased similar to6-fold. The activity of PDK1 localized to the plasma membrane was also increased by insulin treatment. Three tyrosine phosphorylation sites of PDK1 (Tyr-9 and Tyr-373/376) were identified using in vivo labeling and mass spectrometry. Using site-directed mutants, we show that, although phosphorylation on Tyr-373/376 is important for PDK1 activity, phosphorylation on Tyr-9 has no effect on the activity of the kinase. Both of these residues can be phosphorylated by v-Src tyrosine kinase in vitro, and co-expression of v-Src leads to tyrosine phosphorylation and activation of PDK1. Thus, these data suggest that PDK1 activity is regulated by reversible phosphorylation, possibly by a member of the Src kinase family.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.	hemmings@fmi.ch	Hill, Michelle Mei Chih/G-4417-2010; Park, Jongsun/E-7465-2010	Hill, Michelle Mei Chih/0000-0003-1134-0951; Park, Jongsun/0000-0002-4690-1854; Brazil, Derek/0000-0003-1375-1076				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Bandyopadhyay G, 1999, MOL ENDOCRINOL, V13, P1766, DOI 10.1210/me.13.10.1766; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Bevan P, 2001, J CELL SCI, V114, P1429; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; CANTLEY LC, 1994, J CELL SCI, P121; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Cho KS, 2001, P NATL ACAD SCI USA, V98, P6144, DOI 10.1073/pnas.101596998; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Dunant NM, 1997, J VIROL, V71, P199, DOI 10.1128/JVI.71.1.199-206.1997; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0; Frech M, 1998, METH MOL B, V88, P197; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; Grillo S, 2000, EUR J BIOCHEM, V267, P6642, DOI 10.1046/j.1432-1327.2000.01759.x; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Inagaki M, 1999, MOL CELL BIOL, V19, P8344; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Myles T, 2001, BIOCHEM J, V357, P225, DOI 10.1042/0264-6021:3570225; Niederberger C, 1999, MOL GEN GENET, V261, P177, DOI 10.1007/s004380050955; PAPAYANNOPOULOS IA, 1995, MASS SPECTROM REV, V14, P49, DOI 10.1002/mas.1280140104; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Prasad N, 2000, BIOCHEMISTRY-US, V39, P6929, DOI 10.1021/bi000387i; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	88	99	108	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37459	37471		10.1074/jbc.M105916200	http://dx.doi.org/10.1074/jbc.M105916200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11481331	hybrid			2022-12-25	WOS:000171375700080
J	Rothbauer, U; Hofmann, S; Muhlenbein, N; Paschen, SA; Gerbitz, KD; Neupert, W; Brunner, M; Bauer, MF				Rothbauer, U; Hofmann, S; Muhlenbein, N; Paschen, SA; Gerbitz, KD; Neupert, W; Brunner, M; Bauer, MF			Role of the deafness dystonia peptide 1 (DDP1) in import of human Tim23 into the inner membrane of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; INTERMEMBRANE SPACE; PREPROTEIN TRANSLOCASE; PROTEIN TRANSLOCATION; MENTAL DEFICIENCY; CARRIER PROTEINS; COMPLEXES; TRANSPORT; BLINDNESS; SYSTEM	Tim8 and Tim13 of yeast belong to a family of evolutionary conserved zinc finger proteins that are organized in hetero-oligomeric complexes in the mitochondrial intermembrane space. Mutations in DDP1 (deafness dystonia peptide 1), the human homolog of Tim8, are associated with the Mohr-Tranebjaerg syndrome, a progressive neurodegenerative disorder. We show that DDP1 acts with human Tim13 in a complex in the intermembrane space. The DDP1 . hTim13 complex is in direct contact with translocation intermediates of human Tim23 in mammalian mitochondria. The human DDP1 . hTim13 complex complements the function of the TIM8 . 13 complex in yeast and facilitates import of yeast and human Tim23. Thus, the pathomechanism underlying the Mohr-Tranebjaerg syndrome may involve an impaired biogenesis of the human TIM23 complex causing severe pleiotropic mitochondrial dysfunction.	Akad Lehrkrankenhaus Munchen Schwabing, Inst Klin Chem Mol Diagnost & Mitochondriale Gene, D-80804 Munich, Germany; Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany	University of Munich	Bauer, MF (corresponding author), Akad Lehrkrankenhaus Munchen Schwabing, Inst Klin Chem Mol Diagnost & Mitochondriale Gene, Koelner Pl 1, D-80804 Munich, Germany.		Rothbauer, Ulrich/C-7712-2018	Rothbauer, Ulrich/0000-0001-5923-8986; Brunner, Michael/0000-0001-9798-3047				Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bauer MF, 1999, J MOL BIOL, V289, P69, DOI 10.1006/jmbi.1999.2751; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; Davis AJ, 2000, J CELL BIOL, V150, P1271, DOI 10.1083/jcb.150.6.1271; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Jin H, 1999, GENOMICS, V61, P259, DOI 10.1006/geno.1999.5966; Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; Pfanner N, 1998, CURR BIOL, V8, pR262, DOI 10.1016/S0960-9822(98)70168-X; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257; Tranebjaerg L, 2000, EUR J HUM GENET, V8, P464, DOI 10.1038/sj.ejhg.5200483	30	68	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37327	37334		10.1074/jbc.M105313200	http://dx.doi.org/10.1074/jbc.M105313200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11489896	hybrid			2022-12-25	WOS:000171375700063
J	Sakamoto, S; Taniguchi, T				Sakamoto, S; Taniguchi, T			Identification of a phorbol ester-responsive element in the interferon-gamma receptor 1 chain gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; CLASS-II TRANSACTIVATOR; IFN-GAMMA; TYROSINE PHOSPHORYLATION; MACROPHAGE ACTIVATION; BINDING PROTEIN; EXPRESSION; PROMOTER; INDUCTION; CELLS	Human monocytic leukemia THP-1 cells differentiate into macrophage-like cells when treated with 12-O-tetradecanoylphorbol-13-acetate (TPA). During this process, interferon-gamma (IFN-gamma)-inducible expression of human leukocyte antigen-DR alpha is markedly enhanced. The enhancement of human leukocyte antigen-DRa expression is at least due to the TPA-dependent induction of the IFN-gamma receptor 1 chain and IFN-gamma receptor 2 chain genes. Here we have studied the mechanism of TPA-induced up-regulation of the IFN-gamma receptor 1 chain gene. Reporter gene analyses of 5'-deletion constructs of the IFN-gamma receptor 1 gene (IFNGR1) promoter indicated that the critical region for control of transcription and the TPA-responsive element (TRE) were present in the -128 to -109 base pair (bp) region. We confirmed that this region of the IFNGR1 promoter was responsive to TPA-induced signals by using a reporter construct whose promoter consisted of the - 128 to - 109 bp fragment and the minimal herpes simplex virus thymidine kinase promoter. Moreover, a supershift assay indicated that Spl bound to this TRE in TPA-treated THP-1 cells. These results suggest that in TPA-treated cells the binding of Sp1 to the TRE of the IFNGR1 promoter causes the upregulation of this gene.	Kochi Med Sch, Med Res Ctr, Mol Biol Lab, Nanko Ku, Kochi 7838505, Japan	Kochi University	Taniguchi, T (corresponding author), Kochi Med Sch, Med Res Ctr, Mol Biol Lab, Nanko Ku, Kochi 7838505, Japan.	taniguch@pop.med.kochi-ms.ac.jp						AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; Gunther M, 2000, MOL CELL BIOCHEM, V210, P131, DOI 10.1023/A:1007177623283; HANAFUSA T, 1983, LANCET, V2, P1111; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KORMAN AJ, 1985, IMMUNOL REV, V85, P45, DOI 10.1111/j.1600-065X.1985.tb01130.x; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Langmann T, 1999, J LIPID RES, V40, P870; Lee YJ, 1996, J IMMUNOL, V157, P1559; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MAO C, 1990, J IMMUNOL, V144, P4688; Merlin G, 1997, IMMUNOGENETICS, V45, P413, DOI 10.1007/s002510050223; Muller M, 1994, J Viral Hepat, V1, P87, DOI 10.1111/j.1365-2893.1994.tb00109.x; MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203; NACY CA, 1991, CURR OPIN IMMUNOL, V3, P330, DOI 10.1016/0952-7915(91)90033-W; RAHMSDORF HJ, 1990, PHARMACOL THERAPEUT, V48, P157, DOI 10.1016/0163-7258(90)90079-H; Roder K, 1997, GENE, V184, P21, DOI 10.1016/S0378-1119(96)00568-9; Sakamoto S, 1999, J IMMUNOL, V162, P4381; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schultz H, 1997, J CELL PHYSIOL, V173, P310, DOI 10.1002/(SICI)1097-4652(199712)173:3<310::AID-JCP2>3.0.CO;2-Q; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STOUT RD, 1989, J IMMUNOL, V142, P760; Strom AC, 1996, NUCLEIC ACIDS RES, V24, P1981, DOI 10.1093/nar/24.11.1981; TOMODA T, 1992, IMMUNOLOGY, V76, P15; Van Wagoner NJ, 1998, J NEUROIMMUNOL, V85, P174, DOI 10.1016/S0165-5728(98)00010-1; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225	49	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37237	37241		10.1074/jbc.M105543200	http://dx.doi.org/10.1074/jbc.M105543200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11477089	hybrid			2022-12-25	WOS:000171375700051
J	van Zon, A; Mossink, MH; Schoester, M; Scheffer, GL; Scheper, RJ; Sonneveld, P; Wiemer, EAC				van Zon, A; Mossink, MH; Schoester, M; Scheffer, GL; Scheper, RJ; Sonneveld, P; Wiemer, EAC			Multiple human vault RNAs - Expression and association with the vault complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CANCER; CARCINOMA SW-620 CELLS; RIBONUCLEOPROTEIN-PARTICLES; DRUG-RESISTANCE; POLYMERASE-III; P-GLYCOPROTEIN; PROTEIN; LINES; ACCUMULATION; TRANSPORT	Human vaults are intracellular ribonucleoprotein particles believed to be involved in multidrug resistance. The complex consists of a major vault protein (MVP), two minor vault proteins (VPARP and TEP1), and several small untranslated RNA molecules. Three human vault RNA genes (HVG1-3) have been described, and a fourth was found in a homology search (HVG4). In the literature only the association of hvg1 with vaults was shown in vivo. However, in a yeast three-hybrid screen the association of hvg1, hvg2, and hvg4 with TEP1 was demonstrated. In this study we investigated the expression and vault association of different vault RNAs in a variety of cell lines, including pairs of drug-sensitive and drug-resistant cells. HVG1-3 are expressed in all cell lines examined, however, none of the cell lines expressed HVG4. This probably is a consequence of the absence of essential external polymerase III promoter elements. The bulk of the vault RNA associated with vaults was hvg1. Interestingly, an increased amount of hvg3 was bound to vaults isolated from multidrug-resistant cell lines. Our findings suggest that vaults bind the RNA molecules with different affinities in different situations. The ratio in which the vault RNAs are associated with vaults might be of functional importance.	Erasmus Univ, Inst Hematol, NL-3015 GE Rotterdam, Netherlands; Free Univ Amsterdam, Acad Hosp, Dept Pathol, NL-1081 HV Amsterdam, Netherlands	Erasmus University Rotterdam; Vrije Universiteit Amsterdam	Wiemer, EAC (corresponding author), Erasmus Univ, Inst Hematol, POB 1738, NL-3000 DR Rotterdam, Netherlands.			Wiemer, Erik/0000-0002-0673-7236				Abbondanza C, 1998, J CELL BIOL, V141, P1301, DOI 10.1083/jcb.141.6.1301; CHUGANI DC, 1993, J CELL SCI, V106, P23; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALTON WS, 1989, BLOOD, V73, P747; Hamill DR, 1997, DEV BIOL, V190, P117, DOI 10.1006/dbio.1997.8676; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Herrmann C, 1996, J BIOL CHEM, V271, P13908, DOI 10.1074/jbc.271.23.13908; Herrmann C, 1999, J CELL BIOL, V144, P1163, DOI 10.1083/jcb.144.6.1163; Izquierdo MA, 1996, AM J PATHOL, V148, P877; Izquierdo MA, 1996, INT J CANCER, V65, P230; KEATING MJ, 1987, LEUKEMIA RES, V11, P119, DOI 10.1016/0145-2126(87)90017-8; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; Kickhoefer VA, 1996, TRENDS CELL BIOL, V6, P174, DOI 10.1016/0962-8924(96)10014-3; Kickhoefer VA, 1999, J BIOL CHEM, V274, P32712, DOI 10.1074/jbc.274.46.32712; Kickhoefer VA, 1998, J BIOL CHEM, V273, P8971, DOI 10.1074/jbc.273.15.8971; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kickhoefer VA, 2001, J CELL BIOL, V152, P157, DOI 10.1083/jcb.152.1.157; Kitazono M, 2001, INT J CANCER, V91, P126, DOI 10.1002/1097-0215(20010101)91:1<126::AID-IJC1018>3.0.CO;2-8; Kitazono M, 1999, JNCI-J NATL CANCER I, V91, P1647, DOI 10.1093/jnci/91.19.1647; Kong LB, 2000, RNA, V6, P890, DOI 10.1017/S1355838200000157; Kong LB, 1999, STRUCT FOLD DES, V7, P371, DOI 10.1016/S0969-2126(99)80050-1; Kuiper C. M., 1990, J CELL PHARM, V1, P35; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; Li JY, 1999, NEUROSCIENCE, V91, P1055, DOI 10.1016/S0306-4522(98)00622-8; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; Scheffer GL, 2000, CURR OPIN ONCOL, V12, P550, DOI 10.1097/00001622-200011000-00007; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; SCHEPER RJ, 1993, CANCER RES, V53, P1475; Schroeijers AB, 2000, CANCER RES, V60, P1104; Siva AC, 2001, INT J CANCER, V92, P195, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1168>3.0.CO;2-7; TAYLOR CW, 1991, BRIT J CANCER, V63, P923, DOI 10.1038/bjc.1991.202; THALMEIER K, 1994, BLOOD, V83, P1799; VILALTA A, 1994, J BIOL CHEM, V269, P29752; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; ZIJLSTRA JG, 1987, CANCER RES, V47, P1780	37	62	62	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37715	37721		10.1074/jbc.M106055200	http://dx.doi.org/10.1074/jbc.M106055200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479319	hybrid			2022-12-25	WOS:000171375700111
J	Hogeveen, KN; Talikka, M; Hammond, GL				Hogeveen, KN; Talikka, M; Hammond, GL			Human sex hormone-binding globulin promoter activity is influenced by a (TAAAA)(n) repeat element within an alu sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; APO(A) GENE; FAMILY; PLASMA; DNA; IDENTIFICATION; POLYMORPHISMS; TESTOSTERONE; ESTRADIOL	Sex hormone-binding globulin (SHBG) is the major sex steroid-binding protein in human plasma and is produced by the liver. Plasma SHBG levels vary considerably between individuals and are influenced by hormonal, metabolic, and nutritional factors. We have now found that a (TAAAA)(n) pentanucleotide repeat, located within an alu sequence at the 5' boundary of the human SHBG promoter, influences its transcriptional activity in association with downstream elements, including an SP1-binding site. Furthermore, SHBG alleles within the general population contain at least 6-10 TAAAA repeats, and the transcriptional activity of a human SHBG promoter-luciferase reporter construct containing 6 TAAAA repeats was significantly lower than for similar reporter constructs containing 7-10 TAAAA repeats when tested in human HepG2 hepatoblastoma cells. This difference in transcriptional activity reflected the preferential binding of a 46-kDa liver-enriched nuclear factor to an oligonucleotide containing 6 rather than 7-10 TAAAA repeats. Thus, a (TAAAA), element within the human SHBG promoter influences transcriptional activity in HepG2 cells and may contribute to differences in plasma SHBG levels between individuals.	Univ Western Ontario, Dept Obstet & Gynaecol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 4L6, Canada; Univ Western Ontario, Canadian Inst Hlth Res Grp Fetal & Neonatal Hlth, London, ON N6A 4L6, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Hammond, GL (corresponding author), London Reg Canc Ctr, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.			Hammond, Geoffrey/0000-0002-4639-7336				Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; ANDERSON DC, 1974, CLIN ENDOCRINOL, V3, P69, DOI 10.1111/j.1365-2265.1974.tb03298.x; Beutler E, 1998, P NATL ACAD SCI USA, V95, P8170, DOI 10.1073/pnas.95.14.8170; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Durocher F, 1998, PHARMACOGENETICS, V8, P49, DOI 10.1097/00008571-199802000-00007; Gharani N, 1997, HUM MOL GENET, V6, P397, DOI 10.1093/hmg/6.3.397; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAMMOND GL, 1989, MOL ENDOCRINOL, V3, P1869, DOI 10.1210/mend-3-11-1869; HAMMOND GL, 1990, ENDOCR REV, V11, P65, DOI 10.1210/edrv-11-1-65; Janne M, 1998, J BIOL CHEM, V273, P34105, DOI 10.1074/jbc.273.51.34105; Janne M, 1998, MOL ENDOCRINOL, V12, P123; Janne M, 1999, ENDOCRINOLOGY, V140, P4166, DOI 10.1210/en.140.9.4166; Jaquish CE, 1997, METABOLISM, V46, P988, DOI 10.1016/S0026-0495(97)90266-3; KHAN MS, 1981, J CLIN ENDOCR METAB, V53, P448, DOI 10.1210/jcem-53-2-448; Kim HS, 1998, CYTOGENET CELL GENET, V83, P54, DOI 10.1159/000015124; Lim SC, 1999, J CLIN ENDOCR METAB, V84, P4159, DOI 10.1210/jc.84.11.4159; MEIKLE AW, 1982, METABOLISM, V31, P6, DOI 10.1016/0026-0495(82)90019-1; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199; MOOSER V, 1995, HUM MOL GENET, V4, P173, DOI 10.1093/hmg/4.2.173; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PRINCE VE, 1991, J VIROL, V65, P1803, DOI 10.1128/JVI.65.4.1803-1811.1991; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sambrook J., 2002, MOL CLONING LAB MANU; Sharan C, 1999, BIOCHEM BIOPH RES CO, V265, P285, DOI 10.1006/bbrc.1999.1652; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; SIERRA F, 1990, BIOMETHODS LAB GUIDE; SIITERI PK, 1982, RECENT PROG HORM RES, V38, P457; Skafar DF, 1997, J CLIN ENDOCR METAB, V82, P3913, DOI 10.1210/jc.82.12.3913; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; Valenti K, 1999, ATHEROSCLEROSIS, V147, P17, DOI 10.1016/S0021-9150(99)00137-9; VANSANT G, 1995, P NATL ACAD SCI USA, V92, P8229, DOI 10.1073/pnas.92.18.8229; WADE DP, 1993, P NATL ACAD SCI USA, V90, P1369, DOI 10.1073/pnas.90.4.1369; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xie M, 1997, J BIOL CHEM, V272, P26360, DOI 10.1074/jbc.272.42.26360; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729	40	81	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36383	36390		10.1074/jbc.M104681200	http://dx.doi.org/10.1074/jbc.M104681200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11473114	hybrid			2022-12-25	WOS:000171194500045
J	Ibarra-Sanchez, MD; Wagner, J; Ong, MT; Lampron, C; Tremblay, ML				Ibarra-Sanchez, MD; Wagner, J; Ong, MT; Lampron, C; Tremblay, ML			Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-kappa B activation	ONCOGENE			English	Article						T-cell protein tyrosine phosphatase; G1 phase; cyclin D1; NF-kappa B; IKK	PROTEIN-TYROSINE-PHOSPHATASE; CELL-CYCLE PROGRESSION; DEPENDENT KINASE; NEGATIVE REGULATORS; PROLIFERATION; P27(KIP1); EXPRESSION; GROWTH; TRANSCRIPTION; D1	Previous results suggested a potential role for T-cell protein tyrosine phosphatase (TC-PTP) in cell proliferation. However, no conclusive data has supported such a function in the modulation of this process. In order to clarify this issue, we isolated TC-PTP-/- murine embryonic fibroblasts (MEFs) as well as cell lines to characterize the role of TC-PTP in the control of cell proliferation and cell cycle. Both TC-PTP-/- primary MEFs and cell lines proliferate slower than TC-PTP+/+ cells. We also demonstrated that TC-PTP-/- cells have a slow progression through the G1 phase of the cell cycle. Further characterization of the G1 defect indicates that the kinetics of cyclin D1 induction was delayed and that p27(KIP1) remains at higher levels for an extended period of time. Moreover, cells lacking TC-PTP showed a delayed activation of CDK2. This slow progression through the early G1-phase resulted in decreased phosphorylation of the RB protein and subsequent delay into the S phase transition. In contrast, no further defects were detected in other phases of the cell cycle. Survey of the potential signaling pathways leading to this delayed cyclin D1 expression indicated that NF-kappaB activation was compromised and that IKK beta activity was also reduced following PDGF stimulation. Reintroduction of wild-type TC-PTP into the TC-PTP-/- cells rescued the defective proliferation, cyclin D1 expression, NF-kappaB, activation as well as I kappaB phosphorylation. Together, these results confirm that TC-PTP plays a positive role in the progression of early G1 phase of the cell cycle through the NF-kappaB pathway.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Kinetek Pharmaceut Inc, Vancouver, BC V6P 6G5, Canada	McGill University; McGill University	Tremblay, ML (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.		Ong, Ming Thong/R-4045-2018; Ibarra-Sánchez, María de Jesús/C-4722-2008	Ong, Ming Thong/0000-0002-6639-9718; Ibarra-Sánchez, María de Jesús/0000-0003-3623-1903				BARGOU RC, 1997, J CLIN INVEST, V100, P405; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; Ferreira V, 1999, J IMMUNOL, V162, P6442; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Ibarra-Sanchez MD, 2000, SEMIN IMMUNOL, V12, P379, DOI 10.1006/smim.2000.0220; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Liou HC, 1999, INT IMMUNOL, V11, P361, DOI 10.1093/intimm/11.3.361; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LORENZEN J, 1995, J BIOL CHEM, V14, P631; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NAMBIRAJAN S, 1995, J BIOSCIENCE, V20, P461, DOI 10.1007/BF02703529; Nambirajan S, 2000, J BIOSCIENCE, V25, P33, DOI 10.1007/BF02985179; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Radha V, 1997, FEBS LETT, V409, P33, DOI 10.1016/S0014-5793(97)00471-7; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Snapper CM, 1996, J IMMUNOL, V156, P183; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683	47	45	47	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4728	4739		10.1038/sj.onc.1204648	http://dx.doi.org/10.1038/sj.onc.1204648			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498795				2022-12-25	WOS:000170208600013
J	Yen, CLE; Mar, MH; Meeker, RB; Fernandes, A; Zeisel, SH				Yen, CLE; Mar, MH; Meeker, RB; Fernandes, A; Zeisel, SH			Choline deficiency induces apoptosis in primary cultures of fetal neurons	FASEB JOURNAL			English	Article						primary neurons; hippocampus; PC12 cells	LONG-TERM POTENTIATION; RAT HEPATOCYTES; PHOSPHATIDYLCHOLINE SYNTHESIS; LIQUID-CHROMATOGRAPHY; HIPPOCAMPAL-NEURONS; SPATIAL MEMORY; CERAMIDE; SUPPLEMENTATION; AVAILABILITY; ALTERS	Treatment of rats with choline during brain development results in long-lasting enhancement of spatial memory whereas choline deficiency has the opposite effect. Changes in rates of apoptosis may be responsible. We previously demonstrated that choline deficiency induced apoptosis in PC12 cells and suggested that interruption of cell cycling due to a decrease in membrane phosphatidylcholine concentration was the critical mechanism. We now examine whether choline deprivation induces apoptosis in nondividing primary neuronal cultures of fetal rat cortex and hippocampus. Choline deficiency induced widespread apoptosis in primary neuronal cells, indicating that cells do not have to be dividing to be sensitive to choline deficiency. When switched to a choline-deficient medium, both types of cells became depleted of choline, phosphocholine and phosphatidylcholine, and in primary neurons neurite outgrowth was dramatically attenuated. Primary cells could be rescued from apoptosis by treatment with phosphocholine or lysophosphatidylcholine. As described previously for PC12 cells, an increase in ceramide (Cer) was associated with choline deficiency-induced apoptosis in primary neurons. The primary neuronal culture appears to be an excellent model to explore the mechanism whereby maternal dietary choline intake modulates apoptosis in the fetal brain.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Neurol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, CB 7400,Room 2213,McGavran Greenberg Hall, Chapel Hill, NC 27599 USA.	steven_zeisel@unc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [AG09525] Funding Source: Medline; NIDDK NIH HHS [DK56350] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 1996, FASEB J, V10, P510, DOI 10.1096/fasebj.10.4.8647350; Albright CD, 1998, J NUTR BIOCHEM, V9, P476, DOI 10.1016/S0955-2863(98)00047-3; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; Brann AB, 1999, J NEUROSCI, V19, P8199; Cermak JM, 1999, DEV NEUROSCI-BASEL, V21, P94, DOI 10.1159/000017371; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; deChaves EIP, 1997, J BIOL CHEM, V272, P3028, DOI 10.1074/jbc.272.5.3028; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FURUYA S, 1995, J NEUROCHEM, V65, P1551; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Holler T, 1996, FASEB J, V10, P1653, DOI 10.1096/fasebj.10.14.9002559; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; *I MED FOOD NUTR B, 1998, DIET REF INT FOL OTH; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Jones JP, 1999, DEV BRAIN RES, V118, P159, DOI 10.1016/S0165-3806(99)00103-0; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lehtonen JYA, 1999, J BIOL CHEM, V274, P16901, DOI 10.1074/jbc.274.24.16901; LOY R, 1991, ADV EXP MED BIOL, V295, P373; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1997, NEUROREPORT, V8, P2831, DOI 10.1097/00001756-199709080-00005; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; Mitoma J, 1998, J NEUROSCI RES, V51, P712, DOI 10.1002/(SICI)1097-4547(19980315)51:6<712::AID-JNR5>3.3.CO;2-Q; NEWBERNE PM, 1986, ANNU REV NUTR, V6, P407, DOI 10.1146/annurev.nu.06.070186.002203; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; POMFRET EA, 1989, ANAL BIOCHEM, V180, P85, DOI 10.1016/0003-2697(89)90091-2; Previati M, 1996, ANAL BIOCHEM, V233, P108, DOI 10.1006/abio.1996.0014; Pyapali GK, 1998, J NEUROPHYSIOL, V79, P1790, DOI 10.1152/jn.1998.79.4.1790; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shin OH, 1997, J CELL BIOCHEM, V64, P196, DOI 10.1002/(SICI)1097-4644(199702)64:2<196::AID-JCB3>3.0.CO;2-S; Taniwaki T, 1999, NEUROCHEM RES, V24, P685, DOI 10.1023/A:1021008626887; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135	42	53	55	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					1704	1710		10.1096/fj.00-0800com	http://dx.doi.org/10.1096/fj.00-0800com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481217	Green Submitted			2022-12-25	WOS:000170809900005
J	Chattopadhyay, A; Chiang, CW; Yang, E				Chattopadhyay, A; Chiang, CW; Yang, E			BAD/BCL-(xL) heterodimerization leads to bypass of G0/G1 arrest	ONCOGENE			English	Article						BAD; BCL-(xL); apoptosis; cell cycle arrest	DEATH AGONIST BAD; CELL-CYCLE ENTRY; BH3 DOMAIN; BCL-2 EXPRESSION; MICE DEFICIENT; PROTEIN; PHOSPHORYLATION; PROGRESSION; APOPTOSIS; FAMILY	The pro-apoptotic molecule BAD binds BCL-x(L) or BCL2 and inactivates their survival function. In addition to their anti-apoptotic function, BCL2 and BCL-xL also delay cell cycle entry from quiescence. We found that the BH3-only molecule BAD also exerted a cell cycle effect. BAD expression resulted in failure to cell cycle block in growth arrest conditions. In low serum and in confluence, fibroblasts constitutively or inducibly expressing BAD persisted in S phase, continued to incorporate BrdU, and exhibited sustained cyclin E/cdk2 activity. Mutation analysis indicated that the cell cycle effect of BAD was not dependent on its phosphorylation status or subcellular localization, but strictly co-segregated with BCL-xL binding. bclx(-/-) MEFs expressing BAD and bad(-/-) MEFs both arrested in G0/G1 in low serum similar to wild-type controls, suggesting that the ability to overcome the G0/G1 checkpoint resulted from the presence of BAD/BCL-x(L) heterodimers, rather than the absence of BCL-xL or BAD. These data provide evidence that in addition to regulating apoptosis, the BAD/BCLx(L) heterodimer has a novel cell cycle function.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Cell Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Yang, E (corresponding author), Vanderbilt Univ Sch Med, 525 MRB 2, Nashville, TN 37232 USA.	elizabeth.yang@mcmail.vanderbilt.edu			NCI NIH HHS [CA68485, 1RO1 CA78443] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA078443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lind EF, 1999, J IMMUNOL, V162, P5374; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Nagata S, 1999, NAT CELL BIOL, V1, pE143, DOI 10.1038/14094; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Vairo G, 1996, ONCOGENE, V13, P1511; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	45	51	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4507	4518		10.1038/sj.onc.1204584	http://dx.doi.org/10.1038/sj.onc.1204584			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494146				2022-12-25	WOS:000170074900008
J	Jaumot, M; Hancock, JF				Jaumot, M; Hancock, JF			Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions	ONCOGENE			English	Article						Ras; Raf; 14-3-3; phophatases; plasma membrane	CYSTEINE-RICH DOMAIN; RECEPTOR TYROSINE KINASE; DISTINCT BINDING DOMAINS; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; B-RAF; PHOSPHATIDYLINOSITOL 3-KINASE; ONCOGENIC RAS; ZINC-FINGER; PHOSPHORYLATION	Raf-1 activation is a complex process which involves plasma membrane recruitment, phosphorylation, protein-protein and lipid-protein interactions, We now show that PP1 and PP2A serine-threonine phosphatases also have a positive role in Ras dependent Raf-1 activation, General serine-threonine phosphatase inhibitors such sodium fluoride, or beta-glycerophosphate and sodium pyrophosphate, or specific PP1 and PP2A inhibitors including microcystin-LR, protein phosphatase 2A inhibitor I-1 or protein phosphatase inhibitor 2 all abrogate H-Ras and K-Ras dependent Raf-1 activation in vitro. A critical Raf-1 target residue for PP1 and PP2A is S259. Serine phosphatase inhibitors block the dephosphorylation of S259, which accompanies Raf-1 activation, and Ras dependent activation of mutant Raf259A is relatively resistant to serine phosphatase inhibitors. Sucrose gradient analysis demonstrates that serine phosphatase inhibition increases the total amount of 14-3-3 and Raf-1 associated with the plasma membrane and significantly alters the distribution of 14-3-3 and Raf-1 across different plasma membrane microdomains, These observations suggest that dephosphorylation of S259 is a critical early step in Ras dependent Raf-1 activation which facilitates 14-3-3 displacement. Inhibition of PP1 and PP2A therefore causes plasma membrane accumulation of Raf-1/14-3-3 complexes which cannot be activated.	Univ Queensland, Sch Med, Dept Pathol, Expt Oncol Lab, Brisbane, Qld 4006, Australia	University of Queensland	Hancock, JF (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Expt Oncol Lab, Herston Rd, Brisbane, Qld 4006, Australia.		Jaumot, Montserrat/F-2640-2016	Hancock, John/0000-0003-0542-4710; Jaumot, Montserrat/0000-0003-2864-357X				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Cary LA, 2000, NATURE, V404, P945, DOI 10.1038/35010257; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Cissel DS, 2000, J BIOL CHEM, V275, P7066, DOI 10.1074/jbc.275.10.7066; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; Improta-Brears T, 1999, MOL CELL BIOCHEM, V198, P171, DOI 10.1023/A:1006981411691; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Okada T, 1999, MOL CELL BIOL, V19, P6057; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Plyte S, 2000, ONCOGENE, V19, P1529, DOI 10.1038/sj.onc.1203451; Pol A, 2000, J BIOL CHEM, V275, P30566, DOI 10.1074/jbc.M001131200; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rommel C, 1996, ONCOGENE, V12, P609; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sidovar MF, 2000, J BIOL CHEM, V275, P28688, DOI 10.1074/jbc.M909351199; Sieburth DS, 1999, GENE DEV, V13, P2562, DOI 10.1101/gad.13.19.2562; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	69	146	148	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					3949	3958		10.1038/sj.onc.1204526	http://dx.doi.org/10.1038/sj.onc.1204526			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494123				2022-12-25	WOS:000169681500003
J	Yu, HH; Zisch, AH; Dodelet, VC; Pasquale, EB				Yu, HH; Zisch, AH; Dodelet, VC; Pasquale, EB			Multiple signaling interactions of Abl and Arg kinases with the EphB2 receptor	ONCOGENE			English	Article						protein tyrosine kinase; axon guidance; actin cytoskeleton	PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; CHRONIC MYELOGENOUS LEUKEMIA; CENTRAL-NERVOUS-SYSTEM; C-ABL; AUTOPHOSPHORYLATION SITE; NEURITE OUTGROWTH; LIGAND ACTIVATION; AXON GUIDANCE; VISUAL-SYSTEM	The Eph family of receptor tyrosine kinases and the Abl family of non-receptor tyrosine kinases have both been implicated in tissue morphogenesis, They regulate the organization of the actin cytoskeleton in the developing nervous system and participate in signaling pathways involved in axon growth, Both Eph receptors and Abl are localized in the neuronal growth cone, suggesting that they play a role in axon pathfinding. Two-hybrid screens identified regions of Abl and Arg that bind to the EphB2 and EphA4 receptors, suggesting a novel signaling connection involving the two kinase families. The association of full-length Abl and Arg with EphB2 was confirmed by co-immunoprecipitation and found to involve several distinct protein interactions. The SH2 domains of Abl and Arg bind to tyrosine-phosphorylated motifs in the juxtamembrane region of EphB2, A second, phosphorylation-independent interaction with EphB2 involves non-conserved sequences in the C-terminal tails of Abl and Arg, A third interaction between Abl and EphB2 is probably mediated by an intermediary protein because it requires tyrosine phosphorylation of EphB2, but not the binding sites for the Abl SH2 domain. The connection between EphB2 and Abl/Arg appears to be reciprocal. Activated EphB2 causes tyrosine phosphorylation of Abl and Arg, and vice vel sa. Interestingly, treatment of COS cells and B35 neuronal-like cells with ephrin-B1 to activate endogenous EphB2 decreased the kinase activity of endogenous Abl, These data are consistent,vith the opposite effects that Eph receptors and Abl have on neurite ougrowth and suggest that Eph receptors and Abl family kinases have shared signaling activities.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	elenap@burnham.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938, R01HD026351, R29HD026351] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26351, HD25938] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; Cong F, 1999, MOL CELL BIOL, V19, P8314; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; Dottori M, 1998, P NATL ACAD SCI USA, V95, P13248, DOI 10.1073/pnas.95.22.13248; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; Ellis C, 1996, ONCOGENE, V12, P1727; Feldheim DA, 1998, NEURON, V21, P1303, DOI 10.1016/S0896-6273(00)80650-9; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GOFF SP, 1985, P SOC EXP BIOL MED, V179, P403; Helmbacher F, 2000, DEVELOPMENT, V127, P3313; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HILL KK, 1995, GENETICS, V141, P595; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Holder N, 1999, DEVELOPMENT, V126, P2033; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Kalo MS, 1999, CELL TISSUE RES, V298, P1, DOI 10.1007/PL00008807; Koch A, 2000, FEBS LETT, V469, P72, DOI 10.1016/S0014-5793(00)01242-4; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; MULLER AJ, 1993, P NATL ACAD SCI USA, V90, P3457, DOI 10.1073/pnas.90.8.3457; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; Nehme A, 1997, CANCER RES, V57, P3253; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PEREGO R, 1991, ONCOGENE, V6, P1899; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSENBERG N, 1982, CURR TOP MICROBIOL, V101, P95; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOANS C, 1994, ONCOGENE, V9, P3353; Soans C, 1996, J CELL BIOL, V135, P781, DOI 10.1083/jcb.135.3.781; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang BL, 1996, ONCOGENE, V13, P193; Wang BL, 1996, ONCOGENE, V13, P1379; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WANG JYJ, 1984, CELL, V36, P349; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1994, ONCOGENE, V9, P1379; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	91	68	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					3995	4006		10.1038/sj.onc.1204524	http://dx.doi.org/10.1038/sj.onc.1204524			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494128				2022-12-25	WOS:000169681500008
J	Hess, DA; O'Leary, EF; Lee, JT; Almawi, WY; Madrenas, J; Rieder, MJ				Hess, DA; O'Leary, EF; Lee, JT; Almawi, WY; Madrenas, J; Rieder, MJ			Inhibition of cytokine production and interference in IL-2 receptor-mediated Jak-Stat signaling by the hydroxylamine metabolite of sulfamethoxazole	FASEB JOURNAL			English	Article						sulfonamides; reactive metabolites; Janus kinases; adverse drug reactions; immune suppression	ADVERSE DRUG-REACTIONS; SULFONAMIDE HYPERSENSITIVITY REACTIONS; CALCINEURIN PHOSPHATASE-ACTIVITY; T-CELL SUBSETS; CYCLOSPORINE-A; GAMMA-CHAIN; BETA-CHAIN; INTERLEUKIN-2 RECEPTOR; TRIMETHOPRIM-SULFAMETHOXAZOLE; TYROSINE PHOSPHORYLATION	Sulfonamides, used for the treatment of opportunistic infections in immunocompromised patients, are associated with a high incidence of adverse drug events, including severe hypersensitivity reactions. Imbalances in the production and detoxification of reactive sulfonamide metabolites have been implicated in the pathogenesis of these life-threatening reactions. The hydroxylamine metabolite of sulfamethoxazole (SMX-HA) inhibits the proliferation of mitogen-stimulated peripheral blood mononuclear cells (PBMCs) in vitro without reducing Interleukin 2 (IL-2) expression. We investigated the effects of SMX-HA on accessory cytokine expression and IL-2 receptor (IL-2R) mediated signal transduction. SMX-HA did not reduce significantly mRNA production of proinflammatory [tumor necrosis factor alpha (TNF-alpha) and IL-1 beta], Th1-type (IFN-gamma), Th2-type cytokines (IL-4 and IL-10). Sublethal concentrations of SMX-HA (25 muM) reduced significantly the production of TNF-alpha, IL-1 beta, and IL4 protein without inhibiting the production of IFN-gamma. This finding suggests that exposure to SMX-HA might direct a response towards a Th-1 vs. a Th-2 response. Immunoblot analysis of IL-2R-mediated Janus kinases and signal transduction activators of transcription (Jak-Stat) signal transduction revealed diminished phosphorylation of Jak1 and Jak3 and inhibited downstream phosphorylation of Stat3, Stat5a, and IL-2R gamma in phytohemagglutinin/rIL-2 activated PBMCs treated with SMX-HA. SMX-HA did not inhibit Jak association with IL-2R gamma or IL-2R beta. These data illustrated that sublethal concentrations of SMX-HA interfere with IL-2R-mediated signal transduction, resulting in altered cytokine production and inhibition of lymphocyte proliferation.	Univ Western Ontario, Childrens Hosp Western Ontario, Dept Paediat,Gene Therapy & mol Virol Grp, John P Robarts Res Inst, London, ON N6J 1Y5, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6J 1Y5, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6J 1Y5, Canada; Arabian Gulf Univ, Dept Biochem Med, Manama, Bahrain	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Arabian Gulf University	Rieder, MJ (corresponding author), Univ Western Ontario, Childrens Hosp Western Ontario, Dept Paediat,Gene Therapy & mol Virol Grp, John P Robarts Res Inst, 800 Commissioners Rd E, London, ON N6J 1Y5, Canada.	mrieder@julian.uwo.ca	Almawi, Wassim/FGW-0821-2022; Hess, David A/M-2828-2013; Madrenas, Quim/P-5008-2019; Rieder, Michael J/L-2397-2013					Almawi WY, 1996, J LEUKOCYTE BIOL, V60, P563, DOI 10.1002/jlb.60.5.563; BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; BIERER BE, 1995, P ASSOC AM PHYSICIAN, V107, P28; BIERER BE, 1991, TRANSPLANT P, V23, P2850; BLUMBERG DD, 1987, METHOD ENZYMOL, V152, P20; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CARR A, 1993, CLIN EXP IMMUNOL, V94, P21; CARR A, 1993, J INFECT DIS, V167, P180, DOI 10.1093/infdis/167.1.180; CARR A, 1994, AIDS, V8, P333, DOI 10.1097/00002030-199403000-00006; CARR A, 1993, J ACQ IMMUN DEF SYND, V6, pS56; Chau LA, 1998, J EXP MED, V187, P1699, DOI 10.1084/jem.187.10.1699; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRIBB AE, 1991, DRUG METAB DISPOS, V19, P900; CRIBB AE, 1995, DRUG METAB DISPOS, V23, P406; CRIBB AE, 1992, CLIN PHARMACOL THER, V51, P522, DOI 10.1038/clpt.1992.57; CRIBB AE, 1990, DRUG METAB DISPOS, V18, P784; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FONG TAT, 1989, J IMMUNOL, V143, P2887; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; Gesbert F, 1998, J CLIN IMMUNOL, V18, P307, DOI 10.1023/A:1023223614407; Gill HJ, 1997, J PHARMACOL EXP THER, V282, P795; GIRI JG, 1995, J LEUKOCYTE BIOL, V57, P763, DOI 10.1002/jlb.57.5.763; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; Gomez J, 1998, CRIT REV IMMUNOL, V18, P185, DOI 10.1615/CritRevImmunol.v18.i3.20; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V79, P484, DOI 10.1016/0091-6749(87)90366-6; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; Hess DA, 1997, ANN PHARMACOTHER, V31, P1378, DOI 10.1177/106002809703101116; Hess DA, 1999, FASEB J, V13, P1688, DOI 10.1096/fasebj.13.13.1688; Hess DA, 1997, J PHARMACOL EXP THER, V281, P540; ISHII N, 1994, INT IMMUNOL, V6, P1273, DOI 10.1093/intimm/6.8.1273; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KIRKEN RA, 1995, CYTOKINE, V7, P689, DOI 10.1006/cyto.1995.0081; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MALABARBA MG, 1995, J BIOL CHEM, V270, P9630, DOI 10.1074/jbc.270.16.9630; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MEEKINS CV, 1994, J ALLERGY CLIN IMMUN, V94, P1017, DOI 10.1016/0091-6749(94)90120-1; MOSMANN TR, 1991, CURR OPIN IMMUNOL, V3, P311, DOI 10.1016/0952-7915(91)90029-Z; MOSMANN TR, 1994, ADV IMMUNOL, V56, P1, DOI 10.1016/S0065-2776(08)60449-6; Mosmann TR, 1995, CIBA F SYMP, V195, P42; MOSMANN TR, 1991, IMMUNOL RES, V10, P183, DOI 10.1007/BF02919690; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1992, ANN NY ACAD SCI, V664, P89, DOI 10.1111/j.1749-6632.1992.tb39751.x; Nakamura M, 1993, Semin Immunol, V5, P309, DOI 10.1006/smim.1993.1037; NAYLOR MS, 1995, CYTOKINES PRACTICAL, P35; PAI SY, 1994, BLOOD, V84, P3974, DOI 10.1182/blood.V84.11.3974.bloodjournal84113974; Pirmohamed M, 1998, BRIT MED J, V316, P1295, DOI 10.1136/bmj.316.7140.1295; Pirmohamed M, 1996, CLIN PHARMACOKINET, V31, P215, DOI 10.2165/00003088-199631030-00005; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RIEDER MJ, 1992, INT J IMMUNOPHARMACO, V14, P1175, DOI 10.1016/0192-0561(92)90052-M; RIEDER MJ, 1995, TOXICOLOGY, V95, P141, DOI 10.1016/0300-483X(94)02900-F; RIEDER MJ, 1988, J PHARMACOL EXP THER, V244, P724; RIEDER MJ, 1993, J CLIN PHARMACOL, V33, P316, DOI 10.1002/j.1552-4604.1993.tb04663.x; RIEDER MJ, 1995, J ACQ IMMUN DEF SYND, V8, P134, DOI 10.1097/00042560-199502000-00004; RIEDER MJ, 1994, DRUG SAFETY, V11, P196, DOI 10.2165/00002018-199411030-00005; RIEDER MJ, 1991, CLIN PHARMACOL THER, V49, P13, DOI 10.1038/clpt.1991.3; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; SAD S, 1994, J IMMUNOL, V153, P3514; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; Sisson ME, 1997, INT J IMMUNOPHARMACO, V19, P299, DOI 10.1016/S0192-0561(97)00027-1; SPIELBERG SP, 1986, CLIN BIOCHEM, V19, P142, DOI 10.1016/S0009-9120(86)80061-3; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1989, COLD SH Q B, V54, P689; Vig E, 1999, J BIOL CHEM, V274, P13077, DOI 10.1074/jbc.274.19.13077; WEINSHILBOUM RM, 1987, CLIN PHARMACOL THER, V42, P481, DOI 10.1038/clpt.1987.184; YANG X, 1993, J EXP MED, V178, P349, DOI 10.1084/jem.178.1.349	77	10	11	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1855	+		10.1096/fj.00-0583fje	http://dx.doi.org/10.1096/fj.00-0583fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481253				2022-12-25	WOS:000169261200015
J	Leopold, JA; Cap, A; Scribner, AW; Stanton, RC; Loscalzo, J				Leopold, JA; Cap, A; Scribner, AW; Stanton, RC; Loscalzo, J			Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability	FASEB JOURNAL			English	Article						glutathione; nitric oxide; reactive oxygen species	SYNTHASE GENERATES SUPEROXIDE; OXIDATIVE STRESS; CELL-DEATH; TETRAHYDROBIOPTERIN; EXPRESSION; DEHYDROEPIANDROSTERONE; INTERLEUKIN-1-BETA; EPIANDROSTERONE; FIBROBLASTS; INHIBITION	The vascular endothelium compensates for oxidant stress by increasing the activity of antioxidant enzymes such as glucose-6-phophate dehydrogenase (G6PD). G6PD provides reducing equivalents of NAPDH to maintain glutathione stores and modulates nitric oxide synthase (eNOS) activity. To determine whether deficient G6PD activity perturbs these responses, we treated bovine aortic endothelial cells with dehydroepiandrosterone or an antisense oligodeoxynucleotide to G6PD mRNA to decrease G6PD activity and expression. When exposed to hydrogen peroxide, reactive oxygen species (ROS) accumulation was increased in G6PD-deficient cells compared with those with normal activity. To determine the source of increased oxidant stress in G6PD-deficient cells, we used inhibitors of ROS generation, which suggested that eNOS was contributing to ROS production. Treatment with L-NMMA, an inhibitor of eNOS mediated-nitric oxide (NO) but not superoxide, production confirmed this observation; in contrast to L-NAME, L-NMMA promoted ROS generation in G6PD-deficient cells. In addition, deficient G6PD activity was associated with a decrease in endothelium-derived bioavailable NO in response to the agonists A23187 and bradykinin as demonstrated by decreased endothelial cGMP and nitrate/nitrite levels. Enhanced ROS accumulation and decreased NO bioavailability may represent one mechanism by which G6PD deficiency contributes to vascular oxidant stress and endothelial dysfunction.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA	Boston University; Boston University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Leopold, JA (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, CABR-507,715 Albany St, Boston, MA 02118 USA.	jane.leopold@bmc.org	Stanton, Robert C/AAG-7584-2020; Loscalzo, Joseph/ABD-8980-2021	Stanton, Robert C/0000-0002-3056-1277; 				BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Cheng ML, 2000, FEBS LETT, V475, P257, DOI 10.1016/S0014-5793(00)01687-2; CRISS WE, 1969, BIOCHIM BIOPHYS ACTA, V184, P486, DOI 10.1016/0304-4165(69)90262-1; Garcia-Nogales P, 1999, J NEUROCHEM, V72, P1750, DOI 10.1046/j.1471-4159.1999.721750.x; Ho HY, 2000, FREE RADICAL BIO MED, V29, P156, DOI 10.1016/S0891-5849(00)00331-2; Ishii M, 1999, J CARDIOVASC PHARM, V33, P295, DOI 10.1097/00005344-199902000-00018; Laychock SG, 1998, BIOCHEM PHARMACOL, V55, P1453, DOI 10.1016/S0006-2952(97)00666-7; Laychock SG, 1996, ENDOCRINOLOGY, V137, P3375, DOI 10.1210/en.137.8.3375; Leopold JA, 2000, AM J PHYSIOL-HEART C, V279, pH2477, DOI 10.1152/ajpheart.2000.279.5.H2477; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mei JJM, 1998, CANCER LETT, V129, P191, DOI 10.1016/S0304-3835(98)00102-5; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; Sasaki K, 1998, BBA-GEN SUBJECTS, V1380, P275, DOI 10.1016/S0304-4165(97)00152-9; Shimizu S, 1998, LIFE SCI, V63, P1585, DOI 10.1016/S0024-3205(98)00427-5; STANTON RC, 1991, J BIOL CHEM, V266, P12442; Tian WN, 1998, J BIOL CHEM, V273, P10609, DOI 10.1074/jbc.273.17.10609; Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121; Ursini MV, 1997, BIOCHEM J, V323, P801, DOI 10.1042/bj3230801; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701; Zhang ZQ, 2000, J BIOL CHEM, V275, P40042, DOI 10.1074/jbc.M007505200	28	119	122	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1771	+		10.1096/fj.00-0893fje	http://dx.doi.org/10.1096/fj.00-0893fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481225				2022-12-25	WOS:000169261200023
J	Lewis, ML; Cubano, LA; Zhao, BT; Dinh, HK; Pabalan, JG; Piepmeier, EH; Bowman, PD				Lewis, ML; Cubano, LA; Zhao, BT; Dinh, HK; Pabalan, JG; Piepmeier, EH; Bowman, PD			cDNA microarray reveals altered cytoskeletal gene expression in space-flown leukemic T lymphocytes (Jurkat)	FASEB JOURNAL			English	Article						gene expression; cDNA microarray; cytoskeleton; spaceflight; vibration; plectin	PROTEIN-KINASE-C; HUMAN-LEUKOCYTES; PLECTIN; CELL; GRAVITY; RNA; ORGANIZATION; ASSOCIATION; CALPONIN; BINDING	Cytoskeletal disruption and growth arrest consistently occur in space-flown human acute leukemic T cells (Jurkat). Although the microtubules appear to reorganize during spaceflight, cells remain nonproliferative. To test the hypothesis that spaceflight alters cytoskeletal gene expression and may thus affect cytoskeletal function, we flew Jurkat cells on Space Transportation System (STS) 95 and compared RNA message by cDNA microarray in space-flown vs. ground controls at 24 h (4,324 genes) and 48 h (> 20,000 genes). Messages for 11 cytoskeleton-related genes, including calponin, dynactin, tropomodulin, keratin 8, two myosins, an ankyrin EST, an actinlike protein, the cytoskeletal linker (plectin), and a centriole-associated protein (C-NAP1), were up-regulated in space-flown compared with ground control cells; gelsolin precursor was down-regulated. Up-regulation of plectin and C-NAP1 message in both space-flown cells and vibrated controls is a novel finding and implies their role in vibration damage repair. This first report of cDNA microarray screening of gene expression in space-flown leukemic T cells also identifies differential expression of genes that regulate growth, metabolism, signal transduction, adhesion, transcription, apoptosis, and tumor suppression. Based on differential expression of cytoskeletal genes, we conclude that centriole-centriole, membrane-cytoskeletal, and cytoskeletal filament associations are altered in the orbital phase of spaceflight.	Univ Alabama, Dept Biol Sci, Huntsville, AL 35899 USA; Tulane Univ, Med Ctr, Dept Med, New Orleans, LA 70112 USA; Univ Texas, Coll Pharm, Austin, TX 78712 USA; Univ Texas, Med Branch, Galveston, TX 77550 USA; USA, Inst Surg Res, San Antonio, TX USA	University of Alabama System; University of Alabama Huntsville; Tulane University; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Medical Branch Galveston	Lewis, ML (corresponding author), Univ Alabama, Dept Biol Sci, Wilson Hall 360, Huntsville, AL 35899 USA.	lewismml@email.uah.edu						Andra K, 1998, GENE DEV, V12, P3442, DOI 10.1101/gad.12.21.3442; BENNETT V, 1982, J CELL BIOCHEM, V18, P49, DOI 10.1002/jcb.1982.240180106; Burkhardt JK, 1998, BBA-MOL CELL RES, V1404, P113, DOI 10.1016/S0167-4889(98)00052-4; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cogoli A, 1996, J Gravit Physiol, V3, P1; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; CogoliGreuter M, 1996, J BIOTECHNOL, V47, P279, DOI 10.1016/0168-1656(96)01380-6; Cubano LA, 2000, EXP GERONTOL, V35, P389, DOI 10.1016/S0531-5565(00)00090-5; CUBANO LA, 2001, IN PRESS J LEUKOCYTE; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; Eger A, 1997, J CELL SCI, V110, P1307; FANG J, 1996, P NATL ACAD SCI USA, V93, P9154; Fitzgerald J, 1996, EXP CELL RES, V228, P168, DOI 10.1006/excr.1996.0313; FOISNER R, 1991, P NATL ACAD SCI USA, V88, P3812, DOI 10.1073/pnas.88.9.3812; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Fujii T, 1997, J BIOCHEM, V122, P344; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Hammond TG, 1999, NAT MED, V5, P359, DOI 10.1038/7331; Hatton JP, 1999, FASEB J, V13, pS23, DOI 10.1096/fasebj.13.9001.s23; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; Ingber D, 1999, FASEB J, V13, pS3; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; Lewis ML, 2000, J CELL BIOCHEM, V77, P127, DOI 10.1002/(SICI)1097-4644(20000401)77:1<127::AID-JCB13>3.3.CO;2-S; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; Masuda H, 1996, J BIOCHEM-TOKYO, V120, P415; MOSHKOV DA, 1991, TSITOLOGIYA+, V33, P16; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; Papaseit C, 2000, P NATL ACAD SCI USA, V97, P8364, DOI 10.1073/pnas.140029597; Piepmeier EH, 1997, EXP CELL RES, V237, P410, DOI 10.1006/excr.1997.3813; Rijken P J, 1994, Adv Space Biol Med, V4, P159; Schatten H, 1999, CELL BIOL INT, V23, P407, DOI 10.1006/cbir.1999.0371; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; Smith FJD, 1996, NAT GENET, V13, P450, DOI 10.1038/ng0896-450; Szymanski PT, 1999, BIOCHEMISTRY-US, V38, P3778, DOI 10.1021/bi981394y; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; Wiche G, 1998, J CELL SCI, V111, P2477	39	74	83	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1783	+		10.1096/fj.00-0820fje	http://dx.doi.org/10.1096/fj.00-0820fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481229				2022-12-25	WOS:000169261200022
J	Tang, BL; Ong, YS; Huang, B; Wei, S; Wong, ET; Qi, R; Horstmann, H; Hong, W				Tang, BL; Ong, YS; Huang, B; Wei, S; Wong, ET; Qi, R; Horstmann, H; Hong, W			A membrane protein enriched in endoplasmic reticulum exit sites interacts with COPII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-GOLGI TRANSPORT; MAMMALIAN KDEL RECEPTOR; RAB GTPASES; SUBUNIT INTERACTIONS; COAT PROTEINS; LIVING CELLS; YEAST SEC24P; BREFELDIN-A; BETA-COP; ER	Although all mammalian COPII components have now been cloned, little is known of their interactions with other regulatory proteins involved in exit from the endoplasmic reticulum (ER). We report here that a mammalian protein (Yip1A) that is about 31% identical to S. cerevisiae and which interacts with and modulates COPII-mediated ER-Golgi transport. Yip1A transcripts are ubiquitously expressed. Transcripts of a related mammalian homologue, Yip1B, are found specifically in the heart. Indirect immunofluorescence microscopy revealed that Yip1A is localized to vesicular structures that are concentrated at the perinuclear region. The structures marked by Yip1A co-localized with Sec31A and Sec13, components of the COPII coat protein complex. Immunoelectron microscopy also showed that Yip1A co-localizes with Sec13 at ER exit sites. Overexpression of the hydrophilic N terminus of Yip1A arrests ER-Golgi transport of the vesicular stomatitis G protein and causes fragmentation and dispersion of the Golgi apparatus. A glutathione S-transferase fusion protein with the hydrophilic N terminus of Yip1A (GST-Yip1A) is able to bind to and deplete vital components from rat liver cytosol that is essential for in. vitro vesicular stomatitis G transport. Peptide sequence analysis of cytosolic proteins that are specifically bound to GST-Yip1A revealed, among other proteins, mammalian COPII components Sec23 and Sec24. A highly conserved domain at the N terminus of Yip1A is required for Sec23/Sec24 interaction. Our results suggest that Yip1A is involved in the regulation of ER-Golgi traffic at the level of ER exit sites.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 117609, Singapore; Inst Mol & Cell Biol, Cent Imaging & Histol Facil, Singapore 117609, Singapore; Inst Mol & Cell Biol, Microsequencing Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Tang, BL (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, 30 Med Dr, Singapore 117609, Singapore.		HONG, Wanjin/E-9927-2010; Tang, Bor Luen/E-4548-2012	Tang, Bor Luen/0000-0002-1925-636X				Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Barlowe C, 1998, BBA-MOL CELL RES, V1404, P67, DOI 10.1016/S0167-4889(98)00047-0; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN, P137; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; Hauri HP, 2000, J CELL SCI, V113, P587; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; HONG WJ, 1993, BIOESSAYS, V15, P231, DOI 10.1002/bies.950150403; Hong WJ, 1998, J CELL SCI, V111, P2831; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lowe M, 1998, BBA-MOL CELL RES, V1404, P53, DOI 10.1016/S0167-4889(98)00046-9; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; Matsuoka K, 1998, MOL CELL, V2, P703, DOI 10.1016/S1097-2765(00)80168-9; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Paccaud JP, 1996, MOL BIOL CELL, V7, P1535, DOI 10.1091/mbc.7.10.1535; Pagano A, 1999, J BIOL CHEM, V274, P7833, DOI 10.1074/jbc.274.12.7833; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; Salama NR, 1997, MOL BIOL CELL, V8, P205, DOI 10.1091/mbc.8.2.205; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SARASTE J, 1991, J CELL SCI, V100, P415; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; Shugrue CA, 1999, J CELL SCI, V112, P4547; Soussan L, 1999, J CELL BIOL, V146, P301, DOI 10.1083/jcb.146.2.301; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Stephens DJ, 2000, J CELL SCI, V113, P2177; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; Tang BL, 1995, EUR J CELL BIOL, V68, P398; Tang BL, 1999, BIOCHEM BIOPH RES CO, V258, P679, DOI 10.1006/bbrc.1999.0574; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; Tang BL, 2000, J BIOL CHEM, V275, P13597, DOI 10.1074/jbc.275.18.13597; TANG BL, 1995, EUR J CELL BIOL, V68, P199; Tani K, 1999, J BIOL CHEM, V274, P20505, DOI 10.1074/jbc.274.29.20505; Tani K, 1999, FEBS LETT, V447, P247, DOI 10.1016/S0014-5793(99)00303-8; WILSON BS, 1994, J CELL BIOL, V125, P557, DOI 10.1083/jcb.125.3.557; Yang XP, 1998, EMBO J, V17, P4954, DOI 10.1093/emboj/17.17.4954; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	63	59	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40008	40017		10.1074/jbc.M106189200	http://dx.doi.org/10.1074/jbc.M106189200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11489904	hybrid			2022-12-25	WOS:000171789200069
J	Altroff, H; van der Walle, CF; Asselin, J; Fairless, R; Campbell, ID; Mardon, HJ				Altroff, H; van der Walle, CF; Asselin, J; Fairless, R; Campbell, ID; Mardon, HJ			The eighth FIII domain of human fibronectin promotes integrin alpha(5)beta(1) binding via stabilization of the ninth FIII domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CELL-ADHESION; CRYSTAL-STRUCTURE; LIGAND-BINDING; SYNERGY SITE; III MODULE; SEQUENCE; REGION; RGD; 9TH	Binding of the extracellular matrix molecule fibronectin to the integrin receptor alpha (5)beta (1) elicits downstream signaling pathways that modulate cell function. Fibronectin-alpha (5)beta (1) interaction occurs via the conserved RGD sequence in the tenth FIII (FIII10) domain of fibronectin. A synergistic site containing the sequence PHSRN in the adjacent FIII9 domain has also been identified. Here we investigate the function of the eighth FIII domain in integrin-mediated cell adhesion using a wide range of methods, including biochemical, biological, and biophysical assays of integrin binding, cell adhesion, and protein denaturation. Mutation of the FIII9 synergistic site (PHSRN to PHAAA) in FIII9-10 reduced the binding activity for integrin alpha (5)beta (1) to levels observed for FIII10 alone, but the corresponding mutant in FIII8-9-10 showed no loss of binding activity. Cell adhesion assays also demonstrated enhanced functional activity of constructs containing FIII8. Equilibrium chemical denaturation studies indicated that FIII8 confers conformational stability upon FIII9, but only if the exposed loops, PHSRN and VKNEED on FIII9 and FIII8, respectively, are intact. These results demonstrate that the loss of integrin binding activity, observed upon alteration of the PHSRN synergistic site of FIII9-10, results partly from a loss of conformational stability of FIII9. Our data suggest a mechanism for integrin alpha (5)beta (1)-fibronectin interaction, which in addition to the primary RGD binding event, involves a conformation-sensitive scanning by the integrin for accessible sites on the ligand, whereupon full activation of downstream signaling occurs.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynecol, Womens Ctr, Oxford OX3 9DU, England; Univ Bath, Sch Pharm & Pharmacol, Bath BA2 7AY, Avon, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Bath; University of Oxford	Mardon, HJ (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynecol, Womens Ctr, Level 3, Oxford OX3 9DU, England.		van der Walle, Chris/AAB-9641-2022; Altroff, Harri/B-3544-2011					AOTA S, 1994, J BIOL CHEM, V269, P24756; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CAMPBELL ID, 1994, STRUCTURE, V2, P333, DOI 10.1016/S0969-2126(00)00034-4; Copie V, 1998, J MOL BIOL, V277, P663; Cota E, 2000, PROTEIN SCI, V9, P112; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grant RP, 1997, J BIOL CHEM, V272, P6159, DOI 10.1074/jbc.272.10.6159; Hotchin NA, 1999, J CELL SCI, V112, P2937; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; MASSIA SP, 1992, J BIOL CHEM, V267, P14019; Mehta RJ, 1998, BIOCHEM J, V330, P861; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; POTTS JR, 1994, CURR OPIN CELL BIOL, V6, P648, DOI 10.1016/0955-0674(94)90090-6; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sharma A, 1997, VIROLOGY, V239, P150, DOI 10.1006/viro.1997.8833; Spitzfaden C, 1997, J MOL BIOL, V265, P565, DOI 10.1006/jmbi.1996.0736; UMEZAWA K, 1985, FEBS LETT, V186, P31, DOI 10.1016/0014-5793(85)81333-8; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347	29	65	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38885	38892		10.1074/jbc.M105868200	http://dx.doi.org/10.1074/jbc.M105868200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11500513	hybrid			2022-12-25	WOS:000171673200074
J	Le Menuet, D; Isnard, R; Bichara, M; Viengchareun, S; Muffat-Joly, M; Walker, F; Zennaro, MC; Lombes, M				Le Menuet, D; Isnard, R; Bichara, M; Viengchareun, S; Muffat-Joly, M; Walker, F; Zennaro, MC; Lombes, M			Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							11-BETA-HYDROXYSTEROID DEHYDROGENASE; ALTERNATIVE PROMOTERS; ALDOSTERONE ACTION; HEART-FAILURE; HYPERTROPHY; GENE; RAT; SPIRONOLACTONE; HYPERTENSION; METABOLISM	The mineralocorticoid receptor (MR), a ligand-dependent transcription factor, mediates aldosterone actions in a large variety of tissues. To explore the functional implication of MR in pathophysiology, transgenic mouse models were generated using the proximal human MR (hMR) promoter to drive expression of hMR in aldosterone target tissues. Tissue-specific analysis of transgene expression in two independent transgenic animal (TG) lines by ribonuclease protection assays revealed that hMR is expressed in all mineralocorticoid-sensitive tissues, most notably in the kidney and the heart. TG exhibit both renal and cardiac abnormalities. Enlarged kidneys were histologically associated with renal tubular dilation and cellular vacuolization whose prevalence increased with aging. Renal clearance studies also disclosed a significant decrease in urinary potassium excretion rate in TG. hMR-expressing animals had normal blood pressure but developed mild dilated cardiomyopathy (increased left ventricle diameters and decreased shortening fraction), which was accompanied by a significant increase in heart rate. Differential gene expression analysis revealed a 2- to 5-fold increase in cardiac expression of atrial natriuretic peptide, serum- and glucocorticoid-induced kinase, and early growth response gene 1 as detected by microarrays; renal serum- and glucocorticoid-induced kinase was also induced significantly. Altogether, TG exhibited specific alteration of renal and cardiac functions, thus providing useful pathophysiological models to gain new insights into the tissue-specific mineralocorticoid signaling pathways.	Univ Paris 07, INSERM, U478, F-75870 Paris 18, France; CHU Pitie Salpetriere, Inst Federatif Rech 14, Serv Cardiol, F-75013 Paris, France; Univ Paris 07, Inst Federatif Rech Claude Bernard, Ctr Explorat Fonct Integre, F-75018 Paris, France; Univ Paris 07, INSERM, U426, F-75018 Paris, France; CHU Xavier Bichat, Serv Anatomopathol, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Lombes, M (corresponding author), Univ Paris 07, INSERM, U478, 16 Rue Henri Huchard,BP416, F-75870 Paris 18, France.	mlombes@bichat.inserm.fr	Le Menuet, Damien/B-1489-2019; Lombes, Marc/L-5933-2018; Zennaro, Maria-Christina/G-2841-2013; Viengchareun, Say/M-6612-2017; Viengchareun, Say/GOV-6812-2022	Le Menuet, Damien/0000-0002-0802-7190; Lombes, Marc/0000-0003-3189-023X; Zennaro, Maria-Christina/0000-0001-5449-9191; viengchareun, say/0000-0003-4280-3250; Isnard, Richard/0000-0002-3439-8104				ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Berger S, 1998, P NATL ACAD SCI USA, V95, P9424, DOI 10.1073/pnas.95.16.9424; Bhargava A, 2001, ENDOCRINOLOGY, V142, P1587, DOI 10.1210/en.142.4.1587; Bleich M, 1999, PFLUG ARCH EUR J PHY, V438, P245, DOI 10.1007/s004240050906; BRILLA CG, 1990, CIRC RES, V67, P1355, DOI 10.1161/01.RES.67.6.1355; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; de Kloet ER, 2000, KIDNEY INT, V57, P1329, DOI 10.1046/j.1523-1755.2000.00971.x; Farman N, 2001, AM J PHYSIOL-RENAL, V280, pF181, DOI 10.1152/ajprenal.2001.280.2.F181; Gu JW, 1998, HYPERTENSION, V31, P1083, DOI 10.1161/01.HYP.31.5.1083; HEPTINSTALL RH, 1992, PATHOLOGY KIDNEY, V2, P1989; Hubert C, 1999, MOL ENDOCRINOL, V13, P297, DOI 10.1210/me.13.2.297; KROZOWSKI Z, 1981, ENDOCRINOLOGY, V109, P1811, DOI 10.1210/endo-109-6-1811; Le Menuet D, 2000, J BIOL CHEM, V275, P7878, DOI 10.1074/jbc.275.11.7878; LOMBES M, 1995, CIRCULATION, V92, P175, DOI 10.1161/01.CIR.92.2.175; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Massaad C, 1999, MOL ENDOCRINOL, V13, P57, DOI 10.1210/me.13.1.57; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; PITOVSKI DZ, 1993, HEARING RES, V69, P10, DOI 10.1016/0378-5955(93)90088-I; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Ramires FJA, 2000, AM J CARDIOL, V85, P1207, DOI 10.1016/S0002-9149(00)00729-3; ROBERT V, 1995, HYPERTENSION, V26, P971, DOI 10.1161/01.HYP.26.6.971; Saadane N, 1999, BRIT J PHARMACOL, V127, P1165, DOI 10.1038/sj.bjp.0702676; Saadane N, 2000, AM J PHYSIOL-HEART C, V278, pH796, DOI 10.1152/ajpheart.2000.278.3.H796; SABN DJ, 1978, CIRCULATION, V58, P1072; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Silvestre JS, 1998, J BIOL CHEM, V273, P4883, DOI 10.1074/jbc.273.9.4883; Spindler B, 1999, AM J PHYSIOL-CELL PH, V276, pC1154, DOI 10.1152/ajpcell.1999.276.5.C1154; Stokes J, 2000, INVEST OPHTH VIS SCI, V41, P1629; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Suzuki T, 1998, J CLIN ENDOCR METAB, V83, P4022, DOI 10.1210/jc.83.11.4022; Takeda Y, 2000, ENDOCRINOLOGY, V141, P1901, DOI 10.1210/en.141.5.1901; TOBACK FG, 1976, LAB INVEST, V34, P115; TORRES VE, 1990, NEW ENGL J MED, V322, P345, DOI 10.1056/NEJM199002083220601; Verrey F, 2000, KIDNEY INT, V57, P1277, DOI 10.1046/j.1523-1755.2000.00962.x; YOUNG M, 1994, J CLIN INVEST, V93, P2578, DOI 10.1172/JCI117269; ZAINI A, 1987, CLIN EXP PHARMACOL P, V14, P39, DOI 10.1111/j.1440-1681.1987.tb00955.x; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915; ZENNARO MC, 1995, J BIOL CHEM, V270, P21016, DOI 10.1074/jbc.270.36.21016; Zennaro MC, 1996, MOL ENDOCRINOL, V10, P1549, DOI 10.1210/me.10.12.1549; Zennaro MC, 1998, EUR J ENDOCRINOL, V139, P127, DOI 10.1530/eje.0.1390127; Zhang Z, 1997, AM J PHYSIOL-RENAL, V273, pF837, DOI 10.1152/ajprenal.1997.273.5.F837	42	89	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38911	38920		10.1074/jbc.M103984200	http://dx.doi.org/10.1074/jbc.M103984200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495902	hybrid			2022-12-25	WOS:000171673200077
J	Torres, AS; Petri, V; Rae, TD; O'Halloran, TV				Torres, AS; Petri, V; Rae, TD; O'Halloran, TV			Copper stabilizes a heterodimer of the yCCS metallochaperone and its target superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MERCURIC ION REDUCTASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; CHAPERONE; YEAST; GENE; ASSOCIATION; CHEMISTRY; MUTATIONS	The copper chaperone for superoxide dismutase (CCS) activates the antioxidant enzyme Cu,Zn-SOD (SOD1) by directly inserting the copper cofactor into the apo form of SOD1. Neither the mechanism of protein-protein recognition nor of metal transfer is clear. The metal transfer step has been proposed to occur within a transient copper donor/acceptor complex that is either a heterodimer or heterotetramer (i.e. a dimer of dimers). To determine the nature of this intermediate, we generated a mutant form of SOD1 by replacing a copper binding residue His-48 with phenylalanine. This protein cannot accept copper from CCS but does form a stable complex with apo- and Cu-CCS, as observed by immunoprecipitation and native gel electrophoresis. Fluorescence anisotropy measurements corroborate the formation of this species and further indicate that copper enhances the stability of the dimer by an order of magnitude. The copper form of the heterodimer was isolated by gel filtration chromatography and contains one copper and one zinc atom per heterodimer. These results support a mechanism for copper transfer in which CCS and SOD1 dock via their highly conserved dimer interfaces in a manner that precisely orients the Cys-rich copper donor sites of CCS and the His-rich acceptor sites of SOD1 to form a copper-bridged intermediate.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.		O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019457, R01GM054111] Funding Source: NIH RePORTER; NCRR NIH HHS [S10RR13810] Funding Source: Medline; NIEHS NIH HHS [T32ES07284] Funding Source: Medline; NIGMS NIH HHS [R01 GM054111, GM54111, GM19457] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertini I, 1998, ADV INORG CHEM, V45, P127, DOI 10.1016/S0898-8838(08)60026-4; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Eisses JF, 2000, BIOCHEMISTRY-US, V39, P7337, DOI 10.1021/bi000690j; Engst S, 1999, BIOCHEMISTRY-US, V38, P3519, DOI 10.1021/bi982680c; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gamonet F, 1998, EUR J BIOCHEM, V251, P716, DOI 10.1046/j.1432-1327.1998.2510716.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hall LT, 2000, BIOCHEMISTRY-US, V39, P3611, DOI 10.1021/bi992716g; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Hejtmancik JF, 1997, PROTEIN ENG, V10, P1347, DOI 10.1093/protein/10.11.1347; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P1589, DOI 10.1021/bi992822i; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; LIPPARD SJ, 1977, BIOCHEMISTRY-US, V16, P1136, DOI 10.1021/bi00625a017; LIPPARD SJ, 1977, BIOINORG CHEM, V162, P251; Lyons TJ, 1998, J BIOL INORG CHEM, V3, P650, DOI 10.1007/s007750050279; Lyons TJ, 1999, MET IONS BIOL SYST, V36, P125; MARMOCCHI F, 1975, PHYSIOL CHEM PHYS M, V7, P465; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; NISHIDA CR, 1994, P NATL ACAD SCI USA, V91, P9906, DOI 10.1073/pnas.91.21.9906; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Poulos TL, 1999, NAT STRUCT BIOL, V6, P709, DOI 10.1038/11464; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rae TD, 2001, J BIOL CHEM, V276, P5166, DOI 10.1074/jbc.M008005200; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rosenzweig AC, 2000, CURR OPIN CHEM BIOL, V4, P140, DOI 10.1016/S1367-5931(99)00066-6; Rothstein JD, 1999, J NEUROCHEM, V72, P422, DOI 10.1046/j.1471-4159.1999.0720422.x; SCHIERING N, 1991, NATURE, V352, P168, DOI 10.1038/352168a0; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Siddique T, 1997, J NEURAL TRANSM-SUPP, P219; VALENTINE JS, 1982, COPPER PROTEINS, P292; VALENTINE JS, 1994, BIOINORG CHEM, P253; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Wong PC, 1998, CURR OPIN NEUROBIOL, V8, P791, DOI 10.1016/S0959-4388(98)80123-2; Zhu HN, 2000, BIOCHEMISTRY-US, V39, P5413, DOI 10.1021/bi992727+	42	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38410	38416		10.1074/jbc.M104790200	http://dx.doi.org/10.1074/jbc.M104790200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11473116	hybrid			2022-12-25	WOS:000171673200013
J	Arbuckle, JL; Fauss, LJ; Simpson, R; Ptaszek, LM; Rodgers, KK				Arbuckle, JL; Fauss, LJ; Simpson, R; Ptaszek, LM; Rodgers, KK			Identification of two topologically independent domains in RAG1 and their role in macromolecular interactions relevant to V(D)J recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; SINGLE ACTIVE-SITE; DNA-LIGASE-IV; SIGNAL SEQUENCE; SYNAPTIC COMPLEX; PROTEINS; CLEAVAGE; BINDING; TRANSPOSITION; RECOGNITION	V(D)J recombination is instigated by the recombination-activating proteins RAG1 and RAG2, which catalyze site-specific DNA cleavage at the border of the recombination signal sequence (RSS). Although both proteins are required for activity, core RAG1 (the catalytically active region containing residues 384-1008 of 1040) alone displays binding specificity for the conserved heptamer and nonamer sequences of the RSS. The nonamer-binding region lies near the N terminus of core RAGI, whereas the heptamer-binding region has not been identified. Here, potential domains within core RAG1 were identified using limited proteolysis studies. An iterative procedure of DNA cloning, protein expression, and characterization revealed the presence of two topologically independent domains within core RAGI, referred to as the central domain (residues 528-760) and the C-terminal domain (residues 761-980). The domains do not include the nonamer-binding region but rather largely span the remaining relatively uncharacterized region of core RAG1. Characterization of macromolecular interactions revealed that the central domain bound to the RSS with specificity for the heptamer and contained the predominant binding site for RAG2. The C-terminal domain bound DNA cooperatively but did not show specificity for either conserved RSS element. This domain was also found to self-associate, implicating it as a dimerization domain within RAG1.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; NYU, Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Icahn School of Medicine at Mount Sinai; New York University	Rodgers, KK (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.			Rodgers, Karla/0000-0002-7338-0281				Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Aidinis V, 2000, J IMMUNOL, V164, P5826, DOI 10.4049/jimmunol.164.11.5826; Aidinis V, 1999, MOL CELL BIOL, V19, P6532; Akamatsu Y, 1998, MOL CELL BIOL, V18, P4670, DOI 10.1128/MCB.18.8.4670; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; Besmer E, 1998, MOL CELL, V2, P817, DOI 10.1016/S1097-2765(00)80296-8; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; Eastman QM, 1997, NUCLEIC ACIDS RES, V25, P4370, DOI 10.1093/nar/25.21.4370; Eastman QM, 1999, MOL CELL BIOL, V19, P3788; Fugmann SD, 2000, MOL CELL, V5, P97, DOI 10.1016/S1097-2765(00)80406-2; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1998, J BIOL CHEM, V273, P24708, DOI 10.1074/jbc.273.38.24708; Grawunder U, 2001, CURR OPIN IMMUNOL, V13, P186, DOI 10.1016/S0952-7915(00)00203-X; Haren L, 1999, ANNU REV MICROBIOL, V53, P245, DOI 10.1146/annurev.micro.53.1.245; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; Kale SB, 2001, MOL CELL BIOL, V21, P459, DOI 10.1128/MCB.21.2.459-466.2001; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; KWON D, 1995, P NATL ACAD SCI USA, V92, P8234, DOI 10.1073/pnas.92.18.8234; Landree MA, 1999, GENE DEV, V13, P3059, DOI 10.1101/gad.13.23.3059; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McMahan CJ, 1997, J IMMUNOL, V158, P2202; Mo XM, 1999, J BIOL CHEM, V274, P7025, DOI 10.1074/jbc.274.11.7025; Mo XM, 2001, MOL CELL BIOL, V21, P2038, DOI 10.1128/MCB.21.6.2038-2047.2001; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nagawa F, 1998, MOL CELL BIOL, V18, P655, DOI 10.1128/MCB.18.1.655; Rice PA, 2001, NAT STRUCT BIOL, V8, P302, DOI 10.1038/86166; Rodgers KK, 1996, J MOL BIOL, V260, P70, DOI 10.1006/jmbi.1996.0382; Rodgers KK, 1999, NUCLEIC ACIDS RES, V27, P2938, DOI 10.1093/nar/27.14.2938; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; Santagata S, 1998, J BIOL CHEM, V273, P16325, DOI 10.1074/jbc.273.26.16325; Santagata S, 1999, MOL CELL, V4, P935, DOI 10.1016/S1097-2765(00)80223-3; Sawchuk DJ, 1997, J EXP MED, V185, P2025, DOI 10.1084/jem.185.11.2025; Shockett PE, 1999, MOL CELL BIOL, V19, P4159; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; Swanson PC, 1999, MOL CELL BIOL, V19, P3674; Swanson PC, 1998, IMMUNITY, V9, P115, DOI 10.1016/S1074-7613(00)80593-2; Swanson PC, 2001, MOL CELL BIOL, V21, P449, DOI 10.1128/MCB.21.2.449-458.2001; Tung CS, 1995, J BIOMOL STRUCT DYN, V13, P577, DOI 10.1080/07391102.1995.10508868; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; West RB, 1998, MOL CELL BIOL, V18, P6408, DOI 10.1128/MCB.18.11.6408; Yu KF, 2000, MOL CELL BIOL, V20, P7914, DOI 10.1128/MCB.20.21.7914-7921.2000	46	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37093	37101		10.1074/jbc.M105988200	http://dx.doi.org/10.1074/jbc.M105988200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479318	hybrid			2022-12-25	WOS:000171375700032
J	Flynn, ERM; Bradley, KN; Muir, TC; McCarron, JG				Flynn, ERM; Bradley, KN; Muir, TC; McCarron, JG			Functionally separate intracellular Ca2+ stores in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CEREBELLAR PURKINJE-CELLS; INDUCED CALCIUM-RELEASE; ENDOPLASMIC-RETICULUM; INOSITOL 1,4,5-TRISPHOSPHATE; RYANODINE RECEPTORS; CYTOSOLIC CA2+; GUINEA-PIG; THAPSIGARGIN-RESISTANT; PORTAL-VEIN	In smooth muscle, release via the inositol 1,4,5-trisphosphate (Ins(1,4,5)P3R) and ryanodine receptors (RyR) on the sarcoplasmic reticulum (SR) controls oscillatory and steady-state cytosolic Ca2+ concentrations ([Ca2+](c)). The interplay between the two receptors, itself determined by their organization on the SR, establishes the time course and spatial arrangement of the Ca2+ signal. Whether or not the receptors are co-localized or distanced from each other on the same store or whether they exist on separate stores will significantly affect the Ca2+ signal produced by the SR. To date these matters remain unresolved. The functional arrangement of the RyR and Ins(1,4,5)P3R on the SR has now been examined in isolated single voltage-clamped colonic myocytes. Depletion of the ryanodine-sensitive store, by repeated application of caffeine, in the presence of ryanodine, abolished the response to Ins(1,4,5)P-3, suggesting that Ins(1,4,5)P3R and RyR share a common Ca2+ store. Ca2+ release from the Ins(1,4,5)P3R did not activate Ca2+-induced Ca2+ release at the RyR. Depletion of the Ins(1,4,5)P-3-sensitive store, by the removal of external Ca2+, on the other hand, caused only a small decrease (similar to 26%) in caffeine-evoked Ca2+ transients, suggesting that not all RyR exist on the common store shared with Ins(1,4,5)P3R. Dependence of the stores on external Ca2+ for replenishment also differed; removal of external Ca2+ depleted the Ins(1,4,5)P-3-sensitive store but caused only a slight reduction in caffeine-evoked transients mediated at RyR. Different mechanisms are presumably responsible for the refilling of each store. Refilling of both Ins(1,4,5)P-3-sensitive and caffeine-sensitive Ca2+ stores was inhibited by each of the SR Ca2+ ATPase inhibitors thapsigargin and cyclopiazonic acid. These results may be explained by the existence of two functionally distinct Ca2+ stores; the first expressing only RyR and refilled from [Ca2+](c), the second expressing both Ins(1,4,5)P3R and RyR and dependent upon external Ca2+ for refilling.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	McCarron, JG (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, W Med Bldg, Glasgow G12 8QQ, Lanark, Scotland.			Hunter, Elaine/0000-0002-7150-8405				BARO I, 1995, J PHYSIOL-LONDON, V482, P247, DOI 10.1113/jphysiol.1995.sp020514; Beecroft MD, 1997, BIOCHEM J, V326, P215, DOI 10.1042/bj3260215; BENNETT B, 1997, BIOCHEM BIOPH RES CO, V241, P471; Bennett DL, 1998, BIOCHEM J, V329, P349; BEZPROZVANNY I, 1994, MOL BIOL CELL, V5, P97, DOI 10.1091/mbc.5.1.97; BIAN JH, 1991, J BIOL CHEM, V266, P8801; Boittin FX, 1999, AM J PHYSIOL-CELL PH, V277, pC139, DOI 10.1152/ajpcell.1999.277.1.C139; BOLTON TB, 1989, J PHYSIOL-LONDON, V409, P385, DOI 10.1113/jphysiol.1989.sp017504; BUTCHER RW, 1962, J BIOL CHEM, V237, P1244; CHEEK TR, 1991, BIOCHEM J, V275, P697, DOI 10.1042/bj2750697; Cheng H, 1996, AM J PHYSIOL-CELL PH, V270, pC148; COMBETTES L, 1992, FEBS LETT, V301, P287, DOI 10.1016/0014-5793(92)80258-I; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Golovina VK, 2000, GLIA, V31, P15, DOI 10.1002/(SICI)1098-1136(200007)31:1<15::AID-GLIA20>3.0.CO;2-H; Grover AK, 1996, AM J PHYSIOL-CELL PH, V271, pC181, DOI 10.1152/ajpcell.1996.271.1.C181; HILDALGO C, 1995, BIOSCIENCE REP, V15, P387; IINO M, 1988, BIOCHEM BIOPH RES CO, V152, P417, DOI 10.1016/S0006-291X(88)80730-7; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V279, pC1528, DOI 10.1152/ajpcell.2000.279.5.C1528; Janiak R, 2001, AM J PHYSIOL-CELL PH, V280, pC22, DOI 10.1152/ajpcell.2001.280.1.C22; KANAIDE H, 1987, FEBS LETT, V214, P130, DOI 10.1016/0014-5793(87)80027-3; KATSUYAMA H, 1991, PFLUG ARCH EUR J PHY, V419, P460, DOI 10.1007/BF00370789; Khodakhah K, 1997, BIOPHYS J, V73, P3349, DOI 10.1016/S0006-3495(97)78359-0; KOMORI S, 1989, BRIT J PHARMACOL, V97, P973, DOI 10.1111/j.1476-5381.1989.tb12039.x; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; LINO M, 1987, BIOCHEM BIOPH RES CO, V142, P45; McCarron JG, 1999, J PHYSIOL-LONDON, V516, P149, DOI 10.1111/j.1469-7793.1999.149aa.x; McCarron JG, 2000, J PHYSIOL-LONDON, V525, P113, DOI 10.1111/j.1469-7793.2000.00113.x; Misquitta CM, 1999, CELL CALCIUM, V25, P277, DOI 10.1054/ceca.1999.0032; MISSIAEN L, 1994, BIOCHEM J, V300, P81, DOI 10.1042/bj3000081; MISSIAEN L, 1994, MOL CELL ENDOCRINOL, V98, P147, DOI 10.1016/0303-7207(94)90133-3; Missiaen L, 1999, BIOCHEM BIOPH RES CO, V264, P967, DOI 10.1006/bbrc.1999.1607; MISSIAEN L, 1991, BIOCHEM BIOPH RES CO, V174, P1183, DOI 10.1016/0006-291X(91)91546-O; Montero M, 1997, J CELL BIOL, V139, P601, DOI 10.1083/jcb.139.3.601; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; PACAUD P, 1995, J PHYSIOL-LONDON, V484, P549, DOI 10.1113/jphysiol.1995.sp020685; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney JW, 2000, CELL MOL LIFE SCI, V57, P1272, DOI 10.1007/PL00000765; RAEYMAEKERS L, 1990, CELL CALCIUM, V11, P261, DOI 10.1016/0143-4160(90)90002-C; RENZETTI LM, 1990, AM J PHYSIOL, V259, pG1, DOI 10.1152/ajpgi.1990.259.1.G1; ROBINSON IM, 1991, J NEUROCHEM, V56, P1587, DOI 10.1111/j.1471-4159.1991.tb02055.x; ROBINSON IM, 1991, FEBS LETT, V289, P151, DOI 10.1016/0014-5793(91)81057-F; Roderick HL, 2000, J CELL BIOL, V149, P1235, DOI 10.1083/jcb.149.6.1235; Schubert R, 1999, AM J PHYSIOL-CELL PH, V276, pC648, DOI 10.1152/ajpcell.1999.276.3.C648; Shull GE, 2000, EUR J BIOCHEM, V267, P5284, DOI 10.1046/j.1432-1327.2000.01568.x; SITSAPESAN R, 1995, J MEMBRANE BIOL, V146, P133, DOI 10.1007/BF00238004; SOMLYO AP, 1985, CIRC RES, V57, P497, DOI 10.1161/01.RES.57.4.497; SOMLYO AV, 1985, P NATL ACAD SCI USA, V82, P5231, DOI 10.1073/pnas.82.15.5231; Sugita M, 1998, EUR J PHARMACOL, V348, P61, DOI 10.1016/S0014-2999(98)00129-0; TAKEI K, 1994, NEURON, V12, P327, DOI 10.1016/0896-6273(94)90275-5; TANAKA Y, 1993, BIOCHEMISTRY-US, V32, P12062, DOI 10.1021/bi00096a017; TERASAKI M, 1991, J CELL BIOL, V114, P929, DOI 10.1083/jcb.114.5.929; Trafford AW, 1995, J PHYSIOL-LONDON, V489, P319, DOI 10.1113/jphysiol.1995.sp021053; TRIBE RM, 1994, P NATL ACAD SCI USA, V91, P5908, DOI 10.1073/pnas.91.13.5908; Usachev YM, 1999, J PHYSIOL-LONDON, V519, P115, DOI 10.1111/j.1469-7793.1999.0115o.x; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; WANG XD, 1995, CIRC RES, V77, P37, DOI 10.1161/01.RES.77.1.37; Wayman CP, 1998, PFLUG ARCH EUR J PHY, V435, P231, DOI 10.1007/s004240050506; YAMAMOTO A, 1991, CELL STRUCT FUNCT, V16, P419, DOI 10.1247/csf.16.419; YAMAZAWA T, 1992, FEBS LETT, V301, P181, DOI 10.1016/0014-5793(92)81243-F; Yoshikawa A, 1996, AM J PHYSIOL-CELL PH, V271, pC833, DOI 10.1152/ajpcell.1996.271.3.C833; Young SH, 1999, AM J PHYSIOL-GASTR L, V276, pG1204, DOI 10.1152/ajpgi.1999.276.5.G1204; Yu MH, 1998, J BIOL CHEM, V273, P3542, DOI 10.1074/jbc.273.6.3542; Yu MH, 1999, ARCH BIOCHEM BIOPHYS, V362, P225, DOI 10.1006/abbi.1998.1049; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152	68	72	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36411	36418		10.1074/jbc.M104308200	http://dx.doi.org/10.1074/jbc.M104308200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477079	hybrid			2022-12-25	WOS:000171194500049
J	Rose, SD; Lejen, T; Zhang, L; Trifaro, JM				Rose, SD; Lejen, T; Zhang, L; Trifaro, JM			Chromaffin cell F-actin disassembly and potentiation of catecholamine release in response to protein kinase C activation by phorbol esters is mediated through myristoylated alanine-rich C kinase substrate phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC-RECEPTOR STIMULATION; MAJOR SPECIFIC SUBSTRATE; MARCKS-RELATED PROTEIN; NEUROBLASTOMA-CELLS; CALMODULIN-BINDING; SCINDERIN REDISTRIBUTION; 87-KDA PROTEIN; INITIAL RATE; EXOCYTOSIS; SECRETION	The large majority of chromaffin vesicles are excluded from the plasma membrane by a cortical F-actin network. Treatment of chromaffin cells with phorbol 12-myristate 13-acetate produces disassembly of cortical F-actin, increasing the number of vesicles at release sites (Vitale, M. L., Seward, E. P., and Trifaro, J. M. (1995) Neuron 14, 353-363). Here, we provide evidence for involvement of myristoylated alanine-rich protein kinase C substrate (MARCKS), a protein kinase C substrate, in chromaffin cell secretion. MARCKS binds and crosslinks F-actin, the latter is inhibited by protein kinase C-induced MARCKS phosphorylation. MARCKS was found in chromaffin cells by immunoblotting. MARCKS was also detected by immunoprecipitation. In intact or permeabilized cells MARCKS phosphorylation increased upon stimulation with 10(-7) M phorbol 12-myristate 13-acetate. This was accompanied by cortical F-actin disassembly and potentiation of secretion. MARCKS phosphorylation, cortical F-actin disassembly, and potentiation of Ca2+-evoked secretion were inhibited by a peptide (MARCKS phosphorylation site domain sequence (MPSD)) with amino acid sequence corresponding to MARCKS phosphorylation site. MPSD was phosphorylated in the process. A similar peptide (alanine-substituted phosphorylated site domain) with four serine residues of MPSD substituted by alanines was ineffective. These results provide the first evidence for MARCKS involvement in chromaffin cell secretion and suggest that regulation of cortical F-actin crosslinking might be involved in this process.	Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Secretory Proc Res Program, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Trifaro, JM (corresponding author), Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Secretory Proc Res Program, Ottawa, ON K1H 8M5, Canada.							ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Arbuzova A, 1997, J BIOL CHEM, V272, P27167, DOI 10.1074/jbc.272.43.27167; BITTNER MA, 1990, J NEUROCHEM, V54, P205, DOI 10.1111/j.1471-4159.1990.tb13302.x; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; Bubb MR, 1999, J BIOL CHEM, V274, P36472, DOI 10.1074/jbc.274.51.36472; BURGOYNE RD, 1982, PROC R SOC SER B-BIO, V216, P111, DOI 10.1098/rspb.1982.0064; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; Chang S, 1996, J BIOL CHEM, V271, P1174, DOI 10.1074/jbc.271.2.1174; COFFEY ET, 1994, J NEUROCHEM, V63, P1303; DELCASTILLO AR, 1992, J CELL BIOL, V119, P797, DOI 10.1083/jcb.119.4.797; DELCASTILLO AR, 1990, EMBO J, V9, P43, DOI 10.1002/j.1460-2075.1990.tb08078.x; DOUGLAS WW, 1961, J PHYSIOL-LONDON, V159, P40, DOI 10.1113/jphysiol.1961.sp006791; Elzagallaai A, 2000, BLOOD, V95, P894, DOI 10.1182/blood.V95.3.894.003k15_894_902; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; Goodall AR, 1997, J NEUROCHEM, V68, P392; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Harvey AM, 1940, J PHYSIOL-LONDON, V97, P408, DOI 10.1113/jphysiol.1940.sp003818; Houssay BA, 1928, CR SOC BIOL, V99, P172; KENIGSBERG RL, 1980, NEUROSCIENCE, V5, P1547, DOI 10.1016/0306-4522(80)90019-6; KNIGHT DE, 1988, J MEMBRANE BIOL, V104, P21, DOI 10.1007/BF01871899; KNIGHT DE, 1983, FEBS LETT, V160, P98, DOI 10.1016/0014-5793(83)80944-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RWH, 1981, NEUROSCIENCE, V6, P2087, DOI 10.1016/0306-4522(81)90048-8; LIU JP, 1994, MOL CELL ENDOCRINOL, V105, P217; MARCU MG, 1994, MOL CELL BIOCHEM, V141, P153, DOI 10.1007/BF00926179; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MORITA K, 1985, BIOCHEM BIOPH RES CO, V129, P511, DOI 10.1016/0006-291X(85)90181-0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OUIMET CC, 1990, J NEUROSCI, V10, P1683; POCOTTE SL, 1985, P NATL ACAD SCI USA, V82, P930, DOI 10.1073/pnas.82.3.930; Powis DA, 1996, CELL CALCIUM, V19, P419, DOI 10.1016/S0143-4160(96)90115-3; ROSE SD, 1994, J NEUROCHEM, V63, P2314; Rose SD, 1996, J NEUROCHEM, V66, P1766; TACHIKAWA E, 1990, BIOCHEM PHARMACOL, V40, P1505; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; TRIFARO JM, 1980, NEUROSCIENCE, V5, P1533, DOI 10.1016/0306-4522(80)90018-4; TRIFARO JM, 1990, CAN J PHYSIOL PHARM, V68, P1, DOI 10.1139/y90-001; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; VITALE ML, 1992, NEUROSCIENCE, V51, P463, DOI 10.1016/0306-4522(92)90330-5; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; VITALE ML, 1992, J NEUROCHEM, V59, P1717, DOI 10.1111/j.1471-4159.1992.tb11003.x; Wohnsland F, 2000, J BIOL CHEM, V275, P20873, DOI 10.1074/jbc.M910298199; ZHANG L, 1995, J NEUROCHEM, V65, P1297; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9	53	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36757	36763		10.1074/jbc.M006518200	http://dx.doi.org/10.1074/jbc.M006518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477066	hybrid			2022-12-25	WOS:000171194500093
J	Taylor, JC; Horvath, AR; Higgins, CF; Begley, GS				Taylor, JC; Horvath, AR; Higgins, CF; Begley, GS			The multidrug resistance P-glycoprotein - Oligomeric state and intramolecular interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MEDIATED PHOSPHORYLATION; CHLORIDE CHANNELS; CELLS; TRANSPORTER; MEMBRANES; PROTEINS	The human multidrug resistance P-glycoprotein (P-gp), a member of the ATP-binding cassette (ABC) superfamily of transporters, is frequently responsible for the failure of chemotherapy by virtue of its ability to export hydrophobic cytotoxic drugs from cells. Elucidating the inter- and intramolecular interactions of this protein is critical to understanding its cellular function and mechanism of action. Toward this end, we have used both biochemical and genetic techniques to probe potential oligomerization interactions of P-gp. Differentially epitope-tagged P-gp molecules did not co-immunoprecipitate when co-expressed in HEK293 cells or when co-translated in vitro, demonstrating that P-gp is monomeric in both the presence and absence of detergents. The two cytoplasmic domains of P-gp did not interact with each other in vivo when coexpressed as gene fusions in yeast. In contrast, the homologous domains of the transporter associated with antigen processing (TAP), which reside on separate polypeptides and must form a heterodimeric transporter (TAP1/TAP2), did interact in this system, suggesting a role for these domains in TAP dimerization. Implications for understanding the subunit organization of ABC transporters are discussed.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, ICRF Labs, Oxford OX3 9DU, England	University of Oxford	Begley, GS (corresponding author), Marine Biol Lab, 7 MBL St, Woods Hole, MA 02543 USA.		wei, wei/HHR-8613-2022	Horvath, Andrea/0000-0002-7474-3240; Taylor, Jenny/0000-0003-3602-5704				ARSENAULT AL, 1988, BIOCHIM BIOPHYS ACTA, V938, P315, DOI 10.1016/0005-2736(88)90169-1; Bond TD, 1998, J PHYSIOL-LONDON, V508, P333, DOI 10.1111/j.1469-7793.1998.333bq.x; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; GOLEMIS E, 1994, CURRENT PROTOCOLS MO, V2; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; Jette L, 1997, BIOCHEMISTRY-US, V36, P13929, DOI 10.1021/bi970737+; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapinski PE, 2000, J BIOL CHEM, V275, P6831, DOI 10.1074/jbc.275.10.6831; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; NAITO M, 1992, BIOCHEM BIOPH RES CO, V185, P284, DOI 10.1016/S0006-291X(05)80988-X; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; SATO T, 1995, P NATL ACAD SCI USA, V92, P9238; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9	23	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36075	36078		10.1074/jbc.C100345200	http://dx.doi.org/10.1074/jbc.C100345200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11495894	hybrid			2022-12-25	WOS:000171194500005
J	Vitale, M; Matteucci, A; Manzoli, L; Rodella, L; Mariani, AR; Zauli, G; Falconi, M; Billi, AM; Martelli, AM; Gilmour, RS; Cocco, L				Vitale, M; Matteucci, A; Manzoli, L; Rodella, L; Mariani, AR; Zauli, G; Falconi, M; Billi, AM; Martelli, AM; Gilmour, RS; Cocco, L			Interleukin-2 activates nuclear phospholipase-C beta by mitogen-activated protein kinase-dependent phosphorylation in human natural killer cells	FASEB JOURNAL			English	Article						phospholipase C beta; NK cells; nucleus; interleukin-2; MAPK	FC-GAMMA-RIIIA; TYROSINE PHOSPHORYLATION; SWISS 3T3-CELLS; FRIEND-CELLS; IGF-I; RECEPTOR; SIGNAL; CYCLE; LOCALIZATION; STIMULATION	It is not yet clear whether nuclear phospholipase C (PLC) signaling is implicated in the response of primary cells to cytokines or not and, in particular, whether lymphocytes utilize the nuclear phosphoinositides breakdown as a step in the signal transduction generated by cytokine receptor triggering. Therefore, we have studied the repertoire and functional regulation of nuclear PLC, the key enzyme of phosphoinositides turnover, by interleukin-2 (IL-2) in primary human natural killer (NK) cells and its effects on the IL-2-driven NK cell proliferation. We found that 1) IL-2 stimulates nuclear PLC activity within 60 min of treatment; 2) NK cells express only the beta family of PLCs in the nucleus, and the isoform of this enzyme regulated by IL- 2 is PLC beta (1)b; 3) IL- 2 induces nuclear translocation of extracellular signal-related kinase (ERK)-2, or p42, and to a lesser extent, of ERK-1, or p44, of mitogen-activated protein kinase (MAPK), whose specific inhibition prevents the IL-2-driven nuclear PLC beta (1) activation; 4) PLC beta (1)b is serine-phosphorylated after IL- 2, and the phosphorylation is abolished after MAPK inhibition; and 5) inhibition of nuclear PLC activation leads to the inhibition of the IL-2-induced proliferation of NK cells. Altogether, our data indicate that nuclear PLC signaling is a downstream target of the ERK/MAPK pathway stimulated by IL-2 receptor triggering in human primary NK cells, and that the nuclear phosphoinositides turnover is a key step in proliferative response of NK cells to IL-2.	Univ Bologna, Dept Anat Sci, Cellular Signaling Lab, I-40126 Bologna, Italy; Univ Parma, Osped Maggiore, Inst Human Anat, I-43100 Parma, Italy; Res Inst Codivilla Putti, CNR, Inst Cytomorphol, I-40100 Bologna, Italy; Univ Brescia, Human Anat Div, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy; Univ G dAnnunzio, Inst Human Morphol, I-66100 Chieti, Italy; Univ Bologna, Sch Pharm, Dept Anat Sci, I-40126 Bologna, Italy; Univ Auckland, Sch Med, Liggins Inst, Auckland, New Zealand	University of Bologna; University of Parma; University Hospital of Parma; Consiglio Nazionale delle Ricerche (CNR); University of Brescia; G d'Annunzio University of Chieti-Pescara; University of Bologna; University of Auckland	Cocco, L (corresponding author), Univ Bologna, Dept Anat Sci, Cellular Signaling Lab, Via Irnerio 48, I-40126 Bologna, Italy.	lcocco@biocfarm.unibo.it	Cocco, Lucio/AAI-2206-2020; Zauli, Giorgio/ABE-8001-2020; Rodella, Luigi Fabrizio/F-1079-2010; Vitale, Marco/O-8751-2015; Falconi, Massimo/K-2194-2016	Cocco, Lucio/0000-0002-9206-8277; Vitale, Marco/0000-0002-3261-6868; Falconi, Massimo/0000-0001-9654-7243; Rodella, Luigi Fabrizio/0000-0002-9497-4708; Zauli, Giorgio/0000-0002-3750-8698				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AZZONI L, 1992, J EXP MED, V176, P1745, DOI 10.1084/jem.176.6.1745; Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; Bahk YY, 1998, BBA-LIPID LIPID MET, V1389, P76, DOI 10.1016/S0005-2760(97)00128-8; COCCO L, 1994, CELL SIGNAL, V6, P481, DOI 10.1016/0898-6568(94)90001-9; Crawley JB, 1996, EUR J IMMUNOL, V26, P2717, DOI 10.1002/eji.1830261125; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; HEATON KM, 1995, HUM IMMUNOL, V42, P274, DOI 10.1016/0198-8859(94)00106-Z; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IRVINE R, 2000, SCIENCE; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; Karnitz LM, 1996, ADV IMMUNOL, V61, P147, DOI 10.1016/S0065-2776(08)60867-6; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; LEE CW, 1993, J BIOL CHEM, V268, P21318; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LIAO F, 1993, J IMMUNOL, V150, P2668; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; MANZOLI L, 1995, CANCER RES, V55, P2978; Manzoli L, 1997, CANCER RES, V57, P2137; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; Martelli AM, 1999, J CELL BIOCHEM, V72, P339, DOI 10.1002/(SICI)1097-4644(19990301)72:3<339::AID-JCB3>3.0.CO;2-L; MARTELLI AM, 1994, CANCER RES, V54, P2536; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Martelli AM, 2000, FEBS LETT, V486, P230, DOI 10.1016/S0014-5793(00)02313-9; Matteucci A, 1998, CANCER RES, V58, P5057; MAZZONI M, 1992, BIOCHEM BIOPH RES CO, V187, P114, DOI 10.1016/S0006-291X(05)81466-4; MINAMI Y, 1995, CURR OPIN CELL BIOL, V7, P156, DOI 10.1016/0955-0674(95)80023-9; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Nelson BH, 1996, MOL CELL BIOL, V16, P309; NERI LM, 1994, FEBS LETT, V347, P63, DOI 10.1016/0014-5793(94)00508-7; PARK DG, 1993, J BIOL CHEM, V268, P3710; RABEN DM, 1994, J MEMBRANE BIOL, V142, P1; Rebollo A, 1996, ADV IMMUNOL, V63, P127, DOI 10.1016/S0065-2776(08)60856-1; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Sun B, 1997, J BIOL CHEM, V272, P26313, DOI 10.1074/jbc.272.42.26313; Taniguchi T, 1995, ANN NY ACAD SCI, V766, P235, DOI 10.1111/j.1749-6632.1995.tb26671.x; TING AT, 1992, J EXP MED, V176, P1751, DOI 10.1084/jem.176.6.1751; Trotta R, 1998, J IMMUNOL, V161, P6648; Umehara H, 1997, J IMMUNOL, V159, P1200; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; Wei S, 1998, J EXP MED, V187, P1753, DOI 10.1084/jem.187.11.1753; WHALEN MM, 1993, IMMUNOLOGY, V79, P542; Xu AM, 2001, MOL CELL BIOL, V21, P2981, DOI 10.1128/MCB.21.9.2981-2990.2001; York JD, 1998, ADV ENZYME REGUL, V38, P365, DOI 10.1016/S0065-2571(97)00018-6; YORK JD, 1994, J BIOL CHEM, V269, P7847; ZAHO K, 1998, CELL, V95, P625	51	37	39	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1789	+		10.1096/fj.01-0008fje	http://dx.doi.org/10.1096/fj.01-0008fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481231				2022-12-25	WOS:000169261200029
J	Ke, S; Rabson, AB; Germino, JF; Gallo, MA; Tian, YN				Ke, S; Rabson, AB; Germino, JF; Gallo, MA; Tian, YN			Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ARYL-HYDROCARBON RECEPTOR; HEAT-SHOCK PROTEIN; AH-RECEPTOR; GENE-EXPRESSION; TRANSCRIPTIONAL COACTIVATOR; HISTONE ACETYLTRANSFERASE; GLUCOCORTICOID RECEPTOR; HUMAN HEPATOCYTES; CONSERVED FAMILY	Proinflammatory cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin-1 beta, and lipopolysaccharides (LPS), suppress the gene expression of cytochrome P-450 1A1 (cyp1a1). The mechanism of the suppression is not well understood. In present study, we show that activation of nuclear factor-kappaB (NF-kappaB) is a critical event leading to the suppression of cyp1a1 gene expression, thus providing an underlying mechanism for the TNF-alpha- and LPS-induced cyp1a1 suppression. We demonstrated that: W inducible Re1A expression down-regulated aryl hydrocarbon receptor (AhR) activated reporter gene; (ii) the suppressive effects of LPS and TNF-alpha on the AhR-activated reporter gene could be blocked by pyrrolidine dithiocarbamate, which is known to inhibit NF-kappaB action; and (iii) TNF-alpha and LPS-imposed repression could be reversed by the NF-kappaB super repressor (SRI kappaB alpha), thus demonstrating the specific involvement of NF-kappaB. Furthermore, nuclear receptor coactivators p300/CBP and steroid receptor coactivator-1 act individually as well as cooperatively to reverse the suppressive effects by NF-kappaB on the AhR-activated reporter gene, suggesting that these transcriptional coactivators serve as the common integrators for the two pathways, thereby mediating the cross-interactions between AhR and NF-kappaB. Finally, using the chromatin immunoprecipitation assay, we demonstrated that AhR ligand induces histone H4 acetylation at the cypla1 promoter region containing the TATA box, whereas TNF-alpha inhibits this acetylation, suggesting that AhR/NF-kappaB interaction converges at level of transcription involving chromatin remodeling.	UMDNJ, Robert Wood Johnson Med Sch, Environm & Occupat Hlth Sci Inst, Dept Environm & Community Med, Piscataway, NJ 08854 USA; UMDNJ, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Canc Inst New Jersey, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Tian, YN (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, Mail Stop 4466, College Stn, TX 77843 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009859] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 05022, ES 09859] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARKER CW, 1992, J BIOL CHEM, V267, P8050; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Carver LA, 1997, J BIOL CHEM, V272, P11452; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CONNEY AH, 1982, CANCER RES, V42, P4875; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1989, J BIOL CHEM, V264, P16478; ECKNER R, 1994, COLD SPRING HARB SYM, V59, P85, DOI 10.1101/SQB.1994.059.01.012; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; Garrison PM, 1996, FUND APPL TOXICOL, V30, P194, DOI 10.1006/faat.1996.0056; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107, DOI 10.1152/physrev.1980.60.4.1107; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Lai ZW, 1997, MOL PHARMACOL, V52, P30, DOI 10.1124/mol.52.1.30; Ma Q, 1997, J BIOL CHEM, V272, P8878; Medina D, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e61; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Morel Y, 1999, BIOCHEM J, V342, P481, DOI 10.1042/0264-6021:3420481; Morel Y, 1999, MOL CELL BIOL, V19, P6825; Morgan ET, 2001, DRUG METAB DISPOS, V29, P207; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; MUNTANERELAT J, 1995, HEPATOLOGY, V22, P1143; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103	42	167	174	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39638	39644		10.1074/jbc.M106286200	http://dx.doi.org/10.1074/jbc.M106286200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11470802	hybrid			2022-12-25	WOS:000171789200019
J	Salvador, LM; Park, Y; Cottom, J; Maizels, ET; Jones, JCR; Schillace, RV; Carr, DW; Cheung, P; Allis, CD; Jameson, JL; Hunzicker-Dunn, M				Salvador, LM; Park, Y; Cottom, J; Maizels, ET; Jones, JCR; Schillace, RV; Carr, DW; Cheung, P; Allis, CD; Jameson, JL; Hunzicker-Dunn, M			Follicle-stimulating hormone stimulates protein kinase A-mediated histone H3 phosphorylation and acetylation leading to select gene activation in ovarian granulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; ELEMENT-BINDING PROTEIN; PROGESTERONE-RECEPTOR GENE; CIS-ACTING ELEMENTS; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; SIGNALING PATHWAY; PROMOTER ACTIVITY; P300/CBP-ASSOCIATED FACTOR; CONSTITUTIVE EXPRESSION; CATALYTIC SUBUNIT	We examined the phosphorylation and acetylation of histone H3 in ovarian granulosa cells stimulated to differentiate by follicle-stimulating hormone (FSH). We found that protein kinase A (PKA) mediates H3 phosphorylation on serine 10, based on inhibition exclusively by PKA inhibitors. FSH-stimulated H3 phosphorylation in granulosa cells is not downstream of mitogen-activated protein kinase/extracellular signal-regulated kinase, ribosomal S6 kinase-2, mitogen- and stress-activated protein kinase-1, p38 MAPK, phosphatidylinositol-3 kinase, or protein kinase C. Transcriptional activation-associated H3 phosphorylation on serine 10 and acetylation of lysine 14 leads to activation of serum glucocorticoid kinase, inhibin a, and c-fos genes. We propose that phosphorylation of histone H3 on serine 10 by PKA in coordination with acetylation of H3 on lysine 14 results in reorganization of the promoters of select FSH responsive genes into a more accessible configuration for activation. The unique role of PKA as the physiological histone H3 kinase is consistent with the central role of PKA in initiating granulosa cell differentiation.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA; Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA; Univ Virginia, Charlottesville, VA 22908 USA	Northwestern University; Northwestern University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Virginia	Hunzicker-Dunn, M (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Div Endocrinol Metab & Mol Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	mhd@northwestern.edu	Jones, Jonathan C R/T-9467-2017	Jones, Jonathan C R/0000-0002-1496-4922; Maizels, Evelyn/0000-0001-9072-1095; Jameson, James/0000-0001-9538-4059	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036408] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 36408, P01 HD 21921, 5F32 HD 85602] Funding Source: Medline; NIGMS NIH HHS [GM 40922] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI D, 2000, J BIOL CHEM, V270, P27489; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BENDELL JJ, 1988, ENDOCRINOLOGY, V123, P941, DOI 10.1210/endo-123-2-941; BENDER FE, 1982, STAT METHODS FOOD AG; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Cameron MR, 1996, BIOL REPROD, V55, P111, DOI 10.1095/biolreprod55.1.111; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; CARR DW, 1993, J BIOL CHEM, V268, P20729; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; DELIDOW BC, 1992, BIOL REPROD, V47, P428, DOI 10.1095/biolreprod47.3.428; DeManno DA, 1999, MOL ENDOCRINOL, V13, P91, DOI 10.1210/me.13.1.91; DORRINGTON J, 1988, ENDOCRINOLOGY, V123, P353, DOI 10.1210/endo-123-1-353; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; GIBORI G, 1984, ENDOCRINOLOGY, V115, P1157, DOI 10.1210/endo-115-3-1157; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Gonzalez-Robayna IJ, 1999, MOL ENDOCRINOL, V13, P1318, DOI 10.1210/me.13.8.1318; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; HARRISON JJ, 1980, BIOCHEM BIOPH RES CO, V96, P1253, DOI 10.1016/0006-291X(80)90086-8; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Herrera JE, 2000, J BIOL CHEM, V275, P12994, DOI 10.1074/jbc.275.17.12994; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; Horstmann S, 1998, J NEUROSCI RES, V52, P483, DOI 10.1002/(SICI)1097-4547(19980515)52:4<483::AID-JNR12>3.3.CO;2-Y; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; Hu YL, 1996, ENDOCRINOLOGY, V137, P3897, DOI 10.1210/en.137.9.3897; HUNZICKERDUNN M, 1981, J BIOL CHEM, V256, P2185; HUNZICKERDUNN M, 1991, J BIOL CHEM, V266, P7166; Ito M, 2000, MOL ENDOCRINOL, V14, P66, DOI 10.1210/me.14.1.66; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lian JP, 1999, J IMMUNOL, V163, P4527; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lopez D, 1999, ENDOCRINOLOGY, V140, P3034, DOI 10.1210/en.140.7.3034; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; Maizels ET, 1998, ENDOCRINOLOGY, V139, P3353, DOI 10.1210/en.139.7.3353; Merienne K, 2000, ONCOGENE, V19, P4221, DOI 10.1038/sj.onc.1203712; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Mukherjee A, 1998, MOL ENDOCRINOL, V12, P785, DOI 10.1210/me.12.6.785; Mukherjee A, 1996, ENDOCRINOLOGY, V137, P3234, DOI 10.1210/en.137.8.3234; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OKADA T, 1994, J BIOL CHEM, V269, P3563; PARKSARGE OK, 1995, ENDOCRINOLOGY, V136, P5430, DOI 10.1210/en.136.12.5430; PARKSARGE OK, 1994, ENDOCRINOLOGY, V134, P709, DOI 10.1210/en.134.2.709; PEI L, 1991, MOL ENDOCRINOL, V5, P521, DOI 10.1210/mend-5-4-521; RAO MC, 1978, CELL, V14, P71, DOI 10.1016/0092-8674(78)90302-1; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sugawara T, 2000, ENDOCRINOLOGY, V141, P2895, DOI 10.1210/en.141.8.2895; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; TAYLOR SS, 1982, J BIOL CHEM, V257, P6056; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Walia H, 1998, J BIOL CHEM, V273, P14516, DOI 10.1074/jbc.273.23.14516; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WOLFFE AP, 1992, FASEB J, V6, P3354, DOI 10.1096/fasebj.6.15.1464369; Wolffe AP, 1996, CURR BIOL, V6, P234, DOI 10.1016/S0960-9822(02)00465-7; WOODRUFF TK, 1987, MOL ENDOCRINOL, V1, P561, DOI 10.1210/mend-1-8-561; WOODRUFF TK, 1990, ANNU REV PHYSIOL, V52, P807, DOI 10.1146/annurev.ph.52.030190.004111; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	98	130	137	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40146	40155		10.1074/jbc.M106710200	http://dx.doi.org/10.1074/jbc.M106710200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11498542	hybrid			2022-12-25	WOS:000171789200086
J	Carothers, AM; Melstrom, KA; Mueller, JD; Weyant, MJ; Bertagnolli, MM				Carothers, AM; Melstrom, KA; Mueller, JD; Weyant, MJ; Bertagnolli, MM			Progressive changes in adherens junction structure during intestinal adenoma formation in Apc mutant mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; EPIDERMAL-GROWTH-FACTOR; TRUNCATED BETA-CATENIN; E-CADHERIN; CELL-ADHESION; CATALYTIC-ACTIVITY; FORCED EXPRESSION; COMPLEX-FORMATION; ALPHA-CATENIN; GENE-PRODUCT	The C57BL/6J-Min/+ (Min/+) mouse bears a mutant Apc gene and therefore is an important in vivo model of intestinal tumorigenesis. Min/+ mice develop adenomas that exhibit loss of the wild-type Apc allele (Apc(Min/-)). Previously, we found that histologically normal enterocytes bearing a truncated Apc protein (Apc(Min/+)) migrated more slowly in vivo than enterocytes with either wild-type Ape (Apc(+/+)) or with heterozygous loss of Apc protein (Apc(1638N)). To study this phenotype further, we determined the effect of the Apc(Min) mutation upon cell-cell adhesion by examining the components of the adherens junction (A.). We observed a reduced association between E-cadherin and beta -catenin in Apc(Min/+) enterocytes. Subcellular fractionation of proteins from Apc(+/+), Apc(Min/+), and Apc(Min/-) intestinal tissues revealed a cytoplasmic localization of intact E-cadherin only in Apc(Min/+), suggesting E-cadherin internalization in these enterocytes. beta -Catenin tyrosine phosphorylation was also increased in Apc(Min/+) enterocytes, consistent with its dissociation from E-cadherin. Furthermore, Apc(Min/+) enterocytes showed a decreased association between beta -catenin and receptor protein-tyrosine phosphatase beta/zeta (RPTP beta/zeta), and Apc(Min/-) cells demonstrated an association between beta -catenin and receptor protein-tyrosine phosphatase gamma. In contrast to the Apc(Min/+) enterocytes, Apc(Min/-) adenomas displayed increased expression and association of E-cadherin, beta -catenin, and alpha -catenin relative to Apc(+/+) controls. These data show that Apc plays a role in regulating adherens junction structure and function in the intestine. In addition, discovery of these effects in initiated but histologically normal tissue (Apc(Min/+)) defines a pre-adenoma stage of tumorigenesis in the intestinal mucosa.	Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Cornell Univ, Weill Coll Med, Dept Surg, New York, NY USA; Strang Canc Prevent Ctr, New York, NY 10021 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Cornell University; Harvard University; Brigham & Women's Hospital	Bertagnolli, MM (corresponding author), Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.	mbertagnolli@partners.org			NCI NIH HHS [1R29CA74162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; CAROTHERS AM, 2001, P AM ASSOC CANC RES, V42, P674; Elchebly M, 1999, NAT GENET, V21, P330, DOI 10.1038/6859; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; Harroch S, 2000, MOL CELL BIOL, V20, P7706, DOI 10.1128/MCB.20.20.7706-7715.2000; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Iwao K, 1998, CANCER RES, V58, P1021; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lammers R, 2000, J BIOL CHEM, V275, P3391, DOI 10.1074/jbc.275.5.3391; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; LEVY DB, 1994, CANCER RES, V54, P5953; LUONGO C, 1994, CANCER RES, V54, P5947; Mahmoud NN, 1997, CANCER RES, V57, P5045; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; McCartney BM, 1999, J CELL BIOL, V146, P1303, DOI 10.1083/jcb.146.6.1303; MCNEILL H, 1993, J CELL BIOL, V120, P1217, DOI 10.1083/jcb.120.5.1217; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; MIYAKI M, 1994, CANCER RES, V54, P3011; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NELSON WJ, 1987, J CELL BIOL, V104, P1527, DOI 10.1083/jcb.104.6.1527; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orsulic S, 1999, J CELL SCI, V112, P1237; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; OYAMA T, 1994, CANCER RES, V54, P6282; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Perry I, 1999, J CLIN PATHOL-MOL PA, V52, P166, DOI 10.1136/mp.52.4.166; Petrone A, 2000, J CELL SCI, V113, P2345; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Reinacher-Schick A, 2001, J CELL BIOL, V152, P491, DOI 10.1083/jcb.152.3.491; Ren JM, 1998, DIABETES, V47, P493, DOI 10.2337/diabetes.47.3.493; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shih IM, 2000, CANCER RES, V60, P1671; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; SHORE EM, 1991, J BIOL CHEM, V266, P19672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Troxell ML, 2001, J CELL SCI, V114, P1237; Uetani N, 2000, EMBO J, V19, P2775, DOI 10.1093/emboj/19.12.2775; VIJAYASURIAN E, 1999, J BIOL CHEM, V274, P16641; Wallace MJ, 1999, NAT GENET, V21, P334, DOI 10.1038/6866; Weyant MJ, 2001, CANCER RES, V61, P118; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yeo TT, 1997, J NEUROSCI RES, V47, P348, DOI 10.1002/(SICI)1097-4547(19970201)47:3<348::AID-JNR13>3.0.CO;2-Y; Yu X, 1999, MECH DEVELOP, V84, P69, DOI 10.1016/S0925-4773(99)00072-6; Zhang T, 1997, CANCER RES, V57, P169	80	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39094	39102		10.1074/jbc.M103450200	http://dx.doi.org/10.1074/jbc.M103450200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11483600	hybrid			2022-12-25	WOS:000171673200100
J	Chen, CM; Sytkowski, AJ				Chen, CM; Sytkowski, AJ			Erythropoietin activates two distinct signaling pathways required for the initiation and the elongation of c-myc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INDUCED ERYTHROID-DIFFERENTIATION; MURINE ERYTHROLEUKEMIA-CELLS; GROWTH-FACTOR; MAP KINASE; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; PROGENITOR CELLS; DNA-SYNTHESIS; HELA-CELLS	Erythropoietin (Epo) stimulation of erythroid cells results in the activation of several kinases and a rapid induction of c-myc expression. Protein kinase C is necessary for Epo up-regulation of c-myc by promoting elongation at the 3'-end of exon 1. PKC epsilon mediates this signal. We now show that Epo triggers two signaling pathways to c-myc. Epo rapidly up-regulated Myc protein in BaF3-EpoR cells. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 blocked Myc up-regulation in a concentration-dependent manner but had no effect on the Epo-induced phosphorylation of ERK1 and ERK2. LY294002 also had no effect on Epo up-regulation of c-fos. MEK1 inhibitor PD98059 blocked both the c-myc and the c-fos responses to Epo. PD98059 and the PKC inhibitor H7 also blocked the phosphorylation of ERK1 and ERK2. PD98059 but not LY294002 inhibited Epo induction of ERK1 and ERK2 phosphorylation in normal erythroid cells. LY294002 blocked transcription of c-myc at exon 1. PD98059 had no effect on transcription from exon 1 but, rather, blocked Epo-induced c-myc elongation at the 3'-end of exon 1. These results identify two Epo signaling pathways to c-myc, one of which is PI3K-dependent operating on transcriptional initiation, whereas the other is mitogen-activated protein kinase-dependent operating on elongation.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Med, Div Hematol & Oncol,Lab Cell & Mol Biol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Sytkowski, AJ (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Med, Div Hematol & Oncol,Lab Cell & Mol Biol, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA089204] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA89204] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BACON ER, 1987, BLOOD, V69, P103; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; BARBER DL, 1994, MOL CELL BIOL, V14, P2257, DOI 10.1128/MCB.14.4.2257; Bergelson S, 1998, J BIOL CHEM, V273, P2396, DOI 10.1074/jbc.273.4.2396; Bondurant MC, 1996, J CELL PHYSIOL, V168, P255, DOI 10.1002/(SICI)1097-4652(199608)168:2<255::AID-JCP4>3.0.CO;2-O; BUSFIELD SJ, 1992, BLOOD, V80, P412; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHERN YJ, 1991, J BIOL CHEM, V266, P2009; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Corbit KC, 2000, MOL CELL BIOL, V20, P5392, DOI 10.1128/MCB.20.15.5392-5403.2000; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; Devemy E, 1997, CELL SIGNAL, V9, P41, DOI 10.1016/S0898-6568(96)00095-2; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fanger GR, 1997, MOL CELL BIOL, V17, P89, DOI 10.1128/MCB.17.1.89; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; Gomez-Cambronero J, 1999, FEBS LETT, V443, P126, DOI 10.1016/S0014-5793(98)01685-8; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; Johannessen LE, 2000, EXP CELL RES, V260, P136, DOI 10.1006/excr.2000.5004; Khorchid A, 1999, J NEUROSCI RES, V58, P765; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KOMATSU N, 1992, BLOOD, V80, P53; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; Li YK, 1996, J BIOL CHEM, V271, P27025, DOI 10.1074/jbc.271.43.27025; Matsuzaki T, 2000, ONCOGENE, V19, P1500, DOI 10.1038/sj.onc.1203461; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Montmayeur JP, 1997, J BIOL CHEM, V272, P32670, DOI 10.1074/jbc.272.51.32670; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PATEL HR, 1995, EXP HEMATOL, V23, P619; PATEL HR, 1992, J BIOL CHEM, V267, P21300; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Shan RJ, 1999, BLOOD, V94, P4067, DOI 10.1182/blood.V94.12.4067.424k12_4067_4076; SHOWERS MO, 1992, BLOOD, V80, P3070; SHOWERS MO, 1993, MOL CELL BIOL, V13, P739, DOI 10.1128/MCB.13.2.739; SPANGLER R, 1991, J BIOL CHEM, V266, P681; SPANGLER R, 1992, BLOOD, V79, P52; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORTI M, 1992, J BIOL CHEM, V267, P8293; TSUDA H, 1991, INT J CELL CLONING, V9, P123, DOI 10.1002/stem.5530090203; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	58	40	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38518	38526		10.1074/jbc.M105702200	http://dx.doi.org/10.1074/jbc.M105702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11483613	hybrid			2022-12-25	WOS:000171673200027
J	Hales, CM; Griner, R; Hobdy-Henderson, KC; Dorn, MC; Hardy, D; Kumar, R; Navarre, J; Chan, EKL; Lapierre, LA; Goldenring, JR				Hales, CM; Griner, R; Hobdy-Henderson, KC; Dorn, MC; Hardy, D; Kumar, R; Navarre, J; Chan, EKL; Lapierre, LA; Goldenring, JR			Identification and characterization of a family of Rab11-interacting proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GASTRIC PARIETAL-CELLS; CANINE KIDNEY-CELLS; RAB5 EFFECTOR EEA1; RECYCLING COMPARTMENT; MOLECULAR-CLONING; MEMBRANE-FUSION; TRANSFERRIN; TRANSPORT; RAB11A	Rab11a is a small GTP-binding protein enriched in the pericentriolar plasma membrane recycling systems. We hypothesized that Rab11a-binding proteins exist as downstream effectors of its action. Here we define a family of four Rab11-interacting proteins: Rab11-Family Interacting Protein 1 (Rab11-FIP1), Rab11-Family Interacting Protein 2 (Rab11-FIP2), Rab11-Family Interacting Protein 3 (Rab11-FIP3), and pp75/Rip11. All four interacting proteins associated with wild type Rab11a and dominant active Rab11a (Rab11aS20V) as well as Rab11b and Rab25. Rab11-FIP2 also interacted with dominant negative Rab11a (Rab11aS25N) and the tail of myosin Vb. The binding of Rab11-FIP1, Rab11-FIP2, and Rab11-FIP3 to Rab11a was dependent upon a conserved carboxyl-terminal amphipathic alpha -helix. Rab11-FIP1, Rab11-FIP2, and pp75/Rip11 colocalized with Rab11a in plasma membrane recycling systems in both non-polarized HeLa cells and polarized Madin-Darby canine kidney cells. GFP-Rab11-FIP3 also colocalized with Rab11a in HeLa cells. Rab11-FIP1, Rab11-FIP2, and pp75/Rip11 also coenriched with Rab11a and H+K+-ATPase on parietal cell tubulovesicles, and Rab11-FIP1 and Rab11-FIP2 translocated with Rab11a and the H+K+-ATPase upon stimulating parietal cells with histamine. The results suggest that the function of Rab11a in plasma membrane recycling systems is dependent upon a compendium of protein effectors.	Med Coll Georgia, Inst Mol & Med Genet, Dept Med, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol & Med Genet, Dept Surg, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol & Med Genet, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Augusta Vet Affairs Med Ctr, Augusta, GA 30912 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Scripps Research Institute	Goldenring, JR (corresponding author), Med Coll Georgia, Inst Mol & Med Genet, Dept Med, CB-2803,1120 15th St, Augusta, GA 30912 USA.	jgolden@mail.mcg.edu	Chan, Edward K. L./B-5671-2009	Chan, Edward K. L./0000-0003-3938-9503	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI047859, R01AI047859] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043405, R01DK048370, R01DK043405] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47859] Funding Source: Medline; NIDDK NIH HHS [DK48370, DK43405] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BASSON MD, 1991, BIOCHEM J, V279, P43, DOI 10.1042/bj2790043; Bhartur SG, 2000, BIOCHEM BIOPH RES CO, V269, P611, DOI 10.1006/bbrc.2000.2334; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Calhoun BC, 1998, AM J PHYSIOL-CELL PH, V275, pC163, DOI 10.1152/ajpcell.1998.275.1.C163; CARR DW, 1992, J BIOL CHEM, V267, P13376; Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; CHEW CS, 1989, AM J PHYSIOL, V256, pG254, DOI 10.1152/ajpgi.1989.256.1.G254; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; DRIVAS GT, 1991, ONCOGENE, V6, P3; Duman JG, 1999, AM J PHYSIOL-CELL PH, V277, pC361, DOI 10.1152/ajpcell.1999.277.3.C361; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Forte JG, 1996, TRENDS CELL BIOL, V6, P45, DOI 10.1016/0962-8924(96)81009-9; Goldenring JR, 1996, AM J PHYSIOL-GASTR L, V270, pG515, DOI 10.1152/ajpgi.1996.270.3.G515; GOLDENRING JR, 1993, J BIOL CHEM, V268, P18419; GOLDENRING JR, 1994, AM J PHYSIOL, V267, pG187, DOI 10.1152/ajpgi.1994.267.2.G187; Green EG, 1997, BIOCHEM BIOPH RES CO, V239, P612, DOI 10.1006/bbrc.1997.7520; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Mammoto A, 1999, J BIOL CHEM, V274, P25517, DOI 10.1074/jbc.274.36.25517; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; SAKURADA K, 1991, BIOCHEM BIOPH RES CO, V177, P1224, DOI 10.1016/0006-291X(91)90672-T; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; SOROKA CJ, 1993, EUR J CELL BIOL, V60, P76; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Wang DR, 1999, J CLIN INVEST, V104, P1265, DOI 10.1172/JCI8003; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840	42	235	246	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39067	39075		10.1074/jbc.M104831200	http://dx.doi.org/10.1074/jbc.M104831200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495908	hybrid			2022-12-25	WOS:000171673200097
J	Kruidering, M; Schouten, T; Evan, GI; Vreugdenhil, E				Kruidering, M; Schouten, T; Evan, GI; Vreugdenhil, E			Caspase-mediated cleavage of the Ca2+/calmodulin-dependent protein kinase-like kinase facilitates neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; CYTOCHROME-C; RAT HIPPOCAMPUS; SIGNAL-TRANSDUCTION; SYMPATHETIC NEURONS; SURVIVAL; GENE; BAX; DOUBLECORTIN; ACTIVATION	This study was designed to identify the role of a recently identified Ca2+/calmodulin-dependent protein kinase (CaMK)-like kinase (CaMKLK) in neuronal apoptosis. For this purpose, we studied proteolytic cleavage of CaMKLK by caspases in vitro and in neuronal NG108 cells. In addition, we have investigated the effect of overexpression of wild type and mutant CaMKLK proteins on staurosporine- and serum deprivation-induced apoptosis of NG108 cells. We found that CaMKLK is a substrate for caspase-3 and -8, both in vitro and in NG108 cells during staurosporine- and serum withdrawal-induced apoptosis. Substitution of an aspartic acid residue at position 62 in an asparagine residue within a putative caspase cleavage site completely blocked cleavage of CaMKLK, strongly indicating that (DEND62)-D-59 is the caspase recognition site. Overexpression of an Asp(62)--> Asn CaMKLK mutant protected NG108 cells from staurosporine-induced apoptosis to a similar extent as Bcl-x(L). In contrast, overexpression of wild type CaMKLK did not lead to protection. Moreover, microinjection of Asp(62) --> Asn CaMKLK protected NG108 cells from serum deprivation-induced apoptosis, while overexpression of a caspase-generated noncatalytic N-terminal CaMKLK fragment exacerbated apoptosis. Together, our data suggest that cleavage of CaMKLK and generation of the noncatalytic N-terminal domain of CaMKLK facilitate neuronal apoptosis.	Leiden Univ, Med Ctr, Leiden Amsterdam Ctr Drug Res, Div Med Pharmacol, NL-2300 RA Leiden, Netherlands; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94115 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of California System; University of California San Francisco	Vreugdenhil, E (corresponding author), Leiden Univ, Med Ctr, Leiden Amsterdam Ctr Drug Res, Div Med Pharmacol, POB 9503, NL-2300 RA Leiden, Netherlands.	vreugden@lacdr.leidenuniv.nl						Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; CHURN SB, 1993, STROKE, V24, P271, DOI 10.1161/01.STR.24.2.271; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; des Portes V, 1998, CELL, V92, P51; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HAJIMOHAMMADREZA I, 1995, J NEUROSCI, V15, P4093; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kawamura KI, 1996, BIOCHEM PHARMACOL, V52, P1903, DOI 10.1016/S0006-2952(96)00692-2; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin PT, 2000, J NEUROSCI, V20, P9152; Ma JY, 1998, BRIT J PHARMACOL, V124, P756, DOI 10.1038/sj.bjp.0701871; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; Means AR, 1997, RECENT PROG HORM RES, V52, P389; Neame SJ, 1998, J CELL BIOL, V142, P1583, DOI 10.1083/jcb.142.6.1583; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Omori Y, 1998, J HUM GENET, V43, P169, DOI 10.1007/s100380050063; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; Vreugdenhil E, 1996, NEUROSCI LETT, V212, P75, DOI 10.1016/0304-3940(96)12751-8; Vreugdenhil E, 1996, J MOL NEUROSCI, V7, P135, DOI 10.1007/BF02736793; Vreugdenhil E, 1999, J NEUROBIOL, V39, P41, DOI 10.1002/(SICI)1097-4695(199904)39:1<41::AID-NEU4>3.0.CO;2-X; Werth JL, 2000, EXP NEUROL, V161, P203, DOI 10.1006/exnr.1999.7241; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wright SC, 1997, FASEB J, V11, P843, DOI 10.1096/fasebj.11.11.9285482; Yamakawa H, 2000, NEUROL RES, V22, P556; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	50	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38417	38425		10.1074/jbc.M103471200	http://dx.doi.org/10.1074/jbc.M103471200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11479289	hybrid			2022-12-25	WOS:000171673200014
J	Yuan, WH; Varga, J				Yuan, WH; Varga, J			Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; STROMELYSIN GENE-EXPRESSION; HUMAN SKIN FIBROBLASTS; N-TERMINAL KINASE; TGF-BETA; TRANSCRIPTIONAL COACTIVATORS; FUNCTIONAL-CHARACTERIZATION; DIFFERENTIAL REGULATION; MEDIATED TRANSCRIPTION; TARGETED DISRUPTION	Enhanced production of matrix metalloproteinase-1 (MMP-1, collagenase-1) is implicated in pathological tissue destruction. Transforming growth factor-beta (TGF-beta) prevents cytokine-induced AMP-1 gene expression in fibroblasts. In these studies, we examined the hypothesis that repression of MMP-1 may be mediated through the Smad signaling pathway. The results showed that Smad3 and Smad4, but not Smad1 or Smad2, mimicked the inhibitory effect of TGF-beta and abrogated interleukin-1 beta (IL-1 beta)-induced stimulation of MMP-1 promoter activity and NF kappaB-specific gene transcription in dermal fibroblasts. Experiments with truncation mutants indicated that both MH1 and MH2 domains of Smad3 were necessary for inhibitory activity. Dominant negative mutants of Smad3 or Smad4 and antagonistic Smad7, which disrupts ligand-induced Smad3 phosphorylation, abrogated the repression of MMP-1 transcription by TGF-beta. Similar results were obtained using immunoblot and Northern analysis. Furthermore, TGF-beta failed to repress MMP-1 promoter activity in Smad3-deficient murine embryonic fibroblasts. These results implicated cellular Smads in mediating the inhibitory effects of TGF-beta. Overexpression of the transcriptional co-activator p300, but not its histone acetyltransferase (HAT)deficient mutant, was able to relieve repression of MMP-1 gene expression, suggesting that Smad-dependent inhibition may be due to increased competition between Smad proteins and IL-1 beta signaling pathways for limiting amounts of cellular p300. Together, these results demonstrate that MMP-1 is a target for negative regulation by TGF-beta through cellular Smad3 and Smad4. Smad-mediated repression of AMP-1 gene expression may be important for preventing excessive matrix degradation induced by inflammatory cytokines; disruption of Smad signaling, as occurs in certain cancer cells, may thus be causally linked to uncontrolled tissue destruction mediated through AMP-1.	Univ Illinois, Rheumatol Sect, Coll Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Varga, J (corresponding author), Univ Illinois, Rheumatol Sect, Coll Med, Rm 1158 MBRB,900 S Ashland Ave, Chicago, IL 60607 USA.				NIAMS NIH HHS [AR-42309] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042309] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Bond M, 1999, BIOCHEM BIOPH RES CO, V264, P561, DOI 10.1006/bbrc.1999.1551; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; BORGHAEI H, 1997, INFLAMM RES, V46, P177; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DiChiara MR, 2000, J EXP MED, V192, P695, DOI 10.1084/jem.192.5.695; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Hahm KB, 2000, J CLIN INVEST, V105, P1057, DOI 10.1172/JCI8337; HARVEY AK, 1991, EXP CELL RES, V195, P376, DOI 10.1016/0014-4827(91)90387-A; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lum ZP, 1996, J CELL PHYSIOL, V166, P351, DOI 10.1002/(SICI)1097-4652(199602)166:2<351::AID-JCP13>3.0.CO;2-E; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Nagarajan RP, 1999, J BIOL CHEM, V274, P31229, DOI 10.1074/jbc.274.44.31229; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PERELLA M, 1996, J BIOL CHEM, V271, P13766; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; REDINI F, 1993, ARTHRITIS RHEUM, V36, P44; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; VARGA J, 1995, J CLIN INVEST, V96, P475, DOI 10.1172/JCI118058; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Werner F, 2000, J BIOL CHEM, V275, P36653, DOI 10.1074/jbc.M004536200; White LA, 2000, BBA-GENE STRUCT EXPR, V1490, P259, DOI 10.1016/S0167-4781(00)00002-6; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	60	216	230	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38502	38510		10.1074/jbc.M107081200	http://dx.doi.org/10.1074/jbc.M107081200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11502752	hybrid			2022-12-25	WOS:000171673200025
J	Lee, BK; Khare, S; Naider, F; Becker, JM				Lee, BK; Khare, S; Naider, F; Becker, JM			Identification of residues of the Saccharomyces cerevisiae G protein-coupled receptor contributing to alpha-factor pheromone binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE DOMAIN 6; CONFORMATIONAL-ANALYSIS; MATING PHEROMONE; PEPTIDE ANALOGS; MUTATIONS; SPECIFICITY; MUTAGENESIS; SEQUENCE; KLUYVERI	The Saccharomyces cerevisiae pheromone, a-factor (WHWLQLKPGQPMY), and Ste2p, its G protein-coupled receptor, were studied as a model for peptide ligand-receptor interaction. The affinities and activities of various synthetic position-10 alpha -factor analogs with Ste2p expressing mutations at residues Ser(47) and Thr(48) were investigated. All mutant receptors were expressed at a similar level in the cytoplasmic membrane, and their efficacies of signal transduction were similar to that of the wild-type receptor. Mutant receptors differed in binding affinity (K-d) and potency (EC50) for gene induction by alpha -factor. One mutant receptor (S47K,T48K) had dramatically reduced affinity and activity for [Lys(10)]- and [Orn(10)] alpha -factor, whereas the affinity for Saccharomyces kluyveri alpha -factor (WHWLSFSKGEPMY) was increased over 20-fold compared with that of wild-type receptor. In contrast, the affinity of [Lys(10)]- and [Orn(10)] alpha -factor was increased greatly in a S47E,T48E mutant receptor, whereas the binding of the S. kluyveri alpha -factor was abolished. The affinity of [Lys(10)]- and [Orn(10)] alpha -factor for the S47E,T48E receptor dropped 4-6fold in the presence of 1 M NaCl, whereas the affinity of alpha -factor was not affected by this treatment. These results demonstrate that when bound to its receptor the 10th residue (Gln) of the S. cerevisiae alpha -factor is adjacent to Ser(47) and Thr(48) residues in the receptor and that the 10th residue of alpha -factors from two Saccharomyces species is responsible for the ligand selectivity to their cognate receptors. Based on these data, we have developed a two-dimensional model of alpha -factor binding to its receptor.	Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA; CUNY Coll Staten Isl, Dept Chem, Staten Isl, NY 10314 USA	University of Tennessee System; University of Tennessee Knoxville; City University of New York (CUNY) System; College of Staten Island (CUNY)	Becker, JM (corresponding author), Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA.	jbecker@utk.edu			NIGMS NIH HHS [GM22087, GM22086] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022086, R01GM022087, R56GM022086, R56GM022087] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel MG, 1998, BBA-MOL CELL RES, V1448, P12, DOI 10.1016/S0167-4889(98)00109-8; Abel MG, 1998, J PEPT RES, V52, P95; Blomberg A, 2000, FEMS MICROBIOL LETT, V182, P1; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Chen QJ, 1996, MOL CELL BIOL, V16, P247; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLARK CD, 1994, J BIOL CHEM, V269, P8831; Creighton T. E., 1993, PROTEINS STRUCTURES; Ding FX, 2001, BIOCHEMISTRY-US, V40, P1102, DOI 10.1021/bi0021535; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Dosil M, 1998, MOL CELL BIOL, V18, P5981, DOI 10.1128/MCB.18.10.5981; Dube P, 1998, MOL CELL BIOL, V18, P7205, DOI 10.1128/MCB.18.12.7205; Dube P, 2000, J BIOL CHEM, V275, P26492, DOI 10.1074/jbc.M002767200; EGELMITANI M, 1987, NUCLEIC ACIDS RES, V15, P6303, DOI 10.1093/nar/15.15.6303; ERIOTOUBARGIOTA E, 1992, BIOCHEMISTRY-US, V31, P551, DOI 10.1021/bi00117a036; Filizola M, 1998, BIOORGAN MED CHEM, V6, P1491, DOI 10.1016/S0968-0896(98)00084-4; FLOWER DR, 1999, BIOCHIM BIOPHYS ACTA, V142, P207; GOUNARIDES JS, 1993, BIOCHEMISTRY-US, V32, P908, DOI 10.1021/bi00054a023; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hoare SRJ, 2001, J BIOL CHEM, V276, P7741, DOI 10.1074/jbc.M009395200; Jarnagin K, 1996, J BIOL CHEM, V271, P28277, DOI 10.1074/jbc.271.45.28277; JELICKS LA, 1988, BIOPOLYMERS, V27, P431, DOI 10.1002/bip.360270307; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; MARSH L, 1988, P NATL ACAD SCI USA, V85, P3855, DOI 10.1073/pnas.85.11.3855; Oosterom J, 1999, J BIOL CHEM, V274, P16853, DOI 10.1074/jbc.274.24.16853; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; RATHS SK, 1988, J BIOL CHEM, V263, P17333; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; SEN M, 1994, J BIOL CHEM, V269, P968; Sen M, 1997, CURR GENET, V31, P235, DOI 10.1007/s002940050200; Sommers CM, 2000, BIOCHEMISTRY-US, V39, P6898, DOI 10.1021/bi992616a; Turner PR, 1998, J BIOL CHEM, V273, P3830, DOI 10.1074/jbc.273.7.3830; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Xie HB, 2000, BIOCHEMISTRY-US, V39, P15462, DOI 10.1021/bi001432p; YANG W, 1995, BIOCHEMISTRY-US, V34, P1308, DOI 10.1021/bi00004a025; Zhang YL, 1998, BIOCHEMISTRY-US, V37, P12465, DOI 10.1021/bi980787u	42	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37950	37961						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11495900				2022-12-25	WOS:000171526500033
J	Ostrander, DB; Sparagna, GC; Amoscato, AA; McMillin, JB; Dowhan, W				Ostrander, DB; Sparagna, GC; Amoscato, AA; McMillin, JB; Dowhan, W			Decreased cardiolipin synthesis corresponds with cytochrome c release in palmitate-induced cardiomyocyte apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDP-DIACYLGLYCEROL SYNTHASE; HEART-MITOCHONDRIA; RAT-HEART; PHOSPHOLIPID-COMPOSITION; CARDIAC MYOCYTES; CELL-DEATH; METABOLISM; ACID; PHOSPHATIDYLGLYCEROL; BIOSYNTHESIS	Apoptosis has been identified recently as a component of many cardiac pathologies. However, the potential triggers of programmed cell death in the heart and the involvement of specific metabolic pathway(s) are less well characterized. Detachment of cytochrome c from the mitochondrial inner membrane is a necessary first step for cytochrome c release into the cytosol and initiation of apoptosis. The saturated long chain fatty acid, palmitate, induces apoptosis in rat neonatal cardiomyocytes and diminishes content of the mitochondrial anionic phospholipid, cardiolipin. These changes are accompanied by 1) acyl chain saturation of phosphatidic acid and phosphatidylglycerol, 2) large increases in the levels of these two phospholipids, and 3) a decline in cardiolipin synthesis. Although cardiolipin synthase activity is unchanged, saturated phosphatidylglycerol is a poor substrate for this enzyme. Under these conditions, decreased cardiolipin synthesis and release of cytochrome c are directly and significantly correlated. The results suggest that phosphatidylglycerol saturation and subsequent decreases in cardiolipin affect the association of cytochrome c with the inner mitochondrial membrane, directly influencing the pathway to cytochrome c release and subsequent apoptosis.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA; Univ Pittsburgh, Mass Spectrometry Facil, Ctr Biotechnol & Bioengn, Pittsburgh, PA 15219 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA	University of Texas System; University of Texas System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Dowhan, W (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	william.dowhan@uth.tmc.edu		Amoscato, Andrew/0000-0002-1340-9150	NCI NIH HHS [5P30CA47904-12] Funding Source: Medline; NHLBI NIH HHS [HL10019, HL10304] Funding Source: Medline; NIGMS NIH HHS [GM56389] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA047904] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010019, F32HL010304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amoscato AA, 2001, FASEB J, V15, pA511; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bobyleva V, 1997, BIOCHEM MOL BIOL INT, V41, P469; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; CHOI SH, 1995, BIOPHYS CHEM, V54, P271, DOI 10.1016/0301-4622(94)00151-9; CHUA BH, 1977, J BIOL CHEM, V252, P6711; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; ESKO JD, 1980, J BIOL CHEM, V255, P4474; Fiordaliso F, 1999, CIRCULATION, V100, P759; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Hickson-Bick DLM, 2000, J MOL CELL CARDIOL, V32, P511, DOI 10.1006/jmcc.1999.1098; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; KAJIYAMA K, 1987, CIRC RES, V61, P301, DOI 10.1161/01.RES.61.2.301; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; KURIEN VA, 1971, EUR J CLIN INVEST, V1, P225, DOI 10.1111/eci.1971.1.4.225; LEIRIS JD, 1978, CARDIOVASC RES, V12, P585, DOI 10.1093/cvr/12.10.585; Lesnefsky EJ, 2001, AM J PHYSIOL-HEART C, V280, pH2770; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madesh M, 1999, FREE RADICAL BIO MED, V26, P836, DOI 10.1016/S0891-5849(98)00270-6; MCMILLIN JB, 1993, CARDIOVASC RES, V27, P2222, DOI 10.1093/cvr/27.12.2222; MCMILLIN JB, 1993, METHODS TOXICOL, V2, P301; OHTSUKA T, 1993, J BIOL CHEM, V268, P22908; PANDE SV, 1986, BIOCHIM BIOPHYS ACTA, V877, P223, DOI 10.1016/0005-2760(86)90298-5; PARADIES G, 1990, BIOCHIM BIOPHYS ACTA, V1016, P207, DOI 10.1016/0005-2728(90)90060-H; Paradies G, 1997, BBA-MOL BASIS DIS, V1362, P193, DOI 10.1016/S0925-4439(97)00075-6; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SCHLAME M, 1991, EUR J BIOCHEM, V199, P459, DOI 10.1111/j.1432-1033.1991.tb16144.x; Sparagna GC, 2000, AM J PHYSIOL-HEART C, V279, pH2124, DOI 10.1152/ajpheart.2000.279.5.H2124; TAMAI KT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P214, DOI 10.1016/0005-2760(90)90192-Z; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; Watts JD, 1999, CELL DEATH DIFFER, V6, P105, DOI 10.1038/sj.cdd.4400472; Weeks R, 1997, DNA CELL BIOL, V16, P281, DOI 10.1089/dna.1997.16.281; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	42	248	254	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38061	38067						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11500520				2022-12-25	WOS:000171526500047
J	Tibaduiza, EC; Chen, C; Beinborn, M				Tibaduiza, EC; Chen, C; Beinborn, M			A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; EXTRACELLULAR DOMAIN; GLP-1 RECEPTOR; SECRETIN RECEPTOR; I RECEPTOR; ANTAGONIST; CLONING; AGONIST; CELL; LOCALIZATION	The glucagon-like peptide 1 receptor (GLP-1R) belongs to a distinct subgroup of G protein-coupled peptide hormone receptors (class B) that has been difficult to target by small molecule drugs. Here, we report that a non-peptide compound, T-0632, binds with micromolar affinity to the human GLP-1R and blocks GLP-1-induced cAMP production. Furthermore, the observation that T-0632 has almost 100-fold selectivity for the human versus the highly homologous rat GLP-1R provided an opportunity to map determinants of non-peptide binding. Radioligand competition experiments utilizing a series of chimeric human/rat GLP-1R constructs revealed that partial substitution of the amino terminus of the rat GLP-1R with the corresponding sequence from the human homolog was sufficient to confer high T-0632 affinity. Follow-up analysis of receptors where individual candidate amino acids had been exchanged between the human and rat GLP-1Rs identified a single residue that explained species selectivity of non-peptide binding. Replacement of tryptophan 33 in the human GLP-1R by serine (the homologous amino acid in the rat GLP-1R) resulted in a 100-fold loss of T-0632 affinity, whereas the converse mutation in the rat GLP-1R led to a reciprocal gain-of-function phenotype. These observations suggest that in a class B receptor, important determinants of non-peptide affinity reside within the extracellular amino-terminal domain. Compound T-0632 may mimic, and thereby interfere with, the putative "pseudo-tethering" mechanism by which the amino terminus of class B receptors initiates the binding of cognate hormones.	Tufts Univ New England Med Ctr, Tupper Res Inst, Dept Med, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Tupper Res Inst, Mol Pharmacol Res Ctr, Boston, MA 02111 USA	Tufts Medical Center; Tufts Medical Center	Beinborn, M (corresponding author), Tufts Univ New England Med Ctr, Tupper Res Inst, Dept Med, Box 7703,750 Washington St, Boston, MA 02111 USA.	mbeinborn@lifespan.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056674] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK56674, P30 DK3928] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahren B, 1998, BIOESSAYS, V20, P642, DOI 10.1002/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO;2-K; Asmann YW, 2000, MOL PHARMACOL, V58, P911, DOI 10.1124/mol.58.5.911; Beinborn M, 1998, J BIOL CHEM, V273, P14146, DOI 10.1074/jbc.273.23.14146; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BUGGY JJ, 1995, J BIOL CHEM, V270, P7474, DOI 10.1074/jbc.270.13.7474; Cascieri MA, 1999, J BIOL CHEM, V274, P8694, DOI 10.1074/jbc.274.13.8694; CASCIERI MA, 1995, J PHARMACOL TOXICOL, V33, P179, DOI 10.1016/1056-8719(95)00002-Y; DILLON JS, 1993, ENDOCRINOLOGY, V133, P1907, DOI 10.1210/en.133.4.1907; Dong MQ, 2000, ANN NY ACAD SCI, V921, P381; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; FLENTKE GR, 1991, P NATL ACAD SCI USA, V88, P1556, DOI 10.1073/pnas.88.4.1556; Flint A, 1998, J CLIN INVEST, V101, P515, DOI 10.1172/JCI990; FONG TM, 1993, NATURE, V362, P350; Frimurer TM, 1999, PROTEINS, V35, P375, DOI 10.1002/(SICI)1097-0134(19990601)35:4<375::AID-PROT1>3.0.CO;2-2; Gelling RW, 1997, ENDOCRINOLOGY, V138, P2640, DOI 10.1210/en.138.6.2640; GOKE R, 1993, J BIOL CHEM, V268, P19650; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; GRAZIANO MP, 1993, BIOCHEM BIOPH RES CO, V196, P141, DOI 10.1006/bbrc.1993.2226; Graziano MP, 1996, RECEPTOR CHANNEL, V4, P9; Gronberg A, 2000, DIABETES, V49, pA251; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; Gutzwiller JP, 1999, GUT, V44, P81, DOI 10.1136/gut.44.1.81; Henke BR, 1996, J MED CHEM, V39, P2655, DOI 10.1021/jm960249k; Hjorth SA, 1996, ACTA PHYSIOL SCAND, V157, P343, DOI 10.1046/j.1365-201X.1996.37259000.x; Holst JJ, 1999, CURR MED CHEM, V6, P1005; Holst JJ, 1997, ANNU REV PHYSIOL, V59, P257, DOI 10.1146/annurev.physiol.59.1.257; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Kiel D, 2000, FASEB J, V14, pA1351; Knudsen LB, 1996, EUR J PHARMACOL, V318, P429, DOI 10.1016/S0014-2999(96)00795-9; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LANKATBUTTGEREIT B, 1994, EXP CLIN ENDOCRINOL, V102, P341, DOI 10.1055/s-0029-1211301; Liaw CW, 1997, MOL ENDOCRINOL, V11, P2048, DOI 10.1210/me.11.13.2048; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; PERLMAN S, 1995, J BIOL CHEM, V270, P1493, DOI 10.1074/jbc.270.4.1493; Perrin MH, 1998, ENDOCRINOLOGY, V139, P566, DOI 10.1210/en.139.2.566; SCHWARTZ TW, 1995, CURR PHARM DESIGN, V1, P325; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Taniguchi H, 1996, EUR J PHARMACOL, V312, P227, DOI 10.1016/0014-2999(96)00473-6; THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; TUCEK S, 1995, TRENDS PHARMACOL SCI, V16, P205, DOI 10.1016/S0165-6147(00)89023-9; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; VanEyll B, 1996, PEPTIDES, V17, P565, DOI 10.1016/0196-9781(96)00019-8; Wettergren A, 1998, PEPTIDES, V19, P877, DOI 10.1016/S0196-9781(98)00020-5; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; Wilmen A, 1996, FEBS LETT, V398, P43, DOI 10.1016/S0014-5793(96)01214-8; Wilmen A, 1997, PEPTIDES, V18, P301, DOI 10.1016/S0196-9781(96)00321-X; Xiao Q, 2000, J MOL ENDOCRINOL, V25, P321, DOI 10.1677/jme.0.0250321	51	64	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37787	37793						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11498540				2022-12-25	WOS:000171526500010
J	Tremblay, F; Marette, A				Tremblay, F; Marette, A			Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway - A negative feedback mechanism leading to insulin resistance in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-1 TYROSINE PHOSPHORYLATION; RECEPTOR SUBSTRATE-1; MAMMALIAN TARGET; PROTEIN-SYNTHESIS; PHOSPHOINOSITIDE 3-KINASE; TRANSLATION INITIATION; GLUCOSE-TRANSPORT; SERINE/THREONINE PHOSPHORYLATION; STIMULATED PHOSPHORYLATION; TNF-ALPHA	Amino acids have emerged as potent modulators of the mTOR/p70 S6 kinase pathway. The involvement of this pathway in the regulation of insulin-stimulated glucose transport was investigated in the present study. Acute exposure (I h) to a balanced mixture of amino acids reduced insulin-stimulated glucose transport by as much as 55% in L6 muscle cells. The effect of amino acids was fully prevented by the specific mTOR inhibitor rapamycin. Time course analysis of insulin receptor substrate 1 (IRS-1)-associated phosphatidylinositol (PI) 3-kinase activity revealed that incubation with amino acids speeds up its time-dependent deactivation, leading to a dramatic suppression (-70%) of its activity after 30 min of insulin stimulation as compared with its maximal activation (5 min of stimulation). This accelerated deactivation of PI 3-kinase activity in amino acid-treated cells was associated with a concomitant and sustained increase in the phosphorylation of p70 S6 kinase. In marked contrast, inhibition of mTOR by rapamycin maintained PI 3-kinase maximally activated for up to 30 min. The marked inhibition of insulin-mediated PI 3-kinase activity by amino acids was linked to a rapamycin-sensitive increase in serine/threonine phosphorylation of IRS-1 and a decreased binding of the p85 subunit of PI 3-kinase to IRS-1. Furthermore, amino acids were required for the degradation of IRS-1 during long term insulin treatment. These results identify the mT0R/p70 S6 kinase signaling pathway as a novel modulator of insulin-stimulated glucose transport in skeletal muscle cells.	CHU Laval, Res Ctr, Dept Physiol, Quebec City, PQ G1V 4G2, Canada; CHU Laval, Res Ctr, Lipid Res Unit, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Marette, A (corresponding author), CHU Laval, Res Ctr, Dept Physiol, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	andre.marette@crchul.ulaval.ca	Marette, Andre/E-9342-2013					Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; ABUMRAD NN, 1982, J SURG RES, V32, P453, DOI 10.1016/0022-4804(82)90126-3; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Anthony JC, 2000, J NUTR, V130, P2413; Bedard S, 1997, BIOCHEM J, V325, P487, DOI 10.1042/bj3250487; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; FLAKOLL PJ, 1992, DIABETOLOGIA, V35, P357, DOI 10.1007/BF00401203; Fox HL, 1998, AM J PHYSIOL-CELL PH, V274, pC206, DOI 10.1152/ajpcell.1998.274.1.C206; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Kriauciunas KM, 2000, MOL CELL BIOL, V20, P6849, DOI 10.1128/MCB.20.18.6849-6859.2000; Lavigne C, 2001, AM J PHYSIOL-ENDOC M, V281, pE62, DOI 10.1152/ajpendo.2001.281.1.E62; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; MARSHALL S, 1991, FASEB J, V5, P3031, DOI 10.1096/fasebj.5.15.1743436; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PISTERS PWT, 1991, METABOLISM, V40, P59, DOI 10.1016/0026-0495(91)90193-Z; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; Shah OJ, 1999, J BIOL CHEM, V274, P36168, DOI 10.1074/jbc.274.51.36168; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Svanberg E, 1997, AM J PHYSIOL-ENDOC M, V272, pE841, DOI 10.1152/ajpendo.1997.272.5.E841; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TESSARI P, 1985, DIABETOLOGIA, V28, P870, DOI 10.1007/BF00291080; TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910; van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Yang CM, 2000, MOL ENDOCRINOL, V14, P317, DOI 10.1210/me.14.2.317	55	412	430	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38052	38060						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11498541				2022-12-25	WOS:000171526500046
J	Morel, JCM; Park, CC; Woods, JM; Koch, AE				Morel, JCM; Park, CC; Woods, JM; Koch, AE			A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-LIKE SYNOVIOCYTES; HUMAN ENDOTHELIAL-CELLS; RHEUMATOID-ARTHRITIS; SYNOVIAL FIBROBLASTS; KG-1 CELLS; ACTIVATION; 3-KINASE; IL-18; CYTOKINES; EXPRESSION	Interleukin-18 (IL-18) is a novel proinflammatory cytokine found in serum and joints of patients with rheumatoid arthritis (RA). We studied a novel role for IL-18 in mediating cell adhesion, a vital component of the inflammation found in RA and other inflammatory diseases. We examined the expression of cellular cell adhesion molecules E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) on endothelial cells and RA synovial fibroblasts using flow cytometry. Adhesion of the monocytelike cell line HL-60 to endothelial cells was determined by immunofluorescence. IL-18 significantly enhanced ICAM-1 and VCAM-1 expression on endothelial cells and RA synovial fibroblasts. In addition, IL-18 induced E-selectin expression on endothelial cells and promoted the adhesion of HL-60 cells to IL-18-stimulated endothelial cells. Neutralizing anti-VCAM-1 and anti-E-selectin could completely inhibit HL-60 adherence to endothelial cells. IL-18-induced adhesion molecule expression appears to be mediated through nuclear factor kappaB (NF kappaB) and phosphatidyl-inositol 3 kinase (PI 3-kinase) since addition of inhibitors to either NF kappaB (pyrrolidine dithiocarbamate and N-acetyl-L-cysteine) or PI 3-kinase (LY294002) inhibited RA synovial fibroblast VCAM-1 expression by 50 to 60%. Addition of both inhibitors resulted in inhibition of VCAM-1 expression by 85%. In conclusion, the ability of IL-18 to induce adhesion molecule expression on endothelial cells and IRA synovial fibroblasts indicates that IL-18 may contribute to RA joint inflammation by enhancing the recruitment of leukocytes into the joint. IL-18 requires NF kappaB as well as PI 3-kinase to induce VCAM-1 on RA synovial fibroblasts, suggesting that there may be two distinct pathways in IL-18-induced adhesion molecule expression.	Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Vet Affairs Chicago Hlth Care Syst, Lakeside Div, Chicago, IL 60611 USA	Northwestern University	Koch, AE (corresponding author), Northwestern Univ, Sch Med, Dept Med, 303 E Chicago Ave,Ward Bldg 3-315, Chicago, IL 60611 USA.	ae-koch@northwestern.edu	Koch, Alisa E/B-6894-2011; Park, Christy/AAH-1543-2020		NHLBI NIH HHS [HL-58695] Funding Source: Medline; NIAID NIH HHS [AI-40987] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040987, R01AI040987] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BOMBARA MP, 1993, J LEUKOCYTE BIOL, V54, P399, DOI 10.1002/jlb.54.5.399; BUCALA R, 1991, J EXP MED, V173, P569, DOI 10.1084/jem.173.3.569; CARLOS TM, 1990, BLOOD, V76, P965; CHULUYAN HE, 1995, J IMMUNOL, V155, P3135; Coffer PJ, 1998, BIOCHEM J, V335, P1; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; Gracie JA, 1999, J CLIN INVEST, V104, P1393, DOI 10.1172/JCI7317; Kalina U, 2000, J IMMUNOL, V165, P1307, DOI 10.4049/jimmunol.165.3.1307; Katagiri K, 1996, BLOOD, V87, P4276, DOI 10.1182/blood.V87.10.4276.bloodjournal87104276; KAWAI M, 1995, J IMMUNOL, V154, P2333; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; KOCH AE, 1986, ARTHRITIS RHEUM, V29, P471, DOI 10.1002/art.1780290403; Kohka H, 1998, J LEUKOCYTE BIOL, V64, P519, DOI 10.1002/jlb.64.4.519; Kojima H, 1999, J IMMUNOL, V162, P5063; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung BP, 2000, J IMMUNOL, V164, P6495, DOI 10.4049/jimmunol.164.12.6495; Li P, 2000, J IMMUNOL, V164, P5990, DOI 10.4049/jimmunol.164.11.5990; Matsumoto S, 1997, BIOCHEM BIOPH RES CO, V234, P454, DOI 10.1006/bbrc.1997.6665; McMurray RW, 1996, SEMIN ARTHRITIS RHEU, V25, P215, DOI 10.1016/S0049-0172(96)80034-5; Min W, 1997, J IMMUNOL, V159, P3508; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; Mojcik CF, 1997, ARTHRITIS RHEUM-US, V40, P991, DOI 10.1002/art.1780400602; MOREL JCM, 2001, IN PRESS LAB INVEST; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; PITZALIS C, 1994, ANN RHEUM DIS, V53, P287, DOI 10.1136/ard.53.5.287; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Sadeghi NM, 2000, J IMMUNOL, V165, P2712, DOI 10.4049/jimmunol.165.5.2712; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHWACHULA A, 1994, IMMUNOBIOLOGY, V190, P67, DOI 10.1016/S0171-2985(11)80284-6; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Shapiro L, 1998, P NATL ACAD SCI USA, V95, P12550, DOI 10.1073/pnas.95.21.12550; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Szekanecz Z, 1996, J INVEST MED, V44, P124; Szekanecz Z, 2001, Curr Rheumatol Rep, V3, P53, DOI 10.1007/s11926-001-0051-0; Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9; Thomas JA, 1999, J IMMUNOL, V163, P978; VANDINTHERJANSSEN ACHM, 1991, J IMMUNOL, V147, P4207; Vidal-Vanaclocha F, 2000, P NATL ACAD SCI USA, V97, P734, DOI 10.1073/pnas.97.2.734; Wei XQ, 2001, J IMMUNOL, V166, P517, DOI 10.4049/jimmunol.166.1.517	43	127	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37069	37075		10.1074/jbc.M103574200	http://dx.doi.org/10.1074/jbc.M103574200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11477102	hybrid			2022-12-25	WOS:000171375700029
J	Bartoschek, S; Johansson, M; Geierstanger, BH; Okun, JG; Lancaster, CRD; Humpfer, E; Yu, L; Yu, CA; Griesinger, C; Brandt, U				Bartoschek, S; Johansson, M; Geierstanger, BH; Okun, JG; Lancaster, CRD; Humpfer, E; Yu, L; Yu, CA; Griesinger, C; Brandt, U			Three molecules of ubiquinone bind specifically to mitochondrial cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTONMOTIVE Q-CYCLE; IRON-SULFUR PROTEIN; ELECTRON-TRANSFER; BC1 COMPLEX; UBIHYDROQUINONE OXIDATION; BOVINE HEART; C REDUCTASE; Q(O) SITE; NMR; SPECTROSCOPY	Bifurcated electron flow to high potential "Rieske" iron-sulfur cluster and low potential heme b(L) is crucial for respiratory energy conservation by the cytochrome bc(1) complex. The chemistry of ubiquinol oxidation has to ensure the thermodynamically unfavorable electron transfer to heme b(L). To resolve a central controversy about the number of ubiquinol molecules involved in this reaction, we used high resolution magic-angle-spinning nuclear magnetic resonance experiments to show that two out of three n-decyl-ubiquinones bind at the ubiquinol oxidation center of the complex. This substantiates a proposed mechanism in which a charge transfer between a ubiquinol/ubiquinone pair explains the bifurcation of electron flow.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; Goethe Univ Frankfurt, Inst Organ Chem, D-60439 Frankfurt, Germany; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; Univ Frankfurt Klinikum, Inst Biochem 1, D-60590 Frankfurt, Germany; Max Planck Inst Biophys, Abt Mol Membranbiol, D-60528 Frankfurt, Germany; Bruker Analyt GMBH, D-76287 Rheinstetten, Germany	Oklahoma State University System; Oklahoma State University - Stillwater; Goethe University Frankfurt; Max Planck Society; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Max Planck Society	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	cayuq@okstate.edu; cigr@org.chemie.uni-frankfurt.de; brandt@zbc.klinik.uni-frankfurt.de	Brandt, Ulrich/C-4406-2008; Lancaster, C. Roy/E-4313-2010; Brandt, Ulrich/GLV-1242-2022	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811; Lancaster, C. Roy D./0000-0002-2814-0051	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Brandt U, 1996, BBA-BIOENERGETICS, V1275, P41, DOI 10.1016/0005-2728(96)00048-5; BRANDT U, 1989, EUR J BIOCHEM, V182, P705, DOI 10.1111/j.1432-1033.1989.tb14882.x; BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x; BRANDT U, 1991, J BIOL CHEM, V266, P19958; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Brandt U, 1996, FEBS LETT, V387, P1, DOI 10.1016/0014-5793(96)00436-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021; Crofts AR, 2000, BBA-BIOENERGETICS, V1459, P456, DOI 10.1016/S0005-2728(00)00184-5; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GARROWAY AN, 1982, J MAGN RESON, V49, P168, DOI 10.1016/0022-2364(82)90308-0; HE DY, 1994, BIOCHEMISTRY-US, V33, P880, DOI 10.1021/bi00170a005; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lancaster CRD, 1997, STRUCTURE, V5, P1339, DOI 10.1016/S0969-2126(97)00285-2; Lindblom G, 1996, CURR OPIN COLLOID IN, V1, P287, DOI 10.1016/S1359-0294(96)80017-3; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; RICH PR, 1992, PHOTOSYNTH RES, V34, P465, DOI 10.1007/BF00029819; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHLEUCHER J, 1993, ANGEW CHEM INT EDIT, V32, P1489, DOI 10.1002/anie.199314891; STOVER HDH, 1989, MACROMOLECULES, V22, P1574, DOI 10.1021/ma00194a012; VANDERHART DL, 1981, J MAGN RESON, V44, P361, DOI 10.1016/0022-2364(81)90178-5; VOLD RL, 1968, J CHEM PHYS, V48, P3831, DOI 10.1063/1.1669699; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	33	51	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35231	35234		10.1074/jbc.C100365200	http://dx.doi.org/10.1074/jbc.C100365200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11481318	Green Published, hybrid			2022-12-25	WOS:000171109300003
J	Wang, Q; Zhang, HT; Guerrette, S; Chen, JQ; Mazurek, A; Wilson, T; Slupianek, A; Skorski, T; Fishel, R; Greene, MI				Wang, Q; Zhang, HT; Guerrette, S; Chen, JQ; Mazurek, A; Wilson, T; Slupianek, A; Skorski, T; Fishel, R; Greene, MI			Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1	ONCOGENE			English	Article						BRCA1; MSH2; DNA mismatch repair; transcription-coupled DNA damage repair	TRANSCRIPTION-COUPLED REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH-REPAIR; CELL-CYCLE; DNA-DAMAGE; NUCLEAR PHOSPHOPROTEIN; MOLECULAR SWITCH; COLON-CANCER; IN-VIVO; C-MYC	We have identified the physical interaction between the Breast Cancer susceptibility gene product BRCA1 and the Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and DNA mismatch repair (MMR) gene product hMSH2, both in vitro and in vivo. The BRCA1-hMSH2 association involved several well-defined regions of both proteins which include the adenosine nucleotide binding domain of hMSH2. Moreover, the interaction of BRCA1 with purified hMSH2-hMSH6 appears to be modulated by adenosine nucleotide much like G protein downstream interaction/signaling is modulated by guanosine nucleotide. BARD1, another BRCA1-interacting protein, was also found to interact with hMSH2. In addition, BRCA1 was found to associate with both hMSH3 and hMSH6, the heterodimeric partners of IMSH2. These observations implicate BRCA1/BARD1 as downstream effectors of the adenosine nucleotide-activated hMSH2-hMSH6 signaling complex, and suggest a global role for BRCA1 in DNA damage processing. The functional interaction between BRCA1 and hMSH2 may provide a partial explanation for the background of gynecological and colorectal cancer in both HNPCC and BRCA1 kindreds, respectively.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Genet & Mol Biol Program, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA	University of Pennsylvania; Pennsylvania Medicine; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Fishel, R (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.		Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049	NCI NIH HHS [R01 CA067007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; de Boer J, 1998, CANCER RES, V58, P89; Dietmaier W, 1997, CANCER RES, V57, P4749; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; EASTON DF, 1995, AM J HUM GENET, V56, P265; FISHEL R, 1994, CANCER RES, V54, P5539; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Lynch HT, 1997, CANCER GENET CYTOGEN, V93, P84, DOI 10.1016/S0165-4608(96)00290-7; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Schmutte C, 1998, CANCER RES, V58, P4537; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Y, 2000, GENE DEV, V14, P927; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; WILSON TM, 1995, CANCER RES, V55, P5146; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang H, 1999, CANCER RES, V59, P3021; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang HT, 1997, ONCOGENE, V14, P2863, DOI 10.1038/sj.onc.1201140; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	55	58	58	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4640	4649		10.1038/sj.onc.1204625	http://dx.doi.org/10.1038/sj.onc.1204625			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498787				2022-12-25	WOS:000170208600005
J	Zhu, JH; Nozell, S; Wang, J; Jiang, JY; Zhou, WJ; Chen, XB				Zhu, JH; Nozell, S; Wang, J; Jiang, JY; Zhou, WJ; Chen, XB			p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner	ONCOGENE			English	Article						p53; p73; DNA damage; apoptosis	P53 GENE FAMILY; KINASE C-ABL; ANTICANCER AGENTS; CANCER-CELLS; MUTANT P53; IDENTIFICATION; CYTOTOXICITY; NEUROBLASTOMA; ACTIVATION; CISPLATIN	p73, a member of the p53 family, can induce apoptosis in cancer cells, Since p53-mediated apoptosis can be augmented by various cancer chemotherapeutic agents, it has been hypothesized that the status of the endogenous p53 gene in cancer cells is a key determinant in the outcome of cancer therapy. To determine whether p73 can sensitize cancer cells to apoptosis by DNA damage agents, several MCF7 adenocarcinoma cell lines that inducibly express p73 or p53 under a tetracycline-regulated promoter were generated. We found that at relevant physiological levels, p73, but not p53, is capable of sensitizing MCF? cells to apoptosis induced by chemotherapeutic agents. In addition, we found that p73 can cooperate with the DNA damaging agent camptothecin to activate the initiator caspase 2. Furthermore, me found that p73 can cooperate with DNA damaging agents or p53 to induce some p53 target genes and activate their promoters. In contrast, in MCF7E6 cells that ectopically express the human papillomavirus E6 oncogene and are functionally p53-null,, the ability of p73 to sensitize cells to apoptosis is abrogated. Taken together, these results suggest that a functional interaction between p53 and p73 in MCF7 cells leads to enhanced induction of apoptosis.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, CB-2803, Augusta, GA 30912 USA.				NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHEN XB, 1995, CANCER RES, V55, P4257; Chresta CM, 1996, CANCER RES, V56, P1834; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; FAN SJ, 1995, CANCER RES, V55, P1649; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gallardo D, 1996, CANCER RES, V56, P4891; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gong JG, 1999, NATURE, V399, P806; Gupta M, 1997, CLIN CANCER RES, V3, P1653; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAURENZI VD, 1999, CELL DEATH DIFFER, V6, P389; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; MUNGER K, 1989, J VIROL, V63, P4417; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; OConnor PM, 1997, CANCER RES, V57, P4285; Prives C, 1999, J PATHOL, V187, P112; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1998, CANCER RES, V58, P5061	46	44	47	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					4050	4057		10.1038/sj.onc.1204516	http://dx.doi.org/10.1038/sj.onc.1204516			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494133				2022-12-25	WOS:000169681500013
J	Ballester, A; Frampton, J; Vilaboa, N; Cales, C				Ballester, A; Frampton, J; Vilaboa, N; Cales, C			Heterologous expression of the transcriptional regulator escargot inhibits megakaryocytic endomitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPHOBLAST GIANT-CELLS; POLYPLOID DNA CONTENT; FACTOR SNAIL; CYCLIN D3; DIFFERENTIATION; DROSOPHILA; ENDOREDUPLICATION; KINASE; GENE; ACQUISITION	Certain cell types escape the strict mechanisms imposed on the majority of somatic cells to ensure the faithful inheritance of parental DNA content. This is the case in many embryonic tissues and certain adult cells such as mammalian hepatocytes and megakaryocytes. Megakaryocytic endomitosis is characterized by repeated S phases followed by abortive mitoses, resulting in mononucleated polyploid. cells. Several cell cycle regulators have been proposed to play an active role in megakaryocytic polyploidization; however, little is known about upstream factors that could control endomitosis. Here we show that ectopic expression of the transcriptional repressor escargot interferes with the establishment of megakaryocytic endomitosis. Phorbol ester-induced polyploidization was inhibited in stably transfected megakaryoblastic HEL cells constitutively expressing escargot. Analysis of the expression and activity of different cell cycle factors revealed that Escargot affects the G(1)/S transition by influencing Cdk2 activity and cyclin A transcription. Nuclear proteins that specifically bind the Escargot-binding element were detected in endomitotic and non-endomitotic megakaryoblastic cells, but down-regulation occurred only during differentiation of cells that become polyploid. As Escargot was originally implicated in ploidy maintenance of Drosophila embryonic and larval cells, our results suggest that polyploidization in megakaryocytes might respond to mechanisms conserved from early development to adult cells that need to escape normal control of the diploid state.	Univ Autonoma Madrid, Consejo Super Invest Cient, Inst Invest Biomed Alberto Sols, Dept Biochem, Madrid 28029, Spain; John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Oxford	Cales, C (corresponding author), Univ Autonoma Madrid, Consejo Super Invest Cient, Inst Invest Biomed Alberto Sols, Dept Biochem, Arturo Duperier 4, Madrid 28029, Spain.		Vilaboa, Nuria/S-2794-2019; Vilaboa, Nuria/L-1727-2014; Calés, Carmela/AAB-1595-2019	Vilaboa, Nuria/0000-0003-4473-4498; Ballester Jareno, Alicia/0000-0002-6474-7248; Cales, Carmela/0000-0002-6987-2259				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cayirlioglu P, 2001, CURR BIOL, V11, pR178, DOI 10.1016/S0960-9822(01)00088-4; Datta NS, 1998, CELL GROWTH DIFFER, V9, P639; Datta NS, 1996, MOL BIOL CELL, V7, P209, DOI 10.1091/mbc.7.2.209; FRAMPTON J, 1995, EMBO J, V14, P2866, DOI 10.1002/j.1460-2075.1995.tb07286.x; FUSE N, 1994, GENE DEV, V8, P2270, DOI 10.1101/gad.8.19.2270; Garcia P, 1996, ONCOGENE, V13, P695; Garcia P, 2000, ONCOGENE, V19, P1820, DOI 10.1038/sj.onc.1203494; GRAFI G, 1995, SCIENCE, V269, P1262, DOI 10.1126/science.269.5228.1262; Hayashi S, 1996, DEVELOPMENT, V122, P1051; HAYASHI S, 1993, DEVELOPMENT, V118, P105; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; Larkins BA, 2001, J EXP BOT, V52, P183, DOI 10.1093/jexbot/52.355.183; Lilly MA, 1996, GENE DEV, V10, P2514, DOI 10.1101/gad.10.19.2514; MacAuley A, 1998, MOL BIOL CELL, V9, P795, DOI 10.1091/mbc.9.4.795; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; Matsumura I, 2000, J BIOL CHEM, V275, P5553, DOI 10.1074/jbc.275.8.5553; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; Nakayama H, 1998, DEV BIOL, V199, P150, DOI 10.1006/dbio.1998.8914; Okubo T, 2001, CANCER RES, V61, P1338; Palazon LS, 1998, MOL HUM REPROD, V4, P1013, DOI 10.1093/molehr/4.11.1013; Roy L, 2001, BLOOD, V97, P2238, DOI 10.1182/blood.V97.8.2238; Vitrat N, 1998, BLOOD, V91, P3711; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; Zhang Y, 1998, J BIOL CHEM, V273, P1387, DOI 10.1074/jbc.273.3.1387; Zhang Y, 1996, J BIOL CHEM, V271, P4266; Zimmet JM, 1997, MOL CELL BIOL, V17, P7248, DOI 10.1128/MCB.17.12.7248	30	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43413	43418		10.1074/jbc.M106006200	http://dx.doi.org/10.1074/jbc.M106006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11498537	hybrid			2022-12-25	WOS:000172169300101
J	Jin, YJ; Blue, EK; Dixon, S; Hou, L; Wysolmerski, RB; Gallagher, PJ				Jin, YJ; Blue, EK; Dixon, S; Hou, L; Wysolmerski, RB; Gallagher, PJ			Identification of a new form of death-associated protein kinase that promotes cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; LIGHT-CHAIN KINASE; SERINE/THREONINE KINASE; SMOOTH-MUSCLE; MOLECULAR MECHANISMS; CATALYTIC ACTIVITY; TNF RECEPTOR; DAP-KINASE; HELA-CELLS; ZIP KINASE	In this study, two alternatively spliced forms of the mouse death-associated protein kinase (DAPK) have been identified and their roles in apoptosis examined. The mouse DAPK-alpha sequence is 95% identical to the previously described human DAPK, and it has a kinase domain and calmodulin-binding region closely related to the 130-150 kDa myosin light chain kinases. A beta -residue extension of the carboxyl terminus of DAPK-beta distinguishes it from the human and mouse DAPK-alpha. DAPK phosphorylates at least one substrate in vitro and in vivo, the myosin II regulatory light chain. This phosphorylation occurs preferentially at Ser-19 and is stimulated by calcium and calmodulin. The mRNA encoding DAPK is widely distributed and detected in mouse embryos and most adult tissues, although the expression of the encoded 160-kDa DAPK protein is more restricted. Overexpression of DAPK-alpha, the mouse homolog of human DAPK has a negligible effect on tumor necrosis factor (TNF)-induced apoptosis. Overexpression of DAPK-beta has a strong cytoprotective effect on TNF-treated cells. Biochemical analysis of TNF-treated cell lines expressing mouse DAPK-beta suggests that the cytoprotective effect of DAPK is mediated through both intrinsic and extrinsic apoptotic signaling pathways and results in the inhibition of cytochrome c release from the mitochondria as well as inhibition of caspase-3 and caspase-9 activity. These results suggest that the mouse DAPK-beta is a negative regulator of TNF-induced apoptosis.	Indiana Univ, Sch Med, Dept Cellular & Integrated Physiol, Indianapolis, IN 46202 USA; St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Saint Louis University	Gallagher, PJ (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrated Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.			Blue, Emily/0000-0001-8290-4473; Hou, Ling/0000-0003-0705-8099	NHLBI NIH HHS [R01 HL045788, R01 HL054118, R01 HL45788, R01 HL54118, R01 HL054118-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045788, R01HL054118] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; Gallagher PJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1078, DOI 10.1152/ajpcell.2000.279.4.C1078; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; GAUSH CR, 1966, P SOC EXP BIOL MED, V122, P931; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Herring BP, 2000, AM J PHYSIOL-CELL PH, V279, pC1656, DOI 10.1152/ajpcell.2000.279.5.C1656; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Inbal B, 2000, MOL CELL BIOL, V20, P1044, DOI 10.1128/MCB.20.3.1044-1054.2000; Jin YJ, 2001, J BIOL CHEM, V276, P30342, DOI 10.1074/jbc.M102404200; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kawai T, 1999, ONCOGENE, V18, P3471, DOI 10.1038/sj.onc.1202701; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Kogel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Raveh T, 2000, P NATL ACAD SCI USA, V97, P1572, DOI 10.1073/pnas.020519497; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433	43	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39667	39678		10.1074/jbc.M101886200	http://dx.doi.org/10.1074/jbc.M101886200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11485996	Green Accepted, hybrid			2022-12-25	WOS:000171789200023
J	Liu, Y; Merlin, D; Burst, SL; Pochet, M; Madara, JL; Parkos, CA				Liu, Y; Merlin, D; Burst, SL; Pochet, M; Madara, JL; Parkos, CA			The role of CD47 in neutrophil transmigration - Increased rate of migration correlates with increased cell surface expression of CD47	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; SIGNAL-REGULATORY PROTEIN; TRANSENDOTHELIAL MIGRATION; UP-REGULATION; IN-VIVO; ADHESION; ACTIVATION; RECEPTOR; CD11B/CD18; LIGAND	CD47, a cell surface glycoprotein, plays an important role in modulating neutrophil (PAIN) migration across endothelial and epithelial monolayers. Here we show that anti-CD47 monoclonal antibodies (mAbs) delay PMN migration across collagen-coated filters or T84 epithelial monolayers toward the chemoattractant formylmethionylleucylphenylalanine (fMLP). Despite delayed transmigration by anti-CD47 mAbs, the numbers of PMN migrating across in either condition were the same as in the presence of control non-inhibitory m-Abs. Cell surface labeling and immunoprecipitation demonstrated upregulation of CD47 to the PMN cell surface with kinetics similar to those of the transmigration response. Subcellular fractionation studies revealed redistribution of CD47 from intracellular compartments that co-sediment with secondary granules to plasma membrane-containing fractions after fMLP stimulation. Experiments performed to investigate potential signaling pathways revealed that inhibition of tyrosine phosphorylation with genistein reversed the anti-CD47-mediated PMN migration delay, whereas inhibition of phosphatidylinositol 3-kinase only partially reversed anti-CD47 effects that correlated with a rapid increase in PMN cell surface CD47. Analysis of the contribution of epithelial-expressed CD47 to PMN transmigration revealed that PMN migration across CD47-deficient epithelial monolayers (CaCO2) was significantly increased after stable transfection with CD47. These results suggest that cell surface CD47 and downstream tyrosine phosphorylation signaling events regulate, in part, the rate of PMN migration during the inflammatory response.	Emory Univ, Dept Pathol & Lab Med, Div Gastrointestinal Pathol, Atlanta, GA 30322 USA	Emory University	Liu, Y (corresponding author), Emory Univ, Dept Pathol & Lab Med, Div Gastrointestinal Pathol, Woodruff Mem Res Bldg,Rm 2331, Atlanta, GA 30322 USA.		Parkos, Charles a/B-3896-2009		NHLBI NIH HHS [HL 54229, HL 60540] Funding Source: Medline; NIDDK NIH HHS [DK 35932, DK 47622, DK 0283, DK 10013] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060540, R29HL054229, R01HL054229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035932, R01DK035932, F32DK010013] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON DC, 1984, J CLIN INVEST, V74, P536, DOI 10.1172/JCI111451; Babic I, 2000, J IMMUNOL, V164, P3652, DOI 10.4049/jimmunol.164.7.3652; Balsam LB, 1998, J IMMUNOL, V160, P5058; CALAFAT J, 1993, BLOOD, V81, P3122; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Chung J, 1999, BLOOD, V94, P642, DOI 10.1182/blood.V94.2.642.414k35_642_648; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; DANA N, 1984, J CLIN INVEST, V73, P153, DOI 10.1172/JCI111186; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; Furusawa T, 1998, J BIOCHEM-TOKYO, V123, P101; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; HUGHES BJ, 1992, J CLIN INVEST, V90, P1687, DOI 10.1172/JCI116041; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Jung S, 1999, CURR OPIN IMMUNOL, V11, P319, DOI 10.1016/S0952-7915(99)80051-X; KUMAR NB, 1982, AM J SURG PATHOL, V6, P523, DOI 10.1097/00000478-198209000-00004; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Liu Y, 2000, J CELL SCI, V113, P2363; LIU Y, 1997, THESIS U S ALABAMA M; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; Mateo V, 1999, NAT MED, V5, P1277, DOI 10.1038/15233; MAWBY WJ, 1994, BIOCHEM J, V304, P525, DOI 10.1042/bj3040525; MIKSICEK RJ, 1994, J STEROID BIOCHEM, V49, P153, DOI 10.1016/0960-0760(94)90005-1; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Naccache PH, 2000, J BIOL CHEM, V275, P23636, DOI 10.1074/jbc.M001780200; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Parkos CA, 1997, BIOESSAYS, V19, P865, DOI 10.1002/bies.950191006; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; PARKOS CA, 1985, J BIOL CHEM, V260, P6541; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; Pettersen RD, 1999, J IMMUNOL, V162, P7031; PHILIPS MR, 1988, J CLIN INVEST, V82, P495, DOI 10.1172/JCI113623; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; REINHOLD MI, 1995, J CELL SCI, V108, P3419; REPO H, 1993, J IMMUNOL METHODS, V164, P193, DOI 10.1016/0022-1759(93)90312-U; Repo H, 1997, J IMMUNOL, V159, P943; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Sipes JM, 1999, J BIOL CHEM, V274, P22755, DOI 10.1074/jbc.274.32.22755; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; Stockley RA, 1995, AM J MED, V99, pS8, DOI 10.1016/S0002-9343(99)80304-0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Vernon-Wilson EF, 2000, EUR J IMMUNOL, V30, P2130; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; Waclavicek M, 1997, J IMMUNOL, V159, P5345; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865	54	149	151	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40156	40166		10.1074/jbc.M104138200	http://dx.doi.org/10.1074/jbc.M104138200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11479293	hybrid			2022-12-25	WOS:000171789200087
J	Gnesutta, N; Ceriani, M; Innocenti, M; Mauri, I; Zippel, R; Sturani, E; Borgonovo, B; Berruti, G; Martegani, E				Gnesutta, N; Ceriani, M; Innocenti, M; Mauri, I; Zippel, R; Sturani, E; Borgonovo, B; Berruti, G; Martegani, E			Cloning and characterization of mouse UBPy, a deubiquitinating enzyme that interacts with the Ras guanine nucleotide exchange factor CDC25(Mm)/Ras-GRF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SACCHAROMYCES-CEREVISIAE; DEPENDENT ACTIVATION; CATALYTIC DOMAIN; HOMOLOGY DOMAIN; GENE; EXPRESSION; UBIQUITIN; CDC25; ISOPEPTIDASE	We used yeast "two-hybrid" screening to isolate cDNA-encoding proteins interacting with the N-terminal domain of the Ras nucleotide exchange factor CDC25(Mm). Three independent overlapping clones were isolated from a mouse embryo cDNA library. The full-length cDNA was cloned by RACE-polymerase chain reaction. It encodes a large protein (1080 amino acids) highly homologous to the human deubiquitinating enzyme hUBPy and contains a well conserved domain typical of ubiquitin isopeptidases. Therefore we called this new protein mouse UBPy (mUBPy). Northern blot analysis revealed a 4-kilobase mRNA present in several mouse tissues and highly expressed in testis; a good level of expression was also found in brain, where CDC25(Mm) is exclusively expressed. Using a glutathione S-transferase fusion protein, we demonstrated an "in vitro" interaction between mUBPy and the N-terminal half (amino acids 1-625) of CDC25(Mm). In addition "in vivo" interaction was demonstrated after cotransfection in mammalian cells. We also showed that CDC25Mm, expressed in HEK293 cells, is ubiquitinated and that the coexpression of mUBPy decreases its ubiquitination. In addition the half-life of CDC25Mm protein was considerably increased in the presence of mUBPy. The specific function of the human homolog hUBPy is not defined, although its expression was correlated with cell proliferation. Our results suggest that mUBPy may play a role in controlling degradation of CDC25(Mm), thus regulating the level of this Ras-guanine nucleotide exchange factor.	Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Univ Milan, Dipartimento Fisiol & Biochim Gen, I-20133 Milan, Italy; Univ Milan, Dipartimento Biol, I-20133 Milan, Italy	University of Milano-Bicocca; University of Milan; University of Milan	Martegani, E (corresponding author), Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.		Innocenti, Metello/X-2182-2019; Gnesutta, Nerina/I-5432-2015	Innocenti, Metello/0000-0002-7455-2559; Gnesutta, Nerina/0000-0002-2465-8881; Martegani, Enzo/0000-0001-9196-4224; CERIANI, MICHELA/0000-0002-3060-5620; Berruti, Giovanna/0000-0002-1683-0207				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; de Hoog CL, 2001, MOL CELL BIOL, V21, P2107, DOI 10.1128/MCB.21.6.2107-2117.2001; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1994, ONCOGENE, V9, P2179; Hofmann K, 1998, J MOL BIOL, V282, P195, DOI 10.1006/jmbi.1998.1998; Hoog C, 1995, INT J DEV BIOL, V39, P719; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JACQUET E, 1992, J BIOL CHEM, V267, P24181; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Lin HJ, 2001, J BIOL CHEM, V276, P20357, DOI 10.1074/jbc.M008761200; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; MOUNT DW, 1984, NUCLEIC ACIDS RES, V12, P811, DOI 10.1093/nar/12.1Part2.811; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Nielsen KH, 1997, MOL CELL BIOL, V17, P7132, DOI 10.1128/MCB.17.12.7132; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Zhu Y, 1996, MOL CELL BIOL, V16, P4808; Zippel R, 1996, ONCOGENE, V12, P2697; ZIPPEL R, 1997, MOL BRAIN RES, V48, P140	34	56	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39448	39454		10.1074/jbc.M103454200	http://dx.doi.org/10.1074/jbc.M103454200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11500497	hybrid, Green Published			2022-12-25	WOS:000171673200145
J	Grozinger, CM; Chao, ED; Blackwell, HE; Moazed, D; Schreiber, SL				Grozinger, CM; Chao, ED; Blackwell, HE; Moazed, D; Schreiber, SL			Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS GENE MONOPTEROS; YEAST SIR2 GENE; HISTONE DEACETYLASE; SACCHAROMYCES-CEREVISIAE; SIR2-LIKE PROTEINS; VASCULAR DEVELOPMENT; TRICHOSTATIN-A; ACETYLATION; HOMOLOGY; AUXIN	The yeast transcriptional repressor Sir2p silences gene expression from the telomeric, rDNA, and silent mating-type loci and may play a role in higher order processes such as aging. Sir2p is the founding member of a large family of NAD-dependent deacetylase enzymes, named the sirtuins. These proteins are conserved from prokaryotes to eukaryotes, but most remain uncharacterized, including all seven human sirtuins. A reverse chemical genetic approach would be useful in identifying the biological function of sirtuins in a wide variety of experimental systems, but no cell-permeable small molecule inhibitors of sirtuins have been reported previously. Herein we describe a high throughput, phenotypic screen in cells that led to the discovery of a class of sirtuin inhibitors. All three compounds inhibited yeast Sir2p transcriptional silencing activity in vivo, and yeast Sir2p and human SIRT2 deacetylase activity in vitro. Such specific results demonstrate the utility and robustness of this screening methodology. Structure-activity relationship analysis of the compounds identified a key hydroxy-napthaldehyde moiety that is necessary and sufficient for inhibitory activity. Preliminary studies using one of these compounds suggest that inhibition of sirtuins interferes with body axis formation in Arabidopsis.	Harvard Univ, Dept Chem & Biol Chem, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Inst Chem & Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard University; Harvard Medical School	Schreiber, SL (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Howard Hughes Med Inst, 12 Oxford St, Cambridge, MA 02138 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038627, R01GM038627] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38627] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afshar G, 1999, GENE, V234, P161, DOI 10.1016/S0378-1119(99)00162-6; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Carland FM, 1999, PLANT CELL, V11, P2123, DOI 10.1105/tpc.11.11.2123; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Gartenberg MR, 2000, CURR OPIN MICROBIOL, V3, P132, DOI 10.1016/S1369-5274(00)00064-3; Guarente L, 2000, GENE DEV, V14, P1021; Guilfoyle T, 1998, PLANT PHYSIOL, V118, P341, DOI 10.1104/pp.118.2.341; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jensen PJ, 1998, PLANT PHYSIOL, V116, P455, DOI 10.1104/pp.116.2.455; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Perrod S, 2001, EMBO J, V20, P197, DOI 10.1093/emboj/20.1.197; Przemeck GKH, 1996, PLANTA, V200, P229, DOI 10.1007/BF00208313; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Sieburth LE, 1999, PLANT PHYSIOL, V121, P1179, DOI 10.1104/pp.121.4.1179; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tsang AW, 1998, J BIOL CHEM, V273, P31788, DOI 10.1074/jbc.273.48.31788; Yang YH, 2000, GENOMICS, V69, P355, DOI 10.1006/geno.2000.6360; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	29	451	493	0	61	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38837	38843		10.1074/jbc.M106779200	http://dx.doi.org/10.1074/jbc.M106779200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11483616	hybrid, Green Published			2022-12-25	WOS:000171673200068
J	Kishi, H; Nakagawa, K; Matsumoto, M; Suga, M; Ando, M; Taya, Y; Yamaizumi, M				Kishi, H; Nakagawa, K; Matsumoto, M; Suga, M; Ando, M; Taya, Y; Yamaizumi, M			Osmotic shock induces G(1) arrest through p53 phosphorylation at Ser(33) by activated p38(MAPK) without phosphorylation at Ser(15) and Ser(20)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; CELL-CYCLE CHECKPOINT; DNA-DAMAGE; POTENTIAL MEDIATOR; HUMAN FIBROBLASTS; GAMMA-RADIATION; PROTEIN; KINASE; MDM2; STRESS	Osmotic shock induced transient stabilization of p53, possibly due to increased degradation of Mdm2. Stabilized p53 was activated by p38(MAPK), resulting in G(1) arrest through induction of p21(WAF1). Among the postulated phosphorylation sites involved in p53 stabilization or activation (Ser(15), Ser(20), Ser(33), and Ser(46)), only Ser(33) was phosphorylated. Furthermore, interaction of p53 with the transcriptional coactivator p300 was induced, and Lys(382) of p53 was acetylated. Although inhibition of p38(MAPK) did not prevent nuclear accumulation of p53, phosphorylation of Ser(33) was markedly suppressed by SB203580, a specific inhibitor of p38(MAPK). Under these conditions, acetylation of Lys(382) and induction of p21(WAF1) were also inhibited, and cells with elevated levels of p53 showed normal cell cycle progression. Activated p38(MAPK) phosphorylated endogenous p53 at Ser(33) in living cells. In stable transformants expressing dominant negative MKK6, an upstream protein kinase of p38(MAPK), p53 stabilization was induced normally following osmotic shock, but phosphorylation of Ser(33), acetylation of Lys(382), and induction of p21(WAF1) were almost completely inhibited. These results suggest that phosphorylation at Ser(33) by p38(MAPK) is critical for activation of p53 following osmotic shock. Phosphorylation of neither Ser(15) nor Ser(20) was needed in this activation.	Kumamoto Univ, Inst Mol Embryol & Genet, Kumamoto 8620976, Japan; Kumamoto Univ, Sch Med, Dept Internal Med 1, Kumamoto 8600811, Japan; Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan	Kumamoto University; Kumamoto University; National Cancer Center - Japan	Yamaizumi, M (corresponding author), Kumamoto Univ, Inst Mol Embryol & Genet, Kuhonji 4-24-1, Kumamoto 8620976, Japan.	yamaizm@gpo.kumamoto-u.ac.jp						Alarcon R, 1999, CANCER RES, V59, P6046; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Bacus SS, 1996, ONCOGENE, V12, P2535; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BOHLEN HG, 1989, AM J PHYSIOL, V257, pG438, DOI 10.1152/ajpgi.1989.257.3.G438; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Dmitrieva N, 2000, J BIOL CHEM, V275, P18243, DOI 10.1074/jbc.M000522200; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOTTSCHALK CW, 1959, AM J PHYSIOL, V196, P927, DOI 10.1152/ajplegacy.1959.196.4.927; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; ITOH T, 1995, AM J HUM GENET, V56, P1267; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Keller D, 1999, BIOCHEM BIOPH RES CO, V261, P464, DOI 10.1006/bbrc.1999.1023; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIYASHITA T, 1995, CELL, V80, P293; NAFTALIN RJ, 1990, FEBS LETT, V260, P187, DOI 10.1016/0014-5793(90)80100-W; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TSUKADA T, 1993, ONCOGENE, V8, P3313; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; YAMAIZUMI M, 1986, P NATL ACAD SCI USA, V83, P1476, DOI 10.1073/pnas.83.5.1476	57	100	102	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39115	39122		10.1074/jbc.M105134200	http://dx.doi.org/10.1074/jbc.M105134200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495913	hybrid			2022-12-25	WOS:000171673200103
J	Masuda, K; Shima, H; Watanabe, M; Kikuchi, K				Masuda, K; Shima, H; Watanabe, M; Kikuchi, K			MKP-7, a novel mitogen-activated protein kinase phosphatase, functions as a shuttle protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; NUCLEAR EXPORT SIGNAL; AMINO-ACID-SEQUENCE; MAP KINASE; TYROSINE-PHOSPHATASE; MOLECULAR-CLONING; C-JUN; INFLAMMATORY CYTOKINES; IN-VIVO; STRESS	Mitogen-activated protein kinase (MAPK) phosphatases (MKPs) negatively regulate MAPK activity. In the present study, we have identified a novel MKP, designated MKP-7, and mapped it to human chromosome 12p12. MKP-7 possesses a long C-terminal stretch containing both a nuclear export signal and a nuclear localization signal, in addition to the rhodanese-like domain and the dual specificity phosphatase catalytic domain, both of which are conserved among MKP family members. When expressed in mammalian cells MKP-7 protein was localized exclusively in the cytoplasm, but this localization became exclusively nuclear following leptomycin B treatment or introduction of a mutation in the nuclear export signal. These findings indicate that MKP-7 is the first identified leptomycin B-sensitive shuttle MKP. Forced expression of MKP-7 suppressed activation of MAPKs in COS-7 cells in the order of selectivity, JNK >> p38 > ERK. Furthermore, a mutant form MKP-7 functioned as a dominant negative particularly against the dephosphorylation of JNK, suggesting that MKP-7 works as a JNK-specific phosphatase in vivo. Co-immunoprecipitation experiments and histological analysis suggested that MKP-7 determines the localization of MAPKs in the cytoplasm.	Hokkaido Univ, Inst Med Genet,Div Biochem Oncol & Immunol, Sect Biochem Oncol & Immunol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Med, Dept Anat, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University	Shima, H (corresponding author), Hokkaido Univ, Inst Med Genet,Div Biochem Oncol & Immunol, Sect Biochem Oncol & Immunol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.		Watanabe, Masahiko/S-3614-2019; WATANABE, Masahiko/A-4055-2012	Watanabe, Masahiko/0000-0001-5037-7138; WATANABE, Masahiko/0000-0001-5037-7138				Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; ALESSI DR, 1993, ONCOGENE, V8, P2015; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DAI TN, 1995, ONCOGENE, V10, P849; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; GERONDAKIS S, 1994, GENOMICS, V24, P182, DOI 10.1006/geno.1994.1598; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; Masuda K, 2000, CYTOGENET CELL GENET, V90, P71, DOI 10.1159/000015666; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nakamura K, 1999, BIOCHEM J, V344, P819, DOI 10.1042/0264-6021:3440819; NISHI K, 1994, J BIOL CHEM, V269, P6320; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Robinson CJM, 2001, CELL SIGNAL, V13, P29, DOI 10.1016/S0898-6568(00)00121-2; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Smith A, 1997, GENOMICS, V42, P524, DOI 10.1006/geno.1997.4756; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385	50	125	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39002	39011		10.1074/jbc.M104600200	http://dx.doi.org/10.1074/jbc.M104600200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489891	hybrid			2022-12-25	WOS:000171673200089
J	Su, HM; Moser, AB; Moser, HW; Watkins, PA				Su, HM; Moser, AB; Moser, HW; Watkins, PA			Peroxisomal straight-chain acyl-CoA oxidase and D-bifunctional protein are essential for the retroconversion step in docosahexaenoic acid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; BETA-OXIDATION; ZELLWEGER-SYNDROME; ENZYME DEFICIENCY; DISORDERS; METABOLISM; BIOSYNTHESIS; BIOGENESIS; BRAIN	Docosahexaenoic acid (DRA, C22:6n-3) is essential for normal brain and retinal development. The nature and subcellular location of the terminal steps in DHA biosynthesis have been controversial. Rather than direct Delta4-desaturation of C22:5n-3, it has been proposed that this intermediate is elongated to C24:5n-3, desaturated to C24:6n-3, and "retroconverted" to DHA via peroxisomal beta -oxidation. However, this hypothesis has recently been challenged. The goal of this study was to determine the mechanism and specific enzymes required for the retroconversion step in human skin fibroblasts. Cells from patients with deficiencies of either acyl-CoA oxidase or D-bifunctional protein, the first two enzymes of the peroxisomal straight-chain fatty acid beta -oxidation pathway, exhibited impaired (5-20% of control) conversion of either [1-C-14]18:3n-3 or [1-C-14]22:5n-3 to DRA as did cells from peroxisome biogenesis disorder patients comprising eight distinct genotypes. In contrast, normal DHA synthesis was observed in cells from patients with rhizomelic chondrodysplasia punctata, Refsum disease, X-linked adrenoleukodystrophy, and deficiency of mitochondrial medium- or very long-chain acyl-CoA dehydrogenase. Acyl-CoA oxidase-deficient cells accumulated 2-5 times more radiolabeled C24:6n-3 than did controls. Our data are consistent with the retroconversion hypothesis and demonstrate that peroxisomal beta -oxidation enzymes acyl-CoA oxidase and D-bifunctional protein are essential for this process in human skin fibroblasts.	Kennedy Krieger Inst, Dept Neurogenet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	Kennedy Krieger Institute; Johns Hopkins University	Su, HM (corresponding author), Kennedy Krieger Inst, Dept Neurogenet, 707 N Broadway, Baltimore, MD 21205 USA.	su@kennedykrieger.org		SU, HUI-MIN/0000-0002-9970-4459; Watkins, Paul A./0000-0002-3246-1405	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981, R03HD039860] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00052] Funding Source: Medline; NICHD NIH HHS [HD39860, HD10981, HD24061] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AOYAMA T, 1994, BIOCHEM BIOPH RES CO, V201, P1541, DOI 10.1006/bbrc.1994.1879; BRENNER RR, 1971, LIPIDS, V6, P567, DOI 10.1007/BF02531137; Brown TW, 2000, MOL BIOL CELL, V11, P141, DOI 10.1091/mbc.11.1.141; de Vet ECJM, 1998, J BIOL CHEM, V273, P10296, DOI 10.1074/jbc.273.17.10296; DeltonVandenbroucke I, 1997, J LIPID RES, V38, P147; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; Gould SJ., 2001, METABOLIC MOL BASES, P3181; Greiner RS, 1999, LIPIDS, V34, pS239, DOI 10.1007/BF02562305; Hashimoto T, 1999, NEUROCHEM RES, V24, P551, DOI 10.1023/A:1022540030918; HOEFLER G, 1988, J PEDIATR-US, V112, P726, DOI 10.1016/S0022-3476(88)80689-9; Infante JP, 1997, MOL CELL BIOCHEM, V168, P101, DOI 10.1023/A:1006895209833; Infante JP, 2000, FEBS LETT, V468, P1, DOI 10.1016/S0014-5793(00)01083-8; Infante JP, 2001, MOL GENET METAB, V72, P185, DOI 10.1006/mgme.2001.3148; Infante JP, 2001, MOL GENET METAB, V72, P1, DOI 10.1006/mgme.2000.3101; Infante JP, 1998, FEBS LETT, V431, P1, DOI 10.1016/S0014-5793(98)00720-0; INNIS SM, 1991, PROG LIPID RES, V30, P39, DOI 10.1016/0163-7827(91)90006-Q; KELLEY RI, 1992, BIOCHEM BIOPH RES CO, V182, P1002, DOI 10.1016/0006-291X(92)91831-A; LAMPTEY MS, 1976, J NUTR, V106, P86, DOI 10.1093/jn/106.1.86; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martinez M, 1995, J INHERIT METAB DIS, V18, P61, DOI 10.1007/BF00711429; MOORE SA, 1995, J LIPID RES, V36, P2433; Moser AB, 1999, NEUROCHEM RES, V24, P187, DOI 10.1023/A:1022549618333; Moser H., 2001, METABOLIC MOL BASES, VII, P3257; Moser HW, 1999, MOL GENET METAB, V68, P316, DOI 10.1006/mgme.1999.2926; MOSER HW, 1993, ADV HUM GENET, V21, P1; NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021; Purdue PE, 1999, NEUROCHEM RES, V24, P581, DOI 10.1023/A:1023957110171; Retterstol K, 2000, BBA-MOL CELL BIOL L, V1483, P119, DOI 10.1016/S1388-1981(99)00166-3; ROE CR, 2001, METABOLIC MOL BASES, P2297; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; SEEDORF U, 1994, J BIOL CHEM, V269, P21277; Smith KD, 1999, NEUROCHEM RES, V24, P521, DOI 10.1023/A:1022535930009; Sprecher H, 1995, J LIPID RES, V36, P2471; Sprecher H, 1999, PROSTAG LEUKOTR ESS, V60, P317, DOI 10.1016/S0952-3278(99)80006-4; SPRECHER H, 1992, NESTLE NUTR WORKS SE, V28, P13; Su HM, 1998, ANAL BIOCHEM, V261, P43, DOI 10.1006/abio.1998.2706; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; TENBRINK HJ, 1992, J LIPID RES, V33, P41; UAUY R, 1990, J PEDIATR GASTR NUTR, V11, P296, DOI 10.1097/00005176-199010000-00002; van Grunsven EG, 1999, AM J HUM GENET, V64, P99, DOI 10.1086/302180; VANDENBOSCH H, 1993, BIOCHIMIE, V75, P183, DOI 10.1016/0300-9084(93)90076-5; VOSS A, 1991, J BIOL CHEM, V266, P19995; Wanders R.J., 2001, METABOLIC MOL BASES, P3219; Wanders RJA, 2000, BIOCHEM SOC T, V28, P141, DOI 10.1042/bst0280141; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; Wanders RJA, 1999, NEUROCHEM RES, V24, P565, DOI 10.1023/A:1022592014988; WANDERS RJA, 2001, METABOLIC MOL BASES, P3303; WATKINS PA, 1989, J CLIN INVEST, V83, P771, DOI 10.1172/JCI113956; Yin FQ, 1999, BBA-MOL CELL BIOL L, V1438, P63, DOI 10.1016/S1388-1981(99)00039-6	51	80	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38115	38120						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11500517				2022-12-25	WOS:000171526500054
J	Banfi, B; Molnar, G; Maturana, A; Steger, K; Hegedus, B; Demaurex, N; Krause, KH				Banfi, B; Molnar, G; Maturana, A; Steger, K; Hegedus, B; Demaurex, N; Krause, KH			A Ca2+-activated NADPH oxidase in testis, spleen, and lymph nodes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-GENERATING OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; KAPPA-B ACTIVATION; HUMAN-NEUTROPHILS; HUMAN SPERMATOZOA; POLYMORPHONUCLEAR LEUKOCYTES; TYROSINE PHOSPHORYLATION; NITROBLUE TETRAZOLIUM; RESPIRATORY BURST; HYDROGEN-PEROXIDE	Superoxide and its derivatives are increasingly implicated in the regulation of physiological functions from oxygen sensing and blood pressure regulation to lymphocyte activation and sperm-oocyte fusion. Here we describe a novel superoxide-generating NADPH oxidase referred to as NADPH oxidase 5 (NOX5). NOX5 is distantly related to the gp91(phox) subunit of the phagocyte NADPH oxidase with conserved regions crucial for the electron transport (NADPH, FAD and heme binding sites). However, NOX5 has a unique N-terminal extension that contains three EF hand motifs. The mRNA of NOX5 is expressed in pachytene spermatocytes of testis and in B- and T-lymphocyte-rich areas of spleen and lymph nodes. When heterologously expressed, NOX5 was quiescent in unstimulated cells. However, in response to elevations of the cytosolic Ca2+ concentration it generated large amounts of superoxide. Upon Ca2+ activation, NOX5 also displayed a second function: it became a proton channel, presumably to compensate charge and pH alterations due to electron export. In summary, we have identified a novel NADPH oxidase that generates superoxide and functions as a H+ channel in a Ca2+-dependent manner. NOX5 is likely to be involved in Ca2+-activated, redox-dependent processes of spermatozoa and lymphocytes such as sperm-oocyte fusion, cell proliferation, and cytokine secretion.	Univ Hosp Geneva, Dept Geriatr, Biol Aging Lab, CH-1225 Geneva, Switzerland; Geneva Sch Med, Dept Physiol, CH-1211 Geneva, Switzerland; Geneva Sch Med, Fdn Med Res, CH-1211 Geneva, Switzerland; Semmelweis Univ, Dept Physiol, H-1444 Budapest 8, Hungary; Inst Vet Anat, D-35392 Giessen, Germany; Eotvos Lorand Univ, Dept Biol Phys, H-1117 Budapest, Hungary	University of Geneva; University of Geneva; University of Geneva; Semmelweis University; Eotvos Lorand University	Krause, KH (corresponding author), Univ Hosp Geneva, Dept Geriatr, Biol Aging Lab, 2 Ch Petit Bel Air, CH-1225 Geneva, Switzerland.	kkrause@cmu.unige.ch	Krause, Karl-Heinz/E-8030-2011; Hegedus, Balazs/B-6076-2008	Krause, Karl-Heinz/0000-0002-9033-6768; Hegedus, Balazs/0000-0002-4341-4153; Demaurex, Nicolas/0000-0002-9933-6772; Banfi, Botond/0000-0001-9273-1318	NIAID NIH HHS [AI20866, R37 AI020866, R01 AI020866] Funding Source: Medline; NIA NIH HHS [AG19519] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020866, R37AI020866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019519] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AITKEN J, 1994, BIOESSAYS, V16, P259, DOI 10.1002/bies.950160409; AITKEN RJ, 1995, J CELL SCI, V108, P2017; AITKEN RJ, 1992, J CELL PHYSIOL, V151, P466, DOI 10.1002/jcp.1041510305; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BAEHNER RL, 1976, BLOOD, V48, P309; Banfi B, 1999, J EXP MED, V190, P183, DOI 10.1084/jem.190.2.183; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; CHRISTIANSEN NO, 1988, BIOCHIM BIOPHYS ACTA, V971, P317, DOI 10.1016/0167-4889(88)90147-4; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; Dupuy C, 2000, BIOCHEM BIOPH RES CO, V277, P287, DOI 10.1006/bbrc.2000.3671; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; DUPUY C, 1991, J BIOL CHEM, V266, P3739; Ebert BL, 1999, BLOOD, V94, P1864; Elzi DJ, 2001, AM J PHYSIOL-CELL PH, V281, pC350; Fautsch MP, 1997, J BIOL CHEM, V272, P24691, DOI 10.1074/jbc.272.39.24691; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Ginn-Pease ME, 1998, FREE RADICAL BIO MED, V25, P346, DOI 10.1016/S0891-5849(98)00067-7; GRINSTEIN S, 1986, AM J PHYSIOL, V251, pC55, DOI 10.1152/ajpcell.1986.251.1.C55; HALE TW, 1978, HISTOCHEM J, V10, P409, DOI 10.1007/BF01003004; Henderson LM, 1999, J GEN PHYSIOL, V114, P771, DOI 10.1085/jgp.114.6.771; Jaimes EA, 1998, KIDNEY INT, V54, P775, DOI 10.1046/j.1523-1755.1998.00068.x; Jankowski A, 1999, J BIOL CHEM, V274, P26098, DOI 10.1074/jbc.274.37.26098; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; KEY LL, 1994, BONE, V15, P431, DOI 10.1016/8756-3282(94)90821-4; Kikuchi H, 2000, GENE, V254, P237, DOI 10.1016/S0378-1119(00)00258-4; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lee JR, 1998, EUR J IMMUNOL, V28, P4188, DOI 10.1002/(SICI)1521-4141(199812)28:12<4188::AID-IMMU4188>3.0.CO;2-B; LEWIS FA, 1992, IN SITU HYBRIDIZATIO, P121; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Lundqvist H, 1996, J LEUKOCYTE BIOL, V59, P270, DOI 10.1002/jlb.59.2.270; MacLeod J, 1943, AM J PHYSIOL, V138, P0512, DOI 10.1152/ajplegacy.1943.138.3.512; Martin F, 2000, IMMUNOL REV, V175, P70, DOI 10.1034/j.1600-065X.2000.017515.x; Maturana A, 2001, J BIOL CHEM, V276, P30277, DOI 10.1074/jbc.M010438200; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Mocsai A, 1997, BIOCHEM PHARMACOL, V54, P781, DOI 10.1016/S0006-2952(97)00245-1; MONESI V, 1964, J CELL BIOL, V22, P521, DOI 10.1083/jcb.22.3.521; Munzel T, 1999, ANN NY ACAD SCI, V874, P386, DOI 10.1111/j.1749-6632.1999.tb09253.x; NAKAMURA T, 1994, J LEUKOCYTE BIOL, V56, P105, DOI 10.1002/jlb.56.2.105; NAKAMURA Y, 1991, BIOCHEMISTRY-US, V30, P4880, DOI 10.1021/bi00234a007; Pani G, 2000, BIOCHEM J, V347, P173, DOI 10.1042/0264-6021:3470173; ROOK GAW, 1985, J IMMUNOL METHODS, V82, P161, DOI 10.1016/0022-1759(85)90235-2; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Schoonbroodt S, 2000, BIOCHEM PHARMACOL, V60, P1075, DOI 10.1016/S0006-2952(00)00371-3; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schrenzel J, 1998, NATURE, V392, P734, DOI 10.1038/33725; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Steger K, 2000, MOL HUM REPROD, V6, P219, DOI 10.1093/molehr/6.3.219; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Terada LS, 1996, AM J PHYSIOL-HEART C, V270, pH945, DOI 10.1152/ajpheart.1996.270.3.H945; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3; Yang S, 2001, J BIOL CHEM, V276, P5452, DOI 10.1074/jbc.M001004200	57	474	492	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37594	37601		10.1074/jbc.M103034200	http://dx.doi.org/10.1074/jbc.M103034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11483596	hybrid			2022-12-25	WOS:000171375700096
J	Cronan, JE				Cronan, JE			The biotinyl domain of Escherichia coli acetyl-CoA carboxylase - Evidence that the "thumb" structure is essential and that the domain functions as a dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; SITE-DIRECTED MUTAGENESIS; FATTY-ACID BIOSYNTHESIS; POSTTRANSLATIONAL MODIFICATION; CARRIER PROTEIN; EXCEPTIONAL SPECIFICITY; MULTIFUNCTIONAL ENZYMES; SWINGING ARMS; SUBUNIT; CARBOXYLTRANSFERASE	Biotin carboxyl carrier protein (BCCP) is the small biotinylated subunit of Escherichia coli acetyl-CoA carboxylase (ACC), the enzyme that catalyzes the first committed step of fatty acid synthesis. Similar proteins are found in other bacteria and in chloroplasts. E. coli BCCP is a member of a large family of protein domains modified by covalent attachment of biotin to a specific lysine residue. However, the BCCP biotinyl domain differs from many of these proteins in that an eight-amino acid residue insertion is present upstream of the biotinylated lysine. X-ray crystallographic and multidimensional NMR studies show that these residues constitute a structure that has the appearance of an extended thumb that protrudes from the otherwise highly symmetrical domain structure. I report that expression of two mutant BCCPs lacking the thumb residues fails to restore growth and fatty acid synthesis to a temperature-sensitive E. coli strain that lacks BCCP when grown at nonpermissive temperature. Alignment of BCCPs from various organisms shows that only two of the eight thumb residues are strictly conserved, and amino acid substitution of either residue results in proteins giving only weak growth of the temperature-sensitive E. coli strain. Therefore, the thumb structure is essential for the function of BCCP in the ACC reaction and provides a useful motif for distinguishing the biotinylated proteins of multisubunit ACCs from those of enzymes catalyzing other biotin-dependent reactions. Am unexpected result was that expression of a mutant BCCP in which the biotinylated lysine residue was substituted with cysteine was able to partially restore growth and fatty acid synthesis to the temperature-sensitive E. coli strain. This complementation was shown to be specific to BCCPs having native structure (excepting the biotinylated lysine) and is interpreted in terms of dimerization of the BCCP biotinyl domain during the ACC reaction.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, 131 Burrill Hall, Urbana, IL 61801 USA.		Cronan, John/V-6626-2019		NIAID NIH HHS [AI15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS AW, 1972, ENZYMES, V6, P37; Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; BARKER DF, 1981, J MOL BIOL, V146, P469, DOI 10.1016/0022-2836(81)90043-7; BEST EA, 1993, J BACTERIOL, V175, P6881, DOI 10.1128/jb.175.21.6881-6889.1993; Blanchard CZ, 1998, J BIOL CHEM, V273, P19140, DOI 10.1074/jbc.273.30.19140; BROCKLEHURST SM, 1993, PROTEIN SCI, V2, P626; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; Chapman-Smith A, 1999, J BIOL CHEM, V274, P1449, DOI 10.1074/jbc.274.3.1449; ChapmanSmith A, 1997, J BIOL CHEM, V272, P26017, DOI 10.1074/jbc.272.41.26017; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; CRONAN JE, 1988, J BIOL CHEM, V263, P10332; Cronan JE, 2000, METHOD ENZYMOL, V326, P440; Davis MS, 2000, J BIOL CHEM, V275, P28593, DOI 10.1074/jbc.M004756200; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FALL RR, 1971, P NATL ACAD SCI USA, V68, P1512, DOI 10.1073/pnas.68.7.1512; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; HARDER ME, 1972, P NATL ACAD SCI USA, V69, P3105, DOI 10.1073/pnas.69.11.3105; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Janiyani K, 2001, J BIOL CHEM, V276, P29864, DOI 10.1074/jbc.M104102200; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; LEONDELRIO A, 1994, J BIOL CHEM, V269, P22964; LI SJ, 1992, J BIOL CHEM, V267, P855; LI SJ, 1992, J BIOL CHEM, V267, P16841; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MARINI P, 1995, J BACTERIOL, V177, P7003, DOI 10.1128/jb.177.23.7003-7006.1995; Nenortas E, 1996, J BIOL CHEM, V271, P7559, DOI 10.1074/jbc.271.13.7559; Ohlrogge J, 2000, BIOCHEM SOC T, V28, P567, DOI 10.1042/BST0280567; Perham RN, 1998, BIOCHEM SOC T, V26, P299, DOI 10.1042/bst0260299; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; Reche P, 1999, EMBO J, V18, P2673, DOI 10.1093/emboj/18.10.2673; Reddy DV, 2000, BIOCHEMISTRY-US, V39, P2509, DOI 10.1021/bi9925367; Roberts EL, 1999, BIOCHEMISTRY-US, V38, P5045, DOI 10.1021/bi982466o; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SILBERT DF, 1976, J BACTERIOL, V126, P1351, DOI 10.1128/JB.126.3.1351-1354.1976; Thoden JB, 2000, J BIOL CHEM, V275, P16183, DOI 10.1074/jbc.275.21.16183; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; Yao X, 1997, BIOCHEMISTRY-US, V36, P15089, DOI 10.1021/bi971485f; Yao X, 1999, PROTEIN SCI, V8, P307	40	49	49	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37355	37364		10.1074/jbc.M106353200	http://dx.doi.org/10.1074/jbc.M106353200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11495922	hybrid			2022-12-25	WOS:000171375700067
J	Rahlfs, S; Fischer, M; Becker, K				Rahlfs, S; Fischer, M; Becker, K			Plasmodium falciparum possesses a classical glutaredoxin and a second, glutaredoxin-like protein with a PICOT homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE; YEAST SACCHAROMYCES-CEREVISIAE; HYDROGEN DONOR SYSTEM; NF-KAPPA-B; ESCHERICHIA-COLI; GLUTATHIONE-REDUCTASE; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; CALF THYMUS; THIOREDOXIN	The genes coding for two different proteins with homologies to glutaredoxins have been identified in the genome of the malarial parasite Plasmodium falciparum. Both genes were amplified from a gametocytic cDNA and overexpressed in Escherichia coli. The smaller protein (named PfGrx-1) with 12.4 kDa in size exhibits the typical glutaredoxin active site motif "CPYC," shows glutathione-dependent glutaredoxin activity in the beta -hydroxyethyl disulfide (HEDS) assay, and reduces Trypanosoma brucei ribonucleotide reductase. Glutathione:HEDS transhydrogenase activity (approximately 60 milliunits/mg of protein) was clearly detectable in trophozoite extracts from eight different P. falciparum strains and did not differ between chloroquine-resistant and -sensitive parasites. Five different antimalarial drugs at 100 muM did not significantly influence isolated PfGrx-1 activity. In contrast, the second protein (deduced mass 19.9 kDa) with homology to glutaredoxins (31%, identity to Schizosaccharomyces pombe in a 140-amino acid overlap) was not active in the BEDS assay; however, its general dithiol reducing activity was demonstrated in the insulin assay in the presence of dithiothreitol. Interestingly, the sequence contains a PICOT (for protein kinase C-interacting cousin of thioredoxin) homology domain, which might suggest regulatory functions of the protein. We named this protein PfGLP-1, for P. falciparum 1-Cys-glutaredoxin-like protein-1. In contrast to glutaredoxins, PfGLP-1 could not be reduced by glutathione. This is the first report on glutaredoxin-like proteins in the family of Plasmodia.	Univ Giessen, Interdisciplinary Res Ctr, D-35392 Giessen, Germany	Justus Liebig University Giessen	Becker, K (corresponding author), Univ Giessen, Interdisciplinary Res Ctr, Heinrich Buff Ring 26-32, D-35392 Giessen, Germany.							Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; Draculic T, 2000, MOL MICROBIOL, V36, P1167, DOI 10.1046/j.1365-2958.2000.01948.x; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; Farber PM, 1998, FEBS LETT, V422, P311, DOI 10.1016/S0014-5793(98)00031-3; Farber PM, 1996, EUR J BIOCHEM, V239, P655, DOI 10.1111/j.1432-1033.1996.0655u.x; Gamain B, 1996, MOL BIOCHEM PARASIT, V78, P237, DOI 10.1016/S0166-6851(96)02632-1; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; GUAGLIARDI A, 1995, J BIOL CHEM, V270, P5748, DOI 10.1074/jbc.270.11.5748; Gvakharia BO, 1996, J BIOL CHEM, V271, P15307, DOI 10.1074/jbc.271.26.15307; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; Isakov N, 2000, TRENDS BIOCHEM SCI, V25, P537, DOI 10.1016/S0968-0004(00)01685-6; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Kawazu S, 2000, MOL BIOCHEM PARASIT, V109, P165, DOI 10.1016/S0166-6851(00)00243-7; KrauthSiegel RL, 1996, EUR J BIOCHEM, V235, P345, DOI 10.1111/j.1432-1033.1996.00345.x; Krnajski Z, 2001, MOL BIOCHEM PARASIT, V112, P219, DOI 10.1016/S0166-6851(00)00372-8; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; LUTHMAN M, 1979, P NATL ACAD SCI USA, V76, P2158, DOI 10.1073/pnas.76.5.2158; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MCFARLAN SC, 1992, J BIOL CHEM, V267, P10561; McGonigle S, 1998, PARASITOL TODAY, V14, P139, DOI 10.1016/S0169-4758(97)01211-8; MINAKUCHI K, 1994, FEBS LETT, V337, P157, DOI 10.1016/0014-5793(94)80264-5; MORELL S, 1995, FEBS LETT, V369, P149, DOI 10.1016/0014-5793(95)00690-B; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NIKKOLA M, 1993, J BIOL CHEM, V268, P3845; Prieto-Alamo MJ, 2000, J BIOL CHEM, V275, P13398, DOI 10.1074/jbc.275.18.13398; Rahlfs S, 2001, EUR J BIOCHEM, V268, P1404, DOI 10.1046/j.1432-1327.2001.02005.x; RAWLINGS DJ, 1992, J BIOL CHEM, V267, P3976; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; SCHIRMER RH, 1995, ANGEW CHEM INT EDIT, V34, P141, DOI 10.1002/anie.199501411; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Sztajer H, 2001, J BIOL CHEM, V276, P7397, DOI 10.1074/jbc.M008631200; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; White CL, 2000, J VIROL, V74, P9175, DOI 10.1128/JVI.74.19.9175-9183.2000; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902	47	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37133	37140		10.1074/jbc.M105524200	http://dx.doi.org/10.1074/jbc.M105524200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479312	hybrid			2022-12-25	WOS:000171375700037
J	Zawalich, WS; Tesz, GJ; Zawalich, KC				Zawalich, WS; Tesz, GJ; Zawalich, KC			Are 5-hydroxytryptamine-preloaded beta-cells an appropriate physiologic model system for establishing that insulin stimulates insulin secretion?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT PANCREAS; PHOSPHATIDYLINOSITOL 3-KINASE; EXOGENOUS INSULIN; B-CELL; GLUCOSE; ISLETS; RESISTANCE; RELEASE; PHOSPHOINOSITIDE; INHIBITION	The release and oxidation of 5-hydroxytryptamine from 5-hydroxytryptamine-preloaded beta -cells has been used as a surrogate marker for insulin secretion. Findings made using this methodology have been used to support the concept that insulin stimulates its own release. In the present studies, the effects of 5-hydroxytryptamine on stimulated insulin secretion from isolated perifused rat islets was determined. When added together with stimulatory glucose, 5-hydroxytryptamine (0.5 mM) significantly reduced both phases of 8 mm glucose-induced secretion and reduced the first phase of 15 mM glucose-induced release by 60%, without any effect on sustained insulin release rates. Preloading of beta -cells with 0.5 mm 5-hydroxytryptamine for 3 h resulted in a more severe impairment of 15 mm glucose-induced secretion. First and second phase release rates were reduced by 70 and 55%, respectively. In addition, this pretreatment protocol also abolished 200 muM tolbutamide-induced insulin secretion from perifused islets. These findings confirm that 5-hydroxytryptamine is a powerful inhibitor of stimulated insulin secretion. The responses of 5-hydroxytryptamine-preloaded beta -cells may not accurately reflect the biochemical events occurring during the physiologic regulation of insulin secretion. The suggestion that insulin stimulates its own secretion based exclusively on amperometric measurements should be reconsidered.	Yale Univ, Sch Nursing, New Haven, CT 06536 USA	Yale University	Zawalich, WS (corresponding author), Yale Univ, Sch Nursing, POB 9740,100 Church St S, New Haven, CT 06536 USA.	walter.zawalich@yale.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041230] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41230] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANO JDM, 1972, ACTA ENDOCRINOL-COP, V70, P487, DOI 10.1530/acta.0.0700487; AMMON HPT, 1976, ENDOCRINOLOGY, V99, P1468, DOI 10.1210/endo-99-6-1469; AMMON HPT, 1991, J ENDOCRINOL, V128, P27, DOI 10.1677/joe.0.1280027; ARGOUD GM, 1987, DIABETES, V36, P959, DOI 10.2337/diabetes.36.8.959; Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; Aspinwall CA, 1997, J BIOL CHEM, V272, P31308, DOI 10.1074/jbc.272.50.31308; Aspinwall CA, 2000, J BIOL CHEM, V275, P22331, DOI 10.1074/jbc.M909647199; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; CURRY DL, 1968, ENDOCRINOLOGY, V83, P572, DOI 10.1210/endo-83-3-572; CURRY DL, 1986, ENDOCRINOLOGY, V118, P170, DOI 10.1210/endo-118-1-170; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; GAGLIARDINO JJ, 1974, DIABETOLOGIA, V10, P411, DOI 10.1007/BF01221630; GERICH JE, 1974, J CLIN INVEST, V54, P833, DOI 10.1172/JCI107823; GRODSKY GM, 1977, FED PROC, V36, P2714; GYLFE E, 1978, J ENDOCRINOL, V78, P239, DOI 10.1677/joe.0.0780239; HAGIWARA S, 1995, BIOCHEM BIOPH RES CO, V214, P51, DOI 10.1006/bbrc.1995.2255; HELLMAN B, 1972, BIOCHEM PHARMACOL, V21, P695, DOI 10.1016/0006-2952(72)90062-7; IVERSEN J, 1971, DIABETES, V20, P1; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; LERNMARK A, 1971, HORM METAB RES, V3, P305, DOI 10.1055/s-0028-1094131; LILJENQUIST JE, 1978, DIABETES, V27, P563, DOI 10.2337/diab.27.5.563; LORETI L, 1974, DIABETOLOGIA, V10, P309; MALAISSELAGAE F, 1987, ACTA DIABETOL LAT, V24, P17, DOI 10.1007/BF02732049; METZ SA, 1988, DIABETES, V37, P3, DOI 10.2337/diabetes.37.1.3; NIH, 1985, NIH PUBL; Nunoi K, 2000, BIOCHEM BIOPH RES CO, V270, P798, DOI 10.1006/bbrc.2000.2514; PAGLIARA AS, 1974, J CLIN INVEST, V54, P819, DOI 10.1172/JCI107822; RAPPAPORT AM, 1972, ENDOCRINOLOGY, V91, P168, DOI 10.1210/endo-91-1-168; Robinson C, 1998, AM J PHYSIOL-ENDOC M, V274, pE737, DOI 10.1152/ajpendo.1998.274.4.E737; SMITH P, 1994, J PHYSIOL-LONDON, V475P, pP157; SMITH PA, 1995, PFLUG ARCH EUR J PHY, V430, P808, DOI 10.1007/BF00386180; SODOYEZ JC, 1969, P SOC EXP BIOL MED, V130, P568; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; ZAWALICH WS, 1995, ACTA DIABETOL, V32, P158, DOI 10.1007/BF00838485; ZAWALICH WS, 1988, DIABETES, V37, P816, DOI 10.2337/diabetes.37.6.816; Zawalich WS, 2000, J ENDOCRINOL, V166, P111, DOI 10.1677/joe.0.1660111; Zawalich WS, 2000, ENDOCRINOLOGY, V141, P3287, DOI 10.1210/en.141.9.3287; Zawalich WS, 2000, METABOLISM, V49, P1156, DOI 10.1053/meta.2000.8613; Zhou Z, 1996, J BIOL CHEM, V271, P270, DOI 10.1074/jbc.271.1.270	41	28	29	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37120	37123		10.1074/jbc.M105008200	http://dx.doi.org/10.1074/jbc.M105008200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479304	hybrid			2022-12-25	WOS:000171375700035
J	Geiss, G; Jin, G; Guo, JJ; Bumgarner, R; Katze, MG; Sen, GC				Geiss, G; Jin, G; Guo, JJ; Bumgarner, R; Katze, MG; Sen, GC			A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; OLIGONUCLEOTIDE ARRAYS; INTERFERON; INDUCTION; INFECTION; RESPONSES; KINASE; BETA; PKR	Double-stranded (ds) RNA, a common component of virus-infected cells, is a potent inducer of the type I interferon and other cellular genes. For identifying the full repertoire of human dsRNA-regulated genes, a cDNA microarray hybridization screening was conducted using mRNA from dsRNA-treated GRE cells. Because these cells lack all type I interferon genes, the possibility of gene induction by autocrine actions of interferon was eliminated. Our screen identified 175 dsRNA-stimulated genes (DSG) and 95 dsRNA-repressed genes.. A subset of the DSGs was also induced by different inflammatory cytokines and viruses demonstrating interconnections among disparate signaling pathways. Functionally, the DSGs encode proteins involved in signaling, apoptosis, RNA synthesis, protein synthesis and processing, cell metabolism, transport, and structure. Induction of such a diverse family of genes by dsRNA has major implications in host-virus interactions and in the use of RNA, technology for functional ablation of specific, genes.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol NC20, Cleveland, OH 44195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	Cleveland Clinic Foundation; University of Washington; University of Washington Seattle	Sen, GC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol NC20, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Bumgarner, Roger/AAA-6846-2020; Bumgarner, Roger E/K-3531-2015	Bumgarner, Roger E/0000-0002-8168-6985	NATIONAL CANCER INSTITUTE [R01CA068782, P01CA062220] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NCI NIH HHS [CA-68782, CA-62220] Funding Source: Medline; NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [AI12264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANDYOPADHYAY SK, 1995, J BIOL CHEM, V270, P19624, DOI 10.1074/jbc.270.33.19624; Chang YJE, 2000, J VIROL, V74, P4174, DOI 10.1128/JVI.74.9.4174-4182.2000; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Geiss GK, 2001, J VIROL, V75, P4321, DOI 10.1128/JVI.75.9.4321-4331.2001; Guo JJ, 2000, VIROLOGY, V267, P209, DOI 10.1006/viro.1999.0135; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Miyagi Y, 1996, DNA CELL BIOL, V15, P947, DOI 10.1089/dna.1996.15.947; Mossman KL, 2001, J VIROL, V75, P750, DOI 10.1128/JVI.75.2.750-758.2001; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; TIWARI RK, 1987, EMBO J, V6, P3373, DOI 10.1002/j.1460-2075.1987.tb02659.x; VILCEK J, 1996, FIELDS VIROLOGY, P375; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470	23	173	184	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30178	30182		10.1074/jbc.C100137200	http://dx.doi.org/10.1074/jbc.C100137200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11487589	hybrid			2022-12-25	WOS:000170558000077
J	Jayanthi, S; Deng, XL; Bordelon, M; McCoy, MT; Cadet, JL				Jayanthi, S; Deng, XL; Bordelon, M; McCoy, MT; Cadet, JL			Methamphetamine causes differential regulation of pro-death and anti-death Bcl-2 genes in the mouse neocortex	FASEB JOURNAL			English	Article						neurotoxicity; apoptosis; bcl-2 gene family; cDNA array	DISMUTASE TRANSGENIC MICE; CYTOCHROME-C; CELL-DEATH; BRAIN DOPAMINE; PERMEABILITY TRANSITION; ENDOPLASMIC-RETICULUM; LIPID-PEROXIDATION; PREFRONTAL CORTEX; INDUCED APOPTOSIS; RELEASE	Bcl-2, an inner mitochondrial membrane protein, inhibits apoptotic neuronal cell death. Expression of Bcl-2 inhibits cell death by decreasing the net cellular generation of reactive oxygen species. Studies by different investigators have provided unimpeachable evidence of a role for oxygen-based free radicals in methamphetamine (METH)-induced neurotoxicity. In addition, studies from our laboratory have shown that immortalized rat neuronal cells that overexpress Bcl-2 are protected against METH-induced apoptosis in vitro. Moreover, the amphetamines can cause differential changes in the expression of Bcl-X splice variants in primary cortical cell cultures. These observations suggested that METH might also cause perturbations of Bcl-2-related genes when administered to rodents. Thus, the present study was conducted to determine whether the use of METH might indeed be associated with transcriptional and translational changes in the expression of Bcl-2-related genes in the mouse brain. Here we report that a toxic regimen of METH did cause significant increases in the pro-death Bcl-2 family genes BAD, BAX, and BID. Concomitantly, there were significant decreases in the anti-death genes Bcl-2 and Bcl-X-L. These results thus support the notion that injections of toxic doses of METH trigger the activation of the programmed death pathway in the mammalian brain.	NIDA, Mol Neuropsychiat Sect, Intramural Res Program, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Cadet, JL (corresponding author), NIDA, Mol Neuropsychiat Sect, Intramural Res Program, NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	JCADET@intra.nida.nih.gov	Jayanthi, Subramaniam/ABI-4023-2020	Jayanthi, Subramaniam/0000-0002-5209-303X	NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000174, ZIADA000174] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Acikgoz O, 2000, EUR NEUROPSYCHOPHARM, V10, P415, DOI 10.1016/S0924-977X(00)00103-6; Allen RT, 1998, CELL MOL LIFE SCI, V54, P427, DOI 10.1007/s000180050171; Bogdanov MB, 1999, NEUROSCI LETT, V262, P33, DOI 10.1016/S0304-3940(99)00047-6; BOYD JM, 1995, ONCOGENE, V11, P1921; Cadet JL, 1997, SYNAPSE, V25, P176; Cadet JL, 2001, SYNAPSE, V41, P40, DOI 10.1002/syn.1058; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; De Miglio MR, 2000, HEPATOLOGY, V31, P956, DOI 10.1053/he.2000.5411; Deng XL, 1999, J NEUROSCI, V19, P10107; Deng XL, 2000, MOL BRAIN RES, V83, P121, DOI 10.1016/S0169-328X(00)00169-8; DeRisi J, 1996, NAT GENET, V14, P457; Diehn M, 2000, NAT GENET, V25, P58, DOI 10.1038/75603; Eisch AJ, 1998, SYNAPSE, V30, P329, DOI 10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.0.CO;2-V; Eisch AJ, 1998, SYNAPSE, V30, P433, DOI 10.1002/(SICI)1098-2396(199812)30:4<433::AID-SYN10>3.3.CO;2-F; Ernst T, 2000, NEUROLOGY, V54, P1344, DOI 10.1212/WNL.54.6.1344; Gibb JW, 1997, J PHARMACOL EXP THER, V283, P630; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HENKART PA, 1995, J IMMUNOL, V154, P4905; Jayanthi S, 1998, ANN NY ACAD SCI, V844, P92, DOI 10.1111/j.1749-6632.1998.tb08224.x; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McCann UD, 1998, J NEUROSCI, V18, P8417; Nau ME, 2000, J CLIN MICROBIOL, V38, P1901, DOI 10.1128/JCM.38.5.1901-1908.2000; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PRESTON KL, 1985, BRAIN RES, V338, P243, DOI 10.1016/0006-8993(85)90153-2; REED JC, 1996, MECH BCL 2 FAMILY PR, P72; RICAURTE GA, 1980, BRAIN RES, V193, P153, DOI 10.1016/0006-8993(80)90952-X; RICAURTE GA, 1982, BRAIN RES, V235, P93, DOI 10.1016/0006-8993(82)90198-6; Robinson TE, 1997, J NEUROSCI, V17, P8491; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; RYAN LJ, 1990, BRAIN RES, V518, P67, DOI 10.1016/0006-8993(90)90955-B; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Seiden L S, 1996, NIDA Res Monogr, V163, P251; Shimizu S, 1996, AM J PHYSIOL-GASTR L, V271, pG949, DOI 10.1152/ajpgi.1996.271.6.G949; STERANKA LR, 1980, EUR J PHARMACOL, V65, P439, DOI 10.1016/0014-2999(80)90351-9; Stumm G, 1999, FASEB J, V13, P1065, DOI 10.1096/fasebj.13.9.1065; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Vander Heiden MG, 1999, MOL CELL, V3, P159; Volkow ND, 2001, AM J PSYCHIAT, V158, P383, DOI 10.1176/appi.ajp.158.3.383; Volkow ND, 1999, J PHARMACOL EXP THER, V291, P409; WAGNER GC, 1979, DRUG ALCOHOL DEPEN, V4, P435, DOI 10.1016/0376-8716(79)90076-0; WHITE E, 1996, GENE DEV, V10, P10; Wilson JM, 1996, NAT MED, V2, P699, DOI 10.1038/nm0696-699; WON L, 1992, BRAIN RES, V575, P6, DOI 10.1016/0006-8993(92)90416-7; Yamamoto H, 1996, ANN NY ACAD SCI, V801, P327, DOI 10.1111/j.1749-6632.1996.tb17453.x; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin X M, 1995, Curr Top Microbiol Immunol, V194, P331; Zamorano PL, 1996, NEUROENDOCRINOLOGY, V63, P397, DOI 10.1159/000127065	62	137	153	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					1745	1752		10.1096/fj.01-0025com	http://dx.doi.org/10.1096/fj.01-0025com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481222				2022-12-25	WOS:000170809900010
J	Ng, PWP; Iha, H; Iwanaga, Y; Bittner, M; Chen, YD; Jiang, Y; Gooden, G; Trent, JM; Meltzer, P; Jeang, KT; Zeichner, SL				Ng, PWP; Iha, H; Iwanaga, Y; Bittner, M; Chen, YD; Jiang, Y; Gooden, G; Trent, JM; Meltzer, P; Jeang, KT; Zeichner, SL			Genome-wide expression changes induced by HTLV-1 Tax: evidence for MLK-3 mixed lineage kinase involvement in Tax-mediated NF-kappa B activation	ONCOGENE			English	Article						HTLV-1; Tax; microarray; gene expression; MLK-3; JPX-9	T-CELL LEUKEMIA; VIRUS TYPE-I; VIRAL TRANSACTIVATOR TAX; HEPATOCYTE GROWTH-FACTOR; GENE-EXPRESSION; PROTEIN-KINASE; TYPE-1 TAX; MOLECULAR-MECHANISMS; CYCLE PROGRESSION; 1-INFECTED CELLS	The Tax protein of human T-lymphotropic virus type 1 (HTLV-1), an oncoprotein that transactivates viral and cellular genes, plays a key role in HTLV-1 replication and pathogenesis. We used cDNA microarrays to examine Tax-mediated transcriptional changes in the human Jurkat T-cell lines JPX-9 and JPX-M which express Tax and Tax-mutant protein, respectively, under the control of an inducible promoter. Approximately 300 of the over 2000 genes examined were differentially expressed in the presence of Tax. These genes were grouped according to their function and are discussed in the context of existing findings in the literature. There was strong agreement between our results and genes previously reported as being Tax-responsive. Genes that were differentially expressed in the presence of Tax included those related to apoptosis, the cell cycle and DNA repair, signaling factors, immune modulators, cytokines and growth factors, and adhesion molecules. Functionally, we provide evidence that one of these genes, the mixed-lineage kinase MLK-3, is involved in Tax-mediated NF-kappaB signaling. Our current results provide additional insights into Tax-mediated signaling.	NCI, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Zeichner, SL (corresponding author), NCI, HIV & AIDS Malignancy Branch, NIH, Bldg 10,Room 10S255, Bethesda, MD 20892 USA.	kj7e@nih.gov; zeichner@nih.gov	Jeang, Kuan-Teh/A-2424-2008	Iha, Hidekatsu/0000-0002-0999-5636	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; Baba M, 1996, INT J CANCER, V66, P124, DOI 10.1002/(SICI)1097-0215(19960328)66:1<124::AID-IJC21>3.3.CO;2-L; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chen XL, 1997, J GEN VIROL, V78, P3277, DOI 10.1099/0022-1317-78-12-3277; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; Chlichlia K, 1997, ONCOGENE, V14, P2265, DOI 10.1038/sj.onc.1201070; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CLAPHAM P, 1983, SCIENCE, V222, P1125, DOI 10.1126/science.6316502; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FLORENES VA, 1992, CANCER RES, V52, P6088; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Freije JMP, 1998, BIOCHEM SOC SYMP, P261; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Fukuda M, 1996, INT J CANCER, V65, P531, DOI 10.1002/(SICI)1097-0215(19960208)65:4<531::AID-IJC23>3.0.CO;2-B; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Kawakami A, 1999, BLOOD, V94, P3847, DOI 10.1182/blood.V94.11.3847.423a24_3847_3854; Khan J, 1999, ELECTROPHORESIS, V20, P223, DOI 10.1002/(SICI)1522-2683(19990201)20:2<223::AID-ELPS223>3.0.CO;2-A; Khan J, 1998, CANCER RES, V58, P5009; Kibler KV, 1999, JNCI-J NATL CANCER I, V91, P903, DOI 10.1093/jnci/91.11.903; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; Miyazaki H, 1999, CLIN CANCER RES, V5, P4301; Mori N, 2000, BLOOD, V95, P3915; MULLER WA, 1995, J LEUKOCYTE BIOL, V57, P523, DOI 10.1002/jlb.57.4.523; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAGY K, 1983, INT J CANCER, V32, P321, DOI 10.1002/ijc.2910320310; NAKAYAMA H, 1993, JPN J CANCER RES, V84, P184, DOI 10.1111/j.1349-7006.1993.tb02853.x; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Neuveut C, 2000, Prog Cell Cycle Res, V4, P157; Nicot C, 2000, ONCOGENE, V19, P2155, DOI 10.1038/sj.onc.1203536; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; PiseMasison CA, 1997, MOL CELL BIOL, V17, P1236, DOI 10.1128/MCB.17.3.1236; Ratajczak MZ, 1997, BRIT J HAEMATOL, V99, P228, DOI 10.1046/j.1365-2141.1997.3563170.x; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; To CTT, 1998, ONCOL REP, V5, P1013; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Watanabe T, 1997, INT J HEMATOL, V66, P257; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xu X, 1996, ONCOGENE, V13, P135; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; Yao J, 2000, FRONT BIOSCI-LANDMRK, V5, pD138, DOI 10.2741/Yao; Yin MJ, 1996, J MOL BIOL, V264, P20, DOI 10.1006/jmbi.1996.0620; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	75	92	93	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4484	4496		10.1038/sj.onc.1204513	http://dx.doi.org/10.1038/sj.onc.1204513			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494144				2022-12-25	WOS:000170074900006
J	Chalfant, CE; Ogretmen, B; Galadari, S; Kroesen, BJ; Pettus, BJ; Hannun, YA				Chalfant, CE; Ogretmen, B; Galadari, S; Kroesen, BJ; Pettus, BJ; Hannun, YA			FAS activation induces dephosphorylation of SR proteins - Dependence on the de novo generation of ceramide and activation of protein phosphatase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; RNA SPLICING FACTOR-SF2; INDUCED APOPTOSIS; SPHINGOMYELIN TURNOVER; DOWNSTREAM TARGET; BCL-X; KINASE; IDENTIFICATION; PHOSPHORYLATION; PATHWAY	The search for potential targets for ceramide action led to the identification of ceramide-activated protein phosphatases (CAPP). To date, two serine/threonine protein phosphatases, protein phosphatase 2A (PP2A) and protein phosphatase 1 (PP1), have been demonstrated to function as ceramide-activated protein phosphatases. In this study, we show that treatment with either anti-FAS IgM (CH-11) (150 ng/ml) or exogenous D-(e)-C-6-ceramide (20 muM) induces the dephosphorylation of the PP1 substrates, serine/arginine-rich (SR) proteins, in Jurkat acute leukemia T-cells. The serine/threonine protein phosphatase inhibitor, calyculin A, but not the PP2A-specific inhibitor, okadaic acid, inhibited both FAS- and ceramide-induced dephosphorylation of SR proteins. Anti-FAS IgM treatment of Jurkat cells led to a significant increase in levels of endogenous ceramide beginning at 2 h with a maximal increase of 10-fold after 7 h. A 2-h pretreatment of Jurkat cells with fumonisin B-1 (100 muM), a specific inhibitor of CoA-dependent ceramide synthase, blocked 80% of the ceramide generated and completely inhibited the dephosphorylation of SR proteins in response to anti-FAS IgM. Moreover, pretreatment of Jurkat cells with myriocin, a specific inhibitor of serine-palmitoyl transferase (the first step in de novo synthesis of ceramide), also blocked FAS-induced SR protein dephosphorylation, thus demonstrating a role for de novo ceramide. These results were further supported using A549 lung adenocarcinoma cells treated with D-(e)-C-6-ceramide. Dephosphorylation of SR proteins was inhibited by fumonisin B1 and by overexpression of glucosylceramide synthase; again implicating endogenous ceramide generated de novo in regulating the dephosphorylation of SR proteins in response to FAS activation. These results establish a specific intracellular pathway involving both de novo ceramide generation and activation of PP1 to mediate the effects of FAS activation on SR proteins.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; United Arab Emirates Univ, Dept Biochem, Al Ain, U Arab Emirates; Univ Groningen Hosp, Dept Pathol & Lab Med, Groningen, Netherlands	Medical University of South Carolina; United Arab Emirates University; University of Groningen	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Rm 501,Basic Sci Bldg,173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu	Galadari, Sehamuddin/AAK-6039-2020		NCI NIH HHS [CA87584] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Ban J, 1998, BIOCHEM BIOPH RES CO, V248, P147, DOI 10.1006/bbrc.1998.8907; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cain K, 1996, BIOCHEM J, V314, P27, DOI 10.1042/bj3140027; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHALFANT C, 1997, MECH PHYSL SIGNIFICA; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; CHAO R, 1992, J BIOL CHEM, V267, P23459; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; Du C, 1998, MOL CELL, V2, P741, DOI 10.1016/S1097-2765(00)80289-0; El-Assaad W, 1998, BIOCHEM J, V336, P735, DOI 10.1042/bj3360735; Galadari S, 1998, BIOCHEMISTRY-US, V37, P11232, DOI 10.1021/bi980911+; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KIM MY, 1991, J BIOL CHEM, V266, P484; Komori H, 1999, J BIOL CHEM, V274, P8981, DOI 10.1074/jbc.274.13.8981; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LIU J, 1994, J BIOL CHEM, V269, P3047; Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; Meivar-Levy I, 1999, J BIOL CHEM, V274, P4607, DOI 10.1074/jbc.274.8.4607; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Patel NA, 2001, J BIOL CHEM, V276, P22648, DOI 10.1074/jbc.M101260200; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; Reyes JG, 1996, J BIOL CHEM, V271, P21375, DOI 10.1074/jbc.271.35.21375; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schmitt E, 2000, BIOCHEM BIOPH RES CO, V270, P868, DOI 10.1006/bbrc.2000.2537; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Shi B, 1999, BIOCHEM BIOPH RES CO, V254, P779, DOI 10.1006/bbrc.1998.0130; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Srinivasula SM, 1999, CANCER RES, V59, P999; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; Tepper AD, 2000, J BIOL CHEM, V275, P34810, DOI 10.1074/jbc.M005142200; Tepper AD, 2001, BIOCHEM BIOPH RES CO, V280, P634, DOI 10.1006/bbrc.2000.4166; Thomas AL, 1999, CELL DEATH DIFFER, V6, P97, DOI 10.1038/sj.cdd.4400474; Utz PJ, 1998, J EXP MED, V187, P547, DOI 10.1084/jem.187.4.547; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhou M, 1998, J BIOL CHEM, V273, P11930, DOI 10.1074/jbc.273.19.11930	83	128	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44848	44855		10.1074/jbc.M106291200	http://dx.doi.org/10.1074/jbc.M106291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11502750	hybrid			2022-12-25	WOS:000172406700070
J	Cano-Abad, MF; Villarroya, M; Garcia, AG; Gabilan, NH; Lopez, MG				Cano-Abad, MF; Villarroya, M; Garcia, AG; Gabilan, NH; Lopez, MG			Calcium entry through L-type calcium channels causes mitochondrial disruption and chromaffin cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CA2+ HOMEOSTASIS; HIPPOCAMPAL-NEURONS; APOPTOSIS; NIMODIPINE; PEPTIDE; SECRETION; BRAIN; IDENTIFICATION; NEUROTOXICITY; LOCALIZATION	Sustained, mild K+ depolarization caused bovine chromaffin cell death through a Ca2+-dependent mechanism. During depolarization, Ca2+ entered preferentially through L-channels to induce necrotic or apoptotic cell death, depending on the duration of the cytosolic Ca2+ concentration ([Ca2+](c)) signal, as proven by the following. (i) The L-type Ca2+ channel activators Bay K 8644 and FPL64176, more than doubled the cytotoxic effects of 30 mm K+; (ii) the L-type Ca2+ channel blocker nimodipine suppressed the cytotoxic effects of K+ alone or K+ plus FPL64176; (iii) the potentiation by FPL64176 of the K+-evoked [Ca2+](c) elevation was totally suppressed by nimodipine. Cell exposure to K+ plus the L-type calcium channel agonist FPL64176 caused an initial peak rise followed by a sustained elevation of the [Ca2+](c) that, in turn, increased [Ca2+](m) and caused mitochondrial membrane depolarization. Cyclosporin A, a blocker of the mitochondrial transition pore, and superoxide dismutase prevented the apoptotic cell death induced by Ca2+ overload through L-channels. These results suggest that Ca2+ entry through L-channels causes both calcium overload and mitochondrial disruption that will lead to the release of mediators responsible for the activation of the apoptotic cascade and cell death. This predominant role of L-type Ca2+ channels is not shared by other subtypes of high threshold voltage-dependent neuronal Ca2+ channels (i.e. N, P/Q) expressed by bovine chromaffin cells.	Univ Autonoma Madrid, Fac Med, Dept Farmacol, Inst Farmacol Teofilo Hernando, Madrid 28029, Spain; Hosp Princesa, Serv Farmacol Clin, Madrid 28006, Spain; Hosp Princesa, Inst Univ Invest Gerontol & Metab, Madrid 28006, Spain; Univ Fed Santa Catarina, Dept Bioquim, BR-88049 Florianopolis, SC, Brazil	Autonomous University of Madrid; Hospital de La Princesa; Hospital de La Princesa; Universidade Federal de Santa Catarina (UFSC)	Lopez, MG (corresponding author), Univ Autonoma Madrid, Fac Med, Dept Farmacol, Inst Farmacol Teofilo Hernando, C Arzobispo Morcillo 4, Madrid 28029, Spain.	manuela.garcia@uam.es	Lopez, Manuela G/D-2164-2015; GARCIA, ANTONIO G/E-9961-2018	Lopez, Manuela G/0000-0003-4461-8788; GARCIA, ANTONIO G/0000-0002-6517-3565; Cano-Abad, Maria F./0000-0002-2602-6626				AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; Ahmed N, 2000, STROKE, V31, P1250, DOI 10.1161/01.STR.31.6.1250; Albillos A, 1996, PFLUG ARCH EUR J PHY, V432, P1030, DOI 10.1007/s004240050231; Albillos A, 2000, J NEUROSCI, V20, P8323, DOI 10.1523/JNEUROSCI.20-22-08323.2000; ALLEN GS, 1979, NEUROSURGERY, V4, P37, DOI 10.1227/00006123-197901000-00007; BEATRICE MC, 1980, J BIOL CHEM, V255, P8663; BLANK WF, 1977, BRAIN RES, V123, P113, DOI 10.1016/0006-8993(77)90646-1; Cano-Abad MF, 1998, BRIT J PHARMACOL, V124, P1187, DOI 10.1038/sj.bjp.0701955; Carriedo SG, 1998, J NEUROSCI, V18, P7727; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Fern R, 1998, J NEUROPHYSIOL, V79, P95, DOI 10.1152/jn.1998.79.1.95; Fogelholm R, 2000, CEREBROVASC DIS, V10, P189, DOI 10.1159/000016055; FONTERIZ RI, 1987, BRAIN RES, V408, P359, DOI 10.1016/0006-8993(87)90405-7; GARCIA AG, 1984, NATURE, V309, P69, DOI 10.1038/309069a0; GARCIA AG, 2000, SEAFOOD FRESHWATER T, P99; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; GOODMAN Y, 1994, BRAIN RES, V654, P171, DOI 10.1016/0006-8993(94)91586-5; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; GROUSELLE M, 1990, BIOCHEM J, V271, P269, DOI 10.1042/bj2710269; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HENANDEZGUIJO JM, 2001, J NEUROSCI, V21, P2553; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOFFMEISTER F, 1979, Acta Neurologica Scandinavica Supplementum, V60, P358; Horn J, 2001, STROKE, V32, P461, DOI 10.1161/01.STR.32.2.461; Kapila YL, 1999, J BIOL CHEM, V274, P30906, DOI 10.1074/jbc.274.43.30906; KEYSER DJ, 1999, ACTA CLIN BELG, V54, P302; Kobayashi T, 1998, EUR J PHARMACOL, V363, P1, DOI 10.1016/S0014-2999(98)00774-2; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Leski ML, 1999, BRAIN RES, V828, P27, DOI 10.1016/S0006-8993(99)01270-6; LIVETT BG, 1984, PHYSIOL REV, V64, P1103, DOI 10.1152/physrev.1984.64.4.1103; MARK RJ, 1995, J NEUROSCI, V15, P6239; MAROTO R, 1994, EUR J PHARM-ENVIRON, V270, P331, DOI 10.1016/0926-6917(94)90009-4; Maroto R, 1996, BRAIN RES, V714, P209, DOI 10.1016/0006-8993(95)01543-4; Mason RP, 1999, J NEUROCHEM, V72, P1448, DOI 10.1046/j.1471-4159.1999.721448.x; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; MATTSON MP, 1993, EXP NEUROL, V121, P1, DOI 10.1006/exnr.1993.1066; MICHELENA P, 1993, P NATL ACAD SCI USA, V90, P3284, DOI 10.1073/pnas.90.8.3284; MOHR JP, 1994, CEREBROVASC DIS, V4, P197, DOI 10.1159/000108482; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; Pisani A, 1998, STROKE, V29, P196, DOI 10.1161/01.STR.29.1.196; RODA JM, 1995, STROKE, V26, P1888, DOI 10.1161/01.STR.26.10.1888; Schinder AF, 1996, J NEUROSCI, V16, P6125; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; Small DL, 1997, BRAIN RES, V753, P209, DOI 10.1016/S0006-8993(96)01385-6; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Ueda K, 1997, J NEUROCHEM, V68, P265; VALENTINO K, 1993, P NATL ACAD SCI USA, V90, P7894, DOI 10.1073/pnas.90.16.7894; Villarroya M, 1999, J PHYSIOL-LONDON, V516, P421, DOI 10.1111/j.1469-7793.1999.0421v.x; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	67	114	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39695	39704		10.1074/jbc.M102334200	http://dx.doi.org/10.1074/jbc.M102334200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11500491	hybrid			2022-12-25	WOS:000171789200026
J	Reiter, R; Wellstein, A; Riegel, AT				Reiter, R; Wellstein, A; Riegel, AT			An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; ESTROGEN-RECEPTOR; BINDING PROTEIN; HISTONE ACETYLTRANSFERASE; TRANSCRIPTIONAL COACTIVATOR; ALTERNATIVE TRANSLATION; NUCLEAR RECEPTORS; ANDROGEN RECEPTOR; EPITHELIAL-CELLS; C-MYC	The AIB1 (amplified in breast cancer 1) protein is a coactivator that potentiates the transcriptional activity of nuclear hormone receptors, and its gene is amplified in a subset of human breast cancers. Here we report a splice variant of AIB1 mRNA that lacks the exon 3 sequence. We determined that the AIB-Delta3 mRNA encoded a 130-kDa protein that lacks the NH2-terminal basic helix-loop-helix and a portion of the PAS (Per-Arnt-Sim homology) dimerization domain. The 130-kDa protein was detected in MCF-7 breast cancer cells at levels that were 5-10% of the full-length protein, whereas in nontransformed mammary epithelium lines, the AIB-Delta3 protein was present at significantly lower levels compared with the full-length AIB1. Consistent with this finding, the abundance of AIB1-Delta3 mRNA was increased in human breast cancer specimens relative to that in normal breast tissue. To determine whether there were phenotypic changes associated with the overexpression of the AIB-Delta3 isoform, we performed functional reporter gene assays. These revealed that the ability of AIB1-Delta3 to promote transcription mediated by the estrogen or progesterone receptors was significantly greater than that of the full-length protein. Surprisingly, the AIB1-Delta3 isoform was also more effective than AIB1 in promoting transcription induced by epidermal growth factor. Overexpression of AIB1-Delta3 may thus play an important role in sensitizing breast tumor cells to hormone or growth factor stimulation.	Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University; Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20007 USA.			Wellstein, Anton/0000-0002-0570-4950				Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Bouras T, 2001, CANCER RES, V61, P903; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Guan XY, 1996, CANCER RES, V56, P3446; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; ING NH, 1992, J BIOL CHEM, V267, P17617; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; LIST HJ, 2001, BREAST CANC RES TREA, V2016, P1; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; ROCHETTEEGLY C, 1997, CELL, V97, P107; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SOULE HD, 1990, CANCER RES, V50, P6075; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tikkanen MK, 2000, P NATL ACAD SCI USA, V97, P12536, DOI 10.1073/pnas.220427297; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wu XY, 2001, J BIOL CHEM, V276, P23962, DOI 10.1074/jbc.M101041200; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527	47	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39736	39741		10.1074/jbc.M104744200	http://dx.doi.org/10.1074/jbc.M104744200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11502741	hybrid			2022-12-25	WOS:000171789200031
J	Trickett, JI; Patel, DD; Knight, BL; Saggerson, ED; Gibbons, GF; Pease, RJ				Trickett, JI; Patel, DD; Knight, BL; Saggerson, ED; Gibbons, GF; Pease, RJ			Characterization of the rodent genes for arylacetamide deacetylase, a putative microsomal lipase, and evidence for transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; LOW-DENSITY LIPOPROTEIN; ACTIVATED RECEPTOR-ALPHA; FATTY-ACID SYNTHESIS; TRIACYLGLYCEROL HYDROLASE; HEPATOCYTE CULTURES; RAT HEPATOCYTES; ADIPOSE-TISSUE; DEFICIENT MICE; MESSENGER-RNA	In the current study, we have determined the cDNA and the genomic sequences of the arylacetamide deacetylase (AADA) gene in mice and rats. The AADA genes in the rat and mouse consist of five exons and have 2.4 kilobases of homologous promoter sequence upstream of the initiating ATG codon. AADA mRNA is expressed in hepatocytes, intestinal mucosal cells (probably enterocytes), the pancreas and also the adrenal gland. In mice, there is a diurnal rhythm in hepatic AADA mRNA concentration, with a maximum 10 h into the light (post-absorptive) phase. This diurnal regulation is attenuated in peroxisome proliferator-activated receptor a knockout mice. Intestinal but not hepatic AADA mRNA was increased following oral administration of the fibrate, Wy-14,643. The homology of AADA with hormone-sensitive lipase and the tissue distribution of AADA are consistent with the view that AADA plays a role in promoting the mobilization of lipids from intracellular stores and in the liver for assembling VLDL This hypothesis is supported by parallel changes in AADA gene expression in animals with insulin-deficient diabetes and following treatment with orotic acid.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Hammersmith Hosp, MRC, Ctr Clin Sci, Lipoprot Grp, London W12 0NN, England; Radcliffe Infirm, Nuffield Dept Clin Med, Metab Res Lab, Oxford OX2 6HE, England	University of London; University College London; Imperial College London; Radcliffe Infirmary; University of Oxford	Pease, RJ (corresponding author), UCL, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.							ANDERSON RA, 1991, J BIOL CHEM, V266, P22479; ARGILES J, 1981, BIOL NEONATE, V39, P37, DOI 10.1159/000241390; Baker PW, 2000, J LIPID RES, V41, P719; BROWN MS, 1979, J BIOL CHEM, V254, P5144; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Chirieac DV, 2000, AM J PHYSIOL-ENDOC M, V279, pE1003, DOI 10.1152/ajpendo.2000.279.5.E1003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN RA, 1988, J LIPID RES, V29, P33; Contreras JA, 1996, J BIOL CHEM, V271, P31426, DOI 10.1074/jbc.271.49.31426; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DUERDEN JM, 1993, BIOCHEM J, V294, P167, DOI 10.1042/bj2940167; DUERDEN JM, 1990, BIOCHEM J, V272, P583, DOI 10.1042/bj2720583; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; FUKUDA H, 1985, BIOCHIM BIOPHYS ACTA, V835, P163, DOI 10.1016/0005-2760(85)90269-3; GIBBONS GF, 1994, J LIPID RES, V35, P1801; Gibbons GF, 2000, BBA-MOL CELL BIOL L, V1483, P37, DOI 10.1016/S1388-1981(99)00182-1; GIBBONS GF, 1990, BIOCHEM J, V268, P1; GREENBERG ME, 2001, CURRENT PROTOCOLS MO; HAVEL PJ, 1991, CURR OPIN LIPIDOL, V6, P312; Hebbachi AM, 1997, BIOCHEM J, V325, P711, DOI 10.1042/bj3250711; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HEMS DA, 1975, BIOCHEM J, V150, P167, DOI 10.1042/bj1500167; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; HOLM C, 1994, FEBS LETT, V344, P234, DOI 10.1016/0014-5793(94)00403-X; JOHANSSON MBN, 1983, BIOL NEONATE, V44, P278, DOI 10.1159/000241728; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KRAEMER FB, 1991, J LIPID RES, V32, P1303; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; LEWIN B, 2000, GENES, V7, P617; Manjeshwar S, 1999, MOL CARCINOGEN, V24, P188, DOI 10.1002/(SICI)1098-2744(199903)24:3<188::AID-MC5>3.0.CO;2-#; MATSUSHIMA M, 1991, FEBS LETT, V293, P37, DOI 10.1016/0014-5793(91)81147-Z; Mulder H, 1999, DIABETES, V48, P228, DOI 10.2337/diabetes.48.1.228; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Ozols J, 1998, BIOCHEMISTRY-US, V37, P10336, DOI 10.1021/bi9807916; Patel DD, 2001, J LIPID RES, V42, P328; Patel DD, 2000, BIOCHEM J, V351, P747, DOI 10.1042/0264-6021:3510747; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; PROBST MR, 1994, J BIOL CHEM, V269, P21650; PROBST MR, 1991, BIOCHEM BIOPH RES CO, V177, P453, DOI 10.1016/0006-291X(91)92005-5; RODBELL M, 1964, J BIOL CHEM, V239, P375; Rodriguez-Garcia MI, 1999, BIOCHEM J, V337, P125, DOI 10.1042/0264-6021:3370125; Rose ML, 1997, CHEM RES TOXICOL, V10, P1198, DOI 10.1021/tx970079u; ROSSENEU M, 1983, PEDIATR RES, V17, P788, DOI 10.1203/00006450-198310000-00004; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; Sambrook J, 1987, MOL CLONING LAB MANU; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; Schoonjans K, 1996, J LIPID RES, V37, P907; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; WIGGINS D, 1995, METABOLISM, V44, P841, DOI 10.1016/0026-0495(95)90235-X; Womble D D, 2000, Methods Mol Biol, V132, P3; Yamazaki K, 1997, GENOMICS, V44, P248, DOI 10.1006/geno.1997.4879; YANG LY, 1991, J LIPID RES, V32, P1173; Yang LY, 1996, J LIPID RES, V37, P262; YANG LY, 1995, J LIPID RES, V36, P125; YAO ZM, 1988, J BIOL CHEM, V263, P2998; Zammit VA, 1996, BIOCHEM J, V314, P1, DOI 10.1042/bj3140001	64	53	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39522	39532		10.1074/jbc.M101764200	http://dx.doi.org/10.1074/jbc.M101764200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11481320	hybrid			2022-12-25	WOS:000171789200005
J	Ermak, G; Morgan, TE; Davies, KJA				Ermak, G; Morgan, TE; Davies, KJA			Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME CRITICAL REGION; SYNDROME CANDIDATE REGION-1; DOWN-SYNDROME; APOLIPOPROTEIN-E; MESSENGER-RNA; END-PRODUCTS; A-ALPHA; APOPTOSIS; STRESS; BRAIN	The DSCR1 (Adapt78) gene was independently discovered as a resident of the "Down syndrome candidate region" and as an "adaptive response" shock or stress gene that is transiently induced during oxidative stress. Recently the DSCR1 (Adapt78) gene product was discovered to be an inhibitor of the serine/threonine phosphatase, calcineurin, and its signaling pathways. We hypothesized that DSCR1 (Adapt78) might also be involved in the development of Alzheimer's disease. To address this question we first studied DSCR1 (Adapt78) in multiple human tissues and found significant expression in brain, spinal cord, kidney, liver, mammary gland, skeletal muscle, and heart. Within the brain DSCR1 (Adapt78) is predominantly expressed in neurons within the cerebral cortex, hippocampus, substantia nigra, thalamus, and medulla oblongata. When we compared DSCR1 (Adapt78) mRNA expression in post-mortem brain samples from Alzheimer's disease patients and individuals who had died with no Alzheimer's diagnosis, we found that DSCR1 (Adapt78) mRNA levels were about twice as high in age-matched Alzheimer's patients as in controls. DSCR1 (Adapt78) mRNA levels were actually three times higher in patients with extensive neurofibrillary tangles (a hallmark of Alzheimer's disease) than in controls. In comparison, postmortem brain samples from Down syndrome patients (who suffer Alzheimer's symptoms) also exhibited DSCR1 (Adapt78) mRNA levels two to three times higher than controls. Using a cell culture model we discovered that the amyloid beta (1-42) peptide, which is a major component of senile plaques in Alzheimer's, can directly induce increased expression of DSCR1 (Adapt78). Our findings associate DSCR1 (Adapt78) with such major hallmarks of Alzheimer's disease as amyloid protein, senile plaques, and neurofibrillary tangles.	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave,Rm 306, Los Angeles, CA 90089 USA.			Davies, Kelvin/0000-0001-7790-3003	NIA NIH HHS [P50-AG05142, AG16256] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005142, R01AG016256] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; BALAZS L, 1994, NEUROCHEM RES, V19, P1131, DOI 10.1007/BF00965146; Barinaga M, 1998, SCIENCE, V281, P1303, DOI 10.1126/science.281.5381.1303; Bernstam L, 2000, J TOXICOL ENV HEAL B, V3, P293, DOI 10.1080/109374000436355; BRODMAN K, 1909, VERLEICHENDE LOCALIS; Bronson R., 1990, GENETIC EFFECTS AGIN, VII, P279; Crawford DR, 1997, ARCH BIOCHEM BIOPHYS, V342, P6, DOI 10.1006/abbi.1997.0109; Ermak Gennady, 2000, Free Radical Biology and Medicine, V29, pS55; Estus S, 1997, J NEUROSCI, V17, P7736; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; Hansen HH, 2000, J NEUROCHEM, V75, P861, DOI 10.1046/j.1471-4159.2000.0750861.x; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; Honig LS, 2000, AM J MED, V108, P317, DOI 10.1016/S0002-9343(00)00291-6; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; Jiang HS, 1997, MOL IMMUNOL, V34, P663, DOI 10.1016/S0161-5890(97)00054-0; Kayyali US, 1997, J NEUROCHEM, V68, P1668; Ladner CJ, 1996, J NEUROPATH EXP NEUR, V55, P924, DOI 10.1097/00005072-199608000-00008; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Leahy KP, 1999, ARCH BIOCHEM BIOPHYS, V368, P67, DOI 10.1006/abbi.1998.1059; Lee VMY, 2001, SCIENCE, V293, P1446, DOI 10.1126/science.1064684; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Mann D. M. A., 1997, P122; Mattson MP, 1997, MOL MECH DEMENTIA, P103; Miyazaki T, 1996, J BIOL CHEM, V271, P14567, DOI 10.1074/jbc.271.24.14567; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; Ohyagi Y, 2000, NEUROREPORT, V11, P167, DOI 10.1097/00001756-200001170-00033; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Sayre LM, 1997, J NEUROCHEM, V68, P2092; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Smith MA, 1998, INT REV NEUROBIOL, V42, P1, DOI 10.1016/S0074-7742(08)60607-8; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; Strippoli P, 2000, GENOMICS, V64, P252, DOI 10.1006/geno.2000.6127; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; SUBBARAO KV, 1990, J NEUROCHEM, V55, P342, DOI 10.1111/j.1471-4159.1990.tb08858.x; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; WALLACE RW, 1980, BIOCHEMISTRY-US, V19, P1831, DOI 10.1021/bi00550a016; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650	44	180	188	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38787	38794		10.1074/jbc.M102829200	http://dx.doi.org/10.1074/jbc.M102829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11483593	hybrid			2022-12-25	WOS:000171673200062
J	Foubert, TR; Bleazard, JB; Burritt, JB; Gripentrog, JM; Baniulis, D; Taylor, RM; Jesaitis, AJ				Foubert, TR; Bleazard, JB; Burritt, JB; Gripentrog, JM; Baniulis, D; Taylor, RM; Jesaitis, AJ			Identification of a spectrally stable proteolytic fragment of human neutrophil flavocytochrome b composed of the NH2-terminal regions of gp91(phox) and p22(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; PHAGOCYTE NADPH OXIDASE; ELECTRON-PARAMAGNETIC RESONANCE; SITE-DIRECTED MUTAGENESIS; CYTOCHROME-B; POLYACRYLAMIDE GELS; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL LOCATION; PORCINE NEUTROPHILS; HUMAN-GRANULOCYTES	A home-bearing polypeptide core of human neutrophil flavocytochrome b(558) was isolated by applying high performance, size exclusion, liquid chromatography to partially purified Triton X-100-solubilized flavocytochrome b that had been exposed to endoproteinase Glu-C for 1 h. The fragment was composed of two polypeptides of 60-66 and 17 kDa by SDS-polyacrylamide gel electrophoresis and retained a native heme absorbance spectrum that was stable for several days when stored at 4 degreesC in detergent-containing buffer. These properties suggested that the majority of the flavocytochrome b heme environment remained intact. Continued digestion up to 4.5 h yielded several home-associated fragments that were variable in composition between experiments. Digestion beyond 4.5 h resulted in a gradual loss of recoverable heme. N-Linked deglycosylation and reduction and alkylation of the 1-h digestion fragment did not affect the electrophoretic mobility of the 17-kDa fragment but reduced the 60-66-kDa fragment to 39 kDa. Sequence and immunoblot analyses identified the fragments as the NH2-terminal 320-363 amino acid residues of gp91(phox) and the NH2-terminal 169-171 amino acid residues of p22(phox). These findings provide direct evidence that the primarily hydrophobic NH2-terminal regions of flavocytochrome b are responsible for heme ligation.	Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA	Montana State University System; Montana State University Bozeman	Jesaitis, AJ (corresponding author), Montana State Univ, Dept Microbiol, 109 Lewis Hall, Bozeman, MT 59717 USA.		Baniulis, Danas/AAA-9458-2021	Baniulis, Danas/0000-0002-2693-2020; Jesaitis, Algirdas/0000-0001-9001-5617	NIAID NIH HHS [R01 AI 26711] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026711] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; BOLSCHER BGJM, 1991, BLOOD, V77, P2482; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; Burritt JB, 1998, J BIOL CHEM, V273, P24847, DOI 10.1074/jbc.273.38.24847; Burritt JB, 2001, J BIOL CHEM, V276, P2053, DOI 10.1074/jbc.M006236200; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; Coligan JE, 1999, CURRENT PROTOCOLS PR; CROSS AR, 1995, J BIOL CHEM, V270, P8194, DOI 10.1074/jbc.270.14.8194; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DOUSSIERE J, 1993, BIOCHEMISTRY-US, V32, P8880, DOI 10.1021/bi00085a020; DOUSSIERE J, 1995, BIOCHEMISTRY-US, V34, P1760, DOI 10.1021/bi00005a033; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; FUJII H, 1992, BIOCHIM BIOPHYS ACTA, V1136, P239, DOI 10.1016/0167-4889(92)90112-O; FUJII H, 1995, J BIOL CHEM, V270, P3193, DOI 10.1074/jbc.270.7.3193; Fujii H, 1995, FEBS LETT, V377, P345, DOI 10.1016/0014-5793(95)01372-5; Gibney BR, 1999, PROTEIN SCI, V8, P1888, DOI 10.1110/ps.8.9.1888; HARPER AM, 1985, BIOCHEM J, V227, P783, DOI 10.1042/bj2270783; Henderson LM, 1999, J GEN PHYSIOL, V114, P771, DOI 10.1085/jgp.114.6.771; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HOLLAND VR, 1974, TETRAHEDRON, V30, P3299, DOI 10.1016/S0040-4020(01)97504-0; Huang J, 1995, BIOCHEMISTRY-US, V34, P16753, DOI 10.1021/bi00051a024; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; ISOGAI Y, 1995, J BIOL CHEM, V270, P7853, DOI 10.1074/jbc.270.14.7853; JESAITIS AJ, 1995, J IMMUNOL, V155, P3286; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; KLEINBERG ME, 1989, J IMMUNOL, V143, P4152; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leusen JHW, 1996, J LAB CLIN MED, V128, P461, DOI 10.1016/S0022-2143(96)90043-8; LUTTER R, 1985, J BIOL CHEM, V260, P2237; MIKI T, 1992, J BIOL CHEM, V267, P19673; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; PAKRASI HB, 1991, EMBO J, V10, P1619, DOI 10.1002/j.1460-2075.1991.tb07684.x; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, BIOCHIM BIOPHYS ACTA, V932, P71, DOI 10.1016/0005-2728(88)90140-5; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PEMBER SO, 1984, J BIOL CHEM, V259, P590; POULOS TL, 1985, J BIOL CHEM, V260, P6122; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; QUINN MT, 1992, J BIOL CHEM, V267, P7303; QUINN MT, 1995, METHOD ENZYMOL, V255, P477; QUINN MT, 1991, CLIN RES, V39, P353; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Schrenzel J, 1998, NATURE, V392, P734, DOI 10.1038/33725; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; SOJAR HT, 1987, ARCH BIOCHEM BIOPHYS, V259, P52, DOI 10.1016/0003-9861(87)90469-3; SOJAR HT, 1987, METHOD ENZYMOL, V138, P341; SUMIMOTO H, 1989, BIOCHEM BIOPH RES CO, V165, P902, DOI 10.1016/S0006-291X(89)80051-8; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsuda M, 1998, HUM GENET, V103, P377, DOI 10.1007/s004390050836; UENO I, 1991, FEBS LETT, V281, P130, DOI 10.1016/0014-5793(91)80375-D; Wallach TM, 1996, BIOCHEM J, V320, P33, DOI 10.1042/bj3200033; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; WIENTJES FB, 1995, SEMIN CELL BIOL, V6, P357, DOI 10.1016/S1043-4682(05)80006-6; YAMAGUCHI T, 1989, J BIOL CHEM, V264, P112; YOSHIDA LS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P245; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	71	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38852	38861		10.1074/jbc.M104373200	http://dx.doi.org/10.1074/jbc.M104373200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504718	hybrid			2022-12-25	WOS:000171673200070
J	Ito, K; Oleschuk, CJ; Westlake, C; Vasa, MZ; Deeley, RG; Cole, SPC				Ito, K; Oleschuk, CJ; Westlake, C; Vasa, MZ; Deeley, RG; Cole, SPC			Mutation of Trp(1254) in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID RESIDUE; EXPORT PUMP; DEPENDENT TRANSPORT; MOLECULAR-CLONING; DRUG-RESISTANCE; LEUKOTRIENE C-4; P-GLYCOPROTEIN; CMOAT GENE; GLUTATHIONE; CONJUGATE	The ATP-binding cassette (ABC) proteins comprise a large superfamily of transmembrane transporters that utilize the energy of ATP hydrolysis to translocate their substrates across biological membranes. Multidrug resistance protein (AMP) 2 (AJBCC2) belongs to subfamily C of the ABC superfamily and, when overexpressed in tumor cells, confers resistance to a wide variety of anticancer chemotherapeutic agents. MRP2 is also an active transporter of organic anions such as methotrexate (MTX), estradiol glucuronide (E(2)17 betaG), and leukotriene C-4 and is located on the apical membrane of polarized cells including hepatocytes where it acts as a biliary transporter. We recently identified a highly conserved tryptophan residue in the related MRP1 that is critical for the substrate specificity of this protein. In the present study, we have examined the effect of replacing the analogous tryptophan residue at position 1254 of MRP2. We found that only nonconservative substitutions (Ala and Cys) of Trp(1254) eliminated [H-3]E(2)17 betaG transport by MRP2, whereas more conservative substitutions (Phe and Tyr) had no effect. In addition, only the most conservatively substituted mutant (W1254Y) transported [H-3]leukotriene C-4, whereas all other substitutions eliminated transport of this substrate. On the other hand, all substitutions of Trp 1254 eliminated transport of [H-3]MTX. Finally, we found that sulfinpyrazone stimulated [H-3]E(2)17 betaG transport by wild-type MRP2 4-fold, whereas transport by the Trp(1254) substituted mutants was enhanced 6-10-fold. In contrast, sulfinpyrazone failed to stimulate [3H]MTX transport by either wildtype MRP2 or the MRP2-Trp(1254) mutants. Taken together, our results demonstrate that Trp(1254) plays an important role in the ability of MRP2 to transport conjugated organic anions and identify this amino acid in the putative last transmembrane segment (TM17) of this ABC protein as being critical for transport of MTX.	Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada; Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Ito, K (corresponding author), Queens Univ, Canc Res Labs, Rm 328,Botterell Hall, Kingston, ON K7L 3N6, Canada.	coles@post.queensu.ca	Westlake, Christopher/AAG-1150-2019; Deeley, Roger/J-4828-2012; Cole, Susan/I-6389-2017	Westlake, Christopher/0000-0001-7476-2014; Cole, Susan/0000-0001-6571-6884				Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Brechot JM, 1998, J HISTOCHEM CYTOCHEM, V46, P513, DOI 10.1177/002215549804600411; Chen ZS, 1999, MOL PHARMACOL, V55, P921; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Conrad S, 2001, TOXICOLOGY, V156, P81, DOI 10.1016/S0300-483X(00)00354-1; Cui YH, 1999, MOL PHARMACOL, V55, P929; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; de Planque MRR, 1999, J BIOL CHEM, V274, P20839, DOI 10.1074/jbc.274.30.20839; Dietrich CG, 2001, MOL PHARMACOL, V59, P974, DOI 10.1124/mol.59.5.974; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Evers R, 1997, FEBS LETT, V419, P112, DOI 10.1016/S0014-5793(97)01442-7; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; Evers R, 2000, BRIT J CANCER, V83, P375, DOI 10.1054/bjoc.2000.1262; Fritz F, 2000, BBA-GENE STRUCT EXPR, V1492, P531, DOI 10.1016/S0167-4781(00)00132-9; Fromm MF, 1999, BBA-BIOMEMBRANES, V1415, P369, DOI 10.1016/S0005-2736(98)00233-8; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Hagmann W, 1999, EUR J BIOCHEM, V265, P281, DOI 10.1046/j.1432-1327.1999.00735.x; Heijn M, 1997, BBA-BIOMEMBRANES, V1326, P12, DOI 10.1016/S0005-2736(97)00003-5; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hooijberg JH, 1999, CANCER RES, V59, P2532; Ito K, 2001, MOL PHARMACOL, V59, P1077, DOI 10.1124/mol.59.5.1077; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Ito K, 1997, AM J PHYSIOL-GASTR L, V272, pG16, DOI 10.1152/ajpgi.1997.272.1.G16; Ito S, 2001, PHARMACOGENETICS, V11, P175, DOI 10.1097/00008571-200103000-00008; Jedlitschky G, 1996, CANCER RES, V56, P988; Kamisako T, 1999, HEPATOLOGY, V30, P485, DOI 10.1002/hep.510300220; Keitel V, 2000, HEPATOLOGY, V32, P1317, DOI 10.1053/jhep.2000.19791; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Koike K, 1997, CANCER RES, V57, P5475; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kusuhara H, 1998, AM J PHYSIOL-GASTR L, V275, pG789, DOI 10.1152/ajpgi.1998.275.4.G789; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; LESLIE EM, 2001, IN PRESS TAXICOLOGY; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; Mao QC, 1999, BBA-BIOMEMBRANES, V1461, P69, DOI 10.1016/S0005-2736(99)00150-9; Masuda M, 1997, CANCER RES, V57, P3506; Moreau C, 2000, EMBO J, V19, P6644, DOI 10.1093/emboj/19.24.6644; Mottino AD, 2000, J PHARMACOL EXP THER, V293, P717; Muller M, 1998, J HEPATOL, V28, P344, DOI 10.1016/0168-8278(88)80024-2; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Renes J, 2000, BIOCHEM J, V350, P555, DOI 10.1042/0264-6021:3500555; Roelofsen H, 1997, GASTROENTEROLOGY, V112, P511, DOI 10.1053/gast.1997.v112.pm9024305; Ryu S, 2000, J BIOL CHEM, V275, P39617, DOI 10.1074/jbc.M005149200; Schaub TP, 1997, J AM SOC NEPHROL, V8, P1213; Scheffer GL, 2000, CANCER RES, V60, P5269; Suzuki H, 2000, EUR J PHARM SCI, V12, P3, DOI 10.1016/S0928-0987(00)00178-0; Suzuki H, 1998, SEMIN LIVER DIS, V18, P359, DOI 10.1055/s-2007-1007170; Taniguchi K, 1996, CANCER RES, V56, P4124; Toh S, 1999, AM J HUM GENET, V64, P739, DOI 10.1086/302292; Uchiumi T, 1998, BIOCHEM BIOPH RES CO, V252, P103, DOI 10.1006/bbrc.1998.9546; Uhde I, 1999, J BIOL CHEM, V274, P28079, DOI 10.1074/jbc.274.40.28079; van Aubel RAMH, 1998, MOL PHARMACOL, V53, P1062; vanKuijck MA, 1996, P NATL ACAD SCI USA, V93, P5401, DOI 10.1073/pnas.93.11.5401; Wada M, 1998, HUM MOL GENET, V7, P203, DOI 10.1093/hmg/7.2.203; Zeng H, 1999, CANCER RES, V59, P5964; Zeng H, 2000, CANCER RES, V60, P4779; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	73	107	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38108	38114						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11500505				2022-12-25	WOS:000171526500053
J	Johnson, AA; Johnson, KA				Johnson, AA; Johnson, KA			Fidelity of nucleotide incorporation by human mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; DROSOPHILA-MELANOGASTER; REPLICATION FIDELITY; PURIFICATION; PROCESSIVITY; MECHANISM; SEQUENCES; SUBUNIT; EMBRYOS; GAMMA	We have examined the fidelity of polymerization catalyzed by the human mitochondrial DNA polymerase using wild-type and exonuclease-deficient (E200A mutation) forms of recombinant, reconstituted holoenzyme. Each of the four nucleotides bind and incorporate with similar kinetics; the average dissociation constant for ground state binding is 0.8 mum, and the average rate of polymerization is 37 s(-1), defining a specificity constant k(cat)/K-m = 4.6 x 10(7) m(-1) s(-1). Mismatched nucleotides show weaker ground-state nucleotide binding affinities ranging from 57 to 364 mum and slower rates of polymerization ranging from 0.013 to 1.16 s(-1). The kinetic parameters yield fidelity estimates of I error out of 260,000 nucleotides for a T:T mismatch, 3563 for G:T, and 570,000 for C:T. The accessory subunit increases fidelity 14-fold by facilitating both ground-state binding and the incorporation rate of the correct A:T base pair compared with a T:T mismatch. Correctly base-paired DNA dissociates from the polymerase at a rate of 0.02 s(-1) promoting processive polymerization. Thus, the mitochondrial DNA polymerase catalyzed incorporation with an average processivity of 1850, defined by the ratio of polymerization rate to the dissociation rate (37/0.02) and with an average fidelity of one error in 280,000 base pairs.	Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Johnson, KA (corresponding author), Univ Texas, Inst Mol & Cellular Biol, MBB 3-122 A4800, Austin, TX 78712 USA.	kajohnson@mail.utexas.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44613] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Carrodeguas JA, 2000, NUCLEIC ACIDS RES, V28, P1237, DOI 10.1093/nar/28.5.1237; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; Graf WD, 2000, J CHILD NEUROL, V15, P357, DOI 10.1177/088307380001500601; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38097; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1992, PHILOS T ROY SOC B, V336, P107, DOI 10.1098/rstb.1992.0050; KAGUNI LS, 1989, P NATL ACAD SCI USA, V86, P6469, DOI 10.1073/pnas.86.17.6469; KATI WM, 1992, J BIOL CHEM, V267, P25988; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200; Marin-Garcia J, 2000, PEDIATR NEUROL, V22, P122, DOI 10.1016/S0887-8994(99)00117-4; MOSBAUGH DW, 1988, NUCLEIC ACIDS RES, V16, P5645, DOI 10.1093/nar/16.12.5645; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Pesole G, 1999, J MOL EVOL, V48, P427, DOI 10.1007/PL00006487; Santorelli FM, 1996, AM J HUM GENET, V58, P933; Vanderstraeten S, 1998, J BIOL CHEM, V273, P23690, DOI 10.1074/jbc.273.37.23690; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	30	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38090	38096						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11477093				2022-12-25	WOS:000171526500051
J	Kruhlak, MJ; Hendzel, MJ; Fischle, W; Bertos, NR; Hameed, S; Yang, XJ; Verdin, E; Bazett-Jones, DP				Kruhlak, MJ; Hendzel, MJ; Fischle, W; Bertos, NR; Hameed, S; Yang, XJ; Verdin, E; Bazett-Jones, DP			Regulation of global acetylation in mitosis through loss of histone acetyltransferases and deacetylases from chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONALLY ACTIVE CHROMATIN; MITOTIC CHROMOSOME CONDENSATION; INACTIVE X-CHROMOSOME; GENE-EXPRESSION; CELL-CYCLE; IN-VITRO; DNA-BINDING; NUCLEOSOME STRUCTURE; DEPENDENT KINASES	Histone acetylation, a reversible modification of the core histones, is widely accepted to be involved in remodeling chromatin organization for genetic reprogramming. Histone acetylation is a dynamic process that is regulated by two classes of enzymes, the histone acetyltransferases (HATs) and histone deacetylases (HDACs). Although promoter-specific acetylation and deacetylation has received most of the recent attention, it is superimposed upon a broader acting and dynamic acetylation that profoundly affects many nuclear processes. In this study, we monitored this broader histone acetylation as cells enter and exit mitosis. In contrast to the hypothesis that RATs and HDACs remain bound to mitotic chromosomes to provide an epigenetic imprint for postmitotic reactivation of the genome, we observed that RATs and HDACs are spatially reorganized and displaced from condensing chromosomes as cells progress through mitosis. During mitosis, HATs and HDACs are unable to acetylate or deacetylate chromatin in situ despite remaining fully catalytically active when isolated from mitotic cells and assayed in vitro. Our results demonstrate that HATs and HDACs do not stably bind to the genome to function as an epigenetic mechanism of selective postmitotic gene activation. Our results, however, do support a role for spatial organization of these enzymes within the cell nucleus and their relationship to euchromatin and heterochromatin postmitotically in the reactivation of the genome.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94103 USA; McGill Univ, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of California System; University of California San Francisco; The J David Gladstone Institutes; McGill University	Bazett-Jones, DP (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Hendzel, Michael/C-3391-2009; Verdin, Eric/AAB-7999-2019	Hendzel, Michael/0000-0002-9603-7945; Verdin, Eric/0000-0003-3703-3183				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ALMOUZNI G, 1994, DEV BIOL, V165, P654, DOI 10.1006/dbio.1994.1283; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; Berger SL, 2000, NATURE, V408, P412, DOI 10.1038/35044160; BOFFA LC, 1990, EUR J BIOCHEM, V194, P811, DOI 10.1111/j.1432-1033.1990.tb19474.x; Boggs BA, 1996, CHROMOSOMA, V105, P303, DOI 10.1007/BF02524648; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Ferreira J, 1997, J CELL BIOL, V139, P1597, DOI 10.1083/jcb.139.7.1597; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; Grande MA, 1997, J CELL SCI, V110, P1781; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hendzel MJ, 1996, J MICROSC-OXFORD, V182, P1, DOI 10.1046/j.1365-2818.1996.123403.x; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; HONG L, 1993, J BIOL CHEM, V268, P305; HORIUCHI K, 1975, ANAL BIOCHEM, V69, P491, DOI 10.1016/0003-2697(75)90151-7; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Jeppesen P, 1997, BIOESSAYS, V19, P67, DOI 10.1002/bies.950190111; JEPPESEN P, 1992, CHROMOSOMA, V101, P322, DOI 10.1007/BF00346011; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Leresche A, 1996, EXP CELL RES, V229, P282, DOI 10.1006/excr.1996.0373; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PANTAZIS P, 1982, J CELL BIOCHEM, V20, P225, DOI 10.1002/jcb.240200303; Parsons GG, 1997, MOL CELL BIOL, V17, P5791, DOI 10.1128/MCB.17.10.5791; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; Roussel P, 1996, J CELL BIOL, V133, P235, DOI 10.1083/jcb.133.2.235; Sadoni N, 1999, J CELL BIOL, V146, P1211, DOI 10.1083/jcb.146.6.1211; Schmiesing JA, 2000, MOL CELL BIOL, V20, P6996, DOI 10.1128/MCB.20.18.6996-7006.2000; Schwarz PM, 1996, BIOCHEMISTRY-US, V35, P4009, DOI 10.1021/bi9525684; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; Sheridan PL, 1997, GENE DEV, V11, P3327, DOI 10.1101/gad.11.24.3327; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TURNER BM, 1989, EXP CELL RES, V182, P206, DOI 10.1016/0014-4827(89)90292-9; TURNER BM, 1991, J CELL SCI, V99, P13; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; WADE PA, 1997, CURR BIOL, V7, P82; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	85	175	179	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38307	38319						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11479283				2022-12-25	WOS:000171526500079
J	Masuda, CA; Xavier, MA; Mattos, KA; Galina, A; Montero-Lomeli, M				Masuda, CA; Xavier, MA; Mattos, KA; Galina, A; Montero-Lomeli, M			Phosphoglucomutase is an in vivo lithium target in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; GLUCOSE REPRESSION; ION HOMEOSTASIS; XENOPUS EMBRYOS; SALT TOLERANCE; BOVINE BRAIN; UDP-GLUCOSE; GENE	Lithium is a drug frequently used in the treatment of manic depressive disorder. We have observed that the yeast Saccharomyces cerevisiae is very sensitive to lithium when growing in galactose medium. In this work we show that lithium inhibits with high affinity yeast (IC50 similar to 0.2 mm) and human (IC50 similar to 1.5 mm) phosphoglucomutase, the enzyme that catalyzes the reversible conversion of glucose 1-phosphate to glucose 6-phosphate. Lithium inhibits the rate of fermentation when yeast are grown in galactose and induces accumulation of glucose 1-phosphate and galactose 1-phosphate. Accumulation of these metabolites was also observed when a strain deleted of the two isoforms of phosphoglucomutase was incubated in galactose medium. In glucose-grown cells lithium reduces the steady state levels of UDP-glucose, resulting in a defect on trehalose and glycogen biosynthesis. Lithium acts as a competitive inhibitor of yeast phosphoglucomutase activity by competing with magnesium, a cofactor of the enzyme. High magnesium concentrations revert lithium inhibition of growth and phosphoglucomutase activity. Lithium stress causes an increase of the phosphoglucomutase activity due to an induction of transcription of the PGM2 gene, and its overexpression confers lithium tolerance in galactose medium. These results show that phosphoglucomutase is an important in vivo lithium target.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, RJ, Brazil; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Gliobiol, BR-21949900 Rio De Janeiro, RJ, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Montero-Lomeli, M (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, CP 68041, BR-21941590 Rio De Janeiro, RJ, Brazil.	montero@server.bioqmed.ufrj.br	Masuda, Claudio A/F-7214-2014; Galina, Antonio/A-9292-2008; Montero-Lomeli, Monica/D-9885-2013	Masuda, Claudio A/0000-0002-0310-7108; 				Alepuz PM, 1997, MOL MICROBIOL, V26, P91, DOI 10.1046/j.1365-2958.1997.5531917.x; BEHRENS NH, 1970, P NATL ACAD SCI USA, V66, P153, DOI 10.1073/pnas.66.1.153; BEHRENS NH, 1971, P NATL ACAD SCI USA, V68, P2857, DOI 10.1073/pnas.68.11.2857; Bergmeyer HU, 1986, METHODS ENZYMATIC AN; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BOLES E, 1994, EUR J BIOCHEM, V220, P83, DOI 10.1111/j.1432-1033.1994.tb18601.x; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; Daran JM, 1997, FEMS MICROBIOL LETT, V153, P89, DOI 10.1016/S0378-1097(97)00240-1; Dichtl B, 1997, EMBO J, V16, P7184, DOI 10.1093/emboj/16.23.7184; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; DOUGLAS HC, 1954, J BACTERIOL, V68, P662, DOI 10.1128/JB.68.6.662-670.1954; DOUGLAS HC, 1964, GENETICS, V49, P837; DOUGLAS HC, 1961, BIOCHIM BIOPHYS ACTA, V52, P209, DOI 10.1016/0006-3002(61)90924-6; ENTIAN KD, 1977, MOL GEN GENET, V156, P99, DOI 10.1007/BF00272258; FU LW, 1995, J BACTERIOL, V177, P3087, DOI 10.1128/jb.177.11.3087-3094.1995; GEE NS, 1988, BIOCHEM J, V249, P883, DOI 10.1042/bj2490883; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Gonzalez B, 1997, YEAST, V13, P1347, DOI 10.1002/(SICI)1097-0061(199711)13:14<1347::AID-YEA176>3.0.CO;2-O; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; INHORN RC, 1988, J BIOL CHEM, V263, P14559; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JERKADZIADOSZ M, 1995, DEV BIOL, V171, P497, DOI 10.1006/dbio.1995.1299; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; Jope RS, 1999, MOL PSYCHIATR, V4, P117, DOI 10.1038/sj.mp.4000494; KALCKAR HM, 1957, SCIENCE, V125, P105, DOI 10.1126/science.125.3238.105; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Koo SJ, 1996, PLANT PHYSIOL, V112, P1383, DOI 10.1104/pp.112.3.1383; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kosterlitz HW, 1943, BIOCHEM J, V37, P322, DOI 10.1042/bj0370322; LEHLE L, 1980, EUR J BIOCHEM, V109, P589, DOI 10.1111/j.1432-1033.1980.tb04832.x; LELOIR LF, 1951, ARCH BIOCHEM BIOPHYS, V33, P186, DOI 10.1016/0003-9861(51)90096-3; LIVINGSTON BT, 1989, P NATL ACAD SCI USA, V86, P3669, DOI 10.1073/pnas.86.10.3669; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANJI HK, 1995, ARCH GEN PSYCHIAT, V52, P531; MARCUS F, 1980, J BIOL CHEM, V255, P2481; Masuda CA, 2000, J BIOL CHEM, V275, P30957, DOI 10.1074/jbc.M004869200; MURGUIA JR, 1995, SCIENCE, V267, P232; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; NAKASHIMA K, 1976, J BIOL CHEM, V251, P4315; OH D, 1990, MOL CELL BIOL, V10, P1415, DOI 10.1128/MCB.10.4.1415; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; PARODI AJ, 1972, P NATL ACAD SCI USA, V69, P3268, DOI 10.1073/pnas.69.11.3268; PARODI AJ, 1977, EUR J BIOCHEM, V75, P171, DOI 10.1111/j.1432-1033.1977.tb11514.x; Parrou JL, 1997, ANAL BIOCHEM, V248, P186, DOI 10.1006/abio.1997.2138; Parthasarathy R, 1997, BRAIN RES, V778, P99, DOI 10.1016/S0006-8993(97)01042-1; PENG ZY, 1990, J BIOL CHEM, V265, P13871; PETERS DJM, 1989, J CELL SCI, V93, P205; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; POSAS F, 1991, FEBS LETT, V279, P341, DOI 10.1016/0014-5793(91)80183-4; Ramirez J, 1998, J BACTERIOL, V180, P5860; RAY WJ, 1978, BIOCHIM BIOPHYS ACTA, V522, P434, DOI 10.1016/0005-2744(78)90076-1; RHYU GI, 1984, BIOCHEMISTRY-US, V23, P252, DOI 10.1021/bi00297a013; ROBICHONSZULMAJSTER HD, 1958, SCIENCE, V127, P28, DOI 10.1126/science.127.3288.28; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Schou M, 1997, ARCH GEN PSYCHIAT, V54, P9; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; Spiegelberg BD, 1999, J BIOL CHEM, V274, P13619, DOI 10.1074/jbc.274.19.13619; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; TEHEESEN S, 1994, EUR J BIOCHEM, V224, P71, DOI 10.1111/j.1432-1033.1994.tb19996.x; Treger JM, 1998, J BIOL CHEM, V273, P26875, DOI 10.1074/jbc.273.41.26875; Williams RSB, 2000, TRENDS PHARMACOL SCI, V21, P61, DOI 10.1016/S0165-6147(99)01428-5; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yale J, 2001, J BIOL CHEM, V276, P15996, DOI 10.1074/jbc.M008209200; Yenush L, 2000, FEBS LETT, V467, P321, DOI 10.1016/S0014-5793(00)01183-2; YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149	74	67	68	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37794	37801						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11500487				2022-12-25	WOS:000171526500011
J	Schub, O; Rohaly, G; Smith, RWP; Schneider, A; Dehde, S; Dornreiter, IL; Nasheuer, HP				Schub, O; Rohaly, G; Smith, RWP; Schneider, A; Dehde, S; Dornreiter, IL; Nasheuer, HP			Multiple phosphorylation sites of DNA polymerase alpha-primase cooperate to regulate the initiation of DNA replication in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-DEPENDENT PHOSPHORYLATION; SPECIES-SPECIFIC REPLICATION; PROTEIN-KINASE; T-ANTIGEN; P48 CONTROL; SUBUNIT; POLYOMAVIRUS; INHIBITION; COMPLEX; REQUIRES	DNA polymerase a-primase (pol-prim) is the only enzyme that can start DNA replication de novo. The 180-kDa (p180) and 68-kDa (p68) subunits of the human four-subunit enzyme are phosphorylated by Cyclin-dependent kinases (Cdks) in a cell cycle-dependent manner. Cyclin A-Cdk2 physically interacts with pol-prim and phosphorylates N-terminal amino acids of the p180 and the p68 subunits, leading to an inhibition of polprim in initiating cell-free SV40 DNA replication. Mutation of conserved putative Cdk phosphorylation sites in the N terminus of human p180 and p68 reduced their phosphorylation by Cyclin A-Cdk2 in vitro. In contrast to wild-type pol-prim these mutants were no longer inhibited by Cyclin A-Cdk2 in the initiation of viral DNA replication. Importantly, rather than inhibiting it, Cyclin A-Cdk2 stimulated the initiation activity of pol-prim containing a triple N-terminal alanine mutant of the pI80 subunit. Together these results suggest that Cyclin A-Cdk2 executes both stimulatory and inhibitory effects on the activity of pol-prim in initiating DNA replication.	Inst Mol Biotechnol, Biochem Abt, D-07745 Jena, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Nasheuer, HP (corresponding author), Inst Mol Biotechnol, Biochem Abt, Beutenbergstr 11, D-07745 Jena, Germany.	nasheuer@imb-jena.de	Smith, Richard/J-8117-2019; Nasheuer, Heinz P./B-9025-2008	Smith, Richard/0000-0002-6475-6910; Nasheuer, Heinz Peter/0000-0002-9218-9079				Arezi B, 2000, TRENDS BIOCHEM SCI, V25, P572, DOI 10.1016/S0968-0004(00)01680-7; BRUCKNER A, 1995, MOL CELL BIOL, V15, P1716; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; Dehde S, 2001, MOL CELL BIOL, V21, P2581, DOI 10.1128/MCB.21.7.2581-2593.2001; Donaldson AD, 1999, CURR OPIN GENET DEV, V9, P62, DOI 10.1016/S0959-437X(99)80009-4; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Falaschi A, 2000, TRENDS GENET, V16, P88, DOI 10.1016/S0168-9525(99)01917-4; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fanning Ellen, 1994, Trends in Cell Biology, V4, P250, DOI 10.1016/0962-8924(94)90123-6; Ferrari M, 1996, J BIOL CHEM, V271, P8661, DOI 10.1074/jbc.271.15.8661; FOIANI M, 1995, MOL CELL BIOL, V15, P883; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; Herbig U, 2000, MOL BIOL CELL, V11, P4117, DOI 10.1091/mbc.11.12.4117; HIS K, 1990, NUCLEIC ACIDS RES, V18, P6231; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; Ishimi Y, 2001, J BIOL CHEM, V276, P34428, DOI 10.1074/jbc.M104480200; Johnston L H, 2000, Prog Cell Cycle Res, V4, P61; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; Kautz AR, 2001, J VIROL, V75, P1751, DOI 10.1128/JVI.75.4.1751-1760.2001; Kautz AR, 2001, J VIROL, V75, P8569, DOI 10.1128/JVI.75.18.8569-8578.2001; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Lee DG, 2000, CURR OPIN CELL BIOL, V12, P280, DOI 10.1016/S0955-0674(00)00089-2; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mizuno T, 1998, MOL CELL BIOL, V18, P3552, DOI 10.1128/MCB.18.6.3552; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; NASMYTH K, 1996, REPLICATION EUKARYOT, P331; Nesper J, 1997, J VIROL, V71, P7421, DOI 10.1128/JVI.71.10.7421-7428.1997; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Pereverzeva I, 2000, MOL CELL BIOL, V20, P3667, DOI 10.1128/MCB.20.10.3667-3676.2000; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; REHFUESS C, 1998, FUNKTION P 68 UNTERE; Smith RWP, 2000, REC RES DEV VIROL, V2, P67; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Stadlbauer F, 1996, MOL CELL BIOL, V16, P94; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; SU TT, 1995, CELL, V81, P825, DOI 10.1016/0092-8674(95)90000-4; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; TANAKA S, 1982, J BIOL CHEM, V257, P8386; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; Voitenleitner C, 1997, ONCOGENE, V14, P1611, DOI 10.1038/sj.onc.1200975; Voitenleitner C, 1999, MOL CELL BIOL, V19, P646; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WANG TSF, 1996, DNA REPLICATION EUKA, P461; Weisshart K, 2000, J BIOL CHEM, V275, P17328, DOI 10.1074/jbc.M000717200; WEISSHART K, 1996, DNA REPLICATION EUKA, P295; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309	68	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38076	38083						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11502743				2022-12-25	WOS:000171526500049
J	Tapper, AR; George, AL				Tapper, AR; George, AL			Location and orientation of minK within the I-Ks potassium channel complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; CARDIAC-ARRHYTHMIA; KVLQT1; GENE; MUTATIONS; PORE; CONDUCTION; K(V)LQT1; PROTEINS; EPILEPSY	The slowly activating cardiac potassium current (I-Ks) is generated by a heteromultimeric potassium channel complex consisting of pore-forming (KvLQT1) and accessory (minK) subunits belonging to the KCNQ and KCNE gene families, respectively. Evidence indicating that minK residues line the I-Ks. pore originates from the observation that two minK cysteine mutants (G55C and F54C) render I-Ks Cd2+-sensitive. We have identified a single cysteine residue in the KvLQT1 S6 segment (Cys-331) that contributes to Cd2+ coordination in conjunction with cysteine residues engineered into the minK transmembrane domain. This observation indicates that minK resides in close proximity to S6 in the I-Ks channel complex. On the basis of homology modeling that compares the KvLQT1 S6 segment with the structure of the bacterial potassium channel KcsA, we predict that the sulfhydryl side chain of Cys-331 projects away from the central axis of the KvLQT1 pore and suggest that minK resides outside of the permeation pathway. A preliminary model illustrating the orientation of minK with S6 was validated by successful prediction of a novel Cd2+ binding site created within the I-Ks channel complex by engineering additional cysteine residues into both subunits. Our results indicate the location and orientation of minK within the I-Ks channel complex and further suggest that Cd2+ exerts its effect on I-Ks through an allosteric mechanism rather than direct pore blockade.	Vanderbilt Univ, Sch Med, Div Med Genet, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Med Genet, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	George, AL (corresponding author), Vanderbilt Univ, Sch Med, Div Med Genet, Dept Pharmacol, 451 Preston Res Bldg, Nashville, TN 37232 USA.	al.george@vanderbilt.edu			NHLBI NIH HHS [HL46681] Funding Source: Medline; NIGMS NIH HHS [GM07628] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046681] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Kurokawa J, 2001, J GEN PHYSIOL, V117, P43, DOI 10.1085/jgp.117.1.43; Lippard S. J., 1994, PRINCIPLES BIOINORGA; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Romey G, 1997, J BIOL CHEM, V272, P16713, DOI 10.1074/jbc.272.27.16713; Rulisek L, 1998, J INORG BIOCHEM, V71, P115, DOI 10.1016/S0162-0134(98)10042-9; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Schwartz PJ, 2001, CIRCULATION, V103, P89; Schwartz PJ, 1997, CURR PROB CARDIOLOGY, V22, P302, DOI 10.1016/S0146-2806(97)80009-6; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Tai KK, 1998, NATURE, V391, P605, DOI 10.1038/35416; Tapper AR, 2000, J GEN PHYSIOL, V116, P379, DOI 10.1085/jgp.116.3.379; Vincent GM, 1998, ANNU REV MED, V49, P263; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	26	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38249	38254						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11479291				2022-12-25	WOS:000171526500072
J	Trask, BC; Malone, MJ; Lum, EH; Welgus, HG; Crouch, EC; Shapiro, SD				Trask, BC; Malone, MJ; Lum, EH; Welgus, HG; Crouch, EC; Shapiro, SD			Induction of macrophage matrix metalloproteinase biosynthesis by surfactant protein D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE PERITONEAL-MACROPHAGES; HUMAN MONONUCLEAR PHAGOCYTES; HUMAN ALVEOLAR MACROPHAGES; HUMAN-SKIN COLLAGENASE; LYMPHOCYTE-PROLIFERATION; TISSUE INHIBITOR; INNATE IMMUNITY; LUNG COLLECTINS; D BINDING; II CELLS	Recent studies strongly suggest that surfactant protein D (SP-D) plays important roles in pulmonary host defense and the regulation of immune and inflammatory reactions in the lung. Although SP-D can bind to alveolar macrophages and can elicit their chemotaxis, relatively little is known about the direct cellular consequences of SP-D on the function of these cells. Because matrix metalloproteinases (MMPs) are synthesized in increased amounts in response to various proinflammatory stimuli, we investigated the capacity of SP-D to modulate the production of MMPs by freshly isolated human alveolar macrophages. Unexpectedly we found that recombinant rat SP-D dodecamers selectively induce the biosynthesis of collagenase-1 (MMP-1), stromelysin (MMP-3), and macrophage elastase (MMP-12) without significantly increasing the production of tumor necrosis factor alpha and interleukin-1 beta. SP-D did not alter the production of these MMPs by fibroblasts. Phosphatidylinositol, a surfactant-associated ligand that interacts with the carboxyl-terminal neck and carbohydrate recognition domains of SP-D, inhibited the SP-D-dependent increase in MMP biosynthesis. A trimeric, recombinant protein consisting of only the neck and carbohydrate recognition domain did not augment metalloproteinase production, suggesting that the stimulatory effect on MMP production depends on an appropriate spatial presentation of trimeric lectin domains. Although SP-D dodecamers can selectively augment metalloproteinase activity in vitro, this effect may be competitively inhibited by tissue inhibitors of metalloproteinases or surfactant-associated ligands in vivo.	Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Pathol & Immunol, St Louis, MO 63110 USA; Pfizer Global Dev, Ann Arbor, MI 48105 USA	St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Pfizer	Shapiro, SD (corresponding author), Washington Univ, Sch Med, Dept Pediat, Campus Box 8208,660 S Euclid Ave, St Louis, MO 63110 USA.	shapiros@kids.wustl.edu			NHLBI NIH HHS [HL-44015, T32-HL07873, P01-HL29594] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, R01HL044015, T32HL007873] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belaaouaj AA, 2000, SCIENCE, V289, P1185, DOI 10.1126/science.289.5482.1185; Borron PJ, 1998, J IMMUNOL, V161, P4599; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Cai GZ, 1999, AM J PHYSIOL-LUNG C, V276, pL131, DOI 10.1152/ajplung.1999.276.1.L131; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; COOPER TW, 1983, COLLAGEN REL RES, V3, P205; CROUCH E, 1992, AM J PHYSIOL, V263, pL60, DOI 10.1152/ajplung.1992.263.1.L60; CROUCH E, 1994, J BIOL CHEM, V269, P15808; Crouch E, 2000, IMMUNOL REV, V173, P52, DOI 10.1034/j.1600-065X.2000.917311.x; Crouch E C, 2000, Respir Res, V1, P93; CROUCH EC, 1995, AM J RESP CELL MOL, V12, P410, DOI 10.1165/ajrcmb.12.4.7695920; CURY JD, 1988, J IMMUNOL, V141, P4306; Dong Q, 1998, AM J PHYSIOL-LUNG C, V274, pL97, DOI 10.1152/ajplung.1998.274.1.L97; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hartshorn KL, 2000, BIOCHEM J, V351, P449, DOI 10.1042/0264-6021:3510449; Hartzell W, 1999, CHEST, V116, p31S, DOI 10.1378/chest.116.suppl_1.31S-a; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; HAWGOOD S, 2000, AM J RESP CRIT CARE, V161, pA514; Hempel SL, 1996, AM J RESP CELL MOL, V14, P170, DOI 10.1165/ajrcmb.14.2.8630267; Hickling TP, 1999, EUR J IMMUNOL, V29, P3478, DOI 10.1002/(SICI)1521-4141(199911)29:11<3478::AID-IMMU3478>3.0.CO;2-W; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; Holmskov U, 1999, P NATL ACAD SCI USA, V96, P10794, DOI 10.1073/pnas.96.19.10794; Holmskov UL, 2000, APMIS, V108, P7; Kawane T, 1999, BBA-GEN SUBJECTS, V1427, P155, DOI 10.1016/S0304-4165(99)00018-5; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUAN SF, 1994, AM J RESP CELL MOL, V10, P430, DOI 10.1165/ajrcmb.10.4.8136158; Kumar R, 1996, J IMMUNOL, V157, P5104; Lawson PR, 2000, IMMUNOL REV, V173, P66, DOI 10.1034/j.1600-065X.2000.917308.x; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MIYAMURA K, 1994, BIOCHEM J, V300, P237, DOI 10.1042/bj3000237; Ofek I, 2001, INFECT IMMUN, V69, P24, DOI 10.1128/IAI.69.1.24-33.2001; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; Ohashi K, 2000, CANCER-AM CANCER SOC, V88, P2201, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2201::AID-CNCR2>3.3.CO;2-E; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; Pierce RA, 1996, J CLIN INVEST, V97, P1890, DOI 10.1172/JCI118620; PIERCE RA, 1992, J BIOL CHEM, V267, P11593; Prakobphol A, 2000, J BIOL CHEM, V275, P39860, DOI 10.1074/jbc.M006928200; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; Saitoh M, 2000, BIOCHEMISTRY-US, V39, P1059, DOI 10.1021/bi9917939; SALVEMINI D, 1992, P NATL ACAD SCI USA, V89, P982, DOI 10.1073/pnas.89.3.982; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; Senior R. M., 1981, METHODS STUDYING MON, P69; SHAPIRO SD, 1991, J IMMUNOL, V146, P2724; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, pS160, DOI 10.1164/ajrccm/150.6_Pt_2.S160; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; Tino MJ, 1999, AM J PHYSIOL-LUNG C, V276, pL164, DOI 10.1152/ajplung.1999.276.1.L164; VANIWAARDEN JF, 1992, BIOCHEM J, V286, P5, DOI 10.1042/bj2860005; VUKPAVLOVIC A, 1996, AM J RESP CELL MOL B, V15, pA108; Wang JY, 1998, AM J RESP CRIT CARE, V158, P510, DOI 10.1164/ajrccm.158.2.9709111; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Wright JR, 1999, AM J PHYSIOL-LUNG C, V276, pL650, DOI 10.1152/ajplung.1999.276.4.L650; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931	60	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37846	37852						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11481321				2022-12-25	WOS:000171526500019
J	Vadlamudi, RK; Wang, RA; Mazumdar, A; Kim, Y; Shin, J; Sahin, A; Kumar, R				Vadlamudi, RK; Wang, RA; Mazumdar, A; Kim, Y; Shin, J; Sahin, A; Kumar, R			Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; NUCLEAR; COACTIVATOR; DOMAINS; BREAST; REORGANIZATION; COREPRESSORS; REPRESSION; DISTINCT; BINDING	Nuclear hormone receptors (NRs) are transcription factors whose activity is regulated by ligands and by coactivators or corepressors. We report the characterization of a new NR coregulator: proline-, glutamic acid-, leucine-rich protein 1 (PELP1), a novel human protein that comprises 1,282 amino acids and is localized on chromosome 17. The primary structure of PELP1 consists of several motifs present in most transcriptional regulators including nine NR-interacting boxes (LXXLL motifs), a zinc finger, and glutamic acid- and proline-rich regions. We demonstrate that PELP1 is a coactivator of estrogen receptor alpha (ER alpha). PELP1 enhances 17 beta -estradiol-dependent transcriptional activation from the estrogen response element in a dose-dependent manner. PELP1 interacts with ER alpha and also with general transcriptional coactivators p300 and cAMP response element-binding protein-binding protein. PELP1 was differentially expressed in various human and murine tissues with the highest expression levels in the testes, mammary glands, and brain. We also provide evidence supporting the developmental regulation of PELP1 expression in murine mammary glands, the detectable expression of PELP1 in human mammary cancer cell lines, and the enhanced expression of PELP1 in human breast tumors. These findings suggest that PELP1 is a novel coregulator of ER alpha and may have a role in breast cancer tumorigenesis.	Univ Texas, MD Anderson Canc Ctr 108, Dept Cellular & Mol Oncol, Houston, TX 77030 USA; Samsung Biomed Res Inst, Suwon 440746, South Korea; Sungkyunkwan Univ, Sch Med, Suwon 440746, South Korea; Sungkyunkwan Univ, Samsung Biomed Res Inst, Suwon 440746, South Korea	University of Texas System; UTMD Anderson Cancer Center; Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU)	Vadlamudi, RK (corresponding author), Univ Texas, MD Anderson Canc Ctr 108, Dept Cellular & Mol Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rvadlamu@mdanderson.org; rkumar@mdanderson.org	Wang, Brian/HGA-9535-2022		NATIONAL CANCER INSTITUTE [P30CA016672, R01CA084456] Funding Source: NIH RePORTER; NCI NIH HHS [CA80066, CA84456, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; DUBIK D, 1988, J BIOL CHEM, V263, P12705; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Glass CK, 2000, GENE DEV, V14, P121; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Ma H, 1999, MOL CELL BIOL, V19, P6164; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wang RA, 1998, BIOL REPROD, V58, P1250, DOI 10.1095/biolreprod58.5.1250; Warner M, 1999, CURR OPIN OBSTET GYN, V11, P249, DOI 10.1097/00001703-199906000-00003; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhang H, 2000, J BIOL CHEM, V275, P39855, DOI 10.1074/jbc.C000567200	38	152	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38272	38279						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11481323				2022-12-25	WOS:000171526500075
J	Anderson, DE; Trujillo, KM; Sung, P; Erickson, HP				Anderson, DE; Trujillo, KM; Sung, P; Erickson, HP			Structure of the Rad50-Mre11 DNA repair complex from Saccharomyces cerevisiae by electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; ESCHERICHIA-COLI; CHROMOSOMES SMC; PROTEIN; MRE11; MAINTENANCE; RAD50; RECOMBINATION; BINDING; YEAST	The RAD50 gene of Saccharomyces cerevisiae is one of several genes required for recombinational repair of double-strand DNA breaks during vegetative growth and for initiation of meiotic recombination. Rad50 forms a complex with two other proteins, Mre11 and Xrs2, and this complex is involved in double-strand break formation and processing. Rad50 has limited sequence homology to the structural maintenance of chromosomes (SMC) family of proteins and shares the same domain structure as SMCs: N- and C-terminal globular domains separated by two long coiled-coils. However, a notable difference is the much smaller non-coil hinge region between the two coiled-coils. We report here a structural analysis of full-length S. cerevisiae Rad50, alone and in a complex with yeast Mre11 by electron microscopy. Our results confirm that yeast Rad50 does have the same antiparallel coiled-coil structure as SMC proteins, but with no detectable globular hinge domain. However, the molecule is still able to bend sharply in the middle to bring the two catalytic domains together, indicating that the small hinge domain is flexible. We also demonstrate that Mre11 binds as a dimer between the catalytic domains of Rad50, bringing the nuclease activities of Mre11 in close proximity to the ATPase and DNA binding activities of Rad50.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA	Duke University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.			Anderson, David/0000-0001-9334-6438	NCI NIH HHS [CA81020] Funding Source: Medline; NIEHS NIH HHS [ES07061] Funding Source: Medline; NIGMS NIH HHS [GM28553, GM57814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA081020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028553] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhmedov AT, 1999, J BIOL CHEM, V274, P38216, DOI 10.1074/jbc.274.53.38216; Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; Connelly JC, 1997, J BIOL CHEM, V272, P19819, DOI 10.1074/jbc.272.32.19819; Connelly JC, 1998, P NATL ACAD SCI USA, V95, P7969, DOI 10.1073/pnas.95.14.7969; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; ERICKSON HP, 1995, EXTRACELLULAR MATRIX, P187; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hopfner KP, 2000, J BACTERIOL, V182, P6036, DOI 10.1128/JB.182.21.6036-6041.2000; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; JOHZUKA K, 1995, GENETICS, V139, P1521; Lowe J, 2001, J MOL BIOL, V306, P25, DOI 10.1006/jmbi.2000.4379; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Saleh AZM, 1996, FEMS MICROBIOL LETT, V143, P211, DOI 10.1016/0378-1097(96)00314-X; Schurmann G, 2001, MOL BIOL CELL, V12, P1765, DOI 10.1091/mbc.12.6.1765; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tanford C., 1961, PHYS CHEM MACROMOLEC; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619	33	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37027	37033		10.1074/jbc.M106179200	http://dx.doi.org/10.1074/jbc.M106179200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11470800	hybrid			2022-12-25	WOS:000171375700024
J	Di, AK; Krupa, B; Nelson, DJ				Di, AK; Krupa, B; Nelson, DJ			Calcium-G protein interactions in the regulation of macrophage secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR MEDIATED PHAGOCYTOSIS; MAST-CELLS; FOCAL EXOCYTOSIS; CYTOSOLIC CA-2+; CA2+; GTP; DEGRANULATION; LOCALIZATION; ENDOCYTOSIS; ATTACHMENT	The interplay between activated G proteins and intracellular calcium ([Ca2+](i)) in the regulation of secretion was studied in the macrophage, coupling membrane capacitance with calcium-sensitive microfluorimetry. Intracellular elevation of either the nonhydrolyzable analogue of GTP, guanosine-5'-O-(3-thiotriphosphate) (GTP gammaS), or [Ca2+](i) enhanced the amplitude and shortened the time course of stimulus-induced secretion in a dose-dependent manner. Both the ionophore- and the stimulus-induced secretory response were abolished in the presence of guanosine-5'-O-(2-thiodiphosphate) (GDP betaS). The K-d of Ca2+-driven secretion was independent of GTP gammaS concentration, whereas the K-d of the GTP gammaS-driven response decreased from 63 to 31 muM in the presence of saturating concentrations of [Ca2+](i). The time course of stimulus-induced secretion was dependent upon the concentration of [Ca2+](i). The time course of GTP gammaS-driven secretion was concentration-independent at high levels of [Ca2+](i), suggesting that a calcium-dependent translocation/binding step was rate-limiting. Our data strongly support a model in which [Ca2+](i) and activated G proteins act independently of one another in the sequential regulation of macrophage secretion. [Ca2+](i) appears to play a role in the recruitment and priming of vesicles from reserve intracellular pools at a step that is upstream of G protein activation. While activated, G proteins appear to play a key role in fusion of docked vesicles. Thus, secretion can result either from activating more G proteins or from elevating [Ca2+](i) at basal levels of G protein activation.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago	Nelson, DJ (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St,MC 0926, Chicago, IL 60637 USA.	dnelson@drugs.bsd.uchicago.edu			NIGMS NIH HHS [R01 GM36823] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036823] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERNANDEZ JM, 1984, J PHYSIOL-LONDON, V356, P565, DOI 10.1113/jphysiol.1984.sp015483; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; Gillis KD, 2000, PFLUG ARCH EUR J PHY, V439, P655, DOI 10.1007/s004240050990; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; GRIFFIN FM, 1975, J EXP MED, V142, P1263, DOI 10.1084/jem.142.5.1263; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Hackam DJ, 1998, P NATL ACAD SCI USA, V95, P11691, DOI 10.1073/pnas.95.20.11691; Hackam DJ, 1996, J IMMUNOL, V156, P4377; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heymann D, 2001, HISTOL HISTOPATHOL, V16, P37, DOI 10.14670/HH-16.37; HISHIKAWA T, 1991, J CELL BIOL, V115, P59, DOI 10.1083/jcb.115.1.59; Holevinsky KO, 1998, BIOPHYS J, V75, P2577, DOI 10.1016/S0006-3495(98)77703-3; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; ILLINGER D, 1991, BIOL CELL, V73, P131, DOI 10.1016/0248-4900(91)90095-5; KATNIK C, 1993, J MEMBRANE BIOL, V134, P213; LEW DP, 1985, NATURE, V315, P509, DOI 10.1038/315509a0; LINDAU M, 1986, NATURE, V319, P150, DOI 10.1038/319150a0; Mariot P, 1996, EMBO J, V15, P6476, DOI 10.1002/j.1460-2075.1996.tb01038.x; MCNEIL PL, 1986, J CELL BIOL, V102, P1586, DOI 10.1083/jcb.102.5.1586; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; NELSON DJ, 1985, J CLIN INVEST, V76, P500, DOI 10.1172/JCI111999; NUSSE O, 1988, J CELL BIOL, V107, P2117, DOI 10.1083/jcb.107.6.2117; NUSSE O, 1990, BIOSCIENCE REP, V10, P93, DOI 10.1007/BF01116857; PARSONS TD, 1994, NEURON, V13, P875, DOI 10.1016/0896-6273(94)90253-4; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Pinxteren JA, 1998, EMBO J, V17, P6210, DOI 10.1093/emboj/17.21.6210; Pinxteren JA, 2000, BIOCHIMIE, V82, P385, DOI 10.1016/S0300-9084(00)00197-8; SAWYER DW, 1985, SCIENCE, V230, P663, DOI 10.1126/science.4048951; SCEPEK S, 1993, EMBO J, V12, P1811, DOI 10.1002/j.1460-2075.1993.tb05829.x; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; Stewart BA, 2000, P NATL ACAD SCI USA, V97, P13955, DOI 10.1073/pnas.250491397; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; YOUNG JDE, 1984, P NATL ACAD SCI-BIOL, V81, P5430, DOI 10.1073/pnas.81.17.5430; ZIMMERBERG J, 1987, P NATL ACAD SCI USA, V84, P1585, DOI 10.1073/pnas.84.6.1585	45	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37124	37132		10.1074/jbc.M105038200	http://dx.doi.org/10.1074/jbc.M105038200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479305	hybrid			2022-12-25	WOS:000171375700036
J	Takahashi, K; Taira, T; Niki, T; Seino, C; Iguchi-Ariga, SMM; Ariga, H				Takahashi, K; Taira, T; Niki, T; Seino, C; Iguchi-Ariga, SMM; Ariga, H			DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTRACEPTION-ASSOCIATED PROTEIN-1; CARBOXYL-TERMINAL REGIONS; NUCLEAR RECEPTOR; HUMAN PROSTATE; SPERM PROTEIN; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; LIGAND-BINDING; C-MYC	DJ-1 was first identified as a novel candidate of the oncogene product that transformed mouse NIH3T3 cells in cooperation with an activated ras. Later DJ-1 was also found to be an infertility-related protein that was reduced in rat sperm treated with sperm toxicants that cause infertility in rats. To determine the functions of DJ-1, cDNAs encoding DJ-1-binding proteins were screened by the yeast two-hybrid method. Of several proteins identified, PIASx alpha /ARIP3, a modulator of androgen receptor (AR), was first characterized as the DJ-1-binding protein in this study. DJ-1 directly bound to the AR-binding region of PIASx alpha by an in vitro coimmunoprecipitation assay and also bound to PIASxa in human 293T cells. Both proteins were co-localized. in the nuclei. PIASx alpha inhibited the AR transcription activity in a dose-dependent manner in cotransfected monkey CV1 cells with an androgen responsive element-luciferase reporter. Introduction of DJ-I into CV1 cells in a state of inhibition of AR activity by PIASx alpha restored AR transcription activity by absorbing PIASx alpha from the AR-PIASx alpha complex, while a DJ-1 mutant harboring an amino acid substitution at number 130 from lysine to arginine did not restore it. These results indicate that DJ-1 is a positive regulator of the androgen receptor.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Hokkaido Univ, Coll Med Technol, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University; Japan Science & Technology Agency (JST); Hokkaido University	Ariga, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	hiro@pharm.hokudai.ac.jp	Ariga, Sanae/H-9647-2013; Ariga, Hiroyoshi/B-5895-2013	Ariga, Hiroyoshi/0000-0001-7384-2143				BROWN TR, 1995, J ANDROL, V16, P299; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Glass CK, 2000, GENE DEV, V14, P121; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Klinefelter GR, 1997, J ANDROL, V18, P139; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MATHER JP, 1980, BIOL REPROD, V23, P243, DOI 10.1095/biolreprod23.1.243; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; MCPHAUL MJ, 1993, J CLIN ENDOCR METAB, V76, P17, DOI 10.1210/jc.76.1.17; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Taira T, 1999, J BIOL CHEM, V274, P24270, DOI 10.1074/jbc.274.34.24270; TAIRA T, 1992, BIOCHIM BIOPHYS ACTA, V1130, P166, DOI 10.1016/0167-4781(92)90524-4; Taira T, 2001, GENE, V263, P285, DOI 10.1016/S0378-1119(00)00590-4; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tetel MJ, 1997, MOL ENDOCRINOL, V11, P1114, DOI 10.1210/me.11.8.1114; Wagenfeld A, 2000, J ANDROL, V21, P954; Wagenfeld A, 1998, BIOCHEM BIOPH RES CO, V251, P545, DOI 10.1006/bbrc.1998.9512; Wagenfeld A, 1998, BIOL REPROD, V58, P1257, DOI 10.1095/biolreprod58.5.1257; Welch JE, 1998, J ANDROL, V19, P385; Whyard TC, 2000, MOL REPROD DEV, V55, P189, DOI 10.1002/(SICI)1098-2795(200002)55:2<189::AID-MRD8>3.0.CO;2-O; WONG CI, 1993, J BIOL CHEM, V268, P19004; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P206; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	58	278	289	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37556	37563		10.1074/jbc.M101730200	http://dx.doi.org/10.1074/jbc.M101730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11477070	hybrid			2022-12-25	WOS:000171375700091
J	Mazars, A; Lallemand, F; Prunier, C; Marais, J; Ferrand, N; Pessah, M; Cherqui, G; Atfi, A				Mazars, A; Lallemand, F; Prunier, C; Marais, J; Ferrand, N; Pessah, M; Cherqui, G; Atfi, A			Evidence for a role of the JNK cascade in Smad7-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; TGF-BETA RECEPTOR; TERMINAL KINASE SAPK/JNK; SMAD7 PROMOTER; MEDIATED TRANSCRIPTION; SIGNALING PATHWAYS; CELL-DEATH; PROTEIN; ACTIVATION; INDUCTION	Smad proteins are central mediators of the transcriptional effects of transforming growth factor beta (TGF-beta) superfamily that regulate a wide variety of biological processes. Smad7, an inhibitory Smad protein that prevents TGF-beta signaling by interacting with the activated type I TGF-beta receptor, was recently shown to induce sensitization of cells to different forms of cell death. Here we examined the effect of Smad7 on the c-Jun N-terminal kinase (JNK) cascade and investigated the role of this cascade in both the inhibitory and apoptotic functions of Smad7. The transient and stable expression of Smad7 caused a strong and sustained activation of JNK Expression of a dominant-interfering mutant of mitogen-activated protein kinase kinase 4, which completely abolished Smad7-induced activation of JNK, had no effect on Smad7-mediated inhibition of TGF-beta signaling, indicating that the inhibitory function of Smad7 is independent of the JNK cascade. In contrast, expression of the dominant-interfering mutant of mitogen-activated protein kinase kinase 4 impaired the ability of Smad7 to promote cell death. These experiments reveal a novel link between Smad7 and the JNK cascade, which is essential for potentiation of cell death by this inhibitory Smad.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Hop St Antoine, INSERM, U402, F-75571 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Atfi, A (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.		Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273				Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Bitzer M, 2000, GENE DEV, V14, P187; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Lallemand F, 2001, ONCOGENE, V20, P879, DOI 10.1038/sj.onc.1204167; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Mazars A, 2000, ONCOGENE, V19, P1277, DOI 10.1038/sj.onc.1203420; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	40	79	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36797	36803		10.1074/jbc.M101672200	http://dx.doi.org/10.1074/jbc.M101672200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477069	hybrid			2022-12-25	WOS:000171194500098
J	Swain, PK; Hicks, D; Mears, AJ; Apel, IJ; Smith, JE; John, SK; Hendrickson, A; Milam, AH; Swaroop, A				Swain, PK; Hicks, D; Mears, AJ; Apel, IJ; Smith, JE; John, SK; Hendrickson, A; Milam, AH; Swaroop, A			Multiple phosphorylated isoforms of NRL are expressed in rod photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NRL; CELL-FATE DETERMINATION; HOMEOBOX GENE; LEUCINE-ZIPPER; TEMPORAL EXPRESSION; MOLECULAR-GENETICS; CRX; RETINA; HOMEODOMAIN; MUTATIONS	NRL, a bZIP transcription factor of the Maf subfamily, interacts with the homeodomain protein CRX and synergistically regulates rhodopsin expression. Here we report that six isoforms of NRL (29-35 kDa) are generated by phosphorylation and expressed specifically in the mammalian retina. The anti-NRL antibody also crossreacts with a cytosolic 45-kDa protein, which is detected in neuronal tissues but is not encoded by the NRL gene. In both human retinal cell cultures and sections of fetal and adult human retina, NRL is present in the nuclei of developing and mature rods but not cones. We propose that NRL regulates rod photoreceptor-specific gene expression and is involved in rod differentiation.	Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48105 USA; Univ Strasbourg, INSERM E9918, Ctr Hosp Reg, Lab Physiopathol Cellulaire & Mol Retine, F-67091 Strasbourg, France; Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Centre Hospitalier Annecy Genevois; CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Pennsylvania; Pennsylvania Medicine; University of Washington; University of Washington Seattle	Swaroop, A (corresponding author), Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.	swaroop@umich.edu		Swaroop, Anand/0000-0002-1975-1141	NATIONAL EYE INSTITUTE [R01EY004536, P30EY001730, R01EY011115] Funding Source: NIH RePORTER; NEI NIH HHS [EY04536, EY01730, EY11115, EY07003] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Belliveau MJ, 1999, DEVELOPMENT, V126, P555; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Brown NL, 1998, DEVELOPMENT, V125, P4821; Bumsted K, 1997, J COMP NEUROL, V378, P117; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; COLIGAN JE, 1999, CURRENT PROTOCOLS PR, V1; Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2; CURCIO CA, 1991, PROGR RETINAL RES, V10, P89, DOI DOI 10.1016/0278-4327(91)90010-Y; DiPolo A, 1997, NUCLEIC ACIDS RES, V25, P3863, DOI 10.1093/nar/25.19.3863; FARJO Q, 1993, GENOMICS, V18, P216, DOI 10.1006/geno.1993.1458; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Gaudin C, 1996, INVEST OPHTH VIS SCI, V37, P2258; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRIMSBY GL, 2001, INVESTIG OPHTHALMOL, V42, P642; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; He L, 1998, Mol Vis, V4, P32; HENDRICKSON A, 1992, EYE, V6, P136, DOI 10.1038/eye.1992.29; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jacobson SG, 1998, INVEST OPHTH VIS SCI, V39, P2417; Trujillo MJ, 2001, HUM MUTAT, V17, DOI 10.1002/1098-1004(2001)17:1<80::AID-HUMU27>3.0.CO;2-G; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4814, DOI 10.1073/pnas.96.9.4814; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; KUMAR R, 1995, MOL GENETICS OCULAR, P139; Kuo MH, 1997, MOL CELL BIOL, V17, P819, DOI 10.1128/MCB.17.2.819; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; Levine EM, 2000, CELL MOL LIFE SCI, V57, P224, DOI 10.1007/PL00000686; LI ZY, 1995, J NEUROSCI, V15, P5429; Liu Q, 1996, ONCOGENE, V12, P207; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; Mathers PH, 2000, CELL MOL LIFE SCI, V57, P186, DOI 10.1007/PL00000683; Milam AH, 1998, PROG RETIN EYE RES, V17, P175; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; Morrow EM, 1998, J NEUROSCI, V18, P3738; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NATHANS J, 1992, ANNU REV GENET, V26, P403, DOI 10.1146/annurev.ge.26.120192.002155; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Shaaban SA, 1998, INVEST OPHTH VIS SCI, V39, P885; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Swaroop A, 1999, HUM MOL GENET, V8, P299, DOI 10.1093/hmg/8.2.299; Toy J, 1998, P NATL ACAD SCI USA, V95, P10643, DOI 10.1073/pnas.95.18.10643; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wikler KC, 1997, J COMP NEUROL, V377, P500; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Xiao M, 2000, J COMP NEUROL, V425, P545; Yan D, 1998, J BIOL CHEM, V273, P19656, DOI 10.1074/jbc.273.31.19656	54	100	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36824	36830		10.1074/jbc.M105855200	http://dx.doi.org/10.1074/jbc.M105855200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477108	hybrid			2022-12-25	WOS:000171194500102
J	Wheeler, MD; Nakagami, M; Bradford, BU; Uesugi, T; Mason, RP; Connor, HD; Dikalova, A; Kadiiska, M; Thurman, RG				Wheeler, MD; Nakagami, M; Bradford, BU; Uesugi, T; Mason, RP; Connor, HD; Dikalova, A; Kadiiska, M; Thurman, RG			Overexpression of manganese superoxide dismutase prevents alcohol-induced liver injury in the rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED OXIDATIVE STRESS; NECROSIS-FACTOR-ALPHA; LIPID-PEROXIDATION; CHRONIC ETHANOL; MITOCHONDRIAL GLUTATHIONE; KUPFFER CELLS; DIETARY-FAT; EXPOSURE; DISEASE; INVOLVEMENT	Mitochondria are thought to play a major role in hepatic oxidative stress associated with alcohol-induced liver injury. Thus, the hypothesis that delivery of the mitochondrial isoform of superoxide dismutase (Mn-SOD) via recombinant adenovirus would reduce alcohol-induced liver injury was tested. Rats were given recombinant adenovirus containing Mn-SOD (Ad.SOD2) or beta -galactosidase (Ad.lacZ) and then fed alcohol enterally for 4 weeks. Mn-SOD expression and activity of Ad.SOD2 in liver mitochondria of infected animals was increased nearly 3-fold compared with Ad.lacZ-infected controls. Mitochondrial glutathione levels in Ad.lacZ-infected animals were decreased after 4 weeks of chronic ethanol, as expected, but were unchanged in Ad.SOD2-infected animals. Alanine aminotransferase was elevated significantly by ethanol, an effect that was prevented by Ad.SOD2. Moreover, pathology (e.g. the sum of steatosis, inflammation, and necrosis) was elevated dramatically by ethanol in Ad.lacZ-treated rats. This effect was also blunted in animals infected with Ad.SOD2. Neutrophil infiltration was increased about 3-fold in livers from both Ad.lacZ- and Ad.SOD2-infected rats by ethanol treatment. Moreover, ESR-detectable free radical adducts in bile were increased about 8-fold by ethanol. Using C-13-labeled ethanol, it was determined that nearly 60% of total adducts were due to the a-hydroxyethyl radical adduct. This increase in radical formation was blocked completely by Ad.SOD2 infection. Furthermore, apoptosis of hepatocytes was increased about 5-fold by ethanol, an effect also blocked by Ad.SOD2. Interestingly, tumor necrosis factor-alpha mRNA was elevated to the same extent in both Ad.lacZ- and Ad.SOD2-infected animals follows ethanol exposure. These data suggest that hepatocyte mitochondrial oxidative stress is involved in alcohol-induced liver damage and likely follows Kupffer cell activation, cytokine production, and neutrophil infiltration. These results also support the hypothesis that mitochondrial oxidant production is a critical factor in parenchymal cell death caused by alcohol.	Univ N Carolina, Dept Pharmacol, Hepatobiol & Toxicol Lab, Chapel Hill, NC 27599 USA; NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wheeler, MD (corresponding author), Univ N Carolina, Dept Pharmacol, Hepatobiol & Toxicol Lab, CB 7365,Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	wheelmi@med.unc.edu	Mason, Ronald P/G-5967-2019; Kadiiska, Maria B./AAC-9981-2019	Mason, Ronald P/0000-0002-1859-9109; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050117, ZIAES050117] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADACHI Y, 1994, HEPATOLOGY, V20, P453, DOI 10.1002/hep.1840200227; ADACHI Y, 1995, GASTROENTEROLOGY, V108, P218, DOI 10.1016/0016-5085(95)90027-6; ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; CHEN LH, 1995, ALCOHOL, V12, P453, DOI 10.1016/0741-8329(95)00030-U; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; Degoul F, 2001, GASTROENTEROLOGY, V120, P1468, DOI 10.1053/gast.2001.24051; DEVI BG, 1993, HEPATOLOGY, V18, P648, DOI 10.1002/hep.1840180325; Diehl AM, 1999, J BIOENERG BIOMEMBR, V31, P493, DOI 10.1023/A:1005452624640; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; ESSANI NA, 1995, HEPATOLOGY, V21, P1632, DOI 10.1002/hep.1840210623; Fernandez-Checa JC, 1998, SEMIN LIVER DIS, V18, P389, DOI 10.1055/s-2007-1007172; FERNANDEZCHECA JC, 1993, ALCOHOL, V10, P469, DOI 10.1016/0741-8329(93)90067-X; FERNANDEZCHECA JC, 1991, J CLIN INVEST, V87, P397, DOI 10.1172/JCI115010; FERNANDEZCHECA JC, 1987, J CLIN INVEST, V80, P57, DOI 10.1172/JCI113063; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; G?nzler W.A., 1985, HDB METHODS OXYGEN R, P285; GARCIARUIZ C, 1994, J CLIN INVEST, V94, P193, DOI 10.1172/JCI117306; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Horder M., 1983, METHOD ENZYMAT AN, P444; Iimuro Y, 2000, HEPATOLOGY, V31, P391, DOI 10.1002/hep.510310219; Iimuro Y, 1997, HEPATOLOGY, V26, P1530; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KNECHT KT, 1990, MOL PHARMACOL, V38, P26; KNECHT KT, 1995, MOL PHARMACOL, V47, P1028; Koch O, 2000, ALCOHOL ALCOHOLISM, V35, P159, DOI 10.1093/alcalc/35.2.159; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; Kono H, 2000, J CLIN INVEST, V106, P867, DOI 10.1172/JCI9020; LELBACH WK, 1966, ACTA HEPATO-SPLENOL, V13, P321; Li J, 2000, AM J PHYSIOL-GASTR L, V279, pG118, DOI 10.1152/ajpgi.2000.279.1.G118; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; MCCORD JM, 1970, J BIOL CHEM, V245, P1374; MORIMOTO M, 1994, P SOC EXP BIOL MED, V207, P197, DOI 10.3181/00379727-207-43807; MORON MS, 1979, BIOCHIM BIOPHYS ACTA, V582, P67, DOI 10.1016/0304-4165(79)90289-7; NANJI AA, 1995, J LIPID RES, V36, P736; NANJI AA, 1989, ALCOHOL CLIN EXP RES, V13, P15, DOI 10.1111/j.1530-0277.1989.tb00276.x; NOLAN JP, 1988, T AM CLIN CLIMAT ASS, V100, P115; PERERA CS, 1995, ARCH BIOCHEM BIOPHYS, V323, P471, DOI 10.1006/abbi.1995.0069; Polavarapu R, 1998, HEPATOLOGY, V27, P1317, DOI 10.1002/hep.510270518; Polavarapu R, 1996, HEPATOLOGY, V24, P1259; Qu W, 1996, AM J PHYSIOL-GASTR L, V270, pG574, DOI 10.1152/ajpgi.1996.270.4.G574; Qu W, 1999, AM J PHYSIOL-GASTR L, V277, pG1048, DOI 10.1152/ajpgi.1999.277.5.G1048; SHAW S, 1981, J LAB CLIN MED, V98, P417; STRIETER RM, 1993, CRIT CARE MED, V21, pS447, DOI 10.1097/00003246-199310001-00006; THOMPSON JA, 1978, LIPIDS, V13, P540, DOI 10.1007/BF02533593; Thurman RG, 1998, AM J PHYSIOL-GASTR L, V275, pG605, DOI 10.1152/ajpgi.1998.275.4.G605; TSUKAMOTO H, 1984, AM J PHYSIOL, V247, pR595, DOI 10.1152/ajpregu.1984.247.3.R595; VINA J, 1980, BIOCHEM J, V188, P549, DOI 10.1042/bj1880549; Wheeler MD, 2001, GASTROENTEROLOGY, V120, P1241, DOI 10.1053/gast.2001.23253; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	58	157	163	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36664	36672		10.1074/jbc.M105352200	http://dx.doi.org/10.1074/jbc.M105352200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477087	Green Published, hybrid			2022-12-25	WOS:000171194500081
J	Dhar, M; Taneja, R				Dhar, M; Taneja, R			Cross-regulatory interaction between Stra13 and USF results in functional antagonism	ONCOGENE			English	Article						yeast two hybrid; basic helix-loop-helix factors; interaction; transcriptional activity; DNA-binding	LOOP-HELIX PROTEINS; MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR; UPSTREAM ELEMENT; GENE; FAMILY; BINDING; ACTIVATION; REPRESSOR; ENHANCER	Transcription factors belonging to the basic helix-loop-helix (bHLH) family are critical regulators of cellular proliferation and differentiation. The functional activity of these proteins can be regulated by heterodimerization through the HLH domain, as a result of formation of functional or non-functional heterodimers. The presence of a leucine zipper in bHLH-leucine zipper (bHLHZip) proteins, however, prevents such heterodimeric interactions via the HLH domain between bHLH and bHLHZip proteins. To identify cellular proteins that directly interact with and modulate transcriptional repression mediated by the bHLH protein Stra13, we carried out a yeast two hybrid screen. The bHLHZip protein USF (Upstream Stimulatory factor) was identified as a Stra13 interacting protein. We demonstrate a direct interaction between Stra13 and USF that is dependent upon the C-terminal repression domain of Stra13 and the DNA-binding domain of USF. Stra13 and USF also colocalize and functionally interact in mammalian cells. Co-expression of USF abrogates Stra13-mediated repression of target genes and conversely, Stra13 inhibits DNA-binding and USF-mediated transactivation. Taken together, our data demonstrate that Stra13 and USF interact physically and functionally, and identify a novel mode of cross regulatory interaction between members of the bHLH and bHLHZip families that abrogates their functional activity.	Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Taneja, R (corresponding author), Mt Sinai Sch Med, Dept Biochem & Mol Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA.		Taneja, Reshma/F-9658-2014	Taneja, Reshma/0000-0002-2151-2094; Reshma, Taneja/0000-0001-6214-6177				Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; Dang CV, 1999, MOL CELL BIOL, V19, P1; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; James P, 1996, GENETICS, V144, P1425; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; Sirito Mario, 1992, Gene Expression, V2, P231; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Wallin JJ, 1999, J BIOL CHEM, V274, P15959, DOI 10.1074/jbc.274.22.15959	25	22	22	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4750	4756		10.1038/sj.onc.1204637	http://dx.doi.org/10.1038/sj.onc.1204637			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498797				2022-12-25	WOS:000170208600015
J	Signori, E; Bagni, C; Papa, S; Primerano, B; Rinaldi, M; Amaldi, F; Fazio, VM				Signori, E; Bagni, C; Papa, S; Primerano, B; Rinaldi, M; Amaldi, F; Fazio, VM			A somatic mutation in the 5 ' UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency	ONCOGENE			English	Article						BRCA1; translational regulation; somatic mutation; sporadic breast cancer	OVARIAN-CANCER; MESSENGER-RNA; ALPHA-THALASSEMIA; PROMOTER REGION; AUG CODON; PROTEIN; CARCINOMAS; EXPRESSION; METHYLATION; NUCLEOTIDES	Mutations in the 5' UTR which cause increment/ decrement of translation efficiency have been recently described as a novel molecular mechanism of disease. Alterations in the consensus sequence for the translation initiation may promote context-dependent leaky scanning of ribosomes and/or initiation from a downstream AUG codon. Initiation of translation from a downstream in-frame AUG codon in BRCA1 gene was recently identified in normal cells and possibly in breast cancer. Here we present further insight into BRCA1 translational pathophysiology investigating the role of the canonical structure of the initiation consensus sequence of BRCA1. We have analysed the effect of a somatic point mutation (117 G > C) in position -3 with respect to the AUG of the BRCA1 gene, identified in a highly, aggressive sporadic breast cancer. We constructed chimeric genes encoding the luciferase reporter sequence downstream of the wild type or the mutated BRCA1 5'UTR. These transcripts were tested for their activity in in vitro and in vivo systems. In in vitro transcription/ translation assays the estimated translation efficiency of the construct with the mutated BRCA1 5'UTR was 30-50% lower than that with the wild type BRCA1 5'UTR. The same chimeric genes were analysed for their expression in vivo by transient transfection in human cells. While the two constructs were equally transcribed, the plasmid carrying the mutated sequence produced 70% less luciferase activity compared to the wild type sequence. Finally, to obtain a direct evaluation on translational efficiency in vivo, we analysed mRNA translation on translationally active and non-active ribosomes separated from transfected cells. Mutant mRNA was partially localized in subpolysomal particles analytically confirming a polysome recruitment defect. Thus, characterization of BRCA1 5'UTR and translation efficiency seems to provide new insight into BRCA1 role in breast and ovarian cancer pathogenesis.	IRCCS H Casa Solliveo Sofferenza, Lab Mol Pathol & Gene Therapy, I-71013 San Giovanni Rotondo, FG, Italy; CNR, Ist Neurobiol & Med Mol, Area Ric Tor Vergata, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Sch Med, Lab Mol Med & Biotechnol, I-00155 Rome, Italy	IRCCS Casa Sollievo Della Sofferenza; Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata; University of Rome Tor Vergata	Fazio, VM (corresponding author), IRCCS H Casa Solliveo Sofferenza, Lab Mol Pathol & Gene Therapy, I-71013 San Giovanni Rotondo, FG, Italy.	VitoM.Fazio@ims.rm.cnr.it	Signori, Emanuela/H-5134-2019; rinaldi, monica/D-2221-2016; Fazio, Vito Michele VMF/H-3007-2016	Signori, Emanuela/0000-0003-0286-7401; rinaldi, monica/0000-0002-6889-9388; Fazio, Vito Michele VMF/0000-0002-7751-1867; Bagni, Claudia/0000-0002-4419-210X				Bernard-Gallon D, 1998, ONCOL REP, V5, P995; Brown MA, 1996, ONCOGENE, V12, P2507; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Choong CS, 1996, J CLIN INVEST, V98, P1423, DOI 10.1172/JCI118930; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; ESTELLER M, 2000, JNCI, V92, P565; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gorman C., 1985, DNA CLONING, V2; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Jarvis EM, 1998, CANCER GENET CYTOGEN, V101, P109, DOI 10.1016/S0165-4608(97)00267-7; Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lee WY, 1999, HISTOPATHOLOGY, V34, P106; Lida Y, 1996, NUCLEIC ACIDS RES, V24, P3313, DOI 10.1093/nar/24.17.3313; Liu JS, 2000, ONCOGENE, V19, P2767, DOI 10.1038/sj.onc.1203599; LORENI F, 1992, EUR J BIOCHEM, V205, P1027, DOI 10.1111/j.1432-1033.1992.tb16870.x; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MORLE F, 1986, NUCLEIC ACIDS RES, V14, P3279, DOI 10.1093/nar/14.8.3279; MORLE F, 1985, EMBO J, V4, P1245, DOI 10.1002/j.1460-2075.1985.tb03767.x; Papa S, 1998, JNCI-J NATL CANCER I, V90, P1011, DOI 10.1093/jnci/90.13.1011; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Rio PG, 1999, INT J CANCER, V80, P823, DOI 10.1002/(SICI)1097-0215(19990315)80:6<823::AID-IJC5>3.0.CO;2-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.3.CO;2-8; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yoshikawa K, 1999, CLIN CANCER RES, V5, P1249; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	37	70	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4596	4600		10.1038/sj.onc.1204620	http://dx.doi.org/10.1038/sj.onc.1204620			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494157	Green Published			2022-12-25	WOS:000170074900019
J	Luiken, JJFP; Arumugam, Y; Dyck, DJ; Bell, RC; Pelsers, MML; Turcotte, LP; Tandon, NN; Glatz, JFC; Bonen, A				Luiken, JJFP; Arumugam, Y; Dyck, DJ; Bell, RC; Pelsers, MML; Turcotte, LP; Tandon, NN; Glatz, JFC; Bonen, A			Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; BINDING-PROTEIN; SKELETAL-MUSCLE; CARDIAC MYOCYTES; ADIPOSE-TISSUE; MESSENGER-RNA; OLEATE UPTAKE; ADIPOCYTES; LIVER	Giant vesicles were used to study the rates of uptake of long-chain fatty acids by heart, skeletal muscle, and adipose tissue of obese and lean Zucker rats. With obesity there was an increase in vesicular fatty acid uptake of 1.8-fold in heart, muscle and adipose tissue. In some tissues only fatty acid translocase (FAT) mRNA (heart, +37%; adipose, +80%) and fatty acid-binding protein (FABPpm) mRNA (heart, +148%; adipose, +196%) were increased. At the protein level FABPpm expression was not changed in any tissues except muscle (+14%), and FAT/CD36 protein content was altered slightly in adipose tissue (+26%). In marked contrast, the plasma membrane FAT/CD36 protein was increased in heart (+60%), muscle (+80%), and adipose tissue (+50%). The plasma membrane FABPpm was altered only in heart (+50%) and adipose tissues (+70%). Thus, in obesity, alterations in fatty acid transport in metabolically important tissues are not associated with changes in fatty acid transporter mRNAs or altered fatty acid transport protein expression but with their increased abundance at the plasma membrane. We speculate that in obesity fatty acid transporters are relocated from an intracellular pool to the plasma membrane in heart, muscle, and adipose tissues.	Univ Waterloo, Dept Kinesiol, Waterloo, ON N2L 3G1, Canada; Maastricht Univ, Dept Physiol, NL-6200 MD Maastricht, Netherlands; Univ Guelph, Dept Human Biol & Nutrit Sci, Guelph, ON N1G 2W1, Canada; Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB T5G 2S2, Canada; Univ So Calif, Dept Exercise Sci, Los Angeles, CA 90089 USA; Otsuka Maryland Res Inst, Thrombosis Res Lab, Rockville, MD 20850 USA	University of Waterloo; Maastricht University; University of Guelph; University of Alberta; University of Southern California	Bonen, A (corresponding author), Univ Waterloo, Dept Kinesiol, Waterloo, ON N2L 3G1, Canada.			Bell, Rhonda C./0000-0002-4298-9641	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR045168] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45168] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; Berk PD, 1999, J BIOL CHEM, V274, P28626, DOI 10.1074/jbc.274.40.28626; Berk PD, 1997, J BIOL CHEM, V272, P8830, DOI 10.1074/jbc.272.13.8830; Bonen A, 2000, J BIOL CHEM, V275, P14501, DOI 10.1074/jbc.275.19.14501; Bonen A, 1998, ADV EXP MED BIOL, V441, P193; Bonen A, 2000, AM J PHYSIOL-ENDOC M, V278, pE1067, DOI 10.1152/ajpendo.2000.278.6.E1067; Bonen A, 1999, CAN J APPL PHYSIOL, V24, P515, DOI 10.1139/h99-033; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; Bonen A, 1998, AM J PHYSIOL-ENDOC M, V275, pE471, DOI 10.1152/ajpendo.1998.275.3.E471; Bradbury MW, 2000, BIOCHEM J, V345, P423, DOI 10.1042/0264-6021:3450423; BROZINICK JT, 1993, AM J PHYSIOL, V265, pE419, DOI 10.1152/ajpendo.1993.265.3.E419; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Duarte J, 1999, EUR J PHARMACOL, V365, P225, DOI 10.1016/S0014-2999(98)00879-6; Glatz JFC, 1997, PROSTAG LEUKOTR ESS, V57, P373, DOI 10.1016/S0952-3278(97)90413-0; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hamilton JA, 1998, J LIPID RES, V39, P467; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; ISOLA LM, 1995, P NATL ACAD SCI USA, V92, P9866, DOI 10.1073/pnas.92.21.9866; JUEL C, 1997, PHYSIOL REV, V77, P1; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; LUIKEN JJF, 1997, J LIPID RES, V38, P725; Luiken JJFP, 1999, J LIPID RES, V40, P1007; Marques BG, 1998, AM J PHYSIOL-REG I, V275, pR1898, DOI 10.1152/ajpregu.1998.275.6.R1898; Matsuno K, 1996, BRIT J HAEMATOL, V92, P960, DOI 10.1046/j.1365-2141.1996.422962.x; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; McCullagh KJA, 1996, MOL CELL BIOCHEM, V156, P51; Memon RA, 1999, DIABETES, V48, P121, DOI 10.2337/diabetes.48.1.121; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; Schaap FG, 1999, CIRC RES, V85, P329, DOI 10.1161/01.RES.85.4.329; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHWIETERMAN W, 1988, P NATL ACAD SCI USA, V85, P359, DOI 10.1073/pnas.85.2.359; SHIMOMURA I, 1992, BIOCHIM BIOPHYS ACTA, V1124, P112, DOI 10.1016/0005-2760(92)90086-B; SORRENTINO D, 1988, J CLIN INVEST, V82, P928, DOI 10.1172/JCI113700; SORRENTINO D, 1989, J CLIN INVEST, V84, P1325, DOI 10.1172/JCI114301; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; STUMP DD, 1993, AM J PHYSIOL, V265, pG894, DOI 10.1152/ajpgi.1993.265.5.G894; Turcotte LP, 2000, MOL CELL BIOCHEM, V210, P53, DOI 10.1023/A:1007046929776; UPHUES I, 1995, BIOCHEM J, V311, P161, DOI 10.1042/bj3110161; Uphues I, 1995, FEBS LETT, V377, P109, DOI 10.1016/0014-5793(95)01315-6; Van Nieuwenhoven FA, 1999, INT J BIOCHEM CELL B, V31, P489, DOI 10.1016/S1357-2725(98)00122-8; VANNIEUWENHOVEN FA, 1994, J MOL CELL CARDIOL, V26, P1635, DOI 10.1006/jmcc.1994.1183; VORK MM, 1991, BIOCHIM BIOPHYS ACTA, V1075, P199, DOI 10.1016/0304-4165(91)90267-K; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Zorzano A, 2000, BIOCHEM J, V349, P667, DOI 10.1042/bj3490667	46	216	226	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40567	40573		10.1074/jbc.M100052200	http://dx.doi.org/10.1074/jbc.M100052200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11504711	hybrid			2022-12-25	WOS:000171925600027
J	Marina, A; Mott, C; Auyzenberg, A; Hendrickson, WA; Waldburger, CD				Marina, A; Mott, C; Auyzenberg, A; Hendrickson, WA; Waldburger, CD			Structural and mutational analysis of the PhoQ histidine kinase catalytic domain. Insight into the reaction mechanism.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP BINDING; SIGNAL-TRANSDUCTION; DNA-GYRASE; PROTEIN; LIGAND; IDENTIFICATION; SUPERFAMILY; HYDROLYSIS; RESOLUTION; RECEPTOR	PhoQ is a transmembrane histidine kinase belonging to the family of two-component signal transducing systems common in prokaryotes and lower eukaryotes. In response to changes in environmental Mg2+ concentration, PhoQ regulates the level of phosphorylated PhoP, its cognate transcriptional response-regulator. The PhoQ cytoplasmic region comprises two independently folding domains: the histidine-containing phosphotransfer domain and the ATP-binding kinase domain. We have determined the structure of the kinase domain of Escherichia coli PhoQ complexed with the non-hydrolyzable ATP analog adenosine 5'-(beta,gamma -imino)triphosphate and Mg2+. Nucleotide binding appears to be accompanied by conformational changes in the loop that surrounds the ATP analog (ATP-lid) and has implications for interactions with the substrate phosphotransfer domain. The high resolution (1.6 Angstrom) structure reveals a detailed view of the nucleotide-binding site, allowing us to identify potential catalytic residues. Mutagenic analyses of these residues provide new insights into the catalytic mechanism of histidine phosphorylation in the histidine kinase family. Comparison with the active site of the related GHL ATPase family reveals differences that are proposed to account for the distinct functions of these proteins.	Columbia Univ, Dept Microbiol, New York, NY 10032 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute	Waldburger, CD (corresponding author), Columbia Univ, Dept Microbiol, New York, NY 10032 USA.		Marina, Alberto/H-6264-2011	Marina, Alberto/0000-0002-1334-5273	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034102, R37GM034102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41566] Funding Source: Medline; NIGMS NIH HHS [GM34102] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; Bilwes AM, 2001, NAT STRUCT BIOL, V8, P353, DOI 10.1038/86243; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; FASMAN GD, 1975, HDB BIOCH MOL BIOL, V1, P187; Gamble RL, 1998, P NATL ACAD SCI USA, V95, P7825, DOI 10.1073/pnas.95.13.7825; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; GUERGER MJ, 1968, INT TABLES XRAY CRYS, VC; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOCH JA, 1995, 2 COMPONENT SIGNAL T, P25; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Larsen TM, 1998, BIOCHEMISTRY-US, V37, P6247, DOI 10.1021/bi980243s; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MCCLEARY WR, 1990, J BACTERIOL, V176, P3870; McPhillips TM, 1996, BIOCHEMISTRY-US, V35, P4118, DOI 10.1021/bi952500o; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; MOODIE SL, 1993, NUCLEIC ACIDS RES, V21, P1369, DOI 10.1093/nar/21.6.1369; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; SchulzeGahmen U, 1996, J MED CHEM, V39, P4540, DOI 10.1021/jm960402a; Smith CV, 1998, BIOCHEMISTRY-US, V37, P9658, DOI 10.1021/bi9801309; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; TANAKA T, 1998, J BACTERIOL, V386, P88; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Waldburger CD, 1996, J BIOL CHEM, V271, P26630, DOI 10.1074/jbc.271.43.26630; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189	39	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41182	41190		10.1074/jbc.M106080200	http://dx.doi.org/10.1074/jbc.M106080200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11493605	hybrid			2022-12-25	WOS:000171925600108
J	Rodriguez-Fernandez, JL; Sanchez-Martin, L; Rey, M; Vicente-Manzanares, M; Narumiya, S; Teixido, J; Sanchez-Madrid, F; Cabanas, C				Rodriguez-Fernandez, JL; Sanchez-Martin, L; Rey, M; Vicente-Manzanares, M; Narumiya, S; Teixido, J; Sanchez-Madrid, F; Cabanas, C			Rho and Rho-associated kinase modulate the tyrosine kinase PYK2 in T-cells through regulation of the activity of the integrin LFA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; GTP-BINDING-PROTEIN; ACTIN CYTOSKELETON; ADP-RIBOSYLATION; LEUKOCYTE ADHESION; LIGAND-BINDING; ANTIGEN 1; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION	We have examined the role of the small GTPase Rho and its downstream effector, the Rho-associated kinase (ROCK), in the control of the adhesive and signaling function of the lymphocyte function-associated antigen-1 (LFA-1) integrin in human T-lymphocytes. Inhibition of Rho (either by treatment with C3-exoenzyme or transfection with a dominant-negative form of Rho (N19Rho)) or ROCK (by treatment with Y-27632) results in the following: (a) partial disorganization and aggregation of cortical filamentous actin (F-actin); (b) induction of LFA-1-mediated cellular adhesion to the LFA-1 ligand intercellular adhesion molecule-1 (ICAM-1) through a mechanism involving clustering of LFA-1 molecules, rather than alterations in the level of expression or in the affinity state of this integrin; and (c) induction of cellular polarization and activation of the tyrosine kinase PYK2. Transfection of T-cells with a constitutively active form of Rho (V14Rho) blocks the clustering of LFA-1 on the membrane and the LFA-1-mediated activation of PYK2. Importantly, the activation of PYK2 caused by inhibition of Rho or ROCK takes place only when the T-cells are plated onto ICAM-1 but not when they are either prevented from interacting with ICAM-1 with anti-LFA-1 blocking antibodies or when they are plated on the nonspecific poly-l,lysine substrate. These results indicate that the small GTPase Rho regulates the tyrosine kinase PYK2 in T-cells through the F-actin-mediated control of the activity of the integrin LFA-1. These findings represent a novel paradigm for the regulation of the activity of a cytoplasmic tyrosine kinase by the small GTPase Rho.	Univ Complutense, Fac Med, CSIC, Inst Farmacol & Toxicol, Madrid 28040, Spain; Hosp Princesa, Serv Inmunol, Madrid 28006, Spain; Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 606, Japan; CSIC, Ctr Invest Biol, Dept Inmunol, Madrid 28006, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital de La Princesa; Kyoto University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Cabanas, C (corresponding author), Univ Complutense, Fac Med, CSIC, Inst Farmacol & Toxicol, Madrid 28040, Spain.	cacabagu@eucmax.sim.ucm.es	Rodriguez-Fernandez, Jose Luis/Q-5021-2019; Sanchez-Madrid, Francisco/M-7889-2016; Teixidó, Joaquin/J-8543-2014; Bustelo, Xose R./A-9526-2010; Vicente-Manzanares, Miguel/H-1010-2018; CABAÑAS, CARLOS/J-4595-2012	Rodriguez-Fernandez, Jose Luis/0000-0001-8874-1425; Sanchez-Madrid, Francisco/0000-0001-5303-0762; Bustelo, Xose R./0000-0001-9398-6072; Vicente-Manzanares, Miguel/0000-0001-5943-3220; CABAÑAS, CARLOS/0000-0002-8767-060X				Aepfelbacher M, 1996, J IMMUNOL, V157, P5070; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Allen WE, 1997, J CELL SCI, V110, P707; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Barth H, 1999, J BIOL CHEM, V274, P27407, DOI 10.1074/jbc.274.39.27407; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; Dustin ML, 1998, CELL ADHES COMMUN, V6, P255, DOI 10.3109/15419069809004481; EHRENGRUBER MU, 1995, FEBS LETT, V372, P161, DOI 10.1016/0014-5793(95)00880-I; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Herzog H, 1996, GENOMICS, V32, P484, DOI 10.1006/geno.1996.0149; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KOCH G, 1994, BIOCHEM J, V299, P775, DOI 10.1042/bj2990775; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; LANG P, 1992, J BIOL CHEM, V267, P11677; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Leitinger B, 2000, MOL BIOL CELL, V11, P677, DOI 10.1091/mbc.11.2.677; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MORII N, 1995, METHOD ENZYMOL, V256, P196; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; ORTLEPP S, 1995, EUR J IMMUNOL, V25, P637, DOI 10.1002/eji.1830250302; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; Rodriguez-Fernandez JL, 1999, BIOESSAYS, V21, P1069, DOI 10.1002/(SICI)1521-1878(199912)22:1<1069::AID-BIES13>3.0.CO;2-C; Rodriguez-Fernandez JL, 1999, MOL BIOL CELL, V10, P1891, DOI 10.1091/mbc.10.6.1891; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stephens P, 1995, CELL ADHES COMMUN, V3, P375, DOI 10.3109/15419069509081292; Stewart MP, 1996, J IMMUNOL, V156, P1810; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; vanKooyk Y, 1997, BIOCHEM SOC T, V25, P515, DOI 10.1042/bst0250515; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Woodside DG, 1998, J EXP MED, V188, P1211, DOI 10.1084/jem.188.7.1211; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	62	54	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40518	40527		10.1074/jbc.M102896200	http://dx.doi.org/10.1074/jbc.M102896200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11489881	Green Published, hybrid			2022-12-25	WOS:000171925600022
J	Tu, CL; Chang, WH; Bikle, DD				Tu, CL; Chang, WH; Bikle, DD			The extracellular calcium-sensing receptor is required for calcium-induced differentiation in human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE EPIDERMAL DIFFERENTIATION; ALTERNATIVELY SPLICED FORM; HUMAN INVOLUCRIN PROMOTER; CROSS-LINKED ENVELOPE; EPITHELIAL-CELLS; EXPRESSION; ACTIVATION; PROTEIN; TRANSGLUTAMINASE; IDENTIFICATION	In cultured keratinocytes, the acute increase of the extracellular calcium concentration above 0.03 mm leads to a rapid increase in intracellular calcium concentration ([Ca2+](i)) and inositol trisphosphate production and, subsequently, to the expression of differentiation-related genes. Previous studies demonstrated that human keratinocytes express the full-length extracellular calcium-sensing receptor (CaR) and an alternatively spliced variant lacking exon 5 and suggested their involvement in calcium regulation of keratinocyte differentiation. To understand the role of the CaR, we transfected keratinocytes with an antisense human Call cDNA construct and examined its impact on calcium signaling and calcium-induced differentiation. The antisense CaR cDNA significantly reduced the protein level of endogenous CaRs. These cells displayed a marked reduction in the rise in [Ca2+](i) in response to extracellular calcium or to NPS R-467, a CaR activator, whereas the ATP-evoked rise in [Ca2+](i) was not affected. Calcium-induced inhibition of cell proliferation and calcium-stimulated expression of the differentiation markers involucrin and transglutaminase were also blocked by the antisense CaR cDNA. When cotransfected with luciferase reporter vectors containing either the involucrin or transglutaminase promoter, the antisense CaR cDNA suppressed the calcium-stimulated promoter activities. These results indicate that CaR is required for mediating calcium signaling and calcium-induced differentiation in keratinocytes.	Vet Affairs Med Ctr, Endocrine Unit, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Tu, CL (corresponding author), Vet Affairs Med Ctr, Endocrine Unit, 111N,4150 Clement St, San Francisco, CA 94121 USA.	ctu@itsa.ucsf.edu		Tu, Chia-Ling/0000-0002-7323-7733	NIAMS NIH HHS [P01-AR39448, R01-AR38386] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448, R01AR038386] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bikle DD, 1996, J CLIN INVEST, V97, P1085, DOI 10.1172/JCI118501; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; BLACK BL, 1989, FASEB J, V3, P2653, DOI 10.1096/fasebj.3.14.2512193; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Bruce JIE, 1999, J BIOL CHEM, V274, P20561, DOI 10.1074/jbc.274.29.20561; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CARROLL JM, 1992, J CELL SCI, V103, P925; Chang WH, 1999, ENDOCRINOLOGY, V140, P1911, DOI 10.1210/en.140.4.1911; Chang WH, 1998, J BONE MINER RES, V13, P570, DOI 10.1359/jbmr.1998.13.4.570; Chang YH, 1999, ENDOCRINOLOGY, V140, P5883, DOI 10.1210/en.140.12.5883; Chattopadhyay N, 1996, ENDOCR REV, V17, P289, DOI 10.1210/er.17.4.289; FILVAROFF E, 1994, J BIOL CHEM, V269, P21735; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Gibson DFC, 1996, J INVEST DERMATOL, V106, P154, DOI 10.1111/1523-1747.ep12329856; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; JAKEN S, 1988, CARCINOGENESIS, V9, P1033, DOI 10.1093/carcin/9.6.1033; Kanatani N, 1999, BIOCHEM BIOPH RES CO, V261, P144, DOI 10.1006/bbrc.1999.0932; LI LW, 1995, J CELL PHYSIOL, V163, P105, DOI 10.1002/jcp.1041630112; Mailland M, 1997, ENDOCRINOLOGY, V138, P3601, DOI 10.1210/en.138.9.3601; Mariniello L, 1995, J BIOL CHEM, V270, P31358, DOI 10.1074/jbc.270.52.31358; McNeil L, 1998, AM J OBSTET GYNECOL, V178, P305, DOI 10.1016/S0002-9378(98)80017-3; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; MENON GK, 1992, CELL TISSUE RES, V270, P503, DOI 10.1007/BF00645052; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; OCHIENG J, 1991, J CELL BIOCHEM, V46, P250, DOI 10.1002/jcb.240460308; Oda Y, 2000, J BIOL CHEM, V275, P1183, DOI 10.1074/jbc.275.2.1183; Oda Y, 1998, J BIOL CHEM, V273, P23344, DOI 10.1074/jbc.273.36.23344; PILLAI S, 1992, J CLIN INVEST, V90, P42, DOI 10.1172/JCI115854; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; SHARPE GR, 1989, FEBS LETT, V254, P25, DOI 10.1016/0014-5793(89)81002-6; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; Tu CL, 1999, J INVEST DERMATOL, V113, P340, DOI 10.1046/j.1523-1747.1999.00698.x; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	35	114	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41079	41085		10.1074/jbc.M107122200	http://dx.doi.org/10.1074/jbc.M107122200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11500521				2022-12-25	WOS:000171925600095
J	Li, SL; Valente, AJ; Wang, L; Gamez, MJ; Clark, RA				Li, SL; Valente, AJ; Wang, L; Gamez, MJ; Clark, RA			Transcriptional regulation of the p67(phox) gene - Role of AP-1 in concert with myeloid-specific transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CCAAT DISPLACEMENT PROTEIN; SEQUENCE-BINDING PROTEIN; NADPH OXIDASE; RESPIRATORY BURST; GP91(PHOX) EXPRESSION; PROMOTER ACTIVITY; RETINOIC ACID; DNA-BINDING; HL-60 CELLS	We have investigated the myeloid-specific transcriptional regulation of p67(phox), an essential component of phagocyte respiratory burst NADPH oxidase. Analysis was carried out on the p67(phox), 5'-flanking region from -3669 to -4 (relative to ATG), including the first exon and intron and part of the second exon. The construct extending from -985 to -4 produced the highest luciferase activity in myeloid HL-60 cells but was not active in HeLa or Jurkat cells, indicating myeloid-specific expression. Four active elements were identified: Sp1/Sp3 at -694, PU.1 at -289, AP-1 at -210, and PU.1/HAF1 at -182, the latter three being in the first intron. These cis elements bound their cognate transacting factors both in vitro and in vivo. Mutation of the Sp1, PU.1, or PU.1/ HAFT site each decreased promoter activity by 35-50%. Mutations in all three sites reduced promoter activity by 90%. However, mutation of the AP-1 site alone nearly abolished promoter activity. The AP-1 site bound Jun and Fos proteins from HL-60 cell nuclear extract. Coexpression with Jun B in AP-1-deficient cells increased promoter activity by 3-fold. These data show that full p67(phox) promoter activity requires cooperation between myeloid-specific and nonmyeloid transcription factors, with AP-1 being the most critical for function.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Clark, RA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.		Clark, Robert/Q-6764-2019	Clark, Robert/0000-0002-4892-3619	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020866, R01AI020866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019519] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI020866, R01 AI020866, AI20866] Funding Source: Medline; NIA NIH HHS [R01 AG019519] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUPTA JW, 1992, CANCER RES, V52, P2530; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hua J, 2000, J LEUKOCYTE BIOL, V68, P216; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KENNEY RT, 1993, BLOOD, V82, P3739; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEVY R, 1990, J IMMUNOL, V145, P2595; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; Li SL, 1997, J BIOL CHEM, V272, P17802, DOI 10.1074/jbc.272.28.17802; Li SL, 1999, J BIOL CHEM, V274, P32453, DOI 10.1074/jbc.274.45.32453; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; OBERMEIER H, 1995, BBA-MOL CELL RES, V1269, P25, DOI 10.1016/0167-4889(95)00095-A; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Tsunawaki S, 2000, J BIOCHEM-TOKYO, V128, P777, DOI 10.1093/oxfordjournals.jbchem.a022815; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; Voo KS, 1999, BLOOD, V93, P3512, DOI 10.1182/blood.V93.10.3512.410k19_3512_3520; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Zhan SX, 1996, BLOOD, V88, P2714, DOI 10.1182/blood.V88.7.2714.bloodjournal8872714	42	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39368	39378		10.1074/jbc.M106111200	http://dx.doi.org/10.1074/jbc.M106111200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11483614	hybrid			2022-12-25	WOS:000171673200136
J	Palacino, JJ; Murphy, MP; Murayama, O; Iwasaki, K; Fujiwara, M; Takashima, A; Golde, TE; Wolozin, B				Palacino, JJ; Murphy, MP; Murayama, O; Iwasaki, K; Fujiwara, M; Takashima, A; Golde, TE; Wolozin, B			Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; IN-VIVO; MUTATIONS; LOCALIZATION; ACTIVATION; BRAIN; CELLS; PS1; KINASE-3-BETA	Presenilin 1 (PS1) is linked with Alzheimer's disease but exhibits functional roles regulating growth and development. For instance, PS1 binds to beta -catenin and modulates beta -catenin signaling. In the current study, we observed that knockout of PSI inhibited beta -catenin-mediated transcription by 35%, as shown by a luciferase reporter driven by the hTcf-4 promoter. Overexpressing wild-type PS1 increased beta -catenin-mediated transcription by 37.5%, and overexpressing PS1 with mutations associated with Alzheimer's disease decreased beta -catenin-mediated transcription by 66%. To examine whether regulation of beta -catenin by PS1 requires phosphorylation by glycogen synthase kinase 3 beta (GSK 3 beta), we examined whether inhibiting GSK 3 beta activity overcomes the inhibition of beta -catenin transcription induced by mutant PS1 constructs. Cells expressing wild-type or mutant PS1 were treated with LiCl, which inhibits GSK 3 beta, or transfected with beta -catenin constructs that lack the GSK 3 beta phosphorylation sites. Neither treatment overcame PS1-mediated inhibition of beta -catenin signaling, suggesting that regulation of beta -catenin by PS1 was not affected by the activity of GSK 3 beta. To investigate how PS1 might regulate beta -catenin signaling, we determined whether PSI interacts with other elements of the beta -catenin signaling cascade, such as the Tcf-4 transcription factor. Coimmunoprecipitation studies showed binding of PS1 and hTcf-4, and examining nuclear isolates indicated that nuclear hTcf-4 was decreased in cells expressing mutant PS1. These data show that PS1 interacts with multiple components of the beta -catenin signaling cascade and suggest that PS1 regulates beta -catenin in a manner independent of GSK 3 beta activity.	Loyola Univ, Med Ctr, Dept Pharmacol, Mol Pharmacol Lab, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Neurosci Program, Maywood, IL 60153 USA; Mayo Clin Jacksonville, Dept Pharmacol, Jacksonville, FL 32224 USA; RIKEN, Lab Alzheimers Dis, Wako, Saitama, Japan; Fukuoka Univ, Fukuoka 81401, Japan	Loyola University Chicago; Loyola University Chicago; Mayo Clinic; RIKEN; Fukuoka University	Wolozin, B (corresponding author), Loyola Univ, Med Ctr, Dept Pharmacol, Mol Pharmacol Lab, 2160 S 1st St,Bldg 102,Rm 3634, Maywood, IL 60153 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH012479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017485] Funding Source: NIH RePORTER; NIA NIH HHS [AG17485] Funding Source: Medline; NIMH NIH HHS [1F31MH12479] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Beher D, 1999, J NEUROCHEM, V72, P1564, DOI 10.1046/j.1471-4159.1999.721564.x; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Busciglio J, 1997, J NEUROSCI, V17, P5101, DOI 10.1523/jneurosci.17-13-05101.1997; Dale TC, 1998, BIOCHEM J, V329, P209; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Gantier R, 2000, NEUROSCI LETT, V283, P217, DOI 10.1016/S0304-3940(00)00949-6; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; HARDY J, 1997, TRENDS NEUROSCI, V4, pR154; Honda T, 2000, NEUROSCI RES, V37, P101, DOI 10.1016/S0168-0102(00)00106-1; Kang DE, 1999, J NEUROSCI, V19, P4229; Kirschenbaum F, 2001, J BIOL CHEM, V276, P7366, DOI 10.1074/jbc.M004697200; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Levitan D, 1998, DEVELOPMENT, V125, P3599; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Palacino JJ, 2000, J BIOL CHEM, V275, P215, DOI 10.1074/jbc.275.1.215; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Stahl B, 1999, J BIOL CHEM, V274, P9141, DOI 10.1074/jbc.274.14.9141; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Van Gassen G, 2000, NEUROBIOL DIS, V7, P135, DOI 10.1006/nbdi.2000.0306; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	33	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38563	38569		10.1074/jbc.M105376200	http://dx.doi.org/10.1074/jbc.M105376200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504726	hybrid			2022-12-25	WOS:000171673200033
J	Rice, KP; Eggler, AL; Sung, P; Cox, MM				Rice, KP; Eggler, AL; Sung, P; Cox, MM			DNA pairing and strand exchange by the Escherichia coli RecA and yeast Rad51 proteins without ATP hydrolysis - On the importance of not getting stuck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING OLIGONUCLEOTIDES; BRANCH MIGRATION; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; NUCLEOPROTEIN FILAMENTS; NUCLEOSIDE TRIPHOSPHATE; MINOR-GROOVE; DUPLEX DNA; IN-VITRO	The bacterial RecA protein and the homologous Rad51 protein in eukaryotes both bind to single-stranded DNA (ssDNA), align it with a homologous duplex, and promote an extensive strand exchange between them. Both reactions have properties, including a tolerance of base analog substitutions that tend to eliminate major groove hydrogen bonding potential, that suggest a common molecular process underlies the DNA strand exchange promoted by RecA and Rad51. However, optimal conditions for the DNA pairing and DNA strand exchange reactions promoted by the RecA and Rad51 proteins in vitro are substantially different. When conditions are optimized independently for both proteins, RecA promotes DNA pairing reactions with short oligonucleotides at a faster rate than Rad51. For both proteins, conditions that improve DNA pairing can inhibit extensive DNA strand exchange reactions in the absence of ATP hydrolysis. Extensive strand exchange requires a spooling of duplex DNA into a recombinase-ssDNA complex, a process that can be halted by any interaction elsewhere on the same duplex that restricts free rotation of the duplex and/or complex, Le. the reaction can get stuck. Optimization of an extensive DNA strand exchange without ATP hydrolysis requires conditions that decrease nonproductive interactions of recombinase-ssDNA complexes with the duplex DNA substrate.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA	University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Health San Antonio	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu		Eggler, Aimee/0000-0002-7286-2107; Rice, Kevin/0000-0002-7777-4325	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07061] Funding Source: Medline; NIGMS NIH HHS [GM32335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; BALIGA R, 1995, P NATL ACAD SCI USA, V92, P10393, DOI 10.1073/pnas.92.22.10393; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; BESSMAN MJ, 1974, J MOL BIOL, V88, P409, DOI 10.1016/0022-2836(74)90491-4; Bianco PR, 1996, NUCLEIC ACIDS RES, V24, P4933, DOI 10.1093/nar/24.24.4933; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; Campbell MJ, 1999, J MOL BIOL, V286, P437, DOI 10.1006/jmbi.1998.2457; CHOW SA, 1985, P NATL ACAD SCI USA, V82, P5646, DOI 10.1073/pnas.82.17.5646; CHOW SA, 1992, J MOL BIOL, V223, P79, DOI 10.1016/0022-2836(92)90717-X; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1982, J BIOL CHEM, V257, P8523; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; COX MM, 1999, PROG NUCL ACID RES M, V63, P310; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; Goodman MF, 1998, GENETICS, V148, P1475; GRIFFITH J, 1990, MOL MECH DNA REPLICA, V127, P105; Gupta RC, 1999, MOL CELL, V4, P705, DOI 10.1016/S1097-2765(00)80381-0; Gupta RC, 1998, P NATL ACAD SCI USA, V95, P9843, DOI 10.1073/pnas.95.17.9843; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Gupta RC, 1999, J BIOL CHEM, V274, P1248, DOI 10.1074/jbc.274.3.1248; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; HONIGBERG SM, 1985, J BIOL CHEM, V260, P1845; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; JAIN SK, 1992, J BIOL CHEM, V267, P4215; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; KIM MG, 1995, J MOL BIOL, V247, P874, DOI 10.1006/jmbi.1994.0187; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; KUMAR KA, 1992, J BIOL CHEM, V267, P24824; LACKS S, 1966, GENETICS, V53, P207; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; Morrison C, 1999, MOL CELL BIOL, V19, P6891; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; MUNIYAPPA K, 1990, NUCLEIC ACIDS RES, V18, P3967, DOI 10.1093/nar/18.13.3967; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Namsaraev EA, 1998, P NATL ACAD SCI USA, V95, P10477, DOI 10.1073/pnas.95.18.10477; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PODYMINOGIN MA, 1995, BIOCHEMISTRY-US, V34, P13098, DOI 10.1021/bi00040a022; Podyminogin MA, 1996, BIOCHEMISTRY-US, V35, P7267, DOI 10.1021/bi9529465; REGISTER JC, 1987, J BIOL CHEM, V262, P12812; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Rice KP, 2000, BIOCHEMISTRY-US, V39, P10177, DOI 10.1021/bi0003339; Shan Q, 1998, MOL CELL, V1, P309, DOI 10.1016/S1097-2765(00)80031-3; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; STASIAK A, 1984, COLD SPRING HARB SYM, V49, P561, DOI 10.1101/SQB.1984.049.01.063; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; TAKAHASHI M, 1994, ADV BIOPHYS, V30, P1, DOI 10.1016/0065-227X(94)90009-4; TAKAHASHI M, 1995, J BIOCHEM, V117, P947, DOI 10.1093/oxfordjournals.jbchem.a124825; TAKAHASHI M, 1991, BIOCHIMIE, V73, P219, DOI 10.1016/0300-9084(91)90205-F; UMLAUF S, 1990, THESIS U WISCONSIN M; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907; Zhou XH, 1997, BIOCHEMISTRY-US, V36, P4650, DOI 10.1021/bi9630063; ZHURKIN VB, 1994, J MOL BIOL, V239, P181, DOI 10.1006/jmbi.1994.1362	70	46	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38570	38581		10.1074/jbc.M105678200	http://dx.doi.org/10.1074/jbc.M105678200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504729	hybrid			2022-12-25	WOS:000171673200034
J	Zhu, J; Watanabe, I; Gomez, B; Thornhill, WB				Zhu, J; Watanabe, I; Gomez, B; Thornhill, WB			Determinants involved in Kv1 potassium channel folding in the endoplasmic reticulum, glycosylation in the Golgi, and cell surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; MAMMALIAN BRAIN; MOLECULAR-BASIS; ENZYMATIC DEGLYCOSYLATION; XENOPUS-OOCYTES; BETA-SUBUNITS; DIVERSITY; PROTEIN; SIALIDATION; ANTIBODIES	Kv1.1 and Kv1.4 potassium channels are expressed as mature glycosylated proteins in brain, whereas they exhibited striking differences in degree of traps-Golgi glycosylation conversion and high cell surface expression when they were transiently expressed as homomers in cell lines. Kv1.4 exhibited a 70% traps-Golgi glycosylation conversion, whereas Kv1.1 showed none, and Kv1.4 exhibited a similar to 20-fold higher cell surface expression level as compared with Kv1.1. Chimeras between Kv1.4 and Kv1.1 and site-directed mutants were constructed to identify amino acid determinants that affected these processes. Truncating the cytoplasmic C terminus of Kv1.4 inhibited its traps-Golgi glycosylation and high cell surface expression (as shown by Li, D., Takimoto, K., and Levitan, E. S. (2000) J. Biol. Chem. 275,11597-11602), whereas truncating this region on Kv1.1 did not affect either of these events, indicating that its C terminus is not a negative determinant for these processes. Exchanging the C terminus between these channels showed that there are other regions of the protein that exert a positive or negative effect on these processes. Chimeric constructs between Kv1.4 and Kv1.1 identified their outer pore regions as major positive and negative determinants, respectively, for both traps-Golgi glycosylation and cell surface expression. Site-directed mutagenesis identified a number of amino acids in the pore region that are involved in these processes. These data suggest that there are multiple positive and negative determinants on both Kv1.4 and Kv1.1 that affect channel folding, traps-Golgi glycosylation conversion, and cell surface expression.	Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA	Fordham University	Thornhill, WB (corresponding author), Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA.				NINDS NIH HHS [NS29633] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029633] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashcroft FM, 2000, ION CHANNELS DIS; BekeleArcuri Z, 1996, NEUROPHARMACOLOGY, V35, P851, DOI 10.1016/0028-3908(96)00128-1; Bennett E, 1997, J GEN PHYSIOL, V109, P327, DOI 10.1085/jgp.109.3.327; Bertoli A, 1996, EXP BRAIN RES, V110, P401; Castillo C, 1997, DEV BRAIN RES, V104, P119, DOI 10.1016/S0165-3806(97)00159-4; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; COVARRUBIAS M, 1989, J GEN PHYSIOL, V93, P765, DOI 10.1085/jgp.93.5.765; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Dolly JO, 1996, J BIOENERG BIOMEMBR, V28, P231, DOI 10.1007/BF02110698; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GomezHernandez JM, 1997, PFLUG ARCH EUR J PHY, V434, P661, DOI 10.1007/s004240050449; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Manganas LN, 2000, J BIOL CHEM, V275, P29685, DOI 10.1074/jbc.M005010200; Papazian DM, 1999, NEURON, V23, P7, DOI 10.1016/S0896-6273(00)80746-1; Qi YP, 1997, J NEUROSCI, V17, P1217; RECIOPINTO E, 1990, NEURON, V5, P675, DOI 10.1016/0896-6273(90)90221-Z; REHM H, 1989, FEBS LETT, V247, P28, DOI 10.1016/0014-5793(89)81233-5; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; ROSENBERG RL, 1992, NATURE, V360, P166, DOI 10.1038/360166a0; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SCHWALBE RA, 1995, J BIOL CHEM, V270, P15336, DOI 10.1074/jbc.270.25.15336; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; Shamotienko O, 1999, BIOCHEMISTRY-US, V38, P16766, DOI 10.1021/bi991039n; Sheng ZF, 1998, METHOD ENZYMOL, V293, P17; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; Thornhill WB, 1996, J BIOL CHEM, V271, P19093, DOI 10.1074/jbc.271.32.19093; THOTAKURA NR, 1987, METHOD ENZYMOL, V138, P350; Trimmer JS, 1998, CURR OPIN NEUROBIOL, V8, P370, DOI 10.1016/S0959-4388(98)80063-9; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0	40	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39419	39427		10.1074/jbc.M107399200	http://dx.doi.org/10.1074/jbc.M107399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11487588	hybrid			2022-12-25	WOS:000171673200142
J	Boren, J; Cascante, M; Marin, S; Comin-Anduix, B; Centelles, JJ; Lim, S; Bassilian, S; Ahmed, S; Lee, WNP; Boros, LG				Boren, J; Cascante, M; Marin, S; Comin-Anduix, B; Centelles, JJ; Lim, S; Bassilian, S; Ahmed, S; Lee, WNP; Boros, LG			Gleevec (ST1571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTOSE-PHOSPHATE PATHWAY; MASS ISOTOPOMER; GROWTH; RIBOSE; TRANSPORT; KINASE; CYCLE	Chronic myeloid leukemia cells contain a constitutively active Bcr-Abl tyrosine kinase, the target protein of Gleevec (STI571) phenylaminopyrimidine class protein kinase inhibitor. Here we provide evidence for metabolic phenotypic changes in cultured K562 human myeloid blast cells after treatment with increasing doses of STI571 using [1,2-C-13(2)]glucose as the single tracer and biological mass spectrometry. In response to 0.68 and 6.8 mum STI571, proliferation of Bcr-Abl-positive K562 cells showed a 57% and 74% decrease, respectively, whereas glucose label incorporation into RNA decreased by 13.4% and 30.1%, respectively, through direct glucose oxidation, as indicated by the decrease in the m(1)/Sigmam(n) ratio in RNA. Based on the in vitro proliferation data, the IC50 of STI571 in K562 cultures is 0.56 mum. The decrease in C-13 label incorporation into RNA ribose was accompanied by a significant fall in hexokinase and glucose-6-phosphate 1-dehydrogenase activities. The activity of transketolase, the enzyme responsible for nonoxidative ribose synthesis in the pentose cycle, was less affected, and there was a relative increase in glucose carbon incorporation into RNA through nonoxidative synthesis as indicated by the increase in the m(2)/Sigmam(n) ratio in RNA. The restricted use of glucose carbons for de novo nucleic acid and fatty acid synthesis by altering metabolic enzyme activities and pathway carbon flux of the pentose cycle constitutes the underlying mechanism by which STI571 inhibits leukemia cell glucose substrate utilization and growth. The administration of specific hexokinase/glucose-6-phosphate 1-dehydrogenase inhibitor anti-metabolite substrates or competitive enzyme inhibitor compounds, alone or in combination, should be explored for the treatment of STI571-resistant advanced leukemias as well as that of Ber-Abl-negative human malignancies.	Univ Calif Los Angeles, Sch Med, Harbor UCLA Res & Educ Inst, Stable Isotope Res Lab, Torrance, CA 90502 USA; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Boros, LG (corresponding author), Univ Calif Los Angeles, Sch Med, Harbor UCLA Res & Educ Inst, Stable Isotope Res Lab, 1124 W Carson St RB1, Torrance, CA 90502 USA.	boros@gcrc.humc.edu	CASCANTE, MARTA/AAG-4355-2022; Centelles, Josep J./K-2972-2014; Boren, Joan/A-8515-2012; CASCANTE, MARTA/AFK-5991-2022; Marin, Silvia/C-5492-2017	CASCANTE, MARTA/0000-0002-2062-4633; Centelles, Josep J./0000-0002-6289-9678; CASCANTE, MARTA/0000-0002-2062-4633; Marin, Silvia/0000-0003-0693-2207	NATIONAL CANCER INSTITUTE [P01CA042710] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000045] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA42710] Funding Source: Medline; NCRR NIH HHS [M01-RR0045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ahmed N, 1999, LEUKEMIA RES, V23, P395, DOI 10.1016/S0145-2126(98)00179-9; Bading JR, 1996, LIFE SCI, V58, P1445, DOI 10.1016/0024-3205(96)00114-2; BEAUCHAMP RD, 1990, PANCREAS, V5, P369, DOI 10.1097/00006676-199007000-00001; Bentley J, 2001, BRIT J HAEMATOL, V112, P212, DOI 10.1046/j.1365-2141.2001.02428.x; BERTHON HA, 1992, BIOCHEMISTRY-US, V31, P12792, DOI 10.1021/bi00166a012; Boros LG, 2001, PANCREAS, V23, P141, DOI 10.1097/00006676-200108000-00004; Boros LG, 2001, PANCREAS, V22, P1, DOI 10.1097/00006676-200101000-00001; Boros LG, 1997, CANCER RES, V57, P4242; Boros LG, 2000, CANCER RES, V60, P1183; BUCHDUNGER E, 2000, P AM ASSOC CANC RES, V41, P611; BUCHDUNGER E, 2000, P AM ASSOC CANC RES, V42, P720; de la HABA G., 1955, JOUR BIOL CHEM, V214, P409; Gaston I, 2000, EXP HEMATOL, V28, P77, DOI 10.1016/S0301-472X(99)00130-7; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; GROSSBARD L, 1966, BIOCHEM BIOPH RES CO, V24, P32, DOI 10.1016/0006-291X(66)90405-0; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Kasho VN, 1996, ALIMENT PHARM THERAP, V10, P985, DOI 10.1046/j.1365-2036.1996.99271000.x; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; LEA MA, 1970, CANCER RES, V30, P1994; Lee WNP, 1996, ADV EXP MED BIOL, V399, P95; Lee WNP, 1996, DEV NEUROSCI-BASEL, V18, P469, DOI 10.1159/000111442; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843, DOI 10.1152/ajpendo.1998.274.5.E843; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; LIENHARD GE, 1985, SCIENCE, V229, P941; PENG B, 2000, P AM ASSOC CANC RES, V41, P544; PLAGEMANN PGW, 1975, J CELL BIOL, V64, P29, DOI 10.1083/jcb.64.1.29; SABATE L, 1995, MOL CELL BIOCHEM, V142, P9, DOI 10.1007/BF00928908; Schuster S, 1999, TRENDS BIOTECHNOL, V17, P53, DOI 10.1016/S0167-7799(98)01290-6; Smith TAD, 1999, CANCER LETT, V141, P85, DOI 10.1016/S0304-3835(99)00075-0; TIAN WN, 1994, J BIOL CHEM, V269, P14798	30	157	161	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37747	37753						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11489902				2022-12-25	WOS:000171526500005
J	Gotoh, T; Tian, XJ; Feig, LA				Gotoh, T; Tian, XJ; Feig, LA			Prenylation of target GTPases contributes to signaling specificity of Ras-guanine nucleotide exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							R-RAS; INTEGRIN ACTIVATION; STRUCTURAL BASIS; PROTEIN; BINDING; CALCIUM; KINASE; GRF; PHOSPHORYLATION; RHO	Ras-GRF1 and Ras-GRF2 constitute a family of calmodulin-regulated guanine-nucleotide exchange factors (GEFs) that activate Ras proteins. Here we show that whereas Ras-GRF1 activated both Ha-Ras and R-Ras in cells, Ras-GRF2 activated only Ha-Ras. The inability of Ras-GRF2 to activate R-Ras was the consequence of the GTPase being post-translationally modified, since Ras-GRF2 activated unprocessed R-Ras as effectively as unprocessed Ha-Ras when assays were performed either in vivo or in vitro. Moreover, Ras-GRF2 failed to activate fully processed R-Ras in vitro. The particular C-terminal lipid attached to the GTPases played an important role in determining signaling specificity, since R-Ras became more responsive to Ras-GRF2 when it was farnesylated instead of geranylgeranylated. Similarly, Ha-Ras became less responsive to Ras-GRF2 when it was geranylgeranylated instead of farnesylated. Analysis of chimeras between Ras-GRF1 and Ras-GRF2 demonstrated that a 30-amino acid segment embedded with their catalytic domains was responsible for recognizing the presence of different lipids on Ras proteins. These results indicate that the specific lipid moiety attached to GTPases can contribute to signaling specificity of Ras-GEFs.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University	Feig, LA (corresponding author), Tufts Univ, Sch Med, Dept Biochem, 136 Harrison Ave, Boston, MA 02111 USA.							Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Desrosiers RR, 2000, J BIOL CHEM, V275, P14949, DOI 10.1074/jbc.275.20.14949; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; Kiyono M, 2000, J BIOL CHEM, V275, P29788, DOI 10.1074/jbc.M001378200; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Prior IA, 2001, J CELL SCI, V114, P1603; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; Shima F, 1997, MOL CELL BIOL, V17, P1057, DOI 10.1128/MCB.17.3.1057; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	26	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38029	38035						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11500499				2022-12-25	WOS:000171526500043
J	Kautz, B; Kakar, R; David, E; Eklund, EA				Kautz, B; Kakar, R; David, E; Eklund, EA			SHP1 protein-tyrosine phosphatase inhibits gp91(PHOX) and p67(PHOX) expression by inhibiting interaction of PU.1, IRF1, interferon consensus sequence-binding protein, and CREB-binding protein with homologous cis elements in the CYBB and NCF2 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CCAAT DISPLACEMENT PROTEIN; MOTH-EATEN MICE; DNA-BINDING; GAMMA; LEUKEMIA; CELLS; PHOSPHORYLATION; TRANSCRIPTION; PROMOTER	The CYBB and NCF2 genes encode the phagocyte respiratory burst oxidase proteins, gp91(PHOX) and p67(PHOX). Previously, we identified homologous CYBB and NCF2 cis elements that are necessary for lineage-specific transcription during late myeloid differentiation. We determined that these homologous cis elements are activated by PU.1, IRF1, interferon consensus sequence-binding protein (ICSBP), and the CREB-binding protein (CBP). Since expression of PU.1 and ICSBP is lineage-restricted, our investigations identified a mechanism of lineage-specific CYBB and NCF2 transcription. Since PU.1, IRF1, ICSBP, and CBP are expressed in undifferentiated myeloid cells, our investigations did not determine the mechanism of differentiation stage-specific CYBB and NCF2 transcription. In the current investigations, we determine that SHP1 protein-tyrosine phosphatase (SHP1-PTP) inhibits gp91(PHOX) and p67(PHOX) expression, in undifferentiated myeloid cell lines by decreasing interaction of PU.1, IRF1, ICSBP, and CBP with the CYBB and NCF2 genes. We also determine that IRF1 and ICSBP are tyrosine-phosphorylated during interferon gamma differentiation of myeloid cell lines, and we identify IRF1 and ICSBP tyrosine residues that are necessary for CYBB and NCF2 transcription. Therefore, these investigations identify a novel mechanism by which SHP1-PTP antagonizes myeloid differentiation and determine that tyrosine phosphorylation of IRF1 and ICSPB mediates stage-specific transcriptional activation in differentiating myeloid cells.	Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Chicago Lakeside Vet Adm Hosp, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Univ Alabama, Birmingham Vet Adm Hosp, Birmingham, AL 35209 USA; Univ Alabama, Dept Med, Birmingham, AL 35209 USA	Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Robert H. Lurie Comprehensive Cancer Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Eklund, EA (corresponding author), Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA.				NHLBI NIH HHS [HL5400] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, P215; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong Q, 1999, J IMMUNOL, V162, P3220; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1997, J BIOL CHEM, V272, P9344; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Eklund EA, 1996, J IMMUNOL, V157, P2418; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; KENNEY RT, 1993, BLOOD, V82, P3739; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LARRICK JW, 1980, J IMMUNOL, V125, P6; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEVY R, 1990, J IMMUNOL, V145, P2595; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook H., 1989, MOL CLONING LAB MANU; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Sharf R, 1997, J BIOL CHEM, V272, P9785; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tapley P, 1997, EXP HEMATOL, V25, P122; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TUCKER KA, 1987, BLOOD, V70, P372	34	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37868	37878						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11483597				2022-12-25	WOS:000171526500022
J	Morimoto, S; Suemori, K; Moriwaki, J; Taura, F; Tanaka, H; Aso, M; Tanaka, M; Suemune, H; Shimohigashi, Y; Shoyama, Y				Morimoto, S; Suemori, K; Moriwaki, J; Taura, F; Tanaka, H; Aso, M; Tanaka, M; Suemune, H; Shimohigashi, Y; Shoyama, Y			Morphine metabolism in the opium poppy and its possible physiological function - Biochemical characterization of the morphine metabolite, bismorphine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-CELL WALLS; DIFERULIC ACID; PEROXIDASE; PURIFICATION; CULTURES; PROTEIN; INVOLVEMENT; GENERATION; OXYGEN; CHAIN	We identified a novel metabolic system of morphine in the opium poppy (Papaver somniferum L.). In response to stress, morphine is quickly metabolized to bismorphine consisting of two morphine units, followed by accumulation in the cell wall. This bismorphine binds predominantly to pectins, which possess high galacturonic acid residue contents, through ionical bonds. Our newly developed method using artificial polysaccharides demonstrated that bismorphine bridges are formed between the two amino groups of bismorphine and the carboxyl groups of galacturonic acid residues, resulting in crosslinking of galacturonic acid-containing polysaccharides to each other. The ability of bismorphine to cross-link pectins is much higher than that of Ca2+, which also acts as a cross-linker of these polysaccharides. Furthermore, we confirmed that cross-linking of pectins through bismorphine bridges leads to resistance against hydrolysis by pectinases. These results indicated that production of bismorphine is a defense response of the opium poppy. Bismorphine formation is catalyzed by anionic peroxidase that pre-exists in the capsules and leaves of opium poppies. The constitutive presence of morphine, together with bismorphine-forming peroxidase, enables the opium poppy to rapidly induce the defense system.	Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan; Kyushu Univ, Fac & Grad Sch Sci, Fukuoka 8128581, Japan	Kyushu University; Kyushu University	Morimoto, S (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan.	morimoto@shoyaku.phar.kyushu-u.ac.jp						ALBERSHEIM P, 1969, ANNU REV PHYTOPATHOL, V7, P171, DOI 10.1146/annurev.py.07.090169.001131; BAKER CJ, 1995, ANNU REV PHYTOPATHOL, V33, P299, DOI 10.1146/annurev.py.33.090195.001503; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; CERVONE F, 1977, BIOCHIM BIOPHYS ACTA, V482, P379, DOI 10.1016/0005-2744(77)90251-0; CHABANET A, 1993, PHYTOCHEMISTRY, V33, P759, DOI 10.1016/0031-9422(93)85270-2; Dixon R A, 1990, Adv Genet, V28, P165; DOKE N, 1983, PHYSIOL PLANT PATHOL, V23, P345, DOI 10.1016/0048-4059(83)90019-X; HARTLEY RD, 1976, PHYTOCHEMISTRY, V15, P1157, DOI 10.1016/0031-9422(76)85121-7; JOSHI JG, 1962, J BIOL CHEM, V237, P3185; KIM SS, 1980, PHYTOCHEMISTRY, V19, P165, DOI 10.1016/S0031-9422(00)81953-6; KUBIAK EJ, 1980, J PHARM SCI, V69, P152, DOI 10.1002/jps.2600690209; KUTCHAN TM, 1998, ALKALOIDS, V50, P257; Levy Samuel, 1992, Current Opinion in Cell Biology, V4, P856, DOI 10.1016/0955-0674(92)90111-O; MARKWALDER HU, 1976, PHYTOCHEMISTRY, V15, P836, DOI 10.1016/S0031-9422(00)94474-1; MCNEIL M, 1984, ANNU REV BIOCHEM, V53, P625, DOI 10.1146/annurev.bi.53.070184.003205; Morimoto S, 1999, J BIOL CHEM, V274, P26192, DOI 10.1074/jbc.274.37.26192; Morimoto S, 1998, J BIOL CHEM, V273, P12606, DOI 10.1074/jbc.273.20.12606; MORIMOTO S, 1995, PLANTA, V195, P535, DOI 10.1007/BF00195712; NEUHANN H, 1979, PHYTOCHEMISTRY, V18, P61, DOI 10.1016/S0031-9422(00)90916-6; OGURI K, 1984, EUR J PHARMACOL, V102, P229, DOI 10.1016/0014-2999(84)90254-1; RIDGE I, 1971, NATURE-NEW BIOL, V229, P205, DOI 10.1038/newbio229205a0; Roberts K, 1990, CURR OPIN CELL BIOL, V2, P920, DOI 10.1016/0955-0674(90)90093-T; Robinson T., 1979, Herbivores: their interaction with secondary plant metabolites, P413; ROBINSON T, 1981, MOL BIOL BIOCH BIOPH; SARIYAR G, 1990, J NAT PROD, V53, P1383, DOI 10.1021/np50071a044; Sasaki K, 2000, J BIOL CHEM, V275, P27466; Serturner F, 1806, J PHARMACIE ARZTE AP, V14, P47; SRISUMA N, 1991, J AGR FOOD CHEM, V39, P855, DOI 10.1021/jf00005a007; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; TSCHESCH.R, 1971, CHEM BER-RECL, V104, P3549, DOI 10.1002/cber.19711041119; TSCHESCHE R, 1977, CHEM BER-RECL, V110, P2416, DOI 10.1002/cber.19771100702; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; Vitali A, 1998, BIOCHEM J, V331, P513, DOI 10.1042/bj3310513	33	30	32	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38179	38184						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11498543				2022-12-25	WOS:000171526500062
J	Mor-Cohen, R; Zivelin, A; Rosenberg, N; Shani, M; Muallem, S; Seligsohn, U				Mor-Cohen, R; Zivelin, A; Rosenberg, N; Shani, M; Muallem, S; Seligsohn, U			Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION-TRANSPORTER; CONJUGATE EXPORT PUMP; CULTURED RAT HEPATOCYTES; CANCER CELL-LINES; CANALICULAR ISOFORM; P-GLYCOPROTEIN; CMOAT MRP2; EXPRESSION; ACCUMULATION; MRP2/CMOAT	Dubin-Johnson syndrome (DJS) is an inherited disorder characterized by conjugated hyperbilirubinemia and is caused by a deficiency of the multidrug resistance protein 2 (MRP2) located in the apical membrane of hepatocytes. The aim of this study was to identify the mutations in two previously characterized clusters of patients with Dubin-Johnson syndrome among Iranian and Moroccan Jews and determine the consequence of the mutations on MRP2 expression and function by expression studies. All 32 exons and adjacent regions of the MRP2 gene were screened by polymerase chain reaction and DNA sequencing. Two novel mutations were identified in exon 25. One mutation, 3517A-->T, predicting a I1173F substitution, was found in 22 homozygous Iranian Jewish DJS patients from 13 unrelated families and a second mutation, 3449G-->A, predicting a R1150H substitution, was found in 5 homozygous Moroccan Jewish DJS patients from 4 unrelated families. Use of four intragenic dimorphisms and haplotype analyses disclosed a specific founder effect for each mutation. The mutations were introduced into an MRP2 expression vector by site-directed mutagenesis, transfected into HEK-293 cells, and analyzed by a fluorescence transport assay, immunoblot, and immunocytochemistry. Continuous measurement of probenecid-sensitive carboxyfluorescein efflux revealed that both mutations impaired the transport activity of MRP2. Immunoblot analysis and immunocytochemistry showed that MRP2 (R1150H) matured properly and localized at the plasma membrane of transfected cells. In contrast, expression of MRP2 (I1173F) was low and mislocated to the endoplasmic reticulum of the transfected cells. These findings provide an explanation for the DJS phenotype in these two patient groups. Furthermore, the close localization of the two mutations identify this region of MRP2 as important for both activity and processing of the protein.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Chaim Sheba Med Ctr, Inst Thrombosis & Hemostasis, Dept Hematol, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, IL-52621 Tel Hashomer, Israel	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Mor-Cohen, Ronit/AAB-8657-2020					Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; ARIAS IM, 1961, AM J MED, V31, P510, DOI 10.1016/0002-9343(61)90135-8; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; BENEZZER J, 1971, CLIN SCI, V40, P17, DOI 10.1042/cs0400017; BREEUWER P, 1995, APPL ENVIRON MICROB, V61, P1614, DOI 10.1128/AEM.61.4.1614-1619.1995; Broeks A, 1996, EMBO J, V15, P6132, DOI 10.1002/j.1460-2075.1996.tb01001.x; Cantz T, 2000, AM J PHYSIOL-GASTR L, V278, pG522, DOI 10.1152/ajpgi.2000.278.4.G522; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHOWDHURY JR, 1989, METABOLIC BASIS INHE, P1367; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Conrad S, 2001, TOXICOLOGY, V156, P81, DOI 10.1016/S0300-483X(00)00354-1; Cui YH, 1999, MOL PHARMACOL, V55, P929; CUNNINGHAM RF, 1981, CLIN PHARMACOKINET, V6, P135, DOI 10.2165/00003088-198106020-00004; DUBIN IN, 1954, MEDICINE, V33, P155, DOI 10.1097/00005792-195409000-00001; DUBIN IN, 1958, AM J MED, V24, P268, DOI 10.1016/0002-9343(58)90315-2; ELFERINK RPJ, 1993, HEPATOLOGY, V17, P434, DOI 10.1002/hep.1840170314; ELFERINK RPJO, 1990, AM J PHYSIOL, V258, pG699, DOI 10.1152/ajpgi.1990.258.5.G699; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hopper E, 2001, CANCER LETT, V162, P181, DOI 10.1016/S0304-3835(00)00646-7; ICHIKAWA M, 1991, BIOCHIM BIOPHYS ACTA, V1073, P309, DOI 10.1016/0304-4165(91)90136-5; Ito K, 1998, J BIOL CHEM, V273, P1684, DOI 10.1074/jbc.273.3.1684; Ito S, 2001, PHARMACOGENETICS, V11, P175, DOI 10.1097/00008571-200103000-00008; Kajihara S, 1998, BIOCHEM BIOPH RES CO, V253, P454, DOI 10.1006/bbrc.1998.9780; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; Keitel V, 2000, HEPATOLOGY, V32, P1317, DOI 10.1053/jhep.2000.19791; Keppler D, 1997, ADV ENZYME REGUL, V37, P321, DOI 10.1016/S0065-2571(96)00013-1; Keppler D, 1996, Prog Liver Dis, V14, P55; KONDO T, 1974, JPN J HUM GENET, V18, P378; Kool M, 1997, CANCER RES, V57, P3537; Kool M, 1999, CANCER RES, V59, P175; Lu YP, 1998, PLANT CELL, V10, P267, DOI 10.1105/tpc.10.2.267; Madon J, 1997, FEBS LETT, V406, P75, DOI 10.1016/S0014-5793(97)00245-7; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Payen L, 2000, BIOCHEM PHARMACOL, V60, P1967, DOI 10.1016/S0006-2952(00)00496-2; ROELOFSEN H, 1995, HEPATOLOGY, V21, P1649, DOI 10.1002/hep.1840210625; Roelofsen H, 1998, J CELL SCI, V111, P1137; Ryu S, 2000, J BIOL CHEM, V275, P39617, DOI 10.1074/jbc.M005149200; Scheffer GL, 2000, CANCER RES, V60, P5269; SHANI M, 1970, QJM, V39, P549; SPRINZ H, 1954, ANN INTERN MED, V41, P952, DOI 10.7326/0003-4819-41-5-952; Taniguchi K, 1996, CANCER RES, V56, P4124; Toh S, 1999, AM J HUM GENET, V64, P739, DOI 10.1086/302292; Tsujii H, 1999, GASTROENTEROLOGY, V117, P653, DOI 10.1016/S0016-5085(99)70459-2; van der Kolk DM, 1998, CLIN CANCER RES, V4, P1727; vanKuijck MA, 1997, CYTOGENET CELL GENET, V77, P285, DOI 10.1159/000134599; Wada M, 1998, HUM MOL GENET, V7, P203, DOI 10.1093/hmg/7.2.203	49	86	94	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36923	36930		10.1074/jbc.M105047200	http://dx.doi.org/10.1074/jbc.M105047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11477083	hybrid			2022-12-25	WOS:000171375700011
J	Ner, SS; Blank, T; Perez-Paralle, ML; Grigliatti, TA; Becker, PB; Travers, AA				Ner, SS; Blank, T; Perez-Paralle, ML; Grigliatti, TA; Becker, PB; Travers, AA			HMG-D and histone H1 interplay during chromatin assembly and early embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY GROUP PROTEINS; NUCLEOSOME CORE PARTICLE; DNA-BINDING DOMAIN; LINKER HISTONES; CHROMOSOMAL-PROTEINS; RECOGNITION; SITE; TRANSITIONS; INVOLVEMENT; MECHANISMS	MIG-D is an abundant chromosomal protein associated with condensed chromatin during the first nuclear cleavage cycles of the developing Drosophila embryo. We previously suggested that HMG-D might substitute for the linker histone H1 in the preblastoderm embryo and that this substitution might result in the characteristic less compacted chromatin. We have now studied the association of HMG-D with chromatin using a cell-free system for chromatin reconstitution derived from Drosophila embryos. Association of HMG-D with chromatin, like that of histone H1, increases the nucleosome spacing indicative of binding to the linker DNA between nucleosomes. HMG-D interacts with DNA during the early phases of nucleosome assembly but is gradually displaced as chromatin matures. By contrast, purified chromatin can be loaded with stoichiometric amounts of HMG-D, and this can be displaced upon addition of histone H1. A direct physical interaction between HMG-D and histone H1 was observed in a Far Western analysis. The competitive nature of this interaction is reminiscent of the apparent replacement of HMG-D by H1 during mid-blastula transition. These data are consistent with the hypothesis that HMG-D functions as a specialized linker protein prior to appearance of histone H1.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; Univ Santiago de Compostela, Dept Biochem & Mol Biol, Santiago De Compostela 15705, Spain	MRC Laboratory Molecular Biology; European Molecular Biology Laboratory (EMBL); University of British Columbia; Universidade de Santiago de Compostela	Ner, SS (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	ner@zoology.ubc.ca		Perez-Paralle, M Luz/0000-0003-1024-4685; Becker, Peter/0000-0001-7186-0372				ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; An WJ, 1999, BIOCHIMIE, V81, P727, DOI 10.1016/S0300-9084(99)80130-8; ANDERSON KV, 1980, DISS ABSTR B, V41, P28; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BECKER PB, 1994, METHOD CELL BIOL, V44, P207, DOI 10.1016/S0091-679X(08)60915-2; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; Bianchi ME, 2000, EMBO REP, V1, P109, DOI 10.1093/embo-reports/kvd030; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Blank TA, 1996, J MOL BIOL, V260, P1, DOI 10.1006/jmbi.1996.0377; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1999, MOL CELL BIOL, V19, P5237; CARBALLO M, 1983, EMBO J, V2, P1759, DOI 10.1002/j.1460-2075.1983.tb01654.x; Cerdan R, 2001, PROTEIN SCI, V10, P504, DOI 10.1110/ps.35501; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; Churchill MEA, 1999, METHOD ENZYMOL, V304, P99; DIMITROV S, 1993, DEV BIOL, V160, P214, DOI 10.1006/dbio.1993.1299; Dimitrov S, 1996, EMBO J, V15, P5897, DOI 10.1002/j.1460-2075.1996.tb00976.x; ELGIN SCR, 1973, BIOCHEMISTRY-US, V12, P4984, DOI 10.1021/bi00748a026; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; Goodwin G H, 1977, Methods Cell Biol, V16, P257; Grove A, 1996, J MOL BIOL, V260, P196, DOI 10.1006/jmbi.1996.0392; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; ISACKSON PJ, 1980, BIOCHEMISTRY-US, V19, P4466, DOI 10.1021/bi00560a013; JACKSON JB, 1979, BIOCHEMISTRY-US, V18, P3739, DOI 10.1021/bi00584a015; JOHNS EW, 1982, CHROMOSOMAL PROTEINS, P1; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; KLEINSCHMIDT JA, 1983, J CELL BIOL, V97, P838, DOI 10.1083/jcb.97.3.838; KOHLSTAEDT LA, 1994, BIOCHEMISTRY-US, V33, P570, DOI 10.1021/bi00168a023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MITRA S, 1984, NATURE, V308, P247, DOI 10.1038/308247a0; Murphy FV, 1999, EMBO J, V18, P6610, DOI 10.1093/emboj/18.23.6610; Murphy FV, 2000, STRUCT FOLD DES, V8, pR83, DOI 10.1016/S0969-2126(00)00126-X; NER S S, 1992, Current Biology, V2, P208, DOI 10.1016/0960-9822(92)90541-H; NER SS, 1993, NUCLEIC ACIDS RES, V21, P4369, DOI 10.1093/nar/21.18.4369; NER SS, 1994, TRENDS BIOCHEM SCI, V19, P185, DOI 10.1016/0968-0004(94)90017-5; NER SS, 1994, EMBO J, V13, P1817, DOI 10.1002/j.1460-2075.1994.tb06450.x; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nightingale K, 1996, EMBO J, V15, P548, DOI 10.1002/j.1460-2075.1996.tb00387.x; Nightingale KP, 1996, J BIOL CHEM, V271, P7090, DOI 10.1074/jbc.271.12.7090; Payet D, 1999, J MOL BIOL, V294, P79, DOI 10.1006/jmbi.1999.3246; Payet D, 1997, J MOL BIOL, V266, P66, DOI 10.1006/jmbi.1996.0782; PEHRSON JR, 1989, P NATL ACAD SCI USA, V86, P9149, DOI 10.1073/pnas.86.23.9149; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; Renner U, 2000, BBA-GEN SUBJECTS, V1475, P99, DOI 10.1016/S0304-4165(00)00054-4; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SANDALTZOPOULOS R, 1994, EMBO J, V13, P373, DOI 10.1002/j.1460-2075.1994.tb06271.x; SCHROTER H, 1982, EUR J BIOCHEM, V127, P429, DOI 10.1111/j.1432-1033.1982.tb06890.x; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; Tremethick DJ, 1996, J BIOL CHEM, V271, P12009, DOI 10.1074/jbc.271.20.12009; TREMETHICK DJ, 1993, J BIOL CHEM, V268, P11389; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; VANHOLDE KE, 1988, CHROMATIN, P198; VARGAWEISZ P, 1994, BIOCHEM BIOPH RES CO, V203, P1904, DOI 10.1006/bbrc.1994.2410; WAGNER CR, 1992, MOL CELL BIOL, V12, P1915, DOI 10.1128/MCB.12.5.1915; Webb M, 2001, J MOL BIOL, V309, P79, DOI 10.1006/jmbi.2001.4667; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Wisniewski JR, 1999, J BIOL CHEM, V274, P20116	70	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37569	37576		10.1074/jbc.M105635200	http://dx.doi.org/10.1074/jbc.M105635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11473125	hybrid			2022-12-25	WOS:000171375700093
J	Wellner-Kienitz, MC; Bender, K; Pott, L				Wellner-Kienitz, MC; Bender, K; Pott, L			Overexpression of beta(1) and beta(2) adrenergic receptors in rat atrial myocytes - Differential coupling to G protein-gated inward rectifier K+ channels via G(s) and G(i/o)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; CARDIAC MYOCYTES; GAMMA-SUBUNITS; BETA(2)-ADRENERGIC RECEPTOR; VENTRICULAR MYOCYTES; SIGNAL-TRANSDUCTION; GENE-TRANSFER; ACTIVATE; HEART; ACETYLCHOLINE	G protein-activated inwardly rectifying K+ (GIRK) channels, expressed in atrial myocytes, various neurons, and endocrine cells, represent the paradigmatic target of beta gamma subunits released from activated heterotrimeric G proteins. These channels contribute to physiological slowing of cardiac frequency and synaptic inhibition. They are activated by beta gamma dimers released upon stimulation of receptors coupled to pertussis toxin-sensitive G proteins (G(i/o)), whereas beta gamma released from G(s) do not converge on the channel subunits. This is in conflict with the finding that dimeric combinations of various beta and gamma subunits can activate GIRK channels with little specificity. In the present study, we have overexpressed the major subtypes of cardiac beta -adrenergic receptors (beta (1)-AR and beta (2)-AR) in atrial myocytes by transient transfection. Whereas in native cells beta -adrenergic stimulation with isoproterenol failed to induce measurable GIRK current, robust currents were recorded from myocytes overexpressing either beta (1)-AR or beta (2)-AR. Whereas the beta (2)-AR-induced current showed the same sensitivity to pertussis toxin as the current evoked by the endogenous G(i/o)-coupled muscarinic M-2 receptor, isoproterenol-activated currents were insensitive to pertussis toxin treatment in beta (1)-AR-overexpressing myocytes. In contrast to a recent publication (Leaney, J. L., Milligan, G., and Tinker, A. (2000) J. Biol. Chem. 275, 921-929), sizable GIRK currents could also be activated by isoproterenol when the signaling pathway was reconstituted by transient transfection in two different standard cell lines (Chinese hamster ovary and HEK293). These results demonstrate that specificity of receptor-G protein signaling can be disrupted by overexpression of receptors. Moreover, the alpha subunit of heterotrimeric G proteins does not confer specificity to G beta gamma -mediated signaling.	Ruhr Univ Bochum, Inst Physiol, D-4480 Bochum, Germany	Ruhr University Bochum	Pott, L (corresponding author), Ruhr Univ Bochum, Inst Physiol, D-4480 Bochum, Germany.	lutz.pott@ruhr-uni-bochum.de	Pott, Lutz/E-5304-2011	Pott, Lutz/0000-0002-4000-4132				Akhter SA, 1997, P NATL ACAD SCI USA, V94, P12100, DOI 10.1073/pnas.94.22.12100; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; Bender K, 2001, J BIOL CHEM, V276, P28873, DOI 10.1074/jbc.M102328200; Bender K, 1998, FEBS LETT, V439, P115, DOI 10.1016/S0014-5793(98)01350-7; BOLLER M, 1989, PFLUG ARCH EUR J PHY, V415, P276, DOI 10.1007/BF00370877; Brodde OE, 1999, PHARMACOL REV, V51, P651; Bunemann M, 1996, J PHYSIOL-LONDON, V494, P351; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; BUNEMANN M, 1995, J PHYSIOL-LONDON, V482, P81; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; Geng YJ, 1999, CIRC RES, V84, P34; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; Karschin A, 1999, NEWS PHYSIOL SCI, V14, P215; Kilts JD, 2000, CIRC RES, V87, P705, DOI 10.1161/01.RES.87.8.705; KOUMI SI, 1994, AM J PHYSIOL, V266, pH1812, DOI 10.1152/ajpheart.1994.266.5.H1812; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KURACHI Y, 1987, PFLUG ARCH EUR J PHY, V410, P227, DOI 10.1007/BF00580270; Kuschel M, 1999, J BIOL CHEM, V274, P22048, DOI 10.1074/jbc.274.31.22048; Leaney JL, 2000, J BIOL CHEM, V275, P921, DOI 10.1074/jbc.275.2.921; Liliom K, 2001, BIOCHEM J, V355, P189, DOI 10.1042/0264-6021:3550189; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Mark MD, 2000, EUR J BIOCHEM, V267, P5830, DOI 10.1046/j.1432-1327.2000.01670.x; Maurice JP, 1999, J CLIN INVEST, V104, P21, DOI 10.1172/JCI6026; Medina I, 2000, J BIOL CHEM, V275, P29709, DOI 10.1074/jbc.M004989200; MERY PF, 1993, N-S ARCH PHARMACOL, V348, P197, DOI 10.1007/BF00164799; Meyer T, 2001, J BIOL CHEM, V276, P5650, DOI 10.1074/jbc.M009179200; Mullner C, 2000, J GEN PHYSIOL, V115, P547, DOI 10.1085/jgp.115.5.547; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; PELZER D, 1990, REV PHYSIOL BIOCH P, V114, P107; Peppel K, 1997, TRENDS CARDIOVAS MED, V7, P145, DOI 10.1016/S1050-1738(97)00028-5; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; Post SR, 1999, ANNU REV PHARMACOL, V39, P343, DOI 10.1146/annurev.pharmtox.39.1.343; Shah AS, 2000, CIRCULATION, V101, P408, DOI 10.1161/01.CIR.101.4.408; Sorota S, 1999, J PHYSIOL-LONDON, V514, P413, DOI 10.1111/j.1469-7793.1999.413ae.x; Steinberg SF, 1999, CIRC RES, V85, P1101; UI M, 1990, ADV SEC MESS PHOSPH, V24, P63; WANG YG, 1995, CIRC RES, V77, P565, DOI 10.1161/01.RES.77.3.565; Wellner-Kienitz MC, 1999, FEBS LETT, V451, P279, DOI 10.1016/S0014-5793(99)00594-3; Wellner-Kienitz MC, 2000, CIRC RES, V86, P643, DOI 10.1161/01.RES.86.6.643; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Xiao RP, 1999, CIRC RES, V85, P1092; Xiao RP, 1999, CIRC RES, V84, P43; Yamada M, 1998, PHARMACOL REV, V50, P723; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607	50	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37347	37354		10.1074/jbc.M106234200	http://dx.doi.org/10.1074/jbc.M106234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11495921	hybrid			2022-12-25	WOS:000171375700066
J	Jungwirth, H; Bergler, H; Hogenauer, G				Jungwirth, H; Bergler, H; Hogenauer, G			Diazaborine treatment of Baker's yeast results in stabilization of aberrant mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; GENE; SIGNALS; EXPORT; SURVEILLANCE; TERMINATION; RESISTANCE; PROTEINS; BINDING	Upon Northern blotting, Saccharomyces cerevisiae that was treated with diazaborine showed aberrant mRNAs that were extended at the 3'-end and terminated at secondary processing sites. These bands were also detected in untreated Delta upf1, Delta xrn1, and rat7-1 mutants. This finding demonstrates that the aberrant mRNAs also occur in untreated strains in small quantities and can reach the cytoplasm, where they are normally degraded by Xrn1p. Diazaborine treatment stabilizes these mRNAs. The detection of the aberrant bands in the untreated rat7-1 strain indicates that Rat7 is involved in quality control of RNA. The aberrant mRNAs were not detected after diazaborine treatment of a DRG1-1 mutant. Drg1p, a member of the family of AAA (ATPases associated with a variety of cellular activities) proteins, which are thought to represent specific chaperones, may be involved in the process of unfolding the mRNA-ribonucleoprotein complex or in the recognition of aberrant mRNA molecules in the cytoplasm.	Graz Univ, Inst Mol Biol Biochem & Mikrobiol, A-8010 Graz, Austria	University of Graz	Hogenauer, G (corresponding author), Graz Univ, Inst Mol Biol Biochem & Mikrobiol, Univ Pl 2, A-8010 Graz, Austria.	gregor.hoegenauer@uni-graz.at	Heterocycles, BoronNitrogen/Q-1699-2019; Liu, Shih/Q-1672-2019	Bergler, Helmut/0000-0002-7724-309X; Jungwirth, Helmut/0000-0003-4868-4571				AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; BERGLER H, 1994, J BIOL CHEM, V269, P5493; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Czaplinski K, 1999, BIOESSAYS, V21, P685, DOI 10.1002/(SICI)1521-1878(199908)21:8<685::AID-BIES8>3.0.CO;2-4; Das B, 2000, MOL CELL BIOL, V20, P2827, DOI 10.1128/MCB.20.8.2827-2838.2000; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; Guo ZJ, 1996, TRENDS BIOCHEM SCI, V21, P477, DOI 10.1016/S0968-0004(96)10057-8; He F, 1997, MOL CELL BIOL, V17, P1580, DOI 10.1128/MCB.17.3.1580; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnson AW, 1997, MOL CELL BIOL, V17, P6122, DOI 10.1128/MCB.17.10.6122; Jungwirth H, 2000, EUR J BIOCHEM, V267, P4809, DOI 10.1046/j.1432-1327.2000.01537.x; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; RUSSO P, 1993, MOL CELL BIOL, V13, P7836, DOI 10.1128/MCB.13.12.7836; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Sherman F, 1979, METHODS YEAST GENETI; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; Wendler F, 1997, J BIOL CHEM, V272, P27091, DOI 10.1074/jbc.272.43.27091	26	13	13	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36419	36424		10.1074/jbc.M104487200	http://dx.doi.org/10.1074/jbc.M104487200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477081	hybrid			2022-12-25	WOS:000171194500050
J	Vrablic, AS; Albright, CD; Craciunescu, CN; Salganik, RI; Zeisel, SH				Vrablic, AS; Albright, CD; Craciunescu, CN; Salganik, RI; Zeisel, SH			Altered mitochondrial function and overgeneration of reactive oxygen species precede the induction of apoptosis by 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine in p53-defective hepatocytes	FASEB JOURNAL			English	Article						apoptosis; cancer; edelfosine; mitochondria; phosphatidylcholine; reactive oxygen species	MEMBRANE-PERMEABILITY TRANSITION; PROTEIN-KINASE-C; CHOLINE-DEFICIENCY; RAT HEPATOCYTES; CYTOCHROME-C; SIMIAN VIRUS-40; PC12 CELLS; COMPLEX-I; EXPRESSION; ACTIVATION	The mechanism of induction of apoptosis by the novel anti-cancer drug 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3) was investigated in p53-defective SV40 immortalized rat hepatocytes (CWSV1). Exposure to 12 muM ET-18-OCH3 for 36 h induced apoptosis as determined using classical morphological features and agarose gel electrophoresis of genomic DNA. Increased levels of reactive oxygen species (ROS) were detected spectrophotometrically using a nitroblue tetrazolium (NBT) assay in cells treated with ET-18-OCH3. Both the increased generation of ROS and the induction of apoptosis were inhibited when cells were treated concurrently with ET-18-OCH3 in the presence of the antioxidant alpha -tocopherol. Similar results were achieved when cells were switched acutely to choline- deficient (CD) medium in the presence of the antioxidant. The possible role of mitochondria in the generation of ROS was investigated. Both ET-18-OCH3 and CD decreased the phosphatidylcholine (PC) content of mitochondrial and associated membranes, which correlated with depolarization of the mitochondrial membrane as analyzed using 5,5', 6,6'- tetramethylbenzimidazolcarbocyanine iodide (JC-1), a sensitive probe of mitochondrial membrane potential. Rotenone, an inhibitor of the mitochondrial electron transport chain, significantly reduced the intracellular level of ROS and prevented mitochondrial membrane depolarization, correlating with a reduction of apoptosis in response to either ET-18-OCH3 or CD. Taken together, these results suggest that the form of p53-independent apoptosis induced by ET-18-OCH3 is mediated by alterations in mitochondrial membrane PC, a loss of mitochondrial membrane potential, and the release of ROS, resulting in completion of apoptosis.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, CB 7400,2213 McGavran Greenberg Hall, Chapel Hill, NC 27599 USA.	steven_zeisel@unc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [AG09525] Funding Source: Medline; NIDDK NIH HHS [DK55865] Funding Source: Medline; NIGMS NIH HHS [GM14840] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albright CD, 1996, FASEB J, V10, P510, DOI 10.1096/fasebj.10.4.8647350; Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4; Camilleri-Broet S, 1998, EXP CELL RES, V239, P277, DOI 10.1006/excr.1997.3899; Castedo M, 1995, EUR J IMMUNOL, V25, P3277, DOI 10.1002/eji.1830251212; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; Chinopoulos C, 1999, J NEUROCHEM, V73, P220, DOI 10.1046/j.1471-4159.1999.0730220.x; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; DACOSTA KA, 1993, J BIOL CHEM, V268, P2100; Decaudin D, 1998, INT J ONCOL, V12, P141; DRYER RL, 1975, BIOCHIM BIOPHYS ACTA, V380, P370, DOI 10.1016/0005-2760(75)90105-8; Hardman WE, 1997, BRIT J CANCER, V76, P347, DOI 10.1038/bjc.1997.389; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; Isenberg JS, 2000, TOXICOL SCI, V53, P340, DOI 10.1093/toxsci/53.2.340; Kates, 1975, TECHNIQUES LIPIDOLOG; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KunzSchughart LA, 1997, AM J PHYSIOL-CELL PH, V273, pC1487, DOI 10.1152/ajpcell.1997.273.5.C1487; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li LW, 1999, MOL CELL BIOL, V19, P8547; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Matsunaga T, 1996, LEUKEMIA LYMPHOMA, V20, P487, DOI 10.3109/10428199609052434; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Mollinedo F, 1997, CANCER RES, V57, P1320; Okun JG, 2000, BBA-BIOENERGETICS, V1459, P77, DOI 10.1016/S0005-2728(00)00115-8; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; ROOK GAW, 1985, J IMMUNOL METHODS, V82, P161, DOI 10.1016/0022-1759(85)90235-2; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; Sestili P, 2000, EUR J NEUROSCI, V12, P145, DOI 10.1046/j.1460-9568.2000.00891.x; Shin OH, 1997, J CELL BIOCHEM, V64, P196, DOI 10.1002/(SICI)1097-4644(199702)64:2<196::AID-JCB3>3.0.CO;2-S; SULIK K, 1994, DEV DYNAM, V201, P260, DOI 10.1002/aja.1002010309; WAGNER BA, 1993, CANCER RES, V53, P711; WOODWORTH C, 1986, CANCER RES, V46, P4018; WOODWORTH CD, 1987, MOL CELL BIOL, V7, P3740, DOI 10.1128/MCB.7.10.3740; WOODWORTH CD, 1988, MOL CELL BIOL, V8, P4492, DOI 10.1128/MCB.8.10.4492; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Zeisel SH, 1997, CARCINOGENESIS, V18, P731, DOI 10.1093/carcin/18.4.731	45	116	119	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					1739	1744		10.1096/fj.00-0300com	http://dx.doi.org/10.1096/fj.00-0300com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481221				2022-12-25	WOS:000170809900009
J	Hideshima, T; Chauhan, D; Schlossman, R; Richardson, P; Anderson, KC				Hideshima, T; Chauhan, D; Schlossman, R; Richardson, P; Anderson, KC			The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications	ONCOGENE			English	Article						TNF alpha; multiple myeloma; adhesion molecule; IL-6; NF-kappa B	MARROW STROMAL CELLS; NF-KAPPA-B; ADHESION MOLECULES; INDUCED APOPTOSIS; DRUG-RESISTANCE; GROWTH-FACTOR; INTERLEUKIN-6; THALIDOMIDE; ACTIVATION; EXPRESSION	In this study we demonstrate that tumor necrosis factor alpha (TNF alpha) triggers only modest proliferation, as well as p44/p42 mitogen-activated protein kinase (MAPK) and NF-kappaB activation, in MM.1S multiple myeloma (MM) cells. TNF alpha also activates NF-kappaB and markedly upregulates (fivefold) secretion of interleukin-6 (IL-6), a myeloma growth and survival factor, in bone marrow stromal cells (BMSCs). TNF alpha in both a dose and time dependent fashion induced expression of CD11a (LFA-1), CD54 (intercellular adhesion molecule-1, ICAM-1), CD106 (vascular cell adhesion molecule-1, VCAM-1), CD49d (very late activating antigen-4, VLA-4), and/or MUC-1 on MM cell lines; as well as CD106 (VCAM-1) and CD54 (ICAM-1) expression on BMSCs. This resulted in increased (2-4-fold) per cent specific binding of MM cells to BMSCs, with related IL-6 secretion. Importantly, the proteasome inhibitor PS-341 abrogated TNF alpha -induced NF-kappaB activation, induction of ICAM-1 or VCAM-1, and increased adhesion of MM cells to BMSCs. Agents which act to inhibit TNF alpha may therefore abrogate the paracrine growth and survival advantage conferred by MM cell adhesion in the BM microenvironment.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu			PHS HHS [P01 78378] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BORSET M, 1994, EUR J HAEMATOL, V53, P31; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Corral LG, 1999, J IMMUNOL, V163, P380; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dankbar Berno, 2000, Blood, V95, P2630; Davies FE, 2000, J CLIN ONCOL, V18, P2843, DOI 10.1200/JCO.2000.18.15.2843; DAVIES FE, 2001, IN PRESS BLOOD; Filella X, 1996, CANCER DETECT PREV, V20, P52; GARRETT IR, 1987, NEW ENGL J MED, V317, P526, DOI 10.1056/NEJM198708273170902; GUPTA D, 2001, IN PRESS LEUKEMIA; Haslett PAJ, 1998, J EXP MED, V187, P1885, DOI 10.1084/jem.187.11.1885; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Jourdan M, 1999, EUR CYTOKINE NETW, V10, P65; Junn E, 2000, J IMMUNOL, V165, P2190, DOI 10.4049/jimmunol.165.4.2190; KIM I, 1994, BRIT J HAEMATOL, V87, P483, DOI 10.1111/j.1365-2141.1994.tb08302.x; Li P, 2000, J IMMUNOL, V164, P5990, DOI 10.4049/jimmunol.164.11.5990; LICHTENSTEIN A, 1989, BLOOD, V74, P1266; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Marriott JB, 1998, J IMMUNOL, V161, P4236; Ogata A, 1997, J IMMUNOL, V159, P2212; Palombella VJ, 1998, P NATL ACAD SCI USA, V95, P15671, DOI 10.1073/pnas.95.26.15671; PODAR K, 2001, IN PRESS BLOOD; Raje N, 1999, NEW ENGL J MED, V341, P1606, DOI 10.1056/NEJM199911183412110; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; Sati HIA, 1999, BRIT J HAEMATOL, V104, P350, DOI 10.1046/j.1365-2141.1999.01193.x; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Teoh G, 1997, HEMATOL ONCOL CLIN N, V11, P27, DOI 10.1016/S0889-8588(05)70413-5; TREON SP, 2001, IN PRESS J IMMUNOTHE; UCHIYAMA H, 1992, BLOOD, V80, P2306; UCHIYAMA H, 1993, BLOOD, V82, P3712; Urashima M, 1997, BLOOD, V90, P279; Urashima M, 1996, BLOOD, V87, P1928; Vacca A, 1999, BLOOD, V93, P3064	39	310	341	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4519	4527		10.1038/sj.onc.1204623	http://dx.doi.org/10.1038/sj.onc.1204623			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494147				2022-12-25	WOS:000170074900009
J	Miyoshi-Akiyama, T; Aleman, LM; Smith, JM; Adler, CE; Mayer, BJ				Miyoshi-Akiyama, T; Aleman, LM; Smith, JM; Adler, CE; Mayer, BJ			Regulation of Cbl phosphorylation by the Abl tyrosine kinase and the Nck SH2/SH3 adaptor	ONCOGENE			English	Article						signal transduction; protein binding modules	GROWTH-FACTOR RECEPTOR; CHRONIC MYELOGENOUS LEUKEMIA; SRC HOMOLOGY-3 DOMAINS; PROTOONCOGENE C-CBL; SH3 DOMAINS; IN-VIVO; V-ABL; TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR	The Cbl proto-oncogene product is tyrosine phosphorylated in response to a wide variety of stimuli. Cbl and the Abl nonreceptor tyrosine kinase both bind to SH3 domains from the SH2/SH3 adaptor Nck, and are candidate effecters for Nck function. Numerous additional SH2- and SH3-domain-mediated interactions are also possible between Cbl, Abl, and Nck, We find that these three signaling proteins associate when overexpressed in mammalian cells and can regulate each other's activity. Go-expression of mt Cbl together with c-Abl, the activity of which is normally repressed in vivo, led to extensive Abl-dependent phosphorylation of Cbl, The major proline-rich region of Cbl was required for ifs phosphorylation by c-Abl, but not by a constitutively activated Abl mutant, suggesting Cbl activates c-Abl by engaging its SH3 domain. Efficient phosphorylation of Cbl and its stable association with Abl required the SH2 domain of Abl, suggesting that SH2-phosphotyrosine interactions prevent dissociation of active Abl from Cbl, We also show that overexpression of Nck could repress the phosphorylation of Cbl by Abl in vivo. Studies with Nck mutants suggested that the Nck SH2 domain is responsible for inhibiting the activity of Abl toward both Cbl and Nck itself, most likely by competing with the Abl SH2 for tyrosine-phosphorylated binding sites.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	University of Connecticut; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Mayer, BJ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.				NCI NIH HHS [CA82258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler CE, 2000, J BIOL CHEM, V275, P36472, DOI 10.1074/jbc.M005424200; Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; BLAKE TJ, 1991, ONCOGENE, V6, P653; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Izadi KD, 1998, EXP CELL RES, V245, P330, DOI 10.1006/excr.1998.4259; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Majidi M, 1998, J BIOL CHEM, V273, P16608, DOI 10.1074/jbc.273.26.16608; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Parrini MC, 1999, CHEM BIOL, V6, P679, DOI 10.1016/S1074-5521(00)80015-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; Raffel GD, 1996, J BIOL CHEM, V271, P4640; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sattler M, 1996, ONCOGENE, V12, P839; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shishido T, 2000, P NATL ACAD SCI USA, V97, P6439, DOI 10.1073/pnas.060030697; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1995, ONCOGENE, V10, P1977; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wunderlich L, 1999, CELL SIGNAL, V11, P253, DOI 10.1016/S0898-6568(98)00054-0; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	73	29	29	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					4058	4069		10.1038/sj.onc.1204528	http://dx.doi.org/10.1038/sj.onc.1204528			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494134				2022-12-25	WOS:000169681500014
J	Choi, SH; Park, CH; Koo, JW; Seo, JH; Kim, HS; Jeong, SJ; Lee, JH; Kim, SS; Suh, YH				Choi, SH; Park, CH; Koo, JW; Seo, JH; Kim, HS; Jeong, SJ; Lee, JH; Kim, SS; Suh, YH			Memory impairment and cholinergic dysfunction by centrally administered A beta and carboxyl-terminal fragment of Alzheimer's APP in mice	FASEB JOURNAL			English	Article						amyloid beta peptide; learning and memory; acetylcholine; pyruvate dehydrogenase	AMYLOID PRECURSOR PROTEIN; PYRUVATE-DEHYDROGENASE ACTIVITY; HIPPOCAMPUS IN-VIVO; ACETYLCHOLINE-RELEASE; CALCIUM HOMEOSTASIS; CORTICAL-NEURONS; SENILE DEMENTIA; RAT-BRAIN; DISEASE; NEUROTOXICITY	Alzheimer's disease (AD) is characterized by cognitive impairment and excessive deposition of neurite plaques (NPs). Although the pathogenic mechanism of AD is not exactly known, there is increasing evidence that amyloid beta protein (A beta), which is the major constituent of NPs and is derived from amyloid precursor protein (APP), plays a key role in the neuronal degeneration in AD. However, because there are several discrepancies between A beta deposition and neurodegeneration or cognitive impairment in AD, the possible effects of other cleavage products of APP need to be explored. We previously showed that a recombinant carboxyl-terminal 105 amino acid fragment of APP (CT105) induced neurotoxicities both in vitro and in vivo. However, it is unclear whether learning and memory impairments and neurochemical changes are induced by CT105. To elucidate the in vivo neurotoxicities of A beta and CT105, we examined behavioral changes using a Y-maze and a water maze task following a single intracerebroventricular injection of CT105 (68.5, 342 and 685 pmol) or A beta (1-42) (685 pmol) to mice. We also quantified the changes in the acetylcholine (ACh) level and assayed mitochondrial pyruvate dehydrogenase (PDH) activity. CT105 caused much more significant impairments in cued, spatial, and working memory performances of mice in Y-maze and water maze tasks in a dose-dependent manner than A beta (1-42). Also, the mice injected with CT105 revealed significant decreases in ACh levels and reduced PDH activities in the cerebral cortex and hippocampus compared with the saline-treated control and A beta (1-42)-treated groups. These results suggest that learning and memory impairment induced by centrally administered CT105 is in some way related to the reduced ACh levels and mitochondrial PDH activities and that CT105 is more potent than A beta in inducing cognitive dysfunction.	Seoul Natl Univ, Natl Creat Res Initiat Ctr Alzheimers Dementia, Coll Med, Dept Pharmacol, Seoul 110799, South Korea; Seoul Natl Univ, MRC, Neurosci Res Inst, Seoul 110799, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151741, South Korea; Chung Ang Univ, Coll Med, Dept Anat, Seoul 156756, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Chung Ang University; Chung Ang University Hospital	Suh, YH (corresponding author), Seoul Natl Univ, Natl Creat Res Initiat Ctr Alzheimers Dementia, Coll Med, Dept Pharmacol, Seoul 110799, South Korea.	ysuh@plaza.snu.ac.kr	Kim, Hye Sun/J-2752-2012; Suh, Yoo-Hun/J-2761-2012					ABE E, 1994, BRAIN RES, V636, P162, DOI 10.1016/0006-8993(94)90193-7; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Berger-Sweeney J, 1999, MOL BRAIN RES, V66, P150, DOI 10.1016/S0169-328X(99)00014-5; BIERER LM, 1995, J NEUROCHEM, V64, P749; BROWNING M, 1981, J NEUROCHEM, V36, P1932, DOI 10.1111/j.1471-4159.1981.tb10817.x; CAPUTO CB, 1992, BIOCHEM BIOPH RES CO, V185, P1034, DOI 10.1016/0006-291X(92)91730-E; CHONG YH, 1994, LIFE SCI, V54, P1259; CLEARY J, 1995, BRAIN RES, V682, P69, DOI 10.1016/0006-8993(95)00323-I; CLEMENS JA, 1992, NEUROBIOL AGING, V13, P581, DOI 10.1016/0197-4580(92)90059-7; Cullen WK, 1997, NEUROREPORT, V8, P3213, DOI 10.1097/00001756-199710200-00006; DeGiorgio LA, 2000, BRAIN RES, V874, P137, DOI 10.1016/S0006-8993(00)02545-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Fraser SP, 1996, J NEUROCHEM, V66, P2034; FRICK KM, 1995, NEUROBIOL AGING, V16, P149, DOI 10.1016/0197-4580(94)00155-3; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; GEARING M, 1993, J NEUROPATH EXP NEUR, V52, P22, DOI 10.1097/00005072-199301000-00004; GEULA C, 1994, BRAIN RES, V644, P327, DOI 10.1016/0006-8993(94)91697-7; Hartell NA, 2000, J NEUROCHEM, V74, P1112; Holcomb LA, 1999, BEHAV GENET, V29, P177, DOI 10.1023/A:1021691918517; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; ISRAEL M, 1982, J NEUROCHEM, V39, P248, DOI 10.1111/j.1471-4159.1982.tb04727.x; KAMETANI F, 1994, FEBS LETT, V351, P165, DOI 10.1016/0014-5793(94)00851-5; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; Kim HJ, 1999, NEUROREPORT, V10, P1427, DOI 10.1097/00001756-199905140-00008; Kim HS, 2000, FASEB J, V14, P1508, DOI 10.1096/fj.14.11.1508; Kim SH, 1996, J NEUROCHEM, V67, P1172; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P7508, DOI 10.1073/pnas.90.16.7508; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; KOWALL NW, 1992, NEUROBIOL AGING, V13, P537, DOI 10.1016/0197-4580(92)90053-Z; LAURSEN SE, 1986, J PHARMACOL METHOD, V16, P355, DOI 10.1016/0160-5402(86)90038-0; Lee JP, 2000, J NEUROSCI RES, V60, P565, DOI 10.1002/(SICI)1097-4547(20000515)60:4<565::AID-JNR16>3.0.CO;2-I; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; MATSUMOTO A, 1991, BIOCHEM BIOPH RES CO, V175, P361, DOI 10.1016/0006-291X(91)91572-T; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; NEVE RL, 1992, P NATL ACAD SCI USA, V89, P3448, DOI 10.1073/pnas.89.8.3448; PALMER AM, 1990, FASEB J, V4, P2745, DOI 10.1096/fasebj.4.10.2165009; PARNETTI L, 1995, NEUROSCI LETT, V199, P231, DOI 10.1016/0304-3940(95)12058-C; PERRY EK, 1980, NEUROSCI LETT, V18, P105, DOI 10.1016/0304-3940(80)90220-7; PIKE CJ, 1993, NEUROSCIENCE, V56, P269, DOI 10.1016/0306-4522(93)90331-9; QUIRION R, 1993, J PSYCHIATR NEUROSCI, V18, P226; SARTER M, 1988, PSYCHOPHARMACOLOGY, V94, P491, DOI 10.1007/BF00212843; Sberna G, 1998, J NEUROCHEM, V71, P723; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; Song DK, 1998, J NEUROCHEM, V71, P875; SORBI S, 1983, ANN NEUROL, V13, P72, DOI 10.1002/ana.410130116; STERRI SH, 1980, J NEUROCHEM, V35, P249, DOI 10.1111/j.1471-4159.1980.tb12511.x; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TERRY RD, 1983, ANN NEUROL, V14, P497, DOI 10.1002/ana.410140502; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; Yamada K, 1999, EUR J NEUROSCI, V11, P83, DOI 10.1046/j.1460-9568.1999.00408.x; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	56	40	40	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1816	+		10.1096/fj.00-0859fje	http://dx.doi.org/10.1096/fj.00-0859fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481240				2022-12-25	WOS:000169261200018
J	Borre, L; Kanner, BI				Borre, L; Kanner, BI			Coupled, but not uncoupled, fluxes in a neuronal glutamate transporter can be activated by lithium ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; MEMBRANE-VESICLES; ACID TRANSPORTER; CHLORIDE CHANNEL; GLT-1; EXPRESSION; SUBSTRATE; ACCESSIBILITY; MECHANISM; CLEARANCE	In the central nervous system a family of related (Na+-K+)-coupled glutamate transporters remove the transmitter from the cleft and prevent its neurotoxic actions. In addition to this coupled uptake, these transporters also mediate a sodium- and glutamate-dependent uncoupled anion conductance. Most models assume that the initial steps for both processes are the same, leading to the anticipation that both may exhibit a similar requirement for cations. In this study we have tested this idea in the neuronal glutamate transporter EAAC-1. We report that in this transporter lithium can replace sodium in the coupled uptake. Strikingly, the glutamate-dependent gating of the uncoupled conductance mediated by EAAC-1 has a strict requirement for sodium; lithium cannot substitute for it. Moreover, we describe two mutants, T370S and G410S, in which the cation selectivity of the two processes is affected differently. In both mutants sodium, but not lithium, can support coupled transport. On the other hand, the sodium selectivity of the gated anion conductance in oocytes expressing the mutant transporters is not affected. Our observations indicate that although both the coupled and the uncoupled fluxes are sodium-dependent, the conformation gating the anion conductance is different from that during substrate translocation.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.	kannerb@cc.huji.ac.il			NINDS NIH HHS [NS 16708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Auger C, 2000, NEURON, V28, P547, DOI 10.1016/S0896-6273(00)00132-X; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; Diamond JS, 1997, J NEUROSCI, V17, P4672; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Grewer C, 2000, P NATL ACAD SCI USA, V97, P9706, DOI 10.1073/pnas.160170397; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Otis TS, 2000, J NEUROSCI, V20, P2749; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Watzke N, 2000, J GEN PHYSIOL, V116, P609, DOI 10.1085/jgp.116.5.609; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	41	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40396	40401		10.1074/jbc.M104926200	http://dx.doi.org/10.1074/jbc.M104926200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11479303	hybrid			2022-12-25	WOS:000171925600007
J	Holmes-McNary, MQ; Baldwin, AS; Zeisel, SH				Holmes-McNary, MQ; Baldwin, AS; Zeisel, SH			Opposing regulation of choline deficiency-induced apoptosis by p53 and nuclear factor kappa B.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACID-DEFINED DIET; DNA-DAMAGE; CELL-GROWTH; P53-INDEPENDENT APOPTOSIS; RAT HEPATOCYTES; PROTEIN-KINASE; CANCER CELLS; DEVOID DIET; ACTIVATION	We have previously shown that fetal rat brain cells, preneuronal (PC12), and hepatocyte (CWSV-1) cells undergo apoptosis during choline deficiency (CD). The PC12 and epithelial cell culture models were used to determine the molecular mechanism by which CD induces apoptosis. Our data indicate that CD leads to both growth arrest and apoptosis in a subpopulation of cells, which correlate with the up-regulation of the tumor suppressor protein p53 and concurrent up-regulation of the cyclin-dependent kinase-inhibitor p21(WAF1/CIP1). Additionally, CD induced both a G(1)/S and a G(2)/M arrest. Transient transfection of a dominant negative p53 (p53DN) construct. into PC12 cells, which inhibited endogenous p53 activation, significantly reduced the induction of apoptosis associated with CD. Interestingly, CD also induced the persistent activation of the transcription factor NF-B. Activation of NF-KB has been shown to promote cell survival and proposed to antagonize p53. Consistent with this, expression of a super-repressor form of l kappaB alpha (SR-I kappaB alpha) that functions to strongly inhibit NF-KB activation, profoundly enhanced cell death during CD. In summary, these results suggest that the effects of CD on apoptosis and subsequent cell survival are mediated through two different signaling pathways, p53 and NF-kappaB, respectively. Taken together, our data demonstrates the induction of opposing mechanisms associated with nutrient deficiency that may provide a molecular mechanism by which CD promotes carcinogenesis.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Nutr, Sch Publ Hlth, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Holmes-McNary, MQ (corresponding author), Ohio State Univ, Sch Med, Dept Human Nutr, Ctr Comprehens Canc, 347B Campbell Hall,1787 Neil Ave, Columbus, OH 43210 USA.	holmes-mcnary.l@osu.edu	Ariel, Pablo/AGJ-4118-2022		NCI NIH HHS [CA75080, CA72771, 1F32CA77908-01] Funding Source: Medline; NIA NIH HHS [AG09525] Funding Source: Medline; NIDDK NIH HHS [DK55865, DK56350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072771, R01CA075080, F32CA077908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865, P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albright CD, 1996, FASEB J, V10, P510, DOI 10.1096/fasebj.10.4.8647350; Albright CD, 1997, PATHOBIOLOGY, V65, P264, DOI 10.1159/000164137; ALBRIGHT CD, 1997, ADV EXP MED BIOL, V9, P476; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bartke T, 2001, ONCOGENE, V20, P571, DOI 10.1038/sj.onc.1204124; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; CHRISTMAN JK, 1995, ADV EXP MED BIOL, V375, P97; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COPELAND DH, 1946, AM J PATHOL, V22, P1059; Cusack JC, 2000, CANCER RES, V60, P2323; DACOSTA KA, 1993, J BIOL CHEM, V268, P2100; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Eastin CE, 1997, ALCOHOL CLIN EXP RES, V21, P1037, DOI 10.1111/j.1530-0277.1997.tb04250.x; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Food andNutrition Board Institute of Medicine, 1998, DIET REF INT THIAM R, DOI 10.17226/6015; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Holmes-McNary M, 2000, CANCER RES, V60, P3477; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KASTAN MB, 1991, CANCER RES, V51, P6304; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOMBARDI B, 1991, DIGEST DIS SCI, V36, P979, DOI 10.1007/BF01297151; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nakae D, 1998, CANCER RES, V58, P4548; Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001; PINES J, 1994, NATURE, V369, P520, DOI 10.1038/369520a0; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rathmell WK, 1997, CANCER RES, V57, P68; Ravi R, 1998, CANCER RES, V58, P4531; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; RUSHMORE TH, 1986, CARCINOGENESIS, V7, P1677, DOI 10.1093/carcin/7.10.1677; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schottelius AJG, 1999, INT J COLORECTAL DIS, V14, P18, DOI 10.1007/s003840050178; Seitz CS, 2000, CANCER RES, V60, P4085; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shinozuka H, 1986, Adv Exp Med Biol, V206, P253; Tsujiuchi T, 1995, JPN J CANCER RES, V86, P1136, DOI 10.1111/j.1349-7006.1995.tb03306.x; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WU HY, 1994, J BIOL CHEM, V269, P20067; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zeisel S H, 1997, Adv Pediatr, V44, P263; Zeisel SH, 1997, CARCINOGENESIS, V18, P731, DOI 10.1093/carcin/18.4.731	69	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41197	41204		10.1074/jbc.M010936200	http://dx.doi.org/10.1074/jbc.M010936200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11483591	hybrid, Green Published			2022-12-25	WOS:000171925600110
J	Whitney, ML; Otto, KG; Blau, CA; Reinecke, H; Murry, CE				Whitney, ML; Otto, KG; Blau, CA; Reinecke, H; Murry, CE			Control of myoblast proliferation with a synthetic ligand.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SKELETAL-MUSCLE GROWTH; TERMINAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; FACTOR RECEPTOR-1; TRANSPLANTATION; EXPRESSION; ACTIVATION; MOUSE	Skeletal myoblast grafts can form contractile tissue to replace scar and repair injured myocardium. Although potentially therapeutic, generating reproducible and sufficiently large grafts remains a challenge. To control myoblast proliferation in situ, we created a chimeric receptor composed of a modified FK506-binding protein (F36V) fused with the fibroblast growth factor receptor-1 cytoplasmic domain. Mouse MM14 myoblasts were transfected with this construct and treated with AP20187, a dimeric F36V ligand, to induce receptor dimerization. Transfected myoblasts proliferated in response to dimerizer (comparable with basic fibroblast growth factor (bFGF) treatment), whereas the dimerizer had no effect on non-transfected cells. Similar to bFGF treatment, dimerizer treatment blocked myotube formation and myosin heavy chain expression and stimulated mitogen-activated protein (MAP) kinase phosphorylation in transfected cells. Non-transfected cells differentiated normally and showed no MAP kinase phosphorylation with dimerizer treatment. Furthermore, myoblasts treated with dimerizer for 30 days in culture reduced MAP kinase phosphorylation, withdrew from the cell cycle, and differentiated normally upon drug withdrawal, demonstrating reversibility of the effect. Thus, forced dimerization of the fibroblast growth factor receptor-1 cytoplasmic domain reproduces critical aspects of bFGF signaling in myoblasts. We hypothesize that in vivo administration of AP20187 following myoblast grafting may allow control over graft size and ultimately improve cardiac function.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Univ Washington, Div Hematol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Murry, CE (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.		Rolle, Marsha W/D-8286-2012	Rolle, Marsha/0000-0003-2026-4700	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061553, R24HL064387, K08HL003094, P01HL003174] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07312, R24HL64387-01, R01HL61553, K08HL03094, P01HL03174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; Atkins BZ, 1999, ANN THORAC SURG, V67, P124, DOI 10.1016/S0003-4975(98)01197-7; Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Cheng L, 1997, GENE THER, V4, P1013, DOI 10.1038/sj.gt.3300507; CHIU RCJ, 1995, ANN THORAC SURG, V60, P12; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; Jin LQ, 1998, P NATL ACAD SCI USA, V95, P8093, DOI 10.1073/pnas.95.14.8093; Jin LQ, 2000, NAT GENET, V26, P64, DOI 10.1038/79194; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; KIM EG, 1993, AM J PHYSIOL, V264, pF66, DOI 10.1152/ajprenal.1993.264.1.F66; KLINT P, 1999, FRONT BIOSCI, V4, P165; Kudla AJ, 1998, J CELL BIOL, V142, P241, DOI 10.1083/jcb.142.1.241; KUDLA AJ, 1995, MOL CELL BIOL, V15, P3238; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; Menasche P, 2001, LANCET, V357, P279, DOI 10.1016/S0140-6736(00)03617-5; MENDELL JR, 1995, NEW ENGL J MED, V333, P832, DOI 10.1056/NEJM199509283331303; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MORGAN JE, 1990, J CELL BIOL, V111, P2437, DOI 10.1083/jcb.111.6.2437; Murry CE, 1996, J CLIN INVEST, V98, P2512, DOI 10.1172/JCI119070; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ozawa CR, 2000, ANNU REV PHARMACOL, V40, P295, DOI 10.1146/annurev.pharmtox.40.1.295; Reinecke H, 2000, J CELL BIOL, V149, P731, DOI 10.1083/jcb.149.3.731; Reinecke H, 2000, CARDIOVASC PATHOL, V9, P337, DOI 10.1016/S1054-8807(00)00055-7; Richard RE, 2000, BLOOD, V95, P430, DOI 10.1182/blood.V95.2.430; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; TEMPLETON TJ, 1992, DEV BIOL, V154, P169, DOI 10.1016/0012-1606(92)90057-N	32	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41191	41196		10.1074/jbc.M103191200	http://dx.doi.org/10.1074/jbc.M103191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11502737	hybrid			2022-12-25	WOS:000171925600109
J	Appleby, TC; Mathews, II; Porcelli, M; Cacciapuoti, G; Ealick, SE				Appleby, TC; Mathews, II; Porcelli, M; Cacciapuoti, G; Ealick, SE			Three-dimensional structure of a hyperthermophilic 5 '-deoxy-5 '-methylthioadenosine phosphorylase from Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOSIDE PHOSPHORYLASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; TERNARY COMPLEX; PROTEIN; PURIFICATION; THERMOSTABILITY; REVEALS; BINDING	The structure of 5'-deoxy-5'-methylthioadenosine phosphorylase from Sulfolobus solfataricus (SsMTAP) has been determined alone, as ternary complexes with sulfate plus substrates 5'-deoxy-5'-methylthioadenosine, adenosine, or guanosine, or with the noncleavable substrate analog Formycin B and as binary complexes with phosphate or sulfate alone. The structure of unliganded SsMTAP was refined at 2.5-Angstrom resolution and the structures of the complexes were refined at resolutions ranging from 1.6 to 2.0 Angstrom SsMTAP is unusual both for its broad substrate specificity and for its extreme thermal stability. The hexameric structure of SsMTAP is similar to that of purine-nucleoside phosphorylase (PNP) from Escherichia coli, however, only SsMTAP accepts 5'-deoxy-5'-methylthioadenosine as a substrate. The active site of SsMTAP is similar to that of E. coli PNP with 13 of 18 nearest residues being identical. The main differences are at Thr(89), which corresponds to serine in E. coli PNP, and Glu(163), which corresponds to proline in E. coli PNP. In addition, a water molecule is found near the purine N-7 position in the guanosine complex of SsMTAP. Thr(89) is near the 5'-position of the nucleoside and may account for the ability of SsMTAP to accept either hydrophobic or hydrophilic substituents in that position. Unlike E. coli PNP, the structures of SsMTAP reveal a substrate-induced conformational change involving Glu(163). This residue is located at the interface between subunits and swings in toward the active site upon nucleoside binding. The high-resolution structures of SsMTAP suggest that the transition state is stabilized in different ways for 6-amino versus 6-oxo substrates. SsMTAP has optimal activity at 120 degreesC and retains full activity after 2 h at 100 degrees C. Examination of the three-dimensional structure of SsMTAP suggests that unlike most thermophilic enzymes, disulfide linkages play a key in role in its thermal stability.	Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; Univ Naples 2, Dipartimento Biochim & Biofis, I-80138 Naples, Italy	Cornell University; Universita della Campania Vanvitelli	Ealick, SE (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.	see3@cornell.edu			NCI NIH HHS [CA-67763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appleby TC, 1999, STRUCTURE, V7, P629, DOI 10.1016/S0969-2126(99)80084-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTIK K, 1994, BIOPHYS J, V66, P1180, DOI 10.1016/S0006-3495(94)80900-2; BZOWSKA A, 1990, Z NATURFORSCH C, V45, P59; BZOWSKA A, 1995, FEBS LETT, V367, P214, DOI 10.1016/0014-5793(95)00540-P; CACCIAPUOTI G, 1994, J BIOL CHEM, V269, P24762; Cacciapuoti G, 1999, PROTEIN EXPRES PURIF, V16, P125, DOI 10.1006/prep.1999.1076; CACCIAPUOTI G, 1989, PHYSL POLYAMINES, V2, P47; Chen JM, 2000, J MOL BIOL, V303, P125, DOI 10.1006/jmbi.2000.4140; DeDecker BS, 1996, J MOL BIOL, V264, P1072, DOI 10.1006/jmbi.1996.0697; DELANO WL, 1995, ACTA CRYSTALLOGR D, V51, P740, DOI 10.1107/S0907444995001284; DELLARAGIONE F, 1986, J BIOL CHEM, V261, P2324; EALICK SE, 1990, J BIOL CHEM, V265, P1812; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11725, DOI 10.1021/bi961969w; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11735, DOI 10.1021/bi961970v; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; GHODA LY, 1988, MOL BIOCHEM PARASIT, V27, P109, DOI 10.1016/0166-6851(88)90030-8; HASCHENMEYER RH, 1974, PROTEINS GUIDE STUDY; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; JENSEN KF, 1975, EUR J BIOCHEM, V51, P253, DOI 10.1111/j.1432-1033.1975.tb03925.x; Jiang YX, 1996, BIOCHEMISTRY-US, V35, P10269, DOI 10.1021/bi960918w; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koellner G, 1998, J MOL BIOL, V280, P153, DOI 10.1006/jmbi.1998.1799; Koellner G, 1997, J MOL BIOL, V265, P202, DOI 10.1006/jmbi.1996.0730; LESLIE AGW, 1986, DARESBURY LAB INF Q, V18, P33; Luic M, 2001, ACTA CRYSTALLOGR D, V57, P30, DOI 10.1107/S0907444900014402; Maes D, 1999, PROTEINS, V37, P441, DOI 10.1002/(SICI)1097-0134(19991115)37:3<441::AID-PROT11>3.3.CO;2-Z; Mao C, 1997, STRUCTURE, V5, P1373, DOI 10.1016/S0969-2126(97)00287-6; Mao C, 1998, BIOCHEMISTRY-US, V37, P7135, DOI 10.1021/bi9723919; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MORGUNOVA EY, 1995, FEBS LETT, V367, P183, DOI 10.1016/0014-5793(95)00489-V; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARKS RE, 1972, ENZYMES, V7, P483; PEGG AE, 1969, J BIOL CHEM, V244, P682; Pugmire MJ, 1998, STRUCTURE, V6, P1467, DOI 10.1016/S0969-2126(98)00145-2; Pugmire WJ, 1998, J MOL BIOL, V281, P285, DOI 10.1006/jmbi.1998.1941; Saenger W., 1984, PRINCIPLES NUCL ACID; Stoeckler JD, 1997, BIOCHEMISTRY-US, V36, P11749, DOI 10.1021/bi961971n; Szilagyi A, 2000, STRUCTURE, V8, P493, DOI 10.1016/S0969-2126(00)00133-7; Tebbe J, 1999, J MOL BIOL, V294, P1239, DOI 10.1006/jmbi.1999.3327; TOORCHEN D, 1991, BIOCHEM PHARMACOL, V41, P2023, DOI 10.1016/0006-2952(91)90145-U; Toth EA, 2000, J MOL BIOL, V301, P433, DOI 10.1006/jmbi.2000.3970; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WALTER MR, 1990, J BIOL CHEM, V265, P14016; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	45	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39232	39242		10.1074/jbc.M105694200	http://dx.doi.org/10.1074/jbc.M105694200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489901	hybrid			2022-12-25	WOS:000171673200119
J	Roos, T; Kiefer, D; Hugenschmidt, S; Economou, A; Kuhn, A				Roos, T; Kiefer, D; Hugenschmidt, S; Economou, A; Kuhn, A			Indecisive M13 procoat protein mutants bind to SecA but do not activate the translocation ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVELY CHARGED RESIDUES; OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; PLASMA-MEMBRANE; TRIGGER FACTOR; COAT PROTEIN; INSERTION; EXPORT; PREPROTEIN; LEADER	The M13 procoat protein serves as the paradigm for the See-independent membrane insertion pathway. This protein is inserted into the inner membrane of Escherichia coli with two hydrophobic regions and a central periplasmic loop region of 20 amino acid residues. Extension of the periplasmic loop region renders M13 procoat membrane insertion See-dependent. Loop regions with 118 or more residues required SecA and SecYEG and were efficiently translocated in vivo. Two mutants having loop regions of 80 and 100 residues, respectively, interacted with SecA but failed to activate the membrane translocation ATPase of SecA in vitro. Similarly, a procoat mutant with two additional glutamyl residues in the loop region showed binding to SecA but did not stimulate the ATPase. The three mutants were also defective for precursor-stimulated binding of SecA to the membrane surface. Remarkably, the mutant proteins act as competitive inhibitors of the See translocase. This suggests that the region to be translocated is sensed by SecA but the activation of the SecA translocation ATPase is only successful for substrates with a minimum length of the translocated region.	Univ Hohenheim, Inst Microbiol & Mol Biol, D-70593 Stuttgart, Germany; Univ Crete, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Crete, Greece; Univ Crete, Dept Biol, GR-71110 Iraklion, Crete, Greece	University Hohenheim; University of Crete; University of Crete	Kuhn, A (corresponding author), Univ Hohenheim, Inst Microbiol & Mol Biol, D-70593 Stuttgart, Germany.		Economou, Anastassios/P-8292-2017	Economou, Anastassios/0000-0002-1770-507X				ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BASSILANA M, 1992, J BIOL CHEM, V267, P25246; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; Economou A, 1999, TRENDS MICROBIOL, V7, P315, DOI 10.1016/S0966-842X(99)01555-3; Economou A, 1998, MOL MICROBIOL, V27, P511, DOI 10.1046/j.1365-2958.1998.00713.x; FREUDL R, 1989, J MOL BIOL, V205, P771, DOI 10.1016/0022-2836(89)90321-5; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; Kiefer D, 1999, EMBO J, V18, P6299, DOI 10.1093/emboj/18.22.6299; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KUHN A, 1988, EUR J BIOCHEM, V177, P267, DOI 10.1111/j.1432-1033.1988.tb14372.x; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KUHN A, 1985, J BIOL CHEM, V260, P5907; LAMINET AA, 1991, MOL MICROBIOL, V5, P117, DOI 10.1111/j.1365-2958.1991.tb01832.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Miller A, 1998, J BIOL CHEM, V273, P11409, DOI 10.1074/jbc.273.19.11409; MOVVA NR, 1980, J BIOL CHEM, V255, P27; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Soekarjo M, 1996, BIOCHEMISTRY-US, V35, P1232, DOI 10.1021/bi951087h; THIAUDIERE E, 1993, BIOCHEMISTRY-US, V32, P12186, DOI 10.1021/bi00096a031; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; Wang LG, 2000, J BIOL CHEM, V275, P10154, DOI 10.1074/jbc.275.14.10154; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	37	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37909	37915						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11487581				2022-12-25	WOS:000171526500027
J	Yannone, SM; Roy, S; Chan, DW; Murphy, MB; Huang, SR; Campisi, J; Chen, DJ				Yannone, SM; Roy, S; Chan, DW; Murphy, MB; Huang, SR; Campisi, J; Chen, DJ			Werner syndrome protein is regulated and phosphorylated by DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; TUMOR-CELL RADIOSENSITIVITY; CATALYTIC SUBUNIT; MAMMALIAN-CELLS; CHROMOSOMAL DNA; MRE11 COMPLEX; KU; REPAIR; RECOMBINATION; WORTMANNIN	DNA double-strand breaks (DSBs) are a highly mutagenic and potentially lethal damage that occurs in all organisms. Mammalian cells repair DSBs by homologous recombination and non-homologous end joining, the latter requiring DNA-dependent protein kinase (DNA-PK). Werner syndrome is a disorder characterized by genomic instability, aging pathologies and defective WRN, a RecQ-Iike helicase with exonuclease activity. We show that W-RN interacts directly with the catalytic subunit of DNA-PK (DNA-PKCS), which inhibits both the helicase and exonuclease activities of WRN. In addition we show that WRN forms a stable complex on DNA with DNA-PKCS and the DNA binding subunit Ku. This assembly reverses WRN enzymatic inhibition. Finally, we show that WRN is phosphorylated in vitro by DNA-PK and requires DNA-PK for phosphorylation in vivo, and that cells deficient in WRN are mildly sensitive to ionizing radiation. These data suggest that DNA-PK and WRN may function together in DNA metabolism and implicate WRN function in non-homologous end joining.	Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Mol & Cellular Biol, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Chen, DJ (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Mol & Cellular Biol, Div Life Sci, Mail Stop 74-157,1 Cyclotron Rd, Berkeley, CA 94720 USA.		Roy, sashwati/E-3990-2011; Yannone, Steven/ABA-3524-2021; Yannone, Steven/G-1927-2011		NATIONAL CANCER INSTITUTE [R01CA050519, R37CA050519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017242, R01AG011658] Funding Source: NIH RePORTER; NCI NIH HHS [CA50519] Funding Source: Medline; NIA NIH HHS [AG00266, AG11658, AG917709, AG17242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLALUNISTURNER MJ, 1995, CANCER RES, V55, P5200; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; Boulton S, 2000, EUR J CANCER, V36, P535, DOI 10.1016/S0959-8049(99)00311-1; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chernikova SB, 1999, RADIAT RES, V151, P159, DOI 10.2307/3579766; Cooper MP, 2000, GENE DEV, V14, P907; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Goto M, 2000, CLIN EXP RHEUMATOL, V18, P760; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Martin GM, 1999, J AM GERIATR SOC, V47, P1136, DOI 10.1111/j.1532-5415.1999.tb05240.x; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Moser MJ, 2000, NUCLEIC ACIDS RES, V28, P648, DOI 10.1093/nar/28.2.648; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; ROTH DB, 1985, P NATL ACAD SCI USA, V82, P3355, DOI 10.1073/pnas.82.10.3355; RUNGER TM, 1994, J INVEST DERMATOL, V102, P45, DOI 10.1111/1523-1747.ep12371730; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Zhao JK, 1999, BIOCHEMISTRY-US, V38, P2152, DOI 10.1021/bi9825246; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7; Zolnai A, 1998, ACTA VET HUNG, V46, P191	54	173	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38242	38248						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11477099				2022-12-25	WOS:000171526500071
J	Faergeman, NJ; Black, PN; Zhao, XD; Knudsen, J; DiRusso, CC				Faergeman, NJ; Black, PN; Zhao, XD; Knudsen, J; DiRusso, CC			The acyl-CoA synthetases encoded within FAA1 and FAA4 in Saccharomyces cerevisiae function as components of the fatty acid transport system linking import, activation, and intracellular utilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLATION; PEROXISOMAL PROTEINS; BINDING-PROTEIN; TRANSCRIPTION FACTORS; STATIONARY-PHASE; OLE1 GENE; YEAST; MEMBRANE; METABOLISM; DISRUPTION	Exogenous long-chain fatty acids are activated to coenzyme A derivatives prior to metabolic utilization. In the yeast Saccharomyces cerevisiae, the activation of these compounds prior to metabolic utilization proceeds through the fatty acyl-CoA synthetases Faa1p and Faa4p. Faa1p or Faa4p are essential for long-chain fatty acid import, suggesting that one or both of these enzymes are components of the fatty acid transport system, which also includes Fat1p. By monitoring the intracellular accumulation of the fluorescent long-chain fatty acid analogue 4,4-difluoro-5-methyl-4-bora-3a,4a-diazas-indacene-3-dodecanoic acid, long-chain fatty acid transport was shown to be severely restricted in a faa1 Delta faa4 Delta strain. These data established for the first time a mechanistic linkage between the import and activation of exogenous fatty acids in yeast. To investigate this linkage further, oleoyl CoA levels were defined following incubation of wild type and mutant cells with limiting concentrations of exogenous oleate. These studies demonstrated oleoyl CoA levels were reduced to less than 10% wild-type levels in faa1 Delta and faa1 Delta faa4 Delta strains. Defects in metabolic utilization and intracellular trafficking were also found in the fatty acyl-CoA synthetase-deficient strains. The faa1 Delta faa4 Delta strain had a marked reduction in endogenous acyl-CoA pools, suggesting these enzymes play a role in maintenance of endogenous acyl-CoA pools, metabolism and trafficking. In addition, this strain had levels of in vivo beta -oxidation of exogenous oleate reduced 3-fold when compared with the isogenic parent. Northern analyses demonstrated an additional defect in fatty acid trafficking as FAA1 or FAA4 were required for the transcriptional regulation of the genes encoding the peroxisomal enzymes acyl-CoA oxidase (POX1) and medium-chain acyl-CoA synthetase (FAA2). These data support the hypothesis that fatty acyl-CoA synthetase (Faa1p or Faa4p) functions as a component of the fatty acid import system by linking import and activation of exogenous fatty acids to intracellular utilization and signaling.	Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; Univ So Denmark, Inst Biochem & Mol Biol, DK-5220 Odense M, Denmark	Albany Medical College; University of Southern Denmark	DiRusso, CC (corresponding author), Albany Med Coll, Ctr Cardiovasc Sci, MC-8,47 New Scotland Ave, Albany, NY 12208 USA.		DiRusso, Concetta C/M-1884-2014	Faergeman, Nils/0000-0002-9281-5287; Black, Paul/0000-0002-6272-6881; DiRusso, Concetta/0000-0001-7388-9152	NIGMS NIH HHS [GM56840] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056840] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ANDREASEN AA, 1954, J CELL COMPAR PHYSL, V43, P271, DOI 10.1002/jcp.1030430303; Ashrafi K, 1998, J BIOL CHEM, V273, P25864, DOI 10.1074/jbc.273.40.25864; BLACK PN, 1990, BIOCHIM BIOPHYS ACTA, V1046, P97, DOI 10.1016/0005-2760(90)90099-J; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; Choi JY, 1996, J BIOL CHEM, V271, P3581; Choi JY, 1999, J BIOL CHEM, V274, P4671, DOI 10.1074/jbc.274.8.4671; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; DiRusso CC, 1999, MOL CELL BIOCHEM, V192, P41, DOI 10.1023/A:1006823831984; DiRusso CC, 2000, EUR J BIOCHEM, V267, P4422, DOI 10.1046/j.1432-1327.2000.01489.x; DiRusso CC, 1999, PROG LIPID RES, V38, P129, DOI 10.1016/S0163-7827(98)00022-8; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; Elgersma Y, 1996, BBA-REV BIOMEMBRANES, V1286, P269, DOI 10.1016/S0304-4157(96)00012-3; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; Gargiulo CE, 1999, J LIPID RES, V40, P881; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; IGUAL JC, 1992, MOL MICROBIOL, V6, P1867, DOI 10.1111/j.1365-2958.1992.tb01359.x; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; KAMIRYO T, 1976, P NATL ACAD SCI USA, V73, P386, DOI 10.1073/pnas.73.2.386; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; Knudsen J, 1999, MOL CELL BIOCHEM, V192, P95, DOI 10.1023/A:1006830606060; KOS W, 1995, BBA-GENE STRUCT EXPR, V1264, P79, DOI 10.1016/0167-4781(95)00127-3; LOWRY CV, 1984, P NATL ACAD SCI-BIOL, V81, P6129, DOI 10.1073/pnas.81.19.6129; Luo Y, 1996, J BIOL CHEM, V271, P12068, DOI 10.1074/jbc.271.20.12068; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Schjerling CK, 1996, J BIOL CHEM, V271, P22514, DOI 10.1074/jbc.271.37.22514; SPECTOR AA, 1971, BIOCHEMISTRY-US, V10, P3229; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Zhang SR, 1999, GENETICS, V151, P473; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	40	118	120	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37051	37059		10.1074/jbc.M100884200	http://dx.doi.org/10.1074/jbc.M100884200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11477098	hybrid			2022-12-25	WOS:000171375700027
J	Lo, PK; Chen, JY; Tang, PP; Lin, JY; Lin, CH; Su, LT; Wu, CH; Chen, TL; Yang, Y; Wang, FF				Lo, PK; Chen, JY; Tang, PP; Lin, JY; Lin, CH; Su, LT; Wu, CH; Chen, TL; Yang, Y; Wang, FF			Identification of a mouse thiamine transporter gene as a direct transcriptional target for p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROLEUKEMIA CELL-DIFFERENTIATION; PROTEIN-TYROSINE-PHOSPHATASE; TUMOR-SUPPRESSOR P53; WILD-TYPE P53; DNA-DAMAGE; P53-INDUCED APOPTOSIS; FOLATE TRANSPORTER; POTENTIAL MEDIATOR; CYCLE CHECKPOINT; BINDING-SITE	p53 tumor suppressor is a transcription factor that functions, in part, through many of its downstream target genes. We have identified a p53-inducible gene by performing mRNA differential display on IW32 murine erythroleukemia cells containing a temperature-sensitive p53 mutant allele, tsp53(Val-135). Sequence analysis of the full-length cDNA revealed its identity as the mouse homologue of the human thiamine transporter 1 (THTR-1). Induction of the mouse THTR-1 (mTHTR-1) mRNA was detectable as early as 1 h at 32.5 degreesC; upon shifting back to 38.5 degreesC, mTHTR-1 transcript was rapidly degraded with a half-life of less than 2 h. Elevation of mTHTR-1 expression was found in DNA damage-induced normal mouse embryonic fibroblast cells, but not in p53(-/-) mouse embryonic fibroblast cells, suggesting that mTHTR-1 induction was p53-dependent. A region within the first intron of the mTHTR-1 gene bound to p53 and conferred the p53-mediated transactivation. Furthermore, increased thiamine transporter activities were found in cells overexpressing mTHTR-1 and under conditions of DNA damage or p53 activation. Our findings indicate that p53 may be involved in maintaining thiamine homeostasis through transactivation of THTR-1.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; University of Michigan System; University of Michigan	Wang, FF (corresponding author), Natl Yang Ming Univ, Inst Biochem, Shih Pai, Taipei 112, Taiwan.	ffwang@ym.edu.tw	Lin, Jiayuh/E-3515-2011; Chen, Joanne Jeou-Yuan/S-7022-2018					Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; COWAN KH, 1984, J BIOL CHEM, V259, P793; Diaz GA, 1999, NAT GENET, V22, P309, DOI 10.1038/10385; Ding BC, 2001, J BIOL CHEM, V276, P8713, DOI 10.1074/jbc.M005248200; DIXON KH, 1991, CANCER COMMUN-US, V3, P357, DOI 10.3727/095535491820873687; DIXON KH, 1994, J BIOL CHEM, V269, P17; Dutta B, 1999, J BIOL CHEM, V274, P31925, DOI 10.1074/jbc.274.45.31925; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fleming JC, 1999, NAT GENET, V22, P305, DOI 10.1038/10379; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Labay V, 1999, NAT GENET, V22, P300, DOI 10.1038/10372; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Langlais PJ, 1997, METAB BRAIN DIS, V12, P137, DOI 10.1023/B:MEBR.0000007108.14989.e8; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lo PK, 1999, ONCOGENE, V18, P7765, DOI 10.1038/sj.onc.1203167; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MOSCOW JA, 1995, CANCER RES, V55, P3790; Murray RC, 1996, J BIOL CHEM, V271, P19174, DOI 10.1074/jbc.271.32.19174; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pani G, 2000, CANCER RES, V60, P4654; Pannunzio P, 2000, J NEUROSCI RES, V62, P286, DOI 10.1002/1097-4547(20001015)62:2<286::AID-JNR13>3.0.CO;2-0; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Sun J, 1998, FREE RADICAL BIO MED, V24, P586, DOI 10.1016/S0891-5849(97)00291-8; Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang PP, 2000, LEUKEMIA, V14, P1292, DOI 10.1038/sj.leu.2401823; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Vile GF, 1997, FEBS LETT, V412, P70, DOI 10.1016/S0014-5793(97)00748-5; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang MC, 1997, MOL PHARMACOL, V51, P558, DOI 10.1124/mol.51.4.558; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zwacka RM, 1998, HUM GENE THER, V9, P1381, DOI 10.1089/hum.1998.9.9-1381	57	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37186	37193		10.1074/jbc.M104701200	http://dx.doi.org/10.1074/jbc.M104701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11481326	hybrid			2022-12-25	WOS:000171375700044
J	Becker, L; McLeod, RS; Marcovina, SM; Yao, ZM; Koschinsky, ML				Becker, L; McLeod, RS; Marcovina, SM; Yao, ZM; Koschinsky, ML			Identification of a critical lysine residue in apolipoprotein B-100 that mediates noncovalent interaction with apolipoprotein(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE TRANSFER PROTEIN; KRINGLE; ASSOCIATION; EXPRESSION; BINDING; DOMAINS; CELLS; SEQUENCES; MECHANISM	We have previously shown that lipoprotein(a) (Lp(a)) assembly involves an initial noncovalent interaction between sequences within apolipoprotein(a) (apo(a)) kringle IV types 5-8 and the amino terminus of apolipoprotein B-100 (sequences between amino acids 680 and 781 in apoB-100), followed by formation of a disulfide bond. In the present study, citraconylation of lysine residues in apoB-100 abolished the ability of the modified low density lipoprotein to associate with apo(a), thereby demonstrating a direct role for lysine residues in apoB in the first step of Lp(a) assembly. To identify specific lysine residues in the amino terminus of apoB that are required for the noncovalent interaction, we initially used an affinity chromatography method in which recombinant forms of apo(a) (r-apo(a)) were immobilized on Sepharose beads. Assessment of the ability of carboxyl-terminal truncations of apoB-18 to bind to r-apo(a)Sepharose revealed that a 25-amino acid sequence in apoB (amino acids 680-704) bound specifically to apo(a) in a lysine-dependent manner; citraconylation of the lysine residues in the apoB derivative encoding this sequence abolished the binding interaction. Using fluorescence spectrometry, we found that a synthetic peptide corresponding to this sequence bound directly to apo(a); the peptide also reduced covalent Lp(a) formation. Lysine residues present in this sequence (Lys(680) and Lys(690)) were mutated to alanine in the context of apoB-18. We found that the apoB-18 species containing the Lys(680) mutation was incapable of binding to r-apo(a)Sepharose columns, whereas the apoB-18 species containing the Lys(690) mutation exhibited slightly reduced binding to these columns. Taken together, our data indicate that Lys(680) is critical for the noncovalent interaction of apo(a) and apoB-100 that precedes covalent Lp(a) formation.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Dalhousie Univ, Dept Biochem, Halifax, NS B3H 4H7, Canada; Univ Washington, Dept Med, NW Lipid Res Labs, Seattle, WA USA; Ottawa Heart Inst, Ottawa, ON K1Y 4W7, Canada	Queens University - Canada; Dalhousie University; University of Washington; University of Washington Seattle; University of Ottawa; University of Ottawa Heart Institute	Koschinsky, ML (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.		McLeod, Roger/F-8014-2015	McLeod, Roger/0000-0002-6740-5569; Koschinsky, Marlys/0000-0002-2643-2288				Bakillah A, 1998, BIOCHEMISTRY-US, V37, P3727, DOI 10.1021/bi972629t; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; Cheesman EJ, 2000, J BIOL CHEM, V275, P28195; Frank S, 1997, PROTEIN ENG, V10, P291, DOI 10.1093/protein/10.3.291; FRANK S, 1995, ARTERIOSCL THROM VAS, V15, P1774, DOI 10.1161/01.ATV.15.10.1774; FRANK S, 1994, BIOCHEM J, V304, P27, DOI 10.1042/bj3040027; Gabel BR, 1998, ARTERIOSCL THROM VAS, V18, P1738, DOI 10.1161/01.ATV.18.11.1738; Gabel BR, 1996, ARTERIOSCL THROM VAS, V16, P1559, DOI 10.1161/01.ATV.16.12.1559; Gabel BR, 1998, BIOCHEMISTRY-US, V37, P7892, DOI 10.1021/bi973186w; Goldberg IJ, 1998, J BIOL CHEM, V273, P35355, DOI 10.1074/jbc.273.52.35355; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Ingram MF, 1997, J BIOL CHEM, V272, P10279; Keesler GA, 1996, J BIOL CHEM, V271, P32096, DOI 10.1074/jbc.271.50.32096; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; Koschinsky ML, 1997, CLIN GENET, V52, P338; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marcovina S M, 1999, Curr Cardiol Rep, V1, P105, DOI 10.1007/s11886-999-0067-z; MARCOVINA SM, 1995, CLIN CHEM, V41, P246; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; Rahman M, 1998, PROTEIN ENG, V11, P1249, DOI 10.1093/protein/11.12.1249; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Sharp RJ, 1999, CIRCULATION, V100, P109; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; TRIEU VN, 1995, J BIOL CHEM, V270, P15471, DOI 10.1074/jbc.270.26.15471; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; Xu SH, 1998, BIOCHEMISTRY-US, V37, P9284, DOI 10.1021/bi9729662; YAO ZM, 1991, J BIOL CHEM, V266, P3300	31	39	40	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36155	36162		10.1074/jbc.M104789200	http://dx.doi.org/10.1074/jbc.M104789200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11473115	hybrid			2022-12-25	WOS:000171194500016
J	Furusawa, M; Ohnishi, T; Taira, T; Iguchi-Ariga, SMM; Ariga, H				Furusawa, M; Ohnishi, T; Taira, T; Iguchi-Ariga, SMM; Ariga, H			AMY-1, a c-Myc-binding protein, is localized in the mitochondria of sperm by association with S-AKAP84, an anchor protein of cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; MOUSE SPERMATOZOA; CAPACITATION; EXPRESSION	We have reported that a novel c-Myc-binding protein, AMY-1 (Associate of Myc-1), stimulated the transcription activity of c-Myc. To access the molecular function of AMY-1, a two-hybrid screening of cDNAs encoding AMY-1-binding proteins was carried out with AMY-1 as a bait using a human HeLa cDNA library, and a clone encoding cAMP-dependent protein kinase anchor protein 149 (AKAP149), was obtained. AMY-1 was found to bind in vitro and in vivo to the regulatory subunit II binding region of AKAP149 and S-AKAP84, a splicing variant of AKAP149 expressed in the testis. AMY-1 was expressed postmeiotically in the testis, as S-AKAP84 was expressed. Furthermore, S-AKAP84 and regulatory subunit II, a regulatory subunit of cAMP-dependent protein kinase, made a ternary complex in cells, and AMY-I was localized in the mitochondria of HeLa and sperm in association with AKAP149 and S-AKAP84, respectively. These results suggest that AMY-1 plays a role in spermatogenesis.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Hokkaido Univ, Coll Med Technol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; CREST, Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan	Hokkaido University; Hokkaido University; Japan Science & Technology Agency (JST)	Ariga, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	hiro@pharm.hokudai.ac.jp	Ariga, Sanae/H-9647-2013; Ariga, Hiroyoshi/B-5895-2013	Ariga, Hiroyoshi/0000-0001-7384-2143				AITKEN RJ, 1995, J CELL SCI, V108, P2017; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; FLORKE S, 1983, DIFFERENTIATION, V24, P250, DOI 10.1111/j.1432-0436.1983.tb01328.x; Furusawa M, 2000, INT J ONCOL, V16, P339; GalantinoHomer HL, 1997, BIOL REPROD, V56, P707, DOI 10.1095/biolreprod56.3.707; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Leclerc P, 1997, FREE RADICAL BIO MED, V22, P643, DOI 10.1016/S0891-5849(96)00379-6; Leclerc P, 1996, BIOL REPROD, V55, P684, DOI 10.1095/biolreprod55.3.684; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; MALI P, 1989, REPROD FERT DEVELOP, V1, P369, DOI 10.1071/RD9890369; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; NAZ RK, 1991, J CELL SCI, V99, P157; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; REITON N, 2000, DEV BIOL, V223, P194; SORRENTINO V, 1991, ONCOGENE, V6, P149; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Trendelenburg G, 1996, BIOCHEM BIOPH RES CO, V225, P313, DOI 10.1006/bbrc.1996.1172; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129	21	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36647	36651		10.1074/jbc.M103885200	http://dx.doi.org/10.1074/jbc.M103885200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11483602	hybrid			2022-12-25	WOS:000171194500079
J	Wang, J; Sampath, A; Raychaudhuri, P; Bagchi, S				Wang, J; Sampath, A; Raychaudhuri, P; Bagchi, S			Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells	ONCOGENE			English	Article						ubiquitination; proteasome; E7; human papilloma virus (HPV); retinoblastoma protein (Rb); E2F	HUMAN-PAPILLOMAVIRUS TYPE-16; E2F TRANSCRIPTION FACTOR; RETINOBLASTOMA PROTEIN; E6 ONCOPROTEIN; CYCLE; DEGRADATION; LIGASE; PHOSPHORYLATION; ASSOCIATION; CARCINOMA	High-risk human papillomaviruses (HPVs) are etiologically linked to human cervical and oral cancers. The E6 and E7 oncoproteins encoded by HPV target host cell tumor suppressor proteins. E6 induces proteolysis of p53 through the ubiquitin-proteasome pathway. Recent studies showed that overexpression of E7 caused proteolytic degradation of the tumor suppressor Rb. However, unlike p53, Rb is not regulated by proteolysis in normal cells. In addition, it was unclear whether in its natural context E7 regulates Rb through the ubiquitin-proteasome pathway. Therefore, we sought to determine whether Rb is regulated by the ubiquitin-proteasome pathway in HPV-containing tumor cells. We carried out a detailed analysis in Caski cells, that are derived from HPV-containing cervical cancer tissues. Studies with various protease inhibitors revealed that Rb is regulated specifically by the ubiquitin-proteasome pathway in HPV-containing cervical tumor cells. Several inhibitors of the 26S proteasome significantly increased the level of Rb in the Caski cells. Rb controls cell growth by forming complexes with the E2F-family transcription factors. Surprisingly, in spite of a significant accumulation of the hypophosphorylated form of Rb, no Rb/E2F complex was detectable in the proteasome inhibitor treated cells. Further analysis revealed that there was an increased accumulation of the E7 oncoprotein. We showed that the proteasome inhibitors simultaneously blocked the proteolysis of E7 and Rb, suggesting that E7 is also regulated by the ubiquitin-dependent proteolysis in cervical cancer cells. Taken together, this study suggests that targeted inhibition of Rb proteolysis will be required for restoring Rb function in HPV-containing cervical cancer cells.	Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Univ Illinois, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bagchi, S (corresponding author), Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, MC 860,801 S Paulina St, Chicago, IL 60612 USA.	sbagchi@uic.edu			NCI NIH HHS [CA76276] Funding Source: Medline; NIDCR NIH HHS [DE12506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; BEREZUTSKAYA E, 1997, CELL GROWTH DEATH, V8, P1; Boyer SN, 1996, CANCER RES, V56, P4620; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Galloway DA, 1996, SEMIN CANCER BIOL, V7, P309, DOI 10.1006/scbi.1996.0040; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Howley Peter M., 1996, P947; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Ke LD, 1999, ORAL ONCOL, V35, P415, DOI 10.1016/S1368-8375(99)00015-9; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Maki CG, 1996, CANCER RES, V56, P2649; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Niv A, 2000, J LARYNGOL OTOL, V114, P41, DOI 10.1258/0022215001903870; PAGANO M, 1992, ONCOGENE, V7, P1681; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Ruesch MN, 1998, VIROLOGY, V250, P19, DOI 10.1006/viro.1998.9359; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	39	74	79	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4740	4749		10.1038/sj.onc.1204655	http://dx.doi.org/10.1038/sj.onc.1204655			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498796				2022-12-25	WOS:000170208600014
J	Coldwell, MJ; deSchoolmeester, ML; Fraser, GA; Pickering, BM; Packham, G; Willis, AE				Coldwell, MJ; deSchoolmeester, ML; Fraser, GA; Pickering, BM; Packham, G; Willis, AE			The p36 isoform of BAG-1 is translated by internal ribosome entry following heat shock	ONCOGENE			English	Article						BAG-1; IRES; translation; internal ribosome entry; heat shock	APOPTOTIC PROTEIN BAG-1; C-MYC; ALTERNATIVE TRANSLATION; NEGATIVE REGULATOR; MAMMALIAN-CELLS; INITIATION; IDENTIFICATION; LOCATION; CLONING; REGION	BAG-1 (also known as RAP46/HAP46) was originally identified as a 46 kDa protein that bound to and enhanced the anti-apoptotic properties of Bcl-2, BAG-1 exists as three major isoforms (designated p50, p46 and p36 or BAG-1L, BAG-1M and BAG-1S respectively) and one minor isoform (p29), which are translated from a common transcript. The differing amino terminus determines both the intracellular location and the repertoire of binding partners of the isoforms which play different roles in a variety of cellular processes including signal transduction, heat shock, apoptosis and transcription. Although in vitro data suggest that the four BAG-1 isoforms are translated by leaky scanning, the patterns of isoform expression in vivo, especially in transformed cells, do not support this hypothesis. We have performed in vivo analysis of the BAG-1 5' untranslated region and shown that translation initiation of the most highly expressed isoform (p36/BAG-1S) can occur by both internal ribosome entry and cap-dependent scanning. Following heat shock, when there is a downregulation of cap-dependent translation, the expression of the p36 isoform of BAG-1 is maintained by internal ribosome entry.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Southampton Gen Hosp, Oncol Unit, Southampton SO16 6YD, Hants, England	University of Leicester; University of Southampton	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	aew5@le.ac.uk		Packham, Graham/0000-0002-9232-5691; Willis, Anne/0000-0002-1470-8531				Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Cuesta R, 2000, GENE DEV, V14, P1460; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Luders J, 2000, J BIOL CHEM, V275, P14817, DOI 10.1074/jbc.275.20.14817; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; Schneider RJ, 2000, COLD SPRING HARBOR M, V39, P581; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; STONELEY M, 1998, THESIS U LEICESTER; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1996, GENOMICS, V35, P494, DOI 10.1006/geno.1996.0389; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yueh A, 2000, GENE DEV, V14, P414; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	31	79	81	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4095	4100		10.1038/sj.onc.1204547	http://dx.doi.org/10.1038/sj.onc.1204547			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494137				2022-12-25	WOS:000169681500017
J	Reynolds, L; Jones, K; Winton, DJ; Cranston, A; Houghton, C; Howard, L; Ponder, BAJ; Smith, DP				Reynolds, L; Jones, K; Winton, DJ; Cranston, A; Houghton, C; Howard, L; Ponder, BAJ; Smith, DP			C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET	ONCOGENE			English	Article						RET; multiple endocrine neoplasia; MEN2A; receptor tyrosine kinase; transgenic mice	MULTIPLE ENDOCRINE NEOPLASIA; TYROSINE KINASE DOMAIN; PAPILLARY CARCINOMAS; MOLECULAR CHARACTERIZATION; MEDULLARY CARCINOMA; RET/PTC1 ONCOGENE; PROTOONCOGENE; MUTATIONS; ACTIVATION; GDNF	Gain-of-function mutations in the gene encoding the receptor tyrosine kinase RET have been identified as the aetiological factor for multiple endocrine neoplasia type 2A (MEN2A). MEN2A is a dominantly-inherited cancer predisposition syndrome characterized by medullary thyroid carcinoma, a tumour of the calcitonin-producing thyroid C-cells. There are three isoforms of RET: RET9, RET43 and RET51, and although in vitro evidence suggests they vary in cellular transformation activities, little is known about their function in tumorigenesis in vivo. To address this, we used RET51 cDNA to construct mice in which the most frequent MEN2A mutation, Cys-634-Arg, was expressed under the control of the human calcitonin promoter (CT-2A mice), These mice developed C-cell tumours resembling human MTC and follicular tumours resembling human papillary thyroid carcinoma (PTC) depending on the founder line examined, One founder line developed compound MTC/PTC at low frequency (8%) and pancreatic cystadenocarcinoma, CT-2A mice also displayed a developmental defect in thyroid follicular structure, in which much of the thyroid was occupied by large irregular cystic follicles thought to be derived from the ultimobranchial body, a developmental precursor of the thyroid gland, The CT-2A mice will provide a suitable model to further study the effects of the MEN 2A RET mutation in vivo.	Univ Cambridge, Cambridge Inst Med Res, CRC, Dept Oncol, Cambridge CB2 2XY, England	University of Cambridge	Ponder, BAJ (corresponding author), Univ Cambridge, Cambridge Inst Med Res, CRC, Dept Oncol, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.							Acton DS, 2000, ONCOGENE, V19, P3121, DOI 10.1038/sj.onc.1203648; Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1995, ONCOGENE, V11, P2419; Bunone G, 2000, CANCER RES, V60, P2845; CAILLOU B, 1991, P53; DECKER RA, 1993, SURGERY, V114, P1059; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; FABBRO D, 1994, CANCER RES, V54, P4744; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARACH HR, 1994, DIS THYROID, P341; HOFSTRA RMW, 1994, NATURE, V367, P275; Jhiang SM, 1996, THYROID, V6, P115, DOI 10.1089/thy.1996.6.115; Johnston D, 1998, ONCOGENE, V16, P167, DOI 10.1038/sj.onc.1201478; KOVACS CS, 1994, CANCER-AM CANCER SOC, V74, P928, DOI 10.1002/1097-0142(19940801)74:3<928::AID-CNCR2820740321>3.0.CO;2-E; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEDOUARIN N, 1970, CR ACAD SCI D NAT, V270, P2857; LJUNGBERG O, 1983, CANCER, V52, P1053, DOI 10.1002/1097-0142(19830915)52:6<1053::AID-CNCR2820520621>3.0.CO;2-Q; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Manley NR, 1998, DEV BIOL, V195, P1, DOI 10.1006/dbio.1997.8827; MANLEY NR, 1995, DEVELOPMENT, V121, P1989; Marshall GM, 1997, CANCER RES, V57, P5399; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MYERS SM, 1995, ONCOGENE, V11, P2039; OISHI S, 1995, ENDOCR J, V42, P527, DOI 10.1507/endocrj.42.527; Okada Y, 1999, INT J CANCER, V81, P67, DOI 10.1002/(SICI)1097-0215(19990331)81:1<67::AID-IJC13>3.0.CO;2-V; Orlandi F, 2001, J ENDOCRINOL INVEST, V24, P51, DOI 10.1007/BF03343809; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Peleg S, 1989, Henry Ford Hosp Med J, V37, P194; Ponder BAJ, 1996, ADV CANCER RES, V70, P179, DOI 10.1016/S0065-230X(08)60875-1; Portella G, 1996, ONCOGENE, V13, P2021; Powell DJ, 1998, CANCER RES, V58, P5523; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSSEL M, 1995, HUM GENET, V95, P403; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SAAD MF, 1984, MEDICINE, V63, P319, DOI 10.1097/00005792-198411000-00001; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SANTORO M, 1994, ONCOGENE, V9, P509; Santoro M, 1996, ONCOGENE, V12, P1821; Santoro W, 1999, J ENDOCRINOL INVEST, V22, P811, DOI 10.1007/BF03343650; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TRUPP M, 1996, NATURE, V381, P789; WETZEL BK, 1969, ENDOCRINOLOGY, V84, P563, DOI 10.1210/endo-84-3-563; WOLLMAN SH, 1978, ANAT REC, V191, P111, DOI 10.1002/ar.1091910110	56	38	39	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					3986	3994		10.1038/sj.onc.1204434	http://dx.doi.org/10.1038/sj.onc.1204434			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494127				2022-12-25	WOS:000169681500007
J	Shi, YJ; Simmons, MN; Seki, T; Oh, SP; Sugrue, SP				Shi, YJ; Simmons, MN; Seki, T; Oh, SP; Sugrue, SP			Change in gene expression subsequent to induction of Pnn/DRS/memA: increase in p21(cip1/waf1)	ONCOGENE			English	Article						Pnn; cell migration; cell cycle progression; p21(cip1/waf1); RhoA; MMP-7; MIC-1	CELL-CYCLE ARREST; METALLOPROTEINASE MATRILYSIN MMP-7; MACROPHAGE INHIBITORY CYTOKINE; TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; TGF-BETA SUPERFAMILY; C-MYC; MATRIX METALLOPROTEINASES; DESMOSOMAL PROTEIN; DNA-REPLICATION	Pnn (PNN) is a nuclear and cell adhesion-related protein. Previous work has suggested that Pnn/DRS/memA is a potential tumor suppressor involved in the regulation of cell adhesion and cell migration. Using the ecdysone-inducible mammalian expression system, a stable inducible GFP-tagged human Pnn gene (PNNGFP) expressing 293 cell line was created (EcR293-PNNGFP), Cells induced to express PNNGFP not only exhibited increased cell-cell adhesion but also exhibited changes in cell growth and cell cycle progression. cDNA array analyses, together with real time PCR, revealed that the effects of exogenously expressed Pnn on cellular behavior may be linked to the regulation of the expression of specific subset genes. This subset includes cell cycle-related genes such as p21(cip1/waf1), CDK4, CPR2; cell migration and invasion regulatory genes such as RhoA, CDK5, TIMP-1, MMP-7, and EMMPRIN; and MIC-1, Concordant with previous observations of Pnn-induced phenotype changes, genes coding for epithelial associated processes and cell division controls were elevated, while those coding for increased cell motility and cellular reorganizations were downregulated. We utilized p21 promoter-luciferase reporter constructs and demonstrated that a marked stimulation of p21 promoter activity in 293 cells correlated with increased Pnn expression, Taken together, these data indicate that Pnn may participate in the regulation of gene expression, thereby, positively promoting cell-cell adhesion, and negatively affecting cell migration and cell proliferation.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Physiol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Sugrue, SP (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, Archer Rd, Gainesville, FL 32610 USA.	sugrue@anatomy.med.ufl.edu			NEI NIH HHS [EY07883] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007883] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Adachi Y, 1998, INT J ONCOL, V13, P1031; Adachi Y, 1999, GUT, V45, P252, DOI 10.1136/gut.45.2.252; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BISWAS C, 1995, CANCER RES, V55, P434; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bordador LC, 2000, INT J CANCER, V85, P347, DOI 10.1002/(SICI)1097-0215(20000201)85:3<347::AID-IJC9>3.3.CO;2-R; Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J; Brandner JM, 1997, DIFFERENTIATION, V62, P119, DOI 10.1046/j.1432-0436.1997.6230119.x; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dang CV, 1999, MOL CELL BIOL, V19, P1; DeCastro R, 1996, J INVEST DERMATOL, V106, P1260, DOI 10.1111/1523-1747.ep12348959; Degen WGJ, 1999, BBA-GENE STRUCT EXPR, V1444, P384, DOI 10.1016/S0167-4781(99)00012-3; Edwards MC, 1997, GENETICS, V147, P1063; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fischer RS, 1998, VIROLOGY, V249, P427, DOI 10.1006/viro.1998.9337; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guo HM, 1998, GENE, V220, P99, DOI 10.1016/S0378-1119(98)00400-4; GUO K, 1995, MOL CELL BIOL, V15, P3823; Harada K, 2000, ORAL ONCOL, V36, P3, DOI 10.1016/S1368-8375(99)00049-4; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; KANAI Y, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P51; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Kwon YT, 2000, CURR BIOL, V10, P363, DOI 10.1016/S0960-9822(00)00411-5; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Moll I, 1997, J INVEST DERMATOL, V108, P139, DOI 10.1111/1523-1747.ep12332388; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Mueller S, 2000, CANCER RES, V60, P156; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; OUYANG P, 1992, J CELL BIOL, V118, P1477, DOI 10.1083/jcb.118.6.1477; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Pin OY, 1999, BIOCHEM BIOPH RES CO, V263, P192, DOI 10.1006/bbrc.1999.1353; Pin OY, 1996, J CELL BIOL, V135, P1027, DOI 10.1083/jcb.135.4.1027; Rorke EA, 2000, EXP CELL RES, V259, P149, DOI 10.1006/excr.2000.4953; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sander EE, 1999, EUR J CANCER, V35, P1302, DOI 10.1016/S0959-8049(99)00145-8; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Shi YJ, 2000, ONCOGENE, V19, P289, DOI 10.1038/sj.onc.1203328; Shi YJ, 2000, INVEST OPHTH VIS SCI, V41, P1337; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tanimoto H, 1999, TUMOR BIOL, V20, P88, DOI 10.1159/000030051; Wu RC, 1997, J BIOL CHEM, V272, P29091, DOI 10.1074/jbc.272.46.29091; YAMAMOTO H, 1995, J CLIN LAB ANAL, V9, P297, DOI 10.1002/jcla.1860090504	64	32	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4007	4018		10.1038/sj.onc.1204507	http://dx.doi.org/10.1038/sj.onc.1204507			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494129				2022-12-25	WOS:000169681500009
J	Berg, P; Pongratz, I				Berg, P; Pongratz, I			Differential usage of nuclear export sequences regulates intracellular localization of the dioxin (aryl hydrocarbon) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAS DOMAIN; DROSOPHILA PERIOD; DNA-BINDING; GENE; TRANSCRIPTION; PROTEINS; SIGNALS; LIGAND; SPECIFICITY; EXPRESSION	The dioxin receptor belongs to the basic helix-loop helix/Per-Arnt-Sim (bHLH)/PAS family of proteins and functions as a ligand-dependent transcription factor to activate target genes. The function of the PAS domain of the dioxin receptor is only partially understood. Whereas the C-terminal half of the PAS domain has been shown to harbor ligand binding activity and to function as an accessory dimerization interface, the precise functional role of the N-terminal half of the PAS domain remains unclear. We have previously shown that this domain confers dimerization specificity to the dioxin receptor. Here we report the identification and characterization of a novel nuclear export sequence (NES) motif, located in the N-terminal portion of the PAS domain, in addition to the previously identified NES in the bHLH domain. By point mutagenesis, we have generated a dominant positive form of the PAS domain NES motif that inhibits accumulation of the dioxin receptor in the nuclear compartment of the cell. This mutant form of the receptor was furthermore unable to sustain reporter gene activation. Importantly, we demonstrate that the ligand-free and ligand-occupied forms of the dioxin receptor differentially employ the two NES motifs. In the absence of ligand, nuclear export is sustained via the PAS domain NES, whereas following ligand-dependent activation nuclear export of the receptor is mediated by the NES in the bHLH domain.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Pongratz, I (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.							BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; Ikuta T, 2000, J BIOCHEM, V127, P503, DOI 10.1093/oxfordjournals.jbchem.a022633; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; Pollenz RS, 2000, MOL CELL BIOL, V20, P6095, DOI 10.1128/MCB.20.16.6095-6104.2000; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; POWIS G, 1995, PHARMACOL THERAPEUT, V68, P149, DOI 10.1016/0163-7258(95)02004-7; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sun WM, 1997, J BIOL CHEM, V272, P31845, DOI 10.1074/jbc.272.50.31845; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; Yoo HY, 1999, BIOCHEM BIOPH RES CO, V256, P133, DOI 10.1006/bbrc.1999.0299; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079	29	23	26	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43231	43238		10.1074/jbc.M105261200	http://dx.doi.org/10.1074/jbc.M105261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11486007	hybrid			2022-12-25	WOS:000172169300078
J	Bjorkegren, J; Veniant, M; Kim, SK; Withycombe, SK; Wood, PA; Hellerstein, MK; Neese, RA; Young, SG				Bjorkegren, J; Veniant, M; Kim, SK; Withycombe, SK; Wood, PA; Hellerstein, MK; Neese, RA; Young, SG			Lipoprotein secretion and triglyceride stores in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B; TRANSFER PROTEIN; LIPID PEROXIDES; OBESE RATS; HOMEOSTASIS; DEFICIENCY; EXPRESSION; ATHEROSCLEROSIS; METABOLISM; INHIBITOR	The genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in mouse and human heart tissue. Why the heart would express these "lipoprotein assembly" genes has been unclear. Here we demonstrate that the beating mouse heart actually secretes spherical lipoproteins. Moreover, increased cardiac production of lipoproteins (e.g., in mice that express a human apolipoprotein B transgene) was associated with increased triglyceride secretion from the heart and decreased stores of triglycerides within the heart. Increased cardiac production of lipoproteins also reduced the pathological accumulation of triglycerides that occurs in the hearts of mice lacking long-chain acyl coenzyme A dehydrogenase. In contrast, blocking heart lipoprotein secretion (e.g., in heart-specific microsomal triglyceride transfer protein knockout mice) increased cardiac triglyceride stores. Thus, heart lipoprotein secretion helps regulate cardiac triglyceride stores and may protect the heart from the detrimental effects of surplus lipids.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Alabama Birmingham, Dept Genom & Pathobiol, Birmingham, AL 35294 USA; Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Alabama System; University of Alabama Birmingham; University of California System; University of California Berkeley	Bjorkegren, J (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.	jbjorkegren@gladstone.ucsf.edu		Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Belke DD, 1999, AM J PHYSIOL-REG I, V277, pR1210, DOI 10.1152/ajpregu.1999.277.4.R1210; BOREN J, 1994, J BIOL CHEM, V269, P25879; Boren J, 1998, J CLIN INVEST, V101, P1197, DOI 10.1172/JCI1785; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; DISCHE MR, 1970, AM J MED, V49, P568, DOI 10.1016/S0002-9343(70)80053-5; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Erickson S.K., 1995, INT CONGR SER, P414; Forte T, 1972, Adv Lipid Res, V10, P1; Goodwin GW, 2000, AM J PHYSIOL-HEART C, V279, pH1490, DOI 10.1152/ajpheart.2000.279.4.H1490; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; Hamilton RL, 1998, J LIPID RES, V39, P1543; HAMILTON RL, 1969, P 1968 DEUEL C LIP T, P3; Havel RJ, 2001, METABOLIC MOL BASES, P2705; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Kane J, 2001, METAB MOL BASES INHE, P2717; KELLY DP, 1994, NEW ENGL J MED, V330, P913; KELLY DP, 1992, J INHERIT METAB DIS, V15, P171, DOI 10.1007/BF01799626; Kurtz DM, 1998, P NATL ACAD SCI USA, V95, P15592, DOI 10.1073/pnas.95.26.15592; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; Nielsen LB, 1998, J BIOL CHEM, V273, P21800, DOI 10.1074/jbc.273.34.21800; Nielsen LB, 1998, CIRCULATION, V98, P13, DOI 10.1161/01.CIR.98.1.13; Nielsen LB, 1999, J MOL CELL CARDIOL, V31, P695, DOI 10.1006/jmcc.1998.0918; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; SELBY SL, 1995, ARTERIOSCL THROM VAS, V15, P1900, DOI 10.1161/01.ATV.15.11.1900; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; TAEGTMEYER H, 1994, CURR PROB CARDIOLOGY, V19, P61, DOI 10.1016/0146-2806(94)90008-6; TRIPP ME, 1981, NEW ENGL J MED, V305, P385, DOI 10.1056/NEJM198108133050707; VANDERVUSSE GJ, 1992, PHYSIOL REV, V72, P881, DOI 10.1152/physrev.1992.72.4.881; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; Veniant MM, 1999, TRENDS CARDIOVAS MED, V9, P103, DOI 10.1016/S1050-1738(99)00011-0; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	43	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38511	38517		10.1074/jbc.M106839200	http://dx.doi.org/10.1074/jbc.M106839200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11481337	hybrid			2022-12-25	WOS:000171673200026
J	Guillemot, L; Levy, A; Raymondjean, M; Rothhut, B				Guillemot, L; Levy, A; Raymondjean, M; Rothhut, B			Angiotensin II-induced transcriptional activation of the cyclin D1 gene is mediated by Egr-1 in CHO-AT(1A) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; COLONY-STIMULATING FACTOR; SIGNAL-REGULATED KINASE; FACTOR-A-CHAIN; RAT CARDIAC FIBROBLASTS; ELEMENT-BINDING PROTEIN; TERNARY COMPLEX FACTORS; SERUM RESPONSE ELEMENT; N-TERMINAL KINASE; C-FOS	Cyclin D1 protein expression is regulated by mitogenic stimuli and is a critical component in the regulation of G(1) to S phase progression of the cell cycle. Angiotensin II (Ang II) binds to specific G protein-coupled receptors and is mitogenic in Chinese hamster ovary cells stably expressing the rat vascular Ang II type IA receptor (CHO-AT(1A)). We recently reported that in these cells, Ang II induced cyclin Dl promoter activation and protein expression in a phosphatidylinositol 3-kinase (PI3K)-, SHP-2-, and mitogen-activated protein kinase/ extracellular signal-regulated kinase (MAPK/ERK)-dependent manner (Guillemot, L., Levy, A., Zhao, Z. J., Bereziat, G., and Rothhut, B. (2000) J. Biol. Chem. 275, 26349-26358). In this report, transfection studies using a series of deleted cyclin D1 promoters revealed that two regions between base pairs (bp) -136 and -96 and between by -29 and +139 of the human cyclin Dl promoter contained regulatory elements required for Ang II-mediated induction. Mutational analysis in the -136 to -96 by region provided evidence that a Sp1/early growth response protein (Egr) motif was responsible for cyclin Dl promoter activation by Ang II. Gel shift and supershift studies showed that Ang II-induced Egr-1 binding involved de novo protein synthesis and correlated well with Egr-1 promoter activation. Both U0126 (an inhibitor of the MAPK/ERK kinase MEK) and wortmannin (an inhibitor of PI3K) abrogated Egr-1 endogenous expression and Egr-1 promoter activity induced by Ang II. Moreover, using a co-transfection approach, we found that Ang II induction of Egr-1 promoter activity was blocked by dominant-negative p21(ras), Raf-1, and tyrosine phosphatase SHP-2 mutants. Identical effects were obtained when inhibitors and dominant negative mutants were tested on the -29 to +139 by region of the cyclin DI promoter. Taken together, these findings demonstrate that Ang II-induced cyclin Dl up-regulation is mediated by the activation and specific interaction of Egr-1 with the -136 to -96 by region of the cyclin Dl promoter and by activation of the -29 to +139 by region, both in a p21(ras)/Raf-1/MEK/ERK-dependent manner, and also involves PI3K and SHP-2.	Univ Paris 06, UMR Physiol & Physiopathol, F-75005 Paris, France	UDICE-French Research Universities; Sorbonne Universite	Rothhut, B (corresponding author), Univ Paris 06, UMR Physiol & Physiopathol, Case Courrier 256,Batiment A,5Eme Etage,7 Quai St, F-75005 Paris, France.			Rothhut, Bernard/0000-0001-6467-8134				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; Ali MS, 1997, J BIOL CHEM, V272, P12373, DOI 10.1074/jbc.272.19.12373; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; Cohen DM, 1996, P NATL ACAD SCI USA, V93, P11242, DOI 10.1073/pnas.93.20.11242; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; CRAWFORD DC, 1994, CIRC RES, V74, P727, DOI 10.1161/01.RES.74.4.727; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; Day FL, 1999, J BIOL CHEM, V274, P23726, DOI 10.1074/jbc.274.34.23726; de Gasparo M, 2000, PHARMACOL REV, V52, P415; DELAFONTAINE P, 1993, J BIOL CHEM, V268, P16866; Dieckgraefe BK, 1999, AM J PHYSIOL-GASTR L, V276, pG322, DOI 10.1152/ajpgi.1999.276.2.G322; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Guillemot L, 2000, J BIOL CHEM, V275, P26349, DOI 10.1074/jbc.M001614200; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HERBER B, 1994, ONCOGENE, V9, P1295; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INAGAMI T, 1994, J HYPERTENS, V12, pS83; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Kaiser UB, 2000, MOL ENDOCRINOL, V14, P1235, DOI 10.1210/me.14.8.1235; KATO J, 1993, GENE DEV, V7, P331; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; Lavoie J N, 1996, Prog Cell Cycle Res, V2, P49; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE HJJ, 1995, J BIOL CHEM, V270, P15979, DOI 10.1074/jbc.270.27.15979; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; Maltzman JS, 1996, J EXP MED, V183, P1747, DOI 10.1084/jem.183.4.1747; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; Mora-Garcia P, 2000, J BIOL CHEM, V275, P22418, DOI 10.1074/jbc.M001731200; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NEVINS JR, 1992, SCIENCE, V258, P424; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; RUPPRECHT HD, 1992, AM J PHYSIOL, V263, pF623, DOI 10.1152/ajprenal.1992.263.4.F623; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; SEWING A, 1993, J CELL SCI, V104, P545; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TEUTSCH B, 1992, BIOCHEM BIOPH RES CO, V187, P1381, DOI 10.1016/0006-291X(92)90455-T; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; VERVERIS JJ, 1993, CIRC RES, V72, P1285, DOI 10.1161/01.RES.72.6.1285; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe S, 1997, BLOOD, V89, P1197, DOI 10.1182/blood.V89.4.1197; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WEBER H, 1994, MOL ENDOCRINOL, V8, P148, DOI 10.1210/me.8.2.148; Wen YS, 1996, AM J PHYSIOL-CELL PH, V271, pC1212, DOI 10.1152/ajpcell.1996.271.4.C1212; WILLEMS L, 1988, LEUKEMIA, V2, P1; Wung BS, 1999, CIRC RES, V84, P804; Yan GZ, 1997, J NEUROSCI, V17, P6122; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	83	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39394	39403		10.1074/jbc.M103862200	http://dx.doi.org/10.1074/jbc.M103862200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11502738	hybrid			2022-12-25	WOS:000171673200139
J	Aarts, MM; Davidson, D; Corluka, A; Petroulakis, E; Guo, J; Bringhurst, FR; Galipeau, J; Henderson, JE				Aarts, MM; Davidson, D; Corluka, A; Petroulakis, E; Guo, J; Bringhurst, FR; Galipeau, J; Henderson, JE			Parathyroid hormone-related protein promotes quiescence and survival of serum-deprived chondrocytes by inhibiting rRNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; HYPERTROPHIC CHONDROCYTES; NUCLEOLAR-LOCALIZATION; PTH/PTHRP RECEPTOR; BONE-FORMATION; PEPTIDE; GROWTH; NUCLEAR; EXPRESSION; CARTILAGE	Parathyroid hormone-related protein (PTHrP) was initially recognized for its ability to promote parathyroid hormone-like bioactivity in kidney, bone, and squamous epithelial cells. PTHrP is a multifunctional protein in which bioactivity is mediated by two distinct pathways. Its classic parathyroid hormone-like activity results from binding of its amino terminus to cell surface PTH1R and activation of signal transduction pathways. Another less well recognized pathway involves translocation of PTHrP to the nucleus via a mid-region bipartite nuclear targeting sequence (NTS), similar in structure and function to those found in retroviral regulatory proteins. PTHrP was identified in the nucleus of several different cell types in vivo and in vitro, where it has been implicated in cell cycle progression, cellular differentiation, and apoptosis. In previous work we showed that nuclear translocation of PTHrP enhanced the survival of serum-deprived chondrogenic cells, associated with RNA, and localized to a region of the nucleus rich in complexes of newly transcribed ribosomal RNA and protein. In this work we have used two chondrogenic cell lines, CFK2 (PTH1R+) and 27m21 (PTH1R-) to further explore mechanisms whereby PTHrP rescues immature chondrocytes from apoptosis. Endogenous PTHrP and exogenous PTHrP NTS peptide protected serum-deprived cells from apoptosis, in the presence and absence of PTH1R. The survival of cells expressing PTHrP and those treated with PTHrP NTS peptide was associated with a rapid shift into G(o)/G(1) accompanied by a significant down-regulation of rRNA synthesis and a decrease in the number of actively translating polyribosome complexes. Together with our previous observations, this work predicts a role for PTHrP in modulating ribosome biogenesis and preventing chondrogenic cells from progressing through the cell cycle in an unfavorable environment.	McGill Univ, Lady Davis Inst Med Res, Sir Mortimer B Davis Jewish Hosp, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Sir Mortimer B Davis Jewish Hosp, Dept Oncol, Montreal, PQ H3T 1E2, Canada; Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Harvard University; Massachusetts General Hospital	Henderson, JE (corresponding author), Lady Davis Inst Med Res, Rm 602,3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.		Aarts, Michelle/C-5766-2008; Galipeau, Jacques/R-9909-2019	Aarts, Michelle/0000-0002-9171-0571; Galipeau, Jacques/0000-0002-9374-1996				Aarts MM, 1999, J BONE MINER RES, V14, P1493, DOI 10.1359/jbmr.1999.14.9.1493; Aarts MM, 1999, J BIOL CHEM, V274, P4832, DOI 10.1074/jbc.274.8.4832; Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Amizuka N, 2000, BIOCHEM BIOPH RES CO, V273, P621, DOI 10.1006/bbrc.2000.2913; Amizuka N, 1996, ENDOCRINOLOGY, V137, P5055, DOI 10.1210/en.137.11.5055; BERNIER SM, 1993, J BONE MINER RES, V8, P475; Bianco P, 1998, MATRIX BIOL, V17, P185, DOI 10.1016/S0945-053X(98)90057-9; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Broadus Arthur E., 1994, P259; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; DANG CV, 1989, J BIOL CHEM, V264, P18019; Divieti P, 1998, J BONE MINER RES, V13, P1835, DOI 10.1359/jbmr.1998.13.12.1835; Dougherty KM, 1999, CANCER RES, V59, P6015; DUNDR M, 1995, J CELL SCI, V108, P2811; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FARNUM CE, 1989, AM J ANAT, V186, P346, DOI 10.1002/aja.1001860404; FARNUM CE, 1993, CALCIFIED TISSUE INT, V52, P110, DOI 10.1007/BF00308319; Galipeau J, 1999, CANCER RES, V59, P2384; Goltzman David, 1996, P809; Guo J, 2001, ENDOCRINOLOGY, V142, P1260, DOI 10.1210/en.142.3.1260; HASTINGS R, 1997, CHEST S1, V116, pS68; Henderson JE, 1996, J CELL PHYSIOL, V169, P33, DOI 10.1002/(SICI)1097-4652(199610)169:1<33::AID-JCP4>3.0.CO;2-F; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; KAI HY, 1996, PRINCIPLES BONE BIOL, P347; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Lam MHC, 1999, J BIOL CHEM, V274, P18559, DOI 10.1074/jbc.274.26.18559; Lam MHC, 1997, J CELL PHYSIOL, V173, P433, DOI 10.1002/(SICI)1097-4652(199712)173:3<433::AID-JCP16>3.0.CO;2-C; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Maiti T, 1997, J BIOL CHEM, V272, P18333, DOI 10.1074/jbc.272.29.18333; Mallette Lawrence E., 1994, P171; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; MATHEWS M, 2001, TRANSLATIONAL CONTRO, P1; Moseley J. M., 1996, P363; Nguyen MTA, 2001, ENDOCRINOLOGY, V142, P694, DOI 10.1210/en.142.2.694; OKANO K, 1995, ENDOCRINOLOGY, V136, P1782, DOI 10.1210/en.136.4.1782; Ono T, 1997, J BIOL CHEM, V272, P14404, DOI 10.1074/jbc.272.22.14404; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; POOLE AR, 2000, OSTEOPOROSIS PRIMER, P3; ROACH HI, 1995, J CELL BIOL, V131, P483, DOI 10.1083/jcb.131.2.483; Roach HI, 1997, J BONE MINER RES, V12, P795, DOI 10.1359/jbmr.1997.12.5.795; Segre Gino V., 1996, P377; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; SOIFER NE, 1992, J BIOL CHEM, V267, P18236; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Suda N, 1999, J BONE MINER RES, V14, P1838, DOI 10.1359/jbmr.1999.14.11.1838; Terkeltaub R, 1998, ARTHRITIS RHEUM-US, V41, P2152, DOI 10.1002/1529-0131(199812)41:12<2152::AID-ART10>3.3.CO;2-O; Tian B, 2001, J BIOL CHEM, V276, P9936, DOI 10.1074/jbc.M007328200; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Watson PH, 2000, J BONE MINER RES, V15, P1033, DOI 10.1359/jbmr.2000.15.6.1033; Wu TL, 1996, J BIOL CHEM, V271, P24371, DOI 10.1074/jbc.271.40.24371; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	56	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37934	37943						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11489898				2022-12-25	WOS:000171526500031
J	Couture, M; Adak, S; Stuehr, DJ; Rousseau, DL				Couture, M; Adak, S; Stuehr, DJ; Rousseau, DL			Regulation of the properties of the heme-NO complexes in nitric-oxide synthase by hydrogen bonding to the proximal cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN CHARACTERIZATION; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; FEEDBACK INHIBITION; CYTOCHROME P450CAM; IRON LIGAND; BINDING; CHLOROPEROXIDASE; SUBSTRATE; MECHANISM	Nitric-oxide synthase (NOS) catalyzes the formation of NO and citrulline from L-arginine and oxygen. However, the NO so formed has been found to auto-inhibit the enzymatic activity significantly. We hypothesized that the NO reactivity is in part controlled by hydrogen bonding between the conserved tryptophan residue (position 409 in the neuronal isoform of NOS (nNOS)) and the cysteine residue that forms the proximal bond to the heme. By using resonance Raman spectroscopy and NO as a probe of the heme environment, we show that in the W409F and W409Y mutants of the oxygenase domain of the neuronal enzyme (nNOSox), the Fe-NO bond in the Fe3+NO complex is weaker than in the wild type enzyme, consistent with the loss of a hydrogen bond on the sulfur atom of the proximal cysteine residue. The weaker Fe-NO bond in the W409F and W409Y mutants might result in a faster rate of NO dissociation from the ferric heme in the Trp-409 mutants as compared with the wild type enzyme, which could contribute to the lower accumulation of the inhibitory NO-bound complexes observed during catalysis with the Trp-409 mutants (Adak, S., Crooks, C., Wang, Q., Crane, B. R., Tainer, J. A., Getzoff, E. D., and Stuehr, D. J. (1999) J. Biol. Chem. 274, 26907-26911). The optical and resonance Raman spectra of the Fe2+NO complexes of the Trp-409 mutants differ from those of the wild type enzyme and indicate that a significant population of a five-coordinate Fe2+NO complex is present. These data show that the hydrogen bond provided by the Trp-409 residue is necessary to maintain the thiolate coordination when NO binds to the ferrous heme. Taken together our results indicate that the heme environment on the proxima side of nNOS is critical for the formation of a stable iron-cysteine bond and for the control of the electronic properties of heme-NO complexes.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Yeshiva University; Albert Einstein College of Medicine; Cleveland Clinic Foundation	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.		Couture, Manon/F-8326-2015	Couture, Manon/0000-0001-8296-8055	NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM54812, GM54806] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054806, R01GM054812] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; Adak S, 1999, J BIOL CHEM, V274, P26907, DOI 10.1074/jbc.274.38.26907; Adak S, 2000, J BIOL CHEM, V275, P17434, DOI 10.1074/jbc.M000846200; Adak S, 2001, J INORG BIOCHEM, V83, P301, DOI 10.1016/S0162-0134(00)00176-8; BANGCHAROENPAURPONG O, 1986, BIOCHEMISTRY-US, V25, P2374, DOI 10.1021/bi00357a011; BENKO B, 1983, P NATL ACAD SCI USA, V80, P7042, DOI 10.1073/pnas.80.22.7042; CHAMPION PM, 1982, J AM CHEM SOC, V104, P5469, DOI 10.1021/ja00384a037; CHANG CK, 1975, J AM CHEM SOC, V97, P5948, DOI 10.1021/ja00853a069; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Decatur SM, 1996, BIOCHEMISTRY-US, V35, P4939, DOI 10.1021/bi951661p; Deng TJ, 1999, BIOCHEMISTRY-US, V38, P13699, DOI 10.1021/bi991287j; Fan BC, 1998, BIOCHEMISTRY-US, V37, P1178, DOI 10.1021/bi971934b; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hoshino M, 1996, J AM CHEM SOC, V118, P5702, DOI 10.1021/ja953311w; HU SZ, 1991, J AM CHEM SOC, V113, P9760, DOI 10.1021/ja00026a008; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; HU SZ, 1993, J BIOL CHEM, V268, P6189; HU SZ, 1991, J AM CHEM SOC, V113, P2843, DOI 10.1021/ja00008a007; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; Nakano R, 1996, J BIOL CHEM, V271, P8570, DOI 10.1074/jbc.271.15.8570; Obayashi E, 1997, J AM CHEM SOC, V119, P7807, DOI 10.1021/ja9637816; Obayashi E, 1998, J AM CHEM SOC, V120, P12964, DOI 10.1021/ja9813764; Poulos T. L., 2000, PORPHYRIN HDB, V4, P189; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; Reynolds MF, 2000, BIOCHEMISTRY-US, V39, P388, DOI 10.1021/bi991378g; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Schelvis JPM, 1998, BIOCHEMISTRY-US, V37, P16289, DOI 10.1021/bi981547h; Schlichting I, 1997, FEBS LETT, V415, P253, DOI 10.1016/S0014-5793(97)01135-6; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sigman JA, 1999, BIOCHEMISTRY-US, V38, P11122, DOI 10.1021/bi990815o; Spiro, 1988, BIOL APPL RAMAN SPEC, P1; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; TSUBAKI M, 1982, BIOCHEMISTRY-US, V21, P1140, DOI 10.1021/bi00535a005; Uno T, 2001, J AM CHEM SOC, V123, P2458, DOI 10.1021/ja0057880; Wang J., 1996, METHODS NITRIC OXIDE, P427; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; Yeh SR, 1998, ACCOUNTS CHEM RES, V31, P727, DOI 10.1021/ar970084p; Yoshioka S, 2000, J INORG BIOCHEM, V81, P141, DOI 10.1016/S0162-0134(00)00097-0	54	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38280	38288						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11479310				2022-12-25	WOS:000171526500076
J	Rout, MP; Field, MC				Rout, MP; Field, MC			Isolation and characterization of subnuclear compartments from Trypanosoma brucei - Identification of a major repetitive nuclear lamina component	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE COMPLEX; ENDOPLASMIC-RETICULUM; SPINDLE POLE; PROTEIN; TRANSPORT; CHROMATIN; LOCALIZATION; EXPRESSION; ARCHITECTURE; BINDING	Protozoan parasites of the order Kinetoplastida are responsible for a significant proportion of global morbidity and economic hardship. These organisms also represent extremely distal points within the Eukarya, and one such organism, Trypanosoma brucei, has emerged as a major system for the study of evolutionary cell biology. Significant technical challenges have hampered the full exploitation of this organism, but advances in genomics and proteomics provide a novel approach to acquiring rapid functional data. However, the vast evolutionary distance between trypanosomes and the higher eukaryotes presents significant problems with functional assignment based on sequence similarity, and frequently homologues cannot be identified with sufficient confidence to be informative. Direct identification of proteins in isolated organelles has the potential of providing robust functional insight and is a powerful approach for initial assignment. We have selected the nucleus of T. brucei as a first target for protozoan organellar proteomics. Our purification methodology was able to reliably provide both nuclear and subnuclear fractions. Analysis by gel electrophoresis, electron microscopy, and immunoblotting against trypanosome subcellular markers indicated that the preparations are of high yield and purity, maintain native morphology, and are well resolved from other organelles. Minor developmental differences were observed in the nuclear proteome for the bloodstream and procyclic stages, whereas significant morphological alterations were visible. We demonstrate by direct sequencing that the NUP-1 nuclear envelope antigen is a coiled coil protein, containing similar to 20 near-perfect copies of a 144-amino acid sequence. Immunoelectron microscopy localized NUP-1 to the inner face of the nuclear envelope, suggesting that it is a major filamentous component of the trypanosome nuclear lamina.	Rockefeller Univ, Lab Cellular & Struct Biol, New York, NY 10021 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wellcome Trust Labs Mol Parasitol, London SW7 2AY, England	Rockefeller University; Imperial College London	Rout, MP (corresponding author), Rockefeller Univ, Lab Cellular & Struct Biol, 1230 York Ave, New York, NY 10021 USA.	rout@rockvax.rockfeller.edu; mfield@ic.ac.uk	Field, Mark/AAD-6455-2021; Rout, Michael/Y-7090-2018	Rout, Michael/0000-0003-2010-706X; Field, Mark/0000-0002-4866-2885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062427] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM62427-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFOLTER M, 1994, J STRUCT BIOL, V112, P241, DOI 10.1006/jsbi.1994.1024; BANGS JD, 1993, J CELL SCI, V105, P1101; BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; Bastin P, 2000, J CELL SCI, V113, P3321; Belli SI, 2000, INT J PARASITOL, V30, P679, DOI 10.1016/S0020-7519(00)00052-7; BENDER K, 1992, PARASITOLOGY, V105, P97, DOI 10.1017/S003118200007373X; BENDER K, 1992, ACTA TROP, V52, P69, DOI 10.1016/0001-706X(92)90008-L; BRUN R, 1979, ACTA TROP, V36, P289; COOMBES GH, 1998, EVOLUTIONARY RELATIO; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; Ersfeld K, 1999, PARASITOL TODAY, V15, P58, DOI 10.1016/S0169-4758(98)01378-7; FAWCETT DW, 1966, AM J ANAT, V119, P129, DOI 10.1002/aja.1001190108; Ferguson MAJ, 2000, P NATL ACAD SCI USA, V97, P10673, DOI 10.1073/pnas.97.20.10673; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; Field H, 1996, MOL BIOCHEM PARASIT, V82, P67, DOI 10.1016/0166-6851(96)02723-5; Field H, 2000, MOL BIOCHEM PARASIT, V106, P21, DOI 10.1016/S0166-6851(99)00192-9; Field H, 1999, J CELL SCI, V112, P147; FIELD H, 1994, MOL BIOCH PHARASITOL, V69, P131; Field M. C., 1992, LIPID MODIFICATION P, P155; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; FRANKE WW, 1974, INT REV CYTOL      S, V4, P72; Gant TM, 1997, ANNU REV CELL DEV BI, V13, P669, DOI 10.1146/annurev.cellbio.13.1.669; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; GRAB DJ, 1987, J CELL BIOL, V105, P737, DOI 10.1083/jcb.105.2.737; Harlow E., 1988, ANTIBODIES LAB MANUA; HECKER H, 1989, MOL BIOCHEM PARASIT, V37, P225, DOI 10.1016/0166-6851(89)90154-0; Ilgoutz SC, 1999, EMBO J, V18, P3643, DOI 10.1093/emboj/18.13.3643; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Leadbeater BSC, 2000, FLAGELLATES UNITY DI; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Manger ID, 1998, MOL BIOCHEM PARASIT, V97, P1, DOI 10.1016/S0166-6851(98)00118-2; Muramatsu M, 1978, Methods Cell Biol, V17, P141, DOI 10.1016/S0091-679X(08)61142-5; Navarro M, 1999, EMBO J, V18, P2265, DOI 10.1093/emboj/18.8.2265; NAVARRO M, 2000, MOL PAR M WOODS HOL, P18; Ogbadoyi E, 2000, CHROMOSOMA, V108, P501, DOI 10.1007/s004120050402; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; PRADOFIGUEROA M, 1994, MOL BIOCHEM PARASIT, V63, P255, DOI 10.1016/0166-6851(94)90061-2; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P143; Rout MP, 2000, ESSAYS BIOCHEM, V36, P75, DOI 10.1042/bse0360075; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Rout MP, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P120; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; SHAPIRO SZ, 1982, ANAL BIOCHEM, V127, P112, DOI 10.1016/0003-2697(82)90152-X; Strambio-de-Castillia C, 1999, J CELL BIOL, V144, P839, DOI 10.1083/jcb.144.5.839; STRAMBIODECASTILLIA C, 1995, J CELL BIOL, V131, P19, DOI 10.1083/jcb.131.1.19; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; [No title captured]	51	66	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38261	38271						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11477078				2022-12-25	WOS:000171526500074
J	Han, SJ; Lee, JS; Kang, JS; Kim, YJ				Han, SJ; Lee, JS; Kang, JS; Kim, YJ			Med9/Cse2 and Gal11 modules are required for transcriptional repression of distinct group of genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; ACTIVATED TRANSCRIPTION; MEDIATOR COMPLEX; YEAST; HOLOENZYME; SIN4; PROTEINS; RGR1; DOMAIN	The yeast Mediator is composed of two subcomplexes, Rgr1 and Srb4, known to be required for diverse aspects of transcriptional regulation; however, their structural and functional organizations have not yet been deciphered in detail. Biochemical analyses designed to determine the subunit composition of the Rgr1 subcomplex revealed that the regulator-interacting subcomplex has a modular structure and is composed of the Gal11, Med9/Cse2, and Med10/Nut2 modules. Genome-wide gene expression and Northern analyses performed in the presence or absence of the various Mediator modules revealed a distinct requirement for the Gal11, Med9/Cse2, and Med10/Nut2 modules in transcriptional repression as well as activation. GST pull-down analysis revealed that the transcriptional repressor Tup1 binds to distinct but overlapping regions of the Gal11 module that were shown previously to be transcriptional activator binding sites. These data suggest that competition between transcriptional activators and repressors for a common binding site in the Mediator and distinct conformational changes in the Mediator induced by repressor binding may underlie the mechanism of transcriptional repression in eukaryotes.	Yonsei Univ, Dept Biochem, Natl Creat Res Initiat Ctr Genome Regulat, Seoul 120749, South Korea	Yonsei University	Kim, YJ (corresponding author), Yonsei Univ, Dept Biochem, Natl Creat Res Initiat Ctr Genome Regulat, 134 Sinchon Dong, Seoul 120749, South Korea.			/0000-0001-7230-1767				Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Balciunas D, 1999, P NATL ACAD SCI USA, V96, P376, DOI 10.1073/pnas.96.2.376; COVITZ PA, 1994, GENETICS, V138, P577; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; FASSLER JS, 1989, MOL CELL BIOL, V9, P5602, DOI 10.1128/MCB.9.12.5602; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Han SJ, 1999, MOL CELL BIOL, V19, P979; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jabet C, 2000, J BIOL CHEM, V275, P9011, DOI 10.1074/jbc.275.12.9011; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; JIANG YW, 1995, GENETICS, V140, P47; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; Kim S, 2000, MOL CELL BIOL, V20, P2455, DOI 10.1128/MCB.20.7.2455-2465.2000; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Kwon JY, 1999, P NATL ACAD SCI USA, V96, P14990, DOI 10.1073/pnas.96.26.14990; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Lee YC, 1999, MOL CELL BIOL, V19, P2967; Lee YC, 1998, MOL CELL BIOL, V18, P5364, DOI 10.1128/MCB.18.9.5364; Lee YC, 1997, MOL CELL BIOL, V17, P4622, DOI 10.1128/MCB.17.8.4622; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Papamichos-Chronakis M, 2000, J BIOL CHEM, V275, P8397, DOI 10.1074/jbc.275.12.8397; Piruat JI, 1997, GENETICS, V147, P1585; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; SAKAI A, 1990, MOL CELL BIOL, V10, P4130, DOI 10.1128/MCB.10.8.4130; SIKORSKI RS, 1989, GENETICS, V122, P19; Song WJ, 1996, MOL CELL BIOL, V16, P115; Song WJ, 1998, EMBO J, V17, P5757, DOI 10.1093/emboj/17.19.5757; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	40	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37020	37026		10.1074/jbc.M105596200	http://dx.doi.org/10.1074/jbc.M105596200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11470794	hybrid			2022-12-25	WOS:000171375700023
J	Pascual-Ahuir, A; Posas, F; Serrano, R; Proft, M				Pascual-Ahuir, A; Posas, F; Serrano, R; Proft, M			Multiple levels of control regulate the yeast cAMP-response element-binding protein repressor Sko1p in response to stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-A ACTIVITY; SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; BZIP PROTEIN; DNA-BINDING; TRANSCRIPTION; GENE; ACTIVATOR; INDUCTION; CREB	The Sko1p transcriptional repressor regulates a subset of osmoinducible stress defense genes in Saccharomyces cerevisiae by binding to cAMP-responsive elements. We have reported previously that in response to stress Sko1p is phosphorylated by the stress-activated Hog1p mitogen-activated protein kinase, which disrupts its interaction with the Ssn6p . Tup1p corepressor. Here we report that other mechanisms are essential for the regulation of the Sko1p repressor activity upon stress. The nuclear localization of Sko1p depends on the stress-inhibited protein kinase A (PKA). Sko1p is localized in the nucleus of unstressed cells, and it redistributes to the cytosol upon severe salt stress (1 M NaCl). Yeast mutants with low PKA activity localize Sko1p to the cytoplasm in the absence of stress and exhibit deregulated expression of cAMP-responsive element-regulated genes. The central part (315-486) of Sko1p, containing the PKA phosphorylation sites and the basic domain-leucine zipper domain, is essential for its nuclear localization. Salt-induced export of Sko1p from the nucleus is independent of Hog1p and of the Bcy1p regulatory subunit of PKA. Furthermore, phosphorylation by PKA slightly enhanced DNA binding affinity of Sko1p in vitro, whereas Sko1p dimerization in vivo is not regulated by stress. Sko1p repressor activity is associated to its binding to the Ssn6p-Tup1p complex. Interestingly, the Sko1p NH2 terminus (1-315), containing the Hog1p phosphorylation sites, associates in vivo with Tup1p in the absence of Ssn6p, suggesting that Sko1p represses gene transcription by interacting directly with the Tup1p subunit of the Ssn6p-Tup1p complex.	Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, Valencia 46022, Spain; Univ Pompeu Fabra, Dept Ciencia Expt & Salut, Cell Signaling Unit, E-08003 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP); Pompeu Fabra University	Proft, M (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	markus-proft@hms.harvard.edu	Pascual-ahuir, Amparo/K-1338-2014; Posas, Francesc/K-1364-2013; Proft, Markus/K-2323-2014	Posas, Francesc/0000-0002-4164-7076; Proft, Markus/0000-0002-6788-5830; PASCUAL-AHUIR, AMPARO/0000-0001-6173-1526				Bartsch D, 1998, CELL, V95, P211, DOI 10.1016/S0092-8674(00)81752-3; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; Garay-Arroyo A, 1999, YEAST, V15, P879, DOI 10.1002/(SICI)1097-0061(199907)15:10A<879::AID-YEA428>3.3.CO;2-H; Garcia-Gimeno MA, 2000, MOL CELL BIOL, V20, P4340, DOI 10.1128/MCB.20.12.4340-4349.2000; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; Marquez JA, 1998, EMBO J, V17, P2543, DOI 10.1093/emboj/17.9.2543; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; NEHLIN JO, 1992, NUCLEIC ACIDS RES, V20, P5271, DOI 10.1093/nar/20.20.5271; NIKAWA J, 1987, GENE DEV, V1, P931, DOI 10.1101/gad.1.9.931; Norbeck J, 2000, YEAST, V16, P121, DOI 10.1002/(SICI)1097-0061(20000130)16:2<121::AID-YEA511>3.0.CO;2-A; Pascual-Ahuir M, 2001, MOL CELL BIOL, V21, P16, DOI 10.1128/MCB.21.1.16-25.2001; Proft M, 1999, MOL CELL BIOL, V19, P537; Proft M, 2001, EMBO J, V20, P1123, DOI 10.1093/emboj/20.5.1123; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Rep M, 2001, MOL MICROBIOL, V40, P1067, DOI 10.1046/j.1365-2958.2001.02384.x; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VARAGONA MJ, 1994, PLANT J, V5, P207, DOI 10.1046/j.1365-313X.1994.05020207.x; VINCENT AC, 1992, MOL CELL BIOL, V12, P5394, DOI 10.1128/MCB.12.12.5394; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5	28	48	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37373	37378		10.1074/jbc.M105755200	http://dx.doi.org/10.1074/jbc.M105755200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11500510	hybrid			2022-12-25	WOS:000171375700069
J	Sakr, SW; Eddy, RJ; Barth, H; Wang, FW; Greenberg, S; Maxfield, FR; Tabas, I				Sakr, SW; Eddy, RJ; Barth, H; Wang, FW; Greenberg, S; Maxfield, FR; Tabas, I			The uptake and degradation of matrix-bound lipoproteins by macrophages require an intact actin cytoskeleton, Rho family GTPases, and myosin ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; TO-RETENTION HYPOTHESIS; MEDIATED ENDOCYTOSIS; EXTRACELLULAR-MATRIX; SCAVENGER RECEPTOR; ADP-RIBOSYLATION; BINDING; LDL; PHAGOCYTOSIS	A key cellular event in atherogenesis is the interaction of macrophages with lipoproteins in the subendothelium. In vivo, these lipoproteins are bound to matrix and often aggregated, yet most cell-culture experiments explore these events using soluble monomeric lipoproteins. We hypothesized that the internalization and degradation of matrix-retained and aggregated low density lipoprotein (LDL) by macrophages may involve the actin-myosin cytoskeleton in a manner that distinguishes this process from the endocytosis of soluble LDL. To explore these ideas, we plated macrophages on sphingomyelinase-aggregated LDL bound to smooth muscle cell-derived matrix in the presence of lipoprotein lipase. The macrophages internalized and degraded the LDL, which was mediated partially by the LDL receptor-related protein. Cytochalasin D and latrunculin A, which block actin polymerization, markedly inhibited the uptake and degradation of matrix-retained LDL but not soluble LDL. Inhibition of Rho family GTPases by Clostridium difficile toxin B blocked the degradation of matrix-retained and aggregated LDL by >90% without any inhibition of soluble LDL degradation. However, specific inhibition of Rho had no effect, suggesting the importance of Rac1 and Cdc42. Degradation of matrix-retained, but not soluble, LDL was also blocked by inhibitors of tyrosine kinase, phosphatidylinositol 3-kinase, and myosin ATPase. These findings define fundamental cytoskeletal pathways that may be involved in macrophage foam cell formation in vivo but have been missed by the use of previous cell culture models.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Columbia University; Columbia University; Columbia University; University of Freiburg; Cornell University	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu	Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011; Barth, Holger/E-7920-2013	Maxfield, Fred/0000-0003-4396-8866; 	NHLBI NIH HHS [HL-56984, HL-57560] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984, R01HL057560] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEPFELBACHER M, 1995, FEBS LETT, V363, P78, DOI 10.1016/0014-5793(95)00285-H; Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; Ayscough K, 1998, METHOD ENZYMOL, V298, P18, DOI 10.1016/S0076-6879(98)98004-1; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Buton X, 1999, J BIOL CHEM, V274, P32112, DOI 10.1074/jbc.274.45.32112; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DELANEROLLE P, 1993, J BIOL CHEM, V268, P16883; Djouder N, 2000, J BIOL CHEM, V275, P18732, DOI 10.1074/jbc.M001425200; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; Greenberg S, 1999, J LEUKOCYTE BIOL, V66, P712, DOI 10.1002/jlb.66.5.712; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERRMANN C, 1992, BIOCHEMISTRY-US, V31, P12227, DOI 10.1021/bi00163a036; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HOFF HF, 1985, ANN NY ACAD SCI, V454, P183, DOI 10.1111/j.1749-6632.1985.tb11857.x; Kaplan M, 2001, ARTERIOSCL THROM VAS, V21, P386, DOI 10.1161/01.ATV.21.3.386; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lange Y, 1999, J LIPID RES, V40, P2264; LENDON CL, 1991, ATHEROSCLEROSIS, V87, P87, DOI 10.1016/0021-9150(91)90235-U; Leverrier Y, 2001, CURR BIOL, V11, P195, DOI 10.1016/S0960-9822(01)00047-1; Lewis CM, 1998, CANCER RES, V58, P2952; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; Llorente-Cortes V, 2000, ARTERIOSCL THROM VAS, V20, P1572, DOI 10.1161/01.ATV.20.6.1572; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Marathe S, 2000, ARTERIOSCL THROM VAS, V20, P2607, DOI 10.1161/01.ATV.20.12.2607; MCABEE DD, 1983, J CELL BIOL, V97, P1515, DOI 10.1083/jcb.97.5.1515; MISRA UK, 1999, ARCH BIOCHEM BIOPHYS, V327, P328; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; Ory S, 2000, J CELL SCI, V113, P1177; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Ruchhoeft ML, 1997, J NEUROBIOL, V32, P567, DOI 10.1002/(SICI)1097-4695(19970605)32:6<567::AID-NEU3>3.0.CO;2-Y; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SMITH EB, 1976, ATHEROSCLEROSIS, V25, P71, DOI 10.1016/0021-9150(76)90049-6; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; Swanson JA, 1999, J CELL SCI, V112, P307; TABAS I, 1993, J BIOL CHEM, V268, P20419; Tabas I, 1999, CHEM PHYS LIPIDS, V102, P123, DOI 10.1016/S0009-3084(99)00080-8; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; Tabas I, 1999, ANNU REV NUTR, V19, P123, DOI 10.1146/annurev.nutr.19.1.123; Tabas I, 2000, BBA-MOL CELL BIOL L, V1529, P164, DOI 10.1016/S1388-1981(00)00146-3; Tang W, 1999, BBA-MOL CELL BIOL L, V1437, P301, DOI 10.1016/S1388-1981(99)00023-2; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Wang ZX, 1996, CELL GROWTH DIFFER, V7, P123; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Wu SM, 1996, ARCH BIOCHEM BIOPHYS, V326, P39, DOI 10.1006/abbi.1996.0044; XU XX, 1991, J BIOL CHEM, V266, P24849; XU XX, 1991, J BIOL CHEM, V266, P17040; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200	71	53	54	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37649	37658		10.1074/jbc.M105129200	http://dx.doi.org/10.1074/jbc.M105129200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11477084	hybrid			2022-12-25	WOS:000171375700102
J	Tartaglia, N; Du, J; Tyler, WJ; Neale, E; Pozzo-Miller, L; Lu, B				Tartaglia, N; Du, J; Tyler, WJ; Neale, E; Pozzo-Miller, L; Lu, B			Protein synthesis-dependent and -independent regulation of hippocampal synapses by brain-derived neurotrophic factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; LONG-TERM POTENTIATION; DEVELOPING NEUROMUSCULAR SYNAPSES; BDNF KNOCKOUT MICE; CORTICAL-NEURONS; NEUROTRANSMITTER RELEASE; SYNAPTOTAGMIN MUTANTS; TRANSMITTER RELEASE; CA1 REGION; CYCLIC-AMP	A fundamental difference between short-term and long-term forms of synaptic plasticity is the dependence on transcription and translation of new genes. Using organotypic cultures of hippocampal slices, we have investigated whether the modulation of synapses by brain-derived neurotrophic factor (BDNF) also requires protein synthesis. Long-term treatment of hippocampal slice cultures with BDNF increased the number of docked vesicles, but not that of reserve pool vesicles, at CAI excitatory synapses. BDNF also increased the levels of the vesicle proteins synaptophysin, synaptobrevin, and synaptotagmin, without affecting the presynaptic membrane proteins syntaxin and SNA-P-25, or the vesicle-binding protein synapsin-1. The increase in synaptophysin and synaptobrevin expression was moderate (2-fold) and occurred within 6 h after BDNF application. In contrast, synaptotagmin expression took 24 h to reach maximum levels (5-fold). The delayed increase in synaptotagmin was blocked by protein synthesis inhibitors, while the early increase in synaptophysin and synaptobrevin was not. Moreover, the BDNF-induced increase of synaptotagmin was blocked by inhibiting the cAMP/ protein kinase A (PKA) pathway. However, BDNF did not activate PKA, and application of a PKA activator did not mimic the BDNF effect. Taken together, these results suggest a novel, protein synthesis-dependent form of BDNF modulation that requires cAMP gating.	NICHHD, Unit Synapse Dev & Plast, NIH, Bethesda, MD 20892 USA; NICHHD, Sect Cell Biol, NIH, Bethesda, MD 20892 USA; Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA; Howard Hughes Med Inst Natl Inst Hlth Res Scholar, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Alabama System; University of Alabama Birmingham	Lu, B (corresponding author), NICHHD, Unit Synapse Dev & Plast, NIH, Bldg 49,Rm 6A-80,49 Convent Dr,MSC4480, Bethesda, MD 20892 USA.	lub@codon.nih.gov	Lu, Bai/A-4018-2012; Du, Jing/A-9023-2012; Tyler, William/J-1818-2012; Du, Jing/GWC-9642-2022	Du, Jing/0000-0003-3128-9997; Pozzo-Miller, Lucas/0000-0001-6085-5527; Lu, Bai/0000-0001-5418-9759; Tyler, William/0000-0002-7758-5022; Tartaglia, Nicole/0000-0002-8529-6722	NICHD NIH HHS [P01-HD38760-01] Funding Source: Medline; NINDS NIH HHS [R01-NS40593-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000714, P01HD038760] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040593] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; Becher A, 1999, J NEUROSCI, V19, P1922; BERHOW MT, 1995, NEUROSCIENCE, V68, P969, DOI 10.1016/0306-4522(95)00207-Y; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; Bolton MM, 2000, J NEUROSCI, V20, P3221, DOI 10.1523/JNEUROSCI.20-09-03221.2000; Boulanger L, 1999, SCIENCE, V284, P1982, DOI 10.1126/science.284.5422.1982; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; Chang SH, 1999, P NATL ACAD SCI USA, V96, P4095, DOI 10.1073/pnas.96.7.4095; Daly C, 2000, P NATL ACAD SCI USA, V97, P6120, DOI 10.1073/pnas.97.11.6120; DICKINSONNELSON A, 1983, J NEUROSCI, V3, P42; Dubnau J, 1998, ANNU REV NEUROSCI, V21, P407, DOI 10.1146/annurev.neuro.21.1.407; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Fukuda M, 2000, P NATL ACAD SCI USA, V97, P14715, DOI 10.1073/pnas.260491197; Gaiddon C, 1996, J NEUROCHEM, V66, P2279; Ganguly S, 2001, P NATL ACAD SCI USA, V98, P8083, DOI 10.1073/pnas.141118798; Gottschalk W, 1998, J NEUROSCI, V18, P6830; Gottschalk WA, 1999, LEARN MEMORY, V6, P243; He XP, 2000, J CELL BIOL, V149, P783, DOI 10.1083/jcb.149.4.783; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Korte M, 1998, NEUROPHARMACOLOGY, V37, P553, DOI 10.1016/S0028-3908(98)00035-5; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; MILLER LDP, 1993, SYNAPSE, V13, P195, DOI 10.1002/syn.890130302; Nonner D, 2000, J NEUROCHEM, V74, P988, DOI 10.1046/j.1471-4159.2000.0740988.x; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; Peters A., 1991, FINE STRUCTURE NERVO; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; Reist NE, 1998, J NEUROSCI, V18, P7662; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Sherwood NT, 1999, J NEUROSCI, V19, P7025, DOI 10.1523/JNEUROSCI.19-16-07025.1999; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Stoop R, 1996, J NEUROSCI, V16, P3256; STOOP R, 1995, SCIENCE, V267, P695, DOI 10.1126/science.7839148; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Takei N, 1997, J NEUROCHEM, V68, P370; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; Vicario-Abejon C, 1998, J NEUROSCI, V18, P7256; WANG T, 1995, J NEUROSCI, V15, P4796	59	143	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37585	37593		10.1074/jbc.M101683200	http://dx.doi.org/10.1074/jbc.M101683200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11483592	hybrid			2022-12-25	WOS:000171375700095
J	Campana, WM; Myers, RR				Campana, WM; Myers, RR			Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury	FASEB JOURNAL			English	Article						erythropoietin; glial cells; signaling; apoptosis	COLONY-STIMULATING FACTOR; GANGLION NEURONS; IN-VITRO; RAT; ADULT; JAK2; LOCALIZATION; DEATH	Erythropoietin (Epo) is a hematopoietic factor that has recently been shown to function in the central nervous system. The presence or function of Epo or the erythropoietin receptor (EpoR) in the peripheral nervous system is unknown. Our results demonstrate the presence of both Epo and EpoR in the rat sciatic nerve. Epo was present in axons and was up-regulated in Schwann cells after chronic constriction injury (CCI). EpoR was present in endothelial cells, cell bodies of the dorsal root ganglia (DRG), axons, and Schwann cells; it was not changed after injury. Using two different models of nerve injury, CCI and crush injury adjacent to the DRG, we demonstrated TUNEL labeling in DRG cell bodies after adjacent nerve crush, but not after CCI. TUNEL labeling in crush injury correlated with a significant reduction of EpoR in DRG as determined by morphometry and Western blotting. Immunoblotting of uninjured DRG homogenates revealed an immunoreactive band at 90 kDa and 70 kDa. After crush injury, both 70 kDa and 90 kDa proteins were reduced and the 90 kDa protein showed enhanced tyrosine phosphorylation, whereas the 70 kDa showed less. EpoR colocalized with NF200 in normal DRG, but not after crush injury to the adjacent axon. These findings demonstrate Epo and EpoR in the peripheral nervous system and their regulation after painful nerve injury.	Univ Calif San Diego, Sch Med, Dept Anesthesiol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Campana, WM (corresponding author), Univ Calif San Diego, Sch Med, Dept Anesthesiol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	wcampana@ucsd.edu						ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; Assandri R, 1999, J PHYSIOL-LONDON, V516, P343, DOI 10.1111/j.1469-7793.1999.0343v.x; ASSOULINE JG, 1989, DISSECTION TISSUE CU, P247; AVERILL S, 1995, EUR J NEUROSCI, V7, P1484, DOI 10.1111/j.1460-9568.1995.tb01143.x; BAUER C, 1995, J PERINAT MED, V23, P7, DOI 10.1515/jpme.1995.23.1-2.7; Benes FM, 2001, TRENDS NEUROSCI, V24, P11, DOI 10.1016/S0166-2236(00)01660-X; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bittorf T, 1997, CELL SIGNAL, V9, P85, DOI 10.1016/S0898-6568(96)00121-0; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Campana WM, 1998, INT J MOL MED, V1, P235; Campana WM, 1998, FASEB J, V12, P307, DOI 10.1096/fasebj.12.3.307; Degn J, 1999, J COMP NEUROL, V412, P186, DOI 10.1002/(SICI)1096-9861(19990913)412:1<186::AID-CNE14>3.0.CO;2-H; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; EICHLER ME, 1989, BRAIN RES, V482, P340, DOI 10.1016/0006-8993(89)91197-9; HIMES BT, 1989, J COMP NEUROL, V284, P215, DOI 10.1002/cne.902840206; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Juul SE, 1998, EARLY HUM DEV, V52, P235, DOI 10.1016/S0378-3782(98)00030-9; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; KRANTZ SB, 1991, BLOOD, V77, P419; LANFRANCONE L, 1995, ONCOGENE, V10, P907; Lawson SN., 1992, SENSORY NEURONS DIVE, P27; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Mirsky R, 1999, BRAIN PATHOL, V9, P293; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; NAGAO M, 1992, BIOCHEM BIOPH RES CO, V188, P888, DOI 10.1016/0006-291X(92)91139-H; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pulkkanen KJ, 2000, APOPTOSIS, V5, P329, DOI 10.1023/A:1009631424351; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Studer L, 2000, J NEUROSCI, V20, P7377	35	102	111	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1804	+		10.1096/fj.00-0857fje	http://dx.doi.org/10.1096/fj.00-0857fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481236				2022-12-25	WOS:000169261200030
J	Trivedi, HN; Plummer, FA; Anzala, AO; Njagi, E; Bwayo, JJ; Ngugi, EN; Embree, JE; HayGlass, KT				Trivedi, HN; Plummer, FA; Anzala, AO; Njagi, E; Bwayo, JJ; Ngugi, EN; Embree, JE; HayGlass, KT			Resistance to HIV-1 infection among African sex workers is associated with global hyporesponsiveness in interleukin4 production	FASEB JOURNAL			English	Article						HIV-1 resistance; type 1/type 2 immune responses; immunity	CYTOTOXIC T-LYMPHOCYTES; IFN-GAMMA; ANTIRETROVIRAL THERAPY; SERONEGATIVE PARTNERS; CELLULAR-IMMUNITY; IN-VITRO; RESPONSES; EXPRESSION; CELLS; CD4(+)	We previously identified HIV-1 resistant prostitutes who remain persistently HIV-1 PCR- and antibody-negative despite continued heavy exposure to HIV-1 through sex work. We hypothesized that differences in virus-specific cytokine responses are associated with resistance vs. susceptibility to infection. Although polyclonal activation failed to reveal such difference, antigen-mediated activation of peripheral blood mononuclear cells (PBMC) in primary culture by using intact HIV (IIIB) demonstrates that resistance is associated with enhanced virus-driven interferon gamma and markedly reduced IL-4 responses relative to those seen in HIV-1 seropositive prostitutes (CDC stage A1, CD4>500/ml). No changes were detectable in HIV-stimulated interleukin (IL) 10 and IL-13 production, but IL-5 responses were somewhat increased in resistant sex workers. Moreover, the IL-4 response of HIV-1 resistant woman to a panel of unrelated recall antigens were more than 20-fold reduced relative to HIV-infected prostitutes or those of healthy Kenyan women not involved in sex work. Thus, resistant women differ from seropositive-infected women and healthy controls by exhibiting a profound global hyporesponsiveness in their capacity to generate IL-4 responses.	Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0W3, Canada; Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya; Univ Nairobi, Dept Community Hlth, Nairobi, Kenya	University of Manitoba; University of Manitoba; University of Manitoba; University of Nairobi; University of Nairobi	HayGlass, KT (corresponding author), Univ Manitoba, Dept Immunol, 626-730 William Ave, Winnipeg, MB R3E 0W3, Canada.	hayglass@ms.umanitoba.ca		Njagi, Ephantus/0000-0002-1484-0241; HayGlass, Kent/0000-0002-4621-7737				Allen JE, 1997, IMMUNOL TODAY, V18, P387, DOI 10.1016/S0167-5699(97)01102-X; Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691, DOI 10.1002/jlb.65.5.691; Bertoletti A, 1998, J VIROL, V72, P2439, DOI 10.1128/JVI.72.3.2439-2448.1998; Bienzle D, 2000, J INFECT DIS, V182, P123, DOI 10.1086/315670; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Brinchmann JE, 2000, AIDS, V14, P1689, DOI 10.1097/00002030-200008180-00002; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Clerici M, 1999, IMMUNOL LETT, V66, P21, DOI 10.1016/S0165-2478(98)00181-3; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; Dorrell L, 2000, AIDS, V14, P1117, DOI 10.1097/00002030-200006160-00008; Fowke KR, 1998, AIDS RES HUM RETROV, V14, P1521, DOI 10.1089/aid.1998.14.1521; Fowke KR, 1996, LANCET, V348, P1347, DOI 10.1016/S0140-6736(95)12269-2; Galli G, 1998, EUR J IMMUNOL, V28, P3280, DOI 10.1002/(SICI)1521-4141(199810)28:10<3280::AID-IMMU3280>3.0.CO;2-M; Gangur V, 1998, FASEB J, V12, P705, DOI 10.1096/fasebj.12.9.705; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; Hanke T, 2000, NAT MED, V6, P951, DOI 10.1038/79626; Hay CM, 1999, J VIROL, V73, P5509, DOI 10.1128/JVI.73.7.5509-5519.1999; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; IMADA M, 1995, INT IMMUNOL, V7, P229, DOI 10.1093/intimm/7.2.229; Jourdan P, 2000, J IMMUNOL, V165, P716, DOI 10.4049/jimmunol.165.2.716; Jourdan P, 1998, J IMMUNOL, V160, P4153; Kalams SA, 1999, J VIROL, V73, P6715, DOI 10.1128/JVI.73.8.6715-6720.1999; Kaul R, 1999, AIDS, V13, P23, DOI 10.1097/00002030-199901140-00004; Kelso A, 1999, SPRINGER SEMIN IMMUN, V21, P231, DOI 10.1007/s002810050065; Kokkotou EG, 2000, P NATL ACAD SCI USA, V97, P6797, DOI 10.1073/pnas.97.12.6797; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Li Y, 1998, J IMMUNOL, V161, P7007; Lopalco L, 2000, J IMMUNOL, V164, P3426, DOI 10.4049/jimmunol.164.6.3426; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; Maini MK, 1999, GASTROENTEROLOGY, V117, P1386, DOI 10.1016/S0016-5085(99)70289-1; Malhotra U, 2000, J INFECT DIS, V181, P121, DOI 10.1086/315202; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; Mosmann T, 2000, IMMUNOL TODAY, V21, P199, DOI 10.1016/S0167-5699(00)01587-5; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; Panus JF, 2000, J EXP MED, V192, P1301, DOI 10.1084/jem.192.9.1301; Pape GR, 1999, J VIRAL HEPATITIS, V6, P36, DOI 10.1046/j.1365-2893.1999.00006.x; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Poss M, 1997, AIDS RES HUM RETROV, V13, P493, DOI 10.1089/aid.1997.13.493; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; ROMAGNANI S, 1994, IMMUNOL REV, V140, P73, DOI 10.1111/j.1600-065X.1994.tb00865.x; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rowland-Jones S, 1997, ADV IMMUNOL, V65, P277, DOI 10.1016/S0065-2776(08)60745-2; Rowland-Jones SL, 1999, IMMUNOL LETT, V66, P9, DOI 10.1016/S0165-2478(98)00179-5; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Shearer GM, 1998, AIDS RES HUM RETROV, V14, pS149; Stranford SA, 1999, P NATL ACAD SCI USA, V96, P1030, DOI 10.1073/pnas.96.3.1030; Valentin A, 1998, P NATL ACAD SCI USA, V95, P8886, DOI 10.1073/pnas.95.15.8886; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400; Zoeteweij JP, 1998, J IMMUNOL, V161, P3219	57	12	12	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1795	+		10.1096/fj.00-0619fje	http://dx.doi.org/10.1096/fj.00-0619fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481233				2022-12-25	WOS:000169261200020
J	Woynarowski, JM; Trevino, AV; Rodriguez, KA; Hardies, SC; Benham, CJ				Woynarowski, JM; Trevino, AV; Rodriguez, KA; Hardies, SC; Benham, CJ			AT-rich islands in genomic DNA as a novel target for AT-specific DNA-reactive antitumor drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; FRAGILE SITE FRA16D; NUCLEAR MATRIX; PHASE-I; BIOLOGICAL SIGNIFICANCE; DUPLEX DESTABILIZATION; SEQUENCE-SPECIFICITY; SIMIAN-VIRUS-40 DNA; SUPERHELICAL DNA; CANCER-CELLS	Interstrand cross-links at T(A/T)(4)A sites in cellular DNA are associated with hypercytotoxicity of an anticancer drug, bizelesin. Here we evaluated whether these lethal effects reflect targeting critical genomic regions. An in silico analysis of human sequences showed that T(APT)4A motifs are on average scarce and scattered. However, significantly higher local motif densities were identified in distinct minisatellite regions (200-1000 base pairs of similar to 85-100% AT), herein referred to as "AT islands." Experimentally detected bizelesin lesions agree with these an silico predictions. Actual bizelesin adducts clustered within the model AT island naked DNA, whereas motif-poor sequences were only sparsely adducted. In cancer cells, bizelesin produced high levels of lesions (similar to4.7-7.1 lesions/kilobase pair/muM drug) in several prominent AT islands, compared with markedly lower lesion levels in several motif-poor loci and in bulk cellular DNA (similar to0.8-1.3 and similar to0.9 lesions/kilobase pair/muM drug, respectively). The identified AT islands exhibit sequence attributes of matrix attachment regions (MARs), domains that organize DNA loops on the nuclear matrix. The computed "MAR, potential" and propensity for supercoiling-induced duplex destabilization (both predictive of strong MARS) correlate with the total number of bizelesin binding sites. Hence, MAR-like AT-rich non-coding domains can be regarded as a novel class of critical targets for anticancer drugs.	Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA; Univ Calif Davis, UC Davis Genome Ctr, Davis, CA 95616 USA	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; University of California System; University of California Davis	Woynarowski, JM (corresponding author), Inst Drug Dev, Canc Therapy & Res Ctr, 14960 Omicron Dr, San Antonio, TX 78245 USA.		Benham, Craig J/G-1512-2013; Rodriguez, Karl A/F-2689-2012; Woynarowski, Jan M/A-5915-2008		NCI NIH HHS [CA71969] Funding Source: Medline; NHGRI NIH HHS [R01-HG01973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA071969] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Benham C, 1997, J MOL BIOL, V274, P181, DOI 10.1006/jmbi.1997.1385; BENHAM CJ, 1992, J MOL BIOL, V225, P835, DOI 10.1016/0022-2836(92)90404-8; BENHAM CJ, 1993, P NATL ACAD SCI USA, V90, P2999, DOI 10.1073/pnas.90.7.2999; Benham CJ, 1996, J MOL BIOL, V255, P425, DOI 10.1006/jmbi.1996.0035; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Berezney R, 2000, CHROMOSOMA, V108, P471, DOI 10.1007/s004120050399; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; BOERWINKLE E, 1989, P NATL ACAD SCI USA, V86, P212, DOI 10.1073/pnas.86.1.212; Bolzan AD, 2000, CANCER GENET CYTOGEN, V120, P166, DOI 10.1016/S0165-4608(00)00209-0; Boulikas T, 1995, INT REV CYTOL, V162A, P279; CHOU RH, 1990, CANCER RES, V50, P3199; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; Davie JR, 1999, BIOCHEM CELL BIOL, V77, P265, DOI 10.1139/bcb-77-4-265; DESMARAIS E, 1993, NUCLEIC ACIDS RES, V21, P2179, DOI 10.1093/nar/21.9.2179; Duong TH, 1997, J BIOMOL STRUCT DYN, V14, P691, DOI 10.1080/07391102.1997.10508172; FLEMING GF, 1994, J NATL CANCER I, V86, P368, DOI 10.1093/jnci/86.5.368; Foster BJ, 1995, INVEST NEW DRUG, V13, P321, DOI 10.1007/BF00873138; Fye RM, 1999, PHYS REV E, V59, P3408, DOI 10.1103/PhysRevE.59.3408; Glover TW, 1998, RECENT RES CANCER, V154, P185; Handt O, 2000, MOL GENET METAB, V70, P99, DOI 10.1006/mgme.2000.2996; HARTLEY JA, 1988, ACTA ONCOL, V27, P503, DOI 10.3109/02841868809093578; Herzig MCS, 1999, BIOCHEMISTRY-US, V38, P14045, DOI 10.1021/bi991286r; Khodarev NN, 1998, J CELL BIOCHEM, V70, P604, DOI 10.1002/(SICI)1097-4644(19980915)70:4<604::AID-JCB16>3.0.CO;2-G; KOHN KW, 1988, BIOCHEM PHARMACOL, V37, P1799, DOI 10.1016/0006-2952(88)90452-2; Kramer JA, 1996, GENOMICS, V33, P305, DOI 10.1006/geno.1996.0198; Lawley PD, 1996, MUTAT RES-FUND MOL M, V355, P13, DOI 10.1016/0027-5107(96)00020-6; LEBEAU MM, 1986, ADV HUM GENET, V15, P1; LEE CS, 1994, BIOCHEMISTRY-US, V33, P6024, DOI 10.1021/bi00185a043; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; Mangelsdorf M, 2000, CANCER RES, V60, P1683; MURATA M, 1987, CANCER GENET CYTOGEN, V25, P81, DOI 10.1016/0165-4608(87)90162-2; Norris RA, 2001, DNA CELL BIOL, V20, P89, DOI 10.1089/104454901750070292; Pavlidis N, 2000, CANCER CHEMOTH PHARM, V46, P167, DOI 10.1007/s002800000134; Punt CJA, 1996, BRIT J CANCER, V73, P803, DOI 10.1038/bjc.1996.140; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; Sanderson BJS, 1996, MUTAT RES-FUND MOL M, V355, P41, DOI 10.1016/0027-5107(96)00021-8; SARAI A, 1989, BIOCHEMISTRY-US, V28, P7842, DOI 10.1021/bi00445a046; SCHWARTZ GH, 2000, P AN M AM SOC CLIN, V19, pA235; SHAMDAS GJ, 1994, ANTI-CANCER DRUG, V5, P10, DOI 10.1097/00001813-199402000-00002; Singh GB, 1997, NUCLEIC ACIDS RES, V25, P1419, DOI 10.1093/nar/25.7.1419; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; TAKAHASHI E, 1988, HUM GENET, V80, P124, DOI 10.1007/BF00702853; THOMPSON AS, 1995, J MOL BIOL, V252, P86, DOI 10.1006/jmbi.1994.0477; Vassetzky YS, 2000, J CELL BIOCHEM, V79, P1, DOI 10.1002/1097-4644(2000)79:1<1::AID-JCB20>3.0.CO;2-Y; Wang DM, 1996, J LIPID RES, V37, P2117; WEILAND KL, 1991, BIOCHEMISTRY-US, V30, P7559, DOI 10.1021/bi00244a027; Weiss GR, 1998, CLIN CANCER RES, V4, P53; Woynarowski JM, 1999, BBA-GENE STRUCT EXPR, V1444, P201, DOI 10.1016/S0167-4781(99)00002-0; WOYNAROWSKI JM, 1995, BIOCHEMISTRY-US, V34, P13042, DOI 10.1021/bi00040a015; Woynarowski JM, 1998, MOL PHARMACOL, V54, P770, DOI 10.1124/mol.54.5.770; Woynarowski JM, 2000, BIOCHEMISTRY-US, V39, P9917, DOI 10.1021/bi000729k; Woynarowski JM, 1997, BBA-GENE STRUCT EXPR, V1353, P50, DOI 10.1016/S0167-4781(97)00046-8	53	26	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40555	40566		10.1074/jbc.M103390200	http://dx.doi.org/10.1074/jbc.M103390200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11487576	hybrid			2022-12-25	WOS:000171925600026
J	Hanlon, M; Sturgill, TW; Sealy, L				Hanlon, M; Sturgill, TW; Sealy, L			ERK2-and p90(Rsk2)-dependent pathways regulate the CCAAT/enhancer-binding protein-beta interaction with serum response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX FACTORS; LONG TERMINAL REPEAT; MAP KINASE PATHWAYS; C-FOS TRANSCRIPTION; C/EBP-BETA; SIGNAL-TRANSDUCTION; ACTIVATION DOMAIN; FACTOR SRF; UV-LIGHT; HA-RAS	The serum response element (SRE) of the c-fos promoter is a convergence point for mitogenic signaling pathways. Several transcription factors regulate SRE, including serum response factor (SRF), ternary complex factors, and CCAAT/enhancer-binding protein-beta (C/ EBP beta). C/EBP beta can interact with both SRF and the ternary complex factor family member Elk-1, but only in response to activated Ras. Transactivation of the SRE by C/EBP beta is also greatly stimulated by Ras. The Ras effectors that signal to C/EBP beta are unknown. In this report, we demonstrate that a consensus MAPK site in C/EBP beta is necessary for Ras stimulation of both C/EBP beta -SRF interaction and transactivation of the SRE by C/EBP beta. To dissect signaling pathways activated downstream of Ras, different Ras effector constructs were analyzed. We show that activated forms of Raf and phosphatidylinositol 3-kinase stimulate C/EBP beta -SRF interaction. We also show a novel selectivity for the MAPK family member ERK2, where dominant-negative ERK2, but not dominant-negative ERK1, blocks Ras stimulation of C/EBP beta -SRF interaction. In addition, recombinant C/EBP beta protein is phosphorylated by ERK2, but not by ERK1, in vitro. Finally, we demonstrate a requirement for p90(Rsk2) in regulation of C/EBP beta -SRF interaction. These data show that multiple Ras effectors are required to regulate C/EBP beta and SRF association.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA	Vanderbilt University; University of Virginia	Sealy, L (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 702 Light Hall, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM08554] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Bruning JC, 2000, P NATL ACAD SCI USA, V97, P2462, DOI 10.1073/pnas.97.6.2462; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Hanlon M, 1999, J BIOL CHEM, V274, P14224, DOI 10.1074/jbc.274.20.14224; Hanlon M, 2000, BMC Cell Biol, V1, P2, DOI 10.1186/1471-2121-1-2; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; Hochholdinger F, 1999, MOL CELL BIOL, V19, P8052; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KORTENJANN M, 1995, ONCOGENE, V11, P2105; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Mobley CM, 1998, J VIROL, V72, P6592, DOI 10.1128/JVI.72.8.6592-6601.1998; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Sealy L, 1997, MOL CELL BIOL, V17, P1744, DOI 10.1128/MCB.17.3.1744; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106	38	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38449	38456		10.1074/jbc.M102165200	http://dx.doi.org/10.1074/jbc.M102165200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11500490	hybrid			2022-12-25	WOS:000171673200018
J	Richards, N; Schaner, P; Diaz, A; Stuckey, J; Shelden, E; Wadhwa, A; Gumucio, DL				Richards, N; Schaner, P; Diaz, A; Stuckey, J; Shelden, E; Wadhwa, A; Gumucio, DL			Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL MEDITERRANEAN FEVER; DEATH DOMAIN; GENE; ACTIVATION; COMPLEXITY; FREQUENCY; HOMOLOGY; MEMBER	Patients with familial Mediterranean fever suffer sporadic inflammatory attacks characterized by fever and intense pain (in joints, abdomen, or chest). Pyrin, the product of the MEFV locus, is a cytosolic protein whose function is unknown. Using pyrin as a "bait" to probe a yeast two-hybrid library made from neutrophil cDNA, we isolated apoptotic deck protein containing a caspase recruitment domain (CARD) (ASC), a proapoptotic protein that induces the formation of large cytosolic "specks" in transfected cells. We found that when HeLa cells are transfected with ASC, specks are formed. After co-transfection of cells with ASC plus wild type pyrin, an increase in speck-positive cells is found, and speck-positive cells show increased survival. Immunofluorescence studies show that pyrin co-localizes with ASC in specks. Speck localization requires exon 1 of pyrin, but exon 1 alone of pyrin does not result in an increase in the number of specks. Exon 1 of pyrin and exon 1 of ASC show 42% sequence similarity and resemble death domain-related structures in modeling studies. These findings link pyrin to apoptosis pathways and suggest that the modulation of cell survival may be a component of the pathophysiology of familial Mediterranean fever.	Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biochem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Grad Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Gumucio, DL (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, 5704 Med Sci 2, Ann Arbor, MI 48109 USA.	dgumucio@umich.edu	, Eric/GWC-7636-2022		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007080] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07622] Funding Source: Medline; NIAMS NIH HHS [T32-AR07080] Funding Source: Medline; NICHD NIH HHS [T32-HD07505] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aksentijevich I, 1999, AM J HUM GENET, V64, P949, DOI 10.1086/302327; Aksentijevich I, 1997, CELL, V90, P797; Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Bernot A, 1997, NAT GENET, V17, P25; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; BRUNGER AT, 1987, XPLOR VERSION 3 1; Centola M, 2000, BLOOD, V95, P3223, DOI 10.1182/blood.V95.10.3223; Chen XG, 2000, P SOC EXP BIOL MED, V224, P32, DOI 10.1046/j.1525-1373.2000.22362.x; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Dixon MS, 2000, P NATL ACAD SCI USA, V97, P8807, DOI 10.1073/pnas.97.16.8807; Fischer D, 2000, Pac Symp Biocomput, P119; GORCZYCA W, 1993, CANCER RES, V53, P1945; Henry J, 1998, MOL BIOL EVOL, V15, P1696, DOI 10.1093/oxfordjournals.molbev.a025896; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Inohara N, 2000, CELL DEATH DIFFER, V7, P509, DOI 10.1038/sj.cdd.4400679; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kastner DL, 1998, HOSP PRACT, V33, P131, DOI 10.3810/hp.1998.04.90; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Masumoto J, 2001, BIOCHEM BIOPH RES CO, V280, P652, DOI 10.1006/bbrc.2000.4190; Masumoto J, 2001, EXP CELL RES, V262, P128, DOI 10.1006/excr.2000.5078; Matzner Y, 2000, BLOOD, V96, P727; McConnell BB, 2000, CANCER RES, V60, P6243; Papin S, 2000, HUM MOL GENET, V9, P3001, DOI 10.1093/hmg/9.20.3001; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Schaner P, 2001, NAT GENET, V27, P318, DOI 10.1038/85893; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shinawi M, 2000, J RHEUMATOL, V27, P1492; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; Stoffman N, 2000, EUR J HUM GENET, V8, P307, DOI 10.1038/sj.ejhg.5200446; Whyte M, 1999, BIOCHEM SOC T, V27, P802, DOI 10.1042/bst0270802; Xiao T, 1999, CELL, V99, P545, DOI 10.1016/S0092-8674(00)81542-1	38	225	234	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39320	39329		10.1074/jbc.M104730200	http://dx.doi.org/10.1074/jbc.M104730200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11498534	hybrid			2022-12-25	WOS:000171673200131
J	Derjuga, A; Richard, C; Crosato, M; Wright, PS; Chalifour, L; Valdez, J; Barraso, A; Crissman, HA; Nishioka, W; Bradbury, EM; Th'ng, JPH				Derjuga, A; Richard, C; Crosato, M; Wright, PS; Chalifour, L; Valdez, J; Barraso, A; Crissman, HA; Nishioka, W; Bradbury, EM; Th'ng, JPH			Expression of p21(Waf1/Cip1) and cyclin D1 is increased in butyrate-resistant HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITORS; SODIUM-BUTYRATE; TRICHOSTATIN-A; DEPENDENT KINASES; GROWTH-INHIBITION; ESTROGEN-RECEPTOR; GENE-EXPRESSION; CARCINOMA CELLS; COLON-CANCER; P21	Sodium butyrate induced cell cycle arrest in mammalian cells through an increase in p21(Waf1/Cip1), although another study showed that this arrest is related to pRB signaling. We isolated variants of HeLa cells adapted to growth in 5 mM butyrate. One of these variants, clone 5.1, constitutively expressed elevated levels of p21(Waf1/Cip1) when incubated in regular growth medium and in the presence of butyrate. Despite this elevated level of p21(Waf1/Cip1), the cells continue to proliferate, albeit at a slower rate than parental HeLa cells. Western blot analyses showed that other cell cycle regulatory proteins were not up-regulated to compensate for the elevated expression of p21(Waf1/Cip1). However, cyclin D1 was downregulated by butyrate in HeLa cells but not in clone 5.1. We conclude that continued expression of cyclin D1 allowed clone 5.1 to grow in the presence of butyrate and elevated levels of p21(Waf1/Cip1).	NW Ontario Reg Canc Ctr, Thunder Bay, ON P7A 7T1, Canada; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; Aventis Pharmaceut Inc, Bridgewater, NJ 08807 USA; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Vical Inc, San Diego, CA 92121 USA	Lady Davis Institute; McGill University; Sanofi-Aventis; United States Department of Energy (DOE); Los Alamos National Laboratory	Th'ng, JPH (corresponding author), NW Ontario Reg Canc Ctr, 290 Munro St, Thunder Bay, ON P7A 7T1, Canada.							Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Balbin M, 1996, J BIOL CHEM, V271, P15782, DOI 10.1074/jbc.271.26.15782; Ball K L, 1997, Prog Cell Cycle Res, V3, P125; Barboule N, 1998, INT J CANCER, V76, P891, DOI 10.1002/(SICI)1097-0215(19980610)76:6<891::AID-IJC20>3.0.CO;2-4; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; CHALKLEY R, 1985, J BIOL CHEM, V260, P7698; Conley BA, 1998, CLIN CANCER RES, V4, P629; Coradini D, 1997, CELL PROLIFERAT, V30, P149, DOI 10.1111/j.1365-2184.1997.tb00931.x; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; Davis T, 2000, CLIN CANCER RES, V6, P4334; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; FISCHKOFF SA, 1990, LEUKEMIA, V4, P302; Geradts J, 2000, MODERN PATHOL, V13, P945, DOI 10.1038/modpathol.3880172; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hassig CA, 1997, CHEM BIOL, V4, P783, DOI 10.1016/S1074-5521(97)90111-3; Hengst L, 1998, GENE DEV, V12, P3882, DOI 10.1101/gad.12.24.3882; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Hirai H, 1996, MOL CELL BIOL, V16, P6457; JUNG JM, 1995, ONCOGENE, V11, P2021; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Krupitza G, 1996, BRIT J CANCER, V73, P433, DOI 10.1038/bjc.1996.78; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee E, 1996, FEBS LETT, V395, P183, DOI 10.1016/0014-5793(96)01033-2; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; Medina V, 1997, CANCER RES, V57, P3697; MICHIELI P, 1994, CANCER RES, V54, P3391; MILSTED A, 1985, ENDOCRINOLOGY, V117, P2033, DOI 10.1210/endo-117-5-2033; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OHLSSONWILHELM BM, 1984, AM J HUM GENET, V36, P1225; Ohta, 1997, Breast Cancer, V4, P17, DOI 10.1007/BF02967050; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Saunders N, 1999, CANCER RES, V59, P399; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Tada S, 1996, CANCER BIOCHEM BIOPH, V15, P177; THNG JPH, 1994, J BIOL CHEM, V269, P9568; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; XIANG Y, 1993, NATURE, V366, P701; YEN A, 1995, J CELL PHYSIOL, V163, P502, DOI 10.1002/jcp.1041630310; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	55	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37815	37820						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11477082				2022-12-25	WOS:000171526500014
J	Joiner, WJ; Khanna, R; Schlichter, LC; Kaczmarek, LK				Joiner, WJ; Khanna, R; Schlichter, LC; Kaczmarek, LK			Calmodulin regulates assembly and trafficking of SK4/IK1 Ca2+-activated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; INTERMEDIATE CONDUCTANCE; DEPENDENT ACTIVATION; T-LYMPHOCYTES; CA CHANNEL; CALCIUM; EXPRESSION; SUBFAMILY; DOMAIN; ROLES	Calmodulin (CaM) regulates gating of several types of ion channels but has not been implicated in channel assembly or trafficking. For the SK4/IK1 K+ channel, CaM bound to the proximal C terminus ("Ct1 " domain) acts as the Ca2+ sensor. We now show that CaM interacting with the C terminus of SK4 also controls channel assembly and surface expression. In transfected cells, removing free CaM by overexpressing the CaM-binding domain, Ct1, redistributed full-length SK4 protein from the plasma membrane to the cytoplasm and decreased whole-cell currents. Making more CaM protein available by overexpressing the CaM gene abrogated the dominant-negative effect of Ct1 and restored both surface expression of SK4 protein and whole-cell currents. The distal C-terminal domain ("Ct2") also plays a role in assembly, but is not CaM-dependent. Co-immunoprecipitation experiments demonstrated that multimerization of SK4 subunits was enhanced by CaM and inhibited by removal of CaM, indicating that CaM regulates trafficking of SK4 by affecting the assembly of channels. Our results support a model in which CaM-dependent association of SK4 monomers at their Ct1 domains regulates channel assembly and surface expression. This appears to represent a novel mechanism for controlling ion channels, and consequently, the cellular functions that depend on them.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Univ Toronto, Dept Physiol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Div Cellular & Mol Biol, Toronto Western Res Inst, Univ Hlth Network, Toronto, ON M5T 2S8, Canada	Yale University; Yale University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Schlichter, LC (corresponding author), Toronto Western Hosp, MC9-415,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	schlicht@uhnres.utoronto.ca		Khanna, Rajesh/0000-0002-9066-2969	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001919] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC01919] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Brugnara C, 1995, Ann N Y Acad Sci, V763, P262, DOI 10.1111/j.1749-6632.1995.tb32411.x; Cao YJ, 1999, FEBS LETT, V446, P137, DOI 10.1016/S0014-5793(99)00194-5; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; Gerlach AC, 2001, J BIOL CHEM, V276, P10963, DOI 10.1074/jbc.M007716200; Ghanshani S, 1998, GENOMICS, V51, P160, DOI 10.1006/geno.1998.5333; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; GOH JW, 1987, J PHYSIOL-LONDON, V394, P315, DOI 10.1113/jphysiol.1987.sp016872; Hirschberg B, 1998, J GEN PHYSIOL, V111, P565, DOI 10.1085/jgp.111.4.565; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; JOINER WJ, 2000, SOC NEUR ABSTR, V25, P984; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; KHANNA R, 1999, PHYSIOLOGIST, V42; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; MCCANN JD, 1990, AM J PHYSIOL, V258, pL334, DOI 10.1152/ajplung.1990.258.6.L334; Pedarzani P, 2001, J BIOL CHEM, V276, P9762, DOI 10.1074/jbc.M010001200; Roquemore EP, 1998, MOL BIOL CELL, V9, P2125, DOI 10.1091/mbc.9.8.2125; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; Sah P, 2000, CLIN EXP PHARMACOL P, V27, P657, DOI 10.1046/j.1440-1681.2000.03317.x; SCHLICHTER LC, 1994, EXP CELL RES, V215, P211, DOI 10.1006/excr.1994.1334; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; Syme CA, 2001, BIOPHYS J, V80, p138A; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; Vandorpe DH, 1998, J BIOL CHEM, V273, P21542, DOI 10.1074/jbc.273.34.21542; Wang LY, 1998, P NATL ACAD SCI USA, V95, P1882, DOI 10.1073/pnas.95.4.1882; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761	43	92	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37980	37985						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11495911				2022-12-25	WOS:000171526500037
J	Labrou, NE; Bhogal, N; Hurrell, CR; Findlay, JBC				Labrou, NE; Bhogal, N; Hurrell, CR; Findlay, JBC			Interaction of Met(297) in the seventh transmembrane segment of the tachykinin NK2 receptor with neurokinin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTORS; ANGIOTENSIN-II RECEPTOR; SCHIFF-BASE COUNTERION; SUBSTANCE-P-BINDING; LIGAND-BINDING; NK-1 RECEPTOR; NONPEPTIDE ANTAGONISTS; A ANALOGS; IDENTIFICATION	We report the use of thiol chemistry to define specific and reversible disulfide interactions of Cys-substituted NK2 receptor mutants with analogues of neurokinin A (NKA) containing single cysteine substitutions. The NKA analogues were N-biotinylated to facilitate the rapid detection of covalent analogue-receptor interactions utilizing streptavidin reactivity. N-biotinyl[Tyr(1),Cys(9)]NKA, N-biotinyl-[Tyr(1),Cys(10)]NKA were both found to reversibly disulfide bond to the NK2 receptor mutant Met(297) --> Cys. This is consistent with the improved affinities of these particular analogues for the Met(297) --> Cys receptor as compared with those for the wild-type and Met(297) --> Leu receptors. In our three-dimensional model, Met(297) occupies the equivalent position in helix 7 to the retinal binding Lys(296) in rhodopsin. Binding of the NK2 receptor antagonist [H-3]SR 48968 and of I-125-NKA was used to characterize additional receptor mutants. It seems that the aromatic residues Trp(99) (helix 3), His(198) (helix 5), Tyr(266), His(267), and Phe(270) play an important role in NKA binding as structural determinants. The existence of overlapping SR 48968 and NKA binding sites is also evident. These data suggest that the peptide binding site of the NK2R is at least in part formed by residues buried deep within the transmembrane bundle and that this intramembranous binding domain may correspond to the binding sites for substantially smaller endogenous GPCR ligands.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Bhogal, N (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.	Lambrou@audec.aua.gr; N.Bhogal@leeds.ac.uk	Labrou, Nikolaos/B-1089-2011	Labrou, Nikolaos/0000-0003-1925-9867				BHOGAL N, 1994, J BIOL CHEM, V269, P27269; BUCK SH, 1988, LIFE SCI, V42, P2701, DOI 10.1016/0024-3205(88)90246-9; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; Donnelly D, 1999, BIOCHEM J, V339, P55, DOI 10.1042/0264-6021:3390055; DONNELLY D, 1994, RECEPTOR CHANNEL, V2, P61; EMONDSALT X, 1993, REGUL PEPTIDES, V46, P31, DOI 10.1016/0167-0115(93)90008-V; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1992, J BIOL CHEM, V267, P25664; Girault S, 1996, EUR J BIOCHEM, V240, P215, DOI 10.1111/j.1432-1033.1996.0215h.x; GUTHRIE DJS, 1990, BIOCHEM SOC T, V18, P1323, DOI 10.1042/bst0181323; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; HUANG RRC, 1995, BIOCHEMISTRY-US, V34, P10048, DOI 10.1021/bi00031a029; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Labrou NE, 1997, ARCH BIOCHEM BIOPHYS, V337, P103, DOI 10.1006/abbi.1996.9748; Labrou NE, 1999, PEPTIDES, V20, P795, DOI 10.1016/S0196-9781(99)00064-9; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; Maggi CA, 1997, TRENDS PHARMACOL SCI, V18, P351, DOI 10.1016/S0165-6147(97)90663-5; MUNEKATA E, 1987, PEPTIDES, V8, P169, DOI 10.1016/0196-9781(87)90182-3; Phalipou S, 1999, J BIOL CHEM, V274, P23316, DOI 10.1074/jbc.274.33.23316; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAVIANO G, 1991, BIOCHEMISTRY-US, V30, P10175, DOI 10.1021/bi00106a015; Servant G, 1997, J BIOL CHEM, V272, P8653, DOI 10.1074/jbc.272.13.8653; STRADER CD, 1987, J BIOL CHEM, V262, P16439; WERGE TM, 1994, J BIOL CHEM, V269, P22054; YAMANO Y, 1995, J BIOL CHEM, V270, P14024, DOI 10.1074/jbc.270.23.14024; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; ZHUKOVSKY EA, 1992, BIOCHEMISTRY-US, V31, P10400, DOI 10.1021/bi00157a030; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	33	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37944	37949						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11489908				2022-12-25	WOS:000171526500032
J	Kamimoto, T; Zama, T; Aoki, R; Muro, Y; Hagiwara, M				Kamimoto, T; Zama, T; Aoki, R; Muro, Y; Hagiwara, M			Identification of a novel kinesin-related protein, KRMP1, as a target for mitotic peptidyl-prolyl isomerase Pin1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-PHASE PHOSPHOPROTEINS; MONOCLONAL-ANTIBODY; CHROMOSOME SEGREGATION; MITOSIS; PHOSPHORYLATION; CYTOKINESIS; SPINDLE; MOTORS; CELLS; AUTOANTIBODIES	Mitosis utilizes a number of kinesin-related proteins (KRPs). Here we report the identification of a novel KRP termed KRMP1, which has a deduced 1780-amino acid sequence composed of ternary domains. The amino-terminal head domain is most similar to the kinesin motor domain of the MKLP-1 subfamily and has an intrinsic ATPase activity that is diminished by substituting the consensus Lys-168 with Arg. The central stalk domain is predicted to form a long alpha -helical coiled-coil, and can interact with each other in vivo. An in vivo labeling experiment revealed that KRMP1 is phosphorylated, and we also found that the region within the tail domain containing Thr-1604 as the cdc2 kinase phosphorylation site differs from the bimC box conserved in the bimC subfamily of KRPs. Immunofluorescence analysis showed that endogenous KRMP1 was localized predominantly to the cytoplasm during interphase and dispersed throughout the cell during mitosis. Consistent with this finding, overexpressed KRMP1 was detected in a complicated nuclear or cytoplasmic pattern reflecting multiple nuclear localization/export signals. Furthermore, KRMP1 interacted with the mitotic peptidyl-prolyl isomerase Pin1 in vivo, and an in vitro interaction was detected between the tail domain of KRMP1 and the WW domain of Pin1. Overexpression of KRMP1 caused COS-7 cells to arrest at G(2)-M, and co-expression of Pin1 reversed this effect, indicating their physiological interaction. Together, our results suggest that KRMP1 is a mitotic target regulated by Pin1 and vice versa.	Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Bunkyo Ku, Tokyo 1138510, Japan; Keio Univ, Sch Med, Dept Med, Shinjuku Ku, Tokyo 1600016, Japan; Nagoya Univ, Sch Med, Dept Dermatol, Div Connect Tissue Dis & Autoimmun,Showa Ku, Nagoya, Aichi 4660064, Japan	Tokyo Medical & Dental University (TMDU); Keio University; Nagoya University	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.		MURO, Yoshinao/M-8883-2014	Muro, Yoshinao/0000-0003-2329-8375				Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Bodoor K, 1999, J CELL SCI, V112, P2253; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Fontijn RD, 2001, MOL CELL BIOL, V21, P2944, DOI 10.1128/MCB.21.8.2944-2955.2001; Fritzler MJ, 2000, J INVEST MED, V48, P28; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Hill E, 2000, EMBO J, V19, P5711, DOI 10.1093/emboj/19.21.5711; Kamimoto T, 1998, J BIOL CHEM, V273, P1044, DOI 10.1074/jbc.273.2.1044; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KUANG J, 1989, P NATL ACAD SCI USA, V86, P4982, DOI 10.1073/pnas.86.13.4982; KURIYAMA R, 1994, J CELL SCI, V107, P3485; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Muro Y, 2000, ARTHRITIS RHEUM-US, V43, P1516; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISLOW C, 1990, J CELL BIOL, V111, P511, DOI 10.1083/jcb.111.2.511; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; Raich WB, 1998, MOL BIOL CELL, V9, P2037, DOI 10.1091/mbc.9.8.2037; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Vernos I, 1996, CURR OPIN CELL BIOL, V8, P4, DOI 10.1016/S0955-0674(96)80041-X; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	34	25	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37520	37528		10.1074/jbc.M106207200	http://dx.doi.org/10.1074/jbc.M106207200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11470801	hybrid			2022-12-25	WOS:000171375700087
J	Kim, KM; Valenzano, KJ; Robinson, SR; Yao, WD; Barak, LS; Caron, MG				Kim, KM; Valenzano, KJ; Robinson, SR; Yao, WD; Barak, LS; Caron, MG			Differential regulation of the dopamine D-2 and D-3 receptors by G protein-coupled receptor kinases and beta-arrestins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; D2 RECEPTORS; DYNAMIN; INTERNALIZATION; ENDOCYTOSIS; ACTIVATION; SEQUESTRATION; CLATHRIN; CLONING; CELLS	The D-2 and D-3 receptors (D2R and D3R), which are potential targets for antipsychotic drugs, have a similar structural architecture and signaling pathway. Furthermore, in some brain regions they are expressed in the same cells, suggesting that differences between the two receptors might lie in other properties such as their regulation. In this study we investigated, using COS-7 and HEK-293 cells, the mechanism underlying the intracellular trafficking of the D2R and D3R. Activation of D2R caused G protein-coupled receptor kinase-dependent receptor phosphorylation, a robust translocation of beta -arrestin to the cell membrane, and profound receptor internalization. The internalization of the D2R was dynamin-dependent, suggesting that a clathrin-coated endocytic pathway is involved. In addition, the D2R, upon agonist-mediated internalization, localized to intracellular compartments distinct from those utilized by the B-2-adrenergic receptor. However, in the case of the D3R, only subtle agonist-mediated receptor phosphorylation, beta -arrestin translocation to the plasma membrane, and receptor internalization were observed. Interchange of the second and third intracellular loops of the D2R and D3R reversed their phenotypes, implicating these regions in the regulatory properties of the two receptors. Our studies thus indicate that functional distinctions between the D2R and D3R may be found in their desensitization and cellular trafficking properties. The differences in their regulatory properties suggest that they have distinct physiological roles in the brain.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Chonnam Natl Univ, Coll Pharm, Pharmacol Lab, Kwangju 500757, South Korea	Duke University; Howard Hughes Medical Institute; Duke University; Chonnam National University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3287, Durham, NC 27710 USA.		Kim, Kyeong-Man/AAA-9847-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61365] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CHIO CL, 1994, MOL PHARMACOL, V45, P51; CUNNAH D, 1991, CLIN ENDOCRINOL, V34, P231, DOI 10.1111/j.1365-2265.1991.tb00299.x; Cussac D, 1999, MOL PHARMACOL, V56, P1025, DOI 10.1124/mol.56.5.1025; Diaz J, 2000, J NEUROSCI, V20, P8677; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; FREEDMAN SB, 1994, J PHARMACOL EXP THER, V268, P417; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GIROS B, 1990, CR ACAD SCI III-VIE, V311, P501; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; Gurevich EV, 1999, NEUROPSYCHOPHARMACOL, V20, P60, DOI 10.1016/S0893-133X(98)00066-9; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Ito K, 1999, EUR J BIOCHEM, V260, P112, DOI 10.1046/j.1432-1327.1999.00125.x; Itokawa M, 1996, MOL PHARMACOL, V49, P560; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Kebabian J W, 1978, Adv Biochem Psychopharmacol, V19, P131; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; Kuzhikandathil EV, 1999, J NEUROSCI, V19, P1698; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LEE T, 1978, NATURE, V273, P59, DOI 10.1038/273059a0; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MOORE RH, 1995, J CELL SCI, V108, P2983; NEVE KA, 1992, J BIOL CHEM, V267, P25748; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; PILON C, 1994, EUR J PHARM-MOLEC PH, V268, P129, DOI 10.1016/0922-4106(94)90182-1; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; Robinson SW, 1997, MOL PHARMACOL, V52, P508, DOI 10.1124/mol.52.3.508; ROBINSON SW, 1994, MOL PHARMACOL, V46, P352; Robinson SW, 1996, J NEUROCHEM, V67, P212; SEABROOK GR, 1992, FEBS LETT, V312, P123, DOI 10.1016/0014-5793(92)80918-7; SEEMAN P, 1987, SYNAPSE, V1, P133, DOI 10.1002/syn.890010203; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; TANG L, 1994, J PHARMACOL EXP THER, V270, P475; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Welsh GI, 1998, J NEUROCHEM, V70, P2139; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	52	529	559	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37409	37414		10.1074/jbc.M106728200	http://dx.doi.org/10.1074/jbc.M106728200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11473130	hybrid			2022-12-25	WOS:000171375700073
J	Liu, SC; Slepak, M; Ginsberg, MH				Liu, SC; Slepak, M; Ginsberg, MH			Binding of paxillin to the alpha(9) integrin cytoplasmic domain inhibits cell spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PROTEINS; ADHESION; ALPHA-9-BETA-1; ACTIVATION; MODULATION; MIGRATION; SEQUENCE; SUBUNIT; IIIA	alpha (9)beta (1) integrin is a member of the beta (1) integrin family, plays an important role in extravasation of neutrophils at sites of acute inflammation, and is required for the normal development of the lymphatic system. The alpha (9) and alpha (4) integrin subunits are most closely related and form a subfamily of integrin alpha subunits. Previously, we have reported that the alpha (4) cytoplasmic domain directly and tightly binds paxillin, an intracellular signaling adaptor molecule. This interaction accounts for some of the unusual functional responses to alpha (4) integrin-mediated cell adhesion, including stimulation of cell migration and inhibition of cell spreading and focal adhesion formation. In the current studies, we have examined the interaction between the alpha (9) cytoplasmic domain and paxillin. Here we report that the alpha (9) cytoplasmic domain binds paxillin directly and tightly and that the alpha (9)-paxillin association inhibits cell spreading. We have identified amino acid residues in the alpha (9) cytoplasmic domain, Trp(999) and Trp(1001), that are critical for paxillin binding, and alanine substitution of either Trp(999) or Trp(1001) blocks paxillin binding. Furthermore, these mutations also reverse the effect of the alpha (9) cytoplasmic domain on cell spreading. Thus, the alpha (9) and alpha (4) integrin subunits form a paxillin-binding subfamily of integrin a subunits, and direct binding of paxillin to the alpha (9) cytoplasmic domain mediates some of the biological activities of the alpha (9)beta (1) integrin.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Liu, SC (corresponding author), COR Therapeut, 256 E Grand Ave, San Francisco, CA 94080 USA.				NHLBI NIH HHS [HL31950, HL48728] Funding Source: Medline; NIAMS NIH HHS [AR27214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027214, R01AR027214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHEN YP, 1994, BLOOD, V84, P1857; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Huang XZ, 2000, MOL CELL BIOL, V20, P5208, DOI 10.1128/MCB.20.14.5208-5215.2000; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu SC, 2000, J CELL SCI, V113, P3563; Liu SC, 2000, J BIOL CHEM, V275, P22736, DOI 10.1074/jbc.M000388200; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	20	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37086	37092		10.1074/jbc.M105114200	http://dx.doi.org/10.1074/jbc.M105114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11477105	hybrid			2022-12-25	WOS:000171375700031
J	Pan, T; Colucci, M; Wong, BS; Li, RL; Liu, T; Petersen, RB; Chen, S; Gambetti, P; Sy, MS				Pan, T; Colucci, M; Wong, BS; Li, RL; Liu, T; Petersen, RB; Chen, S; Gambetti, P; Sy, MS			Novel differences between two human prion strains revealed by two-dimensional gel electrophoresis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; FATAL FAMILIAL INSOMNIA; DNA POLYMORPHISM; PRP 27-30; PROTEIN; CONFORMATION	The phenotype of human sporadic prion diseases is affected by patient genotype at codon 129 of the prion protein (PrP) gene, the site of a common methionine/valine polymorphism, and by the type of the scrapie PrP (PrPSc), which likely reflects the prion strain. However, two distinct disease phenotypes, identified as sporadic Creutzfeldt-Jakob disease (M/M2 sCJD) and sporadic fatal insomnia (sFI), share methionine homozygosity at codon 129 and PrPSc type 2. One-dimensional gel electrophoresis and immunoblotting reveal no difference between the M/M2 sCJD and sFI species of PrPSc in gel mobility and glycoform ratio. In contrast, the two-dimensional immunoblot demonstrates that in M/M2 sCJD the full-length PrPSc form is overrepresented and carries glycans that are different from those present in the PrPSc of sFI. Because the altered glycans are detectable only in the PrPSc and not in the normal or cellular PrP (PrPC), they are likely to result from preferential conversion to PrPSc of rare PrPC glycoforms. This is the first evidence that a qualitative difference in glycans contributes to prion diversity.	Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Div Neuropathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Canc Res, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Sy, MS (corresponding author), Case Western Reserve Univ, Sch Med, Inst Pathol, Rm 933,BRB,10900 Euclid Ave, Cleveland, OH 44106 USA.		Chen, Shu/Z-2943-2019; Chen, Shu G./O-4750-2014; Wong, Boon-Seng/G-2759-2012; Chen, Shu G./AAK-7301-2021; Petersen, Robert/B-5075-2011	Chen, Shu G./0000-0001-7180-3001; Wong, Boon-Seng/0000-0002-7118-8077; Chen, Shu G./0000-0001-7180-3001; Petersen, Robert/0000-0002-3154-0072	NIA NIH HHS [AG14359] Funding Source: Medline; PHS HHS [CCU515004] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG014359] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; GAJDUSEK DC, 1996, VIROLOGY, P2851; Gambetti P, 2001, J ALZHEIMERS DIS, V3, P87, DOI 10.3233/JAD-2001-3113; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; Mastrianni JA, 1999, NEW ENGL J MED, V340, P1630, DOI 10.1056/NEJM199905273402104; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 2000, P NATL ACAD SCI USA, V97, P10168, DOI 10.1073/pnas.97.18.10168; Parchi P, 1998, BRAIN PATHOL, V8, P539; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Parchi P, 1999, NEUROLOGY, V52, P1757, DOI 10.1212/WNL.52.9.1757; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rudd PM, 2001, BIOCHEMISTRY-US, V40, P3759, DOI 10.1021/bi002625f; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812; Zuegg J, 2000, GLYCOBIOLOGY, V10, P959, DOI 10.1093/glycob/10.10.959	26	54	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37284	37288		10.1074/jbc.M107358200	http://dx.doi.org/10.1074/jbc.M107358200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11489910	hybrid			2022-12-25	WOS:000171375700058
J	Young, AL; Carter, WG; Doyle, HA; Mamula, MJ; Aswad, DW				Young, AL; Carter, WG; Doyle, HA; Mamula, MJ; Aswad, DW			Structural integrity of histone H2B in vivo requires the activity of protein L-isoaspartate O-methyltransferase, a putative protein repair enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; CARBOXYL METHYLTRANSFERASE; ADENOSINE DIALDEHYDE; ASPARTYL RESIDUES; RAT-BRAIN; PEPTIDES; DEAMIDATION; ANTIBODIES; BOVINE; CELLS	Protein L-isoaspartate O-methyltransferase (PIMT) is postulated to repair beta -aspartyl linkages (isoaspartyl (isoAsp)) that accumulate at certain Asp-Xaa and Asn-Xaa sites in association with protein aging and deamidation. To identify major targets of PIMT action we cultured rat PC12 cells with adenosine dialdehyde (AdOx), a methyltransferase inhibitor that promotes accumulation of isoAsp in vivo. Subcellular fractionation of AdOx-treated cells revealed marked accumulation of isoAsp in a 14-kDa nuclear protein. Gel electrophoresis and chromatography of nuclei H-3-methylated in vitro by PIMT revealed this protein to be histone H2B. The isoAsp content of H2B in AdOx-treated cells was similar to 18 times that in control cells, although no isoAsp was seen in other core histones, regardless of treatment. To confirm the relevance and specificity of this effect, we measured isoAsp levels in histones from brains of PIMT knockout mice. IsoAsp was found at near stoichiometric levels in H2B extracted from knockout brains and was at least 80 times greater than that in H2B from normal mice. Little or no isoAsp was detected in H2A, H3, or H4 from mice of either genotype. Accumulation of isoAsp in histone H2B may disrupt normal gene regulation and contribute to the reduced life span that characterizes PIMT knockouts. In addition to disrupting protein function, isoAsp has been shown to trigger immunity against self-proteins. The propensity of H2B to generate isoAsp in vivo may help explain why this histone in particular is found as a major antigen in autoimmune diseases such as lupus erythematosus.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT 06510 USA	University of California System; University of California Irvine; Yale University	Aswad, DW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.				NIAID NIH HHS [AI36529] Funding Source: Medline; NIAMS NIH HHS [AR47759] Funding Source: Medline; NINDS NIH HHS [NS17269] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI036529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR047759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017269] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aswad DW, 2000, J PHARMACEUT BIOMED, V21, P1129, DOI 10.1016/S0731-7085(99)00230-7; ASWAD DW, 1984, J BIOL CHEM, V259, P714; ASWAD DW, 1983, J NEUROCHEM, V40, P1718, DOI 10.1111/j.1471-4159.1983.tb08147.x; BARTEL RL, 1984, MOL PHARMACOL, V25, P418; BRENNAN TV, 1994, J BIOL CHEM, V269, P24586; BRENNAN TV, 1995, DEAMIDATION ISOASPAR, P65; CHIRPICH T, 1968, THESIS U CALIFORNIA; DAVID CL, 1995, PROTEIN EXPRES PURIF, V6, P312, DOI 10.1006/prep.1995.1041; Doyle HA, 2001, TRENDS IMMUNOL, V22, P443, DOI 10.1016/S1471-4906(01)01976-7; FAIRBANKS G, 1972, Journal of Supramolecular Structure, V1, P66, DOI 10.1002/jss.400010110; GEIGER T, 1987, J BIOL CHEM, V262, P785; HARDIN JA, 1983, P NATL ACAD SCI-BIOL, V80, P7410, DOI 10.1073/pnas.80.24.7410; HOFFMAN JL, 1979, TRANSMETHYLATION, P181; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1993, J BIOL CHEM, V268, P6174; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1991, ANAL BIOCHEM, V192, P384, DOI 10.1016/0003-2697(91)90553-6; JOHNSON BA, 1985, J NEUROCHEM, V45, P1119, DOI 10.1111/j.1471-4159.1985.tb05531.x; JOHNSON BA, 1995, DEAMIDATION ISOASPAR, P91; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LINDQUIST JA, 1994, J PROTEIN CHEM, V13, P23, DOI 10.1007/BF01891989; Lindquist JA, 1996, J PROTEIN CHEM, V15, P115, DOI 10.1007/BF01886817; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; Lowenson JD, 2001, J BIOL CHEM, V276, P20695, DOI 10.1074/jbc.M100987200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mamula MJ, 1999, J BIOL CHEM, V274, P22321, DOI 10.1074/jbc.274.32.22321; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; Monestier M, 2000, J BIOL CHEM, V275, P13558, DOI 10.1074/jbc.275.18.13558; MONESTIER M, 1992, RHEUM DIS CLIN N AM, V18, P415; MURRAY ED, 1984, J BIOL CHEM, V259, P722; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; RICKWOOD D, 1978, CENTRIFUGATION PRACT, P135; Schurter BT, 2000, ANAL BIOCHEM, V282, P227, DOI 10.1006/abio.2000.4601; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; WEIKOWSKI M, 1993, METHOD ENZYMOL, V225, P489; Yamamoto A, 1998, J NEUROSCI, V18, P2063	37	57	57	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37161	37165		10.1074/jbc.M106682200	http://dx.doi.org/10.1074/jbc.M106682200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479322	hybrid			2022-12-25	WOS:000171375700041
J	Zhang, J; Martasek, P; Paschke, R; Shea, T; Masters, BSS; Kim, JJP				Zhang, J; Martasek, P; Paschke, R; Shea, T; Masters, BSS; Kim, JJP			Crystal structure of the FAD/NADPH-binding domain of rat neuronal nitric-oxide synthase - Comparisons with NADPH-cytochrome P450 oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON FLOW-THROUGH; REDUCTASE; CALMODULIN; ISOFORMS; PROTOTYPE; PROGRAM; FLAVIN; PTERIN; FMN	Nitric-oxide synthase (NOS) is composed of a C-terminal, flavin-containing reductase domain and an N-terminal, heme-containing oxidase domain. The reductase domain, similar to NADPH-cytochrome P450 reductase, can be further divided into two different flavin-containing domains: (a) the N terminus, FMN-containing portion, and (b) the C terminus FAD- and NADPH-binding portion. The crystal structure of the FAD/NADPH-containing domain of rat neuronal nitric-oxide synthase, complexed with NADP(+), has been determined at 1.9 Angstrom resolution. The protein is fully capable of reducing ferricyanide, using NADPH as the electron donor. The overall polypeptide fold of the domain is very similar to that of the corresponding module of NADPH-cytochrome P450 oxidoreductase (CYPOR) and consists of three structural subdomains (from N to C termini): (a) the connecting domain, (b) the FAD-binding domain, and (c) the NADPH-binding domain. A comparison of the structure of the neuronal NOS FAD/NADPH domain and CYPOR reveals the strict conservation of the flavin-binding site, including the tightly bound water molecules, the mode of NADP(+) binding, and the aromatic residue that lies at the re-face of the flavin ring, strongly suggesting that the hydride transfer mechanisms in the two enzymes are very similar. In contrast, the putative FMN domain-binding surface of the NOS protein is less positively charged than that of its CYPOR counterpart, indicating a different nature of interactions between the two flavin domains and a different mode of regulation in electron transfer between the two flavins involving the autoinhibitory element and the C-terminal 33 residues, both of which are absent in CYPOR.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	Medical College of Wisconsin; University of Texas System; University of Texas Health San Antonio	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	jjkim@mcw.edu	Martásek, Pavel/G-6622-2017	Martásek, Pavel/0000-0001-6165-4444	NHLBI NIH HHS [HL30050] Funding Source: Medline; NIGMS NIH HHS [GM52419, GM52682] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030050, R37HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419, R01GM052682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; DJORDJEVIC S, 1995, P NATL ACAD SCI USA, V92, P3214, DOI 10.1073/pnas.92.8.3214; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; GILSON MK, 1985, J MOL BIOL, V184, P503, DOI 10.1016/0022-2836(85)90297-9; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; Hubbard PA, 2001, J BIOL CHEM, V276, P29163, DOI 10.1074/jbc.M101731200; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; Martasek P, 1999, METHOD ENZYMOL, V301, P70; Masters B.S., 2000, NITRIC OXIDE BIOL PA, P91; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLS A, 1992, GRASP GRAPHICAL REPR; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; NISHIDA H, 1995, BIOCHEMISTRY-US, V34, P2763, DOI 10.1021/bi00009a004; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; ROUSSEL A, 1999, TURBO FRODO VERSION; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Steller I, 1997, J APPL CRYSTALLOGR, V30, P1036, DOI 10.1107/S0021889897008777; TEW DG, 1993, BIOCHEMISTRY-US, V32, P10209, DOI 10.1021/bi00089a042; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411	38	127	130	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37506	37513		10.1074/jbc.M105503200	http://dx.doi.org/10.1074/jbc.M105503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11473123	hybrid			2022-12-25	WOS:000171375700085
J	Chen, LL; Whitty, A; Scott, D; Lee, WC; Cornebise, M; Adams, SP; Petter, RC; Lobb, RR; Pepinsky, RB				Chen, LL; Whitty, A; Scott, D; Lee, WC; Cornebise, M; Adams, SP; Petter, RC; Lobb, RR; Pepinsky, RB			Evidence that ligand and metal ion binding to integrin alpha(4)beta(1) axe regulated through a coupled equilibrium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; FUNCTION-ASSOCIATED ANTIGEN-3; MULTIPLE ACTIVATION STATES; VON-WILLEBRAND-FACTOR; LEUKOCYTE ADHESION; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; SIGNAL-TRANSDUCTION; ALPHA-4 INTEGRINS; DIVALENT-CATIONS	We have used the highly selective alpha (4)beta (1) inhibitor 2S-[(1-benzenesulfonyl-pyrrolidine-2S-carbonyl)-amino]-4-[4-methyl-2S-(methyl-{2-[4-(3-o-tolyl-ureido)-phenyl]acetyl}-amino)-pentanoylamino]-butyric acid (BIO7662) as a model ligand to study alpha (4)beta (1), integrin-ligand interactions on Jurkat cells. Binding of [S-35]BIO7662 to Jurkat cells was dependent on the presence of divalent cations and could be blocked by treatment with an excess of unlabeled inhibitor or with EDTA. K-D values for the binding of BIO7662 to Mn2+-activated alpha (4)beta (1) and to the nonactivated state of the integrin that exists in I mm Mg2+, I mm Ca2+ were < 10 pm, indicating that it has a high affinity for both activated and nonactivated integrin. No binding was observed on alpha (4)beta (1) negative cells. Through an analysis of the metal ion dependences of ligand binding, several unexpected findings about alpha (4)beta (1) function were made. First, we observed that Ca2+ binding to alpha (4)beta (1), was stimulated by the addition of BIO7662. From solution binding studies on purified alpha (4)beta (1), two types of Ca2+-binding sites were identified, one dependent upon and the other independent of BIO7662 binding. Second, we observed that the metal ion dependence of ligand binding was affected by the affinity of the ligand for beta (4)beta (1). ED50 values for the metal ion dependence of the binding of BIO7762 and the binding of a lower affinity ligand, BIO1211, differed by 2-fold for Mn2+, 30-fold for Mg2+, and > 1000-fold for Ca2+. Low Ca2+ (ED50 = 5-10 muM) stimulated the binding of BIO7662 to alpha (4)beta (1). The effects of mum Ca2+ closely resembled the effects of Mn2+ on alpha (4)beta (1) function. Third, we observed that the rate of BIO7662 binding was dependent on the metal ion concentration and that the ED50 for the metal ion dependence of BIO7662 binding was affected by the concentration of the BIO7662. These studies point to an even more complex interplay between metal ion and ligand binding than previously appreciated and provide evidence for a three-component coupled equilibrium model for metal ion-dependent binding of ligands to alpha (4)beta (1).	Biogen Inc, Cambridge, MA 02142 USA	Biogen	Pepinsky, RB (corresponding author), Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA.							Abraham WM, 1997, AM J RESP CRIT CARE, V156, P696, DOI 10.1164/ajrccm.156.3.9609039; ANWAR ARE, 1994, IMMUNOLOGY, V82, P222; Baneres JL, 2000, J BIOL CHEM, V275, P5888, DOI 10.1074/jbc.275.8.5888; Bayless KJ, 1998, J CELL SCI, V111, P1165; Bazzoni G, 1998, J BIOL CHEM, V273, P6670, DOI 10.1074/jbc.273.12.6670; CHAN BMC, 1991, J IMMUNOL, V147, P398; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; Chen LL, 1998, BIOCHEMISTRY-US, V37, P8743, DOI 10.1021/bi980311a; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DUSTIN ML, 1989, J EXP MED, V169, P503, DOI 10.1084/jem.169.2.503; Dutta AS, 2000, J PEPT SCI, V6, P398, DOI 10.1002/1099-1387(200008)6:8<398::AID-PSC270>3.3.CO;2-T; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GULINO D, 1992, J BIOL CHEM, V267, P1001; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; Hesselgesser J, 1998, J IMMUNOL, V160, P877; Hu DD, 1999, J BIOL CHEM, V274, P4633, DOI 10.1074/jbc.274.8.4633; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; Jackson DY, 1997, J MED CHEM, V40, P3359, DOI 10.1021/jm970175s; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Liu L, 1999, J BIOL CHEM, V274, P33334, DOI 10.1074/jbc.274.47.33334; Lobb RR, 1995, CELL ADHES COMMUN, V3, P385, DOI 10.3109/15419069509081293; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MOLOSSI S, 1995, J CLIN INVEST, V95, P2601, DOI 10.1172/JCI117962; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Newham P, 1998, J IMMUNOL, V160, P4508; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PEPINSKY B, 1992, J BIOL CHEM, V267, P17820; PEPINSKY RB, 1991, J BIOL CHEM, V266, P18244; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Takahashi H, 2000, J BIOL CHEM, V275, P23589, DOI 10.1074/jbc.M003526200; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Udagawa T, 1996, J IMMUNOL, V157, P1965; Vanderslice P, 1997, J IMMUNOL, V158, P1710; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; WAHL SM, 1994, J CLIN INVEST, V94, P655, DOI 10.1172/JCI117382; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; WAYER EA, 1992, J CELL BIOL, V116, P489; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Yoshikawa H, 1996, J IMMUNOL, V156, P1832	61	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36520	36529		10.1074/jbc.M106216200	http://dx.doi.org/10.1074/jbc.M106216200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11473127	hybrid			2022-12-25	WOS:000171194500064
J	Furukawa, T; Adachi, Y; Fujisawa, J; Kambe, T; Yamaguchi-Iwai, Y; Sasaki, R; Kuwahara, J; Ikehara, S; Tokunaga, R; Taketani, S				Furukawa, T; Adachi, Y; Fujisawa, J; Kambe, T; Yamaguchi-Iwai, Y; Sasaki, R; Kuwahara, J; Ikehara, S; Tokunaga, R; Taketani, S			Involvement of PLAGL2 in activation of iron deficient- and hypoxia-induced gene expression in mouse cell lines	ONCOGENE			English	Article						PLAGL; PLAG; iron; hypoxia; HIF-1	ZINC-FINGER PROTEIN; LACTATE-DEHYDROGENASE-A; INDUCIBLE FACTOR-1; TRANSCRIPTIONAL ACTIVATION; PLEOMORPHIC ADENOMAS; ERYTHROPOIETIN GENE; BINDING-PROTEIN; IDENTIFICATION; ZAC1; DEFEROXAMINE	We searched iron-deficient inducible cDNA, using subtraction cloning and mRNA from desferrioxamine-treated mouse macrophage Raw264.7 cells. We identified a pleomorphic adenoma gene like 2 (PLAGL2), one of PLAG superfamily proteins exhibiting antiproliferative properties on tumor cells. Mouse PLAGL2 consists of 496 amino acids with seven C2H2 zinc-fingers. PLAGL2 mRNA was induced in RAW264.7 cells, mouse erythroleukemia cells and Balb/c 3T3 cells when they were treated with desferrioxamine. Hypoxia also increased PLAGL2 mRNA. Expression of PLAGL2 in COS-7 cells led to nuclear localization. PLAGL2 had potential binding ability to GC-rich oligonucleotide and activated transcription of a gene with the binding sequence in transient reporter assay, a finding consistent with a case seen in a PLAGL2 homolog, ZAC-1. Transient co-transfection of PLAGL2 or ZAC1 cDNA and a reporter containing a lactate dehydrogenase A (LDHA) promoter carrying the hypoxia inducible factor-1 responsive element led to an increase in the basal transcription in Balb/c 3T3 and HepG2 cells. Activation in transcription from the LDHA promoter increased by desferrioxamine treatment or hypoxia was further enhanced when PLAGL2 was expressed. We propose that PLAGL2 is involved in the cell cycle arrest and apoptosis of tumor cells by regulating iron depletion- or hypoxia-inducible gene expression.	Kansai Med Univ, Dept Hyg, Moriguchi, Osaka 5708506, Japan; Kansai Med Univ, Dept Microbiol, Moriguchi, Osaka 5708506, Japan; Kansai Med Univ, Dept Pathol 1, Moriguchi, Osaka 5708506, Japan; Kyoto Univ, Dept Life Sci, Kyoto 60601, Japan; Univ Tokushima, Fac Pharmaceut Sci, Inst Med Resources, Tokushima 7708505, Japan; Kyoto Inst Technol, Dept Biotechnol, Kyoto 6068585, Japan	Kansai Medical University; Kansai Medical University; Kansai Medical University; Kyoto University; Tokushima University; Kyoto Institute of Technology	Furukawa, T (corresponding author), Kansai Med Univ, Dept Hyg, Moriguchi, Osaka 5708506, Japan.	furukawa@takii.kmu.ac.jp						Abdollahi A, 1997, CANCER RES, V57, P2029; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Kadota Y, 1997, MOL BRAIN RES, V46, P265, DOI 10.1016/S0169-328X(97)00023-5; Kambe T, 1998, BLOOD, V91, P1185, DOI 10.1182/blood.V91.4.1185; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kas K, 1997, GENOMICS, V43, P349, DOI 10.1006/geno.1997.4819; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Mohri T, 1999, EXP CELL RES, V253, P533, DOI 10.1006/excr.1999.4720; NOCKA KH, 1988, CANCER RES, V48, P3571; Piras G, 2000, MOL CELL BIOL, V20, P3308, DOI 10.1128/MCB.20.9.3308-3315.2000; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; SELF AJ, 1995, METHOD ENZYMOL, V258, P3; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Taketani S, 1998, J BIOL CHEM, V273, P31388, DOI 10.1074/jbc.273.47.31388; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; Wang F, 1999, ANTICANCER RES, V19, P445; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Ye Z, 1999, BIOCHEM BIOPH RES CO, V264, P709, DOI 10.1006/bbrc.1999.1554; Zhang YM, 1997, GENE CHROMOSOME CANC, V18, P310, DOI 10.1002/(SICI)1098-2264(199704)18:4<310::AID-GCC10>3.0.CO;2-K	34	47	51	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4718	4727		10.1038/sj.onc.1204647	http://dx.doi.org/10.1038/sj.onc.1204647			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498794				2022-12-25	WOS:000170208600012
J	Whittaker, J; Groth, AV; Mynarcik, DC; Pluzek, L; Gadsboll, VL; Whittaker, LJ				Whittaker, J; Groth, AV; Mynarcik, DC; Pluzek, L; Gadsboll, VL; Whittaker, LJ			Alanine scanning mutagenesis of a type 1 insulin-like growth factor receptor ligand binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; HIGH-AFFINITY BINDING; IGF RECEPTOR; CRYSTAL-STRUCTURE; TYROSINE KINASE; NEGATIVE COOPERATIVITY; ALPHA-SUBUNIT; SPECIFICITY; DETERMINANTS; DOMAINS	The high resolution crystal structure of an N-terminal fragment of the IGF-I receptor, has been reported. While this fragment is itself devoid of ligand binding activity, mutational analysis has indicated that its N terminus (L1 amino acids 1-150) and the C terminus of its cysteine-rich domain (amino acids 190-300) contain ligand binding determinants. Mutational analysis also suggests that amino acids 692-702 from the C terminus of the a subunit are critical for ligand binding. A fusion protein, formed from these fragments, binds IGF-I with an affinity similar to that of the whole extracellular domain, suggesting that these are the minimal structural elements of the IGF-I binding site. To further characterize the binding site, we have performed structure directed and alanine-scanning mutagenesis of L1, the cysteine-rich domain and amino acids 692-702. Alanine mutants of residues in these regions were transiently expressed as secreted recombinant receptors and their affinity was determined. In L1 alanine mutants of Asp(8), Asn(11), Tyr(28), Hi(30), Leu(33), Leu(56), Phe(58), Arg(59), and Trp(79) produced a 2- to 10-fold decrease in affinity and alanine mutation of Phe(90) resulted in a 23-fold decrease in affinity. In the cysteine-rich domain, mutation of Are, Phe(241), Glu(242), and Phe(251) produced a 2- to 10-fold decrease in affinity. In the region between amino acids 692 and 702, alanine mutation of Phe(701) produced a receptor devoid of binding activity and alanine mutations of Phe(693), Glu(693,) Asn(694), Leu(696), His(697), Asn(698), and Ile(700) exhibited decreases in affinity ranging from 10- to 30-fold. With the exception of Trp(79), the disruptive mutants in L1 form a discrete epitope on the surface of the receptor. Those in the cysteine-rich domain essential for intact affinity also form a discrete epitope together with Trp(79).	Hagedorn Res Lab, Receptor Biol Lab, DK-2820 Gentofte, Denmark; SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA	Novo Nordisk; Hagedorn Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Whittaker, J (corresponding author), Hagedorn Res Lab, Receptor Biol Lab, Niels Steensensvej 6, DK-2820 Gentofte, Denmark.	jow@novonordisk.com						Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BAYNE ML, 1990, J BIOL CHEM, V265, P15648; CHRISTOFFERSEN CT, 1994, ENDOCRINOLOGY, V135, P472, DOI 10.1210/en.135.1.472; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; Dubaquie Y, 1999, BIOCHEMISTRY-US, V38, P6386, DOI 10.1021/bi990089p; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HODGSON DR, 1995, EUR J BIOCHEM, V233, P299, DOI 10.1111/j.1432-1033.1995.299_1.x; Hodgson DR, 1996, REGUL PEPTIDES, V66, P191, DOI 10.1016/S0167-0115(96)00102-4; Hoyne PA, 2000, FEBS LETT, V469, P57, DOI 10.1016/S0014-5793(00)01237-0; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jansson M, 1997, BIOCHEMISTRY-US, V36, P4108, DOI 10.1021/bi961553i; Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KJELDSEN T, 1994, J BIOL CHEM, V269, P32942; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; Kristensen C, 1999, J BIOL CHEM, V274, P37351, DOI 10.1074/jbc.274.52.37351; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Marino-Buslje C, 1999, BIOCHEM SOC T, V27, P715, DOI 10.1042/bst0270715; Molina L, 2000, FEBS LETT, V467, P226, DOI 10.1016/S0014-5793(00)01161-3; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; Mynarcik DC, 1997, J BIOL CHEM, V272, P2077; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; Mynarcik DC, 1997, J BIOL CHEM, V272, P18650, DOI 10.1074/jbc.272.30.18650; Ottensmeyer FP, 2000, BIOCHEMISTRY-US, V39, P12103, DOI 10.1021/bi0015921; PULLEN RA, 1976, NATURE, V259, P369, DOI 10.1038/259369a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFFER L, 1993, BIOCHIM BIOPHYS ACTA, V1203, P205, DOI 10.1016/0167-4838(93)90084-5; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SHIER P, 1989, J BIOL CHEM, V264, P14605; SOOS MA, 1992, J BIOL CHEM, V267, P12955; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDENBRANDE JL, 1992, INSULIN LIKE GROWTH, P12; Ward CW, 1999, GROWTH FACTORS, V16, P315, DOI 10.3109/08977199909069149; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001; ZHONG P, 1993, P NATL ACAD SCI USA, V90, P11451, DOI 10.1073/pnas.90.24.11451	52	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43980	43986		10.1074/jbc.M102863200	http://dx.doi.org/10.1074/jbc.M102863200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11500492	hybrid			2022-12-25	WOS:000172297700065
J	Odreman-Macchioli, F; Baralle, FE; Buratti, E				Odreman-Macchioli, F; Baralle, FE; Buratti, E			Mutational analysis of the different bulge regions of hepatitis C virus domain II and their influence on internal ribosome entry site translational ability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' UNTRANSLATED REGION; TRACT-BINDING-PROTEIN; 25-KILODALTON CELLULAR-PROTEIN; STEM-LOOP; FUNCTIONAL REQUIREMENT; NONTRANSLATED REGIONS; SECONDARY STRUCTURE; LA ANTIGEN; GB VIRUS; INITIATION	The hepatitis C virus (HCV) 5'-untranslated region and, in particular, domains II to IV are involved in the internal ribosome entry site (IRES) structure. Recent structural evidence has shown that the function of domain II may be to hold the coding RNA in position until the translational machinery is correctly assembled on the decoding site. However, a comprehensive mutational and functional study concerning the importance of the different RNA regions that compose domain II is not yet available. Therefore, we have taken advantage of the recently proposed secondary structure of domain II to design a series of specific mutants. The bulge regions present in the latest secondary structure prediction of domain II were selectively deleted, and the effects of these mutations on IRES translation efficiency were analyzed. Our results show that the introduction of these mutations can variably affect the degree of HCV translation, causing a moderate to total loss of translation ability that correlates with the severity of changes induced in the RNA secondary structure and degree of p25 ribosomal protein UV cross-linking, but not with the ability of the 40S ribosomal subunit to bind the IRES. These findings support the proposed structural role of domain II in HCV translation.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Baralle, FE (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	baralle@icgeb.trieste.it	Buratti, Emanuele/K-4691-2016	Buratti, Emanuele/0000-0002-1356-9074; Baralle, Francisco/0000-0002-4645-2809				Ali N, 2000, J BIOL CHEM, V275, P27531; ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; Anwar A, 2000, J BIOL CHEM, V275, P34231, DOI 10.1074/jbc.M006343200; BROWN EA, 1992, NUCLEIC ACIDS RES, V20, P5041, DOI 10.1093/nar/20.19.5041; Buratti E, 1998, CELL MOL BIOL, V44, P505; Buratti E, 1997, FEBS LETT, V411, P275, DOI 10.1016/S0014-5793(97)00715-1; Buratti E, 1998, NUCLEIC ACIDS RES, V26, P3179, DOI 10.1093/nar/26.13.3179; Buratti E, 1997, CLIN DIAGN LAB IMMUN, V4, P117, DOI 10.1128/CDLI.4.2.117-121.1997; Di Bisceglie Adrian M., 1999, American Journal of Medicine, V107, p45S; Fukushi S, 1997, J VIROL, V71, P1662, DOI 10.1128/JVI.71.2.1662-1666.1997; Fukushi S, 1999, VIRUS GENES, V19, P153, DOI 10.1023/A:1008131325056; Fukushi S, 2001, VIRUS RES, V73, P67, DOI 10.1016/S0168-1702(00)00228-8; Fukushi S, 2001, J BIOL CHEM, V276, P20824, DOI 10.1074/jbc.C100206200; Grace K, 1999, J GEN VIROL, V80, P2337, DOI 10.1099/0022-1317-80-9-2337; Hahn B, 1998, J VIROL, V72, P8782, DOI 10.1128/JVI.72.11.8782-8788.1998; Hellen CUT, 1999, J VIRAL HEPATITIS, V6, P79, DOI 10.1046/j.1365-2893.1999.00150.x; Honda M, 2000, GASTROENTEROLOGY, V118, P152, DOI 10.1016/S0016-5085(00)70424-0; Honda M, 1999, J VIROL, V73, P1165, DOI 10.1128/JVI.73.2.1165-1174.1999; Honda M, 1996, RNA, V2, P955; Hwang LH, 1998, BIOCHEM BIOPH RES CO, V252, P455, DOI 10.1006/bbrc.1998.9673; Isoyama T, 1999, J GEN VIROL, V80, P2319, DOI 10.1099/0022-1317-80-9-2319; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; Jubin R, 2000, J VIROL, V74, P10430, DOI 10.1128/JVI.74.22.10430-10437.2000; Kaminski A, 1995, RNA, V1, P924; Kieft JS, 1999, J MOL BIOL, V292, P513, DOI 10.1006/jmbi.1999.3095; Kieft JS, 2001, RNA, V7, P194, DOI 10.1017/S1355838201001790; Klinck R, 2000, RNA, V6, P1423, DOI 10.1017/S1355838200000935; Kolupaeva VG, 2000, J VIROL, V74, P6242, DOI 10.1128/JVI.74.14.6242-6250.2000; Laporte J, 2000, J VIROL, V74, P10827, DOI 10.1128/JVI.74.22.10827-10833.2000; Lukavsky PJ, 2000, NAT STRUCT BIOL, V7, P1105; Martinez-Salas E, 2001, J GEN VIROL, V82, P973, DOI 10.1099/0022-1317-82-5-973; Merrick WC., 1996, TRANSLATION CONTROL, P31; Odreman-Macchioli FE, 2000, NUCLEIC ACIDS RES, V28, P875, DOI 10.1093/nar/28.4.875; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Psaridi L, 1999, FEBS LETT, V453, P49, DOI 10.1016/S0014-5793(99)00662-6; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; Reynolds JE, 1996, RNA, V2, P867; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; Rijnbrand R, 2000, J VIROL, V74, P773, DOI 10.1128/JVI.74.2.773-783.2000; Rijnbrand RCA, 1996, VIROLOGY, V226, P47, DOI 10.1006/viro.1996.0626; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409; Spangberg K, 1999, J GEN VIROL, V80, P1371, DOI 10.1099/0022-1317-80-6-1371; Tang SX, 1999, J VIROL, V73, P2359, DOI 10.1128/JVI.73.3.2359-2364.1999; Varaklioti A, 1998, BIOCHEM BIOPH RES CO, V253, P678, DOI 10.1006/bbrc.1998.9842; WANG CY, 1994, J VIROL, V68, P7301, DOI 10.1128/JVI.68.11.7301-7307.1994; WANG CY, 1995, RNA, V1, P526; Zhao WD, 2001, J VIROL, V75, P3719, DOI 10.1128/JVI.75.8.3719-3730.2001	50	35	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41648	41655		10.1074/jbc.M104128200	http://dx.doi.org/10.1074/jbc.M104128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11498532	hybrid			2022-12-25	WOS:000172450400016
J	Fernandez, F; Rush, JS; Toke, DA; Han, GS; Quinn, JE; Carman, GM; Choi, JY; Voelker, DR; Aebi, M; Waechter, CJ				Fernandez, F; Rush, JS; Toke, DA; Han, GS; Quinn, JE; Carman, GM; Choi, JY; Voelker, DR; Aebi, M; Waechter, CJ			The CWH8 gene encodes a dolichyl pyrophosphate phosphatase with a luminally oriented active site in the endoplasmic reticulum of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ISOPRENYLTRANSFERASE ACTIVITY; LINKED OLIGOSACCHARIDES; PROTEIN GLYCOSYLATION; MEMBRANE-PROTEINS; ESCHERICHIA-COLI; PLASMA-MEMBRANES; PIG BRAIN; BIOSYNTHESIS; LOCALIZATION; CELLS	Mutations in the CWH8 gene, which encodes an ER transmembrane protein with a phosphate binding pocket in Saccharomyces cerevisiae, result in a deficiency in dolichyl pyrophosphate (Dol-P-P)-linked oligosaccharide intermediate synthesis and protein N-glycosylation (van Berkel, M. A., Rieger, M., to Heesen, S., Ram, A. F., van den Ende, H., Aebi, M., and Klis, F. M. (1999) Glycobiology 9, 243-253). Genetic, enzymological, and topological approaches were taken to investigate the potential role of Cwh8p in Dol-P-P/Dol-P metabolism. Overexpression of Cwh8p in the yeast double mutant strain, lacking LPP1/DPP1, resulted in an impressive increase in Dol-P-P phosphatase activity, a relatively small increase in Dol-P phosphatase activity, but no change in phosphatidate (PA) phosphatase activity in microsomal fractions. The Dol-P-P phosphatase encoded by CWH8 is optimally active in the presence of 0.5% octyl glucoside and relatively unstable in Triton X-100, distinguishing this activity from the lipid phosphatases encoded by LPP1 and DPP1. Stoichiometric amounts of Pi and Dol-P are formed during the enzymatic reaction indicating that Cwh8p cleaves the anhydride linkage in Dol-P-P. Membrane fractions from Sf-9 cells expressing Cwh8p contained a 30-fold higher level of Dol-P-P phosphatase activity, a slight increase in Dol-P phosphatase activity, but no increase in PA phosphatase relative to controls. This is the first report of a lipid phosphatase that. hydrolyzes Dol-P-P/Dol-P but not PA. In accord with this enzymatic function, Dol-P-P accumulated in cells lacking the Dol-P-P phosphatase. Topological studies using different approaches indicate that Cwh8p is a transmembrane protein with a luminally oriented active site. The specificity, subcellular location, and topological orientation of this novel enzyme are consistent with a role in the re-utilization of the glycosyl carrier lipid for additional rounds of lipid intermediate biosynthesis after its release during protein N-glycosylation reactions.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Rutgers State Univ, Cook Coll, Dept Food Sci, New Brunswick, NJ 08901 USA; Natl Jewish Ctr, Dept Med, Denver, CO 80206 USA; ETH Zentrum, Inst Mikrobiol, CH-8092 Zurich, Switzerland	University of Kentucky; Rutgers State University New Brunswick; National Jewish Health; Swiss Federal Institutes of Technology Domain; ETH Zurich	Waechter, CJ (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.	waechte@pop.uky.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R37GM032453, R01GM028140, R01GM036065, R01GM032453] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36065, GM32453, GM28140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAIR WL, 1983, BIOCHIM BIOPHYS ACTA, V751, P21, DOI 10.1016/0005-2760(83)90252-7; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELOCOPITOW E, 1982, EUR J BIOCHEM, V125, P167, DOI 10.1111/j.1432-1033.1982.tb06664.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; BURTON WA, 1981, ARCH BIOCHEM BIOPHYS, V254, P7129; CARSON DD, 1981, J BIOL CHEM, V256, P1552; CRICK DC, 1991, J NEUROCHEM, V57, P1354, DOI 10.1111/j.1471-4159.1991.tb08301.x; CRICK DC, 1994, J BIOL CHEM, V269, P10559; CRICK DC, 1994, J NEUROCHEM, V62, P247; CULBERTSON MR, 1975, GENETICS, V80, P23; DANILOV LL, 1989, CHEM PHYS LIPIDS, V51, P191, DOI 10.1016/0009-3084(89)90006-6; Faulkner A, 1999, J BIOL CHEM, V274, P14831, DOI 10.1074/jbc.274.21.14831; Frank DW, 1998, J BIOL CHEM, V273, P11791, DOI 10.1074/jbc.273.19.11791; HARFORD JB, 1977, BIOCHEM BIOPH RES CO, V76, P1036, DOI 10.1016/0006-291X(77)90960-3; HELLER L, 1992, P NATL ACAD SCI USA, V89, P7013, DOI 10.1073/pnas.89.15.7013; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HUBBARD SC, 1980, J BIOL CHEM, V255, P1782; IDOYAGAVARGAS V, 1980, FEBS LETT, V112, P63, DOI 10.1016/0014-5793(80)80128-1; Innis MA, 1990, PCR PROTOCOLS GUIDE, P1, DOI [10.1016/0167-7799(90)90215-J, DOI 10.1016/0167-7799(90)90215-J]; Inoue S, 2000, BIOCHEM BIOPH RES CO, V268, P553, DOI 10.1006/bbrc.2000.2170; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KONRAD M, 1996, BIOCHEM J, V316, P5745; LUCAS JJ, 1977, J BIOL CHEM, V252, P4330; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Moore SEH, 1999, TRENDS CELL BIOL, V9, P441, DOI 10.1016/S0962-8924(99)01648-7; OREILLY DR, 1992, INSECT CELL CULTURE, P109; RIP JW, 1981, J BIOL CHEM, V256, P1929; RODRIGUEZVICO F, 1989, ANAL BIOCHEM, V183, P275, DOI 10.1016/0003-2697(89)90479-X; ROSENWALD AG, 1990, J BIOL CHEM, V265, P14544; Rush JS, 2000, GLYCOBIOLOGY, V10, P1102; Rush JS, 1998, GLYCOBIOLOGY, V8, P1207, DOI 10.1093/glycob/8.12.1207; SAGAMI H, 1993, J BIOL CHEM, V268, P10109; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sato M, 1999, MOL CELL BIOL, V19, P471; Schenk B, 2001, GLYCOBIOLOGY, V11, p61R, DOI 10.1093/glycob/11.5.61R; SCHER MG, 1985, METHOD ENZYMOL, V111, P547; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sengstag C, 2000, METHOD ENZYMOL, V327, P175, DOI 10.1016/S0076-6879(00)27275-3; Stukey J, 1997, PROTEIN SCI, V6, P469; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; TEHEESEN S, 1994, EUR J BIOCHEM, V224, P71, DOI 10.1111/j.1432-1033.1994.tb19996.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; van Berkel MAA, 1999, GLYCOBIOLOGY, V9, P243, DOI 10.1093/glycob/9.3.243; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WOLF M J, 1991, Glycobiology, V1, P405, DOI 10.1093/glycob/1.4.405; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868	54	56	58	4	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41455	41464		10.1074/jbc.M105544200	http://dx.doi.org/10.1074/jbc.M105544200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11504728	hybrid			2022-12-25	WOS:000171925600142
J	Huffman, JL; Mokashi, A; Bachinger, HP; Brennan, RG				Huffman, JL; Mokashi, A; Bachinger, HP; Brennan, RG			The basic helix-loop-helix domain of the aryl hydrocarbon receptor nuclear transporter (ARNT) can oligomerize and bind E-box DNA specifically	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; B/HLH/Z DOMAIN; HYPOXIA; PROTEIN; RECOGNITION; COMPLEX; ANGIOGENESIS; CONFORMATION	The aryl hydrocarbon receptor nuclear transporter (ARNT) is a basic helix-loop-helix (bHLH) protein that contains a Per-Arnt-Sim (PAS) domain. ARNT heterodimerizes in vivo with other bHLH PAS proteins to regulate a number of cellular activities, but a physiological role for ARNT homodimers has not yet been established. Moreover, no rigorous studies have been done to characterize the biochemical properties of the bHLH domain of ARNT that would address this issue. To begin this characterization, we chemically synthesized a 56-residue peptide encompassing the bHLH domain of ARNT (residues 90-145). In the absence of DNA, the ARNT-bHLH peptide can form homodimers in lower ionic strength, as evidenced by dynamic light scattering analysis, and can bind E-box DNA (CACGTG) with high specificity and affinity, as determined by fluorescence anisotropy. Dimers and tetramers of ARNT-bHLH are observed bound to DNA in equilibrium sedimentation and dynamic light scattering experiments. The homodimeric peptide also undergoes a coil-to-helix transition upon E-box DNA binding. Peptide oligomerization and DNA affinity are strongly influenced by ionic strength. These biochemical and biophysical studies on the ARNT-bHLH reveal its inherent ability to form homodimers at concentrations supporting a physiological function and underscore the significant biochemical differences among the bHLH superfamily.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Portland Shriners Hosp, Portland, OR 97201 USA	Oregon Health & Science University	Brennan, RG (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Park Rd, Portland, OR 97201 USA.			Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049244] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-49244] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; BASCI SG, 1996, J BIOL CHEM, V271, P8843; BASCI SG, 1995, MOL PHARM, V47, P432; BISHOP P, 1995, J AM CHEM SOC, V117, P8283, DOI 10.1021/ja00136a032; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; CammersGoodwin A, 1996, J AM CHEM SOC, V118, P3082, DOI 10.1021/ja952900z; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; COMPTON LA, 1987, J BIOL CHEM, V262, P13039; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; Kronenberg S, 2000, NUCLEIC ACIDS RES, V28, P2286, DOI 10.1093/nar/28.12.2286; Kunne AGE, 1997, BIOCHEMISTRY-US, V36, P1085, DOI 10.1021/bi962185l; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Mathieu MC, 2001, J BIOL CHEM, V276, P4819, DOI 10.1074/jbc.M008495200; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Michel G, 2000, J BIOMOL STRUCT DYN, V18, P169, DOI 10.1080/07391102.2000.10506656; MUHLEGOLL C, 1995, BIOCHEMISTRY-US, V34, P13554, DOI 10.1021/bi00041a035; Mukhopadhyay CK, 2000, J BIOL CHEM, V275, P21048, DOI 10.1074/jbc.M000636200; Parraga A, 1998, STRUCT FOLD DES, V6, P661, DOI 10.1016/S0969-2126(98)00067-7; PHILLIPS SEV, 1994, STRUCTURE, V2, P1, DOI 10.1016/S0969-2126(00)00002-2; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Sambrook J., 2002, MOL CLONING LAB MANU; SCHECTER A, 1995, AM J PUBLIC HEALTH, V85, P516, DOI 10.2105/AJPH.85.4.516; SCHURR JM, 1977, CRC CR REV BIOCH MOL, V4, P371; SCOPES RK, 1993, PROTEIN PURIFICATION, P72; Shimizu T, 1997, EMBO J, V16, P4689, DOI 10.1093/emboj/16.15.4689; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Swanson HI, 1998, MOL PHARMACOL, V54, P671; Swanson HI, 1999, NUCLEIC ACIDS RES, V27, P3205, DOI 10.1093/nar/27.15.3205; VANHOLDE KE, 1985, PHYSICAL BIOCH, P598; Wendt H, 1998, J BIOL CHEM, V273, P5735, DOI 10.1074/jbc.273.10.5735; Winston RL, 1999, BIOCHEMISTRY-US, V38, P5138, DOI 10.1021/bi982856a; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	44	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40537	40544		10.1074/jbc.M105675200	http://dx.doi.org/10.1074/jbc.M105675200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11502749	hybrid			2022-12-25	WOS:000171925600024
J	Anthony, C; Zong, Q; De Benedetti, A				Anthony, C; Zong, Q; De Benedetti, A			Overexpression of eIF4E in Saccharomyces cerevisiae causes slow growth and decreased alpha-factor response through alterations in CLN3 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; START-SPECIFIC TRANSCRIPTION; EUKARYOTIC PROTEIN-SYNTHESIS; DNA-SYNTHESIS GENES; CELL-CYCLE; MESSENGER-RNA; TRANSLATION INITIATION; ORNITHINE DECARBOXYLASE; BREAST CARCINOMAS; ANTISENSE RNA	The association of G(1) cyclins and Cdc28/cyclin-dependent protein kinase catalyzes the cell cycle entry (Start) in budding yeast. Activation of Start is presumed to be triggered by a post-transcriptional increase in Cln3 during early G(1). Cells arrested by mating pheromone show a loss of cyclin-dependent protein kinase activity caused by transcriptional shutoff of cyclins and/or inhibition by Farl. We report that overexpression of eIF4E (Cdc33), a rate-limiting translation initiation factor, causes an increase in CLN3 mRNA translation, which results in increased expression of CLN2 and in slow growth and decreased a-factor response. This phenotype was abrogated in a Delta cln3 or Delta cln2 background. We isolated the transcription factor MBP1 as a multicopy suppressor of the growth and alpha -factor response defects. Furthermore, elevated MBP1, a transcriptional regulator of cyclins, altered the transcriptional start site in CLN3 mRNA, shifting it 45 nucleotides upstream of the normal. This lengthened 5'-untranslated region likely reduces translation efficiency and down-regulates CLN3 protein synthesis, thereby correcting for the excess translation promoted by elevated Cdc33. In addition, the CLN2 mRNA level returned to normal. We propose that regulation of translation initiation by Cdc33 plays a pivotal role in the activation of Start and cell cycle progression in budding yeast.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Washington; University of Washington Seattle	De Benedetti, A (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	adeben@lsuhsc.edu		de benedetti, arrigo/0000-0002-4198-8647	NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM057912] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69148] Funding Source: Medline; NIGMS NIH HHS [GM 57912] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; Breeden L, 1996, CURR TOP MICROBIOL, V208, P95; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; Danaie P, 1999, BIOCHEM J, V340, P135, DOI 10.1042/0264-6021:3400135; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, NUCLEIC ACIDS RES, V19, P1925, DOI 10.1093/nar/19.8.1925; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; DUNCAN R, 1987, J BIOL CHEM, V262, P380; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; Nathan CA, 1997, ONCOGENE, V15, P1087, DOI 10.1038/sj.onc.1201272; Nathan CAO, 1997, ONCOGENE, V15, P579, DOI 10.1038/sj.onc.1201216; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Parviz F, 1998, J BACTERIOL, V180, P225, DOI 10.1128/JB.180.2.225-230.1998; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SHANTZ LM, 1994, CANCER RES, V54, P2313; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; VERMA R, 1992, P NATL ACAD SCI USA, V89, P9479, DOI 10.1073/pnas.89.20.9479; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	51	10	10	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39645	39652		10.1074/jbc.M101564200	http://dx.doi.org/10.1074/jbc.M101564200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11479284	hybrid			2022-12-25	WOS:000171789200020
J	Meng, XW; Poon, R; Zhang, XY; Cheah, A; Ding, Q; Hui, CC; Alman, B				Meng, XW; Poon, R; Zhang, XY; Cheah, A; Ding, Q; Hui, CC; Alman, B			Suppressor of fused negatively regulates beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APC TUMOR-SUPPRESSOR; NUCLEAR EXPORT; CUBITUS INTERRUPTUS; HEDGEHOG; PROTEIN; TCF; TRANSCRIPTION; ACTIVATION; MUTATIONS; LOCALIZATION	Suppressor of fused (Su(fu)) is a negative regulator of the Hedgehog signaling pathway that controls the nuclear-cytoplasmic distribution of Gli/Ci transcription factors through direct protein-protein interactions. We show here that Su(fu) is present in a complex with the oncogenic transcriptional activator beta -catenin and functions as a negative regulator of T-cell factor (Tcf)-dependent transcription. Overexpression of Su(fu) in SW480 (APC(mut)) colon cancer cells in which beta -catenin protein is stabilized leads to a reduction in nuclear beta -catenin levels and in Tcf-dependent transcription. This effect of Su(fu) overexpression can be blocked by treatment of these cells with leptomycin B, a specific inhibitor of CRM1-mediated nuclear export. Overexpressiou of Su(fu) suppresses growth of SW480 (APC(mut)) tumor cells in nude mice. These observations indicate that Su(fu) negatively regulates beta -catenin signaling and that CRM-1-mediated nuclear export plays a role in this regulation. Our results also suggest that Su(fu) acts as a tumor suppressor.	Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Surg, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Hui, CC (corresponding author), Hosp Sick Children, Program Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	cchui@sickkids.ca; benjamin.alman@sickkids.ca						Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alman BA, 1997, AM J PATHOL, V151, P329; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Methot N, 2000, DEVELOPMENT, V127, P4001; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Murone M, 2000, NAT CELL BIOL, V2, P310, DOI 10.1038/35010610; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Pearse RV, 1999, DEV BIOL, V212, P323, DOI 10.1006/dbio.1999.9335; PHAM A, 1995, GENETICS, V140, P587; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rubinfeld B, 1997, CANCER RES, V57, P4624; Sakamoto I, 2000, J BIOL CHEM, V275, P32871, DOI 10.1074/jbc.M004089200; Shibata T, 1996, ONCOGENE, V13, P883; Stone DM, 1999, J CELL SCI, V112, P4437; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Waltzer L, 1999, CANCER METAST REV, V18, P231, DOI 10.1023/A:1006321324190; Wang GL, 2000, GENE DEV, V14, P2893, DOI 10.1101/gad.843900; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x	39	99	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40113	40119		10.1074/jbc.M105317200	http://dx.doi.org/10.1074/jbc.M105317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11477086	hybrid			2022-12-25	WOS:000171789200082
J	Cases, S; Stone, SJ; Zhou, P; Yen, E; Tow, B; Lardizabal, KD; Voelker, T; Farese, RV				Cases, S; Stone, SJ; Zhou, P; Yen, E; Tow, B; Lardizabal, KD; Voelker, T; Farese, RV			Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRIACYLGLYCEROL SYNTHESIS; TRIGLYCERIDE SYNTHESIS; RAT ADIPOCYTES; MICROSOMES; ENZYMES; PROTEIN; YEAST; DIFFERENTIATION; ESTERIFICATION	Studies involving the cloning and disruption of the gene for acyl-CoA:diacylglycerol acyltransferase (DGAT) have shown that alternative mechanisms exist for triglyceride synthesis. In this study, we cloned and characterized a second mammalian DGAT, DGAT2, which was identified by its homology to a DGAT in the fungus Mortierella rammaniana. DGAT2 is a member of a gene family that has no homology with DGAT1 and includes several mouse and human homologues that are candidates for additional DGAT genes. The expression of DGAT2 in insect cells stimulated triglyceride synthesis 6-fold in assays with cellular membranes, and DGAT2 activity was dependent on the presence of fatty acyl-CoA and diacylglycerol, indicating that this protein is a DGAT. Activity was not observed for acyl acceptors other than diacylglycerol. DGAT2 activity was inhibited by a high concentration (100 mM) of MgCl2 in an in vitro assay, a characteristic that distinguishes DGAT2 from DGAT1. DGAT2 is expressed in many tissues with high expression levels in the liver and white adipose tissue, suggesting that it may play a significant role in mammalian triglyceride metabolism.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Monsanto Co, Davis, CA 95616 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Monsanto	Farese, RV (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056084, R56DK056084] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK056084, DK56084] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abo-Hashema KAH, 1999, J BIOL CHEM, V274, P35577, DOI 10.1074/jbc.274.50.35577; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bouvier-Nave P, 2000, EUR J BIOCHEM, V267, P85, DOI 10.1046/j.1432-1327.2000.00961.x; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brindley D. N, 1991, BIOCH LIPIDS LIPOPRO, P171; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; COLEMAN RA, 1992, METHOD ENZYMOL, V209, P98; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; Farese RV, 2000, CURR OPIN LIPIDOL, V11, P229, DOI 10.1097/00041433-200006000-00002; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GUNSTONE FD, 1994, LIPID HDB, P646; Hobbs DH, 1999, FEBS LETT, V452, P145, DOI 10.1016/S0014-5793(99)00646-8; JAMDAR SC, 1992, ARCH BIOCHEM BIOPHYS, V296, P419, DOI 10.1016/0003-9861(92)90592-K; Lardizabal KD, 2001, J BIOL CHEM, V276, P38862, DOI 10.1074/jbc.M106168200; LEHNER R, 1993, J BIOL CHEM, V268, P8781; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; LEHNER R, 1995, J BIOL CHEM, V270, P13630, DOI 10.1074/jbc.270.23.13630; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; Oelkers P, 2000, J BIOL CHEM, V275, P15609, DOI 10.1074/jbc.C000144200; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; WILLNOW TE, 1994, J CELL SCI, V107, P719	26	586	698	1	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38870	38876		10.1074/jbc.M106219200	http://dx.doi.org/10.1074/jbc.M106219200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11481335	hybrid			2022-12-25	WOS:000171673200072
J	Madden, DR; Thiran, S; Zimmermann, H; Romm, J; Jayaraman, V				Madden, DR; Thiran, S; Zimmermann, H; Romm, J; Jayaraman, V			Stereochemistry of quinoxaline antagonist binding to a glutamate receptor investigated by Fourier transform infrared spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN; PROTEINS	The stereochemistry of the interactions between quinoxaline antagonists and the ligand-binding domain of the glutamate receptor 4 (GluR4) have been investigated by probing their vibrational modes using Fourier transform infrared spectroscopy. In solution, the electron-withdrawing nitro groups of both compounds establish a resonance equilibrium that appears to stabilize the keto form of one of the cyclic amide carbonyl bonds. Changes in the 6,7-dinitro-2,3-dihydroxyquinoxaline vibrational spectra on binding to the glutamate receptor, interpreted within the framework of a published crystal structure, illuminate the stereochemistry of the interaction and suggest that the binding site imposes a more polarized electronic bonding configuration on this antagonist. Similar spectral changes are observed for 6-cyano-7-dinitro-2,3-dihydroxyquinoxaline, confirming that its interactions with the binding site are highly similar to those of 6,7-dinitro-2,3-dihydroxyquinoxaline and leading to a model of the 6-cyano-7-dinitro-2,3-dihydroxyquinoxaline-S1S2 complex, for which no crystal structure is available. Conformational changes within the GluR ligand binding domain were also monitored. Compared with the previously reported spectral changes seen on binding of the agonist glutamate, only a relatively small change is detected on antagonist binding. This correlation between the functional effects of different classes of ligand and the magnitude of the spectroscopic changes they induce suggests that the spectral data reflect physiologically relevant conformational processes.	Marquette Univ, Dept Chem, Milwaukee, WI 53233 USA; Max Planck Inst Med Res, D-69120 Heidelberg, Germany	Marquette University; Max Planck Society	Jayaraman, V (corresponding author), Marquette Univ, Dept Chem, Milwaukee, WI 53233 USA.							Abele R, 2000, J BIOL CHEM, V275, P21355, DOI 10.1074/jbc.M909883199; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Jayaraman V, 2000, BIOCHEMISTRY-US, V39, P8693, DOI 10.1021/bi000892f; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Lampinen M, 1998, EMBO J, V17, P4704, DOI 10.1093/emboj/17.16.4704; Madden DR, 2000, EUR J BIOCHEM, V267, P4281; Spiro T., 1987, BIOL APPL RAMAN SPEC; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N	11	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37821	37826						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11481334				2022-12-25	WOS:000171526500015
J	Olivares-Reyes, JA; Smith, RD; Hunyady, L; Shah, BH; Catt, KJ				Olivares-Reyes, JA; Smith, RD; Hunyady, L; Shah, BH; Catt, KJ			Agonist-induced signaling, desensitization, and internalization of a phosphorylation-deficient AT(1A) angiotensin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; 3RD INTRACELLULAR LOOP; ACIDIC AMINO-ACIDS; MUSCARINIC ACETYLCHOLINE-RECEPTORS; KINASE-MEDIATED PHOSPHORYLATION; DYNAMIN-DEPENDENT ENDOCYTOSIS; DOMINANT-NEGATIVE MUTANT; MU-OPIOID RECEPTOR; ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR	An analysis of the functional role of a diacidic motif (Asp(236)-Asp(237)) in the third intracellular loop of the AT(1A) angiotensin II (Ang II) receptor (AT(1)-R) revealed that substitution of both amino acids with alanine (DD-AA) or asparagine (DD-NN) residues diminished Ang II-induced receptor phosphorylation in COS-7 cells. However, Ang II-stimulated inositol phosphate production, mitogen-activated protein kinase, and AT(1) receptor desensitization and internalization were not significantly impaired. Overexpression of dominant negative G protein-coupled receptor kinase 2 (GRK2)K-220M decreased agonist-induced receptor phosphorylation by similar to 40%, but did not further reduce the impaired phosphorylation of DD-AA and DD-NN receptors. Inhibition of protein kinase C by bisin-dolylmaleimide reduced the phosphorylation of both the wild-type and the DD mutant receptors by similar to 30%. The inhibitory effects of GRK2(K220M) expression and protein kinase C inhibition by bisindolylmaleimide on agonist-induced phosphorylation were additive for the wild-type AT(1)-R, but not for the DD mutant receptor. Agonist-induced internalization of the wild-type and DD mutant receptors was similar and was unaltered by coexpression of GRK2(K220M). These findings demonstrate that an acidic motif at position 236/237 in the third intracellular loop of the AT(1)-R is required for optimal Ang II-induced phosphorylation of its carboxyl-terminal tail by GRKs. Furthermore, the properties of the DD mutant receptor suggest that not only Ang II-induced signaling, but also receptor desensitization and internalization, are independent of agonist-induced GRK-mediated phosphorylation of the AT(1) receptor.	NICHHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA; Semmelweis Univ, Fac Med, Dept Physiol, H-1088 Budapest, Hungary	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Semmelweis University	Catt, KJ (corresponding author), NICHHD, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A-36,9000 Rockville Pike, Bethesda, MD 20892 USA.	catt@helix.nih.gov	Olivares-Reyes, Jesus A/G-3180-2018	Olivares-Reyes, Jesus A/0000-0001-8389-9274				Balmforth AJ, 1997, BRIT J PHARMACOL, V122, P1469, DOI 10.1038/sj.bjp.0701522; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Deng HB, 2000, BIOCHEMISTRY-US, V39, P5492, DOI 10.1021/bi991938b; Diviani D, 1996, J BIOL CHEM, V271, P5049; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Gaborik Z, 2001, MOL PHARMACOL, V59, P239, DOI 10.1124/mol.59.2.239; Garcia-Caballero A, 2001, MOL PHARMACOL, V59, P576, DOI 10.1124/mol.59.3.576; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; Haga K, 1996, J BIOL CHEM, V271, P2776, DOI 10.1074/jbc.271.5.2776; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Hunyady L, 1998, MOL PHARMACOL, V54, P427, DOI 10.1124/mol.54.2.427; Hunyady L, 1996, P NATL ACAD SCI USA, V93, P10040, DOI 10.1073/pnas.93.19.10040; Hunyady L, 2000, REGUL PEPTIDES, V91, P29, DOI 10.1016/S0167-0115(00)00137-3; Innamorati G, 1997, J BIOL CHEM, V272, P2486; JEWELLMOTZ EA, 1995, BIOCHEMISTRY-US, V34, P11946, DOI 10.1021/bi00037a036; KONG GH, 1994, J BIOL CHEM, V269, P13084; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; Lee KB, 2000, J BIOL CHEM, V275, P35767, DOI 10.1074/jbc.M002225200; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Olivares-Reyes JA, 2000, MOL PHARMACOL, V58, P1156, DOI 10.1124/mol.58.5.1156; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALMER TM, 1995, J BIOL CHEM, V270, P29607, DOI 10.1074/jbc.270.49.29607; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEI G, 1995, MOL PHARMACOL, V48, P173; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; QUIAN H, 1999, BIOCHEM J, V343, P637; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; Small KM, 2001, J BIOL CHEM, V276, P4917, DOI 10.1074/jbc.M008118200; Smith RD, 1998, MOL ENDOCRINOL, V12, P634, DOI 10.1210/me.12.5.634; Smith RD, 1998, MOL PHARMACOL, V54, P935, DOI 10.1124/mol.54.6.935; Tang H, 1998, CIRC RES, V82, P523, DOI 10.1161/01.RES.82.5.523; Thomas WG, 1998, MOL ENDOCRINOL, V12, P1513, DOI 10.1210/me.12.10.1513; Thomas WG, 2000, J BIOL CHEM, V275, P2893, DOI 10.1074/jbc.275.4.2893; TSUGA H, 1994, J BIOL CHEM, V269, P32522; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Zhang M, 2000, J BIOL CHEM, V275, P15782, DOI 10.1074/jbc.M000198200	54	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37761	37768						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11495923				2022-12-25	WOS:000171526500007
J	Saito, T; Takahashi, Y; Hashimoto, H; Kamataki, T				Saito, T; Takahashi, Y; Hashimoto, H; Kamataki, T			Novel transcriptional regulation of the human CYP3A7 gene by Sp1 and Sp3 through nuclear factor kappa B-like element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-FETAL LIVERS; FETUS-SPECIFIC CYP3A7; CYTOCHROME-P-450 NIFEDIPINE OXIDASE; BOX-BINDING-PROTEINS; ADULT HUMAN-LIVER; NF-KAPPA; DNA-BINDING; FACTOR-I; RESPONSE ELEMENT; DEFINITIVE ENDODERM	Human CYP3A7 and CYP3A4 are expressed in fetal and adult livers, respectively, although the 5'-flanking regions of the two genes show 90% homology. The purpose of this study was to clarify the mechanism(s) responsible for the transcriptional regulation of the CYP3A7 gene in human hepatoma HepG2 cells that showed fetal phenotypes. Transfection studies using a series of the CYP3A7 or CYP3A4 promoter-luciferase chimeric genes identified a nuclear factor kappaB (NF-kappaB)-like element between nucleotides -2326 and -2297 that conferred the transcriptional activation of the CYP3A7 gene. A 1-base pair mismatch within the corresponding region of the CYP3A4 gene was sufficient for a differential enhancer activity. A gel shift assay using nuclear extracts from HepG2 cells showed that Sp1 and Sp3 bound to the NF-kappaB-like element of the CYP3A7 but not CYP3A4 gene. Specific activation of the CYP3A7 promoter by Spl and Sp3 was confirmed by a co-transfection of the p3A7NF-kappaB or p3A4NF-kappaB reporter gene with Sp1 or Sp3 expression plasmid into Drosophila cells, which lacked endogenous Sp family. Additionally, introduction of mutations into binding sites for hepatocyte nuclear factor 3 beta, upstream stimulatory factor 1, and a basic transcription element in the proximal promoter attenuated luciferase activity to 20% of the level seen with the intact CYP3A7 promoter. Thus, we conclude that the expression of the CYP3A7 gene in HepG2 cells is cooperatively regulated by Sp1, Sp3, hepatocyte nuclear factor 3 beta and upstream stimulatory factor 1.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Drug Metab, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Kamataki, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Drug Metab, Kita Ku, N12W6, Sapporo, Hokkaido 0600812, Japan.							ANG SL, 1993, DEVELOPMENT, V119, P1301; AOYAMA T, 1989, J BIOL CHEM, V264, P10388; Arenzana N, 1996, J IMMUNOL, V156, P168; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BEAUNE PH, 1986, P NATL ACAD SCI USA, V83, P8064, DOI 10.1073/pnas.83.21.8064; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; BORK RW, 1989, J BIOL CHEM, V264, P910; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLARK L, 1988, GENE DEV, V8, P991; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Domanski TL, 2001, MOL PHARMACOL, V59, P386, DOI 10.1124/mol.59.2.386; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GONZALEZ FJ, 1988, DNA-J MOLEC CELL BIO, V7, P79, DOI 10.1089/dna.1988.7.79; GRILLI M, 1993, INT REV CYTOL, V143, P1; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hakkola J, 1996, BIOCHEM PHARMACOL, V51, P403, DOI 10.1016/0006-2952(95)02184-1; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HASHIMOTO H, 1993, EUR J BIOCHEM, V218, P585, DOI 10.1111/j.1432-1033.1993.tb18412.x; HASHIMOTO H, 1995, CANCER RES, V55, P787; Hayashi Y, 1999, J CLIN PATHOL-MOL PA, V52, P19; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Huss JM, 1998, J BIOL CHEM, V273, P16155, DOI 10.1074/jbc.273.26.16155; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Itoh S, 1997, BBA-GENE STRUCT EXPR, V1350, P155, DOI 10.1016/S0167-4781(96)00215-1; ITOH S, 1992, BIOCHIM BIOPHYS ACTA, V1130, P133, DOI 10.1016/0167-4781(92)90520-A; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KELLY JH, 1989, IN VITRO CELL DEV B, V25, P217; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KITADA M, 1987, J BIOL CHEM, V262, P13534; KITADA M, 1987, BIOCHEM PHARMACOL, V36, P453, DOI 10.1016/0006-2952(87)90350-9; KITADA M, 1985, BIOCHEM BIOPH RES CO, V131, P1154, DOI 10.1016/0006-291X(85)90211-6; KITADA M, 1985, ARCH BIOCHEM BIOPHYS, V241, P275, DOI 10.1016/0003-9861(85)90383-2; KITADA M, 1979, BIOCHEM PHARMACOL, V28, P793; KOMORI M, 1990, BIOCHEMISTRY-US, V29, P4430, DOI 10.1021/bi00470a024; KOMORI M, 1989, J BIOCHEM-TOKYO, V105, P161, DOI 10.1093/oxfordjournals.jbchem.a122632; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Lacroix D, 1997, EUR J BIOCHEM, V247, P625, DOI 10.1111/j.1432-1033.1997.00625.x; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Li Y, 1996, ARCH BIOCHEM BIOPHYS, V329, P235, DOI 10.1006/abbi.1996.0214; Li Y, 1997, CANCER RES, V57, P641; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MAUREL P, 1996, CYTOCHROMES P450 MET, P241; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MIYATA M, 1995, ARCH BIOCHEM BIOPHYS, V318, P71, DOI 10.1006/abbi.1995.1206; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Pascussi JM, 1999, BIOCHEM BIOPH RES CO, V260, P377, DOI 10.1006/bbrc.1999.0745; Puzianowska-Kuznicka M, 1996, J BIOL CHEM, V271, P6273, DOI 10.1074/jbc.271.11.6273; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J., 2002, MOL CLONING LAB MANU; SASAKI H, 1993, DEVELOPMENT, V118, P47; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHUETZ JD, 1994, PHARMACOGENETICS, V4, P11, DOI 10.1097/00008571-199402000-00002; SCHUETZ JD, 1989, ARCH BIOCHEM BIOPHYS, V274, P355, DOI 10.1016/0003-9861(89)90449-9; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Shibuya H, 1989, INT IMMUNOL, V1, P43, DOI 10.1093/intimm/1.1.43; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takahashi Y, 1997, J BIOL CHEM, V272, P30025, DOI 10.1074/jbc.272.48.30025; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Toide K, 1997, ARCH BIOCHEM BIOPHYS, V338, P43, DOI 10.1006/abbi.1996.9792; Tronche F., 1994, LIVER GENE EXPRESSIO; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; WRIGHTON SA, 1992, CRIT REV TOXICOL, V22, P1, DOI 10.3109/10408449209145319; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470; YANG HYL, 1994, MOL PHARMACOL, V46, P922; ZABEL U, 1991, J BIOL CHEM, V266, P252	90	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38010	38022						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11495920				2022-12-25	WOS:000171526500041
J	Deeney, JT; Kohler, M; Kubik, K; Brown, G; Schultz, V; Tornheim, K; Corkey, BE; Berggren, PO				Deeney, JT; Kohler, M; Kubik, K; Brown, G; Schultz, V; Tornheim, K; Corkey, BE; Berggren, PO			Glucose-induced metabolic oscillations parallel those of Ca2+ and insulin release in clonal insulin-secreting cells - A multiwell approach to oscillatory cell behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; CYTOPLASMIC FREE CA2+; OXYGEN-CONSUMPTION; CHANNEL ACTIVITY; MOUSE ISLETS; B-CELLS; ATP; PHOSPHOFRUCTOKINASE; HIT; STIMULATION	Insulin secretion from glucose-stimulated pancreatic beta -cells is oscillatory, and this is thought to result from oscillations in glucose metabolism. One of the primary metabolic stimulus-secretion coupling factors is the ATP/ADP ratio, which can oscillate as a result of oscillations in glycolysis. Using a novel multiwell culture plate system, we examined oscillations in insulin release and the ATP/ADP ratio in the clonal insulin-secreting cell lines HIT T-15 and INS-1. Insulin secretion from HIT cells grown in multiwell plates oscillated with a period of 4 min, similar to that seen previously in perifusion experiments. Oscillations in the ATP/ADP ratio in cells grown under the same conditions also occurred with a period of 4 min, as did oscillations in [Ca2+](i) monitored by fluorescence microscopy. In INS-1 cells oscillations in insulin secretion, the ATP/ADP ratio, and [Ca2+](i) were also seen, but with a shorter period of about 1.5 min. These observations of oscillations in the ATP/ADP ratio are consistent with their proposed role in driving the oscillations in [Ca2+](i) and insulin secretion. Furthermore, these data show that, at least in the clonal beta -cell lines, cell contact or even circulatory connection is not necessary for synchronous oscillations induced by a rise in glucose.	Karolinska Inst, Karolinska Hosp, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden; Boston Med Ctr, Evans Dept Med, Obes Res Ctr, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Karolinska Institutet; Karolinska University Hospital; Boston Medical Center; Boston University	Berggren, PO (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden.		; Corkey, Barbara/E-7712-2015	Deeney, Jude/0000-0003-0988-9419; Kohler, Martin/0000-0001-6487-4303; Berggren, Per-Olof/0000-0001-8991-413X; Tornheim, Keith/0000-0002-6235-5128; Corkey, Barbara/0000-0002-5467-1630	NIDDK NIH HHS [DK35914, DK53064] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053064, R56DK035914, R01DK035914, R37DK035914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARKHAMMAR P, 1986, BIOCHIM BIOPHYS ACTA, V887, P236, DOI 10.1016/0167-4889(86)90060-1; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; BERGSTEN P, 1994, J BIOL CHEM, V269, P8749; BRADLEY DC, 1995, COMPUT METH PROG BIO, V46, P67, DOI 10.1016/0169-2607(94)01600-K; CHOU HF, 1991, DIABETES, V40, P1453, DOI 10.2337/diabetes.40.11.1453; CHOU HF, 1990, DIABETES, V39, P112, DOI 10.2337/diabetes.39.1.112; Civelek VN, 1996, BIOCHEM J, V315, P1015, DOI 10.1042/bj3151015; Cunningham BA, 1996, AM J PHYSIOL-ENDOC M, V271, pE702, DOI 10.1152/ajpendo.1996.271.4.E702; Deeney JT, 1996, J BIOL CHEM, V271, P18154, DOI 10.1074/jbc.271.30.18154; DETIMARY P, 1995, J CLIN INVEST, V96, P1738, DOI 10.1172/JCI118219; FINEGOOD DT, 1983, AM J PHYSIOL, V244, pE472, DOI 10.1152/ajpendo.1983.244.5.E472; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; GILON P, 1993, J BIOL CHEM, V268, P22265; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; Kohler M, 1998, FEBS LETT, V441, P97, DOI 10.1016/S0014-5793(98)01539-7; Larsson O, 1996, P NATL ACAD SCI USA, V93, P5161, DOI 10.1073/pnas.93.10.5161; LONGO EA, 1991, J BIOL CHEM, V266, P9314; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1986, DIABETES, V35, P1163, DOI 10.2337/diabetes.35.10.1163; Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091; POLONSKY KS, 1988, NEW ENGL J MED, V318, P1231, DOI 10.1056/NEJM198805123181903; Porterfield DM, 2000, DIABETES, V49, P1511, DOI 10.2337/diabetes.49.9.1511; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; Rosario L M, 1986, Adv Exp Med Biol, V211, P413; Sato Y, 1998, DIABETES, V47, P1713, DOI 10.2337/diabetes.47.11.1713; SCHULTZ V, 1993, ANAL BIOCHEM, V215, P302, DOI 10.1006/abio.1993.1591; STAGNER JI, 1980, J CLIN INVEST, V65, P939, DOI 10.1172/JCI109750; TORNHEIM K, 1976, J BIOL CHEM, V251, P7322; TORNHEIM K, 1975, J BIOL CHEM, V250, P6304; Tornheim K, 1997, DIABETES, V46, P1375, DOI 10.2337/diabetes.46.9.1375; Westerlund J, 1997, J CLIN INVEST, V100, P2547, DOI 10.1172/JCI119797; Westerlund J, 1996, J CLIN INVEST, V97, P1860, DOI 10.1172/JCI118616; YANEY GC, 1995, DIABETES, V44, P1285, DOI 10.2337/diabetes.44.11.1285; ZAITSEV SV, 1995, P NATL ACAD SCI USA, V92, P9712, DOI 10.1073/pnas.92.21.9712	37	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36946	36950		10.1074/jbc.M105056200	http://dx.doi.org/10.1074/jbc.M105056200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11481328	hybrid			2022-12-25	WOS:000171375700014
J	Galan, B; Kolb, A; Garcia, JL; Prieto, MA				Galan, B; Kolb, A; Garcia, JL; Prieto, MA			Superimposed levels of regulation of the 4-hydroxyphenylacetate catabolic pathway in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-LACTOSE DIAUXIE; CAMP RECEPTOR PROTEIN; MOLECULAR CHARACTERIZATION; ACETYL-COENZYME; CHROMOSOMAL INSERTION; POSITIVE REGULATOR; GENE-EXPRESSION; RNA-POLYMERASE; DNA; IDENTIFICATION	The regulation of the Pg promoter, which controls the expression of the meta operon of the 4-hydroxyphenylacetic acid (4-HPA) catabolic pathway of Escherichia coli W, has been examined through in vivo and in vitro experiments. By using Pg-lacZ fusions we have demonstrated that Pg is a promoter only inducible in the stationary phase when cells are grown on glucose as the sole carbon and energy source. This strict catabolite repression control is mediated by the cAMP receptor protein (CRP). This event does not require the presence of the specific HpaR repressor or the 4-HPA permease (HpaX), excluding the involvement of a typical inducer exclusion mechanism. However, the acetic acid excreted in the stationary phase by the cells growing in glucose acts as an overflow metabolite, which can provide the energy to produce cAMP and to adapt the cells rapidly to the utilization of a new less preferred carbon source such as the aromatic compounds. Although Pg is not a sigma (38)-dependent promoter, it is activated by the global regulator integration host factor (IHF) in the stationary phase of growth. Gel retardation assays have demonstrated that both CRP and IHF simultaneously bind to the Pg upstream region. DNase I footprint experiments showed that cAMP-CRP and IHF binding sites are centered at -61.5 and -103, respectively, with respect to the transcription start site +1 of the Pg promoter.	CSIC, Ctr Invest Biol, Dept Mol Microbiol, E-28006 Madrid, Spain; Inst Pasteur, Lab Regulat Transcriptionnelles, F-75724 Paris 15, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Prieto, MA (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Microbiol, Velazquez 144, E-28006 Madrid, Spain.	auxi@cib.csic.es	Prieto, María Auxiliadora/I-8092-2015; Garcia Lopez, Jose Luis/G-9139-2015	Prieto Jimenez, M. Auxiliadora/0000-0002-8038-1223; Garcia Lopez, Jose Luis/0000-0002-9238-2485				Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; Bordes P, 2000, MOL MICROBIOL, V35, P845, DOI 10.1046/j.1365-2958.2000.01758.x; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Cases I, 1998, CURR OPIN MICROBIOL, V1, P303, DOI 10.1016/S1369-5274(98)80034-9; Chang DE, 1999, J BACTERIOL, V181, P6656, DOI 10.1128/JB.181.21.6656-6663.1999; deLorenzo V, 1996, MOL MICROBIOL, V19, P1177; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; Diaz E, 2000, CURR OPIN BIOTECH, V11, P467, DOI 10.1016/S0958-1669(00)00126-9; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; EPSTEIN W, 1975, P NATL ACAD SCI USA, V72, P2300, DOI 10.1073/pnas.72.6.2300; Ferrandez A, 2000, J BIOL CHEM, V275, P12214, DOI 10.1074/jbc.275.16.12214; Ferrandez A, 1997, FEBS LETT, V406, P23, DOI 10.1016/S0014-5793(97)00228-7; Fischer D, 1998, J BACTERIOL, V180, P6203; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; Galan B, 2000, J BACTERIOL, V182, P627, DOI 10.1128/JB.182.3.627-636.2000; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GUNASEKERA A, 1992, J BIOL CHEM, V267, P14713; HenggeAronis R, 1996, MOL MICROBIOL, V21, P887, DOI 10.1046/j.1365-2958.1996.511405.x; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; Hogema BM, 1997, MOL MICROBIOL, V24, P857, DOI 10.1046/j.1365-2958.1997.3991761.x; Inada T, 1996, GENES CELLS, V1, P293, DOI 10.1046/j.1365-2443.1996.24025.x; ISHIZUKA H, 1994, EMBO J, V13, P3077, DOI 10.1002/j.1460-2075.1994.tb06606.x; Kimata K, 1997, P NATL ACAD SCI USA, V94, P12914, DOI 10.1073/pnas.94.24.12914; Kumari S, 2000, J BACTERIOL, V182, P4173, DOI 10.1128/JB.182.15.4173-4179.2000; KUMARI S, 1995, J BACTERIOL, V177, P2878, DOI 10.1128/jb.177.10.2878-2886.1995; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; Law EC, 1999, BIOCHEM J, V337, P415, DOI 10.1042/0264-6021:3370415; LOOMIS WF, 1967, J BACTERIOL, V93, P1397, DOI 10.1128/JB.93.4.1397-1401.1967; Mao WM, 1998, MOL MICROBIOL, V27, P415, DOI 10.1046/j.1365-2958.1998.00690.x; Marques S, 1999, MOL MICROBIOL, V31, P1105, DOI 10.1046/j.1365-2958.1999.01249.x; MATIN A, 1991, MOL MICROBIOL, V5, P3, DOI 10.1111/j.1365-2958.1991.tb01819.x; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NotleyMcRobb L, 1997, MICROBIOL-SGM, V143, P1909, DOI 10.1099/00221287-143-6-1909; NOVOTNY MJ, 1985, J BACTERIOL, V162, P810, DOI 10.1128/JB.162.2.810-816.1985; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Prieto MA, 1996, J BACTERIOL, V178, P111, DOI 10.1128/jb.178.1.111-120.1996; Prieto MA, 1997, FEBS LETT, V414, P293, DOI 10.1016/S0014-5793(97)01012-0; PRIETO MA, 1994, J BIOL CHEM, V269, P22823; Prieto MA, 1997, BIOCHEM BIOPH RES CO, V232, P759, DOI 10.1006/bbrc.1997.6368; ROPER DI, 1993, MOL GEN GENET, V237, P241, DOI 10.1007/BF00282806; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sawers G, 2001, MOL MICROBIOL, V39, P1285, DOI 10.1046/j.1365-2958.2001.02316.x; SCHAEFFER F, 1982, EMBO J, V1, P99, DOI 10.1002/j.1460-2075.1982.tb01131.x; SCHELLHORN HE, 1992, J BACTERIOL, V174, P4769, DOI 10.1128/JB.174.14.4769-4776.1992; ULLMANN A, 1983, ADV CYCL NUCL RES<D>, V15, P1; WEICHART D, 1993, MOL MICROBIOL, V10, P407, DOI 10.1111/j.1365-2958.1993.tb02672.x; Yamashita M, 1996, J BACTERIOL, V178, P2941, DOI 10.1128/jb.178.10.2941-2947.1996	50	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37060	37068		10.1074/jbc.M103033200	http://dx.doi.org/10.1074/jbc.M103033200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11477101	hybrid, Green Published			2022-12-25	WOS:000171375700028
J	Lewis, SE; Listenberger, LL; Ory, DS; Schaffer, JE				Lewis, SE; Listenberger, LL; Ory, DS; Schaffer, JE			Membrane topology of the murine fatty acid transport protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; ENDOPLASMIC-RETICULUM MEMBRANE; BINDING; GLYCOSYLATION; PERMEATION; ADIPOCYTE; INSERTION; DOMAINS; CLONING; OBESITY	The murine fatty acid transport protein (FATP1) was identified in an expression cloning screen for proteins that facilitate transport of fatty acids across the plasma membranes of mammalian cells. Hydropathy analysis of this protein suggests a model in which FATP1 has multiple membrane-spanning domains. To test this model, we inserted a hemagglutinin epitope tag at the amino terminus or a FLAG tag at the carboxyl terminus of the FATP1 cDNA and expressed these constructs in NIH 3T3 cells. Both tagged constructs produce proteins of the expected molecular masses and are functional in fatty acid import assays. Indirect immunofluorescence studies with selective permeabilization conditions and protease protection studies of sealed membrane vesicles from cells expressing epitope-tagged FATP1 were performed. These experiments show that the extreme amino terminus of tagged FATP1 is oriented toward the extracellular space, whereas the carboxyl terminus faces the cytosol. Additionally, enhanced green fluorescent protein fusion constructs containing predicted membrane-associated or soluble portions of FATP1 were expressed in Cos7 cells and analyzed by immunofluorescence and subcellular fractionation. These experiments demonstrate that amino acids 1-51, 52-100, and 101-190 contain signals for integral association with the membrane, whereas residues 258-313 and 314-475 are only peripherally membrane-associated. Amino acid residues 191-257 and 476-646 do not direct membrane association and likely face the cytosol. Taken together, these data support a model of FATP1 as a polytopic membrane protein with at least one transmembrane and multiple membrane-associated domains. This study provides the first experimental evidence for topology of a member of the family of plasma membrane fatty acid transport proteins.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Mol Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Schaffer, JE (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, 660 S Euclid Ave,Box 8086, St Louis, MO 63110 USA.	jschaff@imgate.wustl.edu			NIDDK NIH HHS [DK54268] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054268] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; Azizan A, 1999, ARCH BIOCHEM BIOPHYS, V365, P299, DOI 10.1006/abbi.1999.1171; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; Choi JY, 1999, J BIOL CHEM, V274, P4671, DOI 10.1074/jbc.274.8.4671; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; DiRusso CC, 2000, EUR J BIOCHEM, V267, P4422, DOI 10.1046/j.1432-1327.2000.01489.x; GARGIULO CE, 1999, IN PRESS J LIPID RES, V40; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Hamilton JA, 1998, J LIPID RES, V39, P467; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; MAHADEVAN S, 1974, ARCH BIOCHEM BIOPHYS, V164, P185, DOI 10.1016/0003-9861(74)90021-6; Nilsson I, 2000, J BIOL CHEM, V275, P6207, DOI 10.1074/jbc.275.9.6207; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; RICHIERI GV, 1995, J LIPID RES, V36, P229; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; Stump DD, 2001, J LIPID RES, V42, P509; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; WESSELS HP, 1991, METHOD CELL BIOL, V34, P287; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	36	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37042	37050		10.1074/jbc.M105556200	http://dx.doi.org/10.1074/jbc.M105556200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11470793	hybrid			2022-12-25	WOS:000171375700026
J	Rosen, K; Coll, ML; Li, A; Filmus, J				Rosen, K; Coll, ML; Li, A; Filmus, J			Transforming growth factor-alpha prevents detachment-induced inhibition of c-Src kinase activity, Bcl-X-L down-regulation, and apoptosis of intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING COMPLEX DISC; FACTOR RECEPTOR; CYTOCHROME-C; TGF-ALPHA; EXTRACELLULAR-MATRIX; TYROSINE KINASES; TRANSGENIC MICE; PROTEIN-KINASE; ACTIVATION; DEATH	Detachment of epithelial cells from the extracellular matrix (ECM) results in apoptosis, a phenomenon often referred to as anoikis. Acquisition of anoikis resistance is now thought to be a prerequisite for the progression of carcinomas. Colorectal cancer cells frequently secrete epidermal growth factor receptor (EGFR) ligands, which are known to have anti-apoptotic activity. However, whether these ligands have the ability to inhibit anoikis of intestinal epithelial cells is unclear, since at least in some cell types efficient EGFR signaling requires cell-ECM adhesion. Here we report that transforming growth factor-alpha (TGF-alpha), an EGFR ligand that is frequently secreted by colorectal cancer cells, strongly inhibits anoikis of the non-malignant rat intestinal epithelial cell lines, IEC-18 and RIE-1. TGF-alpha exerts its anti-anoikis effect by preventing detachment-induced inhibition of c-Src kinase activity. We also show that Fas activation, a molecular event known to play a critical role in anoikis, is not suppressed by TGF-alpha. On the other hand, this growth factor strongly inhibits the detachment-induced down-regulation of Bcl-X-L, another change that is involved in the induction of anoikis. We further demonstrate that this inhibition occurs in a c-Src-dependent manner. We conclude that TGF-a has the ability to suppress anoikis of intestinal epithelial cells, at least in part, by reverting the loss of c-Src activity and Bcl-X-L expression induced by detachment from the ECM.	Sunnybrook & Womens Coll Hlth Sci Ctr, Div Cell & Mol Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Filmus, J (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Div Cell & Mol Biol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.			Loza Coll, Mariano/0000-0002-3123-1229; Rosen, Kirill/0000-0002-4317-9907				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; ANZANO MA, 1989, CANCER RES, V49, P2898; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BLAY J, 1985, BIOCHEM J, V225, P85, DOI 10.1042/bj2250085; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; COFFEY RJ, 1986, CANCER RES, V46, P1164; COOPER JA, 1983, J BIOL CHEM, V258, P1108; De Luca A, 2000, ONCOGENE, V19, P5863, DOI 10.1038/sj.onc.1203979; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Frankel A, 2001, CANCER RES, V61, P4837; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Karnes WE, 1998, GASTROENTEROLOGY, V114, P930, DOI 10.1016/S0016-5085(98)70312-9; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krajewska M, 1996, CANCER RES, V56, P2422; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; RAWSON CL, 1991, J CELL BIOL, V113, P671, DOI 10.1083/jcb.113.3.671; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; STROMBERG K, 1992, CANCER RES, V52, P341; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TANAKA S, 1991, AM J PATHOL, V139, P123; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; YOSHIDA K, 1990, INT J CANCER, V45, P131, DOI 10.1002/ijc.2910450124	63	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37273	37279		10.1074/jbc.M106424200	http://dx.doi.org/10.1074/jbc.M106424200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11487584	hybrid			2022-12-25	WOS:000171375700056
J	Ambartsumian, N; Klingelhofer, J; Grigorian, M; Christensen, C; Kriajevska, M; Tulchinsky, E; Georgiev, G; Berezin, V; Bock, E; Rygaard, J; Cao, RH; Cao, YH; Lukanidin, E				Ambartsumian, N; Klingelhofer, J; Grigorian, M; Christensen, C; Kriajevska, M; Tulchinsky, E; Georgiev, G; Berezin, V; Bock, E; Rygaard, J; Cao, RH; Cao, YH; Lukanidin, E			The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor	ONCOGENE			English	Article						angiogenesis; S100A4; stimulation of motility	CALCIUM-BINDING PROTEIN; ENDOTHELIAL GROWTH-FACTOR; NONMUSCLE MYOSIN; MAMMALIAN-CELLS; S100A4 P9KA; TUMOR-CELLS; MTS1 GENE; IN-VIVO; EXPRESSION; MICE	The involvement of Mts1(S100A4), a small Call-binding protein in tumor progression and metastasis had been demonstrated. However, the mechanism by which mts1(S100A4) promoted metastasis had not been identified. Here we demonstrated that Mts1(S100A4) had significant stimulatory effect on the angiogenesis. We detected high incidence of hemangiomas - benign tumors of vascular origin in aged transgenic mice ubiquitously expressing the mts1(S100A4) gene. Furthermore, the serum level of the Mts1(Sl00A4) protein increased with ageing. Tumors developed in Mts1-transgenic mice revealed an enhanced vascular density. We showed that an oligomeric, but not a dimeric form of the Mts1(S100A4) protein was capable of enhancing the endothelial cell motility in vitro and stimulate the corneal neovascularization in vivo. An oligomeric fraction of the protein was detected in the conditioned media as well as in human serum. The data obtained allowed us to conclude that mts1(S100A4) might induce tumor progression via stimulation of angiogenesis.	Danish Canc Soc, Dept Mol Canc Biol, DK-2100 Copenhagen O, Denmark; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Univ Copenhagen, Panum Inst, Prot Lab, DK-2200 Copenhagen N, Denmark; Kommune Hosp Copenhagen, Bartholin Inst, DK-1399 Copenhagen K, Denmark; Inst Gene Biol, Moscow, Russia	Danish Cancer Society; Karolinska Institutet; University of Copenhagen; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Ambartsumian, N (corresponding author), Danish Canc Soc, Dept Mol Canc Biol, DK-2100 Copenhagen O, Denmark.	na@cancer.dk	Klingelhöfer, Jörg/C-1676-2013; Tulchinsky, Eugene/ABD-7070-2021					Ambartsumian N, 1999, INVAS METAST, V18, P96; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Barraclough R, 1998, BBA-MOL CELL RES, V1448, P190, DOI 10.1016/S0167-4889(98)00143-8; BOOTH CJ, 1995, LAB ANIM SCI, V45, P497; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Duarte WR, 1999, BIOCHEM BIOPH RES CO, V255, P416, DOI 10.1006/bbrc.1999.0214; Dunn G A, 1983, Agents Actions Suppl, V12, P14; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FORD HL, 1995, ONCOGENE, V10, P1597; FRITH CH, 1982, LAB ANIM SCI, V32, P157; GESZY C, 1996, BIOCHIM BIOPHYS ACTA, V1313, P246; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Komada T, 1996, BIOCHEM BIOPH RES CO, V220, P871, DOI 10.1006/bbrc.1996.0496; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Kumar R, 1998, INT J ONCOL, V12, P749; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; LIOTTA LA, 1974, CANCER RES, V34, P997; Lukanidin EM, 1996, CURR TOP MICROBIOL, V213, P171; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; PETERS RL, 1972, INT J CANCER, V10, P273, DOI 10.1002/ijc.2910100207; Polverini PJ, 1996, EUR J CANCER, V32A, P2430, DOI 10.1016/S0959-8049(96)00386-3; Rudland PS, 2000, CANCER RES, V60, P1595; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SENIN VM, 1983, EKSP ONKOL, V5, P35; SENIN VM, 1984, VESTN AKAD MED NAUK+, P85; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Takenaga K, 1997, CLIN CANCER RES, V3, P2309; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; Walmod PS, 1998, CELL MOTIL CYTOSKEL, V40, P220; WATANABE Y, 1992, J BIOL CHEM, V267, P17136; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; WEIDNER N, 1995, AM J PATHOL, V147, P9; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	54	206	230	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4685	4695		10.1038/sj.onc.1204636	http://dx.doi.org/10.1038/sj.onc.1204636			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498791				2022-12-25	WOS:000170208600009
J	Li, Q; Qi, B; Oka, K; Shimakage, M; Yoshioka, N; Inoue, H; Hakura, A; Kodama, K; Stanbridge, EJ; Yutsudo, M				Li, Q; Qi, B; Oka, K; Shimakage, M; Yoshioka, N; Inoue, H; Hakura, A; Kodama, K; Stanbridge, EJ; Yutsudo, M			Link of a new type of apoptosis-inducing gene ASY/Nogo-B to human cancer	ONCOGENE			English	Article						ASY; Nogo-B; apoptosis; cancer; endoplasmic reticulum	NEURITE OUTGROWTH; EXPRESSION; INHIBITOR; IDENTIFICATION; TRANSFORMATION; TRANSCRIPTS; CLONING; KINASE; GROWTH; DEATH	Although apoptosis plays an essential role in the embryogenesis and homeostasis of multicellular organisms, this mechanism has not yet been fully clarified. We isolated a novel human apoptosis-inducing gene, ASY, which encodes an endoplasmic reticulum-targeting protein without any known apoptosis-related motifs, This gene is identical to the Nogo-B, a splice variant of the Nogo-A which has recently been shown to be an inhibitor of neuronal regeneration in the central nervous system, Ectopic expression of the ASY gene led to extensive apoptosis, particularly in cancer cells. Furthermore, transcription of the ASY gene was suppressed in small cell lung cancer. These results suggest that a new type of apoptosis-inducing gene, namely, ASY, may be involved in the development of certain types of cancer.	Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, Suita, Osaka 5650871, Japan; Wuhan Univ, Sch Life Sci, Virus Inst, Wuhan 430072, Hubei, Peoples R China; Osaka Natl Hosp, Clin Res Inst, Osaka 5400006, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Thorac Surg, Osaka 5378511, Japan; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Osaka University; Wuhan University; Osaka National Hospital; Osaka Medical Center for Cancer & Cardiovascular Diseases; University of California System; University of California Irvine	Yutsudo, M (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yutsudo@biken.osaka-u.ac.jp						Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BANERJEE A, 1992, CANCER RES, V52, P6297; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Oka K, 1999, GENE CHROMOSOME CANC, V26, P47, DOI 10.1002/(SICI)1098-2264(199909)26:1<47::AID-GCC7>3.0.CO;2-8; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; ROEBROEK AJM, 1989, CANCER RES, V49, P4154; Shimakage M, 1997, HUM PATHOL, V28, P1415, DOI 10.1016/S0046-8177(97)90232-X; STANBRIDGE EJ, 1982, SCIENCE, V215, P252, DOI 10.1126/science.7053574; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	28	97	113	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					3929	3936		10.1038/sj.onc.1204536	http://dx.doi.org/10.1038/sj.onc.1204536			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494121				2022-12-25	WOS:000169681500001
J	Anders, A; Gilbert, S; Garten, W; Postina, R; Fahrenholz, F				Anders, A; Gilbert, S; Garten, W; Postina, R; Fahrenholz, F			Regulation of the alpha-secretase ADAM10 by its prodomain and proprotein convertases	FASEB JOURNAL			English	Article						PC7; furin; Alzheimer's disease; alpha-secretase; ADAM10	AMYLOID-PRECURSOR PROTEIN; TRANS-GOLGI NETWORK; BETA-SECRETASE; INTRACELLULAR MATURATION; CYSTEINE SWITCH; PROHORMONE CONVERTASES; ALZHEIMERS-DISEASE; SNAKE-VENOM; PRO-REGION; CLEAVAGE	Ectodomain shedding of the Alzheimer's amyloid precursor protein is mediated by alpha- and beta -secretases, which, for their part, are also proteolytically processed. The disintegrin metalloproteinase ADAM10 is synthesized as a zymogen with a proprotein convertase (PC) recognition sequence between the prodomain and the catalytic domain. In this study, we investigated the role of the prodomain in the regulation of the alpha -secretase activity of ADAM10. Overexpression of the proprotein convertases PC7 and furin in human embryonic kidney 293 cells revealed an increased ADAM10 maturation resulting in enhanced alpha -secretase-mediated processing of amyloid precursor protein. Mutation of the PC recognition sequence in ADAM10 as well as the use of a PC inhibitor and of the furin-deficient LoVo cell line confirmed the role of PCs, in particular, of PC7, in ADAM10 maturation and activation. Furthermore, we demonstrated that the prodomain of ADAM10 has a dual function. When coexpressed in trans as separate polypeptide, it inhibited the alpha -secretase activity of wild-type ADAM10. However, the prodomain acted as a chaperone and functionally rescued the alpha -secretase activity of a former inactive ADAM10 mutant lacking the prodomain. The results of our study suggest new approaches to enhance the nonamyloidogenic alpha -secretase pathway.	Univ Mainz, Inst Biochem, D-55128 Mainz, Germany; Univ Marburg, Inst Virol, D-35037 Marburg, Germany	Johannes Gutenberg University of Mainz; Philipps University Marburg	Fahrenholz, F (corresponding author), Univ Mainz, Inst Biochem, Becherweg 30, D-55128 Mainz, Germany.	bio.chemie@uni-mainz.de						ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao J, 2000, J BIOL CHEM, V275, P29648, DOI 10.1074/jbc.M001920200; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; DAY R, 1993, NEUROSCI LETT, V149, P27, DOI 10.1016/0304-3940(93)90339-M; DESTROOPER B, 1995, BBA-PROTEIN STRUCT M, V1246, P185, DOI 10.1016/0167-4838(94)00194-L; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; FABRE E, 1992, J BIOL CHEM, V267, P15049; Furukawa K, 1998, NEUROSCIENCE, V83, P429, DOI 10.1016/S0306-4522(97)00398-9; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Lopez-Perez E, 1999, J NEUROCHEM, V73, P2056; Lopez-Perez E, 2001, J NEUROCHEM, V76, P1532, DOI 10.1046/j.1471-4159.2001.00180.x; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Marcinkiewicz M, 2000, J NEUROCHEM, V75, P2133, DOI 10.1046/j.1471-4159.2000.0752133.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; SMALL DH, 1994, J NEUROSCI, V14, P2117; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STOCKER W, 1995, PROTEIN SCI, V4, P823; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; Wouters S, 1998, BIOCHEM J, V336, P311, DOI 10.1042/bj3360311; Yavari R, 1998, HUM MOL GENET, V7, P1161, DOI 10.1093/hmg/7.7.1161	56	177	187	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1837	+		10.1096/fj.01-0007fje	http://dx.doi.org/10.1096/fj.01-0007fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481247				2022-12-25	WOS:000169261200010
J	Watts, JA; Watts, A; Middleton, DA				Watts, JA; Watts, A; Middleton, DA			A model of reversible inhibitors in the gastric H+/K+-ATPase binding site determined by rotational echo double resonance NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE NMR; SUBSTITUTED IMIDAZO<1,2-A>PYRIDINES; ANTIULCER AGENTS; PROTON PUMP; REDOR NMR; H+,K+-ATPASE; H,K-ATPASE; CATION; NA,K-ATPASE; CONFORMATION	Several close analogues of the noncovalent H+/K+-ATPase inhibitor SCH28080 (2-methyl-3-eyanomethyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine) have been screened for activity and examined in the pharmacological site of action by solid-state NMR spectroscopy. TMPIP, the 1,2,3-trimethyl analogue of SCH28080, and variants of TMPIP containing fluorine in the phenylmethoxy ring exhibited IC50 values for porcine H+/K+-ATPase inhibition falling in the sub-10 muM range. Deuterium NAM spectra of a H-2-labeled inhibitor titrated into H+/K+-ATPase membranes revealed that 80-100% of inhibitor was bound to the protein, and K+-competition H-2 NMR experiments confirmed that the inhibitor lay within the active site. The active binding conformation of the pentafluorophenylmethoxy analogue of TMPIP was determined from C-13-F-19 dipolar coupling measurements using the cross-polarization magic angle spinning NMR method, REDOR. It was found that the inhibitor adopts an energetically favorable extended conformation falling between fully planar and partially bowed extremes. These findings allowed a model to be proposed for the binding of this inhibitor to H+/K+-ATPase based on the results of independent site-directed mutagenesis studies. In the model, the partially bowed inhibitor interacts with Phe(126) close to the N-terminal membrane spanning helix MI and residues in the extracellular loop bridging membrane helices M5 and M6 and is flanked by residues in M4.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Manchester; University of Oxford	Middleton, DA (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, POB 88, Manchester M60 1QD, Lancs, England.	middleda@bioch.ox.ac.uk						ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Asano S, 1997, J BIOL CHEM, V272, P17668, DOI 10.1074/jbc.272.28.17668; Besancon M, 1997, J BIOL CHEM, V272, P22438, DOI 10.1074/jbc.272.36.22438; BRIVING C, 1988, BIOCHIM BIOPHYS ACTA, V946, P185, DOI 10.1016/0005-2736(88)90391-4; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; Espe MP, 1997, MACROMOLECULES, V30, P6307, DOI 10.1021/ma970742l; Goetz JM, 1999, J AM CHEM SOC, V121, P7500, DOI 10.1021/ja983792u; Goetz JM, 1997, J MAGN RESON, V127, P147, DOI 10.1006/jmre.1997.1198; HERSEY SJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P49, DOI 10.1016/0167-4838(88)90296-8; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KAMINSKI JJ, 1985, J MED CHEM, V28, P876, DOI 10.1021/jm00145a006; KAMINSKI JJ, 1991, J MED CHEM, V34, P533, DOI 10.1021/jm00106a008; KEELING DJ, 1989, J BIOL CHEM, V264, P5545; Lambrecht N, 2000, J BIOL CHEM, V275, P4041, DOI 10.1074/jbc.275.6.4041; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; Li YK, 2000, BIOCHEMISTRY-US, V39, P281, DOI 10.1021/bi991936r; Lingrel JB, 1997, ANN NY ACAD SCI, V834, P194, DOI 10.1111/j.1749-6632.1997.tb52251.x; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MENDLEIN J, 1990, J BIOL CHEM, V265, P5030; Middleton DA, 2000, P NATL ACAD SCI USA, V97, P13602, DOI 10.1073/pnas.250471997; Middleton DA, 1997, FEBS LETT, V410, P269, DOI 10.1016/S0014-5793(97)00525-5; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; Munson KB, 2000, BIOCHEMISTRY-US, V39, P2997, DOI 10.1021/bi991837d; Ngola SM, 1998, J ORG CHEM, V63, P4566, DOI 10.1021/jo980361l; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; PAN Y, 1990, J MAGN RESON, V90, P330, DOI 10.1016/0022-2364(90)90138-Y; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; Rabon EC, 1996, J BIOL CHEM, V271, P32137, DOI 10.1074/jbc.271.50.32137; Rulli SJ, 1999, J BIOL CHEM, V274, P15245, DOI 10.1074/jbc.274.21.15245; SACCOMANI G, 1977, BIOCHIM BIOPHYS ACTA, V465, P311, DOI 10.1016/0005-2736(77)90081-5; SACHS G, 1995, ANNU REV PHARMACOL, V35, P277, DOI 10.1146/annurev.pa.35.040195.001425; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; Swarts HGP, 1999, MOL PHARMACOL, V55, P541; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; Watts A, 1999, NAT PROD REP, V16, P419, DOI 10.1039/a801189c; Watts A, 1999, CURR OPIN BIOTECH, V10, P48, DOI 10.1016/S0958-1669(99)80009-3; Watts Anthony, 1999, Pharmacy and Pharmacology Communications, V5, P7; WILLIAMS JH, 1993, ACCOUNTS CHEM RES, V26, P593, DOI 10.1021/ar00035a005; Williamson PTF, 1998, BIOCHEMISTRY-US, V37, P10854, DOI 10.1021/bi980390q; Zhang HM, 1997, BIOPHYS J, V72, P363, DOI 10.1016/S0006-3495(97)78675-2	43	29	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43197	43204		10.1074/jbc.M104808200	http://dx.doi.org/10.1074/jbc.M104808200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11479301	hybrid			2022-12-25	WOS:000172169300074
J	Walcher, S; Altschuh, J; Sandermann, H				Walcher, S; Altschuh, J; Sandermann, H			The lipid/protein interface as xenobiotic target site - Kinetic analysis of the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-HYDROXYBUTYRATE DEHYDROGENASE; DEPENDENT MEMBRANE ENZYMES; GENERAL-ANESTHETICS; ACTIVATION; COOPERATIVITY; PHOSPHATIDYLSERINE; DESENSITIZATION; INDUCTION; MISMATCH	Membrane proteins are known to be solvated and functionally activated by a fixed number of lipid molecules whose multiple binding can be described by Adair-type binding equations. Lipophilic xenobiotics such as general anesthetics may act by competitive displacement of protein-bound lipids. A kinetic equation is now presented for various binding stoichiometries of lipid and xenobiotic, and microscopic binding constants of anesthetics and organic solvents are derived from two independent assay systems for the enhancement of agonist binding to the nicotinic acetylcholine receptor. These constants lead to the first available free! energy estimate (-6.4 kcal/mol) for the binding of membrane lipid to an integral membrane protein.	GSF, Natl Res Ctr Environm & Hlth, Inst Biochem Plant Pathol, D-85764 Neuherberg, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Biomath & Biometry, D-85764 Neuherberg, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Sandermann, H (corresponding author), GSF, Natl Res Ctr Environm & Hlth, Inst Biochem Plant Pathol, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.	sandermann@gsf.de	Walcher, Sebastian/A-2120-2013	Walcher, Sebastian/0000-0003-4763-6869				Addona GH, 1998, BBA-BIOMEMBRANES, V1370, P299, DOI 10.1016/S0005-2736(97)00280-0; CORBIN J, 1998, BIOCHIM BIOPHYS ACTA, V1414, P64; ELLENA JF, 1983, BIOCHEMISTRY-US, V22, P5523, DOI 10.1021/bi00293a012; Franks NP, 1998, TOXICOL LETT, V101, P1, DOI 10.1016/S0378-4274(98)00158-1; GENNIS RB, 1989, BIOMEMBRANES MOL STR, P56; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; KLIEM D, 1999, THESIS L MAXIMILIANS; Loeb-Hennard C, 2000, BIOCHEMISTRY-US, V39, P11928, DOI 10.1021/bi000425y; Miller KW, 1998, TOXICOL LETT, V101, P139, DOI 10.1016/S0378-4274(98)00178-7; MILLER KW, 1986, MOL CELLULAR MECHANI, P125; Mosior M, 1998, BIOCHEMISTRY-US, V37, P17271, DOI 10.1021/bi981344t; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; Pflugmacher D, 1998, BBA-BIOMEMBRANES, V1415, P174, DOI 10.1016/S0005-2736(98)00187-4; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; POPOT JL, 1978, EUR J BIOCHEM, V85, P27, DOI 10.1111/j.1432-1033.1978.tb12209.x; RAINES DE, 1995, ANESTHESIOLOGY, V82, P276, DOI 10.1097/00000542-199501000-00033; Rankin SE, 1997, BIOPHYS J, V73, P2446, DOI 10.1016/S0006-3495(97)78273-0; Sandberg WS, 1999, CURR TOP MEMBR, V48, P311; SANDERMANN H, 1986, J BIOL CHEM, V261, P6201; SANDERMANN H, 1993, BIOCHIM BIOPHYS ACTA, V1150, P130, DOI 10.1016/0005-2736(93)90081-A; Sandermann H, 1996, BBA-LIPID LIPID MET, V1300, P219, DOI 10.1016/0005-2760(96)00017-3; SANDERMANN H, 1984, FEBS LETT, V168, P271, DOI 10.1016/0014-5793(84)80260-4; SANDERMANN H, 1991, BIOCHIM BIOPHYS ACTA, V1069, P235, DOI 10.1016/0005-2736(91)90130-Z; SANDERMANN H, 1982, EUR J BIOCHEM, V127, P123, DOI 10.1111/j.1432-1033.1982.tb06845.x; SANDERMANN H, 1993, PROTEIN LIPID INTERA, P67; SEGEL LA, 1991, BIOL KINETICS; Stryer L, 1975, BIOCHEMISTRY	27	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42191	42195		10.1074/jbc.M105136200	http://dx.doi.org/10.1074/jbc.M105136200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11489894	hybrid			2022-12-25	WOS:000172450400087
J	Ho, AT; Voura, EB; Soloway, PD; Watson, KLM; Khokha, R				Ho, AT; Voura, EB; Soloway, PD; Watson, KLM; Khokha, R			MMP inhibitors augment fibroblast adhesion through stabilization of focal adhesion contacts and up-regulation of cadherin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; B16-F10 MELANOMA-CELLS; BETA-CATENIN; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; TUMOR INVASION; EPITHELIAL-CELLS; GENE-EXPRESSION; CARCINOMA-CELLS; DOWN-REGULATION	Increased pericellular proteolysis due to an imbalance between MMPs (matrix metalloproteinases) and TIMPs (tissue inhibitors of metalloproteinases) promotes early stages of tumorigenesis. We have reported that TIMP-1 down-regulation confers tumorigenicity on immortal Swiss 3T3 fibroblasts. In pursuit of the mechanism involved in this transformation, we asked whether MMP inhibitors modulate contact inhibition and cell adhesion, because the dysregulation of these events is essential for cellular transformation. Using both genetic and biochemical means, we demonstrate that MMP inhibitors regulate fibroblast cell adhesion. TIMP-1 down-regulated cells formed dense, multilayered colonies, suggesting a loss of contact inhibition. Recombinant TIMP-1 and synthetic MMP inhibitors (MMPi) restored normal cell contact and density of these cells in a dose-dependent manner. Consequently, the effect of MMPi on both cell-extracellular matrix (ECM) and cell-cell adhesion were investigated. Upon MMPi treatment, p125(FAK) was redistributed, together with vinculin, to points of cell-ECM contact. Furthermore, phosphorylation of p125(FAK) was restored to levels similar to that of wild type. In parallel, MMPi treatment increased cadherin levels and stabilized cadherin-mediated cell-cell contacts. Moreover, enhanced cadherin function was evident as increased calcium-dependent cell-cell aggregation and co-localization of cadherin and beta -catenin at the cell membrane. We also obtained independent evidence of altered cadherin function using timp-1(-/-) mouse embryonic fibroblasts. Our data provide provocative evidence that increased pericellular proteolysis impacts cell adhesion systems to offset normal contact inhibition, with subsequent effects on cell transformation and tumorigenesis.	Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Dept Lab Med & Pathobiol, Hlth Network, Toronto, ON M5G 2M9, Canada; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Roswell Park Cancer Institute	Khokha, R (corresponding author), Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Hlth Network, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rkhokha@uhnres.utoronto.ca	Soloway, Paul/T-8243-2019; Ho, Andrew Tri Van/D-9681-2019	Ho, Andrew Tri Van/0000-0002-5501-6419; Soloway, Paul/0000-0003-1967-0437	NEI NIH HHS [R01 EY011279] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011279] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; Apte SS, 1996, J BIOL CHEM, V271, P2874; Arregui C, 2000, J CELL BIOL, V149, P1263, DOI 10.1083/jcb.149.6.1263; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Couture J, 2000, CLIN GENET, V57, P205, DOI 10.1034/j.1399-0004.2000.570306.x; Cowell HE, 1999, INT J CANCER, V80, P455; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; DECLERCK YA, 1992, CANCER RES, V52, P701; DENHARDT DT, 1992, MATRIX METALLOPROTEI, P281; DHAWAN J, 1990, J BIOL CHEM, V265, P9015; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Fowlkes JL, 1997, ENDOCRINE, V7, P33, DOI 10.1007/BF02778059; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GOLDBERG B, 1977, CELL, V11, P169, DOI 10.1016/0092-8674(77)90327-0; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Honore S, 2000, HISTOCHEM CELL BIOL, V114, P323; KHOKHA R, 1987, ANTICANCER RES, V7, P653; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; KHOKKA R, 1991, J CANCER RES CLIN, V117, P333, DOI 10.1007/BF01630716; Knudsen KA, 1998, J CELL BIOCHEM, P168; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kruger A, 1997, BLOOD, V90, P1993, DOI 10.1182/blood.V90.5.1993; Kruger A, 1998, ONCOGENE, V16, P2419, DOI 10.1038/sj.onc.1201774; Lauer JL, 1998, BIOCHEMISTRY-US, V37, P5279, DOI 10.1021/bi972958l; Li HD, 2000, J CELL BIOL, V149, P1275, DOI 10.1083/jcb.149.6.1275; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Llorens A, 1998, LAB INVEST, V78, P1131; Lochter A, 1997, J BIOL CHEM, V272, P5007, DOI 10.1074/jbc.272.8.5007; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Luo J, 1999, CANCER RES, V59, P3552; Martin DC, 1999, LAB INVEST, V79, P225; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Orsulic S, 1999, J CELL SCI, V112, P1237; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Polakis P, 2000, GENE DEV, V14, P1837; RAZ A, 1988, CIBA F SYMP, V141, P109; Reiske HR, 2000, FEBS LETT, V486, P275, DOI 10.1016/S0014-5793(00)02295-X; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Soloway PD, 1996, ONCOGENE, V13, P2307; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; Van Hoorde L, 1999, CELL ADHES COMMUN, V7, P139, DOI 10.3109/15419069909034397; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WIESER RJ, 1986, J CELL BIOL, V103, P361, DOI 10.1083/jcb.103.2.361; WIESER RJ, 1990, ENVIRON HEALTH PERSP, V88, P251, DOI 10.2307/3431085; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	69	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40215	40224		10.1074/jbc.M101647200	http://dx.doi.org/10.1074/jbc.M101647200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11500488	hybrid			2022-12-25	WOS:000171789200094
J	Oka, T; Murata, Y; Namba, M; Yoshimizu, T; Toyomura, T; Yamamoto, A; Sun-Wada, GH; Hamasaki, N; Wada, Y; Futai, M				Oka, T; Murata, Y; Namba, M; Yoshimizu, T; Toyomura, T; Yamamoto, A; Sun-Wada, GH; Hamasaki, N; Wada, Y; Futai, M			alpha 4, a unique kidney-specific isoform of mouse vacuolar H+-ATPase subunit a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; DUCT INTERCALATED CELLS; RENAL TUBULAR-ACIDOSIS; COLLECTING DUCT; RAT-KIDNEY; LUMINAL ACIDIFICATION; MOLECULAR-CLONING; 116-KDA SUBUNIT; 3 ISOFORMS; V-ATPASE	The vacuolar-type H+-ATPase (V-ATPase) translocates protons across membranes. Here, we have identified a mouse cDNA coding for a fourth isoform (a4) of the membrane sector subunit a of V-ATPase. This isoform was specifically expressed in kidney, but not in the heart, brain, spleen, lung, liver, muscle, or testis. Immunoprecipitation experiments, together with sequence similarities for other isoforms (a1, a2, and a3), indicate that the a4 isoform is a component of V-ATPase. Moreover, histochemical studies show that a4 is localized in the apical and basolateral plasma membranes of cortical alpha- and beta -intercalated cells, respectively. These results suggest that the V-ATPase, with the a4 isoform, is important for renal acid/base homeostasis.	Osaka Univ, Japan Sci & Technol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan; Kansai Med Univ, Dept Physiol, Moriguchi, Osaka 5708506, Japan; Kyushu Univ, Dept Clin Chem & Lab Med, Fukuoka 8128582, Japan	Japan Science & Technology Agency (JST); Osaka University; Kansai Medical University; Kyushu University	Futai, M (corresponding author), Osaka Univ, Japan Sci & Technol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan.		Yoshimizu, Takao/A-1339-2011	Yoshimizu, Takao/0000-0002-2553-8195				ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; ANRAKU Y, 1996, HDB BIOL PHYS, V2, P93; APPS DK, 1989, BIOCHEM J, V263, P81, DOI 10.1042/bj2630081; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; BROWN D, 1985, AM J PHYSIOL, V248, pC348, DOI 10.1152/ajpcell.1985.248.3.C348; BROWN D, 1988, J CLIN INVEST, V82, P2114, DOI 10.1172/JCI113833; Brown D, 2000, J EXP BIOL, V203, P137; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; Futai M, 2000, J EXP BIOL, V203, P107; Graham LA, 2000, J EXP BIOL, V203, P61; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; KAUFMAN MH, 1998, ATLAS MOUSE DEV, P177; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; LEE CK, 1990, MOL IMMUNOL, V27, P1137; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; MADSEN KM, 1986, AM J PHYSIOL, V250, pF1, DOI 10.1152/ajprenal.1986.250.1.F1; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Mattsson JP, 2000, EUR J BIOCHEM, V267, P4115, DOI 10.1046/j.1432-1327.2000.01445.x; Nakamura N, 2000, J BIOL CHEM, V275, P6523, DOI 10.1074/jbc.275.9.6523; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; PENG SB, 1994, J BIOL CHEM, V269, P17262; Peng SB, 1999, J BIOL CHEM, V274, P2549, DOI 10.1074/jbc.274.4.2549; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; SASAKI T, 1994, CELL TISSUE RES, V278, P265, DOI 10.1007/s004410050216; SCHUSTER VL, 1987, AM J PHYSIOL, V253, pF203, DOI 10.1152/ajprenal.1987.253.2.F203; SCHUSTER VL, 1991, AM J PHYSIOL, V260, pF506, DOI 10.1152/ajprenal.1991.260.4.F506; SCHUSTER VL, 1993, ANNU REV PHYSIOL, V55, P267, DOI 10.1146/annurev.ph.55.030193.001411; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; Tomochika K, 1997, FEBS LETT, V404, P61, DOI 10.1016/S0014-5793(97)00090-2; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Tsuganezawa H, 2001, J BIOL CHEM, V276, P8180, DOI 10.1074/jbc.M004513200	37	112	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40050	40054		10.1074/jbc.M106488200	http://dx.doi.org/10.1074/jbc.M106488200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11498539	hybrid			2022-12-25	WOS:000171789200074
J	Averna, M; De Tullio, R; Salamino, F; Minafra, R; Pontremoli, S; Melloni, E				Averna, M; De Tullio, R; Salamino, F; Minafra, R; Pontremoli, S; Melloni, E			Age-dependent degradation of calpastatin in kidney of hypertensive rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEINASE; CALPAIN INHIBITOR ACTIVITY; ENDOGENOUS INHIBITOR; CRYSTAL-STRUCTURE; SKELETAL-MUSCLE; DECREASED LEVEL; MESSENGER-RNAS; CALCIUM; BRAIN; FORMS	Hypertensive rats from the Milan strain show a significant decrease in calpastatin activity as compared with normotensive control animals. Calpastatin deficiency is age-related and highly relevant in kidney, heart, and erythrocytes and of minor entity in brain tissue. In normotensives the changes during aging in the levels of calpastatin activity and mRNA are consistent with an increase of calpastatin protein. In hypertensive rats such a relationship during aging is not observed, because a progressive accumulation of mRNA is accompanied by a lower amount of calpastatin protein as compared with control rats. Together with the low level of calpastatin in kidney of hypertensive rats, a progressive accumulation of an active 15-kDa calpastatin fragment, previously shown to represent a typical product of calpain-mediated calpastatin degradation, is also observed. Evidence for such intracellular proteolysis by Ca2+-activated calpain is provided by the normalization of the calpastatin level, up to that of control animals, in hypertensive rats treated with drugs known to reduce both blood pressure and intracellular Ca2+ influx. Further evidence is provided by the disappearance, in these conditions, of the 15-kDa calpastatin fragment. These data allow the conclusion that calpastatin degradation is a relevant part of the overall mechanism for regulating calpain activity.	Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy	University of Genoa	Melloni, E (corresponding author), Univ Genoa, Dept Expt Med, Biochem Sect, Viale Benedetto XV, I-16132 Genoa, Italy.		Averna, Maurizio/U-9527-2017; AVERNA, MONICA/R-5719-2019	AVERNA, MONICA/0000-0002-9463-7533				Averna M, 2001, BIOCHEM J, V354, P25, DOI 10.1042/0264-6021:3540025; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Blomgren K, 1999, J BIOL CHEM, V274, P14046, DOI 10.1074/jbc.274.20.14046; Brana C, 1999, EUR J NEUROSCI, V11, P2375, DOI 10.1046/j.1460-9568.1999.00653.x; Byrom FB, 1938, J PHYSIOL-LONDON, V93, P301, DOI 10.1113/jphysiol.1938.sp003641; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; De Tullio R, 1998, FEBS LETT, V422, P113, DOI 10.1016/S0014-5793(97)01588-3; De Tullio R, 1999, BIOCHEM J, V343, P467; De Tullio R, 2000, FEBS LETT, V475, P17, DOI 10.1016/S0014-5793(00)01613-6; Goll DE, 1990, INTRACELLULAR CALCIU, P3; GOTO K, 1994, MOL BRAIN RES, V23, P40, DOI 10.1016/0169-328X(94)90209-7; Haenni A, 1997, AM J HYPERTENS, V10, P145, DOI 10.1016/S0895-7061(96)00343-3; Hao LY, 2000, BIOCHEM BIOPH RES CO, V279, P756, DOI 10.1006/bbrc.2000.4040; HAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1094, P249, DOI 10.1016/0167-4889(91)90083-A; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; INOMATA M, 1988, J BIOL CHEM, V263, P19783; KAPLAN NM, 1988, SYSTEMIC HYPERTENSIO, P833; LEE WJ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P251, DOI 10.1016/0167-4781(92)90500-Y; MELLGREN RL, 1980, FEBS LETT, V109, P129, DOI 10.1016/0014-5793(80)81326-3; MELLONI E, 1984, BIOCHEM INT, V8, P477; Melloni E, 1998, FEBS LETT, V431, P55, DOI 10.1016/S0014-5793(98)00724-8; Melloni E, 1996, BIOCHEM BIOPH RES CO, V229, P193, DOI 10.1006/bbrc.1996.1779; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; NAKAMURA M, 1989, BIOCHEMISTRY-US, V28, P449, DOI 10.1021/bi00428a007; NILSSON E, 1990, NEUROBIOL AGING, V11, P425, DOI 10.1016/0197-4580(90)90009-O; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; PALEJWALA S, 1992, P NATL ACAD SCI USA, V89, P4202, DOI 10.1073/pnas.89.9.4202; PONTREMOLI S, 1991, ARCH BIOCHEM BIOPHYS, V288, P646, DOI 10.1016/0003-9861(91)90247-G; PONTREMOLI S, 1986, BIOCHEM BIOPH RES CO, V138, P1370, DOI 10.1016/S0006-291X(86)80434-X; PONTREMOLI S, 1987, BIOCHEM BIOPH RES CO, V145, P1287, DOI 10.1016/0006-291X(87)91577-4; PONTREMOLI S, 1990, ERYTHROCYTE CALPAIN, P225; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Salamino F, 1997, FEBS LETT, V412, P433, DOI 10.1016/S0014-5793(97)00819-3; SALAMINO F, 1991, BIOCHIM BIOPHYS ACTA, V1096, P265, DOI 10.1016/0925-4439(91)90061-D; Sambrook J., 2002, MOL CLONING LAB MANU; SANDMANN S, 2001, BRIT J PHARMACOL, V3, P767; SHI Y, 2000, AM J PHYSIOL, V279, pR509; SIMAN R, 1989, J NEUROSCI, V9, P1579; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; Sorimachi Y, 1997, J BIOCHEM-TOKYO, V122, P743; Sparatore B, 1996, FEBS LETT, V386, P95, DOI 10.1016/0014-5793(96)00418-8; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5	48	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38426	38432		10.1074/jbc.M101936200	http://dx.doi.org/10.1074/jbc.M101936200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11485997	hybrid			2022-12-25	WOS:000171673200015
J	Baboshina, OV; Crinelli, R; Siepmann, TJ; Haas, AL				Baboshina, OV; Crinelli, R; Siepmann, TJ; Haas, AL			N-end rule specificity within the ubiquitin/proteasome pathway is not an affinity effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; SHORT-LIVED PROTEIN; F-BOX PROTEIN; SKELETAL-MUSCLE; DEPENDENT PROTEOLYSIS; 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE; RECOGNITION COMPONENT; CONJUGATE DEGRADATION; MULTIUBIQUITIN CHAIN; ACTIVATING ENZYME	The N-end rule relates the amino terminus to the rate of degradation through the ubiquitin/26 S proteasome pathway. Proteins bearing basic (type 1) or large hydrophobic (type 2) amino termini are assumed to be targeted through this pathway by their higher affinity for binding to the responsible E3 ligase compared with proteins bearing other residues (type 3). Paradoxically, a significant fraction of eukaryotic protein degradation occurs through the N-end rule pathway, although the majority of cellular proteins are type 3 substrates. We have exploited specific interactions between ubiquitin carrier proteins (E2/Ubc) and their cognate E3 ligases to purify for the first time the mammalian N-end rule ligase E3 alpha /Ubr1 to near homogeneity. In vitro studies show that E3 alpha forms lysine 48-linked polyubiquitin degradation signals on type 1-3 substrates and is absolutely dependent on Ubc2/Rad6 orthologs. Biochemically defined kinetic studies show that the basis of N-end rule specificity is a keg, rather than the K-m effect originally proposed, since all three substrate classes show similar binding affinities (K-m similar to5 muM) but V-max values that are 100- and 50-fold greater for type 1 and 2 versus type 3 model substrates, respectively. In addition, the N-end rule dipeptides lysylalanine and phenylalanylalanine are general noncompetitive inhibitors for E3 alpha -catalyzed ubiquitination of type 1-3 substrates rather than type-specific competitive inhibitors as predicted. These observations are consistent with a model in which the N-end rule effect reflects substrate binding-induced transitions in E3 alpha to a catalytically competent conformer, the equilibrium for which depends on the identity of the amino terminus or the presence of basic or hydrophobic surface features. The model reconciles conflicts between specific predictions and empirical observations relating N-end rule targeting in addition to explicating the efficacy of selected dipeptides as potent in vivo inhibitors of this pathway.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Haas, AL (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.			Crinelli, Rita/0000-0002-1235-8910	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BANERJEE A, 1995, J BIOL CHEM, V270, P26209, DOI 10.1074/jbc.270.44.26209; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BOTBOL V, 1983, J BIOL CHEM, V258, P1942; Byrd C, 1998, EMBO J, V17, P269, DOI 10.1093/emboj/17.1.269; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; COOK RJ, 1995, ARCH BIOCHEM BIOPHYS, V321, P336, DOI 10.1006/abbi.1995.1403; COOK RJ, 1991, J BIOL CHEM, V266, P4965; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Gladding RL, 1997, BIOCHEM BIOPH RES CO, V238, P119, DOI 10.1006/bbrc.1997.7251; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Gray WM, 1999, GENE DEV, V13, P1678, DOI 10.1101/gad.13.13.1678; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1985, J BIOL CHEM, V260, P4694; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1991, J BIOL CHEM, V266, P5104; Haas AL, 1997, FASEB J, V11, P1257; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONDERMARCK H, 1992, BIOCHEM BIOPH RES CO, V189, P280, DOI 10.1016/0006-291X(92)91555-5; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kaiser P, 1998, GENE DEV, V12, P2587, DOI 10.1101/gad.12.16.2587; KETTELHUT IC, 1994, BRAZ J MED BIOL RES, V27, P981; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lawson TG, 1999, J BIOL CHEM, V274, P9871, DOI 10.1074/jbc.274.14.9871; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; MEDINA R, 1991, BIOMED BIOCHIM ACTA, V50, P347; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; Obin M, 1999, J BIOL CHEM, V274, P11789, DOI 10.1074/jbc.274.17.11789; Patton EE, 2000, EMBO J, V19, P1613, DOI 10.1093/emboj/19.7.1613; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PIEZ KA, 1961, J BIOL CHEM, V236, P2912; REISS Y, 1988, J BIOL CHEM, V263, P2693; REISS Y, 1990, J BIOL CHEM, V265, P3685; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; Solomon V, 1998, J BIOL CHEM, V273, P25216, DOI 10.1074/jbc.273.39.25216; Turner GC, 2000, NATURE, V405, P579, DOI 10.1038/35014629; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; WING SS, 1992, J BIOL CHEM, V267, P6495; WING SS, 1995, BIOCHEM J, V307, P639, DOI 10.1042/bj3070639; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	61	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39428	39437		10.1074/jbc.M106967200	http://dx.doi.org/10.1074/jbc.M106967200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11493606	hybrid			2022-12-25	WOS:000171673200143
J	Chen, SQ; Guttridge, DC; Tang, E; Shi, ST; Guan, KL; Wang, CY				Chen, SQ; Guttridge, DC; Tang, E; Shi, ST; Guan, KL; Wang, CY			Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor kappa B-independent bone morphogenetic protein/Smad signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; MICE LACKING; ACTIVATION; DIFFERENTIATION; OSTEOBLAST; RECEPTORS; THERAPY; SMADS; MITOCHONDRIA; INHIBITION	The activation of nuclear factor kappaB (NF-kappa B) plays a pivotal role in the regulation of tumor necrosis factor (TNF)-mediated apoptosis. However, little is known about the regulation of TNF-mediated apoptosis by other signaling pathways or growth factors. Here, unexpectedly, we found that bone morphogenetic protein (BMP)-2 and BMP-4 inhibited TNF-mediated apoptosis by inhibition of caspase-8 activation in C2C12 cells, a pluripotent mesenchymal cell line that has the potential to differentiate into osteoblasts depending on BMP stimulation. Utilizing both a trans-dominant I kappaB alpha inhibitor of NF-kappaB expressed in C2C12 cells and I kappaB kinase beta -deficient embryonic mouse fibroblast, we show that BMP-mediated survival was independent of NF-kappaB activation. Rather, the antiapoptotic activity of BMPs functioned through the Smad signaling pathway. Thus, these findings provide the first report of a BMP/Smad signaling pathway that can inhibit TNF-mediated apoptosis, independent of the prosurvival activity of NF-kappaB. Our results suggest that BMPs not only stimulate osteoblast differentiation but can also promote cell survival during the induction of bone formation, offering new insight into the biological functions of BMPs.	Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Lab Mol Signaling & Apoptosis, Ann Arbor, MI 48109 USA; Univ Michigan, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ N Carolina, Ctr Comprehens Canc, Chapel Hill, NC 27599 USA; NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Wang, CY (corresponding author), Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Lab Mol Signaling & Apoptosis, Rm 5223,Box 1078,1011 N Univ Ave, Ann Arbor, MI 48109 USA.			Guttridge, Denis/0000-0002-7276-6609	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE013848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013788, R01DE013848] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE13788, DE13848] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; HOGAN BL, CURR OPIN GENET DEV, V6, P432; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; Krebsbach PH, 2000, HUM GENE THER, V11, P1201, DOI 10.1089/10430340050015248; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lynch MP, 1998, J CELL BIOCHEM, V68, P31; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Tang MK, 2000, DEV BIOL, V218, P89, DOI 10.1006/dbio.1999.9578; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yang X, 1999, DEVELOPMENT, V126, P1571; You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	39	60	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39259	39263		10.1074/jbc.M105335200	http://dx.doi.org/10.1074/jbc.M105335200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11500509	hybrid			2022-12-25	WOS:000171673200122
J	Karim, CB; Paterlini, MG; Reddy, LG; Hunter, GW; Barany, G; Thomas, DD				Karim, CB; Paterlini, MG; Reddy, LG; Hunter, GW; Barany, G; Thomas, DD			Role of cysteine residues in structural stability and function of a transmembrane helix bundle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; FLUORESCENCE ENERGY-TRANSFER; SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; CA-ATPASE; CONFORMATIONAL-ANALYSIS; OLIGOMERIC STRUCTURE; INHIBITORY FUNCTION; MOLECULAR-DYNAMICS; COILED-COIL	To study the structural and functional roles of the cysteine residues at positions 36, 41, and 46 in the transmembrane domain of phospholamban (PLB), we have used Fmoc (N-(9-fluorenyl)methoxycarbonyl) solid-phase peptide synthesis to prepare alpha -amino-n-butyric acid (Abu)-PLB, the analogue in which all three cysteine residues are replaced by Abu. Whereas previous studies have shown that replacement of the three Cys residues by Ala (producing Ala-PLB) greatly destabilizes the pentameric structure, we hypothesized that replacement of Cys with Abu, which is isosteric to Cys, might preserve the pentameric stability. Therefore, we compared the oligomeric structure (from SDS-polyacrylamide gel electrophoresis) and function (inhibition of the Ca-ATPase in reconstituted membranes) of Abu-PLB with those of synthetic wild-type PLB and Ala-PLB. Molecular modeling provides structural and energetic insight into the different oligomeric stabilities of these molecules. We conclude that 1) the Cys residues of PLB are not necessary for pentamer formation or inhibitory function; 2) the steric properties of cysteine residues in the PLB transmembrane domain contribute substantially to pentameric stability, whereas the polar or chemical properties of the sulfhydryl group play only a minor role; 3) the functional potency of these PLB variants does not correlate with oligomeric stability; and 4) acetylation of the N-terminal methionine has neither a functional nor a structural effect in full-length PLB.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Karim, CB (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.	cbk@ddt.biochem.umn.edu	Thomas, David D/B-4257-2012	Karim, Christine/0000-0002-7321-7695; Thomas, David D./0000-0002-8822-2040	NHLBI NIH HHS [1K02 HL04209] Funding Source: Medline; NIDA NIH HHS [DA0037] Funding Source: Medline; NIGMS NIH HHS [GM51628, GM27906] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL004209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027906, R01GM051628] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe A, 2000, BIOCHEM BIOPH RES CO, V268, P14, DOI 10.1006/bbrc.1999.2069; ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; Arkin IT, 1997, J MEMBRANE BIOL, V155, P199, DOI 10.1007/s002329900172; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; BARANY G, 1996, TECHNIQUES PROTEIN C, V7, P503; Brinckerhoff LH, 1999, INT J CANCER, V83, P326, DOI 10.1002/(SICI)1097-0215(19991029)83:3<326::AID-IJC7>3.0.CO;2-X; CASE DA, 1997, AMBER5; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; DUNBRACK RL, 1994, NAT STRUCT BIOL, V1, P334, DOI 10.1038/nsb0594-334; FERNANDEZ JL, 1980, BIOCHIM BIOPHYS ACTA, V599, P552, DOI 10.1016/0005-2736(80)90199-6; FERRER M, 1992, INT J PEPT PROT RES, V40, P194; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; FUJII J, 1989, J BIOL CHEM, V264, P12950; Han YX, 1996, J ORG CHEM, V61, P6326, DOI 10.1021/jo960312d; Hunter GW, 1999, BIOPHYS J, V76, pA122; JONES LR, 1993, J BIOL CHEM, V268, P11486; Karim CB, 1998, BIOCHEMISTRY-US, V37, P12074, DOI 10.1021/bi980642n; Karim CB, 2000, BIOCHEMISTRY-US, V39, P10892, DOI 10.1021/bi0003543; Kates SA, 1996, PEPTIDE RES, V9, P106; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Li M, 1999, BIOPHYS J, V76, P2587, DOI 10.1016/S0006-3495(99)77411-4; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; Luger P, 1999, ACTA CRYSTALLOGR C, V55, P1882, DOI 10.1107/S0108270199009208; MADDEN TD, 1979, NATURE, V279, P538, DOI 10.1038/279538a0; NEMETHY G, 1989, BIOPOLYMERS, V28, P1573, DOI 10.1002/bip.360280907; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Petersen MTN, 1999, PROTEIN ENG, V12, P535, DOI 10.1093/protein/12.7.535; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; Reddy LG, 1999, BIOCHEMISTRY-US, V38, P3954, DOI 10.1021/bi981795d; Reddy LG, 1999, J BIOL CHEM, V274, P7649, DOI 10.1074/jbc.274.12.7649; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmitz S, 2000, J MOL BIOL, V295, P1201, DOI 10.1006/jmbi.1999.3407; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; Starling AP, 1996, BIOCHEM BIOPH RES CO, V226, P352, DOI 10.1006/bbrc.1996.1360; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; TARR GE, 1983, P NATL ACAD SCI-BIOL, V80, P6552, DOI 10.1073/pnas.80.21.6552; Thomas DD, 1998, ANN NY ACAD SCI, V853, P186, DOI 10.1111/j.1749-6632.1998.tb08266.x; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WEGENER AD, 1984, J BIOL CHEM, V259, P1834	43	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38814	38819		10.1074/jbc.M104006200	http://dx.doi.org/10.1074/jbc.M104006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11477077	hybrid			2022-12-25	WOS:000171673200065
J	Li, LY; Tao, JC; Davaille, J; Feral, C; Mallat, A; Rieusset, J; Vidal, H; Lotersztajn, S				Li, LY; Tao, JC; Davaille, J; Feral, C; Mallat, A; Rieusset, J; Vidal, H; Lotersztajn, S			15-deoxy-Delta(12,14)-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts - A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-INHIBITORY PROPERTIES; STELLATE CELL-PROLIFERATION; KAPPA-B KINASE; CYCLOPENTENONE PROSTAGLANDINS; MEDIATED PATHWAY; GENE-EXPRESSION; LIVER MYOFIBROBLASTS; TISSUE-REPAIR; PPAR-GAMMA; ITO CELLS	Hepatic myofibroblasts (hMFs) play a key role in the development of liver fibrosis associated with chronic liver diseases. Apoptosis of these cells is emerging as a key process in the resolution of liver fibrosis. Here, we examined the effects of cyclopentenone prostaglandins on apoptosis of human hMFs. Cyclopentenone prostaglandins of the J series markedly reduced hMF viability, with 15-deoxy-Delta (12,14)-prostaglandin J2 (15-d-PGJ(2)) being the most potent. This effect was independent of peroxisome-proliferator-activated receptors (PPARs), because PPAR gamma and PPAR alpha agonists did not affect hMF cell viability, and PPAR-gamma, the nuclear receptor for 15-d-PGJ(2), was not expressed in hMFs. Moreover, 15-d-PGJ(2) did not act via a cell surface G protein-coupled receptor, as shown in guanosine-5'-O-(3-thiotriphosphate) binding assays. Cell death resulted from an apoptotic process, because 15-d-PGJ(2)-treated hMFs exhibited condensed nuclei, fragmented DNA, and elevated caspase-3 activity. Moreover, the caspase inhibitor Z-Val-Ala-Asp (OCH3)-fluoromethyl ketone blocked the cytotoxic effect of 15-d-PGJ(2). The apoptotic effects of 15-d-PGJ2 were reproduced by H2O2 and blocked by the antioxidants N-acetylcysteine (NAC), N-(2-mercapto-propionyl)-glycine (NMPG) and pyrrolidine dithiocarbamate (PDTC). Accordingly, 15-d-PGJ(2) generated rapid production of reactive oxygen species in hMFs, via a NAC/NMPG/PDTC-sensitive pathway. In conclusion, 15-d-PGJ(2) induces apoptosis of human hMFs via a novel mechanism involving oxidative stress and unrelated to activation of its nuclear receptor PPAR gamma. These data underline the antifibrogenic potential of 15-d-PGJ(2).	Hop Henri Mondor, INSERM 99, F-94010 Creteil, France; Fac Med Alexis Carrel, INSERM, U499, F-69372 Lyon 08, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Lotersztajn, S (corresponding author), Hop Henri Mondor, INSERM 99, F-94010 Creteil, France.		Lotersztajn, Sophie/K-9160-2017; Vidal, Hubert/M-6674-2017; Feral, Chloe C/O-5781-2016; FERAL, Chloe/AAB-6111-2020; Rieusset, Jennifer/F-1595-2018	Vidal, Hubert/0000-0002-9467-0317; Feral, Chloe C/0000-0001-9756-2082; FERAL, Chloe/0000-0001-9756-2082; Rieusset, Jennifer/0000-0002-1587-2253; lotersztajn, Sophie/0000-0002-0053-7807				Arakaki N, 1999, J BIOL CHEM, V274, P13541, DOI 10.1074/jbc.274.19.13541; Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; Galli A, 2000, HEPATOLOGY, V31, P101, DOI 10.1002/hep.510310117; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Gong WR, 1998, HEPATOLOGY, V28, P492, DOI 10.1002/hep.510280229; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; HOLBROOK NJ, 1992, MOL CELL BIOL, V12, P1528, DOI 10.1128/MCB.12.4.1528; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; Knittel T, 1999, GASTROENTEROLOGY, V117, P1205, DOI 10.1016/S0016-5085(99)70407-5; Knittel T, 1999, HISTOCHEM CELL BIOL, V112, P387, DOI 10.1007/s004180050421; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; MALLAT A, 1995, J CLIN INVEST, V96, P42, DOI 10.1172/JCI118052; Mallat A, 1998, J BIOL CHEM, V273, P27300, DOI 10.1074/jbc.273.42.27300; Mallat A, 1996, J CLIN INVEST, V98, P2771, DOI 10.1172/JCI119103; Marra F, 2000, GASTROENTEROLOGY, V119, P466, DOI 10.1053/gast.2000.9365; Miyahara T, 2000, J BIOL CHEM, V275, P35715, DOI 10.1074/jbc.M006577200; Morel Y, 1999, BIOCHEM J, V342, P481, DOI 10.1042/0264-6021:3420481; NARUMIYA S, 1986, J PHARMACOL EXP THER, V239, P500; Odani N, 1996, J BIOL CHEM, V271, P16609, DOI 10.1074/jbc.271.28.16609; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Rieusset J, 1999, DIABETES, V48, P699, DOI 10.2337/diabetes.48.4.699; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Saile B, 1997, AM J PATHOL, V151, P1265; Schieferdecker HL, 1998, FEBS LETT, V434, P245, DOI 10.1016/S0014-5793(98)00990-9; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Takahashi S, 1998, BIOCHEM J, V335, P35, DOI 10.1042/bj3350035; Tao JC, 1999, J BIOL CHEM, V274, P23761, DOI 10.1074/jbc.274.34.23761; Trim N, 2000, AM J PATHOL, V156, P1235, DOI 10.1016/S0002-9440(10)64994-2; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121; Wright DH, 1998, BRIT J PHARMACOL, V123, P1317	38	134	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38152	38158						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11477100				2022-12-25	WOS:000171526500058
J	Rensen, PCN; Sliedregt, LAJM; Ferns, A; Kieviet, E; van Rossenberg, SMW; van Leeuwen, SH; van Berkel, TJC; Biessen, EAL				Rensen, PCN; Sliedregt, LAJM; Ferns, A; Kieviet, E; van Rossenberg, SMW; van Leeuwen, SH; van Berkel, TJC; Biessen, EAL			Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ACETYLGALACTOSAMINE-SPECIFIC LECTIN; FUCOSE-CONTAINING GLYCOPROTEINS; E-ENRICHED LIPOSOMES; RAT KUPFFER CELLS; N-ACETYLGALACTOSAMINE; HIGH-AFFINITY; CLUSTER GLYCOSIDES; MOLECULAR-CLONING; MACROPHAGE LECTIN	The asialoglycoprotein receptor (ASGPr) on hepatocytes plays a role in the clearance of desialylated proteins from the serum. Although its sugar preference (N-acetylgalactosamine (GalNAc) >> galactose) and the effects of ligand valency (tetraantennary > triantennary >> diantennary >> monoantennary) and sugar spacing (20 Angstrom >> 10 Angstrom >> 4 Angstrom) are well documented, the effect of particle size on recognition and uptake of ligands by the receptor is poorly defined. In the present study, we assessed the maximum ligand size that still allows effective processing by the ASGPr of mouse hepatocytes in vivo and in vitro. Hereto, we synthesized a novel glycolipid, which possesses a highly hydrophobic steroid moiety for stable incorporation into liposomes, and a triantennary GalNAc(3)-terminated cluster glycoside with a high nanomolar affinity (2 nm) for the ASGPr. Incorporation of the glycolipid into small (30 nm) [H-3]cholesteryl oleate-labeled long circulating liposomes (1-50%, w/w) caused a concentration-dependent increase in particle clearance that was liver-specific (reaching 85 +/- 7% of the injected dose at 30 min after injection) and mediated by the ASGPr on hepatocytes, as shown by competition studies with asialoorosomucoid in vivo. By using glycolipid-laden liposomes of various sizes between 30 and 90 nm, it was demonstrated that particles with a diameter of >70 nm could no longer be recognized and processed by the ASGPr in vivo. This threshold size for effective uptake was not related to the physical barrier raised by the fenestrated sinusoidal endothelium, which shields hepatocytes from the circulation, because similar results were obtained by studying the uptake of liposomes on isolated mouse hepatocytes in vitro. From these data we conclude that in addition to the species, valency, and orientation of sugar residues, size is also an important determinant for effective recognition and processing of substrates by the ASGPr. Therefore, these data have important implications for the design of ASGPr-specific carriers that are aimed at hepatocyte-directed delivery of drugs and genes.	Leiden Univ, Sylvius Lab, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Rensen, PCN (corresponding author), Leiden Univ, Sylvius Lab, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, POB 9503, NL-2300 RA Leiden, Netherlands.	p.rensen@lacdr.leidenuniv.nl	Van Berkel, Theo/ABD-7677-2021; Rensen, Patrick C.N./D-7176-2018	Rensen, Patrick C.N./0000-0002-8455-4988				AHMED H, 1990, BIOCHEMISTRY-US, V29, P5315, DOI 10.1021/bi00474a015; Andre S, 2000, PHARMACEUT RES, V17, P985, DOI 10.1023/A:1007535506705; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; BAENZIGER JU, 1980, J BIOL CHEM, V255, P4607; Bider MD, 1996, J BIOL CHEM, V271, P31996, DOI 10.1074/jbc.271.50.31996; BIESSEN EAL, 1994, BIOCHEM J, V299, P291, DOI 10.1042/bj2990291; Biessen EAL, 1996, ARTERIOSCL THROM VAS, V16, P1552, DOI 10.1161/01.ATV.16.12.1552; BIESSEN EAL, 1995, CIRCULATION, V91, P1847, DOI 10.1161/01.CIR.91.6.1847; BIESSEN EAL, 1995, J MED CHEM, V38, P1538, DOI 10.1021/jm00009a014; BIESSEN EAL, 1994, BIOCHEM J, V302, P283, DOI 10.1042/bj3020283; BIJSTERBOSCH MK, 1992, ARTERIOSCLER THROMB, V12, P1153, DOI 10.1161/01.ATV.12.10.1153; BIJSTERBOSCH MK, 1991, ARTERIOSCLER THROMB, V11, P1806, DOI 10.1161/01.ATV.11.6.1806; BIJSTERBOSCH MK, 1992, MOL PHARMACOL, V41, P404; BIJSTERBOSCH MK, 1990, BIOCHEM J, V270, P233, DOI 10.1042/bj2700233; CONNOLLY DT, 1982, J BIOL CHEM, V257, P939; DESCHUYTENEER M, 1984, BIOL CELL, V50, P17, DOI 10.1111/j.1768-322X.1984.tb00251.x; DINI L, 1991, CELL MOL BIOL, V37, P165; Dotzauer A, 2000, J VIROL, V74, P10950, DOI 10.1128/JVI.74.23.10950-10957.2000; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Goswami S K, 1970, J Chromatogr, V53, P389, DOI 10.1016/S0021-9673(01)98486-9; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7433; HANGELAND JJ, 1995, BIOCONJUGATE CHEM, V6, P695, DOI 10.1021/bc00036a006; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; II M, 1990, J BIOL CHEM, V265, P11295; IMAI Y, 1994, J IMMUNOL METHODS, V171, P23, DOI 10.1016/0022-1759(94)90224-0; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; ISHIBASHI S, 1994, J BIOL CHEM, V269, P27803; Kichler A, 1998, J DRUG TARGET, V6, P201, DOI 10.3109/10611869808997894; KOLBBACHOFEN V, 1981, BIOCHIM BIOPHYS ACTA, V645, P293, DOI 10.1016/0005-2736(81)90200-5; KOLBBACHOFEN V, 1982, CELL, V29, P859, DOI 10.1016/0092-8674(82)90447-0; KUIPER J, 1994, BIOCHEM J, V299, P285, DOI 10.1042/bj2990285; LEE RT, 1987, GLYCOCONJUGATE J, V4, P317, DOI 10.1007/BF01048365; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEE RT, 1986, BIOCHEMISTRY-US, V25, P6835, DOI 10.1021/bi00370a016; Lee RT, 1997, BIOCONJUGATE CHEM, V8, P762, DOI 10.1021/bc9700796; LEE RT, 1984, BIOCHEMISTRY-US, V23, P4255, DOI 10.1021/bi00313a037; LEE YC, 1983, J BIOL CHEM, V258, P199; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7419; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7426; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MERWIN JR, 1994, BIOCONJUGATE CHEM, V5, P612, DOI 10.1021/bc00030a017; OZAKI K, 1992, J BIOL CHEM, V267, P9229; OZAKI K, 1995, GLYCOCONJUGATE J, V12, P268, DOI 10.1007/BF00731329; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Rensen PCN, 1997, MOL PHARMACOL, V52, P445, DOI 10.1124/mol.52.3.445; Rensen PCN, 1997, J LIPID RES, V38, P1070; Rifai A, 2000, J EXP MED, V191, P2171, DOI 10.1084/jem.191.12.2171; ROELEN HCPF, 1991, J MED CHEM, V34, P1036, DOI 10.1021/jm00107a024; Rotundo RF, 1998, HEPATOLOGY, V28, P475, DOI 10.1002/hep.510280227; Rump ET, 1998, BIOCONJUGATE CHEM, V9, P341, DOI 10.1021/bc970176z; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; SCHLEPPERSCHAFER J, 1986, EXP CELL RES, V165, P494, DOI 10.1016/0014-4827(86)90602-6; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shimada K, 1997, BBA-BIOMEMBRANES, V1326, P329, DOI 10.1016/S0005-2736(97)00036-9; Sliedregt LAJM, 1999, J MED CHEM, V42, P609, DOI 10.1021/jm981078h; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; Tozawa R, 2001, J BIOL CHEM, V276, P12624, DOI 10.1074/jbc.M011063200; TREICHEL U, 1994, J GEN VIROL, V75, P3021, DOI 10.1099/0022-1317-75-11-3021; VANBERKEL TJC, 1985, J BIOL CHEM, V260, P2203; VANBERKEL TJC, 1985, J BIOL CHEM, V260, P2694; Versluis AJ, 1998, BRIT J CANCER, V78, P1607, DOI 10.1038/bjc.1998.730; WADHWA MS, 1995, J DRUG TARGET, V3, P111, DOI 10.3109/10611869509059211; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WHITEHEAD PH, 1966, BIOCHIM BIOPHYS ACTA, V124, P209, DOI 10.1016/0304-4165(66)90336-9; WISSE E, 1985, HEPATOLOGY, V5, P683, DOI 10.1002/hep.1840050427; Wu GY, 1998, ADV DRUG DELIVER REV, V29, P243, DOI 10.1016/S0169-409X(97)00082-3; Yamazaki N, 2000, ADV DRUG DELIVER REV, V43, P225, DOI 10.1016/S0169-409X(00)00071-5	71	164	200	6	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37577	37584		10.1074/jbc.M101786200	http://dx.doi.org/10.1074/jbc.M101786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479285	hybrid			2022-12-25	WOS:000171375700094
J	Rodighiero, C; Fujinaga, Y; Hirst, TR; Lencer, WI				Rodighiero, C; Fujinaga, Y; Hirst, TR; Lencer, WI			A cholera toxin B-subunit variant that binds ganglioside G(M1) but fails to induce toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-LABILE ENTEROTOXIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BREFELDIN-A; MEMBRANE; MECHANISM; ACTIVATION; INHIBITION; INTESTINE; SULFATION	Entry of cholera toxin (CT) into target epithelial cells and the induction of toxicity depend on CT binding to the lipid-based receptor ganglioside G(M1) and association with detergent-insoluble membrane microdomains, a function of the toxin's B-subunit. The B-subunits of CT and related Escherichia coli toxins exhibit a highly conserved exposed peptide loop (Glu(51)-Ile(58)) that faces the cell membrane upon B-subunit binding to G(M1). Mutation of His(57) to Ala in this loop resulted in a toxin (CT-H57A) that bound G(M1) with high apparent affinity, but failed to induce toxicity. CT-H57A bound to only a fraction of the cell-surface receptors available to wild-type CT. The bulk of cell-surface receptors inaccessible to CT-H57A localized to detergent-insoluble apical membrane microdomains (lipid rafts). Compared with wild-type toxin, CT-H57A exhibited slightly lower apparent binding affinity for and less stable binding to G(M1) in vitro. Rather than being transported into the Golgi apparatus, a process required for toxicity, most of CT-H57A was rapidly released from intact cells at physiologic temperatures or degraded following its internalization. These data indicate that CT action depends on the stable formation of the CT B-subunit.G(M1) complex and provide evidence that G(M1) functions as a necessary sorting motif for the retrograde trafficking of toxin into the secretory pathway of target epithelial cells.	Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Digest Dis Ctr, Boston, MA 02115 USA; Univ Bristol, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Bristol	Lencer, WI (corresponding author), Childrens Hosp, Dept Pediat, 300 Longwood Ave, Boston, MA 02115 USA.	lencer@tch.harvard.edu		Lencer, Wayne/0000-0001-7346-2730	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048106, R01DK048106, P30DK034854] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48106, DK34854] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aman AT, 2001, P NATL ACAD SCI USA, V98, P8536, DOI 10.1073/pnas.161273098; Arab S, 1996, GLYCOCONJUGATE J, V13, P159, DOI 10.1007/BF00731490; BACALLAO R, 1994, J CELL SCI, V107, P3301; Badizadegan K, 2000, AM J PHYSIOL-GASTR L, V278, pG895, DOI 10.1152/ajpgi.2000.278.6.G895; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CUATRECASAS P, 1973, BIOCHEMISTRY-US, V12, P3558, DOI 10.1021/bi00742a032; HOLMGREN J, 1975, P NATL ACAD SCI USA, V72, P2520, DOI 10.1073/pnas.72.7.2520; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; KING CA, 1973, J INFECT DIS, V127, P639, DOI 10.1093/infdis/127.6.639; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LENCER WI, 1987, INFECT IMMUN, V55, P3126, DOI 10.1128/IAI.55.12.3126-3130.1987; LENCER WI, 1993, J CLIN INVEST, V92, P2941, DOI 10.1172/JCI116917; LENCER WI, 1992, J CELL BIOL, V117, P1197, DOI 10.1083/jcb.117.6.1197; LENCER WI, 1995, P NATL ACAD SCI USA, V92, P10094, DOI 10.1073/pnas.92.22.10094; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Lencer WI, 2001, AM J PHYSIOL-GASTR L, V280, pG781, DOI 10.1152/ajpgi.2001.280.5.G781; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MERRITT EA, 1994, PROTEIN SCI, V3, P166; MOSS J, 1977, J BIOL CHEM, V252, P2455; MOSS J, 1979, J BIOL CHEM, V254, P1993; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Richards CM, 2001, J VIROL, V75, P1664, DOI 10.1128/JVI.75.4.1664-1671.2001; Rodighiero C, 1999, J BIOL CHEM, V274, P3962, DOI 10.1074/jbc.274.7.3962; Schmitz A, 2000, J CELL BIOL, V148, P1203, DOI 10.1083/jcb.148.6.1203; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Williams NA, 1997, P NATL ACAD SCI USA, V94, P5290, DOI 10.1073/pnas.94.10.5290; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456; ZHANG RG, 1995, J MOL BIOL, V251, P550, DOI 10.1006/jmbi.1995.0455	34	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36939	36945		10.1074/jbc.M104245200	http://dx.doi.org/10.1074/jbc.M104245200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479294	Green Published, hybrid			2022-12-25	WOS:000171375700013
J	Taddei, N; Capanni, C; Chiti, F; Stefani, M; Dobson, CM; Ramponi, G				Taddei, N; Capanni, C; Chiti, F; Stefani, M; Dobson, CM; Ramponi, G			Folding and aggregation are selectively influenced by the conformational preferences of the alpha-helices of muscle acylphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON-TYPE ACYLPHOSPHATASE; TRANSITION-STATE; SECONDARY STRUCTURE; MUTATIONAL ANALYSIS; LOCAL INTERACTIONS; PROTEIN; STABILIZATION; RESIDUES; PREDICTION; SITE	The native state of human muscle acylphosphatase (AcP) presents two alpha -helices. In this study we have investigated folding and aggregation of a number of protein variants having mutations aimed at changing the propensity of these helical regions. Equilibrium and kinetic measurements of folding indicate that only helix-2, spanning residues 55-67, is largely stabilized in the transition state for folding therefore playing a relevant role in this process. On the contrary, the aggregation rate appears to vary only for the variants in which the propensity of the region corresponding to helix-1, spanning residues 22-32, is changed. Mutations that stabilize the first helix slow down the aggregation process while those that destabilize it increase the aggregation rate. AcP variants with the first helix destabilized aggregate with rates increased to different extents depending on whether the introduced mutations also alter the propensity to form beta -sheet structure. The fact that the first a-helix is important for aggregation and the second helix is important for folding indicates that these processes are highly specific. This partitioning does not reflect the difference in intrinsic alpha -helical propensities of the two helices, because helix-1 is the one presenting the highest propensity. Both processes of folding and aggregation do not therefore initiate from regions that have simply secondary structure propensities favorable for such processes. The identification of the regions involved in aggregation and the understanding of the factors that promote such a process are of fundamental importance to elucidate the principles by which proteins have evolved and for successful protein design.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy; Univ Oxford, New Chem Lab, Oxford Ctr Mol Sci, Oxford OX1 3QT, England	University of Florence; University of Oxford	Ramponi, G (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	ramponi@scibio.unifi.it		STEFANI, MASSIMO/0000-0002-4490-1922; Taddei, Niccolo/0000-0003-2513-1018	Telethon [453/BI] Funding Source: Medline	Telethon(Fondazione Telethon)		Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P26, DOI 10.1016/S0968-0004(98)01346-2; Bellotti V, 1999, CELL MOL LIFE SCI, V55, P977, DOI 10.1007/s000180050348; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Chiti F, 1999, J BIOL CHEM, V274, P20151, DOI 10.1074/jbc.274.29.20151; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 1999, NAT STRUCT BIOL, V6, P1005; Chiti F, 1998, J MOL BIOL, V283, P893, DOI 10.1006/jmbi.1998.2010; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; FERSHT AR, 1999, STRUCTURE MECH PROTE, P558; Goldenberg DP, 1999, NAT STRUCT BIOL, V6, P987, DOI 10.1038/14866; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; Kallberg Y, 2001, J BIOL CHEM, V276, P12945, DOI 10.1074/jbc.M010402200; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Lacroix E, 1998, J MOL BIOL, V284, P173, DOI 10.1006/jmbi.1998.2145; Martinez JC, 1999, NAT STRUCT BIOL, V6, P1010; Mok YK, 2001, J MOL BIOL, V307, P913, DOI 10.1006/jmbi.2001.4521; Munoz V, 1996, FOLD DES, V1, P167, DOI 10.1016/S1359-0278(96)00029-6; Paoli P, 1999, ARCH BIOCHEM BIOPHYS, V363, P349, DOI 10.1006/abbi.1998.1097; RAMPONI G, 1966, ARCH BIOCHEM BIOPHYS, V115, P129, DOI 10.1016/S0003-9861(66)81048-2; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Street AG, 1999, P NATL ACAD SCI USA, V96, P9074, DOI 10.1073/pnas.96.16.9074; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Taddei N, 1999, BIOCHEMISTRY-US, V38, P2135, DOI 10.1021/bi9822630; Taddei N, 1996, BIOCHEMISTRY-US, V35, P7077, DOI 10.1021/bi952900b; TADDEI N, 1994, BBA-PROTEIN STRUCT M, V1208, P75, DOI 10.1016/0167-4838(94)90161-9; Taddei N, 1997, BIOCHEMISTRY-US, V36, P7217, DOI 10.1021/bi970173+; Taddei N, 2000, J MOL BIOL, V300, P633, DOI 10.1006/jmbi.2000.3870; Thunnissen MMGM, 1997, STRUCTURE, V5, P69, DOI 10.1016/S0969-2126(97)00167-6; van Nuland NAJ, 1998, J MOL BIOL, V283, P883, DOI 10.1006/jmbi.1998.2009; Vendruscolo M, 2001, NATURE, V409, P641, DOI 10.1038/35054591; Viguera AR, 1997, FOLD DES, V2, P23, DOI 10.1016/S1359-0278(97)00003-5; Villegas V, 2000, PROTEIN SCI, V9, P1700, DOI 10.1110/ps.9.9.1700; Zitzewitz JA, 2000, J MOL BIOL, V296, P1105, DOI 10.1006/jmbi.2000.3507	35	44	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37149	37154		10.1074/jbc.M105720200	http://dx.doi.org/10.1074/jbc.M105720200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479314	hybrid			2022-12-25	WOS:000171375700039
J	Terraz, C; Toman, D; Delauche, M; Ronco, P; Rossert, J				Terraz, C; Toman, D; Delauche, M; Ronco, P; Rossert, J			delta EF1 binds to a far upstream sequence of the mouse pro-alpha 1(I) collagen gene and represses its expression in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; ZINC-FINGER; REGULATORY ELEMENTS; TRANSCRIPTIONAL REGULATOR; PROTEIN DELTA-EF1; REPORTER GENES; MESSENGER-RNA; DNA ELEMENTS; PROMOTER; IDENTIFICATION	The transcription of type I collagen genes is tightly regulated, but few cis-acting elements have been identified that can modulate the levels of expression of these genes. Generation of transgenic mice harboring various segments of the mouse pro-alpha1(I) collagen promoter led us to suspect that a repressor element was located between -10.5 and -17 kilobase pairs. Stable and transient transfection experiments in ROS17/2.8 osteoblastic cells confirmed the existence of such a repressor element at about -14 kilobase pairs and showed that it consisted in an almost perfect three-time repeat of a 41-base pair sequence. This element, which we named COIN-1, contains three E2-boxes, and a point mutation in at least two of them completely abolished its repressor effect. In gel shift assays, COIN-1 bound a DNA-binding protein named delta EF1/ZEB-1, and mutations that abolished the repressor effect of COIN-1 also suppressed the binding of delta EF1. We also showed that the repressor effect of COIN-1 was not mediated by chromatin compaction. Furthermore, overexpression of delta EF1 in ROS17/2.8 osteoblastic cells enhanced the inhibitory effect of COIN-1 in a dose-dependent manner and repressed the expression of the pro-alpha1(I) collagen gene. Thus, delta EF1 appears to repress the expression of the mouse pro-alpha1(I) collagen gene, through its binding to COIN-1.	Hop Tenon, INSERM, U489, F-75020 Paris, France; Univ Paris 06, F-75020 Paris, France; Cohes Technol, Palo Alto, CA 94303 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Rossert, J (corresponding author), Hop Tenon, INSERM, U489, 4 Rue Chine, F-75020 Paris, France.		Ronco, Pierre/AAC-8390-2022					BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Calmont A, 2000, MOL ENDOCRINOL, V14, P1682, DOI 10.1210/me.14.10.1682; Dhar M, 1997, J BIOL CHEM, V272, P18490, DOI 10.1074/jbc.272.29.18490; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUNAHASHI J, 1993, DEVELOPMENT, V119, P433; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Givogri MI, 2000, GENE, V252, P183, DOI 10.1016/S0378-1119(00)00223-7; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; HOGAN B, 1986, MANIPULATING MOUSE E, P115; Hormuzdi SG, 1998, MOL CELL BIOL, V18, P3368, DOI 10.1128/MCB.18.6.3368; JIMENEZ SA, 1986, BIOCHEM J, V237, P837, DOI 10.1042/bj2370837; KAMACHI Y, 1993, MOL CELL BIOL, V13, P5206, DOI 10.1128/MCB.13.9.5206; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; Krempen K, 1999, GENE EXPRESSION, V8, P151; LEROY EC, 1974, J CLIN INVEST, V54, P880, DOI 10.1172/JCI107827; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; LISKA DJ, 1990, CELL REGUL, V1, P487, DOI 10.1091/mbc.1.6.487; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; Niederreither K, 1995, MATRIX BIOL, V14, P705, DOI 10.1016/S0945-053X(05)80013-7; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; PRIE D, 1991, J CELL BIOL, V113, P951, DOI 10.1083/jcb.113.4.951; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAVAZZOLO R, 1991, J BIOL CHEM, V266, P7382; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Rippe RA, 1997, J BIOL CHEM, V272, P1753, DOI 10.1074/jbc.272.3.1753; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; ROSSERT J, 2001, IN PRESS PRINCIPLES; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; SalimiTari P, 1997, GENE, V198, P61, DOI 10.1016/S0378-1119(97)00293-X; SAMBOROK J, 1989, MOL CLONING LAB MANU; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; Takagi T, 1998, DEVELOPMENT, V125, P21; TOMAN D, 1995, MATRIX PRACTICAL APP, P353; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WASSARMAN PM, 1993, GUIDES TECHNIQUES MO, P451; Widom RL, 1997, GENE, V198, P407, DOI 10.1016/S0378-1119(97)00360-0	43	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37011	37019		10.1074/jbc.M104185200	http://dx.doi.org/10.1074/jbc.M104185200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11473112	hybrid			2022-12-25	WOS:000171375700022
J	Khan, JA; Kumar, P; Srinivasan, A; Singh, TP				Khan, JA; Kumar, P; Srinivasan, A; Singh, TP			Protein intermediate trapped by the simultaneous crystallization process - Crystal structure of an iron-saturated intermediate in the Fe3+ binding pathway of camel lactoferrin at 2.7 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; X-RAY-DIFFRACTION; BUFFALO LACTOFERRIN; TRANSFERRIN; LACTOTRANSFERRIN; SCATTERING; OVOTRANSFERRIN; EXCHANGE; COMPLEX; MUTANTS	This is the first protein intermediate obtained in the crystalline state by the simultaneous process of Fe3+ binding and crystal nucleation and is also the first structure of an intermediate of lactoferrin in the Fe3+ binding pathway. Lactoferrin is an iron-binding 80-kDa glycoprotein. It binds Fe3+ very tightly in a closed interdomain cleft in both lobes. The iron-free structure of lactoferrin, on the other hand, adopts an open conformation with domains moving widely apart. These studies imply that initial Fe3+ binding must be in the open form. The protein intermediate was crystallized by the microdialysis method. The protein solution, with a concentration of 100 mg/ml in 10 mm Tris-HCl, pH 8.0, was loaded in a capillary and dialyzed against the same buffer containing 26% (v/v) ethanol placed in a reservoir. FeCl3 and CO32- in excess molar ratios to that of protein in its Solution were added to the reservoir buffer. The crystals appeared after some hours and grew to the optimum size within 36 h. The structure was determined by molecular replacement method and refined to final R- and R-free factors of 0.187 and 0.255, respectively. The present structure showed that the protein molecule adopts an open conformation similar to that of camel apolactoferrin. The electron density map clearly indicated the presence of two iron atoms, one in each lobe with 4-fold coordinations: two by the protein ligands of Tyr-92(433) OH and Tyr-192(526) OH and two other coordination sites occupied by oxygen atoms of bidentate CO32- ions leading to a tetrahedral intermediate. The CO32- anion is stabilized through hydrogen bonds with the synergistic anion-binding site Arg-121(463) and with Ser-122 O gamma in the N-lobe and Thr-464 O gamma in C-lobe. The third oxygen atom of CO32- interacts with a water molecule in both lobes.	All India Inst Med Sci, Dept Biophys, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi	Singh, TP (corresponding author), All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.			Kumar, Pravindra/0000-0003-2128-7736				ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; COWART RE, 1982, J BIOL CHEM, V257, P7560; COWART RE, 1986, J BIOL CHEM, V261, P4607; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; GROSSMANN JG, 1993, J MOL BIOL, V231, P554, DOI 10.1006/jmbi.1993.1308; GROSSMANN JG, 1992, J MOL BIOL, V225, P811, DOI 10.1016/0022-2836(92)90402-6; Grossmann JG, 1998, J MOL BIOL, V279, P461, DOI 10.1006/jmbi.1998.1787; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kappeler S, 1999, J DAIRY SCI, V82, P2084, DOI 10.3168/jds.S0022-0302(99)75450-0; Karthikeyan S, 2000, ACTA CRYSTALLOGR D, V56, P684, DOI 10.1107/S0907444900005151; Karthikeyan S, 1999, ACTA CRYSTALLOGR D, V55, P1805, DOI 10.1107/S0907444999010951; Khan JA, 2001, J MOL BIOL, V309, P751, DOI 10.1006/jmbi.2001.4692; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR P, 2001, ACTA CRYSTALLOGR D; KUMAR P, 2001, THESIS ALL INDIA I M; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LINDLEY PF, 1993, ACTA CRYSTALLOGR D, V49, P292, DOI 10.1107/S0907444992012101; LYDON JP, 1992, BIOCHIM BIOPHYS ACTA, V1132, P97, DOI 10.1016/0167-4781(92)90061-4; MASSON PL, 1968, FERTIL STERIL, V19, P679; MATTHEWS BW, 1972, MACROMOLECULES, V5, P818, DOI 10.1021/ma60030a031; MAZURIER J, 1980, BIOCHIM BIOPHYS ACTA, V629, P399, DOI 10.1016/0304-4165(80)90112-9; Mecklenburg SL, 1997, J MOL BIOL, V270, P739, DOI 10.1006/jmbi.1997.1126; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; Minor W., 1993, XDISPLAYF PROGRAM; Mizutani K, 1999, J BIOL CHEM, V274, P10190, DOI 10.1074/jbc.274.15.10190; Moore SA, 1997, J MOL BIOL, V274, P222, DOI 10.1006/jmbi.1997.1386; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PIERCE A, 1991, EUR J BIOCHEM, V196, P177, DOI 10.1111/j.1432-1033.1991.tb15801.x; Provost F. le, 1994, Biochemical and Biophysical Research Communications, V203, P1324, DOI 10.1006/bbrc.1994.2327; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAMAN A, 1992, ARCH BIOCHEM BIOPHYS, V294, P319, DOI 10.1016/0003-9861(92)90175-V; Sharma AK, 1999, J MOL BIOL, V289, P303, DOI 10.1006/jmbi.1999.2767; SHIRSAT NV, 1992, GENE, V110, P229, DOI 10.1016/0378-1119(92)90653-7	41	24	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36817	36823		10.1074/jbc.M104343200	http://dx.doi.org/10.1074/jbc.M104343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11473113	hybrid			2022-12-25	WOS:000171194500101
J	Lee, M; Cram, EJ; Shen, B; Schwarzbauer, JE				Lee, M; Cram, EJ; Shen, B; Schwarzbauer, JE			Roles for beta pat-3 integrins in development and function of Caenorhabditis elegans muscles and gonads	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(3) CYTOPLASMIC DOMAIN; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; C-ELEGANS; GENE-EXPRESSION; PROTEIN; ADHESION; PHAGOCYTOSIS; TRANSDUCTION; METALLOPROTEASE	Heterodimeric integrin receptors for extracellular matrix (ECM) play vital roles in bidirectional signaling during tissue development, organization, remodeling, and repair. The beta integrin subunit cytoplasmic domain is essential for transmission of many of these signals and overexpression of an impaired beta tail in cultured cells inhibits endogenous integrins. Unlike vertebrates, which have at least nine beta subunit genes, the nematode Caenorhabditis elegans expresses only one beta subunit (beta pat-3), and a null mutation in this gene causes embryonic lethality. To determine the functions of integrins during larval development and in adult tissues, we have taken a dominant negative approach by expression of an HA-beta tail transgene composed of a hemagglutinin (RA) epitope tag extracellular domain connected to the beta pat-3 transmembrane and cytoplasmic domains. Expression of this transgene in muscle and gonad, major sites of integrin expression, caused a variety of phenotypes dependent on the level of transgene expression. Abnormalities in body wall and sex muscles led to uncoordinated movement and egg-laying defects. Significant anomalies in migration and pathfinding were caused by tissue-specific expression of HA-beta tail in the distal tip cells (DTC), the cells that direct gonad morphogenesis. A pat-3 gene with Tyr to Phe mutations in the cytoplasmic domain was able to rescue pat-3 null animals but also showed DTC migration defects. These results show that beta pat-3 plays important roles in post-embryonic organogenesis and tissue function.	Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Schwarzbauer, JE (corresponding author), Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA.	jschwarzbauer@molbio.princeton.edu		Schwarzbauer, Jean/0000-0003-1012-7593; lee, myeongwoo/0000-0003-2652-3646				AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; Baum PD, 1997, NEURON, V19, P51, DOI 10.1016/S0896-6273(00)80347-5; Blelloch R, 1999, CURR OPIN CELL BIOL, V11, P608, DOI 10.1016/S0955-0674(99)00028-9; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; BRENNER S, 1974, GENETICS, V77, P71; BRIESEWITZ R, 1993, MOL BIOL CELL, V4, P593, DOI 10.1091/mbc.4.6.593; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Colavita A, 1998, SCIENCE, V281, P706, DOI 10.1126/science.281.5377.706; Faraldo MM, 1998, EMBO J, V17, P2139, DOI 10.1093/emboj/17.8.2139; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Fitzgerald MC, 1998, CURR BIOL, V8, P1285, DOI 10.1016/S0960-9822(07)00540-4; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; GETTNER SN, 1995, J CELL BIOL, V129, P1127, DOI 10.1083/jcb.129.4.1127; GETTNER SN, 1994, THESIS DEP NEUROBIOL, P152; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Graham PL, 1997, J CELL BIOL, V137, P1171, DOI 10.1083/jcb.137.5.1171; Gu T, 1998, MOL CELL BIOL, V18, P4556, DOI 10.1128/MCB.18.8.4556; Hobert O, 1999, J CELL BIOL, V144, P45, DOI 10.1083/jcb.144.1.45; HRESKO MC, 1994, J CELL BIOL, V124, P491, DOI 10.1083/jcb.124.4.491; Hutter H, 2000, SCIENCE, V287, P989, DOI 10.1126/science.287.5455.989; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; KRAMER JM, 1997, C ELEGANS, V2, P471; LaFlamme SE, 1997, MATRIX BIOL, V16, P153, DOI 10.1016/S0945-053X(97)90003-2; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; McCarter J, 1999, DEV BIOL, V205, P111, DOI 10.1006/dbio.1998.9109; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Moulder GL, 1996, MOL BIOL CELL, V7, P1181, DOI 10.1091/mbc.7.8.1181; Nishiwaki K, 2000, SCIENCE, V288, P2205, DOI 10.1126/science.288.5474.2205; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Riddle Donald L., 1997, Cold Spring Harbor Monograph Series, V33, P739; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; SCHEDL T, 1997, C ELEGANS, V2, P241; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARZBAUER JE, 1993, MOL BIOL CELL, V4, P941, DOI 10.1091/mbc.4.9.941; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; Stroeken PJM, 2000, ONCOGENE, V19, P1232, DOI 10.1038/sj.onc.1203423; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; TAPLEY P, 1989, ONCOGENE, V4, P325; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163	56	69	69	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36404	36410		10.1074/jbc.M105795200	http://dx.doi.org/10.1074/jbc.M105795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11473126	hybrid			2022-12-25	WOS:000171194500048
J	Sasaki, A; Taketomi, T; Wakioka, T; Kato, R; Yoshimura, A				Sasaki, A; Taketomi, T; Wakioka, T; Kato, R; Yoshimura, A			Identification of a dominant negative mutant of sprouty that potentiates fibroblast growth factor-but not epidermal growth factor-induced ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; PROTEIN-KINASE; DROSOPHILA-SPROUTY; FGF; PHOSPHATASE; DIFFERENTIATION; INHIBITION; ANTAGONIST; EXPRESSION; INDUCTION	Various mitogenic stimuli such as epidermal growth factor (EGF), fibroblast growth factor (FGF), and phorbol 12,13-dibutyrate (PDBu) activate the Ras-Raf-MEK-ERK pathway, but the regulatory mechanism of this pathway remains to be investigated. Here we found that in 293 cells, mammalian Sprouty2 and Sprouty4 were rapidly induced by EGF, FGF, and PDBu in an ERK pathway-dependent manner. Forced expression of Sprouty2 and Sprouty4 inhibited FGF-induced ERK activation but did not affect EGF- or PDBu-induced ERK activation. To examine whether endogenous Sproutys were also selective inhibitors, we generated a dominant negative form of Sprouty2 (Y55A) and Sprouty4 (Y53A) in which conserved tyrosine residues were mutated. These mutants reverted the suppressive effect of both Sprouty2 and Sprouty4 but not that of RasGAP or SPRED (Sprouty-related EVH1 domain-containing protein), another Sprouty-related Ras suppressor. Expression of dominant negative Sprouty2 and Sprouty4 enhanced and prolonged FGF- but not EGF-induced ERK activation in 293 cells. In PC12 cells, endogenous Sprouty4 was also induced by FGF. Overexpression of wild-type Sprouty4 blocked FGF-induced differentiation, whereas Y53A-Sprouty4 enhanced it. These observations suggest that endogenous Sprouty2 and Sprouty4 are physiological negative feedback regulators of growth factor-mediated ERK pathway and that there are Sprouty-sensitive and -insensitive ERK activation pathways. Finding a dominant negative form of Sproutys will facilitate the study of the molecular mechanism and physiological function of Sproutys.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Dent Sci, Div Oral & Maxilofacial Oncol, Higashi Ku, Fukuoka 8128582, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Kyushu University; Kyushu University; Kurume University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013	Sasaki, Atsuo/0000-0003-2963-4501				ALESSI DR, 1993, ONCOGENE, V8, P2015; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kramer S, 1999, DEVELOPMENT, V126, P2515; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Minowada G, 1999, DEVELOPMENT, V126, P4465; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Nutt SL, 2001, GENE DEV, V15, P1152, DOI 10.1101/gad.191301; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Reich A, 1999, DEVELOPMENT, V126, P4139; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	31	158	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36804	36808		10.1074/jbc.C100386200	http://dx.doi.org/10.1074/jbc.C100386200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11495895	hybrid			2022-12-25	WOS:000171194500099
J	Gautron, J; Hincke, MT; Mann, K; Panheleux, M; Bain, M; McKee, MD; Solomon, SE; Nys, Y				Gautron, J; Hincke, MT; Mann, K; Panheleux, M; Bain, M; McKee, MD; Solomon, SE; Nys, Y			Ovocalyxin-32, a novel chicken eggshell matrix protein - Isolation, amino acid sequencing, cloning, and immunocytochemical localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-SHELL FORMATION; AVIAN EGGSHELL; EXTRACELLULAR-MATRIX; SOLUBLE MATRIX; UTERINE FLUID; CARBOXYPEPTIDASE; MINERALIZATION; IDENTIFICATION; OVOCLEIDIN-17; PURIFICATION	The eggshell is a highly ordered structure resulting from the deposition of calcium carbonate concomitantly with an organic matrix upon the eggshell membranes. Mineralization takes place in an acellular uterine fluid, which contains the ionic and matrix precursors of the eggshell. We have identified a novel 32-kDa protein, ovocalyxin-32, which is expressed at high levels in the uterine and isthmus regions of the oviduct, and concentrated in the eggshell. Sequencing of peptides derived from the purified protein allowed expressed sequence tag sequences to be identified that were assembled to yield a full-length composite sequence whose conceptual translation product contained the complete amino acid sequence of ovocalyxin-32. Data base searches revealed that ovocalyxin-32 has limited identity (32%) to two unrelated proteins: latexin, a carboxypeptidase inhibitor expressed in the rat cerebral cortex and mast cells, and a skin protein, which is encoded by a retinoic acid receptor-responsive gene, TIG1. High level expression of ovocalyxin-32 was limited to the isthmus and uterus tissue, where immunocytochemistry at the light and electron microscope levels demonstrated that ovocalyxin-32 is secreted by surface epithelial cells. In the eggshell, ovocalyxin-32 localizes to the outer palisade layer, the vertical crystal layer, and the cuticle of the eggshell, in agreement with its demonstration by Western blotting at high levels in the uterine fluid during the termination phase of eggshell formation. Ovocalyxin-32 is therefore identified as a novel protein synthesized in the distal oviduct where hen eggshell formation occurs.	INRA, Rech Avicoles Stn, F-37380 Nouzilly, France; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Glasgow, Dept Vet Anat, Glasgow G61 1QH, Lanark, Scotland; McGill Univ, Fac Dent, Montreal, PQ H3A 2B2, Canada	INRAE; University of Ottawa; Max Planck Society; University of Glasgow; McGill University	Nys, Y (corresponding author), INRA, Rech Avicoles Stn, F-37380 Nouzilly, France.		McKee, Marc D/E-2187-2011; GAUTRON, Joël/A-1753-2017; Mann, Karlheinz/C-4254-2008	McKee, Marc D/0000-0001-8349-965X; GAUTRON, Joël/0000-0001-7800-0578; 				ADDADI L, 1992, ANGEW CHEM INT EDIT, V31, P153, DOI 10.1002/anie.199201531; ARIAS JL, 1992, ARCH BIOCHEM BIOPHYS, V298, P293, DOI 10.1016/0003-9861(92)90126-H; ARIAS JL, 1993, INT REV CYTOL, V145, P217, DOI 10.1016/S0074-7696(08)60428-3; ARIAS JL, 2000, P 21 WORLDS POULTR C; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carrino DA, 1997, CONNECT TISSUE RES, V36, P175, DOI 10.3109/03008209709160219; Dominguez-Vera JM, 2000, POULTRY SCI, V79, P901, DOI 10.1093/ps/79.6.901; DUVIC M, 1997, J AM ACAD DERMATOL, V37, P18; Fernandez MS, 1997, MATRIX BIOL, V16, P13, DOI 10.1016/S0945-053X(97)90112-8; Garcia-Ruiz J.M., 1994, B I OCEANOGRAPHIQUE, P85; Gautron J, 1996, BRIT POULTRY SCI, V37, P853, DOI 10.1080/00071669608417914; Gautron J, 1997, CONNECT TISSUE RES, V36, P195, DOI 10.3109/03008209709160220; GAUTRON J, 2001, IN PRESS CONNECT TIS; Hames B. D., 1981, GEL ELECTROPHORESIS; HATANAKA Y, 1994, EUR J NEUROSCI, V6, P973, DOI 10.1111/j.1460-9568.1994.tb00592.x; HINCKE MT, 1995, CALCIFIED TISSUE INT, V56, P578, DOI 10.1007/BF00298593; Hincke MT, 1999, J BIOL CHEM, V274, P32915, DOI 10.1074/jbc.274.46.32915; Hincke MT, 1995, CONNECT TISSUE RES, V31, P227, DOI 10.3109/03008209509010814; HINCKE MT, 1992, BRIT POULTRY SCI, V33, P505, DOI [10.1080/00071669208417489, NO_DOI]; Hincke MT, 2000, MATRIX BIOL, V19, P443, DOI 10.1016/S0945-053X(00)00095-0; *I NAT RECH AGR, 1989, AL AN MON PORC LAP; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lavelin I, 1998, MATRIX BIOL, V17, P615, DOI 10.1016/S0945-053X(98)90112-3; Mann K, 1999, BIOCHEM MOL BIOL INT, V47, P997; Mann K, 1999, FEBS LETT, V463, P12, DOI 10.1016/S0014-5793(99)01586-0; MCKEE MD, 1995, MICROSC RES TECHNIQ, V31, P44, DOI 10.1002/jemt.1070310105; Nagpal S, 1996, J INVEST DERMATOL, V106, P269, DOI 10.1111/1523-1747.ep12340668; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Normant E, 1995, P NATL ACAD SCI USA, V92, P12225, DOI 10.1073/pnas.92.26.12225; Nys Y, 1999, POULT AVIAN BIOL REV, V10, P143; Panheleux M, 1999, BRIT POULTRY SCI, V40, P240, DOI 10.1080/00071669987665; PARSONS AH, 1982, POULTRY SCI, V61, P2013, DOI 10.3382/ps.0612013; Pines M, 1995, MATRIX BIOL, V14, P765, DOI 10.1016/S0945-053X(05)80019-8; Sambrook J., 2002, MOL CLONING LAB MANU; SHARP RM, 1984, BIOPHYS J, V46, P175, DOI 10.1016/S0006-3495(84)84010-2; Solomon SE, 1991, EGG EGG QUALITY; TERMINE JD, 1984, METHODS CALCIFIED TI, P547; Tullet S. G., 1987, Egg quality - current problems and recent advances., P123; Uratani Y, 2000, BIOCHEM J, V346, P817, DOI 10.1042/0264-6021:3460817	39	119	130	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39243	39252		10.1074/jbc.M104543200	http://dx.doi.org/10.1074/jbc.M104543200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11493603	hybrid, Green Published			2022-12-25	WOS:000171673200120
J	Libeu, CP; Lund-Katz, S; Phillips, MC; Wehrli, S; Hernaiz, MJ; Capila, I; Linhardt, RJ; Raffai, RL; Newhouse, YM; Zhou, FY; Weisgraber, KH				Libeu, CP; Lund-Katz, S; Phillips, MC; Wehrli, S; Hernaiz, MJ; Capila, I; Linhardt, RJ; Raffai, RL; Newhouse, YM; Zhou, FY; Weisgraber, KH			New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; FIBROBLAST GROWTH-FACTOR; GLUCOSAMINYL N-DEACETYLASE; III HYPERLIPOPROTEINEMIA; CELL-SURFACE; ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; E ISOFORMS; TRANSPORT PROTEIN; DIABETIC RATS	Defective binding of apolipoprotein E (apoE) to heparan sulfate proteoglycans (HSPGs) is associated with increased risk of atherosclerosis due to inefficient clearance of lipoprotein remnants by the liver. The interaction of apoE with HSPGs has also been implicated in the pathogenesis of Alzheimer's disease and may play a role in neuronal repair. To identify which residues in the heparin-binding site of apoE and which structural elements of heparan sulfate interact, we used a variety of approaches, including glycosaminoglycan specificity assays, C-13 nuclear magnetic resonance, and heparin affinity chromatography. The formation of the high affinity complex required Arg-142, Lys-143, Arg-145, Lys-146, and Arg-147 from apoE and N- and 6-O-sulfo groups of the glucosamine units from the heparin fragment. As shown by molecular modeling, using a high affinity binding octasaccharide fragment of heparin, these findings are consistent with a binding mode in which five saccharide residues of fully sulfated heparan sulfate lie in a shallow groove of the a-helix that contains the HSPG-binding site (helix 4 of the four-helix bundle of the 22-kDa fragment). This groove is lined with residues Arg-136, Ser-139, His-140, Arg-142, Lys-143, Arg-145, Lys-146, and Arg-147. In the model, all of these residues make direct contact with either the 2-O-sulfo groups of the iduronic acid monosaccharides or the N- and 6-O-sulfo groups of the glucosamine sulfate monosaccharides. This model indicates that apoE has an HSPG-binding site highly complementary to heparan sulfate rich in N- and O-sulfo groups such as that found in the liver and the brain.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; Univ Iowa, Dept Chem, Iowa City, IA 52242 USA; Univ Iowa, Dept Med & Nat Prod Chem, Iowa City, IA 52242 USA; Univ Iowa, Dept Chem & Biochem Engn, Iowa City, IA 52242 USA; Texas A&M Univ, Dept Biochem & Biophys, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Iowa; University of Iowa; University of Iowa; Texas A&M University System	Weisgraber, KH (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.		Hernaiz, Maria J/H-5281-2015	Hernaiz, Maria J/0000-0003-3897-1104; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633, R01HL056083, R01HL052622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56083, HL52622, HL41633] Funding Source: Medline; NIGMS NIH HHS [GM38060] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Dong J, 2001, BIOCHEMISTRY-US, V40, P2826, DOI 10.1021/bi002417n; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; DONG LM, 1994, J BIOL CHEM, V269, P22358; Ebara T, 2000, J CLIN INVEST, V105, P1807, DOI 10.1172/JCI8283; Edward Conrad H, 1998, HEPARIN BINDING PROT, P7, DOI [10.1016/B978-012186060-8/50003-6, DOI 10.1016/B978-012186060-8/50003-6]; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; HOOK M, 1974, BIOCHEM J, V137, P33; HORIE Y, 1992, J BIOL CHEM, V267, P1962; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; JI ZS, 1994, J BIOL CHEM, V269, P13421; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; KJELLEN L, 1980, J BIOL CHEM, V255, P407; KJELLEN L, 1983, DIABETES, V32, P337, DOI 10.2337/diabetes.32.4.337; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; Lindahl B, 1999, J BIOL CHEM, V274, P30631, DOI 10.1074/jbc.274.43.30631; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; Lund-Katz S, 2000, J BIOL CHEM, V275, P34459, DOI 10.1074/jbc.M005265200; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Mahley R.W., 1998, WILLIAMS TXB ENDOCRI, P1099; Mahley RW, 1999, J LIPID RES, V40, P1933; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, J LIPID RES, V40, P1; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1997, MOL GENETIC BASIS NE, P1037; MAHLEY RW, 2001, METABOLIC MOL BASES, V2, P2835; MANN WA, 1995, J LIPID RES, V36, P517; Marz W, 1998, J LIPID RES, V39, P658; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILLERANDERSSON M, 1974, THROMB RES, V5, P439, DOI 10.1016/0049-3848(74)90001-2; MINNICH A, 1995, J LIPID RES, V36, P57; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; Murata K, 1997, ATHEROSCLEROSIS, V132, P9, DOI 10.1016/S0021-9150(97)00049-X; ORR GA, 1981, J BIOL CHEM, V256, P761; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; RALL SC, 1986, METHOD ENZYMOL, V128, P273; RIESENFELD J, 1980, J BIOL CHEM, V255, P922; Shuvaev VV, 1999, FEBS LETT, V459, P353, DOI 10.1016/S0014-5793(99)01285-5; Shuvaev VV, 2000, NEUROSCI LETT, V280, P131, DOI 10.1016/S0304-3940(00)00764-3; UNGER E, 1991, J BIOL CHEM, V266, P8671; Van Uden E, 2000, MICROSC RES TECHNIQ, V50, P268, DOI 10.1002/1097-0029(20000815)50:4<268::AID-JEMT3>3.0.CO;2-1; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253	58	72	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39138	39144		10.1074/jbc.M104746200	http://dx.doi.org/10.1074/jbc.M104746200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11500500	hybrid			2022-12-25	WOS:000171673200106
J	Miyagawa, S; Murakami, H; Takahagi, Y; Nakai, R; Yamada, M; Murase, A; Koyota, S; Koma, M; Matsunami, K; Fukuta, D; Fujimura, T; Shigehisa, T; Okabe, M; Nagashima, H; Shirakura, R; Taniguchi, N				Miyagawa, S; Murakami, H; Takahagi, Y; Nakai, R; Yamada, M; Murase, A; Koyota, S; Koma, M; Matsunami, K; Fukuta, D; Fujimura, T; Shigehisa, T; Okabe, M; Nagashima, H; Shirakura, R; Taniguchi, N			Remodeling of the major pig xenoantigen by N-acetylglucosaminyltransferase III in transgenic pig	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT REGULATORY PROTEINS; SWINE ENDOTHELIAL-CELLS; GAL EPITOPE EXPRESSION; DOWN-REGULATION; HUMAN ALPHA-1,2-FUCOSYL-TRANSFERASE; MEMBRANE-PROTEIN; CDNA CLONING; GENE; ERYTHROCYTES; PURIFICATION	We have been successful in generating several lines of transgenic mice and pigs that contain the human beta -D-mannoside beta -1,4-N-acetylglucosaminyltransferase III (GnT-III) gene. The overexpression of the GnT-III gene in mice and pigs reduced their antigenicity to human natural antibodies, especially the Gal alpha1-3Gal beta1-4Glc-NAc-R, as evidenced by immunohistochemical analysis. Endothelial cell studies from the GnT-III transgenic pigs also revealed a significant down-regulation in antigenicity, including Hanganutziu-Deicher antigen, and dramatic reductions in both the complement- and natural killer cell-mediated pig cell lyses. Changes in the enzymatic activities of other glycosyltransferases, such as alpha1,3-galactosyltransferase, GnT-IV, and GnT-V, did not support cross-talk between GnT-III and these enzymes in the transgenic animals. In addition, we demonstrated the effect of GnT-III in down-regulating the xenoantigen of pig heart grafts, using a pig to cynomolgus monkey transplantation model, suggesting that this approach may be useful in clinical xenotransplantation in the future.	Osaka Univ, Grad Sch Med, Dept Regenerat Med, Div Organ Transplantat, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka 5650871, Japan; Anim Engn Res Inst, Tsukuba, Ibaraki 3002646, Japan; Meiji Univ, Reprod Lab Engn, Kawasaki Ku, Yokohama, Kanagawa 2145871, Japan	Osaka University; Osaka University; Osaka University; Meiji University	Miyagawa, S (corresponding author), Osaka Univ, Grad Sch Med, Dept Regenerat Med, Div Organ Transplantat, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	miyagawa@orgtrp.med.osaka-u.ac.jp	Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016; Okabe, Masaru/B-6917-2015	Taniguchi, Naoyuki/0000-0001-5889-5968; Nagashima, Hiroshi/0000-0001-9940-8783; Okabe, Masaru/0000-0002-0803-9044				Artrip JH, 1999, J BIOL CHEM, V274, P10717, DOI 10.1074/jbc.274.16.10717; Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751; Costa C, 1999, FASEB J, V13, P1762, DOI 10.1096/fasebj.13.13.1762; Cowan PJ, 2000, TRANSPLANTATION, V69, P2504, DOI 10.1097/00007890-200006270-00008; EGGE H, 1985, J BIOL CHEM, V260, P4927; ETO T, 1968, J BIOCHEM, V64, P205, DOI 10.1093/oxfordjournals.jbchem.a128881; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; Galili U, 1998, TRANSPLANTATION, V65, P1129, DOI 10.1097/00007890-199804270-00020; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; Galili U, 2001, BIOCHIMIE, V83, P557, DOI 10.1016/S0300-9084(01)01294-9; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; Inverardi L, 1997, TRANSPLANTATION, V63, P1318, DOI 10.1097/00007890-199705150-00021; Irie A, 1998, J BIOL CHEM, V273, P15866, DOI 10.1074/jbc.273.25.15866; Koike C, 1996, XENOTRANSPLANTATION, V3, P81, DOI 10.1111/j.1399-3089.1996.tb00123.x; Koma M, 2000, GLYCOBIOLOGY, V10, P745, DOI 10.1093/glycob/10.7.745; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; Koyota S, 2001, J BIOL CHEM, V276, P32867, DOI 10.1074/jbc.M102371200; Lambrigts D, 1998, TRANSPLANTATION, V66, P547, DOI 10.1097/00007890-199809150-00001; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; MAYER MM, 1961, EXPT IMMUNOCHEMISTRY, V2, P133; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; Miyagawa S, 1999, BIOCHEM BIOPH RES CO, V264, P611, DOI 10.1006/bbrc.1999.1327; MIYAGAWA S, 1994, TRANSPLANTATION, V58, P834, DOI 10.1097/00007890-199410150-00015; MIYAGAWA S, 1988, TRANSPLANTATION, V46, P825, DOI 10.1097/00007890-198812000-00007; Miyagawa S, 1999, J BIOCHEM-TOKYO, V126, P1067, DOI 10.1093/oxfordjournals.jbchem.a022551; Morozumi K, 1999, TRANSPLANT P, V31, P942, DOI 10.1016/S0041-1345(98)01847-8; Murakami H, 2000, TRANSPLANT P, V32, P2505, DOI 10.1016/S0041-1345(00)01769-3; Murase A, 2000, TRANSPL P, V32, P2507, DOI 10.1016/S0041-1345(00)01770-X; NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; Osman N, 1997, P NATL ACAD SCI USA, V94, P14677, DOI 10.1073/pnas.94.26.14677; ROSENGARD AM, 1995, TRANSPLANTATION, V59, P1325, DOI 10.1097/00007890-199505150-00018; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1994, IMMUNOL REV, V141, P169, DOI 10.1111/j.1600-065X.1994.tb00877.x; SAWA Y, 1988, CIRCULATION, V78, P191; Sepp A, 1997, J BIOL CHEM, V272, P23104, DOI 10.1074/jbc.272.37.23104; SEYA T, 1986, J EXP MED, V163, P837, DOI 10.1084/jem.163.4.837; Sharma A, 1996, P NATL ACAD SCI USA, V93, P7190, DOI 10.1073/pnas.93.14.7190; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; Tanemura M, 1998, J BIOL CHEM, V273, P16421, DOI 10.1074/jbc.273.26.16421; Tanemura M, 1997, BIOCHEM BIOPH RES CO, V235, P359, DOI 10.1006/bbrc.1997.6784; Tanemura M, 2000, TRANSPLANTATION, V69, P187, DOI 10.1097/00007890-200001150-00034; Taniguchi N, 1996, GLYCOBIOLOGY, V6, P691, DOI 10.1093/glycob/6.7.691; UEMURA K, 1978, J BIOCHEM-TOKYO, V83, P463, DOI 10.1093/oxfordjournals.jbchem.a131933; YODOI J, 1985, J IMMUNOL, V134, P1623	56	83	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39310	39319		10.1074/jbc.M104359200	http://dx.doi.org/10.1074/jbc.M104359200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11486004	hybrid			2022-12-25	WOS:000171673200130
J	Roussel, A; Mathieu, M; Dobbs, A; Luu, B; Cambillau, C; Kellenberger, C				Roussel, A; Mathieu, M; Dobbs, A; Luu, B; Cambillau, C; Kellenberger, C			Complexation of two proteic insect inhibitors to the active site of chymotrypsin suggests decoupled roles for binding and selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUSTA-MIGRATORIA; SCHISTOCERCA-GREGARIA; DESERT LOCUST; ELASTASE; CRYSTAL; PEPTIDE; TRYPSIN; RESOLUTION; ELAFIN; DOMAIN	The crystal structures of two homologous inhibitors (PMP-C and PMP-D2v) from the insect Locusta migratoria have been determined in complex with bovine alpha -chymotrypsin at 2.1- and 3.0-Angstrom resolution, respectively. PMP-C is a potent bovine alpha -chymotrypsin inhibitor whereas native PMP-D2 is a weak inhibitor of bovine trypsin. One unique mutation at the P1 position converts PMP-D2 into a potent bovine alpha -chymotrypsin inhibitor. The two peptides have a similar overall conformation, which consists of a triple-stranded antiparallel beta -sheet connected by three disulfide bridges, thus defining a novel family of serine protease inhibitors. They have in common the protease interaction site, which is composed of the classical protease binding loop (position P5 to P'4, corresponding to residues 26-34) and of an internal segment (residues 15-18), held together by two disulfide bridges. Structural divergences between the two inhibitors result in an additional interaction site between PMP-D2v (position P10 to P6, residues 21-25) and the residues 172-175 of alpha -chymotrypsin. This unusual interaction may be responsible for species selectivity. A careful comparison of data on bound and free inhibitors (from this study and previous NMR studies, respectively) suggests that complexation to the protease stabilizes the flexible binding loop (from P5 to P'4).	CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; CNRS, UMR 7509, F-67084 Strasbourg, France; Univ Strasbourg 1, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Roussel, A (corresponding author), CNRS, UMR 6098, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.		kellenberger, christine/AAV-9304-2020					Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BOIGEGRAIN RA, 1992, BIOCHEM BIOPH RES CO, V189, P790, DOI 10.1016/0006-291X(92)92271-X; Botos I, 2000, J MOL BIOL, V298, P895, DOI 10.1006/jmbi.2000.3699; BRUNGER AT, 1996, XPLOR VERSION 3 843; EGUCHI M, 1993, COMP BIOCHEM PHYS B, V105, P449, DOI 10.1016/0305-0491(93)90073-E; Francart C, 1997, J MOL BIOL, V268, P666, DOI 10.1006/jmbi.1997.0983; FUJINAGA M, 1987, J MOL BIOL, V195, P397, DOI 10.1016/0022-2836(87)90659-0; Gillmor SA, 2000, J MOL BIOL, V299, P993, DOI 10.1006/jmbi.2000.3812; Hamdaoui A, 1998, FEBS LETT, V422, P74, DOI 10.1016/S0014-5793(97)01585-8; HUANG K, 1994, STRUCTURE, V2, P679, DOI 10.1016/S0969-2126(00)00068-X; KELLENBERGER C, 1995, J BIOL CHEM, V270, P25514, DOI 10.1074/jbc.270.43.25514; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lam W, 1999, INSECT BIOCHEM MOLEC, V29, P653, DOI 10.1016/S0965-1748(99)00049-1; Lam W, 2000, INSECT BIOCHEM MOLEC, V30, P85, DOI 10.1016/S0965-1748(99)00103-4; Laskowski M, 2000, BBA-PROTEIN STRUCT M, V1477, P324, DOI 10.1016/S0167-4838(99)00284-8; Liang ZC, 1997, P NATL ACAD SCI USA, V94, P6682, DOI 10.1073/pnas.94.13.6682; Malik Z, 1999, BBA-PROTEIN STRUCT M, V1434, P143, DOI 10.1016/S0167-4838(99)00167-3; MCGRATH ME, 1994, EMBO J, V13, P1502, DOI 10.1002/j.1460-2075.1994.tb06411.x; Mer G, 1996, J MOL BIOL, V258, P158, DOI 10.1006/jmbi.1996.0240; MER G, 1994, BIOCHEMISTRY-US, V33, P15397, DOI 10.1021/bi00255a021; NAKAKURA N, 1992, EUR J BIOCHEM, V204, P147, DOI 10.1111/j.1432-1033.1992.tb16617.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Scheidig AJ, 1997, PROTEIN SCI, V6, P1806, DOI 10.1002/pro.5560060902; Tsunemi M, 1996, BIOCHEMISTRY-US, V35, P11570, DOI 10.1021/bi960900l; VELLIEUX FMDAP, 1995, J APPL CRYSTALLOGR, V28, P347, DOI 10.1107/S0021889894012355	29	54	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38893	38898		10.1074/jbc.M105707200	http://dx.doi.org/10.1074/jbc.M105707200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495915	hybrid			2022-12-25	WOS:000171673200075
J	Yoshioka, A; Shirakawa, R; Nishioka, H; Tabuchi, A; Higashi, T; Ozaki, H; Yamamoto, A; Kita, T; Horiuchi, H				Yoshioka, A; Shirakawa, R; Nishioka, H; Tabuchi, A; Higashi, T; Ozaki, H; Yamamoto, A; Kita, T; Horiuchi, H			Identification of protein kinase C alpha as an essential, but not sufficient, cytosolic factor for Ca2+-induced alpha- and dense-core granule secretion in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL ADHESION MOLECULE; MEMBRANE-FUSION; CA2+-ACTIVATED SECRETION; ACTIVATION; PHOSPHORYLATION; EXOCYTOSIS; SYNTAXIN-4; RELEASE; CELLS; BRAIN	Upon activation, platelets release many active substances. Here, we have analyzed the mechanism governing Ca2+-induced secretion of von Willebrand factor stored in alpha -granules and 5-hydroxytryptamine in dense-core granules in permeabilized human platelets. Both secretions were dependent on ATP and cytosol. An essential factor for both granule secretions was purified from rat brain cytosol and identified to be protein kinase C alpha (PKC alpha) by partial amino acid sequencing. Purified PKC alpha efficiently stimulated both secretions in the presence of cytosol, whereas PKC alpha alone did not support the secretion of either type of granules, suggesting that PKC alpha is not a sufficient factor. Finally, in human platelet cytosol fractionated by a gel filtration column, the stimulatory activity for dense-core granule secretion paralleled with the concentration of PKC, suggesting that PKC could also be such a stimulatory factor in platelet cytosol. Thus, we identified PKC alpha as an essential, but not sufficient, cytosolic factor for the Ca2+-induced secretions of both alpha- and dense-core granules in platelets.	Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan; Kansai Med Univ, Dept Physiol, Moriguchi, Osaka 5708506, Japan	Kyoto University; Kansai Medical University	Horiuchi, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan.		Higashi, Tomohito/AHE-7942-2022	Higashi, Tomohito/0000-0001-5616-1477				Ann K, 1997, J BIOL CHEM, V272, P19637, DOI 10.1074/jbc.272.32.19637; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Avery J, 1999, ANNU REV PHYSIOL, V61, P777, DOI 10.1146/annurev.physiol.61.1.777; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; Edman P, 1970, Mol Biol Biochem Biophys, V8, P211; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; GERRARD JM, 1989, BLOOD, V74, P2405; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HASLAM RJ, 1984, FEBS LETT, V174, P90, DOI 10.1016/0014-5793(84)81084-4; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KNIGHT DE, 1982, NATURE, V296, P256, DOI 10.1038/296256a0; KNIGHT DE, 1980, THROMB RES, V20, P437, DOI 10.1016/0049-3848(80)90282-0; Li L, 2001, J BIOL CHEM, V276, P5265, DOI 10.1074/jbc.M003883200; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; Orita S, 1997, J BIOL CHEM, V272, P16081, DOI 10.1074/jbc.272.26.16081; Ozaki H, 2000, BIOCHEM BIOPH RES CO, V276, P873, DOI 10.1006/bbrc.2000.3574; Ozaki H, 1999, J IMMUNOL, V163, P553; PLOW EF, 2000, HEMATOLOGY BASIC PRI, P1741; Polgar J, 1999, BLOOD, V94, P1313, DOI 10.1182/blood.V94.4.1313.416k27_1313_1318; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; SIESS W, 1988, BIOCHEM J, V255, P309; SILVERSTEIN RL, 1992, BLOOD, V80, P1470; Sloan DC, 1997, BIOCHEM J, V328, P13; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9	47	43	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39379	39385		10.1074/jbc.M102933200	http://dx.doi.org/10.1074/jbc.M102933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495897	Green Submitted, hybrid			2022-12-25	WOS:000171673200137
J	Matern, H; Boermans, H; Lottspeich, F; Matern, S				Matern, H; Boermans, H; Lottspeich, F; Matern, S			Molecular cloning and expression of human bile acid beta-glucosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER; PURIFICATION; PROTEIN; ENZYME	A novel microsomal beta -glucosidase was recently purified and characterized from human liver that catalyzes the hydrolysis of bile acid 3-O-glucosides as endogenous compounds. The primary structure of this bile acid beta -glucosidase was deduced by cDNA cloning on the basis of the amino acid sequences of peptides obtained from the purified enzyme by proteinase digestion. The isolated cDNA comprises 3639 base pairs containing 524 nucleotides of W-untranslated and 334 nucleotides of W-untranslated sequences including the poly(A) tail. The open reading frame predicts a 927-amino acid protein with a calculated M-r of 104,648 containing one putative transmembrane domain. Data base searches revealed no homology with any known glycosyl hydrolase or other functionally identified protein. The cDNA sequence was found with significant identity in the human chromosome 9 clone RP11-112J3 of the human genome project. The recombinant enzyme was expressed in a tagged form in COS-7 cells where it displayed bile acid beta -glucosidase activity. Northern blot analysis of various human tissues revealed high levels of expression of the bile acid beta -glucosidase mRNA (3.6-kilobase message) in brain, heart, skeletal muscle, kidney, and placenta and lower levels of expression in the liver and other organs.	Rhein Westfal TH Aachen, Dept Internal Med 3, D-52057 Aachen, Germany; Genzentrum Martinsried, D-82152 Martinsried, Germany	RWTH Aachen University	Matern, H (corresponding author), Rhein Westfal TH Aachen, Med Klin 3, Pauwelsstr 30, D-52057 Aachen, Germany.							Bieberich E, 1997, EUR J BIOCHEM, V246, P681, DOI 10.1111/j.1432-1033.1997.t01-1-00681.x; BJERRUM OJ, 1988, HDB IMMUNOBLOTTING P, V1, P227; DANIELS LB, 1981, J BIOL CHEM, V256, P3004; DINUR T, 1986, P NATL ACAD SCI USA, V83, P1660, DOI 10.1073/pnas.83.6.1660; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MARSCHALL HU, 1987, FEBS LETT, V213, P411, DOI 10.1016/0014-5793(87)81532-6; MATERN H, 1992, FEBS LETT, V314, P183, DOI 10.1016/0014-5793(92)80970-R; Matern H, 1997, J BIOL CHEM, V272, P11261; MATERN H, 1984, P NATL ACAD SCI-BIOL, V81, P7036, DOI 10.1073/pnas.81.22.7036; Nagase T, 2000, DNA RES, V7, P273; PENTCHEV PG, 1973, J BIOL CHEM, V248, P5256; Sambrook J., 2002, MOL CLONING LAB MANU; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; TUKEY RH, 1979, BIOCHEM J, V179, P59, DOI 10.1042/bj1790059	17	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37929	37933						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11489889				2022-12-25	WOS:000171526500030
J	Oriente, F; Formisano, P; Miele, C; Fiory, F; Maitan, MA; Vigliotta, G; Trencia, A; Santopietro, S; Caruso, M; Van Obberghen, E; Beguinot, F				Oriente, F; Formisano, P; Miele, C; Fiory, F; Maitan, MA; Vigliotta, G; Trencia, A; Santopietro, S; Caruso, M; Van Obberghen, E; Beguinot, F			Insulin receptor substrate-2 phosphorylation is necessary for protein kinase C zeta activation by insulin in L6hIR cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; RAT SKELETAL-MUSCLE; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; POTENTIAL ROLE; INHIBITION; IRS-1; ASSOCIATION	We have investigated glycogen synthase (GS) activation in L6hIR cells expressing a peptide corresponding to the kinase regulatory loop binding domain of insulin receptor substrate-2 (IRS-2) (KRLB). In several clones of these cells (B2, F4), insulin-dependent binding of the KRLB to insulin receptors was accompanied by a block of IRS-2, but not IRS-1, phosphorylation, and insulin receptor binding. GS activation by insulin was also inhibited by >70% in these cells (p < 0.001). The impairment of GS activation was paralleled by a similarly sized inhibition of glycogen synthase kinase 3<alpha> (GSK3 alpha) and GSK3 beta inactivation by insulin with no change in protein phosphatase I activity. PDK1 (a phosphatidylinositol. trisphosphate-dependent kinase) and Akt/protein kinase B (PKB) activation by insulin showed no difference in B2, F4, and in control L6hIR cells. At variance, insulin did not activate PKC zeta in B2 and F4 cells. In L6hIR, inhibition of PKC zeta activity by either a PKC zeta antisense or a dominant negative mutant also reduced by 75% insulin inactivation of GSK3 alpha and -beta (p < 0.001) and insulin stimulation of GS (p < 0.002), similar to A-kt/PKB inhibition. In L6hIR, insulin induced protein kinase C zeta (PKC zeta) co-precipitation with GSK3 alpha and beta. PKC zeta also phosphorylated GSK3 alpha and -beta. Alone, these events did not significantly affect GSK3 alpha and -beta activities. Inhibition of PKC activity, however, reduced Akt/PKB phosphorylation of the key serine sites on GSK3 alpha and -beta by >80% (p < 0.001) and prevented full GSK3 inactivation by insulin. Thus, IRS-2, not IRS-1, signals insulin activation of GS in the L6hIR skeletal muscle cells. In these cells, insulin inhibition of GSK3<alpha> and -beta requires dual phosphorylation by both Akt/PKB and PKC zeta.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, Consiglio Natl Ric, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; INSERM, U145, IFR 50, F-06107 Nice, France	University of Naples Federico II; University of Naples Federico II; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Beguinot, F (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.		vigliotta, giovanni/AAW-6401-2020; Formisano, Pietro/J-4237-2018; Vigliotta, Giovanni/GPF-7237-2022; ORIENTE, Francesco/J-6652-2018	vigliotta, giovanni/0000-0001-5132-0037; ORIENTE, Francesco/0000-0003-4375-4526; Formisano, Pietro/0000-0001-7020-6870	Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Caruso M, 1997, J BIOL CHEM, V272, P7290, DOI 10.1074/jbc.272.11.7290; Caruso M, 2000, DIABETES, V49, P1194, DOI 10.2337/diabetes.49.7.1194; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V37, P785; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; GOMEZ J, 1995, EUR J IMMUNOL, V25, P2673, DOI 10.1002/eji.1830250941; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Lavoie L, 1999, J BIOL CHEM, V274, P28279, DOI 10.1074/jbc.274.40.28279; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Liu J, 2000, J BIOL CHEM, V275, P15940, DOI 10.1074/jbc.M909303199; Markuns JF, 1999, J BIOL CHEM, V274, P24896, DOI 10.1074/jbc.274.35.24896; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Miele C, 1999, J BIOL CHEM, V274, P3094, DOI 10.1074/jbc.274.5.3094; Miranda C, 2001, J CELL PHYSIOL, V186, P35; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Smith U, 2000, BIOCHEM BIOPH RES CO, V268, P315, DOI 10.1006/bbrc.2000.2145; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Tsujio I, 2000, FEBS LETT, V469, P111, DOI 10.1016/S0014-5793(00)01234-5; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Whitehead JP, 2000, BIOCHEM J, V349, P775, DOI 10.1042/bj3490775; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Xu JH, 1996, J CELL BIOL, V134, P1301, DOI 10.1083/jcb.134.5.1301; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	45	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37109	37119		10.1074/jbc.M104405200	http://dx.doi.org/10.1074/jbc.M104405200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11481324	hybrid			2022-12-25	WOS:000171375700034
J	Banks, GC; Deterding, LJ; Tomer, KB; Archer, TK				Banks, GC; Deterding, LJ; Tomer, KB; Archer, TK			Hormone-mediated dephosphorylation of specific histone H1 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; TRANSCRIPTION IN-VIVO; TUMOR VIRUS PROMOTER; GENE-EXPRESSION; CHROMATIN STRUCTURE; LINKER HISTONES; CELL-CYCLE; CHROMOSOME CONDENSATION; POSITIONED NUCLEOSOMES; GLOBULAR DOMAIN	We have previously shown a connection between histone H1 phosphorylation and the transcriptional competence of the hormone inducible mouse mammary tumor virus (MMTV) promoter. Prolonged exposure of mouse cells to dexamethasone concurrently dephosphorylated histone H1 and rendered the MMTV promoter refractory to hormonal stimulation and, therefore, transcriptionally unresponsive. Using electrospray mass spectrometry, we demonstrate here that prolonged dexamethasone treatment differentially effects a subset of the six somatic H1 isoforms in mouse cells. H1 isoforms H1.0, H1.1, and H1.2 are non-responsive to hormone whereas prolonged dexamethasone treatment effectively dephosphorylated the H1.3, H1.4, and H1.5 isoforms. The protein kinase inhibitor staurosporine, shown to dephosphorylate historic H1 and down-regulate MMTV in cultured cells, appears only to completely dephosphorylate the H1.3 isoform. These results suggest that dephosphorylation of specific histone H1 isoforms may contribute to the previously observed decrease in transcriptional competence of the MMTV promoter through the modulation of chromatin structure. In a broader sense, this work advances the hypothesis that post-translational modifications of individual histone H1 isoforms directly influence the transcriptional activation/repression of specific genes.	NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Archer, TK (corresponding author), NIEHS, Reprod & Dev Toxicol Lab, NIH, MD E4-06, Res Triangle Pk, NC 27709 USA.		Tomer, Kenneth B/E-8018-2013; Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES071006, Z01ES050171, ZIAES050171, Z01ES050127, Z01ES071006, ZIAES050127] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBIG W, 1991, GENOMICS, V10, P940, DOI 10.1016/0888-7543(91)90183-F; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; Bhattacharjee RN, 2001, MOL CELL BIOL, V21, P5417, DOI 10.1128/MCB.21.16.5417-5425.2001; Borchers C, 1999, J CHROMATOGR A, V854, P119, DOI 10.1016/S0021-9673(99)00479-3; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Brown DT, 1996, NUCLEIC ACIDS RES, V24, P486, DOI 10.1093/nar/24.3.486; Chadee DN, 1997, J BIOL CHEM, V272, P8113, DOI 10.1074/jbc.272.13.8113; Crane-Robinson C, 1999, BIOESSAYS, V21, P367, DOI 10.1002/(SICI)1521-1878(199905)21:5<367::AID-BIES2>3.0.CO;2-4; DETERDING LJ, 1989, ANAL CHEM, V61, P2504, DOI 10.1021/ac00197a011; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; GIANCOTTI V, 1993, EUR J BIOCHEM, V213, P825, DOI 10.1111/j.1432-1033.1993.tb17825.x; Gunjan A, 1999, NUCLEIC ACIDS RES, V27, P3355, DOI 10.1093/nar/27.16.3355; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; HAGER GL, 1993, COLD SPRING HARB SYM, V58, P63, DOI 10.1101/SQB.1993.058.01.010; Hayes JJ, 1996, BIOCHEMISTRY-US, V35, P11931, DOI 10.1021/bi961590+; Howe L, 1998, BIOCHEMISTRY-US, V37, P7077, DOI 10.1021/bi980410o; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; LENNOX RW, 1982, J BIOL CHEM, V257, P5183; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; LU MJ, 1994, CHROMOSOMA, V103, P111; LU MJ, 1995, MOL BIOL CELL, V6, P1077, DOI 10.1091/mbc.6.8.1077; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; PARSEGHIAN MH, 1994, CHROMOSOMA, V103, P198, DOI 10.1007/BF00368013; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; Ramakrishnan V, 1997, CRIT REV EUKAR GENE, V7, P215, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.20; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Sera T, 1998, MOL CELL BIOL, V18, P3668, DOI 10.1128/MCB.18.7.3668; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Talasz H, 1996, BIOCHEMISTRY-US, V35, P1761, DOI 10.1021/bi951914e; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; van Holde K.E., 1988, CHROMATIN; Vermaak D, 1998, CURR BIOL, V8, P533, DOI 10.1016/S0960-9822(98)70206-4; Wolffe AP, 1998, PROG NUCLEIC ACID RE, V61, P379, DOI 10.1016/S0079-6603(08)60832-6; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Zlatanova J, 2000, FASEB J, V14, P1697, DOI 10.1096/fj.99-0869rev; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X; Zlatanova J, 1999, CRIT REV EUKAR GENE, V9, P245, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.90	44	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36467	36473		10.1074/jbc.M104641200	http://dx.doi.org/10.1074/jbc.M104641200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11479299	hybrid			2022-12-25	WOS:000171194500057
J	Arico, S; Petiot, A; Bauvy, C; Dubbelhuis, PF; Meijer, AJ; Codogno, P; Ogier-Denis, E				Arico, S; Petiot, A; Bauvy, C; Dubbelhuis, PF; Meijer, AJ; Codogno, P; Ogier-Denis, E			The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLS AUTOPHAGIC SEQUESTRATION; CELL-DEATH; GENETIC PATHWAYS; PROTEIN; PTEN/MMAC1; PHOSPHORYLATION; PROTEOLYSIS; BREAST; TOR; S6	The tumor suppressor PTEN is a dual protein and phosphoinositide phosphatase that negatively controls the phosphatidylinositol (PI) 3-kinase/protein kinase B (Akt/PKB) signaling pathway. Interleukin-13 via the activation of the class I PI 3-kinase has been shown to inhibit the macroautophagic pathway in the human colon cancer HT-29 cells. Here we demonstrate that the wild-type PTEN is expressed in this cell line. Its overexpression directed by an inducible promoter counteracts the interleukin-13 down-regulation of macroautophagy. This effect was dependent upon the phosphoinositide phosphatase activity of PTEN as determined by using the mutant G129E, which has only protein phosphatase activity. The role of Akt/PKB in the signaling control of interleukin-13-dependent macroautophagy was investigated by expressing a constitutively active form of the kinase ((PKB)-P-Myr). Under these conditions a dramatic inhibition of macroautophagy was observed. By contrast a high rate of autophagy was observed in cells expressing a dominant negative form of PKB. These data demonstrate that the signaling control of macroautophagy overlaps with the well known PI 3-kinase/PKB survival pathway and that the loss of PTEN function in cancer cells inhibits a major catabolic pathway.	INSERM, U504, F-94807 Villejuif, France; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Amsterdam; Academic Medical Center Amsterdam	Codogno, P (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	codogno@vjf.inserm.fr	Ogier-Denis, Eric/E-5030-2016; Codogno, Patrice/G-1384-2013	Codogno, Patrice/0000-0002-5492-3180; Ogier-Denis, Eric/0000-0002-0057-7593; PETIOT, Anne/0000-0001-8038-470X				Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Codogno P, 1997, CELL SIGNAL, V9, P125, DOI 10.1016/S0898-6568(96)00130-1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Gimm O, 2000, HUM MOL GENET, V9, P1633, DOI 10.1093/hmg/9.11.1633; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Lee CY, 2001, DEVELOPMENT, V128, P1443; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang XD, 2000, J IMMUNOL, V164, P1934, DOI 10.4049/jimmunol.164.4.1934; Wang ZJ, 1998, AM J PATHOL, V153, P363, DOI 10.1016/S0002-9440(10)65579-4; Weng LP, 1999, CANCER RES, V59, P5808; Wright K, 1999, J BIOL CHEM, V274, P17193, DOI 10.1074/jbc.274.24.17193; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; ZAKERI Z, 1995, CELL DEATH DIFFER, V2, P87	43	473	505	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35243	35246		10.1074/jbc.C100319200	http://dx.doi.org/10.1074/jbc.C100319200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11477064	hybrid			2022-12-25	WOS:000171109300006
J	Zhang, LJ; Rozek, A; Hancock, REW				Zhang, LJ; Rozek, A; Hancock, REW			Interaction of cationic antimicrobial peptides with model membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; ESCHERICHIA-COLI; ANTIBIOTICS; MECHANISM; ANTIBACTERIAL; TRANSLOCATION; MAGAININ-2; MONOLAYERS; DEFENSINS; BILAYERS	A series of natural and synthetic cationic antimicrobial peptides from various structural classes, including a-helical, beta -sheet, extended, and cyclic, were examined for their ability to interact with model membranes, assessing penetration of phospholipid monolayers and induction of lipid flip-flop, membrane leakiness, and peptide translocation across the bilayer of large unilamellar liposomes, at a range of peptide/lipid ratios. All peptides were able to penetrate into monolayers made with negatively charged phospholipids, but only two interacted weakly with neutral lipids. Peptide-mediated lipid flipflop generally occurred at peptide concentrations that were 3- to 5-fold lower than those causing leakage of calcein across the membrane, regardless of peptide structure. With the exception of two alpha -helical peptides V681(n) and V25(p), the extent of peptide-induced calcein release from large unilamellar liposomes was generally low at peptide/lipid molar ratios below 1:50. Peptide translocation across bilayers was found to be higher for the beta -sheet peptide polyphemusin, intermediate for alpha -helical peptides, and low for extended peptides. Overall, whereas all studied cationic antimicrobial peptides interacted with membranes, they were quite heterogeneous in their impact on these membranes.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Hancock, REW (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503				Bechinger B, 1998, BIOPHYS J, V74, P981, DOI 10.1016/S0006-3495(98)74021-4; BECHINGER B, 1993, PROTEIN SCI, V2, P2077, DOI 10.1002/pro.5560021208; Boman HG, 1996, SCAND J IMMUNOL, V43, P475, DOI 10.1046/j.1365-3083.1996.d01-76.x; CAFISO DS, 1994, ANNU REV BIOPH BIOM, V23, P141, DOI 10.1146/annurev.bb.23.060194.001041; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; Friedrich CL, 2000, ANTIMICROB AGENTS CH, V44, P2086, DOI 10.1128/AAC.44.8.2086-2092.2000; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hancock REW, 1999, ANTIMICROB AGENTS CH, V43, P1317, DOI 10.1128/AAC.43.6.1317; Hancock REW, 1999, DRUGS, V57, P469, DOI 10.2165/00003495-199957040-00002; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Hancock REW, 2000, EXPERT OPIN INV DRUG, V9, P1723, DOI 10.1517/13543784.9.8.1723; Hristova K, 1997, J BIOL CHEM, V272, P24224, DOI 10.1074/jbc.272.39.24224; Kobayashi S, 2000, BIOCHEMISTRY-US, V39, P8648, DOI 10.1021/bi0004549; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; MATSUZAKI K, 1994, BIOCHEMISTRY-US, V33, P3342, DOI 10.1021/bi00177a027; MATSUZAKI K, 1993, BIOCHEMISTRY-US, V32, P11704, DOI 10.1021/bi00094a029; MAYER LD, 1983, BIOCHEMISTRY-US, V22, P316, DOI 10.1021/bi00271a013; MIDGLEY M, 1986, J GEN MICROBIOL, V132, P3187; Oishi O, 1997, BIOCHEMISTRY-US, V36, P4352, DOI 10.1021/bi962171f; PACHE W, 1972, BIOCHIM BIOPHYS ACTA, V255, P358, DOI 10.1016/0005-2736(72)90034-X; Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159; Rozek A, 2000, BIOCHEMISTRY-US, V39, P15765, DOI 10.1021/bi000714m; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6; Wimley WC, 2000, BIOCHEMISTRY-US, V39, P161, DOI 10.1021/bi991836l; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299; Yang L, 2000, BIOPHYS J, V79, P2002, DOI 10.1016/S0006-3495(00)76448-4; Zhang LJ, 2000, BIOCHEMISTRY-US, V39, P14504, DOI 10.1021/bi0011173; Zhang LJ, 1999, BIOCHEMISTRY-US, V38, P8102, DOI 10.1021/bi9904104; Zhang LJ, 2000, ANTIMICROB AGENTS CH, V44, P3317, DOI 10.1128/AAC.44.12.3317-3321.2000	35	318	335	4	58	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35714	35722		10.1074/jbc.M104925200	http://dx.doi.org/10.1074/jbc.M104925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11473117	hybrid			2022-12-25	WOS:000171109300068
J	Low, W; Olmos-Centenera, G; Madsen, C; Leverrier, Y; Collins, M				Low, W; Olmos-Centenera, G; Madsen, C; Leverrier, Y; Collins, M			Role of Bax in apoptosis of IL-3-dependent cells	ONCOGENE			English	Article						apoptosis; IL-3; Bax	COLONY-STIMULATING FACTOR; ACTIVATED PROTEIN-KINASE; COMMON BETA-SUBUNIT; CYTOCHROME-C; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC MALIGNANCIES; INTERLEUKIN-3 STIMULATION; CONFORMATIONAL-CHANGE; SIGNAL-TRANSDUCTION; FACTOR DEPRIVATION	IL-3 removal was reported to induce membrane association of the apoptotic effector Bax. This report demonstrates that IL-3-dependent cells from Bax-null mice failed to activate caspases after IL-3 removal and survived in an 10-fold lower concentration of IL-3. As IL-3 removal also down-regulates expression of Bcl-X, we examined the relationship between Bcl-X decrease and Bax membrane association. IL-3 removal from BAF-3 cells, followed by sorting caspase-active and caspase-inactive populations, showed that both expressed similar levels of Bcl-X. Inhibition of IL-3 signalling via PI-3 kinase and MEK1/2 resulted in cells with minimal Bcl-X, which remained viable with soluble Bax. However BAF-3-derived cells, which maintained Bcl-X expression without IL-3, also remained viable with soluble Bax on IL-3 removal. Therefore a decrease in Bcl-X is necessary, though not sufficient, for Bax membrane association on IL-3 removal. In contrast, treatment of BAF-3 cells with hydroxyurea induced apoptosis in the absence of a Bcl-X decrease. Furthermore, IL-3-dependent cells from Bax-null mice activated caspases after hydroxyurea treatment and show the same sensitivity to a variety of cytotoxic drugs. Thus, apoptosis after IL-3 removal requires a decrease in Bcl-X and Bax membrane association, whereas that induced by cytotoxic drugs does not.	UCL, Dept Immunol & Mol Pathol, Windeyer Inst Med Sci, London W1P 6DB, England; Ecole Normale Super Lyon, CNRS,INRA, UMR 49, Biol Cellulaire & Mol Lab, F-69364 Lyon 07, France	University of London; University College London; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE	Collins, M (corresponding author), UCL, Dept Immunol & Mol Pathol, Windeyer Inst Med Sci, 46 Cleveland St, London W1P 6DB, England.	mary.collins@ucl.ac.uk	LEVERRIER, Yann/M-3767-2014	LEVERRIER, Yann/0000-0002-4227-5446; Olmos Centenera, Gemma/0000-0003-4835-0846				Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Furlong IJ, 1997, J CELL SCI, V110, P653; GonzalezGarcia A, 1997, J BIOL CHEM, V272, P10220; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hara T, 1996, STEM CELLS, V14, P605, DOI 10.1002/stem.140605; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; JUCKER M, 1995, J BIOL CHEM, V270, P27817; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Maurer M, 2000, J INVEST DERMATOL, V114, P1205, DOI 10.1046/j.1523-1747.2000.00005.x; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Mizuguchi R, 1998, J BIOL CHEM, V273, P32297, DOI 10.1074/jbc.273.48.32297; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Oliver FJ, 1997, J BIOL CHEM, V272, P10624; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Palacios C, 2000, ONCOGENE, V19, P3556, DOI 10.1038/sj.onc.1203683; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; Sanz C, 2000, BLOOD, V95, P2742, DOI 10.1182/blood.V95.9.2742.009k24_2742_2747; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; Thomas J, 1998, ONCOGENE, V16, P1399, DOI 10.1038/sj.onc.1201672; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	59	4	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4476	4483		10.1038/sj.onc.1204580	http://dx.doi.org/10.1038/sj.onc.1204580			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494143				2022-12-25	WOS:000170074900005
J	Stanford, SJ; Pepper, JR; Burke-Gaffney, A; Mitchell, JA				Stanford, SJ; Pepper, JR; Burke-Gaffney, A; Mitchell, JA			Cytokine-activated human vascular smooth muscle delays apoptosis of neutrophils: Relevance of interactions between cyclo-oxygenase-2 and colony stimulating factors	FASEB JOURNAL			English	Article						colony-stimulating factors; cyclo-oxygenase; vascular smooth muscle cells; neutrophils; apoptosis	GRANULOCYTE-MACROPHAGE-CSF; GM-CSF; ENDOTHELIAL-CELLS; HUMAN ARTERIAL; INTERLEUKIN-1; SURVIVAL; CYCLOOXYGENASE-2; FIBROBLASTS; MODULATION; EXPRESSION	Leukocytes undergo programmed cell death (apoptosis) as part of the normal course of inflammatory responses. The colony stimulating factors (CSF) are important inhibitors of neutrophil apoptosis. We have recently shown that cytokines stimulate human vascular smooth muscle cells (HVSMCs) to release granulocyte macophage-CSF (GM-CSF) and granulocyte-CSF (G-CSF)-like immunoreactivity, and that the inflammatory form of cyclo-oxygenase (COX-2) differentially modulates their release. However, the biological relevance of these observations is not known. here we have measured human neutrophil apoptosis as a bioassay for the activity of authentic GM-CSF and G-CSF, as well as products released by cytokine-stimulated HVSMCs. Furthermore, we have assessed the biological relevance of COX-2 in the production of survival-promoting factors by HVSMCs. We demonstrate that (i) GM-CSF is more potent than G-CSF as an inhibitor of neutrophil apoptosis; (ii) of the two CSF's, the activity of G-CSF released by HVSMCs predominates when cells are stimulated with cytokines; and (iii), this situation is reversed when COX activity is blocked such that GM-CSF becomes the predominant active CSF produced by cells. These observations identify HVSMCs as important modulators of inflammatory and immune responses and identify a setting where COX-2 activity regulated neutrophil survival indirectly via the production of CSFs.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Royal Brompton & Harefield NHS Trust, Crit Care Unit, London SW3 6NP, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Royal Brompton & Harefield NHS Trust, Dept Cardiothorac Surg, London SW3 6NP, England	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital	Mitchell, JA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Royal Brompton & Harefield NHS Trust, Crit Care Unit, Sydney St, London SW3 6NP, England.	j.a.mitchell@ic.ac.uk	Mitchell, Jane A/A-1991-2009					Bishop-Bailey D, 1998, ARTERIOSCL THROM VAS, V18, P1655, DOI 10.1161/01.ATV.18.10.1655; BRACH MA, 1992, BLOOD, V80, P2920; BROUDY VC, 1987, J IMMUNOL, V139, P464; BurkeGaffney A, 1996, AM J PHYSIOL-CELL PH, V270, pC552, DOI 10.1152/ajpcell.1996.270.2.C552; COLOTTA F, 1992, BLOOD, V80, P2012; COX G, 1992, AM J RESP CELL MOL, V7, P507, DOI 10.1165/ajrcmb/7.5.507; Coxon A, 1999, J EXP MED, V190, P923, DOI 10.1084/jem.190.7.923; Daffern PJ, 1999, AM J RESP CELL MOL, V21, P259, DOI 10.1165/ajrcmb.21.2.3605; FIBBE WE, 1988, BLOOD, V72, P860; FLIEDNER TM, 1964, BLOOD, V24, P402, DOI 10.1182/blood.V24.4.402.402; Fortenberry JD, 1998, AM J RESP CELL MOL, V18, P421, DOI 10.1165/ajrcmb.18.3.2875; Hallsworth MP, 1998, AM J RESP CELL MOL, V19, P910, DOI 10.1165/ajrcmb.19.6.3275; HAMILTON JA, 1992, BLOOD, V79, P1413; HASLETT C, 1985, AM J PATHOL, V119, P101; Ina K, 1999, J GASTROEN HEPATOL, V14, P46, DOI 10.1046/j.1440-1746.1999.01807.x; KAWAKAMI M, 1990, BLOOD, V76, P1962; LEE MT, 1990, J LEUKOCYTE BIOL, V47, P275, DOI 10.1002/jlb.47.3.275; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MAUER AM, 1960, J CLIN INVEST, V39, P1481, DOI 10.1172/JCI104167; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Stanford SJ, 2000, ARTERIOSCL THROM VAS, V20, P677, DOI 10.1161/01.ATV.20.3.677; Stanford SJ, 2000, BRIT J PHARMACOL, V129, P835, DOI 10.1038/sj.bjp.0703151; ZSEBO KM, 1988, BLOOD, V71, P99	23	13	13	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1813	+		10.1096/fj.00-0670fje	http://dx.doi.org/10.1096/fj.00-0670fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481239				2022-12-25	WOS:000169261200021
J	Miyazaki, Y; Boccuni, P; Mao, SF; Zhang, J; Erdjument-Bromage, H; Tempst, P; Kiyokawa, H; Nimer, SD				Miyazaki, Y; Boccuni, P; Mao, SF; Zhang, J; Erdjument-Bromage, H; Tempst, P; Kiyokawa, H; Nimer, SD			Cyclin A-dependent phosphorylation of the ETS-related protein, MEF, restricts its activity to the G(1) phase of the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EWINGS-SARCOMA TRANSLOCATION; TRANSCRIPTION FACTOR PU.1; DNA-BINDING DOMAIN; RETINOBLASTOMA PROTEIN; B-MYB; POTENTIAL MEDIATOR; GENE-EXPRESSION; HUMAN P53; EWS GENE; KINASE	MEF, a recently identified member of the E74 family of ETS-related transcription factors, is a strong transcriptional activator of cytokine gene expression. Using a green fluorescent protein gene reporter plasmid regulated by an MEF-responsive promoter, we determined that the transcriptional activity of MEF is largely restricted to the G(1) phase of the cell cycle. MEF-dependent transcription was suppressed by the expression of cyclin A but not by cyclin D or cyclin E. This effect was due to the kinase activity generated by cyclin A expression, as co-expression of the cyclin-dependent kinase inhibitors p21 or p27, or a dominant negative form of CDK2 (DNK2), abrogated the reduction of MEF transcriptional activity by cyclin A. Cyclin A-CDK2 phosphorylated MEF protein in vitro more efficiently than cyclin D-CDK4 or cyclin E-CDK2, and phosphorylation of MEF by cyclin A-CDK2 reduced its ability to bind DNA. We determined one site of phosphorylation by cyclin A-CDK2 at the C terminus of MEF, using mass-spectrometry; mutation of three serine or threonine residues in this region significantly reduced phosphorylation of MEF by cyclin A and reduced cyclin A-mediated suppression of its transactivating activity. These amino acid substitutions also reduced the restriction of MEF activity to G(1). Phosphorylation of MEF by the cyclin A-CDK2 complex controls its transcriptional activity during the cell cycle, establishing a novel link between the ETS family of proteins and the cell cycle machinery.	Mem Sloan Kettering Canc Ctr, Mol Biol Program, New York, NY 10021 USA; Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Mol Biol Program, 1275 York Ave, New York, NY 10021 USA.	s-nimer@mskcc.org		Kiyokawa, Hiroaki/0000-0002-7942-6455; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052208] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA08748] Funding Source: Medline; NIDDK NIH HHS [R01 DK 52208] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; JEON IS, 1995, ONCOGENE, V10, P1229; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Miyazaki Y, 1996, ONCOGENE, V13, P1721; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NEVINS JR, 1992, SCIENCE, V258, P424; Nimer SD, 1996, BLOOD, V87, P3694, DOI 10.1182/blood.V87.9.3694.bloodjournal8793694; NUSSE M, 1990, CYTOMETRY, V11, P813, DOI 10.1002/cyto.990110707; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; THOMAS RS, 1995, ONCOGENE, V11, P2135; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	59	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40528	40536		10.1074/jbc.M103051200	http://dx.doi.org/10.1074/jbc.M103051200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11504716	hybrid			2022-12-25	WOS:000171925600023
J	Janssen, KP; Rost, R; Eichinger, L; Schleicher, M				Janssen, KP; Rost, R; Eichinger, L; Schleicher, M			Characterization of CD36/LIMPII homologues in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-PROTEIN; ACTIN-BINDING-PROTEIN; CHAIN FATTY-ACIDS; SCAVENGER RECEPTOR; ENDOCYTIC PATHWAY; SORTING SIGNALS; HEAVY-CHAIN; GENE FAMILY; SR-BI; CD36	The CD36/LIMPII family is ubiquitously expressed in higher eukaryotes and consists of integral membrane proteins that have in part been characterized as cell adhesion receptors, scavenger receptors, or fatty acid transporters. However, no physiological role has been defined so far for the members of this family that localize specifically to vesicular compartments rather than to the cell surface, namely lysosomal integral membrane protein type II (LIMPID from mammals and LmpA from the amoeba Dictyostelium discoideum. LmpA, the first described CD36/LIMPII homologue from lower eukaryotes, has initially been identified as a suppressor of the profilin-minus phenotype. We report the discovery and initial characterization of two new CD36/LIMPII-related proteins, both of which share several features with LmpA: (i) their size is considerably larger than that of the CD36/LIMPII proteins from higher eukaryotes; (ii) they show the characteristic "hairpin" topology of this protein family; (iii) they are heavily N-glycosylated; and (iv) they localize to vesicular structures of putative endolysosomal origin. However, they show intriguing differences in their developmental regulation and exhibit different sorting signals of the di-leucine or tyrosine-type in their carboxyl-terminal tail domains. These features make them promising candidates as a paradigm for the study of the function and evolution of the as yet poorly understood CD36/LIMPII proteins.	Univ Munich, Inst Zellbiol, D-80336 Munich, Germany	University of Munich	Janssen, KP (corresponding author), CNRS, Inst Curie, UMR 144, 25 Rue Ulm, F-75248 Paris 05, France.	klaus-peter.janssen@curie.fr	Eichinger, Ludwig/AAJ-8895-2021	Eichinger, Ludwig/0000-0003-1594-6117; Rost, Rene/0000-0002-5393-0370				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; Baillie AGS, 1996, J MEMBRANE BIOL, V153, P75, DOI 10.1007/s002329900111; Buczynski G, 1997, J CELL BIOL, V136, P1271, DOI 10.1083/jcb.136.6.1271; CALVO D, 1995, GENOMICS, V25, P100, DOI 10.1016/0888-7543(95)80114-2; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CLAVIEZ M, 1982, EMBO J, V1, P1017, DOI 10.1002/j.1460-2075.1982.tb01287.x; Crombie R, 1998, J BIOL CHEM, V273, P4855, DOI 10.1074/jbc.273.9.4855; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWRICK P, 1993, EUR J CELL BIOL, V61, P44; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Gough NR, 1999, J CELL SCI, V112, P4257; Graf R, 2000, J CELL SCI, V113, P1747; Gruarin P, 1997, BIOCHEM J, V328, P635, DOI 10.1042/bj3280635; Gupta R, 1999, GLYCOBIOLOGY, V9, P1009, DOI 10.1093/glycob/9.10.1009; Hacker U, 1997, J CELL SCI, V110, P105; HART K, 1993, J MOL BIOL, V234, P249, DOI 10.1006/jmbi.1993.1580; HEWLETT LJ, 1994, J CELL BIOL, V124, P689, DOI 10.1083/jcb.124.5.689; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Janssen KP, 2001, BBA-GEN SUBJECTS, V1525, P228, DOI 10.1016/S0304-4165(01)00108-8; Jenne N, 1998, J CELL SCI, V111, P61; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; Karakesisoglou I, 1999, J CELL BIOL, V145, P167, DOI 10.1083/jcb.145.1.167; KIMMEL AR, 1983, NUCLEIC ACIDS RES, V11, P541, DOI 10.1093/nar/11.2.541; Kundra R, 1999, J BIOL CHEM, V274, P31039, DOI 10.1074/jbc.274.43.31039; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOOMIS WF, 1969, J BACTERIOL, V100, P417, DOI 10.1128/JB.100.1.417-422.1969; LOOMIS WF, 1984, DEV BIOL, V102, P498, DOI 10.1016/0012-1606(84)90216-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; Morio T, 1998, DNA Res, V5, P335, DOI 10.1093/dnares/5.6.335; NOEGEL A, 1985, J MOL BIOL, V185, P447, DOI 10.1016/0022-2836(85)90416-4; Noegel AA, 1995, EXPERIENTIA, V51, P1135, DOI 10.1007/BF01944731; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; OHALLORAN TJ, 1992, J CELL BIOL, V118, P1371, DOI 10.1083/jcb.118.6.1371; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PEARCE SFA, 1994, BLOOD, V84, P384; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Rasmussen JT, 1998, EUR J BIOCHEM, V257, P488, DOI 10.1046/j.1432-1327.1998.2570488.x; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rogers ME, 1997, J BIOL CHEM, V272, P14792, DOI 10.1074/jbc.272.23.14792; Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; Schneider N, 2000, BIOL CELL, V92, P495, DOI 10.1016/S0248-4900(00)01102-3; Seastone DJ, 1998, MOL BIOL CELL, V9, P2891, DOI 10.1091/mbc.9.10.2891; Seastone DJ, 1999, MOL BIOL CELL, V10, P393, DOI 10.1091/mbc.10.2.393; SHARP PM, 1989, NUCLEIC ACIDS RES, V17, P5029, DOI 10.1093/nar/17.13.5029; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Tabuchi N, 2000, BIOCHEM BIOPH RES CO, V270, P557, DOI 10.1006/bbrc.2000.2448; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TEMESVARI L, 1994, J BIOL CHEM, V269, P25719; Temesvari L, 2000, MOL BIOL CELL, V11, P2019, DOI 10.1091/mbc.11.6.2019; Temesvari LA, 1996, J CELL SCI, V109, P663; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEGA MA, 1991, J BIOL CHEM, V266, P16818; WEINER OH, 1993, J CELL BIOL, V123, P23, DOI 10.1083/jcb.123.1.23; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; WILLIAMS KL, 1976, GENETICS, V82, P287; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967	71	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38899	38910		10.1074/jbc.M103384200	http://dx.doi.org/10.1074/jbc.M103384200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11489884	hybrid			2022-12-25	WOS:000171673200076
J	Lardizabal, KD; Mai, JT; Wagner, NW; Wyrick, A; Voelker, T; Hawkins, DJ				Lardizabal, KD; Mai, JT; Wagner, NW; Wyrick, A; Voelker, T; Hawkins, DJ			DGAT2 is a new diacylglycerol acyltransferase gene family - Purification, cloning, and expression in insect cells of two polypeptides from Mortierella ramanniana with diacylglycerol acyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; TRIACYLGLYCEROL SYNTHESIS; YEAST; CDNA; PHOSPHOLIPIDS; ACTIVATION; PROTEINS; FRACTION; MUTATION; ENZYMES	Acyl CoA:diacylgycerol acyltransferase (EC 2.3.1.20; DGAT) catalyzes the final step in the production of triacylglycerol. Two polypeptides, which co-purified with DGAT activity, were isolated from the lipid bodies of the oleaginous fungus Mortierella ramanniana with a procedure consisting of dye affinity, hydroxyapatite affinity, and heparin chromatography. The two enzymes had molecular masses of 36 and 36.5 kDa, as estimated by gel electrophoresis, and showed a broad activity maximum between pH 6 and 8. Based on partial peptide sequence information, polymerase chain reaction techniques were used to obtain full-length cDNA sequences encoding the purified proteins. Expression of the cDNAs in insect cells conferred high levels of DGAT activity on the membranes isolated from these cells. The two proteins share 54% homology with each other but are unrelated to the previously identified DGAT gene family (designated DGAT1), which is related to the acyl CoA:cholesterol acyltransferase gene family, or to any other gene family with ascribed function. This report identifies a new gene family, including members in fungi, plants and animals, which encode enzymes with DGAT function. To distinguish the two unrelated families we designate this new class DGAT2 and refer to the M. ramanniana genes as MrDGAT2A and MrDGAT2B.	Monsanto Co, Davis, CA 95616 USA	Monsanto	Lardizabal, KD (corresponding author), Monsanto Co, Calgene Campus,1920 5th St, Davis, CA 95616 USA.							BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bouvier-Nave P, 2000, EUR J BIOCHEM, V267, P85, DOI 10.1046/j.1432-1327.2000.00961.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindley D. N, 1991, BIOCH LIPIDS LIPOPRO, P171; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; DAHLQVIST A, 1998, ADV PLANT LIPID RES, P211; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; DELEPELAIRE P, 1979, P NATL ACAD SCI USA, V76, P111, DOI 10.1073/pnas.76.1.111; Harwood JL, 1996, BBA-LIPID LIPID MET, V1301, P7, DOI 10.1016/0005-2760(95)00242-1; Hobbs DH, 1999, FEBS LETT, V452, P145, DOI 10.1016/S0014-5793(99)00646-8; JONES A, 1995, PLANT CELL, V7, P359, DOI 10.1105/tpc.7.3.359; Kamisaka Y, 1997, J BIOCHEM-TOKYO, V121, P1107; KAMISAKA Y, 1993, LIPIDS, V28, P583, DOI 10.1007/BF02536050; Kamisaka Y, 1996, J BIOCHEM-TOKYO, V119, P520; KATAVIC V, 1995, PLANT PHYSIOL, V108, P399, DOI 10.1104/pp.108.1.399; KNUTZON DS, 1992, P NATL ACAD SCI USA, V89, P2624, DOI 10.1073/pnas.89.7.2624; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lardizabal KD, 2000, PLANT PHYSIOL, V122, P645, DOI 10.1104/pp.122.3.645; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Metz JG, 2000, PLANT PHYSIOL, V122, P635, DOI 10.1104/pp.122.3.635; NEUWALD F, 1997, CURR BIOL, V7, P465; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oelkers P, 2000, J BIOL CHEM, V275, P15609, DOI 10.1074/jbc.C000144200; Roesler K, 1997, PLANT PHYSIOL, V113, P75, DOI 10.1104/pp.113.1.75; Routaboul JM, 1999, PLANT PHYSIOL BIOCH, V37, P831, DOI 10.1016/S0981-9428(99)00115-1; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; SUZUKI S, 1999, Patent No. 5880334; VOELKER TA, 1992, SCIENCE, V257, P72, DOI 10.1126/science.1621095; ZOU J, 2000, Patent No. 6051755; Zou JT, 1999, PLANT J, V19, P645, DOI 10.1046/j.1365-313x.1999.00555.x	34	269	344	1	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38862	38869		10.1074/jbc.M106168200	http://dx.doi.org/10.1074/jbc.M106168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11481333	hybrid			2022-12-25	WOS:000171673200071
J	Vogel, R; Siebert, F				Vogel, R; Siebert, F			Conformations of the active and inactive states of opsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METARHODOPSIN-II; CONSTITUTIVE ACTIVATION; VISUAL PROCESS; GLYCINE 121; RHODOPSIN; TRANSDUCIN; BINDING; SPECTROSCOPY; ADAPTATION; MECHANISMS	The signaling state metarhodopsin II of the visual pigment rhodopsin decays to the apoprotein opsin and all-trans retinal, which are then regenerated to rhodopsin by the visual cycle. Opsin is known to have at neutral pH only a small residual constitutive activity toward its G protein transducin, which is thought to play a considerable role in light adaptation (bleaching desensitization). In this study we show with Fourier-transform infrared spectroscopy that after metarhodopsin II decay, opsin exists in two conformational states that are in a pH-dependent equilibrium at 30 degreesC with a pK of 4.1 in the presence of hydroxylamine scavenging the endogenous all-trans retinal. Despite the lack of the native agonist in its binding pocket, the low pH opsin conformation is very similar to that of metarhodopsin II and is likewise stabilized by peptides derived from rhodopsin's cognate G protein, transducin. The high pH form, on the other hand, has some conformational similarity to the inactive metarhodopsin I state. We therefore conclude that the opsin apoprotein displays intrinsic conformational states that are merely modulated by bound all-trans retinal.	Univ Freiburg, Arbeitsgrp Biophys, Inst Mol Med & Zellforsch, Biophys Grp, D-79104 Freiburg, Germany	University of Freiburg	Vogel, R (corresponding author), Univ Freiburg, Arbeitsgrp Biophys, Inst Mol Med & Zellforsch, Biophys Grp, Albertstr 23, D-79104 Freiburg, Germany.	vogelr@uni-freiburg.de						Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; CHABRE M, 1979, VISION RES, V19, P1005, DOI 10.1016/0042-6989(79)90226-8; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; Fahmy K, 1998, BIOPHYS J, V75, P1306, DOI 10.1016/S0006-3495(98)74049-4; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; GANTER UM, 1989, BIOCHEMISTRY-US, V28, P5954, DOI 10.1021/bi00440a036; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Han M, 2000, METHOD ENZYMOL, V315, P251; Han M, 1996, J BIOL CHEM, V271, P32330, DOI 10.1074/jbc.271.50.32330; Han M, 1998, BIOCHEMISTRY-US, V37, P8253, DOI 10.1021/bi980147r; Han M, 1996, J BIOL CHEM, V271, P32337, DOI 10.1074/jbc.271.50.32337; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; JAGER F, 1994, BIOCHEMISTRY-US, V33, P10878; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; JIN J, 1993, NEURON, V11, P513, DOI 10.1016/0896-6273(93)90155-K; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; ROTHSCHILD KJ, 1987, BIOPHYS J, V51, P345, DOI 10.1016/S0006-3495(87)83341-6; Sachs K, 2000, METHOD ENZYMOL, V315, P238; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SIEBERT F, 1980, BIOPHYS STRUCT MECH, V6, P147, DOI 10.1007/BF00535751; Surya A, 1998, EXP EYE RES, V66, P599, DOI 10.1006/exer.1997.0453; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; VANBREUGEL PJGM, 1979, BIOCHIM BIOPHYS ACTA, V557, P188, DOI 10.1016/0005-2736(79)90101-9; Vogel R, 2000, CURR OPIN CHEM BIOL, V4, P518, DOI 10.1016/S1367-5931(00)00125-3; Vogel R, 2001, BIOCHEMISTRY-US, V40, P483, DOI 10.1021/bi001855r	36	99	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38487	38493		10.1074/jbc.M105423200	http://dx.doi.org/10.1074/jbc.M105423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11502747	hybrid			2022-12-25	WOS:000171673200023
J	Li, QF; Loeb, JA				Li, QF; Loeb, JA			Neuregulin-heparan-sulfate proteoglycan interactions produce sustained erbB receptor activation required for the induction of acetylcholine receptors in muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-SUBUNIT GENE; NEUROMUSCULAR-JUNCTION; CELL-MIGRATION; PROTEIN-KINASE; SPINAL-CORD; EXPRESSION; ARIA; PATHWAY; SYNAPSE; PHOSPHORYLATION	Neuregulins bind to and activate members of the EGF receptor family of tyrosine kinases that initiate a signaling cascade that induces acetylcholine receptor synthesis in the postsynaptic membrane of neuromuscular synapses. In addition to an EGF-like domain, sufficient for receptor binding and tyrosine auto-phosphorylation, many spliced forms also have an IG-like domain that binds HSPGs and maintains a high concentration of neuregulin at synapses. Here, we show that the IG-like domain functions to keep the EGF-like domain at sufficiently high concentrations for a sufficiently long period of time necessary to induce acetylcholine receptor gene expression in primary chick myotubes. Using recombinant neuregulins with and without the IG-like domain, we found that IG-like domain binding to endogenous HSPGs produces a 4-fold increase in receptor phosphorylation. This enhancement of activity was blocked by soluble heparin or by pretreatment of muscle cells with heparitinase. We show that at least 12-24 h of neuregulin exposure was required to turn on substantial acetylcholine receptor gene expression and that the erbB receptors need to be kept phosphorylated during this time. The need for sustained erbB receptor activation may be the reason why neuregulins are so highly concentrated in the extracellular matrix of synapses.	Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Loeb, JA (corresponding author), Wayne State Univ, Sch Med, Dept Neurol, Elliman 3199,421 E Canfield Ave, Detroit, MI 48201 USA.				NINDS NIH HHS [NS01659] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; BUCCARON MH, 1983, DEV BIOL, V95, P378, DOI 10.1016/0012-1606(83)90039-8; CORFAS G, 1993, J NEUROSCI, V13, P2118; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; HAN B, 2000, SOC NEUR ABSTR, V25, P43; HARRIS DA, 1988, P NATL ACAD SCI USA, V85, P1983, DOI 10.1073/pnas.85.6.1983; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HUNTER WM, 1964, BIOCHEM J, V91, P43, DOI 10.1042/bj0910043; Krufka A, 1996, BIOCHEMISTRY-US, V35, P11131, DOI 10.1021/bi960125+; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu FC, 1996, NEURON, V17, P1133, DOI 10.1016/S0896-6273(00)80245-7; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; Loeb JA, 1997, J NEUROSCI, V17, P1416; Loeb JA, 1999, DEVELOPMENT, V126, P781; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Meier T, 1998, J CELL BIOL, V141, P715, DOI 10.1083/jcb.141.3.715; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Si JT, 1999, J NEUROSCI, V19, P8498; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	33	64	64	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38068	38075						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11502740				2022-12-25	WOS:000171526500048
J	Schagger, H; Pfeiffer, K				Schagger, H; Pfeiffer, K			The ratio of oxidative phosphorylation complexes I-V in bovine heart mitochondria and the composition of respiratory chain supercomplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; ELECTRON-TRANSPORT; YEAST; UBIQUINONE; BINDING	The ratios of the oxidative phosphorylation complexes NADH:ubiquinone reductase (complex I), succinate:ubiquinone reductase (complex II), ubiquinol:cytochrome c reductase (complex III), cytochrome c oxidase (complex IV), and F1F0-ATP synthase (complex V) from bovine heart mitochondria were determined by applying three novel and independent approaches that gave consistent results: 1) a spectrophotometric-enzymatic assay making use of differential solubilization of complexes II and III and parallel assays of spectra and catalytic activities in the samples before and after ultracentrifugation were used for the determination of the ratios of complexes II, III, and IV; 2) an electrophoretic-densitometric approach using two-dimensional electrophoresis (blue native-polyacrylamide gel electrophoresis and SDS-polyacrylamide gel electrophoresis) and Coomassie blue-staining indices of subunits of complexes was used for determining the ratios of complexes I, III, IV, and V, and 3) two electrophoretic-densitometric approaches that are independent of the use of staining indices were used for determining the ratio of complexes I and III. For complexes I, II, III, IV, and V in bovine heart mitochondria, a ratio 1.1 +/- 0.2:1.3 +/- 0.1:3: 6.7 +/- 0.8:3.5 +/- 0.2 was determined.	Univ Frankfurt Klinikum, Zentrum Biol Chem, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Schagger, H (corresponding author), Univ Frankfurt Klinikum, Zentrum Biol Chem, Theodor Stern Kai 7,Haus 25B, D-60590 Frankfurt, Germany.	schaegger@zbc.klinik.uni-frankfurt.de						Albracht SPJ, 2000, FEBS LETT, V485, P1, DOI 10.1016/S0014-5793(00)02172-4; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; AZZONE GF, 1979, METHOD ENZYMOL, V55, P45; BERTINA RM, 1973, BIOCHIM BIOPHYS ACTA, V305, P503, DOI 10.1016/0005-2728(73)90072-8; BRANDT U, 1989, EUR J BIOCHEM, V182, P705, DOI 10.1111/j.1432-1033.1989.tb14882.x; CAPALDI RA, 1988, J BIOENERG BIOMEMBR, V20, P291, DOI 10.1007/BF00769634; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; KROGER A, 1973, EUR J BIOCHEM, V39, P313, DOI 10.1111/j.1432-1033.1973.tb03129.x; MATSUNOYAGI A, 1988, BIOCHEMISTRY-US, V27, P335, DOI 10.1021/bi00401a050; Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625; PENIN F, 1986, BIOCHIM BIOPHYS ACTA, V852, P55, DOI 10.1016/0005-2728(86)90056-3; SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; SMITH S, 1980, FEBS LETT, V110, P279, DOI 10.1016/0014-5793(80)80092-5; Tisdale HD, 1967, METHODS ENZYMOL, V10, P213, DOI DOI 10.1016/0076-6879(67)10042-6; Vinogradov A D, 1979, Methods Enzymol, V55, P118	20	289	294	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37861	37867						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11483615				2022-12-25	WOS:000171526500021
J	Soltoff, SP				Soltoff, SP			Rottlerin is a mitochondrial uncoupler that decreases cellular ATP levels and indirectly blocks protein kinase C delta tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL PROXIMAL TUBULE; GROWTH-FACTOR RECEPTOR; PAROTID ACINAR-CELLS; ENERGY-METABOLISM; ION-TRANSPORT; PC12 CELLS; OXIDATIVE-METABOLISM; EXTRACELLULAR ATP; ACTIVATION; APOPTOSIS	Protein kinase C delta (PKC delta) is activated by stimuli that increase its tyrosine phosphorylation, including neurotransmitters that initiate fluid secretion in salivary gland (parotid) epithelial cells. Rottlerin, a compound reported to be a PKC delta -selective inhibitor, rapidly increased the rate of oxygen consumption (QO(2)) of parotid acinar cells and PC12 cells. In parotid cells, this was distinct from the effects of the muscarinic receptor ligand carbachol, which promoted a sodium pump-dependent increase in respiration. Rottlerin increased the QO(2) of isolated rat liver mitochondria to a level similar to that produced when oxidative phosphorylation was initiated by ADP or when mitochondria were uncoupled by carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP). The effects of rottlerin on mitochondrial QO(2) were neither mimicked nor blocked by the PKC inhibitor GF109203X. Rottlerin was not effective in blocking PKC delta activity in vitro. Exposure of freshly isolated parotid acinar cells to rottlerin and FCCP reduced cellular ATP levels and reduced stimuli-dependent increases in tyrosine phosphorylation of PKCS. Neither rottlerin nor FCCP reduced stimuli-dependent PKC delta tyrosine phosphorylation in RPG1 cells (a salivary ductal line) or PC12 cells, consistent with their dependence on glycolysis rather than oxidative phosphorylation for energy-dependent processes. These results demonstrate that rottlerin directly uncouples mitochondrial respiration from oxidative phosphorylation. Previous studies using rottlerin should be evaluated cautiously.	Harvard Univ, Inst Med, Div Signal Transduct, Beth Israel Deaconess Med Ctr,Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Soltoff, SP (corresponding author), Harvard Univ, Inst Med, Div Signal Transduct, Beth Israel Deaconess Med Ctr,Dept Med, Room 1025,330 Brookline Ave, Boston, MA 02215 USA.				NIDCR NIH HHS [DE-10877] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010877] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BASMA AN, 1992, J NEUROCHEM, V58, P1052, DOI 10.1111/j.1471-4159.1992.tb09361.x; Benes C, 2001, AM J PHYSIOL-CELL PH, V280, pC1498, DOI 10.1152/ajpcell.2001.280.6.C1498; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Chamberlin ME, 1997, J EXP BIOL, V200, P2789; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; Chen CH, 2001, J MOL CELL CARDIOL, V33, P581, DOI 10.1006/jmcc.2000.1330; Cheng AM, 2001, AM J PHYSIOL-CELL PH, V281, pC430, DOI 10.1152/ajpcell.2001.281.2.C430; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEMSEY EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Deszo EL, 2001, J BIOL CHEM, V276, P10212, DOI 10.1074/jbc.M010589200; DICKMAN KG, 1989, AM J PHYSIOL, V257, pC333, DOI 10.1152/ajpcell.1989.257.2.C333; Fryer RM, 2001, AM J PHYSIOL-HEART C, V280, pH1346, DOI 10.1152/ajpheart.2001.280.3.H1346; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; GULLANS SR, 1982, AM J PHYSIOL, V243, pF133, DOI 10.1152/ajprenal.1982.243.2.F133; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Kang D, 1997, ARCH BIOCHEM BIOPHYS, V337, P75, DOI 10.1006/abbi.1996.9727; LEIDTKE CM, 1997, AM J PHYSIOL-CELL PH, V273, pC1632; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luo Y, 1997, P NATL ACAD SCI USA, V94, P9705, DOI 10.1073/pnas.94.18.9705; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; MANDEL LJ, 1981, AM J PHYSIOL, V240, pF357, DOI 10.1152/ajprenal.1981.240.5.F357; MANDEL LJ, 1986, CURR TOP MEMBR TRANS, V27, P261; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; REYNOLDS EE, 1982, BIOCHEMISTRY-US, V21, P4795, DOI 10.1021/bi00262a042; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; SOLTOFF SP, 1990, J GEN PHYSIOL, V95, P319, DOI 10.1085/jgp.95.2.319; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; SOLTOFF SP, 1986, J MEMBRANE BIOL, V94, P153, DOI 10.1007/BF01871195; SOLTOFF SP, 1990, ANN NY ACAD SCI, V603, P76; Soltoff SP, 1998, ANN NY ACAD SCI, V842, P100, DOI 10.1111/j.1749-6632.1998.tb09637.x; SOLTOFF SP, 1984, J GEN PHYSIOL, V84, P623, DOI 10.1085/jgp.84.4.623; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Turner R. J., 1993, BIOL SALIVARY GLANDS, P105; Webster MT, 1998, J NEURAL TRANSM, V105, P839, DOI 10.1007/s007020050098; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	47	206	208	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37986	37992						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11498535				2022-12-25	WOS:000171526500038
J	Jung, DJ; Lee, SK; Lee, JW				Jung, DJ; Lee, SK; Lee, JW			Agonist-dependent repression mediated by mutant estrogen receptor alpha that lacks the activation function 2 core domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-COR; HISTONE DEACETYLASE; HORMONE RECEPTORS; NUCLEAR; COREPRESSORS; SMRT; COACTIVATOR; COMPLEX; PROTEINS; VARIANTS	Nuclear receptor corepressor (N-CoR) and silencing mediator of retinoid and thyroid hormone receptors (SMRT) form heterogeneous complexes with various histone deacetylases (HDACs). In this report, we found that ER alpha-Delta AF2 a mutant estrogen receptor alpha (ER alpha) deleted for the C-terminal activation function 2 (AF2) core domain, directs estradiol (E-2)-dependent repression and impairs E-2-induced transactivation by wild type ER alpha. This repression required coexpressed BRG1 in SW-13 cells that lack BRG1, the ATPase constituent of the chromatin-remodeling SWI-SNF complex, and was abolished by HDAC inhibitor trichostatin A. We further demonstrated that ER alpha-Delta AF2 constitutively associates with SMRT but binds DNA in an E-2-dependent manner in vivo. These results suggest that ER alpha-Delta AF2 and similar mutant receptors recently found associated with certain tumors may actively perturb the normal E-2 signaling via SWI/SNF, N-CoR/SMRT, and HDAC.	Pohang Univ Sci & Technol, Ctr Ligand & Transcript, Pohang 790784, South Korea; Salk Inst Biol Studies, Gene Express Lab, San Diego, CA 92185 USA	Pohang University of Science & Technology (POSTECH); Salk Institute	Lee, JW (corresponding author), Pohang Univ Sci & Technol, Ctr Ligand & Transcript, Pohang 790784, South Korea.							CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; EMMAS CE, 1992, J STEROID BIOCHEM, V41, P291, DOI 10.1016/0960-0760(92)90354-L; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu CZ, 1996, MOL CELL ENDOCRINOL, V118, P173, DOI 10.1016/0303-7207(96)03780-X; Huang EY, 2000, GENE DEV, V14, P45; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jones PL, 2001, J BIOL CHEM, V276, P8807, DOI 10.1074/jbc.C000879200; Koduri S, 2000, J CANCER RES CLIN, V126, P291, DOI 10.1007/s004320050345; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; Lee SK, 1998, MOL ENDOCRINOL, V12, P1184, DOI 10.1210/me.12.8.1184; LEIBOVITZ A, 1973, JNCI-J NATL CANCER I, V51, P691; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Liu Y, 1998, ENDOCRINOLOGY, V139, P4197, DOI 10.1210/en.139.10.4197; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Moore DD, 1995, GLOB MOB SURV; Murphy LC, 1997, J STEROID BIOCHEM, V62, P363, DOI 10.1016/S0960-0760(97)00084-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Song MR, 1998, BIOCHEM J, V336, P711, DOI 10.1042/bj3360711; Tagami T, 1998, MOL ENDOCRINOL, V12, P1888, DOI 10.1210/me.12.12.1888; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470	31	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37280	37283		10.1074/jbc.M106860200	http://dx.doi.org/10.1074/jbc.M106860200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11487586	hybrid			2022-12-25	WOS:000171375700057
J	Scheele, U; Kalthoff, C; Ungewickell, E				Scheele, U; Kalthoff, C; Ungewickell, E			Multiple interactions of auxilin 1 with clathrin and the AP-2 adaptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-ASSOCIATED KINASE; TERMINAL DOMAIN; COATED VESICLES; UNCOATING ATPASE; ALPHA-ADAPTIN; CRYSTAL-STRUCTURE; APPENDAGE DOMAIN; BETA-PROPELLER; BINDING-SITE; PROTEIN	The removal of the clathrin coat is essential for vesicle fusion with acceptor membranes. Disassembly of the coat involves hsc70, which is specifically recruited by members of the auxilin protein family to clathrin lattices. In vitro, this function of auxilin does not require the globular amino-terminal domain of the clathrin heavy chain, which is known to play a prominent role in the interaction of clathrin with adaptors and numerous endocytic accessory proteins. Here we report the unexpected finding that the neuron-specific form of auxilin (auxilin 1) can also associate with the clathrin amino-terminal domain. This interaction is mediated through tandemly arranged sites within the auxilin 1 carboxyl-terminal segment 547-910. The overlapping auxilin I fragments 547-714 and 619-738 bind the clathrin terminal domain with high affinity, whereas auxilin 1-(715-901) interacts only poorly with it. All three fragments also associate with the clathrin distal domain and the a-appendage domain of AP-2. Moreover, they support efficient assembly of clathrin triskelia into regular cages. A novel uncoating assay was developed to demonstrate that auxilin 1-(715-901) functions efficiently as a cofactor for hsc70 in the uncoating of clathrin-coated vesicles. The multiple protein-protein interactions of auxilin 1 suggest that its function in endocytic trafficking may be more complex than previously anticipated.	Hannover Med Sch, Dept Cell Biol, Ctr Anat, D-30125 Hannover, Germany	Hannover Medical School	Ungewickell, E (corresponding author), Hannover Med Sch, Dept Cell Biol, Ctr Anat, D-30125 Hannover, Germany.							ABLE S, 1990, J CELL BIOL, V111, P19; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; Cope MJTV, 1999, J CELL BIOL, V144, P1203, DOI 10.1083/jcb.144.6.1203; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; DRAKE MT, 2001, J BIOL CHEM, V29, P29; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; Gall WE, 2000, CURR BIOL, V10, P1349, DOI 10.1016/S0960-9822(00)00771-5; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Greener T, 2000, J BIOL CHEM, V275, P1365, DOI 10.1074/jbc.275.2.1365; Greener T, 2001, NAT CELL BIOL, V3, P215, DOI 10.1038/35055137; Hannan LA, 1998, MOL BIOL CELL, V9, P2217, DOI 10.1091/mbc.9.8.2217; Harris TW, 2000, J CELL BIOL, V150, P589, DOI 10.1083/jcb.150.3.589; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; HONING S, 1994, J CELL SCI, V107, P1185; Kanaoka Y, 1997, FEBS LETT, V402, P73, DOI 10.1016/S0014-5793(96)01484-6; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lemmon SK, 2001, CURR BIOL, V11, pR49, DOI 10.1016/S0960-9822(01)00010-0; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Morgan JR, 2000, J NEUROSCI, V20, P8667; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; MURPHY JE, 1992, J BIOL CHEM, V267, P10850; Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092-8674(00)00161-6; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Pearse BMF, 2000, CURR OPIN STRUC BIOL, V10, P220, DOI 10.1016/S0959-440X(00)00071-3; Pishvaee B, 2000, NAT CELL BIOL, V2, P958, DOI 10.1038/35046619; RASMJAUN AR, 1998, J NEUROCHEM, V70, P2369; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Umeda A, 2000, EUR J CELL BIOL, V79, P336, DOI 10.1078/S0171-9335(04)70037-0; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079	42	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36131	36138		10.1074/jbc.M106511200	http://dx.doi.org/10.1074/jbc.M106511200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11470803	hybrid			2022-12-25	WOS:000171194500013
J	Zhai, LW; Zhao, PL; Panebra, A; Guerrerio, AL; Khurana, S				Zhai, LW; Zhao, PL; Panebra, A; Guerrerio, AL; Khurana, S			Tyrosine phosphorylation of villin regulates the organization of the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; BINDING; GELSOLIN; PROTEINS; CALCIUM; CELLS	We have previously shown that tyrosine phosphorylation of the actin-regulatory protein villin is accompanied by the redistribution of phosphorylated villin and a concomitant decrease in the F-actin content of intestinal epithelial cells. The temporal and spatial correlation of these two events suggested that tyrosine phosphorylation of villin may be involved in the rearrangement of the microvillar cytoskeleton. This hypothesis was investigated by analyzing the effects of tyrosine phosphorylation of villin on the kinetics of actin polymerization by reconstituting in vitro the tyrosine phosphorylation of villin and its association with actin. Full-length recombinant human villin was phosphorylated in vitro by expression in the TKX1-competent cells that carry an inducible tyrosine kinase gene. The actin-binding properties of villin were examined using a co-sedimentation assay. Phosphorylation of villin did not change the stoichiometry (1:2) but decreased the binding affinity (4.4 mum for unphosphorylated versus 0.6 mum for phosphorylated) of villin for actin. Using a pyrene-actin-based fluorescence assay, we demonstrated that tyrosine phosphorylation had a negative effect on actin nucleation by villin. In contrast, tyrosine phosphorylation enhanced actin severing by villin. Electron microscopic analysis showed complementary morphological changes. Phosphorylation inhibited the actin bundling and enhanced the actin severing functions of villin. Taken together our data show that tyrosine phosphorylation of villin decreases the amount of villin bound to actin filaments, inhibits the actin-polymerizing properties of villin, and promotes the actin-depolymerizing functions instead. These observations suggest a role for tyrosine phosphorylation in modulating the microvillar cytoskeleton in vivo by villin in response to specific physiological stimuli.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Johns Hopkins Univ, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA	University of Tennessee System; University of Tennessee Health Science Center; Johns Hopkins University	Khurana, S (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Nash 402,894 Union Ave, Memphis, TN 38163 USA.		Guerrerio, Anthony/T-2632-2019	Guerrerio, Anthony/0000-0003-2458-7160; Khurana, Seema/0000-0002-6884-810X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054755] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-54755] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albers TM, 1996, CELL BIOL INT, V20, P821, DOI 10.1006/cbir.1996.0105; Becker S, 1998, FEBS LETT, V441, P141, DOI 10.1016/S0014-5793(98)01543-9; DeCorte V, 1997, FEBS LETT, V401, P191, DOI 10.1016/S0014-5793(96)01471-8; Friederich E, 1999, J BIOL CHEM, V274, P26751, DOI 10.1074/jbc.274.38.26751; GETTEMANS J, 1995, J BIOL CHEM, V270, P2644, DOI 10.1074/jbc.270.6.2644; GLENNEY JR, 1981, J BIOL CHEM, V256, P8156; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Izaguirre G, 2001, J BIOL CHEM, V276, P28676, DOI 10.1074/jbc.M101678200; JAMNEY PA, 1987, NATURE, V325, P362; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; Khurana S, 1997, J BIOL CHEM, V272, P30115, DOI 10.1074/jbc.272.48.30115; Khurana S, 2000, J MEMBRANE BIOL, V178, P73, DOI 10.1007/s002320010016; LAMB JA, 1993, J BIOL CHEM, V268, P8999; NUSRAT A, 1992, J CLIN INVEST, V89, P1501, DOI 10.1172/JCI115741; Panebra A, 2001, AM J PHYSIOL-CELL PH, V281, pC1046, DOI 10.1152/ajpcell.2001.281.3.C1046; POLLARD TD, 1983, ANAL BIOCHEM, V134, P406, DOI 10.1016/0003-2697(83)90316-0; SIMCOX ME, 1994, STRATEGIES, V7, P68; Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556; White P, 2000, AM J PHYSIOL-RENAL, V278, pF886, DOI 10.1152/ajprenal.2000.278.6.F886; Yamakita Y, 1996, J BIOL CHEM, V271, P12632, DOI 10.1074/jbc.271.21.12632	20	52	53	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36163	36167		10.1074/jbc.C100418200	http://dx.doi.org/10.1074/jbc.C100418200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11500485	hybrid			2022-12-25	WOS:000171194500017
J	Mandal, AK; Zhang, ZJ; Chou, JY; Mukherjee, AB				Mandal, AK; Zhang, ZJ; Chou, JY; Mukherjee, AB			Pancreatic phospholipase A(2) via its receptor regulates the expression of key enzymes of phospholipid and sphingolipid metabolism	FASEB JOURNAL			English	Article						phospholipase A(2-)receptor; signal-transduction/cyclooxygenase-2; Mg++-dependent neutral sphingomyelinase; acid ceramidase	ACTIVATED PROTEIN-KINASE; CYCLOOXYGENASE-2 GENE-EXPRESSION; SMOOTH-MUSCLE CELLS; BINDING-SITE; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; ARACHIDONIC-ACID; MESANGIAL CELLS; MESSENGER-RNA; CANCER-CELLS	Although the pancreatic secretory phospholipase A(2) (sPLA(2)IB) is considered a digestive enzyme, it has several important, nonenzymatic, receptor-mediated functions. In this study, we demonstrate that via its receptor, sPLA(2)IB stimulates the expression of cytosolic PLA(2) (cPLA(2))-, cyclooxygenase-2 (COX-2)-, Mg++-dependent neutral sphingomyelinase (NSMase)- and acid ceramidase (AC)- mRNAs in NIH 3T3 cells. Moreover, through its receptor, sPLA(2)IB also mediates the activation of cPLA(2) and p38 MAPK. We also found similar effects when the NIH 3T3 cells were treated with interleukin 1 beta (IL-beta), fibroblast growth factor (FGF), and hepatocyte growth factor (HGF) under identical conditions. These effects are not dependent on the catalytic activity of sPLA(2)IB, as both heat- and chemically inactivated enzyme induced these effects. Although protein kinase C and p38 mitogen-activated protein kinases are critical for the sPLA(2) receptor-mediated stimulation of expression of cytosolic PLA(2) and cyclooxygenase-2 mRNAs, respectively, the activation of these kinases is not required for neutral sphingomyelinase and acid ceramidase mRNA expression. Our results, for the first time, raise the possibility that, via its receptor, sPLA(2)IB plays important roles in the regulation of both phospholipid and sphingolipid metabolism.	NICHHD, Sect Dev Genet, NIH, Bethesda, MD 20892 USA; NICHHD, Sect Cellular Differentiat, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mukherjee, AB (corresponding author), NICHHD, Sect Dev Genet, NIH, Bldg 10,Room 9S241, Bethesda, MD 20892 USA.	mukherja@exchange.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912, ZIAHD000910] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000910, Z01HD000912] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; ARITA H, 1991, J BIOL CHEM, V266, P19139; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; Cao WB, 2000, GASTROENTEROLOGY, V119, P1243, DOI 10.1053/gast.2000.19581; Chen BC, 1999, IMMUNOLOGY, V97, P124, DOI 10.1046/j.1365-2567.1999.00747.x; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Ershov AV, 1999, J NEUROSCI RES, V58, P254, DOI 10.1002/(SICI)1097-4547(19991015)58:2<254::AID-JNR5>3.3.CO;2-L; Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915; Fonteh AN, 2000, J IMMUNOL, V165, P2773, DOI 10.4049/jimmunol.165.5.2773; Fonteh AN, 1998, BBA-LIPID LIPID MET, V1393, P253, DOI 10.1016/S0005-2760(98)00079-4; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; GRONROOS JM, 1992, DIGESTION, V52, P232, DOI 10.1159/000200958; HANADA K, 1995, FEBS LETT, V373, P85, DOI 10.1016/0014-5793(95)01005-Y; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; Hanasaki K, 1999, ARCH BIOCHEM BIOPHYS, V372, P215, DOI 10.1006/abbi.1999.1511; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; Huwiler A, 1997, BBA-LIPID LIPID MET, V1348, P257, DOI 10.1016/S0005-2760(97)00073-8; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; ISHIZAKI J, 1993, FEBS LETT, V324, P349, DOI 10.1016/0014-5793(93)80149-O; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Jones MK, 1999, FASEB J, V13, P2186, DOI 10.1096/fasebj.13.15.2186; KANEMASA T, 1992, FEBS LETT, V303, P217, DOI 10.1016/0014-5793(92)80523-J; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; Kinoshita E, 1997, FEBS LETT, V407, P343, DOI 10.1016/S0014-5793(97)00373-6; Kinoshita E, 1996, INT J ONCOL, V9, P1219; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KISHINO J, 1992, BIOCHEM BIOPH RES CO, V186, P1025, DOI 10.1016/0006-291X(92)90849-G; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Kundu GC, 1997, J BIOL CHEM, V272, P2346; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SOMMERS CD, 1992, EUR J PHARMACOL, V216, P87, DOI 10.1016/0014-2999(92)90213-N; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VADAS P, 1986, LAB INVEST, V55, P391; Wadleigh DJ, 1999, BIOCHEM BIOPH RES CO, V264, P865, DOI 10.1006/bbrc.1999.1606; WAITE M, 1987, HDB LIPID RES, V5, P111; WHATLEY RE, 1993, J BIOL CHEM, V268, P16130; Yuan CJ, 2000, CANCER RES, V60, P1084	60	23	24	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1834	+		10.1096/fj.00-0831fje	http://dx.doi.org/10.1096/fj.00-0831fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481246				2022-12-25	WOS:000169261200009
J	Hollande, F; Choquet, A; Blanc, EM; Lee, DJ; Bali, JP; Baldwin, GS				Hollande, F; Choquet, A; Blanc, EM; Lee, DJ; Bali, JP; Baldwin, GS			Involvement of phosphatidylinositol 3-kinase and mitogen-activated protein kinases in glycine-extended gastrin-induced dissociation and migration of gastric epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; TRANSGENIC MICE; SERUM GASTRIN; MAP KINASE; PROGASTRIN; CHOLECYSTOKININ; RECEPTOR; COLON; CANCER; LINES	The various molecular forms of gastrin can act as promoters of proliferation and differentiation in different regions of the gastrointestinal tract. We report a novel stimulatory effect of glycine-extended gastrin(17) only on cell/cell dissociation and cell migration in a nontumorigenic mouse gastric epithelial cell line (IMGE-5). In contrast, both amidated and glycine-extended gastrin17 stimulated proliferation of IMGE-5 cells via distinct receptors. Glycine-extended gastrin(17)-induced dissociation preceded migration and was blocked by selective inhibitors of phosphatidylinositol 3-kinase (P13-kinase) but did not require mitogen-activated protein (MAP) kinase activation. Furthermore, glycine-extended gastrin(17) induced a P13-kinase-mediated tyrosine phosphorylation of the adherens junction protein beta -catenin, partial dissociation of the complex between beta -catenin and the transmembrane protein E-cadherin, and delocalization of beta -catenin into the cytoplasm. Long lasting activation of MAP kinases by glycine-extended gastrin17 was specifically required for the migratory response, in contrast to the involvement of a rapid and transient MAP kinase activation in the proliferative response to both amidated and glycine-extended gastrin(17). Therefore, the time course of MAP kinase activation appears to be a critical determinant of the biological effects mediated by this pathway. Together with the involvement of P13-kinase in the dissociation of adherens junctions, long term activation of MAP kinases seems responsible for the selectivity of this novel effect of G(17)-Gly on the adhesion and migration of gastric epithelial cells.	Fac Pharm Montpellier, EA MNRT 2995, Lab Signalisat Cellulaire Normale & Tumorale, F-34060 Montpellier, France; Univ Melbourne, Austin Hosp, Dept Surg, Melbourne, Vic 3084, Australia	Universite de Montpellier; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Baldwin, GS (corresponding author), A&RMC, Dept Surg, Austin Campus,Studley Rd, Heidelberg, Vic 3084, Australia.		Hollande, Frederic/E-3133-2013; Hollande, Frederic/GLS-4120-2022	Hollande, Frederic/0000-0002-7046-8392; Choquet, armelle/0000-0002-6959-9387; Baldwin, Graham/0000-0002-0944-8747				AZUMA T, 1990, J GASTROEN HEPATOL, V5, P525, DOI 10.1111/j.1440-1746.1990.tb01435.x; BALDWIN GS, 1995, J GASTROEN HEPATOL, V10, P215, DOI 10.1111/j.1440-1746.1995.tb01083.x; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; Chen D, 2000, GASTROENTEROLOGY, V119, P756, DOI 10.1053/gast.2000.16480; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ciccotosto GD, 1996, REGUL PEPTIDES, V62, P97, DOI 10.1016/0167-0115(96)00003-1; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Daulhac L, 1999, FEBS LETT, V445, P251, DOI 10.1016/S0014-5793(99)00129-5; De Hauwer C, 1998, J NEUROBIOL, V37, P373, DOI 10.1002/(SICI)1097-4695(19981115)37:3<373::AID-NEU3>3.0.CO;2-H; Dockray GJ, 1999, J PHYSIOL-LONDON, V518, P315, DOI 10.1111/j.1469-7793.1999.0315p.x; Duan C, 2000, CIRC RES, V86, P15, DOI 10.1161/01.RES.86.1.15; Henwood M, 2001, BRIT J SURG, V88, P564, DOI 10.1046/j.1365-2168.2001.01716.x; HILSTED L, 1988, BIOCHEM J, V255, P397, DOI 10.1042/bj2550397; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; Hollande F, 2001, AM J PHYSIOL-GASTR L, V280, pG910, DOI 10.1152/ajpgi.2001.280.5.G910; Ilic D, 1997, J CELL SCI, V110, P401; Iwase K, 1997, GASTROENTEROLOGY, V113, P782, DOI 10.1016/S0016-5085(97)70172-0; Jais P, 1997, INT J CANCER, V71, P308; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; KAISE M, 1995, J BIOL CHEM, V270, P11155, DOI 10.1074/jbc.270.19.11155; KAMEYAMA M, 1993, DIS COLON RECTUM, V36, P497, DOI 10.1007/BF02050017; Kermorgant S, 2001, BIOCHEM BIOPH RES CO, V285, P136, DOI 10.1006/bbrc.2001.5132; LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2; Miyazaki Y, 1999, GASTROENTEROLOGY, V116, P78, DOI 10.1016/S0016-5085(99)70231-3; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; READ M, 1993, MOL CELL ENDOCRINOL, V93, P31, DOI 10.1016/0303-7207(93)90136-8; READ MA, 1992, ENDOCRINOLOGY, V130, P1688, DOI 10.1210/en.130.3.1688; ROCHE S, 1994, BIOCHEM J, V301, P703, DOI 10.1042/bj3010703; Royal I, 1997, J CELL PHYSIOL, V173, P196, DOI 10.1002/(SICI)1097-4652(199711)173:2<196::AID-JCP20>3.0.CO;2-D; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Seet L, 1987, Biomed Chromatogr, V2, P159, DOI 10.1002/bmc.1130020407; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; SINGH P, 1994, AM J PHYSIOL, V267, pG235, DOI 10.1152/ajpgi.1994.267.2.G235; SINGH P, 1995, J BIOL CHEM, V270, P8429, DOI 10.1074/jbc.270.15.8429; Sipeki S, 1999, CELL SIGNAL, V11, P885, DOI 10.1016/S0898-6568(99)00060-1; Stepan VM, 1999, MOL MED, V5, P147, DOI 10.1007/BF03402058; Stepan VM, 1999, AM J PHYSIOL-REG I, V277, pR572, DOI 10.1152/ajpregu.1999.277.2.R572; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG1363, DOI 10.1152/ajpgi.1999.276.6.G1363; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG415, DOI 10.1152/ajpgi.1999.276.2.G415; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; TODISCO A, 1995, J BIOL CHEM, V270, P28337; Tornhage CJ, 2000, J PEDIATR ENDOCR MET, V13, P1563; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Watson SA, 1999, EUR J CANCER, V35, P1286, DOI 10.1016/S0959-8049(99)00115-X; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587	47	58	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40402	40410		10.1074/jbc.M105090200	http://dx.doi.org/10.1074/jbc.M105090200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11495912	hybrid			2022-12-25	WOS:000171925600008
J	Santiago, FS; Lowe, HC; Bobryshev, YV; Khachigian, LM				Santiago, FS; Lowe, HC; Bobryshev, YV; Khachigian, LM			Induction of the transcriptional repressor Yin Yang-1 by vascular cell injury - Autocrine/paracrine role of endogenous fibroblast growth factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SERUM RESPONSE FACTOR; ADENOVIRUS E1A; FACTOR YY1; GENE-TRANSCRIPTION; ARTERIAL INJURY; NUCLEAR FACTOR; A-MYB; PROMOTER; EXPRESSION	Yin Yang-1 (YY1) is a multifunctional transcription factor that can repress the expression of many growth factor, hormone, and cytokine genes implicated in atherogenesis. YY1 expression is activated in rat vascular smooth muscle cells shortly after injury. YY1 DNA binding activity paralleled elevated protein levels in the nucleus. Smooth muscle cell injury triggered the rapid extracellular release of immunoreactive fibroblast growth factor-2 (FGF-2). YY1 induction after injury was blocked by neutralizing antibodies directed against FGF-2. This growth factor increased YY1 mRNA and protein expression and stimulated YY1 binding and transcriptional activity. Overexpression of YY1 inhibited smooth muscle cell replication. immunohistochemical analysis demonstrated YY1 staining in medial smooth muscle cells, coincident with FGF-2 expression. Proliferating cell nuclear antigen staining, in contrast, was confined mainly to the atherosclerotic intima. This is the first demonstration that YY1 is induced by either injury or FGF-2, is differentially expressed in normal and diseased human arteries, and that its overexpression inhibits vascular smooth muscle but not endothelial cell replication.	Univ New S Wales, Sch Pathol, Ctr Thombosis & Vasc Res, Sydney, NSW 2052, Australia; St Vincents Hosp, Professorial Surg Unit, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia	University of New South Wales Sydney; St Vincents Hospital Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Sch Pathol, Ctr Thombosis & Vasc Res, Sydney, NSW 2052, Australia.		Bobryshev, Yuri/J-2838-2013; Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				BAUKNECHT T, 1995, J VIROL, V69, P1; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; CLOWES AW, 1983, LAB INVEST, V49, P327; Coull JJ, 2000, J VIROL, V74, P6790, DOI 10.1128/JVI.74.15.6790-6799.2000; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Fang Y, 1998, J MOL ENDOCRINOL, V20, P337, DOI 10.1677/jme.0.0200337; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; HAHN CN, 1994, NUCLEIC ACIDS RES, V22, P2410, DOI 10.1093/nar/22.12.2410; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUGHES SE, 1993, CARDIOVASC RES, V27, P1214, DOI 10.1093/cvr/27.7.1214; Jain MK, 1998, J BIOL CHEM, V273, P5993, DOI 10.1074/jbc.273.11.5993; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Khachigian LM, 1999, CIRC RES, V84, P1258, DOI 10.1161/01.RES.84.11.1258; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LINDNER V, 1993, CIRC RES, V73, P589, DOI 10.1161/01.RES.73.3.589; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; Marhamati DJ, 1997, MOL CELL BIOL, V17, P2448, DOI 10.1128/MCB.17.5.2448; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Park KY, 1996, BIOCHEM BIOPH RES CO, V228, P745, DOI 10.1006/bbrc.1996.1726; Patten M, 2000, J MOL CELL CARDIOL, V32, P1341, DOI 10.1006/jmcc.2000.1169; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; Schwenger GTF, 1999, J ALLERGY CLIN IMMUN, V104, P820, DOI 10.1016/S0091-6749(99)70293-9; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Turque N, 1997, J VIROL, V71, P9778, DOI 10.1128/JVI.71.12.9778-9781.1997; Yao YL, 1998, NUCLEIC ACIDS RES, V26, P3776, DOI 10.1093/nar/26.16.3776; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Ye JP, 1999, J BIOL CHEM, V274, P26661, DOI 10.1074/jbc.274.38.26661	39	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41143	41149		10.1074/jbc.M104913200	http://dx.doi.org/10.1074/jbc.M104913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11487577	hybrid			2022-12-25	WOS:000171925600103
J	Adkins, CE; Pillai, GV; Kerby, J; Bonnert, TP; Haldon, C; McKernan, RM; Gonzalez, JE; Oades, K; Whiting, PJ; Simpson, PB				Adkins, CE; Pillai, GV; Kerby, J; Bonnert, TP; Haldon, C; McKernan, RM; Gonzalez, JE; Oades, K; Whiting, PJ; Simpson, PB			alpha(4)beta(3)delta GABA(A) receptors characterized by fluorescence resonance energy transfer-derived measurements of membrane potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC ACID(A) RECEPTOR; MESSENGER-RNA EXPRESSION; ALPHA-4 SUBUNIT; RAT HIPPOCAMPUS; IMMUNOCYTOCHEMICAL DISTRIBUTION; GAMMA-SUBUNIT; BETA 2; CHANNEL; PHARMACOLOGY; BINDING	Selective modulators of gamma -aminobutyric acid, type A (GABA(A)) receptors containing alpha (4) subunits may provide new treatments for epilepsy and premenstrual syndrome. Using mouse L(-tk) cells, we stably expressed the native GABA(A) receptor subunit combinations alpha (3)beta (3)gamma (2), alpha (4)beta (3)gamma (2), and, for the first time, alpha (4)beta (3)delta and characterized their properties using a novel fluorescence resonance energy transfer assay of GABA-evoked depolarizations. GABA evoked concentration-dependent decreases in fluorescence resonance energy transfer that were blocked by GABA(A) receptor antagonists and, for alpha (3)beta (3)gamma (2) and alpha (4)beta (3)gamma (2) receptors, modulated by benzodiazepines with the expected subtype specificity. When combined with alpha (4) and beta (3), delta subunits, compared with gamma (2), conferred greater sensitivity to the agonists GABA, 4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridin-3-ol (THIP), and muscimol and greater maximal efficacy to TRIP. alpha (4)beta (3)delta responses were markedly modulated by steroids and anesthetics. Alphaxalone, pentobarbital, and pregnanolone were all 3-7-fold more efficacious at alpha (4)beta (3)delta compared with alpha (4)beta (3)gamma (2). The fluorescence technique used in this study has proven valuable for extensive characterization of a novel GABA(A) receptor. For GABA(A) receptors containing a4 subunits, our experiments reveal that inclusion of 6 instead of gamma (2) subunits can increase the affinity and in some cases the efficacy of agonists and can increase the efficacy of allosteric modulators. Pregnanolone was a particularly efficacious modulator of alpha (4)beta (3)delta receptors, consistent with a central role for this subunit combination in premenstrual syndrome.	Merck Sharp & Dohme Ltd, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England; Aurora Biosci Corp, La Jolla, CA 92121 USA	Merck & Company	Adkins, CE (corresponding author), Merck Sharp & Dohme Ltd, Neurosci Res Ctr, Eastwick Rd, Harlow CM20 2QR, Essex, England.	charles_adkins@merck.com		Whiting, Paul/0000-0002-4121-1379; Simpson, Peter/0000-0003-0364-2685				Banerjee PK, 1998, EXP NEUROL, V154, P213, DOI 10.1006/exnr.1998.6928; BANNERJEE PK, 2000, SOC NEUR ABSTR, V26; Benke D, 1997, J NEUROCHEM, V69, P806; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; Brickley SG, 1999, J NEUROSCI, V19, P2960; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brooks-Kayal AR, 1999, J NEUROSCI, V19, P8312; Buhr A, 1996, MOL PHARMACOL, V49, P1080; Chang YC, 1996, J NEUROSCI, V16, P5415; Clark M, 1998, NEUROSCI LETT, V250, P17, DOI 10.1016/S0304-3940(98)00422-4; CLARK M, 1994, MOL BRAIN RES, V26, P309, DOI 10.1016/0169-328X(94)90104-X; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; Follesa P, 2000, MOL PHARMACOL, V57, P1262; Gonzalez JE, 1999, DRUG DISCOV TODAY, V4, P431, DOI 10.1016/S1359-6446(99)01383-5; Gonzalez V, 1997, J SEISMOL, V1, P269, DOI 10.1023/A:1009777605524; Granja R, 1998, EUR J PHARMACOL, V345, P315, DOI 10.1016/S0014-2999(98)00025-9; Grobin AC, 2000, EUR J PHARMACOL, V409, pR1, DOI 10.1016/S0014-2999(00)00797-4; HADINGHAM KL, 1993, MOL PHARMACOL, V44, P1211; Hevers W, 1998, MOL NEUROBIOL, V18, P35, DOI 10.1007/BF02741459; JUNE HL, 1995, J PHARMACOL EXP THER, V274, P1105; Knoflach F, 1996, MOL PHARMACOL, V50, P1253; Korpi ER, 1997, BRIT J PHARMACOL, V120, P741, DOI 10.1038/sj.bjp.0700922; Kultas-Ilinsky K, 1998, NEUROSCIENCE, V85, P179, DOI 10.1016/S0306-4522(97)00634-9; Loew L. M., 1993, FLUORESCENT LUMINESC, P150; LOEW LM, 1988, SPECTROSCOPIC MEMBRA, P139; MACDONALD R, 1978, NATURE, V271, P563, DOI 10.1038/271563a0; Mahmoudi M, 1997, J NEUROCHEM, V68, P2485; MCKERNAN RM, 1995, J RECEPT SIGNAL TR R, V15, P173, DOI 10.3109/10799899509045215; MERTENS S, 1993, J BIOL CHEM, V268, P5965; Mihalek RM, 1999, P NATL ACAD SCI USA, V96, P12905, DOI 10.1073/pnas.96.22.12905; Moran MH, 1998, BRAIN RES, V807, P84, DOI 10.1016/S0006-8993(98)00782-3; Nusser Z, 1998, J NEUROSCI, V18, P1693; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Penschuck S, 1997, MOL BRAIN RES, V51, P212, DOI 10.1016/S0169-328X(97)00243-X; Pirker S, 2000, NEUROSCIENCE, V101, P815, DOI 10.1016/S0306-4522(00)00442-5; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; Schwarzer C, 1997, NEUROSCIENCE, V80, P1001, DOI 10.1016/S0306-4522(97)00145-0; Simpson PB, 2000, J NEUROSCI METH, V99, P91, DOI 10.1016/S0165-0270(00)00219-3; Smith AJ, 2001, MOL PHARMACOL, V59, P1108, DOI 10.1124/mol.59.5.1108; Smith SS, 1998, NATURE, V392, P926, DOI 10.1038/31948; Smith SS, 1998, J NEUROSCI, V18, P5275, DOI 10.1523/JNEUROSCI.18-14-05275.1998; Sperk G, 1997, NEUROSCIENCE, V80, P987, DOI 10.1016/S0306-4522(97)00146-2; Stevenson A, 1995, MOL PHARMACOL, V48, P965; Sur C, 1999, MOL PHARMACOL, V56, P110, DOI 10.1124/mol.56.1.110; SUZDAK PD, 1986, SCIENCE, V234, P1243, DOI 10.1126/science.3022383; Tretter V, 1997, J NEUROSCI, V17, P2728; Tsunashima K, 1997, NEUROSCIENCE, V80, P1019, DOI 10.1016/S0306-4522(97)00144-9; TURNER DM, 1989, J PHARMACOL EXP THER, V248, P960; WAFFORD KA, 1993, MOL PHARMACOL, V43, P240; Wafford KA, 1996, MOL PHARMACOL, V50, P670; Waggoner A S, 1977, Ann N Y Acad Sci, V303, P217; Whiting PJ, 1999, ANN NY ACAD SCI, V868, P645, DOI 10.1111/j.1749-6632.1999.tb11341.x; Whittemore ER, 1996, MOL PHARMACOL, V50, P1364; Wingrove PB, 1997, MOL PHARMACOL, V52, P874, DOI 10.1124/mol.52.5.874; WISDEN W, 1992, J NEUROSCI, V12, P1040; Yang W, 1995, EUR J PHARM-MOLEC PH, V291, P319, DOI 10.1016/0922-4106(95)90072-1	56	152	160	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38934	38939		10.1074/jbc.M104318200	http://dx.doi.org/10.1074/jbc.M104318200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495904	hybrid			2022-12-25	WOS:000171673200080
J	Asawakarn, T; Cladera, J; O'Shea, P				Asawakarn, T; Cladera, J; O'Shea, P			Effects of the membrane dipole potential on the interaction of saquinavir with phospholipid membranes and plasma membrane receptors of Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 PROTEASE INHIBITORS; P-GLYCOPROTEIN; MULTIDRUG TRANSPORTER; IMMUNODEFICIENCY-VIRUS; CHOLESTEROL; MODULATION; RAFTS; MONOLAYERS; INSERTION; CAVEOLAE	The combined use of the membrane surface potential fluorescent sensor fluorescein phosphatidylethanolamine (FPE) and the membrane dipole potential fluorescent sensor di-8-ANEPPS to characterize the interaction of molecules with model and cellular membranes and to asses the influence of the dipole potential on the interaction is reported. The study of the human immunodeficiency virus protease inhibitor saquinavir with Caco-2 cells and phospholipid membranes reveals that the compound interacts with the lipidic bilayer of model membranes with a simple hyperbolic binding profile but with Caco-2 cells in a cooperative way involving membrane receptors. Additional studies indicated that colchicine acts as a competitor ligand to saquinavir and suggests, in agreement with other reports, that the identity of the saquinavir "receptor" could be P-glycoprotein or the multiple drug resistance-associated protein. The modification of the magnitude of the membrane dipole potential using compounds such as cholesterol, phloretin, and 6-ketocholestanol influences the binding capacity of saquinavir. Furthermore, removal of cholesterol from the cell membrane using methyl-beta -cyclodextrin significantly decreases the binding capacity of saquinavir. Because removal of cholesterol from the cell membrane has been reported to disrupt membrane domains known as "rafts," our observations imply that the membrane dipole potential plays an important role as a modulator of molecule-membrane interactions in these membrane structures. Such a role is suggested to contribute to the altered behavior of receptor-mediated signaling systems in membrane rafts.	Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham	O'Shea, P (corresponding author), Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2UH, England.		Cladera, Josep/E-6737-2010	Cladera, Josep/0000-0002-1724-3477; O'Shea, paul/0000-0001-9313-8313				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Aungst BJ, 1999, ADV DRUG DELIVER REV, V39, P105, DOI 10.1016/S0169-409X(99)00022-8; BROCKMAN H, 1994, CHEM PHYS LIPIDS, V73, P57, DOI 10.1016/0009-3084(94)90174-0; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Bryson EA, 1999, BIOCHEMISTRY-US, V38, P9758, DOI 10.1021/bi990119o; Cladera J, 1998, BIOPHYS J, V74, P2434, DOI 10.1016/S0006-3495(98)77951-2; Cladera J, 1999, J BIOL CHEM, V274, P29951, DOI 10.1074/jbc.274.42.29951; Cladera J, 2001, PRACT APPROACH SER, P169; Cladera J, 2001, EMBO J, V20, P19, DOI 10.1093/emboj/20.1.19; Clarke RJ, 1997, BBA-BIOMEMBRANES, V1323, P223, DOI 10.1016/S0005-2736(96)00188-5; Clementz T., 1988, PHYSL REGULATION MEM, P41; Demeule M, 2000, FEBS LETT, V466, P219, DOI 10.1016/S0014-5793(00)01087-5; Druley TE, 2001, BIOCHEMISTRY-US, V40, P4323, DOI 10.1021/bi001372n; Ferte J, 2000, EUR J BIOCHEM, V267, P277, DOI 10.1046/j.1432-1327.2000.01046.x; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GROSS E, 1994, BIOPHYS J, V67, P208, DOI 10.1016/S0006-3495(94)80471-0; Gutmann H, 1999, MOL PHARMACOL, V56, P383, DOI 10.1124/mol.56.2.383; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Jones K, 2001, AIDS, V15, P675, DOI 10.1097/00002030-200104130-00002; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lavie Y, 1999, LIPIDS, V34, pS57, DOI 10.1007/BF02562229; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; LOEW LM, 1979, NATURE, V281, P497, DOI 10.1038/281497a0; Luker GD, 2000, BIOCHEMISTRY-US, V39, P7651, DOI 10.1021/bi9928593; Maggio B, 1999, J LIPID RES, V40, P930; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Miller DS, 2000, MOL PHARMACOL, V58, P1357, DOI 10.1124/mol.58.6.1357; MONTANA V, 1989, BIOCHEMISTRY-US, V28, P4536, DOI 10.1021/bi00437a003; Profit L, 1999, AIDS, V13, P1623, DOI 10.1097/00002030-199909100-00004; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; Rokitskaya TI, 1997, BIOPHYS J, V73, P850, DOI 10.1016/S0006-3495(97)78117-7; Shapovalov VL, 1999, BIOPHYS J, V77, P299, DOI 10.1016/S0006-3495(99)76890-6; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Srinivas RV, 1998, ANTIMICROB AGENTS CH, V42, P3157, DOI 10.1128/AAC.42.12.3157; van Veen HW, 1998, BBA-BIOENERGETICS, V1365, P31, DOI 10.1016/S0005-2728(98)00039-5; Voglino L, 1998, BIOCHEMISTRY-US, V37, P12241, DOI 10.1021/bi9805792; WALL J, 1995, MOL MEMBR BIOL, V12, P183, DOI 10.3109/09687689509027506; WALL J, 1995, J CELL SCI, V108, P2673; Watkins PB, 1997, ADV DRUG DELIVER REV, V27, P161, DOI 10.1016/S0169-409X(97)00041-0; Zegers MMP, 1998, BIOCHEM J, V336, P257, DOI 10.1042/bj3360257	42	73	74	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38457	38463		10.1074/jbc.M103269200	http://dx.doi.org/10.1074/jbc.M103269200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11500495	hybrid			2022-12-25	WOS:000171673200019
J	Chiang, PW; Carpenter, LE; Hagerman, PJ				Chiang, PW; Carpenter, LE; Hagerman, PJ			The 5 '-untranslated region of the FMR1 message facilitates translation by internal ribosome entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X-SYNDROME; ENCEPHALOMYOCARDITIS VIRUS-RNA; MESSENGER-RNA; SECONDARY STRUCTURE; ELEVATED LEVELS; CGG REPEAT; C-MYC; INITIATION; PROTEIN; SITE	Fragile X syndrome, the leading heritable form of mental impairment, is generally caused by large expansions of a CGG repeat in the promoter region of the FMR1 gene followed by transcriptional silencing. However, there is growing evidence that translation of the FMR1 message is also impaired, presumably because of the expanded CGG element in the 5'-untranslated region (5'-UTR) of the FMR1 message. To study the properties of the FMR1 5'-UTR, deletions were generated within a normal 5'-UTR with 16 CGG repeats for both monocistronic and dicistronic (luciferase) reporter constructs. Transient transfection experiments revealed a similar to 20-nucleotide region upstream of the CGG repeat element that functions as an internal ribosome entry site (IRES). The normal CGG element itself does not appear to influence the efficiency of IRES-mediated stimulation of downstream reporter activity (similar to 18-fold over controls). Additional controls indicate that the enhanced activity of the downstream reporter is not due to readthrough from the upstream cistron, nor is it due to translation of cryptic monocistronic transcripts. The role of the FMR1 IRES element is not known at present; however, by analogy to other IRES-containing mRNAs expressed in neurons, the FMR1 IRES element may help to promote translation in dendrites.	Univ Calif Davis, Dept Biol Chem, Sch Med, Davis, CA 95616 USA; Univ Colorado, Sch Med, Program Human Genet, Denver, CO 80262 USA	University of California System; University of California Davis; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hagerman, PJ (corresponding author), Univ Calif Davis, Dept Biol Chem, Sch Med, 1 Shields Ave, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035305] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35305] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bernstein J, 1997, J BIOL CHEM, V272, P9356; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; Drouin R, 1997, HUM MOL GENET, V6, P2051, DOI 10.1093/hmg/6.12.2051; FENG Y, 1995, SCIENCE, V268, P731, DOI 10.1126/science.7732383; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; Gosert R, 2000, MOL CELL BIOL, V20, P1583, DOI 10.1128/MCB.20.5.1583-1595.2000; Hagerman R J, 1999, NEURODEVELOPMENTAL D, P61; Hellen CUT, 1995, CURR TOP MICROBIOL, V203, P31; Hunt SL, 1999, RNA, V5, P344, DOI 10.1017/S1355838299981414; Jackson RJ, 1995, RNA, V1, P985; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kim YK, 2000, J MOL BIOL, V304, P119, DOI 10.1006/jmbi.2000.4179; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; NICHOLSON R, 1991, J VIROL, V65, P5886, DOI 10.1128/JVI.65.11.5886-5894.1991; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; Pilipenko EV, 2000, GENE DEV, V14, P2028; Pinkstaff JK, 2001, P NATL ACAD SCI USA, V98, P2770, DOI 10.1073/pnas.051623398; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; Tassone F, 2000, AM J MED GENET, V94, P232, DOI 10.1002/1096-8628(20000918)94:3<232::AID-AJMG9>3.0.CO;2-H; Tassone F, 2000, AM J HUM GENET, V66, P6, DOI 10.1086/302720; Tassone F, 2001, J MED GENET, V38, P453, DOI 10.1136/jmg.38.7.453; Tassone F, 2000, AM J MED GENET, V97, P195, DOI 10.1002/1096-8628(200023)97:3<195::AID-AJMG1037>3.0.CO;2-R; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Weiler IJ, 1999, AM J MED GENET, V83, P248, DOI 10.1002/(SICI)1096-8628(19990402)83:4<248::AID-AJMG3>3.0.CO;2-1; Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395; YU S, 1992, AM J HUM GENET, V50, P968; Zuker M., 1999, V70, P11	41	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37916	37921						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11489899				2022-12-25	WOS:000171526500028
J	Johnson, AA; Johnson, KA				Johnson, AA; Johnson, KA			Exonuclease proofreading by human mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; DEOXYRIBONUCLEIC-ACID; STEADY-STATE; FIDELITY; GAMMA; MECHANISM; FRAGMENT; SUBUNIT	We have examined the ability of the human mitochondrial DNA polymerase to correct errors in DNA sequence using single turnover kinetic methods. The rate of excision of single-stranded DNA ranged from 0.07 to 0.17 s(-1), depending on the identity of the 3'-base. Excision of the 3'-terminal base from correctly base paired DNA occurred at a rate of 0.05 s(-1), indicating that the cost of proofreading is minimal, as defined by the ratio of the k(exo). for correctly base-paired DNA divided by the rate of forward polymerization (0.05/37 = 0.14%). Excision of duplex DNA containing 1-7 mismatches was biphasic, and the rate and amplitude of the fast phase increased with the number of mismatches, reaching a maximum of 9 s(-1). We showed that transfer of DNA from the polymerase to the exonuclease active site and back again occurs through an intramolecular reaction, allowing for a complete cycle of reactions for error correction. For DNA containing a buried mismatch (T:T followed by C:G base pairs), the 3' base was removed at a rate of 3 s(-1). The addition of nucleotide to the reaction that is identical to the 3' base increased the rate of excision 7-fold to 21 s(-1). We propose that the free nucleotide enhances the rate of transfer of the DNA to the exonuclease active site by interrupting the correct 3' base pair through interaction with the template base. The exonuclease contribution to fidelity is minimal if the calculation is based on hydrolysis of a single mismatch: (k(exo) + k(pol,over))/(k(pol,over)) = 10, but this value increases to similar to 200 when examining error correction in the presence of nucleotides.	Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Johnson, KA (corresponding author), Univ Texas, Inst Cell & Mol Biol, MBB 3-122,A4800, Austin, TX 78712 USA.	kajohnson@mail.utexas.edu			NIGMS NIH HHS [GM44613] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Goodman MF, 1998, GENETICS, V148, P1475; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38090; JOHNSON KA, 1992, PHILOS T ROY SOC B, V336, P107, DOI 10.1098/rstb.1992.0050; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197; Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; Miller H, 1996, BIOCHEMISTRY-US, V35, P12919, DOI 10.1021/bi960326d; OLSON MW, 1992, J BIOL CHEM, V267, P23136; REIS RJS, 1983, J BIOL CHEM, V258, P9078; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r	22	107	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38097	38107						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11477094				2022-12-25	WOS:000171526500052
J	Vincent, B; Paitel, E; Saftig, P; Frobert, Y; Hartmann, D; De Strooper, B; Grassi, J; Lopez-Perez, E; Checler, F				Vincent, B; Paitel, E; Saftig, P; Frobert, Y; Hartmann, D; De Strooper, B; Grassi, J; Lopez-Perez, E; Checler, F			The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; NECROSIS-FACTOR-ALPHA; SECRETASE CLEAVAGE; CONVERTING-ENZYME; METALLOPROTEASE; BRAIN; CELLS	We showed previously that PrPc undergoes constitutive and phorbol ester-regulated cleavage inside the 106-126 toxic domain of the protein, leading to the production of a fragment referred to as N1. Here we show by a pharmacological approach that o-phenanthroline, a general zinc-metalloprotease inhibitors, as well as BB3103 and TAPI, the inhibitors of metalloenzymes ADAM10 (A disintegrin and metalloprotease); and TACE, tumor necrosis factor alpha -converting enzyme; ADAM17), respectively, drastically reduce N1 formation. We set up stable human embryonic kidney 293 transfectants overexpressing human ADAM10 and TACE, and we demonstrate that ADAM10 contributes to constitutive N1 roduction whereas TACE mainly participates in regulated N1 formation. Furthermore, constitutive N1 secretion is drastically reduced in fibroblasts deficient for ADAM10 whereas phorbol 12,13-dibutyrate-regulated N1 production is fully abolished in TACE-deficient cells. Altogether, our data demonstrate for the first time that disintegrins could participate in the catabolism of glycosyl phosphoinositide-anchored proteins such as PrPc. Second, our study identifies ADAM10 and ADAM17 as the protease candidates responsible for normal cleavage of PrPc. Therefore, these disintegrins could be seen as putative cellular targets of a therapeutic strategy aimed at increasing normal PrPc breakdown and thereby depleting cells of the putative 106-126 "toxic" domain of PrPc.	IPMC, CNRS UMR6097, F-06560 Valbonne, France; Univ Gottingen, D-37073 Gottingen, Germany; CEA Saclay, F-91191 Gif Sur Yvette, France; Ctr Human Genet, B-3050 Louvain, Belgium	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Gottingen; CEA; UDICE-French Research Universities; Universite Paris Saclay	Checler, F (corresponding author), IPMC, CNRS UMR6097, 660 Route Lucioles, F-06560 Valbonne, France.		de+Strooper, Bart/Z-1638-2019; Checler, Frederic/C-1241-2009; De Strooper, Bart/F-6507-2012; Saftig, Paul/A-7966-2010	Checler, Frederic/0000-0003-2098-1750; De Strooper, Bart/0000-0001-5455-5819; Vincent, Bruno/0000-0003-3876-2118				Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CHECLER F, 1995, J NEUROCHEM, V65, P1431; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lopez-Perez E, 2001, J NEUROCHEM, V76, P1532, DOI 10.1046/j.1471-4159.2001.00180.x; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Middelhoven PJ, 1997, FEBS LETT, V414, P14, DOI 10.1016/S0014-5793(97)00959-9; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Savage MJ, 1998, J NEUROSCI, V18, P1743; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Vincent B, 2000, J BIOL CHEM, V275, P35612, DOI 10.1074/jbc.M004628200; Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342	21	245	251	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37743	37746						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11477090				2022-12-25	WOS:000171526500004
J	Zhang, LX; Paakkarinen, V; Suorsa, M; Aro, EM				Zhang, LX; Paakkarinen, V; Suorsa, M; Aro, EM			A SecY homologue is involved in chloroplast-encoded D1 protein biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; THYLAKOID MEMBRANE; ESCHERICHIA-COLI; PREPROTEIN TRANSLOCASE; ENDOPLASMIC-RETICULUM; TRANSPORT PATHWAYS; PHOTOSYSTEM-II; TRANSLATION; RIBOSOMES; CHANNEL	We have used the photosystem II reaction center D1 protein as a model to study the mechanisms of targeting and insertion of chloroplast-encoded thylakoid membrane proteins. The unusually high turnover rate and distinct pausing intermediates during translation make the D1 protein biogenesis particularly suitable for these purposes. Here we show that cpSecY, a chloroplast homologue of bacterial essential translocon component SecY, interacts tightly with thylakoid membrane-bound ribosomes, suggesting its involvement in protein translocation and insertion. Co-immunoprecipitation and cross-linking experiments indicated that cpSecY resides in the vicinity of D1 elongation intermediates and provided evidence for a transient interaction of cpSecY with D1 elongation intermediates during the biogenesis of D1. After termination of translation, such interactions no longer existed. Our results indicate that, in addition to a well characterized role of cpSecY in posttranslational translocation of nuclear-encoded proteins, it seems to be also involved in cotranslational membrane protein translocation and insertion in chloroplasts.	Univ Turku, Dept Biol, FIN-20014 Turku, Finland	University of Turku	Aro, EM (corresponding author), Univ Turku, Dept Biol, Lab Plant Physiol, Biocity A,6th Fl, FIN-20520 Turku, Finland.		Aro, Eva-Mari/Q-8664-2017	Aro, Eva-Mari/0000-0002-2922-1435; Suorsa, Marjaana/0000-0002-3821-0607				ADIR N, 1990, J BIOL CHEM, V265, P12563; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; BERGHOFER J, 1996, PLANT PHYSIOL, V112, P863; CHUA NH, 1973, J CELL BIOL, V57, P798, DOI 10.1083/jcb.57.3.798; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hashimoto A, 1997, PLANT CELL, V9, P441, DOI 10.1105/tpc.9.3.441; Hirose T, 1996, EMBO J, V15, P1687, DOI 10.1002/j.1460-2075.1996.tb00514.x; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KIM JM, 1991, J BIOL CHEM, V266, P14931; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; Koch HG, 2000, J CELL BIOL, V150, P689, DOI 10.1083/jcb.150.3.689; KYLE DJ, 1984, BIOCHIM BIOPHYS ACTA, V765, P89, DOI 10.1016/0005-2728(84)90001-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Mould RM, 1997, PLANT J, V11, P1051, DOI 10.1046/j.1365-313X.1997.11051051.x; MULLET JE, 1986, EUR J BIOCHEM, V155, P331, DOI 10.1111/j.1432-1033.1986.tb09495.x; Nilsson R, 1999, EMBO J, V18, P733, DOI 10.1093/emboj/18.3.733; Nohara T, 1996, BIOCHEM BIOPH RES CO, V224, P474, DOI 10.1006/bbrc.1996.1051; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Robinson C, 1997, TRENDS PLANT SCI, V2, P431, DOI 10.1016/S1360-1385(97)90027-3; Roy LM, 1998, J CELL BIOL, V141, P385, DOI 10.1083/jcb.141.2.385; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; Schnell DJ, 1998, ANNU REV PLANT PHYS, V49, P97, DOI 10.1146/annurev.arplant.49.1.97; Schuenemann D, 1999, J BIOL CHEM, V274, P12177, DOI 10.1074/jbc.274.17.12177; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; SMITH TA, 1994, J CELL BIOL, V126, P365, DOI 10.1083/jcb.126.2.365; Soll J, 1998, PLANT MOL BIOL, V38, P191, DOI 10.1023/A:1006034020192; Voelker R, 1997, GENETICS, V145, P467; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; Zhang LX, 1999, J BIOL CHEM, V274, P16062, DOI 10.1074/jbc.274.23.16062; Zhang LX, 2000, PLANT CELL, V12, P1769, DOI 10.1105/tpc.12.9.1769	43	81	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37809	37814						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11473124				2022-12-25	WOS:000171526500013
J	Evers, MR; Xia, GQ; Kang, HG; Schachner, M; Baenziger, JU				Evers, MR; Xia, GQ; Kang, HG; Schachner, M; Baenziger, JU			Molecular cloning and characterization of a dermatan-specific N-acetylgalactosamine 4-O-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE SULFOTRANSFERASES; EXPRESSION CLONING; NERVOUS-SYSTEM; CPG ISLANDS; SULFATE; CHONDROITIN; PROTEOGLYCANS; GENE; OLIGOSACCHARIDES; GLYCOSYLATION	We have identified and characterized an N-acetylgalactosamine-4-O-sulfotransferase designated dermatan-4-sulfotransferase-1 (D4ST-1) (GenBank (TM) accession number AF401222) based on its homology to HNK-1 sulfotransferase. The cDNA predicts an open reading frame encoding a type II membrane protein of 376 amino acids with a 43-amino acid cytoplasmic domain and a 316-amino acid luminal domain containing two potential N-linked glycosylation sites. D4ST-1 has significant amino acid identity with HNK-1 sulfotransferase (21.4%), N-acetylgalactosamine-4-O-sulfotransferase I (GalNAc-4-ST1) (24.7%),N-acetylgalactosamine-4-O-sulfotransferase 2 (GalNAc-4-ST2) (21.0%), chondroitin-4-O-sulfotransferase 1 (27.3%), and chondroitin-4-O-sulfotransferase 2 (22.8%). D4ST-1 transfers sulfate to the C-4 hydroxyl of beta1,4-linked GalNAc that is substituted with an alpha -linked iduronic acid (IdoUA) at the C-3 hydroxyl. D4ST-1 shows a strong preference in vitro for sulfate transfer to IdoUA alpha1,3GalNAc beta1,4 that is flanked by GlcUA beta1,3GalNAc beta1,4 as compared with IdoUA alpha1, 3GalNAc beta1,4 flanked by IdoUA alpha1,3GalNAc beta1,4. The specificity of D4ST-1 when assayed in vitro suggests that the addition of sulfate to GalNAc occurs immediately after epimerization of GlcUA to IdoUA. The open reading frame of D4ST-1 is encoded by a single exon located on human chromosome 15q14. Northern blot analysis reveals a single 2.4-kilobase transcript. D4ST-1 message is expressed in virtually all tissues at some level but is most highly expressed in pituitary, placenta, uterus, and thyroid. The properties of D4ST-1 indicate that sulfation of the GalNAc moieties in dermatan is mediated by a distinct GalNAc-4-O-sulfotransferase and occurs following epimerization of GlcUA to IdoUA.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	Washington University (WUSTL); University of Hamburg; University Medical Center Hamburg-Eppendorf	Baenziger, JU (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 S Euclid Ave, St Louis, MO 63110 USA.	Baenziger@Pathology.wustl.edu	Xia, Guoqing/C-2365-2015; Baenziger, Jacques U/E-9430-2012	Xia, Guoqing/0000-0003-4492-9156; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK41738] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baenziger JU, 1996, ENDOCRINOLOGY, V137, P1520, DOI 10.1210/en.137.5.1520; BAENZIGER JU, 1994, METHOD ENZYMOL, V230, P237; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Bovolenta P, 2000, PROG NEUROBIOL, V61, P113, DOI 10.1016/S0301-0082(99)00044-1; Bowman KG, 1999, CHEM BIOL, V6, pR9, DOI 10.1016/S1074-5521(99)80014-3; CHENG F, 1994, GLYCOBIOLOGY, V4, P685, DOI 10.1093/glycob/4.5.685; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; COSTER L, 1975, BIOCHEM J, V145, P379, DOI 10.1042/bj1450379; Eklund E, 2000, ARCH BIOCHEM BIOPHYS, V383, P171, DOI 10.1006/abbi.2000.2043; FRANSSON LA, 1974, BIOCHEM J, V143, P379, DOI 10.1042/bj1430379; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GU KN, 1993, CARBOHYD RES, V244, P369, DOI 10.1016/0008-6215(83)85014-9; Hemmerich S, 2000, GLYCOBIOLOGY, V10, P849, DOI 10.1093/glycob/10.9.849; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; Kang HG, 2001, J BIOL CHEM, V276, P10861, DOI 10.1074/jbc.M011560200; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MALMSTROM A, 1975, J BIOL CHEM, V250, P3419; MALMSTROM A, 1984, J BIOL CHEM, V259, P161; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Mazuruk K, 1996, BBA-GENE STRUCT EXPR, V1305, P151, DOI 10.1016/0167-4781(95)00201-4; Milanesi L, 1999, BIOINFORMATICS, V15, P612, DOI 10.1093/bioinformatics/15.7.612; Nadanaka S, 1999, FEBS LETT, V452, P185, DOI 10.1016/S0014-5793(99)00597-9; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Prydz K, 2000, J CELL SCI, V113, P193; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SILBERT JE, 1986, J BIOL CHEM, V261, P3397; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Woodworth A, 2001, Results Probl Cell Differ, V33, P123; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; Yang HO, 2000, GLYCOBIOLOGY, V10, P1033, DOI 10.1093/glycob/10.10.1033	46	86	89	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36344	36353		10.1074/jbc.M105848200	http://dx.doi.org/10.1074/jbc.M105848200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11470797	hybrid, Green Published			2022-12-25	WOS:000171194500040
J	Frank, G; Qiu, JH; Zheng, L; Shen, BH				Frank, G; Qiu, JH; Zheng, L; Shen, BH			Stimulation of eukaryotic flap endonuclease-1 activities by proliferating cell nuclear antigen (PCNA) is independent of its in vitro interaction via a consensus PCNA binding region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; BASE EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; MISMATCH REPAIR; REPLICATION-FACTOR; CRYSTAL-STRUCTURE; 3' EXONUCLEASE; LIGASE-I; FEN-1; MECHANISM	Interaction between human Rap endonuclease-1 (hFEN-1) and proliferating cell nuclear antigen (PCNA) represents a good model for interactions between multiple functional proteins involved in DNA metabolic pathways. A region of 9 conserved amino acid residues (residues Gln-337 through Lys-345) in the C terminus of human FEN-1 (hFEN-1) was shown to be responsible for the interaction with PCNA. Our current study indicates that 4 amino acid residues in hFEN-1 (Leu-340, Asp-341, Phe-343, and Phe-344) are critical for human PCNA (hPCNA) interaction. A conserved PCNA interaction motif in various proteins from assorted species has been defined as Q(1)X(2)X(3)(L/I)(4)X5X6F7(F/Y)(8), although our results fail to implicate Q(1) (Gln-337 in hFEN-1) as a crucial residue. Surprisingly, all hFEN-1 mutants, including L340A, D341A, F343A, and F344A, retained hPCNA-mediated stimulation of both exo- and flap endonuclease activities. Furthermore, our in vitro assay showed that hPCNA failed to bind to the scRad27 (yeast homolog of FEN-1) nuclease. However, its nuclease activities were significantly enhanced in the presence of hPCNA. Four additional Saccharomyces cerevisiae scRad27 mutants, including multiple alanine mutants and a deletion mutant of the entire PCNA binding region, were constructed to confirm this result. All of these mutants retained PCNA-driven nuclease activity stimulation. We therefore conclude that stimulation of eukaryotic hFEN-1 nuclease activities by PCNA is independent of its in vitro interaction via the PCNA binding region.	City Hope Natl Med Ctr, Dept Cell & Tumor Biol, Duarte, CA 91010 USA	City of Hope	Shen, BH (corresponding author), City Hope Natl Med Ctr, Dept Cell & Tumor Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.			Shen, Binghui/0000-0002-4408-407X	NATIONAL CANCER INSTITUTE [R29CA073764, R01CA073764] Funding Source: NIH RePORTER; NCI NIH HHS [CA73764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Biswas EE, 1997, BIOCHEMISTRY-US, V36, P5955, DOI 10.1021/bi962890u; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Chen C, 1999, MOL CELL BIOL, V19, P7801; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; Frank G, 1998, J BIOL CHEM, V273, P33064, DOI 10.1074/jbc.273.49.33064; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gary R, 1999, MOL CELL BIOL, V19, P5373; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Greene AL, 1999, HUM MOL GENET, V8, P2263, DOI 10.1093/hmg/8.12.2263; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kokoska RJ, 1999, GENETICS, V151, P511; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; MEUSER TC, 1996, CELL, V85, P1101; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Qiu JZ, 1999, MOL CELL BIOL, V19, P8361, DOI 10.1128/mcb.19.12.8361; Qiu JZ, 2001, J BIOL CHEM, V276, P4901, DOI 10.1074/jbc.M007825200; Rumbaugh JA, 1997, J BIOL CHEM, V272, P22591, DOI 10.1074/jbc.272.36.22591; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; Stucki M, 2001, J BIOL CHEM, V276, P7843, DOI 10.1074/jbc.M008829200; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; ZHANG SJ, 1995, J BIOL CHEM, V270, P7988, DOI 10.1074/jbc.270.14.7988; Zhu FX, 1997, BIOCHEMISTRY-US, V36, P5947, DOI 10.1021/bi962889v	48	47	47	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36295	36302		10.1074/jbc.M103397200	http://dx.doi.org/10.1074/jbc.M103397200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11477073	hybrid			2022-12-25	WOS:000171194500034
J	Vieira, MAR; Gao, M; Nikonova, LN; Maack, T				Vieira, MAR; Gao, M; Nikonova, LN; Maack, T			Molecular and cellular physiology of the dissociation of atrial natriuretic peptide from guanylyl cyclase A receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION ACTIVITIES; CLEARANCE RECEPTOR; ADENINE-NUCLEOTIDES; LIGAND-BINDING; C RECEPTORS; ACTIVATION; ATP; EXPRESSION; DOMAIN; PHOSPHORYLATION	Guanylyl cyclase subtype A (GCA) is the main receptor that mediates the effects of atrial natriuretic peptide (ANP) in the regulation of plasma volume and blood pressure. The dynamics of the dissociation of ANP from GCA were investigated in cultured Chinese hamster ovary (CHO) cells stably transfected with wild-type (WT) or mutant GCA receptors. The rate of dissociation of specifically bound I-125-ANP-(1-28) from intact CHOG-CAWT cells at 37 degreesC was extremely rapid (K-off = 0.49 +/- 0.02 min(-1)), whereas in isolated membranes prepared from these cells, the dissociation at 37 degreesC was > 10-fold slower (K-off = 0.035 +/- 0.006 min(-1)). The dissociation of ANP from CHOGCAWT cells showed remarkable temperature dependence. Between 22 and 37 degreesC, K-off increased similar to8 times, whereas between 4 and 22 degreesC it il creased only 1.5 times. Total deletion of the cytoplasmic domain or of the catalytic guanylyl cyclase sequence within this domain abolished ANP-induced increases in cGMP, dramatically slowed receptor-ligand dissociation by at least 10-fold, and abolished the temperature dependence of the dissociation of ANP. Deletion of the kinase-like domain led to maximal constitutive activation of guanylyl cyclase, markedly decreased K-off to 0.064 +/- 0.006 min(-1), and also abolished the temperature dependence of dissociation. Substitution of Ser(506) by Ala and particularly the double substitution of Gly(505) and Ser(506) by Ala within the kinase-like domain markedly reduced ANP-induced increases in cGMP, whereas K-off decreased modestly (albeit significantly) to 0.36 +/- 0.03 and 0.24 +/- 0.02 min(-1), respectively. As a whole, the results demonstrate for the first time that temperature per se or ATP alone cannot account for rapid GCA receptor-ligand dissociation under physiological conditions and suggest that ligand dissociation is modulated in part by the interaction of still unidentified cytosolic factors with the cytoplasmic domain of GCA.	Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA	Cornell University	Maack, T (corresponding author), Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, 1300 York Ave, New York, NY 10021 USA.	tmaack@mail.med.cornell.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053526] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-53526] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMEIDA FA, 1989, AM J PHYSIOL, V256, pR469, DOI 10.1152/ajpregu.1989.256.2.R469; ATLAS SA, 1992, ATRIAL NATRIURETIC F, P1577; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; Cohen D, 1996, J BIOL CHEM, V271, P9863, DOI 10.1074/jbc.271.16.9863; Dubois SK, 2000, P NATL ACAD SCI USA, V97, P4369, DOI 10.1073/pnas.97.8.4369; DUDA T, 1995, BIOCHEM BIOPH RES CO, V209, P286, DOI 10.1006/bbrc.1995.1501; Duda T, 2000, MOL CELL BIOCHEM, V214, P7, DOI 10.1023/A:1007144328682; Duda T, 1995, MOL CELL BIOCHEM, V152, P179, DOI 10.1007/BF01076081; Foster DC, 1998, J BIOL CHEM, V273, P16311, DOI 10.1074/jbc.273.26.16311; GARBERS DL, 1991, PHARMACOL THERAPEUT, V50, P337, DOI 10.1016/0163-7258(91)90049-R; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JEWETT JRS, 1993, EMBO J, V12, P769, DOI 10.1002/j.1460-2075.1993.tb05711.x; Kashiwagi M, 1999, EUR J BIOCHEM, V259, P204, DOI 10.1046/j.1432-1327.1999.00023.x; KOH GY, 1992, J BIOL CHEM, V267, P11987; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; Kumar R, 2001, J BIOL CHEM, V276, P11371, DOI 10.1074/jbc.M010480200; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LAROSE L, 1991, BIOCHEMISTRY-US, V30, P8990, DOI 10.1021/bi00101a012; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; Lucas KA, 2000, PHARMACOL REV, V52, P375; Maack T, 1996, KIDNEY INT, V49, P1732, DOI 10.1038/ki.1996.257; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Matsukawa N, 1999, P NATL ACAD SCI USA, V96, P7403, DOI 10.1073/pnas.96.13.7403; MELOCHE S, 1987, J BIOL CHEM, V262, P10252; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; OKOLICANY J, 1992, AM J PHYSIOL, V263, pF546, DOI 10.1152/ajprenal.1992.263.3.F546; PANDEY KN, 1993, J BIOL CHEM, V268, P4382; Pandey KN, 2000, MOL PHARMACOL, V57, P259; PORTER JG, 1989, J BIOL CHEM, V264, P14179; PORTER JG, 1990, BIOCHEM BIOPH RES CO, V171, P796, DOI 10.1016/0006-291X(90)91216-F; Potter LR, 1998, J BIOL CHEM, V273, P15533, DOI 10.1074/jbc.273.25.15533; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; Sambrook J., 1989, MOL CLONING LAB MANU, V2; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; Wong SKF, 1995, J BIOL CHEM, V270, P30818, DOI 10.1074/jbc.270.51.30818; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862	41	10	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36438	36445		10.1074/jbc.M102208200	http://dx.doi.org/10.1074/jbc.M102208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11479286	hybrid			2022-12-25	WOS:000171194500053
J	Murakumo, Y; Ogura, Y; Ishii, H; Numata, S; Ichihara, M; Croce, CM; Fishel, R; Takahashi, M				Murakumo, Y; Ogura, Y; Ishii, H; Numata, S; Ichihara, M; Croce, CM; Fishel, R; Takahashi, M			Interactions in the error-prone postreplication repair proteins hREV1, hREV3, and hREV7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-THYMINE DIMER; DEOXYCYTIDYL TRANSFERASE-ACTIVITY; SACCHAROMYCES-CEREVISIAE GENE; DAMAGE-INDUCED MUTAGENESIS; ESCHERICHIA-COLI DINB; YEAST DNA-POLYMERASE; CATALYTIC SUBUNIT; TRANSLESION SYNTHESIS; HUMAN HOMOLOG; REV31 GENE	Most mutations after DNA damage in yeast Saccharomyces cerevisiae are induced by error-prone translesion DNA synthesis employing scRev1 and DNA polymerase that consists of scRev3 and scRev7 proteins. Recently, the human REV1 (hREV1) and REV3 (hREV3) genes were identified, and their products were revealed to be involved in UV-induced mutagenesis, as observed for their yeast counterparts. Human REV7 (hREV7) was also cloned, and its product was found to interact with hREV3, but the biological function of hREV7 remained unknown. We report here the analyses of precise interactions in the human REV proteins. The interaction between hREV1 and hREV7 was identified by the yeast two-hybrid library screening using a bait of hREV7, which was confirmed by in vitro and in vivo binding assays. The homodimerization of hREV7 was also detected in the two-hybrid analysis. In addition, the precise domains for interaction between hREV7 and hREV1 or hREV3 and for hREV7 homodimerization were determined. Although hREV7 interacts with both hREV1 and hREV3, a stable complex formation of the three proteins was undetectable in vitro. These findings suggest the possibility that hREV7 might play an important role in regulating the enzymatic activities of hREV1 and hREV3 for mutagenesis in response to DNA damage.	Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Nagoya University; Jefferson University	Murakumo, Y (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	murakumo@med.nagoya-u.ac.jp	TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020; Young, Richard A/F-6495-2012	Takahashi, Masahide/0000-0002-2803-2683; Young, Richard A/0000-0001-8855-8647				Bemark M, 2000, CURR BIOL, V10, P1213, DOI 10.1016/S0960-9822(00)00724-7; Bridges BA, 1999, CURR BIOL, V9, pR475, DOI 10.1016/S0960-9822(99)80299-1; Esposito G, 2000, CURR BIOL, V10, P1221, DOI 10.1016/S0960-9822(00)00726-0; FREIDBERG EC, 1995, DNA REPAIR MUTAGENES; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Kunz BA, 2000, MUTAT RES-FUND MOL M, V451, P169, DOI 10.1016/S0027-5107(00)00048-8; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; Lawrence CW, 1996, CANCER SURV, V28, P21; Lawrence CW, 2001, BIOCHEM SOC T, V29, P187, DOI 10.1042/0300-5127:0290187; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; Masuda Y, 2001, J BIOL CHEM, V276, P15051, DOI 10.1074/jbc.M008082200; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1997, GENETICS, V147, P1557; McDonald JP, 2001, PHILOS T R SOC B, V356, P53, DOI 10.1098/rstb.2000.0748; Morelli C, 1998, CYTOGENET CELL GENET, V83, P18, DOI 10.1159/000015157; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; Murakumo Y, 2000, J BIOL CHEM, V275, P4391, DOI 10.1074/jbc.275.6.4391; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2000, GENE DEV, V14, P1589; Roush AA, 1998, MOL GEN GENET, V257, P686; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Tissier A, 2000, GENE DEV, V14, P1642; TORPEY LE, 1994, YEAST, V10, P1503, DOI 10.1002/yea.320101115; Van Sloun PPH, 1999, MUTAT RES-DNA REPAIR, V433, P109, DOI 10.1016/S0921-8777(98)00067-6; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wagner J, 2000, EMBO REP, V1, P484; Wang ZG, 2001, MUTAT RES-DNA REPAIR, V486, P59, DOI 10.1016/S0921-8777(01)00089-1; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; Wittschieben J, 2000, CURR BIOL, V10, P1217, DOI 10.1016/S0960-9822(00)00725-9; Xiao W, 1998, CARCINOGENESIS, V19, P945, DOI 10.1093/carcin/19.5.945; Yamada A, 2000, NUCLEIC ACIDS RES, V28, P2473, DOI 10.1093/nar/28.13.2473	50	184	190	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35644	35651		10.1074/jbc.M102051200	http://dx.doi.org/10.1074/jbc.M102051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11485998	hybrid			2022-12-25	WOS:000171109300059
J	Silva, J; Dominguez, G; Silva, JM; Garcia, JM; Gallego, I; Corbacho, C; Provencio, M; Espana, P; Bonilla, F				Silva, J; Dominguez, G; Silva, JM; Garcia, JM; Gallego, I; Corbacho, C; Provencio, M; Espana, P; Bonilla, F			Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer	ONCOGENE			English	Article						allelic losses; p14ARF; breast cancer; hypermethylation; overexpression; mutations	CELL LUNG-CANCER; TUMOR-SUPPRESSOR GENE; INK4A/ARF LOCUS; STABILIZES P53; CYCLE ARREST; P19(ARF); METHYLATION; P16(INK4A); INACTIVATION; MUTATIONS	The INK4a/ARF locus encodes two unrelated cell cycle-regulatory proteins that both function in tumor suppression, p16INK4a and p14ARF. In human tumors including breast cancer, alterations affecting selectively p14ARF have been poorly analysed. We have performed a comprehensive analysis of the inactivation mechanisms (mutation, homozygous and hemizygous deletion, and promoter hypermethylation) in a large series of 100 primary breast carcinomas. RT-PCR showed expression variable of the p14ARF transcript, with 17% demonstrating overexpression and 26% demonstrating decreased expression. No detectable alterations were observed in the majority of cases with overexpressed p14ARF mRNA, but 77% of tumors with decreased expression presented at least one of these genetic/ epigenetic alterations. Nevertheless, a statistically significant correlation was observed between decreased p14ARF expression and several poor prognostic parameters.	Clin Puerta Hierro, Dept Med Oncol, E-28035 Madrid, Spain; Clin Puerta Hierro, Dept Pathol, E-28035 Madrid, Spain; Hosp Santa Cristina, Dept Pathol, E-28009 Madrid, Spain	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Bonilla, F (corresponding author), Clin Puerta Hierro, Dept Med Oncol, E-28035 Madrid, Spain.		Gallego, Ignacio/GZK-5910-2022; Provencio, Mariano/ABE-8586-2020	Provencio, Mariano/0000-0001-9053-9197; Provencio Pulla, Mariano/0000-0001-6315-7919				Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Esteller M, 2000, CANCER RES, V60, P129; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Gazzeri S, 1998, CANCER RES, V58, P3926; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herranz M, 1999, LEUKEMIA, V13, P808, DOI 10.1038/sj.leu.2401409; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Iwato M, 2000, CANCER RES, V60, P2113; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Markl IDC, 1998, CANCER RES, V58, P5348; OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, CANCER RES, V55, P2988; Takemoto S, 2000, BLOOD, V95, P3939; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	26	44	45	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4586	4590		10.1038/sj.onc.1204617	http://dx.doi.org/10.1038/sj.onc.1204617			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494155				2022-12-25	WOS:000170074900017
J	Miclo, L; Perrin, E; Driou, A; Papadopoulos, V; Boujrad, N; Vanderesse, R; Boudier, JF; Desor, D; Linden, G; Gaillard, JL				Miclo, L; Perrin, E; Driou, A; Papadopoulos, V; Boujrad, N; Vanderesse, R; Boudier, JF; Desor, D; Linden, G; Gaillard, JL			Characterization of alpha-casozepine, a tryptic peptide from bovine alpha(s1)-casein with benzodiazepine-like activity	FASEB JOURNAL			English	Article						milk; casein peptide; anxiolysis; anticonvulsant; diazepam binding inhibitor	ELEVATED PLUS-MAZE; BINDING INHIBITOR RECEPTOR; RAT CEREBRAL-CORTEX; IMMUNOREACTIVE MATERIAL; LIQUID-CHROMATOGRAPHY; ANXIOGENIC ACTION; KINDLED SEIZURES; MILK-PROTEINS; PENTYLENETETRAZOL; DIAZEPAM	Caseins are a known source of biologically active peptides. In this study, we have shown evidence of a novel anxiolytic activity in a tryptic hydrolysate of bovine alpha (s1)-casein. Injection of 3 mg/kg of this hydrolysate significantly reduced the epileptic symptoms caused by pentylenetetrazole in rats. Anxiety reduction was also observed when the hydrolysate was tested in the elevated plus-maze and in the conditioned defensive burying rat models. Peptides isolated from the hydrolysate were examined for their affinity for the gamma -amino-butyric acid (GABA) type A receptor. Only one peptide, named alpha -casozepine, corresponding to the 91-100 fragment from bovine alpha (s1)-casein, expressed affinity for GABA(A) receptor. In vitro, the peptide had 10,000 less affinity for the benzodiazepine site of the GABA(A) than did diazepam. However, in the conditioned defensive burying paradigm it was 10-fold more efficient than diazepam. The difference observed between the in vitro and in vivo activity of alpha -casozepine could not been explained by an action via the peripheral-type benzodiazepine receptor; alpha -casozepine had no affinity for this receptor. The alpha -casozepine amino acid sequence could be related to the carboxyterminal sequence of the polypeptide diazepam binding inhibitor, an endogenous ligand of the central GABA(A) and peripheral-type benzodiazepine receptors.	Univ Nancy 1, Fac Sci, Lab Biosci Aliment, INRA,UA 885, F-54506 Vandoeuvre Les Nancy, France; Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; INPL, ENSIC, Lab Chim Phys Macromol, CNRS,UMR 7568, Nancy, France; Ingredia, Arras, France; Univ Nancy 1, Fac Sci, Lab Aspects Fonct & Dev Comportements, CNRS,URA 1293, F-54506 Vandoeuvre Les Nancy, France; Univ Rennes 1, Endocrinol Mol Reprod UMR CNRS Interact Cellulair, F-35042 Rennes, France	INRAE; Universite de Lorraine; Georgetown University; Georgetown University; Georgetown University; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Universite de Rennes	Miclo, L (corresponding author), Univ Nancy 1, Fac Sci, Lab Biosci Aliment, INRA,UA 885, BP 239, F-54506 Vandoeuvre Les Nancy, France.	Laurent.Miclo@scbiol.uhp-nancy.fr	Papadopoulos, Vassilios/AAI-2613-2019; BOUJRAD, Noureddine/L-1367-2015	Papadopoulos, Vassilios/0000-0002-1183-8568; 				AGUNOD M, 1969, AM J DIG DIS, V14, P400, DOI 10.1007/BF02239360; ANDERSEN KV, 1991, BIOCHEMISTRY-US, V30, P10654, DOI 10.1021/bi00108a008; BIGGIO G, 1990, PHARMACOL THERAPEUT, V48, P121, DOI 10.1016/0163-7258(90)90077-F; BRETT RR, 1990, EUR J PHARMACOL, V178, P135, DOI 10.1016/0014-2999(90)94806-9; BREZINOVA V, 1972, BMJ-BRIT MED J, V2, P431, DOI 10.1136/bmj.2.5811.431; CORDA MG, 1991, PHARMACOL BIOCHEM BE, V40, P329, DOI 10.1016/0091-3057(91)90562-G; Dalvi A, 1999, PHARMACOL BIOCHEM BE, V62, P727, DOI 10.1016/S0091-3057(98)00220-2; DENCKER SJ, 1990, LANCET, V335, P413, DOI 10.1016/0140-6736(90)90246-2; DENCKER SJ, 1992, PSYCHOPHARMACOLOGY, V107, P69, DOI 10.1007/BF02244967; DIAL EJ, 1995, DIGEST DIS SCI, V40, P2295, DOI 10.1007/BF02063227; DIEHL RG, 1984, EPILEPSIA, V25, P506, DOI 10.1111/j.1528-1157.1984.tb03452.x; DOROW R, 1983, LANCET, V2, P98; EIGEL WN, 1984, J DAIRY SCI, V67, P1599, DOI 10.3168/jds.S0022-0302(84)81485-X; Ferrarese C, 1998, EPILEPSY RES, V29, P129, DOI 10.1016/S0920-1211(97)00074-0; FERRERO P, 1984, NEUROPHARMACOLOGY, V23, P1359, DOI 10.1016/0028-3908(84)90061-3; FILE SE, 1982, NEUROPHARMACOLOGY, V21, P1033, DOI 10.1016/0028-3908(82)90118-6; GRAMLICH CA, 1987, PHARMACOL BIOCHEM BE, V26, P159, DOI 10.1016/0091-3057(87)90549-1; GUIDOTTI A, 1983, P NATL ACAD SCI-BIOL, V80, P3531, DOI 10.1073/pnas.80.11.3531; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; KAMINOGAWA S, 1987, J AM OIL CHEM SOC, V64, P1688, DOI 10.1007/BF02542504; Karle J, 1998, J NEUROSCI RES, V54, P863, DOI 10.1002/(SICI)1097-4547(19981215)54:6<863::AID-JNR14>3.0.CO;2-6; KARLER R, 1989, NEUROPHARMACOLOGY, V28, P775, DOI 10.1016/0028-3908(89)90166-4; KOCH G, 1988, REGUL PEPTIDES, V20, P107, DOI 10.1016/0167-0115(88)90044-4; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; KRUEGER KE, 1991, NEUROPSYCHOPHARMACOL, V4, P237; KUMOSINSKI TF, 1991, J DAIRY SCI, V74, P2889, DOI 10.3168/jds.S0022-0302(91)78470-1; LACOSTE L, 1988, CAN J PHYSIOL PHARM, V66, P1135, DOI 10.1139/y88-186; LAIRD D. A., 1934, Journal of the American Dietetic Association, V10, P89; LAZAROVA-BAKAROVA M, 1990, Acta Physiologica et Pharmacologica Bulgarica, V16, P37; LEBENTHAL E, 1983, J PEDIATR-US, V102, P1, DOI 10.1016/S0022-3476(83)80276-5; LOUKAS S, 1983, BIOCHEMISTRY-US, V22, P4567, DOI 10.1021/bi00288a034; LUDDENS H, 1995, J PSYCHIATR RES, V29, P77, DOI 10.1016/0022-3956(94)00040-X; MEDINA JH, 1988, BIOCHEM BIOPH RES CO, V152, P534, DOI 10.1016/S0006-291X(88)80070-6; MEDINA JH, 1992, MOL NEUROBIOL, V6, P377, DOI 10.1007/BF02757942; Meisel H, 1997, BIOPOLYMERS, V43, P119, DOI [10.1002/(SICI)1097-0282(1997)43:2<119::AID-BIP4>3.0.CO;2-Y, 10.1002/(SICI)1097-0282(1997)43:2&lt;119::AID-BIP4&gt;3.0.CO;2-Y]; MEISEL H, 1986, FEBS LETT, V196, P223, DOI 10.1016/0014-5793(86)80251-4; Meisel H, 1999, ANTON LEEUW INT J G, V76, P207, DOI 10.1023/A:1002063805780; MOSER PC, 1989, PSYCHOPHARMACOLOGY, V99, P48, DOI 10.1007/BF00634451; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NORUSIS MJ, 1994, SPSS ADV STAT 6 1 MA, P117; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PAPADOPOULOS V, 1992, P NATL ACAD SCI USA, V89, P5113, DOI 10.1073/pnas.89.11.5113; PELISSOLO A, 1995, ENCEPHALE, V21, P133; PELLMAR TC, 1977, SCIENCE, V197, P912, DOI 10.1126/science.887932; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; PERRIN E, 1995, J CHROMATOGR B, V664, P267, DOI 10.1016/0378-4347(94)00400-Y; PINEL JPJ, 1978, J COMP PHYSIOL PSYCH, V92, P708, DOI 10.1037/h0077494; POMES A, 1994, J PHARMACOL EXP THER, V271, P1616; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; ROHMER JG, 1990, BEHAV BRAIN RES, V38, P45, DOI 10.1016/0166-4328(90)90023-8; SANOGO T, 1989, J DAIRY SCI, V72, P2242, DOI 10.3168/jds.S0022-0302(89)79354-1; SCHMIDT J, 1987, BIOMED BIOCHIM ACTA, V46, P267; SVEDBERG J, 1985, PEPTIDES, V6, P825, DOI 10.1016/0196-9781(85)90308-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREIT D, 1987, BRAIN RES BULL, V19, P401, DOI 10.1016/0361-9230(87)90143-2; TREIT D, 1981, PHARMACOL BIOCHEM BE, V15, P619, DOI 10.1016/0091-3057(81)90219-7; UMBACH M, 1985, REGUL PEPTIDES, V12, P223, DOI 10.1016/0167-0115(85)90063-1; Walsh LA, 1999, J PHARMACOL EXP THER, V289, P1626; Winer BJ, 1971, STAT PRINCIPLES EXPT; YAMAMOTO N, 1994, J DAIRY SCI, V77, P917, DOI 10.3168/jds.S0022-0302(94)77026-0	61	62	66	3	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1780	+		10.1096/fj.00-0685fje	http://dx.doi.org/10.1096/fj.00-0685fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481228				2022-12-25	WOS:000169261200032
J	Pinnix, I; Council, JE; Roseberry, B; Onstead, L; Mallender, W; Sucic, J; Sambamurti, K				Pinnix, I; Council, JE; Roseberry, B; Onstead, L; Mallender, W; Sucic, J; Sambamurti, K			Convertases other than furin cleave beta-secretase to its mature form	FASEB JOURNAL			English	Article						proprotein convertases; memapsin; aspartyl proteases; proprotein convertases; BACE; zymogen activation; amyloid; Alzheimer	AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE; ALZHEIMERS-DISEASE; SITE; PROPROTEIN; PEPTIDE; ENZYME; INHIBITORS; PRESENILIN; MATURATION	An aspartyl protease, Beta-Site APP cleaving enzyme (BACE), was identified as the beta -secretase responsible for generating the Amyloid beta protein that is believed to cause Alzheimer's disease. BACE has a short propeptide domain that is absent in the mature enzyme because of proteolytic cleavage after the sequence RLPR. This sequence is a predicted substrate for proprotein convertases such as furin. To determine the role of furin and other proprotein convertases, we expressed proBACE in a furin-deficient mutant Chinese hamster ovary (CHO-K1) line, RPE. 40. ProBACE signal was higher in RPE. 40 than in the CHO-K1 parent, which confirmed that furin plays a role in propeptide removal. However, two independent approaches showed that proBACE is cleaved to mature BACE in RPE. 40: proBACE was rapidly turned over in RPE. 40 although total BACE was stable, and decanoyl-RVKR-chloromethylketone, an inhibitor of the proprotein convertase family, substantially increased proBACE levels in both RPE 40 and CHO-K1. Transient transfection shows that furin, PACE4, PC5/6, and PC7 mediate BACE cleavage in vivo, at least when overexpressed. RPE. 40 is proficient in BACE activity despite its furin deficiency. Therefore, our finding that proBACE is cleaved in this mutant leaves open the possibility that maturation is an important regulatory step and a therapeutic target.	Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; Univ Michigan, Dept Biol, Flint, MI 48502 USA	Mayo Clinic; University of Michigan System; University of Michigan; University of Michigan Flint	Sambamurti, K (corresponding author), Mayo Clin, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	samba@mayo.edu	Sambamurti, Kumar/A-1620-2012	Sambamurti, Kumar/0000-0001-9507-9214				Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAI H, 2000, SOC NEUR 30 ANN M NO; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; GANDY S, 1994, NEUROBIOL AGING, V15, P253, DOI 10.1016/0197-4580(94)90125-2; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Harlow E., 1988, ANTIBODIES LAB MANUA; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Inocencio NM, 1997, J BIOL CHEM, V272, P1344, DOI 10.1074/jbc.272.2.1344; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; MOEHRING TJ, 1977, CELL, V11, P447, DOI 10.1016/0092-8674(77)90063-0; OHNISHI Y, 1994, J VIROL, V68, P4075, DOI 10.1128/JVI.68.6.4075-4079.1994; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Sambamurti K, 1999, J BIOL CHEM, V274, P26810, DOI 10.1074/jbc.274.38.26810; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Selkoe DJ, 2000, P NATL ACAD SCI USA, V97, P5690, DOI 10.1073/pnas.97.11.5690; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; Sucic JF, 1999, BIOCHEM J, V339, P639, DOI 10.1042/0264-6021:3390639; Sucic JF, 1998, SOMAT CELL MOLEC GEN, V24, P75, DOI 10.1023/B:SCAM.0000007111.46513.70; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	53	26	26	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1810	+		10.1096/fj.00-0891fje	http://dx.doi.org/10.1096/fj.00-0891fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481238	Green Submitted			2022-12-25	WOS:000169261200035
J	Aguilar, Z; Slamon, DJ				Aguilar, Z; Slamon, DJ			The transmembrane heregulin precursor is functionally active	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; CELL-SURFACE; PLASMA-MEMBRANE; FACTOR-ALPHA; NEUREGULIN ISOFORMS; NDF HEREGULIN; LIGAND; EXPRESSION	A variety of eucaryotic polypeptide growth factors are synthesized as transmembrane precursors. Many of these precursors are released from plasma membranes by proteolytic cleavage and converted into soluble mature proteins. A number of studies, however, indicate that bound growth factor precursors can be biologically active, suggesting a role for these membrane-associated ligands in cell-cell communication. Secreted heregulin is a 45-kDa growth factor with homology to epidermal growth factor. This growth factor binds directly to HER-3 and HER-4 and activates heterodimeric receptor complexes composed of the type I receptor tyrosine kinases, i.e. HER-1 HER-2, HER-3, and HER-4. Heregulin was originally detected in the conditioned medium of the human breast cancer cell line MDA-MB-231 and purified based on its ability to stimulate phosphorylation of p185(HER-2/neu). In the current study, the biologic activity of plasma membrane-anchored heregulin was evaluated in human breast cells. Transmembrane heregulin binds to cells expressing p180(HER-3), induces p185(HER-2/neu) phosphorylation, and increases DNA synthesis in cells overexpressing the HER-2/neu gene product. In addition, when cells containing heregulin receptors are co-cultured with heregulin-producing cells, specific in vivo associations are observed. This study demonstrates that transmembrane heregulin is functionally active and suggest it is capable of playing a role in cell-cell communication and subsequent signal transduction in vivo.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Slamon, DJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA.	dslamon@mednet.ucla.edu			NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NCI NIH HHS [2PO1CA32737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bosenberg MW, 1993, CURR OPIN CELL BIOL, V5, P832, DOI 10.1016/0955-0674(93)90032-L; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; CAGAN RL, 1992, CELL, V69, P393, DOI 10.1016/0092-8674(92)90442-F; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHAZIN VR, 1992, ONCOGENE, V7, P1859; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; Lewis GD, 1996, CANCER RES, V56, P1457; LIN PH, 1991, METHOD ENZYMOL, V198, P251; Loeb JA, 1998, MOL CELL NEUROSCI, V11, P77, DOI 10.1006/mcne.1998.0676; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MEIER PJ, 1990, METHOD ENZYMOL, V192, P534; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; MROCZKOWSKI B, 1988, P NATL ACAD SCI USA, V85, P126, DOI 10.1073/pnas.85.1.126; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRESS MF, 1990, ONCOGENE, V5, P953; Raabe TD, 1996, J NEUROSCI RES, V46, P263; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SCHARSCHMIDT BF, 1981, BIOCHIM BIOPHYS ACTA, V646, P369, DOI 10.1016/0005-2736(81)90305-9; Schroering A, 1998, J BIOL CHEM, V273, P30643, DOI 10.1074/jbc.273.46.30643; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; URBINA JA, 1988, MOL BIOCHEM PARASIT, V30, P185, DOI 10.1016/0166-6851(88)90111-9; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; WU K, 1994, ONCOGENE, V9, P3139; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	53	25	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44099	44107		10.1074/jbc.M103442200	http://dx.doi.org/10.1074/jbc.M103442200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11495899	hybrid			2022-12-25	WOS:000172297700080
J	Yousaf, N; Deng, YP; Kang, YH; Riedel, H				Yousaf, N; Deng, YP; Kang, YH; Riedel, H			Four PSM/SH2-B alternative splice variants and their differential roles in mitogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE; NERVE GROWTH-FACTOR; FACTOR-I RECEPTOR; SR PROTEINS; TYROSINE KINASE; SH2 DOMAIN; PREMESSENGER RNA; ACTIVATION LOOP; ADAPTER PROTEIN; PDGF RECEPTOR	An SH2 domain originally termed SH2-B had been identified as a direct cellular binding target of a number of mostly mitogenic receptors. The complete cellular protein, termed PSM, and respective sequence variants share additional Pro-rich and PH regions, as well as similarities with APS and Lnk. A role of these mediators has been implicated in signaling pathways found downstream of growth hormone receptor and receptor tyrosine kinases, including the insulin, insulin-like growth factor-I (IGF-I), platelet-derived growth factor (PDGF), nerve growth factor, hepatocyte growth factor, and fibroblast growth factor receptors. As a result of this report a total of four PSM/SH2-B sequence variants termed alpha, beta, gamma, and delta have now been identified in the mouse and have been compared with the available rat and human sequences. Variant differences are based on alternative splicing and define distinct last exons 7, 8, and 9 that result in reading frameshifts and unique carboxyl-terminal amino acid sequences. Variant sequences have been identified from cDNA libraries and directly by reverse transcription-polymerase chain reaction. Sequence analysis predicts four distinctly sized protein products that have been demonstrated after cDNA expression. All were found phosphorylated on tyrosine specifically in response to IGF-I and PDGF stimulation. cDNA expression of the four variants caused variant-dependent levels of stimulation of IGF-I- and PDGF-induced mitogenesis. The most pronounced increase in mitogenesis was consistently observed for the delta variant followed by delta, alpha, and beta with decreasing responses. In contrast, the mitogenic response to epidermal growth factor consistently remained unaffected. The variants are expressed in most mouse tissues, typically, most strongly in pairs of alpha and delta or beta and gamma. Our findings implicate differential roles of the PSM/SH2-B splice variants in specific mitogenic signaling pathways.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Riedel, H (corresponding author), Wayne State Univ, Dept Biol Sci, 2171 BSB, Detroit, MI 48202 USA.			Deng, Youping/0000-0002-5951-8213	NATIONAL CANCER INSTITUTE [R01CA077873] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA77873] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Carter-Su C, 2000, RECENT PROG HORM RES, V55, P293; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; Craparo A, 1997, J BIOL CHEM, V272, P11663; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Eggert A, 2000, ONCOGENE, V19, P2043, DOI 10.1038/sj.onc.1203518; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; FENECH M, 1991, NUCLEIC ACIDS RES, V19, P6737, DOI 10.1093/nar/19.24.6737; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; HENRIKSSON G, 1995, ELECTROPHORESIS, V16, P1377, DOI 10.1002/elps.11501601227; Herrington J, 2000, J BIOL CHEM, V275, P13126, DOI 10.1074/jbc.275.17.13126; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; HUANG X, 1995, P NATL ACAD SCI USA, V96, P11618; HUMPHREY MB, 1995, MOL CELL BIOL, V15, P3979; Iseki M, 2000, BIOCHEM BIOPH RES CO, V272, P45, DOI 10.1006/bbrc.2000.2736; Koch A, 2000, FEBS LETT, V469, P72, DOI 10.1016/S0014-5793(00)01242-4; Kotani K, 1998, BIOCHEM J, V335, P103, DOI 10.1042/bj3350103; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Moodie SA, 1999, J BIOL CHEM, V274, P11186, DOI 10.1074/jbc.274.16.11186; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nagase T, 2000, DNA RES, V7, P143, DOI 10.1093/dnares/7.2.143; Nelms K, 1999, MAMM GENOME, V10, P1160, DOI 10.1007/s003359901183; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; QIAN, 2001, MOL CELL BIOL, V21, P1613; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Riedel H, 2000, ONCOGENE, V19, P39, DOI 10.1038/sj.onc.1203253; RIEDEL H, 1994, J VIROL, V68, P411, DOI 10.1128/JVI.68.1.411-424.1994; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; Rui LY, 1999, J BIOL CHEM, V274, P26485, DOI 10.1074/jbc.274.37.26485; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	46	61	63	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40940	40948		10.1074/jbc.M104191200	http://dx.doi.org/10.1074/jbc.M104191200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11502739	hybrid			2022-12-25	WOS:000171925600076
J	Torcia, M; De Chiara, G; Nencioni, L; Ammendola, S; Labardi, D; Lucibello, M; Rosini, P; Marlier, LNJL; Bonini, P; Dello Sbarba, P; Palamara, AT; Zambrano, N; Russo, T; Garaci, E; Cozzolino, F				Torcia, M; De Chiara, G; Nencioni, L; Ammendola, S; Labardi, D; Lucibello, M; Rosini, P; Marlier, LNJL; Bonini, P; Dello Sbarba, P; Palamara, AT; Zambrano, N; Russo, T; Garaci, E; Cozzolino, F			Nerve growth factor inhibits apoptosis in memory B lymphocytes via inactivation of p38 MAPK, prevention of Bcl-2 phosphorylation, and cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PROTEASOME-DEPENDENT DEGRADATION; P75 NEUROTROPHIN RECEPTOR; CELL-DEATH; SYMPATHETIC NEURONS; TRANSGENIC MICE; SURVIVAL FACTOR; PC12 CELLS; IN-VITRO; PATHWAY	Survival of memory B lymphocytes is tightly linked to the integrity of the Bcl-2 protein and is regulated by a nerve growth factor (NGF) autocrine circuit. In factor-starved memory B cells, the addition of exogenous NGF promptly induced p38 mitogen-activated protein kinase (MAPK), but not c-Jun N-terminal kinase (JNK), dephosphorylation. Conversely, withdrawal of endogenous NGF was followed by p38 MAPK activation and translocation onto mitochondria, whereby it combined with and phosphorylated Bcl-2, as assessed by co-immunoprecipitation and kinase assays in vivo and in vitro. Mitochondria isolated from human memory B cells, then exposed to recombinant p38 MAPK, released cytochrome c, as did mitochondria from Bcl-2-negative MDCK cells loaded with recombinant Bcl-2. Apoptosis induced by NGF neutralization could be blocked by the specific p38 MAPK inhibitor SB203580 or by Bcl-2 mutations in Ser-87 or Thr-56. These data demonstrate that the molecular mechanisms underlying the survival factor function of NGF critically rely upon the continuous inactivation of p38 MAPK, a Bcl-2-modifying enzyme.	Univ Florence, Dept Clin Physiopathol, I-50139 Florence, Italy; Univ Roma Tor Vergata, Dept Expt Med, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Internal Med, I-00133 Rome, Italy; Univ Florence, Inst Gen Pathol, I-50139 Florence, Italy; Univ Naples Federico II, Dept Cellular & Mol Biol & Pathol L Califano, I-80131 Naples, Italy; Univ Naples Federico II, Dept Biochem & Med Biotechnol, I-80131 Naples, Italy; CNR, Inst Neurobiol & Mol Med, I-00133 Rome, Italy	University of Florence; University of Rome Tor Vergata; University of Rome Tor Vergata; University of Florence; University of Naples Federico II; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR)	Torcia, M (corresponding author), Univ Florence, Dept Clin Physiopathol, Viale Pieraccini 6, I-50139 Florence, Italy.	g.torcia@dfc.unifi.it	GARACI, ENRICO/AAB-3349-2021; De Chiara, Giovanna/AAJ-7843-2021; Torcia, Maria Gabriella G/K-1840-2018; lucibello, maria/AAI-1417-2020; Nencioni, Lucia/K-5988-2016; Russo, Tommaso/K-1331-2016; Marlier, Lionel NJL/G-9488-2013; Dello Sbarba, Persio/AAX-9887-2020; Zambrano, Nicola/B-9352-2014	De Chiara, Giovanna/0000-0002-2219-6097; Torcia, Maria Gabriella G/0000-0003-4740-4646; Nencioni, Lucia/0000-0003-4427-4823; Russo, Tommaso/0000-0003-4426-0106; Zambrano, Nicola/0000-0001-9395-3481; MARLIER, LIONEL/0000-0002-6840-3127; AMMENDOLA, Serena/0000-0003-1436-0608; PALAMARA, ANNA TERESA/0000-0001-8330-4381; Cozzolino, Federico/0000-0002-2800-640X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Basu A, 2000, INT J ONCOL, V16, P497; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Chadebech P, 1999, BIOCHEM BIOPH RES CO, V262, P823, DOI 10.1006/bbrc.1999.1291; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Grillot DAM, 1996, J EXP MED, V183, P381, DOI 10.1084/jem.183.2.381; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Horstmann S, 1998, J NEUROSCI RES, V52, P483, DOI 10.1002/(SICI)1097-4547(19980515)52:4<483::AID-JNR12>3.3.CO;2-Y; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JOHNSON LN, 1993, ANNU REV BIOPH BIOM, V22, P199, DOI 10.1146/annurev.bb.22.060193.001215; Katoh S, 1996, BIOCHEM BIOPH RES CO, V229, P653, DOI 10.1006/bbrc.1996.1859; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Majdan M, 1997, J NEUROSCI, V17, P6988; Malmqvist M, 1997, CURR OPIN CHEM BIOL, V1, P378, DOI 10.1016/S1367-5931(97)80077-4; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MELAMED I, 1995, J EXP MED, V181, P1071, DOI 10.1084/jem.181.3.1071; Navarro P, 1999, J BIOL CHEM, V274, P18857, DOI 10.1074/jbc.274.27.18857; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Pincelli C, 1997, J INVEST DERMATOL, V109, P757, DOI 10.1111/1523-1747.ep12340768; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang SJ, 1999, BIOCHEM BIOPH RES CO, V259, P67, DOI 10.1006/bbrc.1999.0669; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	64	105	113	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39027	39036		10.1074/jbc.M102970200	http://dx.doi.org/10.1074/jbc.M102970200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11495898	hybrid			2022-12-25	WOS:000171673200092
J	Chan, CL; Gross, CA				Chan, CL; Gross, CA			The anti-initial transcribed sequence, a portable sequence that impedes promoter escape, requires sigma(70) for function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; OPEN COMPLEX; IN-VITRO; NONTEMPLATE STRAND; MALT PROMOTER; ACTIVE-CENTER; BINDING-SITE; SUBUNIT; DNA	The anti-sequence, a portable element extending from +1 to +15 of the transcript, is sufficient to prevent promoter escape from a variety of strong sigma (70) promoters. We show here that this sequence does not function with even the strongest sigma (32) promoter. Moreover, a particular class of substitutions in sigma (70) that disrupt interaction between Region 2.2 of sigma (70) and a coiled-coiled motif in the beta'-subunit of RNA polymerase antagonizes the function of the anti-element. This same group of mutants prevents lambdaQ-mediated anti-termination at the lambdaP(R), promoter. At this promoter, interaction of sigma (70) with the nontemplate strand of the initial transcribed sequence (ITS) is required to promote the pause prerequisite for antitermination. These mutants prevent pausing because they are defective in this recognition event. By analogy, we suggest that interaction of sigma (70) with the non-template strand of the anti-ITS is required for function of this portable element, thus explaining why neither sigma (32) nor the Region 2.2 sigma (70) mutants mediate anti-function. Support for the analogy with the lambdaP(R), promoter comes from preliminary experiments suggesting that the anti-ITS, like the lambdaP(R), ITS, is bipartite.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gross, CA (corresponding author), Univ Calif San Francisco, Dept Stomatol, Campus Mailbox 0512,S-420,513 Parnassus Ave, San Francisco, CA 94143 USA.				NIGMS NIH HHS [GM30477] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; Arthur TM, 2000, J BIOL CHEM, V275, P23113, DOI 10.1074/jbc.M002040200; Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; COWING DW, 1985, P NATL ACAD SCI USA, V82, P2679, DOI 10.1073/pnas.82.9.2679; COWING DW, 1989, J MOL BIOL, V210, P513, DOI 10.1016/0022-2836(89)90127-7; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Daube SS, 1999, P NATL ACAD SCI USA, V96, P8390, DOI 10.1073/pnas.96.15.8390; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; DISSINGER S, 1991, J MOL BIOL, V219, P11, DOI 10.1016/0022-2836(91)90853-X; Dombroski AJ, 1997, J BIOL CHEM, V272, P3487; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; Eichenberger P, 1997, P NATL ACAD SCI USA, V94, P9022, DOI 10.1073/pnas.94.17.9022; ELLINGER T, 1994, J MOL BIOL, V239, P455, DOI 10.1006/jmbi.1994.1388; Estrem ST, 1999, GENE DEV, V13, P2134, DOI 10.1101/gad.13.16.2134; FENG GH, 1994, J BIOL CHEM, V269, P22282; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Gruber TM, 2001, MOL CELL, V8, P21, DOI 10.1016/S1097-2765(01)00292-1; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; Hertz GZ, 1996, METHOD ENZYMOL, V273, P30; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; Hsu LM, 1996, METHOD ENZYMOL, V273, P59; Joo DM, 1997, P NATL ACAD SCI USA, V94, P4907, DOI 10.1073/pnas.94.10.4907; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; Ko DC, 1998, GENE DEV, V12, P3276, DOI 10.1101/gad.12.20.3276; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Marr MT, 2000, MOL CELL, V6, P1275, DOI 10.1016/S1097-2765(00)00126-X; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; METZGER W, 1993, J MOL BIOL, V232, P35, DOI 10.1006/jmbi.1993.1368; MUNSON LM, 1981, BIOCHEMISTRY-US, V20, P2081, DOI 10.1021/bi00511a003; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Qi FX, 1996, METHOD ENZYMOL, V273, P71; RASMUSSEN EB, 1995, J MOL BIOL, V252, P522, DOI 10.1006/jmbi.1995.0517; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; Roberts CW, 1996, CELL, V86, P495; SEVERINOV K, 1995, J BIOL CHEM, V270, P29428, DOI 10.1074/jbc.270.49.29428; SEVERINOV K, 1994, J BIOL CHEM, V269, P20826; Sharp MM, 1999, GENE DEV, V13, P3015, DOI 10.1101/gad.13.22.3015; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; Tagami H, 1998, EMBO J, V17, P1759, DOI 10.1093/emboj/17.6.1759; Tagami H, 1999, P NATL ACAD SCI USA, V96, P7202, DOI 10.1073/pnas.96.13.7202; VO NV, 1998, THESIS U CALIFORNIA; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Young BA, 2001, CELL, V105, P935, DOI 10.1016/S0092-8674(01)00398-1	58	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38201	38209						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11481327				2022-12-25	WOS:000171526500065
J	Hunter, JG; van Delft, MF; Rachubinski, RA; Capone, JP				Hunter, JG; van Delft, MF; Rachubinski, RA; Capone, JP			Peroxisome proliferator-activated receptor gamma ligands differentially modulate muscle cell differentiation and MyoD gene expression via peroxisome proliferator-activated receptor gamma-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); SKELETAL-MUSCLE; DIRECTLY INTERACTS; DOWN-REGULATION; CYCLOPENTENONE PROSTAGLANDINS; TISSUE DISTRIBUTION; DIABETES-MELLITUS; NUCLEAR RECEPTOR	The effects of distinct classes of peroxisome proliferator-activated receptor gamma (PPAR gamma) ligands on myogenesis and Myo gene expression were examined in mouse skeletal muscle C2C12 myoblasts. Treatment of C2C12 cells with the PPAR gamma ligand, 15-deoxy-Delta (12,14)-prostaglandin J2 (15d-PGJ2), repressed morphologically defined myogenesis and reduced endogenous mRNA levels of the myogenic differentiation markers MyoD, myogenin, and alpha -actin. In contrast, two synthetic PPAR gamma ligands, L-805645 and ciglitazone, exhibited no effects. In transient transfection assays, 15d-PGJ2 specifically inhibited the expression of a MyoD promoter-luciferase reporter gene (MyoDLuc) in a cell type- and promoter-specific manner, indicating that 15d-PGJ2 functions in part by repressing MyoD gene transcription. The inhibition of MyoD gene expression by 15d-PGJ2 is mediated by the distal region of the MyoD gene promoter. PPAR gamma on its own also inhibited MyoDLuc expression and further augmented the 15d-PGJ2 response. In contrast, L-805645 and ciglitazone did not inhibit MyoDLuc expression on their own but did so in the presence of ectopically expressed PPAR gamma. Interestingly, a transdominant inhibitor of PPAR gamma (hPPAR gamma2 Delta 500) had no effect on the 15d-PGJ2-dependent repression of MyoDLuc expression but overcame L-805645/PPAR gamma -dependent repression. Finally, saturating concentrations of L-805645, which did not affect myogenesis, failed to ablate 15d-PGJ2-mediated repression of the myogenic program. Thus, distinct PPAR gamma ligands may repress MyoD gene expression through PPAR gamma -dependent and -independent pathways, and 15d-PGJ2 can inhibit the myogenic program independent of its cognate receptor, PPAR gamma.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	University of Alberta; McMaster University	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, MSB 5-14, Edmonton, AB T6G 2H7, Canada.	rachubinski@ualberta.ca; caponej@fhs.csu		van Delft, Mark/0000-0002-3866-4318				Alric S, 1998, ONCOGENE, V16, P273, DOI 10.1038/sj.onc.1201484; Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Bailey P, 1998, NUCLEIC ACIDS RES, V26, P5501, DOI 10.1093/nar/26.23.5501; Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Beamer BA, 1998, DIABETES, V47, P1806, DOI 10.2337/diabetes.47.11.1806; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; Berger J, 2000, MOL CELL ENDOCRINOL, V162, P57, DOI 10.1016/S0303-7207(00)00211-2; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; BUCKINGHAM ME, 1994, CURR OPIN GENET DEV, V4, P745, DOI 10.1016/0959-437X(94)90142-P; Butler R, 2000, CELL GROWTH DIFFER, V11, P49; Camp HS, 2000, DIABETES, V49, P539, DOI 10.2337/diabetes.49.4.539; Chen JCJ, 1999, CELL TISSUE RES, V296, P213, DOI 10.1007/s004410051282; Chinery R, 1999, CANCER RES, V59, P2739; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; FAERMAN A, 1995, DEV BIOL, V171, P27, DOI 10.1006/dbio.1995.1257; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Froeschle A, 1998, ONCOGENE, V16, P3369, DOI 10.1038/sj.onc.1201894; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; Grimaldi PA, 1997, PROSTAG LEUKOTR ESS, V57, P71, DOI 10.1016/S0952-3278(97)90495-6; Hara K, 2000, BIOCHEM BIOPH RES CO, V271, P212, DOI 10.1006/bbrc.2000.2605; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Ikeda U, 2000, HYPERTENSION, V35, P1232, DOI 10.1161/01.HYP.35.6.1232; Jackson SM, 1999, ARTERIOSCL THROM VAS, V19, P2094, DOI 10.1161/01.ATV.19.9.2094; Kassam A, 1998, MOL CELL ENDOCRINOL, V141, P153, DOI 10.1016/S0303-7207(98)00085-9; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kruszynska YT, 1998, J CLIN INVEST, V101, P543, DOI 10.1172/JCI1076; Lapsys NM, 2000, J CLIN ENDOCR METAB, V85, P4293, DOI 10.1210/jc.85.11.4293; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lehtinen SK, 1996, BIOCHEM BIOPH RES CO, V229, P36, DOI 10.1006/bbrc.1996.1754; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; Mbalaviele G, 2000, J BIOL CHEM, V275, P14388, DOI 10.1074/jbc.275.19.14388; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; NEGISHI M, 1995, J LIPID MEDIAT CELL, V12, P443, DOI 10.1016/0929-7855(95)00029-P; Park KS, 1998, J CLIN ENDOCR METAB, V83, P2830, DOI 10.1210/jc.83.8.2830; Park KS, 1997, DIABETES, V46, P1230, DOI 10.2337/diabetes.46.7.1230; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Rawls A, 1998, DEVELOPMENT, V125, P2349; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; Shimokawa T, 1998, BIOCHEM BIOPH RES CO, V246, P287, DOI 10.1006/bbrc.1998.8600; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; TEBOUL L, 1995, J BIOL CHEM, V270, P28183, DOI 10.1074/jbc.270.47.28183; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Vaidya S, 1999, J IMMUNOL, V163, P6187; VANDENHEUVEL JP, 1999, J NUTR, V129, P575; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424; Wang MH, 1999, DIABETES, V48, P254, DOI 10.2337/diabetes.48.2.254; Yoshida N, 1998, J CELL SCI, V111, P769; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zierath JR, 1998, ENDOCRINOLOGY, V139, P5034, DOI 10.1210/en.139.12.5034	69	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38297	38306						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11477074				2022-12-25	WOS:000171526500078
J	Liu, JG; Ruckle, MB; Prather, PL				Liu, JG; Ruckle, MB; Prather, PL			Constitutively active mu-opioid receptors inhibit adenylyl cyclase activity in intact cells and activate G-proteins differently than the agonist [D-Ala(2),N-MePhe(4),Gly-ol(5)]enkephalin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE G-PROTEINS; INVERSE AGONISM; CHO CELLS; BETA-FUNALTREXAMINE; COUPLED RECEPTORS; BINDING PROTEINS; MECHANISMS; MODULATION; CHANNELS; ABILITY	The most convincing evidence demonstrating constitutive activation of mu -opioid receptors is the observation that putative inverse agonists decrease basal G-protein activity in membrane preparations. However, it is not clear whether constitutively active receptors in isolated membranes have any physiological relevance in intact cells. GH(3) cells expressing ix-opioid receptors (GH(3)MOR) exhibit higher basal G-protein activity and lower basal cAMP levels than wild-type GH3 cells, indicative of constitutively active receptors. This study determined whether alkylation of mu -opioid receptors by the irreversible antagonist beta -funaltrexamine would decrease spontaneous receptor activity in intact cells, revealing constitutive activity. GH3MOR cells were pretreated with increasing concentrations of beta -funaltrexamine followed by functional testing after removal of unbound drug. beta -Funaltrexamine pretreatment produced a concentration-dependent decrease in tx-opioid receptor binding with an IC50 of 0.98 nm and an E-max of 77%. Similar concentrations of beta -funaltrexamine pretreatment produced a half-maximal reduction in basal [S-35]GTP gammaS binding, a decrease in basal photolabeling of G-proteins with azidoanilido-[alpha-P-32]GTP, and an increase in basal adenylyl cyclase activity in intact cells. Therefore, mu -opioid receptors are constitutively active in intact cells, producing stimulation of G-proteins and inhibition of adenylyl cyclase. Importantly, photolabeling of G alpha -subunits with azidoanilido-[alpha-P-32]GTP demonstrated that constitutively active mu -opioid receptors activate individual G-proteins differently than the agonist [D-Ala(2),N-MePhe(4),Gly-ol(5)]enkephalin.	Univ Arkansas Med Sci, Coll Med, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Prather, PL (corresponding author), Univ Arkansas Med Sci, Coll Med, Dept Pharmacol & Toxicol, Mail Slot 611,4301 W Markham St, Little Rock, AR 72205 USA.	pratherpaull@uams.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R29DA010936] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10936] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Broadbear JH, 2000, J PHARMACOL EXP THER, V294, P933; Burford NT, 2000, BIOCHEM J, V348, P531, DOI 10.1042/0264-6021:3480531; CHAKRABARTI S, 1995, J NEUROCHEM, V64, P2534; Chiu TT, 1996, MOL PHARMACOL, V50, P1651; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; de Ligt RAF, 2000, BRIT J PHARMACOL, V130, P1, DOI 10.1038/sj.bjp.0703311; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; HENRY DJ, 1995, MOL PHARMACOL, V47, P551; KATADA T, 1986, J BIOL CHEM, V261, P5215; KAZMI SMI, 1987, MOL PHARMACOL, V32, P109; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Liu JG, 2001, MOL PHARMACOL, V60, P53, DOI 10.1124/mol.60.1.53; LIUCHEN LY, 1987, MOL PHARMACOL, V32, P321; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Merkouris M, 1997, J NEUROCHEM, V69, P2115; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; MJANGER E, 1991, J PHARMACOL EXP THER, V258, P544; Mullaney L, 1996, BIOCHEM J, V315, P227, DOI 10.1042/bj3150227; Neilan CL, 1999, BRIT J PHARMACOL, V128, P556, DOI 10.1038/sj.bjp.0702816; PIROS ET, 1995, MOL PHARMACOL, V47, P1041; Prather PL, 2000, J PHARMACOL EXP THER, V295, P552; PRATHER PL, 1995, MOL BRAIN RES, V29, P336, DOI 10.1016/0169-328X(94)00264-F; PRATHER PL, 1994, MOL PHARMACOL, V45, P997; PRATHER PL, 1994, J BIOL CHEM, V269, P21293; Selley DE, 2000, BRIT J PHARMACOL, V130, P987, DOI 10.1038/sj.bjp.0703382; Sim LJ, 1996, EUR J PHARMACOL, V307, P97, DOI 10.1016/0014-2999(96)00211-7; Szekeres PG, 1997, J PHARMACOL EXP THER, V283, P1276; Wang DX, 2000, J NEUROCHEM, V75, P763, DOI 10.1046/j.1471-4159.2000.0750763.x; Wang DX, 2001, J NEUROCHEM, V77, P1590, DOI 10.1046/j.1471-4159.2001.00362.x; WANG Z, 1994, LIFE SCI, V54, pPL339, DOI 10.1016/0024-3205(94)90022-1	35	41	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37779	37786						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11500514				2022-12-25	WOS:000171526500009
J	Wan, KF; Sambi, BS; Frame, M; Tate, R; Pyne, NJ				Wan, KF; Sambi, BS; Frame, M; Tate, R; Pyne, NJ			The inhibitory gamma subunit of the type 6 retinal cyclic guanosine monophosphate phosphodiesterase is a novel intermediate regulating p42/p44 mitogen-activated protein kinase signaling in human embryonic kidney 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED TYROSINE PHOSPHORYLATION; GROWTH-FACTOR STIMULATION; AIRWAY SMOOTH-MUSCLE; G(BETA-GAMMA) SUBUNITS; COUPLED RECEPTORS; BETA-ARRESTIN; INSULIN; EXPRESSION; REQUIRES	The inhibitory gamma subunits of the retinal rod and cone photoreceptor type 6 retinal cyclic guanosine monophosphate phosphodiesterase (PDE gamma) are expressed in non-retinal tissues. Here, we show that PDE gamma interacts with the G-protein-coupled receptor kinase 2 signaling system to regulate the epidermal growth factor- and thrombin-dependent stimulation of p42/p44 mitogen-activated protein kinase in human embryonic kidney 293 cells. This is based upon several lines of evidence. First, the transfection of cells with an antisense rod PDE gamma plasmid construct, which reduced endogenous rod PDE gamma expression, ablated the epidermal growth factor- and thrombin-dependent stimulation of p42/p44 mitogen-activated protein kinase. Second, the transfection of cells with recombinant rod or cone PDE gamma and/or G-protein-coupled receptor kinase 2 increased the stimulation of p42/p44 mitogen-activated protein kinase by epidermal growth factor or thrombin. In contrast, a G-protein-coupled receptor kinase 2 phosphorylation-resistant rod PDE gamma mutant failed to increase the epidermal growth factor- or thrombin-dependent stimulation of p42/p44 mitogen-activated protein kinase and, in fact, functioned as a dominant negative. Thrombin also stimulated the association of endogenous rod PDE gamma with dynamin II, which was increased in cells transfected with rod PDE gamma or G-protein-coupled receptor kinase 2. Dynamin II plays a critical role in regulating endocytosis of receptor signal complexes required for activation of p42/p44 mitogen-activated protein kinase. Therefore, PDE gamma may have an important role in promoting endocytosis of receptor signal complexes leading to the activation of p42/p44 mitogen-activated protein kinase. We conclude that PDE-gamma is an entirely novel intermediate regulating mitogenic signaling from both receptor tyrosine kinase and G-protein-coupled receptors in human embryonic kidney 293 cells.	Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland	University of Strathclyde	Pyne, NJ (corresponding author), Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Physiol & Pharmacol, 27 Taylor St, Glasgow G4 0NR, Lanark, Scotland.	n.j.pyne@strath.ac.uk		Tate, Rothwelle/0000-0001-5857-4267; Pyne, Nigel/0000-0002-5657-4578				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Lochhead A, 1997, J BIOL CHEM, V272, P18397, DOI 10.1074/jbc.272.29.18397; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Rakhit S, 2001, MOL PHARMACOL, V60, P63, DOI 10.1124/mol.60.1.63; STRYER L, 1991, J BIOL CHEM, V266, P10711; Tate Rothwelle J., 1998, Cell Biochemistry and Biophysics, V29, P133, DOI 10.1007/BF02737832; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wang HY, 2000, J BIOL CHEM, V275, P36086, DOI 10.1074/jbc.M004404200; YU YM, 1992, J CELL PHYSIOL, V150, P559, DOI 10.1002/jcp.1041500317	25	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37802	37808						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11502744				2022-12-25	WOS:000171526500012
J	Szewczyk, E; Andrianopoulos, A; Davis, MA; Hynes, MJ				Szewczyk, E; Andrianopoulos, A; Davis, MA; Hynes, MJ			A single gene produces mitochondrial, cytoplasmic, and peroxisomal NADP-dependent isocitrate dehydrogenase in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; ALKANE-ASSIMILATING YEAST; SACCHAROMYCES-CEREVISIAE; BETA-OXIDATION; CARNITINE ACETYLTRANSFERASE; MALATE-DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; CANDIDA-TROPICALIS; SYNTHASE GENES; DOUBLE-BONDS	NADP-dependent isocitrate dehydrogenase enzymes catalyze the decarboxylation of isocitrate to 2-oxoglutarate accompanied by the production of NADPH. In mammals two different genes encode mitochondrial and cytoplasmic/peroxisomal located enzymes, whereas in Saccharomyces cerevisiae three separate genes specify compartment specific enzymes. We have identified a single gene, idpA, in the filamentous fungus Aspergillus nidulans that specifies a protein with a high degree of identity to mammalian and S. cerevisiae enzymes. Northern blot analysis and reverse transcription-polymerase chain reaction revealed the presence of two idpA transcripts and two transcription start points were identified by sequencing cDNA clones and by 5'-rapid amplification of cDNA ends. The shorter transcript was found to be inducible by acetate and by fatty acids while the longer transcript was present in higher amounts during growth in glucose containing media. The longer transcript is predicted to encode a polypeptide containing an N-terminal mitochondrial targeting sequence as well as a C-terminal tripeptide (ARL) as a potential peroxisomal targeting signal. The shorter transcript is predicted to encode a polypeptide lacking the mitochondrial targeting signal but retaining the C-terminal sequence. Immunoblotting using antibody raised against S. cerevisiae Idp1p detected two polypeptides consistent with these predictions. The functions of the predicted targeting sequences were confirmed by microscopic analysis of transformants containing fluorescent protein fusion constructs. Using anti-Idp1p antibodies, protein localization to mitochondria and peroxisomes was observed during growth on glucose whereas cytoplasmic and peroxisomal localization was found upon acetate or fatty acid induction. Therefore, we have established that by the use of two transcription start points a single gene is sufficient to specify localization of NADP-dependent isocitrate dehydrogenase to three different cellular compartments in A. nidulans.	Univ Melbourne, Dept Genet, Parkville, Vic 3010, Australia	University of Melbourne	Hynes, MJ (corresponding author), Univ Melbourne, Dept Genet, Parkville, Vic 3010, Australia.		Szewczyk, Edyta/AAF-4715-2020	Szewczyk, Edyta/0000-0002-2054-5855				ANDRIANOPOULOS A, 1988, MOL CELL BIOL, V8, P3532, DOI 10.1128/MCB.8.8.3532; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Bojunga N, 1999, MOL GEN GENET, V262, P869, DOI 10.1007/s004380051152; BORTHWICK AC, 1984, EUR J BIOCHEM, V141, P393, DOI 10.1111/j.1432-1033.1984.tb08204.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN RD, 1990, PLANT PHYSIOL BIOCH, V28, P141; Clutterbuck A.J, 1974, HDB GENETICS, V1, P447; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; Danpure CJ, 1997, BIOESSAYS, V19, P317, DOI 10.1002/bies.950190409; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; EHINGER A, 1990, MOL GEN GENET, V222, P416, DOI 10.1007/BF00633848; ELGERSMA Y, 1995, EMBO J, V14, P3472, DOI 10.1002/j.1460-2075.1995.tb07353.x; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; Galvez S, 1996, PLANT MOL BIOL, V30, P307, DOI 10.1007/BF00020116; Galvez S, 1998, P NATL ACAD SCI USA, V95, P7813, DOI 10.1073/pnas.95.13.7813; GALVEZ S, 1994, PLANT PHYSIOL, V105, P593, DOI 10.1104/pp.105.2.593; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Geisbrecht BV, 1999, J BIOL CHEM, V274, P30527, DOI 10.1074/jbc.274.43.30527; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; HALLIWELL B, 1994, NUTR REV, V52, P253; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; Haurie V, 2001, J BIOL CHEM, V276, P76, DOI 10.1074/jbc.M008752200; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; Imajo T, 1997, ARCH MICROBIOL, V168, P389, DOI 10.1007/s002030050513; JENNINGS GT, 1994, J BIOL CHEM, V269, P23128; Kawachi H, 1996, EUR J BIOCHEM, V238, P845, DOI 10.1111/j.1432-1033.1996.0845w.x; KELLY JM, 1982, J GEN MICROBIOL, V128, P23; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KISPAL G, 1993, J BIOL CHEM, V268, P1824; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; Lancien M, 1998, PLANT J, V16, P325, DOI 10.1046/j.1365-313x.1998.00305.x; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; MAY GS, 1987, GENE, V55, P231, DOI 10.1016/0378-1119(87)90283-6; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; MCCULLOUGH W, 1977, GENETICS PHYSL ASPER, P97; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; MEIXNERMONORI B, 1986, BIOCHEM J, V236, P549, DOI 10.1042/bj2360549; MIDGLEY M, 1993, FEMS MICROBIOL LETT, V108, P7; Minard KI, 1999, J BIOL CHEM, V274, P3402, DOI 10.1074/jbc.274.6.3402; MINARD KI, 1991, MOL CELL BIOL, V11, P370, DOI 10.1128/MCB.11.1.370; Nekrutenko A, 1998, MOL BIOL EVOL, V15, P1674, DOI 10.1093/oxfordjournals.molbev.a025894; Nikolaev I, 1999, MOL MICROBIOL, V31, P1115, DOI 10.1046/j.1365-2958.1999.01250.x; OAKLEY CE, 1987, GENE, V53, P293, DOI 10.1016/0378-1119(87)90019-9; OSMANI SA, 1983, EUR J BIOCHEM, V133, P551, DOI 10.1111/j.1432-1033.1983.tb07499.x; Plaut G.E.W., 1963, ENZYMES, V7, P105; PLAUT GWE, 1983, BIOCHIM BIOPHYS ACTA, V760, P300, DOI 10.1016/0304-4165(83)90177-0; PUNT PJ, 1990, GENE, V93, P101, DOI 10.1016/0378-1119(90)90142-E; RAMACHANDRAN N, 1980, J BIOL CHEM, V255, P8859; Sambrook J., 2002, MOL CLONING LAB MANU; SANDEMAN RA, 1991, MOL GEN GENET, V228, P445, DOI 10.1007/BF00260638; SCHMALIX W, 1993, J BIOL CHEM, V268, P27428; Small AJ, 2001, MOL GENET GENOMICS, V265, P636, DOI 10.1007/s004380100456; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; STEFFAN JS, 1992, J BIOL CHEM, V267, P24708; Stemple CJ, 1998, J BACTERIOL, V180, P6242; Suelmann R, 1997, MOL MICROBIOL, V25, P757, DOI 10.1046/j.1365-2958.1997.5131873.x; Swiegers JH, 2001, YEAST, V18, P585, DOI 10.1002/yea.712; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Todd RB, 1997, MOL GEN GENET, V254, P495, DOI 10.1007/s004380050444; Ueda M, 1998, BBA-GENE STRUCT EXPR, V1397, P213, DOI 10.1016/S0167-4781(98)00009-8; Valenciano S, 1996, ARCH MICROBIOL, V166, P336, DOI 10.1007/s002030050392; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; Zhao WN, 1996, BIOCHEMISTRY-US, V35, P7873, DOI 10.1021/bi9605189	72	38	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37722	37729		10.1074/jbc.M105645200	http://dx.doi.org/10.1074/jbc.M105645200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11483612	hybrid			2022-12-25	WOS:000171375700112
J	Toivonen, S; Aitio, O; Renkonen, O				Toivonen, S; Aitio, O; Renkonen, O			alpha 2,3-Sialylation of terminal GalNAc beta 1-3Gal determinants by ST3Gal II reveals the multifunctionality of the enzyme - The resulting Neu5Aece2-3GalNAc linkage is resistant to sialidases from Newcastle disease virus and Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDO-BETA-GALACTOSIDASE; LINKED OLIGOSACCHARIDES; MOLECULAR-CLONING; STRUCTURAL CHARACTERIZATION; SUBSTRATE SPECIFICITIES; N-ACETYLGALACTOSAMINE; MAGNETIC-RESONANCE; MASS-SPECTROMETRY; HUMAN-SERUM; O-GLYCAN	Enzymatic alpha2,3-sialylation of GalNAc has not been described previously, although some glycoconjugates containing alpha2,3-sialylated GalNAc residues have been reported. In the present experiments, recombinant soluble alpha2,3-sialyltransferase ST3Gal II efficiently sialylated the X-2 pentasaccharide GalNAc beta1-3Gal beta1-4GlcNAc beta1-3Gal beta1-4Glc, globo-N-tetraose GalNAc beta1-3Gal alpha1-4Gal beta1-4Glc, and the disaccharide GalNAc beta1-3Gal in vitro. The purified products were identified as Neu5Ac alpha2-3GalNAc beta1-3Gal beta1-4GlcNAc beta1-3Gal beta1-4Glc, Neu5Ac alpha2-3GalNAc beta1-3Gal alpha1-4Gal beta1-4Glc, and Neu5Ac alpha2-3GalNAc beta1-3Gal, respectively, by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, enzymatic degradations, and one- and two-dimensional NMR-spectroscopy. In particular, the presence of the Neu5Ac alpha2-3GalNAc linkage was firmly established in all three products by a long range correlation between Neu5Ac C2 and GalNAc H3 in heteronuclear multiple bond correlation spectra. Collectively, the data describe the first successful sialyltransfer reactions to the 3-position of GalNAc in any acceptor. Previously, ST3Gal II has been shown to transfer to the Gal beta1-3GalNAc determinant. Consequently, the present data show that the enzyme is multifunctional, and could be renamed ST3Gal(NAc) II. In contrast to ST3Gal II, ST3Gal III did not transfer to the X2 pentasaccharide. The Neu5Ac alpha2-3GalNAc linkage of sialyl X2 was cleaved by sialidases from Arthrobacter ureafaciens and Clostridium perfringens, but resisted the action of sialidases from Newcastle disease virus and Streptococcus pneumoniae. Therefore, the latter two enzymes cannot be used to differentiate between Neu5Ac alpha2-3GalNAc and Neu5Ac alpha2-6GalNAc linkages, as has been assumed previously.	Univ Helsinki, Biomedicum Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Viikki Drug Discovery Technol Ctr, Dept Pharm, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki	Renkonen, O (corresponding author), Univ Helsinki, Biomedicum Helsinki, Inst Biotechnol, POB 63, FIN-00014 Helsinki, Finland.	ossi.renkonen@helsinki.fi						BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; CASSIDY JT, 1965, J BIOL CHEM, V240, P3501; CORFIELD AP, 1983, BIOCHIM BIOPHYS ACTA, V744, P121, DOI 10.1016/0167-4838(83)90080-8; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; Ervasti JM, 1997, J BIOL CHEM, V272, P22315, DOI 10.1074/jbc.272.35.22315; FUKUDA MN, 1985, BIOCHEMISTRY-US, V24, P2154, DOI 10.1021/bi00330a008; Fukumoto S, 1999, J BIOL CHEM, V274, P9271, DOI 10.1074/jbc.274.14.9271; Gilbert M, 1997, EUR J BIOCHEM, V249, P187, DOI 10.1111/j.1432-1033.1997.t01-1-00187.x; GREEN ED, 1988, J BIOL CHEM, V263, P25; GRONBERG G, 1994, CARBOHYD RES, V257, P35, DOI 10.1016/0008-6215(94)84106-3; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HURD RE, 1991, J MAGN RESON, V91, P648, DOI 10.1016/0022-2364(91)90395-A; KANNAGI R, 1982, J BIOL CHEM, V257, P4438; KANNAGI R, 1982, CANCER RES, V42, P5249; Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUNDU SK, 1984, BIOCHEM BIOPH RES CO, V118, P82; LEE YC, 1994, J BIOL CHEM, V269, P10028; LEPPANEN A, 1991, BIOCHEMISTRY-US, V30, P9287, DOI 10.1021/bi00102a022; Maaheimo H, 1997, CARBOHYD RES, V297, P145, DOI 10.1016/S0008-6215(96)00259-5; MAAHEIMO H, 1995, EUR J BIOCHEM, V234, P616, DOI 10.1111/j.1432-1033.1995.616_b.x; Manzella SM, 1997, J BIOL CHEM, V272, P4775, DOI 10.1074/jbc.272.8.4775; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Natunen J, 1997, GLYCOBIOLOGY, V7, P711, DOI 10.1093/glycob/7.5.711; NEMANSKY M, 1992, BIOCHEM J, V287, P311, DOI 10.1042/bj2870311; Nyman TA, 1998, EUR J BIOCHEM, V253, P485, DOI 10.1046/j.1432-1327.1998.2530485.x; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; Papac DI, 1996, ANAL CHEM, V68, P3215, DOI 10.1021/ac960324z; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PFEIFFER G, 1992, EUR J BIOCHEM, V205, P961, DOI 10.1111/j.1432-1033.1992.tb16863.x; Pykari M, 2000, J BIOL CHEM, V275, P40057, DOI 10.1074/jbc.M007922200; Rabina J, 1997, CARBOHYD RES, V305, P491, DOI 10.1016/S0008-6215(97)00260-7; RENKONEN O, 1991, GLYCOCONJUGATE J, V8, P376, DOI 10.1007/BF00731351; ROPP PA, 1991, J BIOL CHEM, V266, P23863; SABESAN S, 1986, J AM CHEM SOC, V108, P2068, DOI 10.1021/ja00268a056; SCHWARTING GA, 1983, BIOCHEM BIOPH RES CO, V112, P935, DOI 10.1016/0006-291X(83)91707-2; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; SHACHTER H, 1979, METAB CONJUGATION, P1; Smith H, 1995, MICROB PATHOGENESIS, V19, P365, DOI 10.1006/mpat.1995.0071; STRECKER G, 1989, GLYCOCONJUGATE J, V6, P67, DOI 10.1007/BF01047891; TAKEYA A, 1992, J BIOCHEM-TOKYO, V112, P389, DOI 10.1093/oxfordjournals.jbchem.a123910; TANAKA N, 1992, J BIOCHEM-TOKYO, V112, P68, DOI 10.1093/oxfordjournals.jbchem.a123867; Teneberg S, 1996, GLYCOBIOLOGY, V6, P599, DOI 10.1093/glycob/6.6.599; THORN JJ, 1992, BIOCHEMISTRY-US, V31, P6509, DOI 10.1021/bi00143a022; Toivonen S, 2000, GLYCOBIOLOGY, V10, P1103; TOIVONEN S, 2000, 20 INT CARB S, P142; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; UCHIDA Y, 1979, J BIOCHEM-TOKYO, V86, P1573, DOI 10.1093/oxfordjournals.jbchem.a132675; Wakarchuk WW, 2001, J BIOL CHEM, V276, P12785, DOI 10.1074/jbc.M011293200; WATANABE K, 1979, BIOCHEMISTRY-US, V18, P5502, DOI 10.1021/bi00591a037; WESTON BW, 1992, J BIOL CHEM, V267, P4152; YAMASAKI R, 1991, BIOCHEMISTRY-US, V30, P10566, DOI 10.1021/bi00107a028; YATES AD, 1983, CARBOHYD RES, V120, P251, DOI 10.1016/0008-6215(83)88020-3; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Zhou DP, 2000, J BIOL CHEM, V275, P22631, DOI 10.1074/jbc.C000263200	57	18	18	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37141	37148		10.1074/jbc.M105715200	http://dx.doi.org/10.1074/jbc.M105715200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479313	hybrid			2022-12-25	WOS:000171375700038
J	Blumenschein, TMA; Tripet, BP; Hodges, RS; Sykes, BD				Blumenschein, TMA; Tripet, BP; Hodges, RS; Sykes, BD			Mapping the interacting regions between troponins T and C - Binding of TnT and TnI peptides to TnC and NMR mapping of the TnT-binding site on TnC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; REGULATORY DOMAIN; SYNTHETIC PEPTIDES; CRYSTAL-STRUCTURE; CONTRACTION; TROPOMYOSIN; RESOLUTION; SENSITIVITY; FRAGMENTS; COMPLEX	Muscular contraction is triggered by an increase in calcium concentration, which is transmitted to the contractile proteins by the troponin complex. The interactions among the components of the troponin complex (troponins T, C, and I) are essential to understanding the regulation of muscle contraction. While the structure of TnC is well known, and a model for the binary TnC.TnI complex has been recently published (Tung, C.-S., Wall, M. E., Gallagher, S. C., and Trewhella, J. (2000) Protein Sci. 9, 1312-1326), very little is known about TnT. Using non-denaturing gels and NMR spectroscopy, we have analyzed the interactions between TnC and five peptides from TnT as well as how three TnI peptides affect these interactions. Rabbit fast skeletal muscle peptide TnT-(160-193) binds to TnC with a dissociation constant of 30 +/- 6 mum. This binding still occurs in the presence of TnI-(1-40) but is prevented by the presence of TnI-(56-115) or TnI-(96-139), both containing the primary inhibitory region of TnI. TnT-(228-260) also binds TnC. The binding site for TnT-(160-193) is located on the C-terminal domain of TnC and was mapped to the surface of TnC using NMR chemical shift mapping techniques. In the context of the model for the TnC.TnI complex, we discuss the interactions between TnT and the other troponin subunits.	Univ Alberta, Canadian Inst Hlth Res Crp Prot Struct & Funct, Dept Biochem, Edmonton, AB T6E 1X9, Canada	University of Alberta	Sykes, BD (corresponding author), Univ Alberta, Canadian Inst Hlth Res Crp Prot Struct & Funct, Dept Biochem, Edmonton, AB T6E 1X9, Canada.		Blumenschein, Tharin/C-5984-2009	Blumenschein, Tharin/0000-0002-4932-5178				BRIGGS MM, 1989, J MOL BIOL, V206, P245, DOI 10.1016/0022-2836(89)90538-X; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Finley N, 2000, J MOL CELL CARDIOL, V32, P1439, DOI 10.1006/jmcc.2000.1174; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Hernandez G, 1999, BIOCHEMISTRY-US, V38, P6911, DOI 10.1021/bi990150q; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; INGRAHAM RH, 1984, J BIOL CHEM, V259, P9544; JACKSON P, 1975, BIOCHEM J, V151, P85, DOI 10.1042/bj1510085; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KATAYAMA E, 1982, J BIOCHEM-TOKYO, V91, P1449, DOI 10.1093/oxfordjournals.jbchem.a133835; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; Mercier P, 2000, BIOCHEMISTRY-US, V39, P2902, DOI 10.1021/bi992579n; NGAI SM, 1992, J BIOL CHEM, V267, P15715; PEARLSTONE JR, 1978, CAN J BIOCHEM CELL B, V56, P521, DOI 10.1139/o78-080; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; RAGGI A, 1989, BIOCHIM BIOPHYS ACTA, V997, P135, DOI 10.1016/0167-4838(89)90145-3; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SEREDA TJ, 1993, J CHROMATOGR, V646, P17, DOI 10.1016/S0021-9673(99)87003-4; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SLUPSKY CM, 1995, BIOCHEMISTRY-US, V34, P7365, DOI 10.1021/bi00022a009; Stefancsik R, 1998, P NATL ACAD SCI USA, V95, P957, DOI 10.1073/pnas.95.3.957; TANOKURA M, 1983, J BIOCHEM, V93, P331, DOI 10.1093/oxfordjournals.jbchem.a134185; Tao T, 1999, BBA-MOL CELL RES, V1450, P423, DOI 10.1016/S0167-4889(99)00050-6; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TRIGOGONZALEZ G, 1992, BIOCHEMISTRY-US, V31, P7009, DOI 10.1021/bi00146a001; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; Tung CS, 2000, PROTEIN SCI, V9, P1312; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; Wagschal K, 1999, J MOL BIOL, V285, P785, DOI 10.1006/jmbi.1998.2284; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	42	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36606	36612		10.1074/jbc.M105130200	http://dx.doi.org/10.1074/jbc.M105130200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11473120	Green Accepted, hybrid			2022-12-25	WOS:000171194500074
J	Dobashi, H; Sato, M; Tanaka, T; Tokuda, M; Ishida, T				Dobashi, H; Sato, M; Tanaka, T; Tokuda, M; Ishida, T			Growth hormone restores glucocorticoid-induced T cell suppression	FASEB JOURNAL			English	Article						growth hormone; T lymphocytes; glucocorticoid; apoptosis	FACTOR-I; BINDING-PROTEIN; GENE-EXPRESSION; IMMUNE FUNCTION; RAT-TISSUES; RECEPTOR; APOPTOSIS; PROLIFERATION; CHILDREN; THERAPY	Growth hormone (GH) is a potent anabolic hormone, and its clinical use has been extended to the improvement of metabolic imbalance in many disease,s including autoimmune disorders treated with glucocorticoids (GCs). GH has, however, a potential action on the immune system, and this might be a demerit in GH therapy for those diseases. We report here the anti-GC effects of GH on T lymphocytes. Human peripheral T lymphocytes (HPTLs) expressed GH receptor mRNA. GH stimulated tyrosine phosphorylation of cellular proteins, including JAK2 and STAT5b in HPTLs. GH and IGF-I alleviated dexamethasone (Dex)-induced suppression of [H-3] thymidine incorporation into HPTLs. GH alleviated Dex-induced apoptosis in CD4(+) (positive) HPTLs. GH increased Bcl-2 expression in CD4(+) HPTLs but not in CD8(+) HPTLs. In vivo, GH raised the CD4/8 ratio of T lymphocytes in rats chronically administered with Dex. These findings indicate that GH may inhibit GC-induced apoptosis predominantly in CD4(+) T lymphocytes and present important implications of GH therapy, especially for autoimmune disorders treated with GCs.	Kagawa Med Univ, Dept Internal Med 1, Sch Med, Miki, Kagawa 7610793, Japan; Kagawa Med Univ, Dept Environm Hlth Sci, Miki, Kagawa 7610793, Japan	Kagawa University; Kagawa University	Dobashi, H (corresponding author), Kagawa Med Univ, Dept Internal Med 1, Sch Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	hdobashi@kms.ac.jp		DOBASHI, HIROAKI/0000-0003-2944-5583				Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; Auernhammer CJ, 1995, EUR J ENDOCRINOL, V133, P635, DOI 10.1530/eje.0.1330635; BOZZOLA M, 1990, J PEDIATR-US, V117, P596, DOI 10.1016/S0022-3476(05)80697-3; Bresson JL, 1999, ENDOCRINOLOGY, V140, P3203, DOI 10.1210/en.140.7.3203; Clark R, 1997, ENDOCR REV, V18, P157, DOI 10.1210/er.18.2.157; FINE RN, 1991, PEDIATR NEPHROL, V5, P477, DOI 10.1007/BF01453685; FRANCO P, 1990, ACTA ENDOCRINOL-COP, V123, P339, DOI 10.1530/acta.0.1230339; GEFFNER ME, 1990, J CLIN ENDOCR METAB, V71, P464, DOI 10.1210/jcem-71-2-464; GELATO MC, 1993, TRENDS ENDOCRIN MET, V4, P106, DOI 10.1016/1043-2760(93)90088-V; Haeffner A, 1999, EUR J IMMUNOL, V29, P334, DOI 10.1002/(SICI)1521-4141(199901)29:01<334::AID-IMMU334>3.0.CO;2-S; HAYASHIDA T, 1957, J EXP MED, V105, P93, DOI 10.1084/jem.105.2.93; Karlsson H, 1999, MOL CELL ENDOCRINOL, V154, P37, DOI 10.1016/S0303-7207(99)00101-X; KOOIJMAN R, 1995, EUR J IMMUNOL, V25, P931, DOI 10.1002/eji.1830250411; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lee PDK, 1996, J CLIN ENDOCR METAB, V81, P2968, DOI 10.1210/jc.81.8.2968; LeRoith D, 1996, ENDOCRINOLOGY, V137, P1071, DOI 10.1210/en.137.3.1071; LESNIAK MA, 1973, NATURE-NEW BIOL, V241, P20, DOI 10.1038/newbio241020a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Loke KY, 1997, J PEDIATR-US, V130, P793, DOI 10.1016/S0022-3476(97)80023-6; MATSUBARA S, 1995, ENDOCRINOLOGY, V136, P4147, DOI 10.1210/en.136.9.4147; MEMON SA, 1995, J IMMUNOL, V155, P4644; MERCOLA KE, 1981, BLOOD, V58, P337; RAPAPORT R, 1995, J CLIN ENDOCR METAB, V80, P2612, DOI 10.1210/jc.80.9.2612; RIVKEES SA, 1994, J PEDIATR-US, V125, P322, DOI 10.1016/S0022-3476(94)70219-5; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Sabharwal P, 1996, J CLIN ENDOCR METAB, V81, P2663, DOI 10.1210/jc.81.7.2663; TIMSIT J, 1992, J CLIN ENDOCR METAB, V75, P183, DOI 10.1210/jc.75.1.183; TONSHOFF B, 1991, PEDIATR NEPHROL, V5, P454; Touati G, 1998, J CLIN ENDOCR METAB, V83, P403, DOI 10.1210/jc.83.2.403; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WADA Y, 1995, ENDOCRINOLOGY, V136, P3936, DOI 10.1210/en.136.9.3936; WIT JM, 1993, HORM RES, V39, P107, DOI 10.1159/000182708; Xu BXC, 1996, J BIOL CHEM, V271, P19768, DOI 10.1074/jbc.271.33.19768; Yap HK, 1998, PEDIATR NEPHROL, V12, P133, DOI 10.1007/s004670050421; Yokote R, 1998, PEPTIDES, V19, P15, DOI 10.1016/S0196-9781(97)00263-5; YOSHIDA A, 1992, ACTA ENDOCRINOL-COP, V126, P524, DOI 10.1530/acta.0.1260524	36	21	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1861	+		10.1096/fj.00-0702fje	http://dx.doi.org/10.1096/fj.00-0702fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481255				2022-12-25	WOS:000169261200013
